<SEC-DOCUMENT>0001437749-24-030062.txt : 20240926
<SEC-HEADER>0001437749-24-030062.hdr.sgml : 20240926
<ACCEPTANCE-DATETIME>20240926160537
ACCESSION NUMBER:		0001437749-24-030062
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		134
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240926
DATE AS OF CHANGE:		20240926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOPHARMA, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		241328842

	BUSINESS ADDRESS:	
		STREET 1:		7900 E. UNION AVENUE
		STREET 2:		SUITE 920
		CITY:			DENVER
		STATE:			CO
		ZIP:			80237
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		7900 E. UNION AVENUE
		STREET 2:		SUITE 920
		CITY:			DENVER
		STATE:			CO
		ZIP:			80237

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>aytu20240630_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:aytu="http://aytubio.com/20240630" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>aytu20240630_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 9/26/2024 6:04:06 PM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001385818</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">AYTU BIOPHARMA, INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-20243">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="dei:CurrentFiscalYearEndDate" id="ixv-20244">--06-30</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="dei:DocumentFiscalPeriodFocus" id="ixv-20245">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="dei:DocumentFiscalYearFocus" id="ixv-20246">2024</ix:nonNumeric>
<ix:nonFraction id="c117046828" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"/>
<ix:nonFraction id="c117046829" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"/>
<ix:nonFraction id="c117046833" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c117046835" contextRef="i_2023-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c117046836" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000,000</ix:nonFraction>
<ix:nonFraction id="c117046837" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">50,000,000</ix:nonFraction>
<ix:nonFraction id="c117046838" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117046840" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117046839" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117046841" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117046844" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c117046845" contextRef="i_2023-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c117046846" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">200,000,000</ix:nonFraction>
<ix:nonFraction id="c117046847" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">200,000,000</ix:nonFraction>
<ix:nonFraction id="c117046848" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,972,638</ix:nonFraction>
<ix:nonFraction id="c117046850" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,972,638</ix:nonFraction>
<ix:nonFraction id="c117046849" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,517,174</ix:nonFraction>
<ix:nonFraction id="c117046851" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,517,174</ix:nonFraction>
<ix:nonFraction id="c117046943" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,004</ix:nonFraction>
<ix:nonFraction id="c117047052" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c117047150" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117047154" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117047174" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacks" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c117047191" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c117047194" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_RangeAxis-MinimumMember" name="aytu:AccountsReceivableCreditTerms" id="c117047243" format="ixt-sec:durday">30</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember" name="aytu:AccountsReceivableCreditTerms" id="c117047245" format="ixt-sec:durday">60</ix:nonNumeric>
<ix:nonFraction id="c117047278" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117047295" contextRef="d_2023-07-01_2024-04-29" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c117047466" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c117047469" contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ConsumerHealthMember_RangeAxis-MinimumMember" unitRef="Pure" name="aytu:NumberOfProducts" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction>
<ix:nonFraction id="c117047534" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117047564" contextRef="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.5</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c117047576" format="ixt-sec:duryear">5.5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-06-30" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="c117047624">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="c117047625">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-06-30" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="c117047635">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="c117047636">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-06-30" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="c117047641">http://fasb.org/us-gaap/2024#LongTermDebtCurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="c117047642">http://fasb.org/us-gaap/2024#LongTermDebtCurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-06-30" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="c117047648">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="c117047649">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric>
<ix:nonFraction id="c117047687" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:Goodwill" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-07-01_2023-06-30" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="c117047702">http://fasb.org/us-gaap/2024#AssetImpairmentCharges</ix:nonNumeric>
<ix:nonFraction id="c117047809" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember" name="us-gaap:DebtInstrumentTerm" id="c117047910" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember" name="aytu:DebtInstrumentAmortizationPeriod" id="c117047911" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember" name="us-gaap:DebtInstrumentTerm" id="c117047912" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c117047971" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="c117047972">http://fasb.org/us-gaap/2024#AssetImpairmentCharges</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-07-01_2023-06-30" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="c117048033">http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="c117048039">http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet</ix:nonNumeric>
<ix:nonFraction id="c117048082" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117048083" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117048250" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,972,638</ix:nonFraction>
<ix:nonFraction id="c117048252" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,517,174</ix:nonFraction>
<ix:nonFraction id="c117048254" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117048255" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117048256" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c117048288" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c117048297" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c117048303" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c117048313" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c117048317" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c117050812" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.73</ix:nonFraction>
<ix:nonFraction id="c117050820" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.53</ix:nonFraction>
<ix:nonFraction id="c117050827" contextRef="i_2024-06-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction>
<ix:nonFraction id="c117050829" contextRef="i_2024-06-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">290.00</ix:nonFraction>
<ix:nonFraction id="c117048402" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="5">33.333</ix:nonFraction>
<ix:nonFraction id="c117048403" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="5">8.333</ix:nonFraction>
<ix:nonFraction id="c117048413" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="5">33.333</ix:nonFraction>
<ix:nonFraction id="c117048414" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="5">8.333</ix:nonFraction>
<ix:nonFraction id="c117048427" contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="5">33.333</ix:nonFraction>
<ix:nonFraction id="c117048428" contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="5">8.333</ix:nonFraction>
<ix:nonFraction id="c117048434" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117048435" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c117048560" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c117048564" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c117048586" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c117048589" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c117048614" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c117048743" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2015-02-28_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c117048746" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c117048749" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c117048787" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="ecd:Rule10b51ArrAdoptedFlag" id="c117048835" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="ecd:NonRule10b51ArrAdoptedFlag" id="c117048843" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="ecd:Rule10b51ArrTrmntdFlag" id="c117048844" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="ecd:NonRule10b51ArrTrmntdFlag" id="c117048845" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="f98c7406b-0164-46c7-a651-4ef0eae9f56d">	Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fb35717a1-d432-4eda-915f-5e96136e3a49">The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4">Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f9b398ddb-deb9-406f-853a-3630953d420d">Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f8d99ba23-2066-44d9-91b0-1100337ca445">Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company&#8217;s June 2023 equity financing that were exercised in June 2024. The warrants were converted into 367,478 shares of common stock (&#8220;Settlements&#8221;) and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (&#8220;Issued&#8221;). See Note 14 - Stockholders&#8217; Equity and Note 16 - Warrants for further detail.  </ix:footnote>
<ix:footnote xml:lang="en-us" id="f2743343a-4318-4cd7-9fe7-1f7853d6462f">The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fbe5c3633-abc1-4561-8c2d-346405b663d4">Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f6fbcc151-5929-4771-adba-8b2dfa3026fa">The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f094dbb3e-1687-4c38-b1d9-1da7b273debb">As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f68dc4532-adfe-4b08-8152-47796f88bec8">Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="aytu-20240630.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2023-07-01_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-12-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-09-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2022-07-01_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis-ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">aytu:ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:FurnitureAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:FurnitureAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-07-01_2024-06-30_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-FirstThreePercentContributionByEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:FirstThreePercentContributionByEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentAndFivePercentContributionByEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentAndFivePercentContributionByEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentContributionByEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentContributionByEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFivePercentContributionByEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFivePercentContributionByEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-04-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-04-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ConsumerHealthMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AdhdPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AdhdPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementGeographicalAxis-US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementGeographicalAxis-US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_StatementGeographicalAxis-NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:InventoryWriteDownsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:OfficeSpaceInBerwynPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:PrincipalOfficeDenverColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OtherExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OtherExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_CounterpartyNameAxis-TrisKarbinalAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentedTechnologyMember_StatementBusinessSegmentsAxis-AdhdPortfolioMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AdhdPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2022-12-31_BusinessAcquisitionAxis-NeosTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NeosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-12_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-12</xbrli:startDate><xbrli:endDate>2024-06-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-OnOrBeforeJanuary262023Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:OnOrBeforeJanuary262023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262023ButBeforeJanuary262024Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJanuary262023ButBeforeJanuary262024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJanuary262024ButBeforeJanuary262025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember_VariableRateAxis-PrimeRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:AvenueCapitalWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:AvenueCapitalIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-07_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:AvenueCapitalWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-10-25_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:AvenueCapitalWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJanuary262024ButBeforeJanuary262025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-12</xbrli:startDate><xbrli:endDate>2024-06-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-12</xbrli:startDate><xbrli:endDate>2024-06-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-OnOrBeforeJune122025Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:OnOrBeforeJune122025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122025ButOnOrBeforeJune122026Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJune122025ButOnOrBeforeJune122026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122027Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJune122026ButOnOrBeforeJune122027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122028Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJune122026ButOnOrBeforeJune122028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-05-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-14</xbrli:startDate><xbrli:endDate>2024-06-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-17_SubsidiarySaleOfStockAxis-The2020ShelfMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2020ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-04_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-28_SubsidiarySaleOfStockAxis-The2021ShelfMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2021ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_SubsidiarySaleOfStockAxis-The2021ShelfMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2021ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_SubsidiarySaleOfStockAxis-The2024ShelfMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2024ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:TheMarch2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022CommonAndPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-03-07_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022CommonAndPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:TheAugust2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonAndPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:TheAugust2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheACommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsExchangedForPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:CommonWarrantsExchangedForPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-08_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-14</xbrli:startDate><xbrli:endDate>2024-06-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-18_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-18</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aytu:RestrictedStockAndRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aytu:RestrictedStockAndRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PlanNameAxis-The2023EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-13_PlanNameAxis-The2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-13</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-19_PlanNameAxis-Neos2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-19_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-Neos2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-19</xbrli:startDate><xbrli:endDate>2021-04-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-19</xbrli:startDate><xbrli:endDate>2021-04-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-19</xbrli:startDate><xbrli:endDate>2021-04-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-TwoFormerBoardMembersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aytu:TwoFormerBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-12-19_2022-12-19_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-BoardMembersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aytu:BoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-ManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember_TitleOfIndividualAxis-ManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-06_2023-01-06_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">aytu:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-06</xbrli:startDate><xbrli:endDate>2023-01-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityTrancheBPrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityTrancheBPrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:ExitAndDisposalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-ConsumerHealthSegmentMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:ExitAndDisposalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:InventoryWriteDownsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:ExitAndDisposalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:InventoryWriteDownsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-01-31_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-29_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-21_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-02-28_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:PrincipalOfficeDenverColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SabbyLitigationWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:SabbyVolatilityWarrantMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:SabbyVolatilityWarrantMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SabbyLitigationWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:WalleyeOpportunitiesMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-02-22_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:WalleyeOpportunitiesMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:HealightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2016-02-01_2016-02-29_TypeOfArrangementAxis-The2014LicenseAgreementShireMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:The2014LicenseAgreementShireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-01_2024-07-31_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f98c7406b-0164-46c7-a651-4ef0eae9f56d" fromRefs="c117048055 c117048058 c117048060 c117048062 c117048064 c117048066 c117048068 c117048071"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fb35717a1-d432-4eda-915f-5e96136e3a49" fromRefs="c117048657 c117048658"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4" fromRefs="c117048688 c117048689 c117048690 c117048691"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f9b398ddb-deb9-406f-853a-3630953d420d" fromRefs="c117048692 c117048693 c117048694 c117048695"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f8d99ba23-2066-44d9-91b0-1100337ca445" fromRefs="c117048035 c117048036"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f2743343a-4318-4cd7-9fe7-1f7853d6462f" fromRefs="c117048654 c117048655 c117048656"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fbe5c3633-abc1-4561-8c2d-346405b663d4" fromRefs="c117048688 c117048689 c117048692 c117048693 c117048696 c117048697"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f6fbcc151-5929-4771-adba-8b2dfa3026fa" fromRefs="c117048666 c117048667 c117048668"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f094dbb3e-1687-4c38-b1d9-1da7b273debb" fromRefs="c117048656 c117048668"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f68dc4532-adfe-4b08-8152-47796f88bec8" fromRefs="c117048690 c117048694 c117048698"/></ix:resources>
</ix:header></div>
  <div>
    &#160;
  </div>
  <div><hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;<b>UNITED STATES</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#160;&#8203;</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM&#160;<ix:nonNumeric name="dei:DocumentType" contextRef="d_2023-07-01_2024-06-30" id="ixv-22795">10-K</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#160;&#8203;</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;"><tbody><tr style="vertical-align: top; font-size: 9pt;"><td style="width: 9pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> </td><td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: center;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22796">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the fiscal&#160;year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2023-07-01_2024-06-30" id="ixv-22797">June 30, 2024</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">or</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;"><tbody><tr style="vertical-align: top; font-size: 9pt;"><td style="width: 9pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> </td><td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: center;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22798">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: center;">Commission file number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2023-07-01_2024-06-30" id="ixv-22799">001-38247</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
<div style="text-align: center;">
 <img alt="logo01.jpg" src="logo01.jpg"/>
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(Exact name of registrant as specified in its charter)&#160;&#8203;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2023-07-01_2024-06-30" id="ixv-22800">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 2%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2023-07-01_2024-06-30" id="ixv-22801">47-0883144</ix:nonNumeric></b></p> </td></tr>
<tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(State or other jurisdiction of incorporation or organization)</p> </td><td style="vertical-align: top; width: 2%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(I.R.S. Employer Identification No.)</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b></b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2023-07-01_2024-06-30" id="ixv-75"><b>7900 East Union Avenue,&#160;</b><b>Suite</b>&#160;<b>920</b></ix:nonNumeric><b>,&#160;</b><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2023-07-01_2024-06-30" id="ixv-22802">Denver</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2023-07-01_2024-06-30" id="ixv-22803">Colorado</ix:nonNumeric></b></p> </td><td style="vertical-align: middle; width: 2%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2023-07-01_2024-06-30" id="ixv-22804">80237</ix:nonNumeric></b></p> </td></tr>
<tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(Address of principal executive offices)</p> </td><td style="vertical-align: middle; width: 2%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: top; width: 49%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(Zip Code)</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2023-07-01_2024-06-30" id="ixv-22805">720</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2023-07-01_2024-06-30" id="ixv-22806">437-6580</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8203;</b>Title of each class</p> </td><td style="vertical-align: top; width: 1%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 32%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#8203;Trading Symbol(s)</p> </td><td style="vertical-align: top; width: 1%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Name of each exchange on which registered</p> </td></tr>
<tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="vertical-align: top; width: 33%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2023-07-01_2024-06-30" id="ixv-22807">Common Stock, par value $0.0001 per share</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 1%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td><td style="vertical-align: top; width: 32%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2023-07-01_2024-06-30" id="ixv-22808">AYTU</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 1%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td><td style="vertical-align: top; width: 33%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2023-07-01_2024-06-30" id="ixv-22809">Nasdaq</ix:nonNumeric> Capital&#160;Market</b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes &#9744;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2023-07-01_2024-06-30" id="ixv-22810">No</ix:nonNumeric> &#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes &#9744; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2023-07-01_2024-06-30" id="ixv-22811">No</ix:nonNumeric>&#160;&#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by a check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2023-07-01_2024-06-30" id="ixv-22812">Yes</ix:nonNumeric> &#9746;&#160;No&#160;&#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2023-07-01_2024-06-30" id="ixv-22813">Yes</ix:nonNumeric> &#9746;&#160;No&#160;&#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt;">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="vertical-align: bottom; width: 20%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">Large accelerated filer</p> </td><td style="vertical-align: bottom; width: 5%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#9744;</p> </td><td style="vertical-align: top; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: bottom; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">Accelerated filer</p> </td><td style="vertical-align: bottom; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#9744;</p> </td></tr>
<tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="vertical-align: bottom; width: 20%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2023-07-01_2024-06-30" id="ixv-22814">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align: middle; width: 5%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#9746;</p> </td><td style="vertical-align: top; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: bottom; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">Smaller reporting company</p> </td><td style="vertical-align: bottom; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22815">&#9746;</ix:nonNumeric></p> </td></tr>
<tr style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><td style="vertical-align: bottom; width: 20%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: bottom; width: 5%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: top; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="vertical-align: bottom; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">Emerging growth company</p> </td><td style="vertical-align: bottom; width: 25%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22816">&#9744;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22817">&#9744;</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22818">&#9744;</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-07-01_2024-06-30" id="ixv-22819">&#9744;</ix:nonNumeric> No &#9746;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">As of December 29, 2023, the aggregate market value of common stock held by non-affiliates of the registrant&#160;was $<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2023-12-29" id="ixv-22820">10,712,951</ix:nonFraction>&#160;based on the last reported sales price of $2.84 as quoted on the Nasdaq Capital Market on such date.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 5pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;">As of September 16, 2024, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2024-09-16" id="ixv-22821">6,148,993</ix:nonFraction>&#160;shares of common stock outstanding.</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#160;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
  <div class="hf-row">
   &#160;
  </div>
 </div>
</div></div>
  <div>
    &#160;
  </div>
  <div>
    &#160;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" title="toc" href="#"></a>AYTU BIOPHARMA, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 10-K</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">TABLE OF CONTENTS</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>&#8203;</b></p> </td>
      <td style="vertical-align: middle; width: 951px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
      <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td colspan="2" rowspan="1" style="vertical-align: middle; width: 68px;"><a href="#cautionary" style="-sec-extract:exhibit;">Cautionary Information Regarding Forward-Looking Statements</a></td>
      <td style="vertical-align: bottom; width: 4.3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#cautionary">3</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td colspan="2" rowspan="1" style="vertical-align: middle; width: 68px;"><a href="#summary" style="-sec-extract:exhibit;">Summary of Risk Factors</a></td>
      <td style="vertical-align: bottom; width: 4.3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#summary">4</a></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;">&#160;</td>
      <td style="vertical-align: middle; width: 951px;">&#160;</td>
      <td style="vertical-align: bottom; width: 4.3%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#part1" style="-sec-extract:exhibit;"><b>PART&#160;I</b></a></td>
      <td style="vertical-align: middle; width: 951px;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">&#160;</p> </td>
      <td style="vertical-align: bottom; width: 4.3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#part1">6</a></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1" style="-sec-extract:exhibit;">&#8203;Item 1.</a></p> </td>
      <td style="vertical-align: middle; width: 951px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1" style="-sec-extract:exhibit;">&#8203;Business</a></p> </td>
      <td style="vertical-align:middle;width:4.3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;<a class="tocPGNUM" href="#item1">6</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1a" style="-sec-extract:exhibit;">&#8203;Item&#160;1A.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1a" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item1a">19</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1b" style="-sec-extract:exhibit;">&#8203;Item&#160;1B.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1b" style="-sec-extract:exhibit;">Unresolved Staff Comments</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item1b">47</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1c" style="-sec-extract:exhibit;">&#8203;Item 1C.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item1c" style="-sec-extract:exhibit;">Cybersecurity</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item1c">47</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item2" style="-sec-extract:exhibit;">&#8203;Item 2.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item2" style="-sec-extract:exhibit;">Properties</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item2">49</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item3" style="-sec-extract:exhibit;">&#8203;Item 3.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item3" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item3">49</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item4" style="-sec-extract:exhibit;">&#8203;Item 4.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item4" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item4">50</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;">&#160;</td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align:middle;width:4.3%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#part2" style="-sec-extract:exhibit;"><b>PART&#160;II</b></a></td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align:middle;width:4.3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#part2">51</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#item5" style="-sec-extract:exhibit;">Item 5.</a></td>
      <td style="vertical-align: middle; width: 951px;"><a href="#item5" style="-sec-extract:exhibit;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
      <td style="vertical-align: middle; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item5">51</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item6reserved" style="-sec-extract:exhibit;">&#8203;Item 6.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item6reserved" style="-sec-extract:exhibit;">[Reserved]</a></p> </td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><a class="tocPGNUM" href="#item6reserved">52</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item7" style="-sec-extract:exhibit;">&#8203;Item 7.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item7" style="-sec-extract:exhibit;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item7">52</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#item7a" style="-sec-extract:exhibit;">Item 7A.</a></td>
      <td style="vertical-align: top; width: 951px;"><a href="#item7a" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item7a">62</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#item8" style="-sec-extract:exhibit;">Item 8.</a></td>
      <td style="vertical-align: top; width: 951px;"><a href="#item8" style="-sec-extract:exhibit;">Financial Statements and Supplementary Data</a></td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item8">63</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9" style="-sec-extract:exhibit;">&#8203;Item 9.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9" style="-sec-extract:exhibit;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p> </td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item9">106</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9a" style="-sec-extract:exhibit;">&#8203;Item 9A.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9a" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item9a">106</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9b" style="-sec-extract:exhibit;">&#8203;Item 9B.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9b" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item9b">108</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9c" style="-sec-extract:exhibit;">&#8203;Item 9C.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item9c" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item9c">108</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;">&#160;</td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align:middle;width:4.3%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#part3" style="-sec-extract:exhibit;"><b>PART&#160;III</b></a></td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align:middle;width:4.3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#part3">109</a></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item10" style="-sec-extract:exhibit;">&#8203;Item 10.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item10" style="-sec-extract:exhibit;">Directors, Executive Officers and Corporate Governance</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item10">109</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item11" style="-sec-extract:exhibit;">&#8203;Item 11.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item11" style="-sec-extract:exhibit;">Executive Compensation</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item11">113</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item12" style="-sec-extract:exhibit;">&#8203;Item 12.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item12" style="-sec-extract:exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item12">117</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item13" style="-sec-extract:exhibit;">&#8203;Item 13.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item13" style="-sec-extract:exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
      <td style="vertical-align: bottom; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item13">119</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item14" style="-sec-extract:exhibit;">&#8203;Item 14.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item14" style="-sec-extract:exhibit;">Principal Accountant Fees and Services</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item14">120</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;">&#160;</td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align:middle;width:4.3%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"><a href="#part4" style="-sec-extract:exhibit;"><b>PART&#160;IV</b></a></td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align:middle;width:4.3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><a class="tocPGNUM" href="#part4">121</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item15" style="-sec-extract:exhibit;">&#8203;Item 15.</a></p> </td>
      <td style="vertical-align: top; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item15" style="-sec-extract:exhibit;">Exhibits and Financial Statement Schedules</a></p> </td>
      <td style="vertical-align: top; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item15">121</a></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 68px;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item16" style="-sec-extract:exhibit;">&#8203;Item 16.</a></p> </td>
      <td style="vertical-align: middle; width: 951px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item16" style="-sec-extract:exhibit;">Form 10&#8211;K Summary</a></p> </td>
      <td style="vertical-align: middle; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#item16">126</a></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 68px;">&#160;</td>
      <td style="vertical-align: middle; width: 951px; text-align: center;">&#160;</td>
      <td style="vertical-align: middle; width: 4.3%; text-align: center;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td colspan="2" rowspan="1" style="vertical-align: middle; width: 68px;"><a href="#sigs" style="-sec-extract:exhibit;"><b>SIGNATURES</b></a></td>
      <td style="vertical-align: middle; width: 4.3%; text-align: center;"><a class="tocPGNUM" href="#sigs">127</a></td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        2
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="cautionary" title="cautionary" href="#"></a>CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This Annual Report on Form&#160;10-K&#160;for the year ended June 30, 2024, (&#8220;Form 10-K&#8221;&#160;or &#8220;Annual Report&#8221;), includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;suggest,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation, statements regarding the markets for our approved products and our plans for our approved products, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, the potential future commercialization of our product candidates, our anticipated future cash position and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including without limitation the risks described in&#160;Part&#160;I, Item&#160;1A, <i>Risk Factors</i> below and elsewhere in this&#160;Annual Report. These risks are not exhaustive. Other sections of this Annual Report include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Unless otherwise indicated or unless the context otherwise requires, references in this Form</i>&#160;<i>10-K to the </i>&#8220;<i>Company,</i>&#8221;<i> </i>&#8220;<i>Aytu,</i>&#8221;<i> </i>&#8220;<i>we,</i>&#8221;<i> </i>&#8220;<i>us,</i>&#8221;<i> or </i>&#8220;<i>our</i>&#8221;<i> are to Aytu BioPharma,</i>&#160;<i>Inc. and its wholly owned subsidiaries.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This Form 10-K refers to registered trademarks that we&#160;currently own or license, such as Aytu, Aytu BioPharma, Aytu RxConnect, Neos Therapeutics, Adzenys, Adzenys ER, Adzenys XR-ODT, Cotempla, Cotempla XR-ODT, Karbinal, Poly-Vi-Flor&#160;and Tri-Vi-Flor, which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-K also contains trademarks, service marks, copyrights and trade names of other companies, which are the property of their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-K may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We obtained statistical data, market and product data, and forecasts used throughout this Form&#160;10-K from market research, publicly available information and industry publications. While we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified the data, and we do not make any representation as to the accuracy of the information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="summary" title="summary" href="#"></a>SUMMARY OF RISK FACTORS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following list summarizes what we believe to be the principal risks relevant to our company. The following summary is further elaborated on by the full text of the risk factors provided in Part&#160;I, Item&#160;1A, <i>Risk Factors&#160;</i>of this Annual Report. All capitalized terms in this section not defined herein shall have the meanings given to them elsewhere in this Annual Report. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Our Business and Financial Position</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have incurred losses to date and can give no assurance of profitability.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have not established sources of ongoing revenue sufficient to cover operating costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We may need to raise additional funding, which may not be available on acceptable terms, or at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are currently engaged in discussions with various parties regarding potential strategic transactions and there can be no assurance that these discussions will result in the pursuit or consummation of any potential transaction.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have indefinitely suspended development of our AR101 (enzastaurin) clinical development program and shifted our strategic focus towards accelerating the growth of our commercial business. If we fail to execute successfully on this reprioritized strategic focus, our business, results of operations and financial condition could be materially and adversely affected.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have been and, in the future, may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Commercialization</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are heavily dependent on the commercial success of our commercial products. To date, we have not generated sufficient revenues from the sales of these products to achieve companywide profitability and we may never achieve or maintain profitability.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We rely on third parties to manufacture certain products, and third-party manufacturing risks and inefficiencies may result in costs and delays that prevent us from successfully commercializing products and adversely affect our ability to produce our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">If our contract manufacturer fails to manufacture our ADHD products in sufficient quantities and at acceptable quality and pricing levels, or fails to obtain adequate DEA quotas for controlled substances, or to fully comply with cGMP regulations, we may face delays in the commercialization of these products, or be unable to meet market demand, and may be unable to generate potential revenues.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our financial results will depend on the acceptance among clinicians, third-party payors and the medical community of our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">If third-party payors do not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell our products at a profit, our ability to sell those products and our results of operations will be harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Adzenys and Cotempla contain controlled substances, and their manufacture, use, sale, importation, exportation, prescribing and distribution are subject to regulation by the DEA.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are dependent on our relationships and license agreements, and we rely on the intellectual property rights granted to us pursuant to the license agreements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The expiration or loss of patent protection may adversely affect our future revenues and operating results.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to compete may decline if we do not adequately protect or enforce our intellectual property rights.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Our Organization, Structure and Operations</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our efforts to expand and transform our businesses may require significant investments; if our strategies are unsuccessful, our business, results of operations and/or financial condition may be materially adversely affected.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We may have difficulties integrating acquired businesses and as a result, our business, results of operations and/or financial condition may be materially adversely affected.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In fiscal 2024, the great majority of our gross revenue and gross accounts receivable were due to three significant customers, the loss of which could materially and adversely affect our results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our accounts receivable subjects us to credit risk.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to the Company.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Public concern over the abuse of medications that are controlled substances, including increased legislative, legal and regulatory action, could negatively affect our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Certain of our stockholders own a significant percentage of our stock and their interests may conflict with yours.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="part1" title="part1" href="#"></a>PART</b>&#160;<b>I</b></p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item1" title="item1" href="#"></a>ITEM</b>&#160;<b>1. BUSINESS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Company Overview</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Aytu BioPharma, Inc. (&#8220;Aytu,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a&#160;pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (&#8220;Neos&#8221;) in March 2021 (the &#8220;Neos Acquisition&#8221;), the Company changed its name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market&#160;under the ticker symbol &#8220;AYTU.&#8221; Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We operate through two business segments: (i) the Rx segment, consisting of prescription pharmaceutical products sold primarily through third party wholesalers (the &#8220;Rx Segment&#8221;) and (ii) the consumer health segment, which consists of various consumer healthcare products sold directly to consumers&#160;through certain e-commerce platforms (the &#8220;Consumer Health Segment&#8221;).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Rx Segment primarily consists of two product portfolios. The first consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (&#8220;Adzenys&#8221;) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets&#160;(&#8220;Cotempla&#8221;) for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;) (the &#8220;ADHD Portfolio&#8221;). The second consists primarily of Karbinal&#174; ER (carbinoxamine maleate extended-release oral suspension) (&#8220;Karbinal&#8221;), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the &#8220;Pediatric Portfolio&#8221;).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment&#160;consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health, and general wellness, commercialized through direct mail and e-commerce marketing channels. To date, the Consumer Health Segment has generated negative cash flows. We began to wind down the Consumer Health Segment in fiscal 2024. During the first quarter of fiscal&#160;2025, we completed the wind down of operations and entered into a definitive agreement to divest the&#160;Consumer Health Segment to a private, e-commerce focused company (the &#8220;Consumer Health Divestiture&#8221;).&#160;The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for us&#160;to receive up to $0.5 million of revenue-based royalty payments on future sales of former Consumer Health Segment&#160;products. We expect the savings realized from the strategic shift away from the Consumer Health business, coupled with incremental margin improvements expected from the previously announced&#160;closure of our&#160;Grand Prairie, Texas manufacturing site, to significantly enhance our operating results&#160;and drive stockholder value.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have incurred significant losses in each year since inception. Our net loss was $15.8&#160;million for the year ended June 30, 2024, and as of June 30, 2024, we had an accumulated deficit of $320.0&#160;million. We expect to continue to incur significant expenses in connection with our ongoing activities, although we do expect to become profitable through the continued growth of our commercial business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In light of our own business activities and external developments in the biotechnology and biopharmaceutical industries, Aytu management and our board of directors&#160;(the &#8220;Board&#8221; or the &#8220;Board of Directors&#8221;) regularly reviews our performance, prospects and risks such as the potential impact to our business resulting from the Company&#8217;s competitive landscape (i.e., entry of generic competitors, payer pressures, new branded entrants, etc.). These reviews have included consideration of potential partnerships, collaborations, and other strategic transactions such as acquisitions or divestitures of programs or technology to enhance stockholder value. Aytu&#8217;s management and Board continues to evaluate potential strategic transactions and business combinations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Recent Business Development</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of our ongoing strategic evaluation and go-forward operating plan, we continue to prioritize&#160;growing our Rx Segment given the encouraging prescription trends for our ADHD Portfolio&#160;and the current market trends supporting our products&#8217; growth. We believe focusing resources on our most profitable, growing products provides the most effective pathway to achieve&#160;companywide profitability and continued growth. As part of our plan, we began winding down the Consumer Health Segment in fiscal 2024 and completed the&#160;wind down of operations and entered into a definitive agreement to effect the Consumer Health Divestiture in the first quarter of fiscal 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For fiscal 2024, our Rx Segment recorded net revenue of $65.2&#160;million. During the year, the ADHD market continued to encounter&#160;several supply chain interruptions, causing a shortage of medications for patients receiving stimulant prescriptions for the treatment of ADHD. We were able to continue to&#160;increase the production of our ADHD medications, Adzenys&#160;and Cotempla, to provide patients with alternative solutions to products that have experienced supply&#160;interruptions. As a result, we recorded the highest prescription levels for both Adzenys and Cotempla during fiscal&#160;2024,&#160;resulting in $57.8&#160;million of net revenue for our ADHD Portfolio, the highest achieved in our history. We saw a reduction in net revenue&#160;from our Pediatric Portfolio products, largely due to payor changes impacting coverage and recusing prescriptions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">To reduce the costs associated with the manufacture of Adzenys and Cotempla we transferred the manufacturing of these products to a United States-based third-party manufacturer in the fourth quarter of fiscal 2024.&#160;Prior to this, we manufactured these products in our facility in Grand Prairie, Texas.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As an additional result of focusing on building the portfolio of revenue-generating products and generating profitability, in&#160;fiscal 2023 we&#160;indefinitely suspended active development of our&#160;clinical development programs including AR101 (enzastaurin) and terminated our&#160;license agreements relating to Healight and NT0502 (N-desethyloxybutynin).&#160;AR101 is a development-stage asset we had been developing as an investigational treatment for Vascular Ehlers-Danlos Syndrome (&#8220;VEDS&#8221;), a rare connective tissue disorder for which there are no approved treatments. AR101 has received Orphan Drug Designation from both the United States Food and Drug Administration&#160;(&#8220;FDA&#8221;)&#160;and from the European Commission, thus making AR101 eligible for market exclusivity upon product approval. AR101 also received Fast Track Designation from the FDA given the urgent, unmet need in VEDS. We do not expect the development of AR101 to advance until we are able to either fund development through operating cash flows, or through an out-license or sale to a strategic partner as we focus our resources on our commercial operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Debt and Equity Financings</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Eclipse Agreement</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In June 2024, we and certain of our subsidiaries&#160;entered into a Consent, Joinder and Amendment No. 5 (the&#160;&#8220;Eclipse Amendment No. 5&#8221;)&#160;to the loan and security agreement dated October 2, 2019, as amended by Amendment No. 1, dated March 19, 2021, Amendment No. 2, dated January 26, 2022, Amendment No. 3, dated June 1, 2022, Amendment No. 4 dated March 24, 2023, and the Eclipse Amendment No. 5 (together the &#8220;Eclipse Agreement&#8221;) with Eclipse Business Capital LLC (&#8220;Eclipse&#8221;), as agent, and the lenders party thereto (agent and such lenders, collectively, the &#8220;Eclipse Lender&#8221;). Under the Eclipse Amendment No. 5, we have two loan agreements, a term loan&#160;(the &#8220;Eclipse Term Loan&#8221;) and a revolving credit facility (the &#8220;Eclipse Revolving Loan&#8221;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Eclipse Term Loan&#160;consists of a principal amount of $13.0 million, at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (&#8220;SOFR&#8221;) plus 7.0%, with a&#160;four-year term and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of&#160;$5.6 million to be repaid on June 12, 2028, the maturity date. We used&#160;the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below&#160;to repay&#160;in full a $15.0 million term loan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Eclipse Revolving Loan&#160;allows us to borrow up to $14.5 million at an interest rate of SOFR plus 4.5%. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan&#160;amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan&#160;remains subject to a borrowing base and reserve, and availability blockage requirements and the maturity date, as amended, is June 12, 2028.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><i>Equity Financings</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In June 2023, we raised gross proceeds of $4.0 million from the issuance of (i) 1,743,695 shares of our common stock, and (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of common stock (the &#8220;June 2023 Pre-Funded Warrants&#8221;) and (iii), accompanying Tranche A warrants to purchase 2,173,912 shares of common stock at an exercise price of $1.59 (the &#8220;Tranche A Warrants&#8221;), (iv) and accompanying Tranche B warrants to purchase 2,173,912 shares of common stock at an exercise price of $1.59 (the &#8220;Tranche B&#160;Warrants&#8221;). We received&#160;$3.4 million in proceeds net of underwriting fees and other expenses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In June 2024, the Tranche B Warrants&#160;were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 &#8220;pre-funded&#8221; warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the &#8220;Tranche B Pre-Funded Warrants&#8221;). We used a portion of these proceeds as part of the $15.0 million term loan repayment described above.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Commercial Business Overview</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We operate through two business segments (i) the Rx Segment, consisting of various prescription pharmaceutical products sold through third parties, and (ii) the Consumer Health Segment, which consists of various consumer health products sold directly to consumers. We completed the wind down of the Consumer Health Segment and entered into a definitive agreement to effect the Consumer Health Divestiture in the first quarter of fiscal&#160;2025. We generate revenue by selling our products through third party intermediaries in our marketing channels as well as directly to our customers. We transitioned the manufacturing of&#160;our ADHD products to a third-party manufacturer during the fourth quarter of fiscal 2024 and continue to use third party manufacturers for all&#160;other products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Rx Segment</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Rx Segment consists of our ADHD Portfolio and our Pediatric Portfolio. Our prescription products are sold primarily&#160;in the United States and are distributed through multiple channels, including sales to pharmaceutical wholesalers, distributors and pharmacies, using third-party logistics enterprises.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ADHD products are extended-release (&#8220;XR&#8221;) medications formulated in patient-friendly, orally disintegrating tablets (&#8220;ODT&#8221;) that utilize the internally developed microparticle modified-release drug delivery technology platform. Products containing amphetamine or methylphenidate are the most commonly prescribed medications in the United States for the treatment of ADHD. Adzenys (for patients six years of age and above) and Cotempla (for patients six to seventeen years of age) are the first and only FDA-approved amphetamine and methylphenidate extended-release, orally disintegrating tablets, respectively, for the treatment of ADHD.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our prescription Pediatric Portfolio includes Karbinal, an extended-release carbinoxamine (a first-generation antihistamine) suspension indicated to treat numerous allergic conditions for patients two years of age and above and Poly-Vi-Flor&#174; and Tri-Vi-Flor&#174;, two complementary prescription fluoride-based multi-vitamin product lines containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency (Karbinal, Poly-Vi-Flor and Tri-Vi-Flor are collectively the &#8220;Pediatric Portfolio&#8221;). These products serve established pediatric markets and offer distinct clinical features and patient benefits.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We commercialize our Rx Portfolio through our internal commercial organization that includes approximately forty&#160;sales territories for our ADHD Portfolio and approximately five&#160;sales territories for our Pediatric Portfolio.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Aytu RxConnect&#8482; patient support program operates through a network of approximately 1,000 pharmacies to offer affordable, predictable copays and hassle-free availability to all commercially insured patients, regardless of their individual insurance plan. In addition, RxConnect seeks to significantly reduce the challenges and&#160;frustrations that health care professionals and their office staff can face when prescribing branded medications, including our medications, for their patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In July 2023, we entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd&#160;(&#8220;Medomie&#8221;), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. We will supply Adzenys and Cotempla to Medomie, who will be responsible for seeking local regulatory approvals and marketing authorizations for each product. This&#160;agreement&#160;represents Aytu&#8217;s first international commercial agreement&#160;for Adzenys and Cotempla.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Consumer Health Segment</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Consumer Health Segment was&#160;dedicated to commercializing safe and effective &#8220;over-the-counter&#8221; (&#8220;OTC&#8221;) medicines, personal care products, and dietary supplements to improve health and vitality. Our core products competed in categories such as hair loss, digestive health, urological health, diabetes management, and allergy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment sold&#160;directly to consumers primarily in the United States through e-commerce platforms, including branded websites and Amazon.com, which utilized marketing strategies focused on search engine optimization, search marketing and affiliate marketing. Additionally, the segment sold&#160;products through direct mail solicitations and advertisements, allowing consumers to purchase directly through business reply mail, through call centers, or online with shipment directly to their homes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In fiscal 2023, we announced we would wind down&#160;the Consumer Health Segment. We completed the wind down of the Consumer Health Segment and entered into a definitive agreement to effect the Consumer Health Divestiture in the first quarter of fiscal 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Development Portfolio </b>&#8211;<b> AR101</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In April&#160;2021, we entered into an asset purchase agreement with Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, and Rumpus Vascular, LLC (together &#8220;Rumpus&#8221;) pursuant to which we acquired commercial global licenses, relating primarily to the pediatric-onset rare disease development asset enzastaurin, or AR101. AR101 is initially being developed&#160;for the treatment of VEDS with the potential to treat other connective tissue disorder diseases such as Marfan&#8217;s syndrome.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">AR101 is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways. AR101 has been studied in more than 3,300 patients across a range of solid and hematological tumor types in trials previously conducted by Eli Lilly &amp; Company. Harry &#8220;Hal&#8221; C. Dietz III, M.D. developed the first preclinical model that mimics the human condition and recapitulates VEDS, and this model serves as the basis for the plausible clinical benefit and rationale for conducting a clinical trial with AR101 in VEDS. This novel knock-in mouse model has the same genetic mutation most prevalent in VEDS patients and is representative of the human condition in both the timing and location of VEDS-related vascular events. The model has generated identical structural histology and mechanical characteristics, and unbiased findings demonstrated that vascular structure alone does not lead to vascular events. Objective comparative transcriptional profiling by high-throughput RNA sequencing of the aorta displayed a molecular signature for excessive PKC/ERK cell signaling that is the purported driver of disease. PKC inhibitors proved efficacious in multiple pre-clinical and murine&#160;models and indeed prevented death due to vascular rupture.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have secured exclusive global rights to AR101 in the field of connective tissue disorders with the initial license covering VEDS. AR101 is protected by a suite of pending patents being pursued in major markets globally which have been licensed from The Johns Hopkins University (&#8220;Johns Hopkins&#8221;) and have an earliest priority date of March 2017. In December 2021, the FDA granted Orphan Drug Designation (&#8220;ODD&#8221;) to AR101 for the treatment of EDS, inclusive of VEDS, allowing for seven years of marketing exclusivity in the United States. The FDA has cleared the IND application for AR101, although, we do not expect to advance development of AR101 until we are able to either fund development through operating cash flows or through an out-license or sale to a strategic partner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Strategy</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our goal is to become a leading pharmaceutical company that improves the lives of patients. We will do this by employing a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics. Our primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including ADHD.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our strategic priorities are to continue to increase revenues from our Rx Segment and enhance our financial performance through operational and manufacturing efficiencies and portfolio prioritization. Specifically, we intend to:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">continue&#160;to grow our commercial branded, revenue-generating products, by increasing product sales and improving patient access. Our primary commercial objective is to drive revenue growth of our brands, which consist primarily of Adzenys, Cotempla, Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. We expect to increase market share using our internal commercial organization and leveraging our advanced analytics platform to increase prescribing our medicines;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">leverage our novel Aytu RxConnect patient support platform, which is designed to reduce access barriers to medicines facing patients and HCPs by providing coverage for all commercially insured patients, regardless of their individual insurance plan, thus establishing an affordable and predictable monthly co-pay for patients, and eliminating many of the hassles facing HCPs and their staffs by improving availability of Aytu products at participating pharmacies; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">improve gross margins for our ADHD product franchise through the manufacturing transfer of Adzenys and Cotempla to a contract manufacturing organization, a transition that was completed in the fourth quarter of fiscal 2024.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe our history of acquiring companies and in-licensing and acquiring products and pipeline assets, along with our success in building out commercial organizations and executing product growth strategies, is a distinct competitive advantage. Our transactional adeptness and execution orientation enable us to continue to seek growth opportunities through both organic growth and opportunistic in-licensing or strategic acquisitions. Further, our commercial infrastructure and advanced analytics capability is scalable and lends itself to additional on-market assets and future product candidates that fit within our commercial capabilities and infrastructure. As such, in the near term, we may seek to leverage our commercial model and infrastructure by expanding our commercial portfolio with external product opportunities as we have done since our inception.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Products and Markets</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Prescription Products: ADHD Portfolio</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>ADHD Market and Treatment Options</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">ADHD is a neurobehavioral disorder characterized by a persistent pattern of inattention and/or hyperactivity/impulsivity that interferes with functioning and/or development. ADHD can have a profound impact on an individual&#8217;s life, causing disruption at school, work, home and in relationships. It is one of the most common developmental disorders in children and often persists into adulthood. The Centers for Disease Control and Prevention (&#8220;CDC&#8221;) reported that six million children in the United States ages 3 to 17 had previously received an ADHD diagnosis&#160;between 2016-2019, up 36% since 2003. Current ADHD treatment guidelines recommend a multi-faceted approach that uses medications in conjunction with behavioral interventions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In 2023, approximately 96.0&#160;million prescriptions for medications with ADHD labeling were written in the United States, generating $27.4&#160;billion in sales. Approximately 89% of these prescriptions were for stimulant medications, such as amphetamine and methylphenidate, which are and have remained the standard of care for several decades. The market for ADHD medications outside of the United States is less developed, but we believe it will continue to grow as recognition and awareness of the disorder increase.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Extended-release, or long-acting, dosage forms of stimulant medications are the standard of care for treating ADHD, making up approximately 59% of ADHD prescriptions. The most prescribed extended-release medications for ADHD, Adderall XR&#174; and Concerta&#174; (and each of their generic equivalents), are long-acting versions of previously short-acting amphetamine and methylphenidate medications, respectively. Most of these extended-release dosage forms allow for once-daily dosing in the morning, which eliminates the need to re-dose during the day. Our products, Adzenys XR-ODT and Cotempla XR-ODT, are extended-release orally disintegrating tablets that allow for once-daily dosing based upon our internally developed proprietary microparticle delivery technology and are the only approved extended-release orally disintegrating tablet formulations of amphetamine and methylphenidate for the treatment of ADHD.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There is significant competition in the ADHD market, including from well-established companies, many of whom have substantially greater financial, technical and commercial resources than we do, and entrenched existing ADHD products. For example:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Extended-release amphetamine products are currently marketed in the United States by (i) Takeda Pharmaceutical Company Limited under the brand names Adderall XR&#174;, Vyvanse&#174;&#160;and Mydayis&#174;&#160;and (ii) Tris Pharma, Inc. (&#8220;Tris&#8221;), under the brand names Dyanavel&#174;&#160;XR, Dyanavel&#174;&#160;XR tablets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Extended-release methylphenidate products are marketed in the United States by (i) Janssen Pharmaceuticals, Inc. under the brand name Concerta&#174;, (ii) Tris under the brand names Quillivant XR&#174;&#160;and QuilliChew ER&#174;, (iii) Rhodes Pharmaceuticals LP under the brand name Aptensio XR&#174;, (iv) Ironshore Pharmaceuticals Inc. under the brand name Jornay PM&#174;, (v) Alora Pharmaceuticals under the name Methylphenidate HCl ER 72 mg Tablets, (vi) Novartis under the brand names Focalin XR&#174;&#160;and Ritalin LA&#174;&#160;and (vii) Azstarys&#174;, a product developed by KemPharm (now Zevra Therapeutics) and sold by Corium; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A non-stimulant treatment for ADHD was approved by the FDA and commercially launched by Supernus in the United States in 2021 is being sold under the brand name Qelbree&#174;.&#160;Other branded and generic non-stimulant treatments remain available in the United States but are no longer promoted.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Further, makers of branded drugs could also enhance their own formulations in a manner that competes with our enhancements of these drugs. We are also aware of efforts by several pharmaceutical companies with ADHD medications in clinical development, including Cingulate Therapeutics, NLS Pharma, Tris Pharma and Neurovance, a subsidiary of Otsuka Pharmaceutical Co., Ltd.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>ADHD Product Portfolio Overview</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our modified-release drug delivery technology platform has enabled us to create extended-release ODT formulations of amphetamine and methylphenidate. This was achieved by developing an extended-release profile that allows for once daily dosing and an ODT formulation that allows for easier administration and ingestion and twelve-hour duration of action.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Adzenys and Cotempla are the first and only XR-ODT products for the treatment of ADHD. These XR-ODT products offer unique attributes to ADHD patients and caregivers, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ease of administration and ingestion because they disintegrate rapidly in the mouth and may be taken without water;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">taste-masking of bitter ADHD medications, with pleasant-tasting flavor; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">prevention of &#8220;cheeking,&#8221;&#160;the practice of hiding medication in the mouth and later spitting it out rather than swallowing it.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Adzenys XR-ODT: Amphetamine XR-ODT for the treatment of ADHD</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Adzenys is approved by the FDA for the treatment of ADHD in patients six years and older and is the first FDA-approved amphetamine XR-ODT for the treatment of ADHD. The New Drug Application (&#8220;NDA&#8221;) for Adzenys&#160;relies on the efficacy and safety data that formed the basis of FDA approval for the reference listed drug, Adderall XR, 30 mg, together with bioequivalence, bioavailability, and aggregate safety data from the Adzenys&#160;clinical program. Adzenys&#160;contains amphetamine loaded onto a mixture of immediate-release and polymer-coated delayed-release resin particles, which are formulated and compressed into an ODT along with other tableting excipients using our patented Rapidly Disintegrating Ionic Masking (&#8220;RDIM&#8221;) technology. The result is amphetamine with an <i>in vivo</i> extended-release profile delivered through a tablet that quickly disintegrates in the mouth without the need for water. Adzenys&#160;is available in 30-day supply, child-resistant blister packs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The suite of composition-of-matter patents for Adzenys&#160;are scheduled to expire in 2026 and 2032. These patents are listed in the FDA&#8217;s publication of approved drug products with therapeutic equivalence evaluations (the &#8220;Orange Book&#8221;). In addition, we entered into a settlement agreement with Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;) (acquired by Teva Pharmaceutical Industries), which resolved all ongoing litigation involving Adzenys patents and Actavis&#8217; ANDA with the FDA for a generic version of Adzenys. Under the agreement with Actavis, Actavis has the right to manufacture and market its approved generic version of Adzenys&#160;under the ANDA beginning on September 1, 2025, or earlier under certain circumstances.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In conjunction with the approval of the Adzenys&#160;NDA, the FDA has required us to conduct certain clinical studies in preschool (age four to five years) children with ADHD as a post-marketing requirement. A pharmacokinetic study in this population was completed in 2018, and we are in discussions with the FDA to further clarify the design protocols required to conduct the remaining studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cotempla XR-ODT: Methylphenidate XR-ODT for the treatment of ADHD</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The FDA approved Cotempla for the treatment of ADHD in patients six to seventeen years old. The Cotempla&#160;NDA relies on the efficacy and safety data that formed the basis of FDA approval for the reference listed drug, Metadate CD&#174;, together with bioavailability/bioequivalence data and efficacy/safety data from the Cotempla&#160;clinical program. The results of the Cotempla&#160;Phase 3 clinical efficacy and safety trial showed a statistically significant improvement in ADHD symptom control compared to placebo across the school day. Onset of effect was observed within one-hour post-dose and persisted through 12 hours. No serious adverse events were reported during the study, and the adverse event profile was consistent with the drug&#8217;s mechanism of action.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cotempla contains methylphenidate loaded onto a mixture of immediate-release and polymer-coated delayed-release resin particles, which are formulated and compressed into an ODT along with other tableting excipients using our RDIM technology. The result is methylphenidate with an <i>in vivo</i> extended-release profile delivered through a tablet that quickly disintegrates in the mouth. Cotempla&#160;is available in 30-day supply, child-resistant blister packs. Cotempla&#160;is the first FDA-approved methylphenidate XR-ODT for the treatment of ADHD.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We hold composition-of-matter patents in the United States&#160;which we expect will provide Cotempla intellectual property protection until 2032, and a method-of-use patent was issued which&#160;extends protection to&#160;2038. These patents are listed in the Orange Book. In addition, we entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;), which resolved all ongoing litigation involving the Cotempla patents and Teva&#8217;s ANDA with the FDA for a generic version of Cotempla. Under the agreement with Teva, we&#160;granted Teva the right to manufacture and market its approved generic version of Cotempla&#160;under the ANDA beginning on July 1, 2026, or earlier under certain circumstances.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In conjunction with the approval of the Cotempla&#160;NDA, the FDA required us to perform additional clinical studies in preschool (age four to five years) children with ADHD as a post-marketing requirement. A pharmacokinetic study in this population was completed in 2019. In light of a new draft guidance for industry that was published in May 2019, &#8220;Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry,&#8221; we remain in discussions with the FDA to gain concurrence on the design of the protocols required to meet the remaining post-marketing requirements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Prescription Products: Pediatric Portfolio</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Karbinal: Extended release carbinoxamine oral suspension for the treatment of seasonal and perennial allergies</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Karbinal&#174; ER (carbinoxamine maleate extended-release oral suspension) is an H1 receptor antagonist (antihistamine) indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and food, mild, uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled, and amelioration of the severity of allergic reactions to blood or plasma for patients two years of age and above.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">More than 100 million people in the United States&#160;experience various types of allergies each year. Allergic conditions are one of the most common health issues affecting children in the&#160;United States. Numerous allergy treatments exist to address allergies and allergic symptoms depending upon the symptom(s). Oral antihistamines are considered a mainstay of allergy treatment, and the prescription antihistamine market is a large category with approximately 54&#160;million&#160;antihistamine prescriptions written in 2023. The prescription antihistamine category is dominated by generic products and consists of first-generation and second-generation molecules. Generally, first-generation antihistamines block both histaminic and muscarinic receptors and pass the blood-brain barrier. Second-generation antihistamines mainly block histaminic receptors, but they do not pass the blood-brain barrier. First-generation antihistamines, which are generally characterized as more sedating, accounted for 6% of 2023&#160;total prescriptions, while non-sedating, second-generation antihistamines accounted for 94% of total prescriptions. The most widely prescribed oral, second-generation antihistamines are cetirizine (brand name Zyrtec&#174;) and loratadine (brand name Claritin&#174;). Diphenhydramine (brand name Benadryl&#174;) is the most widely prescribed first-generation molecule.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Karbinal is the only FDA-approved, 12-hour carbinoxamine oral suspension and is an effective antihistamine with a broad range of indications. Karbinal is positioned as a second-line allergy treatment for patients who continue to suffer from allergic symptoms following initial treatment with a second-generation, non-sedating antihistamine. Further, as Karbinal is an oral suspension formulation, children are the primary target patient given their preference for liquid treatments and, in many cases, their inability to swallow tablets or capsules. Karbinal is indicated for children as young as two years of age. Karbinal has a pleasant strawberry-banana taste and is available in 480 mL bottles.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Through a supply and distribution agreement with Tris, we own exclusive rights to distribute Karbinal in the United States&#160;through August 2032, unless the agreement is terminated earlier pursuant to the termination provisions in the agreement. As part of the agreement, we pay sales-based royalties based on net revenue. Additionally, we are committed to making annual minimum payments to Tris through August 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Two core patents protect Karbinal in the United States,&#160;and both patents are listed in the FDA&#8217;s Orange Book. The first patent describes a coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin. The priority date for this family is March 29, 2009, so the standard 20-year exclusivity for this patent will expire in 2029. The second patent describes an aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core molecule complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated ion exchange resin complex. The priority date for this family is June 15, 2007, so the standard 20-year exclusivity for this patent will expire in 2027.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Along with second-generation prescription oral antihistamines, Karbinal also&#160;faces competition from OTC products such as non-sedating antihistamines, sedating antihistamines as well as nasal steroids, nasal antihistamines, and anticholinergics.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Poly-Vi-Flor and Tri-Vi-Flor: Our fluoride-based multivitamin prescription supplement product line for infants and children</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Poly-Vi-Flor and Tri-Vi-Flor are two complementary prescription fluoride-based supplement product lines containing combinations of vitamins and sodium fluoride in various oral formulations. These prescription supplements are prescribed for infants and children to treat or prevent fluoride deficiency due to poor diet or low levels of fluoride in drinking water and other sources while also providing multi-vitamin support and folic acid supplementation. Because these products contain at least .25 mg of sodium fluoride, Poly-Vi-Flor and Tri-Vi-Flor are classified as products that should be administered under the supervision of a licensed prescriber.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fluoride supplementation has been proven to protect teeth from decay. Community water fluoridation prevents tooth decay by providing frequent and consistent contact with low levels of fluoride. By keeping the teeth strong and solid, fluoride stops cavities from forming and can rebuild the tooth&#8217;s surface. Community water fluoridation began in the United States in 1945 and as of 2016, more than 200 million people, or nearly 3 in 4 Americans who use public water supplies, drank water with enough fluoride to prevent tooth decay. However, Americans living in municipalities that do not fluoridate the water supply or in rural areas that rely on well water supplies frequently do not receive recommended levels of fluoride through fluoridation. Therefore, many children living in these areas often require daily fluoride supplementation as part of their mineral and vitamin intake. In many instances, physicians prescribe fluoride-based multi-vitamins (Vitamins A, B, C, D and folic acid) regularly to supplement their fluoride intake and enable convenient supplementation. Infants are prescribed easier-to-take multi-vitamin drops while older children are prescribed tablet formulations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In 2023, 7.1&#160;million multi-vitamin prescriptions were written in the United States. Of those prescriptions, multi-vitamins containing sodium fluoride accounted for 0.9&#160;million total prescriptions. Common multi-vitamin combinations contain vitamins A, B, C, D and E, but no other prescription pediatric multi-vitamin products contain Metafolin, which makes the Poly-Vi-Flor and Tri-Vi-Flor product lines distinct, single-source brands. Other brands include Tri-Vite (marketed by Method Pharmaceuticals), Floriva (marketed by BonGeo Pharmaceuticals) and Quflora (marketed by Carwin Pharmaceutical Associates).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Poly-Vi-Flor is available in both chewable tablet and oral liquid suspension multivitamin formulations in six different product presentations: Poly-Vi-Flor Chewable Tablets .25 mg, .50 mg, and 1 mg tablets, Poly-Vi-Flor Chewable Tablets with Iron, Poly-Vi-Flor Oral Suspension and Poly-Vi-Flor Oral Suspension with Iron. Poly-Vi-Flor contains Vitamin A, Vitamins B1, B2, B3, and B6, Vitamin C, Sodium Fluoride in various doses and Metafolin, a proprietary, trademarked L-methylfolate form of folic acid developed by and licensed from Merck &amp; Cie (&#8220;Merck&#8221;). Beginning in the second half of fiscal 2023, we introduced Poly-Vi-Flor and Tri-Vi-Flor containing Arcofolin, Arcofolin offers an improved profile over Metafolin as a body ready L-methylfolate. Arcofolin&#8217;s low water content and low molecular weight of the counterion yield higher levels of assayed folate than other forms of L-methylfolate currently available on the market. It also has an improved purity profile, enhanced water solubility and an excellent overall stability profile. The addition of Arcofolin also broadens the brands&#8217; IP protection and extends the patent life and provides further differentiation with this novel ingredient.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Tri-Vi-Flor is available as an oral liquid suspension (.25 mg fluoride) containing Vitamin A, Vitamin C, Vitamin D3, Sodium Fluoride, Sodium Benzoate and L-methylfolate. By virtue of its&#160;L-methylfolate content, Tri-Vi-Flor offers a similar clinical profile: a fluoride-based multivitamin containing a proprietary, body-ready L-methylfolate.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Arcofolin&#174;, which we also licensed exclusively in our field of use, is Merck&#8217;s manufactured calcium salt of L-5-methyltetrahydrofolic or L-methylfolate. Arcofolin&#160;is a &#8216;body ready&#8217; alternative to folic acid and offers good stability, solubility, and bioavailability. Folic acid supplementation is recommended in various patient groups, but a significant number of patients have difficulty metabolizing folate due to an enzymatic deficiency caused by a genetic mutation affecting the enzyme methylenetetrahydrofolate reductase, or MTHFR. MTHFR converts ingested folate (such as supplemented folic acid) into L-methylfolate, the body&#8217;s usable form. Clinical studies have demonstrated that 75% of patients may have at least one MTHFR genetic mutation while 40% may have two mutations. These mutations lead to impaired function of the enzyme and result in folate deficiency. Both Arcofolin and Metafolin are unaffected by the MTHFR mutation, thereby directly delivering bioavailable L-methylfolate, and offering a distinct clinical advantage over other folic acid supplements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The core family of patent covering Arcofolin has a priority date of March 31, 2017 and describes a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as a process of obtaining the same. Upon issuance, the standard 20-year exclusivity for this patent would expire in 2037.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The prescription multi-vitamin market is dominated by generic products, with brands accounting for 12.3% of the multivitamin plus fluoride market for the calendar year ending December 31, 2023. Poly-Vi-Flor and Tri-Vi-Flor primarily compete in the generic prescription multi-vitamin fluoride market and with the branded products FLORIVA and QFLORA.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Manufacturing</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>ADHD Product Portfolio</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During fiscal 2024 we completed the&#160;process of transferring the manufacturing of our ADHD products to a United States-based contract manufacturing organization (&#8220;CMO&#8221;). The transfer of the manufacturing of pharmaceutical products required&#160;several steps including knowledge and method transfer, manufacturing of materials for feasibility studies and confirmation batch materials, bioequivalence studies, inspections from regulatory agencies, and regulatory filings. We completed the required steps, including the successful completion of bioequivalence studies, which were&#160;required in order to enable the transfer of both Adzenys and Cotempla.&#160;Our CMO started manufacturing both Adzenys and Cotempla during the third quarter of the 2024 fiscal year and will manufacture all of our ADHD products going forward. We are responsible for supplying the active pharmaceutical ingredients for the ADHD products to our CMO. Our CMO is responsible for manufacturing the products, conducting quality control, quality assurance, validation activities, stability testing, packaging and providing related services for the manufacture of the products. We are required to purchase all of our ADHD products from them, with certain exceptions. Our agreement with this CMO has an initial term beginning in November 2023, and ending in November 2028, and automatically renews after the initial term for successive terms of three years, with certain termination rights for both parties as outlined in the agreement</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Pediatric Product Portfolio</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We contract with CMOs for the manufacture and testing of our Pediatric Portfolio products. We have entered into the following key supply agreements for the commercial manufacture and supply of certain of these products:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Karbinal is purchased through a&#160;supply agreement with Tris. This agreement terminates in August 2033, subject to earlier termination or extension in accordance with the terms of the agreement.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Poly-Vi-Flor and Tri-Vi-Flor drops are purchased through supply agreements with CMOs based in the United States. Merck &amp; Cie is responsible for providing Metafolin and Arcofolin to our designated CMO.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe the third-party manufacturers have adequate capacity to manufacture sufficient quantities of our&#160;products to meet anticipated commercial demands. As we rely on CMOs, we continue to employ personnel with extensive technical, manufacturing, supply chain management, analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record-keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among other activities. Our systems and our contractors are required to comply with these regulations, and we assess this compliance regularly through monitoring of performance and a formal audit program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Research and Development</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We&#160;have indefinitely suspended product candidate research and development activities in order to focus our resources on our commercialization efforts. Due to the suspension of product candidate research and development, the development of AR101, our lead product candidate, is on indefinite hold. We are pursuing strategic partnerships in order to advance this program but can make no assurance that a partnership will be consummated.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Our Development Pipeline: AR101 (enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS))</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the protein kinase C (&#8220;PKC&#8221;) beta, PI3K and AKT pathways. AR101 has been studied in more than 3,300 patients across a range of solid and hematological tumor types. AR101 was originally developed by Eli Lilly and Company (&#8220;Lilly&#8221;), and worldwide rights were acquired by Denovo Biopharma in September 2014 following Lilly&#8217;s discontinuation of the enzastaurin development program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. VEDS is the severe subtype of Ehlers-Danlos Syndrome, affecting 1 in 50,000 people worldwide. VEDS results from pathogenic variants in the COL3A1 gene, which encodes the chains of type III procollagen, a major protein in vessel walls and hollow organs. Twenty-five percent of VEDS patients have a first complication by the age of 20 years, and more than 80 percent have at least one complication by the age of 40. VEDS patients have a median lifespan of 51 years. There are currently no FDA approved treatments for VEDS.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The research underpinning the application of enzastaurin for the treatment of VEDS has been conducted by Dr. Harry (Hal) Dietz and his research colleagues. Dr. Dietz is the Victor A. McKusick Professor of Genetics in the departments of medicine, pediatrics, and molecular biology and genetics at The Johns Hopkins University School of Medicine and director of the William S. Smilow Center for Marfan Syndrome Research. He has also been an investigator at Howard Hughes Medical Institute since 1997. Dr. Dietz is a leading scientist in the field of genetic connective tissue disorders and developed the first preclinical model that mimics the human condition and recapitulates VEDS. His group&#8217;s research findings were published in the <i>Journal of Clinical Investigation</i> in February 2020. The VEDS knock-in murine&#160;preclinical model from Dr. Dietz has the same genetic mutation most prevalent in VEDS patients and is representative of the human condition in both the timing and location of vascular events. The model has generated identical structural histology and mechanical characteristics, and unbiased findings demonstrated that structure alone does not lead to vascular events. Objective comparative transcriptional profiling by high-throughput RNA sequencing of the aorta displayed a consistent molecular signature for excessive PKC/ERK cell signaling that is now known to be the driver of disease. Based on the scientific rationale for intervention along the PKC/ERK pathway, PKC inhibition and treatment with PKC&#946; inhibitors proved efficacious in multiple pre-clinical and murine studies and indeed prevented death due to vascular rupture.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In fiscal 2022 we received Orphan Drug Designation for AR101 in Ehlers-Danlos Syndrome including VEDS and in Europe, allowing for seven years&#8217; marketing exclusivity in the United States and ten years in Europe. We also received Fast Track designation for AR101 in VEDS by the FDA, allowing for an accelerated review timeline upon submission of the New Drug Application (&#8220;NDA&#8221;) and more frequent interaction with the FDA during the development process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">AR101 is protected by a suite of five pending patents being pursued in major markets globally which have been licensed from Johns Hopkins and have an earliest priority date of March 2017. The cornerstone of the intellectual&#160;property family surrounds enzastaurin initially targeting the treatment of VEDS focused on the United States&#160;and certain foreign jurisdictions which include Europe, Japan, China, Brazil, Mexico, Canada, Israel, Australia, New Zealand and South Korea. This pending patent provides compositions and methods for treating VEDS and associated connective tissue disorders and has a priority date of October 2018. The second pending patent provides methods and compositions for the diagnosis, treatment, and prevention of Marfan syndrome and related diseases, disorders and conditions and has a priority date of March 2017, in select geographies. The third pending patent, titled &#8220;Targeted Epigenetic Therapy for Inherited Aortic Aneurysm Conditions,&#8221; broadens the coverage of the potential therapeutic application of AR101/Enzastaurin and has a priority date of September 2017. The fourth pending patent, titled &#8220;Pathway Targets for the Treatment of Vascular Ehlers-Danlos Syndrome&#8221;, and the fifth pending patent, titled &#8220;Endothelin-1 Signaling Contributes to Vascular Rupture Risk&#8221;, deepens the scientific evidence of the pathophysiology of Vascular Ehlers-Danlos Syndrome and are highly confirmatory of the therapeutic approach for AR101/Enzastaurin. These pending patents have priority dates of September 2020 and February 2022 respectively. Additional molecule specific intellectual property is afforded through the license with Denovo whose pending patent provides methods and compositions for the prediction of the activity of enzastaurin and has a priority date of September 1, 2016.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Intellectual Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We seek trademark protection in the United States when appropriate. We currently own or license registered trademarks for Aytu, Aytu BioPharma, Aytu RxConnect, Neos Therapeutics, Adzenys, Adzenys ER, Adzenys XR-ODT, Cotempla, Cotempla XR-ODT, Karbinal, Poly-Vi-Flor&#160;and Tri-Vi-Flor&#160;in the United States, as well as trademarks related to our DTRS technology.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">From time to time, we may find it necessary or prudent to obtain licenses from third party intellectual property holders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Government Regulation</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The FDCA and the FDA&#8217;s implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record-keeping, reporting, distribution, import, export, sale, advertising and promotion of our products and product candidates. We may seek approval for, and market, our products in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States,&#160;although there can be important differences.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Development and Approval</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the FDCA, FDA approval of an NDA is required before any new drug can be marketed in the United States. NDAs in the case of new drugs&#160;may require extensive studies and submission of a large amount of data by the applicant, including the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Preclinical Testing</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the toxicity and dosing of the product.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Clinical Trials</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Clinical trials involve the administration of a drug to healthy human volunteers or to patients, under the supervision of a qualified investigator.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase 1 clinical trials generally are intended to evaluate the safety, metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population and are designed to develop initial data regarding the product&#8217;s effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential adverse effects (&#8220;AEs&#8221;).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug&#8217;s overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase 3 clinical development programs consist of expanded, multi-site, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen. Phase 3 data often form the primary&#160;basis on which the FDA evaluates a drug&#8217;s safety and effectiveness when considering the product application.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Post-Approval Regulation</b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Once approved, drug products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met or if safety or manufacturing problems occur after the product reaches the market, the FDA may at any time withdraw product approval or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials, changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution-related restrictions, if there are new safety information developments.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>DEA Regulation</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ADHD products are considered a &#8220;controlled substance&#8221; as defined in the Controlled Substances Act of 1970, or CSA, because Adzenys contains amphetamine and Cotempla contains methylphenidate. Because amphetamine and methylphenidate are Schedule II controlled substances, the DEA has Adzenys&#160;and Cotempla&#160;listed and regulated as Schedule II controlled substances. None of our pediatric products (Karbinal, Poly-Vi-Flor and Tri-Vi-Flor) are considered &#8220;controlled substances.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The DEA establishes annually an aggregate quota for how much of a controlled substance may be produced in and/or imported into the United States-based on the DEA&#8217;s estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. Our manufacturers&#8217; quotas of an active ingredient may not be sufficient to meet commercial demand or complete clinical trials. Any delay, limitation or refusal by the DEA in establishing our manufacturers&#8217; quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Individual states also independently regulate controlled substances. We and our manufacturers will be subject to state regulation on distribution of these products, including, for example, state requirements for licensures or registration. Additionally, we use third-party logistics firms to inventory and fill sales orders for our commercial portfolio.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Human Capital</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of September 16, 2024, we employed 102&#160;employees, of which 99&#160;were&#160;full-time employees. Of our 102&#160;employees, 14&#160;are involved in operations, 58&#160;are involved in commercialization and 30&#160;are involved in general and administrative activities. All of our colleagues are located in the United States.&#160;Of these colleagues, 50% are female and 50% are male. Our colleagues are not represented by a labor union.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our values &#8211; team-oriented, hard-working, relentlessly determined, integrity, visionary, entrepreneurial, and servant-minded &#8211;&#160;are built on the foundation that the colleagues we hire and the way we treat one another promote&#160;innovation, and high productivity, which spur our success. This culture depends in large part on our ability to attract, retain and develop a diverse population of talents and high-performing employees at all levels of our organization. Providing market competitive pay and benefit programs, opportunities to participate in the success they help create, while engaging colleagues in important dialogue regarding organization performance, we create a culture of inclusion in which all colleagues have the opportunity to thrive.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Available Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our principal executive offices are located at 7900 East Union Avenue, Suite&#160;920, Denver, Colorado 80237, and our phone number is (720) 437-6580.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We maintain a website on the internet at <i>https://aytubio.com</i>. We make available, free of charge, through our website, by way of a hyperlink to a third-party site that includes filings we make with the United States Securities&#160;and Exchange Commission (&#8220;SEC&#8221;)&#160;website (<i>www.sec.gov)</i>, our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to&#160;those reports electronically filed or furnished pursuant to Section&#160;15(d)&#160;of the Exchange Act. The information on our website is not, and shall not be deemed to be, a part of this Annual Report&#160;or incorporated into any other filings we make with the SEC. In addition, the public may read and copy any materials we file with the SEC at the SEC&#8217;s Public Reference Room&#160;at 100 F Street, N.E., Washington D.C., 20549. Information on the operation of the Public Reference Room&#160;may be obtained by calling the SEC at 1-800-SEC-0330.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Code of Ethics</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have adopted a written code of ethics that applies to our officers, directors, and employees, including our principal executive officer and principal accounting officer. We intend to disclose any amendments to, or waivers from, our code of ethics that are required to be publicly disclosed pursuant to rules&#160;of the SEC by filing such amendment or waiver with the SEC. This code of ethics and business conduct can be found in the corporate governance section of our website, <i>https://investors.aytubio.com/corporate-governance#CorporateGovernance</i>.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item1a" title="item1a" href="#"></a>ITEM</b>&#160;<b>1A. RISK FACTORS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in this Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our securities to decline and could cause you to lose all or part of your investment.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Our Business and Financial Position</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We have incurred losses to date and can give no assurance of profitability.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have incurred losses in each year since our inception. Our net loss for the years ended&#160;June 30, 2024, and 2023, was $15.8&#160;million and $17.1&#160;million, respectively. We have not demonstrated the ability to be a profit-generating enterprise to date. Even though we expect to have revenue growth in the next several fiscal years, it is uncertain that the revenue growth will be significant enough to offset our expenses and generate a profit in the future. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered by healthcare businesses, many of which will be beyond our control. These risks include the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">uncertain market acceptance of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">difficulties in maintaining coverage and reimbursement for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">lack of sufficient capital;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">United States&#160;and foreign regulatory approval of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">unanticipated problems, delays, and expense relating to product development and implementation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">lack of sufficient intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the ability to attract and retain qualified employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the introduction of generic competition;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">competition; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">technological changes.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of the increasingly competitive nature of the markets in which we compete, our historical financial data is of limited value in anticipating future operating expenses. Our planned expense levels will be based in part on our&#160;expectations concerning future operations, which is difficult to forecast accurately based on our historical strategy of product and/or business acquisition to develop our product and business portfolio. We may be unable to adjust spending in a timely manner to compensate for any unexpected budgetary shortfall.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To obtain revenues from our products, we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing products, manufacturing, marketing and selling our existing products, satisfying any post-marketing requirements, and obtaining reimbursement for our products from private insurance or government payors. We, and our collaborators, as applicable, may not be successful in these activities and, even if we or our collaborators do, we may never generate revenues that are sufficient to achieve profitability.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We have not established sources of ongoing revenue sufficient to cover operating costs. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Since our inception, we have had significant operating losses. As of June 30, 2024, we had accumulated deficit of $320.0&#160;million. Even though during fiscal 2024 we mitigated the conditions that gave rise to&#160;substantial doubt about our ability to continue as a going concern, we may continue to incur net losses, and our ability to generate positive cash flows from operating activities is uncertain for the foreseeable future. We have not established an ongoing source of revenue sufficient to cover operating costs. Our ability to continue as a&#160;going&#160;concern&#160;is dependent on our continued operational improvements, refinancing, or obtaining adequate capital to fund operating losses until we become profitable. If we are unable to generate sufficient cash flows or obtain adequate capital, we may be unable to develop and commercialize our product offerings and we could be forced to cease operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our growth efforts or other operations. Further, future sales and issuances of our common stock or rights to purchase common stock will result in dilution of the percentage ownership of our existing stockholders and could cause our stock price to fall.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are expending resources to commercialize our prescription products and to service our debt obligations. We may require additional funding through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. As of June 30, 2024, our cash and cash equivalents totaled $20.0 million. During the year ended June 30, 2024, we received&#160;$13.0 million of proceeds from the Eclipse Term Loan and&#160;$3.6&#160;million&#160;of&#160;proceeds from the exercise of warrants, a portion of which was used for the repayment of a&#160;$15.0 million term loan, which was replaced by the Eclipse Term Loan.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our operating plans may change as a result of many factors currently unknown to us, and we could need additional capital in the future to continue our operations and may need to seek additional funds sooner than planned. Raising funds in the current economic environment may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we sell common stock, convertible securities or other equity securities in more than one transaction, any such sales may result in material dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior to those of our existing common stockholders. Further, any future sales of our common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock to decline. Any future grants of securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could also have an adverse effect on the market price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. The incurrence of additional indebtedness would result in increased fixed payment obligations, and we may be required to agree to additional restrictive covenants, such as further limitations on our ability to incur additional debt, additional limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek&#160;funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we are unable to obtain funding on a timely basis, we may be unable to expand the market for our products or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have a $13.0 million term loan and up to $14.5 million of secured revolving loans with the Eclipse Lender. As of June 30, 2024, $2.4&#160;million was outstanding under the secured revolving loan. All obligations under our loans are secured by substantially all of our existing property and assets subject to certain exceptions. These debt financings and any future debt financings may create additional financial risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing our outstanding debt obligations at maturity.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result, we may not have sufficient funds, or may be unable to arrange for additional financing, to pay the amounts due on our outstanding indebtedness under our debt agreements. Further, funds from external sources may not be available on economically acceptable terms, if at all. For example, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish potentially valuable rights to our products or technologies, or to grant licenses on terms that are not favorable to us. If adequate funds are not available when and if needed, our ability to make interest or principal payments on our debt obligations, and finance our operations and other general corporate activities would be significantly limited and we may be required to delay, significantly curtail, or eliminate one or more of our programs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Failure to satisfy our current and future debt obligations under our loan agreements with the Eclipse Lender&#160;could result in an event of default and, as a result, our lenders could accelerate all of the amounts due. In the event of an acceleration of amounts due under one or both of our debt agreements as a result of an event of default, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness. In addition, our lenders could seek to enforce their security interests in any collateral securing such indebtedness.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The loan agreements with the&#160;Eclipse Lender subject us to financial covenants and restrictions on our ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the lender. Failure to comply with such covenants could permit the lenders to declare our obligations under the loan agreements, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">These restrictive covenants could limit our flexibility in operating our business and our ability to pursue business opportunities that we or our stockholders may consider beneficial. Any declaration by the lender of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay these outstanding obligations at the time any event of default occurs. Further, if we raise any additional capital through debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We are actively engaged in discussions regarding a potential strategic transaction. There can be no assurance that this process will result in the pursuit or consummation of any potential transaction.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are engaged in discussions regarding a potential strategic transaction which could include a sale or licensing of assets, acquisition, merger, business combination, and/or other strategic transaction or series of related transactions. This process, including any uncertainty created by this process, involves a number of risks which could impact our business and our stockholders, including the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">significant fluctuations in our stock price could occur in response to developments relating to the process or market speculation regarding any such developments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may encounter difficulties in hiring, retaining and motivating key personnel during this process or as a result of uncertainties generated by this process or any developments or actions relating to it;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may incur substantial increases in general and administrative expense associated with increased legal fees and the need to retain and compensate third-party advisors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may experience difficulties in preserving the commercially sensitive information that may need to be disclosed to third parties during this process or in connection with an assessment of our strategic options.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The review process also requires significant time and attention from management, which could distract them from other tasks in operating our business or otherwise disrupt our business. Such disruptions could cause concern to our suppliers, strategic partners or other constituencies and may have a material impact on our business and operating results and volatility in our share price.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There can be no assurance that this process will result in the pursuit or consummation of any potential transaction or strategy, or that any such potential transaction or strategy, if implemented, will provide sufficient funding to conduct our operations. Any outcome of this process would be dependent upon a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, regulatory approvals, and the availability of financing on reasonable terms. The occurrence of any one or more of the above risks could have a material adverse impact on our business, financial condition, results of operations and cash flows.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We have indefinitely suspended development of our AR101 (enzastaurin) clinical development program and shifted our strategic focus towards accelerating the growth of our commercial business. If we fail to execute successfully on this reprioritized strategic focus, our business, results of operations and financial condition could be materially and adversely affected.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have indefinitely suspended our AR101 (enzastaurin) clinical development program and shifted our focus towards accelerating the growth of our commercial business and achieving operating cash flows. Though we expect that the suspension of this program will save us costs related to a projected future study that if started would cost over $20 million&#160;and take three years to complete, the process of reorienting our business strategy may be costly, time consuming and complex, and we have incurred, and may in the future incur, costs related to this strategic shift. Our strategic reprioritization may result in unexpected expenses or liabilities and/or write-offs. There is no assurance that we will be successful at executing on our revised strategy or that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, lead to increased stockholder value, or achieve the anticipated results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we are unable to execute successfully on our reprioritized strategic focus, our cash resources may not last as long as estimated and our business, results of operations and financial condition could be materially and adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of June 30, 2024, we had federal net operating loss carryforwards of&#160;$519.6&#160;million. The available net operating losses, if not utilized to offset taxable income in future periods, will continue to expire and, except for certain indefinite-lived net operating loss carryforwards, will completely expire in 2037. Under the Internal Revenue Code of 1986, as amended (the &#8220;IRC&#8221;) and the regulations promulgated thereunder, including, without limitation, the consolidated income tax return regulations, various corporate ownership changes&#160;limit our ability to use our net operating loss carryforwards and other tax attributes to offset our income.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Ownership changes have&#160;limited our ability to offset, post-change, United States&#160;federal taxable income. Section 382 of the IRC imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on our ability to use all $519.6 million of&#160;pre-acquisition net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our&#160;management is responsible for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management conducted an assessment of the effectiveness of our internal controls over financial reporting for the quarter ended September 30, 2022, and concluded that a certain control was not effective. We concluded that we had a material weakness in internal control over financial reporting related to accounting for complex warrant issuances and the classification of these issued warrants. In addition, we concluded that we had a material weakness in internal control over financial reporting for the year ended June 30, 2023, related to our analysis for the accounting for valuation of our inventory.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As previously reported in our public reports, our Audit Committee conducted an internal investigation to identify and determine a plan to remediate the material weaknesses described above and to enhance our overall control environment. We undertook steps to remediate these deficiencies and strengthen our internal control over financial reporting by enhancing existing controls and establishing additional review and procedure controls over the process of reviewing significant and complex contracts and agreements, and the valuation of inventory. Given the remediation efforts and that a sufficient period of time has passed with&#160;successful testing performed,&#160;management has concluded that the material weaknesses set forth above were remediated as of March 31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If in the future we were to conclude that our internal controls over financial reporting were not effective, we cannot be certain as to the timing of completion of our evaluation, testing and remediation actions or their effect on our operations because there is presently no precedent available by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section 404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn, could require us to restate our operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we are unable to conclude that we have effective internal controls over financial reporting or if our independent auditors are unwilling or unable to provide us, when required, with an attestation report on the effectiveness of internal controls over financial reporting as required by Section 404 of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to maintain listing on the Nasdaq&#160;Capital Market. Due to our current filing status, we are not required to have our independent registered public accounting firm deliver an attestation report on the effectiveness of our internal control over financial reporting.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We have been and, in the future, may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We and certain of our officers and directors have been and may in the future become defendants in one or more stockholder derivative actions or other class-action lawsuits. For example:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Two putative class action lawsuits were filed on February 9, 2022, and March 7, 2022, derivatively and on behalf of all Aytu stockholders, challenging the grant in 2021 of certain stock option awards to directors and officers, and seeking rescission of the awards, unspecified damages to stockholders as a result of the awards, and attorneys&#8217;&#160;fees.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A stockholder&#160;derivative suit was filed on September 12, 2022, derivatively and on behalf of all Aytu stockholders, against certain of our current and former directors and stockholders, alleging breaches of fiduciary duties in connection with certain acquisitions, and seeking unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217;&#160;fees.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">See Part I, Item 3,&#160;<i>Legal Proceedings</i> for more information on these lawsuits.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">These lawsuits can divert our management&#8217;s attention and resources from our ordinary business operations, and we would likely incur significant expenses associated with their defense (including, without limitation, substantial attorneys&#8217; fees and other fees of professional advisors and potential obligations to indemnify current and former officers and directors who are or may become parties to such actions). In connection with these lawsuits, we may be required to pay material damages, consent to injunctions on future conduct and/or suffer other penalties, remedies or sanctions, or issue additional shares upon the exercise of certain warrants, which may cause additional dilution. In addition, any such future lawsuits could adversely impact our reputation and/or ability to launch and commercialize our products, thereby harming our ability to generate revenue. Accordingly, the ultimate resolution of these matters and any future matters could have a material adverse effect on our business, financial condition, results of operation and cash flow and, consequently, could negatively impact the trading price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Commercialization</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We are heavily dependent on the commercial success of our commercial products. To date, we have not generated sufficient revenues from the sales of these products to achieve companywide profitability and we may never achieve or maintain profitability. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to become profitable depends upon our ability to generate increased revenues from sales of our prescription portfolios. While we have been selling pharmaceutical products for several years, we have limited commercial experience selling our current lineup of pharmaceutical products, having only generated revenues from the sale of our pediatric products since acquiring that portfolio in November 2019 and from our ADHD products since acquiring that portfolio in March 2021. None of our marketed prescription have thus far generated product&#160;revenue&#160;at levels sufficient for us to attain profitability. We have not generated any revenue&#160;from product sales of any other product candidates and, to date, have incurred significant operating losses. Due to the completion of our&#160;wind down and divestiture of our&#160;Consumer Health Segment in the first quarter of fiscal 2025, we will not generate significant revenue from the Consumer Health Segment in the future.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have incurred, and anticipate continuing to incur, significant costs associated with commercialization of our approved products and, if approved, any other product candidates that we may develop. It is possible that we will never attain sufficient product sales revenues to achieve profitability.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>If we are unable to differentiate our products from branded drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve additional generic products that compete with any of our products, our ability to successfully commercialize such products would be adversely affected.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We expect to compete against branded drugs with distinct clinical attributes and to compete with their generic counterparts that will be sold for a lower price. Although we believe that our Rx Portfolio is or will be differentiated from branded drugs and their generic counterparts, if any, including through clinical efficacy or through improved patient compliance, ease of administration, and our patient support programs, it is possible that such differentiation will not impact our market position. If we are unable to achieve significant differentiation for our products and accompanying support services against other drugs, the opportunity for our products to achieve premium pricing and be commercialized successfully would be adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">After a New Drug Application (&#8220;NDA&#8221;), including a 505(b)(2) application, is approved, the covered product becomes a &#8220;listed drug&#8221; that, in turn, can be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. The FDCA, implementing regulations and other applicable laws provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use, or labeling as our product candidate and that the generic product is bioequivalent to ours, meaning it is absorbed in the body at the same rate and to the same extent as our product candidate. These generic equivalents, which must meet the same quality standards as the listed drugs, would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product, such as our Rx Portfolio products, can be lost to the generic version. Accordingly, competition from generic equivalents to our products could materially adversely impact our revenues, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in our products. For example, on July 25, 2016, we&#160;received a paragraph IV certification from Actavis advising them that Actavis filed an ANDA with the FDA for a generic version of Adzenys XR-ODT. On October 17, 2017, we&#160;entered into a Settlement Agreement and a Licensing Agreement with Actavis (which is now owned by Teva), pursuant to which we&#160;granted Actavis the right to manufacture and market its now approved generic version of Adzenys XR-ODT under the ANDA beginning on September 1, 2025, or earlier under certain circumstances. On October 31, 2017, we&#160;received a paragraph IV certification from Teva advising them that Teva filed an ANDA with the FDA for a generic version of Cotempla XR-ODT. On December 21, 2018, we&#160;entered into a Settlement Agreement and a Licensing Agreement with Teva, pursuant to which we have granted Teva the right to manufacture and market its now approved generic version of Cotempla XR-ODT under the ANDA beginning on July 1, 2026, or earlier under certain circumstances.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our pharmaceutical products may prove to be difficult to effectively commercialize as planned or on the timeframes we announce and expect.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues from sales of our pharmaceutical product offerings. Moreover, we have limited&#160;experience selling some of our current products given their acquisition from other companies or their recent approval. We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory, and other product development objectives and, from time to time, we may publicly announce the expected timing of some of these milestones. The achievement of many of these milestones may be outside of our control and if we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our products may be delayed and our business, prospects and results of operations may be harmed. Specifically, we may encounter difficulty by virtue of the following, each of which could be negatively impacted if expected timeframe goals are not achieved:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our available capital resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our inability to have clear proprietary rights to the products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our inability to manufacture or cost-effectively manufacture the products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our inability to adequately market and increase sales of any of these products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">of adverse side effects that make using the products less desirable;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our inability to attract and retain a skilled support team, marketing staff and sales force necessary to increase the market for our approved products and to maintain market acceptance for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our inability to secure continuing prescribing of any of these products by current or previous users of the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our inability to effectively transfer and scale manufacturing as needed to maintain an adequate commercial supply of these products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of pharmaceutical products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our inability to effectively identify and align with commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement, and other approvals needed to enable commercial success of our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We rely on limited sources of supply for our products, and any disruption in the chain of supply may impact production and sales of our products, and cause delays in developing and commercializing our currently manufactured and commercialized products. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Some of our products are produced infrequently and by single-source suppliers, including but not limited to Halo Pharmaceutical, Inc. Due to the limited production quantities, production of these products may not be prioritized by the third-party manufacturer and may not be scheduled and produced at all. We are reliant on a limited number of suppliers for resin, drug compounds, coating and other component substances of our final products. If any of these single-source suppliers were to breach or terminate its supply agreement,&#160;with us or otherwise not supply us, we would need to identify an alternative source for the supply of component substances for our products. If we fail to procure supply of our products, we could lose potential revenue and our business, financial condition, results of operation and reputation could be adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Identifying an appropriately qualified source of alternative supply for any one or more of the component substances for our products could be time consuming, and we may not be able to do so without incurring material delays in the development and commercialization of our approved products or a decrease in sales of our approved products, which could harm our financial position and commercial potential for our products. Any alternative vendor would also need to be qualified through an FDA Prior Approval Supplement process which could result in further delay. The FDA, DEA, or other regulatory agencies outside of the United States may also require additional studies if we enter into&#160;agreements with new suppliers for the manufacture of our ADHD products that differ from the suppliers used for clinical development of such products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">These factors could cause a&#160;delay of commercialization of our products, cause us to incur higher costs and prevent us from commercializing them successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of components and APIs on a timely basis and at commercially reasonable prices, including if our suppliers did not receive adequate DEA quotas for the supply of certain scheduled components, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, commercialization of our ADHD products may be delayed or we could lose potential revenue and our business, financial condition, results of operation and reputation could be adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>We rely on third parties to manufacture certain products, and third-party manufacturing risks and inefficiencies may result in costs and delays that prevent us from successfully commercializing products and adversely affect our ability to produce our products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We completed the process of outsourcing the manufacturing of our ADHD products to a third-party manufacturer based in the United States, to produce commercial quantities of our ADHD products during fiscal 2024. If the third-party is not successful or does not meet our expectations (for example, timeliness of production, quantity of production, maintenance of needed documentation or regulatory compliance), we may have to find a different manufacturer and incur expenses and delays in the process. Manufacturers of our ADHD products must comply with good manufacturing practice (&#8220;GMP&#8221;) requirements enforced by the FDA, NMPA, EMA and other comparable foreign health authorities through facilities inspection programs. These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our FDA regulated products may be unable to comply with these GMP requirements and with other FDA, NMPA, EMA, DEA, state, and foreign regulatory requirements. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our drugs, which would seriously harm our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We do not expect to have our own manufacturing capabilities, thus for all other products and any future products, we expect to use third-party manufacturers. In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current market trends, and other related factors. Because of the inherent nature of estimates and our limited experience in marketing our current products, there could be significant differences between our estimates and the actual amounts of product we require. If we do not effectively maintain our supply agreements, we will face difficulty finding replacement suppliers, which could harm sales of those products. If we fail in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured these components ourselves, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reliance on third parties for regulatory compliance and quality assurance;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">possible breaches of manufacturing agreements by the third parties because of factors beyond our control;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">possible regulatory violations or manufacturing problems experienced by our suppliers; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Further, if we are unable to secure the needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition to a third-party CMO for our ADHD products. We may&#160;not be able to meet the demand for our products if one or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers for any of our products in a timely manner and on terms acceptable to us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The manufacturing processes and facilities of third-party manufacturers we have engaged for our current approved products are, and any future third-party manufacturer will be, required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">administrative or judicially imposed sanctions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">injunctions or the imposition of civil penalties;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">recall or seizure of the product in question;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">total or partial suspension of production or distribution;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the FDA&#8217;s refusal to grant pending future clearance or pre-market approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">withdrawal or suspension of marketing clearances or approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">clinical holds;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">warning letters;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">refusal to permit the export of the product in question; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">criminal prosecution.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management&#8217;s&#160;attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Third party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our products. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>If our contract manufacturer fails to manufacture our ADHD products in sufficient quantities and at acceptable quality and pricing levels, or fails to obtain adequate DEA quotas for controlled substances, or to fully comply with cGMP regulations, we may face delays in the commercialization of these products, or be unable to meet market demand, and may be unable to generate potential revenues.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. Pharmaceutical companies often encounter difficulties in manufacturing, particularly in scaling up production of their products. These problems include manufacturing difficulties relating to production costs and yields, quality control, including stability of the product and quality assurance testing, shortages of qualified personnel, as well as compliance with federal, state, and foreign regulations. If our third-party is&#160;unable to demonstrate stability in accordance with commercial requirements, or if our raw material manufacturers were to encounter difficulties or otherwise fail to comply with their obligations to us, our ability to obtain FDA approval and market our products would be jeopardized. We purchase raw materials and components from various suppliers in order to manufacture our ADHD products. If we are unable to source the required raw materials from our suppliers, or if we do not obtain DEA quotas or receive inadequate DEA quotas, we may experience delays in manufacturing our ADHD products, and may not be able to meet customer demand for our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, our contract manufacturer must comply with federal, state, and foreign regulations, including cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. We may be unable to comply with these cGMP requirements and with other FDA and foreign regulatory requirements. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or voluntary recall, or withdrawal of product approval. If the safety of any of our products is compromised due to failure to adhere to applicable laws or for other reasons, we may not be able to obtain, or to maintain once obtained, regulatory approval for such products or successfully commercialize such products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay in commercialization of our products, entail higher costs or adversely impact our commercialization of our products. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation and potential for product liability claims.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i><b>If we do not secure collaborations with strategic partners to test, commercialize and manufacture products, we may not be able to successfully develop products and generate meaningful revenues.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We may enter into collaborations with third parties to commercialize and manufacture our products. If we are able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and safety, obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety are demonstrated. Further, the economic environment at any given time may result in potential collaborators electing to reduce their external spending, which may prevent us from developing our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Collaboration agreements typically provide for the ownership of intellectual property. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration and we may be limited in our ability to use, make or sell these inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Even if we succeed in securing collaborators, the collaborators may fail to develop or effectively commercialize our products. Collaborations involving our products pose a number of risks, including the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">collaborators may not have sufficient resources or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">collaborators may delay the development or commercialization of our products in favor of developing or commercializing their own or another party&#8217;s products; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">collaborators may decide to terminate or not to renew the collaboration for these or other reasons.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result, collaboration agreements may not lead to development or commercialization of our products in the most efficient manner or at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Collaboration agreements are generally terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&#8217;s objectives and meet our expectations, we may be unable to advance our products and may not generate meaningful revenues.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We face substantial competition, including the introduction of generics,&#160;from companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The biopharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We compete with companies that design, manufacture and market already-existing and new products. We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and/or our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. Our competitors may be more successful in acquiring new products than we are. If we fail to acquire new products, implementation of our business plan would be delayed, which could have a negative adverse effect on our business and prospects. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">expand the market for our approved products, especially our pharmaceutical and devices regulated by the FDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">successfully commercialize our products alone or with commercial partners;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">discover and develop products that are superior to other products in the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">obtain required regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">attract and retain qualified personnel; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">obtain patent and/or other proprietary protection for our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Established pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could make our products obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us. Other companies are or may become engaged in the discovery of compounds that may compete with the products we are developing.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">We compete with companies that design, manufacture and market treatments that compete with our products. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products or drug delivery technologies that are more effective or less costly than that of our products or any product candidate that we are currently developing or that we may develop.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We&#160;anticipate that we will face increased competition in the future as new companies enter the market with new technologies our competitors improve their current products, and companies introduce generic equivalents. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. If we are not able to compete effectively against our current and future competitors, our business will not grow, and our financial condition and operations will suffer.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect one or more of the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our or our collaborators&#8217; ability to set a price we believe is fair for our approved products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to generate revenue from our approved products and achieve profitability; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the availability of capital.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Patient Protection and Affordable Care Act (the &#8220;PPACA&#8221;)&#160;and the Health Care and Education Reconciliation Act (the &#8220;Health Care Reconciliation Act&#8221;)&#160;significantly impacted the provision of, and payment for, health care in the United States.&#160;Various provisions of these laws are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide additional support for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and medical devices and reduce demand and prices for our products, if approved. This could harm our or our collaborators&#8217; ability to market any approved products and generate revenues. As we expect to receive significant revenues from reimbursement of our Rx Portfolio products by commercial third-party payors and government payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any of our products approved in the future, and could cause an increase in our compliance, manufacturing or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us to sell any approved product at a price acceptable to us or any of our future collaborators.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, in some foreign countries, the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. A member state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched in the EU do not follow price structures of the United States&#160;and generally tend to have significantly lower prices.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our financial results will depend on the acceptance among clinicians, third-party payors and the medical community of our products.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Physicians may not choose to prescribe our products if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to existing medicines or treatments. Our future success depends on the acceptance by our target customers, third-party payors, and the medical community that our products are reliable, safe, and cost-effective. We cannot predict the degree of market acceptance of any of our approved products. Many factors may affect the market acceptance and commercial success of our products, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to convince our potential customers of the advantages, safety and economic value our products and product candidates over existing technologies and products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the approved labeling for the product and any required warnings;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the prevalence and severity of adverse events or publicity;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">potential product liability claims;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the relative convenience and ease of our products over existing technologies and products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the introduction of new technologies and competing products that may make our products less attractive for our target customers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our success in training medical personnel on the proper use of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the willingness of third-party payors to reimburse our target customers that adopt our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">increases in rebate payments with payors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the acceptance in the medical community of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the extent and success of our manufacturing, marketing, and sales efforts; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">general economic conditions.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If our future products fail to gain market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory, or any, return on our investments. Even if some therapies achieve market access and acceptance, the market may prove not to be large enough to allow us to generate significant revenue.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>If third-party payors do not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While our pharmaceutical products are approved and generating revenues in the United States, they may not receive, or continue to receive, clinician or patient acceptance, or they may not maintain adequate reimbursement from third party payors. In the future, we might possibly sell other products to target customers substantially all of whom receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&#8217;s determination that use of a product is:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a covered benefit under its health plan;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">appropriate and medically necessary for the specific indication;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">cost effective; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">neither experimental nor investigational.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Obtaining coverage and reimbursement approval for a product from each government or third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that allows our potential customers to make a profit or even cover their costs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our products, which would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental drug pricing programs are complex and may involve subjective decisions. Any failure to comply with those obligations could subject us to penalties and sanctions</b>.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a condition of reimbursement by various federal and state health insurance programs, pharmaceutical companies are required to calculate and report certain pricing information to federal and state agencies. The regulations governing the calculations, price reporting and payment obligations are complex and subject to interpretation by various government and regulatory agencies, as well as the courts. Reasonable assumptions have been made where there is a lack of regulations or clear guidance and such assumptions involve subjective decisions and estimates. Pharmaceutical companies are required to report any revisions to their calculations, price reporting and payment obligations previously reported or paid. Such revisions could affect liability to federal and state payers and also adversely impact reported financial results of operations in the period of such restatement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Uncertainty exists as new laws, regulations, judicial decisions, or new interpretations of existing laws, or regulations related to our calculations, price reporting or payments obligations increases the chances of a legal challenge, restatement or investigation. If a company becomes subject to investigations, restatements, or other inquiries concerning compliance with price reporting laws and regulations, it could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on the business, financial condition and results of operations. In addition, it is possible that future healthcare reform measures could be adopted, which could result in increased pressure on pricing and reimbursement of products and thus have an adverse impact on financial position or business operations.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Further, state Medicaid programs may be slow to invoice pharmaceutical companies for calculated rebates resulting in a lag between the time a sale is recorded and the time the rebate is paid. This results in a company having to carry a liability on its consolidated balance sheets for the estimate of rebate claims expected for Medicaid patients. If actual claims are higher than current estimates, the company&#8217;s financial position and results of operations could be adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to retroactive rebates and the potential for 340B Program refunds, if a pharmaceutical firm is found to have knowingly submitted any false price information related to the Medicaid Drug Rebate Program to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), it may be liable for civil monetary penalties. Such failure could also be grounds for CMS to terminate the Medicaid drug rebate agreement, pursuant to which companies participate in the Medicaid program. In the event that CMS terminates a rebate agreement, federal payments may not be available under government programs, including Medicaid or Medicare Part B, for covered outpatient drugs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Additionally, if a pharmaceutical company overcharges the government in connection with the FSS program or Tricare Retail Pharmacy Program, whether due to a misstated Federal Ceiling Price or otherwise, it is required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against a company under the FCA and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our collaborators are also subject to similar requirements outside of the United States&#160;and thus the attendant risks and uncertainties. If our collaborators suffer material and adverse effects from such risks and uncertainties, our rights and benefits for our licensed products could be negatively impacted, which could have a material and adverse impact on our revenues.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our future profitability may depend, in part, on our ability to commercialize our products in foreign markets for which we intend to primarily rely on collaboration with third parties such as the agreement we entered into with Medomie in July 2023 to sell Adzenys and Cotempla in Israel and the Palestinian Authority. If we commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our inability to directly control commercial activities because we are relying on third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">import or export licensing requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">longer accounts receivable collection times;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">longer lead times for shipping;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">language barriers for technical training;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">foreign currency exchange rate fluctuations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our customers&#8217; ability to obtain reimbursement for our products in foreign markets; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Foreign&#160;&#8203;sales of our products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We are subject to United States&#160;and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are subject to the United States&#160;Foreign Corrupt Practices Act of 1977, as amended (&#8220;FCPA&#8221;), the United States&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the United States&#160;Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have adopted a Code of Business Conduct and Ethics that mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. We cannot ensure, however, that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any such action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We are subject to various health care fraud and abuse and reimbursement laws pertaining to the marketing of our approved products.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are subject to various federal and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other remuneration for the purchase of our products, including inducements to potential patients to request our products and services. Additionally, any product promotion educational activities, support of continuing medical education programs, and other interactions with health-care professionals must be conducted in a manner consistent with the FDA regulations, Physician Payments Sunshine Act, and the Anti-Kickback Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payer, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely impact the marketing of our existing products or delay introduction of our products, which may have a material adverse effect on our business, operating results and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Adzenys and Cotempla&#160;contain controlled substances, and their manufacture, use, sale, importation, exportation, prescribing and distribution are subject to regulation by the DEA. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Adzenys&#160;and Cotempla, (collectively, our &#8220;Controlled Substance Products&#8221;), which are approved by the FDA, are regulated by the DEA as Schedule II controlled substances. Before any commercialization of any product candidate that contains a controlled substance, the DEA determines the controlled substance schedule of a&#160;drug, taking into account the recommendation of the FDA. Our Controlled Substance Products are, and our other future products may, if approved, be regulated as &#8220;controlled substances&#8221; as defined in the Controlled Substances Act of 1970, or CSA, and the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to our third-party manufacturers and to distributors, prescribers, and dispensers of our products. For example, Schedule II controlled substances are subject to various restrictions, including, but not limited to, mandatory written prescriptions and the prohibition of refills. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled substances. State-controlled substance laws and regulations may have more extensive requirements than those determined by the DEA and FDA. Though state-controlled substances laws often mirror federal law because the states are separate jurisdictions, they may schedule products separately. While some states automatically schedule a drug when the DEA does so, other states require additional state rulemaking or legislative action, which could delay commercialization. Some state and local governments also require manufacturers to operate a drug stewardship program that collects, secures, transports, and safely disposes of unwanted drugs. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances are considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Amphetamine and methylphenidate, which are the active ingredients in our Adzenys and Cotempla&#160;products, respectively, are listed by the DEA as a Schedule II controlled substance under the CSA. Scheduled controlled substances are subject to DEA regulations relating to supply, procurement, manufacturing, storage, distribution, and physician prescription procedures. Our United States-based contract manufacturer of our Controlled Substance Products is also registered with and inspected by the DEA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Registered entities are subject to DEA inspection and also must follow specific labeling and packaging requirements, and provide appropriate security measures to control against diversion of controlled substances. Security requirements vary by controlled substance schedule with the most stringent requirements applying to Schedule I and Schedule II controlled substances. Required security measures include background checks on employees and physical control of inventory through measures such as vaults and inventory reconciliations. Failure to follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation of a DEA registration. The DEA also has a production and procurement quota system that controls and limits the availability and production of Schedule I or II controlled substances. If we or any of our suppliers of raw materials that are DEA classified as Schedule I or II controlled substances are unable to receive any quota or a sufficient quota to meet demand for our products, if any, our business would be negatively impacted.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Because of their restrictive nature, these laws and regulations could limit commercialization of our products containing controlled substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties, and state actions, among other consequences.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>The </b></i><b><i>design, development, manufacture, supply and distribution of our products are technically complex and require regulatory compliance</i></b><i><b>. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our third-party suppliers, must comply with all applicable regulatory requirements of the FDA and foreign authorities. For instance, because each of our ADHD products is a regulated drug product and subject to the DEA and state-level regulations, we have had to, and will continue to, need to secure state licenses from each required state in which we intend to sell such product allowing us to distribute a regulated drug product in such state.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or revocation of a pre-existing approval, or civil or criminal penalties. As a result, our business, financial condition and results of operations may be materially harmed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>There is a risk we may be unable to sell and distribute certain of our products if we cannot continue to comply with the serialization requirements of the Drug Quality and Security Act within the necessary time frames. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Title II of the Drug Quality and Security Act of 2013 provided increased FDA oversight over tracking and monitoring of the sale and distribution of prescription drugs. We are required to provide product identification information, or serialization, at the manufacturing batch, or lot level. In addition, we are required to track and verify wholesaler and pharmacy authentication and verification. We are required to conduct unit level tracking throughout the entire supply chain. We are now serializing our products and are compliant with the Drug Quality and Security Act, but there is no guarantee that we will be able to continue to satisfy each ever-stringent product identification requirements. Failing to do so could result in a delay or inability to sell our products within the United States.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Failure to comply with health and data protection laws and regulations could lead to United States&#160;federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We and any potential collaborators may be subject to United States&#160;federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties, including research institutions which are subject to privacy and security requirements under HIPAA, as amended by Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;). To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers, the federal government, and media outlets with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Depending on the facts and circumstances, we could be subject to significant civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Compliance with United States&#160;and foreign privacy and data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in&#160;government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We may use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time-consuming and costly.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our research and development processes may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We are dependent on our relationships and license agreements, and we rely on the intellectual property rights granted to us pursuant to the license agreements. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A number of our patent and trademark rights are derived from our license agreements with third parties. Pursuant to these license agreements, we have licensed rights to various patents, patent applications, trademarks and trademark applications within and outside of the United States. We may lose our rights to this intellectual property if we breach our obligations under such license agreements, including, without limitation, our financial obligations to the licensors. If we violate or fail to perform any term or covenant of the license agreements, the licensors may terminate the license agreements upon satisfaction of applicable notice requirements and expiration of any applicable cure periods. Additionally, any termination of license agreements, whether by us or the licensors may not relieve us of our obligation to pay any license fees owing at the time of such termination. If we fail to retain our rights under these license agreements, we will not be able to commercialize certain products subject to patent or patent application or trademark or trademark application, and our business, results of operations, financial condition and prospects would be materially adversely affected. In addition, the licensor may not be able to obtain valid and enforceable patents that protect the licensed products and may not be able to prevent third parties from infringing on those rights.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">From time to time, we may renegotiate the terms of our existing licensing agreements or other material contracts. There can be no guarantee that the terms of the renegotiated license agreement will be viewed favorably by the market although the renegotiated terms might be advantageous to our business or that the other party would agree to material changes to benefit the Company. For example, in May 2022, we negotiated to terminate the License, Development, Manufacturing and Supply agreement with Tris. The negotiations resulted in reducing the future minimum payments we owed to Tris by approximately $8.0 million. If we were unable to renegotiate the terms of the agreement, it would have had a material negative impact on our cash flows and financial position.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>The expiration or loss of patent protection may adversely affect our future revenues and operating results.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The suite of composition-of-matter patents for Adzenys&#160;are scheduled to expire in 2026 and 2032. The composition-of-matter patents in the United States&#160;for Cotempla&#160;expire in 2032, and the method-of-use patent expires in 2038. There is no guarantee that we will be able to extend the life of these patents or to obtain additional patents, licenses, or other instruments that can provide us with a comparable level of exclusivity to the intellectual property underlying the expiring patents.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We rely on patent, trademark and other intellectual property protection in the discovery, development, manufacturing and sale of our products. In particular, patent protection is, in the aggregate, important in our marketing of products in the United States. Patents covering our products normally provide market exclusivity, which is important for the profitability of many of our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As patents for certain of our products expire, we may face competition from lower priced generic or bioequivalent products. In general, the expiration or loss of patent protection for a product may allow market entry by substitute products that could significantly reduce sales for the original product in a short amount of time. If our competitive position is compromised because of generic or bioequivalent products or otherwise, it could have a material adverse effect on our business and results of operations. In addition, proposals emerge from time to time for legislation to further encourage the early and rapid approval of generic or bioequivalent products. Any such proposals that are enacted into law could increase the negative effect of generic competition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our ability to compete may decline if we do not adequately protect or enforce our intellectual property rights.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our success depends in part on our ability to manufacture, use, sell and offer to sell our products and in obtaining and maintaining intellectual property rights in our products, proprietary know-how and technology advances. We rely on patent protection, as well as a combination of trademark and trade secret laws to protect and prevent others from making, using and/or selling our compounds, processes, apparatuses and technology. While a presumption of validity exists with respect to patents issued to us in the United States, there can be no assurance that any of our patents will not be challenged, invalidated, circumvented or rendered unenforceable. Such means may afford only limited protection of our intellectual property and may not (i) prevent our competitors from duplicating our inventions; (ii) prevent our competitors from gaining access to our proprietary information and technology; or (iii) permit us to gain or maintain a competitive advantage. In addition, our competitors or other third parties may obtain patents that restrict or preclude our ability to lawfully practice, produce or sell our products in a competitive manner.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Obtaining and maintaining a patent portfolio entails significant expense and resources. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. In addition, the patent scope can be limited in prosecution or by the courts after issuance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Legal actions to enforce our patent rights and administrative challenges at the United States&#160;Patent and Trademark Office can be expensive and may involve the diversion of significant management time. In addition, these actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could harm our business, prospects, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to patent protection, because we operate in the highly technical field of development of therapies and medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States&#160;may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We may not be able to enforce our intellectual property rights throughout the world.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States.&#160;Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In addition, some countries allow patents to be challenged by third parties in administrative proceedings, which may result in a reduction in scope or cancelation of some or all of the claims. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>A dispute concerning the infringement or misappropriation of our proprietary rights, or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There is significant litigation in the pharmaceutical industry regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products infringe the intellectual property rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs, compositions or devices that relate to our prescription and consumer health business. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies or universities involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation, wrongful disclosure of confidential information, or other similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could lead to:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&#8217;s intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our collaborators having to enter into license arrangements that may not be available on commercially reasonable or acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business, prospects and financial condition. As a result, we could be prevented from commercializing our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Organization, Structure and Operation</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our efforts to expand and transform our businesses may require significant investments; if our strategies are unsuccessful, our business, results of operations and/or financial condition may be materially adversely affected.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We continuously evaluate opportunities for expansion and change. These initiatives may involve making acquisitions, entering into partnerships and joint ventures, divesting assets, restructuring our existing operations and assets, creating new financial structures and building new facilities&#8212;any of which could require a significant investment and subject us to new kinds of risks. We may incur additional indebtedness to finance these opportunities. If our strategies for growth and change are not successful, we could face increased financial pressure, such as increased cash flow demands, reduced liquidity and diminished access to financial markets, and the equity value of our businesses could be diluted.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The implementation of strategies for growth and change may create additional risks, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">diversion of management time and attention away from existing operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">requiring capital investment that could otherwise be used for the operation and growth of our existing businesses;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">disruptions to important business relationships;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">increased operating costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">limitations imposed by various governmental entities; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">difficulties due to lack of or limited prior experience in any new markets we may enter.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our inability to mitigate these risks or other problems encountered in connection with our strategies for growth and change could have a material adverse effect on our business, results of operations and financial condition. In addition, we may fail to fully achieve the savings or growth projected for current or future initiatives notwithstanding the expenditure of substantial resources in pursuit thereof.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We may have difficulties integrating acquired products and businesses and as a result, our business, results of operations and/or financial condition may be materially adversely affected.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have completed a number of acquisitions, and we intend to continue to acquire additional products and businesses through mergers, asset purchases or in-licensing, businesses or products, or form strategic alliances as part of our business strategy. Such growth strategies involve risks, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">inability to efficiently operate new businesses or to integrate acquired products and businesses;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">inability to accurately predict delays in realizing the costs and benefits of acquisitions, partnerships, or joint ventures;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">unexpected losses of customers or suppliers of an acquired or existing business;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">difficulties in retaining key employees of acquired businesses;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">difficulties in realizing projected synergies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">failure of the acquired business to produce the expected value; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">exposure to unanticipated liabilities, including unexpected environmental exposures, litigation challenging a merger, product liability or illegal activities conducted by an acquired company or a joint venture partner.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our inability to address these risks in a timely manner or at all could cause us to fail to realize the anticipated benefits of such acquisitions or joint ventures and could have a material adverse effect on our business, results of operations and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>In fiscal 2024, the great majority of our gross revenue and gross accounts receivable were due to three significant customers, the loss of which could materially and adversely affect our results of operations.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Three customers contributed greater than 10% of our gross revenue during the years ended June 30, 2024, and 2023. During the years ended June 30, 2024, and 2023, three customers accounted for 70% of gross revenue, respectively. While all of these customers have been and continue to be&#160;consistently financially strong, the loss of one or more of our significant customers could have a material adverse effect on our business, operating results or financial condition. Any reduction, delay or cancellation of an order from these customers or the loss of any of these customers could cause our revenue to decline. If we are unable to diversify our customer base, we will continue to be susceptible to risks associated with customer concentration.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our accounts receivable subjects us to credit risk.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are also subject to credit risk from our accounts receivable related to our product sales. As of June 30, 2024, three customers accounted for 80% of gross accounts receivable. Our profitability and cash flow are dependent on receipt of timely payments from customers. Any delay in payment by our customers may have an adverse effect on our profitability, working capital and cash flow. There is no assurance that we will be able to collect all or any of its trade receivables in a timely matter. If any of our customers face unexpected situations such as financial difficulties, we may not be able to receive full or any payment of the uncollected sums or enforce any judgment debts against such clients, and our business, results of operations and financial condition could be materially and adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our success depends to a significant degree upon the technical and management skills of our directors, officers, and key personnel. Any of our directors could resign from our board at any time and for any reason. Although our named executive officers (individually &#8220;NEO&#8221; and collectively &#8220;NEOs&#8221;), Joshua R. Disbrow, Mark K. Oki, Jarrett T. Disbrow and Greg Pyszczymuka have employment agreements, the existence of an employment agreement does not guarantee the retention of the executive officer for any period of time, and the agreements obligate us to pay Joshua R. Disbrow a lump sum severance of two and a half years his base salary, for Mr. Jarrett T. Disbrow a lump sum severance of two years his base salary, and for Mr. Oki, and Mr. Pyszczymuka one year of their base salary paid in installments over 12 months in accordance with the company's payroll schedule. If we terminate them without cause, as defined in their respective agreements, or if a NEO leaves for &#8220;Good Reason&#8221; as defined in their respective employment agreements, such severance payments could negatively affect our liquidity. The loss of the services of any of these individuals would likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers or key personnel. The loss of any of our directors or key executives, or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We compete for such personnel, including directors, against numerous companies, including larger, more established companies with significantly greater financial resources than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We will be exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of therapeutic candidates. Any failure of future therapeutic candidates by us and our corporate collaborators may expose us to liability claims as may the potential sale of any therapies approved in the future. These claims might be made by patients who use our therapies, healthcare providers, pharmaceutical companies, our corporate collaborators or other third parties that research or sell our therapies. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our future therapeutic candidates or any prospects for commercialization of our future therapeutic candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical, medical device, dietary supplement and personal care products. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration of a patient&#8217;s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business, financial condition and operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Although we maintain general liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition, insurance coverage is increasingly expensive and difficult to obtain. For example, we have experienced increasing difficulty in procuring insurance coverage for our products, in particular, our ADHD products, due to their status as controlled substances. Inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products that receive regulatory approval, which could adversely affect our business. Product liability claims could also harm our reputation, which may adversely affect our collaborators&#8217; ability to commercialize our products successfully. A successful product liability claim or series of&#160;claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to the Company.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our certificate of incorporation provides that we will indemnify our directors to the fullest extent permitted by Delaware law. In addition, as permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may, in our discretion, indemnify other officers, employees and agents in those circumstances where indemnification is permitted by applicable law;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we are required to advance expenses, as incurred, to our directors and executive officers in connection with defending a proceeding, except that such directors or executive officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we will not be obligated pursuant to our bylaws to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by our Board of Directors, (iii) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested in the corporation under applicable law or (iv) such indemnification is required to be made pursuant to our amended and restated bylaws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the rights conferred in our bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result, if we are required to indemnify one or more of our directors or executive officers, it may reduce our available funds to satisfy successful third-party claims against us, may reduce the amount of money available to us and may have a material adverse effect on our business and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Public concern over the abuse of medications that are controlled substances, including increased legislative, legal and regulatory action, could negatively affect our business. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Products containing controlled substances may generate public controversy. Certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of controlled substances such as opioids in the United States. State and local governmental agencies have commenced investigations into pharmaceutical companies and others in the supply chain in connection with the distribution of opioid medications. For example, on March 7, 2018, and April 18, 2019, Neos, which we now own, received citations advising Neos that the County of Harris Texas and the County of Walker Texas filed lawsuits on December 13, 2017, and January 11, 2019, respectively, against Neos and various other alleged manufacturers, promoters, sellers and distributors of opioid pharmaceutical products. Through these lawsuits, each of Harris County and Walker County seek to recoup as damages some of the expenses they allegedly have incurred to combat opioid use and addiction. Each of Harris County and Walker County also seeks punitive damages, disgorgement of profits and attorneys&#8217; fees. In addition, multiple lawsuits have been filed against pharmaceutical companies alleging, among other claims, failures to provide effective controls and procedures to guard against the diversion of controlled substances, negligence by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failures to report suspicious orders of controlled substances in accordance with regulations. Certain cases noted above have recently been settled, some for hundreds of millions of dollars. In the future, political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit or restrict, the introduction and marketing of our products, the withdrawal of currently approved products from the market, or result in other legal action.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, we are aware of other legislative, regulatory or industry measures to address the misuse of prescription opioid medications which could affect our business in ways that we may not be able to predict. Liabilities for taxes or assessments under any such laws will likely have an adverse impact on our results of operations, unless we are able to mitigate them through operational changes or commercial arrangements where permitted and may result in us ceasing to continue to sell our products in these jurisdictions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Certain of our stockholders own a significant percentage of our stock and may and their interests may conflict with yours.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of June 30, 2024, two&#160;stockholders hold&#160;approximately 18.2% and 9.5%, respectively, of our outstanding common stock and hold&#160;warrants and pre-funded warrants&#160;which can be exercised to purchase additional shares of our common stock resulting in an ownership of&#160;19.99%&#160;of our currently outstanding common stock, and in excess of 19.99% subject to stockholder approval. Accordingly, these&#160;stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring security holder approval.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, in connection with our recent public offering of securities in June 2023, the 18.2% stockholder has been granted the right to designate an individual to join our Board of Directors, who has since joined the board of directors, and to nominate an additional candidate who is acceptable to us to be elected to the Board, subject to Nasdaq regulations. To date this shareholder only occupies one board seat. The interests of this stockholder could conflict with the interests of our other stockholders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our business could be negatively affected as a result of the actions of activist stockholder</i>s.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Proxy contests have been waged against many companies in the pharmaceutical industry over the last several years. It is possible that one or more of our stockholders may publicly voice opposition to certain aspects of our corporate governance and strategy or undertake a proxy contest to reconstitute our board. If faced with a proxy contest or other type of stockholder activism, we may not be able to respond successfully to the contest or other type of activism which would be disruptive to our business. Even if we are successful, our reputation and/or business could be adversely affected by a proxy contest or other form of stockholder activism because:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">perceived uncertainties as to our company and future strategic direction may result in the loss of potential financing, acquisitions, collaboration, in-licensing or other business opportunities, and may make it more difficult to attract and retain qualified personnel and business partners; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if individuals are elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any or all of these activities could cause our stock price to decline or experience periods of volatility and could be particularly problematic as our company seeks to transition to a commercial enterprise in a challenging environment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risk Related to Securities Markets and Investment in Our Securities</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our common stock. </b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement, the exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting notification, we anticipate that we would take actions to restore our compliance with applicable exchange requirements, such as stabilize our market price, improve the liquidity of our common stock, prevent our common stock from dropping below such exchange&#8217;s minimum bid price requirement, or prevent future non-compliance with such exchange&#8217;s listing requirements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Effecting a reverse stock split, if determined by the Board in its discretion, may not achieve one or more of our objectives.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have effected five reverse stock splits since June 8, 2015, each of which has impacted the trading liquidity of the shares of our common stock. There can be no assurance that the market price per share of our common stock after a reverse stock split will remain unchanged or increase in proportion to the reduction in the number of shares of our common stock outstanding before the reverse stock split. The market price of our shares may fluctuate and potentially decline after a reverse stock split. Accordingly, the total market capitalization of our common stock after a reverse stock split may be lower than the total market capitalization before the reverse stock split. Moreover, the market price of our common stock following a reverse stock split may not exceed or remain higher than the market price prior to the reverse stock split.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Additionally, on June 21, 2024, Nasdaq filed a proposed rule change with the SEC that would change how it views reverse stock splits. Nasdaq&#8217;s proposal suggests it would initiate the delisting process for any company whose common stock bid price had closed below $1.00 per share for 30 consecutive business days (the &#8220;Minimum Bid Requirement&#8221;) if, within the prior year, the&#160;company conducted a reverse stock split, regardless of the ratio. Given our history of effectuating reverse stock splits in order to comply with the Minimum Bid Requirement, there can be no assurance that our securities will continue to be listed on Nasdaq if we do not comply with the Minimum Bid Requirement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There can be no assurance that a reverse stock split will result in a per-share market price that will attract institutional investors or investment funds or that such share price will satisfy investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our common stock may not necessarily improve. Further, if a reverse stock split is effected and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a reverse stock split.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;<i>Risk Factors</i>&#8221; section and elsewhere in this Annual Report, these factors include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success of products we acquire for development or commercialization relative to the success of our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">product safety;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">conditions or trends in the healthcare, biotechnology and pharmaceutical industries, including healthcare payment systems;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to effectively manage operations, financial decisions, internal controls over financial reporting or disclosure controls, performance relative to projections, and attract and retain employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our dependence on third parties, including CROs and scientific and medical advisors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adverse regulatory decisions or changes in laws or regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">general political and economic conditions and effects of natural or man-made catastrophic events; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">other events or factors, many of which are beyond our control.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology, and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this&#160;&#8220;<i>Risk Factors</i>&#8221; section and elsewhere in this Annual Report could have a dramatic and material adverse impact on the market price of our common stock. You might not be able to resell your shares at or above the price you paid for them.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any trading market for our common stock that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our business. We cannot control the number of securities and industry analysts who publish research on us, the extent of their coverage or the content of their reports. Downgrades of our stock or publishing inaccurate or unfavorable research about our business, would likely lead to a decline in our stock price. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose market visibility and demand for our stock could decrease, which might cause our stock price and any trading volume to decline.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Some provisions of our charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Provisions in our Certificate of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the authorization of 50.0 million shares of &#8220;blank check&#8221;&#160;preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">limiting the removal of directors by the stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">allowing for the creation of a staggered Board of Directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">eliminating the ability of stockholders to call a special meeting of stockholders; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">establishing advance notice requirements for nominations for election to the Board of Directors or for proposing matters that can be acted upon at stockholder meetings.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by the Board of Directors. This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired by or beneficial to our stockholders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any provision of our Certificate of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay for our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We do not intend to pay cash dividends on our capital stock in the foreseeable future.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any payment of cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>We are and may continue to be subject to short selling strategies.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Short sellers of our stock may be manipulative and may attempt to drive down the market price of shares of our Common Stock. Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is therefore in the short seller&#8217;s best interests for the price of the stock to decline, many short sellers (sometime known as &#8220;disclosed shorts&#8221;) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum and generate profits for themselves after selling a stock short. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by blogging have allowed many disclosed shorts to publicly attack a company&#8217;s credibility, strategy and veracity by means of so-called &#8220;research reports&#8221; that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market, on occasion in large scale and broad base. Issuers who have limited trading volumes and are susceptible to higher volatility levels than large-cap stocks, can be particularly vulnerable to such short seller attacks. These short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the United States, are not subject to certification requirements imposed by the SEC and, accordingly, the opinions they express may be based on distortions or omissions of actual facts or, in some cases, fabrications of facts. In light of the limited risks involved in publishing such information, and the enormous profit that can be made from running a successful short attack, unless the short sellers become subject to significant penalties, it is more likely than not that disclosed short sellers will continue to issue such reports.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Significant short selling of a company&#8217;s stock creates an incentive for market participants to reduce the value of that company&#8217;s common stock. Short selling may lead to the placement of sell orders by short sellers without commensurate buy orders because the shares borrowed by short sellers do not have to be returned by any fixed period of time. If a significant market for short selling our common stock develops, the market price of our common stock could be significantly depressed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>General Risk Factors</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Our business and operations would suffer in the event of system failures, cybersecurity attacks, data leakages or other security breaches.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate cybersecurity attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and&#160;the confidentiality, availability, and integrity of our data. There can be no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their effects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from such cybersecurity attacks, including computer viruses, unauthorized access, ransomware attacks, phishing expeditions, natural disasters, terrorism, war and telecommunication and electrical failures. Such an event could cause interruption of our operations. To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could suffer reputational harm or face litigation, or adverse regulatory action and the development of our products could be delayed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our sales force and other employees, third party logistics partners, CMOs, CROs, principal investigators, collaborators, independent contractors, consultants and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Major bank failure or sustained financial market illiquidity, could adversely affect our business, financial condition and results of operations.</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We face certain risks in the event of a sustained deterioration of domestic or international financial market liquidity. In particular:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be unable to access funds in our deposit accounts on a timely basis. Any resulting need to access other sources of liquidity or short-term borrowing would increase our costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the event of a major bank failure, we could face major risks to the recovery of our bank deposits. A substantial portion of our cash and cash equivalents are either held at banks that are not subject to insurance protection against loss or exceed the deposit insurance limit. While we are not currently aware of any liquidity issues directly impacting the financial institutions where we hold cash deposits or securities, if financial liquidity deteriorates, there can be no assurance we will not experience an adverse effect, which may be material, on our ability to access capital and on our business, financial condition and results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Deterioration in general economic conditions in the United States and globally, including the effect of prolonged periods of inflation on our customers and suppliers, could harm our business and results of operations.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our business and results of operations could be adversely affected by changes in national or global economic conditions. These conditions include but are not limited to inflation, rising interest rates, availability of capital markets, energy availability and costs (including fuel surcharges), the negative impacts caused by pandemics and public health crises (such as the COVID-19 pandemic), negative impacts resulting from the military conflicts between Russia and&#160;Ukraine&#160;and between Israel and Palestine, and the effects of governmental initiatives to manage economic conditions. Impacts of such conditions could be passed on to our business in the form of a reduced customer base and/or potential for new bookings due to possible reductions in pharmaceutical and biotech industry-wide spend on research and development and/or economic pressure on our suppliers to pass on increased costs.</p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item1b" title="item1b" href="#"></a>ITEM</b>&#160;<b>1B. UNRESOLVED STAFF COMMENTS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">None.</p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item1c" title="item1c" href="#"></a>ITEM</b>&#160;<b>1C. CYBERSECURITY</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Cybersecurity Risks</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We rely on internal and third-party information technology systems and networks to process, transmit and store electronic information in our operations, including our proprietary business information and that of our customers, suppliers and employees. We use various internal and third-party information technology systems and networks to manage our operations and maintain effective internal control over financial reporting. We also collect and store sensitive data, including intellectual property, proprietary business information and personal information of our customers, suppliers and employees, in our data centers and on our networks. The secure operation of these information technology systems and networks, and the processing and maintenance of this information, are critical to our business operations and strategy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Despite our security measures, our internal and third-party information technology systems and networks may be subject to damage, disruption, or unauthorized access due to a variety of factors, including cyber-attacks by computer hackers, computer viruses, ransomware, phishing, denial-of-service attacks, physical or electronic break-ins, employee error or malfeasance, power outages, natural disasters, or other catastrophic events. Any such damage, disruption, or unauthorized access could compromise our internal and third-party networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disruption to our operations, damage to our reputation, loss of customers, potential harm to our competitive position and additional costs to remediate the issue.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Cybersecurity Practices</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have implemented various measures to manage our risk of information technology systems and networks damage, disruption, or unauthorized access, including regular employee training, monitoring of our systems and networks, maintenance of backup and protective systems and use of modern endpoint detection and response tools, which are integrated into Aytu&#8217;s risk management systems and processes. We have implemented multi-factor authentication (&#8220;MFA&#8221;) across many of our systems and email accounts to prevent unauthorized access and impersonation. We also utilize a cloud-based environment for a large portion of our operations, which enhances our scalability, flexibility and resilience and utilize third parties to perform early external vulnerability assessment and risk identification. We have established extensive backup and recovery procedures to ensure the continuity of our operations in a cyber incident. We also maintain cyber liability insurance coverage as part of our comprehensive risk management program. However, these measures may not be sufficient to prevent, detect, or mitigate the impact of such damage, disruption, or unauthorized access. Moreover, the regulatory environment related to information security, data protection and privacy is increasingly demanding and complex, and compliance with applicable laws and regulations may result in significant costs or require changes in our business practices that could adversely affect our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Cybersecurity Governance</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Board of Directors is actively involved in overseeing our cybersecurity risk management. Our Board of Directors delegates certain oversight functions to our Audit Committee, which reviews our cybersecurity policies, procedures, controls and audit results. Our Audit Committee receives quarterly updates on our cybersecurity posture, threats and incidents from Aytu&#8217;s management. Our Board of Directors and our Audit Committee regularly assess the adequacy of our cybersecurity risk management framework and the effectiveness of our mitigation strategies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our cybersecurity operations are led by our Chief Financial Officer. He is responsible for overseeing the development and implementation of our cybersecurity strategy, policies, standards and practices. He also oversees our cybersecurity team, which includes a staff member who has over 20 years of experience in the field. Our cybersecurity team monitors, detects, responds and reports on cybersecurity threats and incidents, and coordinates with our internal and external stakeholders to ensure the security of our information assets.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Aytu adheres to the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework 2.0, which provides a set of standards, guidelines and best practices to manage cybersecurity-related risks. We have developed and documented our systems disaster recovery plan, which outlines the roles, responsibilities and procedures for restoring our critical systems and data in the event of a cyber incident. We have also crafted internal policies to help maintain a secure environment, such as our information security policy, our data classification policy, our incident response policy and our password policy. We regularly conduct phishing simulations, vulnerability scans and audits to test the effectiveness of our controls and backups, and to identify and remediate any gaps or weaknesses in our cybersecurity posture.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Cybersecurity Incidents</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Despite our efforts to prevent and mitigate cybersecurity incidents, we cannot guarantee that we, or third-party providers that we rely on, will not experience any breaches, disruptions, or unauthorized access to our information technology systems and networks. During fiscal 2024, we did not experience any cybersecurity incidents that materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition, however, there can be no assurance that the measures we have taken to address IT and cybersecurity risks will prove effective in the future. For additional discussion of the IT and cybersecurity risks facing our business, please refer to Part 1, Item 1A, <i>Risk Factors</i> of this Annual Report.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We prioritize investment in cybersecurity risk management and governance. We continually assess the adequacy of our resources and capabilities to address emerging threats, regulatory requirements and changes in technology. As cybersecurity threats evolve, we may need to further enhance our processes and technologies, which could require additional financial resources.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item2" title="item2" href="#"></a>ITEM</b>&#160;<b>2. PROPERTIES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We lease or sublease various properties, including office buildings, manufacturing, research and development facilities and sales offices within the United States. We continuously review and evaluate our facilities as a part of our strategy to optimize our business operations. The following table sets forth a list of our properties as of June 30, 2024:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr class="finHeading">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Location</b></p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Leased/Owned</b></p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Purpose</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Denver, CO</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Leased</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Corporate headquarters</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 26%;">Berwyn, PA</td>
     <td style="vertical-align: bottom; width: 5%;">&#160;</td>
     <td style="vertical-align: bottom; width: 16%; text-align: center;">Leased</td>
     <td style="vertical-align: bottom; width: 5%;">&#160;</td>
     <td style="vertical-align: bottom; width: 48%; text-align: center;">Office</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Grand Prairie, TX <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Leased</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Administrative offices, laboratory and manufacturing facilities</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Oceanside, CA <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Leased</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Warehouse</p> </td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the fourth quarter of fiscal 2024, in connection with the transfer of our manufacturing&#160;of Adzenys and Cotempla to a United States-based&#160;third-party manufacturer, we ceased using this property. This lease expires on December 31, 2024.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In the fourth quarter of fiscal 2024, in connection with the wind down of our Consumer Health Segment, we ceased using this property. This lease expires December 31, 2026.</p> </td>
    </tr>

   </tbody>
  </table>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item3" title="item3" href="#"></a>ITEM</b>&#160;<b>3. LEGAL PROCEEDINGS </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">From time to time, we become involved in or are threatened with legal disputes arising out of our business and operations in the normal course of business. Most of these disputes are not likely to have a material effect on our business, financial condition, or operations.&#160;As of the filing of this report, no legal proceedings are pending against us that we believe individually or collectively are likely to have a materially adverse effect upon our financial condition, results of operations, or cash flows.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Witmer Class-Action Securities Litigation</i>. A stockholder derivative suit filed on&#160;September 12, 2022,&#160;in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, and later amended, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steven Boyd (Armistice&#8217;s Chief Investment Officer and Managing Partner, and a former director of Aytu) (collectively &#8220;Armistice&#8221;), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr, Carl Dockery and Ketan B. Mehta. The amended complaint&#160;alleges that (i) Armistice facilitated the sale of assets of Cerecor, Inc., in&#160;2019&#160;and Innovus Pharmaceuticals, Inc., in&#160;2020&#160;to Aytu in exchange for convertible securities, which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants&#8217; breaches of fiduciary duties, in connection with these acquisitions. The amended complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees. While the Company believes that this lawsuit is without merit and has vigorously defended against it, the Company has agreed to settle the matter, as against it and the director defendants other than Mr. Boyd, for various corporate governance modifications and the payment of plaintiff&#8217;s attorneys&#8217; fees. That settlement is subject to court approval, the hearing on which has&#160;not&#160;yet been scheduled.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Sabby Litigation.&#160;</i>A complaint was filed on&#160;February 22, 2023,&#160;in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund Ltd (&#8220;Sabby&#8221;) and Walleye Opportunities Master Fund Ltd (&#8220;Walleye&#8221;), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders&#160;may&#160;receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that&#160;575,000&#160;warrant shares be due to Sabby on exercise of its warrants rather than&#160;312,908&#160;shares, and that&#160;100,000&#160;warrant shares be due to Walleye on exercise of its warrants rather than&#160;54,146&#160;shares. In&#160;October 2023,&#160;the Company entered into a settlement agreement and general release with Sabby and Walleye.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Stein Litigation</i>. Cielo Stein (&#8220;Stein&#8221;), a former sales specialist, filed a complaint on&#160;February 1, 2023,&#160;in Jefferson County Circuit Court in Kentucky against the Company and its wholly owned subsidiary Neos. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company&#8217;s response to Stein&#8217;s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#8217; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which was denied. A Section&#160;16&#160;pretrial conference was held on June 3, 2024. In August 2024, the Company entered into a settlement agreement and general release with Stein. The case has been dismissed with prejudice.</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item4" title="item4" href="#"></a>ITEM</b>&#160;<b>4. MINE SAFETY DISCLOSURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="part2" title="part2" href="#"></a>PART</b>&#160;<b>II</b></p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item5" title="item5" href="#"></a>ITEM</b>&#160;<b>5. MARKET FOR REGISTRANT</b>&#8217;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock has been listed on the Nasdaq&#160;Capital Market under the symbol &#8220;AYTU&#8221; since October&#160;20, 2017.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On September 16, 2024, the closing price as reported on the Nasdaq of our common stock was $2.57, and there were 187&#160;holders of record of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Equity Compensation Plan Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On May 18, 2023, our stockholders approved the adoption of the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the &#8220;2023 Equity Incentive Plan&#8221;). Prior to our adoption of the 2023 Equity Incentive Plan, we awarded equity incentive grants to our directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (&#8220;Aytu 2015 Plan&#8221;) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (&#8220;the Neos 2015 Plan&#8221;) (collectively the &#8220;2015 Plans&#8221;). For the 2023 Equity Incentive Plan, the stockholders approved (a) 200,000 new shares, (b) 87,155 shares available for grant under the 2015 Plans be &#8220;rolled over&#8221; to the 2023 Equity Incentive Plan and (c) any shares that are returned to the Company under the 2015 Plans be added to the 2023 Equity Incentive Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table displays equity compensation plan information as of June 30, 2024, relating to securities reserved for future issuance upon exercise:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Available for</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities to</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Issuance under</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>be Issued</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>upon</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Compensation</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Plans</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Column C -</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Excluding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>and Rights</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>and Rights</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reflected in</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Plan Category</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Column A)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Column B) <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Column (A))</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Equity compensation plans approved by security holders</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">172,419</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">182,322</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Equity compensation plans not approved by security holders <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,255</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173,674</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">182,322</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This reflects the weighted-average exercise prices of options outstanding. Restricted stocks and restricted stock units do not have exercise prices (see <i>Note 15 - Equity Incentive Plans</i>).</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-align: justify;">This reflects the equity plan we assumed pursuant to the Neos Acquisition and restricted stock previously issued outside of the Aytu 2015 Plan (see <i>Note 15 - Equity Incentive Plans</i>).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Dividend Policy</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our Board of Directors. Our ability to pay dividends on our common stock is limited by restrictions under the terms of our debt agreements. In addition, any future indebtedness that we may incur could preclude us from paying dividends. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p>
  <div>
    &#160;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-transform:uppercase;"><b>&#8203;<a id="item6reserved" title="item6reserved" href="#"></a>ITEM 6. [Reserved]</b></span></p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item7" title="item7" href="#"></a>ITEM</b>&#160;<b>7.</b>&#160;<b>MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing strategy, includes forward-looking statements that involve risks and uncertainties. You should read Part 1, Item 1A, </i><i>Risk Factors</i><i>&#160;of this Form</i>&#160;<i>10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Objective</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The purpose of the Management Discussion and Analysis (the &#8220;MD&amp;A&#8221;) is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the year ended June 30, 2024, and our financial condition as of June 30, 2024. The MD&amp;A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and&#160;notes thereto.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Overview</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are a pharmaceutical company focused on commercializing novel therapeutics. In fiscal 2024 and fiscal 2023, we&#160;operated&#160;two business segments: (i) the Rx Segment, consisting of prescription pharmaceutical products sold primarily through third party wholesalers and (ii) the Consumer Health Segment, which consists of various consumer health products sold directly to consumers. We&#160;use third parties to&#160;manufacture&#160;all of our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have incurred significant losses in each year since inception. Our net losses were $15.8&#160;million and $17.1&#160;million for the years ended June 30, 2024, and 2023, respectively. As of June 30, 2024, and 2023, we had an accumulated deficit of&#160;$320.0&#160;million and $304.1&#160;million, respectively. We expect to continue to incur significant expenses in connection with our ongoing activities, including the integration of our acquisitions and the commercialization of our product pipeline.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In light of our own business activities and external developments in the biotechnology and biopharmaceutical industries, Aytu management and our Board regularly reviews our performance, prospects and risks such as the potential impact to our business resulting from the Company&#8217;s competitive landscape (i.e., entry of generic competitors, payer pressures, new branded entrants, etc.). These reviews have included consideration of potential partnerships, collaborations, and other strategic transactions such as acquisitions or divestitures of programs or technology to enhance stockholder value. Aytu&#8217;s management and Board continues to evaluate potential strategic transactions and business combinations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Significant Developments</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Business Environment</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have continued to experience inflationary pressure and have experienced supply chain disruptions related to the sourcing of raw materials, energy, logistics and labor during fiscal 2024. While we do not have sales or operations in Russia or Ukraine and we do not have material sales or operations in the Middle East, it is possible that the conflict or actions taken in response, could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. We expect that inflationary pressures and supply chain disruptions could continue to be significant across the business throughout&#160;fiscal 2025. The Company has not experienced stock outages&#160;for its&#160;ADHD products since the launch of those products, and the pediatric product supply has remained adequate to satisfy demand for the preceding three years.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Rx Segment</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the fourth quarter of fiscal 2024, we successfully completed the transition of&#160;all&#160;manufacturing&#160;of our ADHD products to a United States-based third-party manufacturer to improve the profitability of these products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of our realization of post-acquisition synergies and product prioritization, we have implemented a portfolio rationalization plan whereby we discontinued or divested five non-core products in our Rx Segment: Cefaclor Oral Suspension, Flexichamber, Tussionex, Tuzistra XR, and ZolpiMist. These products, collectively, contributed $0.1&#160;million and $1.6&#160;million in net revenue during the years ended June 30, 2024, and 2023, respectively.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In July 2023, we entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd&#160;(&#8220;Medomie&#8221;), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. We will supply Adzenys and Cotempla to Medomie, who will be responsible for seeking local regulatory approvals and marketing authorizations for each product. This&#160;agreement&#160;represents Aytu&#8217;s first international commercial agreement&#160;for Adzenys and Cotempla.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Consumer Health Segment</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As previously announced, in fiscal 2024 we began the wind down of the Consumer Health Segment in order to maximize profitability. During the first quarter of fiscal&#160;2025, we completed the wind down of operations and entered into and entered into a definitive agreement to effect the Consumer Health Divestiture.&#160;The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for us&#160;to receive revenue-based royalty payments on future sales of former Consumer Health Segment&#160;products. We expect the savings realized from the strategic shift away from the Consumer Health business, coupled with incremental margin improvements expected from the previously announced&#160;closure of our&#160;Grand Prairie, Texas manufacturing site, to significantly enhance our operating results&#160;and drive stockholder value.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Debt and Equity Financings</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Eclipse Agreement</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In June&#160;2024, we and certain of our&#160;subsidiaries&#160;entered into the Eclipse Amendment No. 5, with the Eclipse Lender. Under the Eclipse Agreement No. 5, we have&#160;two loan agreements, the Eclipse Term Loan&#160;and the Eclipse Revolving Loan.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Eclipse Term Loan&#160;consists of a principal amount of $13.0 million, at an interest rate of SOFR&#160;plus 7.0%, with a&#160;four-year term and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of&#160;$5.6 million to be repaid on June 12, 2028, the maturity date. We used&#160;the proceeds of the Eclipse Term Loan&#160;and a portion of the proceeds from warrant exercises described below&#160;to repay&#160;in full a $15.0 million term note.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Eclipse Revolving Loan&#160;allows us to borrow up to $14.5 million at an interest rate of SOFR plus 4.5%. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan&#160;amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan remains subject to a borrowing base and reserve, and availability blockage requirements and the maturity date, as amended, is June 12, 2028.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Equity Financings</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In June 2023, we raised gross proceeds of $4.0 million from the issuance of (i) 1,743,695 shares of our common stock, and (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of common stock (the &#8220;June 2023 Pre-Funded Warrants&#8221;) and (iii), accompanying Tranche A warrants to purchase 2,173,912 shares of common stock at an exercise price of $1.59 (the &#8220;Tranche A Warrants&#8221;), (iv) and accompanying Tranche B warrants to purchase 2,173,912 shares of common stock at an exercise price of $1.59 (the &#8220;Tranche B&#160;Warrants&#8221;). We received&#160;$3.4 million in proceeds net of underwriting fees and other expenses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In June 2024, the Tranche B Warrants&#160;were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 &#8220;pre-funded&#8221; warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the &#8220;Tranche B Pre-Funded Warrants&#8221;). We used a portion of these proceeds as part of the $15.0 million term loan repayment described above.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Results of Operations</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Comparison of the&#160;Years Ended June 30, 2024, and 2023</b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,002</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">107,399</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26,397</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cost of sales</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">26,416</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,767</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,351</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross profit</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">54,586</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,632</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,046</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating expenses:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Advertising and direct marketing</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,875</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,217</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(12,342</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other selling and marketing</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">22,083</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,231</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,148</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">22,514</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,630</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,116</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,791</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,095</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,304</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Amortization of intangible assets</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,212</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,788</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">424</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Restructuring costs</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,365</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,365</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Impairment expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,705</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,705</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gain from contingent consideration</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(969</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">969</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">59,840</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">83,697</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,857</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Loss from operations</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><b>(5,254</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(17,065</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>11,811</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">568</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">184</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">384</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Interest expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(4,792</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(4,963</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">171</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Derivative warrant liabilities (loss) gain</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(4,004</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,793</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(8,797</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Loss on extinguishment of debt</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(594</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(594</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Loss before income tax</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><b>(14,076</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(17,051</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>2,975</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Income tax expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,768</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,768</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Net loss</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(15,844</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(17,051</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>1,207</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Revenue by Segment</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended </b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, </b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Rx Segment net revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,183</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,799</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,616</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consumer Health Segment net revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,819</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,600</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,781</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total net revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,002</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,399</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,397</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, net&#160;revenue decreased by $26.4&#160;million, or 25% compared to the year ended June 30, 2023. The decrease in our Consumer Health Segment was a result of our decision to wind down this business, which we completed in the first quarter of fiscal 2025. We incurred a $18.1 million decrease in net revenue from our Pediatric Portfolio, which was primarily driven by payer changes that negatively affected prescription coverage, and a $1.4 million decrease that resulted from the discontinuation of certain products. These declines were partially offset by an increase in net revenue from the ADHD Portfolio of $10.9 million, driven by a consistent and reliable supply of our ADHD Portfolio products and strong commercial execution. During fiscal 2025 we anticipate minimal net revenue from the Consumer Health Segment due to its wind down and divestiture during the first quarter of fiscal 2025, and an increase in net revenue from our Rx Segment due to continued commercial execution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Gross Margin</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Rx Segment gross margin</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">75</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">71</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consumer Health Segment gross margin</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated gross margin</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, gross profit decreased by 19% compared to the year ended June 30, 2023. Gross margin&#160;increased to 67% for the year ended June 30, 2024, compared to 62% for&#160;the year ended June 30, 2023.&#160;The improvement was&#160;primarily due to a decline in the lower-margin Consumer Health Segment net revenue from the&#160;wind down of our Consumer Health Segment and&#160;improvements in the higher gross margin ADHD Portfolio, which were&#160;primarily due to efficiencies in production related to higher demand for Adzenys&#160;and Cotempla. We expect gross margin to continue to increase in fiscal 2025 due to the completed wind down and divestiture of the Consumer Health Segment and due to reduced costs associated with the successful transition of our ADHD product manufacturing to a United States-based CMO.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Advertising and Direct Marketing</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, advertising and direct marketing expenses decreased by $12.3&#160;million, or 72%, compared to the year ended June 30, 2023. Advertising and direct marketing expense include direct-to-consumer marketing, advertising, sales, and customer support and processing fees related to our Consumer Health Segment. The reduction in advertising and direct marketing costs were primarily due to our wind down of the Consumer Health Segment during fiscal 2024. We expect&#160;advertising and direct marketing expense to decrease in fiscal 2025 primarily from the completed wind down and divestiture of the Consumer Health Segment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Other Selling and Marketing</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, other selling and marketing expense decreased by $2.1&#160;million, or 9%, compared to the year ended June 30, 2023. The decreases&#160;were primarily driven by commission expense based on prescriptions generated by our sales force and commercial marketing program fees that decrease&#160;as product sales decreased. We expect other selling and marketing expense to increase during fiscal 2025 related to increased commission expense and commercial marketing program fees from anticipated increases in prescription product sales.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>General and Administrative</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, general and administrative expense decreased by $6.1&#160;million or 21%, compared to the year ended June 30, 2023. The decrease was&#160;primarily a result of ongoing cost-cutting initiatives and operational improvements.&#160;We expect general and administrative expense to decrease during fiscal 2025 primarily from the completed wind down and divestiture of the Consumer Health Segment and due to reduced costs associated with the successful transition of our ADHD product manufacturing out of our Grand Prairie, Texas-based manufacturing facility to a United States-based CMO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Research and Development </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">AR101</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">973</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,880</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(907</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">ADHD</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,743</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,803</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(60</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Healight</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(240</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Others</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">65</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">162</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(97</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,791</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,095</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,304</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, research and development expense decreased by $1.3&#160;million, or 32%, compared to the year ended June 30, 2023. Historically, our&#160;research and development costs were primarily associated with AR101 and to a lesser extent, the development of Healight and support for our commercialized products. In October 2022, we announced the suspension of the development of AR101 and Healight to focus on our commercial operations. As a result, research and development spending has&#160;significantly declined. Research and development spending on AR101 during fiscal 2024 relates to $0.5 million charge to wind down the clinical trial and the remaining relates to minimum expenses required for regulatory filings and maintenance of our AR101 intellectual property, and spending on ADHD relates to regulatory filings and maintenance of our intellectual property. We expect our research and development expenses to slightly decrease in the future as we continue to look for cost savings and&#160;focus on commercial operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Amortization of Intangible Assets</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, amortization expense of intangible assets, excluding amounts included in cost of sales, were relatively consistent compared to the year ended June 30, 2023. We expect amortization of intangible assets expense to decrease during fiscal 2025 as a result of certain intangible assets that became fully amortized towards the end of fiscal 2024.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Restructuring Costs</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2023, we recognized $2.4&#160;million of restructuring costs, excluding $0.7&#160;million of inventory write-down&#160;included in cost of sales, related to the wind down of our Consumer Health Segment and the&#160;closure of our&#160;Grand Prairie, Texas manufacturing site. We expect restructuring costs to decrease during fiscal 2025 as the majority of our restructuring&#160;activities were completed during fiscal 2024. See <i>Note 17&#160;&#8211; Restructuring Costs</i>&#160;in the accompanying notes to the consolidated financial statements for further information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Impairment Expense</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, there was no impairment expense recorded except for&#160;impairment expense related to exit and disposal activities recorded to the restructuring costs financial statement line item discussed above and we do not anticipate&#160;impairment charges during fiscal 2025 at this time.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2023, we recognized total impairment expense of $5.7 million, consisting of (i) $5.6 million intangible assets, and (ii) $0.1 million other assets. The impairments were due to increased focus on our commercial efforts in the Rx Segment and discontinued product distributions in the Consumer Health Segment. See <i>Note 7 &#8211; Intangible Assets</i> in the accompanying notes to the consolidated financial statements for further information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Gain from Contingent Consideration</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We fair value our acquisition-related contingent considerations based on our projected results, any changes are reflected through income or expense. During the year ended June 30, 2024, there was no gain from contingent consideration, compared to $1.0 million for the year ended June 30, 2023. The decrease was primarily due to all contingent considerations (including CVRs) expiring or winding down during&#160;fiscal 2023. As a result, we do not expect any contingent consideration gain or loss in fiscal 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Other Income, Net</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, other income, net was relatively consistent compared to the year ended June 30, 2023. We expect other income, net to continue to be relatively consistent during fiscal 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Interest Expense</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, interest expense&#160;was relatively consistent with a decreased of $0.2&#160;million, or 3%, compared to the year ended June 30, 2023. We expect interest expense to decrease during fiscal 2025 due to the extinguishment of our $15.0 million term loan while entering into the&#160;$13.0 million Eclipse Term Loan&#160;on more favorable terms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Derivative Warrant Liabilities (Loss) Gain</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The fair value of derivative warrant liabilities is calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation&#160;model are revalued at each reporting period and changes are reflected through income or expense. For the year ended June 30, 2024, we recognized an unrealized loss of $4.0&#160;million from the fair value adjustment primarily driven by an increase in our stock price during fiscal 2024. For the year ended June 30, 2023, we recognized an unrealized gain&#160;of $4.8&#160;million from the fair value adjustment primarily driven by a decrease in our stock price during fiscal 2023.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Income Tax Expense</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the year ended 2024, there was $1.8&#160;million of income tax expense,&#160;which was an effective tax rate of negative 12.6%. This income tax expense was primarily driven by the limitations on losses as a result of Section 382 of the IRC&#160;changes in ownership coupled with existing valuation allowances. We expect that income tax expense will increase during fiscal 2025 due primarily to increased profitability.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For&#160;the year ended 2023, income tax expense was zero with an effective tax rate of zero percent and reflecting the full valuation allowance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Cash Flows</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth the primary sources and uses of cash for the periods indicated:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,388</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,129</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,741</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in provided by investing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(329</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(117</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(212</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash (used in) provided by financing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,262</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,871</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,133</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Net Cash Used in Operating Activities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in operating activities during these periods primarily reflected our net losses, partially offset by changes in working capital and non-cash charges including impairment, stock-based compensation expense, gain or loss on derivative warrant liabilities, depreciation, amortization and accretion, and other charges.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, net cash used in operating activities totaled $1.4&#160;million. The use of cash was primarily the result of&#160;the decrease in accounts payable and accrued liabilities, partially offset by positive cash earnings (net loss offset by non-cash items primarily from depreciation, amortization and accretion, stock-based compensation expense,&#160;derivative warrant liabilities adjustment, inventory write-down, and other certain non-cash adjustments). Additionally, these were partially offset by funds from the Employee Retention Credit program recorded in other operating liabilities (see&#160;<i>Note 9&#160;</i>&#8211;&#160;<i>Other Liabilities</i>) and a decrease in accounts receivable, net,&#160;inventories and a net decrease in various other operating assets and liabilities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the fiscal year ended June 30, 2023, net cash used in operating activities totaled $5.1 million. The decrease in net cash used was primarily the result of the decrease in operating loss, and increases in accounts payable and accrued liabilities, partially offset by an increase in accounts receivable, inventory, and prepaid expenses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Net Cash Used in Investing Activities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in investing activities is generally related to our merger and acquisitions as well as purchase of assets to support our operations and disposal of assets related to exit and disposal costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in investing activities was $0.3 million during the year ended June 30, 2024, and net cash used in investing activities was&#160;$0.1&#160;million during the year ended June 30, 2023, which was primarily used for the purchase of various property and equipment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Net Cash from Financing Activities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in&#160;financing activities of&#160;$1.3&#160;million during the year ended June 30, 2024, was primarily from $15.7 million of payments made related to the&#160;extinguishment of our term loan,&#160;$2.6 million for fixed payment arrangements&#160;and $0.3 million of payments for debt issuance costs. This financing cash used was&#160;partially offset by $13.0 million of proceeds from the Eclipse Term Loan, $3.5 million of net proceeds from the&#160;issuance of common stock and warrants and $0.9 million of proceeds from our Eclipse Revolving Loan.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash provided by financing activities of $8.9 million during the year ended June 30, 2023, was primarily from $3.4 million of net proceeds from our securities purchase agreement in June 2023, $9.1 million of net proceeds from our August 2022 equity raise, and $2.9 million net proceeds from our sales under the ATM Sales Agreement; partially offset by $2.3 million of net payments made under our revolving credit facility, and fixed payment arrangements totaling $4.3 million.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Capital Resources</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Sources of Liquidity</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have obligations related to our loan agreements and&#160;milestone payments for licensed products and manufacturing purchase commitments. We finance our operations through a combination of sales of our common stock and warrants, borrowings under our revolving credit facility and cash generated from operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Shelf Registrations</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On September 28, 2021, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the &#8220;2021 Shelf&#8221;). As of June 30, 2024,&#160;$82.4 million remains available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitations of Form S-3. The 2021 Shelf expires on October 7, 2024. Given the upcoming expiration of the 2021 Shelf, concurrent with the filing of this Form 10-K we expect to file a new shelf registration statement to cover the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of our&#160;common stock, preferred stock, debt securities, warrants, rights and units (the &#8220;2024 Shelf&#8221;).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On June 8, 2020, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance, and sale by us&#160;of up to an aggregate of $100.0 million of our&#160;common stock, preferred stock, debt securities, warrants, rights and units (the &#8220;2020 Shelf&#8221;). In June 2020, under the 2020 Shelf, we initiated an at-the-market offering program (&#8220;ATM&#8221;), which allowed&#160;us to sell and issue shares of our common stock from time-to-time. On June 2, 2021, we terminated our &#8220;at-the-market&#8221; sales agreement with a sales agent, and on June 4, 2021, we entered into a Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;">SM</sup> Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with a sales agent, pursuant to which we agreed to sell up to $30.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2020 Shelf. During the year ended June 30, 2023, we issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of&#160;$2.9 million. The 2020 Shelf expired in June 2023 and the ATM Agreement was terminated in July 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Underwriting &amp; Placement Agency Agreements</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On June 8, 2023, we entered into a securities purchase agreement with certain institutional investors named therein and a placement agency agreement with Maxim Group LLC, pursuant to which the Company agreed in a best efforts offering to issue and sell to investors in the offering an aggregate of 1,743,695 shares of the Company&#8217;s common stock, pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock at an exercise price of $0.0001, accompanying Tranche A warrants to purchase 2,173,912 shares of common stock at an exercise price of $1.59 (the &#8220;Tranche A Warrants&#8221;), and accompanying Tranche B warrants to purchase 2,173,912 shares of common stock at an exercise price of $1.59 (the &#8220;Tranche B&#160;Warrants&#8221;). The Tranche A Warrants and the Tranche B Warrants&#160;may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. The gross proceeds were $4.0 million, and net proceeds were&#160;$3.4 million after deducting offering expenses. The offering closed on June 13, 2023. In June 2024, the Tranche B Warrants&#160;were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 pre-funded&#160;warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the &#8220;Tranche B Pre-Funded Warrants&#8221;). We used a portion of these proceeds as part of the $15.0 million term loan repayment that occurred in the fourth quarter of fiscal 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On August 11, 2022, we closed an underwritten public offering, pursuant to which we sold an aggregate of (i) 1,075,290 shares of our&#160;common stock, (ii), pre-funded warrants to purchase 87,500 shares of our&#160;common stock, and (ii) accompanying warrants to purchase 1,265,547 shares of our common stock. The shares of common stock (or pre-funded warrants) and the accompanying common warrants were issued separately but could only be purchased together. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant is $8.58, which equals the public offering price per share of the common stock and accompanying common warrant, less the $0.001 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants are exercisable at any time after the date of issuance for a period of five years from the date such common warrants are first exercisable. The number of shares of common stock issuable upon exercise of the common warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. The Company received gross proceeds of $10.0 million and net proceeds were&#160;$9.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Avenue Capital Agreement</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On January 26, 2022, we entered into the Avenue Capital Agreement, pursuant to which the Company received $15.0 million term loan. In the fourth quarter of fiscal 2024, we repaid this term loan in full with proceeds from the Eclipse Term Loan&#160;and a portion of the proceeds from the exercise of the Tranche B Warrants.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Eclipse Agreement</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In June&#160;2024, we and certain of our&#160;subsidiaries&#160;entered into the Eclipse Amendment No. 5, with the Eclipse Lender. Under the Eclipse Agreement No. 5, we have&#160;two loan agreements, the Eclipse Term Loan&#160;and the Eclipse Revolving Loan.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Eclipse Term Loan&#160;consists of a principal amount of $13.0 million, at an interest rate of SOFR&#160;plus 7.0%, with a&#160;four-year term and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of&#160;$5.6 million to be repaid on June 12, 2028, the maturity date. We used&#160;the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below&#160;to repay&#160;in full a $15.0 million term note.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Eclipse Revolving Loan&#160;allows us to borrow up to $14.5 million at an interest rate of SOFR plus 4.5%. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan&#160;amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan remains subject to a borrowing base and reserve, and availability blockage requirements and the maturity date, as amended, is June 12, 2028.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Contractual Obligations, Commitments and Contingencies</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of our acquisitions and licensing agreements, we are contractually and contingently obliged to pay, when due, various fixed and contingent milestone payments. See <i>Note 18 &#8211; Commitments and Contingencies</i> in the accompanying notes to the consolidated financial statements for further information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In May 2022, we entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018, related to Tuzistra (the &#8220;Tuzistra License Agreement&#8221;). Pursuant to such termination, as of June 30, 2024, we have accrued a settlement liability of $6.2&#160;million payable to Tris, with a provision that allows us to pay interest on any principal amounts due but remaining unpaid past July 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Upon closing of the acquisition of a line of prescription pediatric products from Cerecor, Inc. in October 2019, we assumed payment obligations that require us to make fixed and product milestone payments. As of June 30, 2024, up to $2.1&#160;million of fixed and product milestone payments remain to be paid through 2026 and are expected to be paid from the revenue generated by Karbinal.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with our acquisition of the assets from Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, Rumpus Vascular, LLC (collectively, &#8220;Rumpus&#8221;), and only if we resume and ultimately complete clinical development of AR101 and gain regulatory clearances to commercialize the product in multiple markets around the world, we may be required to pay up to $67.5 million in regulatory and commercial-based earn-out payments to Rumpus, which are primarily paid against commercial milestone achievements. Under the licensing agreement with Denovo Biopharma LLC (&#8220;Denovo&#8221;), we made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, we may be required to pay up to $101.7 million. Under the licensing agreement with Johns Hopkins University (&#8220;JHU&#8221;), upon achievement of regulatory and commercial milestone, we may be required to pay up to $1.6 million to JHU. In fiscal 2022, two milestones payable to Rumpus were achieved totaling $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash. The Company also assumed the responsibility for royalties of 3.0% of net revenue from the product, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. With clinical development currently suspended, only if and when we resume and ultimately complete clinical development of AR101, are substantially all milestones payable to these parties.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Critical Accounting Estimates</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of any contingent assets and liabilities at the date of the financial statements, as well as reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While our significant accounting policies are described in more detail in Part II, Item 8, <i>Note 2 </i>&#8211;<i> Summary of Significant Accounting Policies</i> in this Annual Report, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements and notes thereto.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Revenue Recognition</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We generate revenue from product sales through our Rx Segment and Consumer Health Segment. We evaluate our contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations and if they are distinct; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net product sales in the Rx Segment consist of sales of prescription pharmaceutical products under the Rx Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We make&#160;estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#8220;Gross to Net&#8221; adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Gross to Net adjustments includes:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Savings offers.&#160;</i>The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Prompt payment discounts.&#160;</i>Prompt payment discounts are based on standard provisions of wholesalers&#8217;&#160;services.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesale distribution fees.&#160;</i>Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rebates.&#160;</i>The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesaler chargebacks.&#160;</i>The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217;&#160;end customers.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Returns.&#160;</i>Wholesalers&#8217;&#160;contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. Our periodic adjustments of our estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. We continually monitor these provisions and do not believe variances between actual and estimated amounts have been material.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A 10% increase or decrease in these estimates impacts net revenue&#160;by a corresponding increase or decrease of approximately $2.9&#160;million. The estimates related to returns and savings offers have the most significant impact on our Gross to Net adjustment calculation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We generate Consumer Health Segment product revenue from sales of various consumer health products through e-commerce platforms and direct mail. Revenue is generally recognized &#8220;free-on-board&#8221; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by us from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sale. We completed the wind down of the Consumer Health Segment and entered into a definitive agreement to effect the Consumer Health Divestiture in the first quarter of fiscal 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Impairment of Long-lived Assets</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We assess impairment of long-lived assets annually and when events or changes in circumstances indicates that their carrying value amount may not be recoverable. Long-lived assets consist of property and equipment, net&#160;and other intangible assets, net. Circumstances which could trigger a review include but are not limited to: (i) significant decreases in the market price of the asset; (ii) significant adverse changes in the business climate or legal or regulatory factors; (iii) changes in business plans or (iv) expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. Such estimates involve projections of future sales and costs, which may vary from actual results. Declines in the outlook for the related products, particularly soon after fair-value measurement upon acquisition or prior impairment, can negatively impact our ability to recover the carrying value and can result in an impairment charge.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our&#160;strategy is to continue building our portfolio of revenue-generating products by leveraging our commercial team&#8217;s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating prescription products, we decided to abandon active development of our NT0502 (N-desethyloxybutynin), a new chemical entity that is being developed for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, we incurred an impairment charge of $2.6 million related to NT0502 and have terminated the licensing agreement. We also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. Further, the acquired product distribution rights from Innovus was impaired by $3.0 million due to discontinuance of products in the Consumer Health Segment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended June 30, 2024, related to our wind down of our Consumer Health Segment we recorded an inventory write-down&#160;of $0.7&#160;million and restructuring costs totaling $0.2&#160;million related primarily to severance costs and the abandonment of our leased warehouse facility, equipment and other assets. Also,&#160;during the year ended June 30, 2024, related to the closure of our Grand Prairie, Texas manufacturing facility we recorded restructuring costs&#160;totaling $2.2&#160;million related to severance costs and the abandonment of our leased manufacturing facility, equipment and other assets. The inventory write-down was recorded in cost of sales and&#160;restructuring costs&#160;have been recorded in restructuring costs on the consolidated statements of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Warrants</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Equity classified warrants are valued using a Black-Scholes option&#160;pricing model at issuance and are not remeasured. Liability classified warrants are carried at fair value using either the Black-Scholes option pricing model or the Monte Carlo simulation model. Changes in the fair value of liability classified warrants in subsequent periods are recorded as a gain or loss on remeasurement and reported as a component of cash flows from operations.</p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item7a" title="item7a" href="#"></a>ITEM</b>&#160;<b>7A.</b>&#160;<b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, we&#160;are not required to provide information under this item.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
    &#160;
  </div>
  <div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item8" title="item8" href="#"></a>ITEM</b>&#160;<b>8.</b>&#160;<b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> &#160;
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: bottom; width: 92%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#report">Report of Independent Registered Public Accounting Firm&#160;(PCAOB ID <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2023-07-01_2024-06-30" id="ixv-22822">248</ix:nonNumeric>)</a></p> </td><td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#report">64</a></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#balance_sheet">Consolidated Balance Sheets</a></p> </td><td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#balance_sheet">66</a></td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#state_of_op">Consolidated Statements of Operations</a></p> </td><td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#state_of_op">67</a></td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#equity">Consolidated Statements of Stockholders&#8217;&#160;Equity</a></p> </td><td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#equity">68</a></td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#cash_flows">Consolidated Statements of Cash Flows</a></p> </td><td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#cash_flows">69</a></td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#notes">Notes&#160;to the Consolidated Financial Statements</a></p> </td><td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#notes">70</a></td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    63
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="report" title="report" href="#"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To the Board of Directors and Stockholders</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Aytu BioPharma, Inc.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Opinion on the financial statements </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have audited the accompanying consolidated balance sheets of Aytu BioPharma, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of June 30, 2024, and 2023, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024, and 2023, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2024,&#160;in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Basis for opinion </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the United States&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    64
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Critical audit matter</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Variable consideration related to certain gross to net adjustments&#160;</b></i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As described further in Note 2 to the financial statements, the Company estimates adjustments to the transaction price of certain product sales (&#8220;Gross to Net&#8221; adjustments). Certain Gross to Net adjustments involve the use of significant assumptions and judgments to develop the estimate. The most significant assumption used in the ADHD Portfolio savings offers Gross to Net adjustment is the inventory levels in the distribution channel as of the balance sheet date. We identified the ADHD Portfolio savings offerings Gross to Net adjustment as a critical audit matter.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The principal considerations for our determination that the ADHD Portfolio savings offerings Gross to Net adjustment is a critical audit matter are (a) the inherent limitations over management&#8217;s visibility and insight into the underlying details of the source data, which requires management to depend and rely on external data from multiple sources and (b) the extent to which the external data is used by management to develop the estimate of the ADHD Portfolio savings offerings Gross to Net adjustment.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our audit procedures related to this critical audit matter included the following, among others:</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We evaluated the relevance and reliability of the external data used by management to develop the estimate of inventory levels in the distribution channel as of the balance sheet date.</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We evaluated the reasonableness of the&#160;identified significant assumption related to inventory levels in the distribution channel to determine the ADHD Portfolio savings offers Gross to Net adjustment by comparing to external data.</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iii)</p> </td><td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">We tested the overall reasonableness of the ADHD Portfolio savings offers Gross to Net adjustment as of the balance sheet date by developing an expectation for comparison to actual subsequent payments.</td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2023-07-01_2024-06-30" id="ixv-22823">GRANT THORNTON LLP</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have served as the Company&#8217;s auditor since 2022.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2023-07-01_2024-06-30" id="ixv-22824">Denver, Colorado</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">September 26, 2024</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    65
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div></div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;<a id="balance_sheet" title="balance sheet" href="#"></a>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share data)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: center;"><b>ASSETS</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046780" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">20,006</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046781" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,985</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046782" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">23,617</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046783" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,937</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046784" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,633</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046785" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,995</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046786" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046787" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,162</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046788" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">61,891</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046789" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">71,079</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046792" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">693</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046793" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,815</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046795" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046796" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046797" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">52,453</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046798" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-4">58,970</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other non-current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046799" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,229</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046800" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,545</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total non-current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046801" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">56,204</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046802" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,384</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total assets</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c117046803" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">118,095</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c117046804" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">136,463</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: center;"><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046807" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">10,440</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046808" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,478</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046809" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">38,574</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046810" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,799</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Revolving credit facility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046811" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:ShortTermBorrowings" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,395</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046812" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:ShortTermBorrowings" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,563</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current portion of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046813" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046814" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046815" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,962</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046816" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">7,090</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046817" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">62,228</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046818" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">69,015</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046820" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,877</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046821" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,713</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046822" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,745</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046823" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046824" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,529</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046825" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,975</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046826" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,151</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046827" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,091</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Commitments and contingencies (note 18)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c117046828">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c117046829">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stockholders&#8217; equity</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Preferred stock, par value $<span style="-sec-ix-hidden:c117046833"><span style="-sec-ix-hidden:c117046835">.0001</span></span>; <span style="-sec-ix-hidden:c117046836"><span style="-sec-ix-hidden:c117046837">50,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c117046838"><span style="-sec-ix-hidden:c117046840"><span style="-sec-ix-hidden:c117046839"><span style="-sec-ix-hidden:c117046841">no</span></span></span></span> shares issued or outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046831" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046832" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock, par value $<span style="-sec-ix-hidden:c117046844"><span style="-sec-ix-hidden:c117046845">.0001</span></span>; <span style="-sec-ix-hidden:c117046846"><span style="-sec-ix-hidden:c117046847">200,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c117046848"><span style="-sec-ix-hidden:c117046850">5,972,638</span></span> and <span style="-sec-ix-hidden:c117046849"><span style="-sec-ix-hidden:c117046851">5,517,174</span></span> shares issued and outstanding, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046842" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046843" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046852" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">347,688</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046853" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">343,485</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046854" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">319,973</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046855" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">304,129</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046856" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,716</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046857" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,357</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Total liabilities and stockholders&#8217; equity</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c117046858" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">118,095</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c117046859" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">136,463</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">The accompanying notes to the consolidated financial statements are an integral part of this statement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="state_of_op" title="state of op" href="#"></a>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in&#160;thousands, except share and per share data)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046866" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">81,002</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046867" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">107,399</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cost of sales</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046868" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,416</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046869" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,767</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross profit</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046870" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:GrossProfit" scale="3" format="ixt:num-dot-decimal" decimals="-3">54,586</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046871" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:GrossProfit" scale="3" format="ixt:num-dot-decimal" decimals="-3">66,632</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating expenses:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Selling and marketing</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046873" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:SellingAndMarketingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,958</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046874" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:SellingAndMarketingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,448</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046875" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,514</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046876" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">28,630</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046877" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,791</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046878" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,095</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of intangible assets</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046879" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,212</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046880" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,788</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Restructuring costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046881" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RestructuringCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,365</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046882" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:RestructuringCharges" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Impairment expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046883" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:AssetImpairmentCharges" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046884" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AssetImpairmentCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,705</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from contingent consideration</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046885" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046886" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046887" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-4">59,840</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046888" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">83,697</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Loss from operations</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><b>(<ix:nonFraction id="c117046889" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,254</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c117046890" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,065</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046891" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">568</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046892" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">184</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Interest expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(<ix:nonFraction id="c117046893" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,792</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c117046894" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,963</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Derivative warrant liabilities (loss) gain</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117046895" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,004</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046896" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,793</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on extinguishment of debt</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046897" contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">594</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046898" contextRef="d_2022-07-01_2023-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Loss before income tax</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><b>(<ix:nonFraction id="c117046899" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">14,076</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c117046900" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,051</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046901" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,768</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046902" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net loss</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117046903" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,844</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117046904" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,051</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted weighted-average common shares outstanding</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046905" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,537,957</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046906" contextRef="d_2022-07-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,339,906</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046907" contextRef="d_2023-07-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.86</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046908" contextRef="d_2022-07-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">5.11</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">The accompanying notes to the consolidated financial statements are an integral part of this statement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="equity" title="equity" href="#"></a>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share data)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Additional</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Common Stock</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Paid-in</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Stockholders&#8217;</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Capital</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Deficit</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Equity</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046924" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,928,941</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046925" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046926" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">331,386</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c117046927" contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">287,078</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046928" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,308</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117046929" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">18,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046930" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046931" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,046</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046932" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046933" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,046</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Issuance of common stock, net of $<span style="-sec-ix-hidden:c117046943">1,004</span> issuance cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046934" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,606,413</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046935" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046936" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,053</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046937" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046938" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046945" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046947" contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,051</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046948" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,051</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances, June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046949" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,517,174</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046950" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046951" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">343,485</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046952" contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">304,129</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046953" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,357</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046954" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046955" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046956" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046957" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117046958" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock from exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046959" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="aytu:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">441,214</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046960" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="aytu:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046961" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="aytu:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,290</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046962" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="aytu:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046963" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,290</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117046965" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046967" contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,844</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117046968" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,844</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances, June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117046969" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,972,638</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117046970" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117046971" contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">347,688</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c117046972" contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">319,973</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117046973" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,716</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes to the consolidated financial statements are an integral part of this statement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cash_flows" title="cash flows" href="#"></a>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flows from operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046981" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,844</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046982" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,051</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Adjustments to reconcile net loss to cash used in operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation, amortization and accretion</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046984" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,272</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046985" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,815</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046986" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,913</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046987" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,046</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Derivative warrant liabilities loss (gain)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046988" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,004</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046989" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,793</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of debt discount and issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046990" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-3">597</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046991" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-3">559</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Inventory write-down</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046992" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,270</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046993" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,351</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Impairment expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046994" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:AssetImpairmentCharges" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117046995" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AssetImpairmentCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,705</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Gain from contingent consideration</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046996" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117046997" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Non-cash loss on extinguishment of debt</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046998" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:NoncashGainLossOnExtinguishmentOfDebt" scale="3" format="ixt:num-dot-decimal" decimals="-5" sign="-">400</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117046999" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:NoncashGainLossOnExtinguishmentOfDebt" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other non-cash adjustments</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047000" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNoncashIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">660</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047001" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNoncashIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts receivable, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047003" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">5,320</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047004" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,153</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Inventories</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117047005" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,908</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047006" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,609</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047007" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047008" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">846</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117047009" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,879</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047010" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,384</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued liabilities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117047011" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">9,567</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047012" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,605</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other operating assets and liabilities, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047013" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,847</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047014" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,872</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash used in operating activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117047015" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,388</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117047016" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,129</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flows from investing activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other investing activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047018" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">329</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047019" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">117</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash used in investing activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117047020" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">329</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117047021" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">117</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flows from financing activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net proceeds from issuance of common stock and warrants</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c117047023" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,467</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047024" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,575</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Payment made to fixed payment arrangement</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117047025" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:PaymentsOfFixedPaymentArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,566</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047026" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:PaymentsOfFixedPaymentArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,266</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net proceeds (payments) made on revolving credit facility</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047027" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="3" format="ixt:num-dot-decimal" decimals="-3">832</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047028" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">2,250</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Payments made to borrowings</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117047029" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,722</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047030" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" format="ixt:num-dot-decimal" decimals="-3">96</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from borrowings</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047031" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-6">13,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047032" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Payment for debt issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047033" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">273</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047034" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">92</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash (used in) provided by financing activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c117047035" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,262</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c117047036" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,871</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net change in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117047037" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,979</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047038" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,625</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047039" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,985</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047040" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-4">19,360</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and cash equivalents at end of period</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c117047041" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">20,006</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c117047042" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,985</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Supplemental disclosure of cash flows information:</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8203;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8203;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Cash paid for interest</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047044" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,039</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047045" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,812</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Cash paid for income taxes</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047046" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxesPaidNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,608</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047047" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxesPaidNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Non-cash investing and financing activities:</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8203;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8203;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other non-cash investing and financing activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047049" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" format="ixt:num-dot-decimal" decimals="-3">787</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047050" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" format="ixt:num-dot-decimal" decimals="-3">147</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes to the consolidated financial statements are an integral part of this statement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" title="notes" href="#"></a>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2740527" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> - Nature of Business and Financial Condition</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Aytu BioPharma, Inc. (&#8220;Aytu,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on <em style="font: inherit;"> August 9, 2002, </em>in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on <em style="font: inherit;"> June 8, 2015. </em>Following the acquisition of Neos Therapeutics, Inc. (&#8220;Neos&#8221;)&#160;in <em style="font: inherit;"> March 2021 (</em>the&#160;&#8220;Neos Acquisition&#8221;),&#160;the Company changed its name to Aytu BioPharma, Inc.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a&#160;focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to&#160;continue building its portfolio of revenue-generating products and leveraging its commercial team&#8217;s expertise to build leading brands within large therapeutic markets. The Company&#8217;s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including attention deficit hyperactivity disorder (&#8220;ADHD&#8221;). The Company operates through <span style="-sec-ix-hidden:c117047052">two</span> business segments: (i) the Rx segment, consisting of prescription pharmaceutical products sold primarily through <em style="font: inherit;">third</em> party wholesalers (the &#8220;Rx Segment&#8221;) and (ii) the consumer health segment, which consists of various consumer healthcare products sold directly to consumers&#160;through certain e-commerce platforms (the &#8220;Consumer Health Segment&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Rx Segment primarily consists of <em style="font: inherit;">two</em> product portfolios. The <em style="font: inherit;">first</em> consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (&#8220;Adzenys&#8221;) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets&#160;(&#8220;Cotempla&#8221;) for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;) (the &#8220;ADHD Portfolio&#8221;). The <em style="font: inherit;">second</em> consists&#160;primarily of Karbinal&#174; ER (carbinoxamine maleate extended-release oral suspension) (&#8220;Karbinal&#8221;), an extended-release <em style="font: inherit;">first</em>-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, <em style="font: inherit;">two</em> complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the &#8220;Pediatric Portfolio&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment&#160;consisted&#160;of multiple consumer health products competing in large healthcare categories&#160;including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health&#160;and general wellness, which was commercialized through direct mail and e-commerce marketing channels. The Company&#160;began to wind down the Consumer Health Segment in fiscal <em style="font: inherit;">2024.</em> During the <em style="font: inherit;">first</em> quarter of fiscal&#160;<em style="font: inherit;">2025,</em> the Company&#160;completed the wind down of operations and entered into a definitive agreement to divest the&#160;Consumer Health Segment to a private, e-commerce focused company (the &#8220;Consumer Health Divestiture&#8221;).&#160;The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for the&#160;Company to receive up to $<ix:nonFraction id="c117047062" contextRef="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember" unitRef="USD" name="aytu:RevenuebasedRoyaltyCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million&#160;of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024,</em> the Company concluded that it had alleviated the Company&#8217;s previously disclosed substantial doubt about its ability to continue as a going concern. This was primarily the result of the extinguishment of its $<ix:nonFraction id="c117047065" contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">15.0</ix:nonFraction> million term loan that was due in <em style="font: inherit;"> January 2025, </em>while entering into a new $<ix:nonFraction id="c117047066" contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-6">13.0</ix:nonFraction> million term loan on more favorable terms to the Company with a maturity date of <em style="font: inherit;"> June 2028. </em>Further, the Company maintained and extended the maturity date of its revolving credit facility&#160;to <em style="font: inherit;"> June 2028 </em>and had $<ix:nonFraction id="c117047067" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction> million of remaining availability to draw upon as of <em style="font: inherit;"> June 30, 2024 (</em>see <i>Note <em style="font: inherit;">10</em> &#8211; Revolving Credit Facility</i> and <i>Note <em style="font: inherit;">11</em> &#8211; Long-Term Debt</i> for further detail). In addition, during fiscal <em style="font: inherit;">2024</em> the Company received $<ix:nonFraction id="c117047071" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.5</ix:nonFraction> million of net proceeds from the exercise of warrants, was in compliance with all of its debt covenants as of <em style="font: inherit;"> June 30, 2024, </em>and through the filing of this Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> June 30, 2024 (</em>&#8220;Form <em style="font: inherit;">10</em>-K&#8221; or &#8220;Annual Report&#8221;). The Company has implemented and continues to implement plans to achieve operating profitability and increase cash flows, including various margin improvement initiatives, the wind down and divestiture of the Company&#8217;s unprofitable Consumer Health Segment, and the indefinite suspension of certain research and development activities. Considering these factors, management has concluded that as of the filing of this Form <em style="font: inherit;">10</em>-K, substantial doubt about the Company&#8217;s ability to continue as a going concern did <em style="font: inherit;">not</em> exist.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial Statements and notes thereto have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within <em style="font: inherit;">one</em> year after the date the consolidated financial statements and notes thereto are available to be issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">70</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>&#160;
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2740528" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note&#160;<em style="font: inherit;">2</em> - Summary of Significant Accounting Policies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ConsolidationPolicyTextBlock" id="c117050705" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Principals of Consolidation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial statements&#160;and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c117050706" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Basis of Presentation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial statements&#160;and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;)</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:GoingConcernPolicyTextBlock" id="c117050707" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Going Concern Determination</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the financial statements are available to be issued. The evaluation is based on relevant conditions and events that are known and reasonably knowable within <em style="font: inherit;">one</em> year after the date that the financial statements are available to be&#160;issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends. See&#160;<i>Note <em style="font: inherit;">1</em>&#160;&#8211; Nature of Business and Financial Condition</i>&#160;for further detail on the evaluation performed by the Company.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:UseOfEstimates" id="c117050708" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results <em style="font: inherit;"> may </em>differ from estimates. In the accompanying consolidated financial statements and notes thereto, estimates are used for, but <em style="font: inherit;">not</em> limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="c117050709" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Prior Period Reclassification</i></b><i>. </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Certain prior year amounts in the Company&#8217;s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did <em style="font: inherit;">not</em> impact operating results or cash flows for the fiscal years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> or its financial position as of <em style="font: inherit;"> June 30, 2024</em>, or <em style="font: inherit;"> June 30, 2023</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Previously Reported Prepaid Expenses Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company identified that certain of the Company&#8217;s prepaid expenses totaling $<ix:nonFraction id="c117047117" contextRef="i_2023-06-30_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis-ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:PrepaidExpenseCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.8</ix:nonFraction> million that were previously reported as current assets as of <em style="font: inherit;"> June 30, 2023, </em>should have been classified as non-current assets as of <em style="font: inherit;"> June 30, 2023. </em>The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99,</em> &#8220;Materiality&#8221; and concluded that the omission was <em style="font: inherit;">not</em> material to any of the previously issued consolidated financial statements and began reporting the prepaid expenses as non-current within this Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c117050710" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Cash and Cash Equivalents</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)&#160;insurance limits, and cash balances in the money market funds are <em style="font: inherit;">not</em> FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">71</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="c117050711" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Accounts Receivable, Net</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company&#8217;s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company&#8217;s customers&#8217; financial condition;&#160;payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers&#160;and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts&#160;which were previously written off are&#160;recorded as a reduction of bad debt expense in the period the payment is collected. If the Company&#8217;s actual collection experience changes, revisions to the&#160;Company&#8217;s allowance for credit losses <em style="font: inherit;"> may </em>be required. After attempts to collect a receivable have failed, the receivable is written off against the allowance for credit losses. The allowance for credit losses&#160;was <span style="-sec-ix-hidden:c117047150"><span style="-sec-ix-hidden:c117047154">zero</span></span> for both years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em> The allowance for discounts was $<ix:nonFraction id="c117047160" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscounts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117047164" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscounts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.8</ix:nonFraction>&#160;million as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> respectively. The allowance for chargebacks was $<ix:nonFraction id="c117047170" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacks" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction>&#160;million at both&#160;<em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below presents the opening and closing balances of accounts receivable, gross&#160;from customers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="c2740529" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accounts Receivable, Gross</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047386" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:AccountsReceivableGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,219</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047387" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,708</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047388" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsReceivableGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,927</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047389" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">6,488</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047390" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccountsReceivableGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,439</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below details the change in allowance for discounts&#160;and allowance for chargebacks for the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="c2740530" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt; width: 55%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Discounts</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Chargebacks</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Total Allowance</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2022</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047396" contextRef="i_2022-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,301</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047397" contextRef="i_2022-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacks" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,206</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047398" contextRef="i_2022-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,507</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047399" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,074</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047400" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,554</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047401" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,628</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047402" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscountsRecovery" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">8,597</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047403" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksRecovery" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,548</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047404" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,145</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2023</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047405" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,778</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047406" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacks" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,212</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047407" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,990</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047408" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,886</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047409" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,812</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047410" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,698</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047411" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscountsRecovery" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">6,024</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047412" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksRecovery" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,842</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047413" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,866</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2024</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047414" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-4">640</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047415" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacks" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,182</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047416" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,822</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:InventoryPolicyTextBlock" id="c117050712" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Inventories</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are <em style="font: inherit;">no</em> alternate uses for the inventory, the Company will record a charge to cost of sales to reduce the value of the inventory to net realizable value in the period the impairment is identified.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c117050713" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally <span style="-sec-ix-hidden:c117047191">two</span> to <span style="-sec-ix-hidden:c117047194">seven</span> years. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">72</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c117050714" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Leases</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#8220;ROU&#8221;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is <em style="font: inherit;">not</em> readily determinable based upon the information available at the lease commencement date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#8217;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#8217;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of <em style="font: inherit;">12</em> months or less.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operating leases are included in other liabilities in the Company&#8217;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of&#160;debt and debt, net of current portion in the Company&#8217;s consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c117050715" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Acquisitions</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do <em style="font: inherit;">not</em> meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does <em style="font: inherit;">not</em> result in goodwill.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Warrants</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c117050716" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenue Recognition</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company generates revenue from product sales through its Rx Segment&#160;and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following <em style="font: inherit;">five</em>-step model: (<em style="font: inherit;">1</em>)&#160;identify the contract with the customer; (<em style="font: inherit;">2</em>)&#160;identify the performance obligations; (<em style="font: inherit;">3</em>)&#160;determine the transaction price; (<em style="font: inherit;">4</em>)&#160;allocate the transaction price to the performance obligations; and (<em style="font: inherit;">5</em>)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is <em style="font: inherit;">not</em> a recognized financing component related to product sales.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rx Segment</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms.&#160;The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within <em style="font: inherit;">one</em>&#160;year.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">73</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Rx Segment net&#160;revenue is recognized net of consideration paid to the Company&#8217;s customers and other adjustments to the transaction price (known as &#8220;Gross to Net&#8221; adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Gross to Net adjustments include:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Savings offers.</i>&#160;The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Prompt payment discounts.</i>&#160;Prompt payment discounts are based on standard provisions of wholesalers&#8217;&#160;services.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesale distribution fees.&#160;</i>Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rebates.&#160;</i>The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from <em style="font: inherit;">third</em>-party providers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesaler chargebacks.</i>&#160;The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217;&#160;end customers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Returns.</i>&#160;Wholesalers&#8217;&#160;contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting <em style="font: inherit;">six</em> months prior to expiry date to <em style="font: inherit;">twelve</em> months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which <em style="font: inherit;"> may </em>vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> follow historical trends. The Company&#8217;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do <em style="font: inherit;">not</em> believe variances between actual and estimated amounts have been material.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Consumer Health Segment</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment, which was divested of&#160;in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2025,</em> had net revenue which was from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue was&#160;generally recognized &#8220;free-on-board&#8221; shipping point, as those were&#160;the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer were&#160;excluded from net revenue. Shipping and handling costs associated with outbound freight after control over a product had&#160;transferred to a customer were accounted for as a fulfillment cost and were&#160;included in cost of sales.&#160;The Company expensed&#160;the incremental costs to obtain a contract as incurred, since they are satisfied within <em style="font: inherit;">one</em>&#160;year.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ConcentrationRiskCreditRisk" id="c117050717" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Concentration of Credit Risk</i></b><i>. </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is <em style="font: inherit;">not</em> exposed to significant credit risk due to the financial position of those institutions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">74</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#8217;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#8217;s products to retailers. The loss of <em style="font: inherit;">one</em> or more of these large customers could have a material adverse effect on the Company&#8217;s business, operating results or financial condition. The Company does <em style="font: inherit;">not</em> charge interest or require collateral related to its accounts receivable. Credit terms are generally <span style="-sec-ix-hidden:c117047243">thirty</span>&#160;to <span style="-sec-ix-hidden:c117047245">sixty</span> days.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table presents customers that contributed more than <em style="font: inherit;">10%</em> of gross revenue and accounts receivable<i>: </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="c2740531" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Gross Revenue</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Accounts Receivable</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer A</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047429" contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">33</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047430" contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047431" contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="1">40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047432" contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer B</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047433" contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="1">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047434" contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047435" contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047436" contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer C</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047437" contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047438" contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047439" contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">11</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047440" contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:num-dot-decimal" decimals="2">14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:CostOfSalesPolicyTextBlock" id="c117050718" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Costs of Sales</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Costs of sales consists primarily of manufactured product cost, products acquired from <em style="font: inherit;">third</em>-party manufacturers, freight, production, inventory write-downs,&#160;indirect manufacturing overhead costs and United States Food and Drug Administration&#160;(&#8220;FDA&#8221;) fees for commercialized products. Certain of the Company&#8217;s sales activities depend on licensing arrangements that <em style="font: inherit;"> may </em>require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company&#8217;s <em style="font: inherit;">third</em>-party logistics companies are included in costs of sales.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c117050719" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for stock-based payment&#160;compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#8217;s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#8220;simplified method,&#8221; which is the midpoint between the vesting date and the end of the contractual term and is&#160;utilized&#160;by the Company as it does <em style="font: inherit;">not</em> have sufficient historical data to determine a more reliable expected term estimate. The risk-free interest rate is based on the United States&#160;Treasury yield in effect at the time of the grant for the expected term of the award. The Company does <em style="font: inherit;">not</em>&#160;anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="c117050720" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Employee Benefits Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company&#160;has a <em style="font: inherit;">401</em>(k)&#160;plan&#160;(&#8220;Aytu <em style="font: inherit;">401</em>(k) Plan&#8221;), which&#160;allows participants to contribute a portion of their salary, subject to eligibility requirements and annual Internal Revenue Service (&#8220;IRS&#8221;) limits.&#160;The Aytu <em style="font: inherit;">401</em>(k) Plan&#160;matches <ix:nonFraction id="c117047258" contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-FirstThreePercentContributionByEmployeesMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" format="ixt:num-dot-decimal" decimals="0">100</ix:nonFraction>% of the <em style="font: inherit;">first</em> <ix:nonFraction id="c117047261" contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-FirstThreePercentContributionByEmployeesMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% contributed by employees and matches <ix:nonFraction id="c117047262" contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentAndFivePercentContributionByEmployeesMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% of the next <ix:nonFraction id="c117047264" contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentContributionByEmployeesMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">4</ix:nonFraction>% and <ix:nonFraction id="c117047265" contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFivePercentContributionByEmployeesMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">5</ix:nonFraction>% contributed by employees. The Company&#8217;s match for the Aytu <em style="font: inherit;">401</em>(k) Plan was $<ix:nonFraction id="c117047268" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction>&#160;million for both of the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c117050721" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Research and Development</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Research and development costs are expensed as incurred and include salaries and benefits;&#160;facilities costs;&#160;overhead costs;&#160;raw materials;&#160;laboratory and clinical supplies;&#160;clinical trial costs;&#160;contract services;&#160;milestone payments and fees paid to regulatory authorities for review and approval of the Company&#8217;s product candidates;&#160;and other related costs.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="c117050722" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are <em style="font: inherit;">not</em> subject to amortization.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">75</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c117050723" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Impairment of Long-lived Assets</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are <em style="font: inherit;">not</em> limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; or (iv)&#160;expectations that the asset will more likely than <em style="font: inherit;">not</em> be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:BusinessCombinationsContingentConsiderationPolicyTextBlock" id="c117050724" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Contingent Consideration</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The consideration for the Company's&#160;acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of <span style="-sec-ix-hidden:c117047278">zero</span> and $<ix:nonFraction id="c117047280" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" format="ixt:num-dot-decimal" decimals="-6" sign="-">1.0</ix:nonFraction> million for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> respectively. The Company did <em style="font: inherit;">not</em> have any contingent consideration recorded on its consolidated balance sheets as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="c117050725" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Advertising and Direct Marketing Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Advertising and direct marketing costs consist&#160;of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $<ix:nonFraction id="c117047286" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.9</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117047287" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">17.2</ix:nonFraction>&#160;million of advertising costs for the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c117050726" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Income Taxes</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the&#160;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than <em style="font: inherit;">not</em> that some portion or all of its deferred tax asset will <em style="font: inherit;">not</em> be utilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em>&#160;to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:DebtPolicyTextBlock" id="c117050727" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Debt Discount and Issuance Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Debt issuance costs reflect fees paid to lenders and <em style="font: inherit;">third</em> parties directly related to issuing debt. Debt discount&#160;and issuance costs related to term loans are reported as direct deductions&#160;to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition to interest expense. Debt issuance costs related to a revolving credit facility are classified as assets and subsequently amortized using the straight-line method over the term of the revolving credit facility as additional interest expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c117050728" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Segment Information</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s operating segments engage in business activities from which it <em style="font: inherit;"> may </em>earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Company&#8217;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#8217;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has <span style="-sec-ix-hidden:c117047295">two</span> reportable segments: the Rx Segment and the Consumer Health Segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">76</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:LegalCostsPolicyTextBlock" id="c117050729" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Paragraph IV Litigation Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Legal costs incurred by the Company in the enforcement of the Company&#8217;s intellectual property rights are charged to expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:BusinessCombinationsPolicy" id="c117050730" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Business Combinations</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:EmployeeRetentionCreditPolicyTextBlock" id="c117050731" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Employee Retention Credit</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> March 27, 2020, </em>the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) to provide certain relief as a result of the COVID-<em style="font: inherit;">19</em> pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (&#8220;ERC&#8221;), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to <em style="font: inherit;">70%</em> of the qualified wages paid to employees after <em style="font: inherit;"> December 31, 2020, </em>through <em style="font: inherit;"> September 30, 2021. </em>The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-<em style="font: inherit;">19</em> pandemic.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As there is <em style="font: inherit;">no</em> authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (&#8220;IAS&#8221;) <em style="font: inherit;">20,</em> Accounting for Government Grants and Disclosure of Government Assistance (&#8220;IAS <em style="font: inherit;">20&#8221;</em>). In accordance with IAS <em style="font: inherit;">20,</em> the Company recorded a $<ix:nonFraction id="c117047306" contextRef="i_2024-03-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="aytu:EmployeeRetentionCredit" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.8</ix:nonFraction> million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em> Further in accordance with IAS <em style="font: inherit;">20,</em> when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (the &#8220;IRC&#8221;), the ERC accrual shall be recognized as a benefit in other income in the consolidated statement of operations. The associated vendor fee of $<ix:nonFraction id="c117047313" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="aytu:EmployeeRetentionCreditVendorFee" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million was expensed as incurred in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c117050732" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Net Income (Loss) Per Share</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company incurred a net loss and did <em style="font: inherit;">not</em> include common equivalent shares in the computation of diluted net loss&#160;per share because the effect would have been anti-dilutive.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth securities excluded from the calculation of diluted earnings per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c2740532" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 56.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants to purchase common stock - liability classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c117047448" contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,057,766</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047449" contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,498,980</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Warrants to purchase common stock - equity classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047451" contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">18,114</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047452" contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">39,072</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee stock options</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047454" contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">146,539</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047455" contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">52,762</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047457" contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047458" contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,996</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock units</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047460" contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,775</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047461" contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,963</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047463" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,249,554</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047464" contextRef="d_2022-07-01_2023-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,636,773</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">77</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c117050733" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Recently Adopted Accounting Pronouncements </b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Financial Instruments - Credit Losses</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments&#8212;Credit Losses</i> (&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>), which requires the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after <em style="font: inherit;"> December 15, 2019. </em>However, in <em style="font: inherit;"> October 2019, </em>the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after <em style="font: inherit;"> December 15, 2022. </em>The effective dates for the amendments in ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> on <em style="font: inherit;"> July 1, 2023. </em>The Company evaluated the impact of adoption of ASUs <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> and <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> and concluded that the application of the new standards did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Debt</i>&#160;-&#160;<i>Debt with Conversion and Other Options</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em> <i>Debt&#8212;Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>)&#8212;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company&#160;adopted the guidance on <em style="font: inherit;"> July 1, 2024, </em>and the adoption of the standard did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Segment Reporting</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07&#8221;</em>). ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods in fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#8217;s consolidated financial statements and disclosures.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other than the application of IAS <em style="font: inherit;">20</em> for the ERC, there have been <em style="font: inherit;">no</em> significant changes to the Company&#8217;s significant accounting policies and there is <em style="font: inherit;">no</em> other accounting guidance has been issued and <em style="font: inherit;">not</em> yet adopted that is applicable to the Company and that the Company expects would have a material effect on the Company&#8217;s consolidated financial statements and&#160;related disclosures as of <em style="font: inherit;"> June 30, 2024</em>, and through the filing of this Form <em style="font: inherit;">10</em>-K.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">78</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="c2740533" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3</em> - Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company disaggregates its revenue into <span style="-sec-ix-hidden:c117047466">two</span> segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys&#160;and Cotempla; and the Pediatric Portfolio, comprised of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. The Company completed its&#160;wind down of the Consumer Health Segment and entered into a definitive agreement to effect the&#160;Consumer Health Divestiture in the <em style="font: inherit;">first</em> quarter of fiscal&#160;<em style="font: inherit;">2025.</em> The Consumer Health Segment was&#160;comprised of over <span style="-sec-ix-hidden:c117047469">ten</span> consumer health products.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenues by Segment</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by segment for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c4EAECB60-5F52-4462-AD27-373E4052829A" escape="true" continuedAt="c50794523-E747-40D8-8F2B-280C3DF5D8A0">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Rx Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047481" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047482" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">73,799</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Consumer Health Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047483" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047484" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-5">33,600</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047485" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">81,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047486" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">107,399</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenues by Product Portfolio</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="c50794523-E747-40D8-8F2B-280C3DF5D8A0">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADHD Portfolio net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047493" contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">57,784</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047494" contextRef="d_2022-07-01_2023-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,855</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pediatric Portfolio net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047495" contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">7,280</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047496" contextRef="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,377</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047497" contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">119</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047498" contextRef="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,567</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total Rx Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047499" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047500" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">73,799</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment was&#160;comprised of <em style="font: inherit;">one</em> product portfolio.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenues by Geographic Location</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by geographic location as determined by the billing address of the Company&#8217;s customers for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="c2740536" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">United States net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047507" contextRef="d_2023-07-01_2024-06-30_StatementGeographicalAxis-US" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">80,911</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047508" contextRef="d_2022-07-01_2023-06-30_StatementGeographicalAxis-US" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">106,918</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">International net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047509" contextRef="d_2023-07-01_2024-06-30_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047510" contextRef="d_2022-07-01_2023-06-30_StatementGeographicalAxis-NonUsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">481</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047511" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">81,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047512" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">107,399</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">79</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:InventoryDisclosureTextBlock" id="c2740537" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em> - Inventories</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="c2740538" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047522" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:num-dot-decimal" decimals="-3">266</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047523" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,301</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Work in process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047524" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,725</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047525" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047526" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,642</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047527" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,738</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047528" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,633</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047529" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,995</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company incurred inventory write-downs of&#160;$<ix:nonFraction id="c117047514" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.3</ix:nonFraction>&#160;million for the year ended <em style="font: inherit;"> June 30, 2024, </em>primarily a result of unsalable and slow-moving products&#160;and a $<ix:nonFraction id="c117047515" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction>&#160;million write-down as part of the wind down of the Consumer Health Segment.&#160;The Company incurred inventory write-downs of $<ix:nonFraction id="c117047516" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.4</ix:nonFraction>&#160;million for the year ended <em style="font: inherit;"> June 30, 2023, </em>primarily as a result of unsalable and slow-moving products.</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2740539" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em> - Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Property and equipment, net consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2740540" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047542" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,117</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047543" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,433</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Office equipment, furniture and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047544" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">945</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047545" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,125</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lab equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047546" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">721</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047547" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">832</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047548" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">35</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047549" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">999</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Assets under construction</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047550" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047551" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">107</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047552" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,818</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047553" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,496</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047554" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,125</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047555" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,681</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047556" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">693</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047557" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,815</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Depreciation expense was $<ix:nonFraction id="c117047531" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117047532" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction>&#160;million during the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively. During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company did <span style="-sec-ix-hidden:c117047534">not</span> record a material gain or loss on disposal of equipment and during the year ended&#160;<em style="font: inherit;"> June 30, 2023</em>, the Company recognized a gain of $<ix:nonFraction id="c117047535" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million on the disposal of equipment.</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:LeasesDisclosureTextBlock" id="c2740541" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">6</em> - Leases</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases were for equipment. These leases have original lease periods expiring between <em style="font: inherit;">2022</em>&#160;and <em style="font: inherit;">2030.</em> Most leases include option provisions under which the parties <em style="font: inherit;"> may </em>extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company&#8217;s lease agreements generally do <em style="font: inherit;">not</em> contain any material residual value guarantees or material restrictive covenants. The Company had <ix:nonFraction id="c117047562" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiability" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> remaining finance leases recorded as of <em style="font: inherit;"> June 30, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $<ix:nonFraction id="c117047563" contextRef="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.5</ix:nonFraction> million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does <em style="font: inherit;">not</em> provide an implicit rate, a borrowing rate of <ix:nonFraction id="c117047566" contextRef="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" unitRef="Pure" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">6.7</ix:nonFraction>% was used to determine the present value of future lease payments.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">80</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024,</em> as part&#160;of the previously announced wind down of the Consumer Health Segment and the closure of the&#160;Grand Prairie, Texas manufacturing site, the Company ceased using the Oceanside, California warehouse and the Grand Prairie, Texas manufacturing facility. As a result, the Company&#160;wrote off the remaining related operating lease ROU assets. The lease for the Oceanside, California warehouse and the&#160;Grand Prairie, Texas manufacturing site are&#160;set to&#160;expire on <em style="font: inherit;"> December 31, 2026, </em>and on <em style="font: inherit;"> December 31, 2024, </em>respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2024, </em>the Company entered into a forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;from the owner of the office space that the Company is&#160;currently renting under a sublease arrangement. The Company has determined that it is an operating lease, and that lease commencement occurred in <em style="font: inherit;"> July 2024. </em>The&#160;initial lease termination date is&#160;<em style="font: inherit;"> July 31, 2030, </em>and under the lease agreement the Company has <em style="font: inherit;">one five</em>-year renewal option to extend the lease through <em style="font: inherit;"> July 2035.&#160;</em>Undiscounted minimum monthly rent payments average approximately $<ix:nonFraction id="c117047571" contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember" unitRef="USD" name="aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,000</ix:nonFraction>&#160;over the initial term of the lease. The Company has elected to utilize the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company will record an operating lease ROU asset of $<ix:nonFraction id="c117047573" contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million and a lease liability of $<ix:nonFraction id="c117047574" contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million at lease commencement in <em style="font: inherit;"> July 2024.&#160;</em>The ROU asset and lease liability will be&#160;recorded at present value using an incremental borrowing rate of <ix:nonFraction id="c117047575" contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember" unitRef="Pure" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">12.3</ix:nonFraction>%.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> May 2023, </em>the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in <em style="font: inherit;"> September 2023 (</em>lease commencement) with an initial term of <span style="-sec-ix-hidden:c117047576">five</span> and a half years. The Company recorded an operating lease ROU asset of $<ix:nonFraction id="c117047577" contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction>&#160;million and a lease liability of $<ix:nonFraction id="c117047578" contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction>&#160;million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of <ix:nonFraction id="c117047579" contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" unitRef="Pure" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">10.3</ix:nonFraction>%. The Company utilized the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components upon recognition. See&#160;<i>Note <em style="font: inherit;">18</em> &#8211; Commitments and Contingencies </i>for further detail.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The components of lease expenses are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:LeaseCostTableTextBlock" id="c57B29103-9D65-430D-B01E-5455C7FE5F5A" escape="true" continuedAt="c721804C7-9DFE-444E-A7D5-A86146A2D3EA">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b><em style="font: inherit;">Statement of Operations Classification</em></b></p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047595" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OperatingExpenseMember" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,247</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047596" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OperatingExpenseMember" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,402</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047598" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OperatingExpenseMember" unitRef="USD" name="us-gaap:ShortTermLeaseCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047599" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OperatingExpenseMember" unitRef="USD" name="us-gaap:ShortTermLeaseCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">97</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047602" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">53</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047603" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-CostOfSalesMember" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">66</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Cost of sales</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047605" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OtherExpenseMember" unitRef="USD" name="us-gaap:FinanceLeaseInterestExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047606" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OtherExpenseMember" unitRef="USD" name="us-gaap:FinanceLeaseInterestExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Interest expense</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047608" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,397</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047609" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,574</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Supplemental balance sheet information related to leases is as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" id="c2740543" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">Balance Sheet Classification</em></b></p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047618" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047619" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating lease right-of-use assets</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047621" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047622" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047624"><span style="-sec-ix-hidden:c117047625">Property and equipment, net</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047627" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047628" contextRef="i_2023-06-30" unitRef="USD" name="aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,213</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047632" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">712</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047633" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,258</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047635"><span style="-sec-ix-hidden:c117047636">Other current liabilities</span></span></em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047638" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047639" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047641"><span style="-sec-ix-hidden:c117047642">Current portion of debt</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047645" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">577</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047646" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">832</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047648"><span style="-sec-ix-hidden:c117047649">Other liabilities</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047651" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLeaseAndFinanceLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047652" contextRef="i_2023-06-30" unitRef="USD" name="aytu:OperatingLeaseAndFinanceLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,175</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">81</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The remaining weighted-average lease term and discount rate used are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="c721804C7-9DFE-444E-A7D5-A86146A2D3EA" continuedAt="c15D8993B-8099-4267-AD45-E89C4CE61EC7">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (years):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2024-06-30" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c117047659" format="ixt-sec:duryear">2.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c117047660" format="ixt-sec:duryear">1.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="c117047662" format="ixt-sec:duryear">0.9</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047664" contextRef="i_2024-06-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="1">10.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047665" contextRef="i_2023-06-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">7.8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047666" contextRef="i_2024-06-30" unitRef="Pure" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047667" contextRef="i_2023-06-30" unitRef="Pure" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">6.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Supplemental cash flow information related to leases is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:continuation id="c15D8993B-8099-4267-AD45-E89C4CE61EC7">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flow classification of lease payments:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047669" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,812</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047670" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,436</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047671" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047672" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047673" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047674" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">96</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, the&#160;Company did <em style="font: inherit;">not</em> have any remaining finance leases. As of <em style="font: inherit;"> June 30, 2024</em>, the&#160;Company&#8217;s future minimum operating lease payments, including the new forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:LesseeLiabilityMaturityTableTextBlock" id="c2740546" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047676" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-4">970</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047677" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">399</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047678" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-3">377</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047679" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:num-dot-decimal" decimals="-3">386</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047680" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" format="ixt:num-dot-decimal" decimals="-3">359</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047681" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" format="ixt:num-dot-decimal" decimals="-3">249</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047682" contextRef="i_2024-06-30" unitRef="USD" name="aytu:LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047683" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">555</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047684" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,185</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric> &#160;&#160;
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="c2740547" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7</em> - Intangible Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A summary of the Company&#8217;s intangible assets&#160;as of <em style="font: inherit;"> June 30, 2024</em>, and <em style="font: inherit;"> June 30, 2023</em>,&#160;is as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c0115E975-B607-4B4E-A887-E59765D086EF" escape="true" continuedAt="BACB9D25-22FD-452C-B46B-D1889C969781">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">June 30, 2024</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Gross Carrying Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Net Carrying Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted-Average Remaining Life</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047720" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,268</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047721" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,184</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047722" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,084</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047723" format="ixt-sec:duryear">10.5</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047724" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-5">30,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047725" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,831</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047726" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,369</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047727" format="ixt-sec:duryear">13.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total definite-lived intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047728" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">71,468</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c117047729" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,015</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047730" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">52,453</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2024-06-30" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047731" format="ixt-sec:duryear">12.0</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">82</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <ix:continuation id="BACB9D25-22FD-452C-B46B-D1889C969781">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average Remaining Life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047732" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047733" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,881</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047734" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,295</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047735" format="ixt-sec:duryear">11.5</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047736" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-5">30,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047737" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047738" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,146</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047739" format="ixt-sec:duryear">14.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047740" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,207</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047741" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,678</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047742" contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,529</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047743" format="ixt-sec:duryear">1.0</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total definite-lived intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047744" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">78,583</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c117047745" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,613</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047746" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-4">58,970</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="c117047747" format="ixt-sec:duryear">12.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with <span style="-sec-ix-hidden:c117047687">zero</span> net carrying amount at the end of a reporting period is <em style="font: inherit;">not</em> presented in the table of a future reporting period. Certain of the Company&#8217;s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_RangeAxis-MinimumMember" name="aytu:FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" id="c117047689" format="ixt-sec:duryear">1</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember" name="aytu:FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" id="c117047690" format="ixt-sec:duryear">20</ix:nonNumeric> years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $<ix:nonFraction id="c117047691" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:AmortizationExpenseOfIntangibleAssets" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117047692" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AmortizationExpenseOfIntangibleAssets" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.1</ix:nonFraction>&#160;million for the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table summarizes the estimated future amortization expense of intangible assets to be recognized over the next&#160;<em style="font: inherit;">five</em> years and periods thereafter:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="c2740550" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047749" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047750" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047751" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047752" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047753" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047754" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,508</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total future amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047755" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">52,453</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired Product Technology Rights</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisition&#160;of the Pediatric Portfolio in <em style="font: inherit;"> November 2019 </em>and the Neos Acquisition in <em style="font: inherit;"> March 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Karbinal</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (&#8220;Tris&#8221;) for the exclusive rights to commercialize Karbinal&#160;in the United States (the &#8220;Tris Karbinal Agreement&#8221;). The Tris Karbinal Agreement&#8217;s initial term terminates in <em style="font: inherit;"> August&#160;</em>of <em style="font: inherit;">2033,</em> with an optional initial <ix:nonNumeric contextRef="d_2022-07-01_2023-06-30_CounterpartyNameAxis-TrisKarbinalAgreementMember" name="aytu:SupplyAndDistributionAgreementExtensionTerm" id="c117047696" format="ixt-sec:duryear">20</ix:nonNumeric>-year extension.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Poly-Vi-Flor</i>&#160;<i>and Tri-Vi-Flor</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the &#8220;Poly-Tri Agreements&#8221;) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>ADHD Portfolio</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys&#160;and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is <ix:nonNumeric contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentedTechnologyMember_StatementBusinessSegmentsAxis-AdhdPortfolioMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c117047697" format="ixt-sec:duryear">16</ix:nonNumeric>&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">83</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired Technology Right</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>TRRP Proprietary Technology</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Neos Acquisition, the Company acquired time release resin particle (&#8220;TRRP&#8221;) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired Product Distribution Rights</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the acquisition of Innovus Pharmaceuticals, Inc. (&#8220;Innovus&#8221;)&#160;in <em style="font: inherit;"> February 2020 (</em>the &#8220;Innovus Acquisition&#8221;), the Company obtained <em style="font: inherit;">35</em> products with a combination of over <em style="font: inherit;">300</em> registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fiscal year ended <em style="font: inherit;"> June 30, 2023, </em>this intangible asset was <span style="-sec-ix-hidden:c117047702">impaired</span> by $<ix:nonFraction id="c117047703" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" format="ixt:num-dot-decimal" decimals="-6">3.0</ix:nonFraction> million due to the discontinuance of products in the Consumer Health Segment.&#160;As of <em style="font: inherit;"> June 30, 2024, </em>this intangible asset was fully amortized and removed from gross carrying value.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired In-Process R&amp;D</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>IPR&amp;D </i>&#8211;<i> <em style="font: inherit;">NT0502</em></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Neos Acquisition, the Company acquired in-process research and development associated with <em style="font: inherit;">NT0502,</em> a new chemical entity that was&#160;being developed for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended <em style="font: inherit;"> June 30, 2023, </em>the Company terminated its development program of <em style="font: inherit;">NT0502.</em> As a result, the Company fully impaired the IPR&amp;D of <em style="font: inherit;">NT0502,</em> recording impairment expense of $<ix:nonFraction id="c117047708" contextRef="d_2022-10-01_2022-12-31_BusinessAcquisitionAxis-NeosTherapeuticsIncMember" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.6</ix:nonFraction> million to its Rx Segment during the <em style="font: inherit;">second</em> quarter of fiscal <em style="font: inherit;">2023.</em></p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:AccruedLiabilitiesTextBlock" id="c2740551" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">8</em> - Accrued liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued liabilities consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2740552" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued savings offers</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047764" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccruedSavingOffers" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,054</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047765" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccruedSavingOffers" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,739</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued program liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047766" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccruedProgramRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,964</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047767" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccruedProgramRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,012</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued customer and product related fees</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047768" contextRef="i_2024-06-30" unitRef="USD" name="aytu:AccruedCustomerAndProductRelatedFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,395</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047769" contextRef="i_2023-06-30" unitRef="USD" name="aytu:AccruedCustomerAndProductRelatedFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,579</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued compensation</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047770" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,935</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047771" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,675</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Return reserve</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047772" contextRef="i_2024-06-30" unitRef="USD" name="aytu:ReturnReserveCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,835</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047773" contextRef="i_2023-06-30" unitRef="USD" name="aytu:ReturnReserveCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,777</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other accrued liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047774" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,391</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047775" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,017</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total accrued liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047776" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">38,574</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047777" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,799</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued savings offers represent programs for the Company&#8217;s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. The return reserve represents the Company&#8217;s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, <em style="font: inherit;">none</em> of which individually or in the aggregate represent greater than <em style="font: inherit;">five</em> percent of total liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">84</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table details the change in return reserve for the periods presented:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="c2740553" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Return Reserve</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047779" contextRef="i_2022-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:num-dot-decimal" decimals="-4">5,770</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Reduction of net revenue</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047780" contextRef="d_2022-07-01_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,353</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047781" contextRef="d_2022-07-01_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">8,346</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047782" contextRef="i_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,777</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Reduction of net revenue</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047783" contextRef="d_2023-07-01_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,128</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047784" contextRef="d_2023-07-01_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">7,070</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047785" contextRef="i_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,835</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric> &#160;&#160;
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="c2740554" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">9</em> - Other Liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Other liabilities consist of the following:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:OtherLiabilitiesTableTextBlock" id="c2740555" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047815" contextRef="i_2024-06-30" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047816" contextRef="i_2023-06-30" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-4">10,420</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee retention credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047817" contextRef="i_2024-06-30" unitRef="USD" name="aytu:EmployeeRetentionCredit" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,759</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047818" contextRef="i_2023-06-30" unitRef="USD" name="aytu:EmployeeRetentionCredit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047819" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047820" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,090</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047823" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherSundryLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">106</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047824" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherSundryLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,555</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047825" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,491</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047826" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,065</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: current portion of other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047827" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,962</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047828" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">7,090</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total other liabilities, non-current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047829" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,529</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047830" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,975</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Fixed payment arrangements</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in <em style="font: inherit;">2019,</em> including fixed and variable payments.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> May 2022, </em>the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated <em style="font: inherit;"> November 2, 2018, </em>related to Tuzistra XR (the &#8220;Tuzistra License Agreement&#8221;). Pursuant to such termination, as of <em style="font: inherit;"> June 30, 2024, </em>the Company has accrued a settlement liability of $<ix:nonFraction id="c117047788" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisLicenseAgreementMember" unitRef="USD" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.2</ix:nonFraction>&#160;million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the Company&#160;to pay interest on any principal amounts due but remaining unpaid past <em style="font: inherit;"> July 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" name="aytu:SupplyAndDistributionCommitmentPeriod" id="c117047789" format="ixt-sec:duryear">20</ix:nonNumeric> years. The Company pays Tris a royalty equal to <ix:nonFraction id="c117047790" contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="Pure" name="aytu:SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" scale="-2" format="ixt:num-dot-decimal" decimals="3">23.5</ix:nonFraction>% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style="font: inherit;"> August 1 </em>through <em style="font: inherit;"> July 31, </em>of <ix:nonFraction id="c117047791" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="Pure" name="aytu:SupplyAndDistributionAgreementMinimumSalesPerYear" scale="0" format="ixt:num-dot-decimal" decimals="INF">70,000</ix:nonFraction> units annually through <em style="font: inherit;">2025.</em> The Company is required to pay Tris a royalty make-whole payment of $<ix:nonFraction id="c117047793" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">30</ix:nonFraction> for each unit under the <ix:nonFraction id="c117047794" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="Pure" name="aytu:SupplyAndDistributionAgreementMinimumSalesPerYear" scale="0" format="ixt:num-dot-decimal" decimals="INF">70,000</ix:nonFraction>-unit annual minimum sales commitment through <em style="font: inherit;">2025.</em> The Tris Karbinal Agreement make-whole payment is capped at $<ix:nonFraction id="c117047796" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million each year. The annual payment is due in <em style="font: inherit;"> August </em>of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $<ix:nonFraction id="c117047797" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementMaximumMilestoneObligations" scale="6" format="ixt:num-dot-decimal" decimals="-6">3.0</ix:nonFraction> million based on cumulative net revenue from the product, the <em style="font: inherit;">first</em> of which is triggered at $<ix:nonFraction id="c117047799" contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" scale="6" format="ixt:num-dot-decimal" decimals="-7">40.0</ix:nonFraction> million. As of <em style="font: inherit;"> June 30, 2024, </em>the fixed payment arrangement balance was $<ix:nonFraction id="c117047800" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.9</ix:nonFraction> million in other current liabilities, and $<ix:nonFraction id="c117047801" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction>&#160;million in other non-current liabilities on the consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Employee Retention Credit&#160;</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The $<ix:nonFraction id="c117047802" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="aytu:EmployeeRetentionCredit" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.8</ix:nonFraction> million ERC accrual in other non-current liabilities as of <em style="font: inherit;"> June 30,&#160;</em><em style="font: inherit;">2024,</em> represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em> Please see <i>Note <em style="font: inherit;">2</em> -&#160;Significant of Significant Accounting Policies</i> for further detail.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">85</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Operating Lease Liabilities&#160;</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to <i>Note <em style="font: inherit;">6</em> - Leases</i> for further detail.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Other</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Other consists of taxes payable, deferred cost related to the Company&#8217;s technology transfer, and various other accruals, <span style="-sec-ix-hidden:c117047809">none</span> of which individually or in the aggregate represent greater than <em style="font: inherit;">five</em> percent of total liabilities.</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ShortTermDebtTextBlock" id="c2740556" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">10</em> - Revolving Credit Facility</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 12,&#160;</em><em style="font: inherit;">2024,</em> the Company and certain of its subsidiaries entered into&#160;consent, joinder and amendment <em style="font: inherit;">No.</em>&#160;<em style="font: inherit;">5</em> (the &#8220;Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5&#8221;</em>) to the loan and security agreement dated <em style="font: inherit;"> October 2, 2019, </em>as amended by amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">1,</em> dated <em style="font: inherit;"> March 19, 2021, </em>amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">2,</em> dated <em style="font: inherit;"> January 26, 2022, </em>amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">3,</em> dated <em style="font: inherit;"> June 1, 2022, </em>amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">4</em> dated <em style="font: inherit;"> March 24, 2023, </em>and the Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5</em> (together the &#8220;Eclipse Agreement&#8221;) with Eclipse Business Capital LLC (&#8220;Eclipse&#8221;), as agent, and the lenders party thereto (agent and such lenders, collectively, the &#8220;Eclipse Lender&#8221;).&#160;Under the Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5,</em> which provided for among&#160;other things, <em style="font: inherit;">two</em> loan agreements, a term loan (the &#8220;Eclipse Term Loan&#8221;) and a revolving credit facility (the &#8220;Eclipse Revolving Loan&#8221;). The Eclipse Term Loan is described further in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>. The Eclipse Revolving Loan&#160;provides for a&#160;maximum amount available under the revolving credit facility provided under the Eclipse Agreement of&#160;$<ix:nonFraction id="c117047851" contextRef="i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" format="ixt:num-dot-decimal" decimals="-5">14.5</ix:nonFraction> million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (&#8220;SOFR&#8221;)&#160;plus <ix:nonFraction id="c117047852" contextRef="d_2024-06-12_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.5</ix:nonFraction>%. In addition, the Company is&#160;required to pay an unused line fee of <ix:nonFraction id="c117047853" contextRef="d_2024-06-12_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="Pure" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.5</ix:nonFraction>% of the average unused portion of the maximum Eclipse Revolving Loan&#160;amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is <em style="font: inherit;"> June 12, 2028, </em>and the effective interest rate was <ix:nonFraction id="c117047854" contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">9.9</ix:nonFraction>% as of <em style="font: inherit;"> June 30, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event that, for any reason, all or any portion of the Eclipse&#160;Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) <ix:nonFraction id="c117047855" contextRef="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-OnOrBeforeJanuary262023Member" unitRef="Pure" name="aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment" scale="-2" format="ixt:num-dot-decimal" decimals="2">2.0</ix:nonFraction>% of the Eclipse Revolving Loan&#160;commitment if such event occurs on or before <em style="font: inherit;"> June 12, 2025, (</em>ii) <ix:nonFraction id="c117047856" contextRef="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262023ButBeforeJanuary262024Member" unitRef="Pure" name="aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment" scale="-2" format="ixt:num-dot-decimal" decimals="2">1.0</ix:nonFraction>% of the Eclipse Revolving Loan&#160;commitment if such event occurs after <em style="font: inherit;"> June 12, 2025,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2026, </em>and (iii) <ix:nonFraction id="c117047857" contextRef="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member" unitRef="Pure" name="aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.5</ix:nonFraction>% of the Eclipse Revolving Loan&#160;commitment if such event occurs after <em style="font: inherit;"> June 12, 2026,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2028. </em>The Company <em style="font: inherit;"> may </em>also be required to pay an early termination fee related to the Eclipse Term Loan&#160;as further described in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>. The Company <em style="font: inherit;"> may </em>permanently terminate the Eclipse Agreement upon written notice to Eclipse.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The&#160;Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company&#8217;s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of <em style="font: inherit;"> June 30, 2024</em>, the Company was in compliance with the covenants under the Eclipse Agreement. The Company&#8217;s obligations under the Eclipse Agreement are secured by substantially all of the Company&#8217;s assets, as defined further in the Eclipse Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff">The Company allocated debt issuance costs of $<ix:nonFraction id="c117047859" contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million related to the Eclipse Revolving</span><span style="background-color:#ffffff">&#160;Loan, bringing to the total debt issuance costs related to the Eclipse Revolving&#160;Loan&#160;to $<ix:nonFraction id="c117047860" contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsNet" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million, which will be amortized straight-line over the term of the loan. </span>Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was $<ix:nonFraction id="c117047861" contextRef="d_2023-07-01_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million&#160;and $<ix:nonFraction id="c117047862" contextRef="d_2022-07-01_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction>&#160;million&#160;for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>. As of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the outstanding amounts drawn on the Eclipse Revolving Loan were&#160;$<ix:nonFraction id="c117047865" contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:LineOfCredit" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117047866" contextRef="i_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:LineOfCredit" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.6</ix:nonFraction>&#160;million, respectively. The unused revolving credit facility amount as of <em style="font: inherit;"> June 30, 2024</em>, was $<ix:nonFraction id="c117047867" contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction>&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">86</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:LongTermDebtTextBlock" id="c2740557" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">11</em> - Long-Term Debt</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Avenue Capital Loan</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> January 26, 2022&#160;(</em>&#8220;Closing Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Avenue Capital Agreement&#8221;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the &#8220;Avenue Capital Lenders&#8221;), and Avenue Capital Management II, L.P. as administrative agent (the &#8220;Avenue Capital Agent&#8221;), collectively (&#8220;Avenue Capital&#8221;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $<ix:nonFraction id="c117047870" contextRef="i_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">15.0</ix:nonFraction> million loan. The interest rate on the loan was&#160;the greater of the prime rate or <ix:nonFraction id="c117047871" contextRef="i_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.25</ix:nonFraction>%, plus <ix:nonFraction id="c117047872" contextRef="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember_VariableRateAxis-PrimeRateMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:num-dot-decimal" decimals="3">7.4</ix:nonFraction>%, payable monthly in arrears. The maturity date of the loan was&#160;<em style="font: inherit;"> January 26, 2025. </em>The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the <em style="font: inherit;">first</em> <em style="font: inherit;">18</em> months following the Closing Date (the &#8220;Interest-only Period&#8221;). The Interest-only Period could be extended automatically without any action by any party for <em style="font: inherit;">six</em> months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to <em style="font: inherit;"> June 15, 2023, </em>a specified amount of net proceeds from the sale and issuance of its equity securities (&#8220;Interest-only Milestone <em style="font: inherit;">1&#8221;</em>). The Interest-only Period was able to be further&#160;extended automatically without any action by any party for an additional <em style="font: inherit;">six</em> months provided, the Company had achieved, prior to <em style="font: inherit;"> December 31, 2023, (</em>i) Interest-only Milestone <em style="font: inherit;">1</em> and (ii) a specified amount of trailing <em style="font: inherit;">12</em> months revenue as of the date of determination.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> January 26, 2022&#160;(</em>&#8220;Issuance Date&#8221;), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $<ix:nonFraction id="c117047880" contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.20</ix:nonFraction> per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $<ix:nonFraction id="c117047881" contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.20</ix:nonFraction> prior to <em style="font: inherit;"> June 30, 2022, </em>the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on <em style="font: inherit;"> January 31, 2027. </em>At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was <em style="font: inherit;">not</em> fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $<ix:nonFraction id="c117047883" contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an equity offering of shares of common stock and warrants, as described in <i>Note <em style="font: inherit;">15</em> - Stockholders Equity</i>, at an offering price of $<ix:nonFraction id="c117047885" contextRef="i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">25.00</ix:nonFraction> per share. As this offering precluded the Company from pursuing any equity financing prior to <em style="font: inherit;"> July 7, 2022, </em>and the effective price of the <em style="font: inherit;"> March 7, 2022, </em>offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $<ix:nonFraction id="c117047886" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.20</ix:nonFraction>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> October 25, 2022, </em>the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (&#8220;Avenue&#8221;) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in <em style="font: inherit;"> January 2022, </em>extended&#160;the interest-only period to <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2024.</em> In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $<ix:nonFraction id="c117047888" contextRef="i_2022-10-25_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.60</ix:nonFraction>, corresponding to the warrant exercise price associated with the Company&#8217;s <em style="font: inherit;"> August 2022 </em>equity financing.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 13, 2023, </em>in conjunction with the Securities Purchase Agreement described in <i>Note <em style="font: inherit;">16</em> - Warrants</i>, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended&#160;to&#160;<em style="font: inherit;"> January 26, 2025.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff">In addition to the debt discount&#160;discussed above, the Company also incurred $<ix:nonFraction id="c117047890" contextRef="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:LoanProcessingFee" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million loan origination, legal and other fees. The debt discount and issuance costs were&#160;being amortized over the term of the loan, using the effective interest method resulting in an effective rate of <ix:nonFraction id="c117047891" contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="Pure" name="aytu:DebtInstrumentPrepaymentFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">16.6</ix:nonFraction>%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $<ix:nonFraction id="c117047892" contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.4</ix:nonFraction> million and&#160;</span><span style="background-color:#ffffff">$<ix:nonFraction id="c117047893" contextRef="d_2022-07-01_2023-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.7</ix:nonFraction>&#160;million for the years ended </span><em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff">.</span></p>
   <p style="text-indent: 36pt; text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">87</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> June 12,&#160;</em><em style="font: inherit;">2024,</em> the Company used proceeds from the Eclipse Term Loan&#160;and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full.&#160;Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to <ix:nonFraction id="c117047897" contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member" unitRef="Pure" name="aytu:DebtInstrumentPrepaymentFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">1.0</ix:nonFraction>% of the loan or $<ix:nonFraction id="c117047898" contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member" unitRef="USD" name="aytu:DebtInstrumentPrepaymentFeeAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of $<ix:nonFraction id="c117047899" contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="aytu:DebtInstrumentFinalPayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million (&#8220;Final Payment&#8221;). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee,&#160;the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs&#160;were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of $<ix:nonFraction id="c117047900" contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">0.6</ix:nonFraction> million related to the retirement of the Avenue Capital loan in the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i><span style="background-color:#ffffff;">Eclipse Term Loan</span></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 12,&#160;</em><em style="font: inherit;">2024,</em> the Company and certain of its subsidiaries entered into Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5,</em> which provided for among other things,&#160;the Eclipse Term Loan&#160;and the Eclipse Revolving Loan&#160;described&#160;further in <i>Note <em style="font: inherit;">10</em> - Revolving Credit Facility</i>. The Eclipse Term Loan&#160;consists of a principal amount of $<ix:nonFraction id="c117047907" contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">13.0</ix:nonFraction> million, at an interest rate of SOFR plus <ix:nonFraction id="c117047908" contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:num-dot-decimal" decimals="2">7.0</ix:nonFraction>%, with a <span style="-sec-ix-hidden:c117047910">four</span>-year term maturing on <em style="font: inherit;"> June 12, 2028,&#160;</em>and a straight-line loan amortization period of <span style="-sec-ix-hidden:c117047911">seven</span> years, which would provide for a loan balance at the end of the <span style="-sec-ix-hidden:c117047912">four</span>-year term of&#160;$<ix:nonFraction id="c117047913" contextRef="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction> million to be repaid on <em style="font: inherit;"> June 12, 2028, </em>the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan.&#160;The effective interest rate on the Eclipse Term Loan was <ix:nonFraction id="c117047914" contextRef="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">12.4</ix:nonFraction>% as of <em style="font: inherit;"> June 30, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) <ix:nonFraction id="c117047915" contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-OnOrBeforeJune122025Member" unitRef="Pure" name="aytu:DebtInstrumentTerminationFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">3.0</ix:nonFraction>% of the Eclipse Term Loan&#160;if such event occurs on or before <em style="font: inherit;"> June 12, 2025, (</em>ii) <ix:nonFraction id="c117047916" contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122025ButOnOrBeforeJune122026Member" unitRef="Pure" name="aytu:DebtInstrumentTerminationFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">2.0</ix:nonFraction>% of the Eclipse Term Loan&#160;if such event occurs after <em style="font: inherit;"> June 12, 2025,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2026,&#160;(</em>iii) <ix:nonFraction id="c117047917" contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122027Member" unitRef="Pure" name="aytu:DebtInstrumentTerminationFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">1.0</ix:nonFraction>% of the Eclipse Term Loan&#160;if such event occurs after <em style="font: inherit;"> June 12, 2026,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2027, </em>and (iv) <ix:nonFraction id="c117047918" contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122028Member" unitRef="Pure" name="aytu:DebtInstrumentTerminationFeePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.5</ix:nonFraction>% of the Eclipse Term Loan&#160;if such event occurs after <em style="font: inherit;"> June 12, 2026,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2028. </em>The Company <em style="font: inherit;"> may </em>also be required to pay an early termination fee related to the Eclipse Revolving Loan&#160;as further described in <i>Note <em style="font: inherit;">10</em>&#160;- Revolving Credit Facility</i>. The Company <em style="font: inherit;"> may </em>permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Company&#8217;s obligations under the Eclipse Agreement&#160;are secured by substantially all of the Company&#8217;s assets, as further defined in the Eclipse Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender&#160;to declare the Company&#8217;s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of <em style="font: inherit;"> June 30, 2024</em>, the Company was in compliance with the covenants under the Eclipse Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff">The Company recorded&#160;total debt discount and allocated debt issuance costs of $<ix:nonFraction id="c117047920" contextRef="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million related to the Eclipse Term Loan, which will be amortized over the term of the loan. The Company incurred&#160;interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $<ix:nonFraction id="c117047921" contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million&#160;</span><span style="background-color:#ffffff">for the year ended <em style="font: inherit;"> June 30, 2024.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">88</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Long-term debt consists of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="c2740558" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>June 30, </b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2024</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2023</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Term loan principal amount</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047925" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" format="ixt:num-dot-decimal" decimals="-6">13,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047926" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" format="ixt:num-dot-decimal" decimals="-6">15,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047927" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">266</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047928" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">925</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Final payment fee</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117047929" contextRef="i_2024-06-30" unitRef="USD" name="aytu:DebtInstrumentFinalPayment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047930" contextRef="i_2023-06-30" unitRef="USD" name="aytu:DebtInstrumentFinalPayment" scale="3" format="ixt:num-dot-decimal" decimals="-3">638</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Financing leases</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047931" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiability" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047932" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">85</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total debt</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047933" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,734</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047934" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,798</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Less: current portion of debt</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047937" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,857</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047938" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">85</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total debt, net of current portion</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047939" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,877</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047940" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,713</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Future principal payments of long-term debt are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="c2740559" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047942" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047943" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117047944" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117047945" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,429</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total future term loan principal payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117047946" contextRef="i_2024-06-30" unitRef="USD" name="aytu:LongTermDebtAndCapitalLeaseObligationsGross" scale="3" format="ixt:num-dot-decimal" decimals="-6">13,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117047947" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">266</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: current portion of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117047948" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117047949" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,877</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric> &#160;&#160;
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:FairValueDisclosuresTextBlock" id="c2740560" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">12</em> - Fair Value Measurements</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company determines the fair value of financial and non-financial assets using the fair value hierarchy, which establishes <em style="font: inherit;">three</em> levels of inputs that <em style="font: inherit;"> may </em>be used to measure fair value as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1:</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2:</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3:</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current&#160;and non-current&#160;debt. The carrying amounts of certain short-term&#160;financial instruments, including cash and cash equivalents, accounts receivable, accounts payable&#160;and accrued liabilities approximate their fair value due to their short maturities. Current and non-current&#160;debt are reported at their amortized costs on the&#160;Company&#8217;s consolidated balance sheets. The remaining financial instruments are reported on the&#160;Company&#8217;s&#160;consolidated balance sheets at amounts that approximate current fair values. The Company&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were <em style="font: inherit;">no</em> transfers between Level <em style="font: inherit;">1,</em> Level <em style="font: inherit;">2</em> and Level <em style="font: inherit;">3</em> in the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">89</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Recurring Fair Value Measurement</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table presents the Company&#8217;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, by level within the fair value hierarchy:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="c914D81BD-06A7-4BB6-91E5-B51ED679B4D5" escape="true" continuedAt="c31AB1039-34CC-4435-BE67-F5ABAA022AE4">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;">Fair Value at</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2024</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048002" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,745</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048003" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048004" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048005" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,745</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048006" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,745</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048007" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048008" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048009" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,745</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <ix:continuation id="c31AB1039-34CC-4435-BE67-F5ABAA022AE4">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;">Fair Value at</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2023</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30, 2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048019" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048020" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048021" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048022" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048023" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048024" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048025" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048026" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds&#160;and reflect their fair value at Level <em style="font: inherit;">1</em> in the fair value hierarchy.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Non-Recurring Fair Value Measurement</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were fixed payment arrangements and&#160;intangible assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from <ix:nonFraction id="c117047964" contextRef="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MinimumMember" unitRef="Pure" name="aytu:FixedPaymentArrangementsMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">10.0</ix:nonFraction>% to <ix:nonFraction id="c117047965" contextRef="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MaximumMember" unitRef="Pure" name="aytu:FixedPaymentArrangementsMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">15.4</ix:nonFraction>%&#160;and are classified as Level <em style="font: inherit;">3</em> inputs in the fair value hierarchy. In <em style="font: inherit;"> May 2022, </em>the Company recognized a fixed payment arrangement liability of $<ix:nonFraction id="c117047967" contextRef="i_2022-05-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.6</ix:nonFraction> million relating to the termination of the Tuzistra License Agreement. See <i>Note <em style="font: inherit;">9</em> - Other Liabilities</i> for further information on fixed payment arrangements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based on the Company&#8217;s impairment analyses for fiscal&#160;<em style="font: inherit;">2024</em> and <em style="font: inherit;">2023</em>, the Company did <span style="-sec-ix-hidden:c117047971">not</span> record an impairment charge on intangible assets during the year ended <em style="font: inherit;"> June 30, 2024</em>, and recorded an <span style="-sec-ix-hidden:c117047972">impairment charge</span> of $<ix:nonFraction id="c117047974" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.6</ix:nonFraction>&#160;million on intangible assets for the year ended <em style="font: inherit;"> June 30, 2023</em>. Valuation of&#160;intangible assets involves significant Level <em style="font: inherit;">3</em> inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted earnings before interest, taxes, depreciation, and amortization margins, and the selection of a discount rate. These assumptions <em style="font: inherit;"> may </em>be affected by expectations about future market or economic conditions. See <i>Note <em style="font: inherit;">7</em> - Intangible Assets</i> and <i>Note <em style="font: inherit;">2</em> - Summary of Significant Accounting Policies</i>, for further discussion on the fair value measurement of intangible assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">90</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Summary of Level <em style="font: inherit;">3</em> Input Changes </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth a summary of changes to those fair value measures using Level <em style="font: inherit;">3</em> inputs for the&#160;year ended <em style="font: inherit;"> June 30, 2024</em>:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="c2740563" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Derivative Warrant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Liabilities</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048029" contextRef="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048030" contextRef="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,998</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048031" contextRef="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><span style="-sec-ix-hidden:c117048033">Included in earnings</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048032" contextRef="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">6,391</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048034" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048035" contextRef="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,148</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlements <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048036" contextRef="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">2,810</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><span style="-sec-ix-hidden:c117048039">Included in earnings</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048038" contextRef="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,004</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048040" contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,745</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin: 0pt; text-align: justify;"><span style="font-size:10pt;">Primarily relates to warrants to purchase <ix:nonFraction id="c117047983" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,173,912</ix:nonFraction> common shares issued with the Company&#8217;s <em style="font: inherit;"> June 2023 </em>equity financing that were exercised in <em style="font: inherit;"> June 2024. </em>The warrants were converted into <ix:nonFraction id="c117047984" contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="aytu:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">367,478</ix:nonFraction> shares of common stock (&#8220;Settlements&#8221;) and <ix:nonFraction id="c117047985" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction> pre-funded warrants to purchase shares of common stock with an exercise price of $<ix:nonFraction id="c117047986" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share (&#8220;Issued&#8221;). See <i>Note <em style="font: inherit;">14</em> - Stockholders&#8217;&#160;Equity</i> and&#160;<i>Note <em style="font: inherit;">16</em> - Warrants</i> for further detail.</span></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Level <em style="font: inherit;">3</em> Inputs</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Significant assumptions as of <em style="font: inherit;"> June 30, 2024, </em>used in valuing the derivative warrant liabilities, marked to market, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="c2740564" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 2023 Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Tranche A</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><em style="font: inherit;">Monte Carlo &amp; Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><em style="font: inherit;">Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Aytu closing stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048053" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.92</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048055" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.92</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equivalent term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048057" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048058" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.6</ix:nonFraction> - <ix:nonFraction id="c117048060" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048061" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">80.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048062" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">83.2</ix:nonFraction>% - <ix:nonFraction id="c117048064" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">87.5</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048065" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048066" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.5</ix:nonFraction>% - <ix:nonFraction id="c117048068" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.6</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048069" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><ix:nonFraction id="c117048071" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto; font-size: 10pt;">Includes <em style="font: inherit;"> August 2022 </em>Warrants, <em style="font: inherit;"> March 2022 </em>Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See <i>Note <em style="font: inherit;">16</em> - Warrants</i> for definitions of these terms and further information.</td></tr>
</tbody></table>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2740565" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">13</em> - Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For fiscal&#160;<em style="font: inherit;">2024</em>, there was $<ix:nonFraction id="c117048075" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.8</ix:nonFraction>&#160;million of income tax expense, which was an effective tax rate of negative <ix:nonFraction id="c117048076" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">12.6</ix:nonFraction>%. This was&#160;primarily driven by Section <em style="font: inherit;">382</em> limitation of the IRC on post-Tax Cuts and Jobs Act&#160;(&#8220;TCJA&#8221;) net operating loss (&#8220;NOL&#8221;) utilization, as further described below, coupled with existing valuation allowances. As of <em style="font: inherit;"> June 30, 2024</em>,&#160;the Company had&#160;$<ix:nonFraction id="c117048078" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction>&#160;million&#160;of deferred tax assets (&#8220;DTAs&#8221;), net of valuation allowance, included in other non-current assets;&#160;$<ix:nonFraction id="c117048079" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction>&#160;million of deferred tax liabilities&#160;(&#8220;DTLs&#8221;) included in other non-current&#160;liabilities; and $<ix:nonFraction id="c117048080" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction>&#160;million of accrued income taxes payable included in accrued liabilities in the consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For fiscal <em style="font: inherit;">2023,</em>&#160;there was <span style="-sec-ix-hidden:c117048082">zero</span>&#160;income tax expense with&#160;an effective tax rate of <span style="-sec-ix-hidden:c117048083">zero</span> percent, reflecting the full valuation allowance. As of <em style="font: inherit;"> June 30, 2023,&#160;</em>the Company had&#160;$<ix:nonFraction id="c117048084" contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.4</ix:nonFraction>&#160;million&#160;of DTAs, net of valuation allowance, included in other non-current assets;&#160;$<ix:nonFraction id="c117048085" contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.4</ix:nonFraction>&#160;million of DTLs included in other non-current&#160;liabilities; and $<ix:nonFraction id="c117048086" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million of accrued income taxes payable included in accrued liabilities in the consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">91</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Section <em style="font: inherit;">382</em> Limitation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the provisions of the IRC, substantial changes in the Company&#8217;s ownership have resulted&#160;in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company <em style="font: inherit;"> may </em>be subject to examination for prior NOLs generated as such NOLs are utilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Company&#8217;s Section <em style="font: inherit;">382</em> analysis, an ownership change was determined to have occurred in <em style="font: inherit;"> March 2022 </em>at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $<ix:nonFraction id="c117048090" contextRef="i_2023-06-30" unitRef="USD" name="aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" scale="6" format="ixt:num-dot-decimal" decimals="-6">12</ix:nonFraction> million) was determined to be fully available to offset fiscal <em style="font: inherit;">2023</em> pre-change income subject to the <em style="font: inherit;">80%</em> limitation. The Company also determined that an ownership change occurred in <em style="font: inherit;"> June 2023 </em>at a time when the Company was in a net unrealized built-in loss position. As a result of the Section <em style="font: inherit;">382</em> analysis, the Company had $<ix:nonFraction id="c117048094" contextRef="i_2023-06-30" unitRef="USD" name="aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million of disallowed recognized built-in loss that was carried forward as a net operating loss as of <em style="font: inherit;"> June 30, 2023. </em>For fiscal <em style="font: inherit;">2024,</em> an additional $<ix:nonFraction id="c117048096" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.8</ix:nonFraction> million of disallowed recognized built-in loss was carried forward as an operating loss. These operating loss carryovers are subject to the <em style="font: inherit;"> June 2023 </em>Section <em style="font: inherit;">382</em> limitation.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company had federal net operating losses of $<ix:nonFraction id="c117048098" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">519.6</ix:nonFraction> million as of <em style="font: inherit;"> June 30, 2024, </em>that is subject to limitation (as described above). Of the available federal net operating losses,&#160;$<ix:nonFraction id="c117048099" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" format="ixt:num-dot-decimal" decimals="-5">186.6</ix:nonFraction> million can be carried forward indefinitely, and $<ix:nonFraction id="c117048100" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLossCarryforwardSubjectToExpire" scale="6" format="ixt:num-dot-decimal" decimals="-6">333.0</ix:nonFraction> million will completely expire in <em style="font: inherit;">2037.</em> Of the amount set to expire,&#160;$<ix:nonFraction id="c117048102" contextRef="i_2024-06-30" unitRef="USD" name="aytu:OperatingLossCarryforwardExpirationsOwnershipChange" scale="6" format="ixt:num-dot-decimal" decimals="-5">329.2</ix:nonFraction> million will expire unused as a result of the ownership change. As of <em style="font: inherit;"> June 30, 2024, </em>the Company had research and development credits of $<ix:nonFraction id="c117048103" contextRef="i_2024-06-30_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">3.0</ix:nonFraction> million, which will begin to expire in <em style="font: inherit;">2025</em> and are also subject to Section <em style="font: inherit;">382</em> limitation. The available state net operating losses, if <em style="font: inherit;">not</em> utilized to offset taxable income in future periods, will begin to expire in <em style="font: inherit;">2025</em> and will completely expire in <em style="font: inherit;">2039.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized. Generally, it is <em style="font: inherit;">not</em> appropriate to use <em style="font: inherit;">zero</em> as an applicable tax rate and rather, a DTA should be recorded at the applicable tax rate and a valuation of an equal amount would be provided. However, under certain circumstances it <em style="font: inherit;"> may </em>be appropriate to follow an alternative approach and use a <em style="font: inherit;">zero</em> rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross DTAs disclosed. The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and <em style="font: inherit;">not</em> apply a <em style="font: inherit;">zero</em> rate to NOL carryforwards expected to expire unutilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In review of the Company&#8217;s consolidated deferred position, excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and <em style="font: inherit;">not</em> utilized against a net DTL.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The provision for income taxes consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="c2740566" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048134" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,549</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048135" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-4">80</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048136" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">219</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048137" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">46</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total current tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048138" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,768</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048139" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048141" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048142" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">109</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048143" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048144" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048145" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048146" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">126</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048147" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,768</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048148" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">92</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Income tax expense&#160;resulting from applying statutory rates in jurisdictions in which the Company is taxed (federal and various states) differs from the income tax expense&#160;in the financial statements. A reconciliation of the United States&#160;federal statutory income tax rates to the Company&#8217;s effective tax rate is as follows.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2740567" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30,</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">2024</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">2023</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands, except tax rate)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048157" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048158" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048159" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048160" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048161" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">779</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048162" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="3">5.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048163" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">430</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048164" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="3">2.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048165" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048166" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048167" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048168" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048169" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="aytu:IncomeTaxReconciliationContingentConsideration" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048170" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="aytu:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048171" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:IncomeTaxReconciliationContingentConsideration" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">193</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048172" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="aytu:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">1.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048173" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,447</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048174" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">38.7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048175" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,087</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048176" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="2" sign="-">24.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048177" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048178" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048179" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:num-dot-decimal" decimals="-3">117</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048180" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net income tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048181" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,768</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c117048182" contextRef="d_2023-07-01_2024-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">12.6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048183" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c117048184" contextRef="d_2022-07-01_2023-06-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3" sign="-">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences, which comprise the deferred tax assets and liabilities, are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2740568" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net operating loss carry forward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048190" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-4">119,170</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048191" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048192" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,845</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048193" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,188</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued rebates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048194" contextRef="i_2024-06-30" unitRef="USD" name="aytu:DeferredTaxAssetsAccruedRebates" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048195" contextRef="i_2023-06-30" unitRef="USD" name="aytu:DeferredTaxAssetsAccruedRebates" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,994</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant derivatives</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048196" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,061</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048197" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048198" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,416</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048199" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,416</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048200" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,259</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048201" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-4">4,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048202" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048203" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">758</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Section 174 capitalization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048204" contextRef="i_2024-06-30" unitRef="USD" name="aytu:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" format="ixt:num-dot-decimal" decimals="-4">780</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048205" contextRef="i_2023-06-30" unitRef="USD" name="aytu:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" format="ixt:num-dot-decimal" decimals="-3">836</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048206" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsInventory" scale="3" format="ixt:num-dot-decimal" decimals="-3">256</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048207" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsInventory" scale="3" format="ixt:num-dot-decimal" decimals="-3">743</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048208" contextRef="i_2024-06-30" unitRef="USD" name="aytu:DeferredTaxAssetsLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">305</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048209" contextRef="i_2023-06-30" unitRef="USD" name="aytu:DeferredTaxAssetsLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">492</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c117048210" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117048211" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048212" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">975</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048213" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,332</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048214" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">138,012</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048215" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,332</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Less: valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048216" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-4">137,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048217" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">135,954</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax assets, net of valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048218" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">762</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048219" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,378</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangibles</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048221" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">563</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048222" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">845</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">ROU asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048223" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">199</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048224" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048225" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048226" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-4">50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048227" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">762</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048228" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,378</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048229" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048230" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">93</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company has recorded a valuation allowance of $<ix:nonFraction id="c117048117" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-5">137.3</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117048118" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-6">136.0</ix:nonFraction>&#160;million at <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively, to reserve its net DTAs. In assessing the realizability of DTAs, management considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of the DTAs&#160;will <em style="font: inherit;">not</em> be realized. The ultimate realization of DTAs&#160;is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than <em style="font: inherit;">not</em>&#160;that it will realize the benefits of these deductible differences, net of the valuation allowance provided.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has <em style="font: inherit;">no</em> accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company&#8217;s NOL, interest expense carryover or research and development credit carryover and therefore do <em style="font: inherit;">not</em> require recognition. As a result of these timing differences, at <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company had gross unrecognized tax benefits related to uncertain tax positions of $<ix:nonFraction id="c117048126" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction id="c117048127" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.9</ix:nonFraction>&#160;million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A tabular roll-forward of the Company&#8217;s gross unrecognized tax benefit related to uncertain tax positions&#160;is below.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="c2740569" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Beginning balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048235" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,948</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048236" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,822</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease resulting from current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048237" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,996</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c117048238" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-4">120</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase resulting from current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048239" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">361</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048240" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Ending balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048241" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,313</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048242" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,948</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The change in the Company&#8217;s gross unrecognized tax benefits relates to filed method changes with the IRS for the tax return year ending <em style="font: inherit;"> June 30, 2023. </em>Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to <em style="font: inherit;">2005</em> being subject to examination</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2740570" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">14</em> - Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company has <ix:nonFraction id="c117048244" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="6" format="ixt:num-dot-decimal" decimals="-8">200.0</ix:nonFraction> million shares of common stock authorized with a par value of $<ix:nonFraction id="c117048245" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share and <ix:nonFraction id="c117048246" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="6" format="ixt:num-dot-decimal" decimals="-7">50.0</ix:nonFraction> million shares of preferred stock authorized with a par value of $<ix:nonFraction id="c117048247" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share. As of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company had <ix:nonFraction id="c117048249" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,972,638</ix:nonFraction> and <ix:nonFraction id="c117048251" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,517,174</ix:nonFraction>&#160;common shares issued and outstanding, respectively, and <ix:nonFraction id="c117048253" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> preferred shares issued and outstanding. As of <em style="font: inherit;"> June 30, 2024, </em>included in common stock outstanding are <ix:nonFraction id="c117048257" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,360</ix:nonFraction> shares of unvested restricted stock issued to executives, directors and employees.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 8, 2020, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was declared effective by the SEC on <em style="font: inherit;"> June 17, 2020. </em>This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $<ix:nonFraction id="c117048259" contextRef="i_2020-06-17_SubsidiarySaleOfStockAxis-The2020ShelfMember" unitRef="USD" name="aytu:SaleOfStockMaximumAmountOfEquityIssuable" scale="6" format="ixt:num-dot-decimal" decimals="-8">100.0</ix:nonFraction> million of its common stock, preferred stock, debt securities, warrants, rights and units. On <em style="font: inherit;"> June 4, 2021, </em>the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $<ix:nonFraction id="c117048260" contextRef="i_2021-06-04_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember" unitRef="USD" name="aytu:SaleOfStockMaximumAmountOfEquityIssuable" scale="6" format="ixt:num-dot-decimal" decimals="-7">30.0</ix:nonFraction> million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the <em style="font: inherit;">2020</em> Shelf (the &#8220;ATM Sales Agreement&#8221;). During the year ended <em style="font: inherit;"> June 30, 2023, </em>the Company issued <ix:nonFraction id="c117048262" contextRef="d_2022-07-01_2023-06-30_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">699,929</ix:nonFraction> shares of common stock under the ATM Sales Agreement, with total net proceeds of&#160;$<ix:nonFraction id="c117048263" contextRef="d_2022-07-01_2023-06-30_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.9</ix:nonFraction> million. The <em style="font: inherit;">2020</em> Shelf expired in <em style="font: inherit;"> June 2023 </em>and the ATM Agreement was terminated in <em style="font: inherit;"> July 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> September 28, 2021, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was declared effective by the SEC on <em style="font: inherit;"> October 7, 2021. </em>This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $<ix:nonFraction id="c117048266" contextRef="i_2021-09-28_SubsidiarySaleOfStockAxis-The2021ShelfMember" unitRef="USD" name="aytu:SaleOfStockMaximumAmountOfEquityIssuable" scale="6" format="ixt:num-dot-decimal" decimals="-8">100.0</ix:nonFraction> million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style="font: inherit;">&#8220;2021</em> Shelf&#8221;). As of <em style="font: inherit;"> June 30, 2024, </em>$<ix:nonFraction id="c117048268" contextRef="i_2023-06-30_SubsidiarySaleOfStockAxis-The2021ShelfMember" unitRef="USD" name="aytu:SaleOfStockMaximumAmountOfEquityIssuable" scale="6" format="ixt:num-dot-decimal" decimals="-5">82.4</ix:nonFraction> million remained available under the <em style="font: inherit;">2021</em> Shelf. This availability is subject to SEC <em style="font: inherit;">1.B.6</em> limitation to the Form S-<em style="font: inherit;">3.</em>&#160;The <em style="font: inherit;">2021</em> Shelf expires in <em style="font: inherit;"> October 2024. </em>Given the upcoming expiration of the <em style="font: inherit;">2021</em> Shelf, concurrent with the filing of this Form <em style="font: inherit;">10</em>-K the Company&#160;expects to file&#160;a new shelf registration statement to cover the offering, issuance and sale by the Company of up to an aggregate of $<ix:nonFraction id="c117048276" contextRef="i_2024-06-30_SubsidiarySaleOfStockAxis-The2024ShelfMember" unitRef="USD" name="aytu:SaleOfStockMaximumAmountOfEquityIssuable" scale="6" format="ixt:num-dot-decimal" decimals="-8">100.0</ix:nonFraction> million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style="font: inherit;">&#8220;2024</em> Shelf&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">94</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an underwritten public offering utilizing the <em style="font: inherit;">2021</em> Shelf, pursuant to which, the Company sold, (i) <ix:nonFraction id="c117048280" contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">151,500</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to <ix:nonFraction id="c117048281" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">151,500</ix:nonFraction> shares of common stock, and (iii) common stock purchase warrants to purchase up to <ix:nonFraction id="c117048282" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">333,300</ix:nonFraction> shares of common stock (the <em style="font: inherit;"> &#8220;March 2022 </em>Offering&#8221;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <em style="font: inherit;">one</em> common warrant to purchase <ix:nonFraction id="c117048284" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.1</ix:nonFraction> shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $<ix:nonFraction id="c117048285" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.002</ix:nonFraction> per share of common stock and were exercised in full in <em style="font: inherit;"> April 2022. </em>The common warrants have an exercise price of $<ix:nonFraction id="c117048286" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.00</ix:nonFraction> per share of common stock and are exercisable <em style="font: inherit;">six</em> months after the date of issuance and have a term of <span style="-sec-ix-hidden:c117048288">five</span> years from the date of exercisability. The Company raised gross proceeds of $<ix:nonFraction id="c117048289" contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.6</ix:nonFraction> million through the <em style="font: inherit;"> March 2022 </em>Offering before commission and other costs of $<ix:nonFraction id="c117048290" contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember" unitRef="USD" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction> million. The pre-funded and common warrants have a combined fair value of approximately $<ix:nonFraction id="c117048291" contextRef="d_2022-03-07_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember" unitRef="USD" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.8</ix:nonFraction> million at issuance and are classified as&#160;derivative warrant liabilities with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (see <i>Note <em style="font: inherit;">16</em> - Warrants</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> August 11, 2022, </em>the Company closed on an underwritten public offering (the <em style="font: inherit;"> &#8220;August 2022 </em>Offering&#8221;) utilizing the <em style="font: inherit;">2021</em> Shelf, pursuant to which it sold an aggregate of (i) <ix:nonFraction id="c117048294" contextRef="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,075,290</ix:nonFraction> shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase <ix:nonFraction id="c117048295" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">87,500</ix:nonFraction> shares of its common stock; and (iii) accompanying warrants to purchase <ix:nonFraction id="c117048296" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,265,547</ix:nonFraction> shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <span style="-sec-ix-hidden:c117048297">one</span> common warrant to purchase <em style="font: inherit;">one</em> share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $<ix:nonFraction id="c117048299" contextRef="i_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.60</ix:nonFraction>, and the combined offering price for each pre-funded warrant and accompanying common warrant was $<ix:nonFraction id="c117048300" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.58</ix:nonFraction>, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $<ix:nonFraction id="c117048301" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.02</ix:nonFraction> per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in <em style="font: inherit;"> August 2022. </em>The common warrants have an exercise price of $<ix:nonFraction id="c117048302" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.60</ix:nonFraction> per share of common stock and are exercisable for a period of <span style="-sec-ix-hidden:c117048303">five</span> years from issuance. The Company raised $<ix:nonFraction id="c117048304" contextRef="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million in gross proceeds through the <em style="font: inherit;"> August 2022 </em>Offering before underwriting fees and other expenses of $<ix:nonFraction id="c117048305" contextRef="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember" unitRef="USD" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million. The pre-funded and common warrants had a combined fair value of approximately $<ix:nonFraction id="c117048306" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-6">6.0</ix:nonFraction> million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (see <i>Note <em style="font: inherit;">16</em> - Warrants</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 8, 2023, </em>using a placement agent, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) <ix:nonFraction id="c117048308" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,743,695</ix:nonFraction> shares of the Company&#8217;s common stock; (ii) pre-funded warrants in lieu of shares to purchase <ix:nonFraction id="c117048309" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">430,217</ix:nonFraction> shares of common stock (the <em style="font: inherit;"> &#8220;June 2023 </em>Pre-Funded Warrants&#8221;); (iii) accompanying tranche A&#160;warrants to purchase <ix:nonFraction id="c117048310" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,173,912</ix:nonFraction> shares of common stock (the &#8220;Tranche A Warrants&#8221;); and (iv) accompanying tranche B warrants to purchase <ix:nonFraction id="c117048311" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,173,912</ix:nonFraction> shares of common stock in a best-efforts offering (the &#8220;Tranche B&#160;Warrants&#8221;&#160;and the&#160;Tranche A Warrants together with the Tranche B Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants <em style="font: inherit;"> may </em>be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $<ix:nonFraction id="c117048312" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share in the same form as the <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants (the &#8220;Exchange Warrants&#8221;). Each pre-funded warrant is exercisable for <span style="-sec-ix-hidden:c117048313">one</span> share of common stock at an exercise price of $<ix:nonFraction id="c117048314" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share. The pre-funded warrants are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $<ix:nonFraction id="c117048315" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.59</ix:nonFraction> per share (or $<ix:nonFraction id="c117048316" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsExchangedForPrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.5899</ix:nonFraction> per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <span style="-sec-ix-hidden:c117048317">five</span> years after the date of issuance or (ii) <em style="font: inherit;">30</em> days following the closing price of the Company&#8217;s common stock equaling <em style="font: inherit;">200%</em> of the exercise price ($<ix:nonFraction id="c117048320" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.18</ix:nonFraction> per share) for at least <em style="font: inherit;">40</em> consecutive trading days. The Tranche B Warrants were exercised in <em style="font: inherit;"> June 2024 </em>as further described below. The Company raised $<ix:nonFraction id="c117048322" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-6">4.0</ix:nonFraction> million in gross proceeds and net proceeds were $<ix:nonFraction id="c117048323" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.4</ix:nonFraction> million after deducting offering expenses. The <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants do <em style="font: inherit;">not</em> have an expiration date. The warrants had a combined fair value of approximately $<ix:nonFraction id="c117048325" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-6">5.0</ix:nonFraction> million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain&#160;along with the issuance costs of $<ix:nonFraction id="c117048326" contextRef="d_2023-06-08_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million in the consolidated financial statement of operations (see <i>Note <em style="font: inherit;">16</em> - Warrants</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">95</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 14, 2024, </em>the Tranche B Warrants were exercised, generating proceeds of $<ix:nonFraction id="c117048329" contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.5</ix:nonFraction> million. The Tranche B Warrants were converted into <ix:nonFraction id="c117048330" contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="aytu:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">367,478</ix:nonFraction> shares of common stock and <ix:nonFraction id="c117048331" contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="Share" name="aytu:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction> pre-funded&#160;warrants to purchase shares of common stock with an exercise price of $<ix:nonFraction id="c117048332" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share (the &#8220;Tranche B Pre-Funded Warrants&#8221;). The Tranche B Pre-Funded Warrants had a fair value of approximately $<ix:nonFraction id="c117048333" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.1</ix:nonFraction> million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#8217;&#160;equity in the Company&#8217;s consolidated financial statements. The Company&#160;used a portion of the&#160;proceeds from the Tranche B Warrants exercise&#160;as part of the Avenue Capital loan&#160;repayment described further in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>.</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2740571" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">15</em> - Equity Incentive Plans</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b><em style="font: inherit;">2023</em> Equity Incentive Plan</b></i><br/> &#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> May 18, 2023, </em>the Company&#8217;s stockholders approved the Aytu BioPharma, Inc. <em style="font: inherit;">2023</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2023</em> Equity Incentive Plan&#8221;). Prior to the Company&#8217;s adoption of the <em style="font: inherit;">2023</em> Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. <em style="font: inherit;">2015</em> Stock Option and Incentive Plan (the &#8220;Aytu <em style="font: inherit;">2015</em> Plan&#8221;) and the Neos Therapeutics, Inc. <em style="font: inherit;">2015</em> Stock Options and Incentive Plan (the &#8220;Neos <em style="font: inherit;">2015</em> Plan&#8221;, and collectively with the Aytu <em style="font: inherit;">2015</em> Plan, the <em style="font: inherit;">&#8220;2015</em> Plans&#8221;). For the <em style="font: inherit;">2023</em> Equity Incentive Plan, the stockholders approved (i) <ix:nonFraction id="c117048347" contextRef="d_2023-05-18_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">200,000</ix:nonFraction> new shares; (ii) <ix:nonFraction id="c117048348" contextRef="i_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">87,129</ix:nonFraction> shares available for grant under the <em style="font: inherit;">2015</em> Plans be &#8220;rolled over&#8221; to the <em style="font: inherit;">2023</em> Equity Incentive Plan; and (iii) any shares that are returned to the Company under the <em style="font: inherit;">2015</em> Plans be added to the <em style="font: inherit;">2023</em> Equity Incentive Plan. With the approval of the <em style="font: inherit;">2023</em> Equity Incentive Plan, <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2015</em> Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the <em style="font: inherit;">2023</em> Equity Incentive Plan have contractual terms of <ix:nonNumeric contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c117048357" format="ixt-sec:duryear">10</ix:nonNumeric> years or less from the grant date and a vesting period ranging from <ix:nonNumeric contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048358" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048359" format="ixt-sec:duryear">4</ix:nonNumeric> years. The restricted stock awards and restricted stock units have a vesting period of <ix:nonNumeric contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048360" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048361" format="ixt-sec:duryear">4</ix:nonNumeric> years. As of <em style="font: inherit;"> June 30, 2024</em>, the Company had <ix:nonFraction id="c117048362" contextRef="i_2024-06-30_PlanNameAxis-The2023EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">182,322</ix:nonFraction>&#160;shares that are available for grant under the <em style="font: inherit;">2023</em> Equity Incentive Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Aytu <em style="font: inherit;">2015</em> Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2015,</em> the Company&#8217;s stockholders approved the Aytu <em style="font: inherit;">2015</em> Plan, which, as amended in <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">2017,</em> provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">13,</em> <em style="font: inherit;">2020,</em> the Company&#8217;s stockholders approved an increase to <ix:nonFraction id="c117048371" contextRef="i_2020-02-13_PlanNameAxis-The2015PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">250,000</ix:nonFraction> total shares of common stock in the Aytu <em style="font: inherit;">2015</em> Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu <em style="font: inherit;">2015</em> Plan will be added back to the shares of common stock available for issuance under the <em style="font: inherit;">2023</em> Equity Incentive Plan. Stock options granted under this plan have contractual terms of <ix:nonNumeric contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c117048375" format="ixt-sec:duryear">10</ix:nonNumeric> years from the grant date and a vesting period ranging from <ix:nonNumeric contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048376" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048377" format="ixt-sec:duryear">4</ix:nonNumeric> years. The restricted stock awards have a vesting period ranging from <ix:nonNumeric contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048378" format="ixt-sec:duryear">4</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048379" format="ixt-sec:duryear">10</ix:nonNumeric> years, and the restricted stock units have a vesting period of <ix:nonNumeric contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2015PlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048380" format="ixt-sec:duryear">4</ix:nonNumeric> years.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Neos <em style="font: inherit;">2015</em> Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to the Neos Acquisition, the Company assumed <ix:nonFraction id="c117048383" contextRef="i_2021-04-19_PlanNameAxis-Neos2015PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,486</ix:nonFraction> stock options and <ix:nonFraction id="c117048384" contextRef="i_2021-04-19_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-Neos2015PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,786</ix:nonFraction> restricted stock units previously granted under the Neos <em style="font: inherit;">2015</em> Plan. Accordingly, on <em style="font: inherit;"> April 19, 2021, </em>the Company registered <ix:nonFraction id="c117048386" contextRef="i_2021-04-19_PlanNameAxis-Neos2015PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,272</ix:nonFraction> shares of its common stock under the Neos <em style="font: inherit;">2015</em> Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos <em style="font: inherit;">2015</em> Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of <ix:nonNumeric contextRef="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c117048389" format="ixt-sec:duryear">10</ix:nonNumeric> years from the grant date and a vesting period ranging from <ix:nonNumeric contextRef="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048390" format="ixt-sec:duryear">1</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c117048391" format="ixt-sec:duryear">4</ix:nonNumeric> years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">96</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Stock Options</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> June 30, 2024</em>, <ix:nonFraction id="c117048392" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">113,500</ix:nonFraction>&#160;stock options were granted. The weighted-average grant date fair value of options granted during the year ended <em style="font: inherit;"> June 30, 2024</em>, was $<ix:nonFraction id="c117048393" contextRef="d_2023-07-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.74</ix:nonFraction>. During the year ended&#160;<em style="font: inherit;"> June 30, 2024</em>, there was $<ix:nonFraction id="c117048394" contextRef="i_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction>&#160;million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#8217;s equity incentive plan. During the fiscal year ended <em style="font: inherit;"> June 30, 2023, </em><ix:nonFraction id="c117048395" contextRef="d_2022-07-01_2023-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">49,212</ix:nonFraction> stock options were granted. The weighted-average grant date fair value of options granted during the year ended <em style="font: inherit;"> June 30, 2023, </em>was $<ix:nonFraction id="c117048396" contextRef="d_2022-07-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction>. During the year ended&#160;<em style="font: inherit;"> June 30, 2023, </em>there was $<ix:nonFraction id="c117048397" contextRef="i_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c117048398" format="ixt-sec:duryear">1.9</ix:nonNumeric>&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stock option activity is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2740572" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048454" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">52,762</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048455" contextRef="i_2023-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-07-01_2023-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c117048456" format="ixt-sec:duryear">9.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c117048457" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">113,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117048458" contextRef="d_2023-07-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.74</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="c117048459" format="ixt-sec:duryear">9.2</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(<ix:nonFraction id="c117048460" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,610</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117048461" contextRef="d_2023-07-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048463" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,113</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c117048464" contextRef="d_2023-07-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">66.84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048466" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">146,539</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048467" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c117048468" format="ixt-sec:duryear">8.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048469" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048470" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.06</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c117048471" format="ixt-sec:duryear">8.0</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table details the options outstanding at <em style="font: inherit;"> June 30, 2024</em>, by range of exercise prices:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="c2740637" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Prices</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="2" rowspan="1" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c117050812">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050814" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">102,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050815" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c117050816" format="ixt-sec:duryear">9.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="2" rowspan="1" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c117050820">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050822" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050823" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.53</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c117050824" format="ixt-sec:duryear">9.6</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">$4.00 - $290.00</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="-sec-ix-hidden:c117050827">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c117050829">&#160;</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117050830" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,039</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050831" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c117050832" format="ixt-sec:duryear">8.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117050833" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050834" contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">225.74</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117050838" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">146,539</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050839" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c117050840" format="ixt-sec:duryear">8.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117050841" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117050842" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">225.74</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restricted Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company granted a total of <ix:nonFraction id="c117048400" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,500</ix:nonFraction> shares of restricted stock, with certain accelerated vesting conditions, to members of its non-employee directors pursuant to the <em style="font: inherit;">2023</em> Equity Incentive Plan, of which <span style="-sec-ix-hidden:c117048402">1/3</span> vest on the grant date and <span style="-sec-ix-hidden:c117048403">1/12</span> on the <em style="font: inherit;">first</em> day of each quarter thereafter, subject to continuing service to the Company through each vesting date. These restricted stock grants have a weighted average grant date fair value of $<ix:nonFraction id="c117048405" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.77</ix:nonFraction> per share.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> June 30, 2023, </em>as a result of the change in members of the Company&#8217;s board, the Company accelerated unvested shares for <em style="font: inherit;">two</em> former members and recorded $<ix:nonFraction id="c117048407" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-TwoFormerBoardMembersMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million of non-cash equity compensation expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> December 19, 2022, </em>the Company entered into a stipulation of compromise and settlement (the &#8220;Stipulation&#8221;). As a part of the terms of the Stipulation, the Company agreed to rescind <ix:nonFraction id="c117048408" contextRef="d_2022-12-19_2022-12-19_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-BoardMembersMember" unitRef="Pure" name="aytu:SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the aggregate <em style="font: inherit;">2021</em> grants to board members. As a result of the recission of the shares, the Company recorded $<ix:nonFraction id="c117048410" contextRef="d_2022-12-19_2022-12-19_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-BoardMembersMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million in non-cash compensation during the year ended <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> June 30, 2023, </em>the Company granted a total of <ix:nonFraction id="c117048411" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,825</ix:nonFraction> shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu <em style="font: inherit;">2015</em> Plan, of which <span style="-sec-ix-hidden:c117048413">1/3</span> vest on the grant date and <span style="-sec-ix-hidden:c117048414">1/12</span> on the <em style="font: inherit;">first</em> day of each quarter thereafter, subject to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $<ix:nonFraction id="c117048416" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-ManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.31</ix:nonFraction> per-share to $<ix:nonFraction id="c117048417" contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember_TitleOfIndividualAxis-ManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">13.4</ix:nonFraction> per-share.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">97</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Restricted stock activity under the <em style="font: inherit;">2023</em> Equity Incentive Plan&#160;is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="c2740574" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048512" contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">38,075</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048513" contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">142.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048514" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048515" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.77</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048516" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,971</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048517" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">113.37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c117048518" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">499</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048519" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">147.15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048520" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,105</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048521" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">100.34</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, there was $<ix:nonFraction id="c117048419" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction>&#160;million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c117048420" format="ixt-sec:duryear">2.5</ix:nonNumeric>&#160;years. The total fair value of restricted stock vested during the year ended <em style="font: inherit;"> June 30, 2024</em>, was $<ix:nonFraction id="c117048421" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company previously issued <ix:nonFraction id="c117048422" contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction> shares of restricted stock outside of the Aytu <em style="font: inherit;">2015</em> Plan, which vest in <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">2026.</em> On <em style="font: inherit;"> January 17, 2022, </em>the Company granted <ix:nonFraction id="c117048425" contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000</ix:nonFraction> shares of restricted stock to a member of its management team outside of the Aytu <em style="font: inherit;">2015</em> Plan, of which <span style="-sec-ix-hidden:c117048427">1/3</span> vest on <em style="font: inherit;"> January 17, 2023, </em>and <span style="-sec-ix-hidden:c117048428">1/12</span> each quarter thereafter, subject to continuing employment with the Company through each vesting date until <em style="font: inherit;"> January 17, 2025. </em>This restricted stock grant has a grant date fair value of $<ix:nonFraction id="c117048429" contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">27.00</ix:nonFraction> per share. As of <em style="font: inherit;"> June 30, 2024</em>, there was $<ix:nonFraction id="c117048430" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction>&#160;million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c117048431" format="ixt-sec:duryear">0.6</ix:nonNumeric>&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Restricted Stock Units</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the years ended <em style="font: inherit;"> June 30, 2024</em>, and <em style="font: inherit;">2023,</em> the Company did <span style="-sec-ix-hidden:c117048434"><span style="-sec-ix-hidden:c117048435">not</span></span> grant restricted stock units (&#8220;RSU&#8221;). RSU activity is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="c2740575" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048530" contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,963</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048531" contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">25.62</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048532" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,249</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048533" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.28</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048534" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">939</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c117048535" contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">31.60</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048536" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,775</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048537" contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, there was <ix:nonFraction id="c117048436" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> material unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company&#8217;s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c117048437" format="ixt-sec:duryear">0.7</ix:nonNumeric>&#160;years. The total fair value of RSUs vested during the year ended <em style="font: inherit;"> June 30, 2024</em>, was immaterial.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="c2740576" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048544" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048545" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-CostOfSalesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048546" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048547" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048548" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048549" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048550" contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,905</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048551" contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,965</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048552" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048553" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,046</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">98</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:WarrantsOrRightsDisclosureTextBlock" id="c2740577" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">16</em> - Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Liability Classified Warrants</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 8, 2023, </em>using a placement agent, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) <ix:nonFraction id="c117048555" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,743,695</ix:nonFraction> shares of the Company&#8217;s common stock; (ii) <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants in lieu of shares to purchase <ix:nonFraction id="c117048556" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">430,217</ix:nonFraction> shares of common stock; (iii) accompanying Tranche A Warrants to purchase <ix:nonFraction id="c117048557" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,173,912</ix:nonFraction> shares of common stock; and (iv) accompanying Tranche B Warrants to purchase <ix:nonFraction id="c117048558" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,173,912</ix:nonFraction> shares of common stock in a best-efforts offering (the Tranche A Warrants together with the Tranche B Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants <em style="font: inherit;"> may </em>be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $<ix:nonFraction id="c117048559" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share in the same form as the <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants (the &#8220;Exchange Warrants&#8221;). Each pre-funded warrant is exercisable for <span style="-sec-ix-hidden:c117048560">one</span> share of common stock at an exercise price of $<ix:nonFraction id="c117048561" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share. The pre-funded warrants are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $<ix:nonFraction id="c117048562" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.59</ix:nonFraction> per share (or $<ix:nonFraction id="c117048563" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsExchangedForPrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.5899</ix:nonFraction> per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <span style="-sec-ix-hidden:c117048564">five</span> years after the date of issuance or (ii) <em style="font: inherit;">30</em> days following the closing price of the Company&#8217;s common stock equaling <em style="font: inherit;">200%</em> of the exercise price ($<ix:nonFraction id="c117048567" contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.18</ix:nonFraction> per share) for at least <em style="font: inherit;">40</em> consecutive trading days. The Tranche B Warrants were exercised in <em style="font: inherit;"> June 2024 </em>as further described below. The Company raised $<ix:nonFraction id="c117048569" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-6">4.0</ix:nonFraction> million in gross proceeds and net proceeds were $<ix:nonFraction id="c117048570" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.4</ix:nonFraction> million after deducting offering expenses. The <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants do <em style="font: inherit;">not</em> have an expiration date. The warrants had a combined fair value of approximately $<ix:nonFraction id="c117048572" contextRef="i_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-6">5.0</ix:nonFraction> million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain along with the issuance costs of $<ix:nonFraction id="c117048573" contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million in the consolidated financial statement of operations&#160;(see <i>Note <em style="font: inherit;">14</em>&#160;- Stockholders&#8217; Equity</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 14, 2024, </em>the Tranche B Warrants were exercised, generating proceeds of $<ix:nonFraction id="c117048575" contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.5</ix:nonFraction> million. The Tranche B Warrants were converted into <ix:nonFraction id="c117048576" contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="aytu:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">367,478</ix:nonFraction> shares of common stock and <ix:nonFraction id="c117048577" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction> Tranche B Pre-Funded Warrants to purchase shares of common stock with an exercise price of $<ix:nonFraction id="c117048578" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share. The Tranche B Pre-Funded Warrants, which do <em style="font: inherit;">not</em> have an expiration date, had a fair value of approximately $<ix:nonFraction id="c117048580" contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.1</ix:nonFraction> million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements. The Company used a portion of the proceeds from the Tranche B Warrants exercise as part of the Avenue Capital loan repayment described further in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">99</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> August 11, 2022, </em>the Company closed on the <em style="font: inherit;"> August 2022 </em>Offering, pursuant to which, the Company issued pre-funded warrants to purchase <ix:nonFraction id="c117048583" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">87,500</ix:nonFraction> shares of its common stock and common warrants to purchase <ix:nonFraction id="c117048584" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,265,547</ix:nonFraction> shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which <em style="font: inherit;">one</em> common warrant to purchase <span style="-sec-ix-hidden:c117048586">one</span> share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $<ix:nonFraction id="c117048587" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.02</ix:nonFraction> per share of common stock and were exercised in full in <em style="font: inherit;"> August 2022. </em>The common warrants have an exercise price of $<ix:nonFraction id="c117048588" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.60</ix:nonFraction> per share of common stock and are exercisable for a period of <span style="-sec-ix-hidden:c117048589">five</span> years from issuance. The common warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a &#8220;Stock Combination Event&#8221;), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (<em style="font: inherit;">x</em>) the sum of the VWAP of the common stock for each of the <em style="font: inherit;">five</em> lowest trading days during the <em style="font: inherit;">20</em> consecutive trading day period ending immediately preceding the <em style="font: inherit;">16th</em> trading day after such Stock Combination Event, divided by (y) five; or $<ix:nonFraction id="c117048594" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.32</ix:nonFraction> and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of <ix:nonFraction id="c117048595" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MaximumMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,325,581</ix:nonFraction> shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the <em style="font: inherit;">second</em> anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $<ix:nonFraction id="c117048597" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.32</ix:nonFraction> (see <i>Note <em style="font: inherit;">14</em> - Stockholders&#8217; Equity</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> November 2022 </em>and throughout the quarter ended <em style="font: inherit;"> December 31, 2022, </em>the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the <em style="font: inherit;"> August 2022 </em>Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $<ix:nonFraction id="c117048599" contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.60</ix:nonFraction>. As a result, the associated common warrants exercise price was adjusted to $<ix:nonFraction id="c117048600" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.30</ix:nonFraction>. On <em style="font: inherit;"> January 6, 2023, </em>the Company consummated a <ix:nonFraction id="c117048601" contextRef="d_2023-01-06_2023-01-06_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20</ix:nonFraction> to <em style="font: inherit;">1</em> reverse stock split. Pursuant to the aforementioned warrant agreement, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest <em style="font: inherit;">five</em> trading days during the <em style="font: inherit;">twenty</em>-day consecutive trading day period beginning on <em style="font: inherit;"> December 30, 2022. </em>Subsequently, as a result of the Securities Purchase Agreement in <em style="font: inherit;"> June 2023, </em>the common warrants from the <em style="font: inherit;"> August 2022 </em>Offering had an adjusted exercise price of $<ix:nonFraction id="c117048605" contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.32</ix:nonFraction>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) <ix:nonFraction id="c117048606" contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">151,500</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to <ix:nonFraction id="c117048607" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">151,500</ix:nonFraction> shares of common stock, and (iii) common warrants to purchase up to <ix:nonFraction id="c117048608" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">333,300</ix:nonFraction> shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <em style="font: inherit;">one</em> common warrant to purchase <ix:nonFraction id="c117048610" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.1</ix:nonFraction> shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $<ix:nonFraction id="c117048611" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.002</ix:nonFraction> per share of common stock and were exercised in full in <em style="font: inherit;"> April 2022. </em>The common warrants have an exercise price of $<ix:nonFraction id="c117048612" contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.00</ix:nonFraction> per share of common stock and are exercisable <em style="font: inherit;">six</em> months after the date of issuance and have a term of <span style="-sec-ix-hidden:c117048614">five</span> years from the date of exercisability (see <i>Note <em style="font: inherit;">14</em> - Stockholders&#8217; Equity</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> January 26, 2022, </em>as consideration for entering into the Avenue Capital Agreement as described in <i>Note <em style="font: inherit;">11</em> &#8211; Long-Term Debt</i>, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $<ix:nonFraction id="c117048617" contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.20</ix:nonFraction> per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $<ix:nonFraction id="c117048618" contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.20</ix:nonFraction> prior to <em style="font: inherit;"> June 30, 2022, </em>the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on <em style="font: inherit;"> January 31, 2027. </em>At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was <em style="font: inherit;">not</em> fixed at the issuance (see <i>Note <em style="font: inherit;">11</em> &#8211; Long-Term Debt</i> for further details).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Outstanding warrants that are classified as derivative warrant liabilities in the consolidated balance sheets&#160;are marked to market at each reporting period (see <i>Note <em style="font: inherit;">12</em> &#8211; Fair Value Considerations</i>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">100</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A summary of warrants is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2740578" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life in Years <sup style="vertical-align:top;line-height:120%;">(4)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding June 30, 2023 <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048654" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,538,052</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048655" contextRef="i_2023-06-30_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-07-01_2023-06-30" name="aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="c117048656" format="ixt-sec:duryear">4.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants issued <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c117048657" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="aytu:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117048658" contextRef="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="aytu:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c117048660" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="aytu:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,247,648</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117048661" contextRef="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="aytu:ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.61</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c117048663" contextRef="d_2023-07-01_2024-06-30" unitRef="Share" name="aytu:ClassOfWarrantOrRightExpiredDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">20,958</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c117048664" contextRef="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="aytu:ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">300.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding June 30, 2024 <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048666" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,075,880</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048667" contextRef="i_2024-06-30_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.71</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="c117048668" format="ixt-sec:duryear">3.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The number of warrants outstanding as of <em style="font: inherit;"> June 30, 2023, </em>is comprised of <ix:nonFraction id="c117048624" contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,068,763</ix:nonFraction> liability classified warrants, <ix:nonFraction id="c117048625" contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">430,217</ix:nonFraction> liability classified <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants and <ix:nonFraction id="c117048626" contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">39,072</ix:nonFraction> equity classified warrants.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">2</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The warrants issued during fiscal <em style="font: inherit;">2024</em> were a result of <ix:nonFraction id="c117048629" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction> Tranche B Warrants being exercise to <ix:nonFraction id="c117048630" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction> Tranche B Pre-Funded Warrants.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">3</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The number of warrants outstanding as of <em style="font: inherit;"> June 30, 2024, </em>is comprised of <ix:nonFraction id="c117048632" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,821,115</ix:nonFraction> liability classified warrants, <ix:nonFraction id="c117048633" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">430,217</ix:nonFraction> liability classified <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants, <ix:nonFraction id="c117048634" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityTrancheBPrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,806,434</ix:nonFraction>&#160;liability classified Tranche B Pre-Funded Warrants and <ix:nonFraction id="c117048635" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">18,114</ix:nonFraction> equity classified warrants.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">4</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As pre-funded warrants do <em style="font: inherit;">not</em> have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.</p> </td></tr>
</tbody></table>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="c2740579" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">17</em> - Restructuring Costs</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As part of the Company&#8217;s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site (Rx Segment), the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations and expense associated with inventory write-downs&#160;is recorded in cost of sales in the consolidated statements of operations. The Company does <em style="font: inherit;">not</em> expect to incur&#160;any additional significant restructuring costs related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site during fiscal <em style="font: inherit;">2025.</em> As of <em style="font: inherit;"> June 30, 2024, </em>the Company did <em style="font: inherit;">not</em> have any material accruals related to the wind down of the Consumer Health Segment. As of <em style="font: inherit;"> June 30, 2024, </em>the Company had accrued $<ix:nonFraction id="c117048673" contextRef="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember" unitRef="USD" name="us-gaap:SeveranceCosts1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million and $<ix:nonFraction id="c117048674" contextRef="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember" unitRef="USD" name="us-gaap:BusinessExitCosts1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million related to accrued severance and employee benefits&#160;and accrued exit and disposal activity costs, respectively, related to the closure of the Grand Prairie, Texas manufacturing facility.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">101</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">A summary of restructuring costs incurred during the year ended <em style="font: inherit;"> June 30, 2024, </em>is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="c2740580" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30, 2024</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Severance and Employee Benefits <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exit and Disposal Activities <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inventory Write-Down <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Wind down of Consumer Health Segment <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048688" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-4">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048689" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">189</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048690" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-4">730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117048691" contextRef="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-ConsumerHealthSegmentMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">939</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closure of Grand Prairie, Texas manufacturing site <sup style="vertical-align:top;line-height:120%;">(4)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048692" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,125</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048693" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,031</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048694" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c117048695" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048696" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,145</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048697" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,220</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048698" contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-4">730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c117048699" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RestructuringCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">2</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">3</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">4</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.</p> </td></tr>
</tbody></table> &#160;&#160;
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2740581" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">18</em> - Commitments and Contingencies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Pediatric Portfolio Fixed Payments and Product Milestone</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company assumed <ix:nonFraction id="c117048701" contextRef="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="Pure" name="aytu:FixedPaymentArrangementsPeriodicPaymentObligationsNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> fixed, periodic payment obligations to an investor (the &#8220;Fixed Obligation&#8221;). Under the <em style="font: inherit;">first</em> fixed obligation, the Company was to pay a monthly payment of $<ix:nonFraction id="c117048703" contextRef="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="USD" name="aytu:FixedPaymentArrangementsMonthlyPaymentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million beginning <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2019,</em> through <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2021,</em> with a balloon payment of $<ix:nonFraction id="c117048707" contextRef="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="USD" name="aytu:FixedPaymentArrangementsBalloonPaymentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">15.0</ix:nonFraction> million that was to be due in <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2021</em> (&#8220;Balloon Payment Obligation&#8221;). A <em style="font: inherit;">second</em> fixed obligation required the Company pay a minimum of $<ix:nonFraction id="c117048710" contextRef="i_2024-06-30_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember" unitRef="USD" name="aytu:FixedPaymentArrangementsBalloonPaymentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million&#160;monthly through <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">2026,</em> except for $<ix:nonFraction id="c117048712" contextRef="i_2020-01-31_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember" unitRef="USD" name="aytu:FixedPaymentArrangementsBalloonPaymentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million paid in <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">29,</em> <em style="font: inherit;">2020,</em> the Company entered into an early payment agreement and escrow instruction (the &#8220;Early Payment Agreement&#8221;) pursuant to which the Company agreed to pay $<ix:nonFraction id="c117048716" contextRef="i_2020-05-29_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="USD" name="aytu:FixedPaymentArrangementsBalloonPaymentAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">15.0</ix:nonFraction> million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the waiver or the investor agreement other than as expressly set forth therein. The <em style="font: inherit;">first</em> fixed obligation was fully paid as of <em style="font: inherit;"> January 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 21, 2021, </em>the Company entered into a waiver, release and consent pursuant to which the Company paid $<ix:nonFraction id="c117048718" contextRef="d_2021-06-21_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="USD" name="aytu:FixedPaymentArrangementsPaymentAmountPaid" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.8</ix:nonFraction> million to the investor in satisfaction of the <em style="font: inherit;">second</em> fixed obligation. The Company agreed to pay the remaining fixed obligation of $<ix:nonFraction id="c117048720" contextRef="i_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="6" format="ixt:num-dot-decimal" decimals="-6">3.0</ix:nonFraction> million in <em style="font: inherit;">six</em> equal quarterly payments of $<ix:nonFraction id="c117048722" contextRef="i_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember" unitRef="USD" name="aytu:FixedPaymentArrangementQuarterlyPayments" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million over the next <em style="font: inherit;">six</em> quarters commencing <em style="font: inherit;"> September 30, 2021. </em>The Company accounted for the waiver, release and consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by <em style="font: inherit;"> January 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company acquired the Tris Karbinal Agreement, under which the Company is granted the exclusive right to distribute and sell Karbinal&#160;in the United States. The initial term of the agreement was&#160;<ix:nonNumeric contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" name="aytu:SupplyAndDistributionCommitmentPeriod" id="c117048724" format="ixt-sec:duryear">20</ix:nonNumeric>&#160;years. The Company pays&#160;Tris a royalty equal to&#160;<ix:nonFraction id="c117048725" contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="Pure" name="aytu:SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" scale="-2" format="ixt:num-dot-decimal" decimals="3">23.5</ix:nonFraction>% of net revenue&#160;from&#160;the product.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style="font: inherit;"> August 1 </em>through <em style="font: inherit;"> July 31, </em>of <ix:nonFraction id="c117048727" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="Pure" name="aytu:SupplyAndDistributionAgreementMinimumSalesPerYear" scale="0" format="ixt:num-dot-decimal" decimals="INF">70,000</ix:nonFraction> units annually through <em style="font: inherit;">2025.</em> The Company is required to pay Tris a royalty make-whole payment of $<ix:nonFraction id="c117048731" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">30</ix:nonFraction> for each unit under the <em style="font: inherit;">70,000</em>-unit annual minimum sales commitment through <em style="font: inherit;">2025.</em> The Tris Karbinal Agreement make-whole payment is capped at $<ix:nonFraction id="c117048734" contextRef="i_2024-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" scale="3" format="ixt:num-dot-decimal" decimals="-2">2.1</ix:nonFraction> million each year. The annual payment is due in <em style="font: inherit;"> August </em>of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $<ix:nonFraction id="c117048735" contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementMaximumMilestoneObligations" scale="6" format="ixt:num-dot-decimal" decimals="-6">3.0</ix:nonFraction> million based on cumulative net revenue from the product, the <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">first</em> of which is triggered at $<ix:nonFraction id="c117048737" contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" scale="6" format="ixt:num-dot-decimal" decimals="-7">40.0</ix:nonFraction> million. As of <em style="font: inherit;"> June 30, 2024, </em>the fixed payment arrangement balance was $<ix:nonFraction id="c117048738" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.9</ix:nonFraction> million in other current liabilities, and $<ix:nonFraction id="c117048740" contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember" unitRef="USD" name="aytu:FixedPaymentArrangements" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million in other non-current liabilities on the consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">102</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Operating Lease</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2024, </em>the Company entered into a forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;from the owner of the office space that the Company is&#160;currently renting under a sublease arrangement. The Company has determined that it is an operating lease, and that lease commencement occurred in <em style="font: inherit;"> July 2024. </em>The&#160;initial is from <em style="font: inherit;"> March 1, 2025, </em>through <em style="font: inherit;"> July 31, 2030, </em>and under the lease agreement the Company has <span style="-sec-ix-hidden:c117048743">one five</span>-year renewal option to extend the lease through <em style="font: inherit;"> July 2035.&#160;</em>Undiscounted minimum monthly rent payments average approximately $<ix:nonFraction id="c117048744" contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember" unitRef="USD" name="aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,000</ix:nonFraction>&#160;over the initial term of the lease.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> May 2023, </em>the Company entered into an operating lease agreement to relocate its principal office from Englewood, Colorado to&#160;Denver, Colorado. The lease has a commencement date of <em style="font: inherit;"> October 1, 2023, </em>with an initial term of <span style="-sec-ix-hidden:c117048746">five</span> and a half years. Undiscounted minimum monthly rent payments average approximately $<ix:nonFraction id="c117048747" contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember" unitRef="USD" name="aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment" scale="0" format="ixt:num-dot-decimal" decimals="INF">15,500</ix:nonFraction> over the initial term of the lease. Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has <span style="-sec-ix-hidden:c117048749">one five</span>-year renewal option through <em style="font: inherit;"> March 2034.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Legal Matters</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Witmer Class-Action Securities Litigation</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A stockholder derivative suit was filed on <em style="font: inherit;">September12,</em> <em style="font: inherit;">2022,</em> in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#8217;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on <em style="font: inherit;"> April 5, 2023. </em>The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in <em style="font: inherit;">2019</em> and Innovus in <em style="font: inherit;">2020</em> to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants&#8217; breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees. While the Company believes&#160;that this lawsuit is without merit and have vigorously defended against it, the Company&#160;agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#8217;s attorneys&#8217; fees. That settlement is subject to court approval, the hearing on which has <em style="font: inherit;">not</em> yet been scheduled.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Sabby Litigation</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A complaint was filed on <em style="font: inherit;"> February 22, 2023, </em>in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#8220;Sabby&#8221;) and Walleye Opportunities Master Fund Ltd (&#8220;Walleye&#8221;), holders of certain warrants to purchase common stock, against the Company. The complaint alleged&#160;that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders <em style="font: inherit;"> may </em>receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint sought&#160;a declaratory judgment of the warrant share calculation, that <ix:nonFraction id="c117048756" contextRef="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">575,000</ix:nonFraction> warrant shares be due to Sabby on exercise of its warrants rather than <ix:nonFraction id="c117048758" contextRef="i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">312,908</ix:nonFraction> shares, and that <ix:nonFraction id="c117048759" contextRef="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000</ix:nonFraction> warrant shares be due to Walleye on exercise of its warrants rather than <ix:nonFraction id="c117048760" contextRef="i_2023-02-22_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">54,146</ix:nonFraction> shares. In&#160;<em style="font: inherit;"> October 2023,&#160;</em>the Company entered into a settlement agreement and general release with Sabby and Walleye.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Stein Litigation</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cielo Stein (&#8220;Stein&#8221;), a former sales specialist, filed a complaint on <em style="font: inherit;"> February 1, 2023, </em>in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos. The complaint alleged&#160;that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleged&#160;that the Company&#8217;s response to Stein&#8217;s subsequent complaint to human resources was inadequate. The complaint sought&#160;an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#8217; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky. A Section&#160;<em style="font: inherit;">16</em>&#160;pretrial conference was held on&#160;<em style="font: inherit;"> June 3, 2024.&#160;</em>During the pretrial conference the parties agreed to settle the matter. The parties entered into a settlement and release agreement on <em style="font: inherit;"> August 5, 2024. </em>The&#160;matter has been closed.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">103</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="aytu:LicensingAgreementsTextBlock" id="c2740582" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">19</em> - License Agreements</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Healight</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> April 2020, </em>the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, <em style="font: inherit;">ten</em> years after the <em style="font: inherit;">first</em> bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency.&#160;Pursuant to the terms of the agreement, the Company paid an initial $<ix:nonFraction id="c117048771" contextRef="d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember" unitRef="USD" name="aytu:LicenseAgreementInitialLicenseFeePaid" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million license fee and $<ix:nonFraction id="c117048772" contextRef="d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember" unitRef="USD" name="aytu:LicenseAgreementPatentProsecutionFeesPaid" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million in earlier patent prosecution fees.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of the Company&#8217;s focus on the revenue growth of its commercial business, the Company&#160;terminated the licensing agreement with Cedars-Sinai Medical Center, effective <em style="font: inherit;"> May 9, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>NeuRx</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> October 2018, </em>Neos entered into an exclusive license agreement (&#8220;NeuRx License&#8221;) with NeuRx Pharmaceuticals LLC (&#8220;NeuRx&#8221;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture&#160;and commercialize certain pharmaceutical products containing NeuRx&#8217;s proprietary compound designated as NRX-<em style="font: inherit;">101,</em> referred to by Neos as <em style="font: inherit;">NT0502.</em> <em style="font: inherit;">NT0502</em> is a new chemical entity that was&#160;being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company <em style="font: inherit;"> may </em>be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the <em style="font: inherit;">first</em> commercial sale of such licensed product in such country and continuing until the later of: (i)&#160;the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii)&#160;expiration of regulatory exclusivity of such licensed product in such country.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> April 2023, </em>the Company returned the <em style="font: inherit;">NT0502</em> rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on <em style="font: inherit;">NT0502.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Teva</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> December 21, 2018, </em>the Company&#160;and Teva&#160;entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under an&#160;abbreviated new drug application&#160;(&#8220;ANDA&#8221;)&#160;filed by Teva beginning on <em style="font: inherit;"> July 1, 2026, </em>or earlier under certain circumstances. The ANDA was approved by the FDA on <em style="font: inherit;"> June 19, 2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Actavis</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> October 17, 2017, </em>the Company entered into an agreement granting Actavis a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on <em style="font: inherit;"> September 1, 2025, </em>or earlier under certain circumstances. The ANDA was approved by the FDA on <em style="font: inherit;"> June 22, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Shire</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> July 2014, </em>Neos entered into a settlement agreement and an associated license agreement (the <em style="font: inherit;">&#8220;2014</em> License Agreement&#8221;) with Shire LLC (&#8220;Shire&#8221;) for a non-exclusive license to certain patents for certain activities with respect to Neos&#8217; New Drug Application (the &#8220;NDA&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">204326</em> for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the <em style="font: inherit;">2014</em> License Agreement, following the receipt of the approval from the FDA for Adzenys, Neos paid a lump sum, non-refundable license fee of an amount less than $<ix:nonFraction id="c117048784" contextRef="d_2016-02-01_2016-02-29_TypeOfArrangementAxis-The2014LicenseAgreementShireMember" unitRef="USD" name="aytu:LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million in <em style="font: inherit;"> February 2016. </em>Neos is paying a single digit royalty on net sales of Adzenys&#160;during the life of the patents. The settlement agreement expired&#160;in <em style="font: inherit;"> May 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">104</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c2740583" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">20</em> - Segment Information</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s CODM,&#160;who is the Company&#8217;s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company manages and aggregates its operational and financial information in accordance with <span style="-sec-ix-hidden:c117048787">two</span> reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company&#8217;s prescription products. The Consumer Health Segment contained&#160;the Company&#8217;s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does <em style="font: inherit;">not</em> regularly review asset information by segment, accordingly, asset information is <em style="font: inherit;">not</em> provided by segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Select financial information for these segments is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c2740584" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Year Ended June 30, 2024</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048795" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048796" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048797" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">81,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048798" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">1,590</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048799" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,664</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048800" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,254</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048801" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,909</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048802" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,547</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048803" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,456</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048804" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,373</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048805" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-4">540</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048806" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048807" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RestructuringCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048808" contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:RestructuringCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">209</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048809" contextRef="d_2023-07-01_2024-06-30" unitRef="USD" name="us-gaap:RestructuringCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,365</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Year Ended June 30, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048811" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">73,799</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048812" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-5">33,600</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048813" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">107,399</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048814" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7,358</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048815" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">9,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c117048816" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">17,065</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048817" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,271</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048818" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,116</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048819" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048820" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,722</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048821" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">324</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048822" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,046</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048823" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember" unitRef="USD" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048824" contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember" unitRef="USD" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,975</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c117048825" contextRef="d_2022-07-01_2023-06-30" unitRef="USD" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,705</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric> &#160;&#160;
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-07-01_2024-06-30" name="us-gaap:SubsequentEventsTextBlock" id="c2740585" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">21</em>&#160;- Subsequent Events</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wind Down and Subsequent Divestiture of Consumer Health Business</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> July 2024, </em>the Company&#160;completed the wind down of its&#160;Consumer Health Segment and on <em style="font: inherit;"> July 31, 2024, </em>the Company&#160;entered into a definitive agreement to divest its&#160;Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company affiliated with the Company&#8217;s&#160;former Vice President of Consumer Health, Jonathan Hughes. Pursuant to the definitive agreement, Mr. Hughes resigned from the Company effective <em style="font: inherit;"> July 31, 2024. </em>The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for the Company&#160;to receive up to $<ix:nonFraction id="c117048827" contextRef="d_2024-07-01_2024-07-31_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="aytu:RevenuebasedRoyaltyCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products. Upon consummation of this agreement, the Company has&#160;completed its&#160;wind down of the Consumer Health Segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">105</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item9" title="item9" href="#"></a>ITEM</b>&#160;<b>9.</b>&#160;<b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">None.&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item9a" title="item9a" href="#"></a>ITEM</b>&#160;<b>9A.</b>&#160;<b>CONTROLS AND PROCEDURES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our management is responsible for establishing and maintaining adequate &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and&#160;forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2024.&#160;Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were&#160;effective as of June 30, 2024, at reasonable assurance levels,&#160;in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.&#160;Accordingly, we believe&#160;that the financial statements presented in this Form 10-K present fairly,&#160;in all material respects, our financial position, results of operations and cash flows for the periods presented herein.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Remediation of Previously Identified Material Weakness</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Warrants</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As previously disclosed in our&#160;<a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023001643/aytu-20220930x10qa.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">September 30, 2022 Form 10-Q/A</span></a>, we identified a material weakness in internal control over financial reporting related to our&#160;accounting for complex warrant issuances and the classification of these issued warrants. This material weakness resulted in the failure to prevent material adjustments in accounting for the warrants as equity classification when the warrants should have been classified as liabilities and marked to market each reporting period. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements, other literature, and consultation with third-party experts, we did not classify the warrants correctly.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Inventory</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As previously disclosed in our&#160;<a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1385818/000155837023016393/aytu-20230630x10k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Fiscal 2023 Annual Report on Form 10-K</span></a>, we identified a material weakness in internal control over financial reporting related to our analysis for the accounting for valuation of our inventory. As of June 30, 2023, it was determined that the analysis of over or under absorbed manufacturing costs was not performed, which could have led to material misstatement of our financial statement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       106
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Remediation Efforts</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As previously reported in our public reports referred to above, our Audit Committee conducted an internal investigation to identify and determine a plan to remediate the material weaknesses described above and to enhance our overall control environment. We undertook to remediate these deficiencies and strengthen our internal control over financial reporting by enhancing existing controls and establishing additional review and procedure controls over the process of reviewing significant and complex contracts and agreements, and the valuation of inventory, which include the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Identified specific clauses and relevant guidance that could result in liability classification of issued warrants;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Identified and engaged a firm that specializes in the analysis and technical accounting for the classification of warrants and utilized this firm to assist with the technical accounting analysis for our warrants issued on June 8, 2023, including arriving at the correct conclusion that these warrants should be classified as liabilities and marked to market each reporting period;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Identified and engaged a firm that specializes in the valuation analysis regarding the fair value of our liability classified warrants to assist us with calculating the necessary mark to market adjustment each reporting period;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Implemented a new quarterly control and related processes effective for the fourth quarter of fiscal 2023, and operating every quarter thereafter, to perform a detailed analysis of over or under absorbed manufacturing costs, quantify any over or under absorbed manufacturing costs, and have the appropriate level of management review and evaluate the analysis and approve the recording of any adjusting journal entries as necessary;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Successfully hired additional personnel with the expertise necessary to improve the technical accounting and financial reporting functions; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Provided additional guidance, education and training to employees relating to our accounting procedures with a continued focus on warrant classification and inventory valuation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Given these remediation efforts above and that a sufficient period of time has passed with&#160;successful testing performed,&#160;management&#160;concluded that the material weaknesses set forth above were remediated as of March 31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Inherent Limitations on Effectiveness of Internal Controls over Financial Reporting</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our management team, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple errors or mistakes. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Changes in Internal Control over Financial Reporting</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There have not been any changes in our internal control over financial reporting during the fourth quarter of fiscal 2024&#160;that have materially affected, or are reasonably likely to materially affected,&#160;our internal control over financial reporting.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       107
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>MANAGEMENT&#8217;S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules&#160;13a-15(f)&#160;under the Exchange Act). The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company&#8217;s internal control over financial reporting includes those policies and procedures that:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that have a material effect on the financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Because of the inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of the changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based on our management&#8217;s assessment and those criteria, our management&#160;concluded that the Company maintained effective internal control over financial reporting as of June 30, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Grant Thornton LLP (&#8220;Grant Thornton&#8221;) the independent registered public accounting firm that audited our financial statements included in this Annual Report, was not required to issue an attestation report on our internal control over financial reporting.</p>
  <div>
    &#160;
  </div>
  <div>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item9b" title="item9b" href="#"></a>ITEM</b>&#160;<b><em style="font: inherit;">9B.</em></b>&#160;<b>OTHER INFORMATION</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> Trading Plans</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the quarter ended <em style="font: inherit;"> June 30, 2024, </em><span style="-sec-ix-hidden:c117048835"><span style="-sec-ix-hidden:c117048843"><span style="-sec-ix-hidden:c117048844"><span style="-sec-ix-hidden:c117048845">none</span></span></span></span> of our directors or executive officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em> under the Exchange Act) adopted or terminated a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221;&#160;(as those terms are defined in Item <em style="font: inherit;">408</em> of Regulation S-K).</p>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item9c" title="item9c" href="#"></a>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENT INSPECTIONS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Not applicable.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       108
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="part3" title="part3" href="#"></a>PART</b>&#160;<b>III</b></p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item10" title="item10" href="#"></a>ITEM</b>&#160;<b>10.</b>&#160;<b>DIRECTORS AND EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth the names and ages of all of our directors and NEOs. Our Board of Directors is currently comprised of five members, who are elected annually to serve for one&#160;year or until their successor is duly elected and qualified, or until their earlier resignation or removal. We have two executive officers that serve at the discretion of the Board of Directors and are appointed by the Board of Directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b></p> </td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joshua R. Disbrow</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">49</p> </td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman and Chief Executive Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark K. Oki</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55</p> </td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer, Corporate Secretary and Treasurer</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:21.3%;">Jarrett T. Disbrow</td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="vertical-align: bottom; width: 5.3%; text-align: center;">49</td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:23.6%;">Chief Business Officer</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Greg Pyszczymuka</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">45</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Commercial Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John A. Donofrio, Jr.</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">57</p> </td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lead Independent Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Carl C. Dockery</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">61</p> </td>
     <td style="vertical-align:bottom;width:1.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Abhinav &#8220;Abi&#8221; Jian</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">33</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vivian H. Liu</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:5.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">62</p> </td>
     <td style="vertical-align:bottom;width:1.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:23.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Biographical Summaries</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following is a biographical summary of the experience of our NEOs and directors during the past five&#160;years, and an indication of directorships held by the directors in other companies subject to the reporting requirements under the federal securities law.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Joshua R. Disbrow&#160;&#8211; Chairman and Chief Executive Officer</b></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Disbrow has been employed by us since April 16, 2015, and a member of our Board of Directors since January 2016. Prior to the closing of the merger between Luoxis Diagnostics, Inc. (&#8220;Luoxis&#8221;) and Vyrix Pharmaceuticals, Inc. that formed Aytu, Mr.&#160;Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow jointly served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. (&#8220;Ampio&#8221;), a public biotechnology company, from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, LLC (&#8220;Arbor&#8221;), a private specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as the company&#8217;s second full-time employee and led the company&#8217;s commercial efforts from inception to the company&#8217;s acquisition in 2010 and growth to over $250 million in net sales in 2012. By the time Mr.&#160;Disbrow departed Arbor in late 2012, he had led the growth of the commercial organization that included a nationwide sales force, marketing, sales training, managed care, national accounts, distribution and other commercial functions. Mr.&#160;Disbrow has spent 27 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, sales management, marketing, commercial operations, commercial strategy, and corporate finance and business development. Prior to joining Arbor, Mr.&#160;Disbrow served in sales management with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics, he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr.&#160;Disbrow began his career in sales. Mr.&#160;Disbrow holds an M.B.A. from Wake Forest University School of Business and BS in Management from North Carolina State University. Mr.&#160;Disbrow&#8217;s experience in executive management and commercialization within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a member of our Board of Directors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Mark K. Oki</i>&#160;&#8211;<i> Chief Financial Officer, Corporate Secretary and Treasurer</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Oki has served as our Chief Financial Officer since January 2022 and as our Corporate Secretary and Treasurer since May 2022. From October 2015 to January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC, formerly Vivus Inc. (&#8220;Vivus&#8221;), a commercial-stage pharmaceutical company. Vivus was a Nasdaq listed company up to December 2020. From April 2006 to October 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance and Chief Financial Officer. Before Alexza, Mr. Oki held roles of increasing responsibility at life science companies, Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation). Mr. Oki began his career in public accounting at Deloitte &amp; Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration &#8211; Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       109
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Jarrett T. Disbrow&#160;</i>&#8211;<i> Chief Business Officer</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Disbrow has served as our Chief Business Officer since November 2022. Until July 2024, he also held the position of President, Consumer Health. Prior to these roles, Mr. Disbrow served as our Executive Vice President, Corporate Operations from April 2021 to November 2022; Executive Vice President, Corporate Development from April 2020 to April 2021; our Executive Vice President, Marketing and Market Access from November 2019 to April 2020; our Chief Operating Officer and Head of Commercial from July 2019 to November 2019; and our Chief Operating Officer from April 2015 to July 2019. Prior to co-founding Aytu BioPharma in April 2015, Mr. Disbrow was the President and Chief Executive Officer of Vyrix Pharmaceuticals, Inc., a specialty pharmaceutical company focused on male sexual dysfunction. Mr.&#160;Disbrow&#8217;s first pharmaceutical start-up was Arbor Pharmaceuticals, LLC (&#8220;Arbor&#8221;), a privately held company focused initially on pediatrics. As the original founder of Arbor, Mr.&#160;Disbrow was responsible for the vision, fundraising, start-up, strategy and growth of the company until its acquisition by a private investor group in 2010. Mr.&#160;Disbrow also held various sales and marketing positions with Accentia Biopharmaceuticals, Inc., a publicly held biopharmaceutical company, and GlaxoSmithKline, a publicly held pharmaceutical company. Mr.&#160;Disbrow received a B.S. in Business Management from North Carolina State University and a M.S. in Organizational Leadership from the University of Colorado Boulder.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Greg Pyszczymuka </i>&#8211;<i> Chief Commercial Officer</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Pyszczymuka has served as our Chief Commercial Officer since January 2022. Prior to joining the Company at the closing of the Company&#8217;s merger with Neos&#160;in March 2021, Mr. Pyszczymuka served as Vice President, Commercial at Neos since June 2020. He previously served as Vice President, Commercial Strategy &amp; Market Access at Neos from November 2018 to June 2020, and as Executive Director of Channel Strategy &amp; Access Programs. Prior to joining Neos, Mr. Pyszczymuka had served in roles of increasing responsibility over a 20-year career including sales management, brand management, channel strategy, managed markets and new products planning. Mr. Pyszczymuka joined Neos most recently from Aqua Pharmaceuticals (an Almirall company), and previously was with Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>John A. Donofrio,</i>&#160;<i>Jr.&#160;&#8211; Lead&#160;Independent Director</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Donofrio joined our Board of Directors in July 2016. He is a senior pharmaceutical executive with over 30 years of experience in the industry across a broad range of areas, including President, Chief Financial Officer, and Chief Operating Officer positions. Mr. Donofrio has significant finance experience in consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. Since March 2022 Mr. Donofrio has served as Executive Vice President, Chief Operating Officer of Novan Inc., a publicly held specialty dermatology company, and as President of Novan Inc.&#8217;s wholly owned subsidiary EPI Health, a specialty pharmaceutical company commercializing products in the dermatology market. From March 2019 until its acquisition by Novan, Inc. in March 2022, Mr. Donofrio served as EPI Health&#8217;s President. Mr. Donofrio previously served as Chief Financial Officer and Head of Business Development at TrialCard from March of 2018 to March 2019. TrialCard is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America (&#8220;Merz&#8221;) from August 2013 to March 2018. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio was accountable for financial performance, cost management, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University. Mr. Donofrio&#8217;s broad executive leadership experience and financial expertise along with experience in the pharmaceutical industry led to the conclusion that he should serve as a member of our Board of Directors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       110
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Carl C. Dockery</i>&#160;&#8211;<i> Director</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Dockery joined our Board of Directors in April 2016. Mr. Dockery is a financial executive with over 30 years of experience as an executive in the insurance and reinsurance industry and more recently since 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery&#8217;s career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as Secretary of Crossroads Insurance Co. Ltd. of Bermuda and as Vice President of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd&#8217;s and the London Underwriting Centre brokering various types of reinsurance placements. From September 2014 through September 2019, Mr. Dockery served as a director of CytoDyn Inc. (OTCQB: CYDY), a publicly traded biotechnology company focused on the development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV and cancers. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities. Mr. Dockery&#8217;s financial expertise and experience, as well as his experience as a director of a publicly traded biopharmaceutical company led to the conclusion that he should serve as a member of our Board of Directors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Abhinav </i>&#8220;<i>Abi</i>&#8221;<i> Jain </i>&#8211;<i> Director</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr. Jain joined our Board of Directors in June 2023. Since July 2019, Mr. Jain has served as an Analyst at Nantahala Capital Management, LLC (&#8220;Nantahala&#8221;) and is focused on investments in various sectors, including specialty and generic pharmaceuticals. From 2015 to 2017, Mr. Jain was an Associate at Angelo, Gordon &amp; Co., an alternative asset manager. At Angelo, Gordon &amp; Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with a M.B.A. with honors in Finance and Entrepreneurial Management. Mr. Jain&#8217;s financial expertise and experience led to the conclusion that he should serve as a member of our Board of Directors. Mr. Jain was appointed pursuant to a board designation right granted to Nantahala to appoint one director to our Board of Directors, pursuant to the Securities Purchase Agreement dated June 8, 2023, with Nantahala and other investors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Vivian H. Liu </i>&#8211;<i> Director</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Ms. Liu joined our Board of Directors in July 2022. Ms. Liu currently serves as Head of Corporate Affairs for PREMIA Holdings (HK) Limited (&#8220;PREMIA&#8221;), a developer of clinical-genomic oncology databases and service provider to pharmaceutical companies seeking to operate clinical trials throughout Asia. Prior to joining PREMIA, Ms. Liu served in various roles, including as a member of Board of Directors and President, Chief Executive Officer and Chief Financial Officer for Innovus Pharmaceuticals, Inc. (&#8220;Innovus&#8221;), a publicly listed consumer healthcare company acquired by Aytu in February 2020. Prior to Innovus, she served as the President and Chief Executive Officer of FasTrack Pharmaceuticals, Inc. From 2017 to 2018, she served as the Chief Operating Officer and a member of the Board of Directors of Cesca Therapeutics, Inc. Previously, Ms. Liu served as Managing Director of OxOnc Services Company, an oncology development company, and prior to that, Ms. Liu co-founded and served as President, Chief Executive Officer, and board director of NexMed, Inc., a drug development company which was later renamed Apricus BioSciences. Prior to her appointment as President of NexMed, Inc., Ms. Liu served in several executive capacities, including as Executive Vice President, Chief Operating Officer, Chief Financial Officer and Vice President of Corporate Affairs. Ms. Liu has an M.P.A. from the University of Southern California and a B.A. from the University of California, Berkeley. Ms. Liu&#8217;s experience in executive management within the pharmaceutical industry, as a director of a publicly traded biotech company and in corporate finance led to the conclusion that she should serve as a member of our Board of Directors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Family Relationships</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Jarrett T. Disbrow, our Chief Business Officer is the brother of Joshua R. Disbrow, our Chairman and Chief Executive Officer. There are no other family relationships among or between any of our current or former executive officers and directors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Involvement in Certain Legal Proceedings</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Mr.&#160;Oki was the Chief Financial Officer of Vivus at the time a Chapter&#160;11 petition was filed under the Federal bankruptcy laws in July&#160;2020.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">None of our other directors or executive officers have&#160;been involved in any legal proceeding in the past 10&#160;years that would require disclosure under Item&#160;401(f)&#160;of Regulation S-K promulgated under the Securities Act.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       111
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Section</b>&#160;<b>16(a)</b>&#160;<b>Beneficial Ownership Reporting Compliance</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Section 16(a)&#160;of the Exchange Act requires our officers and directors and persons who own more than 10% of our outstanding common stock to file reports of ownership and changes in ownership with the SEC. These officers, directors and stockholders are required by regulations under the Exchange Act to furnish us with copies of all forms they file under Section&#160;16(a).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based solely on our review of the copies of forms we have received, we believe that all such required reports have been timely filed, except for one late filing of a Form 4 by Joshua R. Disbrow relating to a rescission of 80,000 shares of restricted common stock on December 20, 2022, which was inadvertently filed one day late on December 23, 2022, and two late filings of Form 4s by Greg Pyszczymuka, one of which related to the conversion of 833 restricted stock units to shares of common stock on April 25, 2023, which was inadvertently filed late on June 20, 2023, and the second of which related to the conversion of 208 restricted stock units to shares of common stock on June 30, 2023, which was inadvertently filed late on July 6, 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Code of Ethics</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have adopted a written code of ethics that applies to our officers, directors, and employees, including our principal executive officer (Joshua R.&#160;Disbrow), principal financial officer (Mr. Oki), and principal accounting officer (Mr. Oki). We intend to disclose any amendments to, or waivers from, our code of ethics that are required to be publicly disclosed pursuant to rules&#160;of the SEC by filing such amendment or waiver with the SEC. Our Code of Ethics and Business Conduct and our Code of Ethics for Chief Executive Officer and Senior Financial Officers can be found on our website at https://www.aytubio.com&#160;under the &#8220;Investors&#8212;Corporate Governance&#8221; section.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Board Committees</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Board has established an Audit Committee, Compensation Committee and a Nominating and Governance Committee. Our Audit Committee consists of Mr. Donofrio (Chair), Mr. Dockery, Mr. Jain, and Ms. Liu. Our Compensation Committee consists of Ms. Liu (Chair), Mr. Dockery, Mr. Jain, and Mr. Donofrio. Our Nominating and Governance Committee consists of Mr. Dockery (Chair), Mr. Donofrio, Mr. Jain, and Ms. Liu. The independence of our directors is discussed in Part&#160;III, Item&#160;13 under the caption &#8220;Director Independence.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Each of the above-referenced committees operates pursuant to a formal written charter. The charters for these committees, which have been adopted by our Board, contain a detailed description of the respective committee&#8217;s duties and responsibilities and are available on our website at https://www.aytubio.com under the &#8220;Investor Relations&#8212;Corporate Governance&#8221; section.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Board has determined Mr.&#160;Donofrio qualifies as an audit committee financial expert, as defined in Item&#160;407(d)(5)&#160;of Regulation S-K promulgated by the SEC.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Stockholder Proposals</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our bylaws establish procedures for stockholder nominations for elections of directors and bringing business before any Annual Meeting or special meeting of stockholders. A stockholder entitled to vote in the election of directors may nominate one or more persons for election as directors at a meeting only if written notice of such stockholder&#8217;s intent to make such nomination or nominations has been delivered to our Corporate Secretary at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary of the prior&#160;year&#8217;s annual meeting of stockholders of the Company. In the event that the date of the Annual Meeting&#160;is more than 30&#160;days before or more than 60&#160;days after the anniversary date of the prior&#160;year&#8217;s annual meeting of stockholders of the Company, or if no annual meeting of stockholders of the Company&#160;was held in the prior year, then the stockholder notice must be no less than the later of (i) 90&#160;days prior to the date of the Annual Meeting&#160;or (ii) the 10th day following the date on which the date of the Annual Meeting is first publicly announced or disclosed by us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the bylaws, a stockholder&#8217;s notice must set forth among other things: (i)&#160;as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act, and the rules&#160;and regulations thereunder; and (ii)&#160;as to any other business that the stockholder proposes to bring before the Annual Meeting, a brief description of the business desired to be brought before the Annual Meeting, the reasons for conducting such business at the Annual Meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There have been no changes to these nominating procedures since the adoption of the bylaws.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       112
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item11" title="item11" href="#"></a>ITEM</b>&#160;<b>11.</b>&#160;<b>EXECUTIVE COMPENSATION</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Executive Compensation</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In accordance with Item&#160;402 of Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the makeup of and compensation of our Company&#8217;s NEOs. In establishing executive compensation, our Board of Directors is guided by the following goals:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the executive officers for work required for a company of our size and scope;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">compensation should align the executive officers&#8217; interests with the long-term interests of stockholders; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">compensation should assist with attracting and retaining qualified executive officers and directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Compensation of Directors</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our current compensation package for non-employee directors, effective July&#160;1, 2024, consists of: (i) an annual cash retainer of $80,000 for the non-executive Board chair or lead independent director; (ii)&#160;$50,000 for each other director; (iii)&#160;$20,000 for each Audit Committee and Compensation Committee chair; (iv)&#160;$10,000 for Nominating and Governance Committee chair;&#160;(v) $10,000 for each other committee member of the Audit and Compensation Committees;&#160;(vi) $5,000 for each other committee member of the Nominating and Governance Committee; (vii) a grant of 6,500 restricted shares of stock or restricted stock units upon appointment to the Board; and (viii) an annual grant of 1,500 restricted shares of stock or restricted stock units thereafter.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table provides information regarding all compensation paid to non-employee directors of Aytu during the year ended June 30, 2024:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fees Earned</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or Paid in Cash</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Awards</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">John A. Donofrio, Jr. <sup style="vertical-align:top;line-height:120%;">(1)(2)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">107,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Carl C. Dockery <sup style="vertical-align:top;line-height:120%;">(1)(2)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Abhinav &#8220;Abi&#8221; Jian <sup style="vertical-align:top;line-height:120%;">(1)(2)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,297</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">79,297</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vivian H. Liu <sup style="vertical-align:top;line-height:120%;">(1)(2)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of June 30, 2024, Mr. Donofrio held 2,262 restricted shares and Mr. Dockery held 9,652 restricted shares, both adjusted for the recission of shares from the Aponowicz and Paguia settlement (for more information, see discussion of the Stipulation in <i>Note 15 - Equity Incentive Plans</i>&#160;to the notes to the consolidated financial statements included in this Form 10-K). As of June 30, 2024, Mr. Jian held 8,000 restricted shares and Ms. Liu held 8,325 restricted shares.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of June 30, 2024, the number of vested stock options held by each non-employee director was as follows: (i) 200 vested stock options for Mr. Donofrio and (ii) 200 vested stock options for Mr. Dockery.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       113
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Executive Officer Compensation</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth all cash compensation earned, as well as certain other compensation paid or accrued for the&#160;years ended June 30, 2024, and 2023, to each of the following NEOs:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 100px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 98px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Non-Equity</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 100px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 98px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Incentive Plan</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>All Other</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Name and Principal Position</b></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 100px; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Salary</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 98px; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Awards <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Awards <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Compensation <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Compensation</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Joshua R. Disbrow</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 89px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 87px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><i>Chairman and Chief Executive Officer since December 2012</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">590,000</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">55,017</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">283,200</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">928,217</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">590,000</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">118,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">708,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 100px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 98px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Mark K. Oki</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 89px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 87px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><i>Chief Financial Officer, Corporate Secretary and Treasurer since January 2022</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">427,450</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">20,435</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">136,784</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">584,669</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">415,000</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">83,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">24,840</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">522,840</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 100px; padding: 0px; margin: 0px;">&#8203;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 98px; padding: 0px; margin: 0px;">&#8203;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#8203;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#8203;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#8203;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#8203;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><i>Jarrett T. Disbrow</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 89px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 87px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Chief Business Officer since November 2022</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2024</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">386,250</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">11,003</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">144,844</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">542,097</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">375,000</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">17,554</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">62,438</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">454,992</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 100px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 98px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Greg Pyszczymuka</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 89px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 87px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 10px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 8%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><i>Chief Commercial Officer since January 2022</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">389,423</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">11,003</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">115,875</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">516,301</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 26%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%; padding: 0px; margin: 0px;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 7%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2023</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 89px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">375,000</td>
     <td style="width: 8px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 87px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">15,046</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">150,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">540,046</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 1pt auto 1pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock awards and option awards are reported at fair value at the date of grant. Stock awards and options are approved by our Compensation Committee of our Board of Directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The amounts reported in this column reflect cash bonuses awarded pursuant to the achievement of our fiscal 2024 and fiscal 2023 corporate objectives, as approved by our Compensation Committee of our Board of Directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our NEOs are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf. NEOs&#160;are reimbursed for business expenses directly related to our business activities, such as travel, primarily for business development as we grow and expand our product lines. On average, each NEO&#160;incurs between $1,000 to $3,000 of out-of-pocket business expenses each month. The executive management team meets weekly and determines which activities they will work on based upon what is determined to be the most beneficial to the Company and our stockholders. No interest is paid on amounts reimbursed to the NEOs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       114
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Outstanding Equity Awards at Fiscal</b>&#160;<b>Year-End</b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table lists all of the outstanding stock awards held as of June 30, 2024, for each of the following NEOs:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px; padding-bottom: 1px;">&#160;</td>
     <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option Awards</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Awards</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Securities Underlying Unexercised Options Exercisable</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Securities Underlying Unexercised Options Unexercisable</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option Exercise Price</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option Expiration Date</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Shares or Unites of Stock That Have Not Vested</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Market Value of Shares or Units of Stock That Have Not Vested <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><i>Joshua R. Disbrow</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">290.00</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6/8/2030</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">35,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.73</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8/11/2033</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#8212;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">108</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,227</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,503</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><i>Mark K. Oki</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">13,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">1.73</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">8/11/2033</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,251</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3,653</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Jarrett T. Disbrow</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px;">4,557</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">3,646</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">4.00</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">10/1/2032</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">7,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1.73</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">8/11/2033</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#8212;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,687</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">4,926</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">917</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,678</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><i>Greg Pyszczymuka</i></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9px; padding: 0px; margin: 0px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3,906</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3,125</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">4.00</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">10/1/2032</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Option award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">7,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1.73</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">8/11/2033</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">626</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,828</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 313px; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><i>Stock award</i></p> </td>
     <td style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">626</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,828</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">Based on $2.92 per share, which was the closing price of our common stock as quoted on the Nasdaq Capital Market&#160;on June 28, 2024, the last trading day of fiscal 2024.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Joshua R. Disbrow&#160;Agreement</b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company entered into an employment agreement with Joshua R.&#160;Disbrow effective April 16, 2015 (the &#8220;Initial Disbrow Agreement&#8221;), in connection with his employment as Chief Executive Officer. On February 13, 2023, we entered into an amended and restated employment agreement with Joshua R.&#160;Disbrow. The agreement supersedes the Initial Disbrow Agreement and any prior employment agreements or amendments with the Company. The agreement was amended to: (i) provide for one-year employment terms with auto-renewal; (ii) modify the acceleration provision in connection with a change of control such that Joshua R.&#160;Disbrow would need to be terminated within 12 months following a change of control for &#8220;Cause&#8221; or resign for &#8220;Good Reason;&#8221; and (iii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his employment to willful malfeasance or willful misconduct; and (b) change material breach of the employment agreement to willful and deliberate breach.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       115
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Mark K. Oki</i>&#160;<i>Agreement</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On January 17, 2022, Mr. Oki was appointed as our Chief Financial Officer pursuant to an employment agreement effective January 17, 2022 (the &#8220;Initial Oki Agreement&#8221;). On February 13, 2023, we entered into an amended and restated employment agreement with Mr. Oki. The agreement supersedes the Initial Oki Agreement and any prior employment agreements with the Company. The agreement was amended to: (i) modify the equity acceleration provision to conform to Joshua R. Disbrow&#8217;s agreement relating to the equity awards referenced and acceleration language; and (ii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his other agreements with the Company to willful malfeasance or willful misconduct; (b) make conforming changes related to Mr. Oki&#8217;s unintended but material breach of the agreement instead of a material and repeated breach; and (c) change gross negligence in connection with his employment to willful malfeasance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Jarrett T. Disbrow&#160;Agreement</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On March 20, 2023, we entered into an amended and restated employment agreement with Jarrett T.&#160;Disbrow. The agreement supersedes any prior employment agreements with the Company. The agreement was amended to: (i) modify the equity acceleration provision to conform to Joshua R.&#160;Disbrow&#8217;s agreement relating to the equity awards referenced and acceleration language; and (ii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his other agreements with the Company, to willful malfeasance or willful misconduct; (b) make conforming changes related to Jarrett T.&#160;Disbrow&#8217;s unintended but material breach of the agreement, instead of a material and repeated breach; and (c) change gross negligence in connection with his employment to willful malfeasance.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Greg Pyszczymuka Agreement</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On March 21, 2023, we entered into an amended and restated employment agreement with Mr. Pyszczymuka. The agreement supersedes any prior employment agreements with the Company. The agreement was amended to: (i) modify the equity acceleration provision to conform to Joshua R.&#160;Disbrow&#8217;s agreement relating to the equity awards referenced and acceleration language; and (ii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his other agreements with the Company, to willful malfeasance or willful misconduct; (b) make conforming changes related to Mr. Pyszczymuka&#8217;s unintended but material breach of the agreement, instead of a material and repeated breach; and (c) change gross negligence in connection with his employment to willful malfeasance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Payments Provided Upon Termination for Good Reason or Without Cause</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the employment agreements, in the event employment is terminated without Cause by us or the officer terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and, in the case of Joshua R. Disbrow, (i) a lump sum payment equal to two and one half (2.5) times his base salary in effect at the date of termination; (ii) continued participation in the health and welfare plans for up to two years; and (iii) a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year. Jarrett T. Disbrow shall receive (i) a lump sum payment equal to two (2) times his base salary in effect at the date of termination; (ii) immediate vesting for the number of awards equal to 1/24th the number of awards multiplied by the number of full months of his employment; and (iii) continued participation in the health and welfare plans for up to two years. Mr. Oki and Mr. Pyszczymuka shall receive, (i) a payment equal to his base salary in effect at the date of termination; (ii) immediate vesting of all stock-based awards; (iii) continued participation in the health and welfare plans for up to 12 months; and (iv) a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#8220;Cause&#8221; means (i) willful malfeasance or willful misconduct in connection with his employment; (ii) conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iii) willful and deliberate violation of a Company policy, (iv) unintended but material breach of any written policy applicable to all employees adopted by the Company which is not cured to the reasonable satisfaction of the Board of Directors within 30 business days after notice thereof; (v) the unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#8217;s relationship with the Company, or (vi) the willful and deliberate breach of the employment agreement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#8220;Good Reason&#8221; means (i) there is a material reduction of the level compensation (excluding any bonuses) except where there is a general reduction applicable to the management team generally; (ii) there is a material reduction in overall responsibilities or authority, or scope of duties; or (iii) without the officer&#8217;s written consent, a material change in the principal geographic location at which the officer must perform his services (it being understood that the relocation of the officer to a facility or a location within 40&#160;miles of the State Capitol Building in Denver, Colorado shall not be deemed material for purposes of the employment agreements).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       116
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Payments Provided Upon a Change in Control</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event the NEO&#8217;s employment is terminated within 12 months of a Change in Control of us, all stock options, restricted stock, and other stock-based grants granted or may be granted in the future by us to the NEO&#160;will immediately vest and become exercisable. In addition, Joshua R.&#160;Disbrow shall be paid a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year. In addition, Mr. Oki shall receive (i) a payment equal to his base salary in effect at the date of the Change in Control; (ii) continued participation in the health and welfare plans for up to 12 months; and (iii) a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#8220;Change in Control&#8221; means: the occurrence of any of the following events:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the sale of all of the stock of the Company to an unrelated person, entity or group thereof acting in concert; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</p> </td>
    </tr>

   </tbody>
  </table>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item12" title="item12" href="#"></a>ITEM</b>&#160;<b>12.</b>&#160;<b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth information with respect to the beneficial ownership of our common stock as of August 31, 2024, for:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">each beneficial owner of 5% or more of our outstanding common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">each of our&#160;non-employee directors and NEOs; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">all of our directors and executive officers as a group.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC. These rules&#160;generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include common stock that can be acquired within 60&#160;days of August&#160;31, 2024. The&#160;percentage ownership information shown in the table is based upon 6,148,993 shares of common stock outstanding as of August&#160;31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       117
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In computing the number of shares of common stock beneficially owned by a person and the&#160;percentage ownership of that person, we deemed outstanding shares of common stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60&#160;days of August 31, 2024. We did not deem these shares outstanding, however, for the purpose of computing the&#160;percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the tables below is based on information known to us or ascertained by us from public filings made by the stockholders. Except as otherwise indicated in the table below, addresses of the non-employee directors, NEOs and named beneficial owners are in care of Aytu BioPharma,&#160;Inc., 7900 East&#160;Union Avenue, Suite 920, Denver, Colorado 80237.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percentage of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Beneficially</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Beneficially</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Owned</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Owned</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>5% or more Beneficial Owners</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Nantahala Capital Management, LLC <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,086,812</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.6</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Stonepine Capital Management, LLC <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: right;">565,484</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: right;">9.1</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Non-employee Directors</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">John A. Donofrio, Jr. <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,462</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Carl C. Dockery <sup style="vertical-align:top;line-height:120%;">(4)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,902</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Abhinav &#8220;Abi&#8221; Jain <sup style="vertical-align:top;line-height:120%;">(5)</sup></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">8,000</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">*</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Vivian H. Liu <sup style="vertical-align:top;line-height:120%;">(6)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,325</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Named Executive Officers</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: right;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Joshua R. Disbrow <sup style="vertical-align:top;line-height:120%;">(7)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Mark K. Oki <sup style="vertical-align:top;line-height:120%;">(8)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,516</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Jarrett T. Disbrow <sup style="vertical-align:top;line-height:120%;">(9)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">20,965</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Greg Pyszczymuka <sup style="vertical-align:top;line-height:120%;">(10)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,537</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">All directors and executive officers as a group, including those named above (eight persons)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">181,302</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.9</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents beneficial ownership of less than 1%.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The number of shares is based on a Form 13D/A filed by Nantahala Capital Management, LLC (&#8220;Nantahala&#8221;) with the SEC on June 18, 2024. Based on such filing, Nantahala are deemed to have the voting and dispositive power with respect to 1,086,812 shares of common stock. Nantahala have their principal business office at 130 Main Street, 2nd Floor, Nan Canaan, CT 06840.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The number of shares is based on a Form 13G/A filed by Stonepine Capital Management, LLC (&#8220;Stonepine&#8221;) with the SEC on February 13, 2024. Based on such filing, Stonepine are deemed to have the voting and dispositive power with respect to 565,484 shares of common stock. Stonepine have their principal business office at 919 NW Bond Street, Suite 204, Bend, OR 97703.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(3)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 495 shares of common stock, (ii) 1,767&#160;unvested restricted shares and (iii) 200 shares of common stock issuable upon the exercise of vested options.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(4)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 7,885&#160;shares of common stock, (ii) 1,767&#160;unvested restricted shares, (iii) 200 shares of common stock issuable upon the exercise of vested options&#160;and (iv) 50 shares of common stock held by Alpha Venture Capital Partners, L.P. Mr. Dockery is the President of the general partner of Alpha Venture Capital Partners, L.P. and therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(5)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 2,640 shares of common stock and (ii) 5,360&#160;unvested restricted shares. Mr. Jain is affiliated with Nantahala, however, the 8,000 unvested restricted shares are held by Mr. Jain in his individual capacity.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(6)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 3,961&#160;shares of common stock and (ii) 4,364&#160;unvested restricted shares.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(7)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 69,325 shares of common stock, (ii) 2,266 unvested restricted shares&#160;and (iii) 14,004&#160;shares of common stock issuable upon the exercise of vested options. Does not include 116 shares of common stock held by an irrevocable trust for estate planning in which Joshua R. Disbrow is a beneficiary. Joshua R. Disbrow does not have or share investment control over the shares held by the trust, Joshua R. Disbrow is not the trustee of the trust (nor is any member of Joshua R. Disbrow&#8217;s immediate family) and Joshua R. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a 8(b) and related rules, Joshua R. Disbrow does not have beneficial ownership over the shares purchased and held by the trust.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(8)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 8,666&#160;shares of common stock, and (ii) 834&#160;shares of unvested restricted shares and (iii) 5,016 shares of common stock issuable upon the exercise of vested options.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(9)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 11,082 shares of common stock, (ii) 1,714&#160;shares of unvested restricted shares&#160;and (iii) 8,169&#160;shares of common stock issuable upon the exercise of vested options.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(10)</sup>&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Consists of (i) 22,663&#160;shares of common stock, (ii) 313&#160;shares of unvested restricted shares&#160;and (iii) 8,561&#160;shares of common stock issuable upon the exercise of vested options.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       118
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item13" title="item13" href="#"></a>ITEM</b>&#160;<b>13.</b>&#160;<b>CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Related Party Transactions</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We describe below all transactions and series of similar transactions, other than compensation arrangements, during the last three fiscal&#160;years, to which we were a party or will be a party, in which:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the amounts involved exceeded or will exceed $120,000; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Jarrett T. Disbrow, the brother of Joshua R. Disbrow, our Chairman and Chief Executive Officer, is employed by us as Chief Business Officer. His total annual salary and other cash compensation was $531,094, which consists of $386,250&#160;base salary and&#160;a $144,844&#160;cash bonus during the year ended June 30, 2024, and he also receives benefits consistent with other employees serving in the same capacity.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On July 31, 2024, we entered into a definitive agreement to divest our Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company affiliated with our former Vice President of Consumer Health, Jonathan Hughes. Pursuant to the definitive agreement, Mr. Hughes resigned from the Company effective July 31, 2024. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for us to receive up to $0.5 million of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products. Upon consummation of this agreement, we have completed our wind down of the Consumer Health Segment.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Review, Approval or Ratification of Transactions with Related Persons</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Effective upon its adoption in July&#160;2016, pursuant to the Audit Committee Charter, the Audit Committee is responsible for reviewing and approving all related party transactions as defined under Item&#160;404 of Regulation S-K, after reviewing each such transaction for potential conflicts of interests and other improprieties. Our policies and procedures for review and approval of transactions with related persons are in writing in our Code of Business Conduct and Ethics available on our website at&#160;https://www.aytubio.com&#160;under the &#8220;Investors&#8212;Corporate Governance&#8221; section.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Prior to the adoption of the Audit Committee Charter, and due to the small size of the Company, we did not have a formal written policy regarding the review of related party transactions, and relied on our Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest. Our Board of Directors reviewed any such transaction in light of the particular affiliation and interest of any involved director, officer or other employee or stockholder and, if applicable, any such person&#8217;s affiliates or immediate family members</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Director Independence</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock is listed on the Nasdaq Capital Market. Therefore, we must comply with the exchange rules&#160;regarding director independence. Audit Committee members must satisfy the independence criteria set forth in Rule&#160;10A-3 under the Exchange Act, for listed companies. In order to be considered to be independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Four of our five directors are independent under the definition of Nasdaq. Joshua R.&#160;Disbrow is not independent due to his position as Chief Executive Officer of Aytu</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       119
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="item14" title="item14" href="#"></a>ITEM</b>&#160;<b>14.&#160;</b><b>PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Grant Thornton has served as our independent auditor since December 12, 2022, and has been appointed by our Audit Committee to continue as our independent auditor for the fiscal year ending June 30, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The following table presents aggregate fees for professional services rendered by our principal independent registered public accounting firms, Grant Thornton for the years ended June 30, 2024, and 2023, for the audit of our annual financial statements:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Audit fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">777</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">940</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Audit related fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Tax fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">231</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">All other fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,018</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">940</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Tax fees of $0.2 million during the fiscal year ended June 30, 2024, represent fees that were pre-approved by our Audit Committee related to analysis of Section 382&#160;of the IRC performed by Grant Thornton.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Policy on Pre-Approval of Services of Independent Registered Public Accounting Firm</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Audit Committee has responsibility for appointing, setting compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit Committee pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm, although it has no written policy on this matter. Prior to engagement of the independent registered public accounting firm for the following&#160;year&#8217;s audit, management will submit to the Audit Committee Chair or the full Audit Committee fees in excess of $25,000, for approval. Any fees approved by the Audit Committee Chair will be presented to the full Audit Committee at the following Audit Committee meeting. A description of services expected to be rendered during that&#160;year for each of following four categories of services:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Audit services include audit work performed in audit of the annual financial statements, review of quarterly financial statements, reading of annual, quarterly and current reports, as well as work that generally only the independent auditor can reasonably be expected to provide;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Audit-related services are for assurance and related services that are traditionally performed by the independent auditor, including the provisions of consents and comfort letters in connection with the filing of registration statements, due diligence related to mergers and acquisitions and special procedures required to meet certain regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Tax services consist principally of assistance with tax compliance and reporting, as well as certain tax planning consultations; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Other services are those associated with services not captured in the other categories. We generally do not request such services from our independent auditor.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Prior to the engagement, the Audit Committee pre-approves these services by category of service. The fees are budgeted, and the Audit Committee requires the independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the&#160;year by category of service. During the&#160;year, circumstances may arise when it may become necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit Committee requires specific pre-approval before engaging the independent registered public accounting firm.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       120
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="part4" title="part4" href="#"></a>PART</b>&#160;<b>IV</b></p>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><a id="item15" title="item15" href="#"></a>ITEM</b>&#160;<b>15.&#160;</b><b>EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>(a)(1) and (a)(2)&#160;Financial Statements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following documents are filed as part of this Annual Report:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 4%;">&#160;</td>
     <td style="vertical-align: bottom; width: 2%;">&#160;</td>
     <td style="vertical-align: bottom; width: 86%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#9679;</td>
     <td style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#report" style="-sec-extract:exhibit;">Report of Independent Registered Public Accounting Firm&#160;(PCAOB ID 248)</a></p> </td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#report">64</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 86%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#9679;</td>
     <td style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#balance_sheet" style="-sec-extract:exhibit;">Consolidated Balance Sheets</a></p> </td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#balance_sheet">66</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 86%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#9679;</td>
     <td style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#state_of_op" style="-sec-extract:exhibit;">Consolidated Statements of Operations</a></p> </td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#state_of_op">67</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 86%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#9679;</td>
     <td style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#equity" style="-sec-extract:exhibit;">Consolidated Statements of Stockholders&#8217;&#160;Equity</a></p> </td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#equity">68</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 86%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#9679;</td>
     <td style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cash_flows" style="-sec-extract:exhibit;">Consolidated Statements of Cash Flows</a></p> </td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#cash_flows">69</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 86%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%;">&#160;</td>
     <td style="vertical-align: top; width: 2%;">&#9679;</td>
     <td style="vertical-align: top; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes&#160;to the Consolidated Financial Statements</a></p> </td>
     <td style="vertical-align: bottom; width: 8%; text-align: center;"><a class="tocPGNUM" href="#notes">70</a></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>(b)&#160;Exhibits</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit&#160;</b><b>No.</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s</b><br/> <b>Form</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date Filed</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b><br/> <b>Number</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filed</b><br/> <b>Herewith</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419010889/aytu_ex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement and Plan of Merger, dated as of September 12, 2019, by and among Aytu BioScience, Inc., Aytu Acquisition Sub, Inc. and Innovus Pharmaceuticals, Inc.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">09/18/19</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.2</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419011717/aytu_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Asset Purchase Agreement, dated October 10, 2019, by and between Aytu Bioscience, Inc. and Cerecor Inc.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/15/19</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.3</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020042028/ea131376ex2-1_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement and Plan of Merger, dated as of December 10, 2020, by and among Aytu BioScience, Inc., Neutron Acquisition Sub, Inc. and Neos Therapeutics, Inc.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/10/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.4</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249110.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Asset Purchase Agreement, dated April 12, 2021, by and among Aytu BioPharma, Inc., Rumpus VEDS LLC, Rumpus Therapeutics LLC, Rumpus Vascular LLC, Christopher Brooke and Nathaniel Massari.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">05/17/21</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.4</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Incorporation effective, June 3, 2015.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/09/15</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000114420416106487/v441568_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Certificate of Incorporation, effective June 1, 2016.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/02/16</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       121
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000114420416111027/v443180_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Certificate of Incorporation, effective June 30, 2016.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">07/01/16</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000114420417045636/v474281_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Certificate of Incorporation, effective August 25, 2017.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">08/29/17</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.5</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390018010718/f8k081018ex3-1_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Restated of Certificate of Incorporation, effective August 10, 2018.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">08/10/18</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">3.6</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%;"><a href="ex_726135.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Restated Certificate of Incorporation, effective May 20, 2020.</a></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.7</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495420013283/aytu_ex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Restated Certificate of Incorporation, effective December 8, 2020.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/08/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.8</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390021016775/ea138107ex3-1_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Certificate of Incorporation, effective March 22, 2021.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/22/21</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.9</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465923001400/tm231530d1_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Certificate of Incorporation, effective January 6, 2023.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">01/25/23</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.10</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022007674/aytu-20220504xex3d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Bylaws.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">05/09/22</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020006311/ea119575ex4-2_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Placement Agent Common Stock Purchase Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/13/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020006311/ea119575ex4-1_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/13/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020007021/ea119842ex4-1_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Common Stock Purchase Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/20/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020007021/ea119842ex4-2_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Placement Agent Common Stock Purchase Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/20/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/ea123752aex4-1_aytubio.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Wainwright Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">07/02/20</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022002837/aytu-20220302xex4d1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Prefunded Common Stock Purchase Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/04/22</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.7</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022002837/aytu-20220302xex4d2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">03/04/22</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.8</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465922088699/tm2222304d3_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">08/10/22</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.9</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465922088699/tm2222304d3_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">08/10/22</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.10</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex4-10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">S-1/A</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/05/23</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.10</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.11</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex4-11.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Tranche A Warrant.</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">S-1/A</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/05/23</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.11</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.12</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022014652/aytu-20220630xex4d9.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Securities</span></a>.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">09/27/22</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.9</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       122
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1467652/000110465919052850/a19-19348_1ex10d1.htm" style="-sec-extract:exhibit;">Loan and Security Agreement, by and between Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, and Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, and Encina Business Credit, LLC, dated October 2, 2019.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10/3/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020042028/ea131376ex10-3_aytubio.htm" style="-sec-extract:exhibit;">Commitment Letter, dated as of December 10, 2020, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc. and Encina Business Credit, LLC.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">12/10/20</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390020042028/ea131376ex10-3_aytubio.htm" style="-sec-extract:exhibit;">Consent, Waiver and Amendment No. 1 to Loan and Security Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, and Encina Business Credit, LLC, dated March 19, 2021.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3/22/21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.4&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d3.htm" style="-sec-extract:exhibit;">Consent, Joinder and Second Amendment to Loan and Security Agreement dated January 26, 2022 between the registrant and Eclipse Business Capital LLC.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2/14/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.5</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023009367/aytu-20230331xex10d1.htm" style="-sec-extract:exhibit;">Amendment No. 4 to Loan and Security Agreement by and among Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Delta Prime Savings Club, Inc. and Eclipse Business Capital LLC, dated March 24, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5/11/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.6#</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/ex_688588.htm" style="-sec-extract:exhibit;">Consent, Joinder and Amendment No. 5 to Loan and Security Agreement dated June 12, 2024, between Aytu BioPharma, Inc., the Obligors and lenders party thereto and Eclipse Business Capital LLC as agent.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6/18/24</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.7</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/ex_688889.htm" style="-sec-extract:exhibit;">Term Loan Note dated June 12, 2024.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6/18/24</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.8</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/ex_688888.htm" style="-sec-extract:exhibit;">Second Amended and Restated Revolving Note dated June 12, 2024.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6/18/24</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.9&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d3.htm" style="-sec-extract:exhibit;">Loan and Security Agreement dated January 26, 2022 between the registrant and the Avenue Capital Lenders and Avenue Capital Agent.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/14/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.3</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.10</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023009367/aytu-20230331xex10d2.htm" style="-sec-extract:exhibit;">Second Amendment to Loan Documents by and among Avenue Capital Management II L.P., certain lenders and Aytu BioPharma, Inc., dated March 24, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">05/11/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.11</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419001148/aytu_ex105.htm" style="-sec-extract:exhibit;">Common Stock Purchase Warrant.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/07/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.5</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.12</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d5.htm" style="-sec-extract:exhibit;">Registration Rights Agreement dated January 26, 2022 between Aytu and each of the warrant holders.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/14/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.5</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.13&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d6.htm" style="-sec-extract:exhibit;">Form of Warrant.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/14/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.6</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.14</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex10-42.htm" style="-sec-extract:exhibit;">Form of Placement Agency Agreement.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">S-1/A</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">06/05/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.42</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.15</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex10-43.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">S-1/A</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">06/05/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.43</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       123
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.16</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-31_aytubio.htm" style="-sec-extract:exhibit;">Amended and Restated Exclusive License Agreement, dated June 11, 2018, between Aytu BioScience, Inc. and Magna Pharmaceuticals, Inc.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">09/06/18</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.31</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.17&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419001148/aytu_ex102.htm" style="-sec-extract:exhibit;">License, Development, Manufacturing and Supply Agreement, dated November 2, 2018.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/07/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.18#</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419008769/aytu_ex101.htm" style="-sec-extract:exhibit;">Amended and restated License and Supply Agreement with Acerus Pharmaceuticals, dated July 29, 2019.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">08/02/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419010889/aytu_ex101.htm" style="-sec-extract:exhibit;">Form of Contingent Value Rights Agreement.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">09/18/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.20</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419012301/aytu_ex101.htm" style="-sec-extract:exhibit;">First Amendment to Asset Purchase Agreement with Cerecor, Inc., dated November 1, 2019.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11/04/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000165495419013481/aytu_ex101.htm" style="-sec-extract:exhibit;">Waiver and Amendment to the July 29, 2019 Amended and Restated License and Supply Agreement, dated November 29, 2019.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">12/02/19</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249111.htm" style="-sec-extract:exhibit;">Termination and Transition Agreement between Aytu BioPharma, Inc. and Acerus Pharmaceuticals Corporation, dated March 31, 2021.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">05/17/21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.9</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249686.htm" style="-sec-extract:exhibit;">Option Agreement between Rumpus VEDS, LLC and Denovo Biopharma LLC, dated December 21, 2019.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">05/17/21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.14</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.24</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_250530.htm" style="-sec-extract:exhibit;">Exclusive License Agreement between Rumpus VEDS, LLC and Johns Hopkins University, dated December 20, 2019.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">05/17/21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.15</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.25&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837021012825/aytu-20210630xex10d79.htm" style="-sec-extract:exhibit;">Asset Purchase Agreement, dated July 1, 2020,&#160;by and between Aytu BioPharma, Inc. and UAB &#8220;Caerus Biotechnologies.&#8221;</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">09/28/21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.79</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.26&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837021012825/aytu-20210630xex10d80.htm" style="-sec-extract:exhibit;">Termination Agreement, dated June 29, 2021 by and between Aytu BioPharma, Inc. and Avrio Genetics, LLC.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">09/28/21</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.80</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.27#&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022008952/aytu-20220331xex10d1.htm" style="-sec-extract:exhibit;">Settlement and Termination of License Agreement between the Registrant and TRIS Pharma, Inc., dated May 12, 2022.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">05/16/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       124
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.28&amp;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000143774924004149/ex_626088.htm" style="-sec-extract:exhibit;">Commercial Manufacturing Services Agreement by and between the Company and Halo Pharmaceutical, Inc., dated November 13, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/14/24</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.29</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d48.htm" style="-sec-extract:exhibit;">Commercial Lease Agreement dated June 10, 1999, between Walstib, L.P. and Pharmafab, Inc.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.48</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.30</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d49.htm" style="-sec-extract:exhibit;">First Amendment to Lease dated September 1, 2002, between Walstib, L.P. and PFAB, LP.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.49</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: center;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.31</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d50.htm" style="-sec-extract:exhibit;">Second Amendment to Lease dated September 4, 2003, between Teachers Insurance and Annuity Association of America and PFAB, LP.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.50</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.32</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d51.htm" style="-sec-extract:exhibit;">Third Amendment to Lease dated October 1, 2003, Between TIAA and PFAB, LP.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.51</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.33</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d52.htm" style="-sec-extract:exhibit;">Fourth Amendment to Lease dated May 1, 2009, between TIAA and Neos Therapeutics, LP (formerly PFAB, LP).</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.52</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.34</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d53.htm" style="-sec-extract:exhibit;">Fifth Amendment to Lease dated April 5, 2010, between TIAA and Neos Therapeutics, LP.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.53</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.35</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d54.htm" style="-sec-extract:exhibit;">Sixth Amendment to Lease dated August 14, 2013, between Riverside Business Green, LP and Neos Therapeutics, LP.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.54</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.36&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000114420417038709/v471569_ex10-1.htm" style="-sec-extract:exhibit;">2015 Stock Option and Incentive Plan, as amended on July 26, 2017.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">07/27/17</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.37&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000110465923074325/tm2319424d1_ex10-1.htm" style="-sec-extract:exhibit;">Aytu BioPharma, Inc. 2023 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">S-8</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">06/23/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.38</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022010509/aytu-20220629xex10d1.htm" style="-sec-extract:exhibit;">Form of Indemnification Agreement.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">07/01/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.1</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.39&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d2.htm" style="-sec-extract:exhibit;">Restricted Stock Award Agreement between Aytu BioPharma, Inc. and Mark Oki, effective January 17, 2022.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">02/14/22</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10.2</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.40&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d45.htm" style="-sec-extract:exhibit;">Amended and Restated Employment Agreement by and between Aytu BioPharma, Inc.&#160;and Joshua R. Disbrow dated February 13, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.45</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.41&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d46.htm" style="-sec-extract:exhibit;">Amended and Restated Employment Agreement by and between Aytu BioPharma, Inc.&#160;and Mark Oki dated February 13, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.46</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.42&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_721289.htm" style="-sec-extract:exhibit;">Amended and Restated Employment Agreement by and between Aytu BioPharma, Inc.&#160;and Jarrett T. Disbrow dated March 20, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.43&#8224;</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1385818/000155837023016393/aytu-20230630xex10d55.htm" style="-sec-extract:exhibit;">Amended and Restated Employment Agreement by and between Aytu BioPharma, Inc.&#160;and Greg Pyszczymuka dated March 21, 2023.</a></p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;&#8203;10-K</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10/12/23</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8203;10.55</p> </td>
     <td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       125
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 10%;">19.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%; text-align: justify;"><a href="ex_721858.htm" style="-sec-extract:exhibit;">Statement of Insider Trading Policy.</a></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_622500.htm" style="-sec-extract:exhibit;">List of Subsidiaries.</a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_622502.htm" style="-sec-extract:exhibit;">Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm.</a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">24.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (contained on signature page hereto).</a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_622504.htm" style="-sec-extract:exhibit;">Certificate of the Chief Executive Officer of Aytu BioPharma,&#160;Inc. pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_622505.htm" style="-sec-extract:exhibit;">Certificate of the Chief Financial Officer of Aytu BioPharma,&#160;Inc. pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_622506.htm" style="-sec-extract:exhibit;">Certificate of the Chief Executive Officer and the Chief Financial Officer of Aytu BioPharma,&#160;Inc. pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.*</a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 45%; text-align: justify;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">97.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 45%; text-align: justify;"><a href="ex_707455.htm" style="-sec-extract:exhibit;">Executive Compensation Clawback Policy.</a></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101 INS</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101 SCH</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Schema Linkbase Document.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101 CAL</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Calculation Linkbase Document.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101 DEF</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Definition Linkbase Document.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101 LAB</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Labels Linkbase Document.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101 PRE</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Presentation Linkbase Document.</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 11%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 11%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td rowspan="1" style="vertical-align: top; width: 45%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p> </td>
     <td rowspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
     <td rowspan="1" style="vertical-align: top; width: 11%;">&#160;</td>
     <td rowspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
     <td rowspan="1" style="vertical-align: top; width: 10%;">&#160;</td>
     <td rowspan="1" style="vertical-align: top; width: 1%;">&#160;</td>
     <td rowspan="1" style="vertical-align: top; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

   </tbody>
  </table>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8224;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicates&#160;a management contract or compensatory plan or arrangement.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">#</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company has received confidential treatment of certain portions of this agreement. These portions have been omitted and filed separately with the SEC pursuant to a confidential treatment request.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="font-size: 10pt;">
     <td style="width: 18pt; padding: 0pt; vertical-align: top; font-size: 10pt;">&amp;</td>
     <td style="width: auto; font-size: 10pt; text-align: justify;">Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit&#160;have been omitted as the registrant has determined that (1) the omitted information is not material and (2) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.</td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">*</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Furnished&#160;herewith.</p> </td>
    </tr>

   </tbody>
  </table>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item16" title="item16" href="#"></a>ITEM</b>&#160;<b>16.</b>&#160;<b>FORM 10-K SUMMARY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       126
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="sigs" title="sigs" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 50%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 47%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 50%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>AYTU BIOPHARMA,</b>&#160;<b>INC.</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 50%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: middle; width: 47%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: September 26, 2024</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Joshua R. Disbrow</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 50%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joshua R. Disbrow</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 50%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman and Chief Executive Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 50%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align: bottom; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer)</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" title="poa" href="#"></a>POWER OF ATTORNEY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We the undersigned directors and officers of Aytu BioPharma, Inc., hereby severally constitute and appoint Joshua R. Disbrow and Mark Oki, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, to file any and all amendments to this Annual Report on Form 10&#8209;K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys&#8209;in&#8209;fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys&#8209;in&#8209;fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities indicated, on September 26, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Signature</b></p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:26.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Joshua R. Disbrow</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman and Chief Executive Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joshua R. Disbrow</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer)</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:26.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Mark K. Oki</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark K. Oki</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Financial Officer)</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;<i>(Principal Accounting Officer)</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:26.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ John A. Donofrio, Jr.</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lead Independent Director</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John A. Donofrio, Jr.</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:26.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Carl C. Dockery</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:bottom;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Carl C. Dockery</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:26.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Abhinav Jain</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Abhinav Jain</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:26.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Vivian H. Liu</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:26.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vivian H. Liu</p> </td>
     <td style="vertical-align:top;width:1.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
     <td style="vertical-align:middle;width:26.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       127
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>ex_726135.htm
<DESCRIPTION>EXHIBIT 3.6
<TEXT>
<html><head>
	<title>ex_726135.htm</title>

	<!-- Generated by ThunderDome Portal - 9/25/2024 11:48:13 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 3.6</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%; text-align: center; font-size: 48pt;"><u>Delaware</u></td>
			<td style="width: 33%; text-align: right; vertical-align: bottom;">Page 1</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;">The First State</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><b><i>I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF </i>&#8220;<i>AYTU BIOSCIENCE, INC.</i>&#8221;<i>, FILED IN THIS OFFICE ON THE TWENTIETH DAY OF MAY, A.D. 2020, AT 7:11 O`CLOCK P.M.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%; vertical-align: bottom;">
			<div style="text-align: right;"><img alt="jwb01.jpg" src="jwb01.jpg"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 33%; vertical-align: bottom;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5759344 8100</p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">SR# 20204290183&nbsp;</p>
			</td>
			<td style="width: 33%; text-align: center;">
			<div><img alt="seal01.jpg" src="seal01.jpg"></div>
			</td>
			<td style="width: 33%; vertical-align: bottom;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Authentication: 202974745</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Date: 05-21-20</p>
			</td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 33%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">You may verify this certificate online at corp.delaware.gov/authver.shtml</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATE OF AMENDMENT </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>OF</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATE OF INCORPORATION </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>OF</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>AYTUBIOSCIENCE, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Aytu BioScience, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;General Corporation Law&#8221;),</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">DOES HEREBY CERTIFY:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FIRST: The name of the corporation is Aytu Bioscience, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on June 3, 2015 under the name Aytu BioScience, Inc. This Certificate of Amendment as duly adopted in accordance with the provisions of Section242 of the General Corporation Law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">SECOND: That the first section of Article IV entitled &#8220;Capital Stock&#8221;&nbsp;of the Certificate of Incorporation of this corporation shall be deleted in its entirety and replaced with the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#8220;CAPITAL STOCK&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The total number of shares of capital stock which the Corporation shall have authority to issue is Two Hundred Fifty Million (250,000,000), of which (i) Two Hundred Million (200,000,000) shares shall be a class designated as common stock, par value$0.0001 per share (the &#8220;Common Stock&#8221;), and (ii) Fifty Million (50,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;Undesignated Preferred Stock&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Except as otherwise provided in any certificate of designations of any series of Undesignated Preferred Stock, the number of authorized shares of the class of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section 242(b)(2) of the DGCL.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance with, or as set forth below in, this Article IV.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">THIRD: That said Certificate of Amendment, which amends the provisions of this corporation's Certificate of Incorporation, has been duly adopted by the board of directors and stockholders of the Corporation in accordance with Section 242 of the General Corporation Law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">IN WITNESS WHEREOF, this Certificate of Amendment of Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 19<sup style="vertical-align:top;line-height:120%;">th </sup>day of May 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 65%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 35%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>/s/&nbsp;</i>Joshua R. Disbrow</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">Joshua R. Disbrow, Chief Executive Officer</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 25%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">State of Delaware</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Secretary of State</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Division of Corporations</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Delivered 07:11 PM 05/20/2020</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">FILED 07:11 PM osn, o 2020</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">SR 20204290183 - File Number 5759344</p>
			</td>
			<td style="width: 25%;">&nbsp;</td>
			<td style="width: 25%;">&nbsp;</td>
			<td style="width: 25%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>3
<FILENAME>ex_721289.htm
<DESCRIPTION>EXHIBIT 10.42
<TEXT>
<html><head>
	<title>ex_721289.htm</title>
	<!-- Generated by ThunderDome Portal - 9/24/2024 3:16:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.42</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED AND RE-STATED </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EMPLOYMENT AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Amended and Re-Stated Employment Agreement (the &#8220;Agreement&#8221;), is effective as of March 20, 2023 (the &#8220;Effective Date&#8221;), between Aytu BioScience, Inc. (the &#8220;Company&#8221;), a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, Colorado, 80112, and Jarrett T. Disbrow (the &#8220;Employee&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>RECITALS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>WHEREAS</b>, the Company is a duly organized Delaware corporation, with its principal place of business within the State of Colorado, and is in the business of developing and marketing pharmaceutical products; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>WHEREAS</b>, the Company desires assurance of the continued association and services of the Employee in order to continue to retain the Employee&#8217;s experience, skills, abilities, background and knowledge, and is willing to continue to engage the Employee&#8217;s services on the terms and conditions set forth in this Agreement; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>WHEREAS</b>, Employee desires to be in the continued employ of the Company, and is willing to accept such continued employment on the terms and conditions set forth in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOW, THEREFORE</b>, the parties hereto agree to the terms and conditions of this Agreement as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Employment for Term</u>. The Company hereby agrees to employ Employee and Employee hereby accepts such employment with the Company for the period of 12 months beginning on the Effective Date, with automatic renewal of the employment period every 12 months. The term of this Agreement (the &#8220;Term&#8221;) shall continue until the termination of Employee&#8217;s employment in accordance with the provisions of this Agreement. The termination of Employee&#8217;s employment under this Agreement shall end the Term but shall not terminate Employee&#8217;s or the Company&#8217;s other obligations that are intended to survive the termination of this Agreement (including without limitation, the payments under Section 7 and 8 and Employee&#8217;s obligations under Section 9).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Position and Duties</u>. During the Term, Employee shall serve as Chief Business Officer (CBO) of the Company, and perform such duties as are consistent with this position. The Employee shall report to the Board of Directors of the Company. During the Term, Employee shall also hold such additional positions and titles as the Board of Directors of the Company (the &#8220;Board&#8221;) may determine from time to time. During the Term, Employee shall devote as much time as is necessary to satisfactorily perform his duties as CBO of the Company. Employee may engage in any civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company during the Term of this Agreement, Employee agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Employee to be adverse or antagonistic to the company, its business or prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of which Employee is or becomes a member of during the term hereof. Employee shall provide written disclosure to the Compensation Committee of the Company&#8217;s Board of Directors as to all advisory boards on which Employee sits, and will provide the Company with written notice within 10 business days of Employee agreeing to sit on any additional advisory boards. On termination of Employee&#8217;s employment, regardless of the reason for such termination, Employee shall immediately (and with contemporaneous effect) resign any dictatorships, offices, or other positions that Employee may hold in the Company or any affiliate, unless otherwise agreed to in writing by the parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">a.&nbsp;&nbsp;&nbsp;&nbsp;<u>Base Salary</u>. The Company shall pay Employee a base salary of $375,000 per annum, payable at least monthly on the Company&#8217;s regular pay cycle for professional employees (the &#8220;Base Salary&#8221;). Except as specifically otherwise provided herein, the Base Salary may be increased only by recommendation of the Compensation Committee of the Board and ratified by the Compensation Committee or a majority of the independent members of the Board.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -18pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">b.&nbsp;&nbsp;&nbsp;&nbsp;<u>Annual Review</u>. The Base Salary shall be reviewed at the end of each fiscal year (the first such review to occur at the end of fiscal year 2020).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -18pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">c.&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity Compensation</u>. Executive acknowledges previous receipt of equity compensation to Employee in the form of restricted stock or options to purchase shares of Company Common Stock, at the discretion of the Compensation Committee. In the event of issuance of options, these options shall vest in accordance with the terms and schedule set forth in Exhibit A hereto. Such vesting schedule will be accelerated, to the extent provided in Section 8 of this Agreement. Equity grants will be made annually during the Term of this Agreement in the amount approved by the Compensation Committee and commensurate with the performance level of the Employee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -18pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">d.&nbsp;&nbsp;&nbsp;&nbsp;<u>Other and Additional Compensation</u>. Subsections (a) and (c) above establish Employee&#8217;s compensation during the Term which shall not preclude the Board from awarding Employee a higher salary or any bonuses or stock options, restricted stock or other forms of additional equity awards in the discretion of the Board during the Term at any time. The Employee shall be eligible for an annual discretionary bonus (hereinafter referred to as the &#8220;Bonus&#8221;) with a target amount of one hundred and twenty-five percent (125%) of the Base Salary, subject to standard deductions and withholdings, based on the Compensation Committee&#8217;s determination, in good faith, and based upon the Employee&#8217;s Individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Employee has met such performance milestones as are established for the Employee by the Board or the Compensation Committee, in good faith, in consultation with the Employee (hereinafter referred to as the &#8220;Performance Milestones&#8221;). The Performance Milestones will be based on certain factors including, but not limited to, the Employee&#8217;s performance and the Company&#8217;s financial and operational performance. The Employee&#8217;s Bonus target will be reviewed annually and may be adjusted by the Board or the Compensation Committee in its discretion, provided however, that the Bonus target may only be reduced upon Employee&#8217;s written consent. The Employee must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Employee Benefits</u>. During the Term, Employee shall be entitled to participate at the same level as other senior executive officers of the Company in any group insurance, hospitalization, medical, health and accident, disability, fringe benefit and tax-qualified retirement plans or programs of the Company now existing or hereafter established to the extent that he is eligible under the general provisions thereof. For the term of this Agreement, Employee shall be entitled to paid time off at the rate of five (5) weeks per annum. In accordance with Company policy, unused paid time off may not be carried over from year to year.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses</u>. The Company shall reimburse Employee for actual, reasonable out-of-pocket expenses incurred by him in the performance of his services for the Company upon the receipt of appropriate documentation of such expenses, which shall be submitted in such form, and with such supporting documentation, as, called for or required by Company policy.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">a.&nbsp;&nbsp;&nbsp;&nbsp;<u>General</u>. The Term shall end immediately upon Employee&#8217;s death. Employee&#8217;s employment may also be terminated by the Company with or without Cause or as a result of Employee&#8217;s Disability, as defined in Section 7 or by Employee with or without Good Reason (as such terms are defined below).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">b.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Termination</u>. Either party shall give written notice of termination to the other party.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">c.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notification of New Employer</u>. In the event that Employee leaves the employ of the Company, Employee grants consent to notification by the Company to Employee&#8217;s new employer about his rights and obligations under this Agreement and the PIA (hereinafter defined).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severance Benefits</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">a.&nbsp;&nbsp;&nbsp;&nbsp;<u>Cause Defined</u>. &#8220;Cause&#8221; means (i) willful malfeasance or willful misconduct by Employee in connection with his employment; (ii) Employee&#8217;s conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iii) Employee&#8217;s unintended but material breach in the performance of duties under this Agreement, including insubordination or failure to implement or follow a lawful policy or directive of the Company, provided that if such failure is curable, it is not cured within 30&nbsp;days following written notice thereof from the Board, (iv) the Employee&#8217;s willful and deliberate breach of his obligations under this Agreement, including Employee&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the Employee owes an obligation of nondisclosure as a result of the Employee&#8217;s relationship with the Company or (v) Employee&#8217;s act of fraud or intentional misrepresentation in connection with the Executive&#8217;s duties or otherwise in connection with the business of the Company, that may result in material injury to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">b.&nbsp;&nbsp;&nbsp;&nbsp;<u>Disability Defined</u>. &#8220;Disability&#8221; shall mean (i) Employee&#8217;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation, that results in Employee being substantially unable to perform his duties hereunder for six consecutive months (or for six months out of any nine month period) or (ii) a qualified independent physician mutually acceptable to the Company and Employee determines that Employee s incapacitated due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation so as to be unable to regularly perform the duties of his position and such condition is expected to be of a permanent or near-permanent duration. Until such time as Employee is terminated for Disability under this paragraph (b), Employee shall continue to receive his Base Salary hereunder, provided that if the Company provides Employee with disability insurance coverage, payments of Employee&#8217;s Base Salary shall be reduced by the amount of any disability insurance payments received by Employee due to such coverage. The Company shall give Employee written notice of termination due to Disability which shall take effect sixty (60) days after the date it is sent to Employee unless Employee shall have returned to the performance of his duties hereunder during such sixty (60) day period (whereupon such notice shall become void). In the event that the Company terminates Employee&#8217;s employment as a result of his Disability, Employee shall be entitled to the same benefits as if his employment had been terminated by the Company without Cause.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">c.&nbsp;&nbsp;&nbsp;&nbsp;<u>Good Reason Defined</u>. For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean, without Employee&#8217;s consent: (i) the Company materially breaches any term of this Agreement, and such breach causes or is likely to cause material harm to the Employee; (ii) there is a material reduction of the level of Employee&#8217;s Base Salary (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may the Base Salary be reduced below the amount stated in Section 3(a)), (iii) there is a material reduction in Employee&#8217;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in Employee&#8217;s responsibilities or authority); or (iv) there is a material change in the principal geographic location at which Employee must perform his services (it being understood that the relocation of Employee to a facility or a location within forty (40) miles of the State Capitol Building in Denver, Colorado shall not be deemed material for purposes of this Agreement and it being further understood that the Employee may be required to travel in connection with Company business and none of such travel shall constitute or give rise to &#8220;Good Reason&#8221;). The Executive&#8217;s voluntary termination shall be deemed to have occurred for Good Reason for purposes of this Agreement only if (x)&nbsp;the Executive provides written notice to the Company within 30&nbsp;days after the Executive becomes aware of circumstances giving rise to Good Reason, (y)&nbsp;the Company fails to correct the circumstances giving rise to Good Reason within 30&nbsp;days following the receipt of such notice (the &#8220;Cure Period&#8221;) and (z)&nbsp;the Executive resigns within 30&nbsp;days following the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">d.&nbsp; &nbsp; &nbsp;<u>Accrued Compensation Defined</u>. Accrued Compensation shall mean an amount which shall include all amounts earned or accrued by Employee through the date of termination of this Agreement but not paid as of such date, including (i) Base Salary, (ii) reimbursement for business expenses incurred by the Employee on behalf of the Company, pursuant to the Company&#8217;s expense reimbursement policy in effect at such time, (iii) any expense allowance pursuant to Company policy, (iv) accrued but unused vacation pay per Company policy, and (v) bonuses and incentive compensation earned and awarded prior to the date of termination. Accrued Compensation shall be paid on the first regular pay date after the date of termination (or earlier, if required by applicable law).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">e.&nbsp; &nbsp; &nbsp;&nbsp;<u>Termination</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 41pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;Cause; Without Good Reason; Death; Disability. If the Company ends the Term for Cause, if Employee resigns as an employee of the Company for reasons other than an event of Good Reason, the Employee dies or Disability occurs, then the Company shall pay to Employee the Accrued Compensation but shall have no obligation to pay Employee any amount, whether for salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after the end of the Term, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be forfeited immediately upon the end of the Term. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date the Company ends the Term for Cause, or the date of Employee&#8217;s death, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the Employee or his personal representative or executor.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 41pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Without Cause; Good Reason. In the event that the Company terminates Employee&#8217;s employment hereunder without Cause, or the Employee terminates his employment with Good Reason, he shall be entitled to the Accrued Compensation and, subject to Section 21 and 22 below:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 68pt; text-indent: 36pt; text-align: justify;">(1)&nbsp;&nbsp;&nbsp;&nbsp;A lump sum payment equal to two times his Base Salary in effect at the date of termination, less applicable withholding;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -45pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 68pt; text-indent: 36pt; text-align: justify;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Continued participation (via state or federal insurance continuation laws such as COBRA, to the extent available) in the health and welfare plans (or comparable plans, if continued participation in the Company&#8217;s plans is not available) provided by the Company to Employee at the time of termination for a period of two years from the date of termination or, if earlier, until he is eligible for comparable coverage with a subsequent employer. The Company agrees to reimburse the payments Employee makes for such coverage, whether via continuation or separate comparable policy. Premium reimbursements shall be made by the Company to Employee consistent with the Company&#8217;s normal expense reimbursement policy, provided that Employee submits documentation to the Company substantiating his payments for insurance coverage. Employee shall give the Company prompt notice of his eligibility for comparable coverage.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 68pt; text-indent: 36pt; text-align: justify;">(3)&nbsp;&nbsp;&nbsp;&nbsp;All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long as the Section 8 below does not apply, then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to 1/24<sup style="vertical-align:top;line-height:120%;">th</sup> the number of option shares multiplied by the number of full months of Employee&#8217;s employment hereunder shall be deemed vested and immediately exercisable by the Employee. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be exercisable by the Employee. Any issued restricted stock will vest 90 days following the termination date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -45pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 68pt; text-indent: 36pt; text-align: justify;">(4)&nbsp;&nbsp;&nbsp;&nbsp;Any severance payments and/or other separation benefits contemplated by this Agreement are conditional on Employee: (i) continuing to comply with the terms of this Agreement and the PIA (as defined herein); (ii) delivering prior to or contemporaneously with any such severance payments, and not revoking, (iii) a customary general release of claims relating to Employee&#8217;s employment and/or this Agreement against the Company or its successor, its subsidiaries and their respective directors, officers, and stockholders and (iv) a customary affirmation of Employee&#8217;s continuing obligations hereunder and under the PIA.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unless otherwise required by law, no severance payments and/or benefits under this Agreement will be paid and/or provided until after the expiration of any relevant revocation period. Subject to the effectiveness of the release, the severance payments shall be paid on the first payroll date that begins 30 days after Employee&#8217;s termination of employment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Change in Control Payments</u>. The provisions of this paragraph 8 set forth the terms of an agreement reached between Employee and the Company regarding Employee&#8217;s rights and obligations upon the occurrence of a &#8220;Change in Control&#8221; (as hereinafter defined) of the Company during the Term. These provisions are intended to assure and encourage in advance Employee&#8217;s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such Change in Control. The following provisions shall apply in the event of a Change in Control, in addition to any payment or benefit that may be required pursuant to Section 7.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">a.&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity</u>. During the Term, if within 12 months after a Change in Control, the Employee&#8217;s employment is terminated by the Company without Cause as provided in Section 7(a) or Employee terminates his employment with Good Reason as provided in Section 7(c), then, subject to signing and not revoking a customary general release of claims relating to Employee&#8217;s employment and/or this Agreement against the Company or its successor, its subsidiaries and their respective directors, officers, and stockholders, all stock options, restricted stock and other stock-based grants to Employee by the Company or that may be granted in the future shall, irrespective of any provisions of his award agreements, immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse. All stock options shall remain exercisable from the date of the Change in Control until the expiration of the term of such stock options.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">b.&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. For purposes of this paragraph 8, the following terms shall have the following meanings:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;Change in Control&#8221; shall mean any of the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 41pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;The acquisition by any individual, entity, or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (the &#8220;Acquiring Person&#8221;), other than the Company, or any of its Subsidiaries, of beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona fide equity financing purposes; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 41pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona fide equity financing purposes) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of shares in the Company held by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 41pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The sale or other disposition of all or substantially all of the assets of the Company in one transaction or series of related transactions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Property Information and Inventions Agreement</u>. As a condition of Employee&#8217;s employment with the Company, Employee agrees to sign the Company&#8217;s standard form of Proprietary Information and Inventions Agreement (&#8220;PIA&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">10.&nbsp;&nbsp;<u>Successors and Assigns</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">a.&nbsp;&nbsp;&nbsp;&nbsp;<u>Employee</u>. This Agreement is a personal contract, and the rights and interests that the Agreement accords to Employee may not be sold, transferred, assigned, pledged, encumbered, or hypothecated by him. All rights and benefits of Employee shall be for the sole personal benefit of Employee, and no other person shall acquire any right, title, or interest under this Agreement by reason of any sale, assignment, transfer, claim, or judgment or bankruptcy proceedings against Employee. Except as so provided, this Agreement shall inure to the benefit of and be binding upon Employee and his personal representatives, distributes and legatees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt; text-align: justify;">b.&nbsp;&nbsp;&nbsp;&nbsp;<u>The Company</u>. This Agreement shall be binding upon the Company and insure to the benefit of the Company and of its successors and assigns, including (but not limited to) any Company that may acquire all or substantially all of the Company&#8217;s assets or business or into or with which the Company may be consolidated or merged. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement (together with the equity award agreements referred to herein) represents the entire agreement between the parties concerning Employee&#8217;s employment with the Company and supersedes all prior negotiations, discussions, understandings, and agreements, whether written or oral, between Employee and the Company relating to the subject matter of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment or Modification, Waiver</u>. No provision of this Agreement may be amended or waived unless such amendment or waiver is agreed to in writing signed by Employee and by a duly authorized officer of the Company. No waiver by any party to this Agreement or any breach by another party of any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If to Employee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3516 Rock Creek Drive</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-indent: 27pt; text-align: justify;">&nbsp; Raleigh, NC 27609</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To the address specified in the payroll records of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If to the Company:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Aytu BioScience, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 59pt; text-indent: 36pt; text-align: justify;">&nbsp; 373 Inverness Parkway, Suite 206</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Englewood, CO 80112</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any provision of this Agreement or the application of any such provision to any party or circumstances shall be determined by any court of competent jurisdiction or arbitrator acting pursuant to Section 19 below to be invalid and unenforceable to any extent, the remainder of this Agreement or the application of such provision to such person or circumstances other than those to which it is so determined to be invalid and unenforceable shall not be affected, and each provision of this Agreement shall be validated and shall be enforceable shall not be affected, and each provision of this Agreement shall be validated and shall be enforced to the fullest extent permitted by law. If for any reason any provision of this Agreement containing restrictions is held to cover an area or to be for a length of time that is unreasonable or in any other way is construed to be too broad or to any extent invalid, such provision shall not be determined to be entirely null, void and of no effect; instead, it is the intention and desire of both the Company and Employee that, to the extent that the provision is or would be valid or enforceable under the applicable law, any court of competent jurisdiction or arbitrator acting pursuant to Section 19 below shall construe and interpret or reform this Agreement to provide for a restriction having the maximum enforceable area, time period and such other constraints or conditions (although not greater than those currently contained in this Agreement) as shall be valid and enforceable under the applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Survivorship</u>. The respective rights and obligations of the parties hereunder shall survive any termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. All descriptive headings of sections and paragraphs in this Agreement are intended solely for convenience of reference, and no provision of this Agreement is to be construed by reference to the heading of any section or paragraph.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding Taxes</u>. All salary, benefits, reimbursements, and any other payments to Employee under this Agreement shall be subject to all applicable payroll and withholding taxes and deductions required by any law, rule, or regulation of and federal, state, or local authority.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together constitute one and the same instrument. The parties agree that facsimile signatures shall have the same force and effect as original signatures.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">19.&nbsp;&nbsp;&nbsp;&nbsp;<u>Applicable Law; Arbitration</u>. The validity, interpretation, and enforcement of this Agreement and any amendments or modifications hereto shall be governed by the laws of the State of Colorado, as applied to a contract executed within and to be performed in such State. The parties agree that any disputes shall be definitively resolved by binding arbitration before the American Arbitration Association in Denver, Colorado in accordance with its rules of arbitration procedure then in effect. The parties consent to the jurisdiction to the federal courts located in Arapahoe County, Colorado, to enforce any arbitration award rendered with respect thereto. Each party shall choose one arbitrator and the two arbitrators shall choose a third arbitrator. All costs and fees related to such arbitration (and judicial enforcement proceedings, if any) shall be borne by the Company unless Employee&#8217;s claim is deemed to be frivolous by the arbitrator(s) or judge.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">20.&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Fees</u>. The Company shall pay the reasonable expenses of Employee&#8217;s counsel in negotiating this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">21.&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 63pt; text-align: justify;">a.&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of Employee&#8217;s separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the Company determines that Employee is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after Employee&#8217;s separation from service, or (B) Employee&#8217;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 63pt; text-align: justify;">b.&nbsp;&nbsp;&nbsp;&nbsp;All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 63pt; text-align: justify;">c.&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#8217;s termination of employment, then such payments or benefits shall be payable only upon Employee&#8217;s &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A 1(h).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 63pt; text-align: justify;">d.&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A 2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">22.&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Internal Revenue Code Section 280G</u>. If any payment or benefit Employee would receive pursuant to a Change in Control from the Company or otherwise (&#8220;Payment&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section of 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;Excise Tax&#8221;), then such Payment shall be equal to the Reduced Amount. The &#8220;Reduced Amount&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, Employee agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determine pursuant to clause (y) in the preceding paragraph, Employee will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Unless Employee and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity, or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Employee and the Company within fifteen (15) calendar days after the date on which Employee&#8217;s right to a Payment is triggered (if requested at that time by the Employee or the Company) or such other time as requested by Employee or the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">23.&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification</u>. As a condition to the effectiveness of this Agreement, the Company and Employee shall enter into a mutually acceptable indemnification agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>AYTU BIOSCIENCE, INC.</b></p>
			</td>
			<td colspan="1" valign="top" width="38%">
			<p style="margin: 0px 0pt 0px 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>EMPLOYEE</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">By: ________________________</p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt 0px 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">_____________________________</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name: Vivian Liu</p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name: Jarrett T. Disbrow</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">Chairwoman of the Compensation Committee&nbsp;</td>
			<td valign="top" width="35%">Chief Business Officer</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">Board of Directors</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Terms of Compensation</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Management equity grant</u>:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A quantity of restricted stock or options to purchase shares of Company Common Stock as agreed upon by Employee and the Company and at the discretion of the Compensation Committee. In the event of issuance of stock options, the strike price for all options will be the last sale price of Company Common Stock as reported during the period immediately preceding the date of grant and in accordance with the terms of the Company&#8217;s Stock and Incentive Plan.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All options fully vest upon Change in Control, Disability, Termination With or Without Cause, Termination for Good Reason, and Death.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">50% of the options are fully vested on the Effective Date of this Agreement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">25% of the options vest 365 days thereafter</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">25% of the options vest 730 days thereafter</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>ex_721858.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html><head>
	<title>Image Exhibit</title>

	<!-- Created by RDG Filings Portal --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; ">
<p style="text-align: right; margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibit 19.1</b></font></p>

<div style="width:100%; text-align:center"><img src="image01.jpg" alt="image01.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image02.jpg" alt="image02.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image03.jpg" alt="image03.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image04.jpg" alt="image04.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image05.jpg" alt="image05.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image06.jpg" alt="image06.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image07.jpg" alt="image07.jpg"></div>

<div class="PGBK" style="width: 100 %; margin-right: 0pt; margin-left: 0pt; ">
<div class="PGNUM" style="width: 100 %; text-align: center; ">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100 %; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0); ">
<div class="PGHDR" style="width: 100 %; text-align: left; ">&nbsp;</div>
</div>

<div style="width:100%; text-align:center"><img src="image08.jpg" alt="image08.jpg"></div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ex_622500.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>ex_622500.htm</title>

	<!-- Generated by ThunderDome Portal - 9/25/2024 1:55:53 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 21.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SUBSIDIARIES OF AYTU BIOPHARMA, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><u><b>Name of Subsidiary</b></u></p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><u><b>State Jurisdiction</b></u></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Aytu Therapeutics&nbsp;LLC</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Delaware</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cherry Creek Therapeutics, Inc.</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Delaware</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Neos Therapeutics, Inc.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Delaware</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Neos Therapeutics Brands, LLC</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Delaware</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Neos Therapeutics, LP</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Texas</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">6.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PharmaFab Texas, LLC</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Texas</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">7.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Innovus Pharmaceuticals, Inc. <sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nevada</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">8.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Delta Prime Savings Club, Inc. <sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nevada</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">9.</p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Semprae Laboratories, Inc. <sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Delaware</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&nbsp;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On July 31, 2024, Aytu BioPharma, Inc. entered into a definitive agreement to divest of these subsidiaries as part of the wind down of its consumer health business.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex_622502.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_622502.htm</title>
	<!-- Generated by ThunderDome Portal - 9/19/2024 10:21:42 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have issued our report dated September 26, 2024, with respect to the consolidated financial statements included in the Annual Report of Aytu BioPharma, Inc. on Form 10-K for the year ended June 30, 2024. We consent to the incorporation by reference of said report into the Registration Statements of Aytu BioPharma, Inc. on Forms S-1 (File Nos. 333-212100, 333-213489, 333-222994, 333-223385, 333-227243, 333-227706 and 333-271556), on Forms S-3 (File Nos. 333-259862, 333-235548, 333-236599, 333-239010 and 333-265479) and on Forms S-8 (File Nos. 333-255325, 333-205462, 333-236598 and 333-272897).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ GRANT THORNTON LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Denver, Colorado</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">September 26, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex_622504.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_622504.htm</title>
	<!-- Generated by ThunderDome Portal - 9/18/2024 11:49:44 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AYTU BIOPHARMA, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Certification by Chief Executive Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section</b>&nbsp;<b>302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Joshua R. Disbrow, certify that:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I have reviewed this report on Form 10-K for the year ended&nbsp;<a data-tblloc="5x1" data-tblname="530716" data-tblv="66" id="led530716F20241231708725028548">June 30, 2024</a>, of Aytu BioPharma, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8212;15(e) and 15d&#8212;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8212;15(f) and 15d&#8212;15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Date: September 26, 2024</b></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Joshua R. Disbrow</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Joshua R. Disbrow</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Chairman and Chief Executive Officer</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;"><i>(Principal Executive Officer)</i></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex_622505.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_622505.htm</title>
	<!-- Generated by ThunderDome Portal - 9/18/2024 11:50:08 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AYTU BIOPHARMA, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Certification by Chief Financial Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section</b>&nbsp;<b>302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Mark K. Oki, certify that:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I have reviewed this report on Form 10-K for the year ended&nbsp;<a data-tblloc="5x1" data-tblname="530716" data-tblv="66" id="led530716F20241231708725069124">June 30, 2024</a>, of Aytu BioPharma, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8212;15(e) and 15d&#8212;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8212;15(f) and 15d&#8212;15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Date: September 26, 2024</b></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Mark K. Oki</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Mark K. Oki</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Chief Financial Officer </b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;"><i>(Principal Financial Officer)</i></td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;"><i>(Principal Accounting Officer)</i></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex_622506.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_622506.htm</title>
	<!-- Generated by ThunderDome Portal - 9/18/2024 11:50:35 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>18 U.S. C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I Joshua R. Disbrow, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10&#8209;K of Aytu BioPharma, Inc. for the fiscal year ended&nbsp;<a data-tblloc="5x1" data-tblname="530716" data-tblv="66" id="led530716F20241231708725115036">June 30, 2024</a>, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10&#8209;K fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>Date: September 26, 2024</b></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Joshua R. Disbrow</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Joshua R. Disbrow</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Chairman and Chief Executive Officer </b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;"><i>(Principal Executive Officer)</i></td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">I Mark K. Oki, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10&#8209;K of Aytu BioPharma, Inc. for the fiscal year ended&nbsp;<a data-tblloc="5x1" data-tblname="530716" data-tblv="66" id="led530716F20241231708725129512">June 30, 2024</a>, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10&#8209;K fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 2pt;"><b>Date: September 26, 2024</b></p>
			</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Mark K. Oki</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Mark K. Oki</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Chief Financial Officer </b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;"><i>(Principal Financial Officer)</i></td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 46%;"><i>(Principal Accounting Officer)</i></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>ex_707455.htm
<DESCRIPTION>EXHIBIT 97.1
<TEXT>
<html><head>
	<title>ex_707455.htm</title>

	<!-- Generated by ThunderDome Portal - 9/6/2024 12:03:15 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 97.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AYTU BIOPHARMA, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CLAWBACK POLICY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>EFFECTIVE December 1, 2023</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Purpose</u>. The purpose of this Aytu BioPharma Inc. (the &#8220;<u>Company</u>&#8221;) Clawback Policy (this &#8220;<u>Policy</u>&#8221;) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified in Section 10D of the Securities Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), Rule 10D-1 promulgated under the Exchange Act (&#8220;<u>Rule 10D-1</u>&#8221;) and the listing standards of the national securities exchange on which the Company&#8217;s securities are listed (the &#8220;<u>Listing</u>&nbsp;<u>Standards</u>&#8221;).<sup style="vertical-align:top;line-height:120%;">&nbsp;</sup>Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in <u>Section 2</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Definitions</u>. As used in this Policy, the following capitalized terms shall have the meanings set forth below.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Accounting Restatement</u>&#8221;&nbsp;means an accounting restatement of the Company&#8217;s financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or to correct an error that is not material to the previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Accounting Restatement Date</u>&#8221;&nbsp;means the earlier to occur of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board&#8217;s action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Applicable Period</u>&#8221;&nbsp;means, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Board</u>&#8221;&nbsp;means the board of directors of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Code</u>&#8221;&nbsp;means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">f.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Covered Executive Officer</u>&#8221;&nbsp;means an individual who is currently or previously was identified by the Company as an &#8220;Officer&#8221;&nbsp;pursuant to Rule 16a 1(f) of the Exchange Act. Covered Executive Officers will include at minimum the executive officers identified by the Company pursuant to Item 401(b) of Regulation S-K of the Exchange Act.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">g.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Erroneously Awarded Compensation</u>&#8221;&nbsp;means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Covered Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the securities exchange on which the Company&#8217;s securities are listed.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">h.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Financial Reporting Measure</u>&#8221;&nbsp;means any measure that is determined and presented in accordance with accounting principles generally accepted in the United States of America (&#8220;<u>GAAP</u>&#8221;) used in preparing the Company&#8217;s financial statements (including non-GAAP financial measures) and any measures derived wholly or in part from such financial measures. Financial Reporting Measures include stock price and total shareholder return. A Financial Reporting Measure is not required to be presented within the Company&#8217;s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a &#8220;Financial Reporting Measure.&#8221;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;<u>Incentive-Based Compensation</u>&#8221;&nbsp;means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is deemed &#8220;received&#8221;&nbsp;for purposes of this Policy in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period. For avoidance of doubt, Incentive-Based Compensation that is deferred (either mandatorily or voluntarily) under the Company&#8217;s qualified and non-qualified deferred compensation plans, as well as any matching amounts and earnings thereon, are subject to this Policy. Incentive-Based Compensation does not include awards which are granted, earned and vested without regard to attainment of financial reporting measures, such as time-vesting awards, discretionary awards and awards based wholly on subjective standards, strategic measures or operational measures.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Administration</u>. This Policy shall be administered by the Board, or, if so designated by the Board, the Compensation Committee of the Board (the &#8220;<u>Compensation Committee</u>&#8221;), the Audit Committee of the Board (the &#8220;<u>Audit Committee</u>&#8221;) or a special committee comprised of members of the Compensation Committee or the Audit Committee. For purposes of this Policy, the body charged with administering this Policy shall be referred to herein as the &#8220;<u>Administrator</u>.&#8221;&nbsp;The Administrator is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Administrator pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Covered Executive Officers, and need not be uniform with respect to each person covered by this Policy.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">In the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to any limitation at applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). Any action or inaction by the Administrator with respect to a Covered Executive Officer under this Policy in no way limits the Administrator&#8217;s decision to act or not to act with respect to any other Covered Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Covered Executive Officer other than as set forth in this Policy.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Application of this Policy</u>. This Policy applies to all Incentive-Based Compensation received by a person: (a) after beginning service as a Covered Executive Officer; (b) who served as a Covered Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c) while the Company had a listed class of securities on a national securities exchange; and (d) during the Applicable Period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Recovery of Erroneously Awarded Compensation</u>. In the event of an Accounting Restatement, the Administrator will determine, in its sole discretion, the method(s) for recovering reasonably promptly Erroneously Awarded Compensation, in amounts determined pursuant to this Policy. The Board&#8217;s obligation to recover Erroneously Awarded Compensation is not dependent on the filing of restated financial statements. Recovery under this Policy with respect to a Covered Executive Officer shall not require the finding of any misconduct by such Covered Executive Officer or such Covered Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the method for recouping Erroneously Awarded Compensation shall be determined by the Administrator in its sole and absolute discretion, in a manner consistent with the requirements of the Exchange Act, the Listing Standards, and Section 409A of the Code.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">Recovery may include, without limitation, (i) reimbursement of all or a portion of any incentive compensation award, (ii) cancellation of incentive compensation awards, (iii) forfeiture of any Incentive-Based Compensation made under the Company&#8217;s deferred compensation plans, (iv) offsetting the recovered amount from any compensation or Incentive-Based Compensation that the Covered Executive Officer may earn or be awarded in the future, or (v) any other method authorized by applicable law or contract as determined by the Administrator.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">The Company is authorized and directed pursuant to this Policy to recover Erroneously Awarded Compensation in compliance with this Policy unless the Compensation Committee<sup style="vertical-align:top;line-height:120%;"> </sup>has determined that recovery would be impracticable, in accordance with Rule 10D 1 of the Exchange Act and the Listing Standards.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Prohibition on Indemnification and Insurance Reimbursement</u>. The Company is prohibited from indemnifying any Covered Executive Officer against the loss of any Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive Officer for the cost of purchasing insurance to cover any such loss. The Company is also prohibited from entering into any agreement or arrangement whereby this Policy would not apply or fail to be enforced against a Covered Executive Officer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Required Policy-Related Disclosure and Filings</u>. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings. A copy of this Policy and any amendments hereto shall be posted on the Company&#8217;s website and filed as an exhibit to the Company&#8217;s annual report on Form 10-K.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">8.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Acknowledgement</u>. Each Covered Executive Officer shall sign and return to the Company within thirty (30) calendar days following the later of (i) the effective date of this Policy set forth below or (ii) the date such individual becomes a Covered Executive Officer, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which the Covered Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">9.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Amendment; Termination</u>. The Board may amend this Policy from time to time in its sole and absolute discretion and shall amend this Policy as it deems necessary to reflect the Listing Standards or to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this Policy at any time; <u>provided</u>, that the termination of this Policy would not cause the Company to violate any federal securities laws, or rules promulgated by the U.S. Securities and Exchange Commission or the Listing Standards.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Other Recovery Obligations; General Rights</u>. The Board intends that this Policy shall be applied to the fullest extent of the law. To the extent that the application of this Policy would provide for recovery of Incentive-Based Compensation that the Company already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, any such amount recovered from a Covered Executive Officer will be credited to any recovery required under this Policy in respect of such Covered Executive Officer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">11.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Effective Date</u>. This Policy shall be effective as of December 1, 2023. The terms of this Policy shall apply to any Incentive-Based Compensation that is received by Covered Executive Officers on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded or granted to Covered Executive Officers prior to such date.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">This Policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">This Policy is binding and enforceable against all Covered Executive Officers and their beneficiaries, heirs, executors, administrators, or other legal representatives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>EXHIBIT A</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>AYTU BIOPHARMA, INC. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>CLAWBACK POLICY</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>ACKNOWLEDGEMENT FORM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Aytu BioPharma, Inc. (the &#8220;Company&#8221;) Clawback Policy (the &#8220;Policy&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment or service with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 67%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 33%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">EXECUTIVE OFFICER</p>
			</td>
		</tr>
		<tr>
			<td style="width: 67%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 33%; border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 67%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 33%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Signature</p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 67%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 33%; border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 67%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 33%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Print Name</p>
			</td>
		</tr>
		<tr>
			<td style="width: 67%;" valign="top" width="50%">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 33%; border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="12%">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 67%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td style="width: 33%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>aytu-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:02PM UTC 2024-09-26--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:aytu="http://aytubio.com/20240630" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://aytubio.com/20240630">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aytu-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aytu-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aytu-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aytu-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://aytubio.com/20240630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-parentheticals" roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-unaudited-consolidated-statements-of-cash-flows" roleURI="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Unaudited Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business-and-financial-condition" roleURI="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Nature of Business and Financial Condition</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue" roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-inventories" roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-intangible-assets" roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities" roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-other-liabilities" roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Other Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-revolving-credit-facility" roleURI="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Revolving Credit Facility</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-longterm-debt" roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - Long-term Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 12 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 13 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stockholders-equity" roleURI="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 14 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 15 - Equity Incentive Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-warrants" roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 16 - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-restructuring-costs-" roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 17 - Restructuring Costs</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-commitments-and-contingencies" roleURI="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 18 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-license-agreements" roleURI="http://aytubio.com/20240630/role/statement-note-19-license-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 19 - License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-segment-information" roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 20 - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-21-subsequent-events" roleURI="http://aytubio.com/20240630/role/statement-note-21-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 21 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-tables" roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 3 - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-inventories-tables" roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 4 - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases-tables" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 6 - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-intangible-assets-tables" roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 7 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities-tables" roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 8 - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-other-liabilities-tables" roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995482 - Disclosure - Note 9 - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-longterm-debt-tables" roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995483 - Disclosure - Note 11 - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements-tables" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995484 - Disclosure - Note 12 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-tables" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995485 - Disclosure - Note 13 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-tables" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995486 - Disclosure - Note 15 - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-warrants-tables" roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995487 - Disclosure - Note 16 - Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-restructuring-costs-tables" roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995488 - Disclosure - Note 17 - Restructuring Costs (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-segment-information-tables" roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995489 - Disclosure - Note 20 - Segment Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business-and-financial-condition-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995490 - Disclosure - Note 1 - Nature of Business and Financial Condition (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995491 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995492 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995493 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995494 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995495 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995496 - Disclosure - Note 3 - Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-disaggregation-of-revenue-details" roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995497 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-revenue-by-geographic-location-details" roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995498 - Disclosure - Note 3 - Revenue - Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-inventories-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995499 - Disclosure - Note 4 - Inventories (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-inventories-schedule-of-inventories-details" roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995500 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995501 - Disclosure - Note 5 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995502 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995503 - Disclosure - Note 6 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases-lease-cost-details" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995504 - Disclosure - Note 6 - Leases - Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases-lease-balance-sheet-information-details" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995505 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995506 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-leases-schedule-of-lease-liability-maturity-details" roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995507 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-intangible-assets-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995508 - Disclosure - Note 7 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-intangible-assets-schedule-of-intangible-assets-details" roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995509 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-intangible-assets-future-amortization-expense-details" roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995510 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995511 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995512 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-other-liabilities-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995513 - Disclosure - Note 9 - Other Liabilities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-other-liabilities-schedule-of-other-liabilities-details" roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995514 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-revolving-credit-facility-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995515 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-longterm-debt-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995516 - Disclosure - Note 11 - Long-term Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-longterm-debt-schedule-of-longterm-debt-details" roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995517 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-longterm-debt-future-principal-payments-details" roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995518 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995519 - Disclosure - Note 12 - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995520 - Disclosure - Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995521 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995522 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-fair-value-measurements-valuation-assumptions-details" roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995523 - Disclosure - Note 12 - Fair Value Measurements - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995524 - Disclosure - Note 13 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-provision-for-income-taxes-details" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995525 - Disclosure - Note 13 - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995526 - Disclosure - Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995527 - Disclosure - Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995528 - Disclosure - Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stockholders-equity-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995529 - Disclosure - Note 14 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995530 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-stock-option-activity-details" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995531 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-stock-options-outstanding-details" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995532 - Disclosure - Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-restricted-stock-activity-details" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995533 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995534 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-equity-incentive-plans-stock-compensation-expense-details" roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995535 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-warrants-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995536 - Disclosure - Note 16 - Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-warrants-schedule-of-warrants-outstanding-details" roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995537 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-restructuring-costs-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995538 - Disclosure - Note 17 - Restructuring Costs (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995539 - Disclosure - Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-commitments-and-contingencies-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995540 - Disclosure - Note 18 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-license-agreements-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995541 - Disclosure - Note 19 - License Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-segment-information-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995542 - Disclosure - Note 20 - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-segment-information-schedule-of-segment-information-details" roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995543 - Disclosure - Note 20 - Segment Information - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-21-subsequent-events-details-textual" roleURI="http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995544 - Disclosure - Note 21 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" name="AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForDiscounts" name="AccountsReceivableAllowanceForDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" name="AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForDiscountsRecovery" name="AccountsReceivableAllowanceForDiscountsRecovery" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForPricingChargebacks" name="AccountsReceivableAllowanceForPricingChargebacks" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" name="AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" name="AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" name="AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" name="AccountsReceivableAllowanceForPricingChargebacksRecovery" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" name="AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccountsReceivableCreditTerms" name="AccountsReceivableCreditTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccruedCustomerAndProductRelatedFeesCurrent" name="AccruedCustomerAndProductRelatedFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_AccruedLiabilitiesTextBlock" name="AccruedLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AccruedProgramRelatedLiabilities" name="AccruedProgramRelatedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_AccruedSavingOffers" name="AccruedSavingOffers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_AdhdPortfolioMember" name="AdhdPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AfterJanuary262023ButBeforeJanuary262024Member" name="AfterJanuary262023ButBeforeJanuary262024Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AfterJanuary262024ButBeforeJanuary262025Member" name="AfterJanuary262024ButBeforeJanuary262025Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AfterJune122025ButOnOrBeforeJune122026Member" name="AfterJune122025ButOnOrBeforeJune122026Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AfterJune122026ButOnOrBeforeJune122027Member" name="AfterJune122026ButOnOrBeforeJune122027Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AfterJune122026ButOnOrBeforeJune122028Member" name="AfterJune122026ButOnOrBeforeJune122028Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AmortizationExpenseOfIntangibleAssets" name="AmortizationExpenseOfIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_AssetImpairmentAndWriteoffCharges" name="AssetImpairmentAndWriteoffCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AtthemarketOfferingMember" name="AtthemarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_August2022CommonAndPrefundedWarrantsMember" name="August2022CommonAndPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_August2022CommonWarrantsMember" name="August2022CommonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_August2022PrefundedWarrantsMember" name="August2022PrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AvenueCapitalIssuanceMember" name="AvenueCapitalIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AvenueCapitalLoanMember" name="AvenueCapitalLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_AvenueCapitalWarrantsMember" name="AvenueCapitalWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_BoardMembersMember" name="BoardMembersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" name="BusinessCombinationsContingentConsiderationPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" name="ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" name="CommonWarrantsExchangedForPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ConsumerHealthMember" name="ConsumerHealthMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ConsumerHealthSegmentMember" name="ConsumerHealthSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_CustomerAMember" name="CustomerAMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_CustomerBMember" name="CustomerBMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_CustomerCMember" name="CustomerCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_DebtInstrumentAmortizationPeriod" name="DebtInstrumentAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_DebtInstrumentFinalPayment" name="DebtInstrumentFinalPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_DebtInstrumentPrepaymentFeeAmount" name="DebtInstrumentPrepaymentFeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_DebtInstrumentPrepaymentFeePercentage" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="aytu_DebtInstrumentTerminationFeePercentage" name="DebtInstrumentTerminationFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="aytu_DeferredTaxAssetsAccruedRebates" name="DeferredTaxAssetsAccruedRebates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" name="EclipseBusinessCapitalLlcLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_EclipseTermLoanMember" name="EclipseTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" name="EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_EmployeeRetentionCredit" name="EmployeeRetentionCredit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_EmployeeRetentionCreditPolicyTextBlock" name="EmployeeRetentionCreditPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_EmployeeRetentionCreditVendorFee" name="EmployeeRetentionCreditVendorFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_EquityWarrantsMember" name="EquityWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ExitAndDisposalActivitiesMember" name="ExitAndDisposalActivitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" name="FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_FirstThreePercentContributionByEmployeesMember" name="FirstThreePercentContributionByEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" name="FixedPaymentArrangementAssumedFromCerecorIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_FixedPaymentArrangementQuarterlyPayments" name="FixedPaymentArrangementQuarterlyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_FixedPaymentArrangements" name="FixedPaymentArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_FixedPaymentArrangementsBalloonPaymentAmount" name="FixedPaymentArrangementsBalloonPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_FixedPaymentArrangementsMeasurementInput" name="FixedPaymentArrangementsMeasurementInput" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" name="FixedPaymentArrangementsMonthlyPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_FixedPaymentArrangementsPaymentAmountPaid" name="FixedPaymentArrangementsPaymentAmountPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" name="FixedPaymentArrangementsPeriodicPaymentObligationsNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_FurnitureAndEquipmentMember" name="FurnitureAndEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_GrandPrairieTexasManufacturingSiteMember" name="GrandPrairieTexasManufacturingSiteMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_HealightMember" name="HealightMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" name="ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_IncomeTaxReconciliationContingentConsideration" name="IncomeTaxReconciliationContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_InventoryWriteDownsMember" name="InventoryWriteDownsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_June2023WarrantsTrancheAMember" name="June2023WarrantsTrancheAMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_LabEquipmentMember" name="LabEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LeasesDisclosureTextBlock" name="LeasesDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LesseeLiabilityMaturityTableTextBlock" name="LesseeLiabilityMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" name="LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_LiabilityPrefundedWarrantsMember" name="LiabilityPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_LiabilityTrancheBPrefundedWarrantsMember" name="LiabilityTrancheBPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_LiabilityWarrantsMember" name="LiabilityWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LicenseAgreementInitialLicenseFeePaid" name="LicenseAgreementInitialLicenseFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LicenseAgreementPatentProsecutionFeesPaid" name="LicenseAgreementPatentProsecutionFeesPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" name="LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LicensingAgreementsTextBlock" name="LicensingAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" name="LineOfCreditFacilityTerminationFeePercentageOfCommitment" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="aytu_LongTermDebtAndCapitalLeaseObligationsGross" name="LongTermDebtAndCapitalLeaseObligationsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_March2022CommonAndPrefundedWarrantsMember" name="March2022CommonAndPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_March2022CommonWarrantsMember" name="March2022CommonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_March2022PrefundedWarrantsMember" name="March2022PrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_Neos2015PlanMember" name="Neos2015PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NeosPlanMember" name="NeosPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NeosTherapeuticsIncMember" name="NeosTherapeuticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NextFivePercentContributionByEmployeesMember" name="NextFivePercentContributionByEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" name="NextFourPercentAndFivePercentContributionByEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NextFourPercentContributionByEmployeesMember" name="NextFourPercentContributionByEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_NoncashGainLossOnExtinguishmentOfDebt" name="NoncashGainLossOnExtinguishmentOfDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NonplanMember" name="NonplanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_NumberOfProducts" name="NumberOfProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_OfficeEquipmentFurnitureAndOtherMember" name="OfficeEquipmentFurnitureAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" name="OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_OfficeSpaceInBerwynPennsylvaniaMember" name="OfficeSpaceInBerwynPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_OnOrBeforeJanuary262023Member" name="OnOrBeforeJanuary262023Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_OnOrBeforeJune122025Member" name="OnOrBeforeJune122025Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_OperatingLeaseAndFinanceLeaseLiability" name="OperatingLeaseAndFinanceLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" name="OperatingLeaseAndFinanceLeaseRightofuseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" name="OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" name="OperatingLeaseUndiscountedMinimumMonthlyPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLossCarryforwardExpirationsOwnershipChange" name="OperatingLossCarryforwardExpirationsOwnershipChange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLossCarryforwardSubjectToExpire" name="OperatingLossCarryforwardSubjectToExpire" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" name="OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" name="OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_OtherWarrantsMember" name="OtherWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_PaymentsOfFixedPaymentArrangements" name="PaymentsOfFixedPaymentArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_PrincipalOfficeDenverColoradoMember" name="PrincipalOfficeDenverColoradoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" name="RestrictedStockAndRestrictedStockUnitsRsusMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_ReturnReserveCurrent" name="ReturnReserveCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="aytu_ReturnReserveMember" name="ReturnReserveMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_RevenuebasedRoyaltyCosts" name="RevenuebasedRoyaltyCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_RxSegmentMember" name="RxSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_SabbyLitigationMember" name="SabbyLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_SabbyLitigationWarrantsMember" name="SabbyLitigationWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_SabbyVolatilityWarrantMasterFundLtdMember" name="SabbyVolatilityWarrantMasterFundLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SaleOfStockMaximumAmountOfEquityIssuable" name="SaleOfStockMaximumAmountOfEquityIssuable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" name="ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_SecuritiesPurchaseAgreementWarrantsMember" name="SecuritiesPurchaseAgreementWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SupplyAndDistributionAgreementExtensionTerm" name="SupplyAndDistributionAgreementExtensionTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" name="SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" name="SupplyAndDistributionAgreementMaximumMilestoneObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" name="SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" name="SupplyAndDistributionAgreementMinimumSalesPerYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
  <xsd:element id="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" name="SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="aytu_SupplyAndDistributionCommitmentPeriod" name="SupplyAndDistributionCommitmentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" name="SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_The2014LicenseAgreementShireMember" name="The2014LicenseAgreementShireMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_The2015PlanMember" name="The2015PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_The2020ShelfMember" name="The2020ShelfMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_The2021ShelfMember" name="The2021ShelfMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_The2023EquityIncentivePlanMember" name="The2023EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_The2024ShelfMember" name="The2024ShelfMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TheAugust2022OfferingMember" name="TheAugust2022OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TheMarch2022OfferingMember" name="TheMarch2022OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_ThePediatricPortfolioMember" name="ThePediatricPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TrancheACommonWarrantsMember" name="TrancheACommonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TrancheBCommonWarrantsMember" name="TrancheBCommonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TrancheBPrefundedWarrantsMember" name="TrancheBPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TrisKarbinalAgreementMember" name="TrisKarbinalAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TrisLicenseAgreementMember" name="TrisLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_TwoFormerBoardMembersMember" name="TwoFormerBoardMembersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_WalleyeOpportunitiesMasterFundLtdMember" name="WalleyeOpportunitiesMasterFundLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="aytu_WarrantsOrRightsDisclosureTextBlock" name="WarrantsOrRightsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" name="statement-statement-note-11-longterm-debt-future-principal-payments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" name="statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-11-longterm-debt-tables" name="statement-statement-note-11-longterm-debt-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" name="statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" name="statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" name="statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-12-fair-value-measurements-tables" name="statement-statement-note-12-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" name="statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" name="statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" name="statement-statement-note-13-income-taxes-provision-for-income-taxes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" name="statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-13-income-taxes-tables" name="statement-statement-note-13-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" name="statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" name="statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" name="statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" name="statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" name="statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-15-equity-incentive-plans-tables" name="statement-statement-note-15-equity-incentive-plans-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" name="statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-16-warrants-tables" name="statement-statement-note-16-warrants-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" name="statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-17-restructuring-costs-tables" name="statement-statement-note-17-restructuring-costs-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" name="statement-statement-note-20-segment-information-schedule-of-segment-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-20-segment-information-tables" name="statement-statement-note-20-segment-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" name="statement-statement-note-3-revenue-disaggregation-of-revenue-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" name="statement-statement-note-3-revenue-revenue-by-geographic-location-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-3-revenue-tables" name="statement-statement-note-3-revenue-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" name="statement-statement-note-4-inventories-schedule-of-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-4-inventories-tables" name="statement-statement-note-4-inventories-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" name="statement-statement-note-6-leases-lease-balance-sheet-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" name="statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-6-leases-lease-cost-details" name="statement-statement-note-6-leases-lease-cost-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" name="statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-6-leases-tables" name="statement-statement-note-6-leases-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" name="statement-statement-note-7-intangible-assets-future-amortization-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" name="statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-7-intangible-assets-tables" name="statement-statement-note-7-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" name="statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" name="statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-8-accrued-liabilities-tables" name="statement-statement-note-8-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" name="statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-note-9-other-liabilities-tables" name="statement-statement-note-9-other-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="aytu_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>aytu-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:02PM UTC 2024-09-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets" xlink:href="aytu-20240630.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows" xlink:href="aytu-20240630.xsd#statement-unaudited-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PaymentsOfFixedPaymentArrangements" xlink:label="aytu_PaymentsOfFixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="aytu_PaymentsOfFixedPaymentArrangements" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-schedule-of-inventories-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aytu_ReturnReserveCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aytu_AccruedProgramRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aytu_AccruedSavingOffers" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="aytu_EmployeeRetentionCredit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherSundryLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="aytu_FixedPaymentArrangements" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentFinalPayment" xlink:label="aytu_DebtInstrumentFinalPayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="aytu_DebtInstrumentFinalPayment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-cost-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>aytu-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:02PM UTC 2024-09-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedLiabilitiesTextBlock" xlink:label="aytu_AccruedLiabilitiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_AccruedLiabilitiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-document-and-entity-information" xlink:href="aytu-20240630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="aytu-20240630.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition" xlink:href="aytu-20240630.xsd#statement-note-1-nature-of-business-and-financial-condition" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FurnitureAndEquipmentMember" xlink:label="aytu_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="aytu_NeosPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue" xlink:href="aytu-20240630.xsd#statement-note-3-revenue" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories" xlink:href="aytu-20240630.xsd#statement-note-4-inventories" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="aytu_InventoryWriteDownsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases" xlink:href="aytu-20240630.xsd#statement-note-6-leases" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LeasesDisclosureTextBlock" xlink:label="aytu_LeasesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_LeasesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember" xlink:label="us-gaap_PatentedTechnologyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentedTechnologyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_AdhdPortfolioMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aytu_NeosTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisLicenseAgreementMember" xlink:label="aytu_TrisLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_TrisLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility" xlink:href="aytu-20240630.xsd#statement-note-10-revolving-credit-facility" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJanuary262023Member" xlink:label="aytu_OnOrBeforeJanuary262023Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_OnOrBeforeJanuary262023Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalIssuanceMember" xlink:label="aytu_AvenueCapitalIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJune122025Member" xlink:label="aytu_OnOrBeforeJune122025Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_AvenueCapitalIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_OnOrBeforeJune122025Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity" xlink:href="aytu-20240630.xsd#statement-note-14-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AtthemarketOfferingMember" xlink:label="aytu_AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2020ShelfMember" xlink:label="aytu_The2020ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2021ShelfMember" xlink:label="aytu_The2021ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2024ShelfMember" xlink:label="aytu_The2024ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheAugust2022OfferingMember" xlink:label="aytu_TheAugust2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_The2020ShelfMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_AtthemarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_The2021ShelfMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_The2024ShelfMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_TheAugust2022OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BoardMembersMember" xlink:label="aytu_BoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2015PlanMember" xlink:label="aytu_The2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2023EquityIncentivePlanMember" xlink:label="aytu_The2023EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TwoFormerBoardMembersMember" xlink:label="aytu_TwoFormerBoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_The2023EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_The2015PlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Neos2015PlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="aytu_TwoFormerBoardMembersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="aytu_BoardMembersMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_NonplanMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants" xlink:href="aytu-20240630.xsd#statement-note-16-warrants" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityPrefundedWarrantsMember" xlink:label="aytu_LiabilityPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReverseStockSplitMember" xlink:label="aytu_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WarrantsOrRightsDisclosureTextBlock" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="aytu_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_LiabilityWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_LiabilityPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_EquityWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies" xlink:href="aytu-20240630.xsd#statement-note-18-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationWarrantsMember" xlink:label="aytu_SabbyLitigationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ThePediatricPortfolioMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="aytu_SabbyLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_SabbyLitigationWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-19-license-agreements" xlink:href="aytu-20240630.xsd#statement-note-19-license-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-19-license-agreements" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_HealightMember" xlink:label="aytu_HealightMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicensingAgreementsTextBlock" xlink:label="aytu_LicensingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2014LicenseAgreementShireMember" xlink:label="aytu_The2014LicenseAgreementShireMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_HealightMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_The2014LicenseAgreementShireMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_LicensingAgreementsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-21-subsequent-events" xlink:href="aytu-20240630.xsd#statement-note-21-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-21-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies" xlink:href="aytu-20240630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:label="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:label="aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GoingConcernPolicyTextBlock" xlink:label="aytu_GoingConcernPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="aytu_GoingConcernPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-tables" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-tables" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-tables" xlink:href="aytu-20240630.xsd#statement-note-6-leases-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeLiabilityMaturityTableTextBlock" xlink:label="aytu_LesseeLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:label="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="aytu_LesseeLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-tables" xlink:href="aytu-20240630.xsd#statement-note-16-warrants-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-tables" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual" xlink:href="aytu-20240630.xsd#statement-note-1-nature-of-business-and-financial-condition-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RevenuebasedRoyaltyCosts" xlink:label="aytu_RevenuebasedRoyaltyCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_RevenuebasedRoyaltyCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableCreditTerms" xlink:label="aytu_AccountsReceivableCreditTerms" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCreditVendorFee" xlink:label="aytu_EmployeeRetentionCreditVendorFee" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FurnitureAndEquipmentMember" xlink:label="aytu_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="aytu_NeosPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscounts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableCreditTerms" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCredit" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCreditVendorFee" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NumberOfProducts" xlink:label="aytu_NumberOfProducts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_NumberOfProducts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="aytu_InventoryWriteDownsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-details-textual" xlink:href="aytu-20240630.xsd#statement-note-6-leases-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AmortizationExpenseOfIntangibleAssets" xlink:label="aytu_AmortizationExpenseOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:label="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:label="aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember" xlink:label="us-gaap_PatentedTechnologyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentedTechnologyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_AdhdPortfolioMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aytu_NeosTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AmortizationExpenseOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:label="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentPeriod" xlink:label="aytu_SupplyAndDistributionCommitmentPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisLicenseAgreementMember" xlink:label="aytu_TrisLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_TrisLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCredit" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual" xlink:href="aytu-20240630.xsd#statement-note-10-revolving-credit-facility-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJanuary262023Member" xlink:label="aytu_OnOrBeforeJanuary262023Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_OnOrBeforeJanuary262023Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalIssuanceMember" xlink:label="aytu_AvenueCapitalIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentAmortizationPeriod" xlink:label="aytu_DebtInstrumentAmortizationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentFinalPayment" xlink:label="aytu_DebtInstrumentFinalPayment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentPrepaymentFeeAmount" xlink:label="aytu_DebtInstrumentPrepaymentFeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentPrepaymentFeePercentage" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentTerminationFeePercentage" xlink:label="aytu_DebtInstrumentTerminationFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJune122025Member" xlink:label="aytu_OnOrBeforeJune122025Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_AvenueCapitalIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_OnOrBeforeJune122025Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoanProcessingFee" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentPrepaymentFeeAmount" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentFinalPayment" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentAmortizationPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentTerminationFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsMeasurementInput" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:label="aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardSubjectToExpire" xlink:label="aytu_OperatingLossCarryforwardSubjectToExpire" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardSubjectToExpire" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual" xlink:href="aytu-20240630.xsd#statement-note-14-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AtthemarketOfferingMember" xlink:label="aytu_AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:label="aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2020ShelfMember" xlink:label="aytu_The2020ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2021ShelfMember" xlink:label="aytu_The2021ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2024ShelfMember" xlink:label="aytu_The2024ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheAugust2022OfferingMember" xlink:label="aytu_TheAugust2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_The2020ShelfMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_AtthemarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_The2021ShelfMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_The2024ShelfMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_TheAugust2022OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BoardMembersMember" xlink:label="aytu_BoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2015PlanMember" xlink:label="aytu_The2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2023EquityIncentivePlanMember" xlink:label="aytu_The2023EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TwoFormerBoardMembersMember" xlink:label="aytu_TwoFormerBoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_The2023EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_The2015PlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Neos2015PlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="aytu_TwoFormerBoardMembersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="aytu_BoardMembersMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_NonplanMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual" xlink:href="aytu-20240630.xsd#statement-note-16-warrants-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityPrefundedWarrantsMember" xlink:label="aytu_LiabilityPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReverseStockSplitMember" xlink:label="aytu_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="aytu_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_LiabilityWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_LiabilityPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_EquityWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1" xlink:label="us-gaap_BusinessExitCosts1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessExitCosts1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual" xlink:href="aytu-20240630.xsd#statement-note-18-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementQuarterlyPayments" xlink:label="aytu_FixedPaymentArrangementQuarterlyPayments" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationWarrantsMember" xlink:label="aytu_SabbyLitigationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentPeriod" xlink:label="aytu_SupplyAndDistributionCommitmentPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ThePediatricPortfolioMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="aytu_SabbyLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_SabbyLitigationWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementQuarterlyPayments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual" xlink:href="aytu-20240630.xsd#statement-note-19-license-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_HealightMember" xlink:label="aytu_HealightMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementInitialLicenseFeePaid" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:label="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2014LicenseAgreementShireMember" xlink:label="aytu_The2014LicenseAgreementShireMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_HealightMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_The2014LicenseAgreementShireMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LicenseAgreementInitialLicenseFeePaid" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual" xlink:href="aytu-20240630.xsd#statement-note-21-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RevenuebasedRoyaltyCosts" xlink:label="aytu_RevenuebasedRoyaltyCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_RevenuebasedRoyaltyCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:label="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveMember" xlink:label="aytu_ReturnReserveMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="aytu_ReturnReserveMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="aytu_LiabilityWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="aytu_EquityWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets" xlink:href="aytu-20240630.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows" xlink:href="aytu-20240630.xsd#statement-unaudited-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PaymentsOfFixedPaymentArrangements" xlink:label="aytu_PaymentsOfFixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="aytu_PaymentsOfFixedPaymentArrangements" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerAMember" xlink:label="aytu_CustomerAMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerBMember" xlink:label="aytu_CustomerBMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="aytu_CustomerAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="aytu_CustomerBMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="aytu_CustomerCMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-schedule-of-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_ManufacturingEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_LabEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetUnderConstructionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccruedSavingOffers" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccruedProgramRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ReturnReserveCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentFinalPayment" xlink:label="aytu_DebtInstrumentFinalPayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentFinalPayment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_June2023WarrantsTrancheAMember" xlink:label="aytu_June2023WarrantsTrancheAMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OtherWarrantsMember" xlink:label="aytu_OtherWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_June2023WarrantsTrancheAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_OtherWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExitAndDisposalActivitiesMember" xlink:label="aytu_ExitAndDisposalActivitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="aytu_ExitAndDisposalActivitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="aytu_InventoryWriteDownsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RxSegmentMember" xlink:label="aytu_RxSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="aytu_AdhdPortfolioMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="aytu_ThePediatricPortfolioMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-revenue-by-geographic-location-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-balance-sheet-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information-schedule-of-segment-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AssetImpairmentAndWriteoffCharges" xlink:label="aytu_AssetImpairmentAndWriteoffCharges" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RxSegmentMember" xlink:label="aytu_RxSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AssetImpairmentAndWriteoffCharges" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-cost-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:href="aytu-20240630.xsd#statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeThreeMember" xlink:label="aytu_ExercisePriceRangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="aytu_ExercisePriceRangeOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="aytu_ExercisePriceRangeTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="aytu_ExercisePriceRangeThreeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:definitionArc order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:definitionArc order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>aytu-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:02PM UTC 2024-09-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DocumentAndEntityInformation" xlink:label="aytu_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="aytu_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DocumentAndEntityInformation" xlink:to="aytu_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="aytu_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="aytu_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Derivative warrant liabilities loss (gain)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-significant-accounting-policies-policies" xlink:label="aytu_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-significant-accounting-policies-policies" xlink:to="aytu_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-3-revenue-tables" xlink:label="aytu_statement-statement-note-3-revenue-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-3-revenue-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-3-revenue-tables" xlink:to="aytu_statement-statement-note-3-revenue-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-4-inventories-tables" xlink:label="aytu_statement-statement-note-4-inventories-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-4-inventories-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-4-inventories-tables" xlink:to="aytu_statement-statement-note-4-inventories-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-5-property-and-equipment-tables" xlink:label="aytu_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-5-property-and-equipment-tables" xlink:to="aytu_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-tables" xlink:label="aytu_statement-statement-note-6-leases-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-6-leases-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-6-leases-tables" xlink:to="aytu_statement-statement-note-6-leases-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-7-intangible-assets-tables" xlink:label="aytu_statement-statement-note-7-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-7-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-7-intangible-assets-tables" xlink:to="aytu_statement-statement-note-7-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-8-accrued-liabilities-tables" xlink:label="aytu_statement-statement-note-8-accrued-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-8-accrued-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Accrued Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-8-accrued-liabilities-tables" xlink:to="aytu_statement-statement-note-8-accrued-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-9-other-liabilities-tables" xlink:label="aytu_statement-statement-note-9-other-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-9-other-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Other Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-9-other-liabilities-tables" xlink:to="aytu_statement-statement-note-9-other-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-11-longterm-debt-tables" xlink:label="aytu_statement-statement-note-11-longterm-debt-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-11-longterm-debt-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Long-term Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-11-longterm-debt-tables" xlink:to="aytu_statement-statement-note-11-longterm-debt-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-tables" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-12-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-tables" xlink:to="aytu_statement-statement-note-12-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-tables" xlink:label="aytu_statement-statement-note-13-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-13-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-13-income-taxes-tables" xlink:to="aytu_statement-statement-note-13-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-tables" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Equity Incentive Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-tables" xlink:to="aytu_statement-statement-note-15-equity-incentive-plans-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-16-warrants-tables" xlink:label="aytu_statement-statement-note-16-warrants-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-16-warrants-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-16-warrants-tables" xlink:to="aytu_statement-statement-note-16-warrants-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-17-restructuring-costs-tables" xlink:label="aytu_statement-statement-note-17-restructuring-costs-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-17-restructuring-costs-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 17 - Restructuring Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-17-restructuring-costs-tables" xlink:to="aytu_statement-statement-note-17-restructuring-costs-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-20-segment-information-tables" xlink:label="aytu_statement-statement-note-20-segment-information-tables" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-20-segment-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Segment Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-20-segment-information-tables" xlink:to="aytu_statement-statement-note-20-segment-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:to="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:to="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:to="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:to="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:label="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue - Disaggregation of Revenue (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:to="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" xlink:label="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue - Revenue by Geographic Location (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" xlink:to="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" xlink:label="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Inventories - Schedule of Inventories (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" xlink:to="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-lease-cost-details" xlink:label="aytu_statement-statement-note-6-leases-lease-cost-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-6-leases-lease-cost-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Leases - Lease Cost (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-6-leases-lease-cost-details" xlink:to="aytu_statement-statement-note-6-leases-lease-cost-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" xlink:label="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Leases - Lease Balance Sheet Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" xlink:to="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:label="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:to="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:label="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Leases - Schedule of Lease Liability Maturity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:to="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:label="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:to="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" xlink:label="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Intangible Assets - Future Amortization Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" xlink:to="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:label="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:to="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:label="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:to="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:label="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:to="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:label="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:to="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" xlink:label="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Long-term Debt - Future Principal Payments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" xlink:to="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:to="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:to="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:to="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Fair Value Measurements - Valuation Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:to="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:label="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Provision for Income Taxes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:to="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:label="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:to="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:label="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:to="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Equity Incentive Plans - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:to="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:to="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:to="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:to="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:to="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:label="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Warrants - Schedule of Warrants Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:to="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:label="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:to="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" xlink:label="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" xlink:type="locator"/>
    <link:label xlink:label="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Segment Information - Schedule of Segment Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" xlink:to="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, options, weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatements" xlink:label="aytu_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="aytu_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NotesToFinancialStatements" xlink:to="aytu_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="aytu_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="aytu_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedIncomeTaxesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SettlementLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SettlementLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_SettlementLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement Liabilities, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ThePediatricPortfolioMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Pediatric Portfolio [Member]</link:label>
    <link:label xlink:label="aytu_ThePediatricPortfolioMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Pediatric Portfolio.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ThePediatricPortfolioMember" xlink:to="aytu_ThePediatricPortfolioMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductAndServiceOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ConsumerHealthMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health [Member]</link:label>
    <link:label xlink:label="aytu_ConsumerHealthMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents consumer health.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConsumerHealthMember" xlink:to="aytu_ConsumerHealthMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ManufacturingEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label xlink:label="aytu_ManufacturingEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents manufacturing equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ManufacturingEquipmentMember" xlink:to="aytu_ManufacturingEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_LabEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label xlink:label="aytu_LabEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents lab equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LabEquipmentMember" xlink:to="aytu_LabEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment, Furniture and Other [Member]</link:label>
    <link:label xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents office equipment, furniture and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:to="aytu_OfficeEquipmentFurnitureAndOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccruedProgramRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued program liabilities</link:label>
    <link:label xlink:label="aytu_AccruedProgramRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedProgramRelatedLiabilities" xlink:to="aytu_AccruedProgramRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AtthemarketOfferingMember" xlink:label="aytu_AtthemarketOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_AtthemarketOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label xlink:label="aytu_AtthemarketOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the at-the-market offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AtthemarketOfferingMember" xlink:to="aytu_AtthemarketOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued (2) (in shares)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period (in shares)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WarrantsOrRightsDisclosureTextBlock" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants or Rights Disclosure [Text Block]</link:label>
    <link:label xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:to="aytu_WarrantsOrRightsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2015PlanMember" xlink:label="aytu_The2015PlanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_The2015PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2015 Plan [Member]</link:label>
    <link:label xlink:label="aytu_The2015PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the &#8220;2015 Plan&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_The2015PlanMember" xlink:to="aytu_The2015PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_NonplanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-plan [Member]</link:label>
    <link:label xlink:label="aytu_NonplanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NonplanMember" xlink:to="aytu_NonplanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Goodwill</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableGross</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableGross-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableGross-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual term (Year)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average period of remaining contractual life of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:to="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_LiabilityWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Warrants [Member]</link:label>
    <link:label xlink:label="aytu_LiabilityWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents liability warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LiabilityWarrantsMember" xlink:to="aytu_LiabilityWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisLicenseAgreementMember" xlink:label="aytu_TrisLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TrisLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tris License Agreement [Member]</link:label>
    <link:label xlink:label="aytu_TrisLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Tris License Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TrisLicenseAgreementMember" xlink:to="aytu_TrisLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income tax expense, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentPeriod" xlink:label="aytu_SupplyAndDistributionCommitmentPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionCommitmentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionCommitmentPeriod</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionCommitmentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Commitment, Period (Year)</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionCommitmentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionCommitmentPeriod" xlink:to="aytu_SupplyAndDistributionCommitmentPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:label="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Agreement, Maximum Yearly Make-whole Payment</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of make-whole payment per year under supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:to="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionAgreementMinimumSalesPerYear</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Agreement, Minimum Sales Per Year</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Th minimum amount of units to be sold per year under supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:to="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Commitment, Royalty, Percentage of Net Sales</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of net sales to be paid for royalties under supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:to="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Agreement, Maximum Milestone Obligations</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of milestone obligations of the supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:to="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Agreement, First Milestone, Minimum Net Revenues</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:to="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</link:label>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetImpairmentCharges-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment expense</link:label>
    <link:label xlink:label="us-gaap_AssetImpairmentCharges-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SeveranceCosts1</link:label>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringCharges-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1" xlink:label="us-gaap_BusinessExitCosts1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessExitCosts1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessExitCosts1</link:label>
    <link:label xlink:label="us-gaap_BusinessExitCosts1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessExitCosts1" xlink:to="us-gaap_BusinessExitCosts1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer concentration risk</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvertisingExpense</link:label>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingAndMarketingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and marketing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter, future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026, future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027, future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028, future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029, future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025, future amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, remaining life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant derivatives</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInventory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock from exercise of warrants (in shares)</link:label>
    <link:label xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised (in shares)</link:label>
    <link:label xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued for the warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="aytu_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock from exercise of warrants</link:label>
    <link:label xlink:label="aytu_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of stock issued for warrants exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="aytu_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</link:label>
    <link:label xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity from shares and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RevenuebasedRoyaltyCosts" xlink:label="aytu_RevenuebasedRoyaltyCosts" xlink:type="locator"/>
    <link:label xlink:label="aytu_RevenuebasedRoyaltyCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_RevenuebasedRoyaltyCosts</link:label>
    <link:label xlink:label="aytu_RevenuebasedRoyaltyCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue-based Royalty Costs</link:label>
    <link:label xlink:label="aytu_RevenuebasedRoyaltyCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of revenue-based royalty revenue costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RevenuebasedRoyaltyCosts" xlink:to="aytu_RevenuebasedRoyaltyCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetUnderConstructionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TrancheBPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_TrancheBPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Tranche B Pre-Funded Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TrancheBPrefundedWarrantsMember" xlink:to="aytu_TrancheBPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:label="aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLossCarryforwardExpirationsOwnershipChange-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLossCarryforwardExpirationsOwnershipChange</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardExpirationsOwnershipChange-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Expirations, Ownership Change</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardExpirationsOwnershipChange-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The operating loss carryforward that will expire related to the ownership change.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:to="aytu_OperatingLossCarryforwardExpirationsOwnershipChange-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardSubjectToExpire" xlink:label="aytu_OperatingLossCarryforwardSubjectToExpire" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLossCarryforwardSubjectToExpire-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLossCarryforwardSubjectToExpire</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardSubjectToExpire-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Subject To Expire</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardSubjectToExpire-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The operating loss carryforward that will expire.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardSubjectToExpire" xlink:to="aytu_OperatingLossCarryforwardSubjectToExpire-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2024ShelfMember" xlink:label="aytu_The2024ShelfMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_The2024ShelfMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2024 Shelf [Member]</link:label>
    <link:label xlink:label="aytu_The2024ShelfMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the The 2021 Shelf registration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_The2024ShelfMember" xlink:to="aytu_The2024ShelfMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carry forward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grand Prairie, Texas Manufacturing Site [Member]</link:label>
    <link:label xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Grand Prairie, Texas manufacturing site.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ConsumerHealthSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health Segment [Member]</link:label>
    <link:label xlink:label="aytu_ConsumerHealthSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the consumer health segment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConsumerHealthSegmentMember" xlink:to="aytu_ConsumerHealthSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeThreeMember" xlink:label="aytu_ExercisePriceRangeThreeMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ExercisePriceRangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label xlink:label="aytu_ExercisePriceRangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents exercise price range three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeThreeMember" xlink:to="aytu_ExercisePriceRangeThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_EclipseTermLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eclipse Term loan [Member]</link:label>
    <link:label xlink:label="aytu_EclipseTermLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Eclipse Term loan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EclipseTermLoanMember" xlink:to="aytu_EclipseTermLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_InventoryWriteDownsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write Downs [Member]</link:label>
    <link:label xlink:label="aytu_InventoryWriteDownsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Inventory Write Downs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_InventoryWriteDownsMember" xlink:to="aytu_InventoryWriteDownsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExitAndDisposalActivitiesMember" xlink:label="aytu_ExitAndDisposalActivitiesMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ExitAndDisposalActivitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exit and Disposal Activities [Member]</link:label>
    <link:label xlink:label="aytu_ExitAndDisposalActivitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exit and disposal activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExitAndDisposalActivitiesMember" xlink:to="aytu_ExitAndDisposalActivitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_June2023WarrantsTrancheAMember" xlink:label="aytu_June2023WarrantsTrancheAMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_June2023WarrantsTrancheAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2023 Warrants Tranche A [Member]</link:label>
    <link:label xlink:label="aytu_June2023WarrantsTrancheAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the June 2023 Warrants Tranche A.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_June2023WarrantsTrancheAMember" xlink:to="aytu_June2023WarrantsTrancheAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentTerminationFeePercentage" xlink:label="aytu_DebtInstrumentTerminationFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="aytu_DebtInstrumentTerminationFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_DebtInstrumentTerminationFeePercentage</link:label>
    <link:label xlink:label="aytu_DebtInstrumentTerminationFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Termination Fee, Percentage</link:label>
    <link:label xlink:label="aytu_DebtInstrumentTerminationFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The termination fee if the debt is terminated before or on a certain date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentTerminationFeePercentage" xlink:to="aytu_DebtInstrumentTerminationFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentAmortizationPeriod" xlink:label="aytu_DebtInstrumentAmortizationPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_DebtInstrumentAmortizationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_DebtInstrumentAmortizationPeriod</link:label>
    <link:label xlink:label="aytu_DebtInstrumentAmortizationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period (Year)</link:label>
    <link:label xlink:label="aytu_DebtInstrumentAmortizationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The duration in which the debt will amortize.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentAmortizationPeriod" xlink:to="aytu_DebtInstrumentAmortizationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentPrepaymentFeeAmount" xlink:label="aytu_DebtInstrumentPrepaymentFeeAmount" xlink:type="locator"/>
    <link:label xlink:label="aytu_DebtInstrumentPrepaymentFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_DebtInstrumentPrepaymentFeeAmount</link:label>
    <link:label xlink:label="aytu_DebtInstrumentPrepaymentFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Amount</link:label>
    <link:label xlink:label="aytu_DebtInstrumentPrepaymentFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The prepayment fee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentPrepaymentFeeAmount" xlink:to="aytu_DebtInstrumentPrepaymentFeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_NoncashGainLossOnExtinguishmentOfDebt</link:label>
    <link:label xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash loss on extinguishment of debt</link:label>
    <link:label xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The non-cash gain (loss) on the extinguishment of debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:to="aytu_NoncashGainLossOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After June 12, 2026, but on or before June 12, 2028 [Member]</link:label>
    <link:label xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2028.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122028Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GrossProfit</link:label>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJune122025Member" xlink:label="aytu_OnOrBeforeJune122025Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_OnOrBeforeJune122025Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">On or Before June 12 2025 [Member]</link:label>
    <link:label xlink:label="aytu_OnOrBeforeJune122025Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Termination is on or before the date of June 12 2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OnOrBeforeJune122025Member" xlink:to="aytu_OnOrBeforeJune122025Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After June 12, 2026, but on or before June 12, 2027 [Member]</link:label>
    <link:label xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122027Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After June 12, 2025, but on or before June 12, 2026 [Member]</link:label>
    <link:label xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the termination fee if the termination is after June 12, 2025, but on or before June 12, 2026.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:to="aytu_AfterJune122025ButOnOrBeforeJune122026Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">ROU asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ManagementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromWarrantExercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoanProcessingFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LoanProcessingFee</link:label>
    <link:label xlink:label="us-gaap_LoanProcessingFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Processing Fee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanProcessingFee" xlink:to="us-gaap_LoanProcessingFee-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentFederalTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable Portfolio Segment [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable Portfolio Segment [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfDebtIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment for debt issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments made to borrowings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase resulting from current period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease resulting from current period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securites excluded (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds (payments) made on revolving credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PaymentsOfFixedPaymentArrangements" xlink:label="aytu_PaymentsOfFixedPaymentArrangements" xlink:type="locator"/>
    <link:label xlink:label="aytu_PaymentsOfFixedPaymentArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_PaymentsOfFixedPaymentArrangements</link:label>
    <link:label xlink:label="aytu_PaymentsOfFixedPaymentArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment made to fixed payment arrangement</link:label>
    <link:label xlink:label="aytu_PaymentsOfFixedPaymentArrangements-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for fixed payments arrangements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsOfFixedPaymentArrangements" xlink:to="aytu_PaymentsOfFixedPaymentArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfRestructuringDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease assets</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeSeveranceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringCostAndReserveAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease assets (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax at statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RxSegmentMember" xlink:label="aytu_RxSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_RxSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rx Segment [Member]</link:label>
    <link:label xlink:label="aytu_RxSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Rx Segment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RxSegmentMember" xlink:to="aytu_RxSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_AdhdPortfolioMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADHD Portfolio [Member]</link:label>
    <link:label xlink:label="aytu_AdhdPortfolioMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the ADHS Portfolio.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdhdPortfolioMember" xlink:to="aytu_AdhdPortfolioMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LeasesDisclosureTextBlock" xlink:label="aytu_LeasesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_LeasesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Text Block]</link:label>
    <link:label xlink:label="aytu_LeasesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for leases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LeasesDisclosureTextBlock" xlink:to="aytu_LeasesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:label="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Lease by Balance Sheet Information [Table Text Block]</link:label>
    <link:label xlink:label="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of leases by balance sheet information.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:to="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeLiabilityMaturityTableTextBlock" xlink:label="aytu_LesseeLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_LesseeLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:label="aytu_LesseeLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LesseeLiabilityMaturityTableTextBlock" xlink:to="aytu_LesseeLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedLiabilitiesTextBlock" xlink:label="aytu_AccruedLiabilitiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccruedLiabilitiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Text Block]</link:label>
    <link:label xlink:label="aytu_AccruedLiabilitiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure regarding accrued liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedLiabilitiesTextBlock" xlink:to="aytu_AccruedLiabilitiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_NeosTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neos Therapeutics, Inc. [Member]</link:label>
    <link:label xlink:label="aytu_NeosTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Neos Therapeutics, Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NeosTherapeuticsIncMember" xlink:to="aytu_NeosTherapeuticsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax at statutory rate, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReverseStockSplitMember" xlink:label="aytu_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="aytu_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReverseStockSplitMember" xlink:to="aytu_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:label="aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:type="locator"/>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementExtensionTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SupplyAndDistributionAgreementExtensionTerm</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementExtensionTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply and Distribution Agreement, Extension Term (Year)</link:label>
    <link:label xlink:label="aytu_SupplyAndDistributionAgreementExtensionTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the extension term of a supply and distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:to="aytu_SupplyAndDistributionAgreementExtensionTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetirementPlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetirementPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecuredDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TrisKarbinalAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tris Karbinal Agreement [Member]</link:label>
    <link:label xlink:label="aytu_TrisKarbinalAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Tris Karbinal Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TrisKarbinalAgreementMember" xlink:to="aytu_TrisKarbinalAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:label="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod</link:label>
    <link:label xlink:label="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)</link:label>
    <link:label xlink:label="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the renewable period for a finite-lived intangible asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:to="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit" xlink:type="locator"/>
    <link:label xlink:label="aytu_EmployeeRetentionCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee retention credit</link:label>
    <link:label xlink:label="aytu_EmployeeRetentionCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Retention Credit</link:label>
    <link:label xlink:label="aytu_EmployeeRetentionCredit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of employee retention credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EmployeeRetentionCredit" xlink:to="aytu_EmployeeRetentionCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FixedPaymentArrangementsBalloonPaymentAmount</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangements, Balloon Payment Amount</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of balloon payment on a fixed payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FixedPaymentArrangementsMonthlyPaymentAmount</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangements, Monthly Payment Amount</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of monthly payment amount on a fixed payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DevelopedTechnologyRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent" xlink:type="locator"/>
    <link:label xlink:label="aytu_ReturnReserveCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return reserve</link:label>
    <link:label xlink:label="aytu_ReturnReserveCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of return reserve classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReturnReserveCurrent" xlink:to="aytu_ReturnReserveCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember" xlink:label="us-gaap_PatentedTechnologyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PatentedTechnologyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patented Technology [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentedTechnologyMember" xlink:to="us-gaap_PatentedTechnologyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued customer and product related fees</link:label>
    <link:label xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued customer and product related fees classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed payment arrangements</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangements-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangements</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangements-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of fixed payment arrangements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangements" xlink:to="aytu_FixedPaymentArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flows information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_EquityWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Warrants [Member]</link:label>
    <link:label xlink:label="aytu_EquityWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Equity Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EquityWarrantsMember" xlink:to="aytu_EquityWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DistributionRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FixedPaymentArrangementsPaymentAmountPaid</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangements, Payment Amount, Paid</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount paid on fixed payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangement Assumed from Cerecor Inc. [Member]</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the fixed payment arrangement assumed from Cerecor Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:to="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementQuarterlyPayments" xlink:label="aytu_FixedPaymentArrangementQuarterlyPayments" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementQuarterlyPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FixedPaymentArrangementQuarterlyPayments</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementQuarterlyPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangement, Quarterly Payments</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementQuarterlyPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of quarterly payments on fixed payments arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementQuarterlyPayments" xlink:to="aytu_FixedPaymentArrangementQuarterlyPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCreditVendorFee" xlink:label="aytu_EmployeeRetentionCreditVendorFee" xlink:type="locator"/>
    <link:label xlink:label="aytu_EmployeeRetentionCreditVendorFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_EmployeeRetentionCreditVendorFee</link:label>
    <link:label xlink:label="aytu_EmployeeRetentionCreditVendorFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Retention Credit, Vendor Fee</link:label>
    <link:label xlink:label="aytu_EmployeeRetentionCreditVendorFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of vendor fee from employee retention credit during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EmployeeRetentionCreditVendorFee" xlink:to="aytu_EmployeeRetentionCreditVendorFee-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJanuary262023Member" xlink:label="aytu_OnOrBeforeJanuary262023Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_OnOrBeforeJanuary262023Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">On or Before January 26, 2023 [Member]</link:label>
    <link:label xlink:label="aytu_OnOrBeforeJanuary262023Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to on or before January 26, 2023.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OnOrBeforeJanuary262023Member" xlink:to="aytu_OnOrBeforeJanuary262023Member-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:type="locator"/>
    <link:label xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment</link:label>
    <link:label xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Termination, Fee, Percentage of Commitment</link:label>
    <link:label xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of commitment used as a termination fee of a line of credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eclipse Business Capital LLC Loan Agreement [Member]</link:label>
    <link:label xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Eclipse Business Capital LLC Loan Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:to="aytu_EclipseBusinessCapitalLlcLoanAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating assets and liabilities, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExtinguishmentOfDebtAmount</link:label>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After January 26, 2024 But Before January 26, 2025 [Member]</link:label>
    <link:label xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to after January 26, 2024 but before January 26, 2025.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="locator"/>
    <link:label xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After January 26, 2023 But Before January 26, 2024 [Member]</link:label>
    <link:label xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to after January 26, 2023 but before January 26, 2024.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:to="aytu_AfterJanuary262023ButBeforeJanuary262024Member-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Space in Berwyn, Pennsylvania [Member]</link:label>
    <link:label xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to an office space in Berwyn, Pennsylvania.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OtherWarrantsMember" xlink:label="aytu_OtherWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_OtherWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Warrants [Member]</link:label>
    <link:label xlink:label="aytu_OtherWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to other warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OtherWarrantsMember" xlink:to="aytu_OtherWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment</link:label>
    <link:label xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Undiscounted Minimum Monthly Payment</link:label>
    <link:label xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the undiscounted minimum monthly payment on an operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:to="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentFinalPayment" xlink:label="aytu_DebtInstrumentFinalPayment" xlink:type="locator"/>
    <link:label xlink:label="aytu_DebtInstrumentFinalPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final payment fee</link:label>
    <link:label xlink:label="aytu_DebtInstrumentFinalPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Payment</link:label>
    <link:label xlink:label="aytu_DebtInstrumentFinalPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the final payment of a debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentFinalPayment" xlink:to="aytu_DebtInstrumentFinalPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentPrepaymentFeePercentage" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_DebtInstrumentPrepaymentFeePercentage</link:label>
    <link:label xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of loan that is payable as a prepayment fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentPrepaymentFeePercentage" xlink:to="aytu_DebtInstrumentPrepaymentFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_AvenueCapitalWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avenue Capital Warrants [Member]</link:label>
    <link:label xlink:label="aytu_AvenueCapitalWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Avenue Capital Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AvenueCapitalWarrantsMember" xlink:to="aytu_AvenueCapitalWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_AvenueCapitalLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avenue Capital Loan [Member]</link:label>
    <link:label xlink:label="aytu_AvenueCapitalLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Avenue Capital Loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AvenueCapitalLoanMember" xlink:to="aytu_AvenueCapitalLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2020ShelfMember" xlink:label="aytu_The2020ShelfMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_The2020ShelfMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Shelf [Member]</link:label>
    <link:label xlink:label="aytu_The2020ShelfMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the 2020 Shelf.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_The2020ShelfMember" xlink:to="aytu_The2020ShelfMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2021ShelfMember" xlink:label="aytu_The2021ShelfMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_The2021ShelfMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Shelf [Member]</link:label>
    <link:label xlink:label="aytu_The2021ShelfMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the 2021 Shelf.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_The2021ShelfMember" xlink:to="aytu_The2021ShelfMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalIssuanceMember" xlink:label="aytu_AvenueCapitalIssuanceMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_AvenueCapitalIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avenue Capital Issuance [Member]</link:label>
    <link:label xlink:label="aytu_AvenueCapitalIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Avenue Capital Issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AvenueCapitalIssuanceMember" xlink:to="aytu_AvenueCapitalIssuanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:label="aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:type="locator"/>
    <link:label xlink:label="aytu_SaleOfStockMaximumAmountOfEquityIssuable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SaleOfStockMaximumAmountOfEquityIssuable</link:label>
    <link:label xlink:label="aytu_SaleOfStockMaximumAmountOfEquityIssuable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Amount of Equity Issuable</link:label>
    <link:label xlink:label="aytu_SaleOfStockMaximumAmountOfEquityIssuable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum monetary amount of equity issuable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:to="aytu_SaleOfStockMaximumAmountOfEquityIssuable-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_SecuritiesPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label xlink:label="aytu_SecuritiesPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Securities Purchase Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecuritiesPurchaseAgreementMember" xlink:to="aytu_SecuritiesPurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2022 Common and Prefunded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the August 2022 Common and Prefunded Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:to="aytu_August2022CommonAndPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TrancheACommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A Common Warrants [Member]</link:label>
    <link:label xlink:label="aytu_TrancheACommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Tranche A Common Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TrancheACommonWarrantsMember" xlink:to="aytu_TrancheACommonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Pre-Funded Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrefundedWarrantsMember" xlink:to="aytu_PrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:label="aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_EmployeeRetentionCreditPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Retention Credit [Policy Text Block]</link:label>
    <link:label xlink:label="aytu_EmployeeRetentionCreditPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the accounting policy for employee retention credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:to="aytu_EmployeeRetentionCreditPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheAugust2022OfferingMember" xlink:label="aytu_TheAugust2022OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TheAugust2022OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The August 2022 Offering [Member]</link:label>
    <link:label xlink:label="aytu_TheAugust2022OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the August 2022 Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TheAugust2022OfferingMember" xlink:to="aytu_TheAugust2022OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_August2022CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2022 Common Warrants [Member]</link:label>
    <link:label xlink:label="aytu_August2022CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the August 2022 Common Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_August2022CommonWarrantsMember" xlink:to="aytu_August2022CommonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_August2022PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2022 Prefunded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_August2022PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to August 2022 prefunded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_August2022PrefundedWarrantsMember" xlink:to="aytu_August2022PrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrants [Member]</link:label>
    <link:label xlink:label="aytu_CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Common Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonWarrantsMember" xlink:to="aytu_CommonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TrancheBCommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B Common Warrants [Member]</link:label>
    <link:label xlink:label="aytu_TrancheBCommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Tranche B Common Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TrancheBCommonWarrantsMember" xlink:to="aytu_TrancheBCommonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</link:label>
    <link:label xlink:label="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement Warrants [Member]</link:label>
    <link:label xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Securities Purchase Agreement Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrants Exchanged for PreFunded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Common Warrants exchanged for Pre-Funded Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock and Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:to="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2023EquityIncentivePlanMember" xlink:label="aytu_The2023EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_The2023EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2023 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="aytu_The2023EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the 2023 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_The2023EquityIncentivePlanMember" xlink:to="aytu_The2023EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseNonoperating</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Included in earnings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Tranche B Prefunded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the tranche B prefunded warrants classified as liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:to="aytu_LiabilityTrancheBPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityPrefundedWarrantsMember" xlink:label="aytu_LiabilityPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_LiabilityPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_LiabilityPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to pre-funded warrants classified as liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LiabilityPrefundedWarrantsMember" xlink:to="aytu_LiabilityPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Walleye Opportunities Master Fund Ltd. [Member]</link:label>
    <link:label xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Walleye Opportunities Master Fund Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sabby Volatility Warrant Master Fund Ltd. [Member]</link:label>
    <link:label xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Sabby Volatility Warrant master Fund Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_SabbyLitigationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sabby Litigation [Member]</link:label>
    <link:label xlink:label="aytu_SabbyLitigationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Sabby Litigation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SabbyLitigationMember" xlink:to="aytu_SabbyLitigationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseCost</link:label>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateEffectivePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCostTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationWarrantsMember" xlink:label="aytu_SabbyLitigationWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_SabbyLitigationWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sabby Litigation Warrants [Member]</link:label>
    <link:label xlink:label="aytu_SabbyLitigationWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to warrants calculated by the claimant in the Sabby Litigation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SabbyLitigationWarrantsMember" xlink:to="aytu_SabbyLitigationWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease assets (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrimeRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immaterial Error Correction of Prepaid Expenses from Current Asset to Noncurrent Asset [Member]</link:label>
    <link:label xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to immaterial correction of previously stated amounts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:to="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:label="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label xlink:label="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced</link:label>
    <link:label xlink:label="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's discounted obligation for lease payments from operating lease, including operating lease that has not yet commenced.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:to="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:type="locator"/>
    <link:label xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced</link:label>
    <link:label xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:to="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of $1,004 issuance cost (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableCreditTerms" xlink:label="aytu_AccountsReceivableCreditTerms" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableCreditTerms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_AccountsReceivableCreditTerms</link:label>
    <link:label xlink:label="aytu_AccountsReceivableCreditTerms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Terms (Day)</link:label>
    <link:label xlink:label="aytu_AccountsReceivableCreditTerms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents credits terms for accounts receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableCreditTerms" xlink:to="aytu_AccountsReceivableCreditTerms-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FurnitureAndEquipmentMember" xlink:label="aytu_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_FurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Equipment [Member]</link:label>
    <link:label xlink:label="aytu_FurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents furniture and equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FurnitureAndEquipmentMember" xlink:to="aytu_FurnitureAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GoingConcernPolicyTextBlock" xlink:label="aytu_GoingConcernPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_GoingConcernPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
    <link:label xlink:label="aytu_GoingConcernPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for going concern determination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GoingConcernPolicyTextBlock" xlink:to="aytu_GoingConcernPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of $1,004 issuance cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:label xlink:label="country_US-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative liability, measurement input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_AccountsReceivableAllowanceForPricingChargebacks</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Pricing Chargebacks</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, allowance for chargeback</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, allowance for chargeback</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the allowance for pricing chargebacks</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacks-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForDiscounts" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_AccountsReceivableAllowanceForDiscounts</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Discounts</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, allowance for discount</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, allowance for discount</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the allowance for discounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForDiscounts" xlink:to="aytu_AccountsReceivableAllowanceForDiscounts-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerBMember" xlink:label="aytu_CustomerBMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_CustomerBMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label xlink:label="aytu_CustomerBMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Customer B.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerBMember" xlink:to="aytu_CustomerBMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerAMember" xlink:label="aytu_CustomerAMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_CustomerAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label xlink:label="aytu_CustomerAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Customer A.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerAMember" xlink:to="aytu_CustomerAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NumberOfProducts" xlink:label="aytu_NumberOfProducts" xlink:type="locator"/>
    <link:label xlink:label="aytu_NumberOfProducts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_NumberOfProducts</link:label>
    <link:label xlink:label="aytu_NumberOfProducts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Products</link:label>
    <link:label xlink:label="aytu_NumberOfProducts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of products.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfProducts" xlink:to="aytu_NumberOfProducts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_CustomerCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label xlink:label="aytu_CustomerCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Customer C.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerCMember" xlink:to="aytu_CustomerCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscountsRecovery-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments, allowance for discount</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscountsRecovery-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents allowance for discount recovery payments received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsRecovery-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of net revenue, allowance for discount</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the allowance for discount credit loss expense (reversal).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments, allowance for chargeback</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in allowance for pricing chargebacks on accounts receivable, from recovery.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputDiscountRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of net revenue, allowance for chargeback</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expense (reversal of expense) for expected credit loss, allowance for chargeback, on accounts receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_PrincipalOfficeDenverColoradoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Office Denver Colorado [Member]</link:label>
    <link:label xlink:label="aytu_PrincipalOfficeDenverColoradoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the principal office in Denver, Colorado.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrincipalOfficeDenverColoradoMember" xlink:to="aytu_PrincipalOfficeDenverColoradoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Space And Manufacturing Facilities Grand Prairie Texas [Member]</link:label>
    <link:label xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the office space and manufacturing facilities in Grand Prairie, Texas.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncashIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNoncashIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNoncashIncomeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating leases, non-current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating leases, current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance leases, current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing leases</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentInLease" xlink:label="us-gaap_NetInvestmentInLease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetInvestmentInLease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment in Lease, before Allowance for Credit Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentInLease" xlink:to="us-gaap_NetInvestmentInLease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringCosts-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs</link:label>
    <link:label xlink:label="us-gaap_RestructuringCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestructuringCosts</link:label>
    <link:label xlink:label="us-gaap_RestructuringCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-cash investing and financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsMeasurementInput" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementsMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FixedPaymentArrangementsMeasurementInput</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangements, Measurement Input</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the measurement input used in valuing fixed payment arrangements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMeasurementInput" xlink:to="aytu_FixedPaymentArrangementsMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLossCarryforwardsNotSubjectToExpiration</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents operating loss carryforwards not subject to expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="aytu_OperatingLossCarryforwardsNotSubjectToExpiration-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="locator"/>
    <link:label xlink:label="aytu_IncomeTaxReconciliationContingentConsideration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration, amount</link:label>
    <link:label xlink:label="aytu_IncomeTaxReconciliationContingentConsideration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents income tax reconciliation for contingent considerations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxReconciliationContingentConsideration" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and accretion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents disallowed recognized built-in loss, carried forward as an operating loss.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation</link:label>
    <link:label xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-change net operating loss determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="locator"/>
    <link:label xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent</link:label>
    <link:label xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to contingent considerations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="aytu_DeferredTaxAssetsLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label xlink:label="aytu_DeferredTaxAssetsLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible lease liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsLeaseLiability" xlink:to="aytu_DeferredTaxAssetsLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="locator"/>
    <link:label xlink:label="aytu_DeferredTaxAssetsAccruedRebates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued rebates</link:label>
    <link:label xlink:label="aytu_DeferredTaxAssetsAccruedRebates-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible accrued rebates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsAccruedRebates" xlink:to="aytu_DeferredTaxAssetsAccruedRebates-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2022 Common and Prefunded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the March 2022 Offering common and prefunded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain from contingent consideration</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TheMarch2022OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The March 2022 Offering [Member]</link:label>
    <link:label xlink:label="aytu_TheMarch2022OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the March 2022 Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TheMarch2022OfferingMember" xlink:to="aytu_TheMarch2022OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_March2022CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2022 Common Warrants [Member]</link:label>
    <link:label xlink:label="aytu_March2022CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the March 2022 Offering common warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_March2022CommonWarrantsMember" xlink:to="aytu_March2022CommonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value $.0001; 200,000,000 shares authorized; 5,972,638 and 5,517,174 shares issued and outstanding, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_March2022PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2022 Prefunded Warrants [Member]</link:label>
    <link:label xlink:label="aytu_March2022PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the March 2022 Offering prefunded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_March2022PrefundedWarrantsMember" xlink:to="aytu_March2022PrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseDiscountRate</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioPreviouslyReportedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:label xlink:label="srt_WeightedAverageMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, authorizzed (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (note 18)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherLiabilities</link:label>
    <link:label xlink:label="us-gaap_OtherLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherSundryLiabilities</link:label>
    <link:label xlink:label="us-gaap_OtherSundryLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilities" xlink:to="us-gaap_OtherSundryLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TwoFormerBoardMembersMember" xlink:label="aytu_TwoFormerBoardMembersMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_TwoFormerBoardMembersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Former Board Members [Member]</link:label>
    <link:label xlink:label="aytu_TwoFormerBoardMembersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents two former board members.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TwoFormerBoardMembersMember" xlink:to="aytu_TwoFormerBoardMembersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfSalesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BoardMembersMember" xlink:label="aytu_BoardMembersMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_BoardMembersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board Members [Member]</link:label>
    <link:label xlink:label="aytu_BoardMembersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents board members.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BoardMembersMember" xlink:to="aytu_BoardMembersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:type="locator"/>
    <link:label xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded</link:label>
    <link:label xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Grants Rescinded</link:label>
    <link:label xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of grants rescinded under a share-based compensation arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:to="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ExercisePriceRangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label xlink:label="aytu_ExercisePriceRangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents exercise price range two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeTwoMember" xlink:to="aytu_ExercisePriceRangeTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ExercisePriceRangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label xlink:label="aytu_ExercisePriceRangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents exercise price range one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeOneMember" xlink:to="aytu_ExercisePriceRangeOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_NeosPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neos Plan [Member]</link:label>
    <link:label xlink:label="aytu_NeosPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Neos Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NeosPlanMember" xlink:to="aytu_NeosPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Next Four Percent and Five Percent Contribution By Employees [Member]</link:label>
    <link:label xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the next 4% and 5% contribution by employees in employee benefit plans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_FirstThreePercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Three Percent Contribution By Employees [Member]</link:label>
    <link:label xlink:label="aytu_FirstThreePercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the first 3% contribution by employees in an employee benefit plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FirstThreePercentContributionByEmployeesMember" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:type="locator"/>
    <link:label xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Payment Arrangements, Periodic Payment Obligations, Number</link:label>
    <link:label xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of fixed, periodic payment obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_NextFourPercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Next Four Percent Contribution By Employees [Member]</link:label>
    <link:label xlink:label="aytu_NextFourPercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the next 4% contribution by employees in an employee benefit plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NextFourPercentContributionByEmployeesMember" xlink:to="aytu_NextFourPercentContributionByEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_NextFivePercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Next Five Percent Contribution By Employees [Member]</link:label>
    <link:label xlink:label="aytu_NextFivePercentContributionByEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the next 5% contribution by employees in a employee benefit plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NextFivePercentContributionByEmployeesMember" xlink:to="aytu_NextFivePercentContributionByEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:label="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:type="locator"/>
    <link:label xlink:label="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum</link:label>
    <link:label xlink:label="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Up-front, Non-refundable License Fee Paid, Maximum</link:label>
    <link:label xlink:label="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a maximum, up-front, non-refundable license fee paid as part of a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:to="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_HealightMember" xlink:label="aytu_HealightMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_HealightMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Healight [Member]</link:label>
    <link:label xlink:label="aytu_HealightMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents licensing agreement related to used of Healight.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_HealightMember" xlink:to="aytu_HealightMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2014LicenseAgreementShireMember" xlink:label="aytu_The2014LicenseAgreementShireMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_The2014LicenseAgreementShireMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2014 License Agreement, Shire [Member]</link:label>
    <link:label xlink:label="aytu_The2014LicenseAgreementShireMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2014 License Agreement with Shire LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_The2014LicenseAgreementShireMember" xlink:to="aytu_The2014LicenseAgreementShireMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCredit</link:label>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:type="locator"/>
    <link:label xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_LicenseAgreementPatentProsecutionFeesPaid</link:label>
    <link:label xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Patent Prosecution Fees Paid</link:label>
    <link:label xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents patent prosecution fees paid as part of a license agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:to="aytu_LicenseAgreementPatentProsecutionFeesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementInitialLicenseFeePaid" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid" xlink:type="locator"/>
    <link:label xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_LicenseAgreementInitialLicenseFeePaid</link:label>
    <link:label xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Initial License Fee Paid</link:label>
    <link:label xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the initial license fee paid as part of a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementInitialLicenseFeePaid" xlink:to="aytu_LicenseAgreementInitialLicenseFeePaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: unamortized debt discount and issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AssetImpairmentAndWriteoffCharges" xlink:label="aytu_AssetImpairmentAndWriteoffCharges" xlink:type="locator"/>
    <link:label xlink:label="aytu_AssetImpairmentAndWriteoffCharges-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment and write-off expense</link:label>
    <link:label xlink:label="aytu_AssetImpairmentAndWriteoffCharges-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset impairment and write-off of assets recognized in the income statement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AssetImpairmentAndWriteoffCharges" xlink:to="aytu_AssetImpairmentAndWriteoffCharges-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsCurrentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsCurrentNet</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsCurrentNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in allowance for chargebacks and discounts for credit loss on accounts receivable, from recovery.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:to="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of net revenue</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of net revenue</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents credit loss expense (reversal) for the allowance for pricing chargebacks and discount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the total allowance for both pricing chargebacks and discounts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:label="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Contingent Consideration [Policy Text Block]</link:label>
    <link:label xlink:label="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for business combinations, contingent consideration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:to="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accounts receivable, gross</link:label>
    <link:label xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the increase (decrease) in accounts receivable before allowance for credit loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term loan principal amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total lease assets</link:label>
    <link:label xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents right-of-use asset for operating lease and finance lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:to="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermBorrowings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingAndMarketingExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers" xlink:type="locator"/>
    <link:label xlink:label="aytu_AccruedSavingOffers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued savings offers</link:label>
    <link:label xlink:label="aytu_AccruedSavingOffers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to accrued saving offers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedSavingOffers" xlink:to="aytu_AccruedSavingOffers-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_OperatingLeaseAndFinanceLeaseLiability</link:label>
    <link:label xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents operating and finance lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:to="aytu_OperatingLeaseAndFinanceLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total debt, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesBalance</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of net revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesDeductions</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicensingAgreementsTextBlock" xlink:label="aytu_LicensingAgreementsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="aytu_LicensingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Text Block]</link:label>
    <link:label xlink:label="aytu_LicensingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for licensing agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicensingAgreementsTextBlock" xlink:to="aytu_LicensingAgreementsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exercise price of warrants or rights exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options, weighted average remaining contractual life (Year)</link:label>
    <link:label xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for option awards granted during the periof, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveMember" xlink:label="aytu_ReturnReserveMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_ReturnReserveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Return [Member]</link:label>
    <link:label xlink:label="aytu_ReturnReserveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents return reserve.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReturnReserveMember" xlink:to="aytu_ReturnReserveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 174 capitalization</link:label>
    <link:label xlink:label="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementBusinessSegmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" xlink:type="locator"/>
    <link:label xlink:label="aytu_Neos2015PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neos 2015 Plan [Member]</link:label>
    <link:label xlink:label="aytu_Neos2015PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Neos 2015 plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Neos2015PlanMember" xlink:to="aytu_Neos2015PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exercise price of warrants or rights expired during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_ClassOfWarrantOrRightExpiredDuringPeriod</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrants expired (in shares)</link:label>
    <link:label xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of warrants or rights expired during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonUsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:type="locator"/>
    <link:label xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_LongTermDebtAndCapitalLeaseObligationsGross</link:label>
    <link:label xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future term loan principal payments</link:label>
    <link:label xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:to="aytu_LongTermDebtAndCapitalLeaseObligationsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationContingentConsiderationLiability</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total other liabilities, non-current</link:label>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of exercise prices (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of options outstanding (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AmortizationExpenseOfIntangibleAssets" xlink:label="aytu_AmortizationExpenseOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="aytu_AmortizationExpenseOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">aytu_AmortizationExpenseOfIntangibleAssets</link:label>
    <link:label xlink:label="aytu_AmortizationExpenseOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization Expense of Intangible Assets</link:label>
    <link:label xlink:label="aytu_AmortizationExpenseOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of amortization expense of intangible assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AmortizationExpenseOfIntangibleAssets" xlink:to="aytu_AmortizationExpenseOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>aytu-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:02PM UTC 2024-09-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedLiabilitiesTextBlock" xlink:label="aytu_AccruedLiabilitiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_AccruedLiabilitiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-document-and-entity-information" xlink:href="aytu-20240630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="aytu-20240630.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition" xlink:href="aytu-20240630.xsd#statement-note-1-nature-of-business-and-financial-condition" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FurnitureAndEquipmentMember" xlink:label="aytu_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="aytu_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="aytu_NeosPlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue" xlink:href="aytu-20240630.xsd#statement-note-3-revenue" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories" xlink:href="aytu-20240630.xsd#statement-note-4-inventories" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="aytu_InventoryWriteDownsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases" xlink:href="aytu-20240630.xsd#statement-note-6-leases" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LeasesDisclosureTextBlock" xlink:label="aytu_LeasesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_LeasesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember" xlink:label="us-gaap_PatentedTechnologyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentedTechnologyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_AdhdPortfolioMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="aytu_NeosTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisLicenseAgreementMember" xlink:label="aytu_TrisLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_TrisLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility" xlink:href="aytu-20240630.xsd#statement-note-10-revolving-credit-facility" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJanuary262023Member" xlink:label="aytu_OnOrBeforeJanuary262023Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_OnOrBeforeJanuary262023Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalIssuanceMember" xlink:label="aytu_AvenueCapitalIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJune122025Member" xlink:label="aytu_OnOrBeforeJune122025Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_PrimeRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_AvenueCapitalIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_OnOrBeforeJune122025Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity" xlink:href="aytu-20240630.xsd#statement-note-14-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AtthemarketOfferingMember" xlink:label="aytu_AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2020ShelfMember" xlink:label="aytu_The2020ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2021ShelfMember" xlink:label="aytu_The2021ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2024ShelfMember" xlink:label="aytu_The2024ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheAugust2022OfferingMember" xlink:label="aytu_TheAugust2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_The2020ShelfMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_AtthemarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_The2021ShelfMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_The2024ShelfMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_TheAugust2022OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BoardMembersMember" xlink:label="aytu_BoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2015PlanMember" xlink:label="aytu_The2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2023EquityIncentivePlanMember" xlink:label="aytu_The2023EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TwoFormerBoardMembersMember" xlink:label="aytu_TwoFormerBoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_The2023EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_The2015PlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_Neos2015PlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="aytu_TwoFormerBoardMembersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="aytu_BoardMembersMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_NonplanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants" xlink:href="aytu-20240630.xsd#statement-note-16-warrants" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityPrefundedWarrantsMember" xlink:label="aytu_LiabilityPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReverseStockSplitMember" xlink:label="aytu_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WarrantsOrRightsDisclosureTextBlock" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="aytu_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_LiabilityWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_LiabilityPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_EquityWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies" xlink:href="aytu-20240630.xsd#statement-note-18-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationWarrantsMember" xlink:label="aytu_SabbyLitigationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ThePediatricPortfolioMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="aytu_SabbyLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_SabbyLitigationWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-19-license-agreements" xlink:href="aytu-20240630.xsd#statement-note-19-license-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-19-license-agreements" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_HealightMember" xlink:label="aytu_HealightMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicensingAgreementsTextBlock" xlink:label="aytu_LicensingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2014LicenseAgreementShireMember" xlink:label="aytu_The2014LicenseAgreementShireMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_HealightMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_The2014LicenseAgreementShireMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="aytu_LicensingAgreementsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-21-subsequent-events" xlink:href="aytu-20240630.xsd#statement-note-21-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-21-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NotesToFinancialStatementsAbstract" xlink:label="aytu_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies" xlink:href="aytu-20240630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:label="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:label="aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GoingConcernPolicyTextBlock" xlink:label="aytu_GoingConcernPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-significant-accounting-policies-policies" xlink:label="aytu_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="aytu_GoingConcernPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="aytu_EmployeeRetentionCreditPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-tables" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-3-revenue-tables" xlink:label="aytu_statement-statement-note-3-revenue-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-3-revenue-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-tables" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-4-inventories-tables" xlink:label="aytu_statement-statement-note-4-inventories-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-4-inventories-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-5-property-and-equipment-tables" xlink:label="aytu_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-tables" xlink:href="aytu-20240630.xsd#statement-note-6-leases-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeLiabilityMaturityTableTextBlock" xlink:label="aytu_LesseeLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:label="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-tables" xlink:label="aytu_statement-statement-note-6-leases-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-6-leases-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="aytu_LesseeLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-7-intangible-assets-tables" xlink:label="aytu_statement-statement-note-7-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-7-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-8-accrued-liabilities-tables" xlink:label="aytu_statement-statement-note-8-accrued-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-8-accrued-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-9-other-liabilities-tables" xlink:label="aytu_statement-statement-note-9-other-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-9-other-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-11-longterm-debt-tables" xlink:label="aytu_statement-statement-note-11-longterm-debt-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-11-longterm-debt-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-tables" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-tables" xlink:label="aytu_statement-statement-note-13-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-13-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-tables" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-tables" xlink:href="aytu-20240630.xsd#statement-note-16-warrants-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-16-warrants-tables" xlink:label="aytu_statement-statement-note-16-warrants-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-16-warrants-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-17-restructuring-costs-tables" xlink:label="aytu_statement-statement-note-17-restructuring-costs-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-17-restructuring-costs-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-tables" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-20-segment-information-tables" xlink:label="aytu_statement-statement-note-20-segment-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-20-segment-information-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual" xlink:href="aytu-20240630.xsd#statement-note-1-nature-of-business-and-financial-condition-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RevenuebasedRoyaltyCosts" xlink:label="aytu_RevenuebasedRoyaltyCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_RevenuebasedRoyaltyCosts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableCreditTerms" xlink:label="aytu_AccountsReceivableCreditTerms-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCreditVendorFee" xlink:label="aytu_EmployeeRetentionCreditVendorFee-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FurnitureAndEquipmentMember" xlink:label="aytu_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:label="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="aytu_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="aytu_NeosPlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_NextFourPercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_NextFivePercentContributionByEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscounts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacks-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableCreditTerms-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCredit-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCreditVendorFee-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NumberOfProducts" xlink:label="aytu_NumberOfProducts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_NumberOfProducts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="aytu_InventoryWriteDownsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWriteDown-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-details-textual" xlink:href="aytu-20240630.xsd#statement-note-6-leases-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AmortizationExpenseOfIntangibleAssets" xlink:label="aytu_AmortizationExpenseOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:label="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementExtensionTerm" xlink:label="aytu_SupplyAndDistributionAgreementExtensionTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember" xlink:label="us-gaap_PatentedTechnologyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentedTechnologyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_AdhdPortfolioMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="aytu_NeosTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AmortizationExpenseOfIntangibleAssets-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementExtensionTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment" xlink:label="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentPeriod" xlink:label="aytu_SupplyAndDistributionCommitmentPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisLicenseAgreementMember" xlink:label="aytu_TrisLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_TrisLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCredit-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual" xlink:href="aytu-20240630.xsd#statement-note-10-revolving-credit-facility-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:label="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:label="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJanuary262023Member" xlink:label="aytu_OnOrBeforeJanuary262023Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="aytu_EclipseBusinessCapitalLlcLoanAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_OnOrBeforeJanuary262023Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJanuary262023ButBeforeJanuary262024Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:label="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:label="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:label="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalIssuanceMember" xlink:label="aytu_AvenueCapitalIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentAmortizationPeriod" xlink:label="aytu_DebtInstrumentAmortizationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentFinalPayment" xlink:label="aytu_DebtInstrumentFinalPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentPrepaymentFeeAmount" xlink:label="aytu_DebtInstrumentPrepaymentFeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentPrepaymentFeePercentage" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentTerminationFeePercentage" xlink:label="aytu_DebtInstrumentTerminationFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EclipseTermLoanMember" xlink:label="aytu_EclipseTermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OnOrBeforeJune122025Member" xlink:label="aytu_OnOrBeforeJune122025Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_PrimeRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_AvenueCapitalIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJanuary262024ButBeforeJanuary262025Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_EclipseTermLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_OnOrBeforeJune122025Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJune122025ButOnOrBeforeJune122026Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122027Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="aytu_AfterJune122026ButOnOrBeforeJune122028Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoanProcessingFee-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentPrepaymentFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentPrepaymentFeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentFinalPayment-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-n2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentAmortizationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentTerminationFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsMeasurementInput" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardExpirationsOwnershipChange" xlink:label="aytu_OperatingLossCarryforwardExpirationsOwnershipChange-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardSubjectToExpire" xlink:label="aytu_OperatingLossCarryforwardSubjectToExpire-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardsNotSubjectToExpiration-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardSubjectToExpire-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLossCarryforwardExpirationsOwnershipChange-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual" xlink:href="aytu-20240630.xsd#statement-note-14-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AtthemarketOfferingMember" xlink:label="aytu_AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SaleOfStockMaximumAmountOfEquityIssuable" xlink:label="aytu_SaleOfStockMaximumAmountOfEquityIssuable-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2020ShelfMember" xlink:label="aytu_The2020ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2021ShelfMember" xlink:label="aytu_The2021ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2024ShelfMember" xlink:label="aytu_The2024ShelfMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheAugust2022OfferingMember" xlink:label="aytu_TheAugust2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_The2020ShelfMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_AtthemarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_The2021ShelfMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_The2024ShelfMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_TheAugust2022OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SaleOfStockMaximumAmountOfEquityIssuable-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_BoardMembersMember" xlink:label="aytu_BoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:label="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded" xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2015PlanMember" xlink:label="aytu_The2015PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2023EquityIncentivePlanMember" xlink:label="aytu_The2023EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TwoFormerBoardMembersMember" xlink:label="aytu_TwoFormerBoardMembersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_The2023EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="aytu_RestrictedStockAndRestrictedStockUnitsRsusMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_The2015PlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_Neos2015PlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="aytu_TwoFormerBoardMembersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="aytu_BoardMembersMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="aytu_NonplanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual" xlink:href="aytu-20240630.xsd#statement-note-16-warrants-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022CommonWarrantsMember" xlink:label="aytu_August2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_August2022PrefundedWarrantsMember" xlink:label="aytu_August2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalWarrantsMember" xlink:label="aytu_AvenueCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:label="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CommonWarrantsMember" xlink:label="aytu_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityPrefundedWarrantsMember" xlink:label="aytu_LiabilityPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:label="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonAndPrefundedWarrantsMember" xlink:label="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022CommonWarrantsMember" xlink:label="aytu_March2022CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_March2022PrefundedWarrantsMember" xlink:label="aytu_March2022PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrefundedWarrantsMember" xlink:label="aytu_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReverseStockSplitMember" xlink:label="aytu_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementMember" xlink:label="aytu_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:label="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TheMarch2022OfferingMember" xlink:label="aytu_TheMarch2022OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheACommonWarrantsMember" xlink:label="aytu_TrancheACommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBCommonWarrantsMember" xlink:label="aytu_TrancheBCommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrancheBPrefundedWarrantsMember" xlink:label="aytu_TrancheBPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheACommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBCommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_CommonWarrantsExchangedForPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_SecuritiesPurchaseAgreementWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_TrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_August2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="aytu_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="aytu_TheMarch2022OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_March2022CommonAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_AvenueCapitalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_LiabilityWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_LiabilityPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_EquityWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_LiabilityTrancheBPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1" xlink:label="us-gaap_BusinessExitCosts1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessExitCosts1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual" xlink:href="aytu-20240630.xsd#statement-note-18-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementQuarterlyPayments" xlink:label="aytu_FixedPaymentArrangementQuarterlyPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:label="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment" xlink:label="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyLitigationWarrantsMember" xlink:label="aytu_SabbyLitigationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues" xlink:label="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations" xlink:label="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementMinimumSalesPerYear" xlink:label="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentPeriod" xlink:label="aytu_SupplyAndDistributionCommitmentPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_TrisKarbinalAgreementMember" xlink:label="aytu_TrisKarbinalAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="aytu_FixedPaymentArrangementAssumedFromCerecorIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ThePediatricPortfolioMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_TrisKarbinalAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_OfficeSpaceInBerwynPennsylvaniaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="aytu_SabbyLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_SabbyLitigationWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangementQuarterlyPayments-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumSalesPerYear-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual" xlink:href="aytu-20240630.xsd#statement-note-19-license-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_HealightMember" xlink:label="aytu_HealightMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementInitialLicenseFeePaid" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum" xlink:label="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_The2014LicenseAgreementShireMember" xlink:label="aytu_The2014LicenseAgreementShireMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_HealightMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="aytu_The2014LicenseAgreementShireMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LicenseAgreementInitialLicenseFeePaid-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LicenseAgreementPatentProsecutionFeesPaid-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual" xlink:href="aytu-20240630.xsd#statement-note-21-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoteToFinancialStatementDetailsTextual" xlink:label="aytu_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RevenuebasedRoyaltyCosts" xlink:label="aytu_RevenuebasedRoyaltyCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_RevenuebasedRoyaltyCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:label="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentInLease" xlink:label="us-gaap_NetInvestmentInLease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_NetInvestmentInLease" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableGross-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableGross-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery-n8" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-4" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForDiscounts-5" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-4" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacks-5" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-4" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-5" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscounts-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacks-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsRecovery" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForDiscounts-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacks-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced" xlink:label="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced-3" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced" xlink:label="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced-1" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:label="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" xlink:label="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveMember" xlink:label="aytu_ReturnReserveMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:label="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="aytu_ReturnReserveMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LongTermDebtAndCapitalLeaseObligationsGross" xlink:label="aytu_LongTermDebtAndCapitalLeaseObligationsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" xlink:label="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_LongTermDebtAndCapitalLeaseObligationsGross-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EquityWarrantsMember" xlink:label="aytu_EquityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LiabilityWarrantsMember" xlink:label="aytu_LiabilityWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="aytu_LiabilityWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="aytu_EquityWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets" xlink:href="aytu-20240630.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows" xlink:href="aytu-20240630.xsd#statement-unaudited-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_NoncashGainLossOnExtinguishmentOfDebt" xlink:label="aytu_NoncashGainLossOnExtinguishmentOfDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_PaymentsOfFixedPaymentArrangements" xlink:label="aytu_PaymentsOfFixedPaymentArrangements-n8" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="aytu_NoncashGainLossOnExtinguishmentOfDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="aytu_PaymentsOfFixedPaymentArrangements-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AvenueCapitalLoanMember" xlink:label="aytu_AvenueCapitalLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="aytu_AvenueCapitalLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AssetImpairmentCharges-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpenseNonoperating-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="aytu-20240630.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:href="aytu-20240630.xsd#statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerAMember" xlink:label="aytu_CustomerAMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerBMember" xlink:label="aytu_CustomerBMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:label="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="aytu_CustomerAMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="aytu_CustomerBMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="aytu_CustomerCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details" xlink:href="aytu-20240630.xsd#statement-note-4-inventories-schedule-of-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" xlink:label="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-4-inventories-schedule-of-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="aytu-20240630.xsd#statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="aytu_ManufacturingEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="aytu_LabEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AssetUnderConstructionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:href="aytu-20240630.xsd#statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:label="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:label="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccruedSavingOffers" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccruedProgramRelatedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ReturnReserveCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EmployeeRetentionCredit" xlink:label="aytu_EmployeeRetentionCredit" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:label="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_FixedPaymentArrangements" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EmployeeRetentionCredit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:href="aytu-20240630.xsd#statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DebtInstrumentFinalPayment" xlink:label="aytu_DebtInstrumentFinalPayment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:label="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DebtInstrumentFinalPayment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_June2023WarrantsTrancheAMember" xlink:label="aytu_June2023WarrantsTrancheAMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OtherWarrantsMember" xlink:label="aytu_OtherWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_June2023WarrantsTrancheAMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="aytu_OtherWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:label="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:label="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:href="aytu-20240630.xsd#statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthSegmentMember" xlink:label="aytu_ConsumerHealthSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExitAndDisposalActivitiesMember" xlink:label="aytu_ExitAndDisposalActivitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_GrandPrairieTexasManufacturingSiteMember" xlink:label="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_InventoryWriteDownsMember" xlink:label="aytu_InventoryWriteDownsMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:label="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="aytu_ExitAndDisposalActivitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="aytu_InventoryWriteDownsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="aytu_ConsumerHealthSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_GrandPrairieTexasManufacturingSiteMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCosts-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AdhdPortfolioMember" xlink:label="aytu_AdhdPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RxSegmentMember" xlink:label="aytu_RxSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ThePediatricPortfolioMember" xlink:label="aytu_ThePediatricPortfolioMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:label="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_RxSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="aytu_AdhdPortfolioMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="aytu_ThePediatricPortfolioMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductAndServiceOtherMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details" xlink:href="aytu-20240630.xsd#statement-note-3-revenue-revenue-by-geographic-location-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" xlink:label="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_NonUsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-balance-sheet-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" xlink:label="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_OperatingLeaseAndFinanceLeaseLiability-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:href="aytu-20240630.xsd#statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:label="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:label="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="aytu-20240630.xsd#statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DeferredTaxAssetsAccruedRebates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details" xlink:href="aytu-20240630.xsd#statement-note-20-segment-information-schedule-of-segment-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_AssetImpairmentAndWriteoffCharges" xlink:label="aytu_AssetImpairmentAndWriteoffCharges" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_RxSegmentMember" xlink:label="aytu_RxSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" xlink:label="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_RxSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="aytu_ConsumerHealthMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_AssetImpairmentAndWriteoffCharges" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details" xlink:href="aytu-20240630.xsd#statement-note-6-leases-lease-cost-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-6-leases-lease-cost-details" xlink:label="aytu_statement-statement-note-6-leases-lease-cost-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-6-leases-lease-cost-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OperatingExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:href="aytu-20240630.xsd#statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:label="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisedDuringPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExpiredDuringPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:href="aytu-20240630.xsd#statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeThreeMember" xlink:label="aytu_ExercisePriceRangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="aytu-20240630.xsd#aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:label="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="aytu_ExercisePriceRangeOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="aytu_ExercisePriceRangeTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="aytu_ExercisePriceRangeThreeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .0 KP# 2(  A$! Q$!_\0
M'P !  (" P$! 0$           @)!@<$!0H# @$+_\0 5!   @(" P ! 04#
M!@L%! ,1!08$!P(#  $("1$2$Q05%A<8(3%76)?5V H9(B-!4524F)G687&1
MN/ D)3=X,C8X0G>!P28H,SE2<J&Q)X<TMM'_Q  > 0$  00# 0$
M     0('" D#!08$"O_$ #<1 0 !! $"! ,&! 4%       ! @,$!1$&(0<2
M,5$30? (%")A<9$R@:'1%3-"L>$)%A=2P?_:  P# 0 "$0,1 #\ ]_'''' <
M<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!
MQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<
M<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''
M'' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <
M<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!
MQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<
M<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''
M'' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <
M<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!
MQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<
M<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''
M'' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!SY;=G>OKZ]
M===_PR_ERZQZ^O77UZZ^O?\ K[_A_P!G\O/KS@SMFG7IS[W98:]>&G=MV[-N
M?V-6K3KQ^NW9MS[_ (8Z]>'?>>>7??76../>7?\ )_!W^415/M,S$3^7,=_T
M]Y[*:YXIF?-33Q',37/%$3'>///^FC_WJ]::>:HF..6N;'NVIZ;$QC]OV.AU
M<!F2LX,0R^-H97&R9F&'6S./IF&9,*/GLUZ_\O;CUL[^[Z^GVN^OKU]=,]>_
M?#O?T[Z]?^9OIWUWWUW^V^N_X]=?R=_3L_U_+_\ \^GU^O*+_:UZ1_2%O&MV
MK&,6J]5PG**8*G1]$L:3A=;^\#C#)@R.MFJ1F?GZL_N-G?77?0F)!P^N/???
M*/+[\?0!T8@\5((T[H6G'=*-HFN-AOD1>M??6R1-6<N\>]VV/CAWWLVB-F6S
M9UACGW$SR[QQU97XTG@_AYVNQ<G;[38:[,R;5-VO'L6\6JW8IN1YK<5SD4S7
M3=BB8JNTU3---7,4]N)G"Z/MBZ"_UON>EL/68M&KQME5@:/J/.S?+B;B;%RG
M&R9KIMS;IQ*+F;%^S@7[DQ:OX]-G(JF8KF7N5_?[\/?Z/7_F?O\ _O=77_XF
M#OG\_?\ /#W\/KZ_\S?3OZ_7Z7?77?TZZ_U]?J#KZ=_]G?TY_FX8Q(&6/VNH
M43^'>77?7<75CEUECWWCECWUWA_#O'OK[/?UZ^O67^3E]._K]-IHM4ZV7[HB
M3@ZHH/O/O[O7C%TZI1'K#+K^&KO+5]=,?K^7/;U_G,\>\L=>/?U^UUTOB+T?
MX<>$_2^?U?UWUUFZ72X'PZ9KO8F%D9N?DW:HIM:_48%FJW?V&?<F?-18L>>J
M*?QU^6GNR3\+=AXG^,_66MZ%\/.B<7=[W/BY=OQ3EW[.#J<&U:BY?VN[V,TU
MXNFU>)1Q=R<K8U8\7;55-K C+S*[6-5_H^UMZ=\^7,3(A*?NVH[3-"869(@)
MK^Q5AM(0QV&6O7W,E10<^;OT1\=V[1JSW9Z_NL,]VO'+/[66/7>]=>?6S##/
MKZ?3/'K+^'?UZ_CU_K^G7U_\.O\ NZYX*_+E@%_+UNH5N5]"UP]J9/ZQ(AX.
M.,30P*<_KJ(QKTO#5CCENP)#LMO>&W9GWMQG:XDG#+#;IQSZ]S]>6 L68C*=
M@)TWHFKN(. >"3=?V.^MD*=HQW8:]O6.>76N3'R[SC2M/U[RTR=.[5E].\.^
M8?>%OC3TYXL974EG38F9JZM-L*XPL+8W<>YG9FDO?#^Y;"_38XBUETU5?!V&
M+;HFSAY%=%JC(RJ9B[&7OC?]GSJ/P.IZ5JVVXP>I,??:JFK-VNJPLO!UF'U!
MCU7/O^KQ;>=-69=PYMQ3D:S.S(P\G8XT7+E6LPJK5=$YQQS\XY=9==]]?7^'
M??7\?]?7/UR\:P1QS^=]_3KZ]_\ 9_\ Q[^G^GZ=?3K_ $_]G/*/\R?^$:LO
MQZ>J8/EGS?4%6W<SJ:4/8[P-6$SLPD<DLK1EJGJ22*Z5^L\=QKI9ZZ86#&7L
MZ[AZ#(71CAKW_B>NWIZIB)J[1$S/'/$1S/#U<\<\\_P;_-ON^5K5=2';5?I%
M->A*DE"6> F([";+@G.HCF,<?I;!>;%JQ(?CEUHUR0S+JU[-L;3T47)$?KZ3
M-O77H8Y$3$^A,3'J<<<<E!QQS^=]]==]=?Z^!_>.>9BV_P#"8:(J7W@Q>#B7
MEN]#;>N>EU?S1OL(:R5[J49!]G9EU:B,>,.66TG, VC>PZ9F>CN)G-RU:>]?
M7>.S;ECJ],W7_;_V_P"CZ?Z?_7_?_+].OY.#Z_?T?WCCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@?C+9AC_#++KKO_3_ -GU^O?7U_[_ *=_3_7RM/Y)
MO17=8UGIJU6*=1GJU(DN%+VQ]G>,L(C8_P"8-S^LL<\,M&\OWGV&@Y]=][,L
M<YVW7CUW&ZRZGT]N % 5F-U:B6D2LJ0>8P')V[+'''2/'1]DC?UUUEWUWGLV
M]:\=>C7C]=F[?GAJU8Y[,NL>_(%>/H$U?EKM]J'<\M';!/RU@16SZ9X@52#]
M=  3KRZ^SCUEA$Q[E3/L]?YV?*D[LO\ Z?76-R/#3IF-WN/\0S+5->MTUVU>
MNTW(GX>5F53%S$QJ?7S113'Q\B/3RVYIYB*N)Q4^U?XLU] ]"W.F]-EUV.J^
MM;-_7X=RQ_G:G4?Y>QVE?XOP57[?Q,/!N<3$9%Z*IIJFU5Q\L,M.O''##+''
M##''7AAUE_DX88]=]8XXX]=_9_A]/IWWCCC]?X?7^3GZ^^U]=]=X[<>LNOI]
M._M]X_R?Q_DQ[QZS[^G7\G?U[[Z_EYJW\_Z_T;,?Y/K_ )./7U^G\?\ 7WW_
M  _A_P"OI_';] 5HS>B+?4*C6N]NG8P2]DD\8UX==XKJD-QPD'S6[OO'O7CG
MA$^U#@=99X_B"<V''QQ[^UWUWDKDYEK$QK^9F78HL8UF[D95^8XFFU:IFY<K
M\L1$<TT1,4TTQ\HB(]]3.KZ?SMYGX&FU>)7F9VWS<;68&#1,3.5F9UVWC6<>
M*KOFCS7[UV/-5<F:>:ZIG\$<1H&R/CQ;["3&GUJB*FWNMD\E]V_A8&C+')@W
M:>_J4;%V#JU9=;Q@#;EKZ<.M'>K#'++;(UX99:)_V-(!076>K1EKQP^YZUZ^
MM'>K'KK7]SUCUUAUAUK^F/>'TZ[ZQZZZ[Q_E^G^GKGO/3:\4D1$$UPN!X$-,
M @\ER((W:->^-*'91ON)71'5MP[US=I+O+=M)9[\,OQF[?OV;^LLMNSO+RW>
MV?(^'F:[9T1;@9X5986<MGK_ &]:\]NL3EGMZ[.)O>S^/7VP$C+K8.QSRQ[S
M#3(7?7URT;.N],7V^*NK^J;^I\0:-EE7^D=)Y-/3H;U5-S'Z=^\S%FWL\6U,
M3Y<GJ"NFW@9>55-R[:N7+=FW7;LU^6/UN?\ 2]S.G/";HF_X-[2C&O=>9N/=
MW=_K:KX]S8=77+=-K*R>GJLVN[-Z]K^EZHN9G3^!D55VYPZ,N_E1D9.-7=O0
M4$@<?X?7'O\ A]GO^3/KZ?3+#+KOZ]?_ +.77?TZZ^G?\OUZ^G??+WOB=OW(
M#O)>:6R=L_+I^PDTU9ND[OX196S3U(9%+3EEGEW]UNZRR.BH_?V>L-W9+5J^
MWWGCAC4.."XZNNLN]??77UZQ[^N6?UZZ[^SWU_#Z_3OKKOK^/TZ_EZ^O7T_C
MS.@)DNJ&PC.KS-@I@7"L(X$GZ.^\-L,G!D82(^[Z_P .\\,L\>]>_#O+O';&
MV[M&7UPR[ZZUY^''B=G>&W76FZLPZKDV<7(IL;O$HJJJIV6FS*K=C88=5N*Z
M8G)N6IBK"KF8BUE6[=<^:FGB=@WC'T3@>*_1&XZ0SHM3?OV:<S19ER*>=9NL
M.FJ[K\V+LT55?=K=SS49M,1-5W$NWJ*9IF?/'L<T=X]X?7'O+OK[7?\ '+^7
MZ_Z?]7_\NOX\^W-$><[K#7U4BK8XS[N-**:>X3$*[V8Y;0S1 ^D<T,SZZ_DP
MPDX928F67\=T+='V]?7[WKOF]OKU_KZ_CU]>OX_R]?Z_^[F[O4;7 WFKUVYU
M611E:W:86/G8&1;_ (+V+D6J+MFJ/S\E5,51ZTU1,3Q,3#1WLM9GZ38YVGVF
M-7B;+5Y>1@9^+<CBNQE8MVJU>HF/:*Z9FF8F8FF:9IFJF8F86_(-[00? ?D*
MYO5#WEHEZ*Y6MW2BN9[.\)#O9!O+H.@),/7CMTR-V; S2Q^B=E%S[W0 V!$M
MWCWH@;<L?\^WX(O$C1\LOR-V/Z-]50-EEU77!P[>WI&6?U[I@*SKEM'LIVBU
MG(^UAGAO&Q,]DIFF#?M]=1EM0%A\?N-<^/WR0/\ A17R E_4GK=7\&4O(G-M
M?^834..T!5W'*?E8OJQLU8"(BW%CQ>L\R4JNQAB,J1(.>&7>EQ/L6K'+O.)J
MV8>PKX;OCY@_'-X4JVE2$6'E;C1CMM7T"<T8X9;RUM.<2-(+#.I7>/V]HQ)'
M:A:2'P^WG'[B .YFG7KSG[^\^Q_+MW[?7/H^;GR6_/3WJJBJGCO/$1QZ1'K,
M_P _E^CP!V$%MC_!\?F7Z* -9F>FTX\]MJG]_EL[[N;QK:DG?J*+VS=UCU'F
MFA*_E/ ;LL.M_P"7OJ7&F8X8=XZ_K_HB>M[TO]P^/IL]-?&L:K1[LZ55@:\:
M8CNZR1=%&S4_3 BM116TCPC,L3([(PJF4R*OY8%.]T5FUQ1<R%EEMWY1JE/\
M*"^.21ZL\?0_4U7K>\K>OCB.5:9483"ZDEW6@B&/6ZSUC[O3JRWR]BAJT:;%
M$:^^_I$TAF'7&Z[D%>_K"[_!,?D7_5"*Y_&U9IS/8<K&.5M;S-*(R=G>PK5Y
MB?\ BWVN(64C;U]YN060EVRB86C7EGVNL\[+_(BA.L,*::?+S$<\?7M$<>W\
MH3,>:WY_2J)B)C\I]_GSSZ1[<MD?!3_A#UV>[?4)_P N>T8%-K+,_)^UB\]&
MZS6&%*BE&=2PE2G>N6.*RMS7]^>E ^LCX#9ID0<^^P1H5E&WRLXGVO8'K^U]
MC'[7_P!+Z?Q_C]>__P /?TZ_RO\ ]K^'77U^OT_AS_,H^?'Q$\?%Q\D:IZN\
MU_B4:O+N?=?HRB6$-%V1QM8>B5,Q'/V"@XYQ=6F)H'SRGW+D($=?6/M6V4P$
MUZMND3(QZ]^GQU>W$GY!O'=-^I4;J+#V.Z_C!?E75NPW2D*TE[+$7825/PZW
MY[-.T,>TR<QW6_OJ1/!2A)3K#[HAJ[[BFJ9[3'$^O;T^7[_V454Q$1,3VGW;
M]]#WQ7GF&D;6]!VT9U :YIU(./;5/SSUXYY#@L'9OUCX?6W+#'>6,S?PX<-"
MZSZSG%IL&'KZ[V[\>N_\^\7_ (4W\PED'6+;4U&T&QB])"66B+*QYON^SF%2
M6"I.3^F833-2[,WX_C=<#K1"WD]HX;&(3M$G;%U=8=XX83+_ ,+7^1G$B11O
MC5K,SGNAB_T]<WJ#H5WOW[9,O+/"73U32-6C5]J3OE;<]=@%QF.S?JD?:2NM
MFKK=W]CEZO\ @^OQP9_'YX679;^&Z'>C_2.X9<EXY[M?6)%>Z(0N^Z]J[9GW
MWWWJT5^J2M.@C$^QK[P:R[3EEUEALU=]5_7URGB(CF?6?2)[Q,?G_O\ L_S>
M;.]&7E8'M5C];NJF+$>DB_HU9NHHC8(34($1[<7#ZZ:#+O=<%)LAQU:I)0&,
MC9K<LAB8E8RMFON1UMW89<]!&W_"3OGAQV;/_P U-"PZQSS_ ,WAX9]69?8^
MG??^;^UF]_Y7V>_\GOOO+Z]_3Z_:_P!/=>_L:1NZ_P (BM#/[W/[>KY6:@[U
MY_;SZRP^Q:57:<,<.\<L?L]88:\.NN\?X_3KOKOOOKOZ<_U7.OKWWW_E=]?3
M+OKKK_)_CUU_W]?7_O\ IWQ]?7U^CEN<444=HJ\]/K5ZTS,4SVXX[]XX^7/;
MN\\/QK_)-[<](_%/[0]?>FZ]4ZZ] 4/)]*[*\7_V16%62U-$U51B_8283,J+
MTP23Y2'+9B!.&3WPS$/3)C0\X6O;&DZ<]F,%/@&^<SW-\EWKQOH[TD,\_04@
M'YI-VS!V5=7[8JL>32/=$%>CX2)YRPVJ'M%_A&:?WLT:Q^C9ENPC[>MF&/TQ
MYZ3OD"^O[AWMSK[67?\ ^:#Z2_A_#^7]C;K_ !Z^G77?7?\ H_A_+_#_ $]=
M<\%W^"#?_K'[&[_T?N--/\?]'_Q3IS_3_)RBNJ:>.(YY_O']W%%$3157SWB8
MCC]>/7MS\^W?W[/]([KOZ]==]]?3Z]==_3_5_P!G_P"#F%66?(JE<6 TA^HO
M9=:26L^+ZG:L]\+LB'!3R,'J9IU;=&S=%_$QM7XC5KW:<]FK[>&&W7EWUGUF
MW-7W?_\ !>WO_O7O_P#_ *H6Y5$\Q$^\<J8CF8CWGAX_O@R^?7WS\B/NM+\Z
M>AQOG6)71VF+/?YNVM*X;E=H[-*&I=R%8ZB9JQV>%C"[VE]_4O5T)PSWX8:_
MN]FKOOOOGM0Z[Z[_ )._K].?Y@O^"E__ *V6LO\ Y7KY_P#XZT7OK_\ AS_3
MYQ_^Z_\ WN__ ,7)CO'/Y1/^W]RY^"Y%$>DQ5/,^O;]GZXXXX0<<<<!QQQP'
M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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MI>G*,*^30?G J^&1HIR0JXN2,UU["IHRI,LXWV!<+"C3V.*[@R@<87UYMZS
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MQO6K_9(D^[ITMZD.4CMBD+;%,C6 'T3X$+J=L5]<?_(W[]6G@6S==_7KKO\
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MOF/<_//B-:OP?[5A**?X[OI$'3$-7N&Y+PHCUBI^W+,W4_:Q%6IGU%YQ:L+
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M=_S._DS_ +W?'^*/\:_[;[._YG?R9_WN^68<<"L__%'^-?\ ;?9W_,[^3/\
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M0DE($S@\LA*,?[&4"'MB1X=[K:X!3MIHMVOF%9K I1 50,Z^A-5**3$#23Y
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MQP-3_L%HS^9>I_ZND_\ L?C]@M&?S+U/_5TG_P!C\VQQP-3_ +!:,_F7J?\
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M... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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M  "^D]OM&H;O\YU5!G*PY$)TGY9(#4*L*Z?K%_1\IU7=EP5,9O;=8<4>=/C
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M@0IG<G.&*SBLT7+7*UP=NJ#OE+XW_3_FR)Y3ZM'SG17JQ?4?#RQY-::N;;+
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MZ*UL5J)@^R$@,!6W,G/(5R8/F58#8131%7-F2JB,A]=.#5AQ;/R-<9MHN9L
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M+T\SQYQ5<%A;EK^E=#+:].%S-.9#09'L>,K/9%RC]Z>!VGH3QEA?LSVM]\9
M)L_U3X4%^,U^RA8/7-L5 BR/WGNF OC-^['2]X.+,O%:8! 2(P:-<PTN2]LK
MJ!MUP9F<$X'Q@-1ZI,(=F4#41*]!JCY831+\K_(O[6BD1TCR[(LEAKBQ*ZL
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MXX#CCC@.... XXXX#CCC@.... XXXX#E='MCQ,S^D+;\L7Y7CBLK]@^9-MT
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M_GH1,,F[)[4E 4M"/C\-&UO,,-O'' H[O_X@SUV5NG5_$NT"I8JGQ>65\?\
MC-B(,K=IDN#K8OE^Q(-H]1(S'!ZU@M<SSO('FEW#9@5EXM/YAH-82(>S3OF/
M9'F?T38J/Z,*"KU5Z9]%WGY;KVB@=K58GF.HE8MJ$V^A&/0W+FL\PR6+N'+A
M70.&1MFHS".A"(4@S!)T E(%ZQL_>.!2*F?&-?2(6,VRLW)48VZ1?R!"?:M<
MC#:Q<%BUMI Z_#<#P.P5J_'7>V9MNLYPO5DYL<8C[^L<?RZQ=P67FN35C3(6
M<.=</QJ>BK=</0;W-ORG!#+Z02_!;*U;(E2.V\$J>AOCZMJ9>%7S%D#,M21)
MF4P[/F 2(_+Y0_@ZY*L,K"!,PTL4B%Q%UG' K(K;PF_Q[G/^E+DL*M&&XGST
M+5%O.4*O*\9%M"@IE(>?+%H^NT8$/:7QOGSV2.2L,R_$[&(=P">^1-CK&L7^
M4*JSNC]M5OC&Q*[]TV!ZA"-M>5K6-C"+(RLJJ*AA6*)C7Z^L$ZN8E;6I<BRS
M.1RJX5DUZGIYL(4L"N4I9?+!E'(G32T2%H7I6.60\<"E-J^+^X96-T:5"[ZV
MA_F/R*+WR94#-:*Z:RV2_<T DO3"M<VX.%OH?6SU?L@"RH@;)32"DSZ=Y*"=
MWRN\A.X.5D=YPHGTI1E[NID_(JIQ">H'ZV/1GJ2Q%Q5,)XL,]"T.@*/\[U+4
M"K+M-@(Z<H-<UT1*V6^,*[)CMT\#B2^@8^R;(\>Q[C@5>6-X*L%L])^H[6"V
M:C::V]9(OE%?>5%F231=F6S/E-K<#H;%<(Q6B$O3E]WAM^[0?TF0NV5#VP_N
MH^,K1+[SCZ_O#XSWFQ;,LZY5*UTX>YF/?E6^W*Z!,ZX_QUF'J3_ RCX+:D!O
M.5Q8Z(^X32BM&;W]4:5%B$:P;7VIQCH)I7]!\*4N#XX%=C#X)!MWA*?Y"CR%
M"E#4IAA6J%:*8#'Y*NE7VMW]"]/IMEP E@,1X^V]P[P" GAP'-;'NR>96)V'
M-DC8)GK1#TRQ>1/D L*UO/?IFQ+]\@R;Z\S%+"#U\NIWGJX0%-%Z[NI"#J]N
M8M&DUZ&:GWMZFFUY>*HQ,6?C+JP&#R@ID"US3^TX*MYXX%.VGXLS4/RI;WGO
M5;ZUO:;>\8>T/.QFP(M<20(N%:WM:R+"M^P[+!J6MM,;UY'AO]B$98VM8#'N
MU0A X2+A&-&@?#QCX"Z_'UZ$KR^PEV4W9",<9G5V^/\ 7]NIOJHFS*J0 \=4
M7ZI4W5A:XT=T&3\H5H96K!!+A@-*BE:]8)PHK]E@ST]:^[Q^.!0#:_Q-^J[(
M\WN%-2O6:C,+W:K?(=G? ?()<RA3A2V?=5A8GP-C*:4FV_%*21/GZMR#96"E
M6SN:8$9GG-!.TF,3F[RINV5+A[^/ XVBZI'0[/""]E=>Z_)WL&?*Z3Y7?ZA%
M>;*'J6F)Z3]UJ.X9PRC9E661:&>D2"&@/!GQ1>V!/_!=;\[1N.!3_P#'9Y->
MJ>].>_K0=\7/77G=Y,%7>.03P+Q$9IU#,I/+TE;VQ*T12T_3-0G#T]<EAB54
MH4T]&=R?5B;!C9CE8>NK8.X#CC@.... XXXX#CCC@.... XXXX#CCC@....
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M19&JF%E3K.=91YS,LPQ#Z=+'WZ(FXF4#E9K'+/!8O3]Z3[/=RBG*7(@?2/\
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ME%2KU[.>EJTUJ-JU87O! .#B,P]%8*;78L>8S6EA@!@$Y Y!5-$J/VVM9?3
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M:]@)SV0/4YY!+^4:4V>X?ALL#71T;T'6K6:(B?*SXRG/9/H0M/7;'.!" MM
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M6I)%T@1J\-96B^#5H5@)0=79UM_2$!:G:9K=I8(,[,EEKC]FY0G6J=E\LE;
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MM+(#T"#IWDHVZ:ZS(AK=&5HFJ2%,1]DD[L@:<-XDEJRSZS@RL=6M/.7K6O\
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MQAE35:MWQ M@F?LK57#1HK^P51DE5U(VI-HN.!5LA!)Y20/TYY52PA=42=C
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M3(RK)DY@DG!TR$'QWQ]PXOLG2AA+"+&@\G22]%^?0VUQT%[TIT5OKLJ*!/\
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MFG3IF0^I!NWL;R_7%H0Z6>+M1ENT9IFO5[I-($=F).$<MLIV#JP69V:H^V$
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MJTQ"$Z80V[(\I"GM>N)Y!?C),HOOW@[2VIMVJ#97%F+%HU^OY>>;5O@82QK
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M^C4MDWTP/4/.EV>9* F$#U!^EZ>*OK/=ZC2+B;9P\IN/-FI?V==6_K5DZMR
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MZ6233R75H_HNE:VJ"1.&"(4_<HY5DV66XAV./HER=6!KJ<5L3K43#[LQ_6<
M/]Q&)QMY#N5"U9</@*9=?Z4:W2RTDQ:R;?J7Z&%%&&BQS544UI7J.9/.S$!/
MTZ??9>\LM-%8N3+HA]8V##/*K+M#L@L[ND"/PTV2=#^HZU] F[-4%;6< /\
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MU-!6C55%5S8:*82-&^>0G^?E=S5DX^MN$5FB8+L(C&<M\]@ RU=@WRIX^-W
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M%56>>G%C,<1)SQ#I%GP9.5C%_P"N!<NS:C^@S-%NS$N2*]B=GPUB477'G"J
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MK:O1(\LW,L9!7<VEV,:<39A= P RP([A=D9Q4[!^](& @@=KG%"L.'M@:O\
MN-Y]'>O_ !K7_GN4Q*OGZU?./H#T/8Y9IJ</DTS3M*7)4%.G:6:([2] V>JC
MZ*S-KBI61&CI)L\(?=($;%VR!F@U(C!,2G?, NJ3B4S1.JM DED7><(R%I6F
M!-*H3,0NEPK)DVL&U2'LK1LBG08^K@@286FFS))HRW;2A&9&V:M47FN?//B3
M52KUZ!<23DH[A7H!:5PAZMJ<JO.C*RC, O)S[<+6FI\=^?!I&W[-P:H6ET<Q
M."QJ):UH9LWA]\S9NE\F8Z,^"6I,39L!,K/BO")I;].IHC8>:CF4/3EMP%+X
M?7MT?CRL[/'&/#T;)$:/WNV8Y2I46-CMD:X;1_D,IF4):MT)1MXLWIOH!,\R
MG*Q6%$0[NNFV; KA;MI5&Z9*.T,B-O 2T%L#L!5MP=/TXJ1,IV3<1!="R/<8
M([P/BME3Z8@478/H>0Z)M9^);O\ #'G+;&I]973-55]<R8'K/)]:"F+$6EV+
M9:Q6*HH)&B:/VU\J&X, X3)*>)MBR(#;3D17P1T=-2M<W83UJ"HO*^LENTX1
MMI#!?$0Q.,W;'UY[->C9+QB=;\].&S/#5EL[PQSRQQZR[JKOOY6$6)Y0ORR_
M/:?;3)<Z!Y?]57-'1YU:1OSVH2OGIKM.DYQ"X%D\S (^N$-OJJW18[!+Q<\5
M9(2*VE \>2"@9%<K0ZM/DVNL:Y:36<;899410/EMD/3W&B;"9E?'D9^<6/WL
MV]Z(V4J3MRT:>]NSO5J[QP[V9_9^UV&=\<<<!QQQP'''' <<<<!QQQP''''
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M2-7+*;0=W2GQUL"]:XL=,EXUA'E^=3OG!L6%.T=UPFM-D2EOH?A(<5@DG;T
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MA.;$U"58YU=, RD;<2$1"\39#GQX^[3*5=#8+B^"7L"1DS@"#C ^!AB);C#
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M%RK*U+.JAT#I1\>+'F$^6UUPW+!QA5IW8%?*;%]EFEQ6#" !LNF)J/"H1'3
M8M\D]N9%5FJ5>@XIZ^?R3VD<<! 6!<[HAR<O(%V@*-BA$8FD54999TBWCSBK
M%AS$<!#5)$TYG%\R6-,@B1 QV[-]>>J2ZO?CK7WD/HQC4% UX^K]/&'_ /!7
M\X79859 K,ETP14M +)96=]>P36H0=G:VPV1:3_V@ZR*PW:>]^\.DG> G7OU
M)9-Q+]BK*NAVK;%26@Z;!VZZY%JLX:MZ;K^F#E0M><RX-E4M:6^K5=CH)<N>
M0)Q2,+-',^QTUQP!NP;?=6^ /+M-E/SA&3FW3,TI-!5J*P8[>MYW'K=>>7VX
M@]46DJ@ES>#PM66D%H*3R<(6!AP-!+.1LUF^B6K+O#O4Y[WKA&H"FK!2H"O8
M%CW5Z95/* \+MA/U; J_M1D<#8,P/M58>UZ':R,10!0 GL9E(RIQF7>>U0(,
M>-$#F(QS1#NXKGOOT7<_CBBGH:/JK!5^3RU_/?H,-5=TW6LKUN+B1X'N'U+6
MA1.L*O\ 56[//7MRW,6#C>E%I?<$)<JCH3C>TV'$$]VX++[)\+^9[9>IUANJ
M6Q23QBP*DMAA@@;3M=,4&RSZ)*JQ>IW]S0TUU I3BU)NY(3X<$LS@2N^2)5E
MT02_&C@8F/#VSIH2JM$F3*UK'?6Z9 N@9*[_ #@YUUNA>@VL.[6UH[ZQ)8_=
M]-+(!%D/MZ>]>P1W&^Y"9CM&W=KSK%LR^_3\RUOF%KWMA5I5:>?/(Z Y4L&!
M2""F\+;6\T?=[%LD:W*(*UYZI9IA4(&^81ES272[KB#MP;5IQSFZ=OV.?)+>
M*+<1GS58%#I&NZ-ERT)6BX2K9CM*U4F*(N'S?>7HX^:/@5NJ,+)GS483YQLA
M9T:%M<F06&4543LV6K#OSS1!#*D7XU2U/WKM9Z/=UFH:;UNGG1D'0%:7=^ZU
M=:5YZHRL:%'4H8E%+CEU<THS&FU2!$S2S,@E2N@.3-=[X!)NP".@BP.RO/\
M6%LNE66*WC#N+U2Y(X0KIJ5W5S1S034TXAM;6$D3$T^"V&EAKU+P/0RK)O\
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M @O%W_E &?VP R<6=T/AE2$AT+Y#;0M*VBP&NO,[>X5LO>A,_.S'.#B'C8R
MYL6I0SX5M8DW2%.-24:O!+BP"D66-V6)TV_@-^35@/[D:\U;H)66YXE\W7BY
MFGRQ4HW/.-JLO)+_ !E^R;.1EJT%11.;F)4!VLG(SBNJEFPULG+(=!NG@,=V
MPQ94NOX;.P!4@+D;D2JBK^O6^WGQ2!Y#&J]W,'8%I$\B9:=^I&M;K=(J0*3Z
MASYTJ")ZA(%<IX+J(%C#X>[H3U-D:-L^3*D[HF^5_8C'=M'V0[V2EPZTO"I0
M6HO:_G(F/=5AWJ Q+1=;A!4'/)V!B]AS1/V:26E=LU,A%:X=Q</:64"I/7%G
M:HT837R->E@DA>2\/+8MMNG'R$L^R6RM:PF6W9L.:#L%P8UU HU'<56JI4+N
MS"D=&<-1!Q>QJ<@:3F */!SG!Y94R'"6E=>!*14[/DW4R##379,>]+VO-:VR
M; M+) 7FB[H#.DDS<6I9SM,J_ILPJ)DF5Y/8<%'7OD09YN5&PBRB\K?L[T7X
M)\UBJK9:-P V$2IQC#"0$>M#]Y7<Q**0,7&?4XJ.%5##=@S^JEEHK%##D*^)
M5QL625?]+BQ%3)8.&N!X\.KV)ZBL:E/2GO:X'44UO;8<]N^/O%7GJO,GB\"Z
MG5X&[_+7F:SY6IDI\!+:E:'D"WN)9V92=;H!QY.NDQG":BT=<FQ9D2>5:^K/
M2]CM].HFSS<,0"C.X^@M%DG+-..:/'U5113/6@09:53)1Q(C.[-&MB-9P7M>
M!O$-!FK$W05R+[2<$=HWE0RQK^/^EC(E5 ",7.%#T>B5?T783*7MNYCMIN[B
MDUX71E(EE;\VPL[+@%E[#!,U"-VEIZ'P@"OT"U#_ ,',W:\\I@>!_*PZI=](
MZ:XG[Z]E"&05(B$;"LHJQ[93;;TB_P ZV=OA)OE/6NPY%V2MMI0[&U,>MX#N
MN,8V&/#Y4&%E'BB=^06[1)^I5'=2J;$8_1%L>J5RHL0A"VK5B"*L\KDC@4HZ
M6/!K:KB;/H:;")Z%G8#5ED 4"K TY*VG6Z24&X")D2?<'O/T?:/C3UP(KBJ2
M_FRP*<\D^<[<N/![>FE-MRO&?T$UL/6Y4K[-%%29.LDE*]=,LS,LP3UJ<;(&
MP0>:! Z,3.W4%R [S5"!,M/$@5IW/@M50UNSS+5V>V+*L"38#*T(6^NPVIR:
MWAQ.GBJ@HABIXH-1INZ:NR&Z4);,XL<T#URIF7N7GZL'JUJ\N\V+.QK0J\,=
M6%5J6W5S49&2FSL"@U,">QPE<\(&N"B78T%/,3UIKAF \B6"B][(G>K9*U2(
MB>I;[O2K?:_B:ODHRJ1Z7L9 ]:MMQ+9,7OEL3+KIQ4KQ@&9!".L?OR%RQ&@[
M-V"<-)$=&)$)NW0:ZE1-,3##KO,_MVW;A<O*G3Y3BBN5C[8\N&O3=,L",W-3
M6T(D83&K-JP1KE$DD<&$%[):#<"?LTN00[N%9OL$VH8"LM$M?,D@W^X^&/+S
M\-6A+76O9.(G4=+\ZJV6#:[#IJ_5DENK!^C#@I,4Q0B(ED!N]-5HVJS^.E17
MQ585,857F,;,UY;<LZ&>:ZO@!1 ,CV_.6@$1:B8HC8]L6?9#!$WNB3-KQAT8
M,CNVG3N4"6I$9P[0.S(90H,B9++0=$<O*DS]M=UB?)3;2O9[+6E94FK>C3Q!
M6]J2:M#5*2LZ'@<L#R1DJ8]5MO?WJMUBNG%N/2SY):; ]<&3?:0^+Q=*ZGG"
M@Z;GIE^FN&[VEY<.Z%.TOT.?:2)ZN7M@25AX4'&NYP)LZ$V&AR5"R(RG8U96
M=&6=,]:D9LHT8>3S92,W"X$V+H#]S0ENO@A:L!"+(.-^""+@@:"#P_O=V_\
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M,T^!"FGP\2'J'EY<2-)GQY&[3KSQH5#>V_4'HFJO3M&6H*0$:TJG\2^P+:]
M@8  B57P6B\0X)R^/</WF1VKAN/MV4LTM>BPL@O9K"<]54W!9Y(*3[C8X[5/
M^S_3%7>F6;RI:-[U7#7]'H/R\A%?3!&LPB+IK17N7RAZ(N0D+EB#+>21.ICS
M<E!+M75J29I><D=W<,8%MT.K/ !2)P7 D//E"EK EVR4I.I25ID(N$(A9,ZN
M5"6^D(6M>(*6N'/;]X?,_-BZU4J36M<>40VZ< )&:(PPZ'RMT?/M:ZIFH*@$
MEP-3U77-8@V"?@4/AZ_2EM.&'">L2/ 8$C$%>&CXQ.?B#$BPW4R=JWR>A8V#
M ^\_"Q-&K77Y5GJJY2OQU>FO0+$X5DSO5'#?9L6N[Y$ ]&%0W %\^E+&'(-U
M])B\U&<QZP3Z5=&EF!C&S?H+2P)PJLD=2^;!YX169_D,M),,O: !])4Y=*F%
MLOP GMWK,"E+(.O*('^I^K#VV5(/Y1'$HDS,!8-)1FI'E'B'Y0L0+T4H;<Q-
MT^'&B$@MRE^2/*<]9")4_P R^?9R:LF2;$MJ4RFJZE+*^?-#>@Q@V$!;US8+
M%%B@?K$01(P(NB7,%XX#Y&[9#PQT];!<JBJBQ5P2GV#6->O2D!D1I8-6<4M;
M9EP-*A#)@2')%!#0V:,';XH4B0$1]L.-IV:1<^:/UY8Q)6_3LI A_('?Z6[1
MR%A6W5UF>7ZU]*O])--S4CHJ_1:MJ:3+?Y]A5,:'5"QLI/-E249HLQ^\WW!-
MH_HK8IBQ50<T(R1NAR=XSG&L[Y'_ $!4)^SJS=SZEML;;Z81@XIQ2I]/,5%5
M?X\??1#C6HJU-[9)886:9:0$.)"UX[+?IPNCK^%K;ILY%VN0: 5%0 NW%T72
M8-*QK4)3]7!JZP09558(0A!51B9KK"=JDZ)M<ZUB$*T!-:)+T3)>F2I80<0.
M_7*D8;8&6.[9UEAJGYK0U'T98OIF%E)WO+[3]3T5$@]CP, *E5K4AVPF@4OK
M. @2/GYZ33%8Y<H8S.3B^W7^7A1XK,<*':8/57ASVKZ@JG.BG.\6>K\*.WV3
M:"98A6FG&DG>\&03/OVO:T\YMA&N^ST\,3#$=!5IK^[%F@9SG88&P\A$E0#3
M^LIBX,Q2R?D6OZG5[V&O-A5,/7;7[LHFJTDJ4VKF7S^J>7[*]G!_.D*W"S2.
M8X)]/>:<0&>0Q6TK^B2B.LZVJNFTL"+DD .WRUL+:=GE*AB=N,=XME85^]V6
M99$II!MCJ@I3$QH11  "PBSN1F0B WL0#,;O&Y'H6^,4_$#CD^=-&[8F6_+K
MF5Z//5!17D_9T6D*BC62UX$M;38$>MT[0[,N!D3% %L3[3J#8'#/YF"@PPI#
MLC.D]RQ$70-D=[(6K#1U4'9?M;U-4R%$M9U>JBDT C7+:V][;$%^\[GO2;+Y
MS UI7C&L-@M%W-<NF33,EV$WFUZR4A 89M@L*-^S8RA+VYP:^EDM^/E1)/4;
MU3\<UFU6;=8K72"-[6]. DH!+FA<K9@54HT1)<:H80)#J)A+S?:G9K"5A<8M
M%TS0;(6&SL.HDB)NQ["X4Q0=%L+:J/Q^F:J./*'I":$=Q,5\IDVA-TK.PAN7
M-2J>FB=Y1>P ;2Q3:%Z$2HGY7L(SLX/W&4K=WG\@?GRA%AF;'5:I"H5UR??S
MO]<MH*MDT0SN?ZFW]263MK/#PL<JQ=L$GKJ0;[+RYG9;?UUNG_B-G767/.2N
M^HH<KU_:7R0;+9/+M8W1\:7KAXI.5$675U@JOGRB?1OEVO:7>(%/,3(M+YAI
ML\\=L&U \OO],BY(2QUK0RG^@,&?OCY]8/KV][/T#1\Z_2M9"Z!^9CS7Y]-O
M:^3IKJ:4J=L\Q5K;+,!N8O7AUHJ79T$>[(/+Q>&.)X@\<10P(S#9QT?MS[#T
M6CD5)$,&;8)4%@8T;%4(BYL8\"+AG<DE:FE22ZH=EH\77/[6 1$Z:GAP/W_Y
M6-F%B4F'%T[ILC/9BNJBJ1TR"<O33E6:I1JSX-VF).NOE+#>5N89%@01MN$=
MV(CK9-LX?#%"XL%]DY;&J)''0=.@KKUQ-&.NHNG?<_IVSG9T/1251ZU!3M#W
M$A/5<&6>J]#$A(_G^/8P^B7Y56@KM*N1E<+$DH*8]MX)Q6%]9EUG<6IQ4LX(
M$4MRSVP7RVVNE:IK*^_0M@(I:U OA/TK<1^]UBAH\^>D$LC?E?/2 K&ONVZ/
MNWKF$A[D0(@MJ<\NBLJ&&(-C,-$ZS?>P+3RJ!6Y*3!W'$M)GR^G@>_C-A9=!
MRY&-D!Q74$4Z#\YD/9LQ=A80?U$@,4;OHY"%PN],>9KBZ.\<>@KZAZ.J4H<.
M57354UH;9]DK:RF*_KQ132K#MG%99V;L.$%T0.EELY9N?.,2<I^Z1WO*399#
M;WE+D;MN=4E!^E7Z_P"SMRQ8!@:?Q\[_ ";#:>5C&$JM)K#O#$?CAD6[/@.D
MNGV-FK?>S@'2T&A=D8+<_#J#I$Q1133V9@3]VW57KEKL"F_E=:O5J:793"UY
M:^/3S\=O&HHAHGB$<O--F>DO5,"\'(2NZ(\Z%,L:G(R"G6TNY_AXLMA#I# C
M]$XGZCC[=07E--5UB\K3:F.M<HK@GOTO5/>E1I4@# MN<[3K%:=,QJ!%A\L6
MP2M.H"$PU2"T67MUXAQ?6&?7X"+]U@9?RQYC85191&#SI11Y(2RALXG)YJI4
M(JKJAIE[(9,99; 3P$@4#)'NRQ3\YFC(D623Z(SNINS?U*W]9T82_>MMHE%%
MHU>7G4M8]>??CO\ $E^T.OV4%%LLOVL:LI-)DSX03*865;9)(QEGK2O3H J@
M[I$M>?;(@G&"<2W9#5C.8EN>F_4U?WNE&]+W7VBHV/Y"?/\ Y V4M(K37+-0
MDVT?-ZPZN10M:$=TRD2GL-9C1ND@9003&6= $#K$3Q9S:5VD((6694+1N5DZ
M[FRIJJN[?U8P<,+4_9\I]6-C@,"35H;A^MNA/3+W@.72,\# Q[)=XPPTV4,C
M]:X6_;IR[;NLZJBF:].9U_7^AAK8<46:I,[%9=P-H0HR)TCS0"OR><'H@L0"
MX(1'AE1B[OA:" H9JCS-&Z)#PPUT@5A\BUJ25&.>D>DJ4OL\P?'#ZD]AN0FM
MZ^$A0WGEMIDND0TO$]E@]$S^]<FS6-OKY@73D<NT%7BO"AH5T$7=!H<,X]K^
MZM-S^F#RQ7GJ'SHN4K47HOPCC5]X:L5RP5D7/]#T7ZLQ>1<D[":L5@HSMD8<
M!7Z[W&-^D6M'6 <0)02^GOJ)M"X[OS'Y@P,.D[OS]16L_:<4]W8<O&K$+67L
M6(9+A3#-L<=^(/&8V:BAX<NE#FXUE/ZF%X(6=.SV3(T';AE<&D*7%UQ)IP;4
M58CZCF]D\IE6P4-6B5W*R-&I#(8RDI6@5K6]V15BERCQ'+8-RRFFI.\I)[V3
MMNS?E3OJO$C>M/-U@O,NNKK@JOF7Y>TY>>8P=>FU1?"E2][4>L)CK "+[*=&
MR1)8<KP@S!E")P-!)G",99<CP%^<#VY2=\[^D6ZU/2EVHK/=M6U7IIWT>]46
MJ>3I0)6U/[K72M6(8^GO\"208A#W$EMNR07?@\P6O$%'>AA-XH<,E]19C9I"
M>\VH:G)26B81K*OYTMW:$MW<Y<Q.7I,EN<JWV+VZO6QFW[AV>T\R(NU15=B>
M;*9RB2UFM <@TF'V)@=Z-?RO/_E((]['>=2?GL19KUI=%_:W2ZXKB ].$>PM
MF$RQ F9[<&U'V#0\;OL2W09W+EZV7;WC(.:)N??V^ZSEIUN2'Z@]W)=/V(#2
MSC]\H_GVMI["WKLNPXJU7O?Q7>9;+;X"BN2#PH<+82V]5(Z@<R5W)!CSQ645
M* S'7<J+O@T*NFV+!OU#]4V1!3/0%O\ EKP#\U!I"08M3+\<2[V3XK]\*5'H
M34L0<_U<UI+I9D- 5-D_<DEL9D(GC-'+FS4/+RQVP/0T1\G>6C 106RWFVA2
MB]7W1_I"!D*A0)HE)Q:IN)%HQ41\E?V15O!D(8833V ;5"Q,2L,)!#J1MPQR
MZV_M457?I+Q]ZT W:#YF$Q'=&T0/V:3)\;B(P'FRNK./W@0+0<  +&(1EX[9
M<?$,+ZU;L.H$7[JC8+[9]($?UL K#TIY]O\ Z8_(E%6^MV>'2%\B!H2ZK)N)
M6JWI;=@:"_XXNB;8,%H.M":$[("6A5TU<?@,#$5_4 6;GGGJ6\O:52Z;)*)W
MHBN((:I;H^/7SYCH/T&..%W(YZFMNFZKM5]8=^AY P!N R'<\!G0%Y<C08PJ
M<L3H#%+9()##.(%GH'S%YL53C(SJ_GRD5MF<EHVEMS& JE%#'VA/92V9]B5&
M$R- QB1E:/'=FPT8!$9,@62+9Y$ID7=,[[W<VB84E9A)JQH^M@39A',2F%+*
MEA$ B24CTX"859II:G2X^Z2#*RUEA/+TD@,VQI>\(:*B]NW*$0E:-M$$KY![
MA7TRPE%]ND:.LZO?5?NZGEED6JSJY:A/B#YC0=%AB62QF.V[#"U;7,5-@,8.
M Z2!/4@X\=Z8<E97@,72TSQ^H:)]&V#>H[VW9ET6<'8Q]H_%=XG]%K7F-OB@
M9U4[V>Q_*-PV38.A#6"4W8PRUF*R"L9YS(&1RE28_</ Z5F;A ^9H"_AA\Y^
M>VX$05VNB::9EHL^S[4*KS!6"29!DK/*=[^R=CD!)$')@3'TCW*E?CW"1'V,
M,S\3(_$$=GWVS[62[:GJW<O2%';6R%FJ2D>96,E9R4%_]/R*W(1\XD^O]P;\
MO_+MB5,B[=D:4K91NP>_1LST[(.6O/+'NG@C[ANF/=#,##6942G.KSY&:S\?
MC?&!1< X6#8=!MWZ&7MUGKY.2Q!7$$?UK[4T^@%TQT)V($ZO:N)*<$84WR=C
M!GL6JO3/J#5ZP\PI=A6/73G6/J69\A&J.G@ZNV*DU!%>9;'7A=2R!#9DWEB1
MTO+4I4N*_9EX.8TL6G=S04$#H@:=<D)YK_DSS\#LYBN3?5%<'K/+.8MT!OAR
MNT:8XH4D)6:S5 <4D-72]K8 (H6IKF<(=KBD>M\..<-P-&_$=-RB]9$(\T><
M5]W-6:!\_P!)!+(9)#+*8K!$52B#7<_*=.NNG&2::X0'2>*R&SKKKIEW3I^_
M8=ZZZZ*92OIROKTWZ>]*TK7_ +FNX&V(Y=6J*Z:$HBJ4C:E#1$.N@=C2?+PV
MT+QLQ^86Z*..=UY$N=Y><-!/>B5ZOJZ?IW.1';"[)%!D4+R^03U35VE$5=UB
M5;IT6:^>JA=2/:P5\]N5AN2_6U"UJ]U9T_Z)EE@?.:3M'66_'!#_ -Z+ @2B
M"&'0#L?]+?J8^2A!=PC>;O.]8=E<JTH6F*[R/25::<R1:O2%'(S+1B6TRE2B
MV2^#'=D9"@7D2"BQMF=[LP)&1OFB\HLC=LV9?9L\Z^?GW8K;7JC*>=-J/.*D
MTK:V5HF,6U0(G2F@X<GJ^PN%F9@)9DU&C%BL@5E$VD24?1-F9;I.G7LQIL)_
M('=R';GF.LS-JJSL\,GH+Q7YROA;CKU1B*TQ9O0'GO\ :M8/58'X[UJM.S2T
M+2677I;<4Q4BUA$7B>@!LP/3P+?N@[R+>F/1RNJT0:=[AKP $]-^X;<IZ;9G
M5=C%Y.\WT?6P3TZS)T/=)96&>*-O5CSZ/2*SEN3N6T L6FP]GZ84<IV >!,"
MTHVCUI84B":8E)(=I8: Z*@PL8!@V*2)&L^&*W82[ (3(TS:/B']8K$"XBHV
M[3J)X#NA9G1NQB?<:^.7J2JS\\^5.UJ@F2;7-02+01**"_/G,A"JC>++6,X]
M+E#]N\Q,KMAPP.(\DALD;E4OA@1!YP9>..WKSQ^-K&:TORXQ.E1,M*M%R3SO
MR!1U'T=.K^&6$,<QU^9FZ4^"Q[A">U08<^MRFU@_6$=5 '],7/=G&R'&\8V.
MKKO;UI^\_15(LCY5;U<"N8[3/DF7/*75EKM:( %^*5NY?&7#]FAX8I5=WP15
M7;4*M8K#62[$</ 17[.81/=U$TL>&B1M"ZH90]'!+%*7 &IJJ1%M&]TF09M$
M97BC L0O(FC88:9O)NT4/J99^Z6('#Q4K;*)[<Y V##@[<LXL71JPR:(FH6K
M2.%PE=3PT*R[,2Q8Z,'$]:5Y4,QQ'X]6A0]<?[ P"5B!0?XL-JUZ8$V.+&??
M1]NN)&^[IU]%O_IN9\4OG>U'6^8B!>QJX?CS.6S9=-RD64L]#[#]G4"#=1D
MX G%4O!/%+K5OU,TT$QF%8P%#&!$UB9%(N1GD?Q;%L7I4%DV[>%7797!:LMO
MHKXMJT-!9==C6/=;(KT98="498#CF^"F:! #PY:):8AGK_8GB<AX\R'(2YFH
MV&*QH<0+7Y/GRAI@?]/3*4J:8 _0:C5OY)+KM1DB?V9U^1VET2O?R[>(SB?H
ME++;]Q145ON?R1>);<YPF#$E9=[>=/&\M^9829C7$+SK14.O,'*=8N"'$J1
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M46C/OQ;Y0]$4_85F(5<Z9HAM]'WC8-<#RK35M.6@7F@4<FFC$YQ&UV],8VT
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MKLTUG(E-"='/1-PN1O-];9T7CZ5OY(NN^ZT4;R.)5J53Z#\>)OE?S1W7-?R
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M7793NOBSK*6QF]I)HO9N/$,_HZ><V3I:ST7BQR?07;"ZGZ=4KK;AT&Q>...
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M(/57QSR9@O=_R>7+UYQHI$]4>?*U<W^H?D?M G?D:N//'H@VX*GE1SKD=1A
MJ,H2_++\\J;TU!G7K5:@E59V$.&S@F?RT$.)=P8\#-/"?LN]_2WRE>-;#=O3
MT9>K/U#\*U6WY#\VDE_0MJS5:$M[F!K$$(@C;9DT<1L 4W"&:RNV\2 +-0ZJ
M8^M$(PM(&!N.ZP]3'.MA&1!*21A#BHV?,#R,(I:)"G194D7*V8?>ZXQ'1HV[
M-L*1GK_SF&F3AJV98?Y>./>/\>>8JS?E%]4BO=1-"$7G3Z=% _*=3GQX+_@0
ME5X<];]E4/8RQ5;(Q^V?U%L:X%M:!"]"=6EA@RP:G&J/0KIDV$3,32$CL_"Y
MWQ6J=XU7X0^9&SZW,JEJ^FY_K[Y.=B.;2*6#JSJ_WC5+3:(U.F&<A1XX1>L6
M=TQ%24-.(;\L$@60Q3@\\G!VZY70>GGCGB!\P>G/.5(-'A&S:$KZO/6/J1_\
M3^HK/?;1Z]P>DF_V)$]34UX[=+:O1+]4^9I$3<-(#7>UE[*KU"&\3B$I9*[,
MIB2LAI(Q<URMP5A\M/R*/%'!VL/>% 3#%ZW?\6U:H+6R!/++\9IIK]IN#*FW
MRIF:F\S>GWYBCU[7V[0L&JNWWEHK>VYVGMH7&G7-,B)TD0'L>XYY&G[Y5/<-
M7)$.@F:X0ABPE+Y&/8/BBUO:<&M/-U9:X(VD?/BU?=.3QZG?MN5GY<6&!_[?
M0B\>_7MB NI41.<A2,(.,^\20SWK2GOWWK9MB.AJS+WHVL:U\D?&CYW]J>BE
M*H:93O1$VV'>Q$:]2+V&07A4O>6H[%0?LK'0S!M2(Y'-9PAN# 0[EK"RIY*:
M'ICG$APS"/L)3X0_"7-B#8F<Z5HB82B,_=C'@P(^6_9KZW39LC/#1$BZ^\M\
MG=ECJTZ\\\NL>^;SPQSOD%MCV.,0ZLN&UM%RC:?^3;X-;FKIZ+*7FA):>P/H
MST&\2S:6V ?+M[7]7$*6F8J@R'!'S6_0]#!._N*^BHYKK*>5M/\ E_HZU?2G
MLRMJ>I2I8-K6L3^.;UF2JTN4]'-?G2/Y^M'==7FU>0_1PLXH0R)HPQ5L:,X3
MQXP7&CD9NCJ8-UD(T:?)^T'I-YU,(^")8PLAQL1/Q)=3\AV4(E#E8S\16_J*
M3RA=Z-VSJ5T-D]]1Y_>CO9U#W]]:9'W>SOK'GE(O?Y'?:7EFY6FBB?INKNW/
MQ<4^+Z@0'GMJKD>R6U\HC!Z3'4T,OZV%1D8&.+9PS>KRCEB=!YU8JQ\9 +*A
MN4Z["DW+;"%PA\M^H&SROX[\D.M.U75K]956> /G\NRK#YM.*,M@ FNN?=$G
M$5 7IXTEKSU)DK\=N.O /4'[DGQ:U(B=F!.KK9+BA[J^.>5N\/E.]1>8J@KV
MRD;U5Y_^1-/M\-=7E]?L&E*C6QV23\CKO7Z=9GCBMCT:N+,>%XLLF])TRLM>
MN!GEOTY:%Z(8U0#4F?.R]/*'$;X",F0;!,#6%]A*B[$=SX89^2"#C?&$0]+*
M8%!OQ,W\H&DS.$V;!&?C)?X"+OU1?Q._[K[W,,KXXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@....!AK)7->N4G7,;T1-:Y>F-C"U2F18"'9.J'AMV[\8FO>4@RMN
M$;'?OW;L=&.76KK;NV[.L.L]F??>0CPXD3F0V"Q8X;L+S\RA78/@QH>9,GLC
MQXFPB0SCZM>4V?G%B1(V<R3WMD91XL?3EL[UZ=>./8\<#\;->O=KV:=VO#;J
MVX9Z]NK9ACGKV:\\>\<]>S#+KO'/#/'OO'/#+KO'+'OOKOKOKOOKF)A:^05L
M:3#+J0H 0YO3E',B@JT%%C2VC./LBYZ"<&#"T19^G.+MVQLM<K5MPRC[=FGO
M'O7GECWE_' P?]F-:]3@Y/JO$;\R7M R, (?I,!^.!Q@N>.P-'#R_P O^_&:
M!.S''8,U0MFC7 SQQRBXZLNNN^<R0A(TS0P19:6IRHK;*CS6J-(7 ^_0S38F
MS7MBRV#3MAY:S,J-MTZMD>01QD[=.S5KSUYXY88]]99QP,.A5W7XV+E!'(R<
M/@Y@IBOG#A+(6+%R62$N1/GKN4?1"UZ<@4Z=,ES9@CO#L?)ERI$C='SW;]N>
M782U!3G]%^IRPNS.F ="$'NI84;(Z-B1GXG\M&%_OHV?YD.'_C9GX*%,^^C1
M/Q<G[C5K^_V_;R'C@8D(0$->QA8 $E1!X#=!:,.P$+88;C C']T:0=CPL84+
M1U%T&M\.'O+:M'6O61W18VR9CNST:LL/O%2DV#N7I$)268>]1A[QRIOB@14?
M<L#Y4?\ "28"]MTQ,,PL.1$_]EWQ1N4;1MC_ .9V89:_\GF3<^6_?HC:_O9&
M[5'U=9ZM?>W?LPU:^MF[;AITX?;V98X_;V[MFO5JQ^OVMFW/#7AUWGECUV'1
M[%%3VL6EOVK"]L;(VCN+':-@4;FQ:(N6G='[C:3>4;LEJT=QY&_1WIPDXZ^]
M.[=J[Q^QLSQR[ :'$AM<G2'%CA6F:0G%IFH;"C0=<LJ3D9RR1.3A%U:L=Y A
M+V;),Z9MZSDRY&>>Z1LV;,LLN^QXX&)C4)%#G);.(2U,4RD,I><]A&K@>"<F
MYD-W4B?G++18>J?)RF[^NM\O+=(S[D[NNMF[O//K[7.$.K"M ^<C:)KQ&%[)
M9(49E[!RD A9R2X*7NGA"LC.,/U9;B0:=(WS14[9WE*'2]^Z3$VZ=VW//+.>
M?+=OT1\<<Y&[5HPSVZ=&&6[9AJQSWR-N&B/IQRS[QZRV[]VS#3IU]=]Y[=N>
M&O#K+/+KKL,8((2*7@DQA5+4R8TT7_/S(\@N!YL$L=[T:(O9LG$DP]NB>7_#
M18T?\RE:]LS[B-HU???=Z=>./+%J*F#ZRQ"K"\'QS$#P&>(L*-']9 1/4K$4
M$RZB1M/60@9C.F]#QO?UAPNIDKJ-IU]2-OV\AXX&#"ZPK0'KSTA:\1A&G9/$
M%=FH6I !^O837Y.V8!(YX1!^G'*>$F;MTH1,RZ[D#9.W;OA;-.W9EEWEF0T=
MD1U%\H$+(MHA;QNDGE%T=D=(Z5OC2I,#5-[U]R=<*3)AQ)&^+AMZT;M\6-MV
M:\MFC5ECS>=9@:#;"VX!K+#-AV/#P(R N$^+D6T#]FSK3KG;AV.WN9JA[-N6
M.K"5GIQT9;,NL,<^\N^NN!P)R@IDS@YF)*ZZ09!&O'4)8)P4;+."]6.>[9CJ
M'%I$;9/A:\=DB1GCA&D:L>L]^[+KK[6W/O+\PTY0'90<QZJMP,QD4Q"&YPP8
MR+D/A,,S61/Q(.6B+AW$BG"&K5.,1X_>O43F:M<F;AOWX8Y]=_OWZ(NC=)D[
MM4>-'U;-\B1OV8:=&C1IP[V;=V[;L[QUZM6K7CEGLV9Y8X888]Y9=]8]=]\^
MO BS<7CBC;MZH6,S@)8,'YUO]2]+(JHCR(:FI$K01H!V(KS')='C^QK*+$33
MN;#$@R-.G;H9180SIEZY(W7]N4W'' <<<<!QQQP'''' <<<_&S9KTZ]FW;LP
MU:M6&6S;MV98X:]>O#'O+/9LSR[ZQPPPQZ[RRRR[ZQQQZ[[[[ZZZ[[X'[XYQ
M<YT+5E"QV3(NO(EN[CCL<Y&K#*?(ZB22'>B%UEGUW*W=0(<N;WJT=;,^HD63
M)^S]SHVYX\K@.... XXXX#CCGRSWZ-6S3IV;M6O;)RSPCZL]F&&R1GKUY;MF
M&G#++K+;EAJPSVYXZ^LN\=>&6>776./??0?7CCC@.... XXY\MDC1JV:-.W=
MJU[9.>>N-JV;,,-DC/7JSW;,-&&6766W/#3KV;<\=?67>.K#/9EUUCCEWT'U
MXXXX#CCC@..<6%.A$HNF<.F19\*3CWG'F0I&J5%WX=9=X]YZ9&C/9IVX]98Y
M8]Y89Y==98]]?7Z]=]<_N4V'C,U#LI<;$AOC;YNF#EOU=3-T.+MC:),O5%[S
MZW[(T;?,B:=^_##O5IVRHVO9GCGOU=9!R>..?+O?HQWZXV6[5C)W:MV_5'[V
M8=;]NB/GHUR-VO5WW]YGJT;)4;#=LQQ[PU9R-&.?>.6[7UD'UXXXX#CCC@..
M?S++'''++++K'''KO++++OKK'''KKZ]Y9=]_3KKKKKKOOOOOOZ==?Q[YP!1<
M2=@:"H0F.,C)7WGX8D*FQB,"1]SMV:-WW$R)MW1]WW6_5MT[/N]F7V-NO9KR
M^F>&6/0=AQQQP'''' <<<<!QQSB]SH747=.[F1>H,?&3GOF=R-/X71A#RV82
M\]TC[?W.O&+EIW8R<L\\>M&6K9CM[Q[PRZZ#E<<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <<<<!QQQP'''' XTV;#'0Y9 A+C0($"-OFSITW?JB
MPX4.+JSWR9<N3OSUZ8\:/IPSW;]^[/#5IU89[-F>.&/??5!_QT6=X@V^E_9W
MHOS5Z \ZJOFEO0*T'QTL=Z3$LS TM-?V?;?5H^LWU/-OYG.LU=Z:;26*O3BS
M#&%&6Z*HP#<S0.%,*AH)7[;->O=KV:MNO#;JVX9:]NK9CCGKV:\\>\<]>S#+
MKO'/#/'OO'+'+KO'+'OOKOKOKOOKFOQU150(QGX":PKP7@4@XC"> Y*6X6)$
M;A(TR\!\_&,-U=2X.$J-'DXQ)'6R/C(CZ=W6OK9JUY8A6MMR5E/YJ%?3IL4Q
M+*V'X O B<4F&TRQ80-.";X\IBE84J5T1.[ 2E]H-B<*ZM0$#"G&914^5F2)
MVR3OV8VEJC:JOBZ);T=F7W)3/1>IH-G53(Y@7C,/O9GJ_%BC(F3+'$(WWNK9
MJ^^B2=NOK9KV:^\OMX9====NKFO9#+@YR$1-WN&O=JD8-FY7";67#?HT:XVC
M?@=S@Y%,=VF-JU1]6SJ5UGKT:]>K#+'7ACCUD8P4,"0(HH,.@"!<'5UHA#1D
M./ @0]/7?>76F+#B:]4>/JZRRRRZUZ=>&'7>7??T^O?? \UOF"PG\5<'QY1]
MOHAFK^MFN^_G8%N $D8#9J#V64OD198-?KQZ8T[L\)Y;.$4W 4B%WME$ \31
MOTJ4>%GNF997=>EY$"&=\V29(1#(D,+O8-H(Q8$++>+4#0KS;Z"9Q;+&(:]^
MC:$V12*]#CD2NOO=E'!22O6K3U*RC2(^\H@&NFD4)E00R4QA(!R8Q I$0<"+
MBH3)B5G29YT3MTZ9$2.<Q.;26^83AY83^BNR=MW;^IF>_+OK9UCU'(L*+3Q-
M\KC?:VP%L;H-6SFA9VV%FM;]1$5N9XJ1(G9,F0+=IQ+C=AK2,['[-71&'E)[
MPZDZ^!#/XZ/2;W?%?O"M=AC64]%4T835^\-:WE79NIHC.W5\O.<'=33W5Y$N
M!:Z].#R73&!CM$V%::^++#X;\NB-DD/(*0+NIIMJ5ZB^3ZN]'H/[F3K%?'/-
M\_UC9$(691U)C8G3\1-; 2?'GAF$^" G1$8DX1 $\9T=ZRQT'B6R3 AR-%\J
MRH*:7!VBTY775,9OE93MXY9"#0,'=-RCQXF4S;$%QHL?9*RBPXD;*1GK[V]Q
MXL?3WGWKT:L<?I+55B>8U,,Y< S3\>#B+T')8<?(,:1F,OJ?B.U$]T?.;K@X
MSNNIN,3#?C'ZE]=2>M?6[KK/@4?MWN+TM6;0]4XSOB:Q9+7R<+/D0C>L=6KV
MN):G4K1\?R#['$;)XZQ'D;4>M^8++:M5%*Y1@8!D(YV;$:!:T3=)8^%(M2\F
M.-MOU (C3>6"!^TJ=FU1#,VLF(2T*!L8%=&(&I,T4F GE@.@NT* T$P-(,&8
M,"%IH)&5T<4FQ!>K=ENLFHJAN$8&&5A>+CF*7%(, \F%&SX1V?!TC8\*:8B2
MHVW03EPXX81HBR9NO?NCZ10W5ISPP@Q<=2/TJ)L$& B=+RJ-W;]8-:"Q^AH.
M#MD_<R)6D.#&ZOPNC/?^'CRI&L? T][/N=$C=CI^QJV98AYZ[)^3J^ZQ533B
MJ6_2WHM[+A_D&F;J#1$&/"F4:#\OO?:LK6 Z38KS,:M@FM>] P3<48UAIS="
MSE FI8Y970Y$WID,,OEWL:Q;'JHC>E8>GJQKBX?C/L%!N>MQBD([%L%MWCHC
MLU2M&2<SG%YB)0Q24!MA>/!8(K'2GVB*#$\9^V##*S[6Z[I:N*O&YP%=:&XR
M9';#C//3X Z6RE8S.Q$&@K *G.H6J<1'YE26[+5#E;-FG#3JBZ\L<\M&.?>9
M!E!27!>D&O*ZZ!"QY>N?H$!@@P6+T3].W5(U3=(^#&T1-<O5OCZ-VN3AIQW8
M;=.K9CGUGKPRQ"E6NO2K$*LQ9\Y@K8HGQ?7(NDC=RJ1TRGK/Z?M-X9/7UW5V
MU)*^.=7%=@Y1$4 B+YAKB*A;MBWL%U@"DV<(@:A(TYO[P[[ N+T;;[[3[A^D
MMA/R4HL56>KYPI3EKNV?ZBSM8P#1<U/3(;3> Q3.4LA;[@WC-&DS&V"[IK_#
M!BASA90!%LG))*89S#["ZBL%=B]-V$@&9( *G9@R.Z1KE[9X?*5$VY#)NV5I
MU2=DJ%WHWYR-6O=EL[V88Y=8/5E(IE0FKE8UC8<FGKXMB;<=AEF$I^;39S5(
M34NO1\.!M[T1_P  N+B17RBLKH;#K9K&C!&K#[[=NV[MVP*X?<'KZSZLN>VJ
MK7;XJ+R^*K;Q#WZ807:V5@0RC[?LS:]V2 +HF, \R+6XDO5V%KQ9D-(E"E9.
MF[=<:Y*RFCL8X:$?Z;XR0LUP](_)+?UB !(VX'&[/-\ P.G*2-BXUF-9/CI\
M2682JG"P04')@-+*P9;,0>D5(,20NTBM[V;#"4:.E2,BW<RJ*[')$S6%; '9
M@"5W.!2S(<<4DA9O>6G/N8)WSHV_:.E=YQH^?<B'GIW=Y:-.7>?UU8=X_0%N
M6R&B4=6=H2;&.S,Y<TP"S@2=!DA TZ .R3*(#^\]9&9"CAXP7/=NW;M\;2+T
M#LLL,(6O3J"COV V6$/]<^_DJ9?LD0E%/B( L5:TNV?D'2(7L8D6]LB2,T**
MWR()LP<'ZE(.=9Y"YNULDP)^5BYY+2)%!->GHK8]W>L//;UZ)IIQ=T"P.ZWO
M'X]TG;=D9#6:RT5:@>K0K;E:;.?@M;YE7.,1?-U]OC5^2=F,(-&27\0+9R;3
M*%P_SN]TFJ*QHA"+F%H 6*CHLZ$/)DPXZ>0@0RD?9$)Q(4V5&VR8L4C%V[8T
MZ/HVZ]4N/MV:9&&S7GECWB>PK3K.*?B&XE6C"#@3YJA:,W9,5BPJ$35>NM9!
M7?I.6R1#CSUSJ;UA-",6>$@/U+ZQWQH_6_Z9AJ/Q^\7*_P!4E#%VY(\P_!LN
MR5Y5849D5&/4U5T!:)@]..MN**3.)R]8?4#5L$/*RM'2PD8PB9F<;=#_ !60
MD=2\#<?,R8.]6^I+Q- W_P"5.AKF]LFZOI5WOMY%63KV5^SW$1\F4W4=0C7G
M1/[J^S?/JW7A> %3E4XO/'ZD=F*?T9G[&'J)Z,  , N"8@=7#AP(*-UNV0!8
M ?"%B8_4S?MF[]D2$.TZ(>KJ5*D;I>[+3JQZW[]^V1GWELVYYY=&9 UV()2;
M-8 J8,+KXR3(F6"8&@X9,*&A09>$S?):YNG7+'#(HV1/PD[-D_3%T0=\O';W
MCHV[NL@I.$^U_2$[:]K=8>DO/?H'%@\GT!;2O:@9( SU^B+EM&Y5FJ>UMX!(
M-A_1U3[!'LIMN21&) ,RJ^BM#X]@8"V)\'.S^&?KGV'77HHRD,]W5U8R4A_*
M'Y[\,E >VD!ZF4::]OKR+7=^S&68>$/4O,:[JC9:L,2#DC!T8'+#IN>HP!G3
M#DB2/O&#I:<O09(L IK(,9-G=$Y@X.!%C(,LECLT[<2$F)"BZ(^^=CMCQ]G4
MO;KSD=;-&G/K9]K5AWCS=BZO[M^R5N!!MLG<8B,.Z1L%PL]^T_ @1A<$YLW9
M:.]F9B$,APQT0GEEW-CP(L:)IWX1]&K7@%!#!\E3VA99GFCU14;9$8=7R)9-
MZ+6%-C6=K\X*?EIG*KR2\30FVS8)8Z:6C(Y9KYT&NA(8&<WFU%HB&@KB6"-F
M,=L5!ZZ]/73.M&K5BR49<8DCY%$WS!&L)D5JYL,_$JV5XP1_33T-+#:A?R%6
MY6E!9B[,EAR, O.$+VV)#CLX J2&E(TBU]$H^L:\#S0X)3#R/S3%IT&2Q<6+
M(G3L!Q8B;.=$FRV<'"46$22161UT.FY;HOX77&T;=>W[GK/O,@*2F*T;J$L*
M2PN0^B6PUU$ @10B-T8W0^AVTMUH'Q(^KHEM']=0=D_K#\5G#ZZC9;>]'7V.
M!0,I?)'ZH%KM:*;8P5DV6?Z@>_07EWS*>AU?*#@IWH;R][ZL;S0_'VT3$L39
MKP'F//$8+Z!R6>B Z%&[JNSHX8Q.[F!UO?/SY>6"P5+XY/4;75UA-57.JVE#
M# MT2MFN.QBM,5N7?S/J%-R[PVCM<@9G+TS"$;?&WQ(>6_;]_CIZW8YRH/4M
M4UB694EC92.]Y[S(YV.=55];+PHRR%LBT$4BLLQQL7Q^G+&0XZTJP&7L;LF[
M8TJ-'L0X5D:)>XWHE8;C892]$#3NVN0&C+\O#6*)=L&V%J#2=9K?J$:1L[\Q
MRQA;M9:3.TC-<.1]K&=NEZH6.O;GOQUYA1K;WO.Y5ELO_17GH*FBI?SQ>GDB
ML*NI,T+0I;5[33[@7:9,.#$MFX[.!E!B[HW6F\5/7[(E#)"(IM%)'Y+%$-XZ
MVK2O3N^3HO\ E7A^Z],DR665YHRK6O'YL"%PH.<FU99UN(5=VRY=D#\>6-ZA
M*E:,[6?)0\XDJ03'CY0R#HRF3-&6,R(B B0)X4I!2E*$36QW0A=(Q%L/&G@1
M/74G'H6%F:86$@6.ZQFS,>H4'9HC==2Y/76KZ;]OV^CN.I$2^JIL2EK.#]'J
M_M%//([<*ZW[8DB0$81^\=+V#Y\?O"6++1,=W4T.8@[-) .4CPR8_?HFQ-&[
M *EO94<,&CVNR*2*F!G:JOD.^)W%/8U]6T],>O)JN+RW59N9,[P[WZ9.Z'4-
MH6$A#\M$&+I%IIF?$QU?3'N3U-+WMZ"</.U85D>4RJ\G1["]&4M3CK;#;&BR
ME>ED&PF/9 9;,-8%),!?TX#M4:.OC);.1A+L,\R"91+N=CJP$D=[.="(5@8U
M+@U?G93"GK#5+3!];BN66YD=D=:,+BF7>IV>C,BT; >PO@R1>I$O3EM: X,I
M+SD:Q_X3;E99JJTZ')P#K(@&%_?I9XQF$6,+I /NCIY3((YQR<:9(W0MFE6-
M:LQ#/JE89:PA37E *XQ9>'>KH*@5WV7<9/L$DL'K'SXN+G7R 6KYO@>I=B8M
MZP%O5<H^<9]Z0P:B/F/G:*O6NJO&12DFECG93%@O-JYH+@U7\P-CX&F/$[Y0
M;@D4 0N^5Z>H%(FIGBY/OM'1I]6:,S?K1Q+>C+TJ)2:4\:3L;\U%5O?H>KZ^
M@)"RO8:V@(S7* )&CP*'&UK\J]"17U'6E+6M<'!-9A]&M# &Q4UZ0N%%9<9B
M:AL%%%EJ686J8.ADH2ZU1R>D'.CPIL#HF-)=Z.M$O3WO[_"E*S_6VY]WJ8:<
M;Z5Z_416@@*%S!2P)K,LY&E/)4'[X.6"]-AS7DOEG)&YZ>\M<41AJPT=CM66
M05)D_==X[[K8X<*S:J6"R9\C-;>2</&C"! ;+/L"D';!)"S;.%&]C6.:Q+5&
M#MK3Z"$FL!\U *5_6!58'0S&Z7DQ[-2Z_DB]"KDE.I^PFE/ZN1C]+)J?:UDH
M!.B3_GROZ+L12]+/%3M],V07<!*?%,VV0I99JT,G^F3R[9&ED8]FT ILV)=/
MGG+_ #])JWZB[;_TT _5G</H=VS_ ),._478_'K+K&#V:_#?F7</'K++KJ-W
M)^YZZRRZZP^G??,0%HM,Y#6Y?#)M8Y!]I31$? @Q=5>QFTT.T03L:.VC8L/\
M+L)P8TX:8T:C&GN5%TS(1#7CAAOT;<@U[Y0<+=L'S\F,UW=H6JRI^UR@$B=8
M,(5I53 H([,H!.:HY '--+D<ZR)XT"Q-8 *6-A%EL(&ER 2FPQFO/NG7RT2O
M:QEF@ $;UG'8;>#?(;\DX-C8K 45AZ=T"NUBV/<*JO!(:O%."-XK>QCU=;D*
M6UP[G P*7&V!5D-F)'!M6F^U2G(O4"$!1)BGT+'!!)4<&4MX?H?!6S6\IH!D
M80\/G^&C!"LD,:TBI>C5A!G;A9/7$V;<X4KK7^08E"Z*'R2T-4.C?1O/%HG@
MX8;\TZ9-4+KK9T?E0-?XO\[UC2?76?1'9^/PA$.NLOIHE_YP/.XB_)Q[%M.N
MZ(P#S::5[);O $#TB).L$JN*\KB[;\CVT]5\:22&RV;'$S5BM@ 2N(+!8&58
MRVQP4M=J""&_; @0@44]>O?]CLU6>7[IMW# .!<*XH>Q+'[U2LMIT"&85! +
ML^>O=LQU0=Q@4/(#LL<]G4>)G/BZ?M_<:>]OW6.?GT*L)8:#J:$M"E+REIES
MANL^N+V\,LQ\-?W\Z9!P(P\H(73AJT??2Y&CJ-ACKT_>;L^L=?VNLQCR(!:!
MHE1=\0D,)1-<B-)C[-,R 0@3-..S3OT;M>6R/*B2H^S'9KV:\MFG?IV8Y8Y9
MX9==]A2_J]T6??WJ.UZ7\OWO1$ZLAE@^*@"?:"Z%%6[&@K=PU%Z3M:VM,><"
M<=(0HTE1U2+$=(DD<LQBWM)]S"@8]%W]Q<XX69\FEX(7C\I8).VU[N_*[K_Y
M56G;H#5G6BLA6)$\#^F7B@$QT<S-IVB.'*P]BF@44<8K2LLF9^:#KT1)+FP(
M"7\NNO0F$2$Q:UZM2XHK #5HST;-.L( %"M>G.+JFZ(V>K"#$T8Z\X^DD1TZ
M,L.NN]6J?-UZ^\<)6_K9PC-;UVQ0XXY@0DLZ/B2BLZ+!,JP,I#C3CLS80-S(
M\6;!WZ-,HS/W;9Q61KPQW$9FW9)EY[MV>6?85-V3\CL\&]595R]9E,:[4;?>
MGDJC&2L-DX7N>(E+7KYRK2VF$@-5)1_%B[W;##:7V@G+J'-%ZX43.!WA)DCI
MN&K0'EXE>MB+M#+T;UEH8;="_(M\E %A8; 45AZ>*^KI6MGW,JKP2&L13@C>
M*W,@U67)"AL;_P :#7TO1F&60V8@:&TZ[X8 "N6*7&=!85).SN^M,:&V0!H(
MG+[Z R]\>/'C'H^G?N[Z#3M4G1IU:I7_ +NEZM^K#'3NPV8]=O!5%861GEQB
MT '%BLWHD4*00PZ(1)$>M$B+U/GS8\;7)F3>HTN5'ZE2-NS?]Q)D:?O/N]VS
M'(/.JE?)GZ(LVDJ^.-M^4%Y@:=WQP[?4L>RW!$@3$NY;N&6;9J"R+(E49W6%
M*P5TT76 -A;E-$/D''3(N(#CI*#8L$-$/3,RLVZ[EINZ[%O$777Z&U,GC]:!
M^8S2)#,:49E=5'R1:3YM?GO!HG=NQP"]6@RBUJ.&B  H>$&$2IO1XCUMST6H
MR$)%F:0,>6EJ<J.K2.Y:QHD+@??I7)7>S#;W) ZML/+ 1([VZM6SO</QC[/O
M->&?VOM88]]9!F.'[<9..R!"V8S).B;,QSBZ,\94R+C%PC2Y/66OOK?)CX0(
M.&C?M^WMTXPXN.O/'J/IZP"A*TOD;?0,_P"0IMH[TE35PK/E]XIR@M-8$(U;
M17ZI[+=O0Z57M^6RXY16-8WPJ<\ZI5CP($ M8VH$O&&ZNK')-;A'5Q.!+=L#
MKV3Z-'NM1UP]VC3U=5E9US>@X(CU+(*U0V;HU7U712%9J<LV)H5V<I2"59;0
MVMSG'ZUQFF5N*5A66L_" "R3%,(B+2I\[S<IV1&0R<RD%JW[?$,&Z(F3Y"&&
MLBT07>S?-:=L9=D9QF=V$=[<)4M@V:H9.'WLPW[R/?VL=F?66C46J=P64J"$
MZO=JZ*._?S5H:O+>84:S:=,:7WNE!HL/N##.Z=$B')^\W1M9#7IWQMWVNL-F
MK+(*X/AZ+RQ/Q'>4#P_O0[$AE('2\?,)HUQ8[@4AL+=-^]%11N177&UL4[7W
MLAQH.1''1U-UZHW<K[&'WE8RY>QGT!;"E=MFV-4-PMKM\ WK:XGBB8JJK?E5
M,-S98GE!^(U<XCAK!/:98H20VQ4?\L=,H3'K(()TCG-BE2LV$)]00#]/_E,3
M!6_)_P BT_?QX.(#\%^4ZOPTG='E:(F([_V/#\/,U2-&_5IZZ^ZDZ]VK9CCM
MPSQZZV&BI Z03ECTY5@2C>)/ S)AKPB+(+X&]FC<9Q)[M$/#9/Q+[8L;:3QE
M9;>I^R/HSE=;<M6OO$*1+]^0"\/.KWZ00#YVNHLK6RK$;S412=2([TU7'GOJ
MY?,U)VW:5WQ AO1:=<V'YMC6VU.SL-LR.J4>7@B8D (W8Y0B0X?L3T7Z&=*7
M2#/H*OK/0?7+S3WDSWBS*#*IB0VL!G-#V1Y#V01#; KH\=&$IE?CI^<MJW!]
MBSF2$C<\Y0]>V;9)#EN.NO$#22/&-*,GZB[3#F#V<KK60N!)C@$?N_S"">G8
MPNI1>'.^YT_C(Q#;(TR?NM?W^&?V,?I_502@ZPD'%'&I^M;CZRX\;BJ0PN(3
M1IE$>^C\&#T(U]0-6N06A9=%XT?[..TC$[_&X928_?V HILGW%Z62&:U!E=>
MC*%]'TG5,:@[9>;G12-#)=CC*U>:RO<O9-85Q&<'_"C["LH-E6B'?@788**F
MC72[:=!;)),YBLGIFW[M^388IK9_0B6U6,!_.VC\8&50HMBQ(BY9#/2?LJY:
M)37)AW5V9) 6"85G*K-:FR%U!'8[D\JNS<24##,%OU<M2_1%)35THK=I]62U
M-1,;I!I=[7U+>NK+!K":)DC>3$]P\A@<OK7#$:3OVRH\>9@%*:=NS+J%,PRV
M9'M6Z_.D QW< 3C)3$7$V+YG:*"$2&(4?-AE8.88AGHW2>A<(CO'D8F4+=^$
MC3=T.9I[PW[-&SL*BK@]:^FZQ[ 'RKVDXH]T_(0[^7 10:J)"AKH*HJT"7D0
MTE3+?;+R+1&6T;3=JG!UP$FMI< L_B'P"*6E4LY[8FDI8QY+<[;?Z$2VB\<$
M#*QI<US@$I]9L8AH4SP4"],H!.9L""\0,+\0^S)PP"=<%\":,AEAN('%X:3E
M1!FK+K>1186C8F: -+P,N");^Y)$*4$P" F?)RG8D\I$T=+C[H<K?D2PP(=[
M=^G9L[G88R^\OQ&/6SKE" PA?&PPH$4-"!QVGJ./$B(,4:-@Z.LLLNM$.!"U
M:8L;3UEEEEUKT:L,.LLLN^L?KWWP/+I?/NN_[G\9OA"3=E8ZB7H+R=\FPZX_
M-JRM+>FUO*/=,4G;[.NL.TK(/[F+#!5F*"Q35D!'I8Z.E&>X0C4 Q4M0;9#C
M7^^6U!2ISR/3(%8@+*RO+5*J179DLI(58 XR-BA",%SF"6CPQ(S5E-F;)).;
M "QM&Z;OV[NL-N<K=WORWOJ1DK1)89FE/5M,QNT[8[9+U+XG7)9X^_5GIWZ&
M'?A$ZVFM.[3LSU;=1+.3ALU9YZ\\>\,N^N^V&D0TS*? #SADK)>F8!"D,;)B
M[NPA# ? (ZQ,Z/&SR_+IF HD,G80=^&G=C GP9..KJ/)T9YAY^:O^1V_;+_;
M4NUM9:>T;/W,/)GH>GK"LQ KV-+%M?I*\;!K<>6:JMIZU#<X&BDD\4GN0RO7
MAC%6@%_'[AY\A&G=R(L;(GWY$[X\G-7H@A>SXFVG4WG3U%O\R%R@:I?TNW&C
MMR>'Z.]*>;Y<_P#*'?<)';YUY-Y3SUGGHA:H!K?9*3/+9 , Y4_'NG3@E+_;
ME[4 /6'6U@$ F&=FGCU3K8;!3=LB>LFYF0;3UF1$R]^,J8");_OH>_=C(D0-
MV6?6S/K&;LHZKKB"+Z[8/>X:%T7+45M2(0DE#7];T^4^VKCK7(UNS[CY;&@;
M%9TQ2GY!MN?4B?\ I@-#QW]1(6,?L.2).6>K><1S+:&U<VW,NTI%.V%M!#]D
M53SLP2C8$&K,0,_-B>S2O]M$>=W!A=&YV6 _[K3T3W]_23E2TT^[O8U&#;(#
MV-9%06 :[\=_'UZ#TN\>I]Z,LTT3]6>JF'SU=;I,'=/!/HY55,I,?*VXW384
M@[X$-2)9-C-T$E3=\#T!E9@L<+)$#<J! "P($R87G%=\>*+ABXL?9O(2B4F7
MGA$CP(\3#=NF;Y6>$?3'PV;-^>.O'+OK T=@IVW%6.\UL;K2SDAH";5R(X(Y
M)7=%5B7!\F?"W 8[ !W$A!<)"E[B<3:+URY$&-)VS]&>C#;LD8=A58A>B_45
MF6\V4/7_ */IUR4Q'J,"F"/3B[6ZPU;"5>$_*+C=3/4.A;7WO!/W6J@.8A.S
M*6)C'[6)::\117Z2U-@<GUA' +\DMV,GF"A[<?O4?G7SD=,>!_1OH]TG,-;8
M3L;'LJCVL>F09BJ&-O.6(U+T[,MAYW20'1YT*[C P0FE!FO3(D8^A$0L+2_!
M'"P*\#"#!&W?N$CA F -@C-TKJ1C)VCHD./ICPMLG&7+QW[(VO5ENZE2.MG>
M76[9]K7I"B:K*M@QN)IP,C(#*.]+% YP@3+51XF0?T,FS?"7Y$#9"B%/S./A
MGU/CXZL^M7>>OO'OOOK/H*J6CY,&#23I1(C-E5)UVOWMSQ13SI0S%.7]]GJM
M2>AO.U16PZ0\U..US"G92(><6>**<869@-&TC=\#7OG[Q4S+",\_TBRB:JL&
MFA'H.F;6"6II^7U19Z*3@ *"]THLU)*O5@#.Q4AF\2&?;L56(:(1[&E%@^V&
M9.W ER%==$C(.1F;Z*)*:H3#>+++5%N4QX8P\<&"2#%[S>&([;EO'XXE=L7*
M?CC W9Y[H?74CKJ+MSRV:.L,\N^^^J@KE:[6%GD# *-L;-D7H6Y;H(L!FPYP
M3NO40Z',^R/H[)913.G7IG=1"N7>DAKUZI/W>['''/H*Q+AOPI2+\27DZ76-
M&A;M^1P-2=GWT17QFL<E!)/AX-=$5K8]Q\C$4Y;U8=@*BQ1J^8:)6H9A.>PV
MB&$,,O0^-/LNJ(MN.UFE%I%E*=Q[Y@&'GNM)&@C1JF];=?66G8Q!8 <^T"8D
M>?GK[SV:1AXA PD];_PF>G1]B-IRLLLK9X>2$'5\(:%&=VB08&%A4 B/*R(O
MX/\ #;R4*9'W1IVZ-^7#_N-LK5MST_@8?W>6/X;1]CL($""*@PQ@R%$'#1\7
M1"@#X$;3#@P8<75CHC1(<2/AKT1HL?3AAIT1].O#5IU88Z]>&.&/770<OCCC
M@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@4%6
MU8WIY2\TW,W4A:YBB=-!>&?9'H)81:OHJE>A#A<R/:EI3Z\Q*#6:L66+I Y0
M4Z3'8$]1% B[M+:NV#8P12>O9N*:Q:GNVZJO?Y0O1J@=:AC$35_B,C'6W>AJ
M[ /J6JK#8=JYZ!M!2@YH,LG._873K'8[_JBF)3:&$[8,HHW CL6/E%[]#R@Z
M)]@@(;6AM:V[*Y#<0CP&12.#&,#-WBB,H04TQ"XB3,'R=HXK!FC)VO3(SRB3
MX<J'OZUR-&W7CW<V="&Q=TXC,BP(4?'K.1,FR-46+HP[RZPZRW2-^>O5JQ[S
MRQQZRSSQZ[RRZQ^OU[ZZX%,-06OZ+MVXR" D>LFUT\\QO6FP>HW^,K>H=[38
M=="?+VVPWFEAQW34(NM"2@H6YF#T0KK4%PB8,QY[/6>9C6P*TDWH^+2U^OR%
M\^;QT?UG;"TD^A?=_L6C3J@I4[Y[TCJ]IBG:A]*N%<Z@K W4VZG>SW;90R]C
MN=V4D0B, EZF!L VN?I#E>KKN/IU_JZ_E^O_ .'OZ_7O_O[^O?\ X]\#RP/G
MR8>G5SQ;0MER[9:P7I.3Y!IVW&30Q@*D0*XLYS;/17528P%]&FT@ZO%DVNSQ
M1)F0ZUS7QJLU>O5CL*>ZWB-KF*D#Y0^8";$M6%Z&59S47M.S GRG>JW -6-J
M!41D-J"W+H6YVRJFQ0BXI(=J1P[T>$A ZVR#"D2!*#;)8Q9FQ(ADUB0NE3+X
MI:PY0B DVFALA)@F69  B1K,*VF3DFF7B=6EK]!P^<G F3TUZ_#IBFV2H43?
M%#&M74.7NUY[=/>S;/ \[51>PO3SO7XYJ2?2I>SG0W\8-Y7#Z%3355(.,/Q[
M[)4!BI^D!0G0MU2M;MYG78YBS4+?0%J,I=CW+U70F7/=.T8%"1Z>WFFP;V >
MAO>-*VW;3[=*G1*;YG;Z\<3-;5\$;\9MCU:ZS[%%@8=9HJ@ :-.3&D1SP$/N
M#%RHJ>?W@-Q$A"[':-5E_P#+_+S";(LA!I]";K1M)O7T&NT,$09G)S:2480O
MK@$7HRD3B90C+SUZ8^C3KQ^F/7>7>S=MRUQX^O;OVZM68>;53^2'T(9*%=0B
M\#>RDYB-\<3]8=H,<>H'BT?-:'Z,M[T2(N%@L'>CT0CUA63]%1T:HQCDA-*[
M:D"FIS=+*2BFG/KN1'R7UO[GN>L4?U(60_:[('%U)5?G5F\@ON:109?]ZTHX
M6\]C;EFENB%*S0;W$4-:\(JZ1/JD:D"5H-]AM,][BA^*R;/1,I6,CO*.'LE7
M91Q)%/CL"PIESSVCATD?LVY:,9.?935"W1<?OL,M.6$S5'VX;>N]>>&.7\.8
M3::'3GIE'M+S_8>F*Z*DW4*6K/489HL(FQ>IT<0X"8$\@ G#"XW;*AY""VGN
M).T9[XFW7CLRST;MNK,*S+U]TMJIZ*5_.:?9G<&S^_DI\]U@Q(6Q#^_+2/*M
MBT6M.AJ1#WD57;$WJ<]HFE-&VR!DW+:+-QYJQBQQ"<3(9CP=3YZ> (3$;HR?
MM%_L<\F^P[A3O.:+3=?B5J[+U"VY: RHEPME 4,3@P5+W!<<""Q7V:R<=3K%
M$8)A[\3A+P-76<UC:MV4S1*_I;+OMRL:;59,W4,CLUJOJK7B_();_P".D?I,
MMQ80.VS=W7\=437)RW[/_N-?? HU7/6_J?95JP\#?4M56)5#P\^(5FS;/2V!
M$L2T_,06RV-V@7^[N?4?SG4=9UBLDM(9(70,&R$IY*5V7)O)IBDPQFM=[&Y/
MX\EZ97@WY4&04<RN:"5]5_( XJK8](ZD9B67$W"X1A9+SU#0E T=L#S,M4*'
M#ZB)N*^Q0H>C?KB2],GO/;?(-)#C(Z 7$3X1425A120LH-E:)PXD.G:-<J%/
M@38NS;&F0ID;;JD194?;LT2-&S7NT[,]>>.7?-_E_EX%-MTVOZDK^^D]D6+J
M:<ZQ+?)?0_EO51\>J:RR18-%N'G8"6<]TYEQ1Y-F22W=B&9;,-<(KR(%@^A\
M!8V"I0[7.ZFZ@]A8FP_M3W1"FW&\+>JS_B'#!*A12NE4)(;?8< U[8_4 936
M9RCT39CJ:/U+#J;@AV74?PU'(>H_/R6)X@=%OQ__ !_R\<#SVW3Z>]I^?7;U
M#6&5SF["2ZUN'XZQA:^+!1ZU19-0U)?89QT>@FW%B1Z6*HHX!$.HP7J,PM-7
MV!A7>-@$>B.<B-$$$!,AW/T5Z%IOPJ3]3.=YU[9P&BO1>3TZ-E"X!+;W6?XX
M6[<[675**&-58(0(O:BLF$#6\J9K&OE74?*5^.' -L68P$2V=Q?,'-66@KCT
MC5D=; HI_LN X%$%2F2\=1IL'H$<-*=)@6)WU]J7H6HS"#W%L\>^OPVLG$RR
M^O6SKZ!YZ!OMGY)=%<7^$*A2)"_?+GF2X[Q?>E^KN]R:QE_3+57=B>.P80=*
M1I<1KF^>J3)76K.0M">".Z<]4_HS=,6N$<TYDI)+]Z7A8!7T"J4![(9[:J&>
M>^/N!57IC.L*F/'Z]9[LMW],7[6BU)#4ZJU'9NJ/4,17>LF6>(-$:K:;*D@V
M&!OVAHXH?=[S5RG>%*OSHW5NBV_5SK8:!GMP?$)3?U-C=$G9'(;!6[!N5@Y:
M8<6\]!33N&[<3,&%EK(:MD//K&3KRU]!4]LN.XJ@]:7FEFF;>A4\=)V3/J9Z
MW#0#"3]%^G5WR75LZ:C6)EVE015=:U!05Y]CIL!=U"Q]L'X!J!@8@Z4[:CL^
MD:T]+/MYBY2%"]!M7K)*S\U>%+ALUV+5DCHD2N;Z>O4(#7O4( ]%1$^4*FMR
ML,,F#=6-6!1HJ,<B!-QLC+D.^W=J]!9P*.8PAE>,:,I(D^+(!BL;#?OC9R!Q
M2)M@S=.,F+LTR8^6V+OV:\=\?=JWZN\NL].S#9CCEU^@H<>O!A( 3IRCBP8R
M '&Q\]VZ1GH'C(NJ%#TY2).S;(WY:HVC7AEND;=N[;WCWGMV9YY99=AYZW;W
MYZ7A^C'M1H!D/VI,QJ[Y62JW0M@1J],/>RT/)$A="TG _9E751I3S7*0U6+T
M=6:PS>K1:&FY4#<+;-L300+Z)<#MS_LFP\(OD[367MS78%87%.-Q/0=]NLRE
M:Q%4W9<2EPQJO*BZ?('EQT1Z[VV8U3&9@E+MA5X5;()!0U+,=F Z)<@06OJ+
MNB<OG5A7/-:V%97;:9T)J\6-C1QMLW+HK:=8-2T*ER=,XYL!A=&XN8P&:).0
MT9JV3IG6F-CWMZ^,5^1IS-&2H3FJ3'&:IZ7V&J16$3(9):/(GXBH[E&":9>9
M+>J[RF6([2P:HV8G;.RQB82\M_?6O@1W\X6ZU,-35^FV/8%.V=ZIC>>T2VW.
M-5)4K&0F\8Z],(M+L$!-*+PR;!3K"+*A?&(2[7(6O7+AE]D #'@1HT/JKRE9
M*W)^/SS@<50"Z]=E/BR]?6(9+.:>'M8E*NC?G0[(]!)C \*6TJPC2=K-%B8&
MPDZ'K%6'M@1")L:;_*X$C3><+25(*T-3L*7QD%N>-"]$;6+1'QQ+'XBG&G1%
MF&1F=_7;NA@M!,GB,B_7&/$S)$=VK7COG2MFWIJQJI II4[1JS6XBFH],KPV
MZ0$#=,VCH9NQG0_83AN'Z9DB3T.ADVYG.%=0F#W'%#/QO<(5"A0-,>+J"$/F
M? M"^0CY+1<2)LA(N0[Q4<AZX@W1$"2+&(5$YAG29^+C1M6$UER25JHH)C#?
M(WS(@" G898:(6R!][6_6_L_T!82Y7Z_5GM!HMNQ;)\?G;&MMAD4!5P\7YDM
M@OZ-HBLD'?#4(E= <]1/&&XV\M0Z[L$B:WN8)$UVI'D:@O<:43NQ5"_FFJ'"
MU\ SJAK3O9EWQ>[._/'6'J-L-W$:C3YPA:W9GB?W^QAT4JKI\X(HC<OJ.214
M.5 &Z(&K;LYP5*^/*%?(M?JRE==58I0D+2Z8D8#;%#L^G '9,_57E&89$]!8
MK)V#[ ,C]:NE'2<KN(T&M/<""0F3\N\,@JS]<>E?0]0O'J"JQ_IEYK5XIWS;
M1CKXO&3JQK%P,>TK7)%W3%^!,@?539>:X23KF.K:HS@ZE8J)NKH&Y$7C:+CX
MX:S0_+K*9_0]47W^N5.SV*"E6Y\HGG6E'ZB8]=UZ?KZ17]@>2*Q%69*(-\]#
MVV41F?K#1')#7$<TK 4=BOPA$E?W1I)?";=WQ_\ C_EX'F^LN^3E&JVMO6O0
MV_SS9W?Q6^-VVHJ14J'1OTW=MW_KN[](1 &09%9G-??YFX,H2O=U65ATKEU@
M38F]VE:8X,)JFB]O^F9TP'Z3\U/)]_8O/M=IWR:V'IL5F0AJ&J*O4-B^*IZ,
M035G'I]>%(;B0(V7(A5P)8FG*3M,;#L,!%RVF8"CL WIE"8X&+(F2TO0/$AX
M$LF3GR<^M<:".'Q]DJ;+D;._X:]$:-IV;MN??\,=>&67^CF,FK'KY:38]B,K
MLJK2'+T 96ER8CPP"LYZ6B4/@+>S(T6DPQ^O\]G%1D$5CMWX9SID^'$CX[)$
MC5KR"H^W,YJ_\G7HCIAM1Y& [!^,=%'5Q6I.4L:T-^;@SMZ]EN2TK#)*E^;F
M#JLO1 CH8P"L>+#%P,0>C4F0LRQ0?7%AV]%^SO+^D+6&B\C[RC:/-GQA.[M:
M3W7]8(D*C0]NW/=]8^BG!</IU*G JNJQE6NT"-UHLA-N*37.!K:?E3=V.[:2
MU^AW4_I&Y=8V[IK ZE9/E-D)K8Y9.+""+DA$G$1SGB;)S-FB&,UK$T23T&I$
MO=JCP.X,G/?MPU:LL^NS LRVTP81198 C$-(B1!X>0!E8):%.!GXGX\$9B2H
M&_?HDBC4'_VP20TYYQ",7_VB'MW:O\O@5JBK$]-RO#-F-&KT!5C59\RTC"A3
M=\TUK 71!%(9NZ B,N$&G5(KJMJ_>K!1H1(T%9MP*O@*@3R!Q)V$?9+V$)VZ
M)!2[?9-;^D6=;[]*VO8J(A?*IY:\H1E=QJ2AM(UIH6\/(]86T[RSYY$I--/;
MB:_8MFE-(5Q7BX&$)TIPT,7CD\MIGN9?IC-AY3-@[&7&R(:8VB;N@X[]7<S5
M#D[9&B-+V1>L_O\ 7&D;XDK3HWY8=:MNV-(UZ\\L].SK'D__ (_Y>!1,-]$V
M;35S>71&]X1Q=(6 Y3ZME^::JBUG75QQK&L3UO<R<MW#LK.55TW;8-)S HN!
M'L+M#:J]9$WH"VV>1[<,B<WJ-@]E^^;F=&U.I2E/2Z'6EJ04SY.ERY&&TD.,
M*3JHLREW(*M>=#MJ2CB;WTEK@[\1(DBBL:-(@. .7I:\0KZ(UZXTV]UFL5&3
M#U>J[6TA@##:[.02ZW#DYF$:<YM8E,:;#)  .G/^,TE#2$EL9M^C#Z=XBP)#
M?]>^]76.6:<#SMG?=M_N0SS[ 7;7&^?T-L2?;($_?=M675.M,:?2E#62IJ"6
MN+U[1_+SO5M@5B0 2;4<D[,'5-8%["$U[EAH+?C@9<*6F3Z$] 7/7&7Q_@[3
MN1<H]#N!:;]?J'TG58L!(1Q5N!:A &$112&BY$IP65-*L]V(.9A8G.:CK/&1
MR6) Z9@Z:1(02%I)DR(7 Y5A8"HX$!!#9QDV;,38PT2'$#(NV:2*%",S;IAP
M!P^'HW2YLV5NU1HL;3MW[]F&K7EEU_ IH.R!A+$NE1IY?/#()H&<#3HQ,09#
ME(NJ<,*BB4+;NAD!Q"%OTRX4V)NVQI4;=JWZ-NS5LQR["@[X[Y-O6?[OV7+>
M+6X-SC+^-FJ!P]G.5PMH ][4X?L_V2N5_8DA:V5JKGT1GLNLUU)MA@2H4X7I
M &'T@)R';0$0#'AQ923=P4%=OO#&H1%B8E/D=]Z>B_+8,M%!R6E<JOT:%QKF
M%75V[5B;V/Z%J&KSP4N%M<FO22S6Y$ZA$T7/&D)QN/UL]4$J="@_A_QLR+#_
M !<K3!B?BI&J/^)FR.\NH\./][GA]]*W]XY=:8^O[6W;WCE]C#+Z=\ZT.R@#
M\MB@A2T(G+4CG2TRQXF[K;L"G^PP=B_*9^/7_P"AF_DC $)]Z>_KWU%)Q=G?
MT^\^G0>583<Y7X^/CFQJKSVY-E*RJ?B_-FX5/B9[K=/K [$\X^X+F7ZG$%YU
MB4K:[$_6:QSC:=VAT\@8KLM\6S+2<(&HD$,%DY[UD7I=]*:_E>?TNV7(C=12
MX_'-@@$=SUKLH2F4,^4)\>2O>_H9/7(]7&S(Y6I4&Y6O]V:_)W-*#S$.9N:D
MUN.AC^)#TH?^O_'^7FJ+5OBCJ)@AR=WW-5%-C6(CT'7R%JV(H5Y!.E^\>L^A
M8>6W& \<F1[P[ZSZ@PMF^3WCWUEUJ^G\>!6W5CWZ<L>75H&+ZZ1&1*:O6S7H
M@V/0V^M+L.E:(6?-TJP-U4OKX2HE"K<4UY6]A]O)C3JQUSXM<;02M)*;G'>7
M.Z81^L_;EG^:*7+QJ?;R%3V"FUQ8UF+"ABLTS7M+M\\I[:<*S6EY74<Z)<'&
MV[58XL>5O;DU),UY!$+NV([GSN!]_B'-7I4U[->[7KVZMF&W5MPQV:MNO+'/
M7LUYX]98;->>/?>.>&>/?66.6/?>.6/?7?7??7?7?/WP*G/4<.9UXM^:W",-
MF2I$Y$],;!T/3#E;-Y;9G\?E6Q]>J!HTZ^]\[*1-U;86KJ)CMSW2L,X^K[6[
M#O#JNA5>O0OC:NS?GRM%1H=7CRA\;%VVOXD;B2RRNF+%03V>\L:%549=F_&3
MH+V?YQ. 6](Z4Y$K<19*Y7ZV/R1<[<7.:N_3U_\ C_EXX%(*Y>]X/QCT K^?
MO9#+<%032'Q\1*M]+2*PJ4^=KEONVZHZE>U<+<@)3JG4MH:^Z<T+[Y)-DPYD
MC4[186T.?@;,H,02,U(']>VVON#"@^A_;SI22%7_ */^19(T6K,IFG^FRR$R
MAQ%*,M2@#)Z54<JO 4I9%6(XR!Y8&E!IUJ[%@0G1.YS26UY2_0S_ .O_  _D
MYJ0F<J7.]4M:), G"]-%4V4>3U;(M)U'9%4[VVJQUBGM037NQBS0\1MT5@/E
M$96C;M@3I<+1#V:L9TSK8%&5S_)1=5;^+IQYJ>I=8^L'_P"-ORW?--KI:LL-
MQ9EN-H9[ "VX2#+NQ,( -C1O@[:T*,]52,)LJLXIK5LD#8@^-/-Y;A;[T/5I
M[$N%02?21N!8;?\ (+Y03Q'DWNKEKL2]5E8- T'%N!KZ:)=?DGHI $(L&P;(
MF6,"<(2<F%*HB()+7&,F=N@I>+GGAKQRSSRQPPPQRSSSSRZQQPPQZ[[RRRR[
M[ZZQQQZZ[[RR[[ZZZZZ[[[[^G-95C=U+W9%-SJ:MVL+;A+1'4(8YE8ORH^Q0
M!;?&QF:19N0JEBND41W0\\)6J%.ST2=D;/'?AJ[U9=9=A2NPV[8=!TE2+ E:
MX5= )-$_%.FW5>,*O%R6X5+3#HYWL!MUTF,!M7.:.]"N(75H5'R=Q3.JUU^I
M2;/T A2"$PAGN/UH1@.E0?':95+5-^B@N/R@>;-\6V-XM:RE'Q@>R+#'[9DG
M.O%5349 Y;_#=KW3*'7QPDO'%:C.>^3LGYS)%RGTZZ_DZZZ_AUU_^#K^3K_N
MZ_T<<#S,>VK*];;*6L18/7S9#HE^EO*7S6ZF%%AU+40@4FC:+ F,:%#*! 55
MTEQTE-:IKF*12:T,K'N?L3$TS @BB^H5L'999?HV\J63; J=:OMIH<_3_A'R
ML^>)E*%5%<,LGUI;)2"SX/R>67-]0,!1PW2&P75=3& E0:$HJB!'HFYS8.&W
MO2<&^@XL_(H!A&*)US5 K6;"'V4,M%F$2./EEU5_ _J<\-$2Y>DA.#+OYF-[
M.$XT?;"$]3XG<[=HZD:N\_K!>$LFTED8:W+!!U A0S&<4(1X7*9PZ\Q;I\<
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M#S_$AOM*H)%WZ%>V_4EE1ZS\$^+_ %P*(61-US,'^_:[MR\V'T340LKTC8@
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M'B?X['>"4LL5TUQX5Y3_ $@^J%TZ%N1K3XHQ=+[JU JQ!PKX-CH%+0W" ;C
M ^&S&9LODXX% D5BLY6N<ZKUTP>P=]DFO9OLV6YURVUO90SSG!\\RZNN]J'&
MU@SHJ^?6DT%+=9M=ME<,W9[-Q>+H+3$3(SO5,RH\;N#Q\IEU+Y#O2[98<"Z1
M)VZO-OALJER3&JUME;LY1/K&U1]JZ<L-,79600@J%MXO1M#&MHN:),%\M06!
M'W%^M,BT_NX:ZZK%BN/]0X_LY51CJ8.L7Y<6ZQ@C:\F&H#?)['90>BV[$1*7
MB^O+#1!V;)743O9"PD:]NG/9WRN]JCG-<!RT5Z)S$%IW)3;IZA$8GY0SQQ0D
MYN%Y;)\.+JF9X"3HF;U*'YRX6>N;JQPDY;,=F& 4S^F%%T3??7JZTE/??X!K
ML3XK@J;0;:D1K29U+;>B4Q^NC<T2*&#!C#6L5E3111&:Q05SA:PVP^QP2,4:
M0,FMG>W#/D4=[\\ZKN5>4.2]>-;XB>>$IB0K?DGKCL*,^68:]!#0LL+K3ZHK
M@\ LBS^@FDH2L"-9^P-6B97IU1UKRG% [F&<MWC,UB(R8>KY6:FD,!8K79R*
M76X<E+PCSG-K$IK389("!TY?QFD8:2DM;+OT8_3O 6"G[_KWWJZQRZJX+<KN
MA*P>;FMIDTJ%:ULND&MS9=\$H4Q$@QFO[R5(UBP<$F;*2<N^\-,,6'&D"A&7
MMT0A\*5+WZ=.844S-EU.WL#R"7;M?I5@O>L_D+^1 L>42B?:.CS8CT9AYK]W
MUYY*/]D-:U%I47&8:VET1TOL$5QP83K/93KJ.D91R9,@@\8J-A]IOGFXN99/
M5S_3]L2/.U.Q+P7'.D/6#$75O5NN\DB4];Q\V<AKF^NTIET1[2H)B%T'T17P
MR@;7+C2I^ A2'L9GT/);<*?%8*X!(K)!%'H?4Z%$;T]K06:-J[V;-7>DRFO(
M9>;5^;ALU9]9P#H4=-QQ^SL[T?=;->>>3\"$]#V6ZVIX;B6%*KM[K)W)UE9&
MF$FMQ1U<FW$HO;VP %.PB5EAA%CGA;IV)A-Z7W8*N"=9*T>!Z698$%^Y0K1
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M.S\"2@=PFE0*;@K&)RUDX<+;NV"RD??#VR8^&Z%NV:L^XLG?KZ^WS+N!3/\
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M/23#Y#K7(L ;!TML]$JS<_HQNMX Z6!U$-,R*RU<\PM9J?&B+,K2#[GQ#6Z
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MZ;G,]=9B:^>#*'7,QSULE: V2PUO?J,15<UK&Q635I&%($:S'C@>:^KO*7K
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-CCC@.... XXXX'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image02.jpg
<TEXT>
begin 644 image02.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# @'_Q  Y$  " @(# 0 !!0 "
M 0," 0T%!@0' @,  0@)%!$2$Q46%R$8(B,Q)$%1"ADE<29A,Y&!P2<U-O_$
M !0! 0                    #_Q  4$0$                     _]H
M# ,!  (1 Q$ /P#OXXXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....!#GT+]!/&?E%U6
MJ\]$^@4>J6YKBAB T:R=F.XT 6Q'LU9?,MAD:*G@T0$=8]6\(&..Y)>$$R<:
M5#A3=^Z+(PU3&Y0)]OZZNOT B=T/2M2^W'ES-J0(RCCJF"T"2\4VL^#;(!,B
MXB>R)=@E8KS$0ULJH#R#!I@3509O4F8ST,F'R6<H?'M_JFU+%<K&NJNWBE6J
MOQ]0R:R&KUK39,#=7M[27*O!C:VEJNTX;]AR.$0&67,2"O3#HCR]Q2%WLT]9
M8][<-0;UDR8T*-(F3)&B)#B:-LF5*D[=>B-&C:->6W?(D;]N6&K3HTZL,]FW
M;LRQUZ]>.6>>6../??43/.GO+R/ZV9VQ0\Y76OVN92Q<<Z:S7133J!R0$HO-
M QV%7:BH$<KO*_M,#I<#$ZDF6$3_ #Z\.NYG6,B/EMDF[#HYA,;A,M=[;XA1
M8/CI2EC+C0,FB/-%2XVY=QG39,*'"[-Z]N0SJ7+F1(T?N3_-ODZ-6&>W#B=]
M&*7KGS/\\?>-?5:&]Z4QX'K*A_+XVC4+UNRU:NWI37HC#VC5D/=6/F:VZL:B
M+H9I0=7.W 3 8W1I*P@I3-?'JK&1$]E/XP[B>.<25U>(_<3,;L294]'^V::^
M<)WULGLA/RU./P;K]&;=L/R>:27JV8M=&?269!NK<IZ$R 3)0+9>\N05,1NK
M>@*Y2)"CYX3HH'R3=M>>L/)V[U!47NKUQ6JEY@\;+/E:V&=Z#*TWS3;:'8U@
M,=VG_528B7W' #G7!=)UC**&-LNWHSBL)N=9["C3.VRA/86\M_U'\?(Z%3E@
MG&&W]\._,+@DU6H+?F3TDYVLQ"J#G28%NL$BH4^JCEE@%M*VZ-.\FP,2N*$;
M!Q(24ARY(TG$E;)OH+L LM%3+&5,R6U7?E1>=%O:9!FE@OL M F(;$;"BVQP
M!;" (9CYT?*8&.#!Y<9([V0B,*+,T[M&'&P'^=/JAFIWYVM=@><[K+7O4WC?
M[?*[JPEF9GQ>4JQ7%[8&;QD&(E(COIV:3;5(93LI"[ZW[_S(\^#%G[\(@H=I
M&S)\9^9_0"OZI\\,GLCS'ZNMF6,\G_-(/Y8LD3:,Z/67E!OJSS[V$]=A[N%:
M;B5NA3C,LW\PXQ:S:?9.RVM<L:N1MDGN)(CX!=?=GT?\1><;BAT)>?H51K*T
MI8%3:-@1H'-400'6WM@GJB@=:'?4O[D10$GV09-"0)[2RAXV9'5C&SV:\]\?
MK;-??OU1]&Z3MR[QTZ-6S?MRQPSV=]:M6'>S/+'7JQSV;.^L<>^^L->&6>7?
M_6&.67?77?/-ZI^<=O\ M3Z1^K +4XO]0^,[J\,^3*JM8TN(::<PO;4C7O>3
MDV5*NO;-LG2Z[,0!!H7B7-!E\D1Q$M66R/E"F:!LOD<DKS%[7A_1P4Y2J:]-
MCK>A_4RXK<=?6A*V,I_F-A^5A6N'076M #@_=DR!,PA&TSJZ5A=6XU7H-++J
MND7;>6@ZL]I3@7V>>?=?FWU1NK7"CVEH;H=N43EZ/0SFZL;*7E@O5>#QLKK*
M?N:6-4%+PQDZ:M.V-TC$R41SS&Z^SVL%F"[P(Y;IEW0BPKM">>]^QF_Y*8*R
M8+=':=*0XR%'_%++,!42NZ;8>@'L0QQS VRBM<55GL4=EG0]NTE#%;A^C;)Q
MXOTGPU]+USR]YU052E_1:WTE_(^EZNMNOU5YZK<Z?++GTK5K(OJC%8M@UAX(
M*YGGS'#:=(N9HGAR)1;G[EO2P:=A3H=MFU>OE[UPQP&:-\\Z$].^64XK\?O:
M%:5 DV2^SQC&FWR\>S*:> RIM)F[6>M"59-CUR(L8Q7N$ULB;DP8=C#L22CI
M'[-(H.KSCG$XT^'?2BWXJF]5=7WTCLX]_P"6$:UJ]\DW'4P!-IT\P+] SEB<
MAV:IU[[<@V:H4G8#9/'%HMM1;#[C)MO+LAOUI1(3/P*D>S&NMK-OKY$WNH*,
MK.6Y-6-K:LPS&;#$7&;8$@YG@44_LWR<SD805[EC]!C.3(S)ZH^,W+?M[W][
M,@S+CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M YA=AUQ7UMJ!:OK32%.QT0]D-S-IKPOBFE7+YABT \(R)@C46:,G9##@L:7@
M=R8VSN(2@0YNC]DB-IV89IQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<
M<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''
M'' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <TDK>E//CO:C+1R
M?=-9,]Q)\0G/9ZS!N8(DZA880C#$'9,Y?BS=I'7J ER, 2>RZT9?TA6;%'%/
MQ)N_7HRW"1F?UP^>0ZB3)_<&'*F?@CM/4DA-_%T9[_Q($?O/7U(F2/V?PQ=/
M>S7UMWYX:^\\>LOW=4A5HQ,+1[T-^NV8/Z)L/SO6E#GD>K.F[R?:%,L5"6OZ
M0OBM8C77B%66:, L&]>F\&+ &+<M><K' ]80:[A2NV?9H:&N0-"X63;M5P[-
M%4M)L9)TV^<6BKD)J_)F#_[Z<H!)$"(6:=*EU+[.=KP^65&Q))G*%B.PE3HT
M;\CO=NPP[SZ1(T1-&^5)VX:(T;3LD2-^W+K#7IT:<,MFW;LS[_3K'#7KQRSS
MR[[_ $QQZ[[[_P"NN5$#3U=G_K2U6@/J-^&?\2>*WU"FVCI\HW !PL6Q&:W
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MCCOU?Z'")_)F*RR_9,QU9XY8XT90[=]B,_T-\R#NJ]]2HRC'M<?7]_2"^_T
M2J*PZM-^ &%_[L;2HP*JB>7:L68OHCH$IQR,&SMMTQ+/!GQID:$"EXR_!AM2
M25[=H"A$&J?,*[ZR"6\D#?M?TW+=CBKB.I'5U;2SFX>-Y,4W: ^=6IH0V]'
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M]\K+3ON__*"YZ#O^UX5CL%LLE@S@ 4-7:W7P&OUI2L][2 X&!K#92BA^9+%
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MS?KPQVYY2=^667?>[9WD'.!:?T3]C: =RWJKV0E*R;Y_\>?*GTP0IN/50<U
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M46$ZOCRAI8DY;<,-N4@ 2E216[+9AAL[V1,N\\,<N^^NLGS!A-GXG\@<7L_
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MT!_E/6/N-"6VQIU6/&(>893BCDZ?R9/,ZG8M3U8?NV,-6+8@]5--'U<YYPD
M3:\@0QSY^/3]QP.60U:7T2=T!Z+XW/Z[4<:P^:_OB^*CG#*M7$MJN9ZJ+U0]
MB/%[-:2^7IGN5IL2P?/P!#.L%8!1*F4;XS%(ED%Z+LG;H>'1!1EYK-K0):QV
M8T[;;KQ0J>?=2CJ#FA<A(9K.KX6^"A<S42A:=&$B:+G]S\!T67-EC(^S1H)X
MQI.>&O/9:38*/9 PD:06L$X"0[2V))0BO$8Q.' ;D5A(*CBNRM\7/9KU%EMD
M$D@Q:'EWUMB3X>_3GUUWC^O?XBE=%KC4],8D.*6<&@V1L2P"T?3EKVFCV 08
M,GLAJ1^NS=+EZ5]=$#<=F7>7XXL1!A1]>N/%TZL0Y=9#%Z3NM04:C?'N_P"Z
M6]+^D7SZ>YGJI:3F:%7&0UD]/V%_>#:\K>R?/B!NI%QJ)+% <[*4Y$.W$-0%
M$4H_L=?[">2'Y_9Z5]5^UZO\SVJ@!CGK65;E:67]/X=#79AH*">FT?YQ=!6/
MG)5L&.H^6[EFW,[N ]DPQKA?VA:JKVR4U5;)#$_;2L*$3A]/];6,D7!7B+;%
M:,4%OKJS%!<?D-K&=2.AK*GMPB(>6ST#J5ICR>H98//ASXW4B/HW]:=^'6W3
MKS_=AU\#U;5;UD6KD&_-XE6*6VY2Z^KF*5V;M7;4Y0$=PLF8"@[L-.R/IE1D
M9 <F3;MG;8L7$> F_K(_G[T:=P<^;$E6 2]4;6+8@.W<<G]\/*MES)V*4R:(
M'2SE\8*T7CSCCMV#?X]*H,=\9ZQ//Y[/ZH:?T[ LR;J(X91^;C]K6=[?U>V&
M"N$2XI/GM C5_P"?2'EXQ(KRW7=#LVQ#[TV87-H<1U8T\^0GTB(T"%!4EUTR
MOR'V'5F6.Y#=&K&9.8HMXJ2[*-DIRO8*"QB&](=@ EI46I?FZ201B73L+22$
M&14^/EGHEP"$&1HE1M^O+O'/5LQ[_P"N_P!>NLHX'/&A65[07;C7;*8K@]!%
MUIR^BWU%H\Y7[DFK>NH4#S94E5>KW>@&")#CU^$*QQ8]TIRLL5"PF1QWQV0:
MURUGLH2@EA&$71=4^K[R#U18[3:5C>MC5JO*3XJT=TO-:6U,?*U#V>Z[P5O>
MK>X1[Q<',HGG6:U3ABL9,U/6%T3$J"NL,<=,7NCP?,3TZLJV!<EQ@4&H3!/K
M#4$*K;&")Z,9(TT!.0-XLP)(1L_UPD02(^5(AR]&?7>.W1NV:\O^LN^:5J#R
MQ2-%L)ANKU;8>FTVL@TB2U/5EVC;C- 15J81(@4-;/VTYNY911!9$K/(14I5
MF!E?&?OZFY"<I.F/MU!SSEO3'N%B\6>7(QI]]# GUL1OH_FZ6 J@WT*X+.=(
M>F1%8>:[?MPJN>0V]XW5^O57.E,)R20I^I]%GZ,M#05ZT$,8H??O.D+E]=V+
M[#!CQ_IF5$K:->"'LI\(:4K3?DKT;X0DTNL'PUD+A]/IO_BX^P6SB7+N$B["
M=Q==)SJ+[628^'$QU+LNZ>Y?+=*7X1A&;( ,^TW"6#B/V<1[1M:I#A)'9I$.
M6P)#"9J5V2";0EEY8^'+G*3)**KV^5HQD9#?YLL\\ONL*S:&\A5&!*.YE<J*
MI5+)%J].&0!,S*''D$Y0Q)KNO4=06!Q P7(S)&P8!6517#3Y^W7KUZ84#N/&
MV=Z@J%^EUJ>MT"T/9NSSZ0LH'DO?+I$:ZL/(5;PF>>-O&;ZC=@)"2ME=R@=V
MFFF(E=0)&Q,WR24#0,_:9S7]?>_80SFMXR)W: ] ^]J3L=UM>T:[J2RJ2G4H
M]VV/$=L)859/G],;7P,)9P*HE+3$!#6!_<90XXX=W@LS2<\'LD:(D># @RRK
M#T+3US,]FJ%8.6MO.TVQ:$ZR]8\*QZ1JHX;H>$[>HRV">'AK\MJ#Z=FO6RK@
MPI.,JDS/$<RPA)#O\7FY^!R*RO8GOFPQ'J.35AKUY6$!GJ#RJT*@UR7M]B6S
M2%JM?T,%U#:@6/H->4ZX1%5O&4B1E26ZJUWNXDL"OQ(C+@=VPOYR<R9U@^D_
M4OCB+Z+M=@9K_O"G_)'O/&HL%%O! IC?==-^F/)7G_;5N ]@A)ZQK8M->^W[
M9#KHAA7HW>(A&)MP0KM*[US3AKZ#8I09.E$H,(C F3@LC1#,0XLR/(E"9<J%
M&)QHI*/JV9[H$B0.FPR&C1*PU;=L*7&EZ\<M&_5LSPRRJJ0K?#!%ZQ@&+*$7
M7M!LH6,W$"L&)@YU>W"7M%+3-(N=!Q*Z0#<!#G=(DKU-#2IHZ)G/'RL=.&/0
M5-?1ZHKL)?'^4DN[9:[[=J2*\IMUNL]3ZY$AY8RZ%=M0-MT'0PU-7)TT@(!C
M!K>SQ!@(!)F8B@$++5HG;HV>,G4'=KW>G@OIMZ$UV7[6N2L:I:Z&JCS+72OH
M%+^6ZKGOSEY&8&^ZEF<3H=@;CA,4[V&_L+^\;%>P)Z8O+KMFKJ&UDB[(^?0-
MQP.:'SU9_M^\?_%*L6BX?2*:G,?T-]Z56Y6.IBN]S6:\UUQ1-HO%(X&K.L?S
MPC2YJU-<8R\,6+0G5@F&VJ/I'Q!D_85SC%.?)0'J+V;TV_/YPN%F]!VE)=Z;
MKI#>/.B(EM2%9$)WCVO=*FR>EK4'DZ/E5E92<P(RXJR+#&3;3IZ76VT#DV+X
M6=M=!6C9T465:M>T\ &-%F-0Y/ &75 KD84*=2>X\QVM-T!5W7R[J_%T2-GY
MS0ZLH)>']YZ\8^,TEHRD[H\?K;OU[!X'*,@^R/:K8(O=@%G/5233A<#\\W5X
M(M2X?M*]/-JA:WI.X4SV!VK:IOD>LAD&TT6J@2/B\5TB)EYKU3Z=I5V3S4SN
M+WW$E60BZ>O?OD"Z0-Q^M6I!,^#?7E65I8+4KM@\185IK][U,R**18HWJH@L
M+=)8U6"T&@!9Q& L+)$U\M%1Q YMUYYEN@[C@<H50^AO=N-)U9.87OT\O>M(
M"3\U8?F3SL)HW*#2-VUV[TKYKG^@V.T\X5,[PD0CO<F+T2+MF01=4;?1$%#7
M9 :.H]XQ=9N7U1O?LR'Z217EEM+T2S*;O]>/9GF0O5+(GA=%1JWDI;I;T(T5
MB<A1A=="V32/'/U:(&Y.LXTX3(<[I@DKW<PH/)Q(N%__ !P*(/H6_>LP/H"^
ME^B6:U447-\__+8:J.U:UP#9"J\P6?\ 4)JK2^22^9-(K5!*%A]#$.M[$O&,
M3 5>5]F;1+!0M6^05V:V9?0/N#S1 N=Y@D[^OM(H#VY?/EH G,E=?Z]SLA!N
M[S'25B><K'GDUQ2 [S@*L/6YS356+P.&9B1=9/K;I89TW8H92M=Y-NWW4=$:
MD7.U7&,L2+/?!58UT*P&'&!@=GTS")$X*RLK:P+-'S$_^J#ER\WN$-W1A0<6
M0+%-\,=#D2M?\T[?U0^@(#:7IMTB/H1)=6*O#S"'&G-:WVWJ1*2&918%C(#(
M8-NU!#$*:)(%E*>;#:"D.6/R(?F1M^G6%#5J63[AJ9S?ZZ(WMZ7;/353&/#Z
M+Y.25BG^IE&>M5Z<@TA']'6391L;3Y$#,P:;.)W\.LDF1>T[.F%)266,1VM;
M9&J>:Q8&W^N_/Z,=7J7'VL-@^LO6?U>\P)$376Q,F*HOT59OTBNMH\Z^I2NW
M:!W3 M<]5,QV8PG#Q_#-)+?Y*N-NG;MQ+=X3^F_GGCRPLMU,[%DAY+H<0E"2
M'8^9&F=02D'+'":-F=QMFS\4A#RRQQE0]_[),?++'K;KP[[ZZ[#GB"FO8=A^
MO(5)[+4]&U94C)]#O;*<U.->HZ@K$S%.U[XBI [5F<US(U42$1A)"U)1Z:(>
M=,763/GM1 % .[^H6N) C_N]7^MVFJ_(Y.^;AOJ@Q.CR7XHLV_[C@"FZLE*N
MV%@NVU =^LM]3 'FVPX0TQ8%95^N"PP]Q<*B554^8W,L3 >**SB8?JMY&"U?
M&OG.[&DFW62BDSA%BA*PQU%P;%L]62K*%))"234Q-M5THN8*O[<$@9<R7U %
MV8LM<#7$E2!V4?(?NV1<@K0^T7I&^*9188'SQK] +UC;* ]$VW7MA5I)*ZZ[
MFV;6(M2W(E;'12QYU]"&[&?VB<7VD%>M#F58(C*L#'+89>-4Z,.WB+LUF9-(
MK:^0(X9:R$X(*F3]><?.+GA-E0(^^5AG%V8X[(V6._/9CE'SQQST]]=Z\L>L
ML>^N:4$^L/.IVQXU1B+66YUD3+/?J8C*6G$G_9[K1JZO =L/Z;CWG PB_P!J
MKUTR VLAWW(ZB=C26CJ-)WR?Y(^$AN XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.<TU+6EZ5?O5[;@CV#['<G50
M^P?H"J&("9'V3*\CKWB%<49&3F+GGNU[&F8F:A)G#\:]ZFLG5KPK2S$@P,;:
MJ;I<79TL\C$2.^??)1I'68:[@D$/8/IL^%&ZE@"2GZ''T"_(KU:K(PL^^-^1
MK%;CJU4[)-(&IF6B#W,@0H?6.&R7KX'.*=MCZ2-7FE63UG3[_$W%7WQS,*UN
M,^ZK+A4B9'W9!O\ \WJA8DI,[&HQ(E@7&*6!MLE(+.I:V$5/2B\PT*)$1\DC
M^):-F&L"L?<@2L[%;_=)*C%2I?.>'E4P@2[SM%.?;+FV?9.'HLAZE?UX(T#B
MYK1#VUCCM@W<;&(@6K)!J>BCAY6%G(&7(\PV*^ )E@&:STZF'IG J2\ZD-NY
M1:HZMV#9RS&%%807G>&UI9,Y^<JENR"P./R6,5"Z@$B0N*/*#Y,D.9'S,M^P
M_)GGSS\96JW]E6#H-^+?I^6MKSS"+.2]V*L1+O9!/>;0*$-VKTL?3%E'5]QL
M;I#,AEB8XN@K5LWZ!3L7'#M&?RX-GMN-4]A-DH][2*@ZI]KVH<J7SL.6_H5'
M;?3U.$/(5''T^L@7I:74H[T0AC MXLMF;J]8;U5M-6L;;HG+3?+R4E6)E ZJ
MN.!0?5/_ )Q./N0V5M.W+DIJ0-]2EBJ[4.5 ^CGVF6WQ[U60_>L)?_)BLY;/
M'( L3DE9&+(^E0F^V%RU%V8-US-HR</B2O@]T&_8<2Z?7G^,(^QX+R+J^BM_
MS-"^?UNQ2E$M-E;M!?=86%YRDY=*5;O[_P"2M<$;9<?T84@ 1%(Y0RR-A&*[
M)Q+"_P#XX%5'D-+O3^/Z(69:-C>F![<;]/\ J).I2(^;V]O5J]II;D1\*K8*
M-I2;HT+YX5_+^097)D$46(N'?78"$7W",] [56-!M+U\"\J1:=F5A[JL\O'L
M(PG8>S1SM[W1"-B'8OE\DS"K8_XGV56;]:H84S9NB*EY5E$78]"#K=ZRD:G'
M8I;.P._J0XX'+@SQ/?<T8"N,4NW4NVS8'S3^)"UZ5LN%5ED3;!&XZ[_]3GO9
MT!86J_Z5W>9;*<#=AQ=X2J]D#K)6EX]/DKL >=_I_P!DY)4?V,M_,Z])576]
M<MSVO-LG(G5YR+2-N5E?"9Y^*VF@Z[(3D19]+$6ZXGZQ$ZKL[:GU*Z/^\JRL
M1:0I#QVDAV)%[)=O+"^ %AD0U0IK8<RUCES 1:S%*+4=#:YP);*M<_\ TK&%
M#3U]+B9" TWH?/;R8.&7)]: HG?-+2H\+9F7 Y@;8JJ[[T-B559P]S.?DM2^
MD_S=;*39;-E^CT:Z!,?#MEC>K#^)UVB)]_ZJ22>Y*03%--@8:AZV];G60HF-
M 4:,RCSG]PU!*R]X?/\ MC->]#'TI4HOVG4$T_64Z\64& L%U'T"1J,?9D.L
M]Y&7H$//2F]:#+*YQ<E8_/7@0]Z)[]<<-'SL[K.[T&VF>[E%-EE)!OSW:>BF
M[*TD0T\5H@N\BLZYMO3%%29FK7I-#LTNU%"9T4@9;(O<N5*A]9=[(F?>6W.!
MR;5NE?13S_Y(H^O:)V>L-9,U\@_')EU#-X5Y==]47"GW71*?<2E5RAEJ#9HU
MK+'F-FMF")JE$R -1O<DJTZ- DN@O^ZG3ZW4AZ:N/YJ>_P"JDN]+'MMIMQ>L
MP'YW@V157HJAW!8%SJU7X9.K-3#ZJ:S]SN AU8]3/#'.;B6UBQ.YLGKD2?DN
M ]7<2\_C@4O>D?03'9U1TL#\Z53[!I]25K=I@-ZEUI_F6XJNMJJO,.S;,A/"
M)54K_"13I@F+9QM>Q&__ ,:?]L4'5:/:#*:4Q[TA"&<7455]D6U<].HII\]]
M+'D[*Q?H]-163>9M"KK79:6"UWYGU^===WM1 **M0=)UVT=OJ11DBQ\PEE,2
M@#6^SN9J/M+PR72'QP.1)SLCZ%TGX9N:R':U?9XUF9OD-XCO)J<G/20P:4#V
M>R7,T +B6JVURE82'0K!U)NU?%%:O$0(.F3KUA"S $F%R,XP1E*VO7IH+LOE
M32E7W]8GF1W]"5JKU-93X7]?UW;53M.7F^P6.Y#4C37]4,?K=DH/?9PNMTY(
M@BU&'7,>YV$YIQ:H59#NA\SH)M*JZ\NQ"8JNM=2$/5?-FB'&9%0[JV;Q)C1
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M*_%$'QD)^@F^[8?_ (E'1\8B)M+2G6#(W3-4ECWJ?X^M$T*>RQ<2,4_$G0B
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MM*%YX)U!\E:\4X27<)Y9PU85K]/K%M+U?_5&]UB#',>?@>>6",9<6SJ?I/L
M:3I'QS!4AJPB:[07;V DJWJ"D?* 1<,/-@7/7#;<G18&PU\,64NJ5(ZKJ^YO
M+[69O"FF7LVPMPV$O@D *UF9\2&<+YQ8XP1)D]R,U/B/N#;&+2YJFY?TR\Q^
MT[J8A&P-JGZ^^NMD+83PF=PL)>'??76<;+?UNQ[[ZZRPZ[[X',M<]#^A$R:W
M>;1B:3G5VS>O?:+[2%.MUF#)B_,\T;//5 QX#V#%-'I^A,B(=#O:P7@PM!BM
MH:2"<</S"@Y0CC<()I=G@RS2-G_,?QOGY"I<KZ"JMMZ\^0CX:QA!T0YCJ1P#
MR=##9A.KXEUTM(?VN&?AA)9-%W6]&"SM1DFUZ)37!!Q(A6SVP%3SQ=<42I6H
MM4O;<+N3_: EBP Z.^Q>Y?0?49Z(B0K'&*Z>Y/2_*TE?RX<;^7^GD:IW\GX6
MW#;EFVIHKY>70,O2Q)P-2D:X(A8DZBX08N[]6&G\<8, [L)&@9MUXZ(_\,&$
M/RRQZTZ/XX^KK#7^W$.9Y!\*^P+$HGSFJ>A4"Z"ARLOEM[\K_(62N0N(E"_3
MQJ[JQS\M!#F*Q<IK$RTCJO%&=J(3+M;F*4<!T39L:\30V 0UR$K%8]2[/9/F
MGSE8+*XYB;3HWS/]#/4,LJ^Y[#Z7;GF:N%.AW"H]0X5,W:\05N7/ HFPR?X<
M[)</2JXN?1E#G=&9$K*W-C]<4V(;[=K-=)DK(MRB\ZBRLNI$2-"D/8&%=A2#
M 2BF$5E)+ 0B.Z@3>V,WM@')&X2"B[=F[1F2E"QA#=$;57FU^)S8>M,V6CJ6
M1X@S+C8 \W[6G1I\DH)%DY&KKMAP68Y0S,(CX4K/H7JGE9,N-JQD3MNS:'/O
M])UEJL[W[8%6@*FON]"1+Y.-)"MTVF;>CUUH2[O)>B2(&M+-*P2=O59"CSA!
MK='SBOT'%@*ID(9.D9#MD7=^WKWZK\D^R\/8X5Q](.7HPVZ!+?I)W6+PJ 93
MTFG"M3I5!5VONU6,IQDLX.ZIB<VV1 MJ%9:4(J+,BV[6,4X@)9(D2_L@]\(C
MNLC[;); /:(:>HRS !RV41VODFV.FD)NTT,#R3,+^8QJ69I''>6@#]LG$5)F
MX[9\?3GOZSV\R7>>!Q2\%?DFA,<\3CR98T)O(P])<A$A]?K+DP1NS=C-EQXO
M7_<G='T[->CK_O;ECUP.;"L/#GM*N/(GSF4ZD#V+6WH^(F>M&/TBXM-LDV>:
MJWY8OAB^J\J9KLLR8=63<R#0ESGJ]C+PT3D>#J6R(*WCAHN.._EU8S/\G^L9
M:B5U4WYS]05)4\6C_+Z_ZLHUP] !YEB^KWQ)]+U@X7[#JEGBW^PZXS6;\_@[
M<3F"UI3M6\JXNWL&N9%)'4'N2+Z9XCBH$!\XM :EN:*&3NQA(G$.#)(\>2QV
MZ=.0^=-TRLXT2=CNDQ]/<3?LU[^MN_3K[U_OVX=9?SVZ)V(.4S9-BSBMP=^V
M+.8.SPOH'#DZ)74+?'E%NY7X$??IF98Q-NG=(PV:Y674?/'K;WUAP*M/GO0E
MJ56I?1G4(JUR\W=7?ZR;;+\Y"[6:1+X:&K1GR5YK0EMI)[!3E8_8X3!L)*8]
M6A-EF9.Q9'B<5V+ U0(42/U"9-\ZWII\Q>:54IY,]8Q32)9U%F/H^JE[U"D&
MWV-M7*IMQ:L,^DF?_(PGK? D>_2=?7$RQ21A"PLU!B#E'^J*XA\$T3T8;65<
MT%QJ_O/A-)XQ&W31 3:5@ZRY6''U[-N^6-&Y[^IDZ-HU:MNS=OBZ=NK5KU;,
M\\\<<,N^O+P?T/9JE;];LHYZ(,CN)-W8,@;+5#E=0IA/N-*V8S>\(\CH:/GD
M.].[O#9U"@S)?>/\$;=LP#G5 >%?2%ADD<=:%9W3$HT)5_UF+5#53#>Q?6=J
M:%;#]Y<W>,JPLB8I6Z0_T#1!" ;A8D(;(:7,34L24)":SH<JJ#NH&#;_ !![
M6C^8K:KN"K7_ ),US>+/C/G8.W?Z&:)[DP>JT[T6US_=YF&Z%+5E,2T\PJIT
M*&+L?6S(,::$"A<,%+([HT?1WT?[+;7];W!3<AY?^I(UOG9<:SNMJ]_QCF-[
M81:]%!],'9_HAFQ$<BT4L.UZ0FT))#]9[\3F,O+1!WY;VZ)V(6:R9-BSBNC9
M&Z&1/=GA?06!+CR,8F^+-*=ROP8LC1*SPC;M&_?KVZY&>.G/''9EUCV% L;P
MUZ KCTU,>:;4[855Y9^H"\1K";NNUN8495\;-OSRC"[/*P$1CLPL&Q13'KHN
M:)-RUN!=FC+1HB$(XG.$*&R(46 /A+VI,\BVDK$X_LS1Z-8J@\YUG=(62T5<
MBI=O6=#]24JX6_<RE;*%>QZQ6QV$J *UMRR^[=J5WC6;81#S]$5AVB%L?TS6
M??M.TY2SMZ(L*P%\+2U=JIAU;;!CR<C8(<M@<-W9.?HV <"6XIEIV:-D75$%
MZ9LR5.ZQ@QH^V7GCI[U[7GK>J[)O*X:+"RLXY6HP=%'.FR:37>E"P=5_A'8\
MHPZ^FQC$B8;FPH**3[*:-D*+EEE)B9C?SM/\^W4%/CKY-O-(LYR7\Z1NZR_"
M0#Z"GGS_ ,?*YL[J4PN]2NG@2F Z^WA];-;ZH4/5HF^R(]FL#76YISA==M)O
MIT&*!:$O]8:_[;?(OI.T_04'%AK6\ _G<W]"?'=E3E0K>$[&2(\](7RU;ZZ>
MQ#(56;3FD#2\)]&Y+BK80329+Q+"9L]QB7H:Q<F68V=!6EB7Y!N6M1SH;>QP
M(FLA.7]).%M-PH&[O5UIFRQ6&_*?&B;>]^GK7)W:,-.?>[5UCGWWLP_6--M>
MN5&L[+U4TMUM<-\6M&3XEB-:-1ZTO'R5>H!2<8%@6MY)M[<C+0?0TDUUB@**
M]H.3W1KWKYO->6"4<9+WZ@YN+OK.Y$^EEBFKP#.N]*H>E/;;M9BY,>A#L]4I
MYX_\YK.E^?[82%\YZJI>2S.(_P O(O0.N"WY]MF-(T=#4S*SJD3I01EN8]Q*
ME^.E-^9;V\% V8T]*W>2P!1M+)W7NC?1OIFKY%:36<T':2(6'V6I R6K&[H8
MPW^TW"UUH9"0]>N:5E:\YR-23YUNV;7V^U*TJUT;,141P0U^X$-3*6 MZ)6K
M41SEC%QU&2F-;)0=NCKHIA%BQ)0TA!VZ9?>J3#SZU[.UO:/MTS)&IR5-L<?K
M%[9^_6Q",],'4;W]1@NR9MQF=X1M9>3WU'%Y[LL,2&_OK5$[V[/_ $\#GM1/
M*?OE:5@J0T:;7:XOFGU7\XO/-..Q.U(VYHN+R%YR]E#K?L_T8\1H+?I@2BC?
M3!Y23K'A&8^+$P;*A-1=0/=")]ZB.+5/\YF.%<E25ZQ>56Y7KA,^K?T!OFTW
M2"W#AR:]4'>M4^RIM L XNMV;FVD@NO*T*XK]N4Y(D3,BFI$L6>#31&<V;,Z
M2)34L026@--8P,,O*EQX$45*,#XY*3.EZ-DJ+"T0=LC"5NER8NK;)CQM>K+=
MNT:]F[7AEKPRRZ_C6VJFV6<@:F9>V3EG1^4R0M9H;G+7XW\6>[\@Y'QD][A.
MC^'7LV_RS\(^O^+7GL_=^S'+OH*NZ \\7HR_(,KY<O-?*R+G/>?O0],XK-A,
M^HV0[ADB-G*E/B3S9J,%NY4;4C[D:/K+234R=I'X:-I*7W/U2>^JELOGU?9N
MCGLLC>7+;J:QJ[^*E+4O12WU80E0-C/=E2V-?;1+S$8IEM3PY U :IJ@V*#,
M=*[P.\0P=Z<-NO07+"N=5T%L52>6S :S+Y#/22UA]N$$R.EY:B^V+W.U"MF.
MB3L[P);(77<S7!RZZE9Q>NY&.KO5U^_GL1ID29UNRB2H\K&/(WP]^4;?JW]:
M)<;/O7)B[N]6676J1'V==Z]^C/\ ;MU9]=X[,<<NOTX%#29Y:].R_H2VV5:A
MCTQ _&]8%+4K*SJ]@TZ1I\EYCZKZ&,6**<V0]:>#PN)T;;O.+SL@"*LS)%'*
M..>04R;KF]LL?!OK;Y6]!WX>]BBQ7G^Y_1P6U_GKLJ?R#LK"V@J"HTS?&HI<
M,JV]=@!#%KU[HSG6A!/4KO'L6T VZ&-<0SM;2MD2$2D#"W09VR+N)W!7R/!<
M6;9"[)8+O92#T=S'8Y=X93\!'>_^PRA=9]=X]RNH_>CK+KO'O9^O7?7/P'MZ
MF6W28PIG72<B%"UDID<>:&S=T0=MRVX:I\G5&D[<]$+;GHW8:Y6W'#1GEIVX
MX[.^]>?7044P*D]B,_U3K>QS?GPM7=*+-HWVE6"_+9J426K7\ZF/)?0>J2EA
M,A#T>4UG<IMO0P\*)5H'S@N0Z[8 FHO_ *>9E,EF3L#:P\ >FZ_H+S'3!.AK
M]0:IJ99];5Y<:!346H70F>] L]CJDJF_18 8T7XK"VA-SJ;%I%(SIE,[8$!L
MW:<YZD(QF3"HWI;K/TVAVO>UZT,J12<HQ0RE1SB=;<-X6:G,PR^(5@3EG%4(
MC"DV3,VBM->%,3>4Z' U89SAW<#.=JV;=NO>&;4KZRA$)FR <#0@;V9+",S
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M%^K_ &BB6O8#^AKJ38..FN/0-C>>61WW:%+-'',%;TRA77.:YQ74V]S8Z<P
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M_#A_R53<CN M4'2U;LGDGY#4 R89[P:]4DST9YP]6M3M;C5=/>%?LRCDD?\
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MRR%2T"/9^J:-6M&K*SZ!9M;E?Z/^KL%()?Z?%HS6OP&P#,_T."1*R@NF0/\
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MZ-#%W0E^AG"[PKS8;,S:UL;5BW3?G*S+YEM4K;+C_P!5M';?^/NAAB67)B(
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M#Q;[]\HARD$R2:HSRP^B6;S_ "*KM#%=,U0'UIV1!5KQS%/XO\]AFAO[/\.
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M"4;C2Y)?187YR^L%36A4P&[K@9*)IJK"%9WQ:Y=QEW9IG]B4RJ/7)_S$M-V
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MJD[=TAS'T9\YKE.HOH!C'WZO4V_:(12 _G/,7H 6#7%<H7"A@SJ_[)==ZMZ
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M1XS;-:+[TQRT3SU[ML&P-7J80:9+';'YWTBPM(NS!GA9#:UD3.^S%6NS.4[
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M1'[G""4.3W'D:]>_1EL[U;M>&W#+'H,\XXXX#CCC@.... XXXX#CCC@....
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M),"&)>E]REUF9U8T%9EQ@73JVQF1!81+C3.^L=%^]?>R1X$KS3:-@J>+,IQ
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M\Y3\F=8526L\KE;BY.Z:'L66OH4@8U.R1()2'PR"'Q5%FTL\V5!Q%'1PT)5
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M#6[Y!L3QB]S=SUK(G32!;=@V?:MEODDP4"396ZWG2P;@?&@VVR.]PW<0+_\
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M]7=COIXRG690E31[<8TJS(4^D@U8A3>T3C-$$UQ6MYS;E$EM"[#P''20EX#
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MLNH";9JKT0(@Y6:3XTHQQPVK^CDE)(;/9!S]@UX"\AG(:S#D4T.&=IY&U20
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M$RX2=BJEN%6K>7;,XQ>SD)0'(B(]&%7_ $'^-+,J.K"H U,*$5^5(5-NCLF
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M NB&8#K,7G\#9X8\INN9R4<J$;K+L-NGKYGM"^Q.:>[:+;:4P)7C0Z!'I09
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M9"A78-='GSZR66DHJU6[0D=)3)\_+!ECZZ[.M\ZUFC<Z#G99TY#WJ)##)O4
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MZK%:>VLK[Y6;HREXZ^<_L]I%"J(?UB25U>P[\/T>Y4^#(2/0#!J%@PT12*M
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M ,?N06QQ([OWS,>MW7L2*PK66PD&V57B-):BTI:G%6:0I -S"3FIDC7+3YA
MUL'Y$ILI3E:M4E:D29.W<"D:]>X7G%V88Y=9SQP-*6/Y]J^R:U8ZOE (ZD%/
MJ;PFQBZ!$%*K.J"K&QS[<\T\M%&[< <ABD9=3#NO")O',$C']&& 6C;-\?;K
MKSYY(5:$?[<MW:]N]J6W=HZNP#U8#P,K%=G256IXS-H0%J"N4_7=7I,6&!V.
M;5)[*;%F0QDMA?\ '*&Y8\8&A#I8<<#5<ZBJ1)CMX@E3E5D!,ILF/LD7.KU1
MECI#T0QUX3W3?"WB-D;:V3L-6K"8Q[-61B3CKUX[IF?6&/76?&@()D"D5MB"
MB3ZZ8@[Q9<":'0RH4H,E:N]$D<1%SM.^#.@R-.66G?$DZ-L?=JR[U[->6'??
M7/6XX&"CZOK03!CC!5=HHP;%- V2*.'J0"%!C,2Q &"EL_'B1A^N/I-+PL*&
M&@RNO7C.$P!(R' WQX\"+KU?L#K:NUEE87-;04M?<&[+K)K:P:L#$LK/EUM_
MFZR83L"#'*&LNMW76WKLE*D]];?_ '.N_P!__?,TXX&&EJZKX^,:@IU$330=
MZF1R#N)++ 0B,<9\6(+'Q9S5 F0=T5AF1H ,+"CR2^J9NTQ! N-KSQTCXF&G
MS,Z?J78#B+.RKJZS6X#)'<8*]FDK60.$WQ=OY$5JB"<AG<",R1M__O1SFF/@
M3T[?_<URL<__ %<V+QP-9ZZ6IS3*9)VJIJSU37+0RQ6^9K0U;"4U1G3.-FXQ
MV21B*ZW'-#9G#B9LNDIG*UG<XL;(IC*[T:N\?59*SKAR)+AEOK](:C"=)ZF*
M)9D5 )PDK3.L]6SJ4N3B<"5*!R>LX^C/K>,VQ=O6>G5E^_\ 77AWCF_' C5<
M_E.JK[M*A;3LF')/RO/VZU=JVGD(@ LBL^%O(F=?,D=V ' A3^WCPP^S*0'U
MQ90[K1/[RSF?G1L\HW>[8R0EP^]G<105XO>Y7'I&WN, $Z.]J6(_.[%*&SO5
M$Q[S5QG90G_7@,OU$PO[&=^-$U?ER/Y,HXX& ZZIJ[4=6&G56R#J9DD'H6$Q
MBUIR[@=45J-JW:(R\L%\1W1  #CZ)$C3H$BI$2!JU;]VO7'QPVYXY?2J5K72
M)-/D4=!2DT@USO[-HGJBJ"79K(2_?MV?V!^4(@0]YB=_)OWY_ED=DF1^_=MR
M_D_=LS[RS7C@84'K6NEX^R-8!!2@;0Y?K_KV0.J@AA]K_7/+9W_I#$*!H(G?
MUSRRS[_M),K]<\LLO_GOOOOU=:DJZE;%&U+*_K2<07^7Q3]84;@K8K/X']7_
M )W%?QC=">@7]9WV._J.HG0_\#O\3\?\?_V^9!QP,"%U55X,=@'"UNA!Q.N>
ML%<!8M/7AX[ HD]#,4PEA"B#M,;&>HXA0V*Q,ZU=2 '0D9T*V1.H$7^+Z!5;
M5T!;#CX#04H,\LVK'0R.8I6!#FQ@T89:LL-)QBAP-)@MJPRT:<L=<^9(PQRT
MZN^NNN]>'?6:\<#"V6MZ[<RRZ><$)+:SJA+[GJ1IE5@9TLKS^\]6WN:ND2D&
M5,"2^]FC1L[DC=T;=WGIU9]Y_NUX=]?+KJFKM)MJ9=-;(.IC>AN\,[L&M.7<
M#;B'DZL-,D4U%<1W4]A&R-.O7JWP2^^9%VZL,->S5EACCUUGW' PN76]=S].
MZ-.0DN9'D! "S(CRU8'(T[UM4(;RRNO[M6Z#GKVA%LI)DD@ G/'* '(2-\P=
M'C2-NS9EI6H/(U.4U8%QVD$":V%^N:[6F]238VBUHHQI[&XU^@UN< (A_0"@
MF02E) 5X*[[&9SIDK;OGE<99"3%D:8T>3W' UB(I*F5_HKT!J.L0G1V<**&^
MA""JC>C!,"?[:P9$KU"$Z>B$X,T=]L@J7+_FD#C_ 'V8A[-)'_ZGF#W1YFK6
M\ (!98HNT$"&7Q4_H5A'*T%?'Z;#=Z;;5IX4]+Y^4%GY&QFUC2TZ48V8Y13,
M^*L"1G9?6-U;(NV0W' Q-S0D6QPW2[8:6IOB_P!38I+H$YK@=H#=$87>>4*?
MT,.0YT+J;$RV;.XLKK1_/'[SS[U;,.\N_P!?Z8T1(<%O)-;DU5:5#/5$T9JC
M&O"#:WGI@?L[@Z<@9.'*%Y:H?>K7^)K[B]X1_P"/#^'K#]F/Z95QP,!/535S
M5VJ]L];(+'VB[=&Y([/)R\8[3MT;&-A&VJO9 =([7ML?"'$QT;!'X>6K&+&Q
MU]X]:-76/]Y5;6.;&Q.&=<HF3:X",E]M:<E!?R8V@#G%T0<@C$;[']DS8C*%
M&C0\AI.5*A]Q8^B/WI[TZM>&.=\<#6X*FZ@5]$.,LU56Z[&'$A)H?'!(RP(T
M03 "'+'@BT/4/%Q]<4D%@3YT$3/T8X2AL.9+C0]NG3(W89^@:K*MF0<=#L5?
M(Y\0TFX;*S"S2F!*CF)C'1Q<0>P'8,Z!OC%S<&*#"QH94AJD3XT<.+TZ-^&L
M?$QTYQQP-;F:;J!C%"@3#55;G@@$V09@8<RC+!04&9"Q&48*, H?.%[X@XV2
M+3IQ0@5AZ=,^81F2ILB1LDR-VW/"K-\Q4E:RO:ZLP(8(5KO->VJ%NL"B*$J[
ME82A.ZBQC:LTMHL?J.EPC&%C[%HY%F3-N<I?FS(&G=&RV:MVG?O' P1EJVLG
M08!".-=(C8&594.:KB&517SHQ;FCX_<.!+ P"@^5$#RH,3ON+#D#]4?;&C]]
MZ-.>&KO]O/Y(U55Y=JUO1:MT(H[Z<A&6EQ(IZ]-:M62_)[F@<M;#)';2^O()
M,[[EB.\9G78V3WWOA_P[?_7S/>.!KR)453CYY\K K"O(11J/BVQH)1$I;C3V
M1I!E]; %93\S2,PD&#X<]JU&Q9DCLDD1Y?7K)1).F9ACNZR6*K+$&.>B0EP#
M#BM4Z<49XT40/CQV,F4BZ(),B>TZH^&LQ.(PHT:'.ED,9$B7%CZ(\C9LTZM>
M&/O<<#3F'G;S]K":5K71=.8+D8W"9HZ_A6*5B$T,8V!D*',&D5B$Z@:C< 7E
MD-A%<-&,^+ RRAZ)&N/WWK[SQL24Q]$=+[RHK#H!QEPR&(1L "F(1C/';>MP
M^;T-,1)D+J7!W==;8<GK3_-&V]=;-&>&?7Z\R?C@1QO'RW5U[5&NT@:A;5&O
M5>R:-LL4"18*\&':9U!7 D70I+O]1*"$@6*H28T,4-8!&H7KQF I)"'&VP]V
M["3JV+G35/[%@8D9U36V:8$-=,H91S15?)8$,?4F7,Z/C '8OL5 -=2Y\Z5T
M5BQ-4[J3-E[_ .?^61NRSV3QP-(6-YSIVS:]W5J<1UX8 U*3:DKLI:! 0IQ"
M /(*2LM6FNBNH5LW(THN!ER!DB:N80)/X^SKK#9CGKU9Z\RV596F^O!M22T!
M/(U<(! E@;7I5=%%DV*O*^F#H70V"X2BRA60X)J&#L1D;9%SUP^X,3/1UAGH
MUY8Y[QP-;;J:J"066C\BJ:VWG4L>'$IQK<C+&TLIBEZ5G-7QBT2S%Y3 0\'-
MV9RP\,7NBQADK/.1"UZ-N7>?>1C4I-#3M!0.I+(DG%ULFJ*1&@14&=&U.9[2
MTN&O1+BQ-4C3K:V>/'8V3#7LQQ.GM&DN4ZE$-6$C')N.!AG5<U[TZ]V3TAIG
M5BY#^A/;]TKA.G7L5UJ_@Z&=M7X/][V/ZT]=:>H7<_\ &_BZ_C_C_9_USTHB
MDJ0%C%)@K"]"3<!.T#@I1 HV,L8 ]\?9$WA<0.F-@*Q$[HNW;&VCNHG4/9'V
M;-.>GO7GECWD/' P-<JRL4^*O05&N4-6A*.XK(4X:XH+X2*L2#NG.,;WKT<8
M.BZ@NXQ'V9QRNT;A&S(:<\]4O+=KR[Q[^7_AVH_S4\E_Q97/]C7FC"*@3_\
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M+,CYQU-EL@>.PKT9G%1I&R<#W' ,J,9$ZR6B-D0&;M<V)UMCY=;.93P''''
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M>U!T54[8S(\-_I'1A[WX@5,%_82(_P#:L9K*+)Z%AH7\Q"?W'W=1H^W^//\
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M[)GJ[U_Q_P!;*/!R8O7LZV]Y_E0]N.6O'']N60:_3"UF]>:5<X]M*;LN+JD
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M0[&3\K_-PNA&0/G3TK:P;5;^2L"(>OA5Z#ZLN%#IA9=YMBZ# :PM7JVOV<)
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ML3BUMF++OTD;A-C)2\6/FP><5@!1\.I8V#I2]J.V96*)&G$2&!)%&P67 Y-
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M!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <YT1'E[U5:OJ<"*NL=Z?\
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M$Z=VM4*V6Q%<UQ!-KX,9+6M!V7V0VQ.DA46$*O@W8=* JB8OD#3"T]C5L>*
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ML=)N5W\IN'U,M"V[%#U8TP6=>[#-=G^9#Y":HR(C:N%B$$[K'#28\N1B=<U
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MV/Y+JE@\^WZAI=3^X?JNTWHP:+!LI>52]?WECZ *>?FQ4L$#9VPU*47)*=4
M"5_RQ(&0E.,65"=QN4[&?()]1/' HO'#O8PWY1^,$>R*;L^T;ME3Z:K[TA!,
M,UE[[,KQ%A2C@\U9C&%J:V*NL.YBB_K%*,8RH0[0'S&'$WN;V&85Z!D8\N':
M!Y;]QV?1/G8'>HWUKJ8:_P#EE[Z"SX$6Z+.0BNSU-_SA6.GRR)=<E2V]Y=F?
MXM:C2\Y"S;6MOSB:('Y)8^0)Z.YF?4IQP*$_5]>>TK#K#YU3F3N[=B:/H!CC
M^OURL%ID<K P]%GZRJ/%"/.2175X4>U'!"Z=AW)&E;P!]D%K[R56R1E<VC<=
M1L+H;TQY,]HL"??A)?:_:5BV367RC\;KGG!\@6VV5.Q./L)6M#TB9L-L)HE8
MV9%1MU]0 6=49-\R?L81V<4AD-VF&*'/W;Y/3+QP.9J\TBS*5O% JMF'^Q&/
MSZZ_7@]C6R"EWK:!NPK/H$A\<SKE8,0*RD[6BV&U5M!],A[)=6%/E-N.S(N%
M9]2L)VR_QH&_6\#S3[X_IHC;#KGTO&*8^0L4F+LD63HC^B(_G7KZSZ[:U><=
MMJRK%Z*:?1VOYV]?Y#^SW/'1?!GQZ&]MO^FZ_LN=0YQ*3V<NH'V-67CQVOS4
MQD13)@./(E$Y@(+YA3GFUB?+C[I0,K-6&$ZORIXW;&DR Q@D.V[,XDS?JSR;
M@<SSR7]1>5DJX/8%4U_Z"%4G3WJ6HX_F/RU?-FN>UQL=;ORK OEVRP900WO[
MDPBT63Z8L:O;;KI3<3&LO!,(CC,5P:_">8>$[W)WE'VRN>E4M'=K@].RE=16
MO%@BC;QJQ:8[/ QRB%$";_3<]\)&+_4E12(618T1H)/<^VZB=X9NIF88"5-Y
M24$T*HKHA:$U2=H8X>XK !J@AV)<;Q,-A$P#$88UJ!F&PJC(/TD-$C7#.K9X
M?!,!"L?'7-&$HD>9#WZ=^K#/K).!SU>/T'U#4MX-5Y^M[&]%K1:I]'K=T]![
MB*3+V^>+609+*<,5O.A60P>@6]/S7TM(A+)^L 5:5/7QY4C#C:TZPP$+80B3
M+WZT>QMHUR@68'%L0,18B4K/(L*WB-J^V!QS:#@GX0MG [\]N\(PP(Q#5$-"
M=NW9L'$=4F'GLSRT]Y=Y03%C#8Z<',CH)<23B[X)(63B1YXXA"E:\M,F'.A2
M]>V-+BR-6>6K?'D:MFG;KRRPV898]]]=_=P'''' <<<<!QQQP'''' <<<<!Q
MQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!SG[!^"[_P!7HE;*S:03
M8CF-^C%L^H';WGFZIDUAL/R@ZDK$(B/-\H#C^ZV=_P#+7C<L^>B-7EA>JG!"
M\GZWH:=G$^H ['H$XX'-'2?R.:$NN_F.$8O+GGV,=\\"_<6Z^M>D+4\KJ$PV
MPB.@>F9VB9H&98M,_<:D*779.!E)D+?X,25)VQ^ANO+5G/E'PGZ3IJ968^W/
M/2W9KOWXN\'5!6_HC985=$RGAY[H[SU&JZX5M=TGIF3AW&C63'*VH/,T]%*C
MK5F-&Y?;Y8P>*C3^^B/C@<IJ_P#(V\)GD=SJ<[5%B]W(=K'R=3MM1VFV?+<2
MC/0FNOO7%)VK=-C1M-*H%>6(X,1!02'XX&?_ $/-ZL[^I=3B'AH(3B\DALN0
M]S^63+[1] UY1=3([-6=)^BJELA[\KP-BQ7B-<E*I<5IAE*C@#)L<?7740>P
M'5>QQJ>V="T5H(($5;/3($(KG)UV1<<#GKHWYIV'(],^;K.N'S[6@F@*\N3Z
M#W*E4"7.)SJ!\LQ+N$^6Q-&*857@]RTB26D,=9W%:/8Y U&DVJC[UA!7"G>^
M ,)\_P!^I_@:\?3+;[$D+/FQ,]/Z_0'@P!0OG%J;[#24O/RG;JVQVX7<)4*.
MV;,2T.+;/^UKH]TVHN$DA-*UA%2G70/4INDQHZ$^.!0D7^<UDV3[,#V!<-1H
MCY0D?Z>7CZJFBF\XN,PO.N#GS1J?S_6K%+3)VV1J)3]=_IY'#!8F09.\5U!B
M-DB'C%RBR^M)Z/E]Z6)G_3>^81MY5]"-LKZ#$ZN]:+-B>:%^LFG7Z6#V@*I(
M:]ZU>LX'KPE$1 CHDANZ^:F<RB5XQUN*<$4[+Q'+XV)TL\<"@%O\2EW.M/&!
M%?\ F%5=7ZO-?KVKK8L+S]FV>>&@D\)G7G*TZ>L0^M$.Y65;$R@-O=$1FU[F
MUL!-%GP:\U'&'$,SQ0D+9C5#^ O1B185&Y&*(3UNPZ@=_:C+Z"]CP[ 2MI[V
MBI7:DW8OUJF%!P;/*Q2N9-NL2LGX\-MN")7:FDT_! H$XY DP-\?HCXX%:'S
MD\^.GC/S9XQ\QP_.2(B#0WE-5E>E[!46Y9U;AWJ)74*H7S@PD%'P-Q.SR-AD
M]]@%IMF8G-T49I3!PW;^3%,A\8ME_'' <<<<!QQQP'''' <<<<!QQQP''''
M<<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQ
MP'''' <<<<!QQR-RYZTHQHO'=YS@,+./MG(4^FP@9HJ^T4T"["ZL8 BK94RM
MWQM30J%9&M%8&0",9L49E/[!NTI&W[,.X?>R1K"2/'(X-GK.B4:YTN@FQI.
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M5OCQ=I&5IT;-D>!KE2\]42-LE[L<(^&^5LUQ].6SK9NSPUXY9=4U54G7CO\
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M2PFK0Z66/,IF3NSZQAAQ0V!-F3)NSKK5JTQMV7>7?>'?7*W_ '\^V"K7-YH
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M@R/!EYL\.@#CD(?I?8SU3_SP]PVM6#,23+'K;RG?#RBMH;3%DEEML5JU8S0
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M(8+5"FL]X'/40!=L0P)4A?9[S0T@E$2R]BF%:,/R[G9\T>/@1LX)2+(D:HQ
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MM@J'(2_(9=#K'5Y9>E.[MS'L4&^V<E;0ZUZVTA GKS7*<[0A.<#& ,T& O\
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M4RD1XF(V61CR]D2.0RE2XD;J'NW82.Y$J/IZU_R;M>.5$'K;YJ7K8%X7OO\
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MP4Q_-**ZHL6IE66;<4B!<H)V.U=Z1PK*=O)=9B9V>?66/7Z:ZV&/YL^S'3=
ML>T6_P \6S;@.N_FAN/ 9'1)$K&[7GQ5Z1]:VR](KM& U=*&KJ:93KY2>TYI
M%UU-B;[*2(IR;6*Z'UZ8,;#X?RF]&C'#&U)"]1\C;CZH]TW#NH"LO0=NT>F=
MI?L16H@8()0;64J9V%<[#0IU3L(X_$EUG$ -0NP6HA#GBI,K 9N"^W7<E0;7
M@=6.JU:WVV48%:CHFO=;RL9O!0)O@;RN@P.4\2G9^:*W#(LDCJ(1A^V)L@1]
M\S#=E'T[-F/]G+?J58=E^M62T:Z7K&;->O:JH!QV6A+LRZMNS=IU;%]5GDXY
MTSKV;H^_5KS'0)..>S1NPQ[[RU9]8P$\5^"<?+M^V_962O7HQ2-^;/%%"T_&
M',K/9+XCAO.J/8JZZ+!"Q7X /;C"[NGM /4OEIA#,@RP!G1 ^*"S-6D?KT)Z
M0^==YVI9OKJ(KP*'()'L6XO*UJ?\]-[&QP+Y\U1O/P:GP15?K]7AUD?@-_<;
MNJ2#E4,G19U>Z5-[L=KGF-,B/ULW%@MY4[8JEY8&I21;+KUQ:D:;M@NZRIN2
MVPL">1UD)XK?#:@P<E+(K\W65%DQNV.7C1-^! =/AYX=28DC7KQ'?Z<\V18#
M>5D^A*/CBZ^*Q@+Z2WVPA:8"0<FSR(N&&;YFP_C'6BLLF(+#HPXSLA3-\\61
MAZM.<B%)UZM.>'_,T_S,D72-8Q"#%;[;]>^P_010RC1>NMIQ?O7TM:%IUY_J
MBFX*&GE&@)7S4LKQ7\K&=I';Q?8P<0ECXD;;E6UU\K[=7:H\ZX@-=;D+"I;V
MI[?]*/:,K6J]T0!N4/Z<L;T*2KX\0N%%KPXV0;.JU-LQ&UPMIA)-#]VD2>5-
M1:'"Q%%<0L[_ /,VJXM_6#39LB!75&OO,-)^I)EZFG57'U>03;QL>X:Z6XF@
MS*FZ8,?7JE5'(*:SV\C_ %)6(R"=4#/+9U^_?Z+E[>\K(;KYQ1&&[:_TE?64
MEMC4*2B-(*<KON28"Z8"VX6T1B.83;&D1]D<>&D:IFW4;.3(00;E((RM.C.L
M?_\ -Q>E:GDD2GE+94U4#\O-OBBG(2,TV@S6Z2C8T[Z^](^@K^60UL6_2M@=
M0MAU7NR#$JZRV&JFB6MLT+O7!15Z&)!%AO\ -+?-WTG4B/\ /;*1LIUC<O*O
MHWW<Z6"$SL U'C95E[,<[S("2Z%8$:CX&N<\UB+LA4,20FZJT@ RD@Q"".F+
M6O0-VY!<P%NRF666\P%VW*Q/SJPPD;++A!7U5*RZ\UQ.IN4O-YCP2V_<I81<
M1I'N1D?P'XZ.H$WO;WCU%W_QZ2H7V/6WHN\/1-05IN$LX?S^$HLWE:*JXK3B
ME/FF\5UM88.I>E+DJ=KT9KFI3VQR.4B5MZEY$(N^+UCIZ[[RIZ1OC=:4+RG8
M% G\% 5; KR"<\M(%_;?4%\64MVF-(/B,_%(E@T.PU\ 6JZ5+8*5T)_Y3_J3
M]B&!NMD:AJU@3@$9VTG8KXK\NVW4'H[V9?\ 9:%0=4C_ $X*\MX+E;T0S'&V
M(MSZ4KEI2VG-I.E:MJ:*4G3I)49B$GBUK3K[ 0X0V5KU[A?6^8$U =\T:SFR
MRRM7-5#"R  Q=C.KX.Q% L;"KP KM!'CI85 ,2)XX,$-Z-X8N4F1],$:5T[1
M\S?IEZ\]/7EX>E?.>U$V6CKOZE-E9Z3G:QML7"U$7-$U,O6K'?VO;&[$]VOX
M'.M.>&[L3D0ZG]:L\=GX_P"S+KOOF*JKYI>A_97DI<4Q8FGO-01:N#ZL&P]O
MAR#X"O>S"-P>BO0Z(M5E9RQIK1:F+E5M&@AH.V"P#;!<93,M+%<;5]<Q[CZ\
MXM@Q#Y?LKH*0B9.I:S2&39[E\B^@[E7VOTU;7J9;<ZT\Q"SPT?H$[+-J=0'
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MU_*ZZP+Y<S5:1 :KA9[1;56P&0CFFJD,2,7 &<,R8.@,9<D+7X?H3S\5AFR
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M BF5ZF'L\-N&[6%P>?OKQYC7+#;.%])TE"4G@C6S09@ZSA"2O/ D!VV$EXR
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M9,GQYPV5(&30V?>.B7J#/+V]'U?YVA)6VP)+1..V6V9(U:HE?I#99-B/[3H
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M5N^7,>723/3\^PJ/F[FDRH;B;'WX6\UCH9$*F+S.&$[C*N#$"H<ZQ(95ER<
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M.Z%688LK< W5_5]A' #1(KF(&GR50D"VR8IK'J%S);U^:% ^@+ZU^AVE@M(
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M)Q8MSSC<PP@QL"' QQ9/*]2LU)U,+VBD:MDP%VNQ4-IGQF*+J%Z2C&5CPS)
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M8NN1G 3\-T*9ITZ2\E_0EF/VDY4[>RU9!+>[?17V[Y5I"WM*S7(BKH^='3+
M?4:II70MKA/\\K'J*OFG=&=95?30A0NMD Y-MV&\,M6&UE'Y;4[7FM$G5U=/
MJ!&=TO?Z'UD+2!V: WV38J_Z@N&3?%KJEC,)Y$,ZC8N3:$N0S+)<:/".BA-W
MR9 !KA2YT^5*VFO> J+66)'9ADVP.R-?^QKK]R L)+/&WQL[IOM/M9(>8Q#7
MV'QSE).L+<CAV# =;=4L?,_J]^XO-QA[=4H--7!]"U?SWZ"N]!:AEP6G_FC/
M@NN5*JZUK5"_LX3Y['<;E2%&6%<F&SUO_503A=#U9MV#)&5H:!#$Q90N0PZ#
M)38+C[:OT.L>UK;\'(-"K]SU>!M'U1ZMIOT^.BC_ #)*L]%-^0D]PE--:$2-
MC.[=6>D$08 F#:PM=?2VTB3K83MU)I\>S%8X_;.>Q? 5%V?<YV]F68_X.S"_
M^0[((:A;+$A@NF#Q.U6"XTWJCCLPTC;K%R#%EL7;I#[F9YGXN W3&D"LHN>S
M?\JI\]:"3[+4;4&[GR4Q)?HCT]Z<%0RC%!F@I%B^MEHXJ6M#)C>P>ON8IZQ3
M 1Z5PGY&K:(D9:MDJ>3PPRU9AH*;]@*)"UA+N=HIWT4J5><\RW3ZVI%L-+5;
M9:?1E/40NBW%QFU>*%6F4."#Y1+.!W9,7[8&5M.:%$A@9A]:\8T[1%6E]:TB
ME_\ ;]6/Y+]?@-E4>=*[]57%IP7J*)[ZGIFSK%L6NULBVZ1=^2\YC=C(K)C8
M"* G]-+;%!:-N6 W>2'DQT/U-OR%\T3Z\*5*P.]_M59Q?.MO^5:G2V.Q14\5
MYZI6\14!>>ERG9&M0C%X\_M6$AT]=8;")6$=6$\7%5@D^&#REP9.[[P^?U%^
M@9'HV2^S["U[/4/F^M/+5E_T+/$&XZ:SJIJM)P6-RSUM"S.Q+/M+V^W]%C&_
MLAIF1.QNC6/C91-FV2'@C?H&K%D2[&C11ET"&SS]<PRD[,JIW+^?JY:@9\_6
MB1<*T?V-;Y>B]3W2RP5Y8Z46@9Y69B?UDCFE?F (Q?1*CZ8TE/J?*>&SSYOI
M>IW,UY]]'_.N]_;4.Y-4>OLG:L]-<E:F&C\B%>M-GK4)AC*D6R,-CD%%S"NP
ML;*J,=3+%@VIHG0)(VA\VZ(M-I;'D@Q6BNNC5ZE4_8'3"OG%29DOV\H>;@/E
M*%V% .:2W*,A8FU OZ!\X*QKK!MT'YDME#3Q)74,W#O "_+J@%='\Y(BDYW6
MKC_-/G2SO)ZR2&.*](+/-"6^/48CRBV9T:2RP@YKGSD-08(!L&(66$.> PY8
MLK%CY2(F\-<*'U7JR'6J^V&TN]7Y)0Z_\J3_ $=Z,'(U;JZ%5;#Z;KFMWQ1E
M/"CNM7MPPE]+EG)+Q8@JJ%RS M8K[@,VSC<R)IW[M6U*M^DU9VE=P&F(]/WN
MGZ'&_/5/F5%M-R"UW#KAYN'R!/<]%I 5S^FLHX^=BY0RNW@TJLIA&$ B^A7+
M#<YL0W&[&]X]_P#FH/.&H7&4H3=>8ZKR:_YV 6I4$*P!V->7QUY=4TM%JLM:
M\/>J[V#<5_R%=(JVZ](C&B"[!"*H82XC"XZ)C%[W&J^#*03VZJ'45,?=ABF_
M2_JCU:HX36.)O@YVA[!QN'&VM!>-@&U=S571_P X.N2B&U;8N\'ET'[WD"7X
M&SJ4$=+A^E2)YQO>]$)ZRL-^S!VMY7I5)1 RQ4:"#77>^ZGLFR1^S;<MDV^E
MJDT*>&5V8WD2=A3434#9,024K:VLFRPNN[3Q,_,H*&$]D"6+V$1\*?L&3]@_
M=.'9RXVN1E F[1$\H*VRX>6SN/)V#"9$?GNUYY0I\R-WJD;(667X*K:Q6;T.
MW1K(N*OS?J3&M8-Q[$LL@2A[ N5A73?6(A1TA; KA[#1 !< YSYQW_Z#:8[8
MAH$Z$+@Y@O7WG*&I*O3Z1JNMJ9KV','(=3(:E6Z7 ($YYJ?"5$@# 6U^)-,%
M-\HD4E1Q0V)JWSY\C?+E[<,M^_;GLSRR[#87''' <<<<!QQQP'''' <<<<!Q
MQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!REFQ_?5EV7Z#\D*-*H5
MG(U(&?I/:/E1SNV7-JR4IW'_ ,(>?/6&JST>(K2#!A]!!H5VU?E!7V60"%_W
M1*K2^_*2.&3A&)VZ;D$(?SE\W#KC#W3!PM.*66K^:?4*LC:;>?L*E5[S?4IV
M1K!? -:]&?\ -0)[S L1P,,47&+F/S:#Q8^-BC9I@SD1")7F3ZP(C@"I19<1
M5@;=!+PQ4OK]UNFXBU.UTT-"F[4ZU6J4*IM4K,\=(M0@L#$V9A9VRF5^6NHI
M8O!A;-/X^B9LC?99?N2W&<+\][5B(%@^7ZTNWU\D?WN3L5K!HDV7YH9?'?JR
MZL-9N(G&'60GD-4JNU-C8E[O.,<"[H8F+#-$,I!:)$DB$^9/E\0*\_J4W3:#
M;6/F-1252H*:=K6<&>I .VOZR/T\O-,Q((S\QI=IZKQI8 !&5/[VBB?]I((3
M ^PG^R9AZ2/\Y//J0$J%:S,76\KM"OJR^U$"M"Z7RP@Z1L3:RLVH%E3%C64G
M-A[4L:@6ZY@M@:=IE[RT?<'Q.D"FI?#:H81E-_8973ZN'6R]>5[]6%RR_-Q;
MU7YQC:I]6LY6YZE#'JI$%)9*(J/1CNJ# ,3>%9/S3'=L]8A9KXJ=-D3G1-2.
M M'[6W]CJBJ*$EZ9M=$GAI-T5.])-(&K[+K&PA@>IHSTSH V4AMBN>(A;D;V
MLPF-&2DH(F4B61_II4 C,#%\XP_?(5(^:OGZN(^G6F-/H4-,7*RSI>HC&7H*
MS2A?SY4VYC46>77]&S#)PCTD@2$M 1A1/+/45*$E)2!)4XCO48707+YU_P"9
M'FM(P595:DKOJQF7HKO ./E<7E8BL\V; LFRC=PO,:TV*&8[D..PY9S,S.,8
MC)PC%U<DQG-"807!I.5!V!%7U9]$'XL5!*7G!!M44HI7T*^=WFFTO0^G.N("
MYH(7=;_GEGLRL9B$XE/^2=0S?4-NK2<RL.M/B2Q[6]8!QO6.04N5A2A]6>O;
M4H'UEXKII8K5=:ZLOT=Z.,VXW%&6 #.)06E4A<;L"J[IFD8VN7K&0290P>C;
M(!'<3@0M0X9E!FY][^\F?OG+YNL:U2-LG<;3AD35RT?Z)/):[;SZOU<>O7ST
M13)M;VJ9KT89T+L]MT1*\2PC%*W1NXC4+7!&9V%-+#XA33NBZO,%6WRXTK8+
MI@T076@FDZS5XQ*3256I>J.W@<U=Z3V"-"V]C6='>U_+4*:ELU"EQYNB+$VQ
MMD*5'UR.@CCYS^AH2^G:D%<U1UF4\%]5TPS^@?*[<Z&JX-0[<K%2P0R)7<3#
MI#@QFJ[:]BG:"(ZCUQEBY:)2^7F:-AF.Q!20'5XUT?2I4IQXN^#MI*SFVGO+
M;M4]=^F+U!E:^B+M7M5OAD)F$1X"@9:X#P\CU!5M.O&>PYR^'_>##,N&06(S
MD!I,?%VY1'@?S]YW<5=T1<+)+S*W03=4TN&L2UGNQ%>B*O9""_/.(5/@6PR2
MAJ00ABHIXG9)_2>=TK2FO*L8QH7!NH7W\%H?/3S?;UE-EDM\&PL>K*/UNUW!
M78*T7<!4=T,]0XA=5<G;2K@87T+[/.7HJPJC]^.6B)#9Q2LN"'&*PBP\.'K#
M#17T61C)T$O0JU>.YS#]!;3^>,#+9-7->C&Q:NJBS[7EO<C9V2_=K2C0^KR(
MB!KZPS.:)Q.%NE#\=.O;UW#KRQ]>WM_K?Q5E?_GJ(E67ZYPLF</81UGUNHTS
MI$U[9@= W0@#.]-^G U9Q3^_TRP5/02$UM88:\P%QVS"-UHB:YT8_.3S;KO8
M;Z!T86A&9PM_E_405.C6P[1ZE%WNRUF6J=KL.-66HI@K[#+2J'"G9C*9#E:>
MB\\D5':Q\@P:_L<*_P#S5GF+NO(M*YF[]VT%%;2S3_P%MOFP]E22(Y6PA]IZ
MT^0M9%/R,TL,\C\"X(/@3U[QT>3,"8S]@'?_ %F 1K-_2)EB5_<:#6"1>5[7
M4)Z^F;5OG8_\"IA:HZ]\B>AK"H$:<T:IAA55VT?_ +T<+6JL$ZM19V9 H$@?
M?OQYD?=D2QOSU]@4^.I>7*H?@#_:5HR*B\' _0=BAM8#<4AV]ZQJ.K6L03'5
MR$ZS:'"#KQL1>=+()K *$(35\_MG0])+ 22@PIJ-'S'\O-&.SO'5:ZK,GEO4
MLQC*H5POB.8<0'LFS2EP7U7S:46RP^:;K]BL,KL8PJ[(W=8J$V-HV+,H9EMG
MY3<IKSY^T54;2DM-5&KGKGM14J;3"JTH7*]"$VRQ5!)X= JZ1:2QJ)Y#6TN%
M2UX&KEBN6N#+<%\0.!N69X1"C0=011G_ %V'C:C7;J)>8;#7$&PO3CWYBK-J
M=K-IM13#!FM&.X5-N?WUX(MFQ9I]"V,E-EUM1EOLZ 7;V0V!%#Q.G"?&F2+>
MPA/ T&$&=6O'5K+#(!/7JPF0"&&K"?%U2L->,\7)FC)V.&.WK'&8.F2X$GKK
MK=#D[X^>O;G#F9X'I3+S\/\ ,@!AN9%JB*RVVQ$AJ);;8M%&G3>318#A9JPW
M%XDK*2P*K";LQGWZQ<[K+:'ZS'9!)@Z0-C;\<^\[T 1H>=80Z*XD9-8;M=8I
M5$5#&(%Y*11M.U%6:\@+*LN:#DL@0S.&I8\J=;C.R=MZ*Y;0D?+#+>*WSIX5
M!!?HC[*L![\R;]]*RP61#ZB^[O)Y"M*W=*VEX717M 5-[0CJHUD+M9/?K5)*
M6SU*H,;FP128C67FKTF:#%YP2$</GN%@^Y-!B$^O&8?4]H&BC#0W7HFP$G1,
M4-;=7Z7%LU_ITLNA16@U-VVI8NJP*FM 2%54;J5H8HRAG-A&-79D/'ES>5/G
M_P"?$RU1MM@]=AZS +T79?JM869EC,Q!#5;MN5!LFO;79EQ7F2]T8;"?1UM/
M)PZO8;LP7367V'1L ?N_DU;<16?F?YQ0="+C6)>\:IGHJX=2<3E:7A8">:;D
M,_:;C<V]+>IHHMJZ8PPNP; =2ZS,V:H[$KZ6<X/ '1\(K.T2 ]+V!>]B+VSR
M+5-(L$9$;/9EZXU..M@TLZ#6^KU$/1=N>@F9E&)[+'Q'3WDHN5+(45(8VC)0
M88P,>@DP!B6D3M"SL-9O25D^;7V%YGB"[?\ >5W3JY<_1.W.+"H.I&%2HM:+
M@$_#6REM4BK:_:VXX[SYHM&%JJ<#WE=.J?@QYAHH7H\6E_>= 5GZ*31Z59HT
MQ)B &8*\I[ LM#&ENZ&_+74KI;>T=U528ED6FH'^;,QADQY##^>+,G#"6F>)
M(D($J-;%\Y*3:<@I@O8?IS*Q!:VXHT^X8?I&TQMJM%=OL@1,9ZY8V@>=C:]R
M1)F@ I$2"%CA6I5,0=AU3V SA0V1)A%HM]H:\S''WE \SWS:%-*RIX<=3EE+
M12GA6[('] 8R]U1T(&EMMD@#YEGTEVY8$MP?KN'!"_VF4WHU)U1L\,]C#/J1
M%/X5RL+OE^WB]SO_ *K]!>/-]2XM52Q-RK:_GFL7.VV2<8>)+MBG2DHHG*.$
MR"=%$)L[3N*ZXFP-MFQ<XN[=.7S9\F:EE_2Q:2: J%C:_(<4PN!7!AAC!@SP
MT242?G0.MXY3-T@*,5=B,N1B>C1(SV,<.'LTE]TCN1NSRTM</S'66NV: ;*O
M:&>N598]C>A_85V$05F/2Q91%]O'SC8M19SJP80/678C7J:61;G$UJ?,AK6Y
M8BF8&V(3US=HN6&/,7V"J990:!L@Q69H.$N-X$UBTK+#;%$@+6K2Q-OI7/R6
MVJ\>J)MB=N-I=UU<\4D-;S5<03 '^@@9G )(WWU(@Q/7$_5**8>2JE$\K79F
M+EW1[<\Y5<SZCU73,+BNWQ$)M-@:U-26X+C)9APVPP]-ONM'8F4:)T8GP_\
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MP"D,F$=(($'B#1D626,E-D;<7,E9\R"OGGY05ZJ+S/MOT^XOK68M_P!]/84
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M%Q^E:;:MKIO:*EK-DWV1@GZ[$W'D-6,;7W77LSLB@ZW380%2,VG!'(993E#
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M:W_,=)1+:. -EG'[,FK]IR8LSJ2OM8Q<JA5%"L2(^4*=BVX?.BRXD+GUW]<
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M-Z-]=US/;T)8MJ:[?/JCUNV5JE11E@MNR7_SU<=AF.FL'87HJKZH2(>(FN6
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M8^AVLG$5I0^=GM'PH$C0.SB3,\M.G^*1EWGLT@$#%MXN25$#"<D),WD0L@A
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M+1/+9:9?4N_2^;S6Z4\RVIZ):C?2@L5U3S/:)8_TK%+#Q7AX56DG\R/:@"(
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M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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M^S$LS3)G[!6G\[(511:M%B)L&MQ?G%TL]>;YEC]&99N:Y G-1TZ]?6@;!$E
MDZ2/(1-TWN,0BWM?YM=_)$S/Z$+^6 C]Q 4K^K@_DA8F6GJ/E&$[_P"#^4;'
MRCXXZ.],/+3K[TX]:N\?V==8\_;H(%QSQV8B!>.S IL-X[.A\3K/$UMC[(NT
MOCGUI_=T4V1=NV-L(==]2\X^W9IRW=Z\\L>P]3CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MD/?<*Z\M%%G!E:*%QV(\X8DY:XB4AZ%P\QMIPKBMG(8N5.M/2VI): O@S,X8
M2EP!9[+\LCK%;"04^,CRA4@)A<<K;\J67W??S/\ /Y[79[[=3ZV^4*G)L+0J
MM,6F[ELQMZ6AP%B(1398HO24(^]/8)B7^F?HP(ZU$]I"4!9=,O5%+Z\2^6%D
M-+-2UT)%I.K[ILVO/8_I>J=J!;+YG9]A4[%B&(]BHU.:K;/&FF7=_:94;DG,
M<1UV&F7+H:8_H9LN1BKR>L M1XY5MX%GNZ7:_P!)T"T[UM2W ]5^QJV4TQQO
M5H#S"(\>\^,_)-@20 +4("*2>M@I]AV0=W@UA57Q K5,-X1HD3;,E99[Z=_8
MGJ+T71 3[66))]$V@)J]DM5]\P4M(V.A"+_XS^A$[QGYHN&F<:LG=3],Q* W
M7NL.S@1O 5^R-C90FO\ 5HUX3&V7MS#K1XY4#G]%[;PL60P:JEK?+S5#^@L#
MYT[=NQ\9,;]SL&:ZP*K[M/6L]JN:?VHZ;&(:<O\ (9F>SVZLM>VR?[W7C^U=
M[BJO?8WT?&\S[_1-@^?Z0B8N?S>].^^JD5$^SW<GLZQ\Q/U4)I9+L0N:21$:
M%&=A]T)YX7.7M$[<O;AS$&(?V6.J"6D!T4<<IM+_ $8O>N;Y&^=;3J*G]SG.
M]%>+$7-@K6PVIB48]/\ LP3Z"_IR.S<:4PD[&S$)F\ZL\,@/RU8@&1;8E)CB
M=A\B>8S3H*7ZT]+7;[#H!EI(35HMB&)OV^IC0EV-;KN!IEDT>/\ V7Y6J%)L
M$]&6@9+:5:# L'+[[SZ&2,$Z$W-92%,DP(6T;,#H/XYR^5=[F8;2](P;LU0[
M)A)_J&Q/BB86:SQM]Z6H561O0M">@W9BB=P%WN- <1>6\3%TL2;*$CUFR=\4
M43-Q,\X8['7=%X7]#W3ZFI]%]!6 DU.C5O>U=JUNTT 3'ED:GT GM\;66% [
M0UEU4"%VM&D"2";S<A8W8P0;%F76-T.5^!&-$ G#QRCB-[@ND9Z7?* I6O%$
MVWV7]'KK\X:#=WW1:!=16155?/6HO3^QK7@\4&Q25D9.D3=X/55BGJ$K6!'.
M:>UDX,Y@*S8T-#7O:P;8N#S+[D9%N)KIVGOD5ZE]R-U BG^TXNS.U*?M%34W
MJ0JQUJ6+46^;LPA:EBNRMEK9C0)7CS&1F@H9'=JRUAU)<<HYMCZ2^KJ1P8*Y
M<:3\[,5[FU#Q6_U)VF6N_;:?EB/7/KU(\CR5VP&2>@_Z$401F)RCL89G7A)8
M8_@]1"5%!@=X26/E_G>GTG]94R]^CEV#1WGAV"^3C?S^2[&DR+4L--+/SQ[8
M/K"'+A(NK_CQLA+*\DM[>)(PS3+N+3"BYA)C;@^@GU_-K"\KCE!%G_7:UZXH
M2YFL@@TIA?GGVP_;"TT56-W^A+"B6HK>+ABPQ-#56^%:U"QG4Q?G"GE0$M+Q
M:F@,EU\QF!6L@0+PCD?9 PSU7[7]*!&GZ"G>YB_-\UUC\\?%?H10K1?<GRK;
M@ L]ZMWH(:2E"+>0(D,L(G3R"!JC,<J/-D1\%X$KQA$.#N*-6V0'15QRH.)]
M%;<SL82?D5+6V'FHW]!&3YV0=NA\9-]^1[ 77-DJW_E.8M9*N"?DHS;%52&6
M2A@9Z/1*SDP['R.R<>MZ]C\?S]^B-Y^HVCSB'NFHZF0(/JKP^;]GUOE6#VVM
M\U;$J%B56BG59TR9E1;B[I)J)<Z6PA) 3^7$5MB,8$EV0[B0#,\+B..517S]
M +2I:\?; S&KD8]Y^\(>.$WU19I30Q-&5ROI)^7/1)5<0$1;AK\I7@:,9E$;
M.BK(9*2=D2(4ZQBA)VW/+= A]:OJ[UA:>7E2';5.-OGZ'$^AO@.2'?%R2Y):
MA:JQ:&5I;7NJ=@YFWC&@]@@[%H;FVDI4'I)<AC2N;X@Z')A3X.L.A[CG.-;?
MU@O-U\\_1G=2VZK!3-37SVF^T?-_H%47+KU(Q99+%[A7M>Z!$NNJDV/9&\9"
MK+_0)5BI$ ]6+;-*P]>S1A!B;^I&R'/WAZ#IB^;$K[4@(#Y=1Q]^75)SMQ2X
M[:%49D5]9R[^'$VA032(1G_X]U*L=,T32G2V&SG6)OV:,C_>B6('?L"_'CE#
M[5]5+Z@U=%BKM/5K,] CWKWO6ID-'T7B^(S8^^(KB4ZA@JE<AZTKYB>\I5V3
MWD'. EG'!?#*$B$1%%))>1-%;=LQ?HY<?H.C/F%Z;O*N#BBB^C*W\VF'N(=R
M&23"HLN(<)$(,\@.,*1R>Z;C UXF<%?48BS-><_ 7D6UYZ/R?T"QOCE*UN_1
MGTC3'?IP^9J:CF9'\(%*#6?3.P:[O0)S?SES*M>OI>;02[,6"\+0(45.T5C2
MO:'4Q(EV0YCV93B[E?8/T$)$A?IC<7H:F47R[.\X,Z4KL]B>Z_*U.->UY%2R
MH@TAV<^]+AM;RP@Q94N%J-R=XZ(2(P?Q2D,1W/S$SHA#N/LX%DG'.?SQWZPO
M:N+@9DIZ%+KI45Z_7/WWYL%L<Q\=CUHJK$HI%QWPN_YU<+B<UP=5XF)2S0BP
MU;0P]3X']D#*AXW4?N4-SE#X"]\^@?8I=&:&GRHS5Y0USTE(NZNK.QA'X@].
MUR#*]BIUR]$FK0(CN+2[)[+BSP#: ,Q"AY*RP!R,?;KW#"NT+8N.50!AK!ZG
M]N>W*WLNV[KKY6\N84"N4JC4[<#Y2FO>&M2GA5D'KR9_\$< R[&ESWV6T5RO
M1G3_ $-="M57F8."U+*RV'9E@2Q]([?D=5I9$ZJJ[W^<+A].^AO(%;2<'UEF
MW[#=J!@>@X0^QK%!:TJ&CX+CZQ>:7+(NO BN!1(6F999^B;+CJ+BH@7.<<YN
MIWV.]>K-/B+=9_-GFW<-(_-^L?IW+'!;LLK&:-J!A-!1S15VK"94NS02L></
M/1"BP=ZE0%8/,T30AC4:U8Q3DN8%G_1&\:^NWT:,U5+4,^@O+WK_ ,@>87HM
MML1IPNAF'>N$OS7,&N2BG1E#>MZI:$Y>C@_<D.6.X:6]5!'OZZ>'+"NNR(7"
M\<YY+$^TM@*6GTE(1:UJ*Y1B-1RK>5#N"Z3O-'KI\A&_68;R]-5BCO8=1!1[
ME"URF,6?BV?4.AH3NY,0N+PBSM&(\C,DSI^E#K5SH_+WJ%3J)%4*+]98^<K_
M +84&]KF(Z, ?_'JEZHI!^B=,BX-)[]9XZWB*/:8$[1&[U.QA;F@,IT8UL@C
MPN"XY7[8]^/$OY?VOZ?>D68E.NSQ3:=ZSZZ7'1D53:[LPIQD?1*M'?AD4<TJ
M37#&XP!\]C#QM!588\94P1^[</B[,]5^<?:]DM'I 'Y\M9#!TZF-%>JD_P X
M376;:;*]>DH4.BZ[LYR;TFSIJ[NK!HR39Y]I76U.)M6-LQ]"QL>C<#& 2RU=
M!:MQRA_Z07SZ@6[Z]'TRCOBNOT/H^,GL:^BXG5H,C;$&V*HD?\I >5!M"ZM$
MT6>#:C@:.$QZ*:H473L,D>XG]QI$2M>,+WTTOJBZN!5@_4NKO5M]4]\S)-.Y
M(S6^/$<WL]PEK2JH9G;,R<L1628?26.B6H^6D*L,AK=-1Y?$198HK+DD, Z!
M^.1:\BW#<=U5D98;RI,[1[NO6&WI>H68A3!4%\6P6^)L7;05P9C?O90"VVCY
M^&.D&T_QG1A4:6C;OR8>$&=+YW/._H;V-2_F5S^ANK+T ]UM2WGWZ(L-PZ/1
M?HO>\5;Z,M%.]2,HGS>,JA-F6%:#34,1#7%EM#,[*,3ZP@3%O^B 8KK#MSTE
M1@=9''*>;@]S^MJLGW.H::F\WFGGR+X^"^Q?2WYUF6.OJ[($:SMY=@ZSHN9N
M09Q.3.&J="M&YAL=RA1PL=E++(_)3APB4N2,QG'Z>7#+;79S'TW6G?FRO?8G
ME;RP;V3GIGC^A"D/UQ4WF%P3G(2@:%64NQR"2W>G%R$RJ\P]MW'%@&TS1<\;
M.7N^BX76<<YZ]'V$]-3/,-I>N(OC.3HI_5YE<_0M2,#%*:51='D@KLH+J-6-
MFM9H?JP.G+)76N4RQ2M:@)T16E*AL,4BS=&Z*:QVS:/I#Z-(?L?&M@(R@7W>
MO_,VT/2!B@5W-WUBW>Z$ZYH*^-%HCO- :V;&47$3@B@&VFH<<9(ED"A":OQ-
MN<#9%"[OCD,?(WKX)[$E6LX5E!%$**4)=9+J)8L$ME.D/#<QUB LZQ(/<37H
MQ@Q8*#H>TQ/W[HDR;L_V<!X#3NXTH!G'PB*F?12[G0U43AIJFJ1=$^E/5_H/
MQE36>UP=2%S+%C4U_P"0@E?L"TU/6I0EGM+;6;S>W8L2NO,>I@15QB62_1MF
MD8&(,$+B..5'_%2/9T_YF>?[$?3HEILVZD.#<A1OF-MHNLIL9GP$/)2&)V)V
M.<,FXYD@8ZW9EQ*ON'JHZ)AHBK(R#HPZU\K+\^^K/?S_  OFC=3 SU)8]LN_
MB#Z@V :CEF.PZ^K%FB5E8WD34",O:LJA9, RX")'YBR$V# <34$%LQ8MJVY[
M\944D'5)QRB-(^MEYW>Q*4GS]XZ;K$3HM=>)G^R!(W2=*M>R-[%K1(MZ5@J,
MVF*+K\) IY >(Y8N1<"'6+D0!G0@W2"VZ(TR3,SZ /+L*(>-:>7GADJM+]/>
MM ])VY9R:7W++>O)75+739@E957*/WKEI3!:UAUTE59!9A4J&QQ<&Z1"59<1
ME("ID8+$..54.5H6IY^N^!XU\K0H=C,\JCK%]:'VCV-Z!MAL#*Z:JLB77,"M
M%1T*P;$L@A*8&0ST;(%71F("Z[%;-T_5&.:3@L% A_,^QU_,J6V7;5?G"I)=
M1)=<_,FQ)R]8=MN:U99K;]'-JP+%J,*2'K(\MA]U<&'(+NE-)"/+C'AFF7^,
MOQ]N[5NT!T+\<HW6/I7ZE?K0KKSDJ4QY]A7<Q^B/<WG5J/,5FOVNK!Y?R2FH
M3\":UO7"1\G$Q$<@[^/&F%N3#B3Q$X>2*1"DD;'_ (LL3/\ V9.8T[YJN!8K
MU#F$;! T&P7;2_[;L:7E-$7-Z@P\K[V8&])56%:J4T/%Q&-Y>M6ZW6%5ZM6$
MMS( L2(D:<I&87Z<<I,4_H]ZC:[/BJT&BZ0VK-C^M?H9XQHS"/9CC_L3=F>-
ME:_&M&:7[3,3X:XMJEB]^?V1:9!HLJ6)+LPH&.P9\^#(EC1\O/%WMN+[1F,A
ME*6(,"O%*JJ&(LAOHKOGD@OH"RULVZ6=1TS7JB8#>R=*KLBOH39OPE=3HK2T
MS@4V#%E!I.O )[\<IV*_3HU ]D9^?02_7=BUR6C^M%P:XI\6[(,I*M'R<D!7
M!F3W%W:*R%4^VE)4C>;6V=:K5N,FJ\-1(N@IO*YX$=46/ZK]=_0^%7*#+8%!
MTK'?;W\?>*/3M!A52T'3:FBB7LV_T'S> 6[G9S:+$G"0BBUVNBN9\\K!B.$9
M9T-8;7U+G#Q9LL'03QRJ_P"=S;;[-?GU'@W22!;FE2]AUBMQP:6[M+I7BV,P
M\->3BNJ.E8M<:#-68AJ23DLQY7U0-&H2UF3FC.02V8Y$Y=;I3T;[??7VOL#;
MM7S!*4?OY9_G*K10LNXUX.[K=3\R^FI\1(L^2O#<^FE-7H?]4RQ1FT>3(,!\
M/HU$I_[]8V="#IRXY0)H^MOI!P%I*A4WE&-8MY1JS]*V#9BXI_[ML4BQ3S;Z
MJLSR3O2:RGC0L$C#W60^56<,"FEYZA#TH&67<3HHMOG2,XE["<;(,RBK,A9;
M*IQ1@7 9LDHG<X>PXJD"HR+/F+9G,?OE0,RH.1(V#".<&5)AY3(N[N-OW:>\
M-F09'QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!S2MU^<:*]'"0@.\ZK3K/&+9&457]#6)U3M@:=/'[Q)+8-EX]ZID/45%2=XT
MO%T2,(A:!L[B$=$J/UCKZW5QP(X,7C[RRUCR(D_0%4SA92KT>E9(W%-#0X&N
MIZS9B#G72 /AP8T:.(645M*3611'"=<+4O&MN)$5^+)T1]FKZ5#R7YGK_17,
M=(HVME7749UV::WR!+ \=(4VFR5\FJV"SCI<?5A*R9'9=-%1+2>E[I)8Y%G2
M.B,N1GG^_J0W' A>L?.WQ$G?Z[_.^:ZUA=/Q=-87?'<-EDL&Q@KQF4G%'/,&
M!2=-P*FU9D0TTH%+3,=I"%L6A.C7(ZB1,-'-D//DCS)9J=:]?6%159.:1>CR
M+LVX%9C5!A4-8EA QZ8*#N;/"EZ=FHBQBQ]>(\6"5SZZE1M:P(_BV8Y1L<NY
M$<I$6_I'9<^Z$BFC!RFASBQ_7>_?&,Q)D:=D=VZ\U5QYPN&WE=QT+NUNUF,&
M+:76JZW3W#*!VO30K-"ZT"8_1P;(V!9AGY%\P;+EZ]"[*&J_.Z\2N#!U9&2D
M*[9/]-J"_P":U-O<GO1_%VX:UOKI>UMW>CMEU@NN@^!3H=UU&ZTCZ#^=E 7%
MY@>?-B,I)]*:3GF:U_*=?NBNE#2<NIZHN3-;F.BVLA-TL;'W "Y=.4RY(%G/
MBQB$U?';-N[#O5WWE5)3GU?]%A::J6T_4MBT8-$^@OF,K^V@3#6% NDO"IWT
MW<E'4\(4=JH5O?+;9(YOG^@U+3E,(M%;B%=C"SB!4S%3Y$K,;MWSQ].[M:"_
MGH5<LZI5U=+_ $5]E^,;EL(D, J(_8M41YYMFUJU*?E [ALNO$IT--2J  &8
MX^PW8,:UPY^ 3.%)G]Z((6?1_"/C(57[E7$?S=3HY">FI7L!V!QE 9 @F6Y"
MZ%9I;-+DZ\<)L:<DZP0O!3WQYNC%7B0\8P?\*-GNU[/"*?.?P6QJ"BE$/)M#
MS4Q(TVATC!-"""T"U:/>)H>RVWTLXP8^C^HTV46&P9C=_6[-&!W5J[B3/Y8&
M_?&VT"2?:'H/U0KUM9;9?B4L5S?7QG^G#XPU"O MW=>6HU5C<(5'$&DF1*L;
M#O!QZKLH.)C"L.,R2PX82W;,=&P0URL!&]*W]Y>EO.E)UA391BH@C_/X\^/[
M@@VF00&5>0O/:S["M1J\RO#!;$*;;,J18:Q74>O1;8(9=C/5L2>P,& DYI'"
M,]>R.%[7_B?YIQ/06;51U:1CHPU4K$,(0E49!V#35#!C*[3$\=JAZ=$>#MK$
M"Q&PZ7A%U:M($:3E0X.O5HV?LZ^BG_+?G3S^7:SU)TQ7M7EW>5+ELTQ,7((7
M,AE.,D6*;&U:XNO#0,&RCY8D:WB16J"+V%9N^?E#[E9_R\J%"^Z_7CKZ$K/R
MJF6QYJ+SIOMZWO.K'Z.!U$?8U&P*ZK;Q"I^M9&:6EC[PR&A[-6&ADET^^;>W
M4^O"R861/Z"Q2.N2 U8BD^N+DZ.*544,_P#GRJ+#L[Z5>]D(XA&*W(,PPE25
M&^QFP!;E^,)P[>*_,7CNI5C15P:,#QI,%ON.P58>$ AEZ,4Q$A=O"\WT,->M
M5FP*F1X=@:+)9KATM\<'%U'=5HN=:#:<:WO"=CCUMQ9&&K0XI%+$>N_Y9B[
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M7H7T8\B3WSCOLO;U'>OGY!<O7-U!@WFP/FLB"^6GY3>J;'"5O&%Z+(M4A/\
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MXDPCPQS#D_9$TDM,2;LQBA?M3GGJC_/<%F&TC5J75\-T.0V=PU)P6*(R:62
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M@7+P<]>C3KRB$)DB/EAIU8=Z^\=>'77ZI58UK6VG=&KJO4=!CR8D&!(T)2F
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M>MR*R6+CZY#N#U8KN9K!<;B9'+82!+.8^&(WNY.'*Z"\,-3]2+C%!<%ZK:Z
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M5]7&J6NT,J/GI[[Y#O)["[LE&UDVE5NM2/GQ3<IN$"9KA!## 3&!1(=54_\
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M/JB=!!'XN@9+":8W];"_'TAI_P"/U.$:M/\ #_'K&3.HD7J7 PQZB2/QH_\
M-JS_ (=?[=35[Y[KJM;)O&UP,8E+</0%B+]GNLHY+T%- UF6J=KZC!_2AKSA
MZ]ZZ-VH5:+D:;"U2=_Y,_,I*[W8ZIW<;7!&E_33[_P#FV[GNTC7GJ-B;JB">
M@8(>#'E0'BY+>ZKV2>Q$/-#L+;3U<[7A4;N]>,ZIV%UI 45FC-$?^R2C.,73
M&)UNUI?'MVR5(6EAKDO\,ME/KEY]J$3:  9W8#?AY3=_(JY:-C!]-BV5Y;J;
M4?2\+6G'P6U_*4X/W*$_/$!!:"?]0,(R@Z43,!$6Q#0Q'1RL&":A1HJXF"$
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MY 6)FGR<!>'RI&J6:F#@0TB:G11NF3OB"8$TC(PUPXN_=K^-<25!0EM<]56
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M3=IP7V7443Y4T@J!,D.'5[0"?M51*_L0<S97 !K@A$ES7G1F4*BC(N(QY]]
M56Y?OK5!SZ'O8G')/7>\!EHR^I]DP-?8J+_%$?9O]F9SE-^C7^W6P[]Y8C)V
ME<96<J9(D][=F09YQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <U%6%X5]<!^ZUE'GD9I7S];.RD[*US@Y 7H'/\
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MS+79/3=S$056O[&APH# A-E:UW.!"C\MON2+7^X^Z+N$S?IBR0Z4_P!>N_\
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M![$L5\,=) /=LA@-T$5C,K'PS8(OYX_2ZI*:KN_42PO3U)6<K5?25P-OD19
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M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M<<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQ
MP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''
M' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<
M<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!Q
MQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'
M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M<<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQ
MP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''
M' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<
M<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!Q
MQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'
M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M<<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQ
..P'''' <<<<!QQQP/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image03.jpg
<TEXT>
begin 644 image03.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# @'_Q  U$  " @(# 0 !!0 "
M @(!  L%!@0' @,  0@)$Q$2%!46%R$8(B,D&3$R"B4F04)1,S52_\0 % $!
M                     /_$ !01 0                    #_V@ , P$
M A$#$0 _ ._CCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.:/1?1-7V5;-MTPDS64XWT9.$A+0(ZD5TC(:XU&5U<;XJ3KLF:"C(AIWCJC>
MK,954 L!,T&$'QLHK$A_G_9CO#G-J9\E6TA7EZ4L_*IO2LFCK+^K;$^WLL4O
M9=J#[!M[S:3\%UB+2'!57URTE\@;K\)Z]Q_([BTS;$<9@9<V"(88PFKNX#B'
M25QSG[HKSAZB=[<\%=7E"]0#J+0"7TV>XJTQW78 QA54DG?%&D_!:-ZC)JEC
M2IMB-H*J<&O>OKSFR//8K 3L$L\N24&E8VV8GT.7+0,OOD>?K4[^L7RT*=;3
MU^F*^\TL#B"L8P3)5UMU4:<,Z:[;DAZ.UNM.4<QFR!P)W9JP8R22:,B9X</,
MVPPM XYSM-5<>N"-QN<X<C^T]%Z&/5WDAG\KV7,M!IV>?:T\8!QGGGNWT>[!
MPJX)5<[F* %"^D ]Q@&=5;7BQW9H7S"M/<,90DX#T?*J3WYV@DX2NF>TAWJ:
M#2?T4B>O+!/6JVRJDN$XS4U<8WS3"\^0YMFDD_)DD7&2IXW1^RIU=6(U@B!3
MX%HVK)&1F-G!TV/+FNUPDN%AM\W,:IH:LP.;01UQ)<_8/75<3+.&YN$&!IDS
MIF<4;!D[\8D*/OER,M?6F-IV[L\,,L%J*_*KO6#L(U@Q2F"+I5JW<]VV0MLX
M+7BNVTFP']"G:=Y\.,C3LC"H2AD=\8=OF20VW;V-.:AQ/7LAXT!^CO+-[+=;
MUW6.FO?;-M5>8^8]U)*R%K&][8+O@CWR^KH[!A9;]:2-P@SAS8U+\K:#3";P
M78ZU62^M[&9!Q'3 -TS,;2_-'MXJ8I&O&@'Z@5ZC@7]\K8K4-4+1=J_@!*@K
MKYU.JWZ"#Z)J6Z!R(-%C7I'65NU!(.3"T'F/='[DX3]O6$[2'4'S5;9=U4I6
MEGV'G83WO2CM?K3B)!]3&QB5#5J&0X&O8;&LJD4TPA,6D@>%9#I9(9&A=#I.
M1J3(T!8LLAHYD_2"%]%QGE874=>4KZ?DOU?D_=!2@KA#6/>;M8X>8H>\6*'Y
M8KZ?"5[^0X4./+\R:U9Q5KCOO9;$(ZJ"]:7VO3-Q O&)R'OSS;>REZ]^@#_4
ME4>A8CGZ#M;Y4OU8VO6C:\ZD]@K6K[WH<!Z?7"LT4^1P (N#2E9HEE5HZ$'2
M9M>;2>P#W-$3R<7L.CGCG-GG4WJZEV&'Z$DE_2RUME^H/M.6O)F=+I>3B(C^
M6=T3U:X^3"VE/:G4I7J6AQ"BS1C%64T0N:-X3;-Q[_-#%%R<?.1/RGTE56V+
MD3;GU6RG^D6"C/.EDDJOL!GMIX#:J[F0VI8EVH(;'.[[L4M[#8UG!FW4U @D
MM4)!-BZ.RVBBG]A/,;PO#XY0IT.]C'?K!7C=KINYJSI]?NR_DFQC@MJN)JJ^
MS?/V7D@E.J*PCA\S=<FEA6ADO# #!#UBE4B(9Z];EO5+,-GY3Y3(K"U/\R?1
M:OO+]3C$G3[#WV387RC$[/4.MJO=_:GXCZ*6/0/FDLVHB@:>[$GQ:_OHKY\.
M^FT^LYBA+5L-$C8'C[#<>2 #3(0=,R9=M;O]DW)4:J=VD7V@B20(M(-F*+0]
M:].L5-@ORCJTDIL+0,,=$U8E$(9[ TN?A!SS[AS\HTO#+3UM?E0/S1J=C1+_
M /H:\X5'?U4U);+]YE*TOJ]$GF5A=#J^G^9DQ+8LXTIV=WUV@"PS0*GC-81H
M-:YXK=CLU:8$&'LCP]$:F"J?7)3TNS:IRGZRDW.5^B"NQKMQB+0;!_E"#\VM
MIE:S:T7<&CV3$K:%OPIG4[*.]-S0.K3E7X0&OD#^1!_AM$4.A/CG-"<I_P"F
M)VD+=#[)7H869\TSZ%\>K$N.R[YKCZ:\YU]Z2UNU^>FD0,O677,EG?K6\VZJ
MG3M4V4](E@$BZ?<*^(-1"C=IU;]ETWY:O@[>7B#!N;?7[9YX //N2U&8:TS+
M6\\"$"1*%><M5!5NXJ6N\76QVNNHC@(M)OK4-;[DRS^YTXM#FBH:Q"$CMP="
M?'.5+JI??(H04K]87_5[724#T:JV7?E_/ NY1_HNVE _M](=SJF[H?7ZO#RW
M95K!U8:;,-;MYN=*J O%>X0!(.N&'%0("Y>P+6\^^V>U+S*ISK2]DM-&:*$]
M"#-3."JE\FW<CWLW7#D7J*:]5HB>J$AS@:*]IR;K4*88[*>+9@+V2[_*M7$.
M=.R=NX.CI:L%3;S[\KKY&3,-UBP#E9UB;PQP;J%'"RN"<X$2-/*#80X[KW+;
M*%(93E^65'Z,YG<"1+U$HLR''S/G/T1\Z>N7:_5]+LDWZH8Z?R^D%1&W-W#V
M:T55H;_/ZS\6X2:U'26NK'D3K 5PW>S1O49T3U:3&7IMED2'6$??W(RG[(+/
MPWU (H]'3/14KT? 3_/?G"R72]#T>R;/(V+0-3+7LVZ]*!;YP"B>@*W=;,8R
M_EJK^AX.6Q96.3.@E^5,VQI$S%C%- =9S.V*R2'V,+FR 5(!IG!AFXXREQX(
M1J(L1F N@(&TD3D18>N8;8"HL&)C9[L=Q$N1@CHF&Z7+T:=F'5]<M>VBRW$H
MI1K>5/4+8T6J+0B;1!@;K /4VND*UHX?1*)P8D4SADCV8FE^R ;=/'XY%?XG
M<K^5&D:M<!/J=3&_TW\[6)8K!$;;=[TM'ERVE=*4"["%<&M-K:^ZDL=ET ^L
MV)2,DV';5H1GD!@90O%)D3F,#3JQQ8NH&>J"(?S3?8"[+&OZHT/TPH2F7ZV^
M,V15'D'FQQ XAXWF^3O)]5WHS.5<&7/,:?':M M_67LG8 DTUQ#"A'D1NXI$
M!#WZ@Z.N.4'>#J:]C"O4NEP]'6%Z-'OBZV>H-EN#9B S2O/UP*32Z%M5+XC+
M,8?0+E7_ $OJRMVDF:Q!U53J&V+O0TVLNL +%W%-$[?GK"C/1MI>WHS76TBS
MAJRA_.Z_9%-EHMD.JG2$+VI,LI,PIR:_J:ZT"%YT-"!']N1AQ',,<!Z F)/;
MNC;-^J+WH"R.W;GKJBEP$V6<<VKX)DLBK*E#2]0HL8SEOESV&MU978;N,&A3
MY.C VZM@,5F0D:M0X=A+[F$)4:)IV;<=I<Y>:P\T>KS-1*,AH_\ *YL98OH+
MY-&[9J"V*Y/B!<)XIWW+4]H7Y=01UL7T->)%U,!4T(SR7X_6D]<J\JKC%R>,
M@E9\/7K&;$2ZO]W*MP7_ &:TY>GGVYDPY[V;!%5"8#FH4;Z3KQ@B69I\JU.)
M]"R/1IM'1 .D!,J"0F9US3U>VXB/@$I%-Y#H>)D^8#I"XYR<C:D]IS*@NB60
M5?8P\,N>J4*V*'HV(L>E<U2V8,KPV+&-U0.6!+UO*]'UU5LKT'O,[(;]*N78
MD+ML#(+D;KB4MD<Q6$KDZIO<#;[<U.MS'/2=02=MZT=85=C*]!L5O4Z$\]C*
M8KWM\H%FM?N_Q%2#A^U[PM91M,FRT)-L)C-R!=@(95@SGA2< .ACFCG3T35Z
M'<57T$8G,L^U[=#M#,IJRJBNCCW$3DR>NB&9X<RRP!*A$!+%&V]6!;&=U) A
M,@T>'#(<F1*V;->N&WT(5K1/OODXC@JWO87E8$V6MGZ;K_S@RMJ_8YDB20,8
ME'&B<2O6](?VBO5IPQ-;F-?6#$K/H]/3CI8(0#!)NZ%#'QUY.ON5ZR\879Z7
M0[ES,5OXG]A+&#J]6<REV!1UE_<%>.7D^K[<*+K[/#.=GB_-4[?'=NCV39@<
M.K97<Q%C)(&/DZ Z"..4^?0!3O7#T]Y@M6G%:][GWI46"'Z\_@MC^I4$PRF"
MXZVW';&9KB0K;01%:6972:+-%1.=Q)=K5TTJ71A6@J^LT7WR>J];;5OII/#"
MZ;IA/]9"[6KJV?LRS[[E(L>P?61L%;^[T*T>-AR\Z%G?\S)NE++ZAAJFD3 N
M *K7H-"@D]RIN"0=^P.C5MNZMD:TZAI=F.[8%BWKJL+=6(/ 26F:C^NK00]D
M=\MQ2'"WB@_]2')PI.O^XF0>R&6[^.._E2,,]6.P6$\+5@!QG.2-D0(N!R9X
MQ*U1)I#;&%B(6\@0D:X Z/+(3=FF)'W;,(D"+)FR<L>M,6/NWYX:\J%]GF:!
M>-X?/O:HT7[;KWSVB%_9/_*W=UV?;ZO8P;?8GG:O 8?04<Y%R&[<$+3,T:IX
MS^-#;1HLP^"&$H/QF@I^)0S,KSZ)]0[_ )%HR[:<2QH_KO#P[-7&"(6(;M5L
M=7)%J4B'@8S#,>?E,R>]I_3 R[-Y%,B<@YGT2DD,I^S;)["QA690KHL+CBMR
MMDY=; (AE S=T&>,W3 IT?'*"Y6T:5BP2@_9(@RM&[."2A0Y\3+/O1,BQY&O
M9JPU15GHZJ[I=[A0ZW(,9\E1+EMKJQ3>:,Z"4>&^PHT>4;3P#X8!0%%P/J^$
MN'I:X"H8,9KLR7I@E>XTOO/3ASYJOG7W9@!=+5-#_6>^Y4'_ /!YKIX;-N>R
M_P#.XY*_5%!_=4S.N=5@Z4%KF?YXA:8^[Y#@".Y&L8DZ7GU+FZ.INSZ%CR;<
M]3V2]-+-3GJJ=YK??I%[V?;X0:4M"W(SW8BBXC@TSRQ9V"XJ6N!9SM7:&7<Z
M[B\)-D:B.XY.23!\+, KV_8/#IXXYSQ4-YT]DL+]Y;*^AM'IW(55GB;V@?%0
M"=Y.NC&%;!;U4HD?(*E=LA&L/ 59EW*?F65@*)26H@UQ,F$2QS9Y,@5T83N1
M +>-_=*]YS7-REE[OWVWH^*2 [$=4CU!>Y(Q(^GBJ:2"(F,3C3;7V09=DK^.
MYE@]*^W#M(G =.0TP((XP!O44.MSFJA]WU09(UB- .PEG[N4<SEJR*J?4QK6
M&P8G0HA!AG0W!<BDU2)&A1IL?+1L)F8.)/=EMBBOYTJ/(TZJ:WP)ZU<_J;6Q
M.+3%R(E, ;\;$.P6X"V78=K>U?,1WP^__P!<Z,!G;=L6E%(?M]"$EE=AUNJT
MCH?U=R41SOL=X\E@F;"<*Z.\Q^Z:F\>>2J0\V5OZ#I*W*H\V?3&LK%@L#BRP
M$N/Z;(TVKA/.[C'+,#V:5#2><;H^$VH6@=,WIHH_B1,XQ0LWHW^0.KWCG-"P
M4GZ7=/\ 0K_GU%]_5#YN9&WYAA'%9M2Z[5&W=(?0?M$,9]8/B0T%[<:GI96!
MGF?9K#W.S+#"!47J=$T3U6,Q9ARAG*UOY[(MMUBN>HD"RHEAPU%9]G7=H\[X
M62SL#H6V^?2L-,8%':&:6TVQ-!=4_P!.8==2_F<+RI4"+JR$Q^M Z!!CZ@G$
MO-JJW8&-JHR@&;6O,)=2/Y@# \Q@#:E^1_$/+1?(?(D=#3X65WU'*AYG>D@/
MW=XZY<?5GEUUWD/.8%4\OW%4#Y< *51OK'32A7ZF>A+L]*"*>>+2P+7?YTMI
M"L@WYW::]*KMLC2K:M*UM'5B;=*4A3AS[IV0(.#.M&@HCN)*N5^>BO=2]YEU
MA;UTV(-FRK3ON=6"];#/)9KC4/.INX'6?0"E9[5_H68C->E^I9:O (;9;:?.
MBM.N$*+FMYL;-[UAO+'TS1TA]I^MQ5A!6)EOD;;96J\U7/<TK[3$HR0#A6EW
MJ:U_416X.Y4GL0X=+CD2D3=O)=31T3#?-'S=&C>_.5'R9\_7L83\.U$Y43Z2
MKM:HLU]8P-\$8ME6HIAM\^UW!8F4F34+) 67V4G)-BI^,.8*D(C".A$&8'NW
M,D306C$<)/IJE+?2)YV>9\;W>_6U=,<GQ_\ /V$D.->H;+91.M+Y5@T?=ZJU
M6KA ]#5_7Z^_G7&+!V/+)=-=6*N,Z#.WBAA>>2'35_4'3,[6&HUWJ6-S<2D#
M=;DZK5>+N4<,<,_S6YNEY05\;OQ!C260R/-E89:]IDKU!!CNOTV$R4/5ECGW
MFO()>\5^[&$3Y0UTEH>]\D1[N\M,%H=(A:8)VZJ3$.F^19>]L[A$!_9%$U"/
MQY- F3W,ASHG[,) ^5CCUCU3S2?CKVQ*K7S\M2V'U>B65=?D[Z- +_L1ZO*T
M&G;75Y0KXJAY\0F)T%H?& $G2U[K6U=IL=.$#M)!"Z.JQ[.6(ER(NT.G/CG-
M*^JGT,N=+J3T-8:;Z#JE4N_T"YM/H[S,N1GI]>*:1T>B@5/46 PKRJK\JAE+
M(9:U$URN9QA5V[RY4XQ:*<:8EHT.7-^\+L:K:9]25SZ;\L[R\KUQZK'&*FJ2
MJ;/)7C =*66Z<K[!0N*4S7$+;Z\OV;5A>R.];"JIEG5+8J+8=LLIH>O, :S(
M4T;OEY!>$$NNJV<TB E9T%-<BS51K=T,FJ8S&9495=)(K@EG*P78%%()V&(T
MBV 8N,24=CSY^R9M[&Q9F \EE$VESD4K/R][,J7PR$HVFJA]9U>^UO\ ,CZO
M5"X+PIY?!T$AZY.-'F75YT.UH6WV.4#DR#*&$/Y&HFY-DZ8<?#MDVQ-PPG)*
M1>I1W+5_IRF+'NBI*Y@>A&VG;*O?P]E42@X7[8Q0M<9+NC+V,>IEX%8S'<:[
M8&N+^&NTIPL,4'?5\7_8A9AKH84A3V$66#I(XY5KX?,+L?YPF8*>XV :8:[#
M^BT:P#+YLL.$[+=T(#*]@[(7-D^PG5_:]F"&Y#YZV#-ZGYIASAP6"4&GI76_
MO9C232R5[/M3QC7C]YY ^Z=.\W\O/)[C<I^TKB<S9F_/2 2U_,MIA#WGV0R6
MNQ;9C 5HI6]#P6*6H[%$(TB;!JY*/X=G,9(D&'53:5V5O3,FK8=B'=H21<UK
MKM)UWAJ%%BG]W9#4)8C@,%LR%0IF(S5+&*IR1F5*=PQ,;^'UKE3=.S?HQV8O
M:/J"E*9<(Z)8K5-"LTFF[2O[6/AJ;>QY?\54P<KM=L1DQ[601CO=M!EK52(^
M 2-CO.DL2N>T:-EZH<K/50S>B1Z?NYE<K0+>?/94ZL-/V7\JW(F5_I(2%>T@
MOF%)\/I5;V$\(HF)8@XDD)F^S]+<0+! !M=<I&TP4TXAXC@0D0M6MF^@?=A&
MJ+&9D:M_2XPKJ\,_:!!\KX'VDY)]"5LN7#Z4\7,WDJK&MV*NA9YCV066:_L0
MPCQC+@:90:,*$@#)B.3";X$8.JS#+K/''/']W6.>..7766.6&7Z9===]?NPS
MZQSPR_3O_O'/''+'O]>LNNN^N^N?URD1/?3_ )FN?V5>OK1#]>ESB+:URNR;
M: !D:SGG8CY3D+0?925:5\B]V3"KLLX[Y$@4E14 4A=6>9OC=,,Y;-XDGD<V
M7:Q]W4C1HD=:]VKK?IU[NM4C7EIWZNMN&.?6O?IS_P#;5NP_=^W9KR_]L,^L
ML>_^^N^!^W''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!QQQP'''' <<<<!S\NM^C+9LTX[M7>[5CCEMU=;,.]FK'/K]<,MF'7?[L,<N
MO^\>\NNNLNO^^N^^?KSG&->,_;KE[3LRY"-%5NAB"M<?2BKY+E6.5*I0.UE.
MX@Z%#\G26PT*9)-XV0YS\5N9.L&3;@\8MUZWY2<D:%&79&B5D'1I_(T?IM[_
M #Z?TT==9;^_R8?IIQ[U];>LMO?[O_CZ[U=];.N\_P!O7>OOK/\ _5[_ %YI
M0Q?R6%]#UMYHD0F&0]VG3UM7:N%(<&)O4M*?3393R:U:297LAA+CEY16[DW,
M+%T#)4:9$P*[=TV+G&T:I5"2E\Z/3OGNM Z[1GFVDIHT]\YOGA25V5J;RK-D
M7K"OBH;P*$/1AXFJ-9T0DVA;"U4AXG-KUXM0YVF-+#$"A3I^<%A=CN_]J+YI
MWYNK5(0[G7H%3)0+SC]BJ[VM.]NKF+(I"1Z2]PT#Z'\@E1 6MR,A178B0FU5
ML:?Z=$ZS2Z\W+4=8QUQXF<*+N#I6SD1]7Z?DWZ=?Z[L(_7[]N&'Z[]O6.6O1
MU^[+K]=VSK+'O#7U_P"^?66/>./?7?7ZZ]3;?K*PCEH+28Z!& [2KEIKZU!L
M+?GU(27*0HK+WI F?SZ].O"5FIN2V9ZVQ\]\7K43QCY2.IL:;&C<V^GSIZ=]
MA>8O.7O#"C(-@^P[P+OGJM:K]@F4RQ^2:^EV/6M25O2*K=2%=I"&RLJ!$IY
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MV/+TJP=DA%U\_P!ZPKL668C;!"2M_9''LO!SE9XK?/2YUN_!]^AJG4P#_O\
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M... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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MO\\?/-7]>8G&R+4MQXNHYZV*MU@.UIV8BG]HJX\J>8QRUWZEI6 PZ9,PFK+
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MY<L.@OCG'LYA+C4JFH@9[0$V"95?*?CGQ4<]32-;;!L*TJ2FK5_W,88.AZO
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MH=I_=(F;NN\-6&7?7?Z!FW',;;7-000FUF>FI<3%S1.#C-[ UFQJ\%T$6$Q
M7@$#<5+28D'5,-GR@P()C9[\=Q L0A#XF&V7*T:L\DX#CCC@..:K2[QI^QW>
MR:V0;(4')ZIXD/"VDLK9J(7)(1LI$ZGP@C/A"SW:A1G.'EA(W"9&W$A#PV:O
MYD:/WMU]9;4X#CCC@..:P&W74)=?LEL'V6D[U:G3[>KVNR9,8O0!KE@K^'J(
M/(IT+R).J NRE&!NUS6+$I(C8"8F?4B;GIU==Y];#'D(!:!!*BIT,F+)PXQ
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M^FO3CGCWLRQ_=C^H?;QS%49X3[-2E&QZ]9 [DAOJT$<4QM7IVDD"9E9E&QC
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M>]#/S8\\>.Z>I1OIGT:)\B^3HSK6K::;D+.OZ")L>FI;$AK-T'Z_.@1UX?\
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M8,O4-[VH:OZ#\U *IDD/-=@>$SI*E=%F60RMF-2E \C3_@CM].399DNUH9M
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M#JB:AMN-4K(J(M[@(O6(0/Q/[A">EF)';]4N41([B)&6GVA]&WK3*%#7_/\
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M^#$VR-D/22[P%S)'<@/(EZ=T6,9B_G%29&K9HCS-FW#+'H*)FHM[QK-ZL?\
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MU=1]F&[(*AQBW[$&*UN67O9_7)E[;/MM62>+63II])+"EXA6?>*$,E_X"O\
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M^ADVV"R:#-:Z2E/5FM]\[8=9WJ)*X;.C\_2MVPYSFA&5,G,&O-HC181 85%
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M[85;JL.KNRT>1%E;[&C2HVLM@.W?KI@B ]37O4MD2K51O;7=-5-] OE?Z$1
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MN@\<A'ZEP-Y3ON1^@_3.B]]28>V7^'"3'[ZW:<L]??67/CW/"5'$SSV]P5]
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ME"N?6WH4!9E,NZ=%M*G+&KT-T'0AK.F,*T#A*3.B:V[5/3BA7/67$2;@+?\
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M?FXQIM9%KE(9S]*S1+5'G+@6\S+S:8)A(3A^DU%7HFB'S9_EOZ,J/J*T$ZL
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MG/ZI$8MZEH%3CF]ITA)!;62VKFD(+)F-IO"-D,UBATXAG*QB1)&[6'-/Z?\
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M P>=]F-2;3$1-LEQKJ)-LJT:G&16OM)$@C!=D#[1CR5Q&C]<,]HV2@;3V =
MFK3W*8ED1$F#M\S+&7T'0:9,41SA=]0*A"P(@V>AP66RDP%,=H)G;AI#S5&*
M4-1=[)$+;MFO2-D!L)NF=MSPUQ<]N>6/78<YTKY'^B>UZN%]W2=-AUR-JOUI
M0^BHZXN&L*_RIP':'M*Z;<K1L2#-CTS8HP&*)4(ZU^D$)E:=JC_6'=?K@E8A
MGHT?5T&N9]X^;GR\/G/Z&\L51G@<L%Z\[EZH2]KPU[]F10UL 1@T"0T.9")G
M*ERI7>C\Q,_-A_R)TK/;,DZ<-N_/K&;#0UJZ. *-;HR %!6"1_Y9IE:# Y?
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M_P!\P]C,8 4J7IQTP)-V,+WMXX(([S9,3T-76:/7&"IM;V+83WQX4"*^'/\
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MPD#9EG$P!VY'/:OE%9/7(M,%\5Z'*^>P,]DNSL@8_CBZT&"QZ^5(X-)[9IZ
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M?OE07.@GEKTD7T/#GYD-G0=Y**%*@5;OC.)VOMBT<)FM(+;+B:PHHD3US,]
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M#9;Z*WKO@YF]70DS>(2CX=@?:WOI4D $K%C_ +-G-00KVH[B1'%DFB<Y ,W
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M(KK,FC35XYH9DYW[!-.DE*_J]L&3/JOO?7F*R"8D&)=#8!@*$+Y"R%Y]0GA
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M$2AEF'>JF,-4+X'\8^70!3;79(P$*7!XQ]#4_P"C%.PC2[VUB?[&N&UEJ&
M8TCLG&+Y S,_O0=QDX:^^\Q;/F_?[DQLWH,G=M30_4!WU]YN]211HNNW710<
M0;YMJLS2P*N)0O<_[WN;+9T]J9C1Y]Z+Q]W^@S7AFE5_H@..$NPNDO5U/^B&
MFRUFI)3BSQ:I;FA"97G*NG@35Y!T1C^Y6=EI1LHN!A)SB44V./)#F-*X7(88
MRHLO.'LF18DF1JDCP*M_>%;^@G7T9\R&:BQ(3,_6-_7FSMC@U([&Z5@EC"OC
M.^U#1O=]2Z?6RX$:SGF" I+YO QAMAL)D5UW$*_NS&RXC /CK<Z14WHZGT[T
M75^87WC5<I&]@FV:GV8B37V9J;KG8[!9O- ^#98\8J+\\5>K4!24MVZ8,4<F
M# M^H^7WRBP+;T \<"G&POFQ8K?:7H(\(9*%$4K=BN_#W7S]/5;I+USZ';F@
M;68Q3L'T&MYW'H6@%D5_%K[9U'M6BPB+8+24(CSC 7V9 (@O?I3/X^6N789;
M?:MSUGZ5FV+6<RD;/3_0HOT(VJ*W3L2W;+LA&0$ N-O\6]/B\H ;58$<M%O-
M@=#;YH%KYHBTA=FB:-EW\\<"G2Q/FQ8#=;/H)B G//JW2%V*E@BW/SMFF7'/
MJ_T$RM(&N@2<W7ZG?\Q1U)<=JXAH?>J!9U%@D6P&.1*$D3)7'%>BBY&XH7BR
MYRWSR],>.;*]"[K ?+]K7T[7BY83#'<6834R]?"VVKB8CP"#NXM-G/RK48]C
MC#AQ]\=RSJPP8'>1$EJ[[CQX]E/' HWN3Y!,EFRO7,D?>\$3#]!U%7B=7BQ)
M4)>:M5-BRY5*_P#DK8G8^,:UYF)%UP_-U-[=&,?8/F!"49OD2Y!/_12,\]HX
M?/?T"6][(OJI_P#3G^^K:LKKO.SD)%,]VGT<5TRXO.):DQ-2KZY_R5MHY?%U
MX;-$V2(Z"JOU.[?#F[(K"6QF=29$ZW?C@<^0'XX6B+4:%#-5A>?K<F4YY#@>
M!C(6P4R\QZ&^>?$XWKG(3:0"HMWK,_18LD5N*![/5R! XE.\>9#P&S%;0,PT
MR9'69\OB3@I>[$Y6L%.3PWK-N\6ETD?$3"/]=6"UY-6*06]BQ)BZSOYBT$]I
MJ:=T T1I<76!C&]&F1F0SCR-LBW_ (X%';+\NO1+]>%L6=8_J6 \B6>G_HE3
M]?=,6JWC)E;6_;!!(D((C8L&+2(5$HA:% IL!)UZ:J0$R78(8>/+LTC,[GNW
M:K:Z$KB73E%TO44\K'.SJKJ:N:XF'(D79!BF9:.GAEB05C0MVZ1MAQR.X7G,
MTQ=LC?LCZ]V.G/=MRP[SRVSQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<
M<<!QQQP'''' <<<<!QQQP'''' <<<<!RHOTW\C:^]-4]ZVJHQ=%@I4[U'ZG&
M^J(KTK"5_H[5S!JI2I*!84T+HEX9QV%4<JWK0L!8])7./NF07LQ&[_\ 6#&R
MW6Z<<"L?/YM0LK*W3L;W<M?GZ3["A^[)% 8J"?WLS]!PFB+8^O+&T\H_;-A6
MVRW846TMJ;_6Y&.V#7D(UN6I0V9+O42?1OR?85KP66J:C7%LMBTJC^8?KCPK
M52V1C)ZSLLB7Z*/4LXZV8F4*3X@<$<#DJ0#C!T3.;J$2-!J7NF2<-D73KWWW
M<<"IYG^9+ ^,#+;;SZE;V3T9+L_RI8:+:LNKT >$2!OD.19$JN$Z=6@39 "M
M,8Y(NZZYSP7V&14L@5?M4A>UK<!7!#=/A+?R[L6OI59N%9>V7Y5MVOIGOXB0
ML@C3=4,F#J0^@MX(]\6!.-)^Z*/ CY".XHHJ8H8 ?ZV'MF:HN92)O":IRZ4M
M^XX%/Z5\>ZJKHU6TA1M9XB+=6,7@DLM+9 .!(Y[17@NL[%K)6"E"_6,7=+SL
M<?8LXJV$M,2+F/(P=6(:+JC2,]6N6OCGRT[>3$%>IV1Z!/VM3M8)82LJ/3#E
M?I:P10J]5=NV&HBV)L :NRCZ<75/2#38QW=J7HTP4$U$"0.6P3IQ?;,OC@4V
MJWQV1E>L[-K33>;Q,A69X6]&^&YI/:L+NJ2+7?1=Q6K<!:PHL?7N[T;V!9FV
MI. C!.WO$;-@"8DJ5MPE2-W6.P&OY<+1YM?K(#7:Z*]D&[*\CW%6[/&6%<I%
MK.QO(U4$:?72&T 2PVP'0 ^*9UBA.0 EF.V:XQR3B *B9\: 4BVI<<"M6M_G
M(*2K1JB[6*ZFYYM-.]079ZRL8[*6%H (M"QKF\TRO*W]5&7A'6.A(4$:L8RE
M#61T.8<*2=RGHWGC16<4(3\O/4?F<KJ7?GCO1;[?-[\]6)[YL,7WN @]7;-,
M]YLMK,K&.)?CV=]0H];R+5GZ%O=%ZV;2^ F)F3QU?R-NO"SKC@4BD_BTM$._
M+,++T8X$%_S#6/@&NP8EJKY5;M^,GP$^ WI::*YGE)^.%.$+HW@H(RY-2Q!G
M[F") #?@GQ]8OJ/*VV>^5BLU:W529+E92]0-?N$[[AAU]M4048F':+#"6,/M
MZN-SK F19I=*="5DE2H:7M$Q&1.U:-8S06,:<\-T>U_C@4Z%_DKM=ZF;ZIM+
MU38#Y$P\-V=\_J7-]5U7ZS.JFEK:P0=+<P&- 31KU6-9Q&)4U8#][#*S60'4
M-3S[A*<"><+3]\Z:]\PBJ_\ 0?J#T#'=#Y OZ>6J+6S /N-"'Z4_71RLX*X\
M@"+1>_YLB<?UN$@A+SE:\,1\N%'ZA]=X9Y]=2BXX%#"K\-A"PFV8O:?5KS_J
MGU%\EI$2U8555YIL73+\A^K)'JQ,LE]-%LCVNV[9;F7?@OO#BY1MF@K$T:R.
ML)HV?_2Y(F)\S&,;9.WTL,]1L>CV%,MMYL<K=F^ITB0GE5EXI^N*+VU1*IO7
M,C"]2D#0J@K>0(+0VF,Y9MZ_O/E6$E",$ 6RU[C@4A//Q9!EJM9JNKKU+9==
MQK5\I6?Y3OIHF(5=NS):0&V+BLF^FUSB_P!C!%A$9B+63=%N[B44$'VBLUIT
MQ"AXX*<O@CL.P.J/+,NH?3/H*_%^SR,]:])#:PG/=6%U4-LU#[&JNOEJJ0SJ
MLNL*3"*P1Q1#4PL$PH$AI>)D8T;3(XH.QD;1^4NN.!5_*^:<#=<)NP8]X,NE
M)*>\43Z#PJZW)B]OE![A6JHRJ5I7M+MKF19DQ$=!.@44P'3@NTNMD8.["$:F
M1)N6C3K)A^/R#.81;T'L1<GOD-Q]AEB$^X//E57JI%$SV'Z7.^HCZI@DO.GN
M()-UR\&]T)*=!)*+NFC-A".W@V*),CP1]QO' B'=WD<+:B_1&U.=25,VIY@-
M:V&B+.2U9.WZE&7NK\S5YY=(H,T1@HE:Z;$D]/"GT@=&7X^K5I$2%PBO3@8F
M7%CR_P#SZM=Z93UF=>S7%?N&S*')^:+K<AE,U;M!-E1;&EK:5: BILW1OPKQ
MGK^4^O6I7921U]ZD]-9'<V"V?.(&Q%VA<<"K$+\K*S4@K&J)ME.0!1)^C?GW
M?J\$S'"B6Q6B?/=6\VJ"#7VHC)RPW%1KL*\UKW^E.3->LA#WGR6<&/LZC:,=
MNAWWYVWBF^D/)Q_SQ:1]?!KWH;Z?>C+&MV<K5VQ::],^S]DYU7TF8AL9"));
M5G0ULL\,.E@L]1K'I>'3C$X;%DR,=UXW' HZC?$=%%'?/TL3Z#=YB_19;RBV
MZ!+LCJ+L6DOWF2_S7HLRV(!Z=MA1J=R] O+"2VW*,30.6@MUJ$?U>X?#%:1V
MR5J;\[EE.<*H;M%I-$_957NOUI[EACI ,-A&-'O62GZ#4C]<3<^MF>>A;4HG
MH,UO%%=/61(CD"@ZINK7A,D9:K&..!5=\[_$.5*>?+\2;;#,6$N^K6N\-BKM
M1\<9/)?E<0QM-5>9*8T&UN;*&1UY(\\CUS '!%2\LPNUC):-V[LEC*SZP:1\
ME/\ 25(9IZR/4C^]+Z_X2O'Y\4!-SKQ 6R504W?2TDI[<S'MH+1HPM"R]:S6
M%;@XQN?BLK_<%:E2.E;2;/$C&5Q7' B[ZF\O!/4WEUZ\R'7 ^GPG!?5Q\)Z
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MF>8#GEV,SHUE.<.N/\60+,;)#BO=1"& ""?@^QA8Y.YC#SIT'!B&Z8@^;O\
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M:7' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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M... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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MD>?-%6[W& QE.[;O.IZ!7]"O"@$9 UNN,_N758NP:IA,;E!58\Z/OR+$H_\
M-EZ-.O/**.FYX;,,*M/LWY:]7>L$CNN:&IJKK)72GGKT(#$-1(?3?5MUSZ%/
M1D_1410*VW9G_#0*]D:8Y^<;<*JC;K;#M815E"90J!AMG8Z/LKY\^@VGT[K<
M2/FU"L4SW]1_./KS7Z[8']#UMH_S(G)BBLFJ7UBB'6ZQ=^^J] P\N#4;O]J
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M)TB"!MH35<.5(XR<%F8<C0Y$G"2/\J+_ ">X7\G1_,ZT?R>XGYM?\GJ-^_\
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MCBB^_:-];I0V-TFR442$!/\ 4+MZ/$1]$J%89,6P+*QF5CR 9'&.&VA;</\
M4?F8NJNSV*]%4432*TD1HECN0^W$":JU_*FR>X4.,[,,9@VB%21+F==Q(VD[
M,@;-\GKO1JQSV]?LYBM[^R/.?G3SB6]96+9JWW0@J,M3,+!62XAE!FHK<Q"U
M<#O7"(XAF-/:9Q0O$ZU[1T[?K[BXR96.66J-M[ZJY3OEB;C4(?3+#HBJF>UH
M=7>7*D!,<+W[[*D#F8?YPL&'8P%N#EVRKV'=Y[G*;L/B6'7"RF*EB1(;%E,7
M& Y.5I&["3)JU/'WIZ\?E\V^2[9M^O''T^SJV>$JT)0B0.KT@R!+8TV.D#3G
M^>5@,^5"AA1"ZELCN/11A4Y-BD7OM.TD9^8/@3=B^F/.$UF4$J'Z!I&6Y6",
M&FD%2BVLB2&9W#&=6[>(+* '4>S*LHPKICR-PV>%B38L[5HW;(NW;AJS[Q]Y
MZN^EZN-JJU9EO5?73&]SM(M( /3^J*)MR)R9L8;''*HI@+#Y[#.WD9L.!IB"
M-$R1MFRXT7#7EOWZM>=0]B?/;TW9Y:^PQ*+YQ7U;U=ZH\J^L7NS?]R]L]WT*
M7H<9048_6%6;=E-+XRQ1T>31>6%3OA5DJG<G1[(=<YJ1/SSZU$LR^H?B/V1[
M+VE4JF[1K #2+34*RJETYP8"**3&6BM7HJ65D\DBR[2=GL%C+,]/7M2\-0LF
MVMQJZS0M3-_+,;R67]4%E4N_O.1!_P Z3G752<VTLRFT1LJ278Z+)?\ (V,"
MQW/<,S0MQG-BR*#UW.(U[860KN7$"Y1SN>K7!RU2N\@EW53@]>@ML^V*U@JA
M-'E6:.9YCRL15Z?6\'(+A-L"&:WE-8V0E1,V1=PDM.J3F#T9'0^.V=CV2A];
MJM&3YQV<3L^Q;'%%:F'E7+ZY>>_=^@YA@7CLVRC:CH2G:E,HA(K'6>Y>UUWS
MTY^S"BNYFY9Z#-TO5N-Q,BY6+E$>I?GS:-KJ/K9<#D%**%\^^MZNJ#Q"H6FM
M- VNIGF_R;Z;6/7!6KGKO; +'2B%8%F&2-%DV42+-P9:9159FAX@S'%[(I0+
MOM7I;R$&5XMKZ;_\W"4MX-$ D*RM5JUC!5V]B 0)Q4J(BN.![4)8#049#)$B
M$#21ESAL"+.F2=6F/HD;,<I+^D/.Z_&KZ8>OJEPD2VXH^=54HO:2.-C6;"+_
M ,+^JF5]OFG=.ISBD_[(=_7R%S(EJF_SX7\;/;_*T?DK"4/G9<9;U2A^HK2C
M4&&PR]RM_J]UIY+*,;FHJ(S_ ,!#WD9*VIAQCK9+_P!7:95VV@[)?FR>IH^C
MK\$?$3C.) ]$PG&-*^-]NKBLDJEAQZPO)7*^1]'DJT$/7ZD]1><UM?!"/1-Z
MVV//*DBGE.7E8H \H7&/7&-":QB9U!)H"[L L^N%WEE&#H:+NZ8OD\0IYN60
MAC-;/N6(HN>%C262@J;1FAH:NH4R5ID]KBYO-AM)XW^+^L$;2PW60DQ\IT;K
M;%KTA[9JWSQ!HHK((+#B(NJYZ7K/:6'V KBQB2F7=&=Y*Q<YB?*W28LI!W8H
M9O$9.PW1(+!W%G?U9;/^ME]8ZC]^^(W#U$#HV+4C0M)!A)/FZKM"6V[CDC%L
M\8WFO1D+U%5H>9 B%"73DTJ8M8+IA4CNU18K<HB)I$AH[_67JALE?)BW%X-6
MH!C>:N;Q-.^Y_,#G6L(MT>FZP7@/QF)>17GJGIG4Q8SQ(6JJYOK 5VY;<<UW
MLE/RE:V;*1K[VY!/;TC] *YHREW.]TD< OVOECRSZ0]0B6&M[<J[>(<1'G+%
M2Z,K*SLUL)(X?Q-26;= DN2NNL:HF$AFD8VS1Y(^!ASI41KOI[=84.GMUJ5K
M%N:6)U&NJ?V/JKW9V _8+[,YS.D7^TQ:-D+4,QV$,IN(G^/W U9S?W]1L>]G
M5(-F?)N_VY NY.!-U-P<K"I[[G5FH82B#7H'@>_IQZ,J2X*-U;M,51V=0!:*
M 0C,&Q- W5MP@EIT/%;T'(^R5)U2"1_F^Q+_ *N=K/>0BW:B P^QI_LU->B7
MJ7TNHM]<N$U &K@M8Z\X  ^^D'?)(*1R8=7:"[B*CRZ_*8B#*CNE0,<9867M
MWH6@J_;(*&^7C3Z2\E)2W!&)C=9:6MMA&:Y3)X]0AP5TR:A&)<IKGBR<%;CQ
MX>S:=F#I\87A*W0Y&&O\!UM>>,K=*5:)LVF.[YW1>]YNNASFC]V[MA1(&HEE
MN**,8E_LLXL87^"?WLEC^]6F!^*5WWC'_9LY2AZE\KWMZ=]K?2BJZZ0J9C*=
M[^&/"M.F+HN*(\##=?:YMF^OIC U4O,"UXSA7IO1!6V,SQ%/>U(W]58L2K&*
M>R0HXWK1)W,!^<]Z#; 0UF41I#NI*]^C%D?0"/>>HTW2/2[=T[%7UJCU$QJV
MVO8RUHF93WKNL6.S=5KDL#%)@!BSKKZ-)S_9&"RG/UWY/U*YUWV>G_/&M+5V
MB.D,S?G=5;8*ZZZ2_P"3_%4#I_)EZ$B&B3_#E_QP!"7'+;OXLG\<3+\&W]N7
M[KZHR,[+5:2+GJ>/8[F-BF4^O]UBJ&IV:Q$Z)((02JTJ9F,3IT;,@1)4V+.%
MP)461$C2).G;GIT[,\:3 OS,]1+]1=5D"&4N 5*D?JV>O#];#/4MR;)7C9T5
MD:XUEHL%*O\ (^8YCN]+A:18XT0&\]6H@O::+3<6F)D];)9>'&@Y\F_,FX,;
MM./GH*2@^E8UFV)Y.O!]?,?1/H[S]O5+>\Z5!5"&0DKGG&L04^GGM9W.]68V
M @03K&HZE_MN-KQL:8%1\-9 +1]GKKRAJ6F%TV^G?/.M.46>.DM;9LNFM\%I
M8<Y><K7$46$[DR]"PK/*V0INN. )2HQ7=G$E8ZXF64?;UAY.7K*G@S!9$*P'
MJL:T3T<]7:Z"L-ONFH8:\^$;&KO79 F,-AZW/8;6YG83J;O%CG$<#GM@D=+:
M5+096,.RO52H?YG^G@=4[JU#!Z5 IM5V#6U@>)ZQ%>IKFRE^/'Y64[I!M-E(
MGH(AYEF/+<O%M]E"A(3SO:*%8*6(4\&R/_N<I)B)$BY5!^87H8Y=R);MNOM'
MV04'^N/"OI:QRO:^0"=-Y+S'X,=/-UB'1*9H5=ZZMGSUS,0]]KP)!E8B0"_&
M_=V2#DA\&%L"V!C]6>74Y'5;.;O25!JM;/>C?)1["8[AKP&CN4:-EAC)D*K8
M38HH%AT1\MFO'?M$3YFO5ELPZV98]Y8_KHOV'[^K'QR-\TL#,K-UCJ?I2XPE
M6BFNMMJ\7")*^22V2P2MOLTJ68AXRZV5D]7),ATF [*2=0+3N*1H\C1I_P#D
MI!],4!97F%;$U\?D1R,+I#^AI,PH)0.RX2_Z"0O4GO1N],(WE]!L->\]7!TL
M/6"3#7E$Z+$B4-A72!\/+26(H#URI<&Y7T;Y@8/:>7AYF=5D:E)285M1K]!U
M.TE=V;7$5[Y\27WY]+U^%G!1LX-.95AFNF!K*3-L@<._A!24X;(VR<8<;:&9
M,/O2MEWW.M>&-ZLU2&8U33=;QFU<9"[&K)-R4-8TG-1F*5-+QS>IIS52XEPW
M?QQ6X6/ & TJ=.U=D,>M7JV7]#_%U65ZKVN<]&5*:K=LO- \Z0G9+L),;E8;
M:MCD8D(*"8#X8_($ L1T69@P,NXA-TYKZQJD'Y^G ?J[V]USUG\S_8R=U35D
M'?0%7L?IY:J/W>%LNX#(<DPB2EOWA6-"TKYB;!*B25=4%C5*VK[S\DZW\"TX
M:/[.=I*=1M9O S+[Y@ZQ\P/:&H+<SR[.U)L]T-GIWYO>F586>L]S:5UF+>)8
M:)&?5QQ?A_G:N]J3IL?%6):%.0J5(SPU4?,@"ID";#C9Y=!=SUZ \[&60S6W
M5VTL6;X2O*9F!!ZLE&G,D1+_ *G25FL!E6_NMI2.K_T4V.2E%9L# 3_4R],S
M;(_A[\-F> B?7M',K(E0J\L2J+!K=D2[=;BMO)MVTX42$^+3F%?[SL2;'CNN
M1LO'U#GV(1-&5P83!(L*+#VNLX'K8U_.=6@O_+VR(K;<DMK#(3=N;;A]E>@Z
MKMF?ZO\ 3_4^OWKU<BV8OZ%@EYOU*6BF#49(ZM$Q76#[T9U["E8#QDW_ (]B
M,L?1%C9"=^='H]=J;Q:MT"]4A5]D^4?FAZ'\DP6&4O;BJG$O"VE;R0,!M8-7
MD)A$-.1<BU".>;#,/ 9,[3J9!1/-+9]O]B&R"<KY[@J(+GY=FU<;4+Z5/3GJ
M*+Y>&NM66(JLJPHL>=3V_:9 S-+@=YP:7R$:*ED@B"_%FQ"6B6=B2=NW5A$V
M:-_R.ONFN$#W+6?A=D572*V6I3FVUUVT,= ?NL8A':QM@(%6YN?L*:BXUQ;-
M"*W$EGK,5L%ELPW8?1-[,3(D/; NG_F[Z07#ZHVO[;7.TQ$^MNGZ!L&G_D=K
MLHGG6N7A#?Y=FK&QTE4S4N#!8>Y\S[8\?_X$6EW_ #LC/OLCT1U=QMLB?2OA
M6P[S](6]<P-T5U.&Q>+JYJ.HR^W(QN:J_P#35.^@V^_JJM21!CCOX.Y55&>:
MIS9&B,6_M"W4$N%WC_ZV=GMW!NWS_P"_?.-YU'Y]LXE8"539OTHJ0&VM*EMB
MPD);L\S")F9H&#H%K>UB[DL&^63@[(L7(!@1U[Y&6,77EW*ZSTX[WT>B//\
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M[6&6[Z0NJR,X-=#5%3=VR_:3IGS^+'+8#4T')B(KUE7%$H@X-!FFW<RPS-!
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ME*DZYN-IH,>DV BA4"!8E#)YV>K=!I*MU5Y@]F&:483%RU"BB/FTR <R)JF
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M3-&&"T$XJ03,F1(&S!<B%U'"L?B_YRJ^N["K4;9-REPMC!O$:Z4FRX](K96
M&\$6_-N2E\(VVN:81X9DT6.S]PVQFYSA-+:XCN^]\HWH*Y=S^OH]C_-,5<-3
MW.A5W/;I)GU+[GH;TI:!^6[0EN56@(6&I&DKUVH,@<+@RY(UI\Q5<SU](4YD
MB?,.YV*PQ=Y/$=)ZCQPR8G[_ )%=1%+T%8P5JF^?_6QGSE6GA^IP*ZG#;A:7
M)^K-SM=G;'<PXO">D)8UJ$900H1<=7(5+%R:[E9Z-FXJ\B0FVT(3.R*"QI/.
M 0%9D1\.=F++:M.@H-REQ]<C* 2TQY$J/I(0^]G<>9JT2I.G7(U[,-4C=AUC
MLRCSZ,\S@O0U084CFYL%7HVW7J&%!R0H4TQPC"KJ"3@6"A* 7%5]HJL,1&T2
MX\X9)#@!IH.3$"9(PI&UQMD??M"H*P6J2J>LJ:3-IO>H5-7Z=6RKN9#,QA8=
MJZCKP]9"[#AXAEG-,%LQHR-D0)2>_P LR5WMWY8X?O\ V8AL7CCC@.... XX
MXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... Y2<(]Y
M.-+79ZB*>Y;29*" TQ'],6$DT08I$1%K2XO,]18QS2=;- >A\LL=MH/\>OL!
M;+:->9LVID7&1F+A9==+B\ A,>V['D"K'^<]"W2X'F:\3UQ70%(K-PJJS6]C
M6:6+U[6L&^EN<G6=,0AT+0,.Q3!53*%%Q?*,3$RR:_#DID*O,E75LQZP#0J7
M]AJ+L';VJIM76LUW*3L*MJW2J83S=&N9MW-6HAV)9@"0.L%4N$O2XF,OI=26
M4;L>&PV2+.($=3WX&Q&.XNNZS&U+!^E57U:-]#27FK;A F/,B)Y->;,59 ])
MD'-/7KQX94%+7A.8]WFAB!E1-JY#MUV]%M0C7%ST[UTFP:\^LN\M.^"5=L2%
M=5</0OJAM9:[LQ1MFJ+=.6:O[;6JIN35I@2H6U1-0T2& FPS:6WMZFZZ718;
M9#T$:36EME&)&_1)CZ\MKY74/=$LK+<[.]*?O<4JBDJU\15M_P +.ZM/G"Q#
M%H5.?M&;L791,TP F9A-ZY68J<##%@D_H&0"[Q\ 5J@!B3']&8#?%;=RFB7I
M5BO67T/ISPW.M,JI4RRKUK6$5]-)M'.JRG 95K;&P<BSIC''%E;*++(<D"@S
MB)%8#FSZ_N%=Z?K_ .H349DIS-?Z>Q^;U,;[0^@=&%-PT=65@IKS7/C5$]5M
M).6UG(-DFG)!**0&@=QIF++Z[-C,#J-U P,7)./;2@Z=/_@10_\ CRB/^YX_
MI"_M0=[VE_\ \4=?S.KX%WB%]"1>M,C^N_36D=6"!@9;%C\>7>07\PWHCCGL
MZE8X3K^9GG'8URSIF;9C0L2+S]"^A8U4LC;#(UJ+??5E:6S5_H",/'X@=#)_
MDK&%7981V>KS6F:.$M)CLDN8AXO6X=O".(K[@>6"M86?9FI1LGO57*C1U@:%
M\>9I-FW'TGT+94*JD$X3<U"W6"K:LV"68C F62*N5\K\E7:O+TLIS1T-ZW[-
M$Y+*]?)U3^>4F_6U,<9&VQV"K49#JM2)5TZ/#C9-S-H9'KU&6SJX^3ZK*2CI
M\Y"RP8M5B8*40+U)-3CD:+%WXZ_&2/&<>O:M(U,M^F/5F(/H>B@DPP6L52/L
MM9K%?2^]P984IIJNYP\N,(0/V 6>79 I^/LX+3H@FC4OO1JW8?!"^?7G<7Y0
M3O'8B&ZB*RKUE$OR(Q#'(C#LY0M %:.ZZA%H+KKJPZWBG(?:,F2V1<XL+6 T
M92-X#6 Q5-F0'@:=8/J IK^@6MY^;/1)&]9?K5?\8E?/ _JE\W]<M=MH0[Z5
M5SI5CD7!'JS;61FHPF3/K=1C[/QBQY.6F8-TS(!&-&V=ZG]5VE1%P>#Z[2:/
MFV0-]5W@X5>_=ZF)+%,"(+6_/UHW#AL!_P!^\+84BP:=Z!((3NOYA,3N6%QH
M@0=V3&45<)GT*_SWI%=,IK>28+5>+&5?4&OU\3LUW<XQ5U?KFB40T^:Q$EVD
MP08H-M4%ZGFK>JKB0LA5A;!ZA0B0.@Z-VLAV1W)?/FU,] $*7/GV)\2W'S]:
M\6Y*L=*Z.P@I\$UXI[=7AB)+TF ["OG5MJ0WQN4F4$;!SXLX0:D?Q\H<[7&F
MZ JF\F_6:$ \[+S1[+'64/GY5[[\NC"^" &KQZ38*7XSOYJ6W5?6EQ,;?](-
M.+%?$DK4#D,J0IAG/H>1W#S,Z?U^<A/KQ[[XJ;V88L]810I];:ZE@U^9:0Q4
M[6SI _H+0@G9JA.@N=/O=D(>\GEFL, YB5.V?!K4R(['4>#PXY$5*G8;A\M_
M*.U$KBLRXEW84BLT+U]6HH$8<9&6HTH^WCO^AO* QRA\,?/ER-Q#_M/(CI0J
M<J8XZ]D+?LEZ=$K7*JDJ8E4P')"9=R7;<V<_(9A'+W:VAVLP'@!X7<&$-&R0
MBPK:,\<]>66\F6*12;*>F]]33QPG)PU[< KDHWUA;+=Y8U_4:Y+U"UYYAWU_
M8-Y$_.8BFA+'VK4:M:&;8OP<K"Z8H+R:N68(#BC9DEHSUIO;#/G* I#SB:H9
M_//6_P"IJA6NH\%L[R_Z>2+8&3O+7]'1\H?2INQ'=>]=W7UY_JYC6)"[=)-'
MQUC;+QD 7P(PN($^I[L(^R2.D19\25LV/L^;-"[0;]6^31=F/G2R=%DZF7RK
MHL\A%H3K.V];!D^=!@T6#I=P(@J3:#K#$3!3[%0 3%.Z+@5,;)BP^X_Q0OFE
M2.XE_I7JP+\MY\UMGEYEB6+:5D1V%T'B_']LZ;MI9$@SX*X''Z$V+8^$AA<M
M?]7DRV!-GR9C<S%B.J!.A!C5._3U#MFXU*E)_G_T)63$U7G>'F/(X\Q*ADJ8
MF_Z$K0E<K=7D@@DVXWDB&HA5X4LT ',.'GI$[;#[7]I^.PXRAL3R:0^J=?7B
MOUVR0//E_H8V[/,C=ZIH;?9.^BU:);J%76]0CV(,$E)%U;0Z4=4]3\H&MV=I
MD$0&25#'3*.,;H$27UJWDM^!J)4;,!VV%[=LG!;]375[$%83FG\P?NX[XI8_
M0[QU+A=#/W;%+I%9"/00'CLZS%&,M)+J9)ZU]Q=D"_-_Q6K0?X\INC_5SI:-
ME/:?Y."^=)<6';1$\C5!NG,B+83Z1H38351$\5N./U<(TG @UPF#K6L)P%$U
M0=:/KG " ;Q5?K35KXLUA.K^B[RL%YM'U;:GC<;6J,0HEB(B+=J*JW*Y&::1
M>XUTZZEFH':*G;RNAQ7GXU%TX3].F9%C2X9"+&]M8^L'GUIK3?9450M:!HS\
M^+=\ EDB$7,&)KG'+N9O-Y.G%S"(T3!9*U%*[@H%!/0-1+_.;"-@)$H*Q%H!
M?N1IV/5WSEHJJV-'<8#%:S0W(OJ.V_8,-A;&L1OE&;HNNF&2B'F<<@+ZPNA,
MEO<C-9;^I60XH..$%\H\N)CC%T=0<M(F/F B"'_YRAT"-LVTKXHM'T+;Q7MO
M<2LYP-F++VDW935=D&&+T"6H!%O(P#M?+(WMB=+9>HT+8.T3YV/\N(&Y/4/L
M-_H#U1XJI #46;P@^C_^?Y-ENN!]0#SZ[$TZAB'#25%ZF1X6=4W1#T32!=KP
M[@%-N0 ;EI 82S>[7#R_SSW]$*_O]SII5ZJ2YJJ&^F:D9KS\Q.=EPJ]U+UY5
MFI=)TPN7 QDRPG%D4R>Q;L!/=1B]8@%2+$5(QT1TZ.ID$D-A[RO/RU7=^.U&
M6.S%7-<=_/;4S,:(=33,&!W+&O:Q(3+"1FP2:$'P+&D/BS(Z%L Z6*P)ZNHT
M68!,A"&GJ7EJJA?GS2GGQUKUT7&6WW/NE*V8:=\^*]G6#N<%/S]5S3+7=QI-
MJ\=L&P9VF+O'IZBLQC+@3;VD:GK(A3&GH@#1M@;@KZ]I?1STFAA/K:FH%<3J
MZ[\0UQ0#/4]YB_\ CYLEF"UIAUYA+CRZ.9:S4R80*:I1>"EX8I>F#U#@2_[^
M0.+R!..Z513Z B&.UJZJ; ';M'6$(]SIOEZQ:]9E*IG0@P:WKR=9'IM*VD3J
MW9;&O+",W)H. :[9EDX9>P+$"R4BBE&C$)TS5LJZ/G+0]YLWI)A:3MJB(?K6
MM:_K:]U%6<80]3;]56SM<E"<H\(BOER2\\@!V'^=Q*+Q88+)@<NXYD*1F:],
M[5DYCP71)R])OH:;D[]6#/\ 0]9^G=_6AGZU >K-J?SDT^6U7\8KH=EW@N95
M<WE^BP?^5WV08OXA?N7JPT?P\PBDF_6<-<%45,XUGY3]4;&?T/1]I>AZJ2\X
MGGW)WC4'7(%0[E7D=$R[RR##EXFWV"H*Z>K2R4AY;)Y+3+AJ&8S\NW'.:E]P
M$:W^5WC?V3?@Q\MUQM&C_#&UVC5PN*W3HX6IZHVTV@1YPI9VE%%7C?R[#M*%
M-G#X<X=$A0.Y. _3E^'3HRS/3\R:"$5]YKKY+;KPKC5Y;I WYK1&]!LC)?>F
M2B&<.K"62L[#8,0LCIC!E]R0HG\)D6$(/@6=?@'U0P (=;]N[PO2_@G_ &'S
M^JCPK0QDBO+%3,OA@ L&V!Y-@VT94_EB_:+="DB(^ A$XOIL'77573\%\S''
M:/Y#7W!V[=D'5LSVZ@\]U^H237U27?9C=0MN+9OS79)^M;QJ]I=O,J>WI<\1
M58:[A!8>7:[]"H;W!>JM8P+0D0$!M9F O_.WCY(<=+&D,='WR_I&(:V:QDNC
M*!N2T)J)XZK[V%(?\^JR5ZQB+%U)=HM-,*A22U6< <<VQNDU<4'SA@U7D10N
MO?U-(EHL./ND8^"Z?(CS8_Z2))H>_0!*R6%ENQC<KIE6""G6@ZZ;^J5>HE^6
MC\XDE3E?2LZ*D3DU'3(:^J IR$)5QV:D2$S99R47DU4OBNDJ:).Q%8C-)#JP
MO/= >8VB QL6TC F59YN V,MU[%TX1HT"1%-215IM>IF,:)..TMMV0=^G5 V
M1.^]H5N5]]=AXJNZKO?TP"=:JTN'SY\[^F3U,B@U0$5&<U^@[C4:G1323:NR
MVY4Z-V\.#H& +RF]RP =?6).MB=& 04AD].K;:_]E_/S6<K1+6J]L(P_6+;U
M@4U_2Z7#S]#3PC+6ZU7[D8RT746N@=23UM-+-G*<]. 5K8#@T,<GIE%:0L<B
MI']$+/P/R7\T!TT$E36N]V6$G4)7GF^OS1NR]<=KKVMZ:N ->5)9*;*MKZ\4
MT-=.V MK4Q$;2N\L9T#U\6./2#VG7O[W['MKY_)]\5!NHVX[^].V%7Q[MFBV
M2.-OJ;HW6RO,^Y;V[U1QS#UP,C!PPCI8C:UV36D2OV,+T38-T0]U+-39&P,B
M]@^[*?\ &<BJ =@ZI1AUNXJW#:Y5(S56*)J)Z$ '&8G4R4<;A?*Y1 @D -G#
M-6S^8R=E"),P)'"A<W9)W;(NID#ZH>>[*5([4KK%K[.CDGR%TC ":N-#,5@B
M_9SONK6N3*K$)GXT&8/5'H!8X*QI&PCJB@-=7-YF!*,!/Z<@4DM>GE=$O2?5
M#-)9[%K&Q:/('YE5VC4[)$ NRI$;@."RX /U8 S4L,"TUAXX_2;!M:R=A;I8
M<*6C:XI@3 GZ,5*>(:</7IYQ]',1*QV&V/,R2Q(RF=,NTR9%=X!\/+$:3%LB
M>XV ]Z95?LNS%DPS(T0MJP:;F:>-UZ^R76O0$'-7W5\?S5FV74*%L5H4ZYI&
M^+]6R2?-J1N(V@C>=9<6&^=!UE=M(DR5Z6+?S-)"OX-V#*SR=!&$J3 STS8N
MP;W/;SGZQ">A'*[JVD5?9M-V50A.OM+LA6G@BYG,05K)NIWK]EBRJZ=W]>_B
MFAF!2#,%2#>DZ#- BL J.T8XQ)$O3>/S/I+"DKB\S86)?W7F^WJXL.J]=']V
M-!V(]7I]FELC#'"JS=N5]C6(RA[=LH>JZV9F;82>"F2@"U#&!MO<+J42)Y\0
M*[NF];Z7\C^3YZ(B53#L/LB6_F!?PTVN%U9/[ C.XVOL5L[&&YO9?/N1)_L9
M7X=_Z:/Q_LR"$4;Z\>7>^UZ*8%6>N&S/FOT)Z2) #*T+UD5:'YJ<C*%8%3G=
MD5@DP,+@FLB=8\945(<R5H/Z*X:Y.DGIQC1\9&M?(GT.;SMBMU97\GVIGI?_
M *&>PO,M/6F1"5*'05/94X!QMM+IDY'7'7_:3"@>K*_>(^]W[3C*_O8%F8((
MNDR;GAMU[J:_DQX[<SUCL!Q?=]TJT_5*)Z_:XFIVGZQN=FHT$C"[ #8>6C/$
M=6;GFP.9!_1M&?\ !:";ZXS)&_1D6QQC;8!^!Z'7SJJQ0,GC*>G^QK>]R"L)
M+/COB;+MNY&M&O'C5.C=CNL921L7+><-0M9[[P[@RM@_?D0D8Q=FJ0$(1GW@
M\D&Z]L*S@"=;+4LJ%(R?0RM&2Y-.NC)9-90[(1JPVR1B^L6T4E(#1-.62ED@
M"7<NRN&0^OE\R$"#WO%&(0^Q"AO48R]2%_JNJK[%KFSO-[X.0;"JUYE5S)9>
MB+)62;;J1.%'$-^=:_F0&]*>P$B'WVY:]XDI_8#&#4+SA=[=NB<?F32N5#MO
MEV;9WHDMYX/JH!'5ZE*V;#FKE3IZNY@79?7:XG9J_3/I@!9:V( ALW(^YS B
M?&_RP64/$Y=Z.2OKJ@T.K[1]!6\L=G/];Z7;D9VLKHD4ZF">C=>U6GT\O]KL
M#J-I_IXG:>C@^B&CO=*[EE>I<[\FOK?UHUA2K47TZ]4W-!^6%F[Z';@6_P!3
M8^Q^K"H&N9=*E^[0ZJ:K]Y]"+K#BZ69J&I*^+.09F,G8R/BF5EF8\B!+'$!\
MT%K(;^9_N5XX7 M<,>N.[% KI0E(^D63O"=5XACKJM[\(D!J3HGH;#8XE\L)
MRB[ C#-8%&F5NQR(\4$E3XN1#"4,PG2>IKYRT/1Q:A""B>M8C \P-5ZL=#KC
M0Y0S(2O!GH,/F&=$6#EB B&C"2)T;I<A.@LQ@V8 ;YFW7_>3(.J'"B^+6?S1
MIBDM%81Z5LOT'5&NN*@J^B2?298PZ-_RM6=-&&$U7(>TNB:H4P)E5S:VM V.
MW*V*@W[0!V:O2#NP-A#A10S#UE?;Y3=P^#EM4F0M*E=WHBT$FV8>X/%)DRJ&
MC^*_4U]Z(("3+DQ>A!;)OJ!7W8S=>W#+=%U21VW+"/,W]\B4.^UU'=TYONAN
MH/TA7 0GYGHOUC7@%V@4Y%/6+3U^62N5*M,460'N(RL(D%=<F]6WNQ.U&)&%
MKJ8;T.\F7D$B$\X-D=Q>>*_O%DIAJ==C%K*T.ZN3\B=@C'8J/_?O5)VE01SL
MUJZC;^R4/_ W X8PHW6<?N,9S&D?R[,8>4;?'E;^=5-HD&LM=;/-TUR?I_R+
M6WBA <U=Q![64-2]7-B:W .MW3(HL"^6:"$E(&!V0H6 31QM=G&1,@+AJG_O
MTAI=W^D*Y75D;IK"&M0G%)>7: L52\_IX:CG.8V6)Z']/E?.M7!T^WEBW"2R
MQN3PYR "]&$:#_5:C%O;I<ICG%D]EA\'1:;]7L:O</4T/TF%=PK!,]Z'//'G
M*CG0KYXK9E5%-!\5^8;N?/[VP3=GKM1[U>$>L!F:1[,0L\\6-Z'-:%A=<S7M
MUQ1TE!WR)\E!E'M1";;;"]:JU6Z]%,HFQI,%M72BCZ?9/9"Y:BT9T#<?Z.T@
M_HEI*/HXQ C:EZ!UU$78*O&6(V ?O)X'S(I<1((LX>T/10RWR%]G_2.N^]5E
M#IEL#K)<*61*"==<.454B"7M2FZN*X51Q:OR:413XLP=#F@A ;(2 UB UO"^
MOE),6"L30:7]%6*IF/&K3[F:6M86$/1$KNFDMA:U!@&GPK)8P!G8+#Q:D\L%
M#*E>!7+IF_'D47B1$+K[(]RLICV+7EL>6I_KLJ,E5Q5(E,9;&*RRKA5MA=P$
M157<FHPQ;3%*/EFJ_?4(/IF=S@V)W_0#9PZ=!GBH^S"/G)_;1X\08]@S[;UO
M5P=VH1\NQO)VZQ-CQAM:L$6&T&7.,WZ9VP/EJPL_2S')A36U91\XF&W"-JQ"
M=1]/X<OSISQ73%/H%[5[UBSV7!].M;:Z>@3%GE(!8M:9UX2@E<LFPW#6PZHK
M"H1%(7 Z_N&*BTO0-NB-MG;X^XO.GD)05KQ/JBWQ/2\AG=ZBO^O?/I3PC0UM
MUY2#"L4J3LJSK<])^LH-'TOM3IB?9++A'8G;_3**I*2W1S4]*E,+Z9K,-%?A
ME$\;0//'J$%?INXD24@/=1VU0+2NJMK578N:9,/ <W10%OB2>'G:\;GE*85I
MM62VN2+)"&7?OT3X!@26@C2 W=IRBH)^1WFV)!(16&P/2C]-V4M6%#+3"ZW2
M3FLE>I%'VR*NZE9B"8$B@L@$XU;8X ">6W+9_./3]H:!_K);+GCNV[I=>?O,
M*-YYEV>PA6%^L&Q+I:A;A:MJ6FP1&-\=":^MC4]7AS) H0NKP@ J+ F&'75Q
M97080=J[FS,8.PF4)SI@0)1/M!0;16(VX&RE?1U4(S=YF.^J*ME.R_6,XQ;2
M&LVC7]-%@J:OI%JMI2&W3+#MNJA"L,=-"G%9HK\%*Q9\>!K([8?\7W]0WNNQ
MVM:3O*%CP[]5O3OA^HK-I"S6"H(96)5OLVRR2*G6.F.:C<)BMCN1^<KMR6N?
MO=.OZ:PA6_4V"(ZV.F$\]R1?E/Y+U5C6=0SQM@&DBIO*3WX[489)YFZR&BJW
M]ZI^R9I?>8%11A+78H!SHRO#B@Z#9(Z8OS!FW?&CY[MNK9'^XK\RZ295>QH#
MC8WH)RL>S'/S\^E;_8;*B9W.#8?*[5B[^?<E(F,61B0"&5HU;C)P:&U(FX6:
M*-+21:XI^><F2L@VU?\ ZXAT$9\WILNF+:L:R/4+:SHE?U_7O=<;B8QK4JA<
MKD-0FTZVV"IIP@=# (YJ!O.:&*>+P(X:LL=^R'LUR-D68_URJ<\GDW! H/T;
M8NJO*5-WSZ(!+@FJ8#!YP3E6PK6JQJ"6)":K77=!RP@KO15R#,4FM);P2+1J
M[-$1&R9$F@,S&T_6_D!^]"VCX,/KMFM"<#\SVO9+R_/J^V:E:V]\9B\R6O4:
M\16-L11**A@I.<',/(;@YD1!6IX#:8U9"YD;+H1MQ'?\F/,^A1CI:JVW_7PP
MO4)*B[?FI-M3QIWT571UT=[%9(=WFIXLI.8&-A=[0M-A)/:SL4'G7OLMU@#&
M(<'+=#HX>"0^N_G_ $!O6[B&1K-:J_\ 'ZG%:G)G RJMR,.L8HM5XU@I*/5Q
M.R1MN:T]@$V0)WB+3<T51JR1J$LDW:XZ!PC.9M^*W_L'YZI$!7$UU5S^30_T
M\X>@=J8"M+S*7W Z>3&+:L[VJ XZKTU5Y9)%F(:=F*2GU$UOK6PYZ)</L5!G
MQLHN>\RGSUJTC9L&V8]FWN";4Q ;*SH[)=<UL0.\YJ3MH2HK$,J*''2>\LH<
MF*@K\:$)LK?8X -'Z(:0PB!K(2,<L/5/EU1-<YKYFJ;$O^J+#&9VWTSVLAV$
M(&O%FQ+QL/*U;&'/ND@H%4K=!(/V>YB7\%5.5-Z)+E3\43>MZ29+7+#"9GUW
MH+ /ZS;Q"!:[$A^04F.Z/!X;A7,)G:8Y!0KYT#]*=-G["#7;#7C0FQA>$"QW
M>O$^M/Y(=G[E-L6&$WR\I1%O11)D\7V/Z63@NM4)CZ3M2Q%")-9ZSLT?A,45
MAD) 2FMCJ5V?:\:!$V2(C3]78-NGZMT79W#F91)>,B/IQ5L\&H;I<FR^3=P>
MALK)#*C\HU.:BOH*/W1(^SM:EJ==]99=)F4J7N+=)@G+7!LZ78X$7GN*=B0T
M'HCOZ[RZK?%U-U'Y]L[SBM9M\M/N>?<AVSV R>TR')L:KZWF)-EM6R; &C0
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M]R.]&(1_]<?1\13K%</F\>OM"=>&_P W^FGZEK![8J);0<QRI.B9]LY2"J"
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M[BE-FW"K 8I"+GL+80F)3+1)SI%DBR1&*:AA#(>2.RLQV>'/+FVW>[PSJ_\
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M_.]) *Q+A&TQO>H/5@^=*MM*6+- =M<C!IF.3GMQ0Q)-;7"/)7-^R.LP13#
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M10F-%-LVZ#$U:-6K(E-U[=O6S/5A)DX_I*F]?S-V_OO<O <<<<!QQQP''''
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MJ_ 3:VL),ODKY;@7?OKPAIHN=Z,"=3HY.H8SKG*Z(=GXS +*)&)S:NZD658
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MJYZP@DT>-%0.RI8Q#5'&=M'Q02\7*Q BSN^:U\IOI*M9--WR\(X2=YJ]]?\
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MI)5%.* V[X*NHG;<L:]+5#K/?<<B*'6*-%EH<3>)T0XL=7#XK)+K9-ZV$:]
MNLS?=%?^\J\ZDSD)&(OP$-[U7PP-J@$[3EZLVUR7*;P#Z8U**939$#*B]^%;
MVZYD:+KE=Y=6_P!55MCL^Z])  ;=*V(,7D!6\C*E5I!(Y<UI,GHOSDPWRQK)
ML9)8, $,LI"%!P-'I)>6GA44 I,>#45ZE#^]F6R3OUE\Z"1:W)%H'HYR832A
MZ:<3J HU!*G/5:QO'K2I)_H,19P<B:%15$ZD&G4#ICQ9!&1$:]<V#VH3CNTZ
MLZ3@83ZH\",,BG/9[53)]W<KUMWQ[YOI*G@4"<IJDM0M_P <F;@>//-M@F@O
MO@0A[")M.U!KH4R(R,8D#%*C?U6J1(E]Q<LP]6^.F75\C;Q\2>? VYM=Y/DE
MLIY#A["@D.0<G<DIR(,DY/,LDR*(T'&MEE3V0L1+S-4?>7)2I$G9WWNRZ[]0
MU]8?+(AC.#(T&XF)04!_FI@?+A7*Q)3ZA04[UH)'F*7>&IOW3(FR*K%HA6!F
MP3( PC,4-&_^S9( X)JW%-?LV']$JEU(LGI"W-6E\<[$]O>>ZPW&%#/(/KN_
MQ*J7F6LG(]UG/QPU*6F=0[ADO$^\L\&77K&ZNM,/^Q[[CAIVP/DV'N)A.VQ<
ME^L%H^@<W:EFE%L9TIZF2ZDH **4+<35-#-4WO7-Z,[!CD'T#=I)U(S,AQF8
M?=XQ)2()N*LOZ(L@*G\(AJLM-3MZ!8&G6R+'ERP/-.(9/JJMJX0L^K#N&%<I
M)^%H:H(CK08G".0L!V@)U!G#R<7/:08Y!HU*(D9U?>_ZSM9KPU5+2&&-"1ZT
M8*;^<]Q3=]F5+)6D:TT?T?Z"\YTW=#Y5(V02VZIZ^(FV>7"[X1#,,:4Y;4DF
M,!DH25#D)LSTSZ)(V1'<D2H=CWI9A.Z/8BT/4Z/HXSH,J%:>6O1)JCFYE<19
M-Y-:I -*8.@J=BZ0B<$C;AWO<0K^M\-G<P&.#3E>?(_NIW,;<]:>F#M?WL"8
MF">O$DBEZM5:"7EIT05I%L%8!>91$:.C@9%B24Y7?G5H7BP@Z;L$ ,+[=VL5
MC/!$,J"_)*L%Q1-)XBW+&SBL7AOT[XO.E2\%8G%R\GUC:4NY+4NZ;G"'"1V#
MG,?RQXM$7H V JQM1;*%&AQXT71KZD_Z@] N=,V7X<5E6& D ?1?IX[45B;3
MHPK)*#DD1Y1],7KE,6<(A ?E 8.F&FU^+EF1B$M/8V22B=COY6[5NTP-MS[*
M()7QGZ&O/SQ75Q0[)5O")GVQ0X>WZJ[7H-D5I,U[@@>QQ(>0VP))=12V68#)
M/4">17"6Y8(#32WT<$G!$^8$L[\\T,NI \(:ZV'SK -^*?0M$.4(7MG"@A)I
M2QU:NWF*PS&>4Z<+"_V@"KKB;+$CC-DV-K($EC2)@]Y[Y<?1MU.#^7F\#3&O
MSO ]/V'&IVM[+7;>\M (U?5?V=\^OJ+>0^_*YG[F8B")[[4%HK,/[6!@1M@Q
MH99%(DA;+V:.=BV05[%<?1!(3!(!#N6%Z%8&5)<JII6^[V8:.7DVO:UO&Y\U
M3<AI-I9I#2=6D\P3U6/6V)/)0W.*BBQWI.P?&X--*[L\/4Z^J=%9J,-YTU3Z
M<DK3#ZKE^,Z\F1J>RW[[4O 8SVDFG(%?#M;%D1**2^RU VBSCT2BAU<=NPT9
M[B/X8IW8%#[$+YTP5V\4/TH[W>W6+=(+T,Z^B7MAVJ2DI@7PZQ>3I?CQ84(B
MN TXQU)0K^LLQ\T-CIFFF$NQ1IQ!B/$_[/\ ;#TG"^.%>0Z9WTUU>-A;1V_Y
M_P#J?P#V=S K/]CBI>IK'$6,?L3K1UA_&_TZK*$:A <9^G0J9!V9;9G>$G''
M/F]JA^H7G^YVX8B+J-Z)!M1P!Z'G !#E2K"O[V)R\HL\%.] 5&OY9[Y.HU9=
M>,A&,)E0!N<E9-D.I<!8:C<\<1BQ=:VO]5EY6K;!RKGS_<SDY+7N7SWXHMFG
MS@M86[!K]BO$G7<N.=QQP;B"BP8R$NR5<FH="6Z0,,'V ,$,$@/7]K(&ALY_
M^=2J_6%;%ARK5<1L^UVGYSM4^!&$@M\81)^=-X[KR3HT+9OU_OWZ;,,[>A#9
MGOQ_>*AX8R0__P W?>'-3=?)T)L7QE8S?15BRJ'KC9Z?+>?ZHQ4$"-E4[3ZE
MKRXJQ8"Y)VU"O]%80ZNU&_;4&5F&+=B]D#2P1<FLJW2PHV7IS-5^CB='+.*>
M0"VG=5H;/0/HRNDZI*:HV5$? 2OYWB5W(L?%BQ)V2:4SD*M9MDJ  Q96EJ6!
MCLQMZZ"3D_84D:HTOY#GU_\ )8J+!.C8%U-Z)_PG2?HEKLQ6JLG)0ZUJ*^+#
M<JN4V:QR96<(GK4T*X(+9"=%3(5+<%V,"-3LP$F. 8<Q ?RR?+9)8NE[\EON
M\/)>H[YT4AHV:0J[LSDCOG3ZDV>I$QBW=[=7?>)2QS^SM7:(^OOJ(*$_K-%8
MY3/VXXY!Y*\C&JI]B^]?0[(.,"UVT;)  _/2Z7-"RH]8K\JDIEB7LS)X\1.F
M:UH;=OI8VY-;$*+_ (3LTVJ:#<J)!CD8VK9(_P!2>KD+R:!JXP[*MGO)&YKD
M6Z&KA/J-.[=6YAL9L7'!J$#^AN9(3$'B_P"G1C\@B?)D88@/KT822LN' _/,
MCZ*3_J+Y/=+WB^?A[(7A-9)XLZJPQLEBK]+1JV:77SK+:M:C](YJ(N'^A2AZ
MDYZ)Q26HQ$LH53SXA;:C9'1$C3 QYV^8=8OM3>A:O/O)Z9E=_LZ/[D"'R*LE
M,6JM[;#&*X8%89I4&D0<4'E-%DZWA:2P)Q$3=3"&-&1TC*'OSA$8>0)OSV65
MYE\P.!1Q _W'FZR[OLWL56M+UM2Z.^$[MIABI$A!))Z'"C1QFL"M'M<J(7SG
M&&,K*&QHY8Q(@X1M$/[T'Z'IEH?Z;M%\\^J3VL+7%36V VZZ[3X.-AUY>)-C
M'U@T)N!.R(6_0.8]*@TEL]KIJ3N@PX%/Q/?UA+K0.W8Y7OU2\TVHSTXLH(2Y
M#V-OT2?](;6;NOL!"=4]3)[N=KAV/7,RGC@N ER5!V6S($J+T9&9TV1"VR%W
M4<@X92L0T&O_ !CK=8\\V-Y?"V>/$5FR5>)IQ#.@//5&J]PIJ$$?%%T%C6NV
M5E:$L-HR845*!K/\DSJ#ZB\2/B>:HK&W:8I_1+:[_ =8>A73U2PV2QL\U;]9
M^0$/QX\IH[ 7#C@U)%:;X:8K@O%-\.;L[9Y,N]RF..@M"(A=&:Z+SWP)\>3-
MAYUTV+]>2D^R"+"B:7FGO/6/SV->J@++=/FL^9(,<\KZ9I*KZXL%97QK\IF&
M=/94IX-[M:OFQ+!\3K-K30Q#HFK*,)FS]4OI30;A=VVCX2Q=0N7K]&6?Y-TV
M4P5O($5(0OZIJ^.VDQU^*;]Y3*05ESD=692P G #R I+>")!MA&(;U8#M@:P
M_P#QB1=M915ONWUU9M13N>H+TK*XJJ\S434<A9>:8Q,Q%^8VHZ4 @KMEZSP=
MK=0K/%/[8H[5!;"?:4/2Y'X]W6_?/WBP12]2^C:K9K0<;8_\GK:NVV[%;30Q
M95S6HG>XV$-:1 *(L#8P8>-%:(N>"]EW W;XFC/1JEY3<X_>[=]_G7VPA^F7
M<FG)%:76N0XU25]>0-XL%0!+2<Z5A:Y _ K9E5\];<29\M;A@J,A ;!.K (A
M&@A9G9>*-E]Z(F^O>Y?J/;8IIL1<5:0>4<?1WU6\U>*#[+*6A#YIN"N;. 54
MQLL5+###W9\>^FXUD:Y 3O4)WC!2K*53TXK&(%R(H0&Q!/R=8%^M(E=+WL.Q
M /9WR*D^%+>8QU4U5F1LWS?57;X.JF/JBDAI""FVRF*5HV"K9V*)U2Q)S0Q]
ME)R)@3%B=\.V-$2EZMD=-KI1AY#E1!5%U*6!^>[;)S@KRL(A@@L/*1NRRW;\
MHPV!&T9;MN66W;WAWGLR[SR[[[KH9/KEY154M49B^JQ8;*SF/0@294I$2G+]
MG)LKRPVZT>]MCB.:'H$KC]:2RRQ([5J'-I:<U[3@C%+AL6R1LUZ+"ZSL=)N*
MN4.VJU8(;77EG)RT_HK./ZW8PF!1;P\,^NF8NN3JT2=6DB)GQ)>&F5HT2M/6
MW\4G1IW8;->(9OQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <JJ3?DW4E?^DV7U J6[;(]_,3_5YH)_)!4:7WK)SU
M]( DGR?M;B]/S; ?(:897X<NK%RT&MV6% 9AH5\@Y):B1QF-JO*JZ1MB\+[B
MWGZB/>C"-,4Q2GI#T56 VDP5:5LRJ\RLO)-NN=5/[#:3 P*Q2TYC;8NRO&5G
M&=U^[I@M0!DUS1J#,LV-/W% WAY_\&5M0-2W[4XQS?6&+Z5/M;+99S5BE5OD
M/*-]? ZS);*R4Z>3Z_0JNQQ7EZ 0ZVJ*O"G37#<4<2TTB=);Y/,3\)_.&K?!
M)&R2U>O+DZ3[.1:%KTUFT+=0JT>,%\\!'1?39NJ%4E:US%*,AB [D-SDT,NH
MX?8B4:-.D$-??Y-7<?6/[#+B+44BY;"\LW<H+39Y68O9% 0-S'4)DU=U.*QV
MIQ!F'JB@WR=H0+%C0;SJMCZ4&J3U#[#LVW5DPX&0I<3%RB']5=0ZZ]M(V/Y.
MNRN2P'TM2/E]^9YC;2;.L)SOZ82H3K14O#8K6,2+LD-@CDQ@YSP"B=O^%E$(
MV_+>?A=[)&L+%+VIQ/\ 1-)7!0-A=E>D.[JP?*E=,@,[$8;Q5;$5RBB?S#D<
M]$O7!*8"R\K*!*VQ)>G1*ZU;-T63JQSTYU.>A_E^^FL$1GK>Z+2>[:.WW\TY
M=L68Q3Z@46,'5GAVVK$<<7U4'#*SAI,AV["687UE DY4+"V3(6/CZ!&GK?.T
MRMV5]]/Q+FS)T<QYQM5%KBS+:]:4'6EL,C94.E=;+C\BE+KP;%?>/R>]!)7#
M.BYY]M,XFN+/B,!=2EB8)8M@/7N'%2&N 7V/KUB474D I1E=WE*]5></*&Q*
MJNVZ+LP*PMOJ08KE:U8%NU5Y\_XXEB(NAHTQV^-..#IJ[,'SM>W&3&ZT2]H8
M\>^8EE+GICS=8-3W_<83(=L]^61Z(]*83J3RM9@N3TR"\X*R3NVH9RIR=8$%
MB$KU-TO"PP"OAD)5@U\E;,MN4_/?.FR JCY<U#Y_9D<[0UC6+6PQ?1*20'A;
MV+U)6!$M>'0<0C 3&9D,654K8RK+N5'ER4!R8:Z,*&!S3MBRH@\07'02FGQE
MSZKU5L!&#%E5N\57L4 ?MS_>ZBY14.CEBQ/"30!#V?5D<Z$*[1QYE:EDWM?Z
M]E#\L1IY<"G-.W=$,#)8_3MRR/:I]4;JCJ-#\VV3:M_V70YOT<<I\:U5NFSJ
MUKA8F)@ [I9F=W9@P">W;'9Y$I:^N@-I'HJ5B&9Y$B!!#NRFT/7\[^(57S*W
ME"%=V2XYUGL/V6S*]-ET^D-P-**6NY&WUHT![$@U2/NN<%BLC,P[EX4=LHIT
M-'D^@\N24%CQL6)Z_IBC62\K:\6[,14#;7%%^@BGHMW-[#>0\O#8$FG['2*P
M!B!>O'O85UEVVSO[DQLS[ZBQ!:IOB;O_ )"L?OK4](?14!Z5N:J*YH^E;#:D
M"R?)5(^QRMT&#:*L+J#7%_&;97D-<.*TMAEMY1]S-5&?ADQ*^-("(./4F1F>
MRU0]/9#1NKZ7VHG7-Z]KNQO.^P\-KGVI5?COR[$KQU3\6BV'JT_/U/W(#!-6
MMD8((I:PZ!N+59)EOGRA8Y?28>"]T&,-8>1K(A-?T3Y 3/1=CT7:)MO<51BH
M["T@&F&O:E2> L"M+P7@RO;=9/ EK6V'#:";Q*Z$PP+K^T$T Y$#K>(,Q^I$
MG7MUUYV^?RA0#O5;I+N:Y;B_\?*1-^=/.8"SMM<8"*;J-CEH6TT'%;42O$HL
MV,!$;5M=KLEO>2+$<V E2%'[W?S9A8@0^&+]!EW5YQ]+7RQTW92Z=\>V":KO
MT54/\M1.MB;.5!:$[-;"&- SLQ8:U094%B ;<ADH1"+,(JV6^#M&#V'3O%:<
M)P^FU2O[E<=+UR&>LK$1[W+><0I/.( BCF"9&H=\N G=Z?()DNXIZJ%"95UI
M(Y YJU2?Y#S798)&A2]\F)&VA]'H3Y5T1Z*M&_[?8'BWE!POVGDNL9FQ)8%Z
M# KUK0VI6:05[UW&+*QC8$N;KNNZO7I;)OD3($I7KM?$;!/>..[=E]S]\NJ*
M>$V\$'6UV2L*UW^3O-/CR>-!D5SOI0K+RR>L\[7LY6VD%N9G@Q3,K2+P3T@K
MV2@R(L"#W"@0=W>W9E#SRM]:20+R704OTI4ER%KF,>$O%-\@"^J=59,]Z@8_
M1+/6OGL?)#0 K,+!(; X7[8*9KU0F[>OC= %\A'-VP?@),C1\E"_T]E FH33
MA'RG;&7I69Z52_-1&E(#O4<O6-(V1YUM/TNCV7JL7-OC*)"MR2'4;=&*2,-L
M=N"F1!>%L4I6<.!B8#9$7YPUS'LN(TYVS<4JJAWJ(S[1&><I$FO.ZO@^DCI<
MLU3G3 YKK[7;&T#C8!XQ9\9$W6+FL:;#F_W7<38.CQPNO7VCY+4='IE2I+78
MMM9+JA\X+N^9D$ILGJ69F33M[:ZVUL[K*V=*F,3NQAN-9", LS7%P7]6N;.Z
ME@96SO3MP]SR;]+07J:P:T0\_/MM5!U;U9>@'U!8'HY5AD<:*^4;F4J%]"*>
M<1!>FLH,R4K$=@<58/%H<$<]!_YY<=JA:H\?5,AI;WT"]:3E[T]D/K?-(T^>
M/KWX[\EH!:MF)*+,EPU<ZW3Y&CME?$P[9-E0!#._IEP%M,L])E@1L$4V#QFK
M(647R9"0%LWH3RVH^B/.N[SH>:W52$1Y-3&EQY49('!T6&^CGY*M"M&N%T>
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M!:]JWB9 ,2_&DQ2VR%LE0).-R/D/YSUT_;U( FZUP*3<7E6A?)QSO2;7)YF
MIT)8-SV<,=HI*>K[NI5@/#?>;F5>B,Z/O#S9&W5D&"A<._Q81O+_ &*B6#Y8
M>[9U4I?_ )TB,_A"]?:E+.^F?0CPZ&D2BVU(17J4&59AYM5A+".*6?7II8B/
M\'(4R &'9OW1X)$7.&:9<[/I&N:+*D L:3LZ92 WUB)\.$?1W1>OL5[7Z-+,
M(Q"C"NT+_2:7W:D8VD8&U;+=M(37KUNDG/O0!V*VC8QXA+"\?/*K?)WSR?9C
M+$(D^<+]"^AE+4 W#].DTU@ZZLRMHP9BZGCYV>Y>W"+1-3).D?E (9SX(W+7
M/U:,9&K?'9)\)Q:-8;8;J1LEBTP',Y>]H+=+-:]4." *M^\M[*R,T[_DH;4>
MZ^A*D2?&@RR;!$"P978G>8F:(>,H'HBKO45%7[1+9JH,+I/>2/0*RM,_E.X/
M651B8Y*LW)KM!+HVRJ]JY_'QP2<W%Y"CG#*VQ7[+$,-.4$=FC%2K!/Z';ETF
M,PEJ?]\*J[YKJB^ND?MV8+RM!1I2I:TJ:SZLLJ*\V>^-!%<6! >V K/JK+H'
MW&%$61A8IIN)@NAA1C3*@;C<'6(EA6#Y_P#DW89H5$J&QAK'0_GY('4+8$,9
M/C>07Y[>O3U-SYPF(PR9"!37^1L2@]=>;YX3>H^AUYC9)[&5$-P<2J' LR=,
ML)\V?+&@_->@"/#LC\]@P_EAT\C30#IFG10[#6C[<[E=;%*)CTA24(<(U(-/
M!A>T8+T<*#AK.$2)$#:)>GN9GAFWZBD9#TF4BO>1K@/^C&"W[RHUGJ3!YIL7
M%1'BD*3KGT')GE+ *.T=7*I3M6%LH!I4/A\I!/O>PZ!QA<&3H\W1&^F\_H:X
MX^%O*?LSRQ5T.P-7INW?$:X/2K!.#5*<(2?4%O5ZAF(4J?N)Z!>EOB=N&M1'
M3-4T@%&,!'0S;]9A=$RM<H,.G?&BJSZEL3'7TEZ5>Q$'RE#\8)N#%-I^+DCT
M:#M6M+45QXG_ "]2+G15K#R:K6EF6X-/]Z78%_#/LQLD%=48CIW[G\]T=?W1
MVA/;6^:WK'MVXOH.I0&,H)B+DV\K3I^U*G[3&"6+5]Y6-5<&':1.7AK&:]C7
MHW18V[LQ-ZUYQ]T8D/W_ &97?JOU2@7(@V&S55G[[\O^8$INAF*SR6J)->AO
M'_E@^KH.L=%FC7!S'R;N?3&;*<C0B703M\'DM&Z6,C$- W<7DKZKU!Z_M==K
MQ 07N"O6*IV$[U58>[J";"L2]6S . E-[I# =SLZKF,VLGI.H ]MFXR&D-%(
M]=]##$+(/F&JOF-Y%OWRL[& Y%-QK"B>Z+25AG7&[9YS9GM\O]9GPAL)V47F
MA$%--RZK I$0Z,PB7))F.10NS#RL,0"WZ&;86D2S_-ZNV6VG&S,[7MD>&=O6
M=#>V2581<T'<GQ+^H=<1$R"=&DYJ/)>= %T4:T3!#6M;6S>/U[1F\BO?TD@A
M*QRC!Y<^@MB"')V3+\2+'9DQV^F/MWRA5M[[R=715<"70'VTS=.U/_EXAL8Y
M9+VQ*K\NEBGDD&SAQ&L7&@,Q+5!GX'M7^[OME5>@'9VWJI99)EK*VO/=7F,U
MF\J&<:@%0O20)Y/)+X]^@%-V,UM7"H"_XV;0+S*99F&(%GV*8J+N*Z&\60Z#
M>LOY;5K#:^[&1+>L]!LSJT?5EB8N.A=I-ZQS$>PK,6;9M.NI*S:=4O"OO5Q[
MDFK!),G]"M;4#S&[M6\\1AE2D2792!$ZP ,*"U2=TW4%$CA.N9)CBX<B7K'0
M],/"3OB QP@+%W;\=/6W;'$"18O1GGEJ'CH43'3&U4Z6)]2@M*V'<79L$].T
M'0W>,$<* (L]%*E(U9.]'TI8=IZFHA?VJ9H&0:_DZ4G>*87A[/F5^2\$4T%7
MV[L6SX[N7"K)O6RK:\QZM6K1J/@Q)O5IT$AAG1IUE8$>?AJTEPLN>&*ZM>._
MK#62$SI@R=AUU*@2Y$7;JW9A[G''' <<<<!QQQP'''' <<<<!QQQP'''' <<
M<<!QQQP'''' <<<<!QQQP'''' <<<<!R'<OPW2&RQVRPQ,RUE*+8S-)=[3J]
M-N"PEFF+2=)\.,/*M+Q6 P[I6IY-AA08$9QU#XPL6^ZH6G%Z',G[Y/\ (F)R
MI0?](K F."XP;*+4-'G)X]R/_P _E!S_ .6C&RW=EN)#E8-6QWP[5^%7=KXZ
MLS=K5L<6.]4>PYK@*69HJP-H68/SEB(P;"[^3_D60E,=>&(EP-*@5IV1YZ50
MS?>5G-4>I*-ELJ@V3*OJ+^^89^24N2RE?(.F5OT=RSV\*E*Z]L,Y @\0?AN1
MJ\)>=W*QFNU#H%BWN#I?_GWTP>EZ&XW%A[[7\QK(=1J4IH':9.,6,*%A00_2
M7!ZM?0X]NUYR26K;MV=Y=5T_.FZ/2Z9\EV3U@R5\U^I?0+##N"W1B.M7+:EG
MM5P,T9Y:!40 )B/B]MPK:-$V"]886AU4MD@49=#Q=RZNSF&9V)D;V4OI9./S
M4H-K3ZT;")?RY[DOIUGH#X^:X",[>-7JB4^93S"O674M=V&IM)3_ )JU8N U
M[3E=B22@;^-F )QINB3D&/T3\BZB&HK4'].;C]NE6:R_>S/TF:;9L^=2@('[
M3MJYR)4NJU\1GB12M8F=&6EMKLN?#P-&06>:>R"M)TSF2>;G;V2_F%Y@2]>S
M+'*V6PGONCSE?DD^^6VX-IR38?E(*%7:4W[)Q.;G^P&MA5X3 F+\?5I&&L(O
MYB>C?)V[M^S4GGCWI<7KX8?EH5*IZ>A)M(4,RW&TE[@-PWY??O1WE=*]*0PU
M4JXVMI$!C"5TOV:FPB#6PMZ=+.$Y!76#$ZI2]MU3=:_)OV/<-@5YXS\[WNG1
M,FIU^7GG3U:IVUA;)JSFVP1?]<DH#I/MCHXG@<A+P>,L*XXZ-HQC=-,W4<,1
M2A**1%__ ' W3Z ^9%96:'J=+3Q0J*EQ/HQ&]\W3J<3[$3GG#4S8Z-#R$5H^
M$>9&W#K ;"@9:.IY63 4O^/RC5$SUR=W<.#(E3?'D2JO0+0K/K$4L]$L505F
MU!%V)3-HN=3.DBNWR2$GM]?F32<4'9FE0R565XUKA$M4B4".AH1M9FA2O6Z7
MNKJ&^]K8$>C'7S[4-21K%=+'^A=_>=!A"[_1+ '3$J%4'ANIO26]C7L E.N1
M4"G$=Y;,)#K(4-GY#S,PLP_Z?=B:W1QD)'WZ96 VVWYH]HR4\MW0:Q\O'WU<
M0\]"?0-F(NS;>,OT)75*2NIL9/5=*99\(.<.0$Y7F6E$VK,18/L[I)6@9>-%
MCY!T U#Y+HJAW#4YU.H;4^9#\_4OY@%"(1HQ*7 U->?R]C&JP6Q@@C-EZ]4H
M-,M1O_F&]VR08,X2HW929*WQ^]VS5%@_.[SE9+S:UA&<+-%,-P.59VHQ?Y*U
M716@@[MI\$NJE?WFB1@Y./DCVL'3U-=3IK"O;8<1D5AFL(SBS,*3.URHDVQ]
M(O2U..4VA&7S-31/T?MM7Q6DKD %Z(;,Z9+J7M-GNY+7FT@\SZ&BN(0I7;)0
M;QK9%;NO"$@X(_IBH*;^XK_!B?/9'TQ]&H5J6DDC_+=2-*Q4OLCR?XC*L>?I
M)B7"[-:?JRIZ+<A1D& VT(9T#4U#;[S7Q!V>6+Y%S*SHEF H/,K#R#2 L7JO
MRC3%1UA8E3! QMD7+B-NC-<1*PFMA>FVUF6PP\1=<3KTTGR$HL5FEUL>,6\-
M6G?#@"ET2*!A(0T6-A1=.C*J^8?CZFBM/'49$8(QBB_/37YEKTB5?7 Y)A5J
MZ&BA\_O*9E"TGHVZ;R+&W=QG0ECO/0(KHUPH<K3%,[]74([8^QS%5'FS*ZRU
M1U1+L&OC_JD==5%#;9L]B<NP'D3TP=\SV*ZU5(3//#1HD(AMC7)DT ]7)IJ!
M8B$R0-6)S.I4F>2&^?>OLCTNLWO]"DAIU!Y]!T3<'R\3:QTUM9ABKK@7Y?IV
MV:>6#.4EDB528BE@)THRD9S@*(F9.62U&WIP[?A#89A(>$[)7S&\C3U%*1YZ
M@URU^O/*U;^.T_#JQ'."2!U#4+DEV'6<D<<%%X!F#824\UZG-0"PH4Z,RCS(
M.'*T3,?V?MYDZ;\_?/2<SJ3]EKL9PLI3O2/Z,RLRP;-;G)Z9[.'4<]^<P4IL
M-ER&WLHMK-1V*RK*VFZ(\%7#9R,2L,7K*[B$R=%./].;%ZC)EH$?/ZC'\ZW%
M=OJ?SY3[1&MTS(M3>]>:%ST<;C&;#KS=5<4&LJ5E2?+UBP8689Y9#";JG+$L
M[!E]S26@5L+PW[\LGTX[)Z);E(IM1&[.\1>>_<J!K1+7+VK&THEVD#X*:GN4
MTQ6=:X#&U:+"(,C3D"T, 8D.+;,.B6B2+RRGA(BH?#?GRCF.J&JO@3%!,4LM
M^EU1#W$6TX6TP@WK6Y%B^+GU3XTR3GI*[R]B* 6>'DS<=FX"/T[1<#+&+L_;
MCX1GY_>>3CC93A+T6#JQMB^Z+]0.*C$L=ICHFZ^_/3)7#,BV2)5^IN4,$;G2
MJEKZ"Y:A6448V#%R''*0<]W>V3G&)B^GAP3ZK.>>4ZI56\1DA2]9[$*?3#O8
M)AG*VUY,5U=A8J68Y352JI4<=[9)S!L4I(1(M5[*5^U:H@MLA==29&^'O;S!
MZS??2?F:R;!V *S2+]1AAL:Q4[K/6?C.J*Q<J\$N8-#NP+9M05C8J2RP=IV!
MF8B;*_FP22]L@LRQ,-#2T;#$/N)_.3SQO;F*Q5@A<=8V2U6-:MD&[#JNY'I#
M;ITR[-:!U9:K)(!">G1+1&"75Z(8C+$V)*C+9X!H.*VT(4D394G^V;QI :?>
MU ^MR6H'("^>O-5FU,K93C3(5?BK\_LRGK%,)_,GIE#RHY)0(%AB0ITB9FM&
MPM;+?GLQUZ)4F3/KZ\U?2/V.X^=_/&LK3E)6S?$SYN55] [E:"%OL=3J;%7S
MZ&D:584JPX=(']$:UWPBK.I)@%9P!%<5[E#%Z,6 G!/0<H4G/6?L&X]WB/R=
MZ>\CZE0(5](7;\]-<"!;G4R-IUUCZON.HUR4M$\!2TW;X)8L,L0<M&R,,=E-
M6QDXZ?![MQP2*B2PDXZ^&_/E@'KM9&4$PR"GH1^\QV59FR*VFX.HDU>1&A/;
MZ4D#=,:3KP#1!!M&7MQJ$/\ Q:&'3'WZ276S&3L[YBE-?.SS91-I2+71(-@Y
MD^EF^$T&HLUE-S36R@J^EK6 W9<@)30S)"2!$P&VR%V$?W8_QY&V)CMDC8NW
M4,RT1(\:!OT6N.9GZ=F'JR\YUZ I+U' \:US.;+TMDL?NF\]BW7+--%KB,A>
M:&UJD_S(SL0A*"PM0&EN99("7,D#@@?5)(ZM!3/JE;'H_P WP.J+HL"#LQ[\
M'^L_35A=M=TME<::V&TTYLU P8-6LNFG"3$Q.9VRA11B"YMJW5_2LM!X6UCE
M"3Y:-#AA/13^8WEBOZ5J>D*]@6:ABZ+>FVQJEL!5MMZ&W"EM3QJ8!S/OB69V
M7W,)8455V4@CR5QCW&5W:EQ@H':+V:  7.#OYS\O5A8:72Z,\[GAL'4/:-7W
M,CEV%\9S39)L2HBO9M0/-C23(2C+7WT4RSDE8AB5OB$NL_X^S3A%UZ=&NC7S
MG]%K8K]9J)+!H['>EH/\;Y&41LGW)Z,."D[>?].^.6*S&.S8V'58NI15FC-R
M9.*O4:/K:2EFF)>9?^4((X:HDF2KA]7;4%5*LEER@*]FW9+)>W54VBDK-LJ>
MIGK$\1^AH7FX[7E1%T.AW1R=F*VW G#*5WTPI"/&UCNMD0IL[E_EV1@F$P_,
MSR,VZ2T-F2F T-//'KNP#@N4[L^N"5.>Y%)C1_1.F5KB$(VW$4T+36:@"($;
M='P5\I.,H'G$E:=>[K&Q/RO\O"55N7>I]WD3+:_TM:?_ "64NY]EVJJV#Y\3
M1]>52T(KQT2UDE*8O(X_I4DQA6.H:=!3S(X[!(QC)/7*R[TQ<3)6COX &&QI
MG%@MJ_&U19AZ+9)-93]!5;\7>G;F)P6&/)5)$RR$CLG5^<(4%*15C?J,YKK?
M(_;)!9!)>DO"'T1L[U.V4RJVW0R93TKT)X2K;W=6/^)MXG:N45(<3H)?*JCM
ML(UG7D84P1<V]2,"<@>Y@A[H1 F/GR(L\/ULGAM85\RO-RS &])!B^4%L%/U
MXV)'M!0OZT!UHR2WI-B!-UWBC3G(8)I!C67]J5EADG@F'$I%&'ET,8 =B2,#
M3)QDXU^?*X=6CSNY,FAB)L7EUI,N=3DY;6?E2XS"?J1VI(K/:)4N=(F.6^8A
MV$S1M^]BD3Y.\K+UF9&_=/UY;=E&_I[U+[6WV)[$3(I!.Q3J*^IGRCJ6E!Z3
M8;/7C=/7;>=/%38P5F[FX2%IC3$VRX-H%\7@B0-G<AN!\XIQ@QP!&%[=F]2'
MUDM345&U (\R1&#T7KNCUY5#0$43-T636@J%Y(U5!/,LXDK5WGURLLI@[P[\
MJT>'B%:T7((@Q-8^BIK^(&A9F GLH>$:'2O^1P@G.S9-4VB.M(8R>?3%KO1>
M@(\6[)I,E:>D'5LTQL!"(;<0.L,W:'C]=@@<AA-;%<4#_G9]8Z[A_,VAH 2O
MX,:P/4/334VB>)JVT]OIFVI-IU^FE5X>KE:\7&V0P[<]:,6$"171<(0AS\BQ
M02%824N4Q @A4=K_ -/>HKAF>1_*3LM*E@^8''UO>OE*E[$U.(H;JM'S,OWX
MUC@[QENT&!Y!?&OXO+9E7ZP8816R"-:F8(8VA-A+3%";/89VZQ?*EITUY4H6
M0X^BK*]%@[>LT5.]:>@6+M1K)+H6#7 YSEXOL2L['LLR3<&*TDR*(4MNDK B
M;-A\V/W  P60*GAF<OY@^/=]=V)5,1#/!T6T/+R9Y ; PIY:]6R53"*WVH^B
M(FLG))RBO;?-;;GL XQO,N;+9V2>9[DF2$S?AGLV;%/>&O/;)8A6TBH)BVMY
MKU#6GL&?+UMQW5#SNZI:2">?$LQK'XROXND'#K1?&CIBUKPZ%$2&O,I*TYR<
MNN\:N&3[567MK5\N*N/*"F;1:8\3)/L:XXKG?\M59QF^;?\ Z+H9\J-"C":?
M:1;B0%D_.+>84'TH04EYAB9C^IPX1B4CYZ-],?TLNM7*F*V*>:J^[NX+]#*<
M\*S%V)?1;?6^O1>OFQ;],*=D]V!OIR(>SS6EAQ#@FU9U5YGLE&!Q;)<)$-<@
M=KS"3LOYM>2B>O1$.(ID^)P(>TI\P&8<V>2)+X?0!DFM/IH>5TZR6G?)'-A,
MA*Z"Z-<G1L4X^S]H'=#W8X[^LCC^&JGWI0-#;W2^[1#+%PTE=ZW)M6\7]],
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M9):6.SF1.Y1W2O*"ZKQBVE;&ZA7<$RWK6QOGV[>A'/W)&]%N%I]+OJ&T?/\
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M:W>XFN ZH)%C!P2\Y-;86G/9JB,BS)E[0QJ/KSRPU$8<C#'O].OTZ#8''''
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M/V'@.VO;%&7"V\1HB[=WX&,C)+KH/3_6X0^PN^A^-?%Z&B,*%&H"DEBO'.O
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M]C*3(/\ 8=DL5C[/3\$S*Q)J-O2=.P6F!*/%EC H,/FM;B>U[8L<F*[+2-O
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M3V""SY8M4*EP[:Q",&;'>/\ [B1)Z[_4,G$^"_%H$>^"@/ENC@8ZS1V@,\Q
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MI5[R'2SH<>.I;8FNMRFT$2&0R6SN&%_2_P"8/,2_'A+RY3-6#M:Q6SS4L49
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M_H*U9SJR%TQLR>T#9_?#K839\K;OL.S1JLFV>P^"+4;G<;6SA@WIB\XDO/[
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M+.O*U8@NW S3,V8PNOT,1+1!A["SE:>M64QQ%P6&=U))QM4G'^@GBSR.M'+
M95_S;2X4_:@%N5["+#*]6X4UI6[ W;9+Z"(;H\##+$2[S-VR<X0(O\>,S$.^
MB!O7.FX8;\:=Z9^@/LOT-M\4ULK6)2=>-=W6]]0*MLRRC510GWJ6'\2.I-.K
MQD6D](OT@CAF4[UH%D7+0+M&P4O=UL)9+A.1"V#=V.QO'?T;M[U2UT#M<[4\
M]^<1!KR-X4OXJBMR]_-9/2S5ZJTN$-]C509-V>L[UI536-6B)"C%"KCX5ZL
MUW!92LV+J'B"069:/"_C>,H8H6CS+2N"?U!LL;L ?X!?SA2HMRKD%/M7^?\
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MUDEAI^PJYT0H4/1'Q5'<\(''&H5^/O0=,1<2A+J1.SV[]FYEM< IZZ!4E81
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M7I<.[!TAIN(=!G@Q70'*UOYX.UQ/U4/QVU;LK&_0^-NL,&IGRN&+-UW:Z[T
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MC C BSTN?U^_+/>/_I6>64'?P-^>>^%_'_B[L\]FK++L-Y\<<<!QQQP''''
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MK@=\?# ^I![C'=BL=&RDKLN1O]3/X52EMAG<!U*@\NG:[+*RH@TH:VB1Q/#
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M:Y@]338 ?'>>O-#\V1XH/^0T2AMVV9J$R4U!9(RYI*;E8N4@'@93/MBP&1H
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M''++K+/]N/>/7??Z_IUWWS^N]F&/??66>&/?7[/UZ[RZZ[Z_+GWAK_7KOO\
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M^U4VQA!Z?"!144M5;4#'GLW:4'4W>(1VI?939-W8QL0OBQE1<L/RXR=&6O\
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M?7?7_7/[_)K_ "?B_)A^7]GY/Q?NQ_)^/]W[?R?L_7]W[/W==X_N_3]O[O\
MK]?U_P"N4^_(F55$81ZT6J_KQ)46L=Z$CL-GL--+-2"_/3$:<:X3R2V$I,_3
MIMC!%@J:I1A49M"FS,QH77PPQ2B?>&IBB8=1^ ^$O0>OT4LEY]'+L1\&_1>W
MO2;Y[RW/"--(6/Y$=IUBS0WG&4 Q(;K>DZ]U<M:GY\FU,96]--@A*=B_BS\L
MI_"B=A:JI>U*&L-X\_)U<L$Y]@>EZWO>TZR?EJ#AN0Y"QYV9:S4K![,%9\F
M1'3O[VTP,(-IQ$2=4[. ;[W2(?4/3W*E=EMUX9Z]>6S#'9M_=^+#+/'K/9^S
M']V?X\>^^LL_V8_^V7[>N_VX_P#??Z=<YAO.OR;<0ZUY)JNU_'-5"U'SK1?T
MRJ^Q\^YU/D$.UK O9PHR10=BBP2V6R*,4(^G)S'&U2[%5PK(@%!$#*6/@28*
MV8S^FN?FCZF(MU$%?3,"\VXU"\^?-X )LBF[-\G:F'S997G5!3A]\@RSS<:6
MPW0$A&[0 &'TFR^9V:?W; ]F++1_0/QZP)2PZ;,Y,;5CLSV2-&O#5UUEMSSV
MZ\,=6/>>>KKO9EEEUUAUWLPSU]=Y=]==YX9X=?\ MCWUU^_.;UW^7[-*JWT(
MQ$O-<APOQ]^FWI#U,HSTZ?YM:L'A&)$K+RH'3?8+T&6CI-@T?_6,(O69J#86
M'LJ4:FQ7I3'P7 +(W2K\*.AV .I:HQ]L!$5:M&!6:+"L9<K#J;U6P%XBK S0
MU!D#$C_]_%+&&]<Z$L83>\I6 71"PWYY[.LL\@VEQQQP'''' <<<<!QQQP''
M'' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <UK_P S4_\ ZQI0
MO^5ZU_W2. VM;JE_[I7_ -8GJ^G5HD;F1I7/[3^X7P&K1*C;MI@M#B#M>J1H
MV9R>L-NO++97*+&_YO>@&FE_9_F7$9YLTJU]7/Z'O1%]&%3;:3MH_+N:W8-U
M"JIMY$UU?&C=*>K=AMHQW8P]JG<S5&B%\9!3L).K8+CA;#%]/>:IZ9C8T'T-
M1LRO<V'!1P?(MM(,A,S:]D79.UK&+1I8,PF3#G"U;9F 7J=V2RBZ]DC&-WJP
MRSZ^Z5Z+\^05E)=9M[4W#3;+G8C*X;95GI,=9L EGORBX#TD]N.8"FN=G)QR
MCXQ 4N?ORWXY:NM?>SKO'E1#1\V+PN"^@]_6$G>7Z\BR_5/A2UF&D$DZQ/Z;
M%1_'*=Z+%S''8Q&J@KZ.R7 W';J7( >/DB!!@-*K!(@[FF3/%:_P_17WSP]&
MTQ::U::XJ^8;CC12WT=4?^+;2;6Q:1Z]K[UY[5,>FZS;$/H?3;]&S,"U&7%0
MK40-(-:'DX&@9! ./<,?N_DA<1%NBG9KV9JV%;%:2[-7!NXRPUU%>U:0]@0\
M?7&W;RIE1U%<V 6-T:9D/;NG3A^B+KURXVS/;CCOU=YZW[]E^/\ $+I9,O5G
MFS%=D9$\8Y[N\ZPZ"[\@NL+M,8Z2G;3_  =N0G4R+NPGUAOR[@:SP7.5UJQ*
M0>]];U'?-)XK.Z&1F<@JP_1!-\>O?0%3W3O]2^@H9H29]01[+B:E]B\P=IVZ
MIMLL OV;-KR<P8OQ8?)4P0<U%6^F#1$B#O"K;Y7-RI7W@=+,@_/LG#RQ\M_1
M?C]RC:!&>X7+]!7>H^7UV18"EIVI.&.Q>,[JGLWMQ8YF@:S$HKCL_.))9FR^
MOH+2)/IJL@#C8Z^_,J36ZT@XU?A"L)RM:J!JZVSK3$'BX@; 'XN>UF79FK0
MWXP=;H%7>FW7LV3DOM@&P",R+[!ST[YK64->M1D]"T<OU@W92<52QSELH0E#
M9\H>W=IF8KS?//QUXUE%W1Y&J3T-(R>]&W1NU[>L<]6?6-(*1\AKXA$:4WV
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MV,TX)<<_*)%90\/OD]$MX'64&X;!9+;'F[XL39OZQVM??OCNU5BU'-<]"U5
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MT]1]3K%-^:;G-]>;OMFR18EN['812"ZG^K/H%4-HU2L16813[S'%,0U&L"$
M8D3_ #4"(75(3^O@"^D?C@4S#HGWVE647?,C2;%1(\D>UK"'/C[VY?T[H+R[
M0@I-,3)FK80QSC-;<.9%T@L+N[' N?A'PLH5#EZ"D'9O@0F?3^FW7QK<GJH?
M%#XM]*TUZ<NYF\V:;)3B%MX*7FIELI8G2Y@^'NSF!AKG-KO'H2=(!<1@_<Q#
M8<K9OD:\L=L!T3Y3>KJH'5Y42\V4:_5>'];_ #']//%M/#I8 RUY\?Q-3OF^
MI+!5@J /K,POSBS'(\Y"FE.8C%E1-& YDG+A89IE1-!K'!M7R&]7%Z*CT@9T
M>44K>@U7]5PJK9U?-3[.:+<9_? >YEJNU&S!A"G%C)72%6/:(UQLPK$9GZ4=
M<49*V UW3I#Y2>PNW7/759[HK@:LHFI4JH)X&G#$ATL:V*F%@9<JXD[IN&AI
M.GIR[/*<\5UET+PQ?0JIVU;N^R"=@=$Z]TS5Z'HKT77--*]-SFP!*L%8]"WM
M3?GA>Q :P1L/L)WF:Z"+;$6_LIVD?/3M'>6$PCN@=D9&^%MU[(,*9UG_ -59
ME?FQZ.7O4XWU(L1Z L__ "+IYS/BZ>L)Q;597;XM?>,G?S$Z&BC%&J9_Z7G-
M18VB,T561_R3%HF -[+!(Y+)(E&VZ9U>C_,EE7=6'CA:#1ZK23]$^J/*E\OP
M$#(,PD&"N4LPZS;DL5GUJ7-4S?CCA^^$FQBPA>C2(VK3_89A^^^]6 ;+->OO
M)-=UC:S8LW%2YY=H"K7*UW-2K*P:X*%%Y'1XY&09E8@1+!ICB8^1*#("1MY#
ML8,R8-NL9OF:)6S+'K$/-'N^F[TJ"BK%<GNC*G<?0@ <RU_5./HBN7M@)PC>
MS7T)%#9X_:#UL33J_D1Q["$6H!;4#8^I8# B2WQ>Y&VM%!^2MR(E,437XB=1
M@5C2/'7U-H.SR #,T.'N+U[<=45MJXKGNBI4:4?!!92Z5GO4L]&TSH9&5U)$
M0#>[;LV=_(X?*CT;.K2[*?#]^;V6!ZE\M^.J(;K7<SK=!>/,I_SC68NN&0W3
M:_!JT]IL$7C)'Y6A4>J4Y5'+5;8DS#A3'='D:]L<+JS/IOS:N'F568?0='@6
M=+W#XSBN&;80A9Y3D%Y@D<*T,HB<?T$ 6XF0/ H _44CQ<YLPT)BQL=N\C#P
MW?<G>A_/]B%08*O[SIUZ.,PTN96PR=9J4SE6 0OS,AQXJ#'!#<Z66&A"&&<$
MO.@:9$4;,PRC3=NG?CWAU5T]_-)V<1OJ.-*'T>3D^@OJUY0]FS,C,&3,UL'G
MBB#OD,DP5\\92$^3F59Y$:D+)P"+<K$FJY9L\7#:9B8%BO>GSD+YFV:A^C1-
MX ME&+\J#])_6OKS(V*#R<F7&K;R\2/GGE% []>E7%=E6(39S((:&M=W'(@/
M>(@9S8AV>6PTZ<0GI:_OWQW3E2/5X,_H.K"U<UHW(R(]FDEZ4W/M5;+%<!"0
ML SF@ :F9"R,DR9T;I$.=E'E11,,J5V:?X8R7LUYF.]35/LEVD186] 3ZRK6
M+6A#3<1RW:CR0&D99ZWJ8@A2+*'.TTDK0,L9$:&-DO8]9U-O<C233<CX;9B0
M[I$A_*WW.WUKZQUV^_T,;N"[O/?@5'"E-3?-(([+;/C'T%8=VL) F"4?,U.C
M:FJZQ,#H( I+()<LPO7P[=)T22C+K$QM<N1KUX ](-'I!I]6Q@?G@B=W^D?)
M?HX-13<[MTM%.[J>\=6OYJ>4MA>H]0R]XXDJ,UIZ[$IMUT5T:T]GDH(1*K*]
M(D8=# M,/^G_ #2J %IK:/0]&+:NYAYS"GLA^VD$. :P R5 @DCBT8(L$8<=
M#CYQ47#G$Q<F5"B2B4"/OWZ]TR/ALW?IW:I&K5OT;=>_1OUX;M.[3GCLU;M6
MS'K/7MU;,.\L-FO9AEUGAGAEWCGCWUECWWUWUWRA%-^4UJ:#LIG>(_GR5L9*
M0^KH;I&'8ECB73MF?0*VJ1=499J[>80!N[:A**J@.@IY:< 2J5+FG-AWC$W$
M4P2X6JS?QQ7WH*GZH0J;N?.L20"HZ)\WUNFLZ4=;3+2SM274PA:N$DZ8L885
M"TP,W<5^5%EC,]\TLOR-DQAC#2??\3H)=\<<<#Q#:RMLN$34QKX1@UCY6$Z!
MK-BH!7"%-U]=]:YD3"?'WXQI6'7??6$C3UAMQZ[[ZZSZY[?'' <<<<!QQQP'
M''' <<<<#R30$&R#]HEB#"3XK=GKV;AAH=#*C]N>G/K9ISVPYVG?&V9ZMG76
M>O++7WWKSZZRQ[ZRZZ[YZ$>/'B1]$2)HTQ8L73JCQHT?5AICQX^G#'7IT:-.
MO''7JTZ=>..O5JUXXX:\,<<,,>L>NNNOVXX#G^?IU^O67Z=?NZZ[ZZR_3K]>
MNLN^N\NNN_\ ]/77?>./??7_ .COO'K]?_T=<_WC@.... XXXX#GD_T +^IV
M ?Z43_1;<-VK:%_K8?\ 4[-<C=G(D:]@[\/\//#?OV;-^[#+3WCMW9Y[,^LL
M\LLN_6XX#GY;]&B5HW196G5)C2=6S1(C[]>&[1OT;L,M>W3NU;,<M>W5MUY9
M8;->>.6&>&66.6/>/??7/UXX'E!0(-;'ZQ*Z&$@!>G/;LTC0HZ&*'ZMF[/O9
MNSUPX.G1'PSV[,N]FW+'7UELS[[RR[[R[[[YZO'' <<<<!QQQP'''' <<<<!
MQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<
M<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <B>D^T:+L;UE:?C)*,%V&WZ6K1>LVR90\7AL1UR&S,,I<'*FUG[F=
M8S'?1(B9S"P.!"DZ0L3/#24(12O6T9KD:XB#)]1:02XS2DMA-+AP0!<8(^"6
MFJ9DD,E0Q;-#%E,-@PE* SMV@I''D=><&9NBX1Y>&4?9LQ[J-\L>1O67D.XK
MS==K)"]')4:EO+U(TX#(9)=9L+[O&6=8[W>]O/+-WK8R<1YT'+@=71DVE-LS
M;;)7]F/68^=I&[= 3>N3V,BT3:E85I8%?7'$$VQ9->4\N6_!31\FHXUGVKD7
MTH2<0-;6*,S;YAN<(R&2"J^HG5Q?(D!45F-!LIG7>N6_*D[;\]W[=?LVE+PW
MTOJ1X7EBQ'IQ%.AKTN<L%'NI,RK*PTI/34OSG.B_X"L[%9RSB!,GKB,+X)KK
M;%=+"UTV]PSW<C7:0FDF,RH*Q=P6=26VE5P(2:$[0<C,^E38IPR-)-+6IEA1
M8,-@U@B6V2+P-Q(42*5QB]3H\;3IWX:\0A+6?T:I>S;O@4=%2+J4YK)<?H[S
M_7MC."6'BU;95P>52#-$N!(56$$UL!>"3'0$AW8E[8ZKJC#; *:RR0,F;*%[
MH7)MXN"EF*('L&E<R!B9&V&4,XFQF0H;+T9ZM>Z*0(]2NX<.1ISWZ,-NB3NU
M[=>>[5CGCUWLPZRI1 ?+!L,4G[;S.L!96].VU:7U +>8'$A;#NSUY2@OV4[V
MMTEOZJD09F*PBMYE&<!D=L.!UN8Z@=)1GB#27Y"9"++T,T?-BR+![=&'+QHI
M^?:_UUSY(41/FGSS;E':,7:X_/5J-=D1KX8HCK5Y.@W4 E1C(U)!K5P*3&:L
M=2WF<VH4OS RL.Z#H@(.BY"PQPTE(!8K*!2F(,NB2(R4P,@R-$W3,=RZ-V3=
M&93&7KT9X1-^K/&'MV?I^^5KU]9[,8Z4S[%KRYK,>JJBKKD@M"%6_FVQB46Q
MM"X#VR\/3:V\,RBGP8X]C,9[W-9B(1>$XBM>6R/$)9ZM(><:BX;9F%4*1X:]
MA";KJ:V2E/42+M)FH)%JKU<YCR5:DZ,R6DVBK61A2[YF3Y-=Z+NHNPAS.WKP
M>=@CMB]0K&L[VH@34MTS>/AZXNZ?E)ZRT5S*KB9Y[I)A=W+PC\JO-B=Z)(V@
M Q:/*%S>3%1A#VC:JA$D*1!AE?X4N8B,R831"H\VWFE\0*D:=(:=))! Z(Z1
M]25Q=Z[9C0._G)8JKO0US^;#&][D@PVLH[TD^EJ^/S@N_47EQY 4T6#RI*]W
M*VQ"LF%^F4H9$W8Y:NOT]-^FD[RRGI38W*K\[[[%MVN*.2E.M18$HT'K"M0U
MV!41VK%H9E!?@P=Y#KOJ<4*L$"' T]=[MVSO'KOE&MD?,'T8P-<EF9D?&S*_
MEWW]0CLFHTZQZ7!E]8CV%?ZM8=2W!"EW?4MEI'9K17P-B3FJ'$Q6WQ'Q:(Y%
M3+E]V)D3OL(]5>7K8E^7_$5>4DJ$[+8?*?HCQ=99-9<K5';V]A2?/)(;FRZI
M5GMT,1 ;7/8/A=9YFC$4'_J"/6^;MP&9ROQ:@DW6'L5"MB5!"+R);PMTAV]L
MI*S:]:U" NNU&N7_ !<1N ?,M03-8.M&I./I,49-5W9$G/2RS;69?Z!D9T7<
M2EC)'X.B=L#RF'6V+.P!!DY0YQS \+S#PYF.S5IRBRB>,KN%'DX[=^C5EHW;
M\-O6S=JP[P_=LPZRI&;?"'HFV;O&>HGM"5@K!9GJ2)85BTR&MK\4RO*,K[YN
M^NO)B2*U6>, 1>B5I.5CWM",'9JG$S#IHTH*Q%$C>:E-.D=#5K\\_3Z"K^=1
MQKS#4-H^?/-MUL<I,\A/)ZA(+TV5TR>80E4!['NQI2:Y6//%J6G5%AC"FM(*
M$U7!L+5XQ9G&AKG6$(C=R0Z#Q%G""+'8J^2$'E+37;"+7,V1MP#"5EQDDD03
M8.^:DD,#4N04'A0Y3.(<V$H0:5")B3..,3>/A=$=NA;+]H(=<7+KI'4D618+
M3)\Y$O30W=7(Y:.PC2,,M1$JC:."Y$&@-E..YE'\8P88]]Z1.2S!)3,"NR9A
M&@2:2/3'F"Q$>^Z8.N'G*IG8%Z ^LOFA[0*"VO8Z:H2T^I_BS:50-JY-+ET_
M6$QU)KS7;!H3X+*"'AV_8)7_ .PQ!PSV.R-X+1\H_79JI3JV$0JO4LF3S#Z/
M1UBL!5ACMBS3,ZYOIM7'K6NZ# %]0$7$GJ%2TJ"(*\<^.%00&HN&T  $' +D
M*V8AU :F)?WDN@^DZ&W%\OYG[16HG"V$LOZ_9AJG_I!PW]RN_P"#MV:]<S]-
M7_UMF>&&[]F66/7?SZ&Q5E0IQ*,S+\D<,G?UA*?H,CMT(>2_+IT?U\Z5KDY:
M(D[\\F/I_B;]FN1^7?IU_C_?MPZRHG4_FU<23;D:\T^LZ1$7'*^L?KKU(9LH
MA)@Y'C7FNW?,_H"M$ "UGQ [6VE@!1Y::I_U]7PR6O3A $YE?V9S1O4CJ+ZC
M\N/7#K2OL!+MRF:=!2?2L7Y'=,%<")M'K58,C!Y?]/S[']>[QBG2U=I*T(2"
MJ#OC0$#%NC,EAM:\/"+;4P;Y8V/'@AU PF "1A:R(\V(GC]TB-$TSX1*%*A;
M94S+1C$C:Y6C=LT9R)64J+C&TX[.]F_*3HZU8Y=[M?64</0_L.FO,+GYV0K/
ME,>##Z<M6#4E>:ET%F;C#C$[.!!Q9G61A)T=+"'&8SR<G3FF1COBQ&Q\2P^W
M5UL.Z=F%;&'G;H3]5!=#UL(3U?RK#4*W^B]BHBX(U!H@#T)7@4WY4J97$  L
M2 N E)P' %:W=6&G3U,R>//4B3WI[U&=NW'+O;'S[]&>S[;](EX]PK5-()+R
M6(\X41CL3QEAD93.?;?^9'>SI>Z5/%SZ[*"[-3J1A!]@S$M)D:JST,&&G5-U
MB\M(7"$F9<#;\XI<\&&2L!DXUE$G$H<67_3C->6TB4ZC;MV&_(? UX99S)F.
MON/&QQ[[V[,.NN:.J+U)5-]1*R8Z=EEG^LK<J.?<J;<(6'$UUSO781!4A:@I
M.62(0&42WD-#?!+1 4U8U]Z!D OF4E#ID37"D5[T;YBNV%Z;LZU/2/DBBK2.
M^B]E,/9>]I[RJ'B?G[1"\J(516MYZ!+[ EDF8PI!;,5'P^IZU>9'4G81<9N2
MSR@D^#.U$J\E+Y/>L\?.]/5! JZH*G/U%\Y7/R0Y]AWL)#4+WL +Z:\=69OR
M(34E9U&H"+Z=K&A[ 57 Z?7]K(LZ&W; 8 I/O/O;.#J T-JI)&Z#49F7I >5
MNWQHI;0:&[1LF1&UR-TF/HGZY.47=NCZH<O;OU:]N6S5KBR,]F...C;WC_N3
M8K8= LLV5?QQ:.\<5K+(R.QZ8LL\=6>/0+ON3UT6[RPWZ<\>A_\ ([[QW:LN
MOUZV8=]\^$OYE6=:%QJS^;\PT=3E S_<ODZ[#GDB,P)C G+JIY_\Z>F$%XML
M@OJZY"K66YV&\V?50GM/7XY+HBM5D%/,4[^?OFBH7E+?S?\ 2E:G?-S/7%,5
MKC:E.V]Z-$K)]P:JK;O.-?>8;*^C+]Z 75'?4K%7I5[5&X%0)%8UU:S^>#R4
MP*S+#"I;1/\ \HNZXF(=(G''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!Q
MQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'
M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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M:/4[P)UEW68AA?BE62OXQG?0T^J8%5K(MB2%):=8UC:Q$K,MB6Z*.><7#B6
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M2SQ"2T"TRIAQ="AY\Z=)WW]6A8JQ3]9V);;O(EQ$RK45ML5NEP(4@G.BK"2
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MU91&U]:5H5EX?\O)]>6P9=?ZHD_F$Q4M97GZ-ZV$) (&UGKK5_-S(Q,"8J9
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MTZ+5=GJS=.NQE\ 3@U@(>W-E:,1H;L1/)X]#=>K5UCI,:3"3%&',C[8DR(L
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MC2]C]$5QZ7^B9KT)553/:^.ZNB?<=UL3UXONE=UXWDJ;+&K] JDV<4"J\;+
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MRZCIJ](^=-%B7,-K>*/L2Z$-WH:K;V#5D$ ;;#%[;*R5LZR(-I,M+6\61.5
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MO,&QE@C:9Y.T#H5B7T!S\7@'(:IWLXSR@[_B+#=C7  E8MB:Z[TBQ^N0PQB
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M2PG&=,>ZK/U)7NOTM&\R]Z27]]*\V3/46#W^<+_QYU7T-_'U]G'[,]E?Y?\
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MVG6+\@/0%E710C-31RBM%7^8_42PTM58G6ZLJNKHI!]*C0*+8#T>67.*=+N
MF<KZXQD3%'PH6_/8GRR]2348HBP?/5%UDX@Q_P!=B1:_ 5G")[5Z'#^V(?I8
M525+,\> E#3PT)K.7+7]A-^QI-%%M3ET^L]@^YI,G(@ .@*!ZZ\ERRE@ A?I
M2@))FKXA,Q9HJ!;*!NGHL$24T SA1PB1SN6X%%$'),4*:F%,(^H69D1Q1'9'
MG[M<?+WK&]-^<:?E;85L7W3=:3=!<<O[H;[92<I2M9\PN&' 0#RCG3$'=T9+
M*J^<8Q@O]G\X@%$SR,31NBQ=NW$*=JY^=_HU>O"M78\OHNU37?;7DZ[SVO\
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M@SVU;9_\W^OU %0@4CFRNTCV-(XCM4*%NV$,X$W7#QWYQ=^.L(:>QO%<5_\
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M=L'YC>GK KYY7[$2:=4C-K^:OO#7IH;FZX/BTI6)]&_7U97GYXTY3,T^#)8
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MGVT$)2-E81>,-V[1VX628\<M1D#-+0@;)!U;I& 4]LQ%RI'\C9IZVA4AYS\
M^HO/+'X0L0A7Z%&?J.H*A:?]-VC8#J@6K6@VD*4(W(1,+%5K!.MR5U(MQ+81
ML'PD1MJEV6:Z/0B&B%8 8GTLQ>LIU^LZZL?Z,_,[^,'H\*LV?8NRC;K5*4NP
MB(RPU]UM=Z%;<-58#,E>+#UTX]HJE*#:MI$#UVO3&WH4RQXFN,7QUS:F^K/,
M0VP6*I2'H>DX-I*!!9$ME<RK02]#PL%'6:JC4X<PJVPUB:"SFP@\IT):BDH4
M;>=DLP72+PE;)\?'/9.=CU]J@O9/<\J.@95\R6/LDEO8A&@<@3H"\*;I\5SG
M;I>$5:W058X'8IF!C;#[BA2<$EO_ !Q).K;D%&U9_.:T8WLN=<MB5PQ:%LUZ
M10O3-=MJ1<=.*6FDUQ8J)551/GAH!"*;E6D9 (I4.PIN*;7]H[J@?$YD[D$M
MXG]2(^5Y7GGY+242I?CK6C[0/GV2'\K3+3<O7ZUV,5#R\Q66Y>8G^MX+AE E
M@<X5GGI5B,0K?),%=&R3!CZ=!+1G^P5"QT7/H_IWSA9L)4(US?-/O<%[<CU=
M)DI0L538M+0_JZV2<F1)!Y"2TK^Q:P"B')LYA?C?D*CE^%O+RXNJ!CU([C/:
MWTY\G5PSQJ\$V8H/5B-'FV\_2E8B@3<N]JUB@:(-8*I]2$N>B<0BX-AAMQ*A
M!$"*.)Y[,U)URRP[EK>^!O"D(5\9?2ZMYN&5NG5K3*RZF_GDV^?[)R!-0H5H
M;;J[]O59=2+FPEHPC#:Q#%RI@#A&!'R7\G%:RE_Y(3IAP)F&&,U5?YM7 F6]
MJO-1KBD@UP2OK=ZA]5E;+ER(7;&8\T6EY=O6K$L"SL H7I;"@<F\L]9=-M71
M"NF+V-&["??Y)H_'?C930GNWS;=]!B[TZN.F5F$+JBJ+.N</G;R06C4/W:ZC
M!:! .R#^LA!B ,L=V^>(@$#L8)@9EB9V,6+KWZ)$71FDWV=Y#&UN*N(CZA\_
M0*G.-^=?!K)FV^A14<H_:X! IDC06?>>P#R7+H<))3.E;5+R.Y:(,G9C [ZU
M9?H% "U\M/8CQYP^C*/9-74:I/7J+RWXV65-.B;:3"U2:]$T <N-GLN6+6*8
MI]37$U*-D&%-"UVR.0ESL'0!U!M;@>E]KF,>%(%C\"7P<N-MO3=YDJ0Q6<OU
M?YTOS/QH<=T70N.*4D?/\KYE*K&[;H6RM9?Z"G+C-PK'1@YJ/%4F7I7Q(:2P
M KT%W:+$.OI)YS!694526.W)Z:X>@+F]"4_36P99E>/"VRR_/L["*3('&)=8
M,HBB89L90R(.1R6O<TBF4E'5#<2(6Z[Q[V4K^U:%[1$5NMNU:2IDG8K$]KBH
MO'KYJP[H/24>Q#M>2<UUF#,'8-CRRGB(O9?0'W2<E4P2Z53V<8["DQ^!3#%^
M1UI- PKC9%,T.2%;O''U43JJJ^:3!-RGYTM'V1Z/2[3\^U,B;R:H.'Z 5:H<
M ^%DO $ '%JA620$JD+$#F.DR+]_/"PYI% 48EV/)ZFV&HT[62P^3.B69GJ6
MY@$H(*:)/1C9UCL*];SD2=M_LL\>LYW[_P"5EUUEM[ZY]*S?%).EC.%0*%NU
MLTVK7N'Y'NN%YU73#NG8]=#^\_\ 3+(\A(,!,M7185^; C$CYZ/[*!UNQP[F
M1_R;8X#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XX
MXX#CCC@.... Y3,%^=MYP;"3568Z4[C0*+]&;(^B<"P($=PQ]&'SSZTV'8.J
MI#8S:-Q3],2 R6.02B5EZG*;--TR&%I'2&-W[-Y+"YGC@5/+OSK<M_R7._.=
MPM 6-=6"I[*K^19R;K8.@<,DW.S0W!9>N/W)763>&U8%APMBAQ9P@C,']%8H
M\A$SW1Y>&N%[YHN$URHBT6%8IM*L!!]BTGZ"M27"NSTMZ/SL1+HOSO?]1I<
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MO[O9%PK=U +'JW;B#9R4K:D,*D/#$U!KC#NIP8L3VP&K3,CZ.Y5^G' H@/\
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E<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image04.jpg
<TEXT>
begin 644 image04.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# 0+_Q  W$  " @,! 0$  04!
M  $! @\%!@0' @,( 0 )%!$2$Q46%R$8(B,D&3$*)4$F,E%A,T(G5''_Q  4
M 0$                     _\0 %!$!                     /_:  P#
M 0 "$0,1 #\ [^/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP0VZ(_0+D;E-]6:NO>V<DZP7!7V.J\ICD"SWLM-4M1_4K[&
M#=IKM*;,!HO%@W:A7\DILA8>RMF./G]<??[OICXY>9XXYX_U_MSQ\RQ_KY[C
M[_3+SSWS^N.7GF6/O]/?_GS+SSWS_P#)[YY[_P#'U!'ZN(G0N-SP;7XN3/T
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M.9^9G+D^&BJB.T5!4'-BSRPIJQOF&[61@OD/NK8*NMVIR4K50=54.# Y'/\
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M>6:H?5ZHKN9_?(@60..%:85V%^/S1PZ$O>E]0>2$S7PP=??S[B_V\1_HXO\
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M%1;J'Q8^C6@%[%Y3()?,<^&;F0L2AE3P 386Z5IQT:<XF .W+3+20Y]S[81
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M.FX1U7W:>9#M+G*U9Y5D'SLMNQLG<4P_WFH6'1)\^YHJ9MC]4++?JNT64I=
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MN1LC^;,/=^&C=GMUZMV>GS+_ "8ZMNS1NPU[/<?,,\].W''+W+7GYX'Z_/O
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M_'OYKU@PGX&AZB*:'0%+LG6O4#9$3O6.-&VRQ "S;B6L-']XK'!L"@MQV/\
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M245:"18U]LN"(-:\=,^&.+:8DS#=CJEQXT_7&GQ?Z_X]N.O=AMQTS(_]_O\
M9GYYCNU?W^_T]Q_N]_K]>,:/C(VS,8^G&7OTQXV^5CJU^2-T>+LD[8L?;O\
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M*+E%'P8V4"#X,@Y1XD?3E#&^>Z/?!\7W7KQ]CP?/8L;WR)I_LC^>Q]'O^/\
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M_GQ5@*&Z=&EX=3],\*V,YN:J3+L-SZ:Y3^KZD.62UG=BRH$SQS77B-(/NFW
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MJ]SAMRNNQ+7*-&AB3&;,AO)F=.F]CY\'+M^C7.EBEKQ_5*6JH/4AMFZ,Y?\
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MT%(;Q9!A*;=HGV1@KRPRO7K%)+;"W^#$=)Q@1)7FO9/T?U"GHO9G7+A^DFH
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MO>B/4X*6_P .9:6A=W8K,C^&R>ZC8S9XOR_[LL/XISW"5[X)D?WX9X_X)_\
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MQ:C3&>,BV/8_/2I;2&P7G3:BUYM:KH!-;A4XQE6-'FMY7<2WFZ4N8,<; O\
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MW==4\?AT2^@C6M. >Y^G=RX <Y4:09#U(7Z-M S2P[7%C63<'^C#0ZJ(*6@
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M24 M-VBX \8/"+(N0PSS7NG+"+Z$-OU!K/<,J/\ +>KQU?CKMQ4_T%Y:7/\
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M<+8S%LD(S_C$^X[IT,;LA&Y$3T;*T;MDFA%^4B83CMAZK8J[6KIV>@>^,?\
MZ$G;P:"6W:($K<!<&#08V"5XG'_V,'S="*3(FW^Z3%S\U^XR-&684A#?RYN^
M'TH 9;;FN%[KTGSA(@-O)4N9%KMLK<SRE75;K#AZ5C-%1,=O>#FJQD,[;F$&
MK+.%Q'Z18[$IN,=;U9D#A3'9?YJ7RP<$] \E&.8N=,[JWCCQ&'TZ:=%HH5ZU
M<A72HF[ 1=YU_P#G4UH $; #")&; 3L":8_XEQ(QA@;286OYA>)<\;[4Y< 6
MG1-.3[LK[)UZ657-SI/7":0<X*^@4<BHB2>\(?BD-HF9O*$G41"5HT>3MW-,
MF.:T \9NX*1UZ-Z/%A(-8@=C59+PH5ZL:9,:%N9'AE"J8'5,FY^ZX<388/31
MX_"3+SQ]PC:,I'FW?GY[CJPS]\]\^"BEPXBZ_$L'1'3?/%55)6G06'3-%WER
M]6YAV#0%>"H;N%JKY!O6M'$TI@Y(,6*'_P 9P9PHV%!GAC; BI171Y#SVQ=\
M7"3GY!MZ[= 1?BB&ZSZ!T5CQI7-=MRE<M=U0]4;GS3NQD-I&;-9:<<K%C^N[
MCI_]AEG*:=PAMM;C+(%9QX[5(UL,N_K3;=4R'B/64>S:]WV3,$8'XE>Z71;V
MO$H%LB_SM9N.IX$LCV\1LA?_ (9@2U0,H><7_P#",=WNK_[?T?FSO[C),;JG
M22_25.[CETOQJLTG_46&I&AWKB!16&PYPP^4&F)$!:]R KDF/#V&=\3&<<)
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M+]C:EDE%F03N0^5$DZM6OQOZF_G47B0YT#LFA=L,A"3RP^1M>AT340 OD_\
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M "+P/1(\'>0T!-0>E^=J[;M$4_2G%#\@1?(7)/&G*-=M=T"2I;)1<;M@I9$
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M5[*=,)@K177A61$)X99WE^EW*T8(QD#!.V5ED6S%2@_:I:^?[L6;J8YU\%3
M6G_^&J,TB0GQYC/I%<9XXJ6JA"L>%DK,_P#O-@G_ )\M_$" [?\ D7>MD\]
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M1^;-IJ;%5M^U_/Y>0.HJQNPO8TP@*2;P8*TM%38:(9J$)A;$EN%QG+'D-(8
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M&)==R$V+9_\ W\/T@O06#.,M;)(,1N?16W5-QC@F->&90&+=AGK'8>[\<].
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M4HDH==DAH]VQF1"&U'L!6K11U3PQ 3,(KY.',G!S/N@AN@>6=_5'@?TS @K
M.U-BA] ](V2T]+=J5:@+-95A4Z;L7('(HU*..2Z2+.=X+Z^3"P(+B-@J;^7+
M RKP6E>#)*H#(9C(Q(-4=!?B:K7NH6*E;NC&T.OVBS=V'V0$=KE3?5>!N[EL
M0;8AH\KJYHA$%!;.J63 WKM>6;NUD3$9;.,,+*%&WD_)4>P5'Y1E5UU@^=,J
MUI%,!=MTS4%46C5I55#$(!LA1.3_ (5TZKK;IDP#"O+T0K(8(;""SB&Q9KW&
M#(CY"MVC/W=6<V?JM(V=-U]9 K*Z='"OOYYT;UX/C(B90Y0U:C=U-:I:MJG7
M6J*W-$VTX^Z42_Y5&4U"M(Z\2E6H?VY-)J2CQ]9'V7#K^I=9UU ;!;CS_P!,
M#+E3+HYXHTMSO$ U"<M22R]4;ID:D&$*4"7//J(NC-DL4>A2&.):.7_/SEIC
MAGH0_>(DX>!J/H#@Z[>ENP.R,Y-H-%,<R]%\4<L<Y.TU>7*W;=]N!@=C]<S;
MJ2QNX_OE,]=L,)!L\.M0F_ 3(&^#+*,S!\&>P Q<X+L)-_*ZMZ[LRTVM-8$>
M$FV8SW6_:0Y;GBHSMM)+Q>ZXP"F^2J]#2AVJP-"O&.M!MH$!)FF2?C93<U7<
MY[TK_P#9_P"_I;]8:Y#.QE'D<R=9RI(+J%;XQFG!JU24]?V]*-U7K]K+]=#Y
M.J^/)T^/(!L,462>= _VOELYJVX,S2'#YZ3.WT7/]7J/1^4D[LDK65S94V>T
MV/M<,]NRE #95.VH'HC7-F#&Q7<+H6R#4=56D&PQO0=/?^G$S<1?)3E^.4T9
MCO2 ? ]_E/5]ET]S123C93K*4.=>&;=X:\D#8 8<:<U>VJ[HM!WV)OE[,)L8
M"W*^RB@;*$A:81,'N+$Y&@I$FCHN,63YC;^8S-9#;MO&RNK&IGZI7RW/$VI;
MK@U-7ZV!K8;SF;M V##[*H';,P;AK?\ 9=MJQ[)F&#6G?+U,L+!*Q1]*\,T8
M8K8WZ*6.&9OT!3CM;MM1*W(_0?)E0)MV 0=:6MBTX7YMYBD_ZPM7TZX5XOX9
M9MUX;M0N=A$'"UI"FQSQ7=X^!LDTEOB)^EU026D9 W5C>,"MVFW+OH2O;ZF
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MD!<X1KTBX(B=#(#M>[5OTF(_7#GW:2*[G2N+XJJNH!GM1>&W+8"PBZ*\:#'
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M7-CUVVW^G.3PGL >C1S=4MLU%VO^;--VP%>M=,/7FVM.N^G:K1R'H<U6%AW
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M84'5,*3I4C7#AZ=46+AL\T1]6O3AAAX&\_GSY\#Y\^? ^?/GP/GSY\#Y\^?
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MPP?A-)*LR\R9BZ;15)HBC674KL"X.V>R%S4P9ZC^CS8WYJTEH;8IG8]79,1
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MMK/_ '9(-_EC8'Z*\^(LDW,U\?.O3-<(-A[AX;=IE ZX*N<84ZYPC/\  ]T
M=P_?F?CAS_\ ^E8HZ5&!%?=TV%*^#Y$;\T4JOB1IG"=+=8$+ +T95_.&FPVQ
MQJ=R8 ]05&ZFG565X0=HI<JA$OYFUA+K[82:$UA(N "=(_Z&3/.[MIS9O+F+
MCFN>20JXIU.WVSDAJM7B*S"5XUO6X^CPLX#]85C&+"C+V0^)%@V,XG;'*0V<
MP,_@A]BX$4UP* "B5Z'&^@ME^ES$@'6<C9547":==J!^:,&/SHF2:,GA!%@]
MX77>%.JD]'L&2S!91CTN821LIKBO#7'!K0<>%V@MF4DBPR-6<UC^L":XV:%K
M=^YYN2F=$NW.D>?C[VVF:F8$Y=NGE^M#ET6 M>?\/8+$S%UN152T<8Q#M#6]
M8O<4@^K.^-I)9^Y8!MEO_+SCQ\'6YL:JXB%K#N*Y<[Z,WM('*V=]*MC06E9:
MTLB@6GFLYL2M"K3>EJ(9 &Z=LF.&7%Z"'E>$M&V?E,SRK>%::J*V5RY%8F_;
MVM7*]J&1L8PP#Y@3*;WE?"/T3=_\F!H!P]NS3&L"OP6"1JPEZO\ 0 <IPZ9D
M8W;]<W3I[BK]/*G[==L$]$17=;UGJ;'W^A'BDE;8@[!6),\-!1<F6<FECHZO
M'S;B?6C6JO6,A_O)0$U_L(F4C_4FM,#5)7],GZN^CNUZML>@YAA(I"Y.5:(Y
MZWU\T)63S;MK=0)J!,3$@Q!:7,.)"Y'&5QE$]302WKP143A,[:<\FD(WG\@-
M^//YM4N]6N=L_;8%YK UJZ-H3K5JJ-0> @BHV3H3G8FA3TJQ"@+>GSF+V2;C
MUBC"GL%#;(BNU1UT85DA-#3#BL.CWJ4_/#G^BG$8ZJNUY-3QM9]"5+Z,;SXX
MR#(J'3/1Q+J&R]),?H!#\I4W.Q"LL>%W^2->F"HY8!I,:?)\R)9;+YNZ;A=
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M *)G+@9D$9-7).O=6ORGV];M>V.\)UN"!K/45K?J;^CG/2E<+Q>9/-AKK*I
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M'\ZV"[-%EVP35[R2]W?#7#2]Z9!I^-4I8=,<Z4+DX>]FALEAJ$8Y'T384+9
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MG,1\#PJ-VQIW\*)_G_P:PR[Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
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MC=8SI5FH.UUP&Y[K@JDAG80PZG8J($RR) +2O.*.5?[(6G=2"9-BP-72T?1
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M_P!7DW.[**$ E[R;X!6E08W,A^ EJH7$A,P%JRA'"+T##=[A%&:L,->.&_\
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M!+V2/U:X^.=$ZOK4W7W_ )*;KY)-59_H("K[6QA5!E$+-8%:8T88N[%&?!D
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M&<39/K1!FYP*_-5/!]EIZ](\AU:QY!<F"MHV.X=GCI0CF2VO>EE#7YBOD/\
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M9!7V%!C]'U%$X1NB8^_2/VT1S"I^-.W=35#+6-L&A.EVV;:[KT-Y9;%J+Y'
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M3%70ZJD2&A,.@?/]+#M9I1C =:\6U02>>1*%A.'R,(T_+V9H\PD>^[/0@?\
MI$3M")R145&R26NT;AZ3Z0YOI"5G6>R32/\ Z !UV4/MNY8*YX08'_)+BFJ
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M"[6#F:7N:#3D&V[A=?+#DQ_4_.)MWW8[* *L0&]?I,@O,$5XD[).Z7NQ]_\
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MI]F<+&E@6C>X7@S\+HG2M3R*E==6ZKSO:8MCEKI=:O4K;X89+T3QXC0](*[
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MIKEF2&LE'"C=,_">Q>1O&";A,UQL9&,L[Y"A^&9..SS<3\B1O)N>_P T:O[
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MG^8W7* <JRC=O^2KW/\ 06QK,JGRK-B^^7I&7VH *84I:R$6/85B( !>W-)
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M#RNK<:JJKX\^W5\X 5AA2KENK!T9(BMC;JLFRHLTC.W:?02P8Z@,:VKK$0-
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MH\1(W==;M?+X48I<*9-F.;K&""<XL3.".&ZM )=6%=84UN'MU2)D0" ':9I
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MF[9YITX>9[=F>S+^N>67OH<R._\ 1?H^Y:$%^$;DI<T7ZXXO[R=':H:R2/\
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M6DRMG)MBL]:U"L# U@\C+4OLZITBRT1]*R;7FG]P]*$%9ZI;Q1S%*^O<35G
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MJW1.FY.P)0 O9,;F"/ZH&E79C#"!"S]+)N%ZUB;)E%54['VAX)F2:@80L)9
M=$AS8$B4',PZ!^WCE4'@G.TS],@0@SS?R0%N\M;1:[Q]Q#NIB?9O/<&PBU&$
MK-SFGH$@;0FWH"7=1"D].?/FI>UI^U=PW:-<W'R3FJH.I2G1"Q24MH[<&<UA
M/U/M7'8S0KDO2(7)\I2_R^#V*%&G[LR9MEB%*<E=FE6%7 SM[AYM%,^O2J@#
M0^8''91+_OM'(_2%,V"%NID ND*.N\\6(_5=<1]BT3%4*E-E8"1AUZP)%&+0
M-A9!%X06AD)K+HW[0'D7W?NP(Y819&6L.<<,!_2QQ3*- 6O;/8E'QXW)$A81
M'T%1'4=XO4#I=8Z8NM;VL=R Z0N2L?\ 8M&ZD1O/IP 4ZB#N5/O Z2ZDCOF!
M&86R)7.\6HKTH= ?IL9<EE@#CK![#KAI2V,N"D!!5@@AG!O'"&8;57W;[GHG
MA/7E-;0>W="WR8\4N&)#?=V6Z%M\\G03;EP2H$'R24U25$8MRV[>:$:I)_1O
M7(8S89VE!>@%I(S#6K:,UY2X6H-'GR26&6K ?IE;=VG7G^ZTR!V]97V]?D;Y
M@!H!"F0)+WCR(R3*#FQ^@H-D;A16)"+C]^^%)T[-@\C!B$8FS+V-,B:)6O9I
MP#G("8=UX; F7^+NO/JG4_\ Z 9]39DI%O\ O+<BF/:NZ0]YQUT)KG[_ &E/
M]_D^;.8O_"\*(U861IRQ=?+/_MV^$_[KCN *Z;:UXWYS#V0P7.SVJ8INL6FW
M2U^6 \V'9^=IGD!:DOL9@(O94D1!2(3%C.B[%05K$ @4K5)TP0T+;LE>[=XT
M==-==&U!7-[5(:W,=9VLIB79(.R110'O*+IN/C)'S-H@W#@%A^>W5EY[E'G0
MX^_#W_\ +A_;[CE[M7X.:+E;DB\E.Z>75;;YVS7=.D.O?V-LR[!D&].C%U/.
M#AG49<IR3,L+_P#;;'5&5K!6C<MU ^0MX?5:LW=+-L6]EUD2FN;Y,3'OW%9A
M9P]/>?G66L1^C.SK?(AOMW+G7>!RJ"__ 'FC5S;@6D94Q_T/MOY<Z_\ @?\
M].&K%UTJN#EY9?\ :6_D^9=.?VC'#I.E:^L[94;P\C5)OBT>]='$MC#A)$+
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M+ F(\3=MVCI>&KST*OTJKE4:C5VLB$Y/#[2FX2M@8N$$0-S-%YYXGC!A:_\
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MN^=_)W?QHQUE^H?)EN5ZG64E,+C+!.O6$3BX?"G))8:P#KO(F28<7#.!Y?\
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MI.X.33LBZ5[VEM#V;I\%SFX(_22]<%AL!'??#:?SLICW" B*H1]56,U=;HA
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M4YA_Z$77^AM;XN4LJ8@1]V9\3=#COR]SY@A(X.<S)O6CC8T:@8KT'!*EJ<J
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M\RS9%/<.8QVK8.FZ]G@5'$/S\Z7)\K.U&Z.=A2_=T*Y!;M<W2@FRJ5Q9>_$
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MS+'WWSWSWX/T^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
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MZ",#-4U_YLO6;V7HU@O]AMV8X>A5@_\ %;?>'<';M/+K>10.>3'/#!=0,B)
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M1TE:06A"UJ1(TK+^V'8O/[/Y*%K=>-Y+H^F8*U;)PNM5H7E6"MZ8KP?7I/\
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M._Y%#_[&?&%J&]N.9%L8"_!:R$R-%6B!3=&@'MNWSP5)E^8Y^XR!2791LA3
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MM9C,O_W/%45W'7F6E+V7'V>T7M&/2J6TBZU-UI L,J)M7%78HZ&R#EB4N,I
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MJ1E_[6M6]"@?GKR)QQ;$++2VBVF&[<BQ[:V 7NNO?=4X.56GF;;Q>*;$L_\
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MGUHMF=%=UT:?L!2GZRN!I1'E)>XA "ELYH^;E##2'6O#/5'1/3U?V! OY?\
M_I]2+MXENE>JX\8L5>R09O,MRYV9:(L<HI.V.D6E/N.-#7LA;3:&V3-0"07
M>$@>#]WDW5'6\?QRMFQ+!OMY0^@U=)D$[%/FN2-TA6,2R7/=?=3:G3']$E&1
MMT3?(163?92QV)L3I,&)IP6V)=2LYN?FN!LWZ;-%+N.B)2M$D.KT."N85_YE
MHVQ L%?;MT%>OSJE2JAGJE#B;_\ 4S,).EJU7*BYPBVJ;-$"-!O3K82\"1$G
M^:,%&_H?1UG3:K]HM[$'@3=UC*Y9.L#]7%_)(,XZ@5VZ9;@EU$QD:LCK;N_+
MIZG3D0COQ*8(0N$),:C#7 +3%J&6#0SA^:+*1<;[-IC772J#L_NC\WNGDT7I
M %-4A4K#AH#R^#+UK,WP\,/=I ]HHIGTIOL3;Z'$Q&J-JG?XO\A/^LDNI^4'
M.^KPYQM59<P*T+I5#ZU4S8DK%*;YQR=T+4HROEF:.V0??(VF.LE8&10OA+]_
MRR(F>&N!_P#A'GOOGQUC^G_#UP+,YS1;GERE2)3VZ_8I]@JRXT<6R5%$9]:5
M/=424[U\O86*.&.,B JD]"%ZQSX#$5#!9,361+C8TG;Z+U]1]AH5S64"GV(,
M5.?=['$MG:]T?=M8FUB6I*FAW88>E4LBO51J898U8E1"FR.M!C&W=KFP-4;#
M=OGPM6\(0J?!E]TBK?GT>I1OHT]:_&W$9/C%I7;4"N4>IFV$TJU!Z3UE)4A4
MQS855DA.-##MG\:6'G>-B0T'5V=.7)_NHM]'7_\ $R.HGF^_J"#6V@&=]J<1
M\/<IKC:RJ!/7F.-<QVQ>5GV&:)CM&TCG"17'=;D$<EJ,">2V+\%?AP2<N;C!
MC3-]J^ON#E3>29 \2YEJ>44DB@['.CQL8X2FQ4WJ)CW*5"&-$2 *D22/_I3#
MKU#0D ;JED]6V>)V$8<+27&;)4+J-_5-$?J,L(O8C F(5_J6K] B@P&42+J$
M4W/!\57/:"'/DZ;#_P"2/C&@D 25I'<+35D TTO0B&<*$A:AY%U1X>H)E\S\
M],%&OG9C:;/@C4/IGJN1T M0PT.9$DK0'=SWS]3G^A/9RO/-4LSZ9IXN<V2H
M'GL3.$;A8Y9>R\97F,+JK_/:Z4\ES$";7BICZ#RG^A74O7B>0AC6K)J<:_Z/
M6NQ9,-78 Q2/(" G] ?.IHWD R)+D Q!;4L9\?6',;<(6R01?OVJO$=R&*+'
M#<[R3Z!\M,D+6Z_N(O4(AL*45)O%066>SLTH6KJ6YP5=6AH7%)S8U2P2RC-'
M3,046:4'ZM_K\-=S5IV)6-:RX)G7$NDISE0=[6.CXI-C)@F&/NE5VSHK%74R
MP@(K4_5OM; C>N"VU0+-@C3+!;1Q$U_L/</-X5?I7XKNZGC,%MARI+N3[01?
M:SN5*<; Z<KI8@+0CI[H2[U[>K@*C>%T%8(F<J7IH!L"!8@R#"C."; 8 [=@
M+(2P_EC_ '7QRU],%^9K KUC&#'+F2RVEV%*3([VW6ZH[BG>M62M30V6]T@P
M ;#3F +&/:#BLQ#<3T+3(A31!1>G0S6<J!&9X_74/B!+G4BM&M<B5O\ IY7G
M UGRK1K6VH\(LLGGS0FL+U6.Z"KA\61KE9[L?%Y.$Y,YH=(VC,CH+/2P OYL
MO)WZ2<=#U(2Z;K+8MXDE%M0@1@#J:N\LW(HBCFR4BW =ME"&5S+>*< 5PVPI
M8-J.6FO* H=+C[O?9>>G#+;X%?C]^6/1!;31U<UU:=9U[S=6IWD9_P#*+"M=
M[PD]$L:D>NLNH;M+KX_:;+2KM]NO=B.&CBMZ&YTI(-A,#(<;'S+R<H6^]?YU
MV!'JY[1HS^BZ2SA^M:G^BG^TP#F=<7)%6NNJWZ)]0B>.K'7)F.VQ60_%+26]
MRR$X3\A_ONS$=%\]URNZ2ZAEUC Y_6::!+%JVSUE8/\ YS0D0HT[0M:2\HM8
M.USL5AM;F#%LDCQ%6:RK]B9,,%L:6,-<O(*#!:]?A?87&^44ZRT<_B59?[%F
M*@.W7*0ZS4Y4YP5;RO:8ZI*&.!DVE[AH:E6!NPEL,J:ST2*W22 XLN MFT5M
MVMFS<?@C]01DX'YM:Z_ZE[:?#_\ O(M35Y:K92G'JR859JE&5:SM&8M=2=$S
ME[3,T:?&);9NC+#GJBXS0_/]=L5ZA7P@W^\<%BY?8W;'YA.=AJ?4NB#8JJ-;
MK:_1NLN]J[RU;']9$28=65I0:.+JFTF! .JSYJC%)55,TO6Q)IO&0LR#:Z;@
MQ"<@3,$3)&M_ZI\%HWOFX_>_F0C"JZAO$@V *SN%O1 %07R6) :DL9J?E&OS
MB6I*;D;$S1,,NS'1,>#/PUQB^0_9OT^9^YE^E?&WD(!(UV6T2BC3;;]0X!*@
MTC?!"S2-PUFCXV8X5YC5<*L]]C1F6#7FV*Z084Y7B_[U;GCBH+,C%GQ<]H0K
M>/S)M7;7J'NHG72?/'1XYVO5^D]"*UK=3-3E53K=TZNM+$ZK15P9B,OH;8U
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MIPS&7=I.OIUA;,A?7%G5&K!5B6#C-J1("[SD>R8@#>X;2,[!(SEYLNY:8_\
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MM%+VL=%%RI.6R=Z0_P!>.(!@Z[^8D +2[A5\R/P^6.-6-2#)C/I_/1-6@;,
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MCN&CU[G>CNE!N3@\I_3'M21>?U=&6\B]@VL=NX'J9Z_6EP!,FC(,0O-6O9[
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M+UP\FJJD:G-6LP81@0J,4 #8, 3G-RT-V,5E6O;8"57]KR)2-SOS';WG.O\
MYFFB+=6-M[V7?R/#G'+$G7?LK&;O(XU/MD%U>=+5XE=C &XL5;BLDY)$@H6E
M_P!AT$;9BQ<^<YGT\:D.'W^WRJMN1A.FV(]Y+G;59\CQ%V1MD'=0N#M&NC.9
M22F.YGU(FB7YZV2FS!:B>'/ R"G?Q:3JB;J#;-70CVR2*7MPVWG\2"N*B3[9
MJ%6F(4_E>@'$M%,9;_5+E*;45424 IGIG[B.Q7*Y9BP^UIG[8^4'OR.%'ZMK
M2L]]]F]6-=0?TWA^&_$ ?MW&\OTDG6S-*R-T+)HPUPLJCRM3?@+UZY$GQO\
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MMNF5H\'DWD"33'4W>_19X7_J\^AK>6/_ "D-FPX,D9:JT%7:F1;YX35YA_\
ML;[;%_FK6L9I5X^7F,@IO'&9O]\J1CYJQ(=^H"H=)SP2[S1T<:/%.JKFX]I\
M/KPI$=*O>T^>3%LC;I-(61>YX&D-6J!"IQK,$W>Q]B1&FZ<-(X/"(F/ZP/=,
M7?\ K,!)4-=WO/=2WX8OA'YGZ\LYO7H("H,F'EY@YR,.]23I%J#6^SX*RPEM
M%S*9> N+5=S;,W-PA7-'X4"<!QBYD0E*:_.6EC=<VW7VUFL6'MM'KS?V^/<X
M9!5W-58WYK:E9R"&T/ NI%5?8%7S"G"U10#FMMP\D)GF!1W I%G>XZO*N?\
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M4GY2_F)T;Y"7&MJE=!/5F](![/ /#@7'!*I=9A^$3-H9!@>\XFR<034U')O
M44XF6B0H0 OFPJ@$3I^72EBE#UP*QQ%*UTZD+(W"9A^P5H\(E 3^EOD+(=6%
M2I)P1-E0B6X4'$8;M>[//#3KW99;/8+SOROIXRFU(HL5W]3M4BA2V,NF6YJL
M]=8F6O >57-5.3% 3I+($I3)B"2"XEA9 \S*QVP]\O2*,8N^LL)@S-4QZ"N6
M+?-,+=JK\VL3>\_'.:_[*QLN98]?ZC80P3"R0\9]DHR8:SW0IP[V$PQ3%> 6
M)7+X$@9A;TE14F-E0Q^>WZ#]&+]=5'INNN_;4/7E7/:O:-TW4Q]8MS-!K&FN
M;;['5TUP4^KB%'1H8O:-C-P(#7=55KJ$+$_ 3J(GV(-))E9XT+,HOY5\NQ*B
M<:4TR+2\37CG'C[ELULS=\,S>%8</S&2=2>4 ED&_I%9<I#45]<C/L?;@Q8Y
M:/,(0[W5[[GDL'\X*2'7 !MN&[WIICJ/15D=5)U3^63[[3RG=MPI5C)=I-(5
M4R"^D,=+M_ZP_-D\1./SA@IT9C9M8C L#AV$4B*^?KV]5536FW+$X_VCLK Y
M$D]D<_*B_?P _.L-%&V+12$72'XI*KL$.JJQQ^GI"J&'R+!]L9+EQBQ4=&=\
MYP.7C[FD7]0[)!WW)I"TN3H2AJ6NNJ.X^>W56Z!%/4 2Z](T\.N.J3RP$DUD
MGE6@1&$FP0BR-!3Q1WJY KKWJFRQ(4,ANBADY;\<.6"%=C:F&N'0:C7>-"\\
M<\.2LH6GJ"C[33N5_(.FDCEC9XK>^45=E8>/C!9IT/( Z&<#JT V<:7%0A\2
M)MBNOS3Y_K'HS/I9=.6GN:-;CTP^C$THT!9%?!FGKLLO'[U(Q(495AM<[QF.
MK(\F,BGV\S$5<\Y4%:TBQ.>H=H_'O[H3H&A"G$T&@@%<L$B].U$"C+ AV(RE
MEF-(2F2MK8:9, 41$HCWO&3)4Y,B2-A_6.W2A>$#")'$E<#$G:-@-0'Z6O=$
M*K/MZ;361LK,QU'^PXQ<N;&T<'9WABN+[8Z7MC2D1JUR3AV>E#"4O5;"A(!/
M)W\,ZRB' %3DP6(-!RF83;0?R[J&IP]7#:LNGIRO2-/5M.HM+:URQEC_ *G5
MSUD9B'ERB#$XM7Y2(=1J](QMN5<G"@^1:*A')%8HVQ,8\[;K^WH,XVKW1TT)
MZM8W2UG^QT\!8*O6(QS:!4I1JH!:6Q8V/0E0A!5L&=(P#.:B)]C1'YB=8Z_[
M[-R6M0?*9MR]UCQAVT[=3G#H5PYCLZDXT>LZ\M=6<BZ_;^5>,@6P=A;#!/R;
MK3HRC=&5G+&H?"(L2\GQ'M6\$&QQ(.]EM7N_'5X5F?H@OUKV74?*6U>KMLBV
MK:T"E=YQ/N;TU:5>/1BCW:\ ^VPJ?T5S_HEI;GATB6.U;"5OQG;9I*!F2(A3
M%XA%F[@E#;/--;W/9-*6JXYLF#30?MKY(?@8SX.&>^W)7)*K7#TY"]B2,B7N
M*P5E9!_<=\7T<3_QS??=_F'NG*.^7YL4J+3N>%>O+ OFGC/,_.D;DY#LJKK#
MA@K',4%H#*0?)#=31%:-"SN&6U'7#T$_'!C&=;98>XVH&5Z7-F>[XTT=^MQ2
MRPB&X61S^IT8BW%0?7]YU,WMO1X28&W0N.[)4:]<H5L$MU:@@=4@&?4\+[,#
M;_\ =-^ X9F0BGP8Z="PU2=,R_T;M*];1YA*UBJ21I6M.X.M.>;$J6LK9*,E
M?=($J_\ RTM7J6NPPEU8*SKDO-7#IQDKG</S9*U&;E]U![I>$$M"@09L\)W>
M?EKRC&1K$K4*+>%Q(L=8XV32  *X;M<<"M<)&1!RA1:Q(G09\Z#C%EA(.MOE
M3Y12<T:/\_LF5'D[]DGV5%*<^H-!R;FE(F1[+;>UX./03S_O2N)3'%^>12T'
M-XA//(L;_6 ?(:H*_@BLO9.4;;_*S_E;/-_F.%<;?^MXOU*#V%3=%%+02)$;
MEO!UL$FWFUVN*3*='U^]6D6QN\\E5A;3,B@*?30=>>/;)K1C$46QW G!3T=:
MCZR!;3[>S]3]I>[R%85CSB\7@EICSSM7%E6C2F%IVD$@,/0J#7]D0V*OBZ+1
M+!4KE5Z I6BFL3F\-MS5=+_YS>7-@EDOJ%X1YH2MG\55_C:S?:2;8MX57JL]
ML%/5Q5I6EA_\_5MMN(H8"!9LK0O2@Q0H -'5]87P+@1K,^@RG48*C:VS:9W^
M[I&V/N[\C.8)R,<JXVSWLR5G[0%U<QU<B,%F8D@//=.7\%UK%AKM+>[ &)09
M,V*D>$HK9UW)/9I24(,=57YL!?RDCI&V>'NSI_7H5[E,];AJ.=D@MHB&:1-O
MQHQ>Z'!FEF88+RN^M&.L*W(UD7,ZUO80!X")=@IK#%V3<EQ\,?Z>?[CI[S]*
M"/\ WF$K*@MV/.&SN/;^?>%R>6?!R??;PU.NVI/^@]I7Q,_C^53G=6K*N/&+
M_P!0];L?/Z-^2#XK?_A_P;Q=> *&?7>Q; /;GW_?V@W<6NK/_":L8T+TSP99
M7MKT5X.C>C-F4.)FV>_WN^CW;MR9('GD75M&;//)'T3J4_*5?R,6Z=Z6;GAU
M%-':/:G2:13P:S2N^F8,7I$Q8"XJMTY?]70AX78H.J'LQ!U01;+N6E=N.&&L
M+JD-&S0=CYC^5SC>3^@]0VUT$3FD"Y;L;K=0%;MEWM]GA%];H_I"X*F@)BD@
M$D)*5*N6$<2G0  W:J8E2ED>0]C@VXC2TC3!QTE97;-YWES)R1T6H(A;GRL;
MX[5_.&55;&#MN*QN5D4-=752"N&@5I*T!4 :$')_K<O ED5 6Q6)!D &B0(-
MGA1H=,%; D+7/Y(<SUNJLBE%:KK98+,0XBF2)C(X+.$\?"_/AY'O_-X,5XL(
MZR-T"Q!<7!B-NR0.E&'$?IRR+%LBN^04V^!U9^8R/<=<,=;I<>3N'WG^@=3=
MA7S.:G0G D0!8K0A*5S"43_4"<\\H5A4T@;ZDWII+9X*FA;"<-I(EMB;_1VV
M*BA^N#TIU9+DJ7/;;=<=$YD[7[(L1NMKH=26V@77',G5]FU$=4H6Q8I'.&T,
M) 8L39]=Q-"ZO"X848*5F@_@0U[6LC($9^@QG5T%9]1U6A.5PV)9G3R#5E1J
MEG6FO5]68$!E^>].=?-[-$.!*H8F)!4PRLVZH\]:FC;6:V6R"LZ<+DBE^;NB
M@ L$ZWJAANSDKINC47(-!:[<YTNBJ$[(SOWCE^(POM:,B@O9%9,&)-DP T<D
M6A^SM\.#+WQ86&W9'B;]FO#3G#1!_*6GXM?AX]F/UX.5OQ4#F58"VN2M/,N[
M4I+YAW2&*O8E'M&Q8&YB!@IX,,9TI*9@[#/L#_;;XE@>GA66H3']AP_1W0@=
M2T'S.TH->;"US/RG43)#4KYC.-JTY9S91KE=D,>^UL*K?%7A*N,1+FAHYB3;
M0YN*0R09O&U[(7"461L^/\W[:M][_,-&MD^QS;1N/,!T60A&K$/RO-K&<5;A
MMT6H0&-BP'E9D49'B!0H3*;K%D-L 3$U?XH4KW1CIS"3@;D91@OE66HPV3<S
M_9U1UI?=5KCVY-XG::FKW1;)5S0^2RT9=6%P%@7'D*>2="=M!!P8Y;'PY,70
M,W^;\,]&@(?Y:T=$-DK$]L[H21T!/LM0M?3TOD]+$.XQC2DU>>I@1A#]$H8Z
MM9 >?6+2RJC8,,5P5U/$<SM(N69TS!#DAL?>)OT/ZCO")P#5[_05:F+'Z8X5
M6.R[3ME?N^6 5U1$D[:R 9&AR'(I600(.[@4L*.7A5^.F8+*[EJVBYC[LBXX
M3\<2J']7A:[3/YX[B B%8.?4*_QT'9,7WH,(6ZA4)_7-B85<AMK2@)=&B$]I
M!13DL=/.-9 Y4.DW"_WF*:NGR"X1B9A/!+_._GU$D5R0#;K%DF:Y0^L$?6?-
M.F\P>=9/:[LD6/T*^6$6F0<Y;-8+<ZH0@[%/>[(<4-ME$80\7J%Y#X(_ Q?Y
M5<N!ZN;ZBA;[1Q5'6IN*:8,;,W;7D8UIW \S1.H?(?/\"XXQ#'LB/AD[D/X^
MS%F\]R\PCC?[OZ^?S\];>>3'"ANUK+9&"R6E6N3O_7)*,9;.48) :G[,Z45E
M%>]*;]>[W1"!IJ@"5 WF6G;K'"!D"/AJSUQL</8["OUILDC4W(K7LX_EY6UV
M31CEU%7E0*UA6M:^I<H)45JH.PSCFUTQRQ8QF$\M1*WU4*'4QM?$EF#_ ",9
M;)88/;[N@1PF3CP'6>B!=JD/L^^Q=17S'OK)NHN"_"_*L$&^EL&3?;C(H0Y*
MK); 4TZ=<&EO@!,FZ:D@&X\1.AE2')W>>8;R+<WU.Q\UR.2VH%(::4GTSJH4
ML -3]^<\O7F"=K1LXDTQ"]A3-9;:"U8^_P"Z@90IT8CYB2@[(DK5ISUUVZ_U
M>):RUH:VKF1FID<B<O[NC4]8Z);&*F+MNF1!YXFWXR)-5UD=J6:MLFVO-@XI
M7EH2(MI;7)%9 3(2)UOL7@VTCNTWV_\ H6ZGN<K2 5B*;*9=(_)WYS]>";*7
M77#PP(&=8=8[ZY*5Q%_BA8F_7)"!*[.02[!CO_P'1K1MB8!H..G/*0$VXOYH
MTI*)?]*^V)?UO/NMNY=9HECVA8T(\Z0!?'UL:;MI=#A31JP$&Z4V-8^,IA<\
M/1.;/8$TA*F-K.5(ZA\V%8C]16H_I7U F5?>%C6K0Z$]!%C]([^Y,5V]8L)Z
M#(U5U/7;Q8@F+9/11A=Y[=2B B*$11!J^]^@+CAJ/LC4-VL\9$&X9E-]UJ2S
MP'9-4G,7.7R@QM603,/)*;##;E8A".BXI2+-6VL?JT0&8!*T2L-X=@A:=,0R
M/SCD8VK7IDX88AD_SY\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?/
MGSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?0Y(\!<EF"EP$2U5;2D*^MKM-M=,(6
M#:$RK6@U8\" /?&G74$ATV5:ONC7J%P))EW6$\*VRRVCT[Z:\-[I!#=,;ZC;
MW]/;Y!/+<SM-95"3Y_3OT6MS@.8"1BCF6Z (R5)+,-2?80T;*]U*64[/>+PQ
M:D;/7[(R5=^YS&GH>B'_ *>0%@*]P%RBM3Q9J+6Y8RRB+8KZ[X[F\6C;ECOL
MNR:G6#J969DR_6"]L[F>&HBPS'PZNJ&SL]1$1BT[V("U[I.[9GZ>GAKF"(5K
MX\-KJ:#8:LNFW^@4-B7'ZR%I@!6A?S2:<KJ)?[H W#21-<L\^P%)#G7YB20K
M\Y&W:1TU8VP(4&-'J>P_4SNKWE:?TOLY%31*[8E;<J/E$MCF0FJM:0F;IWHR
MG:@$54[3P[V\NCK)C(]QCW^-8RPH)8?"0MF0TY4PW2AGDC:EA]9=/T'V)T3&
MNF\^=UZDZ9_.OF^Z60/+KBT]BP,M6Q+?Z4KC>QK^E</-3]NCF&U/7 \X/&'M
M)4TO:%$(#$CF67/,2@FZQ_FWQBTUQ6U3D:BF0D:HPUNK-?0%>T+@2"P)5OOR
M9C<JCL;4M^ -YA1LCR;GXUJYT\3 E/XPW_,/]_U0W^+F([AOF,*^IME@$ NM
M-B,H58B"MRO9UL+((RKTAG(SJ(?8*>!>!ZA:FZO/96_!7*6:";2P[3GYHPG9
M:=6G7KK20N_+%N%AH:)8*%$'.*3^GW0')A$@ (WQ1@8Y!K;\][WZ37GLK43/
M/@LV6LR/T!UPE6EK^M@*$1\V.(WS(E'7=XN-KC^IO0C1RM"/WA5]3ZY%W?G[
MS)WG7XZD;*NNOI:X(L;H>G:^.HK0]BS01Q_F:X5G*;&.)I\P%H\SBLR0>U,
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M-HGN%Y?3@^:TW:2'Y4D=:)PH")D$*P@2ISABN-HMG('HT[.8&CA88?\ SXY
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MUXM74:5:R<$FRZF=[$9W\>@)UE66]"S-<F$@FL^"#+;'@.W](9 ?,!Z"&_\
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MU?T/47)IMRK=>'&[!LWVW.AZ)CV<XKVNXPUG95E)3*\8\M@H"97T9A\=AO\
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M7K)ZB) -HUA"1'7)PGSA6OP7,D;H7GL?ZJ"X/TMO]%N[JL6 W\X;*ZY=N_\
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M(H>>6U2L BN6C>9Y-]6U)CVU_K&O\34,VW^JW7!7D4IS);*S78*RB@9>[1L
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M-5[6PKYD(2+CXR"UW(_B:^S)11C:74M<\A$.XJ^J!IBS</=;?S1H[$5^935
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MH.378U<61;%JFCMW_:K&[&1[JT0#_7[JAYKK0VB2''-9E%G\SG;MYIC6(&L
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M"BRF%FP+/["_?**L<Z;JZ7= F.U4]9O85]5\UQ&<,'E6&=/2'"OIFLD.Q*Y
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MF \60-+7&+P/)(Q).X9X>7I\X$:\A9Z/"@:;+%SO\\&3NT9\W/O1S;1W=/>
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M(:LCZ)\ %F3V X,S2L"A>N5##;#1G8*C;\<]([,L3SAX:<I\KW;R4PNVK_\
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M[6C;)6$Z\^-!*O&?N$).XH,66GX7G,6J/%6/'YO*(E8*]*!;*DG[0+J-=-#
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M,ZF>;.L>XW^N8-Q6 !MPLDV+JJNL8#-+Z!UKUDI*2S<NUM;N^ 9&KE:,X6"
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M]59VF?#P\Q@S28?3-U^RM6J%)]"DSOFJKKB]A]@7_34/HR$Y*GXC7/'IQDK
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MO7-7]A=5/"YU96"-SFC\,=I!Z:?W'H[9H/D:_BWV7[SYW$MO43::.N\Z;5.
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M17RA8%]:-=E8H5MI># /\$GL5.QU84X+OAH7YOE>#BO^G,0_Y\'R3(\B2O\
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MRL!^JYJ,Q8K$ WM@?^&P/-D@"CT!<5+1G'*!R@V1JSO/@7PCDNAVOF.-J/\
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MOMMB5]^AMM\O<\U79]@-[5ILJI.SZUHQ/H-TW,EC,9UD?UFINRCHV2",%I[
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MNY*= &#DV>ZK4-JGDBD+TD,'PEZ03UEY4XB.\]GP(FB'LWS(7GLJ/KV://\
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M&G9&>Q?U0\B4)&7AK]%,J5YCJR'SB#FME2R:X=PMSC62HS=P(KS$_2%EMJR
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M9H&F)&+S/S7OBRH<V#<5+X-L8)SS^X,!+B'[" D(,&Z^HN_,[:Y&EZ8>AO\
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M^# 634(,9G;@Y['?EMC; W"TVJ22*?QM%BJBT)QW2%!3I]/H(.!9-F:3IO=
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M,'PU>D"L&/ORX%T;0+(.K0H'NJJI<6Y=.&ZJ/,+!4O-]C99;/8^R,E1_]O\
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M- V6,#9S9L>?OTP]VC"1LPUY4,G_ ,GNOB];P:.C[>;H5?57S7^Q5'5JX9V
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MY@V2EJ9 W3Y!9<9Q!W &ZK,3&++U:W!>RWKT_9$D81)>>S5GKQD>%L5 9"D
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M<,_S?S=6S1CC?+'/+-0S3V(>8SP$W'Z/ZY:.AE?0$UD->Y?63E.4A6T4"?\
M9^C3AL/:2=7%B,C8.RWC\H)(?YKW^R,9.O73:[_D/VK<^5V3;TZ&JFQFRR.:
M,N>\70\6L(S%:ML?M-0Z-A,A&M-B@+2:G7/:T6-:#LKA!\8!6H_HTDMI@C$F
MRML<+OL.PN3<T/;:6/35!>UGH?\ 556VP?\ UU"_XK79F_S1GI0<FCT]X%\;
M]NB5&FZU_P#F_P"SS';]1+&-[ SQD^X=R;UZG]-\NQ>JIVM<KA!VL5_PIA2:
M]!SB@.4:*NBSJKD/TA]_CA@7_,G@]<9O61//S2-$B2O^/;/E1X69'?#A_P"
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M1OBB]VHK)C;86$G0+V8$MNK&#EYO]J%?OS,Z.N"M.GX3LTT"M6C?'!W'7)0
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M=&;H":77QT4P>&-$S"3E'!3P@J;$(%HI+9&W#H<C5OF8:=>?F7VA=?<_%VY
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M(QC[-?F[##9YECX&W_GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
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MKJP:HPQLR7A7!Q!;6'*+)"MV-M"6]9@QAQ3.,5SD'-_[NGYP6-<1.QWV[^E
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M.1S+V%ZL+\X,(<!+@_\ LDS/Q0_3RQ_T?\V?\7JQ_G9V RVNQ94W[C_TWO\
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M6!L1LU3*TC?^<5^SLT62+4G:Q_517;,]&Z2ME2D+7E)\V+?W3E,\OK6+E=C
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M;'86)4IN OE;1/0 E9)KB3_UZ.*: 90]NWQ=/\49,V$//,X<$ANBQH7OSEQ
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M(FD.O^OZCZ\".>R 08BXW;HJUEJ &M2E*=IG#GX5*F>SYP73LRAY;@P_-PK
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M%6P:0WU8K3:/]9:L@Q*E7F%+_B+*S#:]RXM80B(;[N/N'EN@7.8@VQ:>E89
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M5+%PU)<6^AK.;^F;P8;8HW7=(/%\E"J5BY/->7_!28-CUPP*HZIX:B+ ;O\
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M07HI<9^2*SH>J:UK\1_+!29OJ!+6.?5#$[IG3);#(DS"><0[$QST8ZP\+/\
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M11"0R= M7L0;3A6H8.R 1VQ9\<9JT7HBZ7.9.BPY"K,R,Q)4+=N&98[L-*\
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MC9%&<5T1:'MPNZ(6A.U;N8#Q4#O>R440ID /!>$S @4T"7+#$E-RWV'Q]/\
M'CZ-'^7=O_P:=6G_ #2,_P#+(W?X\,</\N_9_3'_ ";MG]O]^W/^WS^_/W++
M^GG]?Z?!^WSY\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY
M\^!\^?/@?/GSX'SY\^!\^?/@?<ZET]N=J3W2R L8 N @5/\ [9\O\HU[C6]E
M_P"H8[,K)KKRFG<M6=@1S*7'$Q0;#!LG6RM#'_O9$O5H,[%&"O3\E746-]%?
MT03/"',!ZSF"W2*$7]<6FXJKZ#.ZHMC69 3Y]WTP-$A$&T\Z[A-^A TND "
M  BQF.M:I#.)!"8;)Z5PA:O? KM;_P!5?0L?_P!9.UO8X$O2E ?KVWVO12S8
MJ*3KLNZ_FPY5&M-@:4XEJWC,C'O8MAO*15S<%VI8X)!.'<7)2-RLXF@7_OLS
M] NE O.?1R*B\XRDOH55_-JW^NK"(+O0*Y[NYR ,P>U%6E""LS;T6+#L>TLC
M%<NK>3#"XP-;5<$7?HB.3/,*+NHQ/!B_.CC]J@NPXY5.<N+8@3L)>;\,71\C
M>E17>AA</=3QO[HS+J]B>6624P&[WV%_'\6,8/NM2\"8R97F[V+[X(Y:Z8D>
MRK?0#9C=)IYDY].>KEGVK7F+E2C5_P#;+5D_X5XZJV+^HXS?<RHL2Y>&](4O
M(G$Q/\.82([98;,1QINS>:D"!-?'-;87.GT7;/L15F"(SQ"*E%4/+G, N<<"
MG@^LS(D[-V_+?.!D(_\ DW[<O8OOON/N--M-]3W=SY2#M=K0Y7KV<^,_Z773
M^>M85585A4]7BO#CP>UWZ@*J9]YY=IL#Y!)B5Y8#8M)6;B5]):MA63H'>2ML
M?#5?FO !*H !JX&)_ !+8<8 "P?\TB3_  Q(>%H'#HG\B7MWRI'\>'&TZ?\
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MSQ</S]Y4L9@86*RT)CLW<?K]VJW2&LBV[@>E%/1+)7@:N_ JS3&A\**U7?\
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M)O:NPDU=&J[G/*^,.J0QRE"/ D;,K<*1I:MN=:H1J1J!>_Y2LZX"ZUY.7?\
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M2(P'M&F/IP,G(L8N3\E$-&J3@&(]"='V3R-Q#9'2%RJB2ZVA5J+)/G$^L";
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M8Y?53'-]"\ZP#0RBJC0ZH'L6^#O-1$=>@ =)#_5Z=T<3'W80]6']H\/'D2=
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MFNE<2#XF,0CXE, <R+%(:MTS5OQV5,K74?; _9PYT+(8*JL>UIOX5]#]2V-
M8R]B)]7-_P#I&/B=]AGI*BNX$-,NSC$0O+"23.J.($+VUG8)@B'Z*UZ%PATA
MH]85W6B;A7B E+2BB:YC1/P400F' 7O)CLPF6QNW^BM.KR)[FR,K"<-F/,M7
MN,XB6G2-^.><C9_74:?QMRI7X6(N)//U5*X$?7MAU*/#AE 5"'0*OM@L&.6/
M7D&)JT>:8:6X%ET%.,+<;'4(W;14+S")KPT88>!7&H?IYT%<EP:!%$<BLCW5
M"R>Y(!V+MBX2)35J@]04U4EY'7(8V2"J^C@ =*H]T+\XP/+0S$QZVK#7$#3
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MWM 9<4N#,B_Y86D80=WL$&GM+5AKGE)T+64@[M&__;[M^F=7P/GSY\#Y\^?
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MQJM@W#DR2HUU#H[B%>2[Z/'R!Q1E2MJ\6D"IPZ[UFY\H5U<-EA.-)5(UOVZ
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M[,0)YVY]4=U,CG3S=K2)UAMRV!1%N2DZRM>P1>QDFDO27G01/I6G"O\ T?\
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MK*K:^1&N6RL]A! ":J*JDQS6&+GXX'W$:/'00Q:0;A8;/^D)FM._82C8[/\
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M_MW;\M7NW9C_ !<\HW],\LO/X^66G^G^/WW'T.=1$[A[72U2:>?[8!V[ZL\
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MY>_U"C?\I.@NCF3CRL%757*LQO\ 6*ERM7VZAR[K#KG745 2^<D3<BVX/?\
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MS[TN\LNZ*7A\S+UP!=5%&2VE?G"V'HS?64QD2$O5<>2&F$V(F;D;HN!VT_\
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5^?/@?/GSX'SY\^!\^?/@?/GSX/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image05.jpg
<TEXT>
begin 644 image05.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# 0+_Q  ]$  " @,! 0$  00"
M 0,  A,%!@0' @,( 0 )$1(3%!46%R$8(C$C05$*&20R)29Q)T)288$H,S13
MD<'_Q  4 0$                     _\0 %!$!
M /_:  P# 0 "$0,1 #\ [^/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#
MY\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/G
MSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/
MGP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^YPQ5*=R;^A.B&
M-V=>I!K_  K$[=8$N,FIK9.INSJ&:$2SA_,=<PK1E=$DZR7!@4<4K":)!+=)
M*UNA;F5-F<^1&$2BC>0#H\^?<G+?QYW"JU#IF5U_ZY-]B@_RPXM>!FG;TW>A
MZ40_0U=M;#&TI)B$=M29"+V,*1Q\30SKDO7FA2U^1)BR 4O^J-C'WICC=EA]
MQ]21JT&]@LEBUS^MG+\!0L,3:+CYRQ5_. SG/C-RZB0FM4V61 2HH\Y5Q:S]
M$A8)H\^>>?;$KT@H>["D$I/!A?U1UW5MT;5JO<U0GMC/7;EX:]7CFT46";)W
MB^PEE4M_4,.0AY2+_C' 9*)Y_E0]/][&/Y(T_P!R/MU;<]L?<FZ1SMUK7W.@
M!+<*4[8S(0^*GI7Y16>?[%9D/74/:9'I7J=B(M=IPDNU$J$()&EELYK/ICW8
MNDO7 U77'8:0V:-\R<*.RPD#N]MW1]A<CKSG.VO02A-GZ'Z+.WO!K:KPKMLG
MG-LY=3>=-,'V9AA#K+_U=J3UTS!!D-&E._TP[0!AC\8@G>/V!T,?/N6!=H7O
M^/S@P$$]W[&B'YT[D$5TO4;?7+V):38E==#1'I)JJEF9>O6AULBP#HR5I'6!
M[3%JUDFO*(/B#D_8</S(XW#8)&F>L*_QYB>TF3V7TL46GJRB25SM8Z9:%&UK
M$7'V]JRE1_&.P0'34MPJ<O3RT&:C=93^H9]UBCU<%2Z9DJBIDF%A'#I>^T89
MZ,JP)?RMS'N(,A&XVI#EV?K7P"*Z,(E;K^.3(@HC4]N 8#-4$06>/B"P!9S:
MS8K<PF!L^")TRMD7=_1!WO52L U>O/9QH1>F;6Y&%5A?PZPT#E1P=EAWPO\
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M;?\ &A1]>'-8H_FSW![5-8I@ /%IP^J/_P"R\E%.[VVM NRBESL"N+*7N53
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MM3*D:(4L.G//;JP__#V:\/\ SJQ_]^>./_NW;/[6G'_S[Y_YW;?_ */5Y_\
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MM/\ =/&"HL++FT]4T M*SFOL;8I'#]K)@: R+">?@*S8P!-A$Q&])"%AB*0
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MD:,M8I>(B<*D$R1_D@_+FLF3P)CPQT?;[%QG;_S['Y.UYU)KSZ1I/#??<LQ
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M2ZZ//Q(T[JL\KHGU(>)D=U&6739)OVU.$B2B4NR^]1O<Y)RV"(#?&@1I$<I
MV5WB"B9:86R%*R9-<F-LU8@_94-GYK(Q_KFQ.H/-- M,2Y6RCG>S%.\>6E.Z
MW <RT6 7U$(1I:U"KBOR:KS,K"BJ:)F!-0L' *Q!O&U7Q"F)DK/,/JOK]4N:
M:>HJ[;S5/'^ZA-'$(HHS!0*QM+,0USL;8#4TQ^5Z_P A#S1K!A)CF6R&M99$
M-,XH).B9#B,R++E1<-NXIOZ \H"W:'7A>Q3X1GWL%:IY36=J&Z08-*=[BCCY
M=7(5HMQ:NX:C4E@/&@P&R (EGG%%NEY&@NK_ $V&TP,PE15_^YANV[D&U.%Y
M?46/_I\-+;4OTC'@TD+C6%5GL^V8ELHLMY<)=A$A]NX5Y,A:5C1&@*U7YM"[
MNE[&*5(8-D8W#^YI_-5Z>)-I@&7I$)JJ/H^^Z)Z<Z2KI=HW8-*-EN4Q"IB.3
MU5<^%;=/D*NKRR9% 5G(8E@Z(L]B#8#S.A5> _\ N]VS0$WZ8ZLHSH1NMY)I
M]I.-YFAWYFJNTYF-<V6"4UVQTPU*7VQ*BOK*GAD9G8EXI$V:2PU38CN^'HV1
M9VW'R!,BR=V+77W%R]SPUD4JV[+WKI\ GB;#<<!B'9+H)KBOSQR:MA7JUV5%
M3V5:J9.*FAA2#!9[)+JP23D+*;]4W**-G;X^K$'GR[.:!,=+HYD".$:YN^;E
MZ,N%L<P,6! 0*:NRR'Z[7M,#"H[+D3-,WLH@,K),8(>O9JTD#&ML.B(0T;)A
M;L,Z6_/1DNUTZ?.H'0'E1J_:_/JCS?TVM3:I@V,5-)2A'L4!&.54SS'97TUN
MYD42U7)-GSCB[8Z]CJWBST)8B'AO^9)"(?6GZXV92%M=M(Z*ACYX?E[1R!7R
M=L+<[=46!J<K9ZR<5(-BX,U@UN%UI &N*_!-T20*2X>N4TW <B;A*BZB)DB'
M!W31K?\ 1*HXRY)PN6R5DHZ[;DM*HUP#35,=+SV\W*IX"JF[ WG:2*UT9M1)
M*(T5EAD+)U9QV=)0(A0'%(6&0ERLL_<5L7\Q0;M(ZA\%6Z56!G1SA^?K-"'>
M*6DQE7L/@MT0&P.'CS9#)&W,O_8NI"CBB!"7B,W+V,_9+UZS6S1YKV^6*_-I
M\KRX25^TITQ 2[2(W3V)8.<IRI&/8BE[7G96^EC+A6^Y;BV:DS\C2:WT#7+.
MI6!'9(N.><$D'.*!005DQO@EE[V]S!Y9?_4__9F637_R:2C8$,$JP]E>[K!B
M)LBP9%;QK=P4\JGEV7J38DH[E749UW.O^/%D:/ 7^;JSC>?;3_9O.%[4"2ZF
MKJP)6[GH4NE7&1;#BC6)5RK(3 8+QD+.@O?:"FG2C*=!#^;I.YJ$Q)@'W.'/
MC:R&<J!+TZ8DU]^7B?75W6':<.;0C:.L:WG_ * E$[ Y036;H53MVRTV0%:"
MJ'T/@YC=ZVL_\OF3G<.%\KJ:P!-9":GCW/4M[=<?3O$5PTH[OSA _G([.1IE
M2X/'X#D4Y80V#H7F(J$"U-!JKUT@#,I1>&*,;-$'6=C#MTHI!CS/,(DC.=%\
MV>;0\V?^G7$PA&<+$.VR?6UY%_Z=VL41HI2^EARP']!,^"729T+7!^L!UB-2
MQ9S5G_H5!J558TN%2.O?'U%/ZHTC^UOA^Z>IVL5.NFYV*N K7;,N*/KI0BU1
M;!^V&HG(!2V;<+'4LN))>W?"8D# FE&2!)2=$E6BQ=VQCUB_Z/?/H,L?YKV%
M:;Q'MJ].GX3S;(LQQ#'"L*=2$:MER(A<9]0!^J,@<U4RLUQV$&^X'87[$:V_
M6=@!5Z'[$Q4D09$T2H$_?79O#RWULP\_/V^?7D1[YQ;75@3X5QTX*OZHF(58
MZ7*2'-==ZM)-"/O)^2860LH!.!7->,+Y@/HVZI$R#,(0)(>*W?JCP2CZ84Q@
MOV+_ *N53*;T-*/ J\MEM6UNDWUT8*Z7;)>F130S8&NUGQZ5F!4/RWPBN9IY
MP5*'MVH'OQQPRR7/]'N-=:E@Z[;;F:1.=]".8<!VZL+>TN>5\L:?JL%7K?&N
MMB#C8.9EM29,!G4)&"QD*:Q!4-+7R!' P,_RHUV#^4@)VKSHZO0UDJ=6"NA.
M'*:XTV!JDHU?04"O\ZKL7H*R"5B)U>!6K4*'Z' O?YC7M2=,W3H$_P"J\DY,
M)7>1W^ZL ZVX7NS;::A95%-TPLRVW^L_.77+<3D) 8T(HY&JWBK3S66S,B"+
MD"W.ZO/RK1>_VVP827V&+_S_ &Q@FO3($:3'P;SW_IE4TFY*WWAW%+C<GFN3
M>Q>@+(MMM%N2<UH+5RA=_.=.'DTRK-$$&>6YPPG;[0,:%%C48[M@RA XP?!Q
MW2,HDZ1B-W-S!83 (40-A$QSD9L,+549)>JWM.KW>(],U;-MO*@@VFV8E*3.
MNQG"NT1N9$XX>%#@#9J D("Z4)%-/L'V!!3\;PS>#8M3_P!"'3#D^HO7\=_<
MENNQ2OJ(7+U3TMS7TW M)769K,T0%P#4[1S$C+X2MR,QFC,X+.3DQ,^R?MFR
MI_E]:\'=#%:/ZXMD':\BV.Y;?U<ECJ5=:LJ\-5 :F#W-MA&]]4-"@J,[[8LC
M5L E;CM=PM5A,O)&4<3#9Y<$"X J) #;0G49_1'CP#B-W$;<SR'3Q^XW+/C*
M_M \J*BQKLEAJ*.Z6,W@4LDKU>B%+"5&( ">+&+JRF>\$3BH<Q-"Q]I'#-@'
M9G-[/;>ND UA2)#]*;'.OQ7DA(L(:DL=A5U DE7VO5*U2BI#JUP?DX;!)S65
M*5W(NSAXX8[G.%Z/]$7\A0E,?D74D2QEEO2HM#%U6%S[S_S>T(O2G+RMTWKD
MIG.4YHS2CU?L#(ZJ<Q!<RPAR/"VZ>3AO8%@E?ZMAE+?AZ!LFS/K1OSEA\Q-]
MI7'4*ESO9I:"]=+="TZN'>8$$?T6+MJ\<WALV)H_JPB^1?8:7I<7AA&A]DA#
M&,D).,>*95S(!(7]K<%D=K6VGTPL8MSMI=9(G.=B.UQD"L+,MUCW2?8,\GL]
MTI]3J+JV[8L8<+GS9L_6$R@08\;/9,DZ/,M?]>F%+N3F&P&^K46OK$(6"PW'
M5*->21BA5U:#F%QJ*S)90?7]@.;2M)9-8K%=;R00R,!RK+,*6<PD))0,-7DJ
M!*U:=:7WRE=/2],<W+CI?(]&M"LBJNXW1J5U9PGT?>##C6# GN2NSH"]:-8M
MLM%Q<&/RP$@?NL37'$,"PM2#HIBCQ]D'Z.R#^4Q&O _!X!=OL&!RXGK:@JUV
M6@GTK)3^AK55Z1+SBA2O2-M#+>S@"J+MG5OC#'JFV5%L87JBY'90 X++L4PE
MI"P6V.HZ6HYK34^T3S,L3GL\DJX([Y6%IFZ^BL-DMNM#0 S7::\EEJT0R#BY
M;M"VO1WAL7MA,M)BQHWF>4J/[LURC]_\F6/96FI$^T)A)VE.5U5R/T2:XM0,
MN&+#YU(FAMU( )\.) U#//"!DN'"!A1#,LYAV !<ME@#9B_J])?1UZZ_-IAZ
MJOM:MN3T>874P";Y59H]3L*<PNXA68N8>AH=];3=6;8-M)"HF%;BQ&!DBR2;
M+7UB$]HL "G!)HWV!Z.W:7Y8X?Z#DR0K[>3QN!J-+]^?I9U94'.V5;+T!GDL
MUYW)U>L52QFK?%V$3T&$?=5UZ-3XNK62>%,[S-@P?&AAD"UD8%U!G=Z_KU0>
MCE>T;LY/;A-KO:Q2B=T!7@![KVX454L2JF>RE"O9+TK%&E71\'E:#3VC2+.3
M4<N4_P"+,DH0)9_!LN=HAR)!"?T$I(%*;Q=G/RWN8(W0EZTRDJ]-I5YVFVSX
MM%>@MSOM8U(%5TEEC%*^A'ATFT&($*,58KXE _NIZEX$-7OM9E!_DK>%N<*<
MTUUU'?$M1=DC\YDCE%30X=,+PPS1F]P/<]6/;6AY*"[-,C;5:8$CGNNJS"2Q
MOB4&%!0!$W)'FV,[/(^S1#?FV^5Q;LZ^J2Z8'I5HD+?[-=I,MQI"/8BGMKGM
M!AJ%R:ZZS7(UG)4W$\C.=&5ZPJ5@Z&'1A(]AE!)].*"2FV+K#=/0O?=1U,NW
M&O+1B9OO)0H6][=K!8>*UMM9K^SB-*5CML4N)5;+**0- ?<1,.6#FLXI#=RA
MX>$F2YG]F/C!F[X<=)GZGK3-S;6;_4FQ<8KS+,?YN1[*KIG3K33 XU+[GZ$J
M&E)KY7^;>)5Y;XFQLG=OUI3JJ$VE3S85Z+ ,DY6?]Z')PEW_ !_9K&NYRMUX
MZY86_!A']AC0FMIK@J=>%P7UU1VNF9*G@UR[@_X=KKZH?,=QVMT]3JM*PTPI
M&Q?+$YN?\G,O?!_E"X3(Z/-M?J;"PVZK$G@VJZW80E'CJ_B#*XXHZ@J_J0A'
M9@>BQV72S.ESME5+H4TS0Y:V$31.G#U>3MV[,AZ1"?2)V5S?95G>5 G6'M(N
MTJ;8(P!A-2[  *;R4J<GI#V:+K*QF)5%5W:1-!(;O-#:.KIJ9Y@/'3,WS].F
M,/G[HVTK6MM/IA8Q;G;2ZR1.<[$=KC(%869;K'ND^P9Y/9[I3ZG475MVQ8PX
M7/FS9^L)E @QXV>R9)T>9:_ZZW:2_.>+QEBYNU-JW/EGF$0;T2U<_P .1S(B
M*?2VEJMPRQN4!-9>JICYEZ<!QB)Z<G8S_$A.*%5>9&TMYTWG SVR]WWWRE=/
M2],<W+CI?(]&M&LBJNX7/J5U9PGT?>##C6!]/<EAG0%ZT:P;9B-@X,7C^D#]
MMB:XXA@65N0=%,4>/L@_!^C?^H7"Z1#3R)J\/\L:]\^B^K%XDJ5K;SX-]YP+
M%8X73<IT@CH#%#446 1E:-)\NV[P>"QAEE(8L!<?7LVX:[ZE_2JMZ@L*L*<J
MPL+>+2/=G<H\O6..(I-HRDQ4T=!L("29%Q+0# (]8XVL)K(U@]"TV4YR2D6!
MMA3# #*-+CZMVEUS\>8"Y1A6E-70923I)?DGM_*S_D'E<0XOND7MP;]7MV8"
MO^8RL?"?FELSU>(V4_.+_$+'+)GS]W9>89H:_,!HE/?LD!TMXOTW,[:Y][P,
M5AG34 LR3[:IB%745D7M%F2+ T^P$"QYE;!V#(7@E[SRB=WR<![*27,LEW,,
MA[._3 7S.W=,TNMULX';<IG\\K=[A4F8JB6(5ITI/0H+U@#2&]D65[V #&3"
M:=CN,,DIH$"M.F7X U$H[+NBQ,]W(7Z%\PM59M;\5L?,/LK !31*SQTZNK7
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M9%X%+T1Y^\6K3%C!FV8)?C'ZWYZP>>HEC]=>6W+3O$+ FT6&UL[ JVN0=#+
MI"<;8:2MQ+#@[I)0+'3;%8$;0!]2ZXLEI:9; \@YB&(K]FR=AZ_+U#8A+.&/
M\WZR9]G3BN0M*X=%"=<$;'9KCYO@2JYT5P1>K8K^/7SVXAF/;74BVP\@QKB1
MW;P#'L;)7BV+J\9HX;#3LD"]_P#LG^?V!U10Q1SIV\IM@U%;BO<E/W-!5.:%
ME]KYB6TMNK>5 UPE.@020X"'% ?W95=-#\IL^XK 8I&R!N$2HT3=I#W/SIZ)
M?.HJ%<K3L+3-ADX_4_8];@!1=/R0V$$@U#U!:M85Z :E?9OD[QS:%350,-9O
M)6W*7O-1YN^3_P#3[,_?9X_0SYNXS%<R>@(BC>-Z-:^-/=0N3&MO9U-)"[#?
M>I[NC7JS/3OZ$1U^3/9$EBV,85#WCMPJ$-7W%CC3X1*1*TR=$S/@?/GSX'SY
M\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?/GS
MX'SY\^!\^?/@?/GSX'SY\^!\^?5__H!TK:W- #GXO6_BF$7[$OG- N*SW>F+
M<O59IJKXU*7)8DBP":53C2F,&.K8XH*>F^%BS&.71^3;_<([]67NC=K"P#Y]
M',18S[8'-2C9E ,%(7RZ.Z,GL"4Z:3; AT2\>,>H9LD.XR6%PMUD'*/@Z7+8
MA8&/-8RDW5'T+^UACR9.9B-AW 703=U=Q5S%TD_"5D"Z793B98C.&3,"NM4&
MF6,7JFSH:]@=FD3&(K3NSRQA^$ITJ9_:_I_O[<L_Y_@)>_/JJOS8[5L?JH<4
MA7L\TVM7A 4-3:T<JKM(6]35N5$*E/C<K"SC-)M^T&6=8"J7C 8<:*SK*&M@
ML3><G5@2D:M\'1L^<3^B9@'V=V'5MM"Z]4.5>?*C(.B1:\>6P8/K UU$(ITE
MT6-- R&6,,P*7I_0U8+*?XG#I,F:R:"H;=)(E"HF#I"UWY]3ESY^H1HLLO1O
MINM"RJXL'35[5A0%&T=7[O:]K2:LH991R5@G+'AK<]FT8-%9,#$75[4G:(BH
M!!-$0<I"H!0V3%8%]O#OU ILQ8:1 'IMEZ:':N/HW9QGI<XKREJMT2KV(L4T
MHLQTC'O1["OQ&A?4G=BUS2 O3LU:1H2)HA2]IW'*(%E_SZO;_P"Z<<OZ0[-/
M)^VV$.K-K5)3.=>%Z9L&-9IQYOD!J:J<@K:-@&W&R^M^7,]QD?AKT:B <?"G
MR&N OX1=GOF,8_H_6B\Q.'K3N;V2&2<6!6KBI:WH*U3]XJ__ $W7""U='3+0
MA#9# 'G":S-6"NP2C $A@A08F6AH.O-I<\M6G>%F'SZ"5&=:[NC.AHP>L/\
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M_P!.ZH?D7&RKZM-?_31 -VIL0I-)78 2=783OPKLO QA6.%=^]#*HN23"!-
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M[;?6V)B4VM?,*#G'M1JBK&JTDT\'W+)D0KCX46-%S]PD1YO<L]#".I:86+J
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MF"ZT6-H&T2M-6$/;R;';@5*962;8(,R.0 5=,[?O=Q@R6<B;8(_S5LW:A_\
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M3JN?%/3(ZNJBM:I:-,%/>U0X P9Z]@5@(+U-8>Z)N:DV8=<(NF1)A,,G7KV
MC<&SE/\ 0:J+KUZCFVG*&XH0ZR S)I\-K&/_ $2!DMM9 K+*)HO/5*P>T#GP
MJX)>]IFP8PT@#MK4%%>;O5GS&!H=O_:/$QR1;E[U3S#;"J_P/SP-_H;02K>\
MFL!H2SJF$Y0H!4R4]0[98)H"&H3#JT<,AC4Y=/,2H:A257"44WYP(TS:?[\&
M6ATT3Y+*TJ\5Y;"<@I;G8NEM>J-TQ0.UW4Y;<-C*@0?:<]VM(%$@QXL TZUR
ML,:L!.DM 0N2BS8!O$8&VNQ.4P?8%9+=<'75@2-2I:E?6S D"AB\S+["2K\K
ML(:%&QT1N'%%>PJ\/:I$C2<43L3V%(F:A177LUS1$7WZ(M9?DXC5#7=3(B7<
M;/CLJ#G?J[G8'-8*SIID6S:YUKT#6/03I,9JS)I.RO2$$05K&$GCE.*!@+N]
M3,3]'L6+-TPY>FT!W9\4I-:G#,7*-:U9?+L.T3")K0640TAX&^?NBZ3#D=6%
M(7EMU:,_/]@R,0,)#Q_F02*0HFO;OPK$ ?K;5[6C+3&ITC;SLWL?;>K@G57*
M R4([2]5RRZ1F]!0C<6P05R2*C+5SY6^H>2+L@]]VS0,N;+'$@FJ:'(:, PI
M<_'-70E-^5JSZDNZOM%YUFT4WT-_HUNGI =ZK-D=[-=8*K7:L509R[0PY PN
M6S%&L1U<P(P!03V7&#B#(%10PS'MP2$U>KI+4*^48'@M415< FK SS;MW^#E
MY8$Q @6!YNWY[-V[R(-@QH_FW=GGMV>:_P"O9GEG[[[[3];GZQ#V/GBPB5 4
MO?!.Z8_)_7MV' PN)2^TQSA*YO;+)H<H2>L6RSH"DX$8U_UXU+ZV"KZ=8&QI
M@)9XWH'21>$2.2LRY:;V2P>9.<WUR)_[MO=Z(J)O:C/^+#A?[=D9:_7C)PG_
M (0_3&@1/\\G-E2_\6#'T0X_]W^U&TZM.&&&(;W^?/GP/GSY\#Y\^? ^?/GP
M/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#ZI'GK\
MR82K;5L6[=[HWLNXCWW>?8]3UDOV4?F4X/(O(O0NUPX,Z,2"#\-5B)H7<5E1
MAPXA)5!K1OT-6O448(\,E"MN^JG8/TI8E^I>F.D\^><2'.M$63;M'J;#!MB)
MA:-HW!4]S:>>,H&VMYR+$ HJ"VW1@54PSC/L@X9'C1/K8<28 6?&S\#<6/YT
MT:+JOEJL$AFN.LY?&U?[:LH:T4&PM@FTUROB*F!3&15+G)PHJ":1#:'55;<?
MB'UF=JR-+*^?%8BS(>!-T8IN_*CD;VM[,JB %>PZ9;7)P#C5RAP'POM(3*G!
M/%NV/M+8&2F)(IML=B=;QL1@:WDA*GD3Q MA(EZO[FK//=IRPOTRN.K;#TT$
MV<H*<CHF3>7)-5Q%I<Z/VSJIF*/7P>\IB=9&NT"M'A&33DEE^>;)#.R;NJGP
MK[@,B$UJ<?C%AFN3B"O^A72EM](<')*-6-7**K:[S^BU3=-))^SC!>4'>^)+
M+&5*;E5R[0J:SV,06"5&L+0L[I(I/]=M!8>".ZU+R%F7^"4;C^9M"M3YMM(8
MX7I7=C_^H.S.FQ[G7%F[UPP'M*V:14^?6[? QVB"(_<M[JZ3 \6(L%8)(3J)
MY39^_1*\D^:-?B>_DYQ__P!>.%88!;!U++QS6B<OGMFNQ#OAW>IUY;%BWJ#?
M,&#++(ME;TJX;2;+#//<J5)W'&*3'WSQ^V-KWQI$8\?UZ>-/'4/KQ@H2C4>(
MW>WT=J:I&WK5BSLRST#GGUSQ<SH$,H\NM>_(]*Q4,)>@+&C$%Y;&GA,M\=E3
M;NTQ),K*<[J<>C[6)IE&T1 ,(Z)7O.CK;#H_6MK2#ZZ1Z7K;1:RBN)J4-07*
M*Z_\22RB\5>S!%N3H^CTMO'*45M+"Y,#,),V9S:AW3SL;YIMTHY6&FLBH.6#
MC09/8#;&G30LJ 5 N^MI5X"_B+?0#&*$M81B##1N0UE%0"D:+AGH\U^QR5/S
M-H)<?M-J%&R\+ LG_OJIND2;I8=F2&$N<M&EZ9;:&2II+7K%0!ND%KKYT,12
M2V''BA$LGC#):HT7;IV8;H7\6_HYV'<E1<UJQ^B*>M/IZ[T7JBX]NV!>!JL*
MU@U%SK=HBI))$R5SH Y+'.QAL>TU+65("N,0PA#CS'9E;UK1GO&:MD5G^J]A
M7K#>&JC>/3UB(U><*U5V2:AQ;3_IN)B:+B&WOK3^=J\J@/6C!J;77<W40=7-
MS-_S,8$DQY>LD%AEY>0P.6"2PK\WZ.4JZYL0:S<;MJ4ARC61NF:DLNN[$Q%V
M3JJMGTK.+.BMI4F$,@'($=F)2@9WZ3RU*WBV!:$'5W>%*1\I6S/?_137<2\H
MG0"[85Y*#G-7ZJ7;'&K%FSH"O=^FE=TW97A2X!TB!,G,YX;H(2A1<Q *A)C<
M SQ76[,X"UX#\<CY"Z,PZAIV'9>[178LYK-D%UI5:[?F9]UHS$/BCITQ-<\W
M>KZ:=E&P T<K#Q9DELKL"8";-\7=_3+@$(,S?3;R?VAU: O,VD,E8B;K>^K_
M -$._*;5C#1V38L- I>L>.'!NA;!8&N2="$UU:"KBR%C@@VE!#ZF2R36[6P/
M<H;GG[O'A8@(_+VBU*&"T5U9'1E8D$IKO([6;"B6OD,8*P6.D&2(Z7)4RD0G
M "GDJJVQU'"G+0O.&EK)+#,&#%E$Z"WBH/NC:56<&4/1T5OBTYD_5MDV\X5'
MR]C.6G8E@56*^I*9;Y1#-JY4CK($(MAZ#5X/9XRZDY!<D?-R81(KC)DZ9.<R
M"A']AC(&F%7HYAYET0Z6NZBNL;LYG*#;IU%'=VU<P5"]7I"7K93M]8BQ]29V
MS6=>,)Y=* 6ZUL%B3JC@V^$.,RM$3/\ 0M^L%T)1DU$LGC-> ADD%P,^6,56
M.GQ[=+6Z_P#T$MR51U;XB1,JF5C8RV*EOH=EV.BMC*%)N:X#_P!B LTK,)C1
MN\)B5)Q3OH6S%<Y5MK/49'+V-=%^='XM)S4==NDKQL=&2ZS6"+MMAA RN+45
M%87MICP2J"5_5M; "7.TC\,L6:4:]SH;@NF^CV]C=V5EN!#-6!4^BA[=\J.R
M":'"N6F(A9A,0:\L6-$C2_98X;)<G:.+/KNQ;=Q@QT:!,!ICC2^^-]C'Z@7Y
M=7,?%-I75S]'3M]GJA^H( C)[ER8R]H'N-SU^DGMF[7%6VC*7)VAV*9#C:<Q
M^O&/G*])82?[\#3$EZZB=]V?#>.U0;]3=$U>@\2ZJU6G>V7?JXB)4&:U[.IB
MI[B%JHO_ "N>H\\.HC8]K!UC>X&(V!\Z<WB(JI7QLD3W"1X;6?\ \Y>9K$&W
MJ%*!VD.$Z$KKF:JG8,KLF848+2>2F-D9Z;$IL77#VXKF(R>TDHQ?+5[(\*CL
M(<3W"/Y&\SS\UG_-^B3CD=LP TW-6=JF[[?.A\;.K:PO0+@';+0J:O:7L18$
M[YH8N(\KIO3*K0MA12)""6G4QK8ME'2X)>!"D1HTU)^IM@7V44:TJGF, QW4
M:L;L9-: ,V^"RC6XI9XWDU.+<'%4L)BHV$X,$YU-WS4@1+5V&I423JGFC\IC
M*@@BSL,SX=\F_HA;]<<P\^L[ !LSI.W3W#?XO[I05]O$& 7'"RN_^C[OY\P9
MMQJ?7ATL+=!Y]=UEWUO+&3@YP"PU@3 "K.\),,&0N91.+4"L+6+VD@6/>ZQK
M:V(:[V!6\6SYTZM+'L,:E"$'.P7(08@$CTMI-@%\#L;-@QF$B'$X(B,;0(+G
M<Y<^3KAA_->BV#E&L^)\'*[@/.=<UA*IB<C +!T1/+/J^<.'"9:G9Q24OS2!
M?7G!&X:HIQ?W+#0*]F$<PQP=E.W^Y1B:/UL-*Z>T:B5&UV&M]%N7JFEVM:;.
MAB@"IMC)R\LJCI(BIUK1J)--32<M-<?%+&O5K=3H,A,89)=?F;-$P;"],S,Z
M&NEO3_SKO?HEP5V.NW93XZM2Z6!.07'V XIQI=IP\\35]5>F^O=/^I;0^Z%E
M &L##66> @YHURB"I*PB[(.X-A7[RC5O1"'6J"U[FM:BTU95;V[5+ CG<13*
MC/U4Y[L4TT.DEX1X63QAPI<\9*'LH@X/FPYV_/?%]G:XDV-HZN/S,YJJ]:1%
M9>V67+@U[S]TSS4$E''J03)RJYZULA8M6X-QB7[ T_[!GF-RB(D 3G]O3D%A
M^28>N-OQVX9ZM U_^FKA.M->06#GO4-J7;VL*X CV[+N_0Q6$9M.?S="O<*[
M2*R@U,'$^JLS9GDG,DK>_#"\$KNUGQ@ H*RW1HN^^ZKZZ'I1\X*7Z&"UP:AW
MYV'%I>S8EA,95;\G*6Z@+WLK6)#DA:(][Q.[?+K;TQN8-(_*9$D@!H'7!E06
M@E/#AAA#\E.8)8X>O06.^5Y+UBN5HC(A+EME1:;8)_C3VOX]%OCT(P@[/3#F
M'"U:@+;#.C2!PML"*B_@=#RR (*1'[,[HY3;^JI7'D57;9:2/HCL-4Z!=& &
MV%DURCJZS2M[HVG!')BPYG5*8?6NQE?;O#&].E>,+N@\/,;=T7?E!EUX<B_H
MW8%5HZ>&Z74C;.BOUK_KH15;SV6K*?K#E#.,^C[Z;-ZT4KB2E#L1BB+J=;GI
ME>3=5AD"V&: -#3E *.*"Y_LX>(>[WKK@QA%9N6;0IQ88*92[P0[%)KUR>U\
M8".<[/3I0335:E#T>+UVJ-%R0C)O"UY(L]0F@B<J6.>9'@K/_+#Y</RPYY'!
M ,-3=^A$)NAK5M*#O;*5;I$/:]T+]Z/T^T;4C7 W;!DOUJ(LK^5*,T%EAP0S
M2F3",N,A&U8=N]A>>ZP_F%RV;DF=(N'8B,J'Z$H_G<G7Z'8)E=4/^(<P'9;/
MS.R"\,/)+"NV-0A^7D4KES6V$1/C2=$7_?ZS^N/AK\P$3)M3JWKKLFO)5_VY
M0Z;R"UTM7M<*E+34L#*;25BT6CW<;MNQ9#>E.,MOA;2SO_UZIK'OD1#CZ:_9
M]I(4P&"LK<'Q$'^GS))@H%A$.>]6GG>W;LZ.YTJ&T-UOZ-UCLEC<Z+]\DLRK
MW4<>KH(Q'3K,)<WV2)7"PE]:BX3;@"(LRD%@&,L!H3$C\>I<O*CIKU9-UVNQ
M<^WF1Z$0FRQGB&2.>O1"HW^DO\(OK"+Z^#WJ4-&LMIUPUP<&%1L#<K$[OV2"
M.V?MG:M'?FGSX!@U!$53=MJ>^E]_5.A>)@WO#&>?5NS[$WVI?Z"Z8D0Q$>?4
M&=W_ -28%Z/\"(:6=RTOY 3D';#W[9< YG[4V\O5J,M%PXD7A0*7PW3'Z&$X
MH;JF&>)A:!M-PA*1 'NT;Z,":9]N L9?I\.M0).Q+8A.K9'GV*KG,=(>3)C#
M]-V>':#(-8^=AX*B%'OO'\^SMO>W3$F-FI_.+ZQ/2K%T59[742#_ ->$F5N"
M*31G+LB&?5?96QDT"3X&#.D: R58_(CE),;ZH;5@E<8G"HR'*9T2KZ;"PVJ[
M,U<85CE3M%-3E&E MY4F5"UW[J FX8XP'7F'./I+SP?IOS81V?'8/Y>5"(IF
MZ E*C2D^RVGEOM*@42-8[T4\3O=W8EMGNC&Z0P3!H6:3@9Q[L)12 1@&1-Q5
M77M&$ ;KVR(^B9AH(E^SO^ A=7M BD$6SS7.R=R;8"7IJ#H&>RUW<BYUO=S'
M1R?$'VBW4C7\ .7!G58@4G$E\%8%?F!<L9N!O,S#;)V1I AOTHWKSNQIW0%3
MJ]00*UZ?<^8[EL(5<6;K7==F(O)*MV+5SAD<+5M7Y HOV.@LG_#I&J:$ 2EJ
MR-$!<U?[_,\+SVA-CFZB5[G7G6G^>PN?^P$5?6BRB2B>S+;[*9B0P/HBLK45
MD;,O\J6;<3N15F/$I.>4XD9+SR$O;G+D[=F4>N2_SAH'C)M\;JD+VG/D0:87
M>>U<,\N>AC )5/J+RVV$LIRW"TA!<C^V(8'4]_0;.3#;).@[8\<J8GYQM>[Z
M.3?U/?M35@K=W$:T<7$!U ,YA40//DIG=(]7\AUZ43WNPFB];O94>JK19QDJ
M859M*W8S&N53/'AXPZL01;.)"'&V:/-6Z6&Z[<XO=FSCQJK7R]+"H[8QT8UP
MFF$X5A);&!;T% 4Q=>\0V0DV%G^2<M2FZRES8&V[-XIA)+^T;C)%YA@5Q?G7
M0-TV@RW0?GV2OVBP.G.5APF]1;M(Z4IN7+<.U1=6FU@83#F0.O;B(NFPA3%#
M-BC@TS&+1]_^'%)#!\Z/X51?G)3G-2_OV4%-:8CV$Y6.<LHY>RF<BWAM"O*?
MW^VP\YJAQM0R<7(:K%L(O+*DHLJ).E ?[0J-_8STZY'L'T']'XU*"%:B@E?]
M:V=U2VW&Y)CW1_5!(^Y.]$%4NE4NUV3 @[<M4ET"6<*Z,*[(J,-;&TQ/>13+
MN<ITG>;4H0V>%"2[Y\[VL_I:R82&D<H,R+BDUQ1#QTE"O1R)U19%1&+UD-O@
M],6:R)5J0(O9%3#I\YK.36@M5.$P!.%:!,*4R2)0""$9.>/R[L 5CBDVL5RJ
M.DT=9J4Q5Z?4-_-]J.X;J*K9LN!$ZE5+0=:DKP_7$_=7NS.N9U:;=#TGN2X9
M)1FP?_C1?\(K98%Y.1!]@T':Y]OM*P+*YU5+O3TQR?'# P5,C>@2*.3?][AJ
MABA@TI*PVUXLQ5G4.@!A:T/C;8 T;KC9Z]>J!(;]<M16C:DNW.@ID6'9_P"=
M_9W?&P#[8L?/:#T<ASZBA;JQR*>I^&J9(?<;4U;M#5[#C:EWP3GCL!E_\CS+
M7&'J/](.HD:KKILY7KT=4]_!OS%1.N%.OB-X1+5HA4'.%^YK.C<9'_\ 0:T8
M*VX/5MDKTH2@D""7(\CPUB#%DZ\/6[:%E??',#ITGII7)>3DVQ@=9-+BS&T1
MEN)ZH<B5*'TN<E@28>Q$E%LG+",$AGF/,LM%E/9&,YS!DS06@[0V4,KAM/\
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ML-KVM\7G620<&R6[G6W3/'>G-E<9!)D7?GJZH?U/RLKQ"'3J9&0C[+^B^_\
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M4Q0&Z+9=EK6BS")!A#2&* Y[-S($*ABTXCODZKNO]-+5K&Y.@*^4>40MAI=
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M'+VGZ:@.8RKTT#)7#PR6H1TJ%83AJ"%5+>#/1\S&<C(ILE18.Z-4J2_1GK1
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M5^@*^@!2CG*N'8P\>=%$".H0[-+28E!)RZYAK!]AY:1H:-,0(X#5L_V;$/\
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M^LD>[KD5I!+JMP<$R/31M!5#G_-7][]EI),U7)I7,)X-T6]LLR8AJ,!?(29
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M5B7(C7.P4C-NK&<6R.RZTL#2A-:Q%L:NI!C9(([41\T,:IE*FD=G^H_DE/\
M\G:"-1]45HZV38:&E"U=OM[_ (+Y8907LG:]3!A6:G'1D33X*V2]@81&6E*)
M&"08P(>,CY1=.O*3JW[\?-OU,%QVOUC9$7\E'@RQ<WPK$M_LQ(=4^#79BT?^
M "4:S/SX[0;/0]@"O]__ +:SH2[D.Q,+AF"73P-C& L3SP&C^0/266Y9'Z46
MA$_.:N>JM=4+[#=S_P!"1>4M2HL9S-E=1K0]ZX8>29COCBP,8 GJ0]AY:F-H
MP(7;A)+=KGB%::T094G:;TA/]AY$YT:S;\R'ZS'$3=GW!1]^/<_,NRZ=C!;G
M-_\ P'RE'+?KC&=.B+,1/^KT3_!A0-4021]7H_IN 3]WS?9.H;"_,WB*TH!X
M:YTEA*B->^_MC9X"L2UTN0W0^I'2'8M^+[;-27I=F-"?9#R/@-!9)/;R*C",
M0X\P*%&;-6/OD,V[])NH.>UG_?=4\X@J^CFA?3J35DO9.' REPWW6JJJ6)SD
MKC5()9ELP4>)T:N3[ 30JD4L!C;(E@5ONV:IVP(UA\=&35GW3VI8_11ZN /+
MX=GKNF^AZ\YCO\N R#B\PIXG4:"\6I<8%P:[F%D(2*BG[#'[%A"]IML8[ 2Q
MDD@.<()@A%@1PG/8?#_+=JM3NYOE513A^RZU5ZDL/9@TO(<4[I"(:E,:#&:E
MP&SC%PZQ5Z>FRB]?/1$5(>T6?N]DJ;('V8Z\L?="<DT0"V5?*Q660^3IJS3M
MR5P??;2M>RVD!9+)7C-4YAFVM=B.[0RG-TFO'!C5M(]@*E1$$>2SR'P(LG1%
MWZ**MWZ>]JV3Q:XOY71057/%X?C_ -C]\T@RU6-L$P2J9@YXFU\"S''/6Y@]
MA,\\X$N%99%B; @"]"BV B@\O"<Q&J+)(WZ<WFWHW1M1$K4;$]PL8_7:TR'3
MB4%G+0,SB5&0YNDD/!E61J(:\,H\R)A/F_[;;$F$<]TJ+&&QI.@?'"/SW^8_
M#UE#"@=MI#"0//87=&9=(.Q;93LVT5T=:65V70N.4E,>U^2XJ3O:^7KW)4&?
M<66!+!YC,7Q(GWSS'Z5B?4==H+E;-@**U'#.%Y-"\YVJ:U3"4C<W,RH@*E6K
MY65'F39,*#M&H2.K+VO2)C0(VV.(TR)&G=.VR96[G1L_L>]+RMCB"ZS\>KU>
MH)]_?JXO)%6+3?9JK<>0OF?D[KVN(T&W90QAAP)\PZ72YC:9Q5X:Y/JN?.1<
M!!(L:W?[N-L2JOU#OI9H:[;4QK*LYM&<;?G)QI?V]-B%;0<[M?[ Z YM\L0<
MK;']Q<-\* FJ)$?'Q./3;BYN)X-[.(F=V!3"4:VA;=EP)R1E<$>]_:BT8V7#
MMJ5?$ C@YV)K6QMS$D\@@FK,%UWK;L:Y%N+(I%)XAL-CU.-+;,=_^8R9E2.O
M3+U_:E<+\O5\C/57K%=$M-8V*@'*I8JU,V7:[77D.M&/20CF4-*1VMX-*]:*
MDR.5G:/]'7 I4@1].W#5$T:-<>-CI@;'[=[S&&ZNJ-_Y_K>M'V_[^4ZDIR\[
M"BZPU,2Q,OG^V+T?MA*LDB^+2=YS.M[:CDI"+'DV0H#+4*/ "=#VJ_\ HC V
M5IIF[GZVH2W/TW?'ELIRTT+GRK>#]U>5."&,PI3 6%T7I((V37KLS:?FRA-3
MZ7/?)<[((3U Z3P4 OG^GEB=X8AO)!:%L_/WDGP#4JZ*JZ<HP*.K/13%;RJ\
MLRVJU/BZET9CMW_6YUJK][6F=Z2I,L5"(D%Q\+LPLF6QD%R,:43G3I<CWVKB
M/F%SU-7ANLO[<]QO37TP68E]SL!.<X=\:D #5?EFJKRH-8)R1V/.NEH2G;]B
M6= 1) '7,@2(NS45*^3:UK,_0GL>N[@U\FZEOEQ@OK+J;DFFLK/TPK2A4]@@
M]1U!T/9F^5,0<&PBXC+2KO9SV5V9K.RP98EJ66U*,9S%7_?Y>#95\P=;W(Z=
M'71S[T\'0*A>%;&R&RJ*Z')SM$)/5%5]801!A7X+MR:WLM:N:RT[61<D&$\9
M!5G.K##".66>$6W8[BGP88T_DCSDU777#!*7] [GNN>4KJYR@TLNM%J*1B>1
MO&Y$ZUGQH,6*IV"%9F,<Z^A&2)8H=GF&=[Z4:9Y9FG$LY,_7*EQ(XHY;D>->
M'E/K\30[6'S[:K'"&3#PD=+>^5M=?Z>?C,08,+1!X?56>BK$#0$$!HT )(T+
M</26'$=6R5COUOT_T-<:;?G-/,5%0:J&/?0:O?[]G8-U1VDLE  % CZXSGK
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MXZ8OZMH!SN'-CV6NTB-F _S* >LG-O:?7@G&]URV?_D)?PQME^3Y'FREE?\
MTQZ&9J0HNX?'OE)4)]:]+P*#7$!@5&;:4X[%YV:\IL]BNW=_W:/EVBQP(J?
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MSI.3JB8;96S+W)L^<.?=ELXWUG2%3Y7;CKU:_+;]KY5_[&]\T#/])'V9./\
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MS# V'I8@NZ@\M<TC$M3K@?0%-PT!#?0UJ)29'K=1U+*I9JZ0]+ K#7PN(GR
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M83-4",[L!2.Y>@B3 =U%H.&\[(#AEZ&-H98+O>J\HZ\:(\N_5S#3CH._?*Q
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MT_GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
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M+GE\&T^U?OLUK1JWE(TMJ%O&L*'Q@["$;$7G7E;UV]"(@E@UH=P=PPN33WZ
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M?1@?1GY()3=6C9AIRW:_-F7]W?KQS^E1:UI^5%A[3B\)B4G5="-BJP#LO=L
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MFM*;PFS*2'80)+5Y(&EQN[;KU9YQY.KWS9ISRU:\_/\ Z\<<O/?/N?J$R=6
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MOY7GFG;FMF4K'K+@Z596"J"/H";&4@H#VYE'+6N7B3"X#&6-_P!CL'82H/\
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M+V<K(5OU:=D7+3@&S?GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
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M%5&-_M,NU)-]:+19V HIDN=T8YQMOD.[ ;+MCK(QM@PWC: 864T9,Q2L# 8
M(>9B=']L.GOY]S=,H/K*B +XGC2W7+@OO=0?D9N$0K!NRX3+M8]YG+6NL9VF
MA(UDE&:<_I#*;IQ(1"]J!:CD"-ZE&RWL@0&*U3YFC;L=9+VPQ?FU*#4$[='O
M-A)'9PQ;Z]% &R_C/32-7D/I($R="TG53/=3*2MR<SUO0YP8G+1E888Y-K7!
MLMC1/\1O8M$7$+F+JZ!J?GH2GF+78IX7783\$JY#% E%T?FETL%BA%B8E45D
MVOEYI;3I7>) '3$C6,"R=0X,&*F"6V(,'RY6GZ[5O>HJ23+'?K0? :JMU'6A
M>XK&SW[=T\RK5B#C%91)UGJXG3/9\P>G &9UZI44/(_RI0R="B8[Y<;=HPH1
MD<]W-<]F\]32*GV3.YP0OULU-=%2+1L'H]4NZO\ FZ1^>%GAG]N<C)9S$W&!
MK/;U1_?"5H2M4E@^C@C/M 89#E5NP'3_ ._J+S._--_]W.2A4?1CR2OK\6+'
MH>G#-9;[H:$<[>@ ET%ME5@T 4\U,2!!4NMO2822A]A@(RLQ,FPE,!;93MY+
M\E!T@Q9.F9&CS(V?]R/*T:I.C9_3GA_<T[]>.W5G_1LQPV8?U89XY?TYXXYX
M_P _QECYEY[YYYS Q+ZF'G,32=#K2^+U8[R9U@)P@P<=ISVZ]&&Z<3([XT*)
MJSW;=6G'9(WZ\,MNS7K\]]SSQ\]YU;QKCO!!=;K0:B8NLM_.6JVOS_;&=J,$
MKYN]ZE5N=J^\PG3L>J=JO:Z%=)*%$L==Y[*V;7U%/RN17 I!LW)*]'TEY8&9
MMKI#FR\+6_%+HFEY;->?35CL IT:J]''D>TZ(N8BKA;?U.ZE6N*H[6:RW(7W
M+BT(]#*N%EOQA^>1$8%I8_-YN7C%^"YU>N&N&JT;)I< S:"-F5""KMEL96P@
ME-,A:"6OBVYU_.WSI,'2*FX,6",U9:-8N=.W0_\ 4[?".N'EOBX[\5IT?1$U
MDO.PJ;C MK*\VU.%WJP!L26,DY;E3K:[4$Z.>QG^XZO]NJK*2N*.>8[3JA9Q
M L7+#.3L]V2=M#-T4KT!E97:O1?-"OV0 )CZ=_);?S%J]-WZMG7F:DW1:FRX
M [\I.):$VVR83Z[8M@JS%6Z-33J&@&&3O+"L2,K23PVA757=HOO6M7QK)*]9
M!ZF6NFOV"=]F'ME6X@UN6#PK@HO=Q(+L*4H'PTLY4>P#*=R]3J4B9_QHH-%F
M8^D=/"Y%1<X+PBMO5T$ME*HTHR:8EIV(D/\ 8Z:J902FS>:2ZO+H8%[-ZB.F
M#L#QM2^6LU&A[XTTA&G2<S\?.#&E:M$S./H%4_0#D)WM;&CE:XX9>VO9D"%M
M1-2C8,<Y"R*D#8H5+)ZIBG'T"A!4DMGX8PX2WQ I'>'(8PY^[_&V>^5(_G]7
M-\2.N^+;*MM)[@RL)/X&ZN0NN77I.38Y:K1O5#K<G)AX^.J24Z%B2P,7FXDE
M/Q-'\J;5"J\I5X%*T <,RX5BT0IDVHEWI"ZO_2ZP416L:/K9OR]YW3:7;UR(
M4CXG;F26C]!#.U<0BT//#+<]+LE^09^,8;GB0@2&8%OQ]PV3=&606V?:RLRX
MZUIW%!RLEHCK'EH6:I4XA^R()6=_R"RGK9,U*BOI_P!5 G?XD@OF/F8ZIQ'_
M  Q4?W3[_F3X_P#7K_KYONJUGMNK.%.>*QII#[H;;XE\1G[@)7QY=?9=H6A"
M[-C*]2Y::M<U*O6[=KP:C!N2PGA/MV;M-"@M0!G48B;*FFYD++.;EK3I1^ZT
M3LWM%[*<71,_82C[.7BH?=9DSD1>XB7D?W4B'!HG KA2D3U7WSY&RP]\ )_V
MS"M788*LF_)6VQ)&0=$-=V*E6RF K#KIAA-26S:)$D$P#\9.$,EHB3I0V1LT
M8R]$:1YCJG0I4;+S;HU^_P!>G+^//<?Z<O<T^Y,Q]7?I0R<]OK*TD^^H5N5I
M^0A9FJ,**LZYE7<?[H#='=(L2K'85\ PC<+%M+0IA*F@>*;;B:&EZ_.#Q18(
M0A2164"8DFR&?/\ 1D.?N%VO!3IR-V?OJRL'(79/1N5/V.U$>=EU52^:I5=5
MFSQJ&%PQ%YYN[05<'P,4GDG%3W(#1JU^$-LGX+6G;N7D>MK5*TF_WTAIUE =
MR?&80+%-EBHBW*L&'OGHL1E9I</6J+LMOB1MVQ<BFCD&08RQQTP=>[=LUZ\Y
M7?<^/0*K965U_LO5L;G6[[)G]M4I0-4\_P L14K22J%H8IO-CS6A8JS7#-&:
MZH1EU!:S0R2YD6EG&DQD31_D Q1PIA%@;/!1 W:.[O?GFN#2KU"GUDD&K0Y[
MOA^B.O3IZL+:JA=X6\TH5_QC18O_ .FRO_'6^HH[)5@H(S_N!=?QDS>X'M$M
MDFP)0=%GVEJ:Z!J/H> YDZA8ICF 2'=HK8ZQXJ#F&4IS:FF2*TW#5)H9%X0N
M6%"7V$257RYM$),B_$,CY@S<3\EZ,]/E<WYA-?0=ND;A)7FPNDF%RW#&_GO$
MWDVLA)A7/:O.IYFAWAU/OAZ)&>K(I;&9&O( TKMF;#P:>L.8_=LC;I._'VM;
MF_GR[* K>CEBV$G]%0?/4Q9_0P@83.=;$ZC)VL'Z-(=CN!&BC+.)3GN0YKZ^
MTT3)EGJWE9^0Z=*.9;>VVMKSFEQQC<%Q "%^=7']S&QP.*#KJVEP/0"'_K]O
MMGL^A#6>P;A*511B77\ GL8E2N56U;<0):[XMUWH7@,:6K#)+1"'"1P>5KLC
M^YBB]%=NLTQ%8[9J]U9[T(4Q_P#:W6=H-D8%L* )]R\]]^7Q9O2$PF6$?UBI
M>ZJ@K"$<[7DALLQ88:3R*Q?<14F%GE]U;5OWI82W7Z2I'>Z:[OXIQWT9#[3?
MKM=+6&59%[ B:$PE1)6A9S2=E5Q_@XW2*8-@'#G"/"0I'.DV6NO6S40FP(&H
M.F&3)T0XTB7)V8Z8T71MDR-V?\_T:M&C7EMV[,OX\]]_IUZ\<LLOX\]]_CSW
M^//?L80GM2M!)4[&03D5F2'E>$M:FPP<9&$,VO'86DB)*1<)6F/*PT384C3O
MUX2-&G=CCGYCMU89^98^4%\\,_Z46C?:,R6XA]'UI3W4#/NZ^/J)65,7-O)X
M&E4:R:L%\>&Y$#//+"5;S*/YOM^6%U;1V#+MDW%KWPI&O.;N\CE$K/\ 1:?S
M>3L29/[NTW[4GYA_D42JU4CV+;XN P=;PVZT)W6?C/7PX]$"V;8\8<,3Q=P
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MF"9M27?774SM1T#ID]>HJ7(4+',:0+#H!!#(F6I =V(V5]OJ_2ZUR#P0!8+
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M>@6*-@4;2\:UGZ*H:T72\07'0R@-"P5A1)2[C%UAO!V36 -ZOKE(Z%J+"O\
MK^S*Y+?HTX+=7V+)MOK,T[5GS]/XSK9_$.$,K1[+IZ.M:KS'2<NPD0#&C-NM
M03VXM'VL9.&K*.@=X%\S-8Z$FZ&C>S-P 1DE)4ZQVN%((Q\RP-"&X$\YC=."
MQ\]Q? !K]#%M6!'"#G'D21TR)&SVRH^S3C[JZP!FQ?!-*[/TE5]E#C& $4C^
M;,8Y(,9A:"(R?H\W8:]OFF9"DZ)&KS;KU[/,-F/F>&&7\X^<O274G6FHFDW[
M9*!U_P"]1V/_ /:_2E5X^P TR\/)@_ME$5;:.-J79PA2/>K*A9$N8W 3:IKL
M0'!&&;(RED5^9LLG1_>V;(E"^Y?\F1KG0^Z\NH-KQ^>6WF$N/-VYYS&*IJ+6
M7-6OIK3?D86;QI[)AQ>H?3V5ZZ+Q'2[#,:)J7_UEA-EXB_8@=*OS[GRHT#U'
M3%N<^WI9+#UGZE'.AOUXF=5^VW8EFM58HG.*M9-V-/*D[<BLYR4D5ZL:%=.K
MN;5C *"P3$T&>EB=9B4!+1AT2]>M'\#:]<H-HJVHQH6;'3%A[7=+"&(+A_4#
M;@D(^*UF@!73')A"N$ AHQ("B&C3,@2O-L61KQVZLO/@S;Y\^? ^?/GP/GSY
M\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP
M/GS[G^6>/NEX72RTT2*9:(-O"OT3MR^G3N/=:*3*5WKB9CGV1-4*!U@-5C2+
M2R]QK@T@49$ITG6<.M58PK;+4@G]<W".1F!>18]95Y;ZD10[22UI_32V<3=/
M6VL1#-"MTD?*U3AL[&+-U;<=!$9.T:)XLC'_ +4X;/T:)L&1'E:=6W#78D/S
MGQW6H\4%&U_1-8R7E< PX\*-$7@I"Q+<= R<N1Y&S7A_=),SL[,(,'HF3=DB
M=.GSH6G?(\T:L/=4#^+>6;+Y1_)93J5)I-.T]<Y<EZY#S7[NX2)(RR.I)%2X
MP28VS++$L,TB0AG7+3I D#P]LUZ10/+7$!E0PV##V0JS1_Y\]1-O,77BH^\G
M#Y8DWV1^>?3U.<V2O*+1@)<'2N_G KU$(KE"7KYMBKD VWC4JTEN-H9++#8/
M<LIE..S8L@[*D^AU/_/J9_T:YTLNU%/E5RY\YV:W6P:-"O!"LJ%:=-$2>91)
M]E4E *O*_2B>Q7 D3A6*MJ'YPDFS*&-N3#4TB(U2E\<P8&QFB;HF?S-VS$OH
M>G!:F<?$[S]<;"[5V]!Z;0K*17"[3+YQX^I"W AJ)=_B6@R35&X6F&,-)&^N
M1P;^H/'/C,RD";AG&"U_KEEYU'*U5(?2J'%L53O2^*[I)- 3E&*W0=-H.6!R
M4H%IN$C/7FNQQW@0GLS:X6>,X-EECE'R\_OY^^;-!+-(\K5 9UK@-,IFF:T!
M-;R?\%08H%76@L#20:W-J*^Q]?G\^XZ]9,Z>+2O=\R5GY)F2]V[;EEE[0BG\
M'VLT\X<75$Q\8MZ#859=2<5._9;VU7%7#%HZ%G5-#LV%=ET:C2U<#(S-\$P;
M+:&660;H*Z]. )ZT*,I7D#%?:+@3(0^-;2E_FIW1QNRI 8?ML=J_1Q,YQ16@
MR',J@NHK6LNXI_,@_7OT3#<=?5QX!D4Y0@5.RQ(*$'5&C9P(.8[1&U!: K6L
MINK)M75K!C)Z?^OTFS![=K4V357AY8L"0P:%[Q;L#>,U*9\UYI7=Y$LO"RLD
MR%$E !(G#C13<#9MV1]S)[>"^@')%@IPKEIDI^MS5,_B?6[/4^JP:S4<(9#F
M?OBUK%[1SB^51:9$9IPDU PC&.4Q"#$4R^C24>)I\WL6J4-BY.M?G!T6@W 5
M;:62=].E<>[^W]U;OH^Q?-H&L>2[<_/VSU6H/0Z;I;Y\(37&KL8THNG_ %F#
M7,989M'ZG#)9@X:/)GP=(OSZF/\ *_D1\Y\FSVFP5KI6N7.31-65M9BS8YGD
M^14%AVDM[II-NM9<\YYFSW)Y=-YB86B^6M;W@ML9%(U#A%86PE"VZAT'5;C#
MLZQ+1ZK.W9ST[48EW=Q=TO3MBQN/FBDTPS8%HF^G5P]5[ @G6?HMDG62YDJ7
MVM<[!^O(15&&B&<8Z]VPP@PA&$1PZ6'5S5:X36VPWHZ/5TA#6#SFXLQ;=_CB
MEU55Q4LXPG2<C^,O[ \0(@S"$W=_3E_:C1]N?\>_T_Q]K%*Z)K>PKC>*159!
M<DTH51TO=Q0MB+RQ4"*%?A>U0U=S0+!YNRU$YDV33CENGQ,8^K_#B8C-^.W?
M_FYX1ZY%CF*^+/\ RAZIY.LJBZFK1YL&L>HZLI6O!(E-4P)4&TK3&.I5QLE4
M3'"R:VKY_86"= 9G4.CN# JKYCWPD,VP=N6X6/@"[?G5=CH@W\[5YR%-INS1
MGY\<"5SRVJYN53+AA$Z7H6[.D'2S9JWE7UEF4<,Q#/&=(8!M@RR,>0;&'R(W
M&?\ UF&L+O#J-^PL*]##CH[(L82WQ":'&591,L73V,.HE];?#(S8&"<WDAT9
M=<]PW6,WZ672M$"6Q9F;H4(WC"E38VK92O27%%W"N[6FXK?T](>'X/6M[W G
MW8D'.4O^GVSGMQ",(VIZ2?BY+;[U9N5$]=,!%"94ND-DHQFU0$O(@GJBX_Y_
MV.=3<.]%79V'9+%(0"[/S^Z]>_F ^2]?_9$ .**U/0Z3>L*]MVX'';AA7 0,
M.LJ;$8%C9"U['J--_M:Q3 .T3O-06ZW-TRD4I8%$5667GURL3HML8%BNU9 7
MHQB3A$3@>+&\.3,1*E00)=3DT/NARC1&:5_V&[80A0P8DQ.W>QL9%?<YB!^<
M=RXW'R'.8Z54H:?S=T;^O<VMV%EWHC=II6H+FL!B/<4S%\9)+$RN0<;KV B*
MJO0=,LBAXP(FB9# ?XT?S7'<]^??9!?F1BKVO^:'2IK@\_-*]N?^EV\A>=>E
M/>VNKG.=3>:7884Z'MDT8G3HAU7MRP]%L6C%KYS!C;!U5[!C8P=\P<-#J[^C
M[HY1YJBVYY?4:CJSCW'B2F&\;#T*8K4QXGR(_>*(,>,K7HQPQ9IPN3)'3&3S
M5X<E09&^+O(9Z-VS#*C_ *__ "Z;F4KW!G05":H$:+RIPQ7_  _+5;&UI6]5
ML:N[NOAPO DE;\'@-+2'J,#/H9 A9!3,6S,6,PA#ALA/,FPQIV4N_'72*8D=
M"TN@<NJ-C4!8?Z,-;VL)3'(2K0EH_.S!Q;6@F ]U17MF7Q4Z)A*(]4PWG2=%
M.3Y"GJ?K0T66"131KP5,CA>*QW57"RR-R/*/^E+"2JKV749K=:'D66P=M<>3
MSPB&?#* 6+,-'?2YQ:- 0@\3%ED2YN%D,@Q=TO;IU[,\7C4=D  V*'$+0(A\
M.,-18)X01 '(<<K"T3M$0T!+QXA8(6CZM^.DB()Q(I$;,PW0YL?3)T[=>/,T
ME\ ]/AA5=-S_ ,V[G2^&7\' '&92VM;94A-YJWL%'1;-BD-#DX%WV,P[\WB&
MZP$X)9"-/=M>$^)(A'R0E?RP,?996?$'5X%E0,6>BFV;T"-ZHXTM )VE_P!O
MH?J_5_*E8*E#1+@H"7 QLS_LF5LW+"?;]-$:R 5Z7K>P3#WJM0HR29NZ43A!
MT1)" DUL'E+R"KA5$).9&UPFC ,'2/B2VE\9BKFY'Y.K3CCYN*LC4<+G2TS9
M_5MED)\C=GE_[O///R /0QB;'Q/B"&^%/KR6O0BQ0VGL8-7,[60!&8HF:4U%
M!T8"[Z($.5JB'Y"Q/)ZE\SYM#%\HA+5G'\H\Y<X7O&G.@>5+FQJ^8J,&_J3]
M7#W5#;_S\88)%J2NRT[D;.7!AW'-L*9FUF3&UU"6750!'D:$8GJW398L"0FL
M>V9C?8/%W0]CVWV"^P:FL>S1IKI7F^X.;DX65H]RJ.P2%<\5$:I."K\JRX+@
MK.#+IO&P2<R"2BB2@IU'.&("PUB-,Q![)GH=#?SZJWIGFFTND5K\O05CU6ND
MH-;=#I-D];(*HX;]%<K(<7Q]T&KEPL?_ &!L62L.OAMWM2*$B+LO6<_Y&'\B
M[CX><,\)^>50:/S_ .P!]/V0CV%S&YW.R3^:[,I'B8B(O*O VGB6Q1?4O6IF
MMW;>0-VPO$ $*?53KS&SAK.K?4]V,!6*HU5G,&1]>C2'GATDVO?*)33-0ZDX
M^'/2W1EP?]'UU_IQ61*+_P W_P"L;+MSWP_(\WZ?! ?Q0JAMS])>X2//".L?
M#_L?Q,]W:=T?5-=_<U]67/4_&"M2[-IV7?5%EN!]GNG$E  QTEH(_GYU[20B
MW,-,G;');<,;GM!(W:HB_!GFH'A;PEH'^:!LG;HK3L+@/I]OHWHE.HKEM[YH
M7W;A&KZ.;:@*WF@9E+UZB%W.DL9JUPK"B6^U#\)"=7 Q[#SKG<6%+LJT=CM'
MP)BLMR]$SP#H0C\H\U1;<_[YBT=6<>XO"4PWY8>A3%:F/$^0@;A1!CQE8:,<
M,6:<,D2!\QDQU>'),*1OB[R&>G=MPSD#]S,](4"]<^NMH5RJU_6(ZB+<[\K.
MPJ&IFT&90ETS8B6$_.,VOW3D92&NXJJ%SX6J^!T1NGJC2]K$AA> D:P($!@D
M0MVR=J3G?CL]>46EGM&#]6Y<WXU7SA7G.KW3FCC-1<N>GGG*V7Y<Z.9RNRT6
M0\83\[0LM8UV9%LWFXV^P+:0#N<#PH9@^A,R8=8/SZN?\\N7)=!CNFWA\KR.
MKW%>?9W8UDEV>:;T-+&T50U]/6LST1_67UES>(=?U5:96I8A,A[AL1?SF2O)
M(6"7D$?[E+BQ^25SZZ2H40=HB?G8F_D#]2 70/\ =N+S;*8;\LEW5&'C70VD
M-5B^PW'<&V3'(I7,K9O*@JDGYZ9L3:J3(0[=&#J[^PI L=$M0!O:JY:@SDNQ
MF5S3I!@%+PFP=317C<;0W8'GNP_CSR>M."X<7R>K^/\ Z$@-DX8^YX>8YY<_
M ;F?OLOUYQ-8+70T('II!]YM_P"PK_7CE<S71XJ./PHS(UX0;=LTG?WMDL!*
M+T:;W+^^J56EYB(;$"EZQ?6D\=FD)V.H!GYOWBFKJ3747EUK!U#7W7_Z!/%T
MI]*8<?']G1RQ?%HOSUQ];0%=O)HR2VX)1R.R8H!1-M6$FN"86/Y&$L43\ [9
MN0=/;:R0TU59F\A".$AZJOF62<.6091G9)\,&.DDY,)?6@<:::83DK3%ST"0
M8B'+*%I^R/ 'QM\N1IU9_P!B,4.8KQFWR(7ACY0#2Q>02HB>(/18>\=B3_Q"
M($GHB%!9?1HR_LS!!"-&GPIN.R'+T:9&K9KQH"T_G':<.!V66VI=EO[UA^2M
M.\Q<@6+=-E(A^W-=OY5CU\NV@#($TT]#1ERP/-[U42J:L0= &C2$/+W (US0
MVLO+W_ $Y:[4W=I<EO9CG40L*5'N"&!:KA3R=:;3CY167YT-=;LPRU+&)W[[
M93$5'].$X*W_ -3 *0QKO3 7%BR-#8=+R)YJ0%SG/C-1_1:E6';U8J6C7-Z!
MH.MIZR^'ER.&L2;3)[7+LM(5#V7]R3+A01\UU*&O]%[,WQH1<L0VX9[,]GNW
M*1_U>'YHJ5VTORAR[S+<--$T&=0O%7)*H6==[DEL H_:<*OYRO:5=01*V5)$
M84FKYR@$V3&&5EF!9];C$\7I,CP1/V96'_ ^?/GP/GSY\#Y\^? ^?/GP/GSY
M\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP>4=!!&@*57&40,8%\Z/EB30,U!BE!!<7
M/TYQIHXF.FZM\2=!EQ]FS1)BR=.W1OU9Y:]F&6&7OGOJ>>>8^>8X^>>8^>>>
M>>>>>>>>>>>?QYYYYY_X\\\\_P#'GGG_ (\\^_OSX'SY\^!\^?/@?/GSX'SY
M\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?/GSX'SY]'3HGIU YHBU
M?DZ [':S-RV3_P!35NI58AFK!:V1TQ07NS9$+2(#:_?8D.&E5NWF9A*?OBPH
M^D9[AGM_KVX>>A(OY]I]GO%%0Z?U7=86+2BI_P#IE\O.&G$YEF/(O>S2!T 2
MNRD%:&GVR4V[BI6$'_XR'%%"V17;_AZ8^[/'WW[]*$N^ONE:7K*_:HGD2E;6
MZG!7M)(EPQ)=)S%T_%PF#M\\&8CQ2@J5GIS\]VPIT?3(TY?SCLP\]^#;GSZ,
M5$=:U?TB88(U3";/-* 7:?CC;<)5@X+U//,E59-RBPZJ\L X-@B7'4/8(LZ%
MH("O[@HYI'SB2W/,"HVR;YX$KNGFB!=_0?/$]\VPK/Y?IL;?5R#)  WX-7:T
M("?3V\M$-80=@XS-"!=X8J?##-T@H*@LZQOWQ?<347^0EY\^Q-#<P]C(R982
M]@2U@'Q377,%K,C)@4Q@': \,V,P*AB&O3/$DL(4[1C/&3M.J9 E>;8LG7KW
M:L\?,$OF_P"LN;4/785J%2<$1/:%5$6Q*ZN'G%O=7][-15Q(0TE/5QY5A9VU
MK/38HP.)%P-VS/9LV2I><4=%F3(X;G^?8!6%A0[22A#O"5WY+TEMA+3ZLV<F
M&D!U&;A12:)D8%E@_'CSXF&_=!SEC96/FZ"4%[X90=*DPI>C=GKI6Z13'7H>
MT>;U8 Z&&>E%Q.-6FY:AH:-7B>6L$9B?34>24GGXC"4<#BOGBT8QE]7+A!H;
M9H]-'1I"7#@2 D)\^>>^>^?SY[_/GO\ Y\]\_P#CWS_[/T49O:-#PD=@L/(X
M;EK:[TW!Y#VYC5PF1(E;SG7*#H3U9 "X>O=.,1X%FG/ A,E$TY:(.D0>([?/
M\,3(V_!*[Y\^U7(N)/CW8$H+_P#&^][.5:UV_KSC#-NU?'*2DWIZ3(P*FO,O
M-$,R6-N.GP$+]PV;B$,$S2?ZM.(KW'<&U/GS[^>98^^^^>>^>^^?Q_/GGOGO
MOG\^?SY_/\?_ !_/G_GS_P"SY_Y^#^_/M&6WT=4U&M-3*-EG]Z^2N@M8(=+E
M9"Y\H/YNJZIW6ZW24>*QM.R( 'BJ^K]F*8S".>K7*D1-4"-YLE2->'VS$AT5
MK(3%*PT8W"9DE\60+DGL8W+/,<?5V<7%-@#4#/9AKV90R@J;$FQLMFO7L]T[
M\/Z\,,OYQ\#)_GVC[SZ 1>?(%9$7N.Q28]L7A5//ZQXN"]17;I>KB9=*JIR#
M&&V;"\@KNDEOPS-%,,I.T?#_ *M^N%*]\_M^[P^!\^_S_5C_ %>X_P!6/]7G
MF.7N/\^?U>8Y^Y8X>^^?S_/GF7N.7F/OOG\9>XY>>?S[Y[_&A:9Z.0+V$W$8
M1XK/Y&H^Z;5H9QU&1&F!*DO-/3]8UKS7].F?,\)A-\K;CX%(;<X>Z?C_ #[L
MAQ??/Z?@WY\^T)4G1B#=',U?]7*,5FTUE9-,@;T7HAL3J'MV"4Q*&AV'Z2(3
M7.E:(IW_ $TC7CN'8$=VK7-]]T>2\\?/[ON5TA;:M?\ 2]0WNC:3$=)NNKT&
MVT[0PP=8P_I5K'5!+BO:C@W5)FZAY?6(,P\24'7,E81)GFZ/C)WXZ_-N0;0^
M?/GP/GV/-K6NH:HS/#@7B+ZDF+QIK:3Q#++" $75T;)+FR\W/#'//"(-&0Y4
MR3EAAGECITY^XXY>^>>>_P"E5I7GA76G52+1#RJX  [0L'(.66<$TOL Z.6#
M%86>>.&><4B-EQID?++##++3NPRRQQ]_GSP/?^?:7M:]TRG6J@T]KB,4@IT;
M<&ZDD'<$%ZR$"(Y::IM"X\MK-)V3(OHD+DHU&V883]6J=MR+>C(7D3^W+V28
M^5/-I5[6DM @/C8)5Y=IOPVKJ]T%-NS7FUV"8"GV(8J"O[>K9YL*S0JLP$=&
MO;[JUY:!4G_Z7S/S##,,^^?:/H[H!%Z"C6G+18[%'U5!>%F\_M7_ ",7J%92
M'FIB^H(TR0F.J;-_V"YLG;<?!)79[%VS=6.>>R%&]\_I]S*RK2KVG57UWL]M
M$)2GBPIJIZ=-[\M$#QBL%O!H*8(_N88;,O\ +8'!E! 8./\ 1_1_F$='N[/5
MH\V[M8>PVI:<_A=RV]J:RZKLC=HD2 +:!%L@7?OC9_W(V_<+,Q9L';NCY_\
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MG^/_ ,_\?^?X_P#L?^?O[\#Y\^_G\^?SYY_/G\^^>^^>?S_Y]\\_C^??//\
MZ_//Y\_GW_ZOY\_^SY\']^??Y\RQ]Q_K\RQ]P]Q_J\S\]\_I]Q_C^?ZOZOY_
MC^G^/_/\_P _Q_'_ )_G^/O]? ^??S^?////???///?X\\]_GS^/?<O?////
M/?\ ]_OOGGG_ -GWWSSS_P"?G\^>_P _Q[Y[_'O\>_\ G_X]_CSW^/?_ +'O
M\>^>_P#G_P"KWSWX/[\^?/@?/GSX'SY\^!\^?/@?/GSX'SY\^!\^?/@?/GSX
M'SY\^!\^?/@?/GSX'SY\^!\^?/@?0>[CJ\1:2I6T4IS';O2$],>"SPD[J0O
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MO\H69$R98XA&_NZMFK^_$D[M7]S7GA_5_5AEYYB(*ZJ;:'"97BU;59,3^/\
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M>(PYQ5B;LCE'U^J:3C7$(3O(08XK0/$RM@C41FY1[4>K.J:9XPI8Y?M]L?\
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M;>A[:86=ZBLC=5,F';-;WSK**;+)LD].Q*XZ-4XH;E-VW^7Q[H5I[*+UTGT
M-&VY^5$#A^A8S*%CP<J_LK18M\N>_?JC#TPI&44'S6]U]*CS%W+=/P-KV&[
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MY<_[")&:.NJ+DQ+6_:"F<G+6ZYAUF8U;?-?F>=*I8@3]9!YQT1!N##:]O,4
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MQ%!3.)B*XN0E7F5Z@SWB1)9,5-=/2-4<G_BQQ>OWSS5B+TR)+&8V0EL.7)1
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M(B&OB/Y,$#M/T @,/14HT]U6E=R#[*M.16D?44NBS.YJT>4IXM N,P<LL@Q
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MCP;V#DD>&/\ DN$/'"3X>RC^"LI(GS9_GX>MS]QE[1ESC;<]L7)G\&\.\O\
M&>(#U7P$^;L>;VBX67RP_26)R?[JV-N5L9Q,EKR%LP$>!\-OAHA_E?V].[^E
M.BJZY2IUAO*UO&;)'6CE>KI#6FK)-Q9=Y6SK'4JK5(PI9#:]Q4MME-SJ"C[M
M _1OE81=N^1JC[\M/FG/1Z!^@U&/K^G5-Z'M1)M1OO5UYUSKNP4.0M-2I8R5
M09;IO/\ Y=#]GS(XY7:J7%?\N1VJ#+)AV;7/A0(<C$A@1CCPT7TO^;[UT5U
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M_ Q(&O-O^7AE73_Z"TORB[9U\]JET-[-%H>PNES$:JJT(/$1=I>JC(0*_.+
M1T38,(7'7]QZ#)SA[]W^>2T?UZ \<@4V1!TKR6/])^;5USGKW]-F'4Q=;J=0
M'N]5VNC1.B*X>+\%))NJ%AUL#^=&$"6R"K,K6=/(#1A4"G:+ 4LG@NM?[77Y
M@'EVKPN7LSK17Z/'V4J5@(%XC8CQ%K*M&%9N:ZE&"BN*?[4ER6MHMK-'L"IM
M9)KUN 8.Q4>0:E@N%'QEIP%:<<M_L, WXW6/J5E!=9.O@I';3?(/-W*= 3U[
MG+4O^)6[D;HNLNC*1L][CE;E;/;)+9L-0(H>PU:-N20#(.@S\@WJSM);_?K
M.)^P3/7,*_9):DWFHO*3Z4O.@XDUGV!90=UCU!9C.@:C@:8-+3)&).1K7L)C
M&+V0\8(:;.U0AY<SKQSD802N;]3+2$-5B+2I2#TDP:._5'FSBAD99ZG'?8UO
M5U9P&JV)FQ11 <K@=A/IC19&K8!TZ14Z"-5Y*LQ3"&$HU/&" D\^<)V=<3BQ
MV/;M_K!9V:>(>J^-)N2+3,U*51L/I-MJ]D'N88(7M9X+XX(,:ML!OH(HSDI3
M-M*[9^UA$XQ]<+Z;]'UO_P!-TM4%0_[CUA_ZJJ] K?\ W^4+P9D<_P"#*8E8
M_P!QZ-\E3?!_I/\ U?\ F^PO)DOR)[O_ +'DK?YK_NYP68?UKY064I4:2?\
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MXC^0YQ_9NCH@Z$::.=>OD@)(J/G?H.>79J^K#_$7J%Z=>,:WK2U6# #<QR7
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M-Z8K1Y?8(!,>;#+I4('K;J>E[.<&$*7889$+'/+J8G,!P%I(#Y^B>8'PA_\
MA2\Y6$?9K[+\T@'_ ";1;&'1=V^=':^FM_3.[H3:'I/>V[BVWGLMRKH0,$S9
M4_\ U+I1Q]$E]JQ P\0,S^D]AZWYFMI63*PVY]^:=]V)TUR4!N6TMI7UM/75
MUPM^0SRN*3#X17K+KB\:M0UMA6PV68\>P+2,EKH$[_;W2MTHL/F3)<R9+D;I
M.W+;'[6KVI^D*CYN>$M_%%;P<<*]KJPL)M5S4LN[[JZ;;.C!-RY$L_==4&%(
M7T=EA8.$FI,$76Q#_0N]GT[]F&?H0F!?BZ@)R:#2D3K'J)0@QN2&/BQR(0\J
M-+%;*IUSMAYM=NFM&]CIDQH&V"4G6$R!(+BFQE?>#&S=LD=#P)[/9?FZR7Y4
M\Z%SDZ1.).NQ*(W&Z6O)K/&8'UJGH]Y_.X3^:Q2N,)&(CQAQ3XE(!XQ<;L_W
M/IW2V9;-\@K*'^^0_)F=&WTC<NT3:_0]F:S^]"IU(./C5'51/IQCDB047*3O
MBA1?LB'IE$)/OF&B/[-G#ANC/9_DE"0X=IE3H^@1?>]:R9-7P#2%8ZX2MGG?
MH?IQ:B>SJB=X6-:\VF*K$-^6UJJFUK 12!AB\N%0(IL9>:C4&="RGXF20*;%
M_P 3,,=2.!<P,;E^,^]-WE<.OD6T5^QZB\<QU/"/\>*KT'<//(E88,T2L5/>
M?UR%&YC9 ^PS]^Q@-& B_M]F1-&F?IG^;^;_ " 1Y12KXDLXN0):KDZ8NMZ#
MA)K%':]R%1<2P6,+SA50HS$WR8NA32JIT"2 !:C2-NE4W-)8)[G[OC[_ #S&
MZT_5Z@[9ENF"8@W#-%UOS!7G5KZ:F:*G%9+B#:-$Q.A5 3K4"EM0[(9#DM((
M#Q<PPH)+!78MVF8*A%ZC3XQ#*%C>W]B^9P:-L>[)1KOIN(8J6B;MJT+:H:L5
M<S=5?]$.(BO$"<@[\+7GK0DG%=V%? N(6T6*N2"=B>$G3FJ,M2<S.D-M6O\
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MTE9OY<K-RI""KV7?3TR&*]LMCL8>=QJ#E<< -Y,]9'JLG!6ZIX=%85*W_P"
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MIZ,K(&S\PK'75;1['3Z_@%[3IQJ>0%;P"*A 6K1:?1I/0X."3 E0[!VH\?\
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MWH<[5O",A>-$$Z7;!E#N<") ;%X2&]E$\+?P!*:9""2Q%?+JD\B/B39BR?W
M9)L!)D:<-NX26D*QME6]Q"!GE['E[ 3 :%9[M>>4$G,C^X;\PK6;.(S[I^BI
M/I?R:744<'QAA5ZJPPB:N7QD]',1RP%+5;^JNS8TRORGNJJ2-E4X>Q.:X37V
M(%9\I8WAR@L#)BZ_>YXXG=>4&]1!TY:,K;5#=:]J7STQX96ZY7L7)H+56JU;
M7M:UE6E>(BC7U2HVN<.C6>RS4D6(*DV]/D;#.\WOL$S*AZ]!_L=S%)385HNZ
M3>M/4^=1.DWE,MFT51)%)SQ_Z3B)V)<2J U+]C,S/%:H@Y:/,BE'9EQ?$/(
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M?TTF5KVG'ZD/K.E@X[U/##3(SG"N:]:M0;8=RO\ 7-5B;VP@V2_-Q66)5_\
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M.%H(0%I%[N9>&H+J%K7%RZ9Z<9;%IJTX5LU/=TPS2\"T$,QI0CM8%U\;X!I
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M  N,IB*F185/&F&.8X-1(L?D%RG^QTT& OTK[>LYCZ*J0!>FU:8.QNT>7_\
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M2-V =K+0<&L_.;<'=4('MVH-4HPPDMSS82)N<-I07-;6?S+=MG-?^7GC)QH
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MMC]ZK<X_,2'EIM$C=E93V3FM8L>(52)$J?,KQ;J) BHVN3DGZ!<J85WL+!G
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M.%<7E;\_N?/%;0XUB4=:B':54;D50<B&?NJMBH:(^9;/=+OZ0QTX;-E? O\
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M-?8+IP:[.ES778[\8NM7JT_2JPWN3U85A,[8[:ERL&0FI UUJ+EE@8/]CY1
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M M+8 <AI>8"G8!2$B4+B1(FF0:#PYS36S\KV>NHQ><]*//9_EH:Q.UA6-91
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M),Y/9W*59F.#"PO.\.,?V_PQ!56J&Y+AE3<"&K/1I%.^R8>\!X:=VK_03/\
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M" ?FK8%MV8;I.-WW<%VOI'GW\>;#M.KT8'9=R_HK^=D-^2=+P9:5NN7"PH+
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M#%FL1UDCJPG1-.0GP*65\AN$[9LV@I.,;1JU_I</[/\ 3U4R^FJ"D79S>Z=
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MO[(7.1^?Q+[5,LJ0K9MBU@K?[U))&G%GL(@479^P=GN&E-CRZMC9')Z/<9\
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M*X,6*>KT . OJ:&EKJ@["(0E>B1AS:J )\X*ML<35J+@Q4N1 %S(L7=LU92
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M@5FEPX:E6CSD/R=:]6HD8+JC@DENR$C/656&:HH,Y_@1?"4&3YHU^8[G^?!
M#JK\X.=.FN>F_GR"I*E*#'$'SHE36ZKZ[08#!'K#F*W52VZRJC7KE@=D#?7
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MLDA]_/??//?//??//<O?XQ\]]\\]R]_CW+^//_L^_P!..67\>?\ G^//??\
MX\]^#1^',?-FNS!-TZ^>Z.UW& "1EH%;.%3H6%F!5R&'_P"/1  E[Q >-(X)
M% ?R#C"H973!T!_?1FK1A"]]T?>*I\?\F((@<OHG+_/*0"$6$"ML4%3Z7KA8
M$C;45_=_JU94$<$6X,.*^KWLJ5_I&_1IP8!?DG?Y!(:/-VSS*1?SX'SY\^!\
M^?/@?/GSX'SY\^!\^?/Y\_G^/Y\_GWSWWSS_ .OWSS^/Y]_C_P"QY_/G\_\
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M(\QX!%U^Q"#:T7[^D6^>'JRJJ/B1[46)BSMKQ$-AR\Q\8?7/_<6!GN'Z5P,
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M34\^.Q1%=A-6?,5U-1-;LL68G"R?+]-K^F,M\6:*JA7A<H\LV%U^@VZQMX?
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M@^.^0K+GZQ-6EK[%28MB603M79Z#45^U%I17:_KUL8]8 Z?B%II2X6)S!S3
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MTCNW9275:'HY$C (:/355)D-4:3;RKQ%2O%%=C+CJS""*^R. *.'$0]0EH8
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M"\NJZ J1YKXVM*&4?&9$L>L;&LYD&H;Y*D6(J[ZNFG!Q2*+8!4:%M^7;]Q=
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M;=F&C3MW98:_,LL=6K9L]\\PPRR\#]?GSY\#Y\^? ^?/GP/GWS?YL/\ S/\
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MT/Z[.(#(37D8)I8*'DV%>]7;+&G33PZ=IW[5O'R;;WR7>*[TIS;3=Y*C7Z\
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MT7!*U*@?]6"5:RXS!JG0GMO>:M VVSA-$.)!V:1D=$7GVO1).5KGE-V3,19
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MZ&0"HI\<6:Z#YOD3HO3%W+C[.9Q60V,%<0EI"HPJ4(WG)J3$6\]<G26A9:]
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MZLEVXMP8$1KT1;U1K-U&SIC>'TUY4-AO E 9K1T;=4>1KE:J\GLH1G/QY?\
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MR$5'8+,&38(49DD?\H<-_P &5Z3Q%RW7FL-@K5/ C[P%];>H1I,NQNC2=\Z
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M<?//////N=98_3'I9X#KBR;N7EOGDVHTEVI8K3<]IUZ4D(EW.O(W8UL<K?\
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M5F XCYO762%"QT&MI^P%P-"<=PDEKR(-081'/YZ)\,=KE:><^O>[NS+=0KF
M5UT(]PX9#LK\IZ[JRXMJMS_;UA)=7]BG*\C7F ($E*BTVEC)10AE#,8EKWU^
M5EUF=S+B#+(4]%Z?(VR6(G:%5?H%;L52%3+#*GOTDXP5"1QZ1%$T3>8H#\;K
M:*13>)_:F15Y(83M@*:\++6 @CU',))*%5X;O""3<T+("\UVY6J!H4DI/6UV
M!4L"O;C0KT4=]3 UA.V"7Q$/Q2OLS7!C MP;;H;0V)9*<,=XO;O+J+$;&_Y&
MC;(U2='^W3E>FFY<%*$!5%U\LQ;AK:[6 +6P-94(#ZVU8Z";#6H[U'@ _<#X
MC<X  1@SIV>:9Y/8*C1]Q#R+LDZ=_.DN=H_HLR<C.]JP>K*Y\L<S6W),5N4%
M8* LR\N9;_N'KFD:W?1^ZIBW(].K=?K"U7[E92J<K>VB5Q-T0NLA64>S9B?"
MQN=>;VY7S_E^;O7%=*[[:KG9?_I#OD,O/,",I?\ ;K<UXU8U9"O\6(HHXE8_
MY*PS_- C5J5D<7M_JF>> HL K_B3-(;SK-,I:JK"M594C8;VW;A9)_0]EB";
M,/)6,?U&,1E?BFF8*V;L36M&7A*@"K91VXPL0@@8L006B1LG:)6S?EP2EZ=6
M8)$6MU-6B^,+S 9 L."(BL)@E)ZP6R/K4XC$@"H\>;,7CN>9H')DZ]NX26SR
M(P,X\S+W=[RZL#O:(C<P](<X=*68>8Z9_P#M>Z1;*M:T-*JAY,6;8]2VW8;F
M*JQSVDJFD@<X8\\!F(K6J+ZLMV3+C9:O"+#%9(!&>6E:\_H)>TOO9.J^O7"S
M5];VG[NKBTJH> U0YB8.:A^?#7TRG6?6:5"J79<,)&GV4/6("W9C[;)%>=9V
MUL2XB=OU:!N^&%]YBL*T88TR&?KQ&.1"#1$=Y\4PI "<:<Z0(D0?!;YFB:/W
MZI+1"@0(,&(?W8YEHT2%$C:9>&F-IPPPVVZ!KJWZ+>N>BHOQ8K]X4BJI[I2=
M Y>F*OL_^N2/85#'3!VC0[$MF_\ %9E^;_KM^B$P0(<_;%D?V\]>RJC\UKWZ
MS:+-H)+Z"N!UNF!>7Y3\V]BM!)TK.N$'!'O-P9?],Y+2MJK:OT?0/$$Q)N!L
M(J[9)9#8XDOXD(4V!&(SH/F"]V]>]*U7<_78%9NAKIYJJ.G*4:>#:(!52FN8
MCMZR&S6R[7!9+26.NVQQ;MT][AA*?F+U5-R*7J\/)_[*.[<H9",3CA>-KKU3
M_N:B$L&#GL^,X<<WN4E;6?\ DLML%+6U0@N>Z7J#:HOC/&79$H-%(ZH>OR&(
ME2 L33H#;,A_N+4I2251-+(E%*FJ:43452C*>O>S;(Y4NRX_VMGIPXUR/(L>
M*6.MI*41.,\O_"T:"98J0D>Q=6$CW5C2@"Z9[;'7%N<L;4=;!7R_ZO=7\<+7
M/1.LJO 5[KIE.Y4NNRZPS];A5;P+.W%XMN5FLP1]@D[#Q!SAC)O DH$W+W3-
MV;/_ "CZ&ZPOTU$8;NOVI+%#EN>%5GL^H!Y?*?<-(]%%3\/,LLDE@7RYSYHJ
M=5$CMS,IEZXL%CM-^CG5L*5',LD3(+$"(6K %#G?_,;*F5U:F/\ .6TU; /%
M:@021Y)!5^SS6HJH@VI0'Q/[@U0/D?\ FQ->%EA^D,3F9,\T='W;MA3;EFV=
M<U[L=-5D;$-,V6)H@>BM+[FK@\G32+]U9:?1NIIR@^G-<#W3GGJ]AX3O(_NK
M/+7[K_HR]\]YN>PKNL3GWO#]'G*H;E::\O"507YR3:!IP35Z\WC.L[*%MO0H
MC13$XBPH;.5G0F'QBAJQ*#7; G-:I#:-S_)-Z@ZU.RT;7W]Z]!Q[C7Z"D7/$
M7K<Q_2SO2OF-?8JQUD(*IR8C\L=.VESB6>=814QW04/4P0*.90K/K)P&6P1\
M>:,A&C.<5DC0PMT9.::"G=09]%/W@4_9;]5=<T8L*+SK32B][&IERM>XP9E&
M!FPVTWZ_0YEAM)(D0%E-_N@("'S-8^)D*W3_ '?6ZMJ[DN6NQ9""E[[!U#=@
M;4][E8'M<M0C;IV1]HK6SYP,C> W9HW;=&R#C.\BYZ=NS5EJ]PSRQ]YO*SZ^
MOUN#\F1C#L7NFR:ZO[HE0L[H+-.I:V*C>6$3^65\W(,:N6;03J&J_2)185B#
ME^"3A[E(.^!&$@=IYT/M8C?E#FX_#[,_1*N:)6R.^X'"W7>TOS9_/+JMD=WN
MI4!8CT:X71T0N5OTPTKHNK:')XQEU'IYE)/95?;$6VRRE*3LVK(,1#_[=?EA
MTK3JEJHII2HQ.LZ^(QZV_P ?_KK1.3%R7I0?\35#T1/^%:I W9@J_P"+H'P-
M,?\ T6,#^SJ@P]>O^G"-IQP^C75]::F%B;=5=HVIK;AN89L9M:D P86</MU:
M]&P4Q&L1_A(T-V:-.G3G!)29,7/5JUZ\M7N&&/GG.DZ=B=;U:E5=:35V36EK
M4X.N"Y-^*ES V5R]]/= H0<=3$9.2*Y:GKCQ0J.]GI%=&)[BL2#65<T^8<EA
MA3]0I\E'%!I\E3LXPZ2M9J[2Z<H:U;:*W;LB$+:?T(C6<=$D433E:KMPZDQ+
MIVQAL:I4BVJHZ1$!24>&45WQ]LX78D%>;'H 6'Q(T8?H"S4[MJ6I TNP&3.O
M*S +"T'6)SJ:]7$X2OIXZ=_87UV2Q3?]=$%K<$F3_LA@^R7H&1IY#^U!CX2)
M?].S[9=8UK/9MCK/KU'FN6[8$V[FV6I@)+-MVK6[.0N;-A[</S*Y[%^1LSWA
M,\I?N0K=GGM@>Z,\O<O>;7]C;HM1D\[RYZ;[;<*R5052<B3^;:.6ZP5FH;T\
M,<[='3+M="9DE730\DY"@7#QT63#07)0BUD*&8.[3#G1&'3OSV:<[/ZKMSN2
MS.<.:[4L!6D,:1^B-:A5NW@]'$-%87MSGJK6%1E@AU(!3<-O2ZM<6(R=WJA6
MW;%?\KBKF=ZT"P8&='AR807^9UA6NQSQL?97B-G8>']K^E\S4@&3GC_8&20N
MC^EHR'^G,?[(:9+$ZOXG>?VQDJ3 P_IB[]NK+SM%,T_&]8/8U45K'];-+#':
M?="*KZO66.W2($MKT,'NL7C_ +G2SRA0R2PZB/\ DX&I V!N)8R=D./EKAO^
M=?3KUVFCV)T_-BGUBF'EI!J=$U^RKL$$9"1:T5ARU=)TCGCI\-RI!#H+VS4F
M+@8D[=7@2M@Q47HBQS6WW?6O7G<G0['UJ=0A71S ^.(/]:;4Y=RY0UU97L-6
MC\<AD..=9+!G-(^MHS_G.IW7(\<XMD>V3K7MTR)&K1A$EC!O3CL"_0RNU7KG
MP018<D##SBR$6H)%SU!!3(<=QB__ (I!O7_<<8Y>8Z!EK1CCL91?NP^*$1M>
M7LZ/$CX>X1=HC@FO:.M%2MS98]H6FUUI2Y'GJI=MAZ:LAX5S4ADPHFS2Y#EU
MI6%=F'.:6FH*=E,9;.)N['YZ%V2(I.---L4LO3"O=!]SB^6_S%O>4T,/3O3=
MX<R]E=!R1KY0E2P2(ZV17!C0_5=4R1$1JP5C]>!YM@0PJ]/TQC.AL?9<L@+-
MF9@\GH 0/M;>S>JI:>Y@^;>QK!O)>,(7YX[CG2DZB*@WG*"OB_\ NJG:3M*O
M0JP*I]51I&9FD')R:RU6V"MM3E3&:QIDLAR'X:C^8ATI:$A+B[X\F*H*\:1$
M9B;I$D:  K3OBN)N&1'&6R/MUQ,=FEF+CRY:"3/:\L2D^&3(QI4K;IFR<-N"
M><[<_8A2*WC1=.>+I>8-(%@/E9)7@4G/"[I\@/.(B_ G^#-F"=Y4IO&R9.C;
MN@[B4_9%SU9S)&6R*_Z)H;[N_+SM%"47BUFFR(G&MZP5YQ"Z%SVW'-G$U4R2
MAVC5'44P8"R8'*;$U YN"BFAY.>!63_QJ,(*^P)<6H1Z[<O=03K1RJSL!^,%
M*XYMYM;/S]4?^MJD?_/T%=V\<5S> 300@4M@9:RN%B18U"&URJ"%;LU.P!N=
M@/G]R?-D%, Z9C*FK,:Y+3V%: 'E*? P%3E8R&'%%R:,UXX8ZQLL).C;QDF!
MACJU8X0]T7./CCKP\QU^>88^>:Q'I7.3GOUJ0M0I5JDT$?A@]"U"7D<UNIAG
ME!0;; %1@^F')RKTW(7C*XQQ(>B.)F[1)(.5TZ\HLJ)OS@U^S8]O)?G)<,]6
M9K$12JXU\[N9LQ5V,26T"5-7Z*J<X^S?ZMJRT[,@JVI1#C*<D01/]>(P#(VS
M,]@;_9PI=>:E8=QUCT9TS<M,7PXN=?6#^N'YU5(7':42J#JA>M:WAQ[Q!5S]
M9IYO UM$([\XPX[J, 3-7$4107C:;M\(02H^=-AQ Z.=R8GR(+2+D*BUO&/&
MZ7(=1VX$+VP7#?/%0P,[>TQ,XN4=@W308^ &E["VN7G)%088[=EG#C:=.'E0
M:NK,9'T1!M=(@^)%VJ6^+%@J*_$CQMR!YIQ1-VC3''Z]>G:E8QH^*ELUXXYK
MGFC3X']A^:L/Z:5?S5Z5[5OBX@DF\KCJ#S9(3;CD="\K336S=;E'O8*P!H1#
M&+2(,Y?J@I6HA9CXDUX_LL^Z+@_[)@3QC8ED)<?1M*[,=_23LVW:5ZENRKUC
MJQEH(4H_FG#Z)I1,6:FKU^D6AT[HNVS%184Y<QNK-]+%HCMB#5$K96JY, ,;
M7B1V358L+EB"TK:%X1ZH:F:1F@(SU?7;&&C,)%NC"#R4M%QD=K+SY94LSZ(!
M 9(BZF$H4GSB1$UKU8DIL^;+F29.V1)W;,_JGU?695DTN12NT4DWQ]0?1':I
MZB F,FC0NDM1E?TZ3D@?L)ZM0(OITE0^O"5C@,):M4Z%YHE:\=OE%3%T9W9"
MK_\ 1.\95GV M$*BZ Y;HU6J,74%=-BGS;6M@U3PJ]=/W@$C1*ZGV%=3%3<:
MX;O.AXYIC8E*%H3R&F>NGM.K;IA:Q:>Y;E!.B8J#>U6S;R>;_1:N*& =K2ZS
MIPJR.]:-/!/0UQV@APS,"GH51E1E<7:@I&F-=H2MM8=9P,$0S9/,Z$X_[F'1
MVQ)ZDW^!\6Q776C%=.CVA?Q8@@PWX"91/NST6Q!_"463X,.C?=V[T>6A?V)\
M/W;L]CR-?N>7\_"N5X@)Q1A-J*,GJQINF?[%K+KBR%!E&<AYLW;?)S#/&0HL
MLU,\VR)&S_*);9._^YOW9_U_U;<_<N:8=W=U%-1-,VV>K+!HY%&\Y]*.W+]^
MC*'KC(QW)8-?],W'7M,DF%5:J=91>H@R4<J4L_Z*0K9?KUSM7_MV8QJ>^$&@
MPHHS)V/O/O)*+7__ +"3-LGHD]R =M*G^7Z:&J#"H\N6:G\NU2_N*3U%7TNH
M-]W V_VRRS<0K)K'6[8"E9^TF.K: C#C4'&#M#HK,UG6[&?UM3#7R0=:-,$>
M+U,AE4 E#^H8(-QF84.UF)T#>1P@C&2'$8!\3&1Y'A&XL8M&UZI^C5(QQ:*N
M4'<:PQZHB_4=I)AIV.^-VK2'3G19+V*DDLTAER8M6,8D+(.:J65LU,SF2QW&
M@TU>_P!)+RC[A?D;10D&ZUZH@ *^+-/<E<$.9WGJ2G$1]ZAJ7:E7%8]"K)*C
M;;<CR\]FC7'M-T\IAK4N99INOX$X]39\O3^JPF 0YG<9\M>WAY[?C7A/V<2S
MMY \:99I;KG]"#/KD;3L$$TWZ#_=70Y@<ZRTW,0'C@-[0/G1&# ;J#0X6C"?
MKPCP]<;^C5X%I,<6,B#- 6*.@Q@\:#K%QA,>)'TC(XS3'QB:1VB!KUXQ=4'5
M%QQC:XFO5C'UQ\<=..OS7YYC]ABQ4M5).@9%3*SKY1BA2Y)@#1EA,7 &@2>,
M#=H8N;&:10V)K@%RHC?O%$B47'5-G#=VV#*W;8NS/5ES3\3M_18XIQIRTJ=?
MWZ$VL?:?ZDB>JPYM.I)EL9.@U/9]O/\ 5B5,GN='3"->A[,&$%I^UE9L6?F9
M&,$F"B$103>,B!O\N?Z6]:D[*ZU]H-DM@@!7N6>M'>"@6JF5"TV'0+]0W7M'
MT;M<=%85M42ZR+WJQ4CQ:=IJM8V@XVJ>M5=4U!CW0=&,HG"*!T? P=#$"[B@
M+8:I)AU471"@_)84:GR"BXI-6)-E!*[<O0=&<H2NL>,\P?%!#$30,+>3212)
M&D?Y,K?G^VE<HZLO:W68P"JZ_P#<F4H,J,!&$*:M_#>16V$@:@UX+TQH/FMB
MGJ41IED]"YHQ(RP&@[ME8[(&,[W[E\C] VY6]Y]EV%S[T:7LE M7J+\^:YL+
ML6PP28APEJCO_1S;9>6T;+$5>77FIX@^5; )+K:7;'E!FU97D/F0XUZ,G#\V
M ?,4?8?1;$W<BGK)N"D&Y] <*_K-;=9]'A(3"T4[ LI0?N=D.B;!-[]"%6VE
MR**]+.K9C8,E5JE>@-FG)[*(X&.NEHVG8%\)(A7@Y[5XY>8G0;,8P;,-2]9'
M<&C.YQ<%;@A=P'+7^3E@<(AA^_\ X\48H(SW=#C[,!,\CJQ]U1=V'T:4)%C[
M_94=+4]$GW!MU^R-*X'U;_=;\3C&WK#W;A#QV>X.IF'$+MN/N7]+&3BQIYCR
M9*T:MN/.]7_1-J6NF<#F23&Z6U<]3_JA75).%XS/*U=*\LH&Z<I65*N8USO8
M%4U73(-RI38K,)K&=-(H(\\IL84Z%8=\_>EP)L>;?ZPXE14O\[GCRW[&I5(3
M?T*K?.S7A)V*\<&N*S%3%[KHP_8,QM270%"6<':>J*F,ICBZ5'7,<M?AS5MF
M9!)HL+!U1-YT>=P:P4E3I=NDILF2C+SLL+Z0<D*LNL#993E*(5C&0Y.T'NK]
MA'FUW8"@S(N2N6ADQ?L6%*TR=..P(B&C#\A&<!,5(68#<PR .41=$1L@DAND
M;Y;9O$9:8>'HW<SRY,F4P[8?NG,U(D;]Q+*3LV[,LN:'G>[+WY: UNQCW:X6
MVF+0Z7_>(DZ4NGU#71<H$#4[<_6=[(3;6&SU'AM)^TVD^H;L5G0UMN]"=L'N
M$$B*L?&./G;M4M_3U]=+<>]J;F&^[?V5Y0_67Y;6.BVJJS*D9[ 7J?>G_FVQ
MKIBM+M4U"IE>,0:H],YK<V?2(KR5N39ZL167(^RK@DN,E!U$Z*ZH^KUK=/BH
ME55XGIF#(WR)<=745-;5,)0*1";V?;OU08 P'C)6<)41C-991?[X/&1')R<X
M'FS#[\%.LJ'#+,.>C5Y4HA.G;%UZ@2E913QRY*WA->HNIM\7:*':!NW>'U>Z
M22\>U^Y;1V']N8.E:?/Z=GT&/TR9)VK\Q;4(H[+NLT4VK%(JA1QV[!L[UXJ:
MS+8J])LYH(2DV*O LX1RJ&9K+EB * ( :(,B7.T0(HK5[%QC"3[>M;?^K-1\
MZH+/986LL^@;&Y^MJH+!%U!#!^+2QQ:TWNKV76BFO55IN 2@%'D8KC5JVVZX
M-JVT3M[2G#T_/1%&[X07+%1-.WJA!B1P56UP5B>A#7 !,,CUE^1BX^1"]F"&
M<5NGZ2H*;%VCY64D>8B^[->421EMCR/[6WW++[5+*KGM?KU_1O$1O5]0&.6J
MMR5\0!P)H63X?3&BD$$^+\DPM 0R RCQM4E?E80IXGW5HQSVQ/Z,/H(_FAN)
M8\<MP:;"\@KJ9TOW\@US"U1=FF%&J-$[)Z 5*P@"?,L]WDH(-2!(<6#WZ,LM
M&T3"AX1_YU88?S1US[T)W/RQPKR^I5"UMMB?[7\8Z5NX IM-2+4090+(F7+S
M55+016-*75)9O):T>BK<=G%@ /L&V#1,G544Y"7=\/>569 =7&JKZTT0?1>F
MNT72,]5)2'Z.U*0#7!]1INW+?-3/8F _R/ZJ2]^66Z4N_P!O_3R-N66S;#SS
M]]]]\B51]*SEU=4)M05=,4T^;Z24E>57ZG(75<CEMSWY3UT)M$YC0DWW?MV;
MO90R-%W^[=F>SW9_7GEE[#_\ZK NBQDJV#%F7S471"9%LJ/ J!XK1QC6(;@+
MWB8LRV19L%\7J$YO0F@N.:Y9&:'D)U9Q?!(8II76 J3-AY&S77RL=C].2[Q4
M@\B[6LE=!CMSJ"G[:XCVU6BQE>FN2*^C7G_UK=T1@T5OIL;WS_B:A3=HC+4/
M608KVRBMC;Z\!@]\S;"A# Z H0$&-)&# X,)@%V+;!W,!6$.AQ21W<,A:QHW
M:8G:-.N43VCQVK5 @[)NW?E$A:M<71[KT88Z_,(8M%.($D:X-<>MDR82>AL8
M0SGHZR ES[+L;T770G4.,S\(NZ2[O']\*D0L8TG,XQZ]@U=U?Y>OV/$^BK^8
MQ>Z'3A3F"V>@[A=KFMV\*-J.Y7@RZIM>(&Q:8+$KA78BJ8"4Z[24F$("KTV9
MOB8:3F@NP;I_DZ7.)X^2=8^%2,^WG>EWH;92-@76<N6T5#]"/S>? MY5&N5Z
M\<WULOL/Z:K(-54E<)"IROVY#N&M%0)!E635=VE+5WQH2V/<]+E*$&26K<'4
M=%45. M>I<%87H:=D.EA\E.*%&QUK(1/PW:IPOT%IC8"_1TS7)D:Y<'V+_C2
M,-^[#=JSQVY^98ZPKM3KH)@,-0*NP2SZE:4UI*,(Q:& O:Z@83M,=58)Q+1H
M'_\ "H6LN3U:09';_HXV!.=KPBX8S9'FWFS>>SN[PCZVTG.Z)%U>AU[<'<U=
M+G4]V;$&I\W]OK O2A*C$1U/C./KFK>5O'*]GM1"*#6*[K$K<0Q.RAK[/Z<"
MF]4NTOOQZN!4_).\[ (8HC/>@SE8>=.^KR!I?:W.6/L7P6UBWK==V2N%_3BC
M..;I^\ %<%F00UB]D+_9P-)'1L\U!9'N4521,\(2%A>WS\5Z4HXSMP4;MF8J
MD[;'WS5CR3G&RW>+TS=$B[I07S/_ %LC;&C[-L;//3K]QQL/3]2+L:##7ZNK
MH%#&2 $L;%#I*R,C#Y2INGR%>3!T0AFC5$D+>\J4W@-VC'7L#[B4_8.RC9S)
M&6RLCE7I&URW?G2//MH6R2NF'N)7$WUIIJ;% )4M0U<(SXHJ:[5]TCH]2J5K
MUG?_ )@8D8#O6:R[(4;8@06UJ6O]+$&CA\317Z*]#=@UC;_;1NEKM>DA*Y3_
M #RY_P"ET*LERJ*S:P%DW,?O7I$8TAV9D;*\:FZ<"+I-5JZV:4TPT"+QHYR.
M=&E1$[5AD0"RN^.,E*[)OA 39%B4KOF)]DH3-&JX74,X&WK%NE!9JP\3*S:U
M5V:NQ61D*"(DH@[KXL(X3/?=VH@:FZ<M6O3O6O*7K6KZUJ.I516'8)%%+*>I
MU8/+ZO#TM2&(BIBD+,D<3+^2R&LS 5_[PG(YY(\*[XLR?ANE9XSI7FVDZ7U]
MTUATU(4?+C;]-Q?_ '26!S]&X@UU6E9*V?"\LI#@;NA\#&VM]MJ99:*KWRN@
M_P#N7VT,JSP-Q?*AV+V4[^L;LD)^)_I$;Q^326JXK(LJR*\OKI51L13M;8LX
MN54&(/1MM[1($A!$I*<PP<698W!G*-BU9F_\B,9T[UF9$6\H ^.%DOE?458H
M 9IQ2*F>E<"U,94/J\6D]G !G;6QE?6XD,P\A3APYJP;O3?K',B^:2^+'Z5]
M)[/"?LO[;/W+>OWWV:452P2O+B:Z(%*7-?[B=%RX%7T!2$'4WV;SC^BIZON?
M-1&.SU"P#H>$Y-);IIR*#&03UJ:MI!D($I)LK*8\^B_GA[/VC0%&V:U0M(UH
ML6GJS>V0='C;X6B ?;DH(P&(6B'*]]E1-,4B0DZ-<:3[[OT8:\=6[WW9AE[\
M&X?GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^? ^?/GP/GSY\#Y\^?
M ^?/GP/GSY\#Y\^? ^?/N9)-ZCZS9>D+%%U7;]^6E<2E^IW2]'".>V&N_87,
MW_I/4:^)E).T_8,6L!8F)K036X!*!-TBW(S!J<) ]"V1IV@IL@2 Z;?GW+:%
MO#LQEJ@='0.L>EEYT9>)9;=V4\]!<]-@Y:Y>ZZ\LSGB (1J^U .<8!A)).&E
MDZ,KX@'4P%G"*W2UE<M[_1$<0$=A8=II?4?1A"V.)G'.1U7,1&F,,JXCRQ+]
M==5I%&.9T\[HV[JL_8ICF$ IW?SV5K4<)8]\"P2G.S4D4Z,BV/)&;FAIC0M@
M='_S[F$H6V/T/?*DO0_8/6\RF[EU<H7/MMU0:J!O=TFT%T1N:0L-%:DX%JH=
M?5E5:KJ/DS@-0A,E6W_V"L31MD"AS7&5I)V1ZD#JGI71_P"D=[\,=6$U-9>[
M!K%CYY@>/Y.S>EC6GH&M5X+T56-O%.4PPRYJ3$+)-DVX5O;X3FXAG76PRRYL
M,G 0*E2 Z0E1S4'P7N-I#2NN 6.9/KL@LKFAIX9H/JAJ<MLX3=.%R9476676
M$62!FQV>WR6++0)@Z;JT2XV[5ADOW+&6OGL$0+OB+8UI]8TSH6Q7=1SC7&EN
M?_\ 9^W;T4%_0+LQ>4TYY&B:.<HQK(97:WSC&04<SI7@]CJ+XRNDV6?W8R64
M3MEPLW]"=3]T!:QY[OU8/4[;/XZ UR@$Y1"3Z2(9WR4HI=[/'Y>:J_+-CTL0
MHK^_>FI(IY\A(DU=C'-4L9OB2MFP.D/[$7Y^2*K2VBQ[*;5Y#04H+/8VYR;"
MT($MK8(9HRD3RQDN1W1X4"%%TX99[=\C=ACY_P",?/?<\L<?<$Z2-6NM\[7V
MQ4.%TLEX@*6M(U32[)CZY<<]:PM'.SJ\#;XFW+'5*U%&[0(A;(VW/#7OPW^Z
ML\\<<_<O.8#I=EZ!O'DSJ:LD:SNS.A*E,\44NZV8>LRJC*18*1V'HZ)K'.;6
MU?Z\:90R7]QB1L7(G9U9"0[*&KN.M ?(G_'O&+;Y-#K 2G15L937GM'-P650
M:Q<4VN'QN>>R 7$SM?FV)/B9[,->>6C?K]\SUY9889>X^_\ G'S[R%RUZM<?
M7K%1LI :LJN8"BG9F*XXKISVNVD''PF&EIZ\&$97JBP"(FS"44#'_P#7D1\?
M/#?+C:=67F7ONJ2]DIK(1;R/,31D%'Z('K"VD=99F,>Z//X_SC9+5%A:YI#=
M_P#.^1A$CXY^_P#GS7C_ /'W+0@5?=*'9/0B97-1OL)?_3_O3NOG"^V<<ED1
M>M+&JG6#,U [Y)F),/3IUB&?C=@Z'6@#))_LPF)B4ZD&"2\C+=%UXAU%(5@H
M5J*(5_K!W4+'0V31ODKKLA,H9P43T:+,DCI,@*R+TTB&*:(Y"'+@[]L&;OUZ
M9D63&V98[M&W#'*\-NK9[MQU[->S+3L_M;L<,\<_=6W^C#;_ &]OF/OONO9_
M;V:]G]&7\9?T;,,_X_ISQ]]XYX%W=+<P\D\YU!S\A](U0S(;'9C\EPPP%C$5
M:P@#OZJV.DDJO\K07S7:!&P6(5366MA8@C>^5(LKU6M:\Z+9&7*E324#?3(5
MZ*H"Q.[QE:.U_)\NP?UH&M=T3CHBS2H%&XYL?FA9-A+9K*<K4R_R!JXR74N+
MM/FW5(@LDQ$5(6<<UDN:ATYBAAU1?8VH.:A8"] ;D-J7'94*Y3<!C,I&QC&O
MD<QA"6)(X03(>3,'2\H!6!.&S<8\G9[%GPY4/?YA(C[=>%*5)R.NWJZ_SF3G
MOIFU62N=E/\ <ER60WU:@G$-3MK_ *XO[FT5S*AW 9M"L1C=NWP:Y=&T<4)1
M!U;D;>P!EF6'$W RLN5.KSG]=]M+%(<EBA4+IA=NF-+0'DJ4TJY%8KJP SK^
MDS55;NB2*B4.6G2.YM"Q1@[$V]QVY_ID4K5ZS)[ZO221:>9*9AU5(]BHEEP#
M92OVT"XCEMR<:\/S5\C')1P[S7K#/4G=4(;(^>>,8XK,HLB$-#]O].^"0A[X
M^['S+#YE8]>X.\RL\WQ,QL<<HZ[ (5_DT!,7:"A[B>X+J=IBI[.\.QE':9CR
M!.MDWP, V9/1N@8S?96O/5C!+\QP!U=J[IV,?!&0$@A^D'Z.GQ\<V*GB-Q $
MP=AVT7!'8.HA'CYS0QP7+BDPY6-CM@$X$C1,A2-^C;AL]@QUV@O"U^B?2O8]
M?58Y.3]R[P9Q^SJT9>5R<S9<5;[[B[QB=.<_@9FJ)Y&9V0[7!%=;EU7@294^
M/9*U6$W9#\QW:?[H7TJ[2LO"V"<4QA"-JBTB8!Y::%HK!.+S"#*QM<T88"&1
MF^2/*"R$3=JE0I\*1OBRH^S7NT[<]>>.7ON9X>;,,\/?<O/,\<L/?<,\M>?G
MF7GOGON&S#W'/#+SSW^<<\,L<L??XRQ]\]\\]^Y&*RLOK>G^.Z?1U]KZGJ"Q
MZN_,;\^MWY]TI7U(E3*?>]Z3*7C^6<I71'EU&X?WS>FS(2Y75@IS6T)F%9UO
M(_YW&B"I)*4U1YWUN[]DQND@+V<M3HDZI,OZ^]+\Q3:I.J(354:SR2.YEN=O
M4&6'%A5P/8\Q02ST1/G*=GFFV6+V22FQ>SWSQQ'R!L"ZNEJ=0>?ZK1Z9J\3N
M"(5>@] !='RB$XO/\C:]NV3)FE"Y/?*)%RY2?)EE#!4A(WS21.9+G2MN>_?G
ME[K]35.?^5)I,8/+C$&?U1T<V-FB&S-,R1OL*_[* D&L\)5=9N;O]P)%5ZOC
M!N(KAO-,*-! E),*%KQPD>Y<QU0]7=SV-Q4LV71U^==77:#+^4)"]+_(N%-^
M!X%9=$+S90T^L9M*[?:86()]AL9#G=&ZY:LK$';_ )LJIRR[18'I8D.('=U]
M)WM85[W[!=\&;IB'S16?ZQ\CRJK>U/GVQ?"Z#59C\T[F@VDYHX@Y4DYCV(DF
MTFDF.9+#EK9D,MS#,PC GQ=.$'=F'1^Z7K2];'MBO8=JU^BGM"$<M*2.;VL*
MM[(E<+3 M*9YWF;3$R''AK(EF<58#,+RMVF'J*GQ<+W;_?EZL/=K?^/?//?/
MX]\]_CWSW_Y\]_\ K\]\_P#^?<A5DN?7!-88[K#Z[P=VU<_/K],$FAKA;Z?F
M2K+L"IH?Z,\JP.<V%Y3R5;!AN5B.]-!-IN(**UZ"-LRR+\>MRS'VR9DK7<9R
M5:SZU]5= KUW6ST/"MT'T!?J@L\^RZO(#^>Q/-JZ5SD4,\!6C35.H+OW-=>^
M*+?(?=EI22A=Z96%"VZL\!^( 4%HK(YJ"=Z \;FI<5O6ME&)BOXQ&Q@3UD;S
M>,C(,J@?]E)C?[=C+8PY>0P(/_R"<_R+(]BQMOFG9_3ZA8L* "B9TZ3'A0@4
M?-+&3):;&'"A(H=&V3"!,F0F;-,2 /@1-.Z5-FRMVJ-%C:MF_?LUZM>67D$.
M^6*TE[;Q+Y5^HYMQ.]_\\KMC?Z15CM/]JK24-[R:]I?V0&,?\<!X;(XSR>U:
M/]5($^^Z?-1F#_DY>;:-K'/]Q-7-!C%TLCJBP-?4M#_NF@V0@%U ?%&(XNES
MUL1N6-:6,6JR#GE@\:75L6OJY \1,3K$"M$J)$P*Z]R_@,#J$JFVZTO-" VC
M4#J L2NVG3ODK;DKS<"0 Y%C2MT/9+%S]?GFJ;$]D1]N.F5H]SCR<,<=\?9M
MT;->S/8GW+X\OG5E(UD50A-M]CI;16O /.#-^>BDG5C)LV+T-TR=6'V<\(5Q
M$=-'MVD_/!O@ZIJUGUXV&TZ,F5>;E-6J'&RD2FH'MVQ6+MV33WZ'6:)NWI]7
MLF+^AW/G.5)K:TL+11?JZC3]V<4#;!;*G52=7D_6O1B$?K@T3GMHR< 6"Y&*
M:]>$30-(R,PZ)OM1X4O6X^\#'2GHZ1'M,O4J_2A1@VFR6 S.NE=P9GL.+]![
M)G@+3+C,K>=EY&?(6)3;IE80MDOV)IU:<:0%EM[4K#H?7MW7+UM;%;(GZCO/
M,\.OV-(03<1LY:)?G$9Z4VL4DJ/JE5+,Y*+T9E#3D.Q2C9% AML$<@;)N?\
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M.O\ ;MQ?/I;_ ++2:XI-JBL35&(AUY=.U<Q-];:EA?:=+D%#C8D[><B]/[K
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MF4DR&*R9.X.EC'/#/'S+#+'/'W^?/,L<O,L???/?<??//?/??/?X]\]\]_\
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M8W9ZM!)]LID&J"*L:,M>O;[X19&0P-%P?-GFO1CNE8;9.[1&QV;L-@_<R/\
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M_I\R_C^/Y_G^?Z<O,OX_^?Z??/?_ (]\]^X\3/*M[&&2K>4[*YGRZ+Z25_\
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MI@'!ST:L=D3:[=^6K=Y*8,@-;5"77XO/?YJ*%<K29<#%SI/2KZXI:ND2Q6V
MQQ>HNS5_?L#0+52(2=!9T1A&LH<-/#,(P;%'"H^T+4.F.FE3G7DRZ>N-$#RS
MTJH*5<+OT#TXX*RP>5Q45I;9JTK;%[G*#9ZS@^+CZ-*^9R8.S7OU2</=VK+'
M^K*TN\E5K:K63R&0Q1.54P2ATT>8>JV)DRRU 4DIGGOO^E57 ^855N%O<] .
M7I>H*P<BRH6)&2)TAC(&>2B!</+W2ES?E-:O(=A/M8-G4MG<COE+GK!%!]J+
M5).R6Q'++FHOH% %O1F%6]4N='QW9B$\;KV8:=LR&L!]6_ 3$AS=GY?="N;I
MT18%;-M4J;;T-UE9T5K-R"S1'F[N!NFN5>:J#OY1QEC%;"7_ -QAFZBH5BUM
M"V;<EJ(7"BY.;&/WE)G^.%K\#J>HM>U^F.;@C5LHJ+L%3%Y]<K6J.,J6/F<J
M15N2*65I8UZ(RA^GU49-TW4);HBZPS@@>0XCQ,I.G"SDO)FKI/G5$6E5S=[\
MI5-3WN%I))#6U6FC+RTY#I.F/(CSU4Z7.PQ;#"D:)<3?IE")4S1MTRH^S7LR
MPW:\LJS,/S9;?_5&&LG<"I*12R[^CZ]U@$2Y6F7-DBZI3/R7"\,)8B$!EJ6\
M-I<EBX  AI#QL2'D,<N#H1R(9P.QM,#&J>W>>K&X_5D6K[#_ .-.^^O^=6+6
M0IU2DM8/WIR 0[;O'H&O.=J%>)W+=N:]KE&#:493(+2S,J<LLD&)/U9L&:K(
MAG5L.J"P+4A(W_5NR,(]:8MI6.N5] FCFI$"1AFID#'36AG\V.#0N^-$#1'"
M>^8@$C_DCH4PF:Y0-;)PXA'?$_VAWE2=IDR 2L;AJRQC(D=$,%1"'8*DWDQ@
MB?OV1H)0A 7RY&5"'3).G='B3I.K7&D;]6S5IVY[,,L?(X=4T*^=(^\2L*YH
M!K.ZC^O:CZ4>PCE-WZB$155J[L\";7Q.8:"9B37"(3>ANB-HV;X@G=C$(;/3
M&K'#1_?ASP-^;UD\E&^"B)/73HO1SOPUT9SO=GM=?YT*0Z6A;=R\[V>N'Q_\
M*83_ )(#B>UQ8<XH18=L$C%8&?=*ACY.9<C,]"UDI9-,@;*'HYI^K$-<!U:W
M$!2@4:54=91E.&Y%2.^:/7Y<_2T$5J!D/-SMTF-$W"XN4$K*SSU^QI>>'\@6
M;3&G1M,#+!K#5&8DWRY-Y6 V*F&@[7N$,:/QM7;.CS_-9--P'ZP\+QYSV[PF
M,/ ;&\*>:,8N'E?EI<>727[JT="4S&KVLE-_&):KTR\%[&,.I:Z*M442QUH8
MD1:'.4[*$(;XNFG2+L6[41[R6O-ZKZ;'-"T>R([1F^NN-^379A^M*V0&[1RH
M-BT!^=7-G&R)"B6#9+@)N9IYAZDHN\/Z;7A$*85]"A45[I]'1$IO "-;^47H
M[@Q:)&EG@_V8WH6\,G=O-86_*H1"[=5WJ<_\\7!>BCTO-LJN]-7PQM>VK3E4
M'$H2W2B?D*439C5E#]_NT49_Q/<U*8/F:=TS7IQCS,9&]330>QF;VA=5%O3O
M&1MS R&QH('JDFR,00&C["Q23%@8;RY8A %C-64CS9/(S8D*+CMDR=.K.H2U
M^#+=Z L A9;K5'+M=;)W G=',PQ!6CI)\%+EJ])--&SDAO\ ]\1IM(URXV\!
M7;5#>F"$M#RT;PK&'0AQN+OF;\O._0*F+% _D55%$3@*U:=I)C3^7B"<$EXK
M$UHK6U(O6_*0QHEL6<,"39)B)(WA2I)C,;5_=,T+'D\I/@8^Z]^GP+2=W1O/
M49!PM:1>]-:*NV&-J[KLG=:"1J0=C!HD2(N\%@XYG,5W,QIE194;:,Q(^S=<
MB-(TYZ,=FG9CC]QJ^*.6S(!=8KFJ@"P-8#6UJP(U8B@+,LJOMC$)FID "YQC
M1-,@-D044E:S [1)'9QAI#?C)]U0Y&6NDAE_,/H\_;9#I/>*J,28(]0VW;V[
ME&L>B+7J2K("R^\SU+SJ/;P=S*%+036-Q22%3YV$V[)%0PPAV._L@782P)QO
M]L4VB*_*H.&9F_+93M1LE4RORE6.$E6J&.X;*-'A['G8=TM]@J$>_P XBE+,
M#UPQ";!7PVFP84'_ )=KVC-4G4F1, XS1K"TW;TWS;H11UH;^A*/TUF7+;@(
MFQ-ML(6M%*'(_NSS>&'-V9_P!-+:/=.[S<.C$-LS7[JV?UZ<?Z,OX]8W?E%+
M1\"J,=TU* :&G!9V+"V;L9.%'V/!TE2H*=F!#SC.@B7P;)L&;#6<A\:1X>E0
MY4<7[*W1]V&%.U?\)]KI+#2EHN(OFCH*32HGIVJT"@[=>Y_@I)IN[PO/<1+(
MR;N!<T:==A6PER*69%8^S&J/#SV"J[,)*\AD(DADLHQ:=R_&>Z1G/5U5;'8Z
M29[&9/S_ .&^7JIL<M@;A2T^P>=KSORX+!Q$D-BF3/*-<0O^Q:^%UAD(E2BV
M6E! 9%1@:0#'[M(7/+76M:;XEC&[0GAJ&45.^VRA49ON!P5TH+<99+AC8QH\
MA[6$@)SE0L7/!T28<#9CG.(ST(V5&^3 \B'*S_7J#J17Y;C421;0^9$/=O0Z
M)0'IK(Z)7Q2/L=P;@=_YPP3S.6N)F!"1D^1A.CZ]VF1L]F:<]6W''5GYE'7]
M%>5;8Z)BU"V<^!T@;T!3VRT=]27*YVB43X=-,%AIVA4VF"5;;:6NM(O9)-:,
M,8[W7;<)6Y4X6/C15MJ#2R4TA$S7L#EMXZ4 \9"-TFOSVVB.O:'Z M7QI@[X
M@1F 5BNNL1A_XR#Q'']'^[DL)X847Q)';'A1L(^7]XQIVQ=.6X)(E.C>>@:<
MK6&:OBF0Z \[\HJ4\E+02!Z<X2<,]NO*.K,TLYI"L&_'9HW89:A,V7L\ST[<
M?<?,M>?GF6%[1K-?Q/Y'K$10F*HNAV]IR+MP ;BM*;%*)0E]H/\ LPAI\#KI
MV:&,1 YLC[&&DY0DE'A2=^V#*PU4IJ_YR]%50\1;(74;EB\8^@A^F2<*I.WV
MMH7*S2Z][.[$(=%ULR+6V%3=@QM1 <FY:*[ME"AJX>&4![] \"V[(T#?HGZD
MM7\GNMH7/S5052,E"V-E:/Y@\8\'N]C6\\/Z;/7VKDMZMD^2< ZZN5:_9MP1
M\7;B*#UZ(48EF6KDE8/Z3R*P)6[' +ZMU\T;'+/@#?<]4:#M6#_"UG!=UBJ&
MLM7(KW'3GX3?!V9C&8H#_<),?+R:P:1T;W'?IR\V?QMP]RCQ8'?-"H-H\Y)T
MES0B5;=%(W0CV+Z T6>C1JD6('/FVM(AB.09Y!3_ $Q/,^0L?6.A[QY;^T-F
M ">F=Y[G_&.JLV[OR^Z;L)SO6!5I*M*BH)^O:%TX9J+?=CRT9W]= KHRL;BD
M%);S%H\!87,:_8J^FLNNP%M9;KK6(SV:6IZPL0Q"SNV%=MHOYF%H5S\]VN2K
M*LEH.IY]X-UP)+A>5C]13"EH]2)5"(:TU@7"TZV ;=N$X+5)K2ZA] ,")$:2
MNS(7J89IT[OW!;(SWA2J3M4-#G;]7*.^P?(_J#I9[ 4P&UX\E_XO^)ZH:RI:
M)FR^2O\ -A?X_H7&;_>_RXO]O^K_ "-7]>AZQZ\IPF4Z6#,^:I1(3GOJK?S3
M*//;8H*B_85A,%25/>_A8!NF214;$DR:KEQC8B)&>\Z6+"#!3S_)\DY?VZF\
M?RUZE#4"/JK_ $O+EOLMC?DOS3^<K\QVTW.>O_HEWI1:LX"?M"I\L:B<9+PG
MM,RSM#605),BM3,UOK-+(>F].&>O>$VK$_-OH!+O:'=@[VE;XCKW6EA69#KV
MYVYE""'"N[+X,Y9Y3SLQB.:*OL?"!>">XT.S%M8WQ4-"S*-8#:/C-PHF8_C$
M+,N4>J5/J+EJO^JL!7_6J<\@61DW0FE@#2M*X'6F1@ 3")1DB[- 3T=GI7]Q
MC_8X[=</2/D8;-NWS'7GG]GVKI#G?>DP++T7U2^ZN"AR2L#+ U6DC[$DBRPX
ML^;+7H#7@=]!3#D6$+)RY(F//V3]$4=/D;8^.J'(SUP*H?COIF@OR5!\;(#;
M2:OT\H4PZ)2BSZP>YKHD2VF&=D-!]6L&U*$K.2HZQQ;0)PTFD4S'%^>^;I"R
MP1H7HZ?&:LOS#OOV8HDK@QI\]KB_L *_0QB!&F["S/\ ]'8[AOWG[3 ]*0Z!
MIU:)V?!MZ/$<!NN!7"R$ACL=1+ [D9B_UR M6NKL"A:7H\Q>9"SZR.+^=:O]
MCUO$B6:D0,+DCH"E/;IHBM#$TO\ ZQGES(D+7HPDAMA*/$]F1Y,GSS1EY[EM
MBG+&C7#4-5VW#$RP,.TJW1[&B I^_3*G!8SNL"V;0)FR8WF,>1+':B>$.1OT
M>>:=V[3GLU>>898^?4&$?R;Z/$I+@O!@'*]G;;%YU_1WFC!;M)C:A"32HCJ+
MKVZ^AJ;>Z]BCZ==<C.CQ)L9:1;30XXQ$\C[4=-U+S3-% O,/+V>=T U4_/\
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M26P2A*PBM4?01(DB4;1O,W^<-@DGYZ=8CA6\;>X?K74?Z!9[O1AG IMJ:N:
MJZG)U;$Y>H=_7)<IDQ,9)4#/+;N7-85@]C;I6O9)G1_@FOL[HXMU)IBQ-G67
M.>*$OLFQ0-.?_<M?Y*XYHU19<[8"DG,3_H[$EC!'D9OL;R1EG_AC2,OSS_'@
M2]FG8)KI'GI<9*]33]YU$&;+9&0357K9*QE&&;L,*4_CP693!N\OA+9!!79E
MAI%$Q.J5!)2=FJ-!WR)&W7KRIA&_FUWPIUSY4M7WW6M4<[1,]JX!X_6;2NLL
MEJBE,IQ_2IF]2Z;8TJ=?BZM1[#8E-R%4%#&YI(]?6)"?#>(@TGNP]WUR[P=T
M?R@X5"35&#GVP@>_C3@OEZ\I3]X_8GE,UQC"/BI[31T> %D1#B\\P&TN3&KK
M<23Y2\["0;=O)E,-LT'K"0](_I+SGTGMK8A2+@ELZFY/O0M>LY([9J HM:06
MYZVM<8W/UUX2-[V5Q#,&:B0-#R"YCMUBT:6.=CGD$7OW:X^[PO9_(+&E/5D
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M";K/F E^7_U@OV*$P!X'#&4#7/AZK,/# <"4N ?\N1-EL>A;R($!4#=(#+!
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M)J'XYR<<;0NP^5;2KN?;U<]#T\[54+95U-(60M/RX61HC4VEP:^M@-S3$G[
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M([$KXE70AQALG^A,XP)TOT.2VZ,]:^X*"7.5+I[!'L!1EJVAEBTSE@#XBZ=
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M<KRQ*LFMH;]1[#[R6UIP@N$%7(5U:')1+E9BK@T4!8R28MP'0V=A>!1F ,+
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M0J#MT>;)_P!O"]'TG!/8S]L<=GJW&]PW&'[I@:I4B*K5^:(!GY7[9YFRM.7
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M#SZ CYE-$:/-5G_Q,?QN!81((*,:--QVX!A<S\X N\/882):D\= >OT;H/\
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MUET"TVL9MRZJ;GT<LI*HP66K'^> :TQV^P'=P=_FUW)2E,0]5YMP85=_9,6
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MD?5/Z55[:EVKE.84I>J3"=K_ .J^842TW*!6>BOW6X^09SSA9@0%& V8>?<
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M,ZJN0G5*U,:**[8Z%#T>L6@MSUZW2@?"7L.1VY$U+YPX*-*5D: N;H$T*?I
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%/GP?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image06.jpg
<TEXT>
begin 644 image06.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'P !  (# 0$! 0$!          @)!@<*!00# @$+_\0 .Q   @(" P$   8!
M P,$  (+!08$!P(#  $("1$2$Q05%A<8(2(C)#$*&25!,C,T429"<34VD;'!
M\/_$ !0! 0                    #_Q  4$0$
M_]H # ,!  (1 Q$ /P#OXXXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#D<:W
M]945;MA,E8UPS,C0S*)IX7#TZ)5MKQ4.,P5LQ;E%Y"1;5))$*KRQ5;9HTH'/
M@"'"?)[)0YL:/JWYPY76K>["5V@0)LWH#F&+<'$D2FH OZ8D@\;V#XFZ7@)"
M1R$T;!WEB.6KJ(.TS",&+ME[M.O?+CZ\LMV%-'E33;5)VP\,-:5_[8V>)AR&
M0_=U+>*NO3K,/>H+N](#&>>W4^LF_P"(L457B( <K".VP083FA8(QS4*>J0"
M\M-([=X60O'K7SU6ULJ%(/-BQUNQWLZMJJN,G+K?V"G-CE'+2DY1EO4=?WH0
M5M;M (KDK*YQF&GF+*+^D&'S=NZ/AND;RFGT,NVOZ!]D>="HNM_4DNL_+5WG
M+,L^NK/3ZS#^838NO*[L757]JU(=!8:K-M*\9-ADT0Q4:]L;SR6%[[+E'A82
M& $,SY;DFL63@H*K;FOLBEFT+@1BR57(?I$-ZUD:&1B78!J%1Y9#0,8P_<G^
M/-CM,Z9KA$X\F-A*D8ZNMN88_6ULUW< QE,5JTP6P8GV'8-4,LL?JFZM8BPZ
MK:R:/8*M(ZG18FS*<L-88F%G;=&&V'LDP]F<.3)C]Z]V?FW9==<>>:X+VS;)
MW:MH@(LG!"AC2*+&]D8B^NJ]7JOIZ&@X1$GNQGM;2$'9[=$39KB82\IDO+3#
MCR-^N@$+X]]%M+]L76E2]'IU7[K ^_UDE(%=6N^U('9F^X_755M?D$RT;*S>
M%F<P[&M-G/S=5&!/?MU0M\>83ZPAY_J8;X]6Q17N:V*>W"K]I_V7:5[N%1?(
MP]6,U4>CT*J$["NR_GYI]B+=OJ@VRP"'(L^%<*]:[D_:'!29C#*O3$G^IRI?
M2YGV$#JG2; 5+$B'IRB0DDHJRY-M?FMLD,;"]QFM%-RUQH'Z=9T<-VD(P\Q!
ME1-)D=A+"%,=7[L01GP\]<C/_%2P5-W)/(A:(29T^MF[)%<M,@*<%8#&C%=7
MVOL?&DF!L"*;T_P#2"G=%0.XF'[RFY0^I_<^).BQN?=LKCZ,KXEV+H@[T"4/
M7OZE^C_D>='DNI&;IIRCO2?HTZR>8/9H485:=>D(I>>58>2S6MJUEH*1E9['
M0- GN(.B:H/NM54^J0E_&=KXH^PW_P BA/H)8,K!3JVT;%U60708W@/R@E>>
M'>$97[+4WLC1Z_>*W=?;2.@M&@?A:Q2 [LP63%AE"\<+QZ/NVM_1E6*=T5$=
MVLM=.^DG(6S>\27![9VH.<)KI#+,4=A#BT3O07#D(O6,N%HRV]:.M^KK/1MU
M;,\X:V<*DJ[(YLDON NJ( PSGYV,>3+RA!0(Z25*R\8L/5OER>XT&)OW=1XN
MC=)W=X?IZ-6S;ECAER1I%-_0/S_XB(5T"I'V+L:;"^/5M^>ZS24 _P!E&:L?
M6FJ]+Y-C3SR1C/\ !%*3Y-2[+1CL*R8Q.429XBX9&B"L\U##AB<L;E3_ &V]
M>W)6T)2%YIU?QM7J>J7B7 :[>=4"X:?)>!SN-0N; P'+MDTE'VM_H;,&&$UH
MI4H-:4=T7M<\^Y[M[&7DF NS8_8'GE1\^UUZB97S:+I2V8%13J]9\%-T+DVC
MN^-R]%J4:,30"\6=9!QTG-0 >,!ZU_(IC/):8DJ+HW8[<<-E5)<E:7JH8O55
M-,=J7,3)Q;G;>H!8(6!LRP2WB&-7:%EB'B&=39P1*/MB%UQE#B38_9UK[E0=
M6&[3ELJ.L'SM>1_Y9?,ZD0RI82Y:];.OR+SL6$K1%G8]U+%IRS//I.V&;9%:
M1["KX3:M&K1\N5Q*AV 9JR#;_P!P+)QL<]&V'KCY6]=5SJ$U]V.]$;ZE%>IO
M>[+?5G(8=FL=^]).=TY5#8'EKT.S)=(WGY_9)8A?1##Y4IR.G:XJ8FVLBB\]
M]8BEG" 2"!U <<YG6Y"]94F[/#.2:?6E]Q]_B-A7+'N>ZXKE4 _SW_CSP^VS
M-5I(1A!NXA2+LRV-;>D..?:XRK0G9*K:QT_8,6S)8-5'S,].5"F^S7ZDD!VI
MA4]SCZC9/)/SF+>K1;[<KK/MST"TQ[5KYIOXEY@96"XRI$8VF?-_;R/?C5?-
M=="G..;6EA<W['"'C''!UB\<YW!M >EK +5DMB0?L1&\D%?JDO-RJE--R6JJ
M7&I^217@:RPU@:K$8=-F3;1"T8Y>N\-<A;KUG;>S&N$;&925X -(B8<? :PJ
M[VJCMOBEE/J?JVTF>N7RRJEW4M8!JU<*N TK_P"X%:$),O<]>@.[@X_79J!Y
M0&HI?L+?"C;D6W:X&*RJ)U161@/2=H7K5]ZOHFT[&&U2C-\TL\%ZR/7! #RE
M%R =[D!9LTA3YHUGO8@ G3&V1;!%S@NL;)STDINC3B9@Q9(3?&([OT9/55'*
M;V"K4XU$HCDQVU.H\2*Q2W?=KEV8.H5@],2U^.1U+N0R7KUTPLEFOHO F2PV
M6_3BOXS^V/O(5AS-;O/WKJ'D-:KDHSWI8#C,\!^Q:J6FVHK$;@S\%OHQ[ZLI
M]\[1&]G 6PHL6SN.D;DYF4IAZ>:1%M;U1-[)%CCX\?7&FF&I/W(0O*MV"X5V
MQG,RA^Z%1_EN PIGO31 ?/\ ]/HR4@^NM<:\RL?2MI93V<Q,*WJQ"01>G981
MV7,ZB];YNZ9F%Z:);E;67%!2$IO$EY#)7B=; L'LSWB&W_'%@8D/Z6X$DPWI
M'-H(,Q[1!B(.WG H[+80#EQN>O">+GQH^QN<O59>*O0AMAK8Z]K7I"NO0MK?
M$'QA5(STKK?K#[QK/VU0 ^V6FP!%ZEA-@=Z!I+:6/5QNE]-0@@OND_%RAZR6
M1\@;[)6V?,:Q;(]$>?9?L>SQ9M/)>PF:-<Z5515@FFXE2U)I3E5#K54'8Y2-
M@71M/A$_.SC<T#'T12YRP)TS9EM_#3CI"QGCCC@.... XXXX#CCC@.... XX
MXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#C
MCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.
M... XXXX#CCC@.... XXY@S_ &?6M4!X[#:5AHU:@)A#6)B'']M )P>45W1I
M<W4,CDV(@.A;R&V' G2]<+5ORDYQH<O?CJ[U1]V> 9SQS&-;LF;5#"P=3:L;
M4+8"Z:-;OK/"LU#-9RA_R.+%@RXR^PV0+(?WU.Z+XS>Q_</O]SU(_0_Y\_53
M<%)]7AK:BM"ZZ*AC#=M$,RF;&,:\5UQI6^%(V#30>5,&SL(\R-)B;LXLG;CJ
ME1]\?/O';JV88AD7'/$$LJX?E'(0)@"&IJP5[!,L025@$92\;ZA1"788Y'A[
M]VT25Z'$($_L=/PCR^H4V)*[T_H2=.S/!,KXH["P.JFSN6J<+4RF=#L:TRL1
M0QL#(AD.P,=0>DWLQTQ]S.Q.S64ZC=#?UNQVS"=UA^VRQV]AM;CCC@....!Y
M9L(&90I=<8A0XZOL L@$.A"\..1$F0Q6)M@$Q10?+U[8LX<0A;]\2;#DZML>
M5&W;=&[7GKSRQ[_D !"*H(*L+(@:OK:X)' 5\"&A1AH<($#P](\2(%#H>O3$
M'C1L"/'A08475JC18NG5HT:\-6O''K1Q7UUY4!S#@\UZ5H81.6;%B5 Q1"5M
MH<&0#M>?&E3(M:EM4D]JS@/FV) (2OZG)ZUG=<<>0W;(.&N#+RT[R!G0C.&%
M,:T8%,*\='Q"P0\#(1"P8P*GZ,),$F**0-TB"0'S8VS7(B3(F_=&DZ-F&W3L
MSUY8Y=AZO''' <<QAL=4]"&PS#NTKZB)(L*NI0"3(7@!8,UI=F$:I)Z[%E$=
M\?3(-M#08$KX$9JSRF%3!&$/A:=TJ1JUY?<"8E]I@9%5DZ&8Q>,\L*R) B<(
MO Q* 2DP(<&Y3!^^1'ZGAC0^>(+0^]G4@<4@S!\S7IEQMVG /M(CH!<?.$E8
M44D+*0Y0XD.G:-4J%/@3=&<:9"F1MV.>F1%E1]NS1(T;<,]6[5LSU[,<L<N^
MN_A6UM?35T H*004M*JJ%%+:RN H$86$7U\'!T# P0.,A:],,<*%#HL: /@1
M-.J-#B:-,?1KPU:\,>O:XX#CCC@.... XYBX%W36DNX %IJ7CYRO3D18? X8
MP/)$TUCGKP5MA F>#$D;I(,M+5V, PQH!+7&D[PQD:1UZ\HLS1MSRC@..8OL
M=TW2Z0JXVM:[KL$BKDW> D9F1^+9,30Q82!+-<9?[D?RNY='&SP41,,X1>Q\
M<D5@0MDC&3)U:\LHX#CCC@...?YWWUCUWEEWUUCUUWWWWWWUUUUUUU^/????
M?^W7777^_???^W77 _WCF,);JGV.IK[Y7[2O.Z2V"HAQ8;50Q /K;"'G:^ML
M,H&,B]\H>1@R=??66F3$D;=6?7X]=9?CUWUUD_ <<<<!QQQP'''' <<Q=4=D
MU[AE""2U+K= !LS,EF9BV9'FHPEO3#4Q<;E<EN'2)&N"P+)\?.#'1$G+5/%$
MHF^'-T:=^O+#K*. XX__ -_^.. XXYB[&[)J?+5(#6U+JU.>V;4EI,0\9'B9
M#:X;PYEAT*RYIG2-&9E@W@ET\7TAQ^,B?M'!B<O7HRT0I&> 91QQQP'''_C_
M ,\<!QQQP''',7<7=-KP'FSOK4NI:WK*+X38?:C(\ &UEVL^,5%@9L)E)$6'
MKG,#,:$  \;/=CN(F"< =%PVRI6G5F&4<<<<!QSX29,<%'3RYB?"%"14&63*
M$R,K1"'CAT#1G*G3YTR3GKCQ(4.-KV2)4K?LUZ(^G7GMVYX88Y9=?$LLJZZ+
M:^XJ!P2SJ;8$%,JNR@"$4L"85T[ CE IP*5@[=\(F)+#94:>.(0]VZ+,AR-,
MF/MV:MF&?8>WQQSQ5UE7&\1%8%,^$: ,W.9JA&UTK!-")>P?-DC9^N*2&[Y,
M*1G!(PY8^9AJW9Y1IL63%W=8;]&W7B'M<<Q=J=DU%C!YCHU+JG%86A<20$AC
M,CPNDVY.!6.#5%43L(2(^)%B9#,N,+!AHG>X@4G;]<:''W;<NL>?<OLBZVB8
MYY5/!68'+VSH\4ROE()D3)WC)\D42TQR(W?)A[MH\G"F#IVO7NRSB3XDF'OQ
MUR-&W7@'M<<QV X*14>:+"VA=)"ELB<$,1. ;&3!X LL;]T9E%FIL>5LC"B*
M])CR(YR%.VZ)(G?HW:I^J/LU9XX_VJ-:P]JZX[I3"&;4YO!BF=4:5PE$,K[(
MN'8.@F%.@RX_=(@E!)8=*C3AQ"'OW19D3?JD:-N>K9CEV'O\<\H\="JX,RS,
MI<: 7%T41.GSIF;'&B H41#W$"I<J1F;-,2 -&P8^^9.FRMNJ/%BZ=N_?LPU
M:\LNO]!G S,%#LBX6''EYA%CS@$X'FQR(DR&+1-,\66%D(FS=$GCB,&1HF0I
ML7;MCRHV[5OT[,]>S'+L/4XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.
M... XXXX#CCC@.... Y6+]-5NH"X#S6V6?Z$5?.IRE[W+7#5K(^5'HNA)9G,
M?1=PUM*56%*E;1^!3'8LVB;."8 X\%92!H*/TK4C,GCAWJLZXX%4%:^NPK7X
MJ2='JM=2:)O"7Y1IVZ[2K]PH"T'&E:XAV,UST1&-GT/1K';-"SJ=EGHF8K.>
M[BV^M@N.B0Y$ (T?L8\=4_*NQDJNZL<JT<M7<<C>GN?V/*JZQU:M+ 2JE])0
MY,+?>K3;U:K,P+)'4Y5FD3+9$8)#,M91?/,-<F"*F]N^YEAD)UVO' H$^>=[
M^+*$LWZ=0ZN.I"Q4._V/09.O@-5J+$5A$5^P?,7BBC]#<$"*Z^0*'PQ*_2IA
M?;'&%')0H+)BPF&8G&CQB)'#&:4GSMGLGZE50LWSY]I"WK4]8O.NFA[?1\LS
MZ([<#/S^\VA$VUJ[L(V^15B8EKC0*F2-Z_NJAMT%>UIP#8GH,DIU^RZ(>.!S
M/EO=_N2TJ17?008B5H^N6CT10/E^VNF)1G(&=#R*VI&TSWK&S-S(:H:\2:NK
MN/J\@F><@MAG*Z<4T$!2]+1&R7XC'FT8;V\W._M6X/27GZL7OUX;D(6KQ9=E
MSEW"AT9&G(=K->CU/NKBFIK(]6A0 ,F5+KU0SH.3/H3E6L@C\SCMS>)#QE:3
MHU3[ZN.!4]\W/1'H/TL<LC?;$XO"A>75A2\A6O#E+H(.*L?VW6!5BZ].6>O;
M8PZ(2_I6R!_C+)%Q']Q5J5I:V3'1"_<C,/VT5QWJ[U-GZ>%+'^6K)F7-+^DC
M51QWQ7OJ17T5L%\$0#['"$7OK8<:OTOV..=3PUJ\8US;;9VJ!-M*[JDU"MN_
M9@"C7>533Z!2H)@7J\#[A(]JL.Q;48LY9,F:(&'JU7(P]NAR>4,2YI"3MGGS
M<S]KIVR<HXL9J@!QVJ,-'0XVG9O Y'Z$HNR K]\^B<:X_347&+]!/N"8DZIB
MU44B O[ K5['T#6R5J*4!)W;,[4'PX64R0R22(TKTW%<$S2)T$X&F))_Q5ZJ
MO$UI\YJ]T6ZXTTR:O!_SY>O.]!K5.HZLD>H'^UZ0R)W?_:HT:GILX/F'M'7U
M7<A,KL_5HNE 8B,WEA4046PGZKQ\?4%!YV.OU'JLT#(L9HL1WJ4(K1=9.5-E
M6/6]<0;=>%';OCP-L" 57:W)0&N9@1EQ-.R!+T:HNZ1-SZB\_6R_3-$4\3)!
M;)LH"K&!&FII),5+Q(RR,.+>EL1:-J:7NA#8,V1U%=;8FQDH;)ZU]Z=!/9WM
M(YPH&O9,P#FM!^O_ */'O(]FVAI]0A(MLRJ8\_:WNOEU/P>;N\X>C;']3TJC
MM<>'6C)Y&J=6KY=445JM%0/5Q8).Y3,Z4!7W *P20<4NPD^F6OV=26SNGSS+
MMDO9%NH]<K3XQYNNP!W8I1+:6!J6EYX9=:BL*"GU@;/)[.)TY P B-UO!R,?
MXV/C^GLW>^I6U63UWJQ47M8.[=[%8:G%BPBT3][-8JF9Y2798N!!V[-4R?N2
M&F%("L6</1OT#Y?6G]7;UJDQMF[T M>I:\XNU@!E^%"=+&UK&AU8\>]^TF?B
M)8^6,58$G=(W;>M T#%($^QPV%A&@:)98P1ZC]D"Y*5*#G7]J6K:;]Z.<ZDL
M>X;,6-R#]1?D[$I7RT J0"<0K"\SQ;Y\EV(<OHB\85D5;]N6VSYUHQ61G'V0
M,74/=4X1,-!XTT_AV4]*D;?]LMSZFKZ6XO*Z)4JE^Q-\]5*GU)5:6M7G;%*_
M2QAK;S@B.9F=5FZ<"%-"05_^2Q3YRNRV#HE;W(B;FD)Q,W.Z-AQL,7WEXPDN
M,*2%\GV$/1QT^)-WA#/0^ 6[$%]4;;MV#2?0LJ+)=P)F.F7T/)0)G>K]O,C[
M-GI\#EHK_P!C^[]WGV7:IOT^NF%8KJ\;CO2!1;6MSW>WCZ79ER#PWHYZBI,[
MR'3ZN@P%-$F%@4JM796ND_6LH)_?R4K8#@3=A78=\/MBK'J&G+ZH;T3>=UEM
M_P P??B]YGG&UY6'(GIKTM6MI5JRU?4C# %TXO V1C=XXZ;U"E+?2B0L,<A#
M3:1.Q@3BV1GI4XX'+G9/LOUH-ICTE(\P^I[DOT*&\A^?WC9?C/0]>:F:D?5[
M]Z%445A0E=<'4HE+,_>5K$R?9V*H'):<3M3R%F)_-SQN#)KCY=$M7L:J$)3J
M V6^9M:V:L34YH>Y;IM6^[$W+]AE'*(G-+5H3E=.4]/3#-2FR .Q KHJ-AJ7
MMF.<'3W^END[GYH3HU0E77K%4.MX5<OCU/#97F-$[BEI+#98VA5Y%6#\[,IW
MHEP88U !-2;#CB=\X9#U[#\B8)@2"!$[)VA3):_N2^]7T;A5'6#/<Z^F"W_T
M;45CUJ_B*VF"LX"#X1=O0"';-;I8BB<G48A%[0$J4!-LYNO$Q'>BF38FXH^R
M-L':A<>Q'JWZ (-&)$YIOZYG0G;OS4^?/I^T;4-T76DEB\['[5]&U_7?K!ZK
ME*0J;#B9<RNZ#<6RPMR(Y GJ>++(49AVPM\;(R-(=37' IZ^5,G^5LSZ>,L2
MQW*Y5YG]KI!)1M]W3Q:@4L-:B>'O(X*&5BXKZ:AK+(*%2A$U9'MZZMPQ+-'"
M8%X^4C]WW)W1FIKTEZCM"X*D1&2\[>RN>U/1WL&I?57E*#5R8#6?+/GA66_0
MVJIK=26_94&MB S0<U7\_;DEX<[!=5Z[IUGS?X> 6Z_1C [UE2X:M>-^Z*J/
MRN:F:')[KWN#&+1L)^]UK C($V$N0H,C/3+($D\A$D:#VJ!IDX0.M7>[;GUH
M[QVY?[4-N5U?59)-R5&T1'6L[& 0VA*:X$8A#AGP)#K+*&2C12T,>2TZM^..
M7>&$R%&W===?CEJZZ[Z_$.17S9KN6+3_ )<<*JO^_ ]L4%\$/5<AG8]R=7['
M8*7?=5O?F$MN\Y,^MVIR?U#R6'M=E0I*N<!3+'/A!_<;4TR!V>HEOGG-]<>]
M[!])(JYJM*N_/,8ZC>$'.FDFQ8QX(HWQKMY?5F+T9'Q6(GFFQVBQ2<8_+::N
MB@%N^:H(51L@!6YACPX4W(W/O?M2_::I))L.Q+0L->5E&IH(@E9)+9(W%9"7
M!/[XT8)(/A@6@F<A8%MDR/V/ZS&]YR].SN3IQSCX;-N&6-MB)"'.2!K@S"UZ
M?9#A'K]%BD=W>K<SN<H&=98ZZ+QQPR_6([@2R>)8:\N\,.XXR1W^?K/]/#,(
M-_-XU=]@UM;=N7E<5CV"7:_47KE-4$AO3T%+6ZOK2G/6%WU;68A1'K"&JLI3
M630EA>(S&5Q-,4P]'V#9,79IT:^M\RICKUW]#)VCURV$;N3DJQ:J1?I.3,>7
MI \@P6*FAJC5+5_TJL-7UWCY87M,:9C.7ZO=M3\V7S;"7;2XV%!P<5,,R1X\
M/T_<C%47M#RI?;P9K6G;YKJP'T#'99A!3 G->TUW!3&N2B-\\=$D81\C0]6<
MXF]88IX;N?#"G,=8XCNC2=^C7L"BA]O#Z"59@YF8/JR];!ZK6@?DI?& 9@HJ
MB,!SU8/J[TXR4UZ-3B6:E2(,G'K\97:?J/:TI<F#VM),,^T_*<^H4&-$V9NG
M>T/11[UZY(@'T18+L[+'UO/^:X/EG74Z5A7F?C;"M$L_8+>3;A]4QW#N34,$
MN;?X#_E:>B!%,#!=>G!I.4RQHLZ_.R+@K:HLD#&QVJ&K96E92Q3Z#U,C$9/]
MDLERUD=JRJQ?XZ',_;S"VL21RTR9_P"T':NHN?[F9H[RU]9Z_P#-2O0,%2<+
M,\Z2H19-]%68U7RP,PPV9."VY\:=(E=9&,=F8E2>QL:5THP(G\2-UP1,3?!W
M9Q8.G/?ORV!S#T5Z(](4=X8J--"V_;'G]DJCY8>6WKQ%3JW3 %NB>M/2A</9
MN#O6S?&9:F=&@T3TN2_5]:SJX4F%$8E);<)%C3=FJ%/C'A-AMA^LO=X&T_5?
MG2OA1IPNKS;5/H[VH!TY)HB6%?:RL>CS>/CGSK#EC1&S!B,PO2A:R%3;O"Z/
M[(47_,@[]^3);G7=C+OUYK%;I]"5+0LZY PJ5JL.WQ->@7DY*+E9^,\'5L5C
MC(X@>.FS-XX&.#9-[3._:!HL+3,*'RI.;C(FR]N_(.<CKUK[P&TS_=%?U%7]
MHUBR7!Y=4++LX;.*DW[S8ON"O:I&Y&1T;-?@Q36*Q76)H#5&H:0QR@;'.47*
M9V$BZ% \"2.(AKA_#]VLI:KZL2+]O:J[9NBRL;S=*L-5_N,;LK"H^M+%& (A
MV41(UU5,-H/)8QV15UN< =>)2XVD)D5C7 F<"?NEY3^YIG9W2D;T+%ZW;%W'
MT89IJ=T/U;MLC:V;*56W8?V7R&Z=F6<6"O:WEI"]&=D/"-(*D=@+$EE-U!1?
M0\*VO0/HRVE/W&_5H;N)UJ%;6*&IMT\BU6L(( ZN^O[=:6FU@]FJ;<RDJX<3
MTS)<GAJK4]B:F-:$:6PCENL29*R@=X&!-?H[VK[!Q\]60XUYZ(MRXK2B_)'U
MWZ#]$ F6BTT!M\=>XJ]1T,E4"*H"8%,J6V.:(O)BV5.-2+U(L%@(!ZR'->W]
M:!NDESW4;SRHAX'/*%P<$R*FFU_$?D>#Q",.24"8E]&R2*R+C].[.6-Q)QM.
MZ0/[F:=/4W1JV;8W>W7AEET'.1;MZ>UZPG7_ %MO]E%AX2NMOS^M;JV+E6:S
MJUA<PUPHOHJ??=&5<^*GFISKA(.,):FT\VE[6BK6O)>G&C"/+8QN;4OE!GDV
M9]%/1B\&MC*(S776[':2'\@7[R/7MH4Z'WVY&7KIM<*M>KNV<2MU]( [&'0)
MT&!=KY$HF@(B$]V&0:*KZ"0+7OZ+DRQ4>P\F[!)9AC)DANIJNG'H9MRV]KSP
MN:H.XXLD?S88?I$QFHE SE:L?SXX8RM7X9Y?CW^&63)<8?$E3YN_7&APH^^7
M+D[<ORZH\:-JRW;]^W+O_;'7JU89[,\O_K''OO\ ^N!RGIT-C1?2/E:Q#SA>
M%4( 7Z?_ ':%FY2.$&:@;,RN]\/;)5:P?T-*$R#",FV-8$D!0\9\D=H8<Y&Z
M,JD]!F=$E]?N@>\O8]Q ;LUUG<]V*X9F;_D"1KUA<$RF;,MFFNO6GMQKJ+TN
MEL T%YNKRN0;"KU,' ]NE9G EC;:G,9$Y/;O^VG=Z(W1XS>F:(3Z%T>H&&R0
M<*@Y2VJN$6S=.HF2 REEWF!X"J8C:Q<":3WQ#4L^'U1N]4#/9A^^UYR,-.O#
M=GKWKP.8AW=+G-VCYHEWMZ'] K"+Y8^RGIGS_G><<$EKA$G5!_Q;8ABI#5K2
M!-/Y(<^#OLES'4F#;,% (KSX++U'([<VW,>PC[4/ICZ!.T;6U6#%P_;B&5MF
MS9B3%LZN2%>+"PD2!M<O#I&[L]\L:GKW&J85AE+6D(K:A-<$S36\2 "IHF0H
M96;UOLBW[]$71NDR=VJ/&CZMF^1(W[,-.C1HTX=[-N[=MV=XZ]6K5KQRSV;,
M\L<,,,>\LN^L>N^^?***BSHL:;"$H!D*9@0RH@N*F1R(LJ+(Q]<L>2&D(FS=
M$G0)T3=IE0YD7=MCR8^W7NT[,]>>.78<MLGV#]"6>@3?HG&Z[26&2I_EW\I?
M4.=4+M)5S@J67Z'O9[N;7Z$@M71RJ"3OD/* $D('/HJ475=R[J,Z"H[%>WQ8
M&'>:.=IVI;/M;S"$LZW[.)/E8_9RU@V_RWLJ(+"KZJO/RAY\]7J_GRUXCE!K
M"*V=1;$0":<]Y.!RSBZXU';/,K@H='W)NV$&Z;>:*#^F:(/O92L15E I#Z&M
MDO1<]8V8$89+&V0-1@[X,)4;J;!CZ2!(?43($>-^^!NDCNA4[#5C-RGZI$/4
M$&O<M[.];>EO.J$RWR[>5_-3?4]Z-1FX$)&6G HX7^E'JFUUG2Q4@TUO9X]?
M'ETD[9;E""1 HD]9)!7_ *R!-92XFP9-BD ]7>HI7IH"M[+=LR;<A#Z)M-+G
MO%\RFEX370;P9#(,ND%?/93?5VBQH&4FK8:M>.BV9UL[%>:X&-].="=TO+H#
M&Z!^.!R886-[PN7PH>3;(N[T';#3ZP^"'JKTH=@:JNKE'9%+TBB[*N%):+7.
MFOZC7RHHB^@K8.IS KF]S"T,.(&,:6\@9O*5+URY!>A;7%O1%L1?2GJ2V_+/
MGSY-)7IP4 JVO*2:WN^[;GV)Z,63\/>=8Z2PV%'976D ($%UV-CJW?\ -Q L
MYM@2Y,<CJ,WE.ERU37+?5R ]V K*;I=C 85*E63I:,/+V"QKZ].:S097B;\L
M=A.>-71LPK*T:?QRPCZNNNOQV[M.O9LS@<NU<>Z_4IRNK%[/7T_@J0$_03SM
M5K1Z>B@Z\M-UJ'RY;'D,):3*6C/0GSA7U8%='?I @N5$1?YE+EQ]5QWDQH*&
MB>2O'/0_H]#6C=5:^H;3O?SQ>E[6HYL7R16)7F?$\A@\E6]G:N;NO7JP"$"O
M]=/!M3I85=()H)<FI25>@!=XV[!TL<'GHY>*)T=)!FS$!>?$>KSC:$%V%90M
MR-(*?,FZ])UM%5YK ;7>>$A9?]2;'5];2N[#&>O_ /1,#$'+/K\-W7?6<\#F
MF;/2_IMA9LZS\U>Q[VM.C6CTG\W*\$^K=M-U))> ,V\7&[1_J>K 17=00.M3
M\1>056GVR:PS*^(3JE/V%+73,[]U$UAX%A7UK5663\\S:BOF6<RSQ[K\$CH;
M7L!#FIJRFBO<7F?O<ZD08\1%"%" [&)N:"^O6$A NNXLO=M@0Q>&>G58V'L5
M(/NSI7 9E&$7FNX"F3=UF-MRR)K0]ZTF)"C*)ZN\.L-6H_H &=L#O'//O9@/
MW]Y]8?AC^;RZSMVN+B@MI*M6F(UP42R'ZHFR1#C$8V :QZO8IBF^JV_HC#A9
M[I:XQ0)@N5)B8R!V_=HRS@S)6CO';D'/IZ#]C>DZ;1/4%3E+>](;G%+]AW_6
M=#^@.@5'H@K^IIOA^G?3RTLVHU2/,KXJFY92Q[';$2H 2+50PO8TY9T*1%FT
M;@Q#,AM?REZ_]'M/K/SJ)NBSF*Q!GHOS_0YF%2M1!%P+&\[MA;Q^LV_9[1Z?
M0CM)1F\8J.%A3"F:#9BI>?8H4PGU2IBB!$DP"V^5?YQP*,OHK GA_=_G!L*V
M=::0ELW@OZ$UH-#!<1&58.]K29_G0\IUD?\ Y-&8X_;-9*Q'=YPV'F9#GB?5
M;P-*3-@$-!F.<@77-Z^Y?-'E"IJ[K9\L!JA;?E-\O[;ASG*LE^/'\Y;V:XT^
MD_0$Y/C(E&LQC^-0*#E2W N <4ZXVA;E)V3?L$E8^)801ZP>.! +YVN5PO53
M/IRU+KKR^PW^76*'4KPAEYK5*CUUI J^WI<<WO\ PU0:Z^L@9NWM.O2RJ%9!
M@O8#<&#29),\',2\Z(TKT;[RF4([%U:WK,J'JF?EQ[2]7@DVM_/]+ @[MZ(J
M[V#?(^MA9L66I,S^@/+)B8'$&D=*BK19S'F\F/N=@7F;"T_J\:6=>25EB<VX
MR/7%11!%V=G82\G7#% EX /D%31DG,V]XZHH\6-B29TV3MRZUZ(VC;MS[ZQP
M[[YB=0VVB7M7*K;-9$"YA"=ANLRJF3*@XH\DR&D=]]PB\8 ]@%ICQ%$M/6,P
M01WB-,,N.W1B8S=+'2HTK:'-YZ4NNWKDOM/3[,M.QP;(F_6OYI;ZY\J JD!D
M:\E>:L2%%/\  N_>XXU?.>]6!:P&!YGL;MOM74M*Y12AUD5"#B,?\F_UJJ]/
M>W0-4>>4@.7)A#7N;JY:/IXJ$H)=""//EY5I[JLR(YV,<#JZ&.5 0EG\EM!V
MPA?;D"VBC;70NK?JVRRCS,[G].W' YASOHR]8AE[0WNXWKS13S'='V4'BW>M
M* KP@0LZV:ROX4I>>*A.CY%*M\<IB>JP^_6 ,(XCH#U>QQ>UZ(KR5)BMVF7I
MA#]C^D?-7BE+J:"YN2 V:OFY\-]_D=2QJ;(N8Z.N,_JOO5&P9 P1BVZ9N&!X
M:^-?H[=^MU7\7N%-ZT@,)>B3OZGWFUJUK0,X'WUX6E<77Z3/LATVE"L75)6T
M$9C/RFMY0=KSV$M #3V*):NB7[3*-ND094;1GLD:-FK'.8LJ/.BQIL3=KD1)
MFC3*BR-6766K?'D:\=NG=KRZ_P!LM>W7GCGAEU_MWCEUW_\ ? YA;B]C7=;-
MZ>R*2 &K?GT\<\D?611;JGLD>ADBBH]>>-2*DU>85UM$HM/9*\7'^"R/!"M<
M'.WK1+V\A30;3L%BRT?+?MOF\419$+QIY(A3(TB%+B>9*%BRH<N/MBRHDB/5
M:IJWQI,7?AKWQI&C9AEJW1]VO7MT[,,M>S#'/'O'J3?' <<<<!QQQP'''' <
M<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'.=)UK[WA#
MJ3VM8RPU^LM3NU?3B4KXP"1^\':8H_/L-:J/@9)^7:657]#G]0Y:OV5(Q2]2
M$0]FFEO)G@)3/C)U"AVKHMYCX1L5F:6RP5QC!'YJ8?R5&^(&+0"<E6:,0P=B
MR7&'1"W[M@8Y@ 80)K(40QCSL11H5/RT=19\7;M#G=8!'KJM-?GA]7K4]E^N
M18"R;7EK'FC_  =[L\OX-:R[VS5,5=U.]REK#=7D1OI2% ;RJ9I]TM)]*L&M
MV%A&2M([(.,G;=8HCM[2?FMY)>8F?V,V>@P/O#Z]HA(K;1*S27BZ%0J"5]6*
M5$K<"0=V[*.[)*EV"J%6*MC#L<K&&3P[X+9>M=7P->O#I]-&@ZV&+,3"5' @
M  9/-'#9B;&&B0P<5%VSB94H1F;-,2 .'0M&^7.FRMVJ-%C:=N_?LPU:\LNM
M-U+-H57,&JMIJ$!$;3$&7Z1)P4X 2TJ1_3?[TYLI&QX39$'=IIXC83Q'<&$E
MB).S2NW?(R,3(4<>3'290<[CH+]OG*H/!/.Y#Z:!!!GS?Y'"W:7MLA=XZX1?
MJ4I[-\]P+"*440L["2>@[X%"[_0$N[)U*:=OGO0OZU#<NZMD?"=CWLJ\ESU_
M77^=-"F=]PNBA1?MNS6&B*-BSO9343]650=\9>>6 +7&WU141LG:==JP/T.V
M6]_C1NLHT;I>(SP)JJ^:)014AZAG2AQP.9&U%'T:R>JD"P+TKOV]OJ9.^E'I
MTKKF4V,MIA<:SH1V^8]3K@#4IGZ;ZDOHZJ=MY$'16C&*GE8[Y[AT>T@)&>S=
M/ZRP;M'^A-@5BKKER*?IAR'=5C\K&06$=!9LR8[EHGVL8'B26L2+%PVQ,O0B
MKXU U&T>A94CKMC':1,TDT98=Q=^S'I3FW370^[EKSO*-;\+9;:M=;F!KN(D
MMLCRJ\KYK0TEI-[#F$+('&VP&2RD^!K&2"&LG+Q)9R8L3;&BR=NO:G YL]5&
MW.]^D_%EFWTO>QL!@'T9]KZDE6"E'?0(X_6:S</K.?M\@&C$:L2^D@L589JI
M:AQE1W+B.ZZBK Y'BMY'4LZ@?6J;'R]?_1%S2K;9[T,MW6KS=J!^!\(Y8_OE
MB+:N7S">;0WH3U#T,PRVPMNRW6,BK#0DW;)WDAT=/.#Y76G=)DXYVZ<UROK%
M742CG< (Y6K*O@TY^LEFD?JQ 2Z,FM!\]8UCN9TA,W:HL3^3/F&%K9#$^1AJ
MQWRYTV3NUZNLN\ YZ3507/45Z>TNEE/]N+ZO:/U*JNXKN/5$0]'&=KWX;;?+
MM8C"QJCS2@6)CMS..]*+D!=LX536<7T(N4L(,KP*%%6QX>+'F_2O7M7KP3[B
M[1_\LXVKVP>LN_GI_J+_ )C.ZL4/^FY?X"ZL?JR.\G;LEU:'3%VG8V_WVY_T
M/^E?WWKN5^]ZY;>,)C38T>9#$(18.7@Q"8HJ,E:)PTF-GQ]<J"0'SHNS;&F0
MIL7;JDQ)4?;LT2-&S7NT[,]>>.7>G;P]$5EY[BU]ML26S;"5K6$/JRMUA)1G
M*QF]R>" )A:\A(961@A\ULT"U)2:6H^8D1(X4"O+Y0H6(1(^CKO,*9Y4IXD!
M/)/]<T?57#ROTVL4KU]TU1?7D3T]G8,VC(>=;8Z^H&.GT]_BC4_XL'5H1:-_
M"M(UBYJW0+5BA9&.1=-H/TE;JGMP\RL?O\.W5Q\JO1+CYU&+S\_I[&>]$#/3
MWH4MY2CV:,0I488^^F]/G\)14)\3&3$QD>V%S ]U7BTN5UG$ZJO_ /O_ -7_
M /GC@<OOH YZMH*):"H<L?V_JJ@K]&/E6N5^RQF]^.6PYH=N)M8Q/4"?6;5L
MRQ82P(V[9,>AG0U+=J#+!F2;$)8%?S[AB='I+-&>Q+BMQ%U")/J=%3\5_P"P
MJ!Y5O>Y--EZ;DI5 L<1X[Z\_F[28GS+7:0K=.MY4MB;54&UI>E\/5$ 7X!7O
M/K5ECCT;O59H%G1UB)8*B#;XR6\J=F*>D[!U3M:^_HI/ RGMPOK;UW^U.+A7
M7A/%3M?X;8LC'K/#O_SUWFN[3JD:=L?=AULT[]6S3MU]_C^&>K;CWALP[_#O
MKO\ #+#+O'O\.^N_P[_V[ZX%97S;M6T?8-&V#ZNL[0[UV)]+',(58U7O:M^>
MZIZ_KA2'U06F+^R!WA'"&7>UP=H6)#-BMV[=.7#:/*_>;<X&CO75\K3?K3.-
MJ*VT0_1\%>,[%CY;-A"-I*QY(N75KLH,;;]68;!WKE2>AMQ53*M98'N/Z\'7
MK;Q2/WIF8SY6G1)Z3$%"3*M25.MZZ6A":AHJ^*55!5 Q-<$,OKP2'J@"A(Z)
MK_XZ8L.)HU:=?7?>6>76/>>S//9EGGEEW YLX]1WPP>J_'EU7ZF>L3BO4?T9
M^LBO'8EZ9?DF8E5-9[@T1?+18B JXG@P94<=& 0H(,S2@\VOXBK*'#&J7&3R
MN[';G?R@ISTM0._Y\I[6,])A41B^;5KX>@%"TB[X10:\OM(N'S]C4"W%46#?
MTK5*VZ41PM\5""K@D#*:E<#KEGM!@H"V%]G0CQP.7OW)YALV>^_;_2H53Z:/
MN7J&A/*A:C":EA=;E7#YH4!0E2L<<NQXDP]3\"R$HR+A2@ZTP"H;>+";Y9%.
M'YK!%A_5D0PKGM)"]+&Z\2#7K.70R[]'Z>-+;L5(6);$K71KC\R;:FVI*Q9&
MZ2PSFVI0/J'!8E9)TN3,2E^S9 U=%BA^,J$*U7^<<"JCY3R[N'5K8E<W&'O9
ME_QR61!J_P"E[XD>C5Y@].2RB(.G-CG&I?U+.(672LX 9PQ#-:R#DY5219MQ
M C6W6H1U(CZ*VJT\3^P@'A@]?"V6L:#ZCI(;]$@7E.CXM> *_=:T'^B?9+N?
ML-T$E3TJ88=+6;Z9 1)5(["^X"IQ=Y\,0_KQ0C.'&(?1O<%K)%$5/9EVV84W
M@ZYJ!!;[-?34882,[PZ:B@)[,S%-0D/%G%2.0\,,FR_V8^')E[^M/>O3ISS[
MZZ[]C8^I6C<CQ9;2#'3K+V[8]?#"I&,*+N<J.MD'&7!7!)'9%)%B$%5$E6*?
M AQ=LR '&$"$S1HC0I.S4'.Z>0+R?;JJ_*M$[VNV^54KW'\W'Y'_ -4(N[R]
M@JSBO!/2N'J5Q@_Y]QW70,I\.$GT)@7+-?>M+AV'*=?Z/GB"V_CWZWCZ5ZKB
ME?-./LZ/]#]V6'E.A]M;:T"%>>T5UZ'[] W;%OS'U'L4\.A&)WI#D41V"TW]
MMPK;&K,6O>O8=-6B3LQZ.>.!3C\[F3T@Y7M=M<VRVV":2O 6#1Y$U-;2;V3/
M]1MAN#0$N0';K%CHF3,"YQ,\T2J !;)Y>9*)Q7>P+7TYZM7Y\)$B-I:U/86G
MZ%E6J,@^EJ4H]2V^\UNTR3>Q^@W:D#"2@U,MF_/5UZYUA08WDQ'#MC.-)&T4
M35>7]F!89&%NRC4F5))P>KZTNN46NO[9VCJPA8R>W4[8SED)B]1\V1Z9NHF)
MYI+Y_CEG++D]<"#ID2MF7??Z$.+'PZPT1]6O#)2X@4?%$P1T8/-@S8^:(,AB
M\*,2%%Q1*-MAD1A,=,U;H<\?/A[MT6;"E:=L:5&V[=&_5LU;,L>PY9*IMB[1
MH3:L/*[[-:+VL]7\=Y.].3+X^CLP[5E5[Q[Q"M_V5%B)FK!QG+[M;FL(C,U0
M>;1@_)$V1PTF<Q:4*69[Q\ OL^JY[Q_6^.W/VH-MV1\G;P"'YH2+88*Q87I+
M5[$H /7Y"3W)B8'=%[84?&<" HF<C;G2>IX,)<ME-_<%M^Z_^OTSQ5Y0F/LN
MJUBO$(YFVU76%D::_$D&IL"GWLB(AU*F-0U<T,;(I@YLA_%D%X9/BB50(*9.
MV/O :%D2B74R^!SA7XE>MZ]*>H%12=O;)FJZC]8538M&IFG9[(M$SZ<4R_A^
M%*L"E/\ 4)29J9>E:5U+O?9-,0&R.Q2:M2K6C15ED7NE<EO'#I+>,*X:U[Z-
M>MKBLVH/1-6GO2- ^+GY2CGFVY7VHH)-;J,TKV]7+(UBBY&CY-BUFT?QP35&
M:HHUCDZI$MA0HW8L\5W;KI^88A6 J68O[&A,G3"036?;%?.5.!GU[=_-H[07
M3&:+B/9!@@EGI@,8$K TD,(F0TIKC8D!$N>,DQ9F\*$@U:^SK6]< DVS6/VL
MJ>?)?MOZ636 BD6#;-6AY%,:*<I>-YKAR'%0(!BT"N,F^8Z3JEQ%&1L&0S#B
M>H7ND:/Y6!+QOS6;]T07#PTZVU$]<VP[V)Y*\Z5_==6,(+TS4:SYL>8E-69)
MM"_F-N'2(7F*Y&QC:<PPVP*VM6#ON80X?U,JA3.]>GH5JZ(SK:JJ\A<B,S*!
M7I3BPZ5)2CFR\ 5O9VJ2,*FHZTOZITC1F8/2 X,T4T"!_4B?N'B24O7'RT0I
M.S7AU/W+7M\*$UZK$Q(.K ]]M.M),^2', ]F+A3-EME16$.QA&X(^;LU!GQ)
M8Q&J=A'[A$,8/4R!OD1-VK;D'*3;U=^W[0\>Z4"^U#Z .]IFO#'RMZIQ30Q]
MQ$T@JZA\T$Q[)C>B!8/\R)+NO18HX_+L+1=.K-MR0HP#JN<>Y^!?KDV]"][O
MG7)Z:8S]P^G5M^7;&]Y24JJ5^A?3ABK;'H3:AVE#\G!T>XL+BG>3EDM#@[ZF
M:09%)JP3?6^U0AE3/Y[HQDI-D]%O(R5_['\W6I8>^KZ]LG4U-&HDQ!8LL:K.
M_P#1SIM0PW;&H(I6C(6M%9.9I<PC2\C8A3;S1(9^QG]3(VGN!,ZT!H?S71;G
MH^:B95;^>O=OMRS?*@G_ "F0N>V;#/7#)MI_IP;%=!Y!O:6'$\D$8[/)EPM8
M8#,6A"I.PD=CX S=^ZV[*Q?%]/76)6?ETH15;W<HU]Y\^;UR$KEITS8_H^G@
MC![/JW=Y!64^K'\@Y'!^!)9WR,;EZJ4!&+YU).!0B$E>CDDN.4'2>DWC@<K]
M>,OT':*P]:E_Z3[AKE&8Q'R\=):!B3]<-%YHRVQ7)8./T,1_.CM?PT78K!<*
MS3X]:'G.Z;T04[9.PU&*:&QRQP7NF9+7*-ZK3K"L\M3"I[6!5Q8/T@]E6#JG
M63!M:.\-U3Y_&984*=8VJ4Z_F?IZEAZ+502I4TJPMF3;H<%Q<$EN\7,;OU:^
MGOC@<NXW1[IH:GER'(9/8[/OLCY\?,XV]R+3LJVF)P*>P6GT\&4_0==J+68F
MDF"L+/::G.$P;JKU1##GQD+2/:A8'^V#8Y&391\V[=@Y"F.GIV?I!RL;=;/H
M8U9^^RI?HFQU_P SF0A>MV=,\YMMK^D)W3CL,_XCM^N35;[80N*$L$% :VB'
M&@[XDK]Y9+957UY<2@10;235Y\32NV#(FKS*.T$A^<P7,TD11'3ANQ[SAE!)
M&-&(B2L/9'(BR$:/.@2H\K1JW8:E\HQ?.$2JIFCRPNA%VL(-DVLN3,0*Z4 Q
MBUA(E@'Z]L@MOE&HD<DUR>W%3*C.G';(*QST09$VC2TT7JA98!4+]!Z+]H>@
M[V]!VU2%+JA;?X^J>E^O)+#8+LW)C24OU.>P'JVT&"E5R%4+L">(=D"%BJ?.
M1&5.;DR+)G0'E5DE<1LDOWA_IL/[$-7U8?H%5D>UAT2=]1/!@>O*T.,5I#*R
M ^,GSSKYDB^C,YE*]3=25O4Q34\V_C8)L\)*XI%@IN\B)F@"X@UF2N'<_5E#
MH5K"*28G.;E9I?M0_.N+J18#IJ7<+ ,RU]&WOI]-53ZU6L5N,0)\->EV$868
MI;N#-WPMVZ-%W[M<A^!2/]8$/T*9L6O["\\J%I%7)"^=WUX%*3C5@LS(.J-S
MNM.49C2 \,8#:LY A\:6Q<EZZ[TZ,\"1(Z&V]"L=DF)WUC'.PJM];I^=S((B
MY/<X.N!*?\VK57F O$]>7^=M&R<1?I.+Z?I_-PI,MLONM5=[Z2*7WV=+IR<(
M%5RTEQN_^OC%QQ*B9'2)SP6IF"I2PR.3')W0EY2 F&8],C#R):1$"@1\@J4D
MZ!0>)/+D]VB#$W[=0\7!FD9F>&,:#$DR=FK3F'.0>/>\FEEUM;A7/MZI:%8.
M_E.6N2K*_;+7?;<K^MY%:>E]GH1.K)W1-N5JMK&#N3+SS&]*'ZRSZM4NA],,
MTIITDY$S3AHI"JKV&K*@-8A$/:%$T"W>@_JZ[%&C&G/6=G7U*L!]]) SWEUS
MM!;\VVO4]R2PARK23N?3& _.8T&>S:M.FT!6W*4'DZNF$KZ(I@.GM[Q+>Q^X
M,@)"U8[O!%031UQ5$QQ'2RRJ9/UV$&D; &=,(X>0E"1\M9UE9N XCCH@Y[($
MO#3NC'+K+''+K\>NLNNLNNLL<L,NNN^OQZ_-AGUCECW_ +_[XY==98]_[=]=
M=]=]<"ICQ#5_H;3ZK]3N_H6R_2CW!35+R2A5 3=2KW6E(N^[/RK7,B\;)5*#
M@GLZX@LS3;FQADM\/?K9\D9FQEA1$V#/TDI<^*_H&J?7[7?_ *H<%AY]Q+XO
MOZ1?.2O:E@UU9=F+]<B?)S97?EQ>]9,B6DCMN:214,=S?=$Q[;R88U_2VA;V
ML8"<L'A!&;,Z$..!R^>@S'O-1\?,E3K"'[<;["&6+]:QE,72(=_6TZPU 75-
MN.T7PR(9(]$19MA7!+M5-F@-M3/%YF=]2Y"E7/\ ODUBS8P^&$K2#OZQA^S*
M*\\%G"R(ZIZ?K^AO:%BMA GBOZ*)7/)2ZJ@/3E2X0]&_1*61-UV/*\X12(>-
M##A=^NP+TZD]Z]^6S7*O6YKLM4E9'G$C8)M&6S#F6KN=4A-@)C-$Z=/K(F5R
M-DT:7W)QVZ=RV2*Y?O2(S/5WHG;L=?[K';AJU8X!#?U"Q!_9'RW](LU+#7YK
M%W_XLNDE50@..<TQ_;-S94;/L2APD3#R"MVH@RS]PV,/&Z.\,6"-/TQ<<" H
MI^254S H/W"DI'KB549/VR,,U?XN\!K?FU**7-<14'B98UP_G[)WU<MV*VS5
MILOH G1I856T,N9G0BO6"A# # 1#&%EA>79OK+SQY\!-49G*FA4>L&BH:IVJ
M"=5U@L)62Y7'D)&5!7]=+*FI3MSP69,B@N .$($<WJ#?F_;%_P")ZB2,-&R,
M;UK?_+B116XF4AVG851N%X+:M.6V"%OSKI"8Z[4FHJ3F21NL>%("F&U$L;M
ME940WEN);N\(&6$&7EJ"ADNJ>K'BU5]4IHO]$UWQJ;]K^)M,8G831Z,3KJTJ
M<6GO2)#UGHFL]JRHWHL'YR)G(?G@64G-L\:*UV!,<<J_(CH.0B=IV1XT1_92
M#Z5\YRW!G]D,E<G[!^L5?6C#NYSL!Z30U3U=Z*#B/"TXOH:_UX TD;K$;L))
M-ES_ ,SW90TL9VFVID';(<:!?[QP.=CZ.T]<HGU=[#O"GT_U5NL)]^-EBUIY
MO?*.GWZ57=?IE&/WH=$I,R%6Q24G*[1M'MR:=08;V)&+AUHRF$%O;)>M6[/;
M^EIU/[#9[?M9S$.ONP-H(_5_R;6RV*4;1M< B"O$!SS5YVA7J>7DD?+Q5-")
M->V"U/[98&P7((J+@$D%E(\I,$(E.F]$?-36U=U;T?'KZ59)S<#TVC;*#2*3
MEH$EBW96R+-*9ATT'MQ$PIO8[23GX9ZMI8CU%$P,<?U)TV/AECWD'/:6 >^Y
M%=^:$YXL+URB50%(_3),:WL177K2\+PUM"QZZ/K/B0M9T?SA:M47FPKTKS3"
MWED1U/EFA'9">D*2L^&1_F!)3G0Y20UR#4W4XBQ'$C8;\,K=('NKZ74=2 7=
M6J(MC=!]J+(VF<3TIQ0^4URBI%8TD9NH%,E;AFN3NPC8Y][/XX#CCC@....
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M:=,K';KUR=^&..W(,ZXXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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MFZ\/$_H4;=/I>?4_F^F'GSW;5E^%@D!!*KM&M& >C:2HJWU%\E5)4UMSA%.
M&]2?35>B T1ZBZP_2+-;9ZN+FGH /7ADOS=\7>HZ%?\ QHU7FO0X6%0_+*5Y
M<L&?D\K[20&V[A?R>Z#%C1_$RM_1,3$2 6S+0:%8Y (G470(C9ZORQ]/5JXS
MU/YA-J9E^#>CJ&+HJZ;$K3 Z#+?KZ>I@F,]*TP08 RQQ&':'%FS4V3'AB14V
M9HG$94C3'AZ-V[;AAE]Z?Z2\\V*3$ JYO:FK#8&(09/+:^CVDAM!MC#KLK.
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M5J#[#'C.^!U%?*,(N3JH;[;^?S+3!JPX+JQM(-3L2.N^2K(\RV)VL/$%';V
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MO0]BW4X0F>8E@!AH17-EKYU=KF*V ^Y;F,#;2&[^O_I"H0Z9OU@\$-)[P7]
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M "VW\B;H\*J\9T8&$20TW*_WVE6>$*E]8M3/1XB-J75V='E&8VZ:6T&<XNC
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MFPSU+%J)>-IRE[^KOC@<MRO\??:RK2#QMVEZ%>+OW?6J@?I6MK%A6ZZ,8%S
M5Q7M9+KK5U@W-&\^ 24=D/&%H]UTUC*8DB2,;7'V;P$+"?GHC95G\IO:*EZ6
M:/8"N \@VBY2_77N*X!WG^X7VP>ZLG5Y[(\X>:ZKC%M[O"I,[.TV!7S53)\8
M4%[:W_CG"LF D)CL2]-,;,(G3/QP.6B'\*+H7ZJ'UA)8Z-M20H_!J\_F^F-K
MMJ+=217J>SW4@T 7('&(*!Z2N5>M0R\P(,9XDK^XPQD:)'P6<,=N[#78#Z5^
M;SKZ/KOY25BWRUL@K^/[)16CT/K'V59: ;-!U?RQ8=0R=E7N5?Z03GV7Z?F,
M*1B2/YY)D[P^J1ND3M?YI [=<MQP.2EC^$7H^4'I=498-*^BJZI*J_7GD,?7
MS9Z?]!^9,GJ@+FO37;-2W ].M$U>>*GK/U@9<Q/] H),9-'6@0$C7.2^S6(A
M-E1]'U,))H?UU=JZ'4M;S6(7_H#LB4=7L3M\C]4;OC^(T#SP']JM !V\UL&J
MRZ005,,6!P&@O[9%#V:1/&,0JHL&+"-HV]HW' X\9?PS^CC]4GL"#=]LT!8-
MQ^D/&5%>:L#L^P3Q5<(-M-^K(EP$3^T0&\W5>!KFMV!%[EPE>NEU;:.E*;%A
MAI!<E&E[B$*47T"^-?H"XF7W4O>5E+Q5"J+VQYC\\5,+_P M0V10/^8FGS@Q
M/!N*.IQ10JP8UV0LV1L;(YO?/P/INY4=HN3'N$L6$&-#(]-G' Y[P_RBNJ5Z
M. 68\:J+9:]A_9V_/H857BA(R;W;*AL/QH,I%$AZA)-$R&3+*!6D(AG9(R1O
MCBAD6(,.#F.3/C=1M% ]E>;;4\06Q7_G"Y*D:[X@*OG&J(IFB:+D6,O!?6&>
MSZ:^B/4253U.M6SR3<D5MG).ENKJ<\@A#CY4T!-8N>#*N9Q=D=S]7_0(XX%8
MWLKS)Z+>/1OCCVEY;QJ(E;'F$)?*.QU!?+(V)"G8]9^A@2+J81L&QD%5LJ8D
MNRHPUTMD1)+)'; A&/M+0)>&O7E&D90">/E_[+:6:)[&+_Z7FOV4P?1^B?:;
MS3V+D_+-%0*@H7S.\>7T>B5:X9=3-;L1:8BZTP'EE?2U3C C*UP=\>$I HD0
M?OD=&W' YGIOQ@O1FERIQ(I1Z2QNGU*^@7KIUL-1(FIKR(HCUIY\O2I4@4&.
MYH  JPNZH4LA;S)K9"<#7_V(31OCF]V</1HU:47_ (1W5$\ >EO.NRN//BMZ
M-LCS]Y*\V#+<P]9>FKM4;<5?/-P+CV>*M*-:]9CPE(+A 0%V;$^OTB \:Q1(
MB6$[S<4-(T]\ZS..!6-[C\3NEB(OE MXV&4G75E^)/2JWZ)J*MG(:02*/:X4
M91L1"=ZU*9URO%9J)J9URS#T\2T U$[_  S/&AS9(2;HE3,\8T>D?(?OR]+,
M\K>LB%>>&FFZZ40_853,GG)VL6V2-'1TOTT 1PBNQ@[0FTH6.,#VF:TO(>^X
MR*@4A#RILQ]6#R5W'O66E7H<<#D];O@E?>?FVY*3',5!6"VE?CWY7\"578KO
MM.:)L&X*AMBS;"L$M^,E$/D%"N945F5X2G.&2B1J1@NA-1(*/R$Z=VGY/?/A
MFYJFLQ38DFMZ*:0WI'[Y>(+QINM-XIIFU<$6D;Q$9K _MN86L5S,T(@R<\HI
M;;L/B K/#A[YX4\2ZD3)/\9LZS>.!Q[7O\/?I?9U)W#4:]<OG!61_3Y+V%;5
MCT@I-I],K.H[EOZYURSTP(O,V7G1G>;CJ\.NJ\("46MV^DAD2P)\]_C#I^O3
MI@29Y6G\GKH=?0%_7@+@T'K-63]1_F9[!4C\P@6P;Q](>/%"C@EFK<HUC7^Z
M<+9YI!(><TU?@3I 8G&-[\B1H-D8FZNNA?C@<F-A?"3T$U.!-T9@E(7BN.3;
M](UIOHXWZF]'>;EG37/L+UN0] 5PZX6!2]:'CK.0@+<K^NVK4IE=A@#'6@)@
M,;Y.X9C)CV.U5X!]"T_],]/HJHM=74QY4*I018O!9'6TZVHV>D>T'SNK4]2I
M"=7CW4&B/3SS59,)W!)6.G762E66A" \!K7MIF<9E;KL>. XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@?YWWUUUWWWWUUUUUWWWWWW^'7777^_?????^W777
M7^_???\ XY$;S+ZLD^IM<ET2J2L5?H0M'.2JOO5L,UQ&"6S !LF]:UGUI($N
M9:Q1:JUY0I[ B'V=;#ZV54TQ#N48;H,!]<V6N_5COT[M&7>6..[5LU998_E_
M-CCLP[P[[Q_-CEC^;KKOOOK\V.6/X_A^./?7^W=!7E'YK>I/('^+BE4A/(2^
MU>9?)5A>;$DT -V0&U^OCC ZU;-0;"]4QAE<#)RWC7B37,[^."!S=J3];X[,
MDD(R@53+2*V!9NI^R%IL]C-GC3JJKB66A7I\Q<<2R'%:&+M<.P( ]KE?F(J'
MLE'<VT[C"-,\'O\ GMZL.6B&G7(S"ERFO#'9E+Z1LV:M&_;IT9R=NO3LV:HV
MO/7KSD;,,,LL-&&S=GKTX9[<NNM>.>W/#7CWEUELSQQZ[[ZK=VTIZED_2L9Z
MFS1*,T4H*\U-OF75(ZO)XVV9)'F[16;4A6!FC]>>]:SHW=2%K%<D*.-D;N]7
M[WLM@S;\(_[#=.:I]MI[ZU1]UX0D,=;VU;&;+&@5?./$Z\AMN4?'LQ'3B#1#
M'L,L#JE=YXP-YB%'G9ZNNN]V'YO^785?N/U2<D4-[4)LWB6U@VSPC5LBR[JQ
MG6]0DB!CU*IPA<ZJ"!R5]W/DR&]C!PM(W*=J"9ZA)"9AE(T;]&G;EU.V=ZEK
M&8.425<LJ);>H]<ZA2++VC6]4F[2@M31HSDR8YR45=!T<D<!1_VTC>@+N96Q
M2\>9HW+ZJ3P_4[P@C?\ X N&U%S[+" #'747=]#J92ZZIOLQ//8:5LLO>995
M,$M]C8QUV7U ';V/?U-AY <6';M#_CMD:(\K_M.\-L/YIVH<]/%;;2YU.KE;
M;?1WS7N00G:-AD1E!!^.E*WE:RX>H0*4,PT4X=A.2<,2N]&>464& _M2\P-J
M&#8N86WU[<%2VYJ.[ZHM&NK.T*Y;8 9MU>NRTZ:ET[I_/^L%.[%LF2P$%M7Z
M>S]0<0RCS,/R9_FT]?ER_"#;O])EE"]$O5)EJ)MN:E5G?OF_S4]WL&F5]/35
MRS_5:LBG*CU25'^X:;)E+4TY9:,EG&$<J3-(0V?U2]\?8#B$"<7\_G/Y8O+R
MB(L)!<MZ"IT!$'5X$\XT,GV"Q79)ID> U-FQYA?YI=*JJ9X/IY^:8 ?TI):H
M#C-1(@4AC'=9NL[L@0L=B?-U=:_4?MOT%:N <I*O%QJ=H\^%1S*ZD9M3F4+R
MRLT9LL&;7I&5#K/59BRS1F0Y7C?H%FF,)$DPID(Z%GZ]6F*$A;P]QT95GGWU
M1>B,[U_>TWR;4%EVS8-;UG9J88:-&NM5@\QS5HO_ !<\QFI$R6:].%:=IR#A
MU&FZ]N.R/LSC[=76<PO4-9#A]EGK3/IU)JM;V& KC:VV3:=5#%\R98:U1+&A
MX?O(SE*R526S0[XC(RJ\ZEIPG:AN#'$ [%LX")3J;)?RP]/M'GJ93A:+Y9K<
MQ7/R6]/?-ZO#]7,#O(PO%JO94K5<"6;<>J95"KN1E!7E5A@UQDD;)M(C$=+"
M=#.EBW=8]=E]VG/GQZ$!^D"WII4A4'9<Z%[0?[Y"TY9#>VJJ:=0K,\!^9_)T
MLY-:8%4V'L7K=1'2C39-:_(CL @C7[D?&YG@A0IEUH"X"-9E<3-'<F'8"3+C
M=-4%%[D1FL%OT].Y./!EC4[O;JGYX=-1"*3&R82]WE_+2HY"#NT1-FJ7HRV>
M78-T4[4N]=BVK;%:5G)<"'0A2C6"]JR9O:"N6Z-'Q&+NEC*C=ALAWOFP]'4(
M9C*D][I<;5UJ_/OU8YU)I?G%YS^H X+(&+("A$^G:D]O6BE)BS/UH&OW;*1G
M'R K=)IDH-@Q/Z9HII1(,N@%#BP3@]G1$9K-1-$DMI[YE?U<\7>Q/:"FRUC1
M%B5>"JE^\VVY5#0JNAW)#*Q[/;32>12WJ6VCJ*N=C:D48*"%QQBM0Y2L.Y)O
M:"8MK-/V#H^@:%F,^_J(%V%'J,G==2#K6EDX86+6,^R$Z'84DP1#:6,>)CI<
M@SK9-Q.<O28YZ' UC<I4D-(TE-&K.#MU[\M#LGN2H!WJFBO**@;4K)=+=GWL
M(:I"98JB7GTT:HI/$M94._*@^7/.0B9C(IB(PA2\!DH3-T]]SM.76W#7U#ZQ
M_G-8S==GI2X!.ZH8A:X_H5\TO4RV<DX$M;>/JCQL(\RB['52IC2J[)6EA+:J
MNL^(C#8A"2&E#W#..6(A=1LQ'QP#S%\V;_IB]/%+"S1O-VQ \9S?;@G99RV9
M<)EZWJ"]-SLRJDT-H>=6(0*L-.N7GA+M0=G8+K&8&KK>S"36.O+ =D%FSY["
M\_UOZ#3/+#982^'O6QJL<+<14@H6&"M[*N)S"N*\F!!DSYFC'-B-%V73BMA-
M>K;.-PPK1-@ZMNE=(]Z\5\H>WZ0]5>?*]O4.Z5^IS&:C*UO6PZXEV<E'F6D5
M^RDZ*Y08EF;!A#5TNX#X>V9'WE34(/#WYBR&S''5U&WX:<4N3SQ:YOVW0/J"
MO(U9FEE4\\>A?-UEAG(Z<5VH(+N%SI!]7["0IHE*<H3*1 3JB(KQ%3,[U#5L
M'-^^?"9/S82X.ZJJ7\8;JF>=Z&I@8XT\E$*W^7]7>2'62J3W( ,<[RJ_T3YS
MOOO?.GK*X$.]U:]Y5._K+&T:<L'0=KL<V3@K<V22(8R0Z$:_LNN+97-3A5=@
M)-F*6^7*@:&FOVL$YKFZ=!SZUS86HVN3R0S9+A[,L<)4?"5WNCYY=8[L,,N^
MNN:]8/4WF)3;BZ U>C:'67Q?&%S9Y)8+>KX,W! R^+V&SQ<NMD6&,9&C @75
MM+EY\R%IBC1>O9/F[=,3#+;UJ?QIYRRH@;;C$:KH573]=-B0WAXBB/2]U>HM
M)J4$2EA'"E9CO=2PE$QY' .NQQV0H$KPAN V$+RDRR)#'?MUT.3*G>KYM3TQ
MY<U#B!Z1ZB@?6BFES1-$M"H0\:!_4FRRF+9=UN*Y'ST#P9%A\.+M=* F9OOI
MRV[=;VO%JW7I(V<1T@PZ/[ OU.2R2Z"%3%QS8BEA5,CGUT;8]:@3:8/N(D0'
MJ;<9&MS8"ES8!'$24D@%\%J*.#K@.(:4H"?WP)NN/IXG[JI/KU%5_F)2:4:P
M"[LC^DW%X:5*S$PO$IB1YLG5(/8%ZQ P^=-GAR9>3:G>K\".T7D"VJQ342T9
M9[<?V]=6[YX^O+(OTS?5H8>:DN26O3Y66'&44%_L=YP'J'ADA;I*SM$IB8ZC
M1.YS0Q3[+_60HT<'#%X#]/\ 'F2L>3#[)E-*:OCSZ;/577U&ES/FRN@U1^"?
M;?B@5=E<'; VVU;4_P!"'ZA*H-IV%!QKA5_K_9?"N2Y.XUR \MDZ0UNSF< ,
ML_(_WJBA<*^^XZ=!;O-VZLCZC?(#T3ZD$>6M#155AJ3.!2&DE5-GVO(*FB0.
M69A2\A@NMOV4M?TRHI7K)C&3N^\(^'Y-^5)/L6ACJC4YE[L^IJA<K<449L7Z
MP<KMIR:U9Z;$D2AZG$$RU=X.+SC@P&(!$,NEDPL=#LA(?-B YLV1%D:=5>:G
M\X[!TO%#6G_1:ZJQ[2O7U)W3;FS3ZK]#>EM#K6M*>;O1E-+T);(V]7ZODJ'!
MA6ZXN@$M"P\49N5XF71UHWR1(B#IC:)^.=Z1O+#S4,TI0&VT"'R9\2^$T9Q_
M48-VI=M?S?9=]V"\L&@[M1OYX0D&95@5Y/ 31D?(O(8%/3.GAX&P0+F]A?MW
M=E-8V!.J;*VZQZM08+VG"5:=OJKU8 \)HAX$=YB<F]E?['$%Z1^W7.VD) W7
M$UP]F$G/=UHSQS[]"N+7JVXU_-LJ*RD"U%77/WBMC-7#BNO"_@4BZM&Z4-S,
MK!$H.QGQM,J+NWP\I/4C3JDZ-FS7CANU]Y4XC_EJ<RMF[9ME(2/>B"]>A_3G
MI5':&;U[Z?KV7!+>@4%R58];--#*">3KO.$!AO!NM?[X-<I.[75VR),T)FUD
M%0X&4U?GY05]><JT;:\N%B5]J4/90,+SY6X%MEVF2INHEZO5!6B(;'=A:KJ<
M8;7D:3X4S/!%V5'Q.KZI*!J<QE9L ^F;@&7V-[:J)+]!^?/-J\>3[&LB[+D:
MZ>9%Y4L=/E-5.35;S[;'H'8<>DJ/-F,FB),#U;D#PB;X8W='D,HDCMV]QN\-
M,K:D?U#YGEK+HZ1/1-%RDZMY\ 58C9'MQ W+*$3*3OXL8-=#VM@R%JT\B3_^
M.@0SDJ#(F3O^TCZ]DC_I\IQU?+/T/-;*R49Q#S\"KRL?3?T6N37Z/ &7"3ZG
M:UKW72WJ=,%;9XK970D*(>JV:O0:\/-3O\G&X;BKUDF3H>U<E (H?=\R=\GV
M@;2H9?=:*KAAN>N4GS'7B0^!?H=ZRB8S>_.K)O;P=B+.+913>"IDB =NH[PI
MI41+LH7MDD6!7,F_X39KW$ NURO>C\3" O97+5.)^V!<<Y5@/*PU'HQ9067I
M_<13" ,[,=37(7)C_P#7CD%W01B;M/\ U=>[+#_ES1KG[=IH<(@':K:*_OP3
MLSL^*;(5?<]0%=*T5K6FW.XLPLV'_<LCAHR='*'8O0&4 S&9"ZB>#4P#1RD-
M)F(T//.OCSV+3]X86S;<KS%Z78[<J3R>HW=9C+(-HK-6C=YV+M_9S=3B0&IX
MPMLJR>$L<%B5]'1FF]8:U(9-KW 8P\C'%C]65[\L+71?,GS7I0<3I80P>1!'
MI+JVY8'^;' 6AGN_R5Z%HV(?5\HJ?&E$Y>]YML*<;2)J +G[Q>@Q-T=%2&$>
M+*"RWSS[.HCT'1"M>(NQJU7HTJGZOMVSE>39R45(4;"L]('NP\-:$Z$3UQUB
M1 B2Y<7*<<TAXT_L7-E1L,=.K9UKV#)],^<HJ4NV/MOZDM: XF-ZVFN^ZUT/
M0G-S+&_?=;EU::=I_$&;-ZLAA'':+&SI4W3W F_J:,?VF_\ 3H3B?'[U$V4Y
M5B4XRO-%5L5 ^.O)/FT"*HVP+7&J?HH]Y\OZG;U99]P,D"JZ_;Z_3B>NH,E!
M+BKL2P6!=)64_.>V=N_6U+L^3(WYUVJGV155[H%.^?M[;I+^K,+FIJ\?3M_^
MA40Y/]+)U'J>-U!K+LFHBIV380,918U08$O37JR 9:Z=7 )K;(!2?+)$ GC4
M_LD3:O@-8]YQ$$L(!LWF:3Z4CUKN.#IQK0,T(4Q\P5>V*-&P%[Y^^-%Z@:RF
MN+U#_5W8R/T>]77>'>74=[!HB[:2#W7 LRL@0W36E=V-: >19R43V4GA8BA
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M919P:*VG*UL6R]Y(Z1!2S4.3M$C$'"--7-<F(6ZZ8AL[OO7'ZZQWUY)'S!]
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M(2%'KV4PW:O[(UJKU<MJ%N6A#8[ZSJQ<$WH;5)[O)*7V#H4*L@A^I!1YIO\
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M<,@29LG3'ST*U_0KQ>BP5(BX>@DI<BNBSN=1?97 Y%WBTR,Q;5"8X/$/,/\
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MS0HV"#D(!;7HU3H) (8M7U22AU[T=*48KC8?F*T?'/J6]9W=?45;+G<\)_\
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M.*5%DH(F)I_1W]S=VD]OG8Z\<\]RW+\JJNN9E;'4W8;+H:R8/QAI399!20'
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MMB]5W7 &6*E&M".UK##==A!HAT+MDB2X0K%Q9%<Q-$"I4,+=3;@K+BB7?CC
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M\I9JLV(4Z,AM$1](_*)P02,CFUI[T _/=]^EV*%/KMV"FUFO?,+YHK"\Q;&
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M-(Y[]6?. 52['YA;:^N]V@'/.![V-^YV%%A/,0;,KWVS?@_T+:*(>B;X6O8
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M4=4KRE8U?7[77D?U9Z%IL]8"BO[Z_L#7YU786DR>7NQC49*;AP1I;$>9@/>
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MS=A-&X4E-+1 6XR[&TY=2(OSR^LWM.JIMP=7RJK:HTT;.5-<-:;U;0X*FQH
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MO$-Q\<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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MOHPI&VKEN6G@)>QG ^MUJT7VM-BO98I3#ERDO1 32L1Y:YXY2V=[PX$P:E$
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M;J1Y?N1VJA7\0^;?H':C;H9*R!RJZ\_>@\K9E2,\U\PTZ9S2\5VO4VXLQE;
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MH?G+[CRML\#/A?R.P+3BHEJ(29(!])5";:(NO22ARI9V@@"XKTN>@%H)",7
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M1T''R:Q,UZI8:7#DZM>W'8@?R_0"^:3V(+5:N.-H%KW#>282CZ)/4E>MJ_\
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M%>)_*OF9@WM=$THHUPRR4876.TZ&_E9!7NN@1B8? (^$TL2([]*JO%"$S<O
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M;K!C1S!-FG8,$7C%BQ#,N44CZM<V1MWY[%PK*MM1[%JUU\D:V?!HG/&#'@J
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M.K=CNCZ<\ I[5_I_>A>15-J,VZD5KR&5]$^HJ;L&\4]6EV]O_=(?O]C\H>=
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M(7Q*JJ@8FZ5OF[HP=?!Q((H;HW394F7MU0XFG#9*D;Y&>.6[=LSRR[@....
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MEBE4F2)B]23NWV'9NWTY475C:4NV3/A_W%Z$P$&_/XL^HJ]U+LGXR^K/1@E
MUKQEXL[=#LU5GR(ZLR0,&DX/RD[%,_J@#)1+8,C!TF<<JV^>7JCUQZ1SB'[T
MJJOPE6O5"U?=5?6&E&*R&YZ3SYO(;2%>?U!/]-^CV!I6XH/L837[8,85;K*3
M(9\/)1X\S7IZBPD2/:7J^L9_KF&;M^JWZ8R?8R-XLJR=9"*RQECS(GOJD@LP
ME@<\H%Q1I+$DQ@LC-904C5NKW:<M!B&[MCQB.9/XP>'1)S_/QZ_'K'\>OS=]
M=]]=?CU^/?77?77??77_ )[ZZ[RQZ[[_ /'7??7X_P#GKE?'F#UE8%BU?Z^,
MV((47QM\A7C;M.[6&D1I86H7?JK>MTBRX91*733(]$%]AV=.W^-VE8R;VW2%
MLI49AD8O)U:<8T>B<Y]#?0P"\_.7KPH4\Z6C8-Q_,!+*)J+5,<H"4ZED>M_=
MWD!&C;+;Q>[\B@V /5D=HBP<G:>ZTW%8V,*U!"&*/#[RGQ@ZX..<Y7J%@]7>
MAU[P>B>BE>H:ZWD/K>(K&<N,Z>LV2D7:@+7EZ[+90C]@U96/JNQ *K^P:E\J
M/,5(P6\[;);(II]@YR14'&& DZ1J_P"FOIY5\VE3=.+'F%*1Z$^9EW^^F9::
M%N[WZ>RF*U]/WTF[ZT4316^=)-87VM3JXEGTQ,I9ZF*K.2B:H J<NXZQ@D.J
M/CE,:;[Q]>6EZQ=T6MJ(4)]#5?ZN4O-KWK8#-9+CE!4C%6J3Z=N;2VG/3 EO
MD3(V;E -)M9!?+C!_>DH;/WBWG"?)PD0/1^I'T7;O%<.?JJ0HD,=@H5/;?0[
MO4C143HV;3-20[43JSWFM]IC+8K=6JX=-,,,L!!G;0-I,&1[N%+Q3-HF/(ZF
M!<5^/7X_A^/7X_\ C\/Q_P!_Q_#KO\/_ .W?7?\ _#OKOG^\Y>_/!*7E]2TB
M'D6F[=.7TU^O&C]IF3E;-&6J-Y,\P2=43N+E(RU9:86R1LW:(W>OO5$V[=FW
M3KU9[,LLK8SOJNTB'MZT_/P9FHJIZP\]5UYTL)TD6^*8)KS=,:^&FP L["LB
M\)_4 R8%3HR3J!Q3LU6LG)@L<M&6-PX/HZPWR0LAXYS%6M]1;\M_S=])-%2V
M.K#H"3\R9'MOS+Z,4*5<ZA/8!#A^\UG;V(5&R[GXV>T;A5612%?V62UU>2'F
MR>\@6K25%@1H>^4V/NCW-O\ 03-1-95U5=Y1J&_TB0[%;(L*O:T&76)]%Q0S
M">L%)-/GL(8:KU? *1>2.3>P587_ ![#L=6/@84L9W*T"Q@7G\<YY&[ZG>FA
M8[T%9ZM%HPW75-XV,L&%@M5[X"TUL\=^Q5ORQ4Q5UNK==^R"]H,18(LU[6\:
M3*B!0E9739Z[+,KQ(J/FZ<R>_H%[ 7;LB>35=B\IMEF[O9'F.@\O0&FLK(ZJ
MOM"]!^:?1-['H&ZIAE\%#,2YZYVT3JSU"N[FW@3JL\I1,C%7\C.S..%]/'.=
M;OWG?R7?-L^?J/JQ(EOUB>]/4R-(=>]&;6*WZZ#\K^2W^5EK3+F]9TBOZ'E]
M(6?N[AKJO;8$"!2D1A-C$ T5T'">Z2X#W/ZF W3Y3#^FD2J_.U3WDA4(KSI
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M-[*]R=VG+O7LV98=]X\VHJJBNBK@5.25L"GJ*V.C"%U65@X]?70(J'AUJB#
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M0VA_KYN^E_R:IMBSTIM4M >_TOT7Y\\74FX/1)^5%^'$T9#P3K%9%&?5FA3
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MMV!"1$/FQC]$<QF*GS1^4SN)*WZ<ZROG;["M>^ZW]YS6VQ(EDQ_/5O;UNH[
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M#/K_ ,'1/9->/%-N<*NJNZE^T$<'>JW6V,ZG!"<(K,6J;F<9H)5\RE!<RK!
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MT;:,)$AMVDCY5J*'Z/5%>[#)UIK& %8&[T;1LW0O5XS5S!BEYX$!Z0_E:7=
MA=OR.Z(\X?A.ZK$].9>W+R)_090@T-ZQ6D6Q/ 'UMK4C4AN=Z;M9.:K:#,"
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M[K]$)_L+Q2-L*L/1"8QJ+[32/ZN:0A_T0YT#;:>;\",QZT7_ $@10KKQHAI
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M/\R:+I+7J7OMMI>L'&^]WHBRK"L>R8EOF48#F\"B>=@'C6U4P#&,-XC4J -
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M:G7WSA\_EJO&'V1+LXF\&V*N>_5O5A@!A&XCI^P,,E;<X+6]F&F9O472S,1
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M\UJKIFK>J!R(?'M*M%H%L87L4RLD\M-Z%9OHNG(*DX.7;?\ OH-?UNLVTZ@
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M <;G@",)?Z2QZ?$6,EDZS/F;99GX"<';&7J:/+K-U]!^BTST1U='::+9!?\
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MZQVZ=N..S5LQ_#/7LQQSPRZRZZ[Y^O YBPGRL:^J+)P#OG*\H#["G>7>LJ_
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M3 *F?/X4=5G^J;Z(65*\MU#8/G"9B*7O5DFEIM.OHF/>]2.%*R":,,1K&4S
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MMJA'_O\ [$2_84IF@9@![3/\WS/FW/\ /DGJ?/A@,"DD]*]#$R)B2HR)._\
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M//;AY.KQ'[3L^UR-J.]/5Q54?8__ !*DC5R-<X]Y)Y*O@F][?LB_"Y.6.5!
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M.%COQU9]XZ@1/:7EJQ<KPZ7;PKO7AYPLXK4%T;SK.(6XR*\AOX77,@%Y!V9
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MK#5])$8Y4TU6$G6:PV<L)):9I(KV]66%#=,(W_===================?\
MCKKK_P"NO_'^W7_UP/\ >... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCFG;BL1_KD6'(H=&N-X;9L_
M?H-0%!PJE/VJXS1$SD?S9*7:STBCI<+/;AU&_0$S)T[7EWWOW1M<?#O9V&XN
M.1'I?U=G>WDY$]5)%%V](U64$CGTRGMV5<Z[)+C"K-N +A/&?L?M5;Q@;"-Z
MAN\(_*>](O4D$(YB3(U[_P T#K*_,'I57]1(;,X+ZLWHAA!M6S*1L9#>M(+I
MD2[/J-HF*3F DSE4XS*IR%KGQ,)P8^M,)<.8#SH$W1)U[=NZ+'"1O'(<T'[8
MK'T;?WIB@Z_!./<SS+'K.0;L,E%"85[8>JR"5HKOZU:DH)R<5-0U)PIY\362
M>2#B(?\ 80<S0'W%(FKN9WO<==U+EWC.LA-O5>4LG5),P]M?#G]4FO&N6N88
M[6&+FIQBVT]A) Z\\-AG1E ZVB\,\<YV.C'+KOL-G\<U:!O*DVK>9BJ]PU:R
M2EQD$)K#& V"I&-X%O8)^X6!53.D<7D;!;(;)QI X0#G8Z"9*?HW0X47=(U9
MZ\<@D6-7L2+)G2WM,BP819@ 3)DAH":8L0ZIBRAQI"R9&R=CIT%EH*#-%V ;
MMSPF!A8<H0(Z8T0?+W:0S+CF%)]E5S8:G@^(#^DO"-LQG9:W-/:@3,I[,1>>
MS63RP8@L^:'RQ';-.["=WC,[ZB9ZMF,CO7EAEUU$;TQ]"O/WG_S:R>CUUXKB
MZ 8I_KBI@@]*N&LX0<U9MJ/JS7ZPLD7XDP=J:MI@SF?0Q-9 I+SV+J8*.L>T
M?*CC-FK,)W<<T_NO&M5I#2WFS["JZMX;BM1&"+*-6:JXJTCOL!I82^*XXD9(
M46UB1,#/;-_GAVG5$E"-6)GO3&A[>N\?1*7=2X/8AZC5O5>'VVG@/V5CK*/Z
MH/V6-K+=0\A6:'A++:<F_ EB0@9#\E_HAC,ZG0^XW>SJ3I_.&S^.:P&W=3!A
MWV5D(MVL"MD:=YJ+MKX:_*DYWU25O\O]BC[%2*6VGL-X'\^'\UIR@=;!?YL?
MWV.C\W7XQ!>OHW4:]<IBGT&((NN0!\\.U^E&.NK;IS +!R1;EK>FRU>DRC6[
M+:P!9^B=B8&,MK*T!(N&@ 3$:L9)S;%@[ L-XYK ==U+EWC.LA-NU@3LG5),
MP]E?#GY4FO&N6N:\=K#%S4XQ;:>PD@M6>&PSHR@=;1>O/'.=CHQRZ[[_ "3K
MUI&Q&HZBU_<=5O+NK:=LEF3DZPE%F:EV/HF8#]\@ZO!2\XN(TZ9^S7!V[2$.
M/KUS,\(V>6.[+'#L-J<<U;&O&E)AIX6X=P5;*8JQ&D#%D@8U@*>\U7H@3U^8
MJ5>!>HOG.4QHS'_D0G'M ^+"Z_WD[=77/I$W-3YY'G6<#M:MC-:B]DO43L(2
M]*Y%'';1\C")/U3FR&4W (FR%*V81I>$@AKRC2,\-.[K#9EUCV&R>.:7D^D/
M.\-4F/DN^Z7BHP]IEH\]SDVDCZ%2"ZP(>PA.3YC%M.XAXS3#@:=TZ6O[IF!:
M/#U;).Z)AIPRSZ]_1<U/R7>!6<:UJUD604$Z3PROM#TK[7<B#DP>R<<U 5-9
M3(]+$R!N.1#21CP-D/;!Z[EX;LH_7>S@;)XYJI8O:D':<7&)ER54W$E\#BTG
MAZQ8:B?G!%C//9JP8R\047ER!H'+9JVZ\2\S7I'Y9Z]F'4CO+#+KKR-?I;SE
MM19UH:K_ *3VUH,+ZE\E8FNU43-%'GM^6K'2$G-N)[L!$+[LM^C'4-D$-<W9
MENU=8:>^]F'78;LXYK:1<U/Q&A41Y=K5M%=7L;I,HZ?(>E?2T.0B1HVRM!54
M7]A3$LQ#=\;1OD:9PB),B[-&G;MPVY:]>>6.A3GM2IX?JBEO*2L3 6"X6M ]
M ;F DGNZJ8[J8OY_'H<XTMOJ_!G2S0XT;S>M,.+"WZHD@;)%RL2&C'];5UT$
MP^.:^QMJJL["RJ3"S*^RM; =D8SK+%S7,K"P$8Z-<K(IDE]$NV3$=C&VZI.4
M[L;U&ZT;->[O;UKSQR[\//T#0VL2\GMEVU%@#K C%#V69SLE-Q$UX7G3.AT(
M6\D<C74-2(S"&6,&+!/[A\F1,RZBZM6>_OK#@;=XYK@!<=1-?0W)7M2N&3$S
M@T[!&0!X63'176C;8$=VS&]CBDGJ=@G[RHO2TY1?U<5_:2@:RW<3.9'QV:Y_
MU1U-!+N^UF;$E/K-03*B>(-V,5J5)%K5L$W+FTX*^P3-T/,@R*B[NEK7D,,-
M8=?!N.)B)DC$677#*9P@D;QR%EH^]?/U(2#Q&X6H*A5["=?-]?K%H3G2O"JJ
M[LGIXEM%HG0Z*!;B;*N!!^S#$D:8WH&KA-JSK)-H&::6@A<I#V(']2U)VO.S
MB^-Z-4Z6I6@1K$:Y/5KU'J5G"3&#!C@PV%/!'DP,&Z6"$8[V#%EHE 7K5IA;
MI9-7@1)$'=*"1_'-4';XHY6+  +-<U4+AQJC+DQ7#';$4!!9DB.,V4-490 <
M0,1YAB,TD8,Z N;QVF3J.38<J*,RE;X^[7A_>^]:1BEWP!)N.JXYVK!&U@LX
M+OL)1TEZY :(^F7O./@W87QF* C3%D1Y.TDP:1T+7'WZ=V>_K7MPRR#:G'/X
MU[->[7KVZMF&W5MPQV:MNO+'/7LUYX]98;->>/?>.>&>/?66.6/?>.6/?7?7
M??7?7?/[X#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#D7?9U46C?'FZQZ0J5E"I9VWXH>M6EQ,2"&C>KU*Y'Q@*
MZ"ZM@.A2]LE\UU3-;XR%JW[AD+2W20\Z:4B1XFSO.47' AC;0'U@EHKO77CQ
M+\\+JZK4-7ZEYUS<V1I!9+5CQ68@L'AID&,2F8# KQ!J6*N&$+O1J+RS+E&V
MKAP/'7>_W^.O/.M+WU4515M1P.NT*IT^0S7/INARB7VPVU<TKI\6V-PT7NLN
M1&E44&QW*]WPQSC;S#:5B* "PM\@H#_?Z.H*Q L1XX%,_GOP+Z4\:W':+K2U
MQP[@1)?G7PKYTJY.O#<A+.S>OT?:%JYVR=?RU14.L$<SZS6]G,+'64T9NE;G
MJPF@]KLO=OT:QI.%A8OY@69!<]SB/EU6I-!WZM^F_9##8RGNFC[!QH>[/+MZ
M46!&1SNA4BD9MBBBUAILR6 EDL5W6/7<,L6"5E!B:.[S..!STU#\EK)4_.QE
M&++J:J^CJQ\U5;5%$7O&]27/;*J<M&A'U.NFJWHC4C95ZL(JL)NNRMUAU,Y"
M23RT"H1UK6!<R6-FSI)K\T'Y'6R+SM4/<.NJKLJFV* N*QWVI9%E/R9FX?13
MURCK*%ZR;QEA0T R;1*D8@:\TX(9T<-),:Y(MEGSCI\/]MMV3.AKC@5#CO$O
MJ&P/G!Z@\?6_::<&>[>&6:H4Z:"2-+)IKZKS"V"$5^B6H[+=:T]MM,CAN%E!
MC\YQJ["%C2D=Z%2,3Y(=M+EM,/?SK]!W).N-X-5[Y;HTG817Y> Q%-UBT&FJ
MN<P/ASV)J] 6)8K2;D4M7^$ER9*[,&*KKX)%2I&,!27P@$RQ809W[83>_P <
M"G3Z+I;HP>OOE#MKRGZ]MR8I6UZG*9JUG;RZ_7L2)K\BV+!AY3VT/75G1DXE
ME-W0XRU.(J<N%NG]XP=7>G?LU;M4,U#XT6XN#UM?L. D76DO/G%6I*R:_7_4
MMW><EBE-L3T'>MX%UJHLT6K&68Y5&)AW0'4589-QKL_"PJ=;F:-4#45PCKO2
MOQP*,1_R^LZ*U9,X^=5J8S'OJ-ZY]<LUEJ&V= L;51E_>7O0E$JT**>T*T0F
M2L4.5LI#($04XKK7\8:QISZ8)>P9"U\B::^/_JMKK+2D;$SQS61!:^9J_P"#
MX).O6YRG[+'<TKT/1=EPK-;]FVD5#,$ML:U6K*7C+W_[8&EYQ8B&B68+Z"V\
MK'Z@..!1V&^=E@UJ^ZKMQ#5CN- OK)Z.]]MA1+'E)MD-OG^P/,5WU0'0H60Y
M4BFF2R9Q1R3X<E.S(] Y< 5KT:#TO=&AQ\M6_&R667K#EUZ5!P;$*"O&U"KI
MB\DN;JT*-90:F*% *KYN<U79YPH8HO6K.ENKR[3<F S9[G(&KTH<XG8600!L
M,="W' YL9OR0],D:)4: _:>:U_917G_W_62S>X1I:I5B>H&7UM3%IU<HYW$
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M,KBS5MTK>$O7^GT2\.[0>*U#7\N<ZM::4-UG7H*,DYPEQ4#+Z\4:)<*5(VC
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MLT)W"%6AO6]75;?1/U#.OE*9D\Q$KEGSG.-<B8 0,RJ)42&%&-YHWI'.$?5
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M0AP(>Y&;(IR5&W,+V.>DY0\GI2C['K7T<;H:[:[/^;%+?,:[BRFEPT+J0_W
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ML.9C&T])?' IV9?G+91>Q[$?QS%5D*:Y_67SY[RUDLM!O4P;J:IWS[3=.DT
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M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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M;,JB=O7)]L.BXH!YQN<=>0(:)U$U,>D]J!=$]C4RPH_\>G F U-'CI-.%O\
MRW])619=W/ W*A%J!91#U.1! !)]FUBP'=X?)CSIX?5Q$"/V@QL(P,-;M3,4
MN5CCITYQJ\WB24:!N)[MX"-F>7R[M,%,5(:&-HU44PE5?$A6GKX'=/71LES^
M='ME@O\ NTY@*$)6F!*_EJPGC5NNRTO'$F4FQ-0<IJ!#-&O?B%R$J]*2@R'N
M)-N*K(<NKM.B39L658*E'D5U'D[.M4;>]Z=I?#8HZ9&WOK7HVL&(_#;L[ZPU
MY99=]=<T^<]?5[$O+RG3BGC$L49ZR6KX:$NSTIF &T@</H@,GERN>4T?)F:C
MNI@[;M<$=)#2MVB)*&R^I>7X98]8UP)OB;VE4OG)EHBKE+R>/<UFTF!F"^DR
MQZ,;M6_$9P]5PKH;H[2,=/,[TNU19[-7.9& 2=#>-\C!UL#EAH&@Y,2''F!/
MJ\A_.?T#23[XO;WHI7'[*@[2^ICR\#PSA.99_0CVM;G3]5 X$0AU15X,V2!"
MN\HCOMC)J&'B3<?SKX?9&V]18X6.P_;WE21;]X45,O"O%^RO.D-#(6T$:FH$
ML:UJ'8X[ FM2.YILA"C2]66J1 C%-D?// 01*B!Q#+1,*0M.[WH/J2I=Y1[D
M$VU* 5BE)U8.NB[REIU+W6+.+M&4WPQ/8PC!>IA<1HB25+9IUE6T.O!63:2T
M8)Q%A_8ELH%77KKYOW=>5F>Z,5T!0S)6/LSOY]G=Q1\/%8)U?E>2;F23UCH3
M,G:ZT9QK8N6'7@"1M$ENVF)AJ)1L%TL RA[M!75G5[>*O5^ST/?=Q^<"U+KR
MW:./S[7(ZR;_ ((>:EUIYEW^GL;/6 4YJI.XDVMC^W.X$*6AL>A";\^A(-H"
M1\%6=.&F(H3XC^IDXGZ;J[S@NP.VC5;'F:S/3RU:*^="E4J0IUQ8=+('8V'L
MA;Y&PML8]ETB#8@P.W;A?8X5)Z[SVY2X^>&Q9E_T0.GNHHA=E202E;0\R%BC
M9ED)L:>@P-<N+ SG.L/<9PD*T/"=-A0LY)S7 TXRY<6/WGUND:L,ZKOGK\]+
MX\LLWC(Q91BN)\6@/%'K#SL[:E1D+FM^QUNWU?3-W)>U<V24-+A$UD8F5Z4&
M%I^0A5V13.<**,6M8W/K./@C_P#+.U6!6]!D@FRL]+V^?56+[P@#1;BS5OW<
M%1+ZDMK@"IK(M-81C#2K'H4F.590$B.O.@0"TA%K=_U(LN?*AA<C_G>C_P E
M>[/\RU3^G;>_*-5.?^0U'\EFR<)$6)G'KW+^8_*Z;\94V%&RU+?9+9C(EQ=/
M>/6R1JQSPVYO357U#2MC7-BR++I%1JVNNPPZRNMZYD6?\Z&6V(^_K"EMRG;=
M$\R#WK)$,>PCXR>EHEIWZSFN)E%D88511OF[<:"U^?[)\WUS7M)W$O,C&4LF
MR'+U?8OH@2.4+&]&K]SW"A$*]M#SM,B6-K=1HB<653J:PT2=K^S"V$H2=Z#B
M,"!;5+3\N?7AP0MU3 C^>(%9U1 ^RD5*=]EEO,AV=97T8SMHW4FPDB:Z?B D
M6$E3;3V@;#QTO;E)W]"\3 #J1IS[@;PMDJ#Z!>8+;/,B+A9JFF6;7](TY?5G
M(;@R! T]#1KI0Y%B IQ&?/F1(4V*#6XV<YK)PN\AZ]$E")I7=$C&1^>Z32Y:
MM7N.I4W*-D(35I>QATVC[5QP7CFIR#*\R$/92ZIL&$96+",79Y(=!.SQ'<R(
M(F3X48AMC[I6C#92M*^:-J9Z_1RDZ5A2UV5OZ3\2^+J79H>5WNU*-X:T_* 9
M@"%!D%F 4N]3I*XU;C )E7''/?&RAS4R(OLZ.1#3^]VB3/EI9OVO[/H^J?0]
M5(MK6.J5OZ=>B'IX.%#Z>J%KU_N!/T4U1 M\&U#6H>S[%L17$D=URL*HKU?T
M5(U,/;3JG+UL0F;+"TWCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX
M#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC
M@.... XXXX#CCC@.... XXXX#CCFF;GL.QZZ$""==TB<NO;*G2=1Z&&?*Y0N
ME83'B9R>SD^=8S"O0)D3O9A^AEH';]\K3U^:1MUX:,.\N!N;CD0Z2]6$;X\D
M(/JI,H6T]N^S5Z.R)M,YD:YQ?2HHNQ[PRN6Z-RW6#7F@ Q!_X][C'-[=KCZ4
MHEH(Y:]D_'^+SR/S#Z>6O35<MSR/46ZO"];6G:E*6:B.6L/,/)]DTVSSE5U$
M8D%$JQ+S*-ZEPL2 ,XME2,(P*FPMVOK1,RD08P29XY7]X_\ H0C>P6;<LKU5
M6G7.PG1U;^F$$F]=(LP:\4;;;$Y+"*R];4=S;=J@TS"**<S,5VYZ@K6"C_M>
MYD7*3B0C#L\H_P!H5I;6F]MK'(!U)_@Z]O0U-R\7EV7(7;,$\V;P.#_:D#N7
MM&_L4T7'81\T](D=;M"I&W1]IPAIU2X^S,)B\<TH)]*>=#ZJX/8*_:4-)%>[
M8VA^<A-J(I)51]TW5'WP]+@PPSNX0L[9>B7%W1M9J9"SWZI,?9JZSPW:\LO?
M 753;8'&L*M;59LH PMLCD(. 'Q6,ARJ@FS8(QO:AI,<5DPIRVJD2@T>R'(N
M_:+!S2,&(3E1=\N/KV!LSCFJ62^*.3AL,RWW+5*J'(#U@M +,EAJ(,9.%N_\
MQ_3"4.>3,18LF W?UX__ %B9HVYQSW\&7_BMDO\ C9GZ.IO0GKFOJ6\=7)[.
M3]H>\Z[JFHG>W1_5<.*^0$OXM(&$9\R MN<':67LNY.X9*']$=>R9%C2M6[#
M;CEGIV:^@E?QS4"[Z!HELB8S%RZ:D/:?[M"K';L!64F&M&FSB$;J7#KC*0--
M2=/;U*C]_KQ53K+^>E:/^OH'YZN^LN:L?/<OE6MK:I>E&ZZD$<]WZP6JI5U&
M_M2]F,F-E+[8,*P%4H5_E<8HAE$&R$=7Q!2\L2F]KZW+>,7$OISB]!++CF!L
M-J5BH[6C0UV,B+&Y'61KHZ:6%N7PVU03C,PL.#M;/K(D(V8!:*D )R"-.%>H
M@R=,#%8L65MWCY>&GP(5_402L/NHAUUU)/M?&<6%]UA"L=.E6'T3 B\#9T=V
ME:#.QDZG!0NS67+1.QG[@<+V8$)FO3$RQW=AMOCFD!GIKS<: .S6']!4@65Z
MTFP1EC,@RUT.> 0"1.7^P&CW8Q%/[1RK-(3N^H4&(=DP-\N7W^WT:]F[_AS\
M,_4GF76HQ[ V>BZ)P0Y;,22XKMG;M?XJ,EQ##YA<PIQV3)AZ#;F84*'$"9(#
MKFY%((^#,FRHNJ-&W[< WMQS2IWTIYT5P:,S,M^THNK=H:-$JM&$[:B*(!V'
M&DX1=L:0C%B!V/ ;=$C5-A;-&X!((:]N$N+GKRRQD:N\\PF6C68Z:5'$+$1H
M) $VJB";@3&T!&FAWI\TA)".EE(NXAAO'MCE'95S>JKLO7J+L.D^%VB(<O I
M!RWAG7'-/*GH:@7QB,*"->5/.;:NCC!A@5U2S$MB8@0E=+_U]@*& @<W,)C!
MP(_UV#,3IL;1&&%^OXV;MT3?^ASRLO4GF7!#V6GGZ+HG&L-3%FH;;'RMVO\
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MU@)8K3U72(D6U9UZM3R$;UHXS:GN,[,E15+I.659-Z,!0[<$5N4) 7)<)EI
M"?*GRXPP>'S>5??0;TR[A4(E2EFTJ8L#STJ^L*;R?R* 7T690+@;C@H#+IS1
M6QFZ66L/)*JV]M1C7>)!>B.:QELG2I$R7&@;9L7U]2JF(L_!-L2I+-L&H"JJ
M(L&KQ-XU&M,J=*9W9>2<=3I);6T4+2)$.8P:L]<-KDB916?KCKPO5)/%!D&3
M >A/G]<=#W(V^CZY0O+M2O,"H*N\T4[4*Y9%[635*S3>V[ENP;\,F&5I5DXX
M--DE0-&'4I7*8G"42OBB\/B$2)H6>*;(6N+7^9/I!UT>K:^KADI^G: O=QZL
MV'4N5C65:@5CNZ5[%JOT$7O.3BUU>*+424/HJ6X#6^J:\9GVO&FQW30PZ,ER
M& B9;@M@8O77E!0;S=?-GISSVL/JT+/'&-(8;GK@,W+X55%[#C.7-K9%DC&1
M(M<"ZMA<]/GPH\00,PRG$-L>+UWMYX,[UW2Y86LF*@L.I;O'E[KKVDS\Q#O*
MHLX*B=L"1HQC=SI\YNU1"S#$@2HA.#703;-?FF/*TX+($ELS_#KGT9:CN:[G
MGU3Y>6@A=C*^G0_UDIY3ANR]:M= ?'(GU7LL=AQNBR]4RB/ZV^JEC'PE<K43
M$;;;;/SU/08_78+:/E,V@?8)87S-M!C]$2+256.IEQ$QM_Y46$,4XVDZ-V#0
M_@TM;NVQX$0:,7.@\4@Q@W=3"U]AHV81/X]>_8&MX6) &:NPW=Y6^F*5ZK/8
M?U$)6$=%+7MZ%IM9/#O2U6,#QD*\][7:"1?VNK._X8Z)@O,U'($U$ G$K$)Q
MD.8/L!KVK@#=WEU*S?[)\AQDC?9DCU1YQT5Q%8=JC)?MMW5IK2]#7HB9$-ZS
MN:,V;H)K/Z1^.1#8'SG=$,('7<S*/U&Z_5Y50T?)NWWBIZOJHI9Z L:%UR^P
M<YK9EO%BWEQZ]]&NO2D*KR*;'V!ANN2RUL.NL#VSZ"4L3%PV YD8$0(:<(FS
M9GEM^2?H1:-(5Q6H6=Y)I3 &G'ZPM!%IMS>UP'9:G)H$S6*>6C6M/\Z$W%,%
M)3J0U&(=1 DG&&32<]ZH0M3/#5UW*"SDEZ@\TAG4'6Q?T/1HJQ6;<I1UM!(V
MRA0G0_O?L,LT32%5I)_4<*;77##+)2P@P=^3'UCWV'ZF\Q/S[[&\\^GV>\4N
MG+$!,[;YVMEIIJT5K24$9'0K6H?QF!6=K$124LCM5]DPGT+',6V-'@SRH\M
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MRI6C97G?U7X"5F3*4);"]8YRZ7J-J7&-K+SA*T7/+2?T1#9;1+D17,\5TA-
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MTS$L'*AX$T7MZVA*3CFO;/MJK:34Y#Y<5C)%6),6<-%R&RP6@*H+VLH9EZX
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M'+'$)!\<C9$]E>1IRT\.</U!Y^DI]93@ VQFS5<"!FLHDUK8-:FL:6X]T?\
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M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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MJ3OL4AI'3.(@.)V9U):-:[MV:>I#L/@&^!CZ?M5 ;ZC(LL3ZO=?0-/5&V2Y
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M SC40]8.>2Z+'DIQ.5KF:-HC3O/Q_P"BX'KCS!1WI@8I$40?=E> G^*G%BD
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M6T&_4OFQ:MH=0K#?-1A+I+21$$=5I1_683U*(L,3*>O"L%R02UD\2[# Q[G
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MO:LT&8M<.'HP@H6Z':S(T*']%[0>\'-@BH*EO+;W3-/C@R*Z=6"XW7NV$9L
M7+M@]H>5%.TM-),]^U>%MC9L)1]J1*:(?\G"F!5_MK.0R&WK\(@R2$6?RL!:
M.3WPI(P)NC%)^F+#EQMNT).\<K]L[Z?^+JTI:1?W5P@WVN!UY5-Y[/$*YW:&
M6>LV+<#4J+@"&QB^M\2:'BCAK>/=BV4S5KE9IFG>5#1"VW</B3<LB>\O/88/
M8+-:EKTQ72LKW5.IQ3+X6T&9M[D0BUPEV7AJE!HPP846W;6OMV10S76,<X6
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image07.jpg
<TEXT>
begin 644 image07.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# @'_Q  ]$  " @(# 0  !@("
M 0$& 0T%!@0' @,  0@)$1(3%!46%R$B,1@C"ADD)3)!42:!,T)287$G-#9#
MD<'_Q  4 0$                     _\0 %!$!
M /_:  P# 0 "$0,1 #\ [^.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#FHK<O&OJ0@@B+_ )/'4=D)[0XG!'J>U[8F;)^F-E+SPF#:H2G4B)C]Z,,N
M]<XO%@P=NSK]#5)SW]]:N]N\BQ[4+7H/\UV2*\T "QJ]7R()JZN"8K?$BXUV
M<L\X.1-EQEY<S9CJC@J:''IUGEOT]4N3)BJF4&-#D[Y6O7V'M*WK7STZ^?QO
MJ17L6.6HHSA*[$.^I=;M&PINAMDM$V#QRI+7X[K-+[G"#)78 6,N;"Y,GCKC
MC84ON1'[VYK3MYU-?R%JLZHG48Y).19E7Y1:/I("I =B3#4]<;UME"'H8H^K
M,BN=&3Q3 OL8L49$3(NW3/A:,OR_C%AA="?BBCB%)T%Y9O"WA/FSS55W^)L5
MF"+*![)*YGYE6BJ\U&=)/<T3WM<TA(%CVF1[5=_Z:>:S8X.\T<W;!&6 ^&\]
MM-5DF).RI_0C:VWO>OH>P_0-KL],2JG#C[:=(IZ[7)Z/(K87BL *LV4N0A5)
M4N"^*/Y2)(T((*]X;]!,QM"3R+[2\L6BF6[8=9W:EV(CT2T;TJT&A&D36T0O
MMF@$ 9.@$&4 A$,6LC*#M2[O&Z$[H_V6D%X0T7W,)[?V?6PJ2OFI?1:7NL"F
MG&,Y+$-F9THKOQ&G !9?<DLO(!-:DT*[0,"-*JS+Y6+MB% +&&%E8O?>G=LB
M=1Y,;=MJA\YO3LK.GU*;8WG/VB@@[9N^L[+J"4KT,#7G7>@C/)_D_P \E3%9
M@K'QF)\UH3')%<3.I,-@II,@N+NTL+4V+.3'%2-B_.&'<E&*!Y#?Z2O.>%O7
MVGZ5<4:U'M?1!=G]5BQ*^-I1KD]?0 +% A++:[V-&;JU3XBVIBYNU>U5=I,(
M:1^K,C10MVXY7]]'Z\MFTJ<J%*J39:D>44]D^-L['FTZZL=?. ^CH7H=#EW3
M/V-:D:7V$8N1:YTG]K/F+):I607J7UJQRSZQ[QJ$>*']OC-D!$(8^IH7EI$]
M3?0<(+'+>%M76^9)381ITUY%9I$59](55<KC6@2/*O\ B*1:6W.,11/S5+0?
M7=0",,)+X=/G'.<2W:3^EBH>3DJIW[TC8JX/ISSE[18+=93 4(?>?0?CQ%BJ
M39Y"<%. S%!:]C[&FA*F8F]?7)LM5R-P;1V2"13(E.,2)76&@^VS7RK9NDK*
MPUCU];1P==KJJP6602L=%6[3]%"+8MVE$&=,>4K1 9$*A#+-420#"OB?HUDP
MD$<"9!)&3H-8A<;QSG2@TOZ%#(=';R4OVU:_F2;[<8FZX*:!@;3HRX4^N9'G
M<@M5P/4!LST"SWV9H41Z.Q$V*[BCUMYD-YPC,*Q%&0@AOR3(@TH3]J;/)\-Y
M20/LVZ8M@^&/KUYF38P)^,698RIZ<@^Y[%'TA-LMD,V!CJ'N0%(#2UA>M3>P
M$I,#M8G@1AK'9D'AD@ZE_P#-U48,S$GSG<0%8%=V4JV)0V7]VKZ)3Z^+<!N4
M%%<),486+<3I]?)PYL& HS3>[+9EN@;<=9*),B:-J<Y=[?\ ,WJI^%$"]PU5
MZ/M5)J#WO\NKS$JHQR<)K9G6B%XNIZOO0S#5P4*^B"Q4HNVL0<I+B/79/1N>
MRQVEBB1BQ/5LE[9N^0]=U$O=-P>?C+&_RJ*\*D'Q^5F1@>F0H1LV=[F_C[0J
M"NVV,9)D3I;5Y82)-N(N$!WG3INN ?J@U#PPSA:L](75\<Y]%JMO8>CU K2M
MBIZKCWMH^BUF.=CW*4LEHD^12OSMG'+ EIB,%6]MCRZRV:^ZEG5FI!T2!7N%
ME@[M#$G,C_'P=4YCG[A\D^??5%>?)RT18"9;8'Z 6I3OH@A!+7A:CJ[M8J[R
M,RTHM-9ZYKZVL0=)&!M4Y1U !X#L.O#1N@7(GQMNR/OD9!:O!N>NR-ULWGF(
M;W;+84*O2;D/+F0DOKT1:\L-J?DI4-ZS>R%B#E9D&2LG*!L&QB.TG$Z&8R)4
M35&E1MNS\W*[:W0+*IRHFD[M'/U^$'@95H; 46F:V&97*?+>V_7N)0H6\8'Z
M&+$*1/PV&9D#"=GCU$@929>6.GOF=F^>O46<^\WGS%3WN*I5EF\U?,E&<-EY
MM;L\7JU+M9>F;^8?72/6DD_?T)ZV,FNNW -/8PX.U$'%XRFM>U"(R-S8)D'=
MH,/G2W!TOPBV.ZG[?]$4^G>B_:[<ZB5]6>J@MFH*HM#SF725!'&AM=]'+V[K
M/-[VS9"Y$,V@3L*7I.8BY [I>'C1&8=)&3<J8M>I#R9@&+QN7M[=I3NS _II
MVJD8E'#2&;6 [D?RN8#07EQ1>TQC$['ZR,C3"RD=2=F&OO(><Y'C_P U^@U/
MU?X)O7U-5-]L3'UX9MBDO\@2G!H;S%6L,+TQ_D:C4WTCM77N3"WL4/SV7@A6
MYK98#4$8K)$%\31L@>BP)V>:W?6WKR=Z2NV8$5_5!&]C'LGS$R>2+?4+";!_
MDE"\=!L:![N!9L%='V2*KZ)CJ@A?24.SE1OKHJY6 4:U24H:6/K<(G+X62S?
MH9YBBFB:]$-V2?*P?01'RR,T*U&70SZW*]5X<VEGA(K^4$1)L9X_QJ.0G:59
M;$M;B*LB8*IO!C-P=L/+7W-WG,)7WS?<X5D^=S>%*VB"G+_UI^I=J$CI.U;A
MCKZI5+JG>U-WG:T2, ?9O6F N.C69IK# N*']&F**6C036$B.9+:)F!J_G[Z
M#8^+/5GZ[;[7R]5F/!YJNF]!R7G5.T-OJ\FP 9LJSJPN8UZ7M;!E=P\F([#D
MPW2L% 1Y: SPMIB ,+C 2\.#J%&V J%WIJK:!/E;G%)!*3*R#=@4[&B00KS(
M98JQ+T'90W0OE=A&0H,6O;"$%)\\9V/ZR+1H.$R!E*S+G/A?WF#TN/N>P:KI
M_KU7I\Y[7KXR ETPOWU;V9/M&5_5GH]@]GD!MASK%W/T7+37)Y+E7$5BFXY4
MP$E <=FZ9W A?LHV6O7WKL0#8/..L5?193'6]].C=?+&VX[(R=5WSA$:*3PH
MNZHI4;Z&K"SK  UO.>''36T!A>CN&WHQK7L!<79J $P(=47'.9^JVF.G,EK^
M@8DKU=:W@FVO(;O8[)Z L Q>=1L-!TB-\Q5?_10] SFB\)RO;&VUMPXJ73QH
MVL$RZJQL8D8,,#P9SWP^^^AVHL1F-45AB%CND0/C7B5B)BV1L);;$C#.EL9U
M CONTSOE%]CIIB]:M;3L*RI)+,YC.RG;]TKO;LR#8?''' <<<<!QQQP''''
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M"]D8/>S;W"G=C2<;]W$[V[>XTC]33^IG^3\W<4#WTA\A+67LC27LN9'F^"<
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MN@;_ $XHJWHT7*J)\0$3TE-TZ:8TSZ/;9!31N%QHFJ%(%;H<V;EOD:XU!_\
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M2M8'9@7#5GZSI!^$4G&+656B/:EXUDAV6L4B>LI/PLW9">U.,UQ8 U6WD8+
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MG8NG(J#C@];024Q0 QA(>.M07K.*'&GI6/64&-^Z[VKI\$>IX5Z:/6X[#S?
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MO1Q%E5$\+=BH)[:6CB&Q3*1RX6;* F)Z^<AZY<;/+'&:&.BR08K#V]:Y0\G
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M/VM31,0Z$[>+U &]G;@%*VIWP]<A;0,Z]ZN/GK\J*P,:WKKO5BM)88K)(/\
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MB!%-!)&Y*EDZPD:3BYB9$,A2&>G:M)X;)E;INJV>G?67GB_SQ19J*S13@:&
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MOF?RQ4C,GV(V6KZ0MR@[9C_F:(DA!DU%YPN"Y6O^LEN@N"FUL2JV(2HE/ >
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M%J9W\F:G]36PS-69)VJXO5MJI0)+;E72FKM@5T4 D@^M24"J,6'M>4<-T%E
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M^)5>NU;,3E5^1Q[5'TRC"&Q'4]Z#C9^G/;LA$5@D-(8ZMVK3LDA%F\?E?']
MLMZCGZWOU:;],5UXLJJY4L6H;A[B13O'TV\VR-H4WK)FE8JQ1YL&RDPOO,Z
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MMOGJ0=BV)J**:PYG+&KU?V[E-MUI[39"BJAVS<O[XD';KG$0D4F'MU]\Y%]
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MDI=%2.F1\%,2Z,:M4B=O"X](XB2%&"NYDW3WHIX^>B0\5UZ]KF593V.@^O\
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MO4T 46>YOE&M:<\M&Z3_ (G.EXE:'X=]U1C;63\TQ=\>5>\QF9M)")%4,(Y
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M"^^"?*B'!'QP=[J.T+J%EQFUY&#B?<<(8ZV-P:%I%-6_,1UM"2+@N.!!,?\
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M+4U36_5X&G;&74/5A'CL_?3&AKT(9WN<6=N_B)6Z<5 ZQ9*3W)Q\(;\J_/\
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M3F5L)3%M<KEKWY[(XD)N@QBP_P#& :QGZL]O>RQ3C@:' >:*878GHL=&4-9
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M&]Y[F*OIEWHJV#3&CY^>A$SSC:"WT^S DJ&QQW)V<H>-?G(02%ID];!_3#!
M#Y)0L"F%)\-^89,A@D=5KJA=,MZ4!Z.(Q!9]E%#-=L>7EZK%6CS0P2/+QA@D
M4E+],5V,TJXV)&6B>@%U_+BIV<J3ELB]87RQJ9WOZK':'+8E2G4VO?>\5G54
MJV;KKZQ35M>\+MJ"Y+$;QC\AO"\9BK92>HV-H.*V\K_%8;' 7@'&1XXK3^T#
M&A7UYJAA=_&8Q<6EHRD>SNZ*A*V^+<Z9LNU#*^AJK8[21-SO0,>#*+#5:/&
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M-Q;?6("HHXXC8[\1MDD+G6 49IFVO]1>)L6A!E?6Y0PK*Z/\NW=KL]U@V@\
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M9S$+7-8.R>[+;EGZSIXW\L6&)-A'2AJU8!S#9I*Z"FN8N1,9&5LF@L-=-V+
MGQNM! .WFP4'0*-&P\J!-+PLY>DCMDXD)_[D*G;8^K7K>O5>V7C9Y&KM.T^<
MO*7COTA>%76Y:K"NVC$8O3-GW#71>IP.Q43'!;'R .%33C0MO-;]W6O&8/@%
MU;&21E=K^RX7T5]1%K07?.L"G?/L:["/N>ZO&QDW-LRP=E50-->^(@WM=<>A
M>W%"C-Y69*76@0DFE?:,']238XH0@&8 V7HV0+)"/D?S(7!-RR2HNM):\^U_
M6E5.8;8KCNAS+7%-SSA2K$PM%PU8ZI0!"(,AV8M0,\?TQN\I*ST_AWGU^715
M\?.>@+ZM&G7]A55&*"0[SL?T%9B+L2QQ(=>%C/WF\GYMC,K02V2XLD2RK"QV
MISAK+!T2B>?]*"0-></O7C.TA"[S1[D]4^GO8?E@<+QJU&I]V\?^IFB[JKW;
M33/LZN/S5[.4_,SVV5F\QPP>666Y4_3)VUAO-:X$$HHGR)0X'R)]BML;2_O/
MT5?_ )Q]\>C[X #D&RECR[X)\IME15,VV1<B8&UM_I3U!>5',1\B-6)4^OLC
MI^6#'CS+(:364B-4EI5B@=<.9L-;=MUH_P C^9 \FC9H6C*U!R_- J:!H22"
M6( 3?5($EH@1R8)/VBM<3,:$*8BQNTF(Z[S'$9D"'/FQM\Z-JD8>X_\ FN@[
M4)MYFQJC170J_J2*ANI!@!1"$IG3:R=2MC5^M&-V[#O*8(47LX7:@D/9WWKA
MFI\B9AU^IEU^ 5A6C]&/2U19^E39^I*).IWA4OY^5O3^(A\?1S@[L-UJ]=OA
M>1Y_#3U*3%R#)JG::Q'7.W>7C,L]R',BQ$P4,X6B9M\,3]&/8[A::FD)M&^9
M^@=P>V?=/B>I"3/;MFP"\(QX^ZN\Q&M-_A"*O,Q,!#*!H5O'3T4!*VDM)N<O
MSHS7I&S9T859X\^1?,%FV<'N>P:%JYPM,%M7-X]X/J D@=[D)L[843))"3OC
MY8&)2:3V["2?),:Y^]6(9Y3@.P?*[_5YD(OSE1 4JLG!-3I \PF6?9]U*I**
M#B:I@&V+ICN,2V+ &[^L?SQV>P8U@NNAH)8]_K%-3*5PW_CU([ZZ"L?T/[GN
MAT^'YGZ T/T IFXW'RJB7FO:3/X.8=$(L^I:(GX439($=:SF<"!/*Q0<H@$P
MU;]_[+?/@Z/_ %<=6B8?JCTUYZ]A>ZFAJ'U\]H("_P#Y151:@G)ZL/3K5Y/J
M -5U'%)- )Q$:1#C(XALL@*]EL& P*P:(V@G$D?I%\-9#EW,3S_2,&D-7FJ-
M5:-C0&E#[K#"G]B\/D5__CW(9D'R3\UN1IVCMH+(9EE#R@[=.>O+5WW^/XY?
M\N84&\=^75\ 75Q-&5Y& L!*G#)X?L!ZI>LV6\]D !6DB1;;-RD2"4VL2*LN
MRU&3,W;MHO:'@_I9=XZ>L>!5X@>_;10)R)K*UI&2?-AWU)[;KNS/2=O/=V7"
MM+KE7OT9>_,R35N#4,7V214TIYA1^BR(3M*0"I\'(D+E5+,S5^VU]ZO>^G$Z
MX#WJKRM3E5X^H6"38GDCZ(&A:-YF]"[O.\[=:R=.\A"JEL1S9]UJU:#E!:^(
M/;!A&Q.9NT2'(9<]NQ":(V<D9OL3)>(?(A@VN,17SK5!$LIMK6^ =\U3'2(\
M-S=[()W"SLVP?MUY#IYDE:ADI86,TC$E[H#=.WG1N4.?EUNZWB3K=#,ORE:9
M52!$+&0UUQ4DUTE0-.UA6EJP9:I.=@@@CECWOACV>6C*,@O'UY=8R]B^-[S_
M /T'X=A3D)][^IJE4&C=9";4UCK'C&RO''D;UPZXM;*(MZU;PN)+\U86?:]0
M) U(CJ$!3"M'HQ<F*ZR;F1-UB9!VR$,()_>@/HE0ZJ'WFW^95:,2+A7"XF@8
M!^GI(!O;+T>H"J58-GW#%>5*L!MJ_+U,BU!7UC.T0&4JS]HHLR(%:KQ5=7X&
M0;?LA\O_ &;R1YC<[=%7VUT15Y^Y L]:+P+%)J(F4RXFDOK/%+.RYF<?O$D?
M2^L__P CSQ+7++JO>O1V FC^X^CO7\4CQOY5EC3 :9Y^JJ:(8$VVZ\-C)B@*
MEP"J/?-B]VY<:M.B2=&W1)"V+9W?;VSPMF&6J>S_ /S7OK"3UUGT$.KU]W7)
MY&CP!WHU"IV4<:J2N4Q6!&KG1PEAK*].HYI(UUCYR&"&17B&Q3';P!^C35[3
M^L9EY=IS@1P[R'Z]&O19TLEMI45'Z(2@6YB':H8]NAKQ'HD.#M.(Z%,+"<-V
M?6$O7C'SF:]L;60T19V<"1#D[XVK]QAUW#5O^?U%&.O+(!-5U2N:V\R>F8GJ
MF(B U*+*Q;[* UO8*2H$)!V40QF"IX$V[#FS<;V1S)0CTI!U_'?!&_CGJE@E
MUC7U<S'L@B)X%3FV>\3K+L*2$@:8.YP?R88$O$6X]GJZZ[GG9H187QDB=M_'
M;MB"86O+OO\ 2Z[[#.N... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XYX
MK*=%JZX?9CA# 2%70I4Z7*[-.V3K&"Q$'>0($-D>/KV[]^$.)'W2<].G5MV[
M<=?>&O7GGECCWSV?*&V+5$6QUEZ,MZSHB_:'AFO[\KJ9;5PFK)4/1JWIM0MK
M9O:6K!K8B0[RP5; %F4V$F>;!G< 0N"3@CO#9OE@Y<8>'1;QRF6]V%SK7Z;>
M,67HI<*C4%KVK9M1,#EK]!EW6K;:>"7FMY+(]#Y>9HK1O"UY!76%*.6!MM/2
ME8$X#:D=!S);5!?,YNBX@.9$,(L>< %1IP(6B:9XHP'G128LE!DX=;(\T>0A
M;=\29$WZ\L=FF1&W;-.W#OK+#/+'OKO@>EQSG1J[VEZQ3BK+4]7]5U8Y]Q]!
M?=>S9+7Z);K&(Z4A'\3^OU=1KNO%."M]2YLH%)@VO 5XPO,@)@J (5&GB<)N
M(_M?*6=3O:0G=X$J+V;G+5:SW7A5'G1W41KT->G82.;/2.E U)B3BO5:$,6"
M]GY9M]'K:^NIX?LLTG]D ?JV"]$S<1A!/3CE'M1_2ST7>&- 5NGUC3*Q=%C6
ME[_47<Y:$JUD:MX:SX&LD36IW<#4BX"/9JXZ6B0<T\Q 67#5LEH*X*L$L5C,
MNT!&'2ZFI7KWTH<^*CG5R 238T6F?D9Y[N:W+<?[/L8=;C&S^EI%EC@^ZH6T
M/U(RW_TT369J3DRL)#9-:W$N$3H<<1ICSS&8=D_'.?HMZE](S_4"(AT<RJE=
M@2WV6O+S':4&R3-C6Q$L%35OG1-O(;K$Z#;!CMKD+V1#2YL1#19J\L#W48JD
MX&O3").,,SX5'_1>^355EP5)5U5$";3WG_TQZWLB5Z%N2WW#)D55+V)ZBJ(*
M@)3<9V'6V+)V::)9#+,Y-I,^!JZ&Q(2L*4)X/9&Q'AT1<<H@7OJM>KB\[VT)
M4%5B?-\/TS\XO/V<)A.NF-]2L?H/3'G!]B$]P_1 T)0,C533Z068DZ')WD<&
MD"*.:<,5TK!B;2UZ^>>O='W=Z]O66'Y9&K+9IV]?CALU9;-.['K9KR_'#;IV
MX9Z\_P ,NL]6W#+'O\N>'?70?1QSCN\>>S?2WG+S2/\ 1QGJQ#^P-\<5;U!_
M2[\]&V-?$/U?:F=GI8LU=Z_,,L+=U3PRM D_L8[J(*<!FE>KO2>B*]KTJ$*=
MRQWUMZX<VGV/75)X1]BVL>7OIMY) YDDH\9Q8;& 67X!])7DPK3<(CRHL25K
MT$]0W2+7LLML,MAI#S9D;N3C&V]!?IQRJ?Y\^V_3WKB0EN%C^7YU=T;<?GX-
M?==69#U]#QBM*820#> J5CWEVTJ1L!A.I;1$:(KHLK*D"@;UMC$$ F&R2*E9
M^@]CWQ/^MGEW.-<MTF4.Y/*OM<N>J(JW:-5+KA&J&CQ**4)B^C PP:'N.89O
MKE/WL;=+:&/]8_,AP"D(/A&&QPM(XYQB^C[QO"'\VJ6]%:+JN A<_M'R%]"C
M?IX1/N"Q\E<(52ZG:K)BE4]#R8Y*O0LGSW:2JKTR&*UTNJFQ<#-$]8<\3A\M
MJD=V^VVV^Q_5\Z]O((K96"Q;'G^SO!/H/<PTOZ"NZFU&U?-UD6,QL[M2Q:U5
M!=GV,F/Q!;I.P 9*:%C9C&=2;$IDUP%_ I,'10N]XY6CXY].CK,I.J%A.HGT
MBBX,#'?E2&V'<X1O0X6F'ZD[6L"JW78SWR_N3*4>QFYS4BY"OFV0.;!; 'W!
M]>Z!#BZ]P:'Y'S$S>!VWW\ANMJVY<.NK/H+82$HMETN&YU<-:IH\^^:674,T
MD.H(D6,!ZF!F89XU?7 P5<$9$9.@4+B:N\L.PM%XY3@U?0F_5Z]+M$QZ_HR7
M1M#?0+RWXB9(V;<WXWJT:/4ZAYIS!/:T$T#]RU'DI3KZ.%2YH.9U)Q;499;I
M,"8 (K?ZQK7%'_17V+>(;R^*&('F)9??8S=ZPE5=+)%;1(I2)5GDECE*K!M<
M?T,H!5SL^PB<L#.7U=<WK8==7(K:;EF6'('_ !^P+UN.<]9'ZY^D6Y%%.%4T
MU0XS:O>#O7GL.THK\ZOQ8?F:\<WK+I!K4*T)K $?V<4K&) C)E)=#,0?MA@)
MP4U*#E<OU!,O.%'ZJWO(>%]!>*:J0>98[_\ G0HX;U)R<#8P-4WOU(>&>/C-
ME%@(/=.L.M2*'/%Y%=,2$KMF@L-DZ@X61KW0\PO<XYSGMGO1X.>C5_T%_"0\
MA_F^E?\ V@-?AUZN.9W2H6?%\4^A_(B$@&V'#5B0C9,!<8)([=\B*(,R DMA
M,1UZ-M[D]0MTC(OOCT9$K1D.LF^CX#@Y7U/J3RS&T^=O9V<R\AB?1\JW'\F"
MIR,$)W(6VB"D!B5MQSH2N)X0=7SNX3"Q(=K"PB(72<<YJL?JWZ-B'-GK*2)6
M)OGCOXLT#[U(>8!PHQ,<,++LUPL0=*B '[+.'E'TQ2VD )/&RX&1!@I0O]QV
MLQ37[@GE+&;[S]LJP4 G6%YB5D&T+8]/T1YVI&R'_$TF4P?SM5&?; >3)I1A
M-SM86&ZKX=6,BF/PR-!8ME-SC7,83L ZY9O3!"Z3CE2/S!>[$F>??9C98) <
MPO*S[[^@.F5%%M+"UJ<+>HW(SQX:XJ%C^K27C*,#N!A#%#/V4/H1&[RA:8.G
M+3WAW%2P?LC<JO0E7V@!IRI2;E8?RLHCWSFL%6YG@B!MD7-<M(U9JKZ5-A1)
MY2$BQ<+1,R8Q[8.EF>YX#J/EHDXZ9NOL.AGCE,&'T ]/?YED>2LT&A.O1./M
M+5YRQ=<B5AZ:-C5_UXF7O;\EAVQ<L<W:586Q5-;J[#KW6V"'+'(DEK[GPQ<*
M2$[@/X]^A/K94H*N:6IZBMGHBYH2?[1]-O&S0</V*,:]&7T2]/UHJT_7#@69
MDR1#C=S%&<*'V,T9E1"HMYI.O<F;XDSO7##J7XY /RCZ.OOT'>/K<.U)M8(E
M,^=+>@42#&12#":N8J^[:/H:Z34ENDQY>RO1@@#HN+>L]:EV0>W%R(SN7JF0
M8,;#:8J8]NWOZ[FN/T[1H]DJ$NM:.])_'F#2Z=!Q:D9H7YUN^A?,A(D'GOR\
M0WR=2JYSY)B"\Y;1!S=-'D),8='A#^I0N2'3'QRBHW].O2@YXW><!5)I37Z)
MC>M+Z\]R&)&%-[56G2O2OGBEO2G3-$3IS,IM<QG.JE\*:QDO9N4.-%*+SBQ1
MIT\7"AC=\Y6HGZA]&_/A@EAX^7B'UI:=*DAXZ*[EH)+"F;2*ZMHF-H(,"W(*
M]Q(4V=UC@-/!-DQD7X9F"3@1<F8=JA]!/#CG/$E^]7>F9:YY,J3SA:(7U@;O
MAX1KCK^U+PLOVDK5433_ #HA7MV3KVPV.S];)8*M8*$SJI-36.FRO2BZ2WO,
M]I3PY$7F-,3&\]>S/5=_7!C6Q6AZ[\^2J?J_S<X^G$VX6PK-L/4U^AI;SJT+
M56;4K(LJ:!BZ,2-L\>89"!:2TL);!"W"UD@(*', M7XYS]DOL3:<'RQ75\XU
M-6&34W?+GV[[Z-*.UF8=<4,X^67:B%)51\>L<=A7!2;N[6/?S1.5IQ)QIZ[K
MBC]G66N;CWAWL?U/[!JB-ZJA!V*M*Z]*5U2WRA;"[JL,=M-]-Q8?HOWA==2M
M*JMU@Z&?Z^'SC+"[@*/6,/""V=U%%Y?1&*,R$K&M>#HUXY0W8/O"XZ6]'WK4
M:O5N-@W*U>C?)'GF 5@,%GM]>1&!O\2N?HMU<0U/&G6- 40\ ;6I\(#3DIF5
MY;J6(P#K:P33$.;)E;/7??OK 19/FX1Z6\X"/)]76C'!*#/8%BBV]QA,UZ,U
MYLE/JE7K12MBS$#I.8_ X2/8J!(NW?NA,&RQQU=]%([&"GD)@7*\<II^EQ"P
MR/JCYR5JH!K>>UU^)^N=[G4]3>BV[S5(?.E&DAI9;WGG52=T*1+BK);=E.@#
MY9K]/"5*RDZ]&?>&S'+QFWZ2L?G>Z+>\PEJD@RH?F#SF\^H)A+;8)AI/-=#U
MCY[C.,.EP)HX:9SSAZWT/N<;IJB&BA"'E36,"V)&XA+;QD36%U_'*(;FM3V&
MY&?DVV%9'GT/8]M>N9K KAJ^?K4V5=L1'CYU^P6_6(LB/C$A%+ TJ4X7_.!)
MD"0, OQ<**W:123G#RF<P-G^SST%\^T[<,)1JH@^_L092^:-%K]]-1G #E[,
M,>-3CDHV*KJ$]!JE**M*>['D(Q<LW9+8-XC:M9#,-PT@7[#H:XY2_I^C5]Q?
M1A=7,5O3O^ AGTQ@_.73,&G'/9;\XNR>>@EO@[(V:9,74F0((IA.0 98'UG/
MDE@^V9-AR1$P;'TFM(C/K)Z=)5X0N,52*2U)+?K\P)%8 %]$O$26!7EZJN;N
MMEU*:'9YTJRQ: >N%S#2RM1ZK1,4*QE3JV!$GPL<N,,$PZ#N.1/\HW'==EU@
MWL?I2GI5$-"78#>LZ-Y?&&#"OZ&#B#"P2VQ(#<TMQ)'!%H1.2+F+[0R$"@TL
MM&9>4S:*E#MV5#GG#Z>,E:-7J/TQ8)>Z[.1?2?E;TW[HINH'Q<MM) H?_B"9
M.]J-*TM/?D48H;H]P>4#%56>R3DJ2=BYM*?83OU!F02T?;+#J3XY3#?MW>_U
MDC\ZX4=[\J)[+>?LZ#7SW&2([^[H[-7S'Y%]!VN(5)_9?:)-81X9ZO)<F,Q!
MB@_8VD!R29B:%L;D>79LMO3GHFXDJ]/.'F2AUZL-MD^@5>]W_%WN6<T:4);6
M*"AUOB9"P@:AAH-M#HUE;57>Q<#4<$1PRR%;V25_+9"M J6$Z..<[]97Q9_O
M'VM\OK5[@IB?7A'R%Z^NT_4Y5CM R.@VQ3'ICSG2C4ZJ$Q684U5=>X\<_+PI
M9C?%4E T*3(TEY@']^;$]#IM^P8#TM>W?F*XK]QW4.6W_P!,/U4-]/AF^.&I
M<PN0_%'L&Q\B;,J!0D FV'-S6GJ4Z/O<&,Z($9KT+8!$"IFR7)E!:+QSGBJL
MAZ[I7W7Y)2[M(WQVZ7A;/T+E7XTF+Y7W/S:_T N 7BP*(:ZMIC59[#/J(?4N
M&%((^DK)J>K>Q)!Q. 6<@Z$&D83ZQH-?=U>;KM]JU;K'^D0C0_IWB?.CZ_97
MFUO=6">L6S9]PU3:?M;LNGRK-,HH[KJ)L(F:GB102]@3J]1GP!VN&]3,@P=(
M7'*I_B]:.RSO 5>22%C6E:Q94M7TU7LBP;GQL/>_L\%1]*6[ 4-QD_9@L6?9
MYD5!T+43?-U=S(XW9#W+^S9%FA)HZ#\OO?Z('/)=A+:PBZ$!_DA)/G,I;=9[
MU&[#+X,1/0_HL50(-LR?TE8)U+4T'&5N8"*QNM KGN>"BP9##AL#3$Z*2 MB
MXY750'K>UG;UI=?G.]U!5I<B%*6D4\^H4T!8';M;]+5HTIBWHO@)9,G';4CD
MN,.MS"S3B6K;HCK5\PX!#MD*3LE;9N&LW[Z%,JW[@K?SLG1:_L.MFR]3GFEY
MG!DZ\([!4]J#O)[OZBA1F:VI:QJH:><D"U"'$FU4%,S7(<M- 9KD$,=O4L)'
M"V'CG-+J^P/MN#0ZS=IFC_)^V.S_ "Y-?4_H,/L"W8^\16E?2$_>VU1WLW*<
MW67=7$&] I*LQ=;0X)-,:"PHW ;X<>&8G3LD>\_2K/Z]L.FJA\N%7RH:3]#4
MKY_M)EU1_P!$[C'M"N*TLEQMV&T3FT,N+ZC4X"V5\KO6Y"PT&7X8O,7\&3$$
M)(R%P+;N.<ZJU]CO0@&BP/H&WJ4IJ2M6IY!]J>D:E5JP:7C>:@G/(]R575\0
M+8YMF':H$57?!]P+K(7++PJ7,0]01APV:F2-U'DZ\/E>S?4WF_V7[!%O"PAV
MC==GL'RY\[H2O5)Y_9JB3V&S*^]A/IYXW)+.3"FQ6W</22H_M9&G1$QUDQZ_
ME2V&!D7ZU#@Z6N.<\OH7W9[2=:6O.EI%"I%!VLN>!/9/H.UIUL-C"H;R2.EF
MG.I:U8J7Q1B[>23IK;&&;;),2',S-)UI&G*P.5'(RC.ABCW$>-)DPCY \ID"
M$Z:3GSO-M&3)Q(E+D3R)"9)K!7WR9Q"=*SVRILV7NSSD2I<G9LD2-^S9NW9Y
M[,\LNPDEQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' _
MC9KU[M>S5MUX;=6W#+7MU;,<<]>S7GCWCGKV89==XYX9X]]XY8Y==XY8]]]=
M]=]=]]<BN"\+^-EA:L!,7O,%'AE*U!$1?L1:'5RLQ0C:O#R&TJ/72XW4/QB;
MEX>3W;2$ %AJUB8<W/N3&AZMW76?4J^.!H01Y7\U@+<*WV%H>IA=TF]I604M
M"$B+FAVES#P[2(/D,C^ _J?K)GQ.C4,/$].W7/-#\/V923+CY9:^]E5]7J+4
MZ0K5I62BOH5?(X2"MIZ8J"H@1<6@(S3C'@"0PF!JTPX$&)IQZPTZ-&K##'K\
M>_P[R[[[[S'C@:4&^<:!$ELS@NG:VA&OQN7K83BJ077.[R]$,@=TO7]21C$_
M5RRMMG!A#[]WGEWDS$!L&23_ ''>G7^'VFJ!H]EIN%YY8*H0#E%C%I93!U2E
M5<200!ZND8B]:>#A+4F-M&1(*GD"#9KNK1'UY!) @=('91I$*/LUT)5E<-[E
M2GS[L"K+7"T]L]A?5GZ3"KY%/0(I8 E\AUN-]E)U8)<S]!VKK=B' (_G!.65
M<)'E:]_]OA))S1ENZ 3@C'B]$^W[L\@(1&?+ 5_:%//_ *N^\D]<1 PUTPNO
M%@\MW%Z]]"A=63N3<B"Q-A,^NM6:NHR5!K[1N QIBB6B-A##61"QPO.S\0>.
M]J6KUQM\PT7L0DE[.V>I*&RLU/-?7;#:9!*4T.(D9D,[BQ#[-N,ENV,AJU];
MCN!*;I*]R],G;KR\QB\#^(FX.H+K/Y-\]'P2!7F=2)04M4Z7.&J]8=[_ -WK
M00T'>(SCP5.'-V9D!H/5KQ@"B._<1':8LV1MD;-'>"?1WKJ^91*=Z!J9'7J\
M/T[4=LUK9263K89H*$+$UG9!E)_IB?Z:]+&RX 4-A!RRO:Q6?7\5MU2RL#%'
M'2Q6S+*'OT4\P&O/?AOZ2^AXM\VFY6"9\U^IIH"81+Z4W8G2[5?R%A2-J\94
M.ADP7+!J BIZ:#&-7X3X"-4:SLT[-<V:8ZE!;>R^6/-SE +"VJC*N/P#MN0K
M]+1RB8$EXS+N'#!H2%;.>>R)WLUV#'"B!P?%KTYZS/8J-T.SEY0]F[3LQ-E\
M.>-G$*JKK9Y>HAB (TEJEJ(@U6*B0&K_ &\,\MU=(HZ+*%[-.D6VMTZ6RLH?
MO'(2;-;LB)*%)DXX;,:P;G]&//S6JROIJ9Y_I) TW985@)YE(AWE8MW:4@UL
M4%N0H>IW=[."UDA!\\57KA;]7I 9!5L9BV&.)QP.U=2".^/*^3TKZENBYO,G
MUP%$VFCD>MJ&JKV7YOTHNP2UB;];V5.\9%+"SMD.QY61L#@1+1/,2&!)1(R$
M9(95A%_N?5BR9<?*'D%Q\WSW1A*:=)3ZDKZ7/9K$K>VV"9O5A&R07LZGH:B/
MJI\G;<HO>6]HKR"A)<-0+Y=_NP,99#:1^S1KA:L<?QH6CUB@*UCUPO3R[!KD
M,CZ\-+(R[8\HXXO=I.K!8EA-)C]MHC0=4AB;V@T1Q'08L88+B;XXH=&T0(<?
M5C3\A^];BJ(&6HFTG&E!#J&I;YI$:!85"D+<L;H^R>S-US(,&H#"!HN@09>F
MT86\^G)H)\P=JM6R4 _&F,0<#V,DZ).(HGTX]B756_E0M7HGS2B.%L>7?I/>
M-HS+!0[.9145@\'W77M+ (*4I+UP+LT*.L,JW[B;$./N[))4(>>>(\VRR G[
M9@"Y_KR[YPZ3E2ONZ,JO-'1:T;*935/:D+^T"LU,^B10%WK@*-VP<XT!,;@P
M,,,9%_1KP&FH8N#H(QY&$;5UCCB-XM\CUELA;J\\VTJE;X#TM6?&DK-=K(:5
MC9":HE$)5?=TF".T[Y3@OI9LPL"F.5LW%H@4E,@ZI?6G?GCW5^@?2ST1?UB>
M=%FHP]4JO^4Z^\:6PQHQZK'^S#\ZO?0=-;[MM4V*LH9<57HR%+K8-&_KZXOL
M05L.N4Z7$G"(9'.5_%Q-O?.WVQZ_]<S:SL*R:(4%+SW=]&&K>5V<26K84PUT
MPQFA>@ :U)C _IBX72S-LL&;)1VQKG551O\ 1G53FKAA7_<FHD4:%A-4^8?.
MM%'65FIFD*OJT\X=9X,A1#2P*Q**:=D_<5VQ-F0F%%QT0=Y3?N)R($3'1"D$
M<^YV[1G*ZQV]8^<\=>66:YQ?HI@H6LS%ZA"$,H%MF>LP9#V(G0=8;3'WC&'/
M#N? ZZUKH+K=IB[=6B5V)@92M6[*-JRQI9]\^L#BA[6F7>#+7YKKCYDD_/X]
MV#(-9VRQ4B[8>E2F[7[*SMEW3 !"NH<SS_Y89:FM-5AV 7B?UM@G2Y^C"%W,
MV2<]]V3[%]+6;0OTH=T2PZ'IT?1.CW)2=2J?8!I,^@H+KYUK-@) [:S.=6:%
M!SIC3N%;W]41!U?P,Q==ED]YV.9S#N4'F!9'EXL\BYR;:E9^:J1SWWN#8UJY
M>\ZW5<\+*7G*?_+. 5PTY#>])@8WE\<3#5#E:\M#(8U:BIG"<0TZI.'F:O"O
MC+2D'ZYA>8*-@(38Y"[$8%8572R,"F'8*-P#A&F5&'0(V&98.%UX!0\O#O'(
M8%_,)@_H#MF<;**?GKRZ5]#H/DSTSZ NO=:CKK1?*-IX;$@',15$W,JM-?FQ
M*V3-.#TYD24V8^6_O>'0MVP;(#<54UX=B&%+6,H+MS7YD.D?;2-BU=OW1Q\"
MDO9'MSSY6,">7VRR\^MJ<]'V")4(>G^0V=2YNM35-XE;U]1<=NJ&(##NMN?Y
MN\L\@G:K5C72,@#ZI24943ZS$A-ZT*0E<$- *0T#*PWZY0F !$QX@Z'"DXRI
M.4C3'CZ\=VR1OW;/S;=VS/+5])^1_,OFXJT'*%HVMZD,.W>K)P)(JU! S&C=
MIZT=:Y1[?#PPV%9OY8L7#.=-[W3-NN+&U[-^>O1JQPK$]>_1OT)1%R^W@J5W
MYL_H'B>D_*%Z;T=Y'.LJX[R'7:U64#<D%,(BK% AEM@WZ4B %K([DG..F=8+
M "5BJY-U&-<Z)Y^_Z&^K-"Y<#=)U>;1X4C]02OSFHN1+3+&_BZV'![>(($JZ
M?0;#NM>'%:MTB&+EAA"(H0:ZB$W4DI1,W:#J/;X X)TU[\]_/JEZ&O/TZUI*
M+9UMVU?P6^U5R;:[5][74)0!0U742+ J+1LT2RN_0/'UT08Q17;G$G"2+L>C
MP,-/7?<J3MYA\@>66RM5JG67SY41RKDLP284Y%)(J_*75,\9FER)@RLP-D+O
M "4+3#YW:3G"NXDF?B9*Z96S;H(2]>VJ5C^J]O4K_E"5<@&EG!4JJYO3ODG5
M8E9ZF99!VCZC1Z&JGT5YJ6%8(?<'/^#[M@8S6)1#.F;6UD)A;]3XH(8TRM$_
M.!'QQ0]F>B@7LJQ/,VL7YVJ^X'6W5:+;5MO>VW'"J,2=9_-WR[=KJHJJ?,N<
M###M;"W69)'IG:XP 0@RJ*^;'5C67QNC3R,X+E__ !C\Z]0,!6JCZLC"M=-'
M/.^D7"2%Z",CT0R[8N\_4$8?#@:(<:NR^Z%$VSU/1IUAI&<?5EG$[[PZ[YY3
M#Y(\P-@9J7F6@JG.!'@;5X=N%DD@%)AL(VDL]FVGXA/5LA]]2-=9;-NS-'[R
M_#-:RR[[%9QN<YO@GW#[%6/*'EFD?-=0)%R%J]\)TYZ3;I+&?1H\.TI=O7A=
MRI)656PK/]04KN2%$+%K2=ISL_!+O'N"=95X>548NK5HUG+C?+WK2Y7OU'<_
MG?T@.1:P<H/^4'JB:K6TXH6F-OGM!L\?7@VW,;Z$VR[(KE+E;CB^/>4*57U3
M.*"WDM@7,.9@C)I/L-NNW@OS>7J!AJ:LJPK>C-1%0MQ.73E<U@A1,5$5?# M
MM-RCH"W*!;%V4 MLVH+V5I -L+5'=A\#J%/D:=G4>7&TW3/R\H50PM3?="E3
MMT96B](3[TBB:*6*RH:O3E;IA1' G*SIC68=!RHZ&P["Q:; =M)^06=HA"*)
M(8: XW3!V:O-_1%QS^@M8>9T JB/%3NU_6EY==IG=-V"O&JKMJNO)3+Z8VP>
M[:+VKK6;&+Q^P0N";4ERIA8R* ;!\C3879H9.@;:$J>5[0W)OA)V=&GSY8,1
MQA?:OTVZB&2C;+V3++M:D'(H!UNUC-&CU!K(-3R*$S9H>J7C"**,4X'W]:P.
M)&9#'S(H=<?7C[RIUU7./7G2F/TJCK0G3%:Q^ZZ5NXJ;4)H/BOE:N#1>QG<;
M17Q -AU E)^>K8 VZ?S=Y0/U,\\\O)A>(?'XZL3]+PO--+:*I:389D84'&OE
MW):+GUN1#EK9F8.S@Y:MA%;DCH.Y=E]?EW <XFC^)RA]:\>NJ9*W^D/J"!YL
M];6BI _.8&KO#7RW\X>CU1*+KMP-SBWVA9GBPC>XY>/OA6Y,,X=<+18!"$]2
M)@]G?6<3*W]$F:,8TY'I^SCOT$]Q5Q<#PB/>OR*R@:AL/Y:B7O<I(]Q+)AE
M?2"[8]#S%]3WFK59X 0Q4AS64;1SL8CEH3Z%P@B9* G3>Y$S(+JZNI^J:17)
M2?3M<)-7*<T^;:I2T@K0A4!;V5EF9$& [L%!8L.%V4-3LLIA.;^AUOF2<N]V
M_///OOOFAP?S^\.K&ADC+GDKSX"TN #4IM6(FJ4X?DPJL=R@V'#62^R**U;)
MZ] >1@]K&A)&>8P:;AQY\&+'W:\<NJIV7Z7W-;!CV!6E0.:/-2\OG[[:]'>=
M+V T?8E>%5YJ\WVEKI#=%C:&NXCV^U(\4V9V9X.(]?JF)";5.3L&AF($1B9Z
M<2KCVW=53[T:T7\A5ELR5CYO_,OT!Z!MW7%M%=F$:&NF_;L2[B;(:SLN-UKV
M,P5"I#M]N%W?6'C2W#J VQ">R"%R6 RX%XCUY4\TV=@V86)1%5.W3T^*EHN&
M3,D@3&UAL=%6!:4FO)+=-A;MV]J64X,-50QS\_1""O1>@^G?B/V[X^S$ROAC
MQF;7$=0*>6Z'E*U9R6:57J_E6"CJ$)?]T8Y+>X1%N#H%ZHXD4TM$R0?8@L/#
M4(,E=G4PC!D;M>O+"JUA^FWLEU9%=2\\TC73,3L*G/27JBJR):*JY!+!H%%N
MZ96'GN+V0L;U/Y[&A"%DIL4+:]@V&%+/45'5["3<M=8[OQD;9$^O6'J.VZ9I
MSS"76U5"0K8],7M0M%$)-HRY#W6=$F+4%%3[.2;=Z2RIN+[B%[7"-?J&L(YJ
MPMOL)A3M6HY'&D>\-P325*]146:Z$DQ17E>?8S;F]OLL"*AC-[>Z;%]?4]K0
MP;(FK5V3.[%M36P>PC*_4DYC@8V+EL[UQ=?76LG+RKYKL-Z(6:]435;981<8
MF!B[D>2@1%A+C*Z<1E@(,,J3DP\Y)+6ENH88RJ_<[/?L!E8>J0-SC]_FZRYX
M_,_L;U171.P:3I8#65M6U>'N+ZT6,8=A\4(Q5W^7SI:-4 -">B@;,]4T!JB[
M&&18\8L6CX6PSS4)=76"5#6&B+IWSQWJV1Z+O2HO3GK[W,](%5%K,IOY^?+S
MI>HXW!T/,^C73U]9EYUX[B5.[(MU!JV@)RQ8&LHT6PYA( L795<KR[ Q;U:"
M!WM1,.@!V\E^8[)&LXA]H2J6X>YV+A;S/H.I((AD6M36JA47&Q=^_=#RDZG7
M)+7 BGL98V[26W+H[2'VRLX'>S1GL?;5=9[ZYZI_?7R9OJG%<TJ'5;[UH1N1
M_P"K1X^$30O=J^V)F&[#Z8VO7IUC^X?<;####\NOKO'KOJH7_P Q?H?JL;SK
M1#+7M!5:[WMZELVH1=COZU$98!:IT;R(R^B\W2#3=)^NK0_J;H/;%Z4G9K+-
M?4S6PKV$%HUXK>LY%PC8?2OU$OMWT^.+3ME4K6K_ #GZ K%!"DG)80V:TI[Q
MZV9;)M>M9E+ L1=R!F:C0K5+0012I&1QK6V5UFF,!96,N0@FL3-^\+1MOB/Q
M_NK.-3>SS/2>57PV[=8$1*_QTL]!HS](C909+UHU8C^MVISDCL\Q4EJU[L3T
M@1GF(W3\QN>47OV9/D;RY,;:T?)/GRG]KG30$"K54S]H"WB90%M5(Y&%8"L3
ML!^.X6(5S.69E;@1\L8P$SLVEA.N&0V[).5/E4?0KZ=75Y]'7E7/E&IST&W:
M,2;<J3"6QU0&V*9IGM= 7"*!M6H_LQA:+P.#*V:V@M'_ ).-Y:VR+20^JQFP
MAIEP&1QD]='NE&Q^?D_V-NM]-V"Q<(DO3K(W47:$!;CV8.M;=2>Y=E4'H>"M
MCX%H]I8=(6Y5C65)T263'O?&>,%K=K/8!N*%X)\3CI;T0'^4//\ "GV<J6(B
M6#.B54G1YK@D6V:@L=EIYZ5J$X[YZPZL(V$=/ =NSL7,+Z.B647&9GMW9[0=
M/.U#6/\ Y#_O].5LY]6TB+586;TS)P(UB]UXFDF4RI)S1C/A;\2X!9+N#.4
MCY?6S2*(FILV%CIDYX[<*7Q?U5OC;3TB8V0*P0K$#>VO3WDLV\$*0LUI$]1J
M&K(_9"T8Z\X*UV2'6$RNDB*%3C(K3>)D8J2]LMAWSI(_=U"&9-*^EE_IEQ>2
M:F;=E3-;@ZVCY3HGUTA+-%6.I:*9L[T_3#/;(Z&!N<G?[@GS"H2&/"S(2@&4
M+'@F0.R=OEOX(A*CQ!P6EEO&_E(\N'5([YXJ$TN,_=>YL HLB@",<M(J9>CJ
M58SIF4R'NW;":"LQ= )3*];>B0,9K_:#Y6C5EGCE_$+QEY+',=<MT'SA3$9E
MJ(>(&5B9U5XM=346*ODB9D#VM[.Q_?0R8%-&S)H22T8XD1QDL2*PY6DA.DR-
MM#R#]&_3Z[59>!2"UYQ4@-<>4/J?[+:H]AC+SM.>9)^3_=5EU>&3%TA/O 67
M&#+"&Q)I ^7,GC>E.,2\<50!VM08"G$DY9OOST20G7XG&9*3YY&6IY9LA_\
M \_17IZS&"SS*[Y&7+S;&$C:ZQ<D .HNM6FR[)U)JIPIY(D$5L2NM2Z],FLK
MA$WA;5=/F;S]Z,Q5>KUI]!M7-&E&)R9O=%Z"9E*LMA'="#T@!,D:^Y0K:9%X
MXCR>4+=I_>Q,<=$C]37CCCU_ +S#YW68P&&!I6MAD=7;9[Z UQU,3^(MT*(.
MVJR;1&V;(V>SHT0K;=FC3I^>>>^4K_IAM^6<+3JU858V->MFK_PK6_0MJ,*7
M?KZ4\Q^<WHL:T:[ K0*W;7+?5>>>T^32;:E.>3#JV&=TDZP+;X BL!S3NW=
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M9RV'="/V!&U:]NW(;LDV*SF),+<8R@38GJVIY-\QWBW@K N*@:DLYW6(@:
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M_G>O7WWGWWAAWWLQZQV=]XX]]YX]==]=8Y]_A_RQZZRRZZZR_'KKK+O\.O\
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M3[K/6=G&=77_ #U5*:NO\%HBG?:U>F]I 4.KI>'H<M=\S?UN$)DKBFPJ 6!
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M-H\I5=:+3<9FO$!,V5=Z.8&PJ**U%'E5FA5\%B]LJEJWMTNL&N"=L>J=@#5
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MJIR- NB]=X&OQ,F.F^2=5]599BNXFH+B1WD8M7%QRI8-C"=H<0OM88CH*:I
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MKY-AUE+W^=-9W9+MIRMBI[E"5NG;9*OTN=D,:S,GICK/5U")T/[.R=V%X/'
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M2I_.=I4)>],+U&M?4.NZ3A,82/K1+*:1![:]XV+%-X!8;G_5".(B4(E]1/'
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M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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ME^'W(_?)9UM3 5AK8TMUMT:]/4@NELP%AB_M=LC7^Q)Q_P!3/7O_ %-.&P>
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M&D%A/ACZA,#]*5)MI5DU,-S5W?U7)_D&'992:IKCO+>=U9RSK&B0V2$!<'W
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MZ[YIZWO050T1MKN):+;_  !2VWF+6U9@!X!G;FAW=90DJ?[#+RJF!6%C(=0
M(,N<-DM0O^(7PPZ44.SQT#5E(Y6C:W5FQ? _D./Y]A>N U?:+2H*%Z6'PH%]
MZ?807SQ'W$M%L0 <![U;O1<4T/<=2W".:TW7M=8U7:V7_%O>4+ #LY$Q/HV]
M[@]&^)F1[#^R)U(U?]"_:$VE6RPVV^4.T57RL7\3EL$LI=!;,TLVA#%'/1,1
MO3ZWDW;MUOIBLRR\J,G[J,S$H! .D;CE/7ILCZ(3_H+4+97&OT#=26?6JQKK
M*B5\;Z.K:DJEFE6JP-S-Z1/VTB_I^;[/CCADL5#L6HKOQV-4,&OKDFLYFLR;
MU#Y-=5>B_I'%\T-#H5NOV(0O774-3C_4M)0O-_IL*Z1F*7Z-JJ3Z*<?-%IV[
M:3]492R5JC\+N#U.N>350.J-@TLM&882.RA57K .IKF&6%8B/5"@7?[(9Q*:
MF >QW1ED.R>H@L=V6*P0@WJ5([ZRZU_O2Q* /T?CUW^>3*TX?Z_-^/**KVL*
M\:UD[F.@@_T8;J3/?/SWW7%9BB5>>F'VU.O6.QOIECHPR:#NH*3;BX6W!-5C
M#Z@L>Z/X?;IAZB874Q18NP=IWZ'+)GT)W5#[8LW-B]SYW L4Y\TE*@%:,X6W
M!#;C16K* G^I&%/KT?*BB6=]V-N]YA6D:(P#A #/BL&K\!$[>:VRPZ.V>W*P
M2X/\DT/JJ&@]/RI5FR3*,P\M<>QW@J#"*23,_1V[<H3(>)LR_&@"I?6F5G_,
MCM^>&$>5JW9;%YSBB:HNNH+8]MQJY4_5X"P+*^S7B2X^RD#?>IRKG/R0]61X
MNU6JRK1;=,*T]N"1A8&XUVU((C;';%:O%_M?9H8Y.%B8VK"4-*^@+<B73+M+
MUOZNHN\Y%;>G@-O U7QU["LQ<$,!RTH8RK6RC6C7:3/31/0HJ^B.1K_3Y 2E
MI],I!DW)*8PV@+KD1 Z8BA08$&$31HC!$!Q$&64+%BDN/ &"QD"/LESR)&?+
MV:HL*#"BZMLF7+D[=4>-'U;-V[9AKPRRZ^K5MU2-6K?HVZ]VC=KPVZ=VK/'9
MJVZMF/6>O;JV8=Y8;->S#+K/#/#OO'+'OK+'OOKOKOE+)Y4NOTU\;_9-3'*8
MN14M)DHSU]5E:JC18UW&; N&="778=6#F(+7E,#W^!6K@,="]X.O;@D1V@6M
M$L5!DZG@]O64R$;IGZCBHMI1ZFB?2((?'^6/.<?YE@P8OU1H 1KJCQ3VFSQ?
MJB.[1-X_03@VYI'07N+ZRW8),3S]J@Y5+WUKZU;>!T?L-NUPJ636]0,+5!&6
M3;HQ\,UPJ;M$_.<U#*PBK\U\EP=^B)M@:-:W%:E_=,QGRXFS=B3T]0L).6&[
M'5L?E+'T=3CQ+UK\]WM@5O5DZKD^N?<P2VG7QXMW 8:TN>Z5Y3O:C'GF*3'S
MK/7H+*<6YVA9VKOZ! @P"QT>?GD"U'>NH.HP3ZB-D^G1E^W7Z.HANQ\[^/)%
M0LZKYW])7E!DO>#.R3+GP]!PJ/M--I2#;4@7 4!-K0/32DPI6D08(DE3*-)A
MENL ZB>.4Q_2BPC*_P"M_GS7I%S]7 J@L95]ORK56/)4JV.G5H[2:QK4FE32
MHVD-,FSI<9:-$I.T),4=&1& P%8&J3LP!SS..RO1U??IPD>7K,%N07VX;ONU
M?FMXS%TQE5R%93D:6[_7_0/HJ#;A)R-HHN2K5?>.5+M= F;BD&R(*6QY"CFL
M5T4G <A/0=4_-=C;9KLQ:C=20UHA2[30TE'L9N3L-$_$@$2;)+NX!'8),C9$
MP&[(K"7KAW@Q-46;OEZMJ],REQX^K9%SD4,-:A[#%X^CK,/L7NN4IL/UCZ3'
MP"C-=U$VI8^=PH"'SB$?+]9IFS:='+)6SI"WN;'2H $RSMM;Y6'I43L>/$RC
M:< ]%U=Z'E-WLST!YJA^[A;(F?.OQ-AYGG3MMO+3Q9-IUIZ;]F'Y*W8 29&'
M-]MG0"B<7-9Y!M/$S.F(EA_O7]?D,A>.7@ATU<<YV#[O[3;O?+9#5E+V!0=6
M?Q7T$KAX9L(7I6[T?(<L5JH;/,UZ)"JU+4?S1#(,#)%)M-0HE)3I;L1E;IJ,
M_E)I<A,&:-1AYGNR76U!(1&3ZR5*)0;?LI.O#T;FJ?0RQ[3]"S(_GNO2E46[
MHIO78%:>]*BJ\E8VY^6G!/!GIB",L\7")C]<ZNR^O&('1W;UO5O0M<L]MV\U
MP4BN4R-"EL[22T3Y,(1&(%((6%MD:!<2?/V8[RA*##QZCQ-V76R1AEGUCKZS
MSQV1SDL]CU5[/;Z/N^I+7/>[?1K;)\M>)(GF$S4E3W&CUQ:TB#84<QZ')WU5
MH/>R)RY<&$V+!P?5Z\"\AQTH$(7O1>_[!)-=]W$>[=EC]7OYTUL&WUI&\BYU
MGZ*RLS?XTT7+NL?_ #[CE575$ZW?OSY&E6[K0LE;.YLQ'\+A@I;+&P4]=B99
MA.XFO,+2^.4?_/=$]DM=\++Q[)8O3(TC77@/QSV-5RSPV*]/,%X-[EZRAVX3
M?4U6F#Z^>;P#5X(H_"QX<C$F*7V(MA-Q$X2NP$R!K;TF4]UJ7I/V?&\WZO1M
MW-=H4M;N%&SR J_ZMJ'R&Y*?F@;FABEB&U8]>/\ T/'LRS(6K>JLP75A:RU9
MK$0&M?9%."D=T,+Q+,MJNJ=%+ARRVF$IBFVPJ]JE<F3M,[?K*V%:S<*1*]6-
M&(^),VX36=N."@D+=OPU0M,F;KV3946-CLWX?FRV_6RA8]95&R-<$38UR1GF
M76:KOT3\YS;&K46,-/.V!NCQ-T'1BO"S R9+Z(2X>6W7+UXP^I.S'9AASU-2
M9>+\W@153K/NEV\Q@K^^.SWUI]= ;R(66%O!(]SA&>_V9:U79!U/45'5J:$+
M;!<I,3K[IP(QPOW5>[HHW6>ZQ_ORNB>D63VUX"L.ZUCV@9MQ T_1J'ZX8;5!
MVAL\X(K^YR5R&@::@),L+"LA:"PAQG0^H<Z:D]IY!'CQ-)S+-QSE_G#I;XY1
M*\/WK4O]3*A@*E7>F4"IUKTX50+++]GO23I2-I^?)_BI[9A5DY!\5S_Q#05#
M7>W2@JQ?V9R;>$6Q@\[:9E#0[!%$ZX8HZM].TGR[61Q1/^W6:_;<^;_MDY<.
MBTVBP6XNJ7RL7WYYE4Y"2EQRS[6:TN_*FFR]150P1XT5-<<PX'86U')P/HGV
M'3 NV]6[99-DU"NM4$I9%0#T0K9*IIT3\)RH/LV$<(HDF=OWQ-4#?@QPELY(
MB=0)<O/3B.W=3,8V>>G'9YA&^*>%NU75U*L!?S<;JEV) JX/ D;2O3C.J6#L
M(61#'$1>F8*TRDZ-IW]&M!"=#VZ)4>3 PQV3H^^-KJX^;-?E0WK?Z$/8]<]:
M1*@L5*\.PZN<O6@NWAKPU_U"M;3'NL(*6NJ+!L^;I6C171B;ULV7\H-9"\_9
M#[U@IH++.N_RUXR>HSWX:J0JD^TJ[BU)ZJ^N/^=FO:S>BUN,L@;,/VH8I RD
MW,3);1@Y0M!1/*1R.TTVVP=;0Z[9F1PGN9I9^-*#JRXYRQI>CZ96,O><]-P7
M%ZF\_,LKQ!X^Z06T+YK]47%)U>F(3.ZZ/0,N^%ZG[00$30^;] FNNS</U(JL
M5<ET\T4)CL8I3!C[Y/CZ.OI0+[#\35T:<O8HFHWOSI]!C]AJOC3=;>3JPL5?
M:?*?5=G20JD]$RP]FQ9FM[#%4B ;7WHA-3*-@L6[I1*L6&T+@7!N6:_4FA[=
M#<!:3DI>,MC6Q%=W4<8!6UT=)+FS)#?WUW^C"&#8DF;*V_AW^31ISRZZ[[Z_
M#OTQ)8:>%##@:;')"#(^$6%$8F?6V+/&D8VJ9!FQMO7^MD>5%W:M^G/K_6>O
M9CEU_KOG-LC)'T08*<]A6%<C!ZZB7ZA?'&AX5,J2\YV*$2C/K]L\]>F<+3+K
MZ$M2H2F]>@AK4,JJ,P]:(AJ.NV!.@R 0Z(0V YFC;, E[#Z+^P->[OV9EZVT
M5SOU>'(>8BV<_(NU?W^%EF4I;W^3)AQZ!VOW?IG38&NQ\[.)Z[2BOW:I"6\M
M"A(TZMP= '/A*%!@,81-&B,$.&#P990L6*2XX\8+&#X^R7/(D9\O9IBPH,*+
MIVR9<N3MU1XT?5LW;MF&O#++JJ/YF+UVP-CZR6%=]_OZZ4K:G(TFK;[\_>H*
MJ-I-OQ8;/OL4R'>/55J6.8;99W'<'%,X*K9 ZEP9 */*J&J/_.SM?=5V0CV]
MZJK'Z55XP4GZ]0TV[OEI:G]6H^RF_P!0,G\3Z^Z<[M$AJ\6K.N@4HKDUJ.+N
M:7!8ESSY+C48V*\D9%C1BPO9NDR0ZN->S7NUZ]NK9AMU;<,=FK;KRQSU[->>
M/66&S7GCWWCGAGCWUECECWWCECWUWUWWUWUWS7ENVW7-#UHZ7%;C3"2*TKP'
M)9'1L):)TF  !P^\,9)&5H&1)T_;IT][,.LL8L.1M[_-^..OOKKO\*W+1)62
MB_/2D;E\L+GJ-C8O.A6I;AE4,>CV_HOV[$14(Y KIHMG7[JZSLHH9*)1]SEI
MP!AT2X?;<M(VU<T[ L,)LQJMM]$^FMB>1?;/G:Z M]V<30/']W,*ZW"0!CK7
MZ$LKV66KJRD2NE0'I'R\&HOX[T0KEJ6.*C=$-8(=N2Y$F%'_ #0=/0=1#A8B
M.@;TZ,Z,XE:WV"YC:\2M163U'S97<P/+%1:P*Z[Z[_<%IPX$7EQHW7X=[-(^
M3WUW^.'77?E63;U;U#K1]MD-<%4UV39*C4*/E.T3]_3#9#Y*WPU%4B?L(DOO
M5.-R8V_3&WR^HT#7EKR[E2]&/?67=)+$O^WJ]]4%ZWKDIZA9:1!_0?R6?5FE
MW.64^B2-7N'BRX-MX13#V4VD2,RC(=XBD:4WKL*9K3DML+?QX8>#TSH(K1HF
M/7%SW9YB\2+C0*^AI;T6/]A^!'/V64MH-=8J,BOB\V.N%ZM-.&&P-H456O@Q
M;(GCL8*!SCUD(KN77I6 0AL._,CD'3IQRG^KV;U%5G@3V?V>K?T3>%BU#=WM
MM5H)(*.;J(ONS:5 7(Z1J4V+-K&-!^P6*5M094':DOD?%F;C8<:+P!9&S/4#
M"1">K0GMNPEI$13AGVDKU[)^S\*!N*CCOJI0<L/#>?A6<ZS!T^P+T' _1O=$
M3/1V^8N3&%VD#B< _LC!09H-N'KVR '1FZ."U7B<V/[F6T 4]&6CK@V'96$C
M;&"K2R+E&CI:1JB:9$K9H'"X4J9NPC:-\C/7IRQTZ=NSO'#+^DYN7+ 455\3
MBN@ZHNRV#;E4W&PWZHQE<9!D4R#*Q]<K3'E:]! 9-BR]6$G1IWX:]V..[3KV
M=988\M]DKOMEEH<[6]V1OH0?3<_*7T^JRE(53Z+F/6(XWF#]3W8@T-AZ)(JL
M:49:,&;RJ/J.53K#>.>VLW/$@[,!:9-9"(V1GT6^109I8\H>85IE$$%YC7O/
M-+ SX M#W#RH,T)K9:@%1!,?(PU[X) ;.C[X4V'OUX;HTG1MT[,,<\,L>@D-
MQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP
M'''' <<<<!QQQP,?:FQ615XJW.S* 3U4%&_>&V5H,#P  1$_4PT_NB9@K(B#
MX$?O=MU:NMTJ1JU][=FO7UEWGGCCWI%%8//3IZ1OG>FP14OT;42S5%074P=+
MY6"='*)D68N6KD_:PS84<:<#:HUAGF>)H"RY^L9/8)^DAE'F;.]&,=?K;13?
MZ3^<GK"G$!/,6"[M%:9RE5( FY0$PTFE@Z&:X@8;,C&U[]Q/E]A,L8 N26C1
M"T[J,/W]Y]2.L>ZS=OFZZ\+@],^A*:K7U6F9$/4OQZ.4,+*O%K+1"?32I,H1
M%]1YNJ(:>,<';M9J.;:2I9.JTXK1(A"A>W(;^.Z%KF[@Z2N:NN*YJ[H1)QL2
MTC>Y=4<G*M$+LII$&#?>#/;MCJE3(4'.$#@D9^.LR]NRV&SF?MOVD#^0ZF3]
MT>'IW[]=,WABG_88WU=DX>A[%]&#W-?=/4VZUA,RNFZ1Y^MY,:'@QJI'$39C
M)Z"<JXU+RLI]I!NLP=44XAN"_P!#S:R[P T7<5T3=5^UJ*]#6;Z$O0>=JOUK
M9!,G[&^9S_YH9J[=V31YC5O+=77!YG9[D$MZ?IL(6BYMJP^*]Z/#M#9$DFVE
MH9.N&)>D20R[LWKX=&!,F-"#2!DR0@B0XF#+)E2I.7'@#1@V!HV2IQ A.E;-
M46%!A1=6V3+ER=NJ/&T:MF[=LPUX99=?F&,AV,.)85XJ..@#PV"9!FP\V,2$
M& Y2+JG#2HLC#V[H9 <0A;]$N#-B;ML:5&W:M^C;LU;,,N^<%7K#V9>GHGV
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M +DR;T-@7).[*79A[BT^Q(-*><+Z\Z5^\R_0"!)U '[SZL6)@9@;Q5^U:2K
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MXESLF!!BPY!HM@.@","A;='U:]A(CB)%"Q>,V9ENDXCAL"%UMZC0X^K7Z7'
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M:%?!*G+9],^/D/R_":G-EN9A:'6WZ/J]9M@JN37-Q/LG0<9:4=R=;4W=3=,
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M@^C>N]0I6!G1MF8;1NS1MUS,=.>&774"*Y^N_D&SG*F-82R:]!4O=OE0SZ=
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M+LWZL,NL-N<:/GLQRRTZ^\0YAIWR0]$;:$]F"6M(K2T_2S[X3^?GF>H[G+L
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M39H5F35P05F+-"CF5M3]"]!G'&,KA":BT.<"QVU_+OH:^K(\T/UCJ_FT&UU
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M" ;*D!=HT&< "V.>+A2OUR8/=ECG$S"QWT=[1\Z^4TJI[%N:P@Z\D75:U:5
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MQ3X*P:^3I]AOB.6L=1@-J6B"@O\ 923>U+TDOK+ %V"N?_E#*+%8D6%H!?\
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M7)C9S,PV,?"3'RV];L*F /QJ;0@>Z!F5[+L[7='C*Z41CAY(TZ..E_0#TY6
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MN,GOIRWJ$N9:L-2NI3K!F2;)]4W;Z2A%597JRY5J1KQU:+O/IK>@-TP^":(
MX'W$/@=0S;@3WA+^9=M@K# Q4ZUJJ&^;DKZ)+7T,!*6VLFB?;^!&(K$!;54$
M=ET.NA7U@M).;NVHIO2M;"D%:_8)<Z+LB#,2$X+0;OM_33@NNR.[!-SZ?;IJ
MBH-73F^:$'1U(L]MA*VC)>D[P1[IH<,=LW'M:1-6H;(;2'6(S2;%YY]2.L*J
M'VIY/OUSDUY2WH"L;,=8@MG-;EU098A>?V-26?0EN<C3UH[[U2LE)KEPP++'
MC;=TH$1G0-)/3%_?1.]VA':E+X]B^>_*9&XHZA2EKHOJ?SYZG<4Z#"*FH(]:
MIJZ<+'#5UL[S+;MT)Z((D$"'9IW4\D$%N^1O]AA+#ZXG-9>:/G$WT,P^%C1&
MT5H_J\D+WO4.R1QJT2&Y/4CV+;*U9(24*[VDMV CI-U MT,YU.QGYFILG&7%
MRB]=9_B$WN_6_F7"TF.E9%XUQ!M%2 L[0Q*!-DA"IPP D1!A!V);)1+.*,W:
M4N 9%SV_&+.W[E>%,U2SNN!'_/LQB6E_53S*ZV[>XL=:%4[?.-'><O.%W&?0
MT=X[S#X'O0MGW17H5(*BMXJ/C!WRM-<IQ10W1YTR:WYV"(C"1^_]V.RE1>N/
MY-7UZ%O.S&RXO6&UFJUQ7?>2$K1]W=IRW!$K3V?3&FIUQ+6DV78_5)KFJB].
M<SH>=6DH2Q6./ZB[VLI'*9D-TSWF3YM^J;';F&Z[!N_SS'NT:L_/WNL(*+4+
MP#J:&[>$;NNBV8FU_#R[!ELC"I67&MZ>*[@!RP4BB2- S>)D%L5J'F6#;E2_
M5% LHW:,OO35^NLZ\]#^HZAA-XBW-1!D<$_S'Y]0[P87%%1>E7+>['<<VDR"
M;E2 ;&9H\4!V5D3R^[=M':-C4S].O.%TJ:);@QWKQ)HQS\GCO5$]LLNQ1Z6^
MI 2>PK@+<*;JW*B=<:$!$R&..)(OT-UG!]SCAJ5@\(KU,AEM\=JR^7]KA;N%
M758]T5Z5)R?47LWT2U"T2OSJW!ZB^K?,2%0<!67=99G.;-<M'(J,D]..$Y&_
M)GT2M6S9$'3]DG\-7"OD/>)"N*A47*_*JP8Z#\8>>_*M>, &M6R<#.&?)'J"
ME/1-+/CVKFW;#=,%-&NC@"W;*>-8-.,[LR:W #,>+E%BZ0L]S]]>+]-=Z;8E
M>EJD@U[MLD73>3*2:H8V/$MDY$[( ZV)0Y_[8F*=S<#O5.#+1.%$+%8<J#*@
M19&B?"V2-\55;-;7BA@K0J-S!6!7[+_)X@VI;F=314_:%+SU\S%PV_EPV:9H
M<Z*)ABL&3KTS!I4?,'S=&B5&W:L*LI7S:MU\M>/Z$M2V:S_RJ?\ ;7ECU ZK
MR&DLT.MX2/Y6JMMK)71EC!B9"IZ<ZL&33N8C+X7SB1L-F@8&AK^F* A2Y._?
M,U1WOYKL.13\*,LN=1V/<?O'U7:=H21A8-N7"7H'TH4M&EJG2M/1J;K*L<"
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MQC5,[@LPR5ELD8A9L4^@/B\(F+]@&/1E;BE5JL+;4J[-(E)$.<6L_4O9-O\
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M?2X3=#B&@A4O_&B#0LA+UVK?.$<,^<S[\VFNZ&-IJ\[6+K2J&^PD]?6GU%K
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MGM@$)4;+7NS#V^... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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M$^QYHY=*8QBP0+'BMEHUU3J]W+.3]<+1L)/=GG0*V.U:^\LN]<73M(FB&_\
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M9H!<L-/KJ WGU_)3JY6M0HLEW4 I0EM47#A47/EJ07$7%L-A><%B/JD:%?\
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M?35@@!?\)M<J_0[5:6M/$+@%5A2B).U;(@%Z^?\ =)5D_#&',%K6$L6=F;S
MV'MM.]#78&\\>=KP]&&PIAD7J.IBRKJ,+H?J/#/'0M:)!IY(!QG1?9#C1BQ*
M %W0X?1+9&TZ9>[7U+RU8XY_@$5C/S$\W&A@4?MGVF/E*WG7S'YM3F .\8C&
M1.7?(%E3;<H=^6B\8/CN'VHJ/LW^8DLW>.X:9TQ]0HDO[Q.\A"FS*K&O)==J
M>:P8L:P[<F2"!$A/;K5GK9-EG]DN\>LH.S4I*Z:K01,35AC'A"PRR,A:=?>S
M//3MD;Y&[;60Y_7E)JK N#N6@K+JNS2<+SH;J"NF!JK,G(M59].DWP$@FLV1
M9:#0%#S7#=7OL2R!;/(QG+D8)HGA,&O46'X;<KJSZ@1KH?\ SW6E<^:;8-LM
MRQ_195PDS"RHNKU5*WE^RZKK2Q7/HJRRQ$FSE<T0MQ7(5R4KP64UN$>5HT_E
M%;.BF8<,N#?+VDP57A:<A6IZ1[K^NFA/;_/ ;;9X_OORX9KYG(LR/G2$O2I:
M9$>,KZRDE0%QK(SL?#JN_P $"5W)5-DD7OS6N/G=1E;V,C7!%/VLU6JG-E^O
MQ1^<W.,6.V,\>CU*O4)_:'_7#!BQ$F7 2JJ055*%JXM57% $MCQ@L)A%TX:\
M8\U=]:%NWZK07E*H-O*/=SWA"H>GZ.T694>5G[V_<EV19)>/=8C8T:<_/A-,
MKVIG=K<EEYU[V(?%@0X(> ?)S\(FOY2_UJC]?Q2\F>4;?=+1A*WM$Y:E=:G2
MH06=0E?"K152O;P-@:RCETNL.!S?;JG-KPNGR#48_$+ALR>@#C+*Y@0SF7\C
M?,V=<+%5B&R\5E1!^&#?SK/1PCT$RDV+YD+!28B$ >-QE.,:]C2L;39DRMN*
MMH5C$4F4G:I^PD&W]B.LN])_,#SUZB;Q[L\L5LKQC34E?4>=P269;@QFZN:M
MM@;=B.(,Y,2:SSA,P380[HG),I$Y1+'(,R4&/S"@G&'$B3,K.V56VJ9KZ]4_
MN;N2+,K%4ME7[(X1!1':JN:K < G<["=,TP1TW,02C?NL)A#5$A[^\^I$S7I
MUY[^J:;*^H\NZ:LML/2N[JK+/HGU3\MEEN8$RSJ7O)5.5=Z[]G537A <-<Z\
M,.JMJ*F$Z)9*<ZK\C'61 =;XTP44G1B< EB$\>OGG4&8[T2FR7Z])E+^FHGH
M'58/GW;8FG14(Z?ZBT%/\X&5$=! 0VX/-<2S"U-&N#+<2J^NM;:R,"R$#SR6
M>S#8E,T1:55V -_D[Y>[ IM'HA7JA+5GB<",-C(WQFXZ>8;2L@L%3%$=(8AZ
MUBH(*IT$BZL)(:$?*,_\@:(19,>M]3^N[0J0+.CWW30@>T2O?/I/R'YT'*CX
MO#Q;P$H@DXDS!]]+&)TS%,R4D93_ 'S 6QC3\CY<H/AA5J)CGNSU[E0/JX)M
M%G "$3RU?IH'AY')>OK*-;="P*-U^J"7VYZPW(@^OBI6([6&_GG6DF.&B15,
M3N!N0:>)8(1N- FP_P!V$FBG@^CB]X2?0,N0]=/LOTTB>L=FO2RZ=8#JU*\\
MK'/'8'7@+_BLL\5;94+!/S)A?W?>V8U]1S?1#3IU=CL]8Y_,&B-JQ6->2'F[
MI-3U=<9&_1U4[V]9S4S]K3/2C?ZMA-1TETCXOD*2%MASG9PM*<YJ<<DJ#0JL
MSZF ;$WXR]U^+?58KV12 >ZPZV+48)K?'PU+P^S$.SIPGJ6""G>A;3-021"*
MJN@GHS_%-2*=QAL*R8A28LZ/GJSC2-VB&GZ2+2W83[ T4E8YRB:D],5GY M7
MT3 .5]'7U*];4*UFMA1^A (-$6P#R2!;[DK52;G&"(PR'F3TW8%",(@"5*:
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M%PV+TR"D*-MAYYXM]L@?9XZRC %#FUW&0' LJY+C6[(Y&T(68EI;5?+JS:K
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MQ8K@NV"C7M:MD6':;<])CL**QC861*8K5?8& K'?O![%5C)*D\;."2Y43?\
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M;X7>\/8U.,/HKR+ZF\^J)(.&:KU\Y7=3BT88LY^L )/6=6C,DB"9O8+CRR>
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M.+DY,%MN)"&5KW-D2T>)I'=YPBFS.7^MMB>X5]O72@^@K%J%,J438=GN_P!
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M!K*7M E\BC!\09TQ=P-&$?J6'' A1;GB"L&CQ!Z'\34R/ T@I7M3]V5KV7'
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MC&PEB&R2A)!XJJK4;;)V0!P.5T/U1/T(\7'1,OC@55^E?F8!M7;KUT^0IJM
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?'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image08.jpg
<TEXT>
begin 644 image08.jpg
M_]C_X  02D9)1@ ! 0$ 4@!2  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .* KP# 2(  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# @'_Q ! $  " @(# 0 !! (!
M P$% 1$%!@0' @,  0@)$Q$2%!46%R$8(C$C"ADD)5$R,T%"88$F-'&1P?!2
M)T-48K'_Q  4 0$                     _\0 %!$!
M     /_:  P# 0 "$0,1 #\ [^.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXX
MX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@..
M.. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... X
MXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
M XXXX#CCC@.... XXYS&T)LOVR/63V3KL?ZT-.5??9+T@&:+3-6BYD?,0#QP
MNJVV/8-4;%>79,A'B829Y$>&0E?*O-;6-LS(<T IH\ (E$8H='IVPU%:;T1$
M-$I$5HLO<R:$P?K#FYN@IM4@V3 ?QDEH V4'"=0Q./<G5D?("\".SK^(,RF3
M?_A^9KSF53_,_O\ K_Q[\[EZG)'I47Z/+>1O7)_T$:LZYWIQF@/7CUX?D+]2
M2;:)/SL<@1=(:\\! ]0$_IL6%,J.T2H<.#LUR9N[(K&KR\CM7>7-%)5G[WK.
MB1+NPRO6Z?;6=T6Q=+.YD::@QTACS6AWJ50MYK1@-@:B&FP<41WU*I1XE@&L
M6JM (<4.#0Z2..1Q\AI[P@>9:43K(?+$LQT H@J&:=K: C%FS#667Y9$#%X!
MB#S3$@L8L7NA!R76UE/DI&\?W+-&")C?/E[:45NL/:&BP%_/8H^OM/ID?Z%]
MKG?25M$K);]OF.P?+9].]*ZZ!5JK#[;0E(&4[=(.>7X-5K*:@ W6O&939B+5
M@M:HY8BP!T><U8U7;529J9,SCJ*RD)K%7RHWB06,QL850_:I@(#KV RK2I%-
M, +IIGL8;,?+*#(L'$9-Z-RI,<+HDD-,<_G!3A^D?$GFA5>NK-_VT2I*I&:\
M,[?L-WLNP<[J+5FHXV7TQ'WMD9R,:?H9XLV'(##)L8 ,WQMF@5 C:?UZRJIN
MSS9>"?[!]]/=4U-Z%B-_H&]?E+9%<6O7+<\X);%5-;7IYU ^HEXK,&OV@ #*
M D]0<Y1M7. H$F97.Z?D"QFA)T^+@'1KS"]5A*6ZQ)U4ZR,C)[&I@NP9@CL,
M<QB:E,R;+K@TEBP9C<5O=OD& 12+D(T%]IJ/KC8S)0[3!DQ9._GT7?'/HQBM
M*ES3QE[.P#63[>^L^GT3IT>H+W !(_F4RU^F#7D<-T-7;4&P%"NR<D;2I*MX
MJEH%2-.XA&C[]^H.9*0).L&&H?I0\T-5P-CT^LH;D>^<7QV2[+GKED,RFYPK
M\6_= 4K[$E='%]J'3A5MBJ0W$R=DM\'?K.3U''='F%I_7>4/,.H[CG,];-<>
MI4\L_>=U-?O1O3#/NCT0P4G5YF\K.P--GF>+XNHXIDUC'/*_:YM,_7:-ZH?&
MV:.%]V;WJ'-$[4)CB8^C6 FA[J?!+)73;XR\U':G<FNPT.14BG##/3U!;!;D
MVR0\'H,?/M UX*G6B <)L8\M*(PR9PUU&D[-FF"8)C<(<[>$IC1D6NARS <G
M1Q84$,GF3!.7G^.(.%C(NV:0G2=GZ=_CCQ(FC=(W9_IW^S7KRR_3_CFL:&O-
M"](U:K7-5W^6;Z^>(&DRGE7!"=*YG,:[.T:9@9H%K[\"7&#<M,0V3%++AO(9
MA -B948@/W;XV['/OGGK^B/9C$'44QPK_P!>9V_.J'W(J_1)ML*U' C1MZZW
M>K;( U"(I&%)M DI2)Q:SBE?%JDVU$NJDRMZP@L2TSR5N?+[$RKI?G/3DFA?
M"GDBKRRVPIS4M^=:5C/BJT'V)A,KM@85DJZ'4)*DLIH_,@=BV+1/@_TT.?T(
M$Y:,X@N-'B88:^!MYL]+4>F%$(,6L$+,(V1>N/FE;T+>>YL_'>':<U/NVOF'
M-:U%<%0U"5TT\1)8,G8O2+_#%T$=L7>0@X;]Z\Y>8?AFQ-%[,*9_H[T$$BE/
MN?(]4MM@ 7:PHB:<\R._G"X-8A[67J _;] C;'=6+_#K CK>2\\B^S<<+.UX
M#\AN_1X[30OON2L50DN1CUPMTRM@_>M<I4A!&V=<]KI#OH]MVI"\MOK9_C_I
M*J6\W^'R;C7?^F7VR2MCJ0KH=,VO6D3O-ZY98.I[CF(H0LX&0TL*T,!-L912
MBN"V)J,01H@RRG((:'$+L!0:#V[0XPF9GZI!&=!#[M@V%*D[8X_;G%U:<^^0
MKS@F^TKZ\#HS/YYB>W(U@/'R6O#"X;(M>ZGTJ)NV^"I&LB7ES?1!0O:K'!CV
M)K@!+6E##JH-3=8E&9@BLZF,#)**-@!V1\P*U;-3*5J^R+DL8IL!U[4R$WV8
M]FM4">4V!TU$7R+0SE,!@N-,)D,QX05.EXPA\23-E=Z?P18^[?GAKRY[[(K_
M -<>J/1KH:RKCVI6GG"P???@HED!(N[C2Q?+SLG>5K8@W?,UQ$.QH;&G5T2M
M.0J![%"QY@(D>*;8FXB-V[,]$O5D%Q4_?)Q4^J]:M]/>N[$NVP:R]A(_EAN7
MG)Q*>:R7G1N\FS5ZC:P%!9UF1J]Z9,&OK:NG!!%(D623N2?VY2YQ %)[888=
M"X X,9@05D"R,I0=A$CC@F5GHD1<Y(PM#TSX$C*++U:)4;+=%D:MF6B3HTR-
M/>7>O=JU[,<L.O6YS8ME->IZ</-E8JE+^D+.\]6*@_._4R&S5O>AGN36;_%4
M/4XGT.\+RFAWQ7-FN<K7N6/.*N[5VGV$F(X4@<!6#)%[](:;CEY])(/NI>S^
M6S]8JKZBMBXESSSYZK&[*>L679RU6205D6@?PM*^FJX56[8ZS&NA)1\(4IZ2
M+B2+D[M)2"J2TLD=;&88)F\.E[CE"_R_IKUXJ6J(9?2]A>E(UD!*J?%[T6L.
MR"Q=4M:MHDWD'(#NH&SFCT':JJQ;%_"";W5;E2B'7XJ/7C#.$N0U?E:!ZQIE
MC]"5:TC[MY.(:%>];!\M G>SMOJ"O_.+*VKUDF]Q"N94.DS!"+7K<D/[37RT
M]=S9+,MJQF3NS-3%$X5!E H.?G#"S?CE!'B/SEZH(^FZ*<O4<3TS'2*O\E6)
M.0Q[U>+M,#B&\U[;N W1J[= Y3L.8LV?>B/Y)FU@ :I[MVZ?BD]%L")$D6Q[
MEZIP_3E">+"\_+ Q#8KO"D@MS(;<2$TBFO+WO?A"U$82.==6<!JZSZ>LK_4S
M63P&1F,BDO@DH,,:5N9/US5W6;B[0L6YJNF+IKKT AZ;+JHYM8DR0UV,E:2N
MX46"Y[&*J+%:JI>874 W"'D,<!+RE,8C"3G%QCSL8/4Z#LD0I$??LY^C.'T%
M=_2GAYBD>6;I\]2T9]\1]6+_ (I;-UW*HSZ?8*O;M'I!?=7'?>,6FQ0:M6F7
M#260 R54_60]3=8^R,F_;NSBDXNCM/F'W0*44!)-Z_353U)*@>]\E2/22.W/
M;E7GH.R?HEZ-L-,M XM5_P"A:8ZA3#U*MU>,]1M;Y'>JT%=8'];/% =EN]9D
M.LKCFA*-MD(^;+"KF$79VUH\[GU:HK,?#*] #!V^Q?\ 620\'I8&6&W[P!"7
M#T. ^,X0@W>J*L-W99;[TX]CL<LZ>O?%<>MV.YO6>U24?6+8VM%(U ,^:+G0
MEE-"E4E.77!T.&AZ(W$/!V0G)XG=_L66F-;P>MA;80;73X[!1 2I\N"25Y0=
M '-7OMSUK6!*&*?&7I<D34FQ;&PD2A![>(C)53PPI"P#Q,]!%R@8;0O0F$3)
MRC%B,*<2U2=G8>*0[A3NHT,?)%)O8CU1] [OM?"WL2++Z+!J]&8MUEOA*LNJ
M*A^7O,.9&75M93&J:BKXDE=$*S<")>,NQ3DHN,FZ,Y?6G5GCNU+]*JJOZUWE
M=6ZU7K,9JL8_GU]1*[L4(FL!@0L&[+?TOSU!HA>8X8HX(QG,IV6-L&"CR-N&
MS?"RS8L(\N!A,DY;@LAI"Z$KT+5ZE<-<ZVWI&>AFDVJRG5$<JX,E@4S''>*.
MZE=\"+S)I#G(&R.5!SY0O1H*"I<6?$RV:-^&7-K\BGX:JG*D_'OFFM9((\KF
M5JD*NB-"VRGV%D, 6_I(!?Y4(E3V8T?(Z>QQWJ=$Q&ZB.8X9UI_A#=6B'IU:
ML:1%^OO:",KW6)6$GUW9 %/]2>0_1)6[6V99Z/Z!M5;5_?>I_O>@!52';K=T
M^PX"EY^UD.A+?3T2J:XL1&V"T'>FD2\./UL#IGYJRMKHKJVS%N@4(WN,DZ+M
M&33-F:-@DL,P V)#2$>Q)(/3O)PH>DOAJ4[&42/9,1G-&99DLHNN7G)BRM6K
MGZ#KGJMEL68_WW2_O8AY<9?:7NYCE5"BN38#M>./8E#SKJ\@-Q0'7%LA6>/2
M,/0J7[J$K0UCQ!*3ZW)Q-O7Q.421,%YB+\S^E53T [WRDI/H589&G[-TTS[X
M65B,'^-D/&[!XZ\_UQ;;4SH@AWF5RR ]AX.P FEC)CF UK9E.-/$D/WAQTO$
M.B?CE8?V)9VI/\#/IQ**64)8\;N\5B(NRG6R4D6:1@LWMOSNL'5Q,9XAM<V#
M#36OF"BSHRVFQL21B6SBS96J+NW9=5?.=1>TYI.?O3 7KE.\)[_7MDDQM4MG
M^XK8] #4Z3YMK4.(8BJL&])(]W$:'F^FX%N,2PH1+1)314@VOM,NO]"CLA;
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M[=>6O_\ #ZS[Z[P__"ZZYRK&?EWZ\F>6&^I5JDEE*EF_''V2J '7(ZX%R<'
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M90B?;&KN%!]'%_26!GQXOS9*]:DO4<E1T/#0:J[N0;/K2?A" 2<"HX@MC]\
M.L3TCZ/J[RA5,VY[D(EQ2&.;JT29<X(!)LD[4>MJQU6JDS5V,$Z-\ON-,<7,
M#"ER_P ?X84>1LE;N_V:N\<O2<?051(-RTQY_;6W 1;?H0;:!>H%+(0>EYN
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M1P$N-%?XX)%QL:.>5O74ZAO82"$IBZA7LYVLRV#!GUW#M]%U+-^T29]<@+(
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MY]=9==]X9Y8X98X9=?K_ -N>6.S7ECCW^G?>.>'?77Z98_KA/;Y#ZL;76_\
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M%S@;H\[/K3IWX<".'MI$MIX\P TBCJ.K=[WSG6EHSI3MC+M:L.@13<%L [[
MAHZFXL@>E#-CIB[&RW)@5P9]5<[YXS+5G+(1\8$>74&E?-OTI*\[>:ZNM>LG
MK^E2O+WV%I.R%JJK5IM1L]>!^L?4U1/'G=)KTMF;RJD;(FTTERQ<<1HD[*Q2
MX8N*C&\(P#9H'[;F]OT,\6]VQ2=+BO2-0,[MZ$R>8]78*%AIK0%.$T#4H[3
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M,K++,B\BL<\%2MX3KJ9UL(C=9>./IG2'HVN^R%@O%:U?;0>/Z69'1!R9Y/\
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M^8& H<AFSAY+FK,KUE#O]+?$E>9AO\FN[1U%.T=7'IF&67D*T70!$\]6R9+
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MD3D==!1D58WRC\X?/*D:!K5)IDFOIUL5E0=FFW?R,-?T$(89_.:\7FCF2*J
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MB[Z6H*LZ?77QS!C/8=Y>4?1** KJ,=>&UM2?"<WU2JCZSDS38Z!$%Z-S57A
MDV%" 43UICGQA*5!A1\YVT/A@?*PF(ETUM WJN+,ZJ;UM.YL[26J5G O1\H1
M:WM"P_7C33ZS<@FWX \%5#7H?.ZF?TUOKVR@+4NQ29R*, F#F?\  @U3WACT
M58#&1I\^FV#5BR>"2GYRMZU5$02*>=[HJWU$C>K: 3O.)&'>;\AVK5LRY11
MI:2X%0*R77A;40!@B476 C'":)*,OU+E,=L3#]:NFI6\]%/,GDAZ"=-U)EV9
M]6;FN#Z*,/CJPTIQ2];>CGX9P1/$Y5<=#YGM46OG.$4:]G3+##;@Y>S&D?62
M-Z";7$%7:7;4A05&*P%&#<Y5'S'TZ],U5.<FO;"$HK7T2WSBG2ZY#RP/27)
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M31AN*#EI&%G]"6@C3C&UD@R@O !I(X:WP]DS?BCC?3N!][4!YE@Q%W.N[/\
M*_J2ZF.=(@S]C3H;*8M#RFF*L461P)ZQT8+)%W:U;2\60(E2I,N,*V1YL77'
MW:M\"JT^QB:!K]JEWZ@V:P/"-']F6Z^SJ*JJ<90J\\R>;O<%^>7X+^W%C#=U
MU%G"%NI-#&V#X<F::)1HIXVO ),:)(@Q ]A%^6%QUB@)BJB^P5T8R /$BW\]
M&!O*>:=1O!B\YUG)8.J9,0%[.[841?O!$%N+A!)O&<PV@.>XYJFEJAT9"(.K
MJ95N>(4>R? ASY_ VMA24'?YW!>=U5RQTPV)D6@B@IB591.3(LWN'#8)@_6"
M%RBL3;M'8F<=<J/C*'92<9.B*WJ'Z39+]E5;5/GP*]E).CZ$>5?)UNVUNK7!
M@I/];0* 3EE5L)=>B^.V*XBD,^,QE,>L-F  LA.$N:S&]DSVC(_H8_;+PWM7
M;);H;$XE%I!I^RKY"$@8M6/RK8JVI&4$J/3)6JX$<R#;EV.*LZ[L'BWT A%F
M(47CFEV$4%:9LN*&0'?G$TNVWT&PO=_C9[UZ-N3Y]W0WE5:H]JRLB#OA-WJ-
MUQ&@5HI9S=/Q&VE(JB-&D8S6:3M4>C&[;HS/?Q<->[V/*WS62?+-G_Y: C^>
M6): .5Y.E=&9'E97%>G%23>K@QMQT*4].:GB>18@H;_+V%;@[(M>KA\NJRH@
M=E.F,(>S;,S3U)[?9//_ ),5/3@;S=;I\FTVYY]KCNG&:(M*MC@1]UWPE4_V
M58AW^43AHHEKC->N2OAMAC9*DL118#L. #1+-2PNBJ,^D,K9?M_5!?BK8@4?
MA[W@>5Z7;X]>"HB(DR&GRK2%RIE760X"6<G')/1IJ8K A:S #0PAXDJ<LAS1
M85J) MLT)6W#Y<<F*_UKU)1%NB:>N<=5<JCG'MSK/.W:XL>K/\IVO"\)8U&
M^U<QP6%&;)Q\JGLB^^B\8NMK9AYL2?A3X^J%&9B^:+PS[[263'I_"=3_ *+O
M>A_2OHY,WTD(TN3G;%,0J9B%^J\L,6^C(-9HUF?Z"K3H^N3T5_. (HPGI5G
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MLA*;IBM.*\R=+.06;W-U!L+V9YLU>O/-UB>>=SE(K_4_;DG;DW10NIBWB?\
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MG4GOJV''03&C;#$KT9I6MLP7!"#RR[M*#.Y*9_4,I(\UJ'J@'Y%MTQ6EV/\
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M.E1S$S7(S[U!]/I7Y;@GM51J\1-[*<7WSZ6%/8-]ECC2*"R1=:6;&;2%^UC
MQ&CALMBKBSA6R'4Y%'V=S9DT.W;3!4C)Q7]>W38Q;_G5,NE^\Z6 U3S.F;YM
MLEQLM7"POZG8OL\]XHJV?/YL(XP28LAL( LT^X&*5KBP=X[;D4C0.Y&[?#ZW
MQ=T 6WZXJ5?6]OI1VH6P83PC&:.5KX"+)T&^FJL:_0/]+-2P00(HZ"<ZT/\
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ME'5L#SG:ODJ-=%Q:_/=@5>=J%51-8>BX<^ITLZR0V3^N57X738ZQ6' )E!U
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M6B/57:\%F-15;UM;CU8N=BD6,>F%%S_!;II_8%'196HW.97V(ORX@W$.<)P
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M5@3)Q#0IT3+?OR3#URS^QTA=I[S9L:J)NZS*L-OSHUL\<!,.>7(2)Z%#4=8
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M-UF$#=.6FWN]@6)G/-$S,XS,?G%WL9R:3]AS9\EI)&3DN7)(;,LOTYJ7TO\
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MFP9LU:L=7,\:?)GG1TN87Z$9JJ7R5Q"1ZZ+UNO6\O"DDH2?/)E$_4RBAY*(
M;LU$D9*3E60U"C,E<E3=NX+N@Y_M[QC!Z5]$R817YR--7 .KAS] 6L\RT30G
M6ZU5PM.66GP-ZDO1.QT;8TH<M.BZ[S48.($P[.'S5D/_ 'L!SV#])H"/W:/U
M\G>VC5E^<KCLGT1+KRK+=\\@]I[T/6\E8M2N.O.^_P#U,&M?>NVC L& 0/28
MX@'/E&=5A)^!M1=$[J$S*>K;CNV0<0W2K^"_(2::JXZNT6IP9-*+*RHU0.W2
M3Y)71!"8LE$M4V@$PH8FJ$8^ 4S19=&-N0/8UQA!"7!P-?@W98=YO1_E3S]Y
MMR+_ .CZW&U[H,PX0O:/%%&*8(&!1DB9+'+JL%,&"0E,6($F?+W0EA1A U^+
MGM_] ;AUKU=81$\&^YG[U.T>HD=H4UJ:1HB/2#*E-B<I6]58:SU*]ZMWV"M8
MZ$V_5]?= VX=,&SQ>EHDX=@&@;+&FH,05CA+A]1T1?IK<IBJL@%G1*<IGVW/
M?552V>5#M0^IW)[1R+77ME6+!3-B6@+Y]GN>7) U>S&AEO5A)C5%.4P[*QR"
M W:O]!R@6%+?@3QNH&W%@6_/B")(O2Q8*6<QCQ2&0R(I6Q)V3+/75$%O(;0=
M?B+!F;<YCC!0ARUH8I?[))7"5OUZ]F.QG?S!05CTH"\ZNM8+QVF%6"ACU5&W
M?V$6&K:JND!Y5=25DF/FQ#R^62Y0 /(73@@K#,C-\#1MC3\,_P!^6?/QE]*[
M#RL:M_;@BO3)0M=/R9\1,(#S_#9CLU,#VSZN]QP*A%E94?/6/_-!5RSY"R)E
MM@L6PD5T7@#RFCI$G7MCVM@/6/I0'XW]@7Q=/GG97MD^:E:\&=#%F8^:ZL7D
M"K>I,+*5VX<L:&QU;$D.8+[)B*8#&3<\MK(KA,N*ER(!&!KCA)WKR;YT_-ND
M[*I79$J3>JSZ:E3)FPI-F2[\3E!=05JU)DN61W29;6*4%-=!ZIDG;MU;HPO1
MME:-\K/?OVZJ5_F[X:30-BJJ]YMK^,L6O6.JEWQ=F8&C(,O4L4T>8QU<Q!1H
MN1@KR>$/,YTNN@EK0(@+D\AG( Z1VS3&[TPEM#Z?7&O=%!%>UG3YYKRI[Y&N
M8&,RN3*."8/7TK]3._GLX"99@0<8(BEY#&+H9H7IL<9+*S\2FW?,A38O<71G
M_:7]%O3%@6B \R *_P#/8^^!]^^S*S?75H9'\12\E0\BK=*-6<I1@1HA-PCN
M;_ ]&5SJZ'E9T^"K052SV7K!EA"A8V4%D3MY#\Z6/7U>5@\UM%9E2I=\>56>
MPFPM^QN1YD83+ ]3ENQL&#78@R?*!3YP0G/CM.,PN(F21A3?,A;]FC*+#[\I
M_,-B7'4[0?1$O&B*A\HV;Y?6//(A<G+:_"@638E;.9 ]#/K+"&DZ!\D0CE59
ME6=HZ1H;HS42E'B,O#=.ASZLO#GT#]8@/*GDZIJ/\ZM?J!CK'POY&O"VI\D@
M18FFSIOH W8$/2JIS\><00M?DB5ZM68GC8+MBTP"IG., V@Q^N!))[KD/*'H
MR[_05W^RA#(OU.N4GYN]",GG)+V@93<1M)M95I&JI]G,S3E/[C*80+C!L78*
MT#1>HE/ES8?4K9)'Q]7XIP;(>/#?DNQS\YE;Z+3)Y4I7:94Q?^#K)KXPU7%<
M,\=RKQ0-@5TB)!&A"$RQ=)1+UE!LO:K;/RZ >V#$D2(^WZ87B;RF-MLA><&D
M$R-:),VU-,ECUZ2'4?4X/0/>LNSP.6^Y_:J(?'!>ES0K2\B0D)M/C2!&(5,R
M])";COI,">K+5^=$"S5ST:K65>?L0VDCFRKK)$^E;$M#SYZM2[&]75A2X6QH
ME1FF/: \SG*Y/7U7.#"F+B(# 3%3(S KYX-#]>V.'F&#]Q>VS;[5'G,IYP1J
MKO&UWF]O\2L.Y,CZO5#A4-%H-6MY)L6J^6FITL"*W'V*U-"-#5#S3#UQ8B.Y
MV%'GF!6B*O<"Q^N_,E"5*5KXY7%7K:B6JJD!7FVO)XK7,QWJE%@YP4D)K49W
MOE[L>EZ#/70LK3AOQW3/RCM&6<O+K\G6>N)G@GR"0EK,J=1BK+TJ+BR6"&"R
M);%M5,W5MMDS>QMF-IN9KM3:2VRXF Q8PZ2T!3'8)JFYDP70W;JT=:JE+I]8
M>FP1SZU[; 9$QPIRA6'PL-K&O$)KL:N6M4GW4OT"5)_TMTH95:8]RO*(L[(8
M(3-$.--99..D?CB'69Q0'LD_5WT0N]Q;//[6?K6IH5$^L+V]2T'4P@0RM^5X
MHA;SHN^@6. XV@/FB^U<B':='G!N@. 1?P%R*M+LZ@/D&V_/,CLT!-V_/#WD
M[U$:V,5_4<G6:8D()*K",P]B5U=FZY*$-IC>EL6@62'QF1?B&M\@Z%''M)'2
MO'I$@V!Z&E9&Z9GD.CR5YTB7&1OV%5H2!:QJ9T3.L8Z:='P6 WTL_P"%XLC$
MI0BNA-8&K!1ZP6L&HROSF+6$TQQN!/&+'T:]<!OGY] [Y]+N%!K%Z5U3ZGUZ
M9^?B-[QKW94IYR+YJP8XTJ*V92'#:W0HF!.=(BV&GFQ4\+IBZ1>_4QK\WHOC
M"&L)/'G!NMBBOI%Z?)CK4N&TEO3\Q'+T8O50\M&<^K5Q^6KH8X2^$1D19$@A
M(G#H*(B@9!;..5=S4/=EV58B._O#+H)QKG@+QZI*QQ&7J+6!Z4P%J_-2T_\
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MF#!4:86WJ27!-,'6L_.U)(9=[V'-$4QUWB1B19.G*ZU\=^9*B7K55*_IM3#
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MR'X%I@84&UXWSL\2PB5<E(?G&O(N^J5VJU1*B:(I+4&B@Z-C:(E-1SR]@2Q
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M+556EJUW: F/V*5"\M\Q)2"U7]02[@QGV$PHC-0(UA8$*"!6V6 <[U:@02;
M[CRH0:OICZ/L:GJS?=:54*.G>XJ=]F3O,\A>9G4E:E*--$5!95DJ9:YX^<4<
M*-QR A!G1'+_  W-;EUI8,P IX[FG*=V5TA<6*\XT\-7//*SO4\#T7ROV"WT
M8292),X>2RJ[6)ZG(+!K-39><XJ?VURTLBX0*%]LZ00TG",J3WLF[L9&&G&3
MYT^)&U>6E4]YU1)8%3T6' #P(_\ =C/W!+9=R%DV6J&9(HO"F,Z0\/94BTLB
M,S2"Z>3+2]N_>$RZ[ZQZYBJ\*7=6-;"+"<&%4=%*AO\ V>27[3!JP:RO5"<R
MDG:U%NQS3J\8/D:XYY6!<C[-7X<%DM+/7+-"1W_I)VE<V=]R,+H'_P"D=QUS
M6GLZ_A=3UZ8H;QDVRZ-Q32+>Z[;XL6T!-?U>?Q8\"4L=-71R3F>LX1#PC%.R
MS*71QY*RY)^+MVQEJ6%B3QXV\LV2<:F5WHFNF Z[>?IOE1H)2@6G3(*^=9Y;
M([(J+/\ AY1M<5.Q,]XDXD&%A&VCYFJ/O@;XV<:/WJ^)M\4^6G<M7QU@IM:R
M+U:F@*Y29X>2=5]XZNE:9I(+=>$.U<L'Q94($0TXSA:6T8F5F%,V296@7AOF
M2]FZN9S]\>\D9/6 ['Y>0TZSK"]C^=?,M9NEG]LR/5+L O!;82C0V05(*TOU
M@PB-3F5J<(EQB)**/=M4D9+$;174J7K&R:\V^MKG=/45L><?2"DCTTTA,K$)
M4LCZ5VR-3%<=6UJ>1UR9?*A893N55S<F,,ES&S2"0OSM;]5F1Q<#.D:9)E;Y
M^(2GV^6?.LE^NNT)E-H1!\]'(J_65[,1(%&)2+6K]7$E (11=(L_J0/, X@,
MR1#[86^)^.>,VZH)'^7&APM<?#U#Q!Y811RD*7*C%:H2%9*U;J7B6/-[-(6+
M"3%PVH*!\+-9F$Q-@8*ZRR'0@ +HD8@!$ I+U0!>C\GZ]5\LOU/: OHNP*U6
M1%:VA6,.I/>3:GN*PL7DMZ %B^&=BA":$5CL%R5!U96CL(&6 LOMG^HB,GJO
MV$#*$R"!W+'.3UK(#]5_3L1-!PWJHZ#UVQ<U ?-VYJ0P6FBPO]8*LWZ"WL2\
M_1Q=TG"@SMAS"5DP1(C5+-*0C1D>'RO\9U1H!#*.;D!</7-#!4DSZ!/GCA.P
MI_HNQ)+HXQ&G7A)7( '0BJ]9+E?AEC;ME!8JT(1U$9!*?I%ZW-9B8<.F^MNX
MI_&C8$I>$_)2,M0TY8I1<@+(ZE+!\X#1&\@RE8XRAK3+"CCW4HS,P<G[QJ*;
M)!!&[ !"VZ(8C2.B0@> V#JQC<@3Y(O^P*FK7[/7I=FJ"]G/.?K^[W$BI5HU
ML;(OR0%1^$_*SKVIU]TV8;IJON/_ ,*?+DJF.C?$7G(\9A=;BF>O;.EP3LCU
M%Z*&^@&VS+QP0IDQD\4?*-C$(GGR\;G54F)']#_3K6E;R^1H=+!,$4R'@,W4
M"4;#[^AMJK(76$-QXBL<)K,<+\H'BCRT(L!7M$-3J\$>4\4BA@YD'.80NJ1!
MJ\-J7JX_R0,+,Q 3I-1 4>,)4BCB,/%%\?%B11DR-JB1\=7Z67XL\LW,]2[&
MMNEU.RF:<+S$R\'CLLS*^_1FM&4WN;FA%R4I$_OL5-A.+FIGQ6^F/2%*3!VD
MKA&W9:^5LEOI5Z;#H3@\YT]5YS_.?I1;'SS\T+R9V[LAS5G4=N7T@'+8N73,
M(+L3?L(":.)9A4%.F0/YQ\@,C;'.)K+ZXHW8E;^X/8]DVDAT*0\\UQ1UJ"ZE
ML.^K?VWJP&@@<]5ZA>4NH5&;5P=.(M\];D6&(';WPK*>S1+=5<(FN"BX)KS,
M:2.(3 2? /CVNXF4)3HU;@Z\[*J>X-LB<4:CY+?9=%CAX>H&^278CY4K))UZ
M)$C!:UU(F[(D$= B0OXV<;1KUXYW4_D[SO13:PNU15>%03C-B;P(:P,T[I7H
M>#*=Q9V/4M)VXKO3TW4P,6.)LWJ400/66)]=3)^,C=_W\J,I_P!N^S8U@6]6
M!0Q2]ALMI?5ST!X\\_&'$0W+"G3256%,L%[RM3S)7Y&V2Y98)*1)7T!6@]KQ
ME@=C^>TFZ="-6&J-MVD_H/Z:O2_J>H1=K&C QB+&]O[/1IF8QO109*W>)/2]
M7>=S'5 ;=<$3T1B6=+LF&3%RWSJ%K29>HH.)_P"1[ES/6?"P!;\7^6E&XY%_
M+=*)PBV=[ V-^MIC:2'>H:YOL+8.>W<$N;9VQ577=W@;I4-P<@(,<SL\:<1U
M'"L[ C.ZD??+\A^:YM#8^8I-0JV=#ZR>1N+7&&)'2)''.WW;:6D\)F:)^LR(
M.P;%W9.8LT+)Q"@E@QU$1DN)NT:,M<>O!'K2U?2J_8Z]>ZTGT_Z2KK0IDK!\
M\1EBQPS724=^TLV2D-<R#EUJ"V8,+9JI?<O6?5Q/8CN48<4Q'8#)0_=JY5!\
MJK^]4C.O-5:;,*3=9WJ +[B]=^A;::"UYG+%E :%];JE.F!*N-/M;'#+M!G7
M90\4I1^IZNJ*H$'"U8 9_P#78P3 7KUWXS\P5/-KTE7U.K*X3JIJMUX0">G<
M9G$EUPOO/?MN1DT$"A2=,FF+$VR9&YEG$]\W=,W;MFW'+7LS[R[U:I^!J@0?
M17G"XT, HJ"1Y2\T6AYXI*M RQLPW*.JU6RNS!DY%;))B1+R'C%NO<%<* V#
M\^XN#2TS\RFW(CU'U5NG/KQZ"3O.:OZ<9Z>I&8G>A?"7K/V?YW5%9Q=I[.C[
MO-]6BK@$5_?$^8)BC2>MD5CXP,VL2=& Y(]AZ=J9_4&]9"$?UYP:^D'L.N;?
M=:[LJI?,<P/4EN?.90L<HDO=I=EYZW]%;1@TRN#TD><4M<':Q5(V[)QXRQ'2
M,,2]K&F+&@+2B5W[NXH6KG/*_G]FN8/Z!9*U$G[:79, B 934\Z4AA#0L"35
MQK,)5)I7>FCVZ MF2H&&WQ%_4SQA!"4/TEL(NW+7WI)>^8W@A5&.88)Y@KC0
M+L&KNJ3;(<O4:+:R52:63%Q&U['[+EYV8=67FG#4>4A83,=H3R>B/*5NA&R-
MH[UZ4]E>YO0=2>A8GFWS+YXDW4_#/-A7TV;T[ATXEK9A>MZFU^MUDL?Q&93C
M+YX^<%3>BKR;G& RCHGK^Z6L%=9+9G&U^U?4=Z0C=CHSA146):E*G[HLRV*S
M',7]DR!/'E<>4=GI)=M.#C!REQI+:QMS-7GG3.+HVS5K;:G^;9P)N8P1&QR"
M>83Q/Y97H>^&-IQ>[ZF579])$9I*<PG#1>K;H,@F"TE V?-F2)PY#=2ZROS#
M$PN1FE<^Q$#1'GZ(VC#3U(525%U#5%E'4!,4 I)J\%5%<%!ZSQA!5U=&QA 0
M3#QV9[-G44<-AQH<?K9LV9]:=.'6>>67ZY=T;]?23W9IID8_$?*2(O$+5</"
MBM1KJ[S3ZE49$[[*O%>J4BE&^X#.X/K'+K$0U+SCD^KP 0 9H13N+@O!YL+"
M&0O-6,67!<!8.>\');L1 [%FD+$6?"7-Q[J+JZ+; 40K,($XPC.=^?(=H(3I
M<W7%[U8R9&W=UGGV'N<<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
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MCND8.<S[,C5W^/\ UT(K^A&/IUR\<=W6=UU1]/5(C2JRK2LTE)KXAM*[R:>
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M^%^_3GD$SRGYHG@CRO*H6I<UIHIT1YZ/KVM#7(X,I1:_*8IH.I) F./U0/\
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M5AXZ=&KSXWFT&V-UI>7$X YKJ@!?3"V*LGU52M<.Q6*I,X1B %\8R(ULN<K
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ML$_L#;!(C7LBI[@-$M8\ML@_@'F(4-ACR\]>K63QSW93/1TLJRB'0HH*Y)Q
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M'ZPV[,/Q_MSRZ[IPJ@G0=<^G?<*O[B5EXI=MN^J89FB9]D505?9%H^;Y5=5
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MQ**36+J%N#[!$I(?BM?5ZSON,&/)V1,I,R?HRS#R+Z ].OK-Y9E^OG[U17+
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M(R8^1EBGC@Q:;""C^I!&5%&SMVB-LPC;N\(V^83'D6");9_FJPD0\.O$[/\
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M;ORPQ[S_ $Z#W.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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MA^R/-MGV-(JM!LN.T-FDJQ 8^\:LNG:4:/J&O?M:E]7L_>MZ:S;CZWA%F=G
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M>Q6@)K/48=0L:1)TBN@Z/NYL/K"/L[EQNM<O/#7%V=[]76$G/9_]SPCY?O\
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M8GD*30'H:Z=K:L-L*V=6FM:\3K):VSIN5I#DIV;Z=E=.Z/";3JUCD5F39)[
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M>IVB)WYC*S2"9A'FF-LU0@QPVUF$ZB)2MQ^.G''J-*'PXW,ZM[Y_V/:A6F#
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MF>??ZQY.[#_NYL7.3'U_A_)(TX?R,L<(_P"_;KQ_/GGU^[##3^N77Y<LNO\
MG''#]W>77_/77?7.8\_\P[M#&;%%K?G01"KG7]+KB]2-@>HN_(D23Z8H2WD1
M[UUH%T!;O665%(,_G:PVJ,5(UK>*D%39^6N4;0G.25PA;H_ZMORFM.::00)1
M<]4/-,]^7T*JZ]C#[C\2[KN\K6(,NZVK";YW;O8U3SAB;$V 7FNXR<^^4-XY
MH21]5CT4>"* AJN1CAT &[_2P/HI$\S3H3#T]6#3%IWF(+ZX4+_$(:?43I4:
M(S12I;:2U3(QV2:N=3V"(6H7(C2X6DOOW38NR)JTR=V9[].O9JTY[M6&[?\
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M<M[XR(^>S\6&_3GM_;LR_'CMPRV?MT[?P;<OV=9=Y?MU;O\ T=G?Z?IAM_\
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MR5 [F0->V-(_',VZ]?>SNA?T_P#/&];8,6VVH'F3S>I;;_\ E-Z+\41E$0Z
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M3@[J;#WX:9X<GT.(P]DX*6BPBXS;M_C$84:3AGJQI@I?YPW0LVA1PEPJ:A(
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M8HB1-DZ\]6.MK2]W^5*GI%AO\O<B4QH0;S_8WIT3TE,@!C-/=-U;I#?Y6V(
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M^74$P^.1T2O7?EZQ1$ ZD7Y5;())"+2.Q9@YR#98_P!32,X -N"7*U[9.K?
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M#VWYEDB.Q(8_J(X7 E]190$].VC(!R#MS*XXD VHCHWP2Q2%_(@K\O1OCGI
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MWZHK,G:A*98=4IQ"LX;5:ZJ2-;]8:88KP.R0P1#/7@?VB]&[3OV>;/\ I=Y
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MI[SPUY9Y988Y=8Y99=]=]]P>(_3GQH"KJT+0:K"<TI;IP+5C0_#WFC+V3'J
MHW<WZ4.IW$-6;+6XRQ&]4>V[=V!!GD]7.P-A*/,AR-L>1#DZM4UDQK'O*J";
MQ0]F%#F$?I)PQSDI,R&TP]&_KOO#0=3G(4#:5TAA^G?YAAP0/(:/^/S1L/UZ
M_4,FXXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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M"0"?\)8BHLVJ@Z\FHT39-C; 6S5D889I>/+)E,^:_HE%!7-XGJX;YUOB</\
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M1?ZJ^9%U,7FQD$70MDV67=_\.N3M7DAMF0E[S@R8)MU.QI5WS>L@JDCM^?\
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M@(4!+T S,UJ2F!FH#T,<]""IBI4%*4^*:BI?SQ:_G76N,P*L$E?C3844#;C
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M][W585S9;M2[!&9V$VV%Z$>"\T?H%PU*'K[B1!82%'PZPQT"X>&K\9?6]AO
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M&G#4=Y?/;SQZ"=W9W=\;*&=VVJ*:)>ZDBV@X)"+?Z4CRB6]76;?60!"+%98
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M%E@/]LOC3\6+&-0!\Z(&-^=?H:%]27(%K2J*'M[)2V^=Z-]&.-JN?^))(E!
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M9%=C32B+.8!V-B4QPB4<'81>X\(68 DR'KQ/FEY/&5C;]/AU-D#H-W^2J_\
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MB)"_9&P#2&[ZG,PHX8JID\JFPOHZ:_>4$>M*CUW"I% C?CZW4;.>E(HS69$
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MZ,](7\)C5,S.PIE]_2AH[?"] :O-,O/U-H]28>: =4Y6Z!P29^O;Y=&^O_\
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M(V2<MNW=LV9!1D]?7$_:GG_UI!&4K,6V*MZ(]^WE,&Q;9/HC61\D4Y2(Q_\
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MV7,Q"XGCE0GG;Z</7J*P?)BU6?G@ ,4K_P##X#W!8S.Z7#-&&JP5BKO$1)"
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MVQ)8:=C,X%NW'*XO"WM>Q?8Q=K*3:LKA2JT;5]/OX!M3+/?GTGM8;=B'S?\
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MI3*M04<8%SC:V(H%LO'*+3OV&>DV@0/I)T\N@!M?77XM],>S/,0X->D@TW-
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M/"R)K;)0"6,M5:FM\*NW2P:T_L%&E@N];K%8A2:_:UJ6 7U9?DR ND0O2!4
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M#5O;KLLX1;2 UV FVI8>%*"?/B^W&>E:QZ]:%YD3JM"P5H'N G, <H=C(U&
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M]4UXGX^?5_/98M=W?4C1%WLC[)$YUAZ0+XG[N0 (.0V;0R:I6 <ZV%R8--@
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M.<*KD=/*E8F.8_6HQS(_$-LWEM\CE@'.<STK[=]KM-,7[0SS75'^;[# _/\
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MU=N@0=E>PY6K;'3LH<3_ !_6/ZCZ>L(;5W\UTE(]))OHDE8Y5J(5HZ738B%
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MZDB2=Y+##;)D=[->?2:AO6GK2]7Z!1U3+)(?Y4\NXL/GU^LQV::MP'>UGNP
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M$(TC^BJX2DP_W8S(48T.[_F#LID>/E*T8[,]>/?X]G6.2_IU^OZ_IU^O_/\
MS^G7Z_\ =W^O?_[>^NN^_P#Z]]?KWRC+P13YRLO??H=H?E/T$JD;8\F^")U?
MRR>NZ<Z4.;*ZI5@1+4!D?X_4BG@+NB'8H.+TJ.6P4Y0-QR846!FR.9+R<]/(
M=I^B%;S&ZF;33_H5:?KPV_1U/TPE1?\ J4KFI:YAE_3T);R>J19D"K&+9W6"
M37\K4P#-'C:$TN[A348M,8.\VCO%A$AT7]====?IUU^G77_'777_ (ZZ_P#I
MQ^G77_CK]/\ SW_^7OO]>^__ ,O?_/?_ ./G-71ZW[@N8-X+2+<=_;R4JX=_
M7.-<1A:-7/6+87!H]V#UKQ?JLUS:%97M?';LKB3K-529=(RZ[N7]?C-,_P!K
M_+/CI^]9[EZV9?*'R.8KRS]1JZDV5RH$OH;.I!7M.!Z(&OV[S3_.4X;:%J,'
M/N];52=TXR]5F[D 3"+PCO\ CD(Q(&K,PQCV%[_'.=&@6GUI_L>F='KTQ[^%
MU5JKAPG^;=Z$BVCFZ-+/!]BVZ.2L/:>BL$N=KA6+O\JZ?-\S^@NV,&KF;%*6
MH0:8.3S!*9CO)P:/7.GR?=)R<:]]Y^Z5JV5UIO1<AI5U;*I%UX@>]ZU)MPGS
M1%Q3<*Y9PIGRW#9M"(%\^D6 Y9%;R&#!SU'&O=&[UATB<?\ C_QSGB&3_5OI
M3T:&&R3'NRLO.C7]6[AU=S=(VW_/Q3KRPF?,-'/)<.1((AP#<HT6Y^JP9OL%
MLDXK<@RUF2D*-N&,$O?HC;Y^B(CWOON$74_D5NM);$>OZB@H06W D&8>2?(-
MK^<F8W;TQZ9-^[1OA+<+TO71>=2^<R5(U8D69>6OUS_E]:^]@6OL5LUPI6'6
M]3L36-$V);T9VF5LJ2,97]BW1JY&C3#QN&]ZH^R+CBNC3(R9._ER(W>6N9J_
MC];\_P!^..Q><WH-*].>QKY\&WG=*CZFHX)939]#&XRL -KA7;IYJKK?3%.5
M#5U>%VP:)'L-<]6&6K@E:P;'"2!+'V9HFY:-TJ++FP-^L$$M]+K+C>9LK>N3
MT/YX9RGC+PB4KYCB^9?5%K0YGH/;(-;O3^V\UBGF5:K_ $/.TF)6!C0O>F <
MM,UI['L.@8L#?K/28P=2/_\ '_[/_'-!V9ZF\V4PWKR!;%Z5573LT1=,T"K-
M[L !')@V3.Z&1BF0^?-TR(0>42Z['12T_"*,E3]6V%HE;).G;JPJ)HD1['!>
MF:;L1G:?6YP)8OTZ^EU9V4J/9-U)4^J^1@@'TV6\VSH"3O'QEE82L6>NZ@RJ
MVQ-VKN>0U-6Y>AL1(";&"8<AJK/RO,OIWWJ.NZI;J<9'IZ_DZS:=L5#H^Q;E
M5GVIN_/5,U:+J,LSHBTT#$256+HG6)EO 6A-3EG6)<-C*&G2H)4[(C!;9_Y_
M\<<Y>]++] -*1JG#"7NW?ZQVH/T4W>PE\PK6?KH=8U#J;O:5YIR\XR2BWKJ'
MIGQN*%0L6AN_.Q8NQ,:7.;9-@_VA;7(W1OD>J_\ ?E<@CQFO;8^A+0?2/(OR
MRN%>''F=R<X;5Z;>/2K.F^K11@7+6=W9K*%3BV EV-3&G+4AKL)@+-<M(&DI
M \J.#J/YJBY*82[T4XJB[9L\..+80S<OG$IP9$1M66M>V[-P5A7V=4)"RT"?
M!RW;\/V?R-L&7'W[XA"'+B;MNC/GY5K9],-OK:[X]:NWLUZLJM_KY'K<.EZX
M3[*\DC_&\"F:A9+N5&0_)!8TB*P%@C[?-4>VIFBV )MT@C1T[7K&$2NJ9I'5
M9'T5?:>]PS$59]U4YM=?.GAIHK54*RO3#M:537@V^I7Q:]$+B*^WG42?_)>U
M>J8ZUML,+3(DY2 X?HU&EG#:'DR-N8=,%$^?ZX\ZJQQ6KF(<RZ;7,[8SNS-K
M*;<W9\?F7"#',M[DVL4R>8/')(\2'#ZI$N1WKA! H</ TQAPV'&U;KYS@7-9
MOLKQDS>@G=*(^D+8KVLO9(#SU2*':1P\W1K3%>TO)GF\163%"=7;=E/;ERIO
M?)6,#PEP=QO%*372U 0[5AI%ZQ?5_E1J+ @U56J,V.!:PFI.0E%89WT])VRS
M;LQ P, :;;2TG=UCLW$&(G&E%Y>66.'_ *TS/K'##'KK#$-A\<<<!QQQP'''
M' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<=_P#'7??Z=]_I
MU_XZ_3]>_P#\77Z]]=?KW_\ C[ZZ_P#KWUP(]57ZL\_W:Z,J!55BPG5D5-!B
M45_J@K/BO28R\Q=J)Z2NN<P)%37".%9NNP97>HGSFJ 2Z[BRL]6SKOKJ0O.9
M9IK'VK6*1Z!HCYWK'K>O_.^JN2CCVC76K@QK'0]C2?3%:&7"K?$;O&=$UXL(
M(\440] %8"[_ +++JR4<AHD&L[D5C#)K71F3#ZY]$K.%-$7%C]ZW)XW-7U<Y
M&RJQ04'T]2MQH4G?2"/!IH=&%%;Z??7+10'5C#;&8C&TK8^V%$M)@ ;MP#57
MH^+)P#I#YAC982>C$$86TF.A4^R7#4@I6CN"3F?W;;N7V!JUB,=H^%+TP,L@
M"J?(_P PILA#^L!V>C*7U*WQ=&^A=]F>RAMRLZ LH/M@@%L3Z5_-&XT=H[[/
MDT]&\A!:K\L![_ /KMI:M@(3$@.]<VY%N:NQDDIL*%678RR1AP$=)&]'J>?*
M.]8*-2^"C[!M]:2[0>/I+=;5ZVZ=[AMQD)!_/W^->^@=?1CXTT[3!J;4L?69
MHO("#6H@P1LF[D4I)C2BL6!-TA=N.NFJC)Y#6P3R!825G@G1E0=JW(S8@K0#
MKR:"&N<\<RA=4];[P D&4+#DZ=Y;3)W29>>J'ID9PYW4;:'.2BC?/7O&E_*=
M44OYC0_3M1VS6?D/ZGHKJ,;6"S9*%WZ-(6;YYF^>BZC,='S>B')+,CQ;(G4F
MSJIX>KX,4TT0V&5\KM8)FB0A*E?0V[SD\$ UY>[\ <J^J/; %32_-_KX07W]
MHM:O&3Q7#!EN]6MWK235MP,6Y.[?W52M@6E*UD+88BO"#2<=<-4T.DV1'T2X
M^^)*TZI,65IVQY,??ACMT[]&_#+7NT[M>?7>&S5MUY98;,,NN\<\,N\<NN^N
M^^N><OKX-3 A598$#E];6Q(X"O@@\/0/$A0HB)I@"Q0R!%PU1H0\?"CZ(D.)
M'UZ],>/JUZM6&.&&/755GHEH]"FO%7DW5+\Q6D*<+',TV&] (2=;-\-SEYG#
MSJ\-DV$P>,^?WQ*NN]="LWCP:05B"GR%M($S\5X;"$R"ODLML%_)U-?0YO&)
M3K:,[TN%NRN_CA682J=5G638JU6/?N^8\^J \TE;:/BX_P"+OMFA5O\ U!D>
MF67J:Y&A<+PYY>3.*;(Y*,'2ES#+'L%2J6O'RU'XKT"1*S3&BP74YW$FS^@R
MDF YS&QE>X(V/+(S>AP<;,E]Q($25-D_A_#%C[M^>O7E4S\K:]]!+L]D9[?L
MKTM+[GTU50)\JF^*FMU2&0;UA2#<MX?@3]=/H.^)KBSS_P VX(U[:?D+U+D1
M^A8)A-$F7JUXQJF$,7Z@]"^?&ONLAGMZR7!D7_MO7E_,5B/%B-M#V55.TIZV
MKCSK6]8"6AU*H9!_B7)C3X&NH"<O#70&NK-E0F/?&79HK(J'5#2BI3X-1EMU
M*  X55NY@)7X1GAX4T?@Y,]L:8;*7>R$4ACJFZBS3ANAD)^,F/%W8[.^L-L6
M/MQSU]>B;N*NURVJ]HTR?[AV?:B=9#ZB+?8PONZ.JM1SZ_&6 2Q+1X&T+![
M3+01]6<0D0B3)O\ =X9#]$K&-+[T4&5C3/M/OTDFP&]_]*4^-6&3R%*H[0IU
M!;KY4>FBT_SC4(^T*S=CPKT2"H5'VG;/@7"O6U%M*D"5@Q\IH%@K<V6[_H<0
M<: :/Z>21:A=+4K^V4_T+6/S"^C-?WY;]V/#600]?M^SF[S)_A'= $')\(K8
M?18KTL,NZJ9%3ZEM.GI>A"#A<XC"OSX@8.MCFO+<M5$HJJ['NJT3?^-5M4J.
MTV._,7]>3*] DY,"S6%D,=C0T,@6G8C1 ^7+SBCH,N9NQT]X:(^W9WCCWS4]
MCKZ)CF5"KTQZ05#JI[,1G3VK2<,C[)O*Q*I\ZNGF-N%4$.4=FWTVNV;8=:--
MRJ^=B6/%HVVA#'$F,,L622BR\F]QR&'^JO/?KE@\VWG4KSG]"O3VMX^8KLB^
M32=?P;&JOO&]&-WO[>]*'I2NAEL%_P I[=7)CSHJ*NZ^##Q+::[5W@1MG2[0
M+E()4.K^#-C$H4,C"V?FASXL>;$W?LV:ORQI6K#?HV?CW8:]NO\ ?JV89?LV
MZ\-F'Z_MSPQRZ[QZ^KE/GT^[OV11M25]4-/V^U[&M9L^,PV%4C5?PYDI]Q7J
M3,SZMBRT;SE85;.+5N?7SJ.KC#S"S?Z^KLS'B'&B')ZE0,M>AO*0OV&M^LO.
M;;9X3TU;TVT//U#!;[U6?KN:N*[\H'U_Q^MRWEB62^BQ<O.]W;[&NW"6(>$2
M96.%NJ=J,3"QZ&:0L+([3#"_SFL+CN6N*"09]H6RQ8JB,+.)*Y/.9#2Q;&.8
ML1X7*X4(O< '!)$]O]JXM@ 1UMT0]NJ+W.ZES,]$+1(D:JFGT+Z:[]0>VNM0
M'U1-N4W _;\\7I;//./C=-49WE,<*'Q;%$PVJ#4$5B'^DX%@D[#PLU9)MI*.
M6KB6F=3QT6/_ %L GFF?5UB5++6:WJSW/*3LJ.\;9>A$_P!-M%B.IUO]@I_N
MSRT[&FVLX-G.[9(E;%BKU2\CUN--59#Z;*"=B)FO;)^P7UI'ATQU7<=<W6):
MC=:,.+(,2;.LVG&>3B.+#?ZRQJ>=#%>V&O=ZR\&!LEY &T"4%Y$8.$D3/[C=
MR1LZ9%SPW99E!:%HF=.JXUB!$&97TAY+,NP2T"6=78[#JE[P&\Z(T2-A 1I.
M:($[<'VD(\? GJA2]D++?A&W=X<J7I1$]VI'GN]Z^ICS]Z/#OC#Z&^NM]5!:
M=5FK[C'8EE,GL0RT^=@^A%I&Q4(-LTV8EG^[%2+%N_\ RBM= D.17L58CM:B
M$*9OOU#Y]]-KOJ7Z-691*)Z&"6)Z#JKY]FD:T4$A:!P >K>L'V2O>P$I>'K]
MM(J:(N:!4^$C% 4)QROVTG_82-E6L0PT8DD\ Z3N8+:-E)E,UG8EP6.8Z7J\
MJE&;;(?#_<*>1Z!IB.!GL[08R'BHTTG.Q&!!<Z;E$'PY4V1UH[U18V[?GAKR
MHG6O.OH)RA^04N=9GM)II)C^A5DO-GQL='HORL;KN@1WBZW-(*NV*4U7F^>@
MR=(&O1P]5*1MEC6+MGD61KR "X(Y:BKV>R.3PJ^Y[?._0H/OH/TBBJEJ_-/Z
MB5E(J$RS^@K/3#U]:'=82_+NA;<;7L=EK5O;[)K"6ZL"/W1*@F+HX$TS$\IN
M*[P4;$>'0]9OJ&EJB6*I;')C,Y0+R:UQ(J(6J(CZ^MM@,[2M&',4+7DA'66!
MOD=ZT]>/M1B7N":(*\OA2A0])&Q8>W/&0/\ _'_T_P#^\J$]'>:6"U6KXW[R
M*%9)&%2EWRREJ2U)M?$S.M%[9X7OT#J+M4I&:%W?"U=6SKKE6_F[]DG9^<M(
M6NL_ZAF.025;>U'^A_=22X2RO^YH7K6#YN^A\7V6SL-@61+J*P7TK2UI#_-^
MGS+I*O1&N\FO9=TJK25!2//X8*13*VA'A;KO#F-O\&0'4_S";*L10J&N7^V;
M"+= $&KTEJL1X.]Q)Q#H*H)0*>RLI;N ,C3"4WH<%&39G<0?$E3I/6G\,2-O
MWYZ]65<UDIEF4#\W5E2K&N+WO.PI >DH#\'/W=?C#=.K:YLR/"N2Q"SF#>O]
MXL\U+AS6)S/UU73:"(L\0:445G$/"(]Z->@*G0?4#;\:/:]56:L6ZP7$R)?T
MN0Z?47^&];K)84!D8+T%^<U\;%L]I=;,E1"R,331B1%?G%D;<0^X1 +F94C3
M^_H+LEAD#.*VO-RY-Z(KS4#$L@$AUHDQNIX8Y CDQ<WJ-,TQY<?J5!E:-_6B
M5'T2=7Y/Q[].K;CEAC[G.;;=7GL,4T2 XQ4]D#K_ (UW>#_^EQD6FRQ!OD=%
M\HKE?^9(E]K%J 1SIHJ*'*@2@GIL?:R_82@1L%F-F5'=7N@Q'[![P^EV.-]'
M'?/Z(FDRHO7%+R[$^<7K>"H5N.=_1S+FN>N15T&@5+:*NLZR[+8 1VR3%<2<
MV9:9//@.OT7^E,Q!,&)+S7!^(\.K'CE2'GB)<WF#TQZ72B"5ZSM;SX[,WB@)
M3IQH:FV[=@%Q?4-^$7_8Q)RM!VGFQB MDU5%(6A@&E[AR^?,8SP:KCF=G=<M
MOX#F"-M8H#VPUNUN"H)8&.GVR>]UD8(Z<MLQ+;RB8TUV0/A=F.>'6B?+279K
M6]V>>.S#(:<G:_V=;,L-F&=\<!QQQP,'KNM42IEG_#JY61RFL_W[>TY"1G6[
M\&UC?FPT].1G?LD[=\C>08FYB-GR4C=NV9[IY*1GUWCAWAACG''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP, 1:LKRLI+],05(0
MJRK1?RMIV#N%:<].;989L2" EFTMWGLV=;2\\.L@($C=AUKPRT"XO76OK+'+
M++/^..!@KU6:%9F"EK?5@:T:T1Z6[,4=1/'=LU WU.W[Y2NSQ=6O;JUYD@4N
M1LF#<I&.[3'F=:I>.K^1'T;=6=<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQ
MQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <Q)'04BLUW2
MH5XIKR0K1RC&;CKJN)A! V@NX,A9P:26D</TZ(NJ8P-1XTPE]^&K'.<7*3I^
M_O.1)VYY9;QP'/ :E17>EPRGNJX";E-B@;Q9]99A,$Z -C9./[9$ L()Z)4
MA#W=?IULC2H^W5G^G7>6'??77Z>_QP-4U)15,T($)+E*U<BU8#,E<CA@:BK0
MI<C%S.46- _M"F(V-HR(S\8,.)"URIF6[=JAQ8\77GCHTZ]>.UN.. XXXX#C
MCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.
M... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
MXXXX#CCC@.... XXXX#CCC@.... XXXX&O+!MVJJFZ4^[1LI#KG_ #QO!U^C
MXO#:!5<W%Z9IND<O)RM@;GPLS[.:G;],88#%8RR4S;GUCHC9_IWWU_A:WJI
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MLLN^NL>NN^^^^NNN897-DU[;Z2NV55+NJV17K="R)*SND'AC.JL4#"1OAYS
MQX/)F#24;"7&DQ<]L23MPPD1]VC+OK;JSQQP*@[M'^BZ26;E%UY;-7P'".S_
M ($"[$:37]J!.UYD.JN[!E2=\HC*%;"F\'L+A-?<G?F2 $1)+#'#J=CIPXQZ
M(I[W@+\84W7JZ5^@% P*,^ OHR[$]"IV3;E2Z"/N2M?0;P0IM/9 X@+IFE[
M)#"NF;C6N'<0V[KF(W44'%EO#"-L#NJYXC,R DU;8&]I*10:RJ!"S(Q&IV?>
MN"(! H$@H7*3-G6.7>N*/'Q9$N1GUCEWCITYY=8]]]?ISC%]KWY[21R-VV9:
M]C_1RK'?9(^1^/FB95PNV$GRIIJVV(U"K_KK&VIRT&B5<NO!.Y#5GK#-'=2
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M... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@....
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M#D!4MJ>UP(R3(I&9_7#)F0F>0TRXD(J1_4<)F3=<:*4(8;(0_;)E:MFK'?7
M<<<<!QQQP'',#7K.06QUL.NEQI&%W>I]RO'L9;B9[<B*CO=06+,JZBV.>K#5
MAD< YXE(76G;N_=%RZRV?CR[_;S/. XXXX#CCC@.... XXXX#CCC@.... XX
MXX#CCC@.... XXXX#D<O6.^N8U$/4BSTB38 '6.V?U:[!J!GO(ADW;-.[2I3
MQZ"GJ#P=D3H!S9$WQ"\8!LUA=W6$[?,@ZM>4C"1O' YA;>A!V3X->2:UG41=
M+%Z,1O/'CRJ0*M)\=>@#MK(;[44OS;E>(R*([IZ:U)$>(-5B6$E@VZ X)OU
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MDR]G1F[/:76R[);[ :0*6K0YX$5+868I$#AXQ)H/C%5<@[R$[;IC:I)MD-"
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M\V_P*A;]??3+7\VJ(=U6NO25&MC&P>7-WHY$6BK+8OKFK_/\VPE&+?>I8-!
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M6_9#8([:(R'Y$=&$U_X;]8;_ #I+%F%OU5*N38<^;<"WJ[LG_2D.M'RQZ?\
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M80*(]/AO/?D,37WE_P!+)WHNL/0/F9R]:&[0OJ#F)OMU0ZINP7;;C_E\6[[
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3XXX#CCC@.... XXXX#CCC@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>jwb01.jpg
<TEXT>
begin 644 jwb01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !@ .4# 2(  A$! Q$!_\0
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ME?3H$;_ONZH ]8HKQ35OCUXD\-P[]7^"_CPKN^]I*V&HC;_NQ76__P =K4\
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M%I\/[*ZECE=';YD2X^1=J/\ ]\M3M!\6?$77_#UKJZ_MA^'=/BN;>"\\K4_
MUA:W%O%+_JI75[KY=Z?-\W\- 'UG'\+-#MOC!=_$=4N?^$EN-'30V=I?W7V5
M9?-^5/[VYJH_%#XY>%OA/)IUOJ]Y<W6M:F773]!TRS:ZU"_V_>\J!/F;_>^[
M7SUJ.E_&?3=&UK5F_:MT6[M-)L9]2NDLO =G=2K!$S*[[4N/X7B=?]Y7KA_"
MOA/XA^._C-+JFB?M007GC2*TNM :Y_X5U!Y7D6KI++_RUV;=]TGS_P 7_ *
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M"YT*76&T.SFA^&=GNNKI79/DW7'W?D?YFV_<H ^E_$7[-OAR\U:76_"]W?\
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M-;37]K_HMPGWK6Y7Y[>9?]R5$;_@->7^!U;]K/\ 9Z\/R>(=6U;0;^9)=/\
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MU=D3>V^65V?;_%0![I1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>logo01.jpg
<TEXT>
begin 644 logo01.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  J )8# 2(  A$! Q$!_\0
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M-&R. RL-I!Z$&ORUUG]C[]H+]EWXU:MXG^""+K&CWYD6)X)( 1 [A_L\\$K
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&P]** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>seal01.jpg
<TEXT>
begin 644 seal01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !P '$# 2(  A$! Q$!_\0
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M (.1]J@0';MRSY/7%=M^T3X2>SUD>)GU5H?[46ST&&SM=,-Y>2L)FF58?G4
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M6O1WRR1S?*FK7.M3D1(&8C]W(S$1X/RK&,8*#%4O#?QLT7QE?1:#XPTV._\
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390759280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 16, 2024</div></th>
<th class="th"><div>Dec. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOPHARMA, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-0883144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7900 East Union Avenue,&#160;Suite&#160;920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Denver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">437-6580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,712,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,148,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Denver, Colorado<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390932512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,006<span></span>
</td>
<td class="nump">$ 22,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">23,617<span></span>
</td>
<td class="nump">28,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">12,633<span></span>
</td>
<td class="nump">11,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,635<span></span>
</td>
<td class="nump">7,162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total current assets</a></td>
<td class="nump">61,891<span></span>
</td>
<td class="nump">71,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">52,453<span></span>
</td>
<td class="nump">58,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">56,204<span></span>
</td>
<td class="nump">65,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">118,095<span></span>
</td>
<td class="nump">136,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,440<span></span>
</td>
<td class="nump">13,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">38,574<span></span>
</td>
<td class="nump">46,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Revolving credit facility</a></td>
<td class="nump">2,395<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-Term Debt, Current Maturities</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current</a></td>
<td class="nump">8,962<span></span>
</td>
<td class="nump">7,090<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">62,228<span></span>
</td>
<td class="nump">69,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Liabilities, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">10,877<span></span>
</td>
<td class="nump">14,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="nump">6,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent</a></td>
<td class="nump">4,529<span></span>
</td>
<td class="nump">6,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">28,151<span></span>
</td>
<td class="nump">28,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $.0001; 200,000,000 shares authorized; 5,972,638 and 5,517,174 shares issued and outstanding, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">347,688<span></span>
</td>
<td class="nump">343,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(319,973)<span></span>
</td>
<td class="num">(304,129)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">27,716<span></span>
</td>
<td class="nump">39,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 118,095<span></span>
</td>
<td class="nump">$ 136,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391996320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorizzed (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">5,972,638<span></span>
</td>
<td class="nump">5,517,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">5,972,638<span></span>
</td>
<td class="nump">5,517,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389639968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 81,002<span></span>
</td>
<td class="nump">$ 107,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">26,416<span></span>
</td>
<td class="nump">40,767<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">54,586<span></span>
</td>
<td class="nump">66,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">26,958<span></span>
</td>
<td class="nump">41,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,514<span></span>
</td>
<td class="nump">28,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">4,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">5,212<span></span>
</td>
<td class="nump">4,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Gain from contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(969)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">59,840<span></span>
</td>
<td class="nump">83,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,254)<span></span>
</td>
<td class="num">(17,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(4,792)<span></span>
</td>
<td class="num">(4,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative, Gain (Loss) on Derivative, Net</a></td>
<td class="num">(4,004)<span></span>
</td>
<td class="nump">4,793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(14,076)<span></span>
</td>
<td class="num">(17,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1,768)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,844)<span></span>
</td>
<td class="num">$ (17,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">5,537,957<span></span>
</td>
<td class="nump">3,339,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (5.11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember', window );">Avenue Capital Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (594)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389749008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1,928,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 331,386<span></span>
</td>
<td class="num">$ (287,078)<span></span>
</td>
<td class="nump">$ 44,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense (in shares)</a></td>
<td class="num">(18,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,046<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of $1,004 issuance cost (in shares)</a></td>
<td class="nump">3,606,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of $1,004 issuance cost</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,051)<span></span>
</td>
<td class="num">(17,051)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">343,485<span></span>
</td>
<td class="num">(304,129)<span></span>
</td>
<td class="nump">39,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense (in shares)</a></td>
<td class="nump">14,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,844)<span></span>
</td>
<td class="num">(15,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of warrants (in shares)</a></td>
<td class="nump">441,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">5,972,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 347,688<span></span>
</td>
<td class="num">$ (319,973)<span></span>
</td>
<td class="nump">$ 27,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for the warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued for warrants exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387674288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391121536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,844)<span></span>
</td>
<td class="num">$ (17,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and accretion</a></td>
<td class="nump">8,272<span></span>
</td>
<td class="nump">8,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">6,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative warrant liabilities loss (gain)</a></td>
<td class="nump">4,004<span></span>
</td>
<td class="num">(4,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">2,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Gain from contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NoncashGainLossOnExtinguishmentOfDebt', window );">Non-cash loss on extinguishment of debt</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash adjustments</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">5,320<span></span>
</td>
<td class="num">(7,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,908)<span></span>
</td>
<td class="num">(3,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,879)<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(9,567)<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities, net</a></td>
<td class="nump">3,847<span></span>
</td>
<td class="num">(1,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,388)<span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">3,467<span></span>
</td>
<td class="nump">15,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_PaymentsOfFixedPaymentArrangements', window );">Payment made to fixed payment arrangement</a></td>
<td class="num">(2,566)<span></span>
</td>
<td class="num">(4,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Net proceeds (payments) made on revolving credit facility</a></td>
<td class="nump">832<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments made to borrowings</a></td>
<td class="num">(15,722)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Proceeds from borrowings</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment for debt issuance costs</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,262)<span></span>
</td>
<td class="nump">8,871<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(2,979)<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">22,985<span></span>
</td>
<td class="nump">19,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">20,006<span></span>
</td>
<td class="nump">22,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,039<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Other non-cash investing and financing activities</a></td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NoncashGainLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-cash gain (loss) on the extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NoncashGainLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsOfFixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for fixed payments arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsOfFixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity from shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391085264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> - Nature of Business and Financial Condition</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Aytu BioPharma, Inc. (&#8220;Aytu,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on <em style="font: inherit;"> August 9, 2002, </em>in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on <em style="font: inherit;"> June 8, 2015. </em>Following the acquisition of Neos Therapeutics, Inc. (&#8220;Neos&#8221;)&#160;in <em style="font: inherit;"> March 2021 (</em>the&#160;&#8220;Neos Acquisition&#8221;),&#160;the Company changed its name to Aytu BioPharma, Inc.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a&#160;focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to&#160;continue building its portfolio of revenue-generating products and leveraging its commercial team&#8217;s expertise to build leading brands within large therapeutic markets. The Company&#8217;s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including attention deficit hyperactivity disorder (&#8220;ADHD&#8221;). The Company operates through <span style="-sec-ix-hidden:c117047052">two</span> business segments: (i) the Rx segment, consisting of prescription pharmaceutical products sold primarily through <em style="font: inherit;">third</em> party wholesalers (the &#8220;Rx Segment&#8221;) and (ii) the consumer health segment, which consists of various consumer healthcare products sold directly to consumers&#160;through certain e-commerce platforms (the &#8220;Consumer Health Segment&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Rx Segment primarily consists of <em style="font: inherit;">two</em> product portfolios. The <em style="font: inherit;">first</em> consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (&#8220;Adzenys&#8221;) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets&#160;(&#8220;Cotempla&#8221;) for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;) (the &#8220;ADHD Portfolio&#8221;). The <em style="font: inherit;">second</em> consists&#160;primarily of Karbinal&#174; ER (carbinoxamine maleate extended-release oral suspension) (&#8220;Karbinal&#8221;), an extended-release <em style="font: inherit;">first</em>-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, <em style="font: inherit;">two</em> complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the &#8220;Pediatric Portfolio&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment&#160;consisted&#160;of multiple consumer health products competing in large healthcare categories&#160;including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health&#160;and general wellness, which was commercialized through direct mail and e-commerce marketing channels. The Company&#160;began to wind down the Consumer Health Segment in fiscal <em style="font: inherit;">2024.</em> During the <em style="font: inherit;">first</em> quarter of fiscal&#160;<em style="font: inherit;">2025,</em> the Company&#160;completed the wind down of operations and entered into a definitive agreement to divest the&#160;Consumer Health Segment to a private, e-commerce focused company (the &#8220;Consumer Health Divestiture&#8221;).&#160;The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for the&#160;Company to receive up to $0.5 million&#160;of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024,</em> the Company concluded that it had alleviated the Company&#8217;s previously disclosed substantial doubt about its ability to continue as a going concern. This was primarily the result of the extinguishment of its $15.0 million term loan that was due in <em style="font: inherit;"> January 2025, </em>while entering into a new $13.0 million term loan on more favorable terms to the Company with a maturity date of <em style="font: inherit;"> June 2028. </em>Further, the Company maintained and extended the maturity date of its revolving credit facility&#160;to <em style="font: inherit;"> June 2028 </em>and had $5.6 million of remaining availability to draw upon as of <em style="font: inherit;"> June 30, 2024 (</em>see <i>Note <em style="font: inherit;">10</em> &#8211; Revolving Credit Facility</i> and <i>Note <em style="font: inherit;">11</em> &#8211; Long-Term Debt</i> for further detail). In addition, during fiscal <em style="font: inherit;">2024</em> the Company received $3.5 million of net proceeds from the exercise of warrants, was in compliance with all of its debt covenants as of <em style="font: inherit;"> June 30, 2024, </em>and through the filing of this Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> June 30, 2024 (</em>&#8220;Form <em style="font: inherit;">10</em>-K&#8221; or &#8220;Annual Report&#8221;). The Company has implemented and continues to implement plans to achieve operating profitability and increase cash flows, including various margin improvement initiatives, the wind down and divestiture of the Company&#8217;s unprofitable Consumer Health Segment, and the indefinite suspension of certain research and development activities. Considering these factors, management has concluded that as of the filing of this Form <em style="font: inherit;">10</em>-K, substantial doubt about the Company&#8217;s ability to continue as a going concern did <em style="font: inherit;">not</em> exist.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial Statements and notes thereto have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within <em style="font: inherit;">one</em> year after the date the consolidated financial statements and notes thereto are available to be issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391959968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note&#160;<em style="font: inherit;">2</em> - Summary of Significant Accounting Policies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Principals of Consolidation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial statements&#160;and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Basis of Presentation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial statements&#160;and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;)</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Going Concern Determination</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the financial statements are available to be issued. The evaluation is based on relevant conditions and events that are known and reasonably knowable within <em style="font: inherit;">one</em> year after the date that the financial statements are available to be&#160;issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends. See&#160;<i>Note <em style="font: inherit;">1</em>&#160;&#8211; Nature of Business and Financial Condition</i>&#160;for further detail on the evaluation performed by the Company.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results <em style="font: inherit;"> may </em>differ from estimates. In the accompanying consolidated financial statements and notes thereto, estimates are used for, but <em style="font: inherit;">not</em> limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Prior Period Reclassification</i></b><i>. </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Certain prior year amounts in the Company&#8217;s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did <em style="font: inherit;">not</em> impact operating results or cash flows for the fiscal years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> or its financial position as of <em style="font: inherit;"> June 30, 2024</em>, or <em style="font: inherit;"> June 30, 2023</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Previously Reported Prepaid Expenses Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company identified that certain of the Company&#8217;s prepaid expenses totaling $1.8 million that were previously reported as current assets as of <em style="font: inherit;"> June 30, 2023, </em>should have been classified as non-current assets as of <em style="font: inherit;"> June 30, 2023. </em>The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99,</em> &#8220;Materiality&#8221; and concluded that the omission was <em style="font: inherit;">not</em> material to any of the previously issued consolidated financial statements and began reporting the prepaid expenses as non-current within this Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Cash and Cash Equivalents</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)&#160;insurance limits, and cash balances in the money market funds are <em style="font: inherit;">not</em> FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Accounts Receivable, Net</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company&#8217;s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company&#8217;s customers&#8217; financial condition;&#160;payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers&#160;and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts&#160;which were previously written off are&#160;recorded as a reduction of bad debt expense in the period the payment is collected. If the Company&#8217;s actual collection experience changes, revisions to the&#160;Company&#8217;s allowance for credit losses <em style="font: inherit;"> may </em>be required. After attempts to collect a receivable have failed, the receivable is written off against the allowance for credit losses. The allowance for credit losses&#160;was <span style="-sec-ix-hidden:c117047150"><span style="-sec-ix-hidden:c117047154">zero</span></span> for both years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em> The allowance for discounts was $0.6&#160;million and $1.8&#160;million as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> respectively. The allowance for chargebacks was $1.2&#160;million at both&#160;<em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below presents the opening and closing balances of accounts receivable, gross&#160;from customers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accounts Receivable, Gross</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,708</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">31,927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below details the change in allowance for discounts&#160;and allowance for chargebacks for the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt; width: 55%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Discounts</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Chargebacks</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Total Allowance</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2022</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,206</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2,507</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">9,074</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">4,554</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">13,628</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,597</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,548</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,145</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2023</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,778</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,212</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2,990</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">4,886</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">3,812</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">8,698</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,024</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,842</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,866</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2024</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">640</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,182</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,822</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Inventories</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are <em style="font: inherit;">no</em> alternate uses for the inventory, the Company will record a charge to cost of sales to reduce the value of the inventory to net realizable value in the period the impairment is identified.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally <span style="-sec-ix-hidden:c117047191">two</span> to <span style="-sec-ix-hidden:c117047194">seven</span> years. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Leases</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#8220;ROU&#8221;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is <em style="font: inherit;">not</em> readily determinable based upon the information available at the lease commencement date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#8217;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#8217;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of <em style="font: inherit;">12</em> months or less.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operating leases are included in other liabilities in the Company&#8217;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of&#160;debt and debt, net of current portion in the Company&#8217;s consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Acquisitions</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do <em style="font: inherit;">not</em> meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does <em style="font: inherit;">not</em> result in goodwill.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Warrants</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenue Recognition</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company generates revenue from product sales through its Rx Segment&#160;and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following <em style="font: inherit;">five</em>-step model: (<em style="font: inherit;">1</em>)&#160;identify the contract with the customer; (<em style="font: inherit;">2</em>)&#160;identify the performance obligations; (<em style="font: inherit;">3</em>)&#160;determine the transaction price; (<em style="font: inherit;">4</em>)&#160;allocate the transaction price to the performance obligations; and (<em style="font: inherit;">5</em>)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is <em style="font: inherit;">not</em> a recognized financing component related to product sales.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rx Segment</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms.&#160;The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within <em style="font: inherit;">one</em>&#160;year.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Rx Segment net&#160;revenue is recognized net of consideration paid to the Company&#8217;s customers and other adjustments to the transaction price (known as &#8220;Gross to Net&#8221; adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Gross to Net adjustments include:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Savings offers.</i>&#160;The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Prompt payment discounts.</i>&#160;Prompt payment discounts are based on standard provisions of wholesalers&#8217;&#160;services.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesale distribution fees.&#160;</i>Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rebates.&#160;</i>The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from <em style="font: inherit;">third</em>-party providers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesaler chargebacks.</i>&#160;The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217;&#160;end customers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Returns.</i>&#160;Wholesalers&#8217;&#160;contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting <em style="font: inherit;">six</em> months prior to expiry date to <em style="font: inherit;">twelve</em> months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which <em style="font: inherit;"> may </em>vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> follow historical trends. The Company&#8217;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do <em style="font: inherit;">not</em> believe variances between actual and estimated amounts have been material.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Consumer Health Segment</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment, which was divested of&#160;in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2025,</em> had net revenue which was from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue was&#160;generally recognized &#8220;free-on-board&#8221; shipping point, as those were&#160;the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer were&#160;excluded from net revenue. Shipping and handling costs associated with outbound freight after control over a product had&#160;transferred to a customer were accounted for as a fulfillment cost and were&#160;included in cost of sales.&#160;The Company expensed&#160;the incremental costs to obtain a contract as incurred, since they are satisfied within <em style="font: inherit;">one</em>&#160;year.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Concentration of Credit Risk</i></b><i>. </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is <em style="font: inherit;">not</em> exposed to significant credit risk due to the financial position of those institutions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#8217;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#8217;s products to retailers. The loss of <em style="font: inherit;">one</em> or more of these large customers could have a material adverse effect on the Company&#8217;s business, operating results or financial condition. The Company does <em style="font: inherit;">not</em> charge interest or require collateral related to its accounts receivable. Credit terms are generally <span style="-sec-ix-hidden:c117047243">thirty</span>&#160;to <span style="-sec-ix-hidden:c117047245">sixty</span> days.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table presents customers that contributed more than <em style="font: inherit;">10%</em> of gross revenue and accounts receivable<i>: </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Gross Revenue</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Accounts Receivable</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer A</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer B</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer C</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Costs of Sales</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Costs of sales consists primarily of manufactured product cost, products acquired from <em style="font: inherit;">third</em>-party manufacturers, freight, production, inventory write-downs,&#160;indirect manufacturing overhead costs and United States Food and Drug Administration&#160;(&#8220;FDA&#8221;) fees for commercialized products. Certain of the Company&#8217;s sales activities depend on licensing arrangements that <em style="font: inherit;"> may </em>require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company&#8217;s <em style="font: inherit;">third</em>-party logistics companies are included in costs of sales.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for stock-based payment&#160;compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#8217;s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#8220;simplified method,&#8221; which is the midpoint between the vesting date and the end of the contractual term and is&#160;utilized&#160;by the Company as it does <em style="font: inherit;">not</em> have sufficient historical data to determine a more reliable expected term estimate. The risk-free interest rate is based on the United States&#160;Treasury yield in effect at the time of the grant for the expected term of the award. The Company does <em style="font: inherit;">not</em>&#160;anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b></b></i></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Employee Benefits Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company&#160;has a <em style="font: inherit;">401</em>(k)&#160;plan&#160;(&#8220;Aytu <em style="font: inherit;">401</em>(k) Plan&#8221;), which&#160;allows participants to contribute a portion of their salary, subject to eligibility requirements and annual Internal Revenue Service (&#8220;IRS&#8221;) limits.&#160;The Aytu <em style="font: inherit;">401</em>(k) Plan&#160;matches 100% of the <em style="font: inherit;">first</em> 3% contributed by employees and matches 50% of the next 4% and 5% contributed by employees. The Company&#8217;s match for the Aytu <em style="font: inherit;">401</em>(k) Plan was $0.7&#160;million for both of the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Research and Development</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Research and development costs are expensed as incurred and include salaries and benefits;&#160;facilities costs;&#160;overhead costs;&#160;raw materials;&#160;laboratory and clinical supplies;&#160;clinical trial costs;&#160;contract services;&#160;milestone payments and fees paid to regulatory authorities for review and approval of the Company&#8217;s product candidates;&#160;and other related costs.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are <em style="font: inherit;">not</em> subject to amortization.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Impairment of Long-lived Assets</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are <em style="font: inherit;">not</em> limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; or (iv)&#160;expectations that the asset will more likely than <em style="font: inherit;">not</em> be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Contingent Consideration</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The consideration for the Company's&#160;acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of <span style="-sec-ix-hidden:c117047278">zero</span> and $1.0 million for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> respectively. The Company did <em style="font: inherit;">not</em> have any contingent consideration recorded on its consolidated balance sheets as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Advertising and Direct Marketing Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Advertising and direct marketing costs consist&#160;of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $4.9&#160;million and $17.2&#160;million of advertising costs for the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Income Taxes</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the&#160;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than <em style="font: inherit;">not</em> that some portion or all of its deferred tax asset will <em style="font: inherit;">not</em> be utilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em>&#160;to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Debt Discount and Issuance Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Debt issuance costs reflect fees paid to lenders and <em style="font: inherit;">third</em> parties directly related to issuing debt. Debt discount&#160;and issuance costs related to term loans are reported as direct deductions&#160;to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition to interest expense. Debt issuance costs related to a revolving credit facility are classified as assets and subsequently amortized using the straight-line method over the term of the revolving credit facility as additional interest expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Segment Information</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s operating segments engage in business activities from which it <em style="font: inherit;"> may </em>earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Company&#8217;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#8217;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has <span style="-sec-ix-hidden:c117047295">two</span> reportable segments: the Rx Segment and the Consumer Health Segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Paragraph IV Litigation Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Legal costs incurred by the Company in the enforcement of the Company&#8217;s intellectual property rights are charged to expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Business Combinations</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b></b></i></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Employee Retention Credit</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> March 27, 2020, </em>the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) to provide certain relief as a result of the COVID-<em style="font: inherit;">19</em> pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (&#8220;ERC&#8221;), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to <em style="font: inherit;">70%</em> of the qualified wages paid to employees after <em style="font: inherit;"> December 31, 2020, </em>through <em style="font: inherit;"> September 30, 2021. </em>The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-<em style="font: inherit;">19</em> pandemic.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As there is <em style="font: inherit;">no</em> authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (&#8220;IAS&#8221;) <em style="font: inherit;">20,</em> Accounting for Government Grants and Disclosure of Government Assistance (&#8220;IAS <em style="font: inherit;">20&#8221;</em>). In accordance with IAS <em style="font: inherit;">20,</em> the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em> Further in accordance with IAS <em style="font: inherit;">20,</em> when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (the &#8220;IRC&#8221;), the ERC accrual shall be recognized as a benefit in other income in the consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Net Income (Loss) Per Share</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company incurred a net loss and did <em style="font: inherit;">not</em> include common equivalent shares in the computation of diluted net loss&#160;per share because the effect would have been anti-dilutive.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth securities excluded from the calculation of diluted earnings per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 56.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants to purchase common stock - liability classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">6,057,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,498,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Warrants to purchase common stock - equity classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18,114</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee stock options</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock units</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">6,249,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,636,773</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b></b></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Recently Adopted Accounting Pronouncements </b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Financial Instruments - Credit Losses</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments&#8212;Credit Losses</i> (&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>), which requires the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after <em style="font: inherit;"> December 15, 2019. </em>However, in <em style="font: inherit;"> October 2019, </em>the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after <em style="font: inherit;"> December 15, 2022. </em>The effective dates for the amendments in ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> on <em style="font: inherit;"> July 1, 2023. </em>The Company evaluated the impact of adoption of ASUs <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> and <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> and concluded that the application of the new standards did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Debt</i>&#160;-&#160;<i>Debt with Conversion and Other Options</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em> <i>Debt&#8212;Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>)&#8212;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company&#160;adopted the guidance on <em style="font: inherit;"> July 1, 2024, </em>and the adoption of the standard did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Segment Reporting</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07&#8221;</em>). ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods in fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#8217;s consolidated financial statements and disclosures.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other than the application of IAS <em style="font: inherit;">20</em> for the ERC, there have been <em style="font: inherit;">no</em> significant changes to the Company&#8217;s significant accounting policies and there is <em style="font: inherit;">no</em> other accounting guidance has been issued and <em style="font: inherit;">not</em> yet adopted that is applicable to the Company and that the Company expects would have a material effect on the Company&#8217;s consolidated financial statements and&#160;related disclosures as of <em style="font: inherit;"> June 30, 2024</em>, and through the filing of this Form <em style="font: inherit;">10</em>-K.</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390160832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3</em> - Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company disaggregates its revenue into <span style="-sec-ix-hidden:c117047466">two</span> segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys&#160;and Cotempla; and the Pediatric Portfolio, comprised of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. The Company completed its&#160;wind down of the Consumer Health Segment and entered into a definitive agreement to effect the&#160;Consumer Health Divestiture in the <em style="font: inherit;">first</em> quarter of fiscal&#160;<em style="font: inherit;">2025.</em> The Consumer Health Segment was&#160;comprised of over <span style="-sec-ix-hidden:c117047469">ten</span> consumer health products.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenues by Segment</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by segment for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Rx Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Consumer Health Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">15,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenues by Product Portfolio</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADHD Portfolio net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">57,784</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,855</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pediatric Portfolio net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,377</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,567</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total Rx Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">65,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">73,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment was&#160;comprised of <em style="font: inherit;">one</em> product portfolio.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenues by Geographic Location</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by geographic location as determined by the billing address of the Company&#8217;s customers for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">United States net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80,911</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">International net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">481</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389933312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em> - Inventories</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">266</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Work in process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,725</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">6,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,633</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,995</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company incurred inventory write-downs of&#160;$2.3&#160;million for the year ended <em style="font: inherit;"> June 30, 2024, </em>primarily a result of unsalable and slow-moving products&#160;and a $0.7&#160;million write-down as part of the wind down of the Consumer Health Segment.&#160;The Company incurred inventory write-downs of $2.4&#160;million for the year ended <em style="font: inherit;"> June 30, 2023, </em>primarily as a result of unsalable and slow-moving products.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388928592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em> - Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Property and equipment, net consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Office equipment, furniture and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lab equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">721</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">832</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">999</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Assets under construction</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,818</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">693</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,815</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Depreciation expense was $0.9&#160;million and $1.3&#160;million during the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively. During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company did <span style="-sec-ix-hidden:c117047534">not</span> record a material gain or loss on disposal of equipment and during the year ended&#160;<em style="font: inherit;"> June 30, 2023</em>, the Company recognized a gain of $0.1 million on the disposal of equipment.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392092096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LeasesDisclosureTextBlock', window );">Leases Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">6</em> - Leases</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases were for equipment. These leases have original lease periods expiring between <em style="font: inherit;">2022</em>&#160;and <em style="font: inherit;">2030.</em> Most leases include option provisions under which the parties <em style="font: inherit;"> may </em>extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company&#8217;s lease agreements generally do <em style="font: inherit;">not</em> contain any material residual value guarantees or material restrictive covenants. The Company had no remaining finance leases recorded as of <em style="font: inherit;"> June 30, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $3.5 million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does <em style="font: inherit;">not</em> provide an implicit rate, a borrowing rate of 6.7% was used to determine the present value of future lease payments.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024,</em> as part&#160;of the previously announced wind down of the Consumer Health Segment and the closure of the&#160;Grand Prairie, Texas manufacturing site, the Company ceased using the Oceanside, California warehouse and the Grand Prairie, Texas manufacturing facility. As a result, the Company&#160;wrote off the remaining related operating lease ROU assets. The lease for the Oceanside, California warehouse and the&#160;Grand Prairie, Texas manufacturing site are&#160;set to&#160;expire on <em style="font: inherit;"> December 31, 2026, </em>and on <em style="font: inherit;"> December 31, 2024, </em>respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2024, </em>the Company entered into a forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;from the owner of the office space that the Company is&#160;currently renting under a sublease arrangement. The Company has determined that it is an operating lease, and that lease commencement occurred in <em style="font: inherit;"> July 2024. </em>The&#160;initial lease termination date is&#160;<em style="font: inherit;"> July 31, 2030, </em>and under the lease agreement the Company has <em style="font: inherit;">one five</em>-year renewal option to extend the lease through <em style="font: inherit;"> July 2035.&#160;</em>Undiscounted minimum monthly rent payments average approximately $13,000&#160;over the initial term of the lease. The Company has elected to utilize the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company will record an operating lease ROU asset of $0.5 million and a lease liability of $0.5 million at lease commencement in <em style="font: inherit;"> July 2024.&#160;</em>The ROU asset and lease liability will be&#160;recorded at present value using an incremental borrowing rate of 12.3%.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> May 2023, </em>the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in <em style="font: inherit;"> September 2023 (</em>lease commencement) with an initial term of <span style="-sec-ix-hidden:c117047576">five</span> and a half years. The Company recorded an operating lease ROU asset of $0.8&#160;million and a lease liability of $0.8&#160;million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of 10.3%. The Company utilized the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components upon recognition. See&#160;<i>Note <em style="font: inherit;">18</em> &#8211; Commitments and Contingencies </i>for further detail.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The components of lease expenses are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b><em style="font: inherit;">Statement of Operations Classification</em></b></p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,247</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">94</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Cost of sales</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Interest expense</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Supplemental balance sheet information related to leases is as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">Balance Sheet Classification</em></b></p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating lease right-of-use assets</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047624"><span style="-sec-ix-hidden:c117047625">Property and equipment, net</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">712</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047635"><span style="-sec-ix-hidden:c117047636">Other current liabilities</span></span></em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047641"><span style="-sec-ix-hidden:c117047642">Current portion of debt</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">577</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">832</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047648"><span style="-sec-ix-hidden:c117047649">Other liabilities</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The remaining weighted-average lease term and discount rate used are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (years):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Supplemental cash flow information related to leases is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flow classification of lease payments:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,812</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,436</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, the&#160;Company did <em style="font: inherit;">not</em> have any remaining finance leases. As of <em style="font: inherit;"> June 30, 2024</em>, the&#160;Company&#8217;s future minimum operating lease payments, including the new forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">377</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">359</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">249</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
    &#160;&#160;
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387244064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Intangible Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7</em> - Intangible Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A summary of the Company&#8217;s intangible assets&#160;as of <em style="font: inherit;"> June 30, 2024</em>, and <em style="font: inherit;"> June 30, 2023</em>,&#160;is as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">June 30, 2024</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Gross Carrying Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Net Carrying Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted-Average Remaining Life</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,268</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(13,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,084</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,831</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,369</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total definite-lived intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">71,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,015</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average Remaining Life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,881</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total definite-lived intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,583</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with <span style="-sec-ix-hidden:c117047687">zero</span> net carrying amount at the end of a reporting period is <em style="font: inherit;">not</em> presented in the table of a future reporting period. Certain of the Company&#8217;s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $6.5&#160;million and $6.1&#160;million for the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table summarizes the estimated future amortization expense of intangible assets to be recognized over the next&#160;<em style="font: inherit;">five</em> years and periods thereafter:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total future amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired Product Technology Rights</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisition&#160;of the Pediatric Portfolio in <em style="font: inherit;"> November 2019 </em>and the Neos Acquisition in <em style="font: inherit;"> March 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Karbinal</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (&#8220;Tris&#8221;) for the exclusive rights to commercialize Karbinal&#160;in the United States (the &#8220;Tris Karbinal Agreement&#8221;). The Tris Karbinal Agreement&#8217;s initial term terminates in <em style="font: inherit;"> August&#160;</em>of <em style="font: inherit;">2033,</em> with an optional initial 20-year extension.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Poly-Vi-Flor</i>&#160;<i>and Tri-Vi-Flor</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the &#8220;Poly-Tri Agreements&#8221;) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>ADHD Portfolio</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys&#160;and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 16&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired Technology Right</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>TRRP Proprietary Technology</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Neos Acquisition, the Company acquired time release resin particle (&#8220;TRRP&#8221;) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired Product Distribution Rights</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the acquisition of Innovus Pharmaceuticals, Inc. (&#8220;Innovus&#8221;)&#160;in <em style="font: inherit;"> February 2020 (</em>the &#8220;Innovus Acquisition&#8221;), the Company obtained <em style="font: inherit;">35</em> products with a combination of over <em style="font: inherit;">300</em> registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fiscal year ended <em style="font: inherit;"> June 30, 2023, </em>this intangible asset was <span style="-sec-ix-hidden:c117047702">impaired</span> by $3.0 million due to the discontinuance of products in the Consumer Health Segment.&#160;As of <em style="font: inherit;"> June 30, 2024, </em>this intangible asset was fully amortized and removed from gross carrying value.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Acquired In-Process R&amp;D</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>IPR&amp;D </i>&#8211;<i> <em style="font: inherit;">NT0502</em></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Neos Acquisition, the Company acquired in-process research and development associated with <em style="font: inherit;">NT0502,</em> a new chemical entity that was&#160;being developed for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended <em style="font: inherit;"> June 30, 2023, </em>the Company terminated its development program of <em style="font: inherit;">NT0502.</em> As a result, the Company fully impaired the IPR&amp;D of <em style="font: inherit;">NT0502,</em> recording impairment expense of $2.6 million to its Rx Segment during the <em style="font: inherit;">second</em> quarter of fiscal <em style="font: inherit;">2023.</em></p>
  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389919696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedLiabilitiesTextBlock', window );">Accrued Liabilities [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">8</em> - Accrued liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued liabilities consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued savings offers</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,054</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,739</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued program liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,964</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,012</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued customer and product related fees</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,395</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,579</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued compensation</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,935</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,675</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Return reserve</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,835</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,777</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other accrued liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,391</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,017</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total accrued liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,574</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,799</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued savings offers represent programs for the Company&#8217;s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. The return reserve represents the Company&#8217;s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, <em style="font: inherit;">none</em> of which individually or in the aggregate represent greater than <em style="font: inherit;">five</em> percent of total liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table details the change in return reserve for the periods presented:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Return Reserve</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,770</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Reduction of net revenue</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,353</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,346</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,777</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Reduction of net revenue</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,128</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(7,070</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,835</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

     </tbody>
    </table>
    &#160;&#160;
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure regarding accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391857792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">9</em> - Other Liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Other liabilities consist of the following:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee retention credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,759</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">13,491</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: current portion of other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(8,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total other liabilities, non-current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Fixed payment arrangements</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in <em style="font: inherit;">2019,</em> including fixed and variable payments.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> May 2022, </em>the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated <em style="font: inherit;"> November 2, 2018, </em>related to Tuzistra XR (the &#8220;Tuzistra License Agreement&#8221;). Pursuant to such termination, as of <em style="font: inherit;"> June 30, 2024, </em>the Company has accrued a settlement liability of $6.2&#160;million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the Company&#160;to pay interest on any principal amounts due but remaining unpaid past <em style="font: inherit;"> July 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style="font: inherit;"> August 1 </em>through <em style="font: inherit;"> July 31, </em>of 70,000 units annually through <em style="font: inherit;">2025.</em> The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through <em style="font: inherit;">2025.</em> The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in <em style="font: inherit;"> August </em>of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the <em style="font: inherit;">first</em> of which is triggered at $40.0 million. As of <em style="font: inherit;"> June 30, 2024, </em>the fixed payment arrangement balance was $1.9 million in other current liabilities, and $0.2&#160;million in other non-current liabilities on the consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Employee Retention Credit&#160;</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The $3.8 million ERC accrual in other non-current liabilities as of <em style="font: inherit;"> June 30,&#160;</em><em style="font: inherit;">2024,</em> represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em> Please see <i>Note <em style="font: inherit;">2</em> -&#160;Significant of Significant Accounting Policies</i> for further detail.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Operating Lease Liabilities&#160;</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to <i>Note <em style="font: inherit;">6</em> - Leases</i> for further detail.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Other</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Other consists of taxes payable, deferred cost related to the Company&#8217;s technology transfer, and various other accruals, <span style="-sec-ix-hidden:c117047809">none</span> of which individually or in the aggregate represent greater than <em style="font: inherit;">five</em> percent of total liabilities.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391949632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Revolving Credit Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Debt [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">10</em> - Revolving Credit Facility</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 12,&#160;</em><em style="font: inherit;">2024,</em> the Company and certain of its subsidiaries entered into&#160;consent, joinder and amendment <em style="font: inherit;">No.</em>&#160;<em style="font: inherit;">5</em> (the &#8220;Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5&#8221;</em>) to the loan and security agreement dated <em style="font: inherit;"> October 2, 2019, </em>as amended by amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">1,</em> dated <em style="font: inherit;"> March 19, 2021, </em>amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">2,</em> dated <em style="font: inherit;"> January 26, 2022, </em>amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">3,</em> dated <em style="font: inherit;"> June 1, 2022, </em>amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">4</em> dated <em style="font: inherit;"> March 24, 2023, </em>and the Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5</em> (together the &#8220;Eclipse Agreement&#8221;) with Eclipse Business Capital LLC (&#8220;Eclipse&#8221;), as agent, and the lenders party thereto (agent and such lenders, collectively, the &#8220;Eclipse Lender&#8221;).&#160;Under the Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5,</em> which provided for among&#160;other things, <em style="font: inherit;">two</em> loan agreements, a term loan (the &#8220;Eclipse Term Loan&#8221;) and a revolving credit facility (the &#8220;Eclipse Revolving Loan&#8221;). The Eclipse Term Loan is described further in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>. The Eclipse Revolving Loan&#160;provides for a&#160;maximum amount available under the revolving credit facility provided under the Eclipse Agreement of&#160;$14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (&#8220;SOFR&#8221;)&#160;plus 4.5%. In addition, the Company is&#160;required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan&#160;amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is <em style="font: inherit;"> June 12, 2028, </em>and the effective interest rate was 9.9% as of <em style="font: inherit;"> June 30, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event that, for any reason, all or any portion of the Eclipse&#160;Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) 2.0% of the Eclipse Revolving Loan&#160;commitment if such event occurs on or before <em style="font: inherit;"> June 12, 2025, (</em>ii) 1.0% of the Eclipse Revolving Loan&#160;commitment if such event occurs after <em style="font: inherit;"> June 12, 2025,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2026, </em>and (iii) 0.5% of the Eclipse Revolving Loan&#160;commitment if such event occurs after <em style="font: inherit;"> June 12, 2026,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2028. </em>The Company <em style="font: inherit;"> may </em>also be required to pay an early termination fee related to the Eclipse Term Loan&#160;as further described in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>. The Company <em style="font: inherit;"> may </em>permanently terminate the Eclipse Agreement upon written notice to Eclipse.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The&#160;Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company&#8217;s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of <em style="font: inherit;"> June 30, 2024</em>, the Company was in compliance with the covenants under the Eclipse Agreement. The Company&#8217;s obligations under the Eclipse Agreement are secured by substantially all of the Company&#8217;s assets, as defined further in the Eclipse Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff">The Company allocated debt issuance costs of $0.1&#160;million related to the Eclipse Revolving</span><span style="background-color:#ffffff">&#160;Loan, bringing to the total debt issuance costs related to the Eclipse Revolving&#160;Loan&#160;to $0.2 million, which will be amortized straight-line over the term of the loan. </span>Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was $0.1 million&#160;and $0.7&#160;million&#160;for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>. As of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the outstanding amounts drawn on the Eclipse Revolving Loan were&#160;$2.4&#160;million and $1.6&#160;million, respectively. The unused revolving credit facility amount as of <em style="font: inherit;"> June 30, 2024</em>, was $5.6&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388891648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">11</em> - Long-Term Debt</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Avenue Capital Loan</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> January 26, 2022&#160;(</em>&#8220;Closing Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Avenue Capital Agreement&#8221;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the &#8220;Avenue Capital Lenders&#8221;), and Avenue Capital Management II, L.P. as administrative agent (the &#8220;Avenue Capital Agent&#8221;), collectively (&#8220;Avenue Capital&#8221;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan was&#160;the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was&#160;<em style="font: inherit;"> January 26, 2025. </em>The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the <em style="font: inherit;">first</em> <em style="font: inherit;">18</em> months following the Closing Date (the &#8220;Interest-only Period&#8221;). The Interest-only Period could be extended automatically without any action by any party for <em style="font: inherit;">six</em> months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to <em style="font: inherit;"> June 15, 2023, </em>a specified amount of net proceeds from the sale and issuance of its equity securities (&#8220;Interest-only Milestone <em style="font: inherit;">1&#8221;</em>). The Interest-only Period was able to be further&#160;extended automatically without any action by any party for an additional <em style="font: inherit;">six</em> months provided, the Company had achieved, prior to <em style="font: inherit;"> December 31, 2023, (</em>i) Interest-only Milestone <em style="font: inherit;">1</em> and (ii) a specified amount of trailing <em style="font: inherit;">12</em> months revenue as of the date of determination.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> January 26, 2022&#160;(</em>&#8220;Issuance Date&#8221;), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to <em style="font: inherit;"> June 30, 2022, </em>the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on <em style="font: inherit;"> January 31, 2027. </em>At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was <em style="font: inherit;">not</em> fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an equity offering of shares of common stock and warrants, as described in <i>Note <em style="font: inherit;">15</em> - Stockholders Equity</i>, at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to <em style="font: inherit;"> July 7, 2022, </em>and the effective price of the <em style="font: inherit;"> March 7, 2022, </em>offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> October 25, 2022, </em>the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (&#8220;Avenue&#8221;) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in <em style="font: inherit;"> January 2022, </em>extended&#160;the interest-only period to <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2024.</em> In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company&#8217;s <em style="font: inherit;"> August 2022 </em>equity financing.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 13, 2023, </em>in conjunction with the Securities Purchase Agreement described in <i>Note <em style="font: inherit;">16</em> - Warrants</i>, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended&#160;to&#160;<em style="font: inherit;"> January 26, 2025.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff">In addition to the debt discount&#160;discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs were&#160;being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $3.4 million and&#160;</span><span style="background-color:#ffffff">$2.7&#160;million for the years ended </span><em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em><span style="background-color:#ffffff">.</span></p>
   <p style="text-indent: 36pt; text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> June 12,&#160;</em><em style="font: inherit;">2024,</em> the Company used proceeds from the Eclipse Term Loan&#160;and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full.&#160;Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to 1.0% of the loan or $0.2 million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of $0.6 million (&#8220;Final Payment&#8221;). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee,&#160;the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs&#160;were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of $0.6 million related to the retirement of the Avenue Capital loan in the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i><span style="background-color:#ffffff;">Eclipse Term Loan</span></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 12,&#160;</em><em style="font: inherit;">2024,</em> the Company and certain of its subsidiaries entered into Eclipse Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">5,</em> which provided for among other things,&#160;the Eclipse Term Loan&#160;and the Eclipse Revolving Loan&#160;described&#160;further in <i>Note <em style="font: inherit;">10</em> - Revolving Credit Facility</i>. The Eclipse Term Loan&#160;consists of a principal amount of $13.0 million, at an interest rate of SOFR plus 7.0%, with a <span style="-sec-ix-hidden:c117047910">four</span>-year term maturing on <em style="font: inherit;"> June 12, 2028,&#160;</em>and a straight-line loan amortization period of <span style="-sec-ix-hidden:c117047911">seven</span> years, which would provide for a loan balance at the end of the <span style="-sec-ix-hidden:c117047912">four</span>-year term of&#160;$5.6 million to be repaid on <em style="font: inherit;"> June 12, 2028, </em>the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan.&#160;The effective interest rate on the Eclipse Term Loan was 12.4% as of <em style="font: inherit;"> June 30, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) 3.0% of the Eclipse Term Loan&#160;if such event occurs on or before <em style="font: inherit;"> June 12, 2025, (</em>ii) 2.0% of the Eclipse Term Loan&#160;if such event occurs after <em style="font: inherit;"> June 12, 2025,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2026,&#160;(</em>iii) 1.0% of the Eclipse Term Loan&#160;if such event occurs after <em style="font: inherit;"> June 12, 2026,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2027, </em>and (iv) 0.5% of the Eclipse Term Loan&#160;if such event occurs after <em style="font: inherit;"> June 12, 2026,&#160;</em>but on or before <em style="font: inherit;"> June 12, 2028. </em>The Company <em style="font: inherit;"> may </em>also be required to pay an early termination fee related to the Eclipse Revolving Loan&#160;as further described in <i>Note <em style="font: inherit;">10</em>&#160;- Revolving Credit Facility</i>. The Company <em style="font: inherit;"> may </em>permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Company&#8217;s obligations under the Eclipse Agreement&#160;are secured by substantially all of the Company&#8217;s assets, as further defined in the Eclipse Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender&#160;to declare the Company&#8217;s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of <em style="font: inherit;"> June 30, 2024</em>, the Company was in compliance with the covenants under the Eclipse Agreement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff">The Company recorded&#160;total debt discount and allocated debt issuance costs of $0.3 million related to the Eclipse Term Loan, which will be amortized over the term of the loan. The Company incurred&#160;interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $0.1 million&#160;</span><span style="background-color:#ffffff">for the year ended <em style="font: inherit;"> June 30, 2024.</em></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Long-term debt consists of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>June 30, </b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2024</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2023</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Term loan principal amount</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">15,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(266</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(925</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Final payment fee</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">638</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Financing leases</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total debt</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">12,734</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">14,798</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Less: current portion of debt</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(85</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total debt, net of current portion</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,877</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,713</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Future principal payments of long-term debt are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total future term loan principal payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(266</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: current portion of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,877</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
    &#160;&#160;
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391956304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">12</em> - Fair Value Measurements</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company determines the fair value of financial and non-financial assets using the fair value hierarchy, which establishes <em style="font: inherit;">three</em> levels of inputs that <em style="font: inherit;"> may </em>be used to measure fair value as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1:</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2:</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3:</em></p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current&#160;and non-current&#160;debt. The carrying amounts of certain short-term&#160;financial instruments, including cash and cash equivalents, accounts receivable, accounts payable&#160;and accrued liabilities approximate their fair value due to their short maturities. Current and non-current&#160;debt are reported at their amortized costs on the&#160;Company&#8217;s consolidated balance sheets. The remaining financial instruments are reported on the&#160;Company&#8217;s&#160;consolidated balance sheets at amounts that approximate current fair values. The Company&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were <em style="font: inherit;">no</em> transfers between Level <em style="font: inherit;">1,</em> Level <em style="font: inherit;">2</em> and Level <em style="font: inherit;">3</em> in the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Recurring Fair Value Measurement</b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table presents the Company&#8217;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, by level within the fair value hierarchy:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;">Fair Value at</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2024</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;">Fair Value at</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2023</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30, 2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds&#160;and reflect their fair value at Level <em style="font: inherit;">1</em> in the fair value hierarchy.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Non-Recurring Fair Value Measurement</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, were fixed payment arrangements and&#160;intangible assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from 10.0% to 15.4%&#160;and are classified as Level <em style="font: inherit;">3</em> inputs in the fair value hierarchy. In <em style="font: inherit;"> May 2022, </em>the Company recognized a fixed payment arrangement liability of $7.6 million relating to the termination of the Tuzistra License Agreement. See <i>Note <em style="font: inherit;">9</em> - Other Liabilities</i> for further information on fixed payment arrangements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based on the Company&#8217;s impairment analyses for fiscal&#160;<em style="font: inherit;">2024</em> and <em style="font: inherit;">2023</em>, the Company did <span style="-sec-ix-hidden:c117047971">not</span> record an impairment charge on intangible assets during the year ended <em style="font: inherit;"> June 30, 2024</em>, and recorded an <span style="-sec-ix-hidden:c117047972">impairment charge</span> of $5.6&#160;million on intangible assets for the year ended <em style="font: inherit;"> June 30, 2023</em>. Valuation of&#160;intangible assets involves significant Level <em style="font: inherit;">3</em> inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted earnings before interest, taxes, depreciation, and amortization margins, and the selection of a discount rate. These assumptions <em style="font: inherit;"> may </em>be affected by expectations about future market or economic conditions. See <i>Note <em style="font: inherit;">7</em> - Intangible Assets</i> and <i>Note <em style="font: inherit;">2</em> - Summary of Significant Accounting Policies</i>, for further discussion on the fair value measurement of intangible assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Summary of Level <em style="font: inherit;">3</em> Input Changes </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth a summary of changes to those fair value measures using Level <em style="font: inherit;">3</em> inputs for the&#160;year ended <em style="font: inherit;"> June 30, 2024</em>:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Derivative Warrant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Liabilities</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,796</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,998</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><span style="-sec-ix-hidden:c117048033">Included in earnings</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,391</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlements <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><span style="-sec-ix-hidden:c117048039">Included in earnings</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin: 0pt; text-align: justify;"><span style="font-size:10pt;">Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company&#8217;s <em style="font: inherit;"> June 2023 </em>equity financing that were exercised in <em style="font: inherit;"> June 2024. </em>The warrants were converted into 367,478 shares of common stock (&#8220;Settlements&#8221;) and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (&#8220;Issued&#8221;). See <i>Note <em style="font: inherit;">14</em> - Stockholders&#8217;&#160;Equity</i> and&#160;<i>Note <em style="font: inherit;">16</em> - Warrants</i> for further detail.</span></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Level <em style="font: inherit;">3</em> Inputs</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Significant assumptions as of <em style="font: inherit;"> June 30, 2024, </em>used in valuing the derivative warrant liabilities, marked to market, were as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 2023 Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Tranche A</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><em style="font: inherit;">Monte Carlo &amp; Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><em style="font: inherit;">Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Aytu closing stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equivalent term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.6 - 3.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.2% - 87.5%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5% - 4.6%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">0%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto; font-size: 10pt;">Includes <em style="font: inherit;"> August 2022 </em>Warrants, <em style="font: inherit;"> March 2022 </em>Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See <i>Note <em style="font: inherit;">16</em> - Warrants</i> for definitions of these terms and further information.</td></tr>
</tbody></table>
  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387238880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">13</em> - Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For fiscal&#160;<em style="font: inherit;">2024</em>, there was $1.8&#160;million of income tax expense, which was an effective tax rate of negative 12.6%. This was&#160;primarily driven by Section <em style="font: inherit;">382</em> limitation of the IRC on post-Tax Cuts and Jobs Act&#160;(&#8220;TCJA&#8221;) net operating loss (&#8220;NOL&#8221;) utilization, as further described below, coupled with existing valuation allowances. As of <em style="font: inherit;"> June 30, 2024</em>,&#160;the Company had&#160;$0.8&#160;million&#160;of deferred tax assets (&#8220;DTAs&#8221;), net of valuation allowance, included in other non-current assets;&#160;$0.8&#160;million of deferred tax liabilities&#160;(&#8220;DTLs&#8221;) included in other non-current&#160;liabilities; and $0.3&#160;million of accrued income taxes payable included in accrued liabilities in the consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For fiscal <em style="font: inherit;">2023,</em>&#160;there was <span style="-sec-ix-hidden:c117048082">zero</span>&#160;income tax expense with&#160;an effective tax rate of <span style="-sec-ix-hidden:c117048083">zero</span> percent, reflecting the full valuation allowance. As of <em style="font: inherit;"> June 30, 2023,&#160;</em>the Company had&#160;$1.4&#160;million&#160;of DTAs, net of valuation allowance, included in other non-current assets;&#160;$1.4&#160;million of DTLs included in other non-current&#160;liabilities; and $0.1&#160;million of accrued income taxes payable included in accrued liabilities in the consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Section <em style="font: inherit;">382</em> Limitation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the provisions of the IRC, substantial changes in the Company&#8217;s ownership have resulted&#160;in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company <em style="font: inherit;"> may </em>be subject to examination for prior NOLs generated as such NOLs are utilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the Company&#8217;s Section <em style="font: inherit;">382</em> analysis, an ownership change was determined to have occurred in <em style="font: inherit;"> March 2022 </em>at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $12 million) was determined to be fully available to offset fiscal <em style="font: inherit;">2023</em> pre-change income subject to the <em style="font: inherit;">80%</em> limitation. The Company also determined that an ownership change occurred in <em style="font: inherit;"> June 2023 </em>at a time when the Company was in a net unrealized built-in loss position. As a result of the Section <em style="font: inherit;">382</em> analysis, the Company had $0.3 million of disallowed recognized built-in loss that was carried forward as a net operating loss as of <em style="font: inherit;"> June 30, 2023. </em>For fiscal <em style="font: inherit;">2024,</em> an additional $8.8 million of disallowed recognized built-in loss was carried forward as an operating loss. These operating loss carryovers are subject to the <em style="font: inherit;"> June 2023 </em>Section <em style="font: inherit;">382</em> limitation.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company had federal net operating losses of $519.6 million as of <em style="font: inherit;"> June 30, 2024, </em>that is subject to limitation (as described above). Of the available federal net operating losses,&#160;$186.6 million can be carried forward indefinitely, and $333.0 million will completely expire in <em style="font: inherit;">2037.</em> Of the amount set to expire,&#160;$329.2 million will expire unused as a result of the ownership change. As of <em style="font: inherit;"> June 30, 2024, </em>the Company had research and development credits of $3.0 million, which will begin to expire in <em style="font: inherit;">2025</em> and are also subject to Section <em style="font: inherit;">382</em> limitation. The available state net operating losses, if <em style="font: inherit;">not</em> utilized to offset taxable income in future periods, will begin to expire in <em style="font: inherit;">2025</em> and will completely expire in <em style="font: inherit;">2039.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized. Generally, it is <em style="font: inherit;">not</em> appropriate to use <em style="font: inherit;">zero</em> as an applicable tax rate and rather, a DTA should be recorded at the applicable tax rate and a valuation of an equal amount would be provided. However, under certain circumstances it <em style="font: inherit;"> may </em>be appropriate to follow an alternative approach and use a <em style="font: inherit;">zero</em> rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross DTAs disclosed. The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and <em style="font: inherit;">not</em> apply a <em style="font: inherit;">zero</em> rate to NOL carryforwards expected to expire unutilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In review of the Company&#8217;s consolidated deferred position, excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and <em style="font: inherit;">not</em> utilized against a net DTL.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The provision for income taxes consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total current tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,768</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,768</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Income tax expense&#160;resulting from applying statutory rates in jurisdictions in which the Company is taxed (federal and various states) differs from the income tax expense&#160;in the financial statements. A reconciliation of the United States&#160;federal statutory income tax rates to the Company&#8217;s effective tax rate is as follows.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30,</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">2024</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">2023</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands, except tax rate)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(193</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,447</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(38.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,087</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net income tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,768</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(12.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences, which comprise the deferred tax assets and liabilities, are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net operating loss carry forward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,170</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,845</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,188</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued rebates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,994</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant derivatives</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,061</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,504</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,027</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">758</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Section 174 capitalization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">780</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">138,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Less: valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(137,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(135,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax assets, net of valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangibles</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(845</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">ROU asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company has recorded a valuation allowance of $137.3&#160;million and $136.0&#160;million at <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively, to reserve its net DTAs. In assessing the realizability of DTAs, management considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of the DTAs&#160;will <em style="font: inherit;">not</em> be realized. The ultimate realization of DTAs&#160;is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than <em style="font: inherit;">not</em>&#160;that it will realize the benefits of these deductible differences, net of the valuation allowance provided.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has <em style="font: inherit;">no</em> accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company&#8217;s NOL, interest expense carryover or research and development credit carryover and therefore do <em style="font: inherit;">not</em> require recognition. As a result of these timing differences, at <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company had gross unrecognized tax benefits related to uncertain tax positions of $1.3&#160;million and $2.9&#160;million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A tabular roll-forward of the Company&#8217;s gross unrecognized tax benefit related to uncertain tax positions&#160;is below.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Beginning balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,948</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease resulting from current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase resulting from current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">361</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Ending balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,948</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The change in the Company&#8217;s gross unrecognized tax benefits relates to filed method changes with the IRS for the tax return year ending <em style="font: inherit;"> June 30, 2023. </em>Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to <em style="font: inherit;">2005</em> being subject to examination</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388973328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">14</em> - Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company had 5,972,638 and 5,517,174&#160;common shares issued and outstanding, respectively, and no preferred shares issued and outstanding. As of <em style="font: inherit;"> June 30, 2024, </em>included in common stock outstanding are 25,360 shares of unvested restricted stock issued to executives, directors and employees.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 8, 2020, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was declared effective by the SEC on <em style="font: inherit;"> June 17, 2020. </em>This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units. On <em style="font: inherit;"> June 4, 2021, </em>the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the <em style="font: inherit;">2020</em> Shelf (the &#8220;ATM Sales Agreement&#8221;). During the year ended <em style="font: inherit;"> June 30, 2023, </em>the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of&#160;$2.9 million. The <em style="font: inherit;">2020</em> Shelf expired in <em style="font: inherit;"> June 2023 </em>and the ATM Agreement was terminated in <em style="font: inherit;"> July 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> September 28, 2021, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was declared effective by the SEC on <em style="font: inherit;"> October 7, 2021. </em>This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style="font: inherit;">&#8220;2021</em> Shelf&#8221;). As of <em style="font: inherit;"> June 30, 2024, </em>$82.4 million remained available under the <em style="font: inherit;">2021</em> Shelf. This availability is subject to SEC <em style="font: inherit;">1.B.6</em> limitation to the Form S-<em style="font: inherit;">3.</em>&#160;The <em style="font: inherit;">2021</em> Shelf expires in <em style="font: inherit;"> October 2024. </em>Given the upcoming expiration of the <em style="font: inherit;">2021</em> Shelf, concurrent with the filing of this Form <em style="font: inherit;">10</em>-K the Company&#160;expects to file&#160;a new shelf registration statement to cover the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the <em style="font: inherit;">&#8220;2024</em> Shelf&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an underwritten public offering utilizing the <em style="font: inherit;">2021</em> Shelf, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants to purchase up to 333,300 shares of common stock (the <em style="font: inherit;"> &#8220;March 2022 </em>Offering&#8221;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <em style="font: inherit;">one</em> common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in <em style="font: inherit;"> April 2022. </em>The common warrants have an exercise price of $26.00 per share of common stock and are exercisable <em style="font: inherit;">six</em> months after the date of issuance and have a term of <span style="-sec-ix-hidden:c117048288">five</span> years from the date of exercisability. The Company raised gross proceeds of $7.6 million through the <em style="font: inherit;"> March 2022 </em>Offering before commission and other costs of $0.8 million. The pre-funded and common warrants have a combined fair value of approximately $2.8 million at issuance and are classified as&#160;derivative warrant liabilities with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (see <i>Note <em style="font: inherit;">16</em> - Warrants</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> August 11, 2022, </em>the Company closed on an underwritten public offering (the <em style="font: inherit;"> &#8220;August 2022 </em>Offering&#8221;) utilizing the <em style="font: inherit;">2021</em> Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <span style="-sec-ix-hidden:c117048297">one</span> common warrant to purchase <em style="font: inherit;">one</em> share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in <em style="font: inherit;"> August 2022. </em>The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of <span style="-sec-ix-hidden:c117048303">five</span> years from issuance. The Company raised $10.0 million in gross proceeds through the <em style="font: inherit;"> August 2022 </em>Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants had a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (see <i>Note <em style="font: inherit;">16</em> - Warrants</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 8, 2023, </em>using a placement agent, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company&#8217;s common stock; (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the <em style="font: inherit;"> &#8220;June 2023 </em>Pre-Funded Warrants&#8221;); (iii) accompanying tranche A&#160;warrants to purchase 2,173,912 shares of common stock (the &#8220;Tranche A Warrants&#8221;); and (iv) accompanying tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the &#8220;Tranche B&#160;Warrants&#8221;&#160;and the&#160;Tranche A Warrants together with the Tranche B Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants <em style="font: inherit;"> may </em>be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants (the &#8220;Exchange Warrants&#8221;). Each pre-funded warrant is exercisable for <span style="-sec-ix-hidden:c117048313">one</span> share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <span style="-sec-ix-hidden:c117048317">five</span> years after the date of issuance or (ii) <em style="font: inherit;">30</em> days following the closing price of the Company&#8217;s common stock equaling <em style="font: inherit;">200%</em> of the exercise price ($3.18 per share) for at least <em style="font: inherit;">40</em> consecutive trading days. The Tranche B Warrants were exercised in <em style="font: inherit;"> June 2024 </em>as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants do <em style="font: inherit;">not</em> have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain&#160;along with the issuance costs of $0.6 million in the consolidated financial statement of operations (see <i>Note <em style="font: inherit;">16</em> - Warrants</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 14, 2024, </em>the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 pre-funded&#160;warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the &#8220;Tranche B Pre-Funded Warrants&#8221;). The Tranche B Pre-Funded Warrants had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#8217;&#160;equity in the Company&#8217;s consolidated financial statements. The Company&#160;used a portion of the&#160;proceeds from the Tranche B Warrants exercise&#160;as part of the Avenue Capital loan&#160;repayment described further in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389946384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">15</em> - Equity Incentive Plans</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b><em style="font: inherit;">2023</em> Equity Incentive Plan</b></i><br/> &#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> May 18, 2023, </em>the Company&#8217;s stockholders approved the Aytu BioPharma, Inc. <em style="font: inherit;">2023</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2023</em> Equity Incentive Plan&#8221;). Prior to the Company&#8217;s adoption of the <em style="font: inherit;">2023</em> Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. <em style="font: inherit;">2015</em> Stock Option and Incentive Plan (the &#8220;Aytu <em style="font: inherit;">2015</em> Plan&#8221;) and the Neos Therapeutics, Inc. <em style="font: inherit;">2015</em> Stock Options and Incentive Plan (the &#8220;Neos <em style="font: inherit;">2015</em> Plan&#8221;, and collectively with the Aytu <em style="font: inherit;">2015</em> Plan, the <em style="font: inherit;">&#8220;2015</em> Plans&#8221;). For the <em style="font: inherit;">2023</em> Equity Incentive Plan, the stockholders approved (i) 200,000 new shares; (ii) 87,129 shares available for grant under the <em style="font: inherit;">2015</em> Plans be &#8220;rolled over&#8221; to the <em style="font: inherit;">2023</em> Equity Incentive Plan; and (iii) any shares that are returned to the Company under the <em style="font: inherit;">2015</em> Plans be added to the <em style="font: inherit;">2023</em> Equity Incentive Plan. With the approval of the <em style="font: inherit;">2023</em> Equity Incentive Plan, <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2015</em> Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the <em style="font: inherit;">2023</em> Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of <em style="font: inherit;"> June 30, 2024</em>, the Company had 182,322&#160;shares that are available for grant under the <em style="font: inherit;">2023</em> Equity Incentive Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Aytu <em style="font: inherit;">2015</em> Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2015,</em> the Company&#8217;s stockholders approved the Aytu <em style="font: inherit;">2015</em> Plan, which, as amended in <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">2017,</em> provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">13,</em> <em style="font: inherit;">2020,</em> the Company&#8217;s stockholders approved an increase to 250,000 total shares of common stock in the Aytu <em style="font: inherit;">2015</em> Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu <em style="font: inherit;">2015</em> Plan will be added back to the shares of common stock available for issuance under the <em style="font: inherit;">2023</em> Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Neos <em style="font: inherit;">2015</em> Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos <em style="font: inherit;">2015</em> Plan. Accordingly, on <em style="font: inherit;"> April 19, 2021, </em>the Company registered 5,272 shares of its common stock under the Neos <em style="font: inherit;">2015</em> Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos <em style="font: inherit;">2015</em> Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Stock Options</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> June 30, 2024</em>, 113,500&#160;stock options were granted. The weighted-average grant date fair value of options granted during the year ended <em style="font: inherit;"> June 30, 2024</em>, was $1.74. During the year ended&#160;<em style="font: inherit;"> June 30, 2024</em>, there was $0.2&#160;million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#8217;s equity incentive plan. During the fiscal year ended <em style="font: inherit;"> June 30, 2023, </em>49,212 stock options were granted. The weighted-average grant date fair value of options granted during the year ended <em style="font: inherit;"> June 30, 2023, </em>was $4.00. During the year ended&#160;<em style="font: inherit;"> June 30, 2023, </em>there was $0.1 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stock option activity is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">113,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">9.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(16,610</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(3,113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">66.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table details the options outstanding at <em style="font: inherit;"> June 30, 2024</em>, by range of exercise prices:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Prices</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="2" rowspan="1" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c117050812">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">102,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="2" rowspan="1" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c117050820">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">$4.00 - $290.00</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="-sec-ix-hidden:c117050827">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c117050829">&#160;</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,039</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">225.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">225.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restricted Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company granted a total of 12,500 shares of restricted stock, with certain accelerated vesting conditions, to members of its non-employee directors pursuant to the <em style="font: inherit;">2023</em> Equity Incentive Plan, of which <span style="-sec-ix-hidden:c117048402">1/3</span> vest on the grant date and <span style="-sec-ix-hidden:c117048403">1/12</span> on the <em style="font: inherit;">first</em> day of each quarter thereafter, subject to continuing service to the Company through each vesting date. These restricted stock grants have a weighted average grant date fair value of $1.77 per share.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> June 30, 2023, </em>as a result of the change in members of the Company&#8217;s board, the Company accelerated unvested shares for <em style="font: inherit;">two</em> former members and recorded $1.5 million of non-cash equity compensation expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> December 19, 2022, </em>the Company entered into a stipulation of compromise and settlement (the &#8220;Stipulation&#8221;). As a part of the terms of the Stipulation, the Company agreed to rescind 25% of the aggregate <em style="font: inherit;">2021</em> grants to board members. As a result of the recission of the shares, the Company recorded $0.6 million in non-cash compensation during the year ended <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> June 30, 2023, </em>the Company granted a total of 6,825 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu <em style="font: inherit;">2015</em> Plan, of which <span style="-sec-ix-hidden:c117048413">1/3</span> vest on the grant date and <span style="-sec-ix-hidden:c117048414">1/12</span> on the <em style="font: inherit;">first</em> day of each quarter thereafter, subject to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $3.31 per-share to $13.4 per-share.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Restricted stock activity under the <em style="font: inherit;">2023</em> Equity Incentive Plan&#160;is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">142.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(25,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">113.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">147.15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, there was $1.0&#160;million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.5&#160;years. The total fair value of restricted stock vested during the year ended <em style="font: inherit;"> June 30, 2024</em>, was $0.1&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company previously issued 4 shares of restricted stock outside of the Aytu <em style="font: inherit;">2015</em> Plan, which vest in <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">2026.</em> On <em style="font: inherit;"> January 17, 2022, </em>the Company granted 5,000 shares of restricted stock to a member of its management team outside of the Aytu <em style="font: inherit;">2015</em> Plan, of which <span style="-sec-ix-hidden:c117048427">1/3</span> vest on <em style="font: inherit;"> January 17, 2023, </em>and <span style="-sec-ix-hidden:c117048428">1/12</span> each quarter thereafter, subject to continuing employment with the Company through each vesting date until <em style="font: inherit;"> January 17, 2025. </em>This restricted stock grant has a grant date fair value of $27.00 per share. As of <em style="font: inherit;"> June 30, 2024</em>, there was $0.2&#160;million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.6&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Restricted Stock Units</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the years ended <em style="font: inherit;"> June 30, 2024</em>, and <em style="font: inherit;">2023,</em> the Company did <span style="-sec-ix-hidden:c117048434"><span style="-sec-ix-hidden:c117048435">not</span></span> grant restricted stock units (&#8220;RSU&#8221;). RSU activity is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,249</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">24.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">31.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> June 30, 2024</em>, there was no material unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company&#8217;s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.7&#160;years. The total fair value of RSUs vested during the year ended <em style="font: inherit;"> June 30, 2024</em>, was immaterial.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,905</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,965</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388937888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_WarrantsOrRightsDisclosureTextBlock', window );">Warrants or Rights Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">16</em> - Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Liability Classified Warrants</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 8, 2023, </em>using a placement agent, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company&#8217;s common stock; (ii) <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants in lieu of shares to purchase 430,217 shares of common stock; (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock; and (iv) accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche A Warrants together with the Tranche B Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants <em style="font: inherit;"> may </em>be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants (the &#8220;Exchange Warrants&#8221;). Each pre-funded warrant is exercisable for <span style="-sec-ix-hidden:c117048560">one</span> share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <span style="-sec-ix-hidden:c117048564">five</span> years after the date of issuance or (ii) <em style="font: inherit;">30</em> days following the closing price of the Company&#8217;s common stock equaling <em style="font: inherit;">200%</em> of the exercise price ($3.18 per share) for at least <em style="font: inherit;">40</em> consecutive trading days. The Tranche B Warrants were exercised in <em style="font: inherit;"> June 2024 </em>as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants do <em style="font: inherit;">not</em> have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain along with the issuance costs of $0.6 million in the consolidated financial statement of operations&#160;(see <i>Note <em style="font: inherit;">14</em>&#160;- Stockholders&#8217; Equity</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 14, 2024, </em>the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 Tranche B Pre-Funded Warrants to purchase shares of common stock with an exercise price of $0.0001 per share. The Tranche B Pre-Funded Warrants, which do <em style="font: inherit;">not</em> have an expiration date, had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements. The Company used a portion of the proceeds from the Tranche B Warrants exercise as part of the Avenue Capital loan repayment described further in <i>Note <em style="font: inherit;">11</em> - Long-Term Debt</i>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> August 11, 2022, </em>the Company closed on the <em style="font: inherit;"> August 2022 </em>Offering, pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which <em style="font: inherit;">one</em> common warrant to purchase <span style="-sec-ix-hidden:c117048586">one</span> share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in <em style="font: inherit;"> August 2022. </em>The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of <span style="-sec-ix-hidden:c117048589">five</span> years from issuance. The common warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a &#8220;Stock Combination Event&#8221;), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (<em style="font: inherit;">x</em>) the sum of the VWAP of the common stock for each of the <em style="font: inherit;">five</em> lowest trading days during the <em style="font: inherit;">20</em> consecutive trading day period ending immediately preceding the <em style="font: inherit;">16th</em> trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the <em style="font: inherit;">second</em> anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see <i>Note <em style="font: inherit;">14</em> - Stockholders&#8217; Equity</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> November 2022 </em>and throughout the quarter ended <em style="font: inherit;"> December 31, 2022, </em>the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the <em style="font: inherit;"> August 2022 </em>Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the associated common warrants exercise price was adjusted to $3.30. On <em style="font: inherit;"> January 6, 2023, </em>the Company consummated a 20 to <em style="font: inherit;">1</em> reverse stock split. Pursuant to the aforementioned warrant agreement, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest <em style="font: inherit;">five</em> trading days during the <em style="font: inherit;">twenty</em>-day consecutive trading day period beginning on <em style="font: inherit;"> December 30, 2022. </em>Subsequently, as a result of the Securities Purchase Agreement in <em style="font: inherit;"> June 2023, </em>the common warrants from the <em style="font: inherit;"> August 2022 </em>Offering had an adjusted exercise price of $2.32.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> March 7, 2022, </em>the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common warrants to purchase up to 333,300 shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <em style="font: inherit;">one</em> common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in <em style="font: inherit;"> April 2022. </em>The common warrants have an exercise price of $26.00 per share of common stock and are exercisable <em style="font: inherit;">six</em> months after the date of issuance and have a term of <span style="-sec-ix-hidden:c117048614">five</span> years from the date of exercisability (see <i>Note <em style="font: inherit;">14</em> - Stockholders&#8217; Equity</i>).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> January 26, 2022, </em>as consideration for entering into the Avenue Capital Agreement as described in <i>Note <em style="font: inherit;">11</em> &#8211; Long-Term Debt</i>, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to <em style="font: inherit;"> June 30, 2022, </em>the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on <em style="font: inherit;"> January 31, 2027. </em>At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was <em style="font: inherit;">not</em> fixed at the issuance (see <i>Note <em style="font: inherit;">11</em> &#8211; Long-Term Debt</i> for further details).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Outstanding warrants that are classified as derivative warrant liabilities in the consolidated balance sheets&#160;are marked to market at each reporting period (see <i>Note <em style="font: inherit;">12</em> &#8211; Fair Value Considerations</i>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A summary of warrants is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life in Years <sup style="vertical-align:top;line-height:120%;">(4)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding June 30, 2023 <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,538,052</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants issued <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">1,806,434</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">0.0001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(2,247,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(20,958</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">300.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding June 30, 2024 <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,075,880</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The number of warrants outstanding as of <em style="font: inherit;"> June 30, 2023, </em>is comprised of 6,068,763 liability classified warrants, 430,217 liability classified <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants and 39,072 equity classified warrants.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">2</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The warrants issued during fiscal <em style="font: inherit;">2024</em> were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">3</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The number of warrants outstanding as of <em style="font: inherit;"> June 30, 2024, </em>is comprised of 3,821,115 liability classified warrants, 430,217 liability classified <em style="font: inherit;"> June 2023 </em>Pre-Funded Warrants, 1,806,434&#160;liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">4</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As pre-funded warrants do <em style="font: inherit;">not</em> have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.</p> </td></tr>
</tbody></table>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsOrRightsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsOrRightsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388773104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Restructuring Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Related Activities Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">17</em> - Restructuring Costs</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As part of the Company&#8217;s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site (Rx Segment), the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations and expense associated with inventory write-downs&#160;is recorded in cost of sales in the consolidated statements of operations. The Company does <em style="font: inherit;">not</em> expect to incur&#160;any additional significant restructuring costs related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site during fiscal <em style="font: inherit;">2025.</em> As of <em style="font: inherit;"> June 30, 2024, </em>the Company did <em style="font: inherit;">not</em> have any material accruals related to the wind down of the Consumer Health Segment. As of <em style="font: inherit;"> June 30, 2024, </em>the Company had accrued $0.9 million and $0.4 million related to accrued severance and employee benefits&#160;and accrued exit and disposal activity costs, respectively, related to the closure of the Grand Prairie, Texas manufacturing facility.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">A summary of restructuring costs incurred during the year ended <em style="font: inherit;"> June 30, 2024, </em>is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30, 2024</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Severance and Employee Benefits <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exit and Disposal Activities <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inventory Write-Down <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Wind down of Consumer Health Segment <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closure of Grand Prairie, Texas manufacturing site <sup style="vertical-align:top;line-height:120%;">(4)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,031</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">2</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">3</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">4</em>)</sup>&#160;</p> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.</p> </td></tr>
</tbody></table> &#160;&#160;
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389921776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">18</em> - Commitments and Contingencies</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Pediatric Portfolio Fixed Payments and Product Milestone</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company assumed two fixed, periodic payment obligations to an investor (the &#8220;Fixed Obligation&#8221;). Under the <em style="font: inherit;">first</em> fixed obligation, the Company was to pay a monthly payment of $0.1 million beginning <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2019,</em> through <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2021,</em> with a balloon payment of $15.0 million that was to be due in <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2021</em> (&#8220;Balloon Payment Obligation&#8221;). A <em style="font: inherit;">second</em> fixed obligation required the Company pay a minimum of $0.1 million&#160;monthly through <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">2026,</em> except for $0.2 million paid in <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">29,</em> <em style="font: inherit;">2020,</em> the Company entered into an early payment agreement and escrow instruction (the &#8220;Early Payment Agreement&#8221;) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the waiver or the investor agreement other than as expressly set forth therein. The <em style="font: inherit;">first</em> fixed obligation was fully paid as of <em style="font: inherit;"> January 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> June 21, 2021, </em>the Company entered into a waiver, release and consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the <em style="font: inherit;">second</em> fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in <em style="font: inherit;">six</em> equal quarterly payments of $0.5 million over the next <em style="font: inherit;">six</em> quarters commencing <em style="font: inherit;"> September 30, 2021. </em>The Company accounted for the waiver, release and consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by <em style="font: inherit;"> January 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company acquired the Tris Karbinal Agreement, under which the Company is granted the exclusive right to distribute and sell Karbinal&#160;in the United States. The initial term of the agreement was&#160;20&#160;years. The Company pays&#160;Tris a royalty equal to&#160;23.5% of net revenue&#160;from&#160;the product.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from <em style="font: inherit;"> August 1 </em>through <em style="font: inherit;"> July 31, </em>of 70,000 units annually through <em style="font: inherit;">2025.</em> The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the <em style="font: inherit;">70,000</em>-unit annual minimum sales commitment through <em style="font: inherit;">2025.</em> The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in <em style="font: inherit;"> August </em>of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">first</em> of which is triggered at $40.0 million. As of <em style="font: inherit;"> June 30, 2024, </em>the fixed payment arrangement balance was $1.9 million in other current liabilities, and $0.2 million in other non-current liabilities on the consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Operating Lease</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2024, </em>the Company entered into a forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;from the owner of the office space that the Company is&#160;currently renting under a sublease arrangement. The Company has determined that it is an operating lease, and that lease commencement occurred in <em style="font: inherit;"> July 2024. </em>The&#160;initial is from <em style="font: inherit;"> March 1, 2025, </em>through <em style="font: inherit;"> July 31, 2030, </em>and under the lease agreement the Company has <span style="-sec-ix-hidden:c117048743">one five</span>-year renewal option to extend the lease through <em style="font: inherit;"> July 2035.&#160;</em>Undiscounted minimum monthly rent payments average approximately $13,000&#160;over the initial term of the lease.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> May 2023, </em>the Company entered into an operating lease agreement to relocate its principal office from Englewood, Colorado to&#160;Denver, Colorado. The lease has a commencement date of <em style="font: inherit;"> October 1, 2023, </em>with an initial term of <span style="-sec-ix-hidden:c117048746">five</span> and a half years. Undiscounted minimum monthly rent payments average approximately $15,500 over the initial term of the lease. Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has <span style="-sec-ix-hidden:c117048749">one five</span>-year renewal option through <em style="font: inherit;"> March 2034.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Legal Matters</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Witmer Class-Action Securities Litigation</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A stockholder derivative suit was filed on <em style="font: inherit;">September12,</em> <em style="font: inherit;">2022,</em> in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#8217;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on <em style="font: inherit;"> April 5, 2023. </em>The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in <em style="font: inherit;">2019</em> and Innovus in <em style="font: inherit;">2020</em> to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants&#8217; breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees. While the Company believes&#160;that this lawsuit is without merit and have vigorously defended against it, the Company&#160;agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#8217;s attorneys&#8217; fees. That settlement is subject to court approval, the hearing on which has <em style="font: inherit;">not</em> yet been scheduled.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#8203;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Sabby Litigation</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A complaint was filed on <em style="font: inherit;"> February 22, 2023, </em>in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#8220;Sabby&#8221;) and Walleye Opportunities Master Fund Ltd (&#8220;Walleye&#8221;), holders of certain warrants to purchase common stock, against the Company. The complaint alleged&#160;that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders <em style="font: inherit;"> may </em>receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint sought&#160;a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In&#160;<em style="font: inherit;"> October 2023,&#160;</em>the Company entered into a settlement agreement and general release with Sabby and Walleye.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Stein Litigation</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cielo Stein (&#8220;Stein&#8221;), a former sales specialist, filed a complaint on <em style="font: inherit;"> February 1, 2023, </em>in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos. The complaint alleged&#160;that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleged&#160;that the Company&#8217;s response to Stein&#8217;s subsequent complaint to human resources was inadequate. The complaint sought&#160;an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#8217; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky. A Section&#160;<em style="font: inherit;">16</em>&#160;pretrial conference was held on&#160;<em style="font: inherit;"> June 3, 2024.&#160;</em>During the pretrial conference the parties agreed to settle the matter. The parties entered into a settlement and release agreement on <em style="font: inherit;"> August 5, 2024. </em>The&#160;matter has been closed.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389920720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicensingAgreementsTextBlock', window );">Licensing Agreements [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">19</em> - License Agreements</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Healight</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> April 2020, </em>the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, <em style="font: inherit;">ten</em> years after the <em style="font: inherit;">first</em> bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency.&#160;Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and $0.1 million in earlier patent prosecution fees.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of the Company&#8217;s focus on the revenue growth of its commercial business, the Company&#160;terminated the licensing agreement with Cedars-Sinai Medical Center, effective <em style="font: inherit;"> May 9, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>NeuRx</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> October 2018, </em>Neos entered into an exclusive license agreement (&#8220;NeuRx License&#8221;) with NeuRx Pharmaceuticals LLC (&#8220;NeuRx&#8221;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture&#160;and commercialize certain pharmaceutical products containing NeuRx&#8217;s proprietary compound designated as NRX-<em style="font: inherit;">101,</em> referred to by Neos as <em style="font: inherit;">NT0502.</em> <em style="font: inherit;">NT0502</em> is a new chemical entity that was&#160;being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company <em style="font: inherit;"> may </em>be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the <em style="font: inherit;">first</em> commercial sale of such licensed product in such country and continuing until the later of: (i)&#160;the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii)&#160;expiration of regulatory exclusivity of such licensed product in such country.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> April 2023, </em>the Company returned the <em style="font: inherit;">NT0502</em> rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on <em style="font: inherit;">NT0502.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Teva</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> December 21, 2018, </em>the Company&#160;and Teva&#160;entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under an&#160;abbreviated new drug application&#160;(&#8220;ANDA&#8221;)&#160;filed by Teva beginning on <em style="font: inherit;"> July 1, 2026, </em>or earlier under certain circumstances. The ANDA was approved by the FDA on <em style="font: inherit;"> June 19, 2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Actavis</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> October 17, 2017, </em>the Company entered into an agreement granting Actavis a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on <em style="font: inherit;"> September 1, 2025, </em>or earlier under certain circumstances. The ANDA was approved by the FDA on <em style="font: inherit;"> June 22, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Shire</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> July 2014, </em>Neos entered into a settlement agreement and an associated license agreement (the <em style="font: inherit;">&#8220;2014</em> License Agreement&#8221;) with Shire LLC (&#8220;Shire&#8221;) for a non-exclusive license to certain patents for certain activities with respect to Neos&#8217; New Drug Application (the &#8220;NDA&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">204326</em> for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the <em style="font: inherit;">2014</em> License Agreement, following the receipt of the approval from the FDA for Adzenys, Neos paid a lump sum, non-refundable license fee of an amount less than $1.0 million in <em style="font: inherit;"> February 2016. </em>Neos is paying a single digit royalty on net sales of Adzenys&#160;during the life of the patents. The settlement agreement expired&#160;in <em style="font: inherit;"> May 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicensingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicensingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387675056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">20</em> - Segment Information</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s CODM,&#160;who is the Company&#8217;s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company manages and aggregates its operational and financial information in accordance with <span style="-sec-ix-hidden:c117048787">two</span> reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company&#8217;s prescription products. The Consumer Health Segment contained&#160;the Company&#8217;s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does <em style="font: inherit;">not</em> regularly review asset information by segment, accordingly, asset information is <em style="font: inherit;">not</em> provided by segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Select financial information for these segments is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Year Ended June 30, 2024</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">65,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">81,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(3,664</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,547</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,456</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">540</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">209</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Year Ended June 30, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">73,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">33,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">107,399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(7,358</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(9,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(17,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,271</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,722</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,705</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    &#160;&#160;
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389942640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 21 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Note <em style="font: inherit;">21</em>&#160;- Subsequent Events</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wind Down and Subsequent Divestiture of Consumer Health Business</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> July 2024, </em>the Company&#160;completed the wind down of its&#160;Consumer Health Segment and on <em style="font: inherit;"> July 31, 2024, </em>the Company&#160;entered into a definitive agreement to divest its&#160;Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company affiliated with the Company&#8217;s&#160;former Vice President of Consumer Health, Jonathan Hughes. Pursuant to the definitive agreement, Mr. Hughes resigned from the Company effective <em style="font: inherit;"> July 31, 2024. </em>The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for the Company&#160;to receive up to $0.5 million of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products. Upon consummation of this agreement, the Company has&#160;completed its&#160;wind down of the Consumer Health Segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390167456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arr Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390000464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Principals of Consolidation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial statements&#160;and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Basis of Presentation</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s consolidated financial statements&#160;and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;)</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_GoingConcernPolicyTextBlock', window );">Going Concern [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Going Concern Determination</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the financial statements are available to be issued. The evaluation is based on relevant conditions and events that are known and reasonably knowable within <em style="font: inherit;">one</em> year after the date that the financial statements are available to be&#160;issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends. See&#160;<i>Note <em style="font: inherit;">1</em>&#160;&#8211; Nature of Business and Financial Condition</i>&#160;for further detail on the evaluation performed by the Company.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results <em style="font: inherit;"> may </em>differ from estimates. In the accompanying consolidated financial statements and notes thereto, estimates are used for, but <em style="font: inherit;">not</em> limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Prior Period Reclassification</i></b><i>. </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Certain prior year amounts in the Company&#8217;s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did <em style="font: inherit;">not</em> impact operating results or cash flows for the fiscal years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> or its financial position as of <em style="font: inherit;"> June 30, 2024</em>, or <em style="font: inherit;"> June 30, 2023</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Previously Reported Prepaid Expenses Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the year ended <em style="font: inherit;"> June 30, 2024, </em>the Company identified that certain of the Company&#8217;s prepaid expenses totaling $1.8 million that were previously reported as current assets as of <em style="font: inherit;"> June 30, 2023, </em>should have been classified as non-current assets as of <em style="font: inherit;"> June 30, 2023. </em>The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99,</em> &#8220;Materiality&#8221; and concluded that the omission was <em style="font: inherit;">not</em> material to any of the previously issued consolidated financial statements and began reporting the prepaid expenses as non-current within this Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Cash and Cash Equivalents</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)&#160;insurance limits, and cash balances in the money market funds are <em style="font: inherit;">not</em> FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Accounts Receivable, Net</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company&#8217;s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company&#8217;s customers&#8217; financial condition;&#160;payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers&#160;and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts&#160;which were previously written off are&#160;recorded as a reduction of bad debt expense in the period the payment is collected. If the Company&#8217;s actual collection experience changes, revisions to the&#160;Company&#8217;s allowance for credit losses <em style="font: inherit;"> may </em>be required. After attempts to collect a receivable have failed, the receivable is written off against the allowance for credit losses. The allowance for credit losses&#160;was <span style="-sec-ix-hidden:c117047150"><span style="-sec-ix-hidden:c117047154">zero</span></span> for both years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em> The allowance for discounts was $0.6&#160;million and $1.8&#160;million as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> respectively. The allowance for chargebacks was $1.2&#160;million at both&#160;<em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below presents the opening and closing balances of accounts receivable, gross&#160;from customers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accounts Receivable, Gross</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,708</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">31,927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below details the change in allowance for discounts&#160;and allowance for chargebacks for the periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt; width: 55%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Discounts</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Chargebacks</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Total Allowance</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2022</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,206</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2,507</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">9,074</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">4,554</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">13,628</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,597</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,548</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,145</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2023</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,778</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,212</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2,990</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">4,886</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">3,812</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">8,698</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,024</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,842</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,866</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2024</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">640</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,182</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,822</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Inventories</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are <em style="font: inherit;">no</em> alternate uses for the inventory, the Company will record a charge to cost of sales to reduce the value of the inventory to net realizable value in the period the impairment is identified.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally <span style="-sec-ix-hidden:c117047191">two</span> to <span style="-sec-ix-hidden:c117047194">seven</span> years. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Leases</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#8220;ROU&#8221;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is <em style="font: inherit;">not</em> readily determinable based upon the information available at the lease commencement date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#8217;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#8217;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of <em style="font: inherit;">12</em> months or less.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operating leases are included in other liabilities in the Company&#8217;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of&#160;debt and debt, net of current portion in the Company&#8217;s consolidated balance sheets.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Acquisitions</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do <em style="font: inherit;">not</em> meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does <em style="font: inherit;">not</em> result in goodwill.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Warrants</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Revenue Recognition</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company generates revenue from product sales through its Rx Segment&#160;and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following <em style="font: inherit;">five</em>-step model: (<em style="font: inherit;">1</em>)&#160;identify the contract with the customer; (<em style="font: inherit;">2</em>)&#160;identify the performance obligations; (<em style="font: inherit;">3</em>)&#160;determine the transaction price; (<em style="font: inherit;">4</em>)&#160;allocate the transaction price to the performance obligations; and (<em style="font: inherit;">5</em>)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is <em style="font: inherit;">not</em> a recognized financing component related to product sales.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rx Segment</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms.&#160;The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within <em style="font: inherit;">one</em>&#160;year.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Rx Segment net&#160;revenue is recognized net of consideration paid to the Company&#8217;s customers and other adjustments to the transaction price (known as &#8220;Gross to Net&#8221; adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Gross to Net adjustments include:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Savings offers.</i>&#160;The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Prompt payment discounts.</i>&#160;Prompt payment discounts are based on standard provisions of wholesalers&#8217;&#160;services.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesale distribution fees.&#160;</i>Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rebates.&#160;</i>The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from <em style="font: inherit;">third</em>-party providers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Wholesaler chargebacks.</i>&#160;The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217;&#160;end customers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Returns.</i>&#160;Wholesalers&#8217;&#160;contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting <em style="font: inherit;">six</em> months prior to expiry date to <em style="font: inherit;">twelve</em> months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which <em style="font: inherit;"> may </em>vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> follow historical trends. The Company&#8217;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do <em style="font: inherit;">not</em> believe variances between actual and estimated amounts have been material.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Consumer Health Segment</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Consumer Health Segment, which was divested of&#160;in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2025,</em> had net revenue which was from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue was&#160;generally recognized &#8220;free-on-board&#8221; shipping point, as those were&#160;the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer were&#160;excluded from net revenue. Shipping and handling costs associated with outbound freight after control over a product had&#160;transferred to a customer were accounted for as a fulfillment cost and were&#160;included in cost of sales.&#160;The Company expensed&#160;the incremental costs to obtain a contract as incurred, since they are satisfied within <em style="font: inherit;">one</em>&#160;year.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Concentration of Credit Risk</i></b><i>. </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is <em style="font: inherit;">not</em> exposed to significant credit risk due to the financial position of those institutions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#8217;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#8217;s products to retailers. The loss of <em style="font: inherit;">one</em> or more of these large customers could have a material adverse effect on the Company&#8217;s business, operating results or financial condition. The Company does <em style="font: inherit;">not</em> charge interest or require collateral related to its accounts receivable. Credit terms are generally <span style="-sec-ix-hidden:c117047243">thirty</span>&#160;to <span style="-sec-ix-hidden:c117047245">sixty</span> days.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table presents customers that contributed more than <em style="font: inherit;">10%</em> of gross revenue and accounts receivable<i>: </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Gross Revenue</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Accounts Receivable</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer A</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer B</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer C</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Costs of Sales</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Costs of sales consists primarily of manufactured product cost, products acquired from <em style="font: inherit;">third</em>-party manufacturers, freight, production, inventory write-downs,&#160;indirect manufacturing overhead costs and United States Food and Drug Administration&#160;(&#8220;FDA&#8221;) fees for commercialized products. Certain of the Company&#8217;s sales activities depend on licensing arrangements that <em style="font: inherit;"> may </em>require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company&#8217;s <em style="font: inherit;">third</em>-party logistics companies are included in costs of sales.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company accounts for stock-based payment&#160;compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#8217;s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#8220;simplified method,&#8221; which is the midpoint between the vesting date and the end of the contractual term and is&#160;utilized&#160;by the Company as it does <em style="font: inherit;">not</em> have sufficient historical data to determine a more reliable expected term estimate. The risk-free interest rate is based on the United States&#160;Treasury yield in effect at the time of the grant for the expected term of the award. The Company does <em style="font: inherit;">not</em>&#160;anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Pension and Other Postretirement Plans, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Employee Benefits Plan</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company&#160;has a <em style="font: inherit;">401</em>(k)&#160;plan&#160;(&#8220;Aytu <em style="font: inherit;">401</em>(k) Plan&#8221;), which&#160;allows participants to contribute a portion of their salary, subject to eligibility requirements and annual Internal Revenue Service (&#8220;IRS&#8221;) limits.&#160;The Aytu <em style="font: inherit;">401</em>(k) Plan&#160;matches 100% of the <em style="font: inherit;">first</em> 3% contributed by employees and matches 50% of the next 4% and 5% contributed by employees. The Company&#8217;s match for the Aytu <em style="font: inherit;">401</em>(k) Plan was $0.7&#160;million for both of the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Research and Development</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Research and development costs are expensed as incurred and include salaries and benefits;&#160;facilities costs;&#160;overhead costs;&#160;raw materials;&#160;laboratory and clinical supplies;&#160;clinical trial costs;&#160;contract services;&#160;milestone payments and fees paid to regulatory authorities for review and approval of the Company&#8217;s product candidates;&#160;and other related costs.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are <em style="font: inherit;">not</em> subject to amortization.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Impairment of Long-lived Assets</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are <em style="font: inherit;">not</em> limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; or (iv)&#160;expectations that the asset will more likely than <em style="font: inherit;">not</em> be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock', window );">Business Combinations, Contingent Consideration [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Contingent Consideration</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The consideration for the Company's&#160;acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of <span style="-sec-ix-hidden:c117047278">zero</span> and $1.0 million for the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023,</em> respectively. The Company did <em style="font: inherit;">not</em> have any contingent consideration recorded on its consolidated balance sheets as of <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Advertising and Direct Marketing Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Advertising and direct marketing costs consist&#160;of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $4.9&#160;million and $17.2&#160;million of advertising costs for the&#160;years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Income Taxes</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the&#160;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than <em style="font: inherit;">not</em> that some portion or all of its deferred tax asset will <em style="font: inherit;">not</em> be utilized.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em>&#160;to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Debt Discount and Issuance Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Debt issuance costs reflect fees paid to lenders and <em style="font: inherit;">third</em> parties directly related to issuing debt. Debt discount&#160;and issuance costs related to term loans are reported as direct deductions&#160;to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition to interest expense. Debt issuance costs related to a revolving credit facility are classified as assets and subsequently amortized using the straight-line method over the term of the revolving credit facility as additional interest expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Segment Information</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company&#8217;s operating segments engage in business activities from which it <em style="font: inherit;"> may </em>earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Company&#8217;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#8217;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has <span style="-sec-ix-hidden:c117047295">two</span> reportable segments: the Rx Segment and the Consumer Health Segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Paragraph IV Litigation Costs</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Legal costs incurred by the Company in the enforcement of the Company&#8217;s intellectual property rights are charged to expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Business Combinations</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCreditPolicyTextBlock', window );">Employee Retention Credit [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Employee Retention Credit</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> March 27, 2020, </em>the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) to provide certain relief as a result of the COVID-<em style="font: inherit;">19</em> pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (&#8220;ERC&#8221;), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to <em style="font: inherit;">70%</em> of the qualified wages paid to employees after <em style="font: inherit;"> December 31, 2020, </em>through <em style="font: inherit;"> September 30, 2021. </em>The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-<em style="font: inherit;">19</em> pandemic.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As there is <em style="font: inherit;">no</em> authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (&#8220;IAS&#8221;) <em style="font: inherit;">20,</em> Accounting for Government Grants and Disclosure of Government Assistance (&#8220;IAS <em style="font: inherit;">20&#8221;</em>). In accordance with IAS <em style="font: inherit;">20,</em> the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em> Further in accordance with IAS <em style="font: inherit;">20,</em> when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (the &#8220;IRC&#8221;), the ERC accrual shall be recognized as a benefit in other income in the consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2024.</em></p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Net Income (Loss) Per Share</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended <em style="font: inherit;"> June 30, 2024, </em>and <em style="font: inherit;">2023</em>, the Company incurred a net loss and did <em style="font: inherit;">not</em> include common equivalent shares in the computation of diluted net loss&#160;per share because the effect would have been anti-dilutive.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth securities excluded from the calculation of diluted earnings per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 56.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants to purchase common stock - liability classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">6,057,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,498,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Warrants to purchase common stock - equity classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18,114</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee stock options</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock units</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">6,249,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,636,773</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Recently Adopted Accounting Pronouncements </b></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Financial Instruments - Credit Losses</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments&#8212;Credit Losses</i> (&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>), which requires the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after <em style="font: inherit;"> December 15, 2019. </em>However, in <em style="font: inherit;"> October 2019, </em>the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after <em style="font: inherit;"> December 15, 2022. </em>The effective dates for the amendments in ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> on <em style="font: inherit;"> July 1, 2023. </em>The Company evaluated the impact of adoption of ASUs <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> and <em style="font: inherit;">2022</em>-<em style="font: inherit;">02</em> and concluded that the application of the new standards did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Debt</i>&#160;-&#160;<i>Debt with Conversion and Other Options</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em> <i>Debt&#8212;Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>)&#8212;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company&#160;adopted the guidance on <em style="font: inherit;"> July 1, 2024, </em>and the adoption of the standard did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s consolidated financial statements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Segment Reporting</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07&#8221;</em>). ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods in fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#8217;s consolidated financial statements and disclosures.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other than the application of IAS <em style="font: inherit;">20</em> for the ERC, there have been <em style="font: inherit;">no</em> significant changes to the Company&#8217;s significant accounting policies and there is <em style="font: inherit;">no</em> other accounting guidance has been issued and <em style="font: inherit;">not</em> yet adopted that is applicable to the Company and that the Company expects would have a material effect on the Company&#8217;s consolidated financial statements and&#160;related disclosures as of <em style="font: inherit;"> June 30, 2024</em>, and through the filing of this Form <em style="font: inherit;">10</em>-K.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combinations, contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EmployeeRetentionCreditPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the accounting policy for employee retention credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EmployeeRetentionCreditPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern determination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481097/715-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 60<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 80<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480576/715-80-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641393130704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accounts Receivable, Gross</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,708</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">31,927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease in accounts receivable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt; width: 55%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Discounts</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Allowance for Chargebacks</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b><em style="font: inherit;">Total Allowance</em></b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2022</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,206</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2,507</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">9,074</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">4,554</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">13,628</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,597</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,548</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,145</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2023</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,778</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,212</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">2,990</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reduction of net revenue</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">4,886</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">3,812</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">8,698</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Payments</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,024</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,842</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,866</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balances, June 30, 2024</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">640</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,182</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,822</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Gross Revenue</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Percentage of Accounts Receivable</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer A</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer B</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Customer C</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 56.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants to purchase common stock - liability classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">6,057,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,498,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Warrants to purchase common stock - equity classified</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 16)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18,114</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee stock options</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee unvested restricted stock units</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><em style="font: inherit;">(Note 15)</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">6,249,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,636,773</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641393179664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Rx Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Consumer Health Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">15,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADHD Portfolio net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">57,784</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,855</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pediatric Portfolio net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,377</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,567</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total Rx Segment net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">65,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">73,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">United States net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80,911</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">International net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">481</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392106080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">266</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Work in process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,725</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">6,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,633</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,995</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389933312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Office equipment, furniture and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lab equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">721</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">832</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">999</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Assets under construction</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,818</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">693</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,815</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390895920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b><em style="font: inherit;">Statement of Operations Classification</em></b></p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,247</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">94</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Cost of sales</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Interest expense</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (years):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flow classification of lease payments:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,812</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,436</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock', window );">Schedule of Lease by Balance Sheet Information [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">Balance Sheet Classification</em></b></p> </td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating lease right-of-use assets</em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047624"><span style="-sec-ix-hidden:c117047625">Property and equipment, net</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 34%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">712</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047635"><span style="-sec-ix-hidden:c117047636">Other current liabilities</span></span></em></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047641"><span style="-sec-ix-hidden:c117047642">Current portion of debt</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">577</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">832</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"><span style="-sec-ix-hidden:c117047648"><span style="-sec-ix-hidden:c117047649">Other liabilities</span></span></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LesseeLiabilityMaturityTableTextBlock', window );">Lessee, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">377</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">359</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">249</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LesseeLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LesseeLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of leases by balance sheet information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389915232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">June 30, 2024</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Gross Carrying Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated Amortization</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Net Carrying Amount</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted-Average Remaining Life</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,268</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(13,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,084</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,831</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,369</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total definite-lived intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">71,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,015</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30, 2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average Remaining Life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,881</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired product distribution rights</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total definite-lived intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,583</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2029</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total future amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387646288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued savings offers</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,054</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,739</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued program liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,964</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,012</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued customer and product related fees</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,395</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,579</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued compensation</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,935</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,675</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Return reserve</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,835</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,777</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other accrued liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,391</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,017</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total accrued liabilities</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,574</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,799</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Return Reserve</em></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,770</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Reduction of net revenue</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,353</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,346</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2023</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,777</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Reduction of net revenue</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,128</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(7,070</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance, June 30, 2024</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,835</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641476210944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Employee retention credit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,759</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">13,491</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: current portion of other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(8,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,090</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total other liabilities, non-current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641482065632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>June 30, </b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2024</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>2023</b></p> </td><td style="font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#8203;</p> </td><td style="font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>(in thousands)</b></p> </td><td style="font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Term loan principal amount</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">15,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(266</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(925</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Final payment fee</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">638</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Financing leases</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total debt</p> </td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">12,734</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 1%; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">14,798</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt;"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Less: current portion of debt</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(85</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total debt, net of current portion</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,877</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,713</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total future term loan principal payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(266</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Less: current portion of debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,877</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391854032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;">Fair Value at</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2024</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30, 2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;">Fair Value at</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements at June 30, 2023</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30, 2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 3)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Derivative warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Derivative Warrant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Liabilities</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,796</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,998</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><span style="-sec-ix-hidden:c117048033">Included in earnings</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,391</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlements <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><span style="-sec-ix-hidden:c117048039">Included in earnings</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 2023 Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Tranche A</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><em style="font: inherit;">Monte Carlo &amp; Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><em style="font: inherit;">Black-Scholes</em></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Aytu closing stock price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equivalent term (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.6 - 3.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.2% - 87.5%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5% - 4.6%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">0%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388845856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total current tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,768</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,768</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30,</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">2024</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">2023</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands, except tax rate)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(193</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,447</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(38.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,087</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net income tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,768</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(12.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net operating loss carry forward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,170</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,845</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,188</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued rebates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,994</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant derivatives</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,061</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,504</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,027</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">758</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Section 174 capitalization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">780</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">138,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Less: valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(137,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(135,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax assets, net of valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangibles</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(845</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">ROU asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Fixed assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Beginning balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,948</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Decrease resulting from current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,996</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Increase resulting from current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">361</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Ending balances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,948</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389941088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Life in Years</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">113,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">9.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(16,610</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">3.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(3,113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">66.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Prices</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="2" rowspan="1" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c117050812">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">102,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="2" rowspan="1" style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c117050820">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">$4.00 - $290.00</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><span style="-sec-ix-hidden:c117050827">&#160;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c117050829">&#160;</span></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,039</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">225.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 154px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">225.74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">142.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(25,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">113.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(499</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">147.15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average Grant</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Date Fair</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,963</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,249</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">24.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">31.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cost of sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,905</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,965</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387675056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life in Years <sup style="vertical-align:top;line-height:120%;">(4)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding June 30, 2023 <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,538,052</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants issued <sup style="vertical-align:top;line-height:120%;">(2)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">1,806,434</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">0.0001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">N/A</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(2,247,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Warrants expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(20,958</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">300.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding June 30, 2024 <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,075,880</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641481877568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Restructuring Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended June 30, 2024</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Severance and Employee Benefits <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exit and Disposal Activities <sup style="vertical-align:top;line-height:120%;">(1)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inventory Write-Down <sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Wind down of Consumer Health Segment <sup style="vertical-align:top;line-height:120%;">(3)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closure of Grand Prairie, Texas manufacturing site <sup style="vertical-align:top;line-height:120%;">(4)</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,031</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391957584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Rx</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Consumer Health</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Consolidated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Year Ended June 30, 2024</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">65,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">81,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(3,664</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,547</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,456</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">540</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">209</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Year Ended June 30, 2023</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">73,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">33,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">107,399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(7,358</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(9,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(17,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8203;</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,271</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,722</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Impairment expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,705</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390441856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Business and Financial Condition (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember', window );">Avenue Capital Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_RevenuebasedRoyaltyCosts', window );">Revenue-based Royalty Costs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenuebasedRoyaltyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue-based royalty revenue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenuebasedRoyaltyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390984384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expense, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,635<span></span>
</td>
<td class="nump">$ 7,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForDiscounts', window );">Accounts Receivable, Allowance for Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacks', window );">Accounts Receivable, Allowance for Pricing Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">$ 1,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCredit', window );">Employee Retention Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCreditVendorFee', window );">Employee Retention Credit, Vendor Fee</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCredit', window );">Employee Retention Credit</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan [Member] | First Three Percent Contribution By Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan [Member] | Next Four Percent and Five Percent Contribution By Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan [Member] | Next Four Percent Contribution By Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan [Member] | Next Five Percent Contribution By Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableCreditTerms', window );">Accounts Receivable, Credit Terms (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableCreditTerms', window );">Accounts Receivable, Credit Terms (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_FurnitureAndEquipmentMember', window );">Furniture and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_FurnitureAndEquipmentMember', window );">Furniture and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember', window );">Immaterial Error Correction of Prepaid Expenses from Current Asset to Noncurrent Asset [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expense, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the allowance for discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the allowance for pricing chargebacks</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableCreditTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents credits terms for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableCreditTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of employee retention credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EmployeeRetentionCreditVendorFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of vendor fee from employee retention credit during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EmployeeRetentionCreditVendorFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_FirstThreePercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_FirstThreePercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_NextFourPercentAndFivePercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_NextFourPercentAndFivePercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_NextFourPercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_NextFourPercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_NextFivePercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_NextFivePercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389915648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Balance</a></td>
<td class="nump">$ 31,927<span></span>
</td>
<td class="nump">$ 24,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease', window );">Increase (decrease) in accounts receivable, gross</a></td>
<td class="num">(6,488)<span></span>
</td>
<td class="nump">7,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Balance</a></td>
<td class="nump">$ 25,439<span></span>
</td>
<td class="nump">$ 31,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in accounts receivable before allowance for credit loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389192624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForDiscounts', window );">Balance, allowance for discount</a></td>
<td class="nump">$ 1,778<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacks', window );">Balance, allowance for chargeback</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts', window );">Balance</a></td>
<td class="nump">2,990<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal', window );">Reduction of net revenue, allowance for discount</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="nump">9,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal', window );">Reduction of net revenue, allowance for chargeback</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal', window );">Reduction of net revenue</a></td>
<td class="nump">8,698<span></span>
</td>
<td class="nump">13,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForDiscountsRecovery', window );">Payments, allowance for discount</a></td>
<td class="num">(6,024)<span></span>
</td>
<td class="num">(8,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery', window );">Payments, allowance for chargeback</a></td>
<td class="num">(3,842)<span></span>
</td>
<td class="num">(4,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery', window );">Payments</a></td>
<td class="num">(9,866)<span></span>
</td>
<td class="num">(13,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal', window );">Reduction of net revenue</a></td>
<td class="nump">8,698<span></span>
</td>
<td class="nump">13,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForDiscounts', window );">Balance, allowance for discount</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacks', window );">Balance, allowance for chargeback</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts', window );">Balance</a></td>
<td class="nump">$ 1,822<span></span>
</td>
<td class="nump">$ 2,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for chargebacks and discounts for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the allowance for discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the allowance for discount credit loss expense (reversal).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForDiscountsRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents allowance for discount recovery payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForDiscountsRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the allowance for pricing chargebacks</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents credit loss expense (reversal) for the allowance for pricing chargebacks and discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total allowance for both pricing chargebacks and discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss, allowance for chargeback, on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for pricing chargebacks on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387653584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aytu_CustomerAMember', window );">Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration risk</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aytu_CustomerAMember', window );">Customer A [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration risk</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aytu_CustomerBMember', window );">Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration risk</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aytu_CustomerBMember', window );">Customer B [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration risk</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aytu_CustomerCMember', window );">Customer C [Member] | Revenue from Contract with Customer Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration risk</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aytu_CustomerCMember', window );">Customer C [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration risk</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aytu_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aytu_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aytu_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aytu_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aytu_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aytu_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641496452752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded (in shares)</a></td>
<td class="nump">6,249,554<span></span>
</td>
<td class="nump">6,636,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_LiabilityWarrantsMember', window );">Liability Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded (in shares)</a></td>
<td class="nump">6,057,766<span></span>
</td>
<td class="nump">6,498,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_EquityWarrantsMember', window );">Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded (in shares)</a></td>
<td class="nump">18,114<span></span>
</td>
<td class="nump">39,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded (in shares)</a></td>
<td class="nump">146,539<span></span>
</td>
<td class="nump">52,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded (in shares)</a></td>
<td class="nump">25,360<span></span>
</td>
<td class="nump">40,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securites excluded (in shares)</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">4,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_LiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_LiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_EquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_EquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392041600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_ConsumerHealthMember', window );">Consumer Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NumberOfProducts', window );">Number of Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390039792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 81,002<span></span>
</td>
<td class="nump">$ 107,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember', window );">Rx Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">65,183<span></span>
</td>
<td class="nump">73,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember', window );">Rx Segment [Member] | ADHD Portfolio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">57,784<span></span>
</td>
<td class="nump">46,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember', window );">Rx Segment [Member] | The Pediatric Portfolio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">7,280<span></span>
</td>
<td class="nump">25,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember', window );">Rx Segment [Member] | Product and Service, Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 15,819<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_AdhdPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_AdhdPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_ThePediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_ThePediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391754640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue - Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 81,002<span></span>
</td>
<td class="nump">$ 107,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">80,911<span></span>
</td>
<td class="nump">106,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387218208">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Inventories (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,270<span></span>
</td>
<td class="nump">$ 2,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember', window );">Inventory Write Downs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember', window );">Inventory Write Downs [Member] | Consumer Health Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390151968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">2,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,642<span></span>
</td>
<td class="nump">7,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 12,633<span></span>
</td>
<td class="nump">$ 11,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388924208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (Loss) on Disposition of Property Plant Equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392278208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="nump">$ 5,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(2,125)<span></span>
</td>
<td class="num">(3,681)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember', window );">Office Equipment, Furniture and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Asset under Construction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389408576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Leases (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
<th class="th"><div>Feb. 28, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">829,000<span></span>
</td>
<td class="nump">2,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">1,289,000<span></span>
</td>
<td class="nump">$ 2,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember', window );">Office Space And Manufacturing Facilities Grand Prairie Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember', window );">Office Space in Berwyn, Pennsylvania [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment', window );">Operating Lease, Undiscounted Minimum Monthly Payment</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=aytu_PrincipalOfficeDenverColoradoMember', window );">Principal Office Denver Colorado [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment', window );">Operating Lease, Undiscounted Minimum Monthly Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the undiscounted minimum monthly payment on an operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=aytu_PrincipalOfficeDenverColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=aytu_PrincipalOfficeDenverColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392278784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Leases - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 2,397<span></span>
</td>
<td class="nump">$ 1,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease assets (Year)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease assets (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,812<span></span>
</td>
<td class="nump">$ 1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389119824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Leases - Lease Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 2,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset', window );">Total lease assets</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases, current</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating leases, non-current</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseAndFinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="nump">$ 2,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents operating and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents right-of-use asset for operating lease and finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392285504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 693<span></span>
</td>
<td class="nump">$ 1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current</a></td>
<td class="nump">8,962<span></span>
</td>
<td class="nump">7,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-Term Debt, Current Maturities</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Liabilities, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Liabilities, Noncurrent</a></td>
<td class="nump">28,151<span></span>
</td>
<td class="nump">28,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent</a></td>
<td class="nump">$ 4,529<span></span>
</td>
<td class="nump">$ 6,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-Term Debt, Current Maturities<span></span>
</td>
<td class="text">Long-Term Debt, Current Maturities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391187920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Leases - Schedule of Lease Liability Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced', window );">Total lease payments</a></td>
<td class="nump">2,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced', window );">Lease liabilities</a></td>
<td class="nump">$ 2,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's discounted obligation for lease payments from operating lease, including operating lease that has not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389654704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Intangible Assets (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AmortizationExpenseOfIntangibleAssets', window );">Amortization Expense of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Asset Impairment Charges<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NeosTherapeuticsIncMember', window );">Neos Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-Lived</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember', window );">Patented Technology [Member] | ADHD Portfolio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementExtensionTerm', window );">Supply and Distribution Agreement, Extension Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod', window );">Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod', window );">Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AmortizationExpenseOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of amortization expense of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AmortizationExpenseOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the renewable period for a finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the extension term of a supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NeosTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NeosTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AdhdPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AdhdPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aytu_TrisKarbinalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aytu_TrisKarbinalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389399552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 71,468<span></span>
</td>
<td class="nump">$ 78,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, amortization</a></td>
<td class="num">(19,015)<span></span>
</td>
<td class="num">(19,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">$ 52,453<span></span>
</td>
<td class="nump">$ 58,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining life (Year)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 41,268<span></span>
</td>
<td class="nump">$ 42,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, amortization</a></td>
<td class="num">(13,184)<span></span>
</td>
<td class="num">(10,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">$ 28,084<span></span>
</td>
<td class="nump">$ 31,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining life (Year)</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">11 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 30,200<span></span>
</td>
<td class="nump">$ 30,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, amortization</a></td>
<td class="num">(5,831)<span></span>
</td>
<td class="num">(4,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">$ 24,369<span></span>
</td>
<td class="nump">$ 26,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining life (Year)</a></td>
<td class="text">13 years 9 months 18 days<span></span>
</td>
<td class="text">14 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390827968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Intangible Assets - Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025, future amortization expense</a></td>
<td class="nump">$ 4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026, future amortization expense</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027, future amortization expense</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028, future amortization expense</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029, future amortization expense</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter, future amortization expense</a></td>
<td class="nump">27,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 52,453<span></span>
</td>
<td class="nump">$ 58,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390419984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedSavingOffers', window );">Accrued savings offers</a></td>
<td class="nump">$ 11,054<span></span>
</td>
<td class="nump">$ 15,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedProgramRelatedLiabilities', window );">Accrued program liabilities</a></td>
<td class="nump">9,964<span></span>
</td>
<td class="nump">11,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedCustomerAndProductRelatedFeesCurrent', window );">Accrued customer and product related fees</a></td>
<td class="nump">5,395<span></span>
</td>
<td class="nump">6,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ReturnReserveCurrent', window );">Return reserve</a></td>
<td class="nump">4,835<span></span>
</td>
<td class="nump">5,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,391<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 38,574<span></span>
</td>
<td class="nump">$ 46,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedCustomerAndProductRelatedFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued customer and product related fees classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedCustomerAndProductRelatedFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedProgramRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedProgramRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedSavingOffers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to accrued saving offers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedSavingOffers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ReturnReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of return reserve classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ReturnReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390384720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details) - SEC Schedule, 12-09, Reserve, Return [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 5,777<span></span>
</td>
<td class="nump">$ 5,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Reduction of net revenue</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">8,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments</a></td>
<td class="num">(7,070)<span></span>
</td>
<td class="num">(8,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 4,835<span></span>
</td>
<td class="nump">$ 5,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=aytu_ReturnReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=aytu_ReturnReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390652288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Other Liabilities (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="nump">$ 8,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,420,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCredit', window );">Employee Retention Credit</a></td>
<td class="nump">3,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCredit', window );">Employee Retention Credit</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisLicenseAgreementMember', window );">Tris License Agreement [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement Liabilities, Current</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionCommitmentPeriod', window );">Supply and Distribution Commitment, Period (Year)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales', window );">Supply and Distribution Commitment, Royalty, Percentage of Net Sales</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumSalesPerYear', window );">Supply and Distribution Agreement, Minimum Sales Per Year</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit', window );">Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment', window );">Supply and Distribution Agreement, Maximum Yearly Make-whole Payment</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations', window );">Supply and Distribution Agreement, Maximum Milestone Obligations</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues', window );">Supply and Distribution Agreement, First Milestone, Minimum Net Revenues</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member] | Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of employee retention credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of milestone obligations of the supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of make-whole payment per year under supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumSalesPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Th minimum amount of units to be sold per year under supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumSalesPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales to be paid for royalties under supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_TrisLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_TrisLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641393933728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="nump">$ 8,337<span></span>
</td>
<td class="nump">$ 10,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EmployeeRetentionCredit', window );">Employee retention credit</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilities', window );">Other</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total other liabilities</a></td>
<td class="nump">13,491<span></span>
</td>
<td class="nump">14,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Less: current portion of other liabilities</a></td>
<td class="num">(8,962)<span></span>
</td>
<td class="num">(7,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other liabilities, non-current</a></td>
<td class="nump">$ 4,529<span></span>
</td>
<td class="nump">$ 6,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of employee retention credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389718144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Revolving Credit Facility (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember', window );">Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt Issuance Costs, Current, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-Term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember', window );">Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member] | On or Before January 26, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment', window );">Line of Credit Facility, Termination, Fee, Percentage of Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember', window );">Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member] | After January 26, 2023 But Before January 26, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment', window );">Line of Credit Facility, Termination, Fee, Percentage of Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember', window );">Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member] | After January 26, 2024 But Before January 26, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment', window );">Line of Credit Facility, Termination, Fee, Percentage of Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of commitment used as a termination fee of a line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_OnOrBeforeJanuary262023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_OnOrBeforeJanuary262023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_AfterJanuary262023ButBeforeJanuary262024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_AfterJanuary262023ButBeforeJanuary262024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_AfterJanuary262024ButBeforeJanuary262025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_AfterJanuary262024ButBeforeJanuary262025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392398752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Long-term Debt (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 12, 2024</div></th>
<th class="th"><div>Jan. 26, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentFinalPayment', window );">Debt Instrument, Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-Term Debt, Maturity, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_AvenueCapitalIssuanceMember', window );">Avenue Capital Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember', window );">Avenue Capital Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember', window );">Avenue Capital Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoanProcessingFee', window );">Loan Processing Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentPrepaymentFeePercentage', window );">Debt Instrument, Prepayment Fee, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentFinalPayment', window );">Debt Instrument, Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (594)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember', window );">Avenue Capital Loan [Member] | After January 26, 2024 But Before January 26, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentPrepaymentFeePercentage', window );">Debt Instrument, Prepayment Fee, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentPrepaymentFeeAmount', window );">Debt Instrument, Prepayment Fee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember', window );">Avenue Capital Loan [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentAmortizationPeriod', window );">Debt Instrument, Amortization Period (Year)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-Term Debt, Maturity, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member] | On or Before June 12 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentTerminationFeePercentage', window );">Debt Instrument, Termination Fee, Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member] | After June 12, 2025, but on or before June 12, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentTerminationFeePercentage', window );">Debt Instrument, Termination Fee, Percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentTerminationFeePercentage', window );">Debt Instrument, Termination Fee, Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentTerminationFeePercentage', window );">Debt Instrument, Termination Fee, Percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember', window );">Eclipse Term loan [Member] | Secured Overnight Financing Rate (SOFR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration in which the debt will amortize.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the final payment of a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentPrepaymentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentPrepaymentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of loan that is payable as a prepayment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentTerminationFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The termination fee if the debt is terminated before or on a certain date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentTerminationFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanProcessingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses paid for obtaining loans which includes expenses such as application and origination fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanProcessingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_AvenueCapitalIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_AvenueCapitalIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_AfterJanuary262024ButBeforeJanuary262025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_AfterJanuary262024ButBeforeJanuary262025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_OnOrBeforeJune122025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_OnOrBeforeJune122025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_AfterJune122025ButOnOrBeforeJune122026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_AfterJune122025ButOnOrBeforeJune122026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_AfterJune122026ButOnOrBeforeJune122027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_AfterJune122026ButOnOrBeforeJune122027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_AfterJune122026ButOnOrBeforeJune122028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_AfterJune122026ButOnOrBeforeJune122028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641481873872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan principal amount</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentFinalPayment', window );">Final payment fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total debt</a></td>
<td class="nump">12,734<span></span>
</td>
<td class="nump">14,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: current portion of debt</a></td>
<td class="num">(1,857)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total debt, net of current portion</a></td>
<td class="nump">$ 10,877<span></span>
</td>
<td class="nump">$ 14,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the final payment of a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389853440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Long-term Debt - Future Principal Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-Term Debt, Maturity, Year Four</a></td>
<td class="nump">7,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LongTermDebtAndCapitalLeaseObligationsGross', window );">Total future term loan principal payments</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(266)<span></span>
</td>
<td class="num">$ (925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of debt</a></td>
<td class="num">(1,857)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total debt, net of current portion</a></td>
<td class="nump">$ 10,877<span></span>
</td>
<td class="nump">$ 14,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LongTermDebtAndCapitalLeaseObligationsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LongTermDebtAndCapitalLeaseObligationsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390424816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,337<span></span>
</td>
<td class="nump">10,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Asset Impairment Charges<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember', window );">Tranche B Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="nump">367,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember', window );">Tranche B Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">1,806,434<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Measurement Input, Discount Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMeasurementInput', window );">Fixed Payment Arrangements, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Measurement Input, Discount Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMeasurementInput', window );">Fixed Payment Arrangements, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the measurement input used in valuing fixed payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for the warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390441904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 12,745<span></span>
</td>
<td class="nump">$ 6,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="nump">6,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="nump">6,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">$ 12,745<span></span>
</td>
<td class="nump">$ 6,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641394071024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 6,403<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issued</a></td>
<td class="nump">5,148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(2,810)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Included in earnings</a></td>
<td class="nump">4,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 12,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,403<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company&#8217;s June 2023 equity financing that were exercised in June 2024. The warrants were converted into 367,478 shares of common stock (&#8220;Settlements&#8221;) and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (&#8220;Issued&#8221;). See Note 14 - Stockholders&#8217; Equity and Note 16 - Warrants for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641392082224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative, Gain (Loss) on Derivative, Net</a></td>
<td class="num">$ (4,004)<span></span>
</td>
<td class="nump">$ 4,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Derivative, Gain (Loss) on Derivative, Net<span></span>
</td>
<td class="text">Derivative, Gain (Loss) on Derivative, Net<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390649424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Fair Value Measurements - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | June 2023 Warrants Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Other Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | June 2023 Warrants Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Other Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Other Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | June 2023 Warrants Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.832<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | June 2023 Warrants Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | June 2023 Warrants Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Other Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_June2023WarrantsTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_June2023WarrantsTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_OtherWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_OtherWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389826608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="num">(12.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">$ 138,012<span></span>
</td>
<td class="nump">$ 137,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued Income Taxes, Current</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation', window );">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss', window );">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss</a></td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">519,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating Loss Carryforwards, Not Subject to Expiration</a></td>
<td class="nump">186,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardSubjectToExpire', window );">Operating Loss Carryforward, Subject To Expire</a></td>
<td class="nump">333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardExpirationsOwnershipChange', window );">Operating Loss Carryforward, Expirations, Ownership Change</a></td>
<td class="nump">329,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">137,250<span></span>
</td>
<td class="nump">135,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">2,948<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardExpirationsOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The operating loss carryforward that will expire related to the ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardExpirationsOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardSubjectToExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The operating loss carryforward that will expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardSubjectToExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents disallowed recognized built-in loss, carried forward as an operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post-change net operating loss determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents operating loss carryforwards not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641393179664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 1,549<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,768<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net income tax expense, amount</a></td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390488800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate, amount</a></td>
<td class="num">$ (2,956)<span></span>
</td>
<td class="num">$ (3,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit, amount</a></td>
<td class="num">$ (779)<span></span>
</td>
<td class="num">$ (430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation expense, amount</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation expense</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_IncomeTaxReconciliationContingentConsideration', window );">Contingent consideration, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent', window );">Contingent consideration</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, amount</a></td>
<td class="nump">$ 5,447<span></span>
</td>
<td class="nump">$ 4,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(38.70%)<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, amount</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net income tax expense, amount</a></td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax expense</a></td>
<td class="num">(12.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents income tax reconciliation for contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388460048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 119,170<span></span>
</td>
<td class="nump">$ 113,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="nump">4,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsAccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,819<span></span>
</td>
<td class="nump">6,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Warrant derivatives</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">2,416<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Section 174 capitalization</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">138,012<span></span>
</td>
<td class="nump">137,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(137,250)<span></span>
</td>
<td class="num">(135,954)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU asset</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(762)<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsAccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible accrued rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsAccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390020032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 2,948<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Decrease resulting from current period tax positions</a></td>
<td class="num">(1,996)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase resulting from current period tax positions</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 2,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641386267728">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,972,638<span></span>
</td>
<td class="nump">5,517,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,972,638<span></span>
</td>
<td class="nump">5,517,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022PrefundedWarrantsMember', window );">March 2022 Prefunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonWarrantsMember', window );">March 2022 Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonAndPrefundedWarrantsMember', window );">March 2022 Common and Prefunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember', window );">August 2022 Prefunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember', window );">August 2022 Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonAndPrefundedWarrantsMember', window );">August 2022 Common and Prefunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember', window );">Tranche A Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember', window );">Tranche B Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">367,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember', window );">Common Warrants Exchanged for PreFunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember', window );">Securities Purchase Agreement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember', window );">Tranche B Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_The2020ShelfMember', window );">The 2020 Shelf [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SaleOfStockMaximumAmountOfEquityIssuable', window );">Sale of Stock, Maximum Amount of Equity Issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_AtthemarketOfferingMember', window );">At-the-market Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SaleOfStockMaximumAmountOfEquityIssuable', window );">Sale of Stock, Maximum Amount of Equity Issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_The2021ShelfMember', window );">The 2021 Shelf [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SaleOfStockMaximumAmountOfEquityIssuable', window );">Sale of Stock, Maximum Amount of Equity Issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_The2024ShelfMember', window );">The 2024 Shelf [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SaleOfStockMaximumAmountOfEquityIssuable', window );">Sale of Stock, Maximum Amount of Equity Issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_TheMarch2022OfferingMember', window );">The March 2022 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_TheAugust2022OfferingMember', window );">The August 2022 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,075,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SaleOfStockMaximumAmountOfEquityIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum monetary amount of equity issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SaleOfStockMaximumAmountOfEquityIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for the warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonAndPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonAndPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonAndPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonAndPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_The2020ShelfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_The2020ShelfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_The2021ShelfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_The2021ShelfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_The2024ShelfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_The2024ShelfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_TheMarch2022OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_TheMarch2022OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_TheAugust2022OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_TheAugust2022OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389540640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 18, 2023</div></th>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th"><div>Jan. 17, 2022</div></th>
<th class="th"><div>Apr. 19, 2021</div></th>
<th class="th"><div>Jun. 01, 2015</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,539<span></span>
</td>
<td class="nump">52,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,500<span></span>
</td>
<td class="nump">49,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,913<span></span>
</td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,105<span></span>
</td>
<td class="nump">38,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">4,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">87,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] | Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember', window );">The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Two Former Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Grants Rescinded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member] | Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock [Member] | Maximum [Member] | Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember', window );">The 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_NonplanMember', window );">Non-plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_NonplanMember', window );">Non-plan [Member] | Restricted Stock [Member] | Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_NonplanMember', window );">Non-plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_NonplanMember', window );">Non-plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of grants rescinded under a share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=aytu_RestrictedStockAndRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=aytu_RestrictedStockAndRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_The2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_The2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aytu_TwoFormerBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aytu_TwoFormerBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aytu_BoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aytu_BoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Neos2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_NonplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_NonplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641385438656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">52,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, options, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, options (in shares)</a></td>
<td class="nump">113,500<span></span>
</td>
<td class="nump">49,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted, options, weighted average remaining contractual life (Year)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled, options (in shares)</a></td>
<td class="num">(16,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, options (in shares)</a></td>
<td class="num">(3,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 66.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">146,539<span></span>
</td>
<td class="nump">52,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.18<span></span>
</td>
<td class="nump">$ 18.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, options (in shares)</a></td>
<td class="nump">25,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, options, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted during the periof, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387561152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices (in dollars per share)</a></td>
<td class="nump">$ 6.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">146,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding (Year)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">25,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 225.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices (in dollars per share)</a></td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding (Year)</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding (Year)</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices (in dollars per share)</a></td>
<td class="nump">$ 16.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">43,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding (Year)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">25,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 225.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices (in dollars per share)</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices (in dollars per share)</a></td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389358816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, shares (in shares) | shares</a></td>
<td class="nump">38,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 142.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares (in shares) | shares</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares (in shares) | shares</a></td>
<td class="num">(25,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 113.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/cancelled, shares (in shares) | shares</a></td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 147.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, shares (in shares) | shares</a></td>
<td class="nump">24,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 100.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389201040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, shares (in shares) | shares</a></td>
<td class="nump">4,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares (in shares) | shares</a></td>
<td class="num">(2,249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/cancelled, shares (in shares) | shares</a></td>
<td class="num">(939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, shares (in shares) | shares</a></td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390374912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,913<span></span>
</td>
<td class="nump">$ 6,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,905<span></span>
</td>
<td class="nump">$ 5,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641387426304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Warrants (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 06, 2023</div></th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 25, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,075,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,538,052<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=aytu_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember', window );">Tranche A Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember', window );">Tranche B Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="nump">367,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember', window );">Common Warrants Exchanged for PreFunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember', window );">Tranche B Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">1,806,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember', window );">August 2022 Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember', window );">August 2022 Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember', window );">August 2022 Common Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember', window );">August 2022 Common Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022PrefundedWarrantsMember', window );">March 2022 Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonWarrantsMember', window );">March 2022 Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonAndPrefundedWarrantsMember', window );">March 2022 Common and Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember', window );">Avenue Capital Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityWarrantsMember', window );">Liability Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,821,115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,068,763<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityPrefundedWarrantsMember', window );">Liability Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">430,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_EquityWarrantsMember', window );">Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,114<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityTrancheBPrefundedWarrantsMember', window );">Liability Tranche B Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember', window );">Securities Purchase Agreement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_TheMarch2022OfferingMember', window );">The March 2022 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for the warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=aytu_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=aytu_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonAndPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_March2022CommonAndPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_EquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_EquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityTrancheBPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityTrancheBPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_TheMarch2022OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_TheMarch2022OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641391951392">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Warrants - Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,538,052<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife', window );">Outstanding, weighted average remaining contractual term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Warrants issued (2) (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,806,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,247,648)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExpiredDuringPeriod', window );">Warrants expired (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,958)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,075,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="nump">6,538,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice', window );">Warrants issued, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod', window );">Warrants exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod', window );">Warrants expired, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="nump">$ 4.42<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise price of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise price of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average period of remaining contractual life of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641386112512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Restructuring Costs (Details Textual) - Grand Prairie, Texas Manufacturing Site [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePortfolioSegmentAxis=aytu_GrandPrairieTexasManufacturingSiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePortfolioSegmentAxis=aytu_GrandPrairieTexasManufacturingSiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388365472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">$ 3,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=aytu_ExitAndDisposalActivitiesMember', window );">Exit and Disposal Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember', window );">Inventory Write Downs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">730<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember', window );">Consumer Health Segment [Member] | Consumer Health Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">939<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember', window );">Consumer Health Segment [Member] | Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember', window );">Consumer Health Segment [Member] | Exit and Disposal Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember', window );">Consumer Health Segment [Member] | Inventory Write Downs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">730<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_GrandPrairieTexasManufacturingSiteMember', window );">Grand Prairie, Texas Manufacturing Site [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_GrandPrairieTexasManufacturingSiteMember', window );">Grand Prairie, Texas Manufacturing Site [Member] | Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_GrandPrairieTexasManufacturingSiteMember', window );">Grand Prairie, Texas Manufacturing Site [Member] | Exit and Disposal Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_GrandPrairieTexasManufacturingSiteMember', window );">Grand Prairie, Texas Manufacturing Site [Member] | Inventory Write Downs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=aytu_ExitAndDisposalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=aytu_ExitAndDisposalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=aytu_InventoryWriteDownsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePortfolioSegmentAxis=aytu_ConsumerHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePortfolioSegmentAxis=aytu_ConsumerHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_GrandPrairieTexasManufacturingSiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_GrandPrairieTexasManufacturingSiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390470976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,337,000<span></span>
</td>
<td class="nump">$ 10,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_SabbyVolatilityWarrantMasterFundLtdMember', window );">Sabby Volatility Warrant Master Fund Ltd. [Member] | Sabby Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_SabbyVolatilityWarrantMasterFundLtdMember', window );">Sabby Volatility Warrant Master Fund Ltd. [Member] | Sabby Litigation [Member] | Sabby Litigation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_WalleyeOpportunitiesMasterFundLtdMember', window );">Walleye Opportunities Master Fund Ltd. [Member] | Sabby Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_WalleyeOpportunitiesMasterFundLtdMember', window );">Walleye Opportunities Master Fund Ltd. [Member] | Sabby Litigation [Member] | Sabby Litigation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember', window );">Office Space in Berwyn, Pennsylvania [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment', window );">Operating Lease, Undiscounted Minimum Monthly Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=aytu_PrincipalOfficeDenverColoradoMember', window );">Principal Office Denver Colorado [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment', window );">Operating Lease, Undiscounted Minimum Monthly Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionCommitmentPeriod', window );">Supply and Distribution Commitment, Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales', window );">Supply and Distribution Commitment, Royalty, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumSalesPerYear', window );">Supply and Distribution Agreement, Minimum Sales Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit', window );">Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations', window );">Supply and Distribution Agreement, Maximum Milestone Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues', window );">Supply and Distribution Agreement, First Milestone, Minimum Net Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member] | Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember', window );">Tris Karbinal Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit', window );">Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementAssumedFromCerecorIncMember', window );">Fixed Payment Arrangement Assumed from Cerecor Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber', window );">Fixed Payment Arrangements, Periodic Payment Obligations, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyPaymentAmount', window );">Fixed Payment Arrangements, Monthly Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount', window );">Fixed Payment Arrangements, Balloon Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsPaymentAmountPaid', window );">Fixed Payment Arrangements, Payment Amount, Paid</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementQuarterlyPayments', window );">Fixed Payment Arrangement, Quarterly Payments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementAssumedFromCerecorIncMember', window );">Fixed Payment Arrangement Assumed from Cerecor Inc. [Member] | The Pediatric Portfolio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount', window );">Fixed Payment Arrangements, Balloon Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementQuarterlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of quarterly payments on fixed payments arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementQuarterlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of balloon payment on a fixed payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsBalloonPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of monthly payment amount on a fixed payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount paid on fixed payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of fixed, periodic payment obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the undiscounted minimum monthly payment on an operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of milestone obligations of the supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumSalesPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Th minimum amount of units to be sold per year under supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumSalesPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales to be paid for royalties under supply and distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aytu_SabbyVolatilityWarrantMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aytu_SabbyVolatilityWarrantMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=aytu_SabbyLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=aytu_SabbyLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_SabbyLitigationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_SabbyLitigationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aytu_WalleyeOpportunitiesMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aytu_WalleyeOpportunitiesMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=aytu_PrincipalOfficeDenverColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=aytu_PrincipalOfficeDenverColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementAssumedFromCerecorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementAssumedFromCerecorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ThePediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ThePediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641388176304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - License Agreements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_HealightMember', window );">Healight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementInitialLicenseFeePaid', window );">License Agreement, Initial License Fee Paid</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementPatentProsecutionFeesPaid', window );">License Agreement, Patent Prosecution Fees Paid</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_The2014LicenseAgreementShireMember', window );">The 2014 License Agreement, Shire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum', window );">License Agreement, Up-front, Non-refundable License Fee Paid, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementInitialLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the initial license fee paid as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementInitialLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementPatentProsecutionFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents patent prosecution fees paid as part of a license agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementPatentProsecutionFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents a maximum, up-front, non-refundable license fee paid as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_HealightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_HealightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_The2014LicenseAgreementShireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_The2014LicenseAgreementShireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389530096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Segment Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641389691568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Segment Information - Schedule of Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 81,002<span></span>
</td>
<td class="nump">$ 107,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(5,254)<span></span>
</td>
<td class="num">(17,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,456<span></span>
</td>
<td class="nump">7,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">6,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetImpairmentAndWriteoffCharges', window );">Impairment and write-off expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember', window );">Rx Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">65,183<span></span>
</td>
<td class="nump">73,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(1,590)<span></span>
</td>
<td class="num">(7,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,909<span></span>
</td>
<td class="nump">6,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,373<span></span>
</td>
<td class="nump">5,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetImpairmentAndWriteoffCharges', window );">Impairment and write-off expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">15,819<span></span>
</td>
<td class="nump">33,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(3,664)<span></span>
</td>
<td class="num">(9,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetImpairmentAndWriteoffCharges', window );">Impairment and write-off expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AssetImpairmentAndWriteoffCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset impairment and write-off of assets recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AssetImpairmentAndWriteoffCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45641390950464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 21 - Subsequent Events (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_RevenuebasedRoyaltyCosts', window );">Revenue-based Royalty Costs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenuebasedRoyaltyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue-based royalty revenue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenuebasedRoyaltyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>128
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZS!:^3@%#>Y[I H_7VOH88'&Y#2I5<F5?M\$/?!.9Q2.*_93OP^T-5BLUDG
M=8V1'</6FZ6O-P\R]M=^0- L"9\(4Z+:Y^G-MCVPG+X2EU9/KTNMBJMT]>9!
MMGX:N92)=I5&RA.TX*)[(LK0F"8B((F<1#UU=X75)U=*@%K-O2ZU*L#2WINP
M/\\!WN-7-/5$5_6??3<+YD#K@R6=?ML8#&S340]P6HV_+K4JO=+ZF[!;S^F-
M/$^HQR?;%RB=T[B-U&T.ENR?&0:ZPC%'#Y'\&D8;$B7D)#OI1>)SDKT\LY0A
M 59OC/<8,<$L<X()6_OW>,=R2W3K>_H2*='NR1TDVBA;]!@N;$SM&'G!+ .#
M";O\]]2*T7#.Z,:/7'6KA#7'MTIL6H.#+K7J3&N9'"S8^;_'-J<Q%][X'W]=
M>_O8HS@P+%MY"X;KFG+3I5;E5H8)"\X ::<<,8+K,<$"??5(!E<UAG2,#&&5
M&<*"C?\-32<Z5C2";-T>$<?NMWO=@9J6UMR@2ZU*J\P-%FSU[WTN["]]1J;U
M\>D/M"!NPD0K4R*#E<8T#,5-=,&I^^L$K3%#&QPD!'TP3N7$-UH3AN(59LI@
M 6LW9GJ,8&&5P<*",X&(8)X?+='B+7RB@1(E+"!GOI64M.8)76I52F6>L&#'
MOVUJZ.K57>%H26H?$^P1FHT6D]'?2EY:XX,NM2JO,CY8!\6''R0(VK\B8<M$
M9\6Q&.4\-(WCI&:8@S5G5(E-:V[0I5;%5N8&ZZ#<\)T&(I]BEN5]IIS1W:-4
M TMK"M"E5H55I@#KH!2P?<Z232"E0YDPMNII\#V*CT15-8:K&E,[1@JPRA1@
M'90"IA$G+%MK(B<M\1:CDAJL6$=-:PC0I59=H%"& /N@$)!V1S06N6E)F=)W
M[-&9T:B-79<(&2'B98+*%0E:HX NM2J],@K8L)//Z2U"' 3H,HG%V[&R?^[1
MJ7NL )<UAG6,2&"7D<"&W7P.ZRHD;"E'L\]"@:]$B K7.%*W.5BP=H(<KFN,
M[1C9P-Y90P0[^NGX^@Z-$L_GE*$1YT2D]'2^LFY]PAZ]>FIZ%PL=P_W;I?NW
M8?.^\Q0YPI'KBS":3@NE^ZX82^?*Q8TA6YOX4[)4K\:"/Z8>IM:0H$NM"K,,
M"?9!#QT6*^%ZP?X*R]3#TIH0=*E5894)P3XH(<R3I\!W12>E6.D]8)7&Z_RT
MAH5<K9NJR77%FZ%I]$WKK&N>=S8J.F40L \* M5IBH6<D(C1;<+%V!;)U*XD
MIM/CCW.UWLXU]DQG<'9F%Y>8PSA&&+#+,&##UGT[\E_[+$33B1(,K& YRI6.
M<%7C)G,,\V^7YM^&K?J64MWDQ9[RSW>CV3VZ_W)[-[N_G:&;F[F2F%;CKTNM
MNIRV-/X.;-BWQ.1$K;P'JJCMD<@>+YV(SAQ0ACUE,(<E&B^HU6KW.SN+ZJ4I
M37^<$"-7/D//UM<7>XL?0(S29?^=\O#LUQ/?L/2T,0K(LR@U3OMB[&39#Q*R
M#4[7Z1+])\HY#=.7*X(]PN0!XOUG2OEV0WY \;.0X?]02P,$%     @ KH Z
M66LGZM=\!@  _!L  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RU66UO
MVS80_BN$6Q0MX,0BJ=>\&$B3#>O0EZ!IMP_#/C 2'0N519>DG&:_?D?9L6R1
M8EPL^Y!8LA^>GB./]]Q19_="?E-SSC7ZL:AJ=3Z::[T\F4Q4/N<+IH[%DM?P
MRTS(!=-P*^\F:BDY*]I!BVI"@B">+%A9CZ9G[7?7<GHF&EV5-;^62#6+!9,/
M;WDE[L]'>/3XQ>?R;J[-%Y/IV9+=\1NNORZO)=Q-ME:*<L%K58H:23X['UW@
MDTL:F@$MXH^2WZN=:V1<N17BF[EY5YR/ L.(5SS7Q@2#CQ6_Y%5E+ &/[QNC
MH^TSS<#=ZT?KO[;.@S.W3/%+4?U9%GI^/DI'J. SUE3ZL[C_C6\<BHR]7%2J
M_8_N-]A@A/)&:;'8# 8&B[)>?[(?FXG8&8##@0%D,X <.H!N!M#6T36SUJTK
MIMGT3(I[) T:K)F+=F[:T>!-69MEO-$2?BUAG)Y>BEJ)JBR8Y@5ZRRI6YQS=
M&',*':&O-U?H]<LWZ"4J:_1E+AK%ZD*=330\V8R?Y)NGO%T_A0P\Y?>F/D8T
M&",2D- Q_/+PX71_^ 3\W3I-MDZ3UAX=<KJ1DM<:,:7 SQ.7/VL#H=N V5LG
M:LER?CZ"S:.X7/'1]-4+' >G+N^>R=B>KW3K*_59GUXR-4>P:B@W%_Q[4ZY8
M!<X[5W%M*FI-F02PFD(Z".*SR6K7'0>*9&FT1>WQ#+<\0R_/BSP7#=""W)!S
MX'A;\3&JN7;17%N*=PG0&"<]F@Y4FM'$33/:THR\--_5*Y@\(4ONG,#(>B8F
M,:4]9@X4SK*!"8RWS&(OLVO)EZPL$/\!*5YQU2ZZT',N(8_LQKN+=VPQBF(:
M]6C;H 3'Q,TZV;).O*R_",VJ P@FUK-CG&:XQ]!&)3A(,C?%=$LQ]6:+CZ(^
MRI_.&.ES9HQG,K;G;[;U-WLBD*!(D/IAC*Y!#G0;1[] WEB">NLQ^NC>DYF]
M0%D_[FT,3O% V..@4[# R_<3L&6ZK.]0Q4'0D33*?21F1PW<#$?4QNHNFY1D
M/<8.$ FB<(#RCNCB)[*(9O5="3EN0W PU6T,[>U,$D;]F77!TBP)!HAV0HF]
MVC3]U.:/VMH!3JK$GBMBSZ@#%85#0="I'/;+W#J/'$B4.K(="<(^4QL61S0=
M6OQ.Z+!?Z=94/?1LX<(X#;)^.G;A:!S&=(!@)W$X\B:\]R6[+:M2@\:-T6.M
M]-?%K=(2JNZ_G9R]JOFSV>^YK.W[WPDI]BOIMA19L@=3AS@=ML40!V$8]-?(
M :-AD@XL4:>:V"^;0%$V4+%7W5(Y6=J"2-,HL2+=AH5QD@WH)NZ$$WMU:OJ9
MKT2U,IDYE[PH-9JQW+!]<')-'56='?0V"D>#(=])'O9KWGM1WQU]X7*!KOBM
M[J+^ ].-')Y>EZ!%_3K4@1HJEDDG>N0)T6L3LVNG.KL9A]9E.Z7;IDVQ44F0
M#6@(Z<2.^,5NO\1[(F*)+60QJ$C:I^J 9<%0+4%V&D-_9[@WH5#XY0=E/_*\
MW>+_T2Z23DF)7TG7&P#*$21FVU5;"FE.79S.VS*)@S3I[P(7+$SPP,XEG9H2
MOYI><0G=HCD+0O=,2G9 B#ETDR1A/],X8'$8#/'MQ)7X&TC'QNWBS$G7[A;#
MR"JK'*@X2X;V0R>%Q"^%=EGUU.3:@D>@QN\W:DY8L-//[?/M=)'X=?%2+!:E
M-HW*NO_-16TZ U[GP!>]KH7F"*=OG,R]EMW;#CGW[W\WM.]]I[?$WZG>:)%_
MFXNJX%*]>I$2G)RV)SYNP27/VK$^E[5]USL!)T\UK7S&(4(+I,PDC*%VDVC%
MJH:CE\=!$.!3% 5CN#!_2,V9-"<DC9X+6?[#BU.(\<=O2Z5,:24D$HU6T*@5
M$$'.";2%O5__>2'[YWF=]%._])L8%_6PGR3P.AJ-LX2,8YJV&R0:1S@9XR3L
M>=\>'G7NCQ'\MN3MF7OEC"9J%P_]3>^%[$]&5UQ0?W%Q44!="<H$6<J<?AV5
M-<K9LH2LY21IEPU0C<=IO[QPXF@X5+;1KKZ@_GX:ZO9FT53M:7O!9V5>.G,^
MM9OD(XJS+.GW_4Y@$&(R4+O3G6/C0QIJ]5,9A=H:3Y($6^?'-HQF-!HXF:5=
M*4 /::QW!*J-XI]T(;0.MYW-MPOG:KXG.Z]FS'NQ#TS>E;5"%9_!P. X 0MR
M_:II?:/%LGU;<RNT%HOV<LX9D#< ^'TF0,,V-^8%T/:%W_1?4$L#!!0    (
M *Z .EE.)B;HI0(  ",)   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
MI99=;YLP%(;_BH5VT4I=('R$I")(:Z9IFS0I:K3MVH638-78S#9)UU\_&P@*
M#6E RT6PS7N.G]<<8Z(#%\\R U#H):=,+JU,J>+>MF6208[EA!? ])TM%SE6
MNBMVMBP$X+0*RJGM.L[,SC%A5AQ58VL11[Q4E#!8"R3+/,?B[P-0?EA:4^LX
M\$AVF3(#=AP5> <;4#^+M= ]N\V2DAR8))PA =NE]6EZOUH8?27X1> @3]K(
M.'GB_-ETOJ5+RS% 0"%1)@/6ESVL@%*32&/\:7):[90F\+1]S/ZE\JZ]/&$)
M*TY_DU1E2VMNH12VN*3JD1^^0N,G,/D23F7UCPZU-M#BI)2*YTVP)L@)JZ_X
MI5F'DX"I?R' ;0+<H0%>$^!51FNRRM9GK' <"7Y PJAU-M.HUJ:*UFX(,T]Q
MHX2^2W2<BE><24Y)BA6DZ %3S!) &Y-.HILU%L!4!HHDF,I;]!%]0#:2F1Z6
MD:WT]":)G313/=13N1>F^EZR"?*<.^0ZKM\3OAH>[G7#;6VZ=>ZVSMTJGW\A
MWUK7"PBA;>M%3I[O4($%VF-: KHA#*6<4BPD*D#4CF_['-=3A-449L/L8V?B
M.,XTLO>GSJ[*.@Z\UH$WS@$N5<8%>7W50\9#_:1ZP>O,LQ.BP*E_;] '"#OP
M?@OOCX,G4I;7N?TSG+? [RDZI$%+&HPCU2]#J3!+"=M=PPVNXKZGZ.#.6MS9
MN[@KGN?Z_?@?13T;5M1791W\L,4/1^ ?*_IZ881GZ^@Z_14]1-E!G[?H\Q'H
MP^IY?KZ]%J$[\^9OH'MTP32<AGX_\J)%7HQ 'E'8BX'</;I>;OOD"#.?#S^P
MV!$F$86MCG0FH=XGHCZ2ZX[B176J/7&ES\BJF>FO&!!&H.]O.5?'CCDHV^^B
M^!]02P,$%     @ KH Z6>%7)F5V!0  [10  !@   !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6RM6%UOVS84_2N$5PPM$,<B]9TY!A)WZS+T"TV[/0Q[8"S:
M%BJ1'DG;V7[]2$J1;)%B5R OMD3=>WDN+WD.R?F1\:]B2X@$CW5%Q?5D*^7N
M:C83JRVIL;AD.T+5ES7C-9;JE6]F8L<)+HQ37<U0$"2S&I=TLIB;MH]\,6=[
M6964?.1 [.L:\W]N2<6.UQ,X>6KX5&ZV4C?,%O,=WI![(K_L/G+U-NNB%&5-
MJ"@9!9RLKR<W\&J)$NU@+'XOR5&</ .=R@-C7_7+77$]"30B4I&5U"&P^CN0
M):DJ'4GA^+L-.NGZU(ZGST_1?S')JV0>L"!+5OU1%G)[/<DFH"!KO*_D)W;\
ME;0)Q3K>BE7"_()C8YN&$[#:"\GJUEDAJ$O:_./'=B!.'& RXH!:!S1TB$8<
MPM8A-(DVR$Q:K['$BSEG1\"UM8JF'\S8&&^534EU&>\E5U]+Y2<72T8%J\H"
M2U* >ZG^5(VD &P-/NP(QWJL!9B"+_>OP<L7K\ +4%+P><OV M-"S&=28="1
M9JNVO]NF/S32'T3@':-R*\#/M"#%>8"9 M]E@)XRN$7>B+_MZ24(@PN  A0Y
M "W_OWOH@1-V QJ:>-%(O/=JZ7%R('1/7*/3.,?&62^QPR*#08#FL\,I9-L*
M!FF8YYW9&;2H@Q9YH2V9D+JP E?$6;K&/3GI%B413 ;@;*LH2)/4C2WNL,5>
M;&\X$P+L.%N7T@4MMCJ-HS@;0K.MDB0)D1M:TD%+C%LX JU=!W0#R*-B3T'$
ME0MAXLM/L_&5V.$5N9XHNA6$'\AD\>,/, E^<LW99PIVEF_:Y9MZ2W&O.%5G
MJQ:X8AK^E>C<71FGCNF2Q]F@)K95!*,H<]<DZS!F_NE"J"I*93#B0O%B*:0N
MTL&YZ#(;*(IA- #JL,J2,' #S3N@N1?H)U4>S%=;@[10O%"QG698%\S<!I#F
M<(#2-HJ"/':#A$&O H$7YDW-N"S_-72O*:*D$M--^5 1@(4@TLWT@;TH$1QR
MF<,J2K.1^L,3W8+?&EC)]RNYYWJNKA2UN3%">U##)!YBM*U&Z@Y1#Q!Y =[5
M.UQR7>LGWG#B0YZ>6W"V29P&8R7O=0KZA>J-VN.!-6>U&CRJE[A&JAY%6;2Z
M[\0;?ANO;3+-DQ'M@KUX0;]Z?692+7AFD;$3I:U1<9Y%%E+;+ N3?$3*8*]E
MT"]F;[66F:%EW1[*"=/6JVF,XB$QN<Q@&B1C4Z 7-NC5D<4'N25<K?45J\D%
MH,3)2FV,L[%,AB3O,()9-(*O%R+H5Z([*HG2-_\"LO5E&J6YQ4(NLSP)1R#V
M.@3]0O2:\/)@A.<"F!7U4A?_%5 T>OKI_<C8VIHSC8+ F@"VF4IQ#'LO3="O
M36::/A!U%B3M)  2/SIQVJHSA7K7-P3JLE-<!=U04:]/R*]/=QT\WUQ MM2H
M[JW)ZC ;87O4RQ'RRY'>]E=J/)VPH+6=G\(XBX9E=MIY1J^7(N27HELLRE6S
M RFKO3[I'<WQEA13?% $M2&*^.M:S5FQQ6K! 77>%VH#4&B>?5D^-;]R)N=0
MISA,\S@=9F<;AJ$ZTP3)2'J]DB&_DMGIT;8:0-%O ]ZD4;"JPORDU9U1TUMV
M6@9T:9TU7&;Q)1PK5J]SR*]S-^;L")9X5VK!>\LP!7^^(_4#X7\YX7K#?>_!
MX[FBG2??*R>*G^.LA;SZ^]TY/U.T\YQ[%49^%38TK-8>>=2)[TNQ-9M&M0LO
MR(-3-MJ 9T01YQ:=V%9#FIN=7!S5A&_,?9I09+"GLKF!Z5J[.[L;<U,U:+^%
M5\OFYJT/TUP$OL-\4U(!*K)6(8/+5.'AS=U:\R+9SEQ//3 I66T>MP2K/:@V
M4-_7C,FG%]U!=\.Y^ ]02P,$%     @ KH Z6>:G^B6T!   ]Q<  !@   !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6RU6&UOVS80_BN$%FPM$$>B1+TXLPTT
MB89U0(<@:;</PSXP$AT+D427I./TWX^4%=FB9"INM2^V*-T]Y#UW/-YQMJ7L
MB:\($>"ER$L^MU9"K"]MFR<K4F!^0=>DE%^6E!58R"%[M/F:$9Q62D5NNXX3
MV 7.2FLQJ][=LL6,;D2>E>26 ;XI"LR^79&<;N<6M%Y?W&6/*Z%>V(O9&C^2
M>R*^K&^9'-D-2IH5I.09+0$CR[GU 5[&,%0*E<1?&=GR@V>@3'F@]$D-/J9S
MRU$K(CE)A(+ \N^97),\5TAR'5]K4*N94RD>/K^B_U89+XUYP)Q<T_SO+!6K
MN159("5+O,G%'=W^3FJ#?(67T)Q7OV"[DPT]"R0;+FA1*\L5%%FY^\<O-1$'
M"JY[1,&M%5Q-P0N.*'BU@J?/$!Y10+4"TA3@,1O\6J$RW=[97A%W@P5>S!C=
M J:D)9IZJ-BOM"5?6:D"Y5XP^363>F)Q34M.\RS%@J3@7L@_&06" [J4(YH\
MK6B>$L9_ ?'732:^@0GX<G\#WIV]!V<@*\'G%=UP7*9\9@NY&H5I)_7,5[N9
MW:,S%X6,E&H6\,\G4CP0]F\/S+49YD.:9BKD< YN<99.Y**N\3H3<FP O3&#
MWA$A]YAD),:LS,I';L**S5B?J5Q+6\V63FH\Y3:><BL<= 3G"N>X3 AX)RWD
M*\P(?P^P ']LR@O@.>? =5RWSPL[U*!"56GC>0&G;C1%<&8_'])LG%WEJTN^
MQ@F96S(A<<*>B;7X^2<8.+_VT3LF6#P26(MUKV'=>Q/K;V%ZA^0?,.UH''<E
M/ ]Z4= 6N^F*3=PH=,*H+1=WY1#RG+U4RV+46(R,%E<;<J*2;PH26L@3B>,J
MIY,7]=P*P#X64"?>)C""D4Z%<1&GAMN88/%(8"WR_89\_X?([R/<'PP[O^.2
MP$%ZT'6%-)AX *9E<- 8'!@-_LCYIMI@\L!)=B<"5QR<@U)62?+E&3QW' 2R
M5[F$<C$4@D%GH5[@! AZ&B_&I9T:@V."Q2.!M5P2-BX)QW=)GQO"3F#J9T[8
M$U&^YJ6;KI >F+TPJ#\PHX:%R,C"G]+6G/+>PB8:W'%&[%,C*^K)J*'C:V3&
M@V(M'J8-#],?+3N\/HZFG=7X/@QAB#2FC+.?RM288/%(8"W6H;.ORYWO*3QZ
MN:ZA3#NM%FGE1.2AR-<V6X_<Q',0=*=:M/4!3CT_[(\V>-"/P/^U_*CA6_4N
M<GU]@YI7<6K<C8H6CX76]L"^SX#F1N-[:I :TI028;<1<:?ZD7S3(Z5G^R&@
MMMG[0A^:*WU3PH?#I;T9_>2 \GJ2N1\AI',Q*-=F8]\$0',7<*P( $M&"QD)
MA"49K[YN,6-871D,;<QN8X!D7H'Z@6!>V,E$CMH:C(76=LJ^.8#F[N!TI_0Z
M8KAA@-U27YX CKY7AUN&(: V$?NF 9J[AC<4):C7]&YGX$]#-_ BG8!16X-1
MT>*QT-K<[[L#:&X/CA0F_7P/MP ](AX*@RC2@ZTK-_'@=!IZ>LAU!=TPA'J?
M:A_<F:HK\4^8/68E!SE92CWG(I0 ;'?+O!L(NJZN41^H$+2H'E<$IX0I ?E]
M2:EX':B;V>:N?_$?4$L#!!0    ( *Z .EE5<R=1*0(  % $   8    >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL?51A3]LP$/TKIPAI("&2IK!-*(W4%J8Q
M":FB8_MLXFOCX?B"?:'P[[&=-.NDP9?89]][]^Y\EV)']M'5B POC39NEM3,
M[66:NJK&1K@S:M'XFPW91K W[39UK44A(ZC1:9YEG]-&*).413Q;V;*@CK4R
MN++@NJ81]G6!FG:S9)+L#^[4MN9PD)9%*[:X1KYO5]9;Z<@B58/&*3)@<3-+
MYI/+Q33X1X=?"G?N8 \ADP>BQV#<R%F2!4&HL>+ (/SRC$O4.A!Y&4\#9S*&
M#,##_9[]6\S=Y_(@'"Y)_U:2ZUGR-0&)&]%IOJ/==QSRN0A\%6D7O[ ;?+,$
MJLXQ-0/8*VB4Z5?Q,M3A )#G[P#R 9!'W7V@J/)*L"@+2SNPP=NSA4U,-:*]
M.&7"HZS9^EOE<5PNR3C22@I&"6OVBZ\X.Z"-MZAZK$E+M.X37#]UBE_A>"6L
M=ZB1526T.X$C4 9^UM0Y8:0K4O:B G5:#0(6O8#\'0&3'&[)$SJX-A+EOP2I
MSV9,*=^GM,@_9/S1F3.89J>09_D4[M=7<'QT\@'O="S5-/*>O\,[EW_\>_3E
M88*YE"HTEM"P$DJ&,BQ%JUCHT[YT<.-<A_(TKL)4"$MR_-\2]8$O8N P1L_E
M),O.B_3Y4&YZ\,H-VFWL90<5=8;[!Q]/QW&9]UWRU[V?M5MAM\HXT+CQT.SL
MBP]M^_[M#:8V]LP#L>_ N*W]R*,-#OY^0\1[(P08?R+E&U!+ P04    " "N
M@#I9G/.SJX8'  "[(0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U:
MW6[CN!5^%<)=%#/ >"R2^G.:&,ADNNTLL+O!IM->TQ)MLR.)7I*VDSY]2<JV
M;)&B'< WL:0<'G_G]^.A?+_CXH=<4:K :UTU\F&T4FI]-YG(8D5K(C_S-6WT
M?Q9<U$3I6[&<R+6@I+2+ZFJ"HBB=U(0UH]F]??8L9O=\HRK6T&<!Y*:NB7C[
M0BN^>QC!T>'!'VRY4N;!9':_)DOZ0M7W];/0=Y.CEI+5M)&,-T#0Q</H$=X]
MQ7:!E?@WHSMY<@V,*7/.?YB;;^7#*#*(:$4+9500_;&E3[2JC":-X\^]TM'Q
M.\W"T^N#]I^M\=J8.9'TB5?_8:5:/8SR$2CI@FPJ]0??_9/N#4J,OH)7TOX%
MNU8VPR-0;*3B]7ZQ1E"SIOTDKWM'G"R Z< "M%^ ^@OB@05XOP!;0UMDUJRO
M1)'9O> [((RTUF8NK&_L:FT-:TP87Y30_V5ZG9I];\BF9(J6X(DWDE>L).;F
M1>D/'2TE 5^ )R)7X&<=<0G&X/O+5_#AIX_@)\ :\*\5WTC2E/)^HC0:HW-2
M[+_Y2_O-:.";(0*_\D:M)/A[4]+R7,%$FW&T!1UL^8*"&G_9-)\!CCX!%*'8
M ^CI^N4X  <?78NM/CR@SWIM8;VV$+P&NO0$4:Q9MKG+%*/RSN>W5FWL5VOJ
M^DZN24$?1KIP)15;.IK]]2\PC?[FL_E&RLX\$!\]$(>TSW[3;:CBTIL<[<K$
MKC2]9CL;PR2/==RVI_!]8EF4P*/8&;#D""P)AN:Q_*\NK3:_%=?MJ.!-P2H*
MFCUB\[0P\=M(70TZT:\.7G++X-U(V9F/TJ./TF#POE*MM&#$=-M/@-1<*/8_
MTO;>IM1N* 0U=SXGM)K3DZCE*$.]T'J$<ICX YL=06=!T"^*%S_&IJ^7H."U
M)CO90J:OYIKZP&8.#C2%N ?6%4JC./6#S8]@\PL>%FQ+#(V!'1&"-#KW&)FS
MRF97FX<?EIJ*/_I@YPZB.(KZY>,*C>-LBOVXIT?<TR#NQ]-<T/10TKD")9,%
MWV@33'(P*3>D*:B.@53>\I\ZP))IU@/OD4FF?N@PZO@N"H+_UFQUV7/Q!G9"
M\]ZXY#MO"N_5G*4%RJ(>1)\4'NI.\(248=C#4NI&]*U>$R9,EP)/*R*6U,^R
MT('@H'1%$MU$!U"B#B4*HOR'3LV6VG3[-+W1(-67DI6V6?I[PUYI$*\K,IZF
M0Z'O^!@&R6[V&V_&MJG;RK)-P:#>,+FR3MZGLA<T]E5;'[8K% U@[A@4ABGT
M=[6B C0'Y*0C+B_,V&U3J0/3%<H&8'9\"L.$JO-3AU_VF-)DL;0-X:2O>5D3
MWI0V;Z7MW!D=<<(P<SX6MA-*LZ^@NL//*_K)["R\AKLLF&#DA,R5&F<P&>CC
ML&-+&*;+0S-D ZW%9;TQFD9Y'YU'#*?14+UV] C#_/@LJ&Z Y8&[VTSBMB"*
MC1"F9-L4\V)WJ0\FJ$\Q'JE\B-9AQX_P D$>$F!-WDSTO?A<=ANC/)OV ;IB
M".>Q'R'J6!"%65 C%!MZ5I<^D,BEM_$T2?M>](CI^ _P"^I8$(59L.U]E_K)
M8&DAE_6TYQSLKM08YB>;U7/P'3FB,#F:V>?B!.&%[2$_B/-^T?G$$H@&B@YU
M)(G>-[4RW2+D-8,/NNG8>BMMYU[H:!==0[L^V[VFNXPZQJA?RCXI" >H%W74
MBX)LYB;:U:B3JU![I(91=QR)TG>EV8(U>F"X)LV"W/ON-+N1MG,O=/R+POQK
M8K<6O*"T/)3;87+2FU$]P-9ZERK-3&N[WGY*]$?3)6$<NYW:E8))D@VUZHZJ
MT06J)F]V"UV3DIJSDP5[U<FXWC^UL)?V/-$+W3.EHB1-^]A]PRQ*!]@:=6R-
MPFQ]%H0/>\SR8VN+/:S>\FIK4K,0M&0*+$AAN.?-:XO+USGNGWQXA,8()0/#
M NY8'8=9?1\%>0S#G NM1$/WI@SVL#M,,M2'ZY.;#K@==^R.P^S^?);W%Y"Z
M) UQY Q@'K$AGW8\CL,\?LCL!1?M0<?ELPWLH6:4]4^4?%+3@6T'/CESOC#C
M'MC@PYX./IK<WNJ)O 3S-V^;]9K@CK)CB%(G,URQ/,\&CC]PQ[[X\KEQ82=*
MPV?MX*O;G[V@?V[T2%4-3<#80[)HZFRK/6(X10-M$'=<C,-<_#0$%1 %YG3)
MFL;X7O=VO1EDO/1:X!(N0M,\Z5O@BL$I3H?RO2-F'!Y>@R90,X %P;N#*M)U
MVF_E/K$S&\_!=WR*L^"NXF6S7E>69TAE3R0K+C>B)=-NP\&:]O4GXXW__4N0
MM-_] N9&VLY=TC$S#C.SC:<=HTT'8XVB^EN\-(Q])\K8J1Q7"N=PJ&]U)(S#
M)-R'J?<^FL'(ZT![<@E4.ZP_(GFD!LHC[B@VCH(9=CQ#/-EEZZ*X>OL:!QG\
MO;EU*VWGSN@H/+YF0&^N=XG7(]!YQ9?E_7VK1PC&_2%D<O(:O*9B:7\=(($]
MBVG?(A^?'G^!\&C?N_>>?X%W3^WO"#HU[<\:?B5"-W$)*KK0*J//F48DVE\*
MM#>*K^W+]CE7BM?V<D7U;DP8 ?W_!>?J<&.^X/A[C=G_ 5!+ P04    " "N
M@#I9MF(ZCY$%  ![#   &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(U7
M;6\;-PS^*X(+%!W@^"U)FS6)@;RL: >T"Y)N^S#L@ZSCW0G125=)5\?]]7LH
MG2].X 8#BEI'D13Y\"&EG*V=OP\U410/C;'A?%3'V+Z?3H.JJ9%AXEJRV"F=
M;V3$IZ^FH?4DBV34F.EB-GL[;:2VH^59DMWXY9GKHM&6;KP(7=-(O[DDX];G
MH_EH*[C551U9,%V>M;*B.XI_MC<>7]/!2Z$;LD$[*SR5YZ.+^?O+(]9/"G]I
M6H>=M>!,5L[=\\>GXGPTXX#(D(KL0>+G.UV1,>P(87SK?8Z&(]EP=[WU_B'E
MCEQ6,M"5,W_K(M;GHY.1**B4G8FW;OV1^GR.V9]R)J3_Q;K7G8V$ZD)T36^,
M"!IM\Z]\Z''X/P:+WF"1XLX'I2BO993+,^_6PK,VO/$BI9JL$9RV7)2[Z+&K
M81>77UPD,1<'XHN,G2?A2G'9!2B%(*0MQ =MI55:&G'E;*$9R;-IQ,%L/E7]
M(9?YD,5/#IDOQ&=G8QW$;[:@XJF#*2(>PEYLP[Y<O.CQ]\Y.Q.%L+!:SQ=$+
M_@X'& Z3O\,78 @BNIU\[Z*,!/K%L"_A[.YHOSONI/>AE8K.1VB50/X[C9:O
M7\W?SDY?"/9H"/;H)>_+/WPEK?XAN1ACKDMP1A<RLQPUN^$C;<P"%'1?3N):
M!V5<X)K_\Y4>HK@T3MW_NR_7%Z/9GVM/JXM-[,2E=C>U1 >-Q2>K)N+-ZU<G
MB\7LE#?':3T_%;$FT<NO7--*NQFV>O&:GDNZ,$B<WPI=YWOA+V.A06+1IL,5
M=5$K8*"R>U$ZM!<5 AA!U)!GA/0/;2MAW7<R')*7;3(+$_$5 ?:1B;4,.%%7
MP-68C=!6.=\Z#VP+@:U;%VBM48BK7ISJ8,5%5Z&AQ:_,VMEB+$!B$B?\-3^>
MB,_2JYKY/!=O=D_C;.;O3H,(D4^H-IP5F+HBA$W(SV 6<]0_R3/6,@K=M!Y)
MA82ST;P",5J$QF1XFAU08=BV^,@6IA*AP4#; Z,5CV1;C3%1OW7:IV5!0,RU
M68S,]R/*_%!>MPF077CA&( 6Y#DQA5&A;4=BU6F3,M/@*X",)7CN. Z/XZ!Q
M4)$EQI>S]Z[H5,Q3RV#?RVIK^QB-B"2; 5%Z:,E''2CAR:<-8*X\_ 0,XU@C
M-B-]1;L18P3[>WJ&W."W]9ION PAEVL/Q[0%)I*OI*>P#'FDNLFB\#R*U7;X
M!E%Z^M:A:B!>CSJ3V(M"R\HZKA@"5C62J9TKQLQ.TZ6<9(RPXT-P;6FEHZ@W
M "!=C#K"G0ZY"$.'7G^\WC;34XXXMDLCL_:NJVH1UPYK[8ND=OL@[JCB0=-C
MH1$M<@@ZQ,0\5B^U1S<$XMSZ#Q;G8RQ>"8CD(TD3Z\%9[X(3+D6#BU>WAI(T
M:==9>X"06X!B1KNO8591$F-/<3>AC2GL8F0,^6HS%K74'CRK,)MC/69T5\0)
MAZYE*K*DHI#JEWV.D<I#!XHQ 3OOC*M2'_9!L333%5<\'B%\PX[%NM;H+)XG
MN_Q ?EM<"^WQ?@'=='9,![TB]13DH%4MK27SK(]7A&N"F9UF4>'6J>=^BBT@
M*G$G(#R^4R=]1; ^'HOKCML\F9<8L#'-J2-,,&D[)GK62O,,RY/)XS*OMC<U
M)EN^&6;][SR+GRB->?NY&43X9UW<VW!JN .)J;3GNF/L;+[DT<4$5&J)TJV(
MN.6H!2%X=@.9G"AZ+^Y.?&W,XV"2/!\KEZ!W5I&WVTJR"C6M2;V!1[+IKVGF
M*[Q3'PF[#M@(I53;;0.&:8,F3WQ,*I;?G7QNYT-ZFJVV3[-^+CF M.]!,=UY
M$*+457KV,DR=C?EM.$B'E_5%?E ^JN=G.:XES-& P5C"=#9Y=SP2/C]U\T=T
M;7I>KES$8S4M07F,$5; ?ND >__!!PQ_;RS_ U!+ P04    " "N@#I9^N\#
MFXD8  !L10  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*U<:W/;1K+]
M*U/:9*]=!=%\B2(MVU5ZQ(FVO+%*LK,?;MT/(# D$8, ,P!$*;_^]NF>&0SX
M4'SW;E5"D\!@IJ>G^_03>K<MS;=JI76MGM9Y4;T_6=7UYNV;-U6RTNNXZI4;
M7="=16G6<4T_S?)-M3$Z3OFA=?YFV.]/WJSCK#CY\(ZOW9D/[\JFSK-"WQE5
M->MU;)ZO=%YNWY\,3MR%^VRYJG'AS8=WFWBI'W3]=7-GZ-<;/TN:K751966A
MC%Z\/[D<O+T:8SP/^"W3VRKXKK"3>5E^PX_;]/U)'P3I7"<U9HCIGT=]K?,<
M$Q$9?]@Y3_R2>##\[F;_R'NGO<SC2E^7^;^RM%Z]/YF>J%0OXB:O[\OM+]KN
MYPSS)65>\:?:RMBSX8E*FJHNU_9AHF"=%?)O_&3Y$#PP[1]Y8&@?&#+=LA!3
M>1/7\8=WIMPJ@]$T&[[P5OEI(BXK<"@/M:&[&3U7?_BUK+4:JE/U(*>BRH5Z
MR)9%MLB2N*C599*435%GQ5+=E7F69+IZ]Z:FA?'XF\0N<B6+#(\L,ABJ?Y9%
MO:K43T6JT^X$;XAB3_;0D7TU?''&?S1%3XWZD1KVA^,7YAMY-HQXOM$+;*A4
M7:J/61$721;GZJ&.:TWB5Q_<L$PW/CP=-.EMM8D3_?Z$5*72YE&??/C[WP:3
M_L4+Q(X]L>.79O_P%^>C_ON+?JK555XFW_[G$.TOSGZ8=BLF=R8CYFSBO(*<
M7)=%16NF,>O7EY6F*^M-7#S__6_3X>#\HE*)'Z%3M?"LK3QK55RDJA#FK[31
M= *T0MZD&K])9WEW6.VMNGRN&ZQBXHUNZBRI(O7ITW6D;HNB?&PJ=;>*24T3
MOD<4XD;2XP5^U66U\Z2_1\MDAN"EVF@&"+5=E7E.>K MB.:JF5=9FL6&^-I3
MESG1'C _*VIM3A/9-(%#3OO3LJ?:Q$45,_)4:A73O'.M"Z7SC)28V9$5 7MH
M6$]=Q57&C+T#WXOZ/\O7E@@ZUDULA 1PV*2@FX"G7CF.0YXV<M@YS;'4!3$/
M;*'[>F/)QPE]+3+\8F6IU"M0..Q??.T]]-3/EY=W_'MP\5K]7&)*DIA$FT+=
M:&(<,P([O&5.%!:GF0Q,+63*$+(^2L<)T5<4#>T4VV/N9^M@__1 :81VNE.F
M$2%E0:8%+%'Z,<X;IG*[TF"*<$81)^@>,ZU>Q77D=A8OET8OZ8%(F3BK-,M"
M3<>.E=*RF=<JGI.9X\&[!Q3/LSRKGX$HM#4BJ:$)Z;):,A\2RP?LE98K"\W_
MLY8-U%=:C*3@IZK.UDSPEQUNT,VCA[XHRUH.WN@_FLR(!*A&Y@SYX::/U.]-
MNFQGB"NRT!N67!+YI&Z8LQ69N8J>?X98 0CH1.Z8R^I>)SD]Q%K!]/74M38U
M>020(1KWK&.CXK6HLF7OOR?2>/*86!M/!LT@C(?3@J]X+&F,P;Z9F$V@83WP
ME]AC=K91J31C)5)D;;2W-OPYBKH7.[]&4.#'K&PJ4IA[EDFBZ X'2!/^]$0.
M544[N"W$IP+';AH#N0"=3)^&G=Q=M[/&SL\>"4]/S681$SSHJ^NX6C'+^,M/
M) HD_\S'0X!"YR36?_Z[P&#%*I<5]*UF<2'AB1_C+(_G.?&2)S?:Z2FLA!?-
M)-YDM=51W(=K6.N",89NYQG1DI)R]$)*[%(D'CCI[D(>6$ETYG'QC;RN35EE
M5B36I#G/M(CY1B[LHBG22B;^JT<-:S2VZR3DHTZ!<H1./(8.J&H,DWU=&CI%
MV:'#N(\WM]<>WC(_% !?DTZ!M#T2F!U[]#(M.+9Z9;1V)KV"7FDZ->)#1":L
M;F\8?P.0)Z+L]2LEJ%F8<FV]1VTJ11!.B^3D@ LE.-J$# #M,2^K"A"09I6=
M'(23."2,4V12EWH>)]\ !44[QZ$I"%8+56AB(@$O&3(XRRGA&N]Z3H?K(0=B
MP!#+)./7QI1S.?!P3K!,/V450WJ\OWNLF9%1H,52:U$ 'MC\(8A9T4RE@7.@
MMH;,UFFY6-#\L!4:>\+.\3-A"&KJAH[%.OB60( Z/"R_M;(00+?&A5&#/:,=
M<'-'8:\$ $<H11NF!R_4)GYF51,ZGR_H7FZCERJD$^NR 7,LN1#2::IRG25J
M07Y'2<<.FRF&S>^*)#U>+"#S=G_!$O_'$P9@9Q7[9K2\.\LLI04%@C$!O"H
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M5PT<8TTC_*7:9"XJNFB]:2OD=&E-9HCTMP@S\2B!DM?IHQCKP_-R-IN3V2R
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M0#M+8IBF"7Q&&M]:B1)XTVIUWU<<TAQFLQE<&H-TZZAKM0_6ZJ[?'(Y\G%Q
M')V]FJ&-5L80VVD\A7R4S2;DC02L*+JF$]1=)>T*Z@]JMWX;D3EKE+;\5R\X
M33SS=W":CB;3F ['BG$"DUGJTS2-\R&[5X<>\($6MT'8,@,GT7A&VT.(O>N3
M>)P.@K)/OZOJ(S)M -WD/I73E7'4U_%_,JGL,U'Z4L>'!]NI0;WQ.]A0BCMI
M^T4U2(<U?]EOMR?U_A]QS?2&2P,"*S*-QF=Y +K?N_W%JM;ONEME:7/Z8TV_
M*M1.@;Y7BAI]=W$.AI_?\C=02P,$%     @ KH Z6:BQ>0CR!0  ^@\  !D
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MQ<LYE88 OR<")Z%J800TU_W)OU!+ P04    " "N@#I9XA+\^Z\'  !=%0
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M:0.>SQ6 75_0 >T7U8N_ 5!+ P04    " "N@#I9?U:"08<$  "E"@  &0
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M 3Q?:KR(F@49:%^FL_\ 4$L#!!0    ( *Z .EEJ3[T2X@0  )P*   9
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MWD#?EX:RUKVP@_Y .O\?4$L#!!0    ( *Z .EGY0CS[0P4  /\+   9
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MR#=&0[*;DJ.V]J1TI6E36?9QI 9>I^LD=%VE:@<Q!P!TQ!HJ\**KREZQ4(T
MU\+RCDKV$@Z5JM$1A>);W+!HE!8J1J,2*AL0BQEXV9/43JR[#NV:DBF=/G\)
M_46B;S&-@%H/<%RFPVZQ[4V :I#T HUM.>"X5M?<^UCI&UW!N^Q-I<7<HLW^
M;71<BP<-BP-.VD[,!2YE##0#B^T*-[MDN&:_8I]A5 G)H#,*.BM95"'@"1*4
MX8R,X<@SDX9M \3(TJHV=!/4]<F(SFFIM)'LP0GT<F/NLF]0#[NM4+K68'IE
MD&/?9M"IN#1JOUY]$MW"Z%57D!9Y\H<9 I/I5IR*E4S?G]P4-V8SB"!&B71=
MXY(%4<#9JN5TC@E6"P/J:$P;$C&IIC&ZE,W=>J'G6HG'LX%G:#] *B2*>W[Q
M/5WI1'72[*%$Z>"26B AR%J:ASW:3..W;5@0E"L3W4ES@&Q"BQZ4=(8\2C]-
M1AA:;4Q^GIDDVQ'=8:(9T@(LM^H\%KGH9  .&?A?@'(*-XJM&T/:K#78:X.E
M)!F) K'_ QCTK9+WV5.Y#0D)R'64+&W)T0!PM)^0? G]]QX=NN3'.X^RU/WR
M]$Q-:&-^G_6[_>OV/#_JOHOGIS$NQ97PG^$E5">CY\\&Y/-S,R^B:](3;^$B
M"#)]KO%"9R\".%\ZD&RW$ /]FW_^+U!+ P04    " "N@#I9*"$TV40'  !H
M$@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R=6%F3VS82_BM=BI,:
M5RDZJ--S58WMN#8I)W'%3O9A:Q\@$I)0!@D% $<S^^OWZ^8A4:.93?9% H&^
MCZ]!7N^=_QJV6D=ZR&T1;GK;&'>7PV%(MSI78>!VNL#)VOE<13SZS3#LO%:9
M,.5VF(Q&\V&N3-&[O9:]3_[VVI71FD)_\A3*/%?^\:VV;G_3&_>:C=_,9AMY
M8WA[O5,;_5G'WW>?/)Z&K93,Y+H(QA7D]?JF=S>^?#ME>B'XP^A].%H3>[)R
M[BL__)C=]$9LD+8ZC2Q!X>]>O]/6LB"8\6<ML]>J9,;C=2/]@_@.7U8JZ'?.
M_M-D<7O36_8HTVM5VOB;V_]#U_[,6%[J;)!?VE>TDU&/TC)$E]?,L" W1?6O
M'NHX'#$LGV-(:H9$[*X4B97O552WU][MR3,UI/%"7!5N&&<*3LKGZ'%JP!=O
M?W%1TWA,W]-'5VR^C]KG]%ZOXO4P0CK3#--:TMM*4O*,I'%"/[LB;@/]4&0Z
MZPH8PJS6MJ2Q[6WRHL2?RF) DU&?DE$R?4'>I/5U(O(F+_@:*#KZ8 I5I$99
M^AQ5U*BQ&,XY7(F;GA?'[7(9=BK5-SWT0]#^7O=NO_MF/!]=O6#LM#5V^I+T
M6TG'ER8=]*\O^B'26^O2K_\^9^J+PLZ;VJ3^[EX7I:9W:F<B0O+1J8)^+>@G
M591H4TKFDH"$+DZW9@/Z5/I0JB)R5.-6G\JZVW@MX>W+Z3N7[U3Q2'L5T-!_
MEL;KC#ES]563*5!\.D1RA7VDG7J4M!!P1WC7QN-LO*1@'@B5 =-G8L6D3^/O
MOEDFR?A*SM[K5.<K[6DR;LXO:$PHSV><8EEUE27]EJ+F7@RH<)%9?U8^W=*B
MH:NB-P,[K&UW3XC ]FL:'5N3S$XU/'F:#NBNW*#G*]/87/%STOA1Z9R?R<./
MP+<L,P)T=2HR+IO,A-251;4H0T"\U<K=ZVX^E T.\4]+SPEY-1I, 376LC#+
MU>"\V:!E6'J?K-X@LZK(R$&&I[7684!?GFAD"A.X.E)-J0O(Y1X)II4VQ894
M[GPT_X$Z6%-E6+#'K67-:OM4!B;E9[U>:\'O0YGD.FY=ACH* &"F,XA!<43I
MT=HL;SP?S+^%A8XKLF77#YAK 03%N<(5MQ$16V8L^L2SRO8Z'N+4J\E1S-CS
M5\E@T6XT-?RHE0^D&1X[93>M$DR#0\Z3YF#M2A^W=7G\D%JS@]&""VVC=AE^
M<0.:-;4R$OX.R;)/0</;LR<=JZ2L)/H@1XMO5>R++UPSN $$=E]92_76CL,"
M=^L<-L:V((!RD"1S*2$".V\X+E6U\FTC*RVV,6E+;^(C9:#J2U9/*KO&!M8C
MVLL8(F+.B8), /NN+M"RV"F#BD]37T)RD_MN\9LN%D$X*2YJPB;D8.O"O*;)
M8/3MJ6.'+)@U;C5H_"I0+D4G!:XL^+?2B)CNQ'G6;V#GL''\.#\]GW?/%T_(
M.UD<((2/;?YY_>5L-E),:]S:0GW-8$!1:\ L$L#MDZ(Q,29CZ%.!EN_N27C%
MV\!1J:]!J(; :TP?CK8$2QU&P*&?NG(X)][(+2W45886 UD%,'$+%EA19ZF3
M/&0GP+2P?J14>W:'TKJ%I<%1."58K,FQ5RDX0J[V&G#DZ[%!X5@7SYCQX@H"
M5L9R?<8:,R$=2-*O'YIB%:QAW-!9H0..9<@U1F;FWF0PKS('R )]J[(R<&_0
M[S!A!QQC)>PVU 6=<E\8#5FZV.#&S"'.M=]H7XE1*2B#J:2@]#H:%< _(EA6
M5QK0-54S21?N(3D"$U 3H6ZMXTK_R)CE,9YHK8SEB,*N%''![!-S01R.RP-
M:='AW.SQC"1FSW1J53>=;8C=RII-G:^R8NB64G0;+3D4[:<-+M'@N<2$Z$ R
M>:XS SR!O1E@GL_1Z&IE@3 [6P;!+[7;69/RYG$648HEN^2U53)G(%(A;+J%
M(=^BF@P$Z8&0(J'-M$7@I$TZZ"I=V=2QUZGSF2 0U^[320J@<ZG IIR=#%;(
MQM2>M -';*WP["Q@86IM#?!J#WJ.SU^8QH..O>UEX;EY>D;EL^/TZ46A.V$K
M[\9GQ^FY:3HX>I<155S5IHZ3W"4=HKF')9?$)3>:7!T$-!N2(IG*S<Z%()HK
M PP.KRO/Y)YP-'2D5N@5W]E&HQ$O9K+XO3B$^']Z?Y',Y_2:+MXD,_SQRXIM
M9QX/)FF3Y(KFDV7S*H.@6@QD]'9SN)S5-QY1A]FPF$QI/.TOWBS1A"%<DF00
M(H_&MM!>C/O+V8(-6++^@Q0>! (-IYQP<]1?+A:\@(;Q(68?2L'?0X3:>SW$
MV&Z6& Q4J),37DC-22)X@+)FL9KGX6&Y."R7N)5/DS>U.^O*KG@FAZV%=0ZK
M8)7_1P+_8IC_3H#/O5@.C][^91SP-PZ!X")6'P+:W?8SREWU]>! 7GV#P>O+
MAF\$5J_!.AHL9CWRU7>-ZB&ZG7Q+6+F(*X,LMUH!H)D YVN':T?]P K:CTNW
M_P502P,$%     @ KH Z6<J#KBH="   <A<  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&ULS5AK;^,V%OTKA-L,$L"Q9<EVXKR )--!4W2Z@TFF\Z'8
M#[1$Q]Q(HH:DXKB_?L\E)47VR-XI=@KTBTWQ<1^']QY>\F*E])-9"F'92Y;F
MYK*WM+8X&PY-O!09-P-5B!PC"Z4S;O&I'X>FT((G;E&6#L,@F XS+O/>U87K
M^Z"O+E1I4YF+#YJ9,LNX7M^(5*TN>Z->W?%1/BXM=0RO+@K^*.Z%_51\T/@:
M-E(2F8G<2)4S+1:7O>O1V>V4YKL)OTNQ,JTV(T_F2CW1QUURV0O(()&*V)($
MCK]G<2O2E 3!C"^5S%ZCDA:VV[7T=\YW^#+G1MRJ]+-,[/*R=]ICB5CP,K4?
MU>IG4?DS(7FQ2HW[92L_=S+KL;@T5F758EB0R=S_\Y<*A]:"TV#'@K!:$&XM
M&(UW+(BJ!9%SU%OFW'K++;^ZT&K%-,V&-&HX;-QJ>"-SVL5[JS$JL<Y>_::L
M8*.0';-W7&KV.T]+P=X+;DHML%G68.33_5MV^.,1^Y')G#TL56EXGIB+H85^
MDC*,*UTW7E>X0Q?4O%>Y71KV4YZ(9%/ $(8WUH>U]3?A7HF_E/F 14&?A4$X
M[C#H]MN71WO,B1HP(R<OVB'O+H]5)MB]Y=:!Q_ZXGANK$:K_[D++"QMW"Z/T
M/3,%C\5E#_EIA'X6O:LW/XRFP7F7I]])V(;?X\;O\3[I5]?&@&_NL@(AY/R^
M77+]*#I#Q$N:.$E$,<]7P<7PN>W)US,F)\&DF;1AX:2Q<+)W9RC,#;.*O9,Y
MSV/)T]==ZC1S\CWWYCL)V_!\VG@^W;LWK;1^*TV<*LILP_YX$"^6W:0J?NJ,
MS?U":]9X6 IVJ[#O^1K<:84&0Q'.Z%Z0WF>G5RW8HH$=U,%RE1^W>BAZ#"N-
MS!^WERZET%S'RW6?K98R7C)A+)^G$H1':K00(,,U^U4\BY2-SMA=7I261KBE
M,X8."U;F//D/F%0D[$NIZ*_0,L9Z69\BD*&?1+V.:X%^3#!RG@H*FNNU+1E.
M3"83Q(N,7XU&7RKY7*;22F'.*T/"QA"9QVF9B"W%),K(3*9<UX((EI:DEFVD
M-M^R$WV-J6I.(</)U(7K%UYFV[8U$Q(#FB52 Y)T[:767^=.O;<].F.?\I9,
MV4*4U)FR*)0F9^9KR+<V=2;FJAT,;WXX#4<GYZ:U[S('$Y;^2*E1B;E9.M6N
M(;Z4$KM.,_JT :JDN;!02&=*J[/@ZZ9'EV(#NCXB46.% VS%M>8@I(WQ&(<0
M8HV("DV#3=7<U10;LQ;RA7:,KQVC.3F/GB_ZWN92:S=2!73]G8BY'3@P8BQ:
M4U#SS)N-1(B%MJBMF%D"Q&/*F&Z,^A5(M/S_A<FM[4"*\:+0ZD6B&!(4-\BZ
M5NHEI8M]W^_,1?C94KNE W:[QWT7*%I4<8+ \4( @[;R3W3%RA <N8O6[9BA
M/5&I3+@+,IX"'(0=53C&XXK*!! 2,MWAM:']KRLA@^L=\V'?@JEV\Q6HRJAM
M!06DQVLFW:F#W5&/.5QGJ 9RLQ#:9WB>#)$[**X=1W;0'E*9AL@#,I46>1ZD
M'N1K[M(\7E)LTF L=5QFX,B<>";FI8%[-+?6ZXP%/BOZ0=*.4/RPB'T4Y!A!
MVET&.A<7*D71[UC:A94[K3Q*^S)_!\,Y:)T95;S"4B(P;C?.#J!$\%76H6('
MHAX45&^B*?Y\#<=(?1"=-_\M;R!W5XF+H0UAS?+-WL/JF#FJ6V'3BHZ:-8>2
M(JXJDH_8KZ\NGWUEWO;_V[W,A0)\%/9/QA,T',[A^4:K&GQ0%JA_V]SO@E?4
MB5?T3\!KVA\'T0X(_%B-UO^>62N]W47'3'JNV<<M]=$WY_D3N+)01E:YD:E<
MK*L3GBU*@.&ZZRKF*W[&)E3XLM_ O]^4P7]GDM(AL)VH2:GKHFXM.$A/T,6O
M,W/?[3QN*SZO&'3G>5*I]&5D!:-C;A1=1)T)JE_R@.&P%][3JM+3@MPJB]?C
M+E=4#P"6!<KRVLEGU$]69F+ [B5,6: .)$N-*;."II-NR$$0T(*FF-WME\-U
MRZR%5AD;!8/@@*P930;C@\;4.(4RZ"4,3%VNL?>H?X%@V&>N*I\U<7K#S>[S
M3[Y>UC@<79NJ+%W '/CM^,[M"Z#8HL'6TMC=\[;2/G(EN3/FQ/^%[-X_$A%M
MUW9WG2@N!F&&18+5#TNN:G('G/$;I,S&%2'S,5[O?"V^F]!;A/&Y(HQZJ$4\
MN[CIILKEK\^?D"BU?S*;LCO$ V ?!?W9[)3="RJ0_7;7?'+G*<!%"I*""AG#
M#J?]:#9B^W1$%0]5&@[!JY/^:+RIA'H/P_[I*("L3DWC?A",]Z@9OYX.A^"6
M#QJ%CY:X,FB1\NH679&M:Q<E"A6$&@O[HY.H/\.U,%89V R4QVE?I+=WA1M(
M9R@ZY<Z_NC4>^+@9C:O_:;.MNU*OLR38.):<AL^UX4VCGO. SQC67;-_N9L2
M 4FO5;"7ZU2Q-SPKD%,ICY^.[^.E2N'9YI>[)=(%F\+06-RL_7T/>(:#65C_
M_=0<&,R5_X>.&8]8-)AAPI0=HX59+P58'[ ]*Z#N[W"GP2!B!^P4XP>8=GHR
MF!RPC](\'2_H(DP$PL:#,::,:>08?],#W/J?Z=J:L+44:<("#(-<:&NK\(#E
MY2/NQSZ.WU/=Z9L5]ETO&GN?!_[JB\:P]7R9"1 *O>I2B0Y:]&^!36_S<'SM
MWDNW^F]&9[?^_?=5C'^-AE>/N"*P5"P@,AB<3'I,^Q=>_V%5X1Y)Y\I:E;GF
M4G#<#&D"QA<*8%0?I*!Y9K_Z+U!+ P04    " "N@#I9G U?%9P(  " %0
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M?$GZY2X8XD;;)"UL993XQ[UZ=.(Z+9+O_SRE\<LRFU #S6()H7  N5;$TTC
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M!GS3M):*A[FB3985[!(/,JV@!<TF2^[W:41@*:0S)3JJ3VR"MJ1_;>.RH!2
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MB&33\]8P/+E(C+P5^,'94FVTB?%D+,2#^?@\.6\%QB"6LTP;!(K7([MD>6Z
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MY^6*:BE-_'XT:!9XXJWR7V=M6%%XKCY10#GCUF#ID.C.&JL?"AH^8;Z@L/!
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MG>59 *9[5'0#IQM_D3]H1\\"+Y;T#D/#"K2^U'1\;P?LH'_9S?\"4$L#!!0
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MVH)ND4!ZW,Q',EO_S-W<U@$N K_8A7AH%!P>(,>L/9Q*R\"V+E6U,0&H5%J
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M45 4+!ZB_^<*0@=@#:20A8^=V9<G=]>+,;#/&I9Z0BQA%Z+;5/J.[?""3^B
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MT/#,?5?QQ2L(+<VK'62Y2OBPE^O\"VPH>3"NM$1IZUWO*9#8)ZWC_J3U1ZK
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M/V/X/E$EM;O< (94]'NJYNP'T+VWV"YD_/B7'\&O?.7!"WSY5\H-SV9$02-
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M4;D"N[Z2]GYM)FZ#X77-_P%02P,$%     @ KH Z62C5:3?F @  208  !D
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M:>8V2NM@[N?"=,'F8 .T?X+)7U!+ P04    " "N@#I9KK 7-"X#  #Z!P
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M2U,/C"S=[3Z3AMX*9R[I<49E'6A]+NFR:P8V0?O<3_X 4$L#!!0    ( *Z
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M=/OH:2=6K=Q#8Z8L/EO<<(GO1*Z) /?G"F_>W804]"_/Z;]02P,$%     @
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MVS80_BL'M2@20(VH=SNU#=3IAF98BR#N-@S#/M#2V1(BB2I)Q>Y^?8^DHWJ
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M ^E>'+?0HK=3?BTTO1G6K.B11FDNT/E&T+P[+$R \=E?? 502P,$%     @
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MFF=!EM5GV=%BY0JXF="F''3-I:G84=H%9GXN3!%7=>P&]?\ P_\!4$L#!!0
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MQIY,3AKRC/;FE^U:=I5(Z_9QU>WCEW;[C*NE5:VQ5VO,5V2.%U];!3"6TU4
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M<5Z>!F5+U#AQ)="2L_CIV!6Z$()()-GNBU/%O9T@H1#WE*4BVI9OD9+0'#!
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M2*4%ZOZ&JVZU'>@%NH^=^1]02P,$%     @ KH Z6>[)E]!2 P  "P\  !D
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M&H^>X?&FZ7[-Q.DJ-)"-=MB.PK#$!P.,#\#]K<8FTD[\ =T3E/T$4$L#!!0
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M'ZK)5 Z2OS3E6+O%?$FH0"DL%*5ST5&*>#DJRHUDN>FV<R95[S;+1$U7X#I
MW2^8ZKC51K^@GM?A'U!+ P04    " "N@#I9BX/&1&$#   V"P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U-2YX;6RM5EUOTS 4_2M60&A(T'SU8RMMI:T%
M#:2A:0/V,/'@);>-A6,7VVF&Q(_GVLE"UZ5AP%Z:^,;GW'M.;N,[*:7ZIC,
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M"^CO ?1K0-\Y4TEQ/BRHH;.)DB51=C>RV1MGID.C?";L>[\T"I\RQ)G91VF
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MD%8MC%R[L>5&&AR"W&V&@RTHNP&?+R6.+O7")FA&Y=DO4$L#!!0    ( *Z
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MX._&HRD;+MTK7EE-NYQP-O^M+,(8/L)"4V5H^PA,EG!^W_*&WLK"X1PMX\+
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M2Y[SPXJZ(FH70/M+14[I)^Z H<_F_P!02P,$%     @ KH Z6>'<B$!_ P
M] T  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULK5=1DYLV$/XK&IKI
M)#.7 P'&^&I[)O$UTW1ZS4VN:1\Z?9!A,9J Y$C"3OKK*P&'P6!ZE^'%1M+N
MQ[?[:<5J>>3BLTP!%/J:9TRNK%2I_8UMRRB%G,AKO@>F5Q(N<J+T4.QLN1=
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M?7PNA'K;,>^,Y*\M#?\%4$L#!!0    ( *Z .EGM(@ORY@,  ',/   9
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ME0/%UZ9)FG.E6R[SF.JNF(C"0+]?<MTH58-B@;K/GOP/4$L#!!0    ( *Z
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MJ?'+^JJI.UJ4[K2>"VW.?M?,S>T,T@K,_$J8$[OIV N@O>\G_P%02P,$%
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MR0RO,O6%;WXEI:#0X$UY)HM/L"EC/0=,5U+QO$S6#'+*MM_X1UF(G004'4E
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M8+D^50_(^RM*Q>%$-9!O#D[^!U!+ P04    " "N@#I9 ^W\1\H"   ="
M&0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6R=EEU/VS 4AO^*%>T")"!I
MOHO22J,,;1,;B,)V[3:GC85C9[9+Z;^?[82L-$F%=M/8SOL>/\?QL9MMN7B6
M!8!"KR5E<N(42E67KBN7!9187O *F'ZSXJ+$2G?%VI65 )Q;4TE=W_-BM\2$
M.=/,CMV+:<8WBA(&]P+)35EBL;L"RK<39^2\#3R0=:',@#O-*KR&.:BGZE[H
MGMM&R4D)3!+.D(#5Q/D\NIRE1F\%OPALY5X;F4P6G#^;SK=\XG@&""@LE8F
M]>,%9D"I":0Q_C0QG79*8]QOOT6_L;GK7!98PHS3WR17Q<1)'93#"F^H>N#;
MK]#D$YEX2TZE_47;1NLY:+F1BI>-61.4A-5/_-JLPYYA% X8_,;@?]00-(;
M)EJ3V;2NL<+33/ M$D:MHYF&71OKUMD09K[B7 G]EFB?FO[D"M 8G:,[58!
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M#K99Z/L;A!'H]RNNS_2F8ZZ(]A_!]"]02P,$%     @ KH Z6<E;>XLE!0
M%R   !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULO5IA;^(V&/XK%CM-
M=Q)'XC30T@%2@53KJ;U5[?7V8=H' R]@76(SVZ&MM!\_.Z2!T."1SNN7$CM^
MG]=^'K^VW[B]1RY^R"6 0D])S&2_L51J=>YY<KJ$A,@67P'3;^9<)$3IHEAX
M<B6 S#*C)/8"W^]X":&L,>AE=;=BT..IBBF#6X%DFB1$/ \AYH_]!FZ\5-S1
MQ5*9"F_06Y$%W(-Z6-T*7?(*E!E-@$G*&1(P[S<N\'F$N\8@:_&=PJ/<>49F
M*!/.?YC"U:S?\$V/((:I,A!$_ZQA!'%LD'0__LI!&X5/8[C[_()^F0U>#V9"
M)(QX_#N=J66_<=9 ,YB3-%9W_/%7R ?4-GA3'LOL+WK,V_H--$VEXDENK'N0
M4+;Y)4\Y$3L&.#Q@$.0&P;Y!YX#!26YP<JR',#<(CS5HYP;9T+W-V#/BQD21
M04_P1R1,:XUF'C+V,VO-%V5FHMPKH=]2;:<&7[D"A'WT&=W!FL=KRA9H)&!&
M%;HD4QI3]8P^CD$1&DOT#9Y42N)/NO7#_1A]_/ )?4"4H1L:QUIUV?.4[I(!
M]J:Y^]'&?7# /0[0#6=J*5'$9C K WAZ+,6 @I<!#0,KXI>4M1 .FBCP@["J
M0T>8G_@'S<?'FY]4F$=V\QLB6B@(J[R7R#@IU#W)\,(#>->ZC/A\7]&F%MLL
M(D;L(1<:-).=K/1[]5S1[:'5C5G,SJ4VAGY#KU82Q!H:@Y]_PAW_ERH%-F#=
M#,PL9.M!N]7I>>M=FETZC!R!E20("PE"JP31-*8K"6B82OU&2D,S521&U]<C
M=,T)0Q<+ :#77H7^N(%D N)/]#>ZAVFJ14-CF&SKJY2Q>J^KC$NPL4NPR!%8
M2<)V(6'[;5%T0YYHDB9'QE#[U;3'8:M=GO<C:T_J*N 2+'($5E*@4RC0L2J0
M1<$5DTJD)E"::$@DE>@^.QLA?=[X3@0EDQC0'5%01?X&'P<[[/LM/]RGW]J-
MNO2[!(L<@97H/RWH/WU; #RP5.I%ZF76-]&()PE5V6)V"8!N04SULSYQ5FER
M6JF)OZ^)M6]U-7$)%CD"*VER5FAR5B\DKI@"[49E(=!$T7P.V2'\7T2P>JF[
M?YQ5*MKM[FWN+GU&CL!*(G0+$;I'B"!E2M@4].272NH82(7(%/D*JHIQ*V1=
MQKNO-A6_A??H=NDP<@16HAO[VVS%KT_X 9[M4'6)SM',SP[5P1[53GU&KM#*
M9.^DAMA*=K&B1$\K8%(O*H;^2JJM0+6IQE54[\_JO%5YZI^6&T6N.E9F,-@R
M&-@W3LX6G[^!2%!Y"ZWDT I5F\/@-8=!*]SG,'A])MU/Q2)7'2MSN$UA\3OE
ML'8_M0D^)HMUZC)RA5868IO(XO?+9'7];PQQ@88PYP+0%\)2(IY1T-E\.K&F
MO/9^UA;2:=+K%"URA596?)OWXC<FOF9)HXR83[U-<]!O[APR,X,B#:C4SV5>
M.G**-G:*%N5H&)</Q-M30UF8;3J,[?FPXU"\F.N-_G4,#E-U(#Y#>WRZ3'Q'
M3M'&3M$B5VCE:;!-R_$;\_+_&)\ND^214[2Q4[0H1]N/3WP@/K>Y.;8GY^\1
MGZ$E/MOV^'2:\SM%&SM%BURAE:?!]NL MG\>^+_BT^D7!*=H8Z=H48YF^42X
M4<;;N0!-0"RRFV>)ICQE:G-U6-06M]L7V9WN7OT(GX\W=]1;F,V5^0T1"\HD
MBF&N(76FJ;=VL;F%WA047V77K!.N%$^RQR60&0C30+^?<ZY>"L9!\;\ @W\
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MYG6-MS8H*\#UI<1.W@[LQ=#]#YC\!U!+ P04    " "N@#I9$JD0T (#  "
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6R=EF]OVC 0QK^*E553
M*Y4F!$B  =)*56W3.J'^V;27)CG :F)GM@/M/OW.3AHQ""GB#;$=/Y??8W-G
MCS9"/JL5@"8O:<+5V%EIG0U=5T4K2*FZ$AEP?+,0,J4:NW+IJDP"C:TH35S?
M\P(WI8P[DY$=F\G)2.0Z81QFDJ@\3:E\O89$;,9.VWD;N&?+E38#[F24T24\
M@'[*9A)[;A4E9BEPQ00G$A9CYW-[.!V8^7;"3P8;M=4FQLE<B&?3^1J/'<\
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M \CBO"\Z6F3VR)P+C0>P;:[PB@323,#W"X''9MDQIW!UZ9K\ U!+ P04
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M"RU@B7.JKOGZ"U0)#0Q?S*DL?]&ZBG4L%.=2\;0":P4I89LG?J@*L05P@QT
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MO&Z?'H*J^IEJ8N2ZK/#/TE"_4 Y3:@%160/ZOI04IGIB-VB:RLD_4$L#!!0
M   ( *Z .EE0HD$]\ (  (L'   9    >&PO=V]R:W-H965T<R]S:&5E=#<X
M+GAM;+5544_;,!#^*Z<,344J)$U:V%@;B;:P,0&JZ& /: ]N>FTL$KNSG1;^
M_<Y.&LI6*J1M+ZU]OOOR?7>^<W<EU8-.$0T\YIG0/2\U9G'B^SI),6?Z4"Y0
MT,E,JIP9VJJYKQ<*V=0%Y9D?!L&1GS,NO+CK;",5=V5A,BYPI$ 7><[44Q\S
MN>IY+6]MN.'SU%B#'W<7;(YC-+>+D:*=7Z-,>8Y"<RE X:SGG;9.!AWK[QSN
M.*[TQAJLDHF4#W9S,>UY@26$&2;&(C#Z6^( L\P"$8V?%:97?](&;J[7Z.=.
M.VF9,(T#F7WG4Y/VO \>3''&BLS<R-47K/0X@HG,M/N%5>4;>) 4VLB\"B8&
M.1?E/WNL\K 1T(Y>"0BK@/"M 5$5$#FA)3,G:\@,B[M*KD!9;T*S"Y<;%TUJ
MN+!5'!M%IYSB3'PM#4(KA ,X9US!'<L*A"MDNE!(Q3*:3L9EA4'.X!*7F$$$
M@Y2).6IH#-$PGNE]:(R8(O\4#4^8-1S [7@(C;U]V ,NX%LJ"\W$5'=]0[SM
MU_VDXM@O.8:O<"1Z5Y*@-9R)*4Y? O@DN%8=KE7WPYV(7PMQ"%'0A# (VUL(
M#=X>'NV@$]5%B!Q>] K>A4ADCC VS+BDP_WI1!M%5_S'MFR58.WM8+;M3_2"
M)=CSJ*\UJB5Z\?MWK:/@TS:E_PCLA>YVK;N]"ST>HN)+9ONX"9]IXD#C4FJZ
M.M3>FT?7:+:EH<3N.&P[K);Q03L(J)S+37U_>K6//T:UTPO>G9IW9R?OYU9I
MPB5G$YYQ\]2$&TP*I;B80Y]IKIMP*^3$YHQ-,H0+L2B,]9$BH0!FI]@+V<V-
M"T"M5ET*J6 @<TI^:D?G$M?V^[-'8RT6^DP4.2J'N/7"[%;S5U48_!_LLBS^
MQEPC@7,W[C4DLA"F;/;:6K\HIVZ0_F;OTTM3/@S/,.4S=<74G L-&<X(,C@\
M)CVJ'/WEQLB%FYX3:6@6NV5*KR4JZT#G,TD3M-K8#]3O;_P+4$L#!!0    (
M *Z .EF!TMQ=;@0  !T9   9    >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM
M;+U9;6_J-A3^*U8F39O4D=B\%#I HG35.JEW57O7^^'J?G##*5A-XLQVH%?:
MC[]VDB9I"J:D9%\@L7->'\XY3\QXP\637 $H]!P&D9PX*Z7B,]>5_@I"*CL\
MADCO/'(14J5OQ=*5L0"Z2(7"P"6>-W!#RB)G.D[7;L1TS!,5L AN!)))&%+Q
M_1P"OIDXV'E9N&7+E3(+[G0<TR7<@?HGOA'ZSBVT+%@(D60\0@(>)\X,G\W)
MR BD3]PSV,C*-3*A/'#^9&ZN%A/',QY! +XR*JC^6L,<@L!HTG[\FRMU"IM&
ML'K]HOTR#5X'\T ES'GPA2W4:N(,';2 1YH$ZI9O_H0\H+[1Y_- II]HDS_K
M.<A/I.)A+JP]"%F4?=/G/!$5 =S;(4!R 5(7Z.X0Z.8"W330S+,TK NJZ'0L
M^ 8)\[369B[2W*32.AH6&1COE-"[3,NIZ2>N &&"?D.7E ET3X,$T#50F0C0
M:"FI=\PB39,^DQKNV%Q*],L%*,H"^>O85=H1H\[U<Z/GF5&RP^A?2=1!7>\$
M$8_T7HN[VO\B"%($05)]O1WZ*OZBJRA.U FZ6U$!Z$8P']#7:P@?0'Q#_R%M
M&8S5+OI"A: FOL_Z2Q<'FA7/;0O(ZH"IM3,94Q\FCBXF"6(-SO3GG_# ^]T2
M7K<(KVL-[P($6U/S<T<!HP\L8.K["0HK03,3]#:W,\7FMZ0UFY)>3TEG1,;N
M>HL_O<*?WI'2_;=:@2A3;4NPU63#!/>+@/IM);B_)\'I4W.[^:_XFR6(01'$
MX%!4_GB.=;>$!?H,(CQ*&5A=:(C2:1'@:5LH98JQ5T&IVQEMKX)AX<[P:/G>
M40=ZYYI%+$Q":]*M?C1,^JB(<M16TD=ODTXZ@UIEV*W;*P-[Y9#S_@^LZ/->
MK.R.- 0+5Z8Y;@NN7'.M2.J=;(_]/8"5 QT?/-&SX7+/ QV>">LH_<SN1E.X
MRL&.6YOLN6;<J\#E=89>=WM7P^5PQP=/=UOJ/];:[+XTS7\Y]W%K@S_77,]_
M]TW!?&3VXW+XXX.G?T/4WM/DVJ !N.0!N#4BD&NNHW;:KZ-F]V /:B6%P =S
MB%LFG]"E - +"G3Z%+JEZC@O,79OFN)64@G<&I?(-==P\WJ][=V.E,R ',P,
MWH' QYJ>W:6&,)"2(Y#6.$*N^0T,]?+9XX&]?$CEM?]@EO Q\-[1^^PN-06O
M9 RD-<9 MC(&KU>GY'L\V ->R3/(P3RCX.07;,T6$"V.U_KLSC2%K20:I#6B
MD6L>5%';T?5*MD":GQ7LS/T!ASEV\TVS71($TAI!R#5OSW9>'Q_A!L1P@]<K
MY?PD>]^&KR(_2!8@T2Q9)KJWZ5(@!20GNH$)?_5Z$5$-Y6P-40)H3F.F:%#L
M=;8YZE8.DT,0R_2,72*?)Y'*SBR+U>P<_QR?S=/C[MKZC S/YCK>;3NCEZ-_
MMS21_7&@0UBR2*( 'K4YKW.J?_XB.XO/;A2/T^/L!ZX4#]/+%= %"/. WG_D
M7+W<& /%/R+3'U!+ P04    " "N@#I9<"I((FT%  ")&@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970X,"YX;6S%66U3XS80_BN:]-J!F4 L.Z\T9";$T%X'
M#H:7ZW0Z_: XFT0]V\I),H'^^LHOV+$M=)#ZIE_ =G8?[?-H)>]:XRWC7\0:
M0**GP _%:6LMY>:DTQ'>&@(BCMD&0O7+DO& 2'7+5QVQX4 6B5/@=VS+ZG<"
M0L/69)P\N^&3,8ND3T.XX4A$04#X\QGX;'O:PJV7![=TM9;Q@\YDO"$KN /Y
ML+GAZJZ3HRQH *&@+$0<EJ>M*3YQ[<0AL?A,82MVKE%,9<[8E_CFX^*T9<41
M@0^>C"&(^O<(,_#]&$G%\34#;>5CQHZ[UR_H%PEY169.!,R8_SM=R/5I:]A"
M"UB2R)>W;/LK9(1Z,9['?)'\1=O,UFHA+Q*2!9FSBB"@8?J?/&5"[#C@_BL.
M=N9@5QVZKS@XF8/S5H=NYM!-E$FI)#JX1)+)F+,MXK&U0HLO$C$3;T6?AO&\
MWTFN?J7*3TX^,0D(.^@(?0P]%@"Z)T\@T($+DE!?H'MXDA'Q#Y7!PYV+#CX<
MH@^(ANA^S2)!PH48=Z0*(P;K>-F09^F0]BM#8AM=L5"N!3H/%[ H W14_#D)
M^X7$F6U$_"T*CY%CM9%MV5U-0+.WNSL:=_?M[K:!C9-/B9/@=5_!*R8"G3^I
M]2T '9Q!"$LJ#W5JIVB]!"U>YH\3/.@/QYW'707J1E;9PC4&%6\_)V)#/#AM
MJ?U% '^$UN2G'W#?^ME N9M3[AHIGR^7D&P .UF(;HE*S5OP6.A1GY)XFVBC
M&^ >A%*G@WF( VP?]ZT?=0K.4D^,#>H8P?=4IY>KTS.&[L(2.(=%HLI4")"B
MC7[A3&@77Z^>#L[0PG8E(71F \>IF+G&R/;DW<]Y]]_.^Y*2N4H#2<%$/@7L
M[[ :]*O,ZS:*>66]N,;(]N0]R'D/C+RGGL<C17MW1VZC6:2TT&?^H,;(L2H)
M/*O;X*J-:PQK3]+#G/302/IZ URM\7"%+M7<HAGA_%F5-5O"%XK\)0VH3+8
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M)S7'K.+PCG"X'KIG5&8"?:,II.\=V"JI)C/O+;.9=]+CSY)>(=^Y1)[C!3U
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MDI4U9;+D# F:+[T/^/T:3W2"B?BSI'MY=(UT*4^</^O!IVSI!9J(5C156H+
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M*+]^,Y\7CQ]4$SS,\T^KIWKV_U!+ P04    " "N@#I96+'SIR(2   7& $
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M3""99QD53Y>0\LW$P<[VP6VR6"KSP)V.5W0!=Z#^6,V$OG/K*'&2 9,)9TC
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MC4&8#_3[.>=J>V, ZE.RZ7]02P,$%     @ KH Z61,)E(D$ P  40H  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#DN>&ULS99;;]HP%,>_BA7MH97:7)Q
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MN\&L+X0I>M7 !JBO0*,_4$L#!!0    ( *Z .EEBJ/8\-@,  *\+   9
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MHHF41.8.LXGB<V.PQERA73/#"!TU"!V [R<<358^T1\H/'KO/U!+ P04
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MTZ*Y0_WWFSROGGYI!GC(B]^63]GY_P-02P,$%     @ KH Z6<H@CR)E!0
M:A8  !D   !X;"]W;W)K<VAE971S+W-H965T.3,N>&ULM5AM;]LV$/XKA#<,
M*:!:HM[C.082)\8VH%O0=BN&8!]HB8Z)2J)+4G'S[W>49-F6:<5UTR^V=.2]
M/,]1QR/':RX^RR6E"GW-LT)>#99*K4:V+9,ES8D<\A4M8&3!14X4O(I'6ZX$
M)6FEE&>VZSBAG1-6#";C2G8O)F->JHP5]%X@6>8Y$<\W-./KJP$>; 3OV>-2
M:8$]&:_((_U U=^K>P%O=FLE93DM).,%$G1Q-;C&HQD.M4(UXQ]&UW+G&6DH
M<\X_ZY??TZN!HR.B&4V4-D'@[XE.:99I2Q#'E\;HH/6I%7>?-]9G%7@ ,R>2
M3GGVB:5J>36(!RBE"U)FZCU?_T8;0(&VE_!,5K]HW<QU!B@II>)YHPP1Y*RH
M_\G7AH@=!>P=47 ;!;>CX!Y3\!H%[U0/?J/@=ST$1Q2"1B$XU4/8*%3)M&NR
M*J9OB2*3L>!K)/1LL*8?JG15VD P*_3*^J $C#+04Y,_N:((A^@M^D2$((62
M\/@!UF]:9A3QQ5;\5ZFD(D7*BD=T<4L589E\ Y-_1C:22R*H'-L*(M)V[:3Q
M/JV]NT>\8Q>]XX5:2G17I#3=-V #E!:/N\$S=7LM_E$60^0Y%G(=US<$='>Z
MNF=0G_6K/^#_>C!X;4Z\RHI_Q,H.TQ9\-ADI$HHN6-'0_,80UTV_Q8.X:BIK
MI;!2TB7H:1(&7NP$[MA^VN6LU[BN?2.Y(@F]&D!QDU0\T<'DEY]PZ/S:0X;?
MDN&?3L:Z*A0T1>2)"BA\4-MT]=1+,H%U)*!.E21#BHH<7?Q+B3!RU>_PP35R
MU:_DH6?P)A%&N5[/*$0I>39]$+<O./=,SN_ZE?S&>5P[ARA<@_L]]H.6_:#7
M=/OU,RE+X/W"??/22NPW^. ;V0T.5B*.G=#W_,Y*[#5^YDH,6R["T[B@7ZE(
MF-1T]%(Q#0]0O75=/PK]N .KU_&9L*(65G0JK!43+X.*#*"<RZ +J=?IF9#B
M%E+\V@5T&A_60B<*XMC9QW7;[_G(]VLPWBFT>S@O6YR7_:G;E,/KIAP^O*/Y
MG KC)]9KZO2$U(!>R=@>:NQL>Q;G._:$S>>)5H(U>4]YEND*N:*B7@/&RO6"
MUR.;:*,5[R37'_K=+;3?]KF,[71Y^%OJ^*NRUN_Y2,%OM'"T0YLS=!P'=XGK
M-7\N<>Z6./<;B_XK<C=MG.M>?[OQ#<,##GIC/)>#;3N*^[O'[@[QJ@P<]J">
MXW3Q_X@&%&\[4/P]+>CYT/V#PN$-HT[N;U^([<B&8["]5Y3VF=#=X+YDVQ/A
M_J8(BN+')45%J?<=?5Y<;Q8+WSDO$JF'X'!%V\.5!:4(FO8<6-.=% R'EA/&
M5A1Z*&-DSC*FGE&2$2G9@L&,C6$+^6##Q9%Y6N5$.T#W@KZ=E?I<N3W$0CS(
MN[2<R$7T2WG$PQ". ->0/=!?U/HMJ)2C@BNTA.2#K?J#(-4524H4M9!:TN=Z
M=$ZI'D^R4AM8")[K0920+"FS6@4P:]&)AYJ,+2B"Q57U^D/(^UF\^X>\>U;L
M8@OCX,?Q;B%L03]O04-OUOX(TQ+ <W,T:SB&$/W>K/D5)>O.D24MA:9BP21P
M7U$ C M('_ LRTQI"K;1;0-IO<^IUF\_<\6-TPUQ#TW5Q]ZYJ\FI>*QNU71&
MRD)5^^&.N+VZNZDNK#KRJ;[2,\G=T:UI_ITWFGDFN3^:^29Y,)H%)GDXFH4F
M>32:129Y/)K%)OGE:'9IDF,'@#G&$0W9A!FV2!@QHL8 &QMQ8P".3<BO<3"Z
MPR;L4 YAI+YZVV:OOH5]1\0C*R3*Z (RZ0PC.*R*^F*S?E%\55W$S;E2/*\>
MEY2D5.@),+[@7&U>M(/V>GGR/U!+ P04    " "N@#I9Y^7UA#D"  "R!
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M2G>A-HW("? T4=X%F[3!DE>"#6&J%946;E6!Q;_XR GOU2?/ZB?)0<*OC1S
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M$P2PJI@W; ?C2!1A"-2BO4;#$)F=$#[V]<%V21!$D1T!S.X@"# $=B..8 [
M X8$0?D<W'L>>=OGE-?\LV'R!U!+ P04    " "N@#I9EXJ[',     3 @
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MK:\4<W^F<\5IYG[NM!G;]M3N>]]?#KQY_$\(C__%X?5_4$L#!!0    ( *Z
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MLY>5 +V#ZAT >@?5.P#T#JIW .@=5.\ T#NJWA&@=U2](T#OJ'I'@-Y1]8X
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "N@#I9F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M *Z .EFG$#_1K@<  "(R   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "N@#I9:R?JUWP&  #\&P  &
M            @('R#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ KH Z64XF)NBE @  (PD  !@              ("!I!8  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *Z .EGA5R9E=@4  .T4
M   8              " @7\9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " "N@#I9YJ?Z);0$  #W%P  &               @($K'P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ KH Z655S)U$I
M @  4 0  !@              ("!%20  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( *Z .EF<\[.KA@<  +LA   8              "
M@70F  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "N@#I9
MMF(ZCY$%  ![#   &               @($P+@  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ KH Z6?KO YN)&   ;$4  !@
M     ("!]S,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M *Z .EGW_^;[W@,  +D)   9              " @;9,  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ KH Z69=Q3>7, @   @8  !D
M             ("!RU   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " "N@#I9#2U\L3P#   (!P  &0              @('.4P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *Z .EFHL7D(\@4
M /H/   9              " @4%7  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ KH Z6>(2_/NO!P  714  !D              ("!
M:ET  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "N@#I9
M?U:"08<$  "E"@  &0              @(%090  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( *Z .EEJ3[T2X@0  )P*   9
M      " @0YJ  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ KH Z6?E"//M#!0  _PL  !D              ("!)V\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "N@#I9*"$TV40'  !H$@
M&0              @(&A=   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( *Z .EG*@ZXJ'0@  '(7   9              " @1Q\  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ KH Z69P-7Q6<
M"   @!4  !D              ("!<(0  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " "N@#I9@ 04("X#  "B!P  &0
M@(%#C0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *Z
M.EF\C2^&6@8  "L1   9              " @:B0  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ KH Z65NV)W,=!0  .0P  !D
M         ("!.9<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " "N@#I96;KMS*8$  "4#   &0              @(&-G   >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *Z .EDL;V$$J00  $H*
M   9              " @6JA  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ KH Z61^G(L0D P  O@8  !D              ("!2J8
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "N@#I9!O7'
M?20$  #E"0  &0              @(&EJ0  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( *Z .EE=J9L320(  "\%   9
M  " @0"N  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MKH Z66X3D=1% @  H@8  !D              ("!@+   'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " "N@#I9V:=HIR\;   $6@  &0
M            @('\L@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( *Z .EG2'3FIM00  &D,   9              " @6+.  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ KH Z66(F1#L9 P
M\ <  !D              ("!3M,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " "N@#I9M37U2( "  !I!0  &0              @(&>
MU@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( *Z .EDH
MU6DWY@(  $D&   9              " @579  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ KH Z6<1<.226!   . T  !D
M     ("!<MP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z .ED68W?N#@0  %H+   9              "
M@=?N  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ KH Z
M6>"0DOJ+!0  A0X  !D              ("!'/,  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " "N@#I9^*I'GO,$  #X#@  &0
M        @('>^   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( *Z .EDD>#+FZ@(  '\&   9              " @0C^  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ KH Z63$;6"3G @  (08
M !D              ("!*0$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " "N@#I91U/_&%$#   ""   &0              @(%'! $
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *Z .EG"([+-
M?@,   \,   9              " @<\' 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ KH Z65P=U>KA!P  ;3\  !D
M ("!A L! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "N
M@#I9910&-(8"   U!@  &0              @(&<$P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( *Z .EG6WH_Y=0,  /@,   9
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M970U,RYX;6Q02P$"% ,4    " "N@#I9F]>$L:D"  "[!P  &0
M    @(%Z)P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M *Z .EF+@\9$80,  #8+   9              " @5HJ 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ KH Z65,555%- @  Z 4  !D
M             ("!\BT! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " "N@#I9ZO:"*E0"  !S!0  &0              @(%V, $ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *Z .EGAW(A ?P,
M /0-   9              " @0$S 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ KH Z6>@5*_$"!0  PB0  !D              ("!
MMS8! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "N@#I9
M[2(+\N8#  !S#P  &0              @('P.P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( *Z .EGV"S\,G@(  /L'   9
M      " @0U  0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ KH Z66@Q6P:C P  XPX  !D              ("!XD(! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " "N@#I9OL=0#X("   3!P
M&0              @(&\1@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( *Z .EF47^J?M@0  -D8   9              " @75) 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ KH Z61XOQD#^
M P  NA,  !D              ("!8DX! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " "N@#I9V'%5N)8"  !#"0  &0
M@(&74@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( *Z
M.EGG/Q5HO (  !P(   9              " @615 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ KH Z6?#R6Y*E @  P@8  !D
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M=#<R+GAM;%!+ 0(4 Q0    ( *Z .EG3=3INT (  !,(   9
M  " @6MR 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @
MKH Z61*I$- " P  @ D  !D              ("!<G4! 'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6Q02P$"% ,4    " "N@#I98WL' K<%  !')0  &0
M            @(&K> $ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4
M Q0    ( *Z .EF<+ ZS\ (  /4+   9              " @9E^ 0!X;"]W
M;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ KH Z6>\6M#SE P
M8 H  !D              ("!P($! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX
M;6Q02P$"% ,4    " "N@#I94*)!/? "  "+!P  &0              @('<
MA0$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( *Z .EF!
MTMQ=;@0  !T9   9              " @0.) 0!X;"]W;W)K<VAE971S+W-H
M965T-SDN>&UL4$L! A0#%     @ KH Z67 J2")M!0  B1H  !D
M     ("!J(T! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z .EG)QI#AS1(  /@> 0 9              "
M@;.A 0!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ KH Z
M65BQ\Z<B$@  %Q@! !D              ("!M[0! 'AL+W=O<FMS:&5E=',O
M<VAE970X-BYX;6Q02P$"% ,4    " "N@#I9&VBQ# 8$  #]$0  &0
M        @($0QP$ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0
M   ( *Z .EG^,0;V%@0  #$3   9              " @4W+ 0!X;"]W;W)K
M<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ KH Z61,)E(D$ P  40H
M !D              ("!FL\! 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q0
M2P$"% ,4    " "N@#I9#$@,0. "   ."0  &0              @('5T@$
M>&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( *Z .EEBJ/8\
M-@,  *\+   9              " @>S5 0!X;"]W;W)K<VAE971S+W-H965T
M.3$N>&UL4$L! A0#%     @ KH Z6=LS*/GU$   4_0  !D
M ("!6=D! 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4    " "N
M@#I9RB"/(F4%  !J%@  &0              @(&%Z@$ >&PO=V]R:W-H965T
M<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( *Z .EGGY?6$.0(  +($   9
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M970Y."YX;6Q02P$"% ,4    " "N@#I97&5:I%X$  #0$@  &0
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *Z .EG#*Q\]U@(  ,<Z   :
M          "  8P: @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *Z .EF%GR=*6 (  ,,X   3              "  9H= @!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !L &P K!T  ",@ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>303</ContextCount>
  <ElementCount>488</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>146</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Unaudited Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows</Role>
      <ShortName>Unaudited Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Nature of Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition</Role>
      <ShortName>Note 1 - Nature of Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-3-revenue</Role>
      <ShortName>Note 3 - Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-4-inventories</Role>
      <ShortName>Note 4 - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases</Role>
      <ShortName>Note 6 - Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-7-intangible-assets</Role>
      <ShortName>Note 7 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities</Role>
      <ShortName>Note 8 - Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-9-other-liabilities</Role>
      <ShortName>Note 9 - Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Revolving Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility</Role>
      <ShortName>Note 10 - Revolving Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-11-longterm-debt</Role>
      <ShortName>Note 11 - Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 12 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements</Role>
      <ShortName>Note 12 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 13 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes</Role>
      <ShortName>Note 13 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 14 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-14-stockholders-equity</Role>
      <ShortName>Note 14 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 15 - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans</Role>
      <ShortName>Note 15 - Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 16 - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-16-warrants</Role>
      <ShortName>Note 16 - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 17 - Restructuring Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-</Role>
      <ShortName>Note 17 - Restructuring Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 18 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies</Role>
      <ShortName>Note 18 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 19 - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-19-license-agreements</Role>
      <ShortName>Note 19 - License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 20 - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-20-segment-information</Role>
      <ShortName>Note 20 - Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 21 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-21-subsequent-events</Role>
      <ShortName>Note 21 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995474 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995476 - Disclosure - Note 3 - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-3-revenue-tables</Role>
      <ShortName>Note 3 - Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-3-revenue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Note 4 - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-4-inventories-tables</Role>
      <ShortName>Note 4 - Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-4-inventories</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995478 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-5-property-and-equipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995479 - Disclosure - Note 6 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases-tables</Role>
      <ShortName>Note 6 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-6-leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995480 - Disclosure - Note 7 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables</Role>
      <ShortName>Note 7 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-7-intangible-assets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995481 - Disclosure - Note 8 - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables</Role>
      <ShortName>Note 8 - Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995482 - Disclosure - Note 9 - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables</Role>
      <ShortName>Note 9 - Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-9-other-liabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Note 11 - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables</Role>
      <ShortName>Note 11 - Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-11-longterm-debt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995484 - Disclosure - Note 12 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables</Role>
      <ShortName>Note 12 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Note 13 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables</Role>
      <ShortName>Note 13 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-13-income-taxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995486 - Disclosure - Note 15 - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables</Role>
      <ShortName>Note 15 - Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Note 16 - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-16-warrants-tables</Role>
      <ShortName>Note 16 - Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-16-warrants</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995488 - Disclosure - Note 17 - Restructuring Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables</Role>
      <ShortName>Note 17 - Restructuring Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995489 - Disclosure - Note 20 - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-20-segment-information-tables</Role>
      <ShortName>Note 20 - Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-20-segment-information</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995490 - Disclosure - Note 1 - Nature of Business and Financial Condition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual</Role>
      <ShortName>Note 1 - Nature of Business and Financial Condition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995491 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995492 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995494 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995496 - Disclosure - Note 3 - Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual</Role>
      <ShortName>Note 3 - Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-3-revenue-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details</Role>
      <ShortName>Note 3 - Revenue - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995498 - Disclosure - Note 3 - Revenue - Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details</Role>
      <ShortName>Note 3 - Revenue - Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995499 - Disclosure - Note 4 - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual</Role>
      <ShortName>Note 4 - Inventories (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-4-inventories-tables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995500 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details</Role>
      <ShortName>Note 4 - Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995501 - Disclosure - Note 5 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995502 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995503 - Disclosure - Note 6 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases-details-textual</Role>
      <ShortName>Note 6 - Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-6-leases-tables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995504 - Disclosure - Note 6 - Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details</Role>
      <ShortName>Note 6 - Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details</Role>
      <ShortName>Note 6 - Leases - Lease Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995506 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals</Role>
      <ShortName>Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details</Role>
      <ShortName>Note 6 - Leases - Schedule of Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995508 - Disclosure - Note 7 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual</Role>
      <ShortName>Note 7 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995509 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details</Role>
      <ShortName>Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>995510 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details</Role>
      <ShortName>Note 7 - Intangible Assets - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>995511 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details</Role>
      <ShortName>Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>995512 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details</Role>
      <ShortName>Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Note 9 - Other Liabilities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual</Role>
      <ShortName>Note 9 - Other Liabilities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>995514 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details</Role>
      <ShortName>Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual</Role>
      <ShortName>Note 10 - Revolving Credit Facility (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>995516 - Disclosure - Note 11 - Long-term Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual</Role>
      <ShortName>Note 11 - Long-term Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details</Role>
      <ShortName>Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>995518 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details</Role>
      <ShortName>Note 11 - Long-term Debt - Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>995519 - Disclosure - Note 12 - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual</Role>
      <ShortName>Note 12 - Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>995520 - Disclosure - Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details</Role>
      <ShortName>Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>995521 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details</Role>
      <ShortName>Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>995522 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals</Role>
      <ShortName>Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Note 12 - Fair Value Measurements - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details</Role>
      <ShortName>Note 12 - Fair Value Measurements - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>995524 - Disclosure - Note 13 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual</Role>
      <ShortName>Note 13 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Note 13 - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details</Role>
      <ShortName>Note 13 - Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>995526 - Disclosure - Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details</Role>
      <ShortName>Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>995528 - Disclosure - Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details</Role>
      <ShortName>Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>995529 - Disclosure - Note 14 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual</Role>
      <ShortName>Note 14 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-14-stockholders-equity</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>995530 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual</Role>
      <ShortName>Note 15 - Equity Incentive Plans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>995531 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details</Role>
      <ShortName>Note 15 - Equity Incentive Plans - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>995532 - Disclosure - Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details</Role>
      <ShortName>Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details</Role>
      <ShortName>Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>995534 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details</Role>
      <ShortName>Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details</Role>
      <ShortName>Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>995536 - Disclosure - Note 16 - Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual</Role>
      <ShortName>Note 16 - Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-16-warrants-tables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details</Role>
      <ShortName>Note 16 - Warrants - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>995538 - Disclosure - Note 17 - Restructuring Costs (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual</Role>
      <ShortName>Note 17 - Restructuring Costs (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>995539 - Disclosure - Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details</Role>
      <ShortName>Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>995540 - Disclosure - Note 18 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 18 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>995541 - Disclosure - Note 19 - License Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual</Role>
      <ShortName>Note 19 - License Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-19-license-agreements</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>995542 - Disclosure - Note 20 - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual</Role>
      <ShortName>Note 20 - Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-20-segment-information-tables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>995543 - Disclosure - Note 20 - Segment Information - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details</Role>
      <ShortName>Note 20 - Segment Information - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="aytu20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>995544 - Disclosure - Note 21 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual</Role>
      <ShortName>Note 21 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/20240630/role/statement-note-21-subsequent-events</ParentRole>
      <Position>100</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aytu-20240630.xsd</File>
    <File>aytu-20240630_cal.xml</File>
    <File>aytu-20240630_def.xml</File>
    <File>aytu-20240630_lab.xml</File>
    <File>aytu-20240630_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="aytu20240630_10k.htm">aytu20240630_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="974">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>135
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aytu20240630_10k.htm": {
   "nsprefix": "aytu",
   "nsuri": "http://aytubio.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "aytu-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "aytu-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aytu-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aytu-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aytu-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aytu20240630_10k.htm"
     ]
    }
   },
   "keyStandard": 402,
   "keyCustom": 86,
   "axisStandard": 43,
   "axisCustom": 0,
   "memberStandard": 50,
   "memberCustom": 84,
   "hidden": {
    "total": 95,
    "http://fasb.org/us-gaap/2024": 80,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://aytubio.com/20240630": 5,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "contextCount": 303,
   "entityCount": 1,
   "segmentCount": 146,
   "elementCount": 794,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 974,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://aytubio.com/20240630/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
     "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows",
     "longName": "006 - Statement - Unaudited Consolidated Statements of Cash Flows",
     "shortName": "Unaudited Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
     "longName": "007 - Disclosure - Note 1 - Nature of Business and Financial Condition",
     "shortName": "Note 1 - Nature of Business and Financial Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
     "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aytubio.com/20240630/role/statement-note-3-revenue",
     "longName": "009 - Disclosure - Note 3 - Revenue",
     "shortName": "Note 3 - Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aytubio.com/20240630/role/statement-note-4-inventories",
     "longName": "010 - Disclosure - Note 4 - Inventories",
     "shortName": "Note 4 - Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment",
     "longName": "011 - Disclosure - Note 5 - Property and Equipment",
     "shortName": "Note 5 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases",
     "longName": "012 - Disclosure - Note 6 - Leases",
     "shortName": "Note 6 - Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
     "longName": "013 - Disclosure - Note 7 - Intangible Assets",
     "shortName": "Note 7 - Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R15": {
     "role": "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities",
     "longName": "014 - Disclosure - Note 8 - Accrued Liabilities",
     "shortName": "Note 8 - Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
     "longName": "015 - Disclosure - Note 9 - Other Liabilities",
     "shortName": "Note 9 - Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
     "longName": "016 - Disclosure - Note 10 - Revolving Credit Facility",
     "shortName": "Note 10 - Revolving Credit Facility",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
     "longName": "017 - Disclosure - Note 11 - Long-term Debt",
     "shortName": "Note 11 - Long-term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
     "longName": "018 - Disclosure - Note 12 - Fair Value Measurements",
     "shortName": "Note 12 - Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R20": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
     "longName": "019 - Disclosure - Note 13 - Income Taxes",
     "shortName": "Note 13 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
     "longName": "020 - Disclosure - Note 14 - Stockholders' Equity",
     "shortName": "Note 14 - Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
     "longName": "021 - Disclosure - Note 15 - Equity Incentive Plans",
     "shortName": "Note 15 - Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aytubio.com/20240630/role/statement-note-16-warrants",
     "longName": "022 - Disclosure - Note 16 - Warrants",
     "shortName": "Note 16 - Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:WarrantsOrRightsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:WarrantsOrRightsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
     "longName": "023 - Disclosure - Note 17 - Restructuring Costs",
     "shortName": "Note 17 - Restructuring Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
     "longName": "024 - Disclosure - Note 18 - Commitments and Contingencies",
     "shortName": "Note 18 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
     "longName": "025 - Disclosure - Note 19 - License Agreements",
     "shortName": "Note 19 - License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:LicensingAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:LicensingAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aytubio.com/20240630/role/statement-note-20-segment-information",
     "longName": "026 - Disclosure - Note 20 - Segment Information",
     "shortName": "Note 20 - Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
     "longName": "027 - Disclosure - Note 21 - Subsequent Events",
     "shortName": "Note 21 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies",
     "longName": "995474 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
     "longName": "995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aytubio.com/20240630/role/statement-note-3-revenue-tables",
     "longName": "995476 - Disclosure - Note 3 - Revenue (Tables)",
     "shortName": "Note 3 - Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aytubio.com/20240630/role/statement-note-4-inventories-tables",
     "longName": "995477 - Disclosure - Note 4 - Inventories (Tables)",
     "shortName": "Note 4 - Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables",
     "longName": "995478 - Disclosure - Note 5 - Property and Equipment (Tables)",
     "shortName": "Note 5 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases-tables",
     "longName": "995479 - Disclosure - Note 6 - Leases (Tables)",
     "shortName": "Note 6 - Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables",
     "longName": "995480 - Disclosure - Note 7 - Intangible Assets (Tables)",
     "shortName": "Note 7 - Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables",
     "longName": "995481 - Disclosure - Note 8 - Accrued Liabilities (Tables)",
     "shortName": "Note 8 - Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "aytu:AccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "aytu:AccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables",
     "longName": "995482 - Disclosure - Note 9 - Other Liabilities (Tables)",
     "shortName": "Note 9 - Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables",
     "longName": "995483 - Disclosure - Note 11 - Long-term Debt (Tables)",
     "shortName": "Note 11 - Long-term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables",
     "longName": "995484 - Disclosure - Note 12 - Fair Value Measurements (Tables)",
     "shortName": "Note 12 - Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables",
     "longName": "995485 - Disclosure - Note 13 - Income Taxes (Tables)",
     "shortName": "Note 13 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables",
     "longName": "995486 - Disclosure - Note 15 - Equity Incentive Plans (Tables)",
     "shortName": "Note 15 - Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aytubio.com/20240630/role/statement-note-16-warrants-tables",
     "longName": "995487 - Disclosure - Note 16 - Warrants (Tables)",
     "shortName": "Note 16 - Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "aytu:WarrantsOrRightsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "aytu:WarrantsOrRightsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables",
     "longName": "995488 - Disclosure - Note 17 - Restructuring Costs (Tables)",
     "shortName": "Note 17 - Restructuring Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables",
     "longName": "995489 - Disclosure - Note 20 - Segment Information (Tables)",
     "shortName": "Note 20 - Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
     "longName": "995490 - Disclosure - Note 1 - Nature of Business and Financial Condition (Details Textual)",
     "shortName": "Note 1 - Nature of Business and Financial Condition (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "longName": "995491 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details",
     "longName": "995492 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2023-06-30",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-06-30",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
     "longName": "995493 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "i_2023-06-30",
      "name": "aytu:AccountsReceivableAllowanceForDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-06-30",
      "name": "aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details",
     "longName": "995494 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details",
     "longName": "995495 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
     "longName": "995496 - Disclosure - Note 3 - Revenue (Details Textual)",
     "shortName": "Note 3 - Revenue (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
     "longName": "995497 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)",
     "shortName": "Note 3 - Revenue - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details",
     "longName": "995498 - Disclosure - Note 3 - Revenue - Revenue by Geographic Location (Details)",
     "shortName": "Note 3 - Revenue - Revenue by Geographic Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_StatementGeographicalAxis-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
     "longName": "995499 - Disclosure - Note 4 - Inventories (Details Textual)",
     "shortName": "Note 4 - Inventories (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details",
     "longName": "995500 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details)",
     "shortName": "Note 4 - Inventories - Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
     "longName": "995501 - Disclosure - Note 5 - Property and Equipment (Details Textual)",
     "shortName": "Note 5 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
     "longName": "995502 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
     "longName": "995503 - Disclosure - Note 6 - Leases (Details Textual)",
     "shortName": "Note 6 - Leases (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details",
     "longName": "995504 - Disclosure - Note 6 - Leases - Lease Cost (Details)",
     "shortName": "Note 6 - Leases - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details",
     "longName": "995505 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)",
     "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "aytu:ScheduleOfLeaseByBalanceSheetInformationTableTextBlock",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
     "longName": "995506 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)",
     "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details",
     "longName": "995507 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)",
     "shortName": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "aytu:LesseeLiabilityMaturityTableTextBlock",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "aytu:LesseeLiabilityMaturityTableTextBlock",
       "aytu:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
     "longName": "995508 - Disclosure - Note 7 - Intangible Assets (Details Textual)",
     "shortName": "Note 7 - Intangible Assets (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:AmortizationExpenseOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details",
     "longName": "995509 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details",
     "longName": "995510 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)",
     "shortName": "Note 7 - Intangible Assets - Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
     "longName": "995511 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "shortName": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "aytu:AccruedSavingOffers",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "aytu:AccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "aytu:AccruedSavingOffers",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "aytu:AccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details",
     "longName": "995512 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)",
     "shortName": "Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "i_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "aytu:AccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "aytu:AccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
     "longName": "995513 - Disclosure - Note 9 - Other Liabilities (Details Textual)",
     "shortName": "Note 9 - Other Liabilities (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisLicenseAgreementMember",
      "name": "us-gaap:SettlementLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details",
     "longName": "995514 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)",
     "shortName": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:OtherSundryLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
     "longName": "995515 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual)",
     "shortName": "Note 10 - Revolving Credit Facility (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
     "longName": "995516 - Disclosure - Note 11 - Long-term Debt (Details Textual)",
     "shortName": "Note 11 - Long-term Debt (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "aytu:DebtInstrumentFinalPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
     "longName": "995517 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)",
     "shortName": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
     "longName": "995518 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)",
     "shortName": "Note 11 - Long-term Debt - Future Principal Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
     "longName": "995519 - Disclosure - Note 12 - Fair Value Measurements (Details Textual)",
     "shortName": "Note 12 - Fair Value Measurements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2022-07-01_2023-06-30",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
     "longName": "995520 - Disclosure - Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)",
     "shortName": "Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details",
     "longName": "995521 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)",
     "shortName": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
     "longName": "995522 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)",
     "shortName": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
     "longName": "995523 - Disclosure - Note 12 - Fair Value Measurements - Valuation Assumptions (Details)",
     "shortName": "Note 12 - Fair Value Measurements - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
     "longName": "995524 - Disclosure - Note 13 - Income Taxes (Details Textual)",
     "shortName": "Note 13 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details",
     "longName": "995525 - Disclosure - Note 13 - Income Taxes - Provision for Income Taxes (Details)",
     "shortName": "Note 13 - Income Taxes - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
     "longName": "995526 - Disclosure - Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "longName": "995527 - Disclosure - Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details",
     "longName": "995528 - Disclosure - Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "i_2023-06-30",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
     "longName": "995529 - Disclosure - Note 14 - Stockholders' Equity (Details Textual)",
     "shortName": "Note 14 - Stockholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
     "longName": "995530 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)",
     "shortName": "Note 15 - Equity Incentive Plans (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details",
     "longName": "995531 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)",
     "shortName": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "i_2023-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
     "longName": "995532 - Disclosure - Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)",
     "shortName": "Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
     "longName": "995533 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)",
     "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
     "longName": "995534 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)",
     "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
     "longName": "995535 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)",
     "shortName": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
     "longName": "995536 - Disclosure - Note 16 - Warrants (Details Textual)",
     "shortName": "Note 16 - Warrants (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-06_2023-01-06_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "aytu:WarrantsOrRightsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
     "longName": "995537 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)",
     "shortName": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "i_2023-06-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "aytu:WarrantsOrRightsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "aytu:WarrantsOrRightsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
     "longName": "995538 - Disclosure - Note 17 - Restructuring Costs (Details Textual)",
     "shortName": "Note 17 - Restructuring Costs (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
     "longName": "995539 - Disclosure - Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)",
     "shortName": "Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
     "longName": "995540 - Disclosure - Note 18 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 18 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
     "longName": "995541 - Disclosure - Note 19 - License Agreements (Details Textual)",
     "shortName": "Note 19 - License Agreements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember",
      "name": "aytu:LicenseAgreementInitialLicenseFeePaid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "aytu:LicensingAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember",
      "name": "aytu:LicenseAgreementInitialLicenseFeePaid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "aytu:LicensingAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual",
     "longName": "995542 - Disclosure - Note 20 - Segment Information (Details Textual)",
     "shortName": "Note 20 - Segment Information (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R99": {
     "role": "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
     "longName": "995543 - Disclosure - Note 20 - Segment Information - Schedule of Segment Information (Details)",
     "shortName": "Note 20 - Segment Information - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-07-01_2024-06-30",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual",
     "longName": "995544 - Disclosure - Note 21 - Subsequent Events (Details Textual)",
     "shortName": "Note 21 - Subsequent Events (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "d_2024-07-01_2024-07-31_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "aytu:RevenuebasedRoyaltyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-07-01_2024-07-31_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "aytu:RevenuebasedRoyaltyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu20240630_10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r864"
     ]
    },
    "aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForChargebackAndDiscountsRecovery",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_AccountsReceivableAllowanceForChargebackAndDiscountsRecovery",
        "negatedLabel": "Payments",
        "documentation": "Amount of increase in allowance for chargebacks and discounts for credit loss on accounts receivable, from recovery."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "aytu_AccountsReceivableAllowanceForDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_AccountsReceivableAllowanceForDiscounts",
        "terseLabel": "Accounts Receivable, Allowance for Discounts",
        "periodStartLabel": "Balance, allowance for discount",
        "periodEndLabel": "Balance, allowance for discount",
        "documentation": "Represents the allowance for discounts"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of net revenue, allowance for discount",
        "documentation": "Represents the allowance for discount credit loss expense (reversal)."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForDiscountsRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForDiscountsRecovery",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments, allowance for discount",
        "documentation": "Represents allowance for discount recovery payments received."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForPricingChargebacks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForPricingChargebacks",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_AccountsReceivableAllowanceForPricingChargebacks",
        "terseLabel": "Accounts Receivable, Allowance for Pricing Chargebacks",
        "periodStartLabel": "Balance, allowance for chargeback",
        "periodEndLabel": "Balance, allowance for chargeback",
        "documentation": "Represents the allowance for pricing chargebacks"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of net revenue",
        "terseLabel": "Reduction of net revenue",
        "documentation": "Represents credit loss expense (reversal) for the allowance for pricing chargebacks and discount."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForPricingChargebacksAndDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_AccountsReceivableAllowanceForPricingChargebacksAndDiscounts",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Represents the total allowance for both pricing chargebacks and discounts."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of net revenue, allowance for chargeback",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss, allowance for chargeback, on accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForPricingChargebacksRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableAllowanceForPricingChargebacksRecovery",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments, allowance for chargeback",
        "documentation": "Amount of increase in allowance for pricing chargebacks on accounts receivable, from recovery."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in accounts receivable, gross",
        "documentation": "Represents the increase (decrease) in accounts receivable before allowance for credit loss"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableCreditTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccountsReceivableCreditTerms",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_AccountsReceivableCreditTerms",
        "terseLabel": "Accounts Receivable, Credit Terms (Day)",
        "documentation": "Represents credits terms for accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccountsReceivableGross",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r292",
      "r293",
      "r1129"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "aytu_AccruedCustomerAndProductRelatedFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccruedCustomerAndProductRelatedFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued customer and product related fees",
        "documentation": "Represents the amount of accrued customer and product related fees classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccruedIncomeTaxesCurrent",
        "terseLabel": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r141"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "aytu_AccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccruedLiabilitiesTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Text Block]",
        "documentation": "The entire disclosure regarding accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccruedProgramRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccruedProgramRelatedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued program liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccruedSavingOffers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AccruedSavingOffers",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued savings offers",
        "documentation": "Represents information related to accrued saving offers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r183",
      "r660"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r864",
      "r1164"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r941",
      "r942",
      "r943",
      "r946",
      "r1098",
      "r1165"
     ]
    },
    "aytu_AdhdPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AdhdPortfolioMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADHD Portfolio [Member]",
        "documentation": "Relating to the ADHS Portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Error Correction, Type [Domain]",
        "documentation": "Type of error correction."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r123"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdvertisingExpense",
        "terseLabel": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r843"
     ]
    },
    "aytu_AfterJanuary262023ButBeforeJanuary262024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AfterJanuary262023ButBeforeJanuary262024Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After January 26, 2023 But Before January 26, 2024 [Member]",
        "documentation": "Relating to after January 26, 2023 but before January 26, 2024."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AfterJanuary262024ButBeforeJanuary262025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AfterJanuary262024ButBeforeJanuary262025Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After January 26, 2024 But Before January 26, 2025 [Member]",
        "documentation": "Relating to after January 26, 2024 but before January 26, 2025."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AfterJune122025ButOnOrBeforeJune122026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AfterJune122025ButOnOrBeforeJune122026Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After June 12, 2025, but on or before June 12, 2026 [Member]",
        "documentation": "Represents the termination fee if the termination is after June 12, 2025, but on or before June 12, 2026."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AfterJune122026ButOnOrBeforeJune122027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AfterJune122026ButOnOrBeforeJune122027Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After June 12, 2026, but on or before June 12, 2027 [Member]",
        "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2027"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AfterJune122026ButOnOrBeforeJune122028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AfterJune122026ButOnOrBeforeJune122028Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After June 12, 2026, but on or before June 12, 2028 [Member]",
        "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2028."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r476"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r294",
      "r300",
      "r303",
      "r304",
      "r1129"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AmortizationExpenseOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AmortizationExpenseOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_AmortizationExpenseOfIntangibleAssets",
        "terseLabel": "Amortization Expense of Intangible Assets",
        "documentation": "The value of amortization expense of intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount and issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r828",
      "r829",
      "r935",
      "r1110"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r325",
      "r332",
      "r824"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securites excluded (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "aytu_AssetImpairmentAndWriteoffCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AssetImpairmentAndWriteoffCharges",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment and write-off expense",
        "documentation": "Amount of asset impairment and write-off of assets recognized in the income statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment expense",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r40"
     ]
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset under Construction [Member]",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r152",
      "r187",
      "r212",
      "r248",
      "r254",
      "r279",
      "r283",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r526",
      "r528",
      "r562",
      "r651",
      "r736",
      "r815",
      "r816",
      "r864",
      "r892",
      "r993",
      "r994",
      "r1117"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsNoncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r526",
      "r528",
      "r562",
      "r993",
      "r994",
      "r1117"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AtthemarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AtthemarketOfferingMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-market Offering [Member]",
        "documentation": "Represents the at-the-market offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898"
     ]
    },
    "aytu_August2022CommonAndPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "August2022CommonAndPrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Common and Prefunded Warrants [Member]",
        "documentation": "Relating to the August 2022 Common and Prefunded Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_August2022CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "August2022CommonWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Common Warrants [Member]",
        "documentation": "Relating to the August 2022 Common Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_August2022PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "August2022PrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2022 Prefunded Warrants [Member]",
        "documentation": "Relating to August 2022 prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AvenueCapitalIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AvenueCapitalIssuanceMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue Capital Issuance [Member]",
        "documentation": "Relating to Avenue Capital Issuance."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AvenueCapitalLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AvenueCapitalLoanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue Capital Loan [Member]",
        "documentation": "Relating to the Avenue Capital Loan."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AvenueCapitalWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "AvenueCapitalWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avenue Capital Warrants [Member]",
        "documentation": "Relating to the Avenue Capital Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r343",
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_BoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "BoardMembersMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Members [Member]",
        "documentation": "Represents board members."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r520",
      "r837",
      "r838"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r520",
      "r837",
      "r838"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain from contingent consideration",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r934"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_BusinessCombinationContingentConsiderationLiability",
        "terseLabel": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r135",
      "r521",
      "r544",
      "r545",
      "r546"
     ]
    },
    "aytu_BusinessCombinationsContingentConsiderationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "BusinessCombinationsContingentConsiderationPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations, Contingent Consideration [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for business combinations, contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_BusinessExitCosts1",
        "terseLabel": "Business Exit Costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r181",
      "r796"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r105",
      "r209"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r105"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Represents the exercise price of warrants or rights exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expired, weighted average exercise price (in dollars per share)",
        "documentation": "Represents the exercise price of warrants or rights expired during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "aytu_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_ClassOfWarrantOrRightExercisedDuringPeriod",
        "negatedLabel": "Warrants exercised (in shares)",
        "documentation": "The number of warrants or rights exercised during period."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExpiredDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightExpiredDuringPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_ClassOfWarrantOrRightExpiredDuringPeriod",
        "negatedLabel": "Warrants expired (in shares)",
        "documentation": "Represents the number of warrants or rights expired during the period."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued (2) (in shares)",
        "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)",
        "documentation": "The number of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued, weighted average exercise price (in dollars per share)",
        "documentation": "Exercise price per share of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)",
        "periodStartLabel": "Outstanding, balance (in shares)",
        "periodEndLabel": "Outstanding, balance (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted average remaining contractual term (Year)",
        "documentation": "The weighted average period of remaining contractual life of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (note 18)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r145",
      "r654",
      "r723"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r356",
      "r357",
      "r780",
      "r982",
      "r988"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r883",
      "r884",
      "r886",
      "r887",
      "r888",
      "r889",
      "r941",
      "r942",
      "r946",
      "r1098",
      "r1162",
      "r1165"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r724"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, issued (in shares)",
        "terseLabel": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, outstanding (in shares)",
        "terseLabel": "Common Stock, Shares, Outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r724",
      "r742",
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $.0001; 200,000,000 shares authorized; 5,972,638 and 5,517,174 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r656",
      "r864"
     ]
    },
    "aytu_CommonWarrantsExchangedForPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "CommonWarrantsExchangedForPrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants Exchanged for PreFunded Warrants [Member]",
        "documentation": "Relating to Common Warrants exchanged for Pre-Funded Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Relating to the Common Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r291",
      "r779"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r291",
      "r700",
      "r779"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r291",
      "r779",
      "r911"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r162"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer concentration risk",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r291"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r291",
      "r779"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r805"
     ]
    },
    "aytu_ConsumerHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ConsumerHealthMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consumer Health [Member]",
        "documentation": "Represents consumer health."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ConsumerHealthSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ConsumerHealthSegmentMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consumer Health Segment [Member]",
        "documentation": "Represents the consumer health segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r612"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r376",
      "r396",
      "r600",
      "r609",
      "r650",
      "r802",
      "r804"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CurrentFederalTaxExpenseBenefit",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r938",
      "r1094"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CurrentIncomeTaxExpenseBenefit",
        "totalLabel": "Total current tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r938"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r938",
      "r1094"
     ]
    },
    "aytu_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "CustomerAMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]",
        "documentation": "Represents Customer A."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "CustomerBMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]",
        "documentation": "Represents Customer B."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "CustomerCMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]",
        "documentation": "Represents Customer C."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r291"
     ]
    },
    "aytu_DebtInstrumentAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DebtInstrumentAmortizationPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_DebtInstrumentAmortizationPeriod",
        "terseLabel": "Debt Instrument, Amortization Period (Year)",
        "documentation": "The duration in which the debt will amortize."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r140",
      "r144",
      "r216",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r853",
      "r936",
      "r983",
      "r984",
      "r985",
      "r1109",
      "r1111"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan principal amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r144",
      "r389"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r571",
      "r572",
      "r826",
      "r827",
      "r853"
     ]
    },
    "aytu_DebtInstrumentFinalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DebtInstrumentFinalPayment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final payment fee",
        "terseLabel": "Debt Instrument, Final Payment",
        "documentation": "Represents the final payment of a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r391",
      "r571",
      "r572",
      "r853"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r374"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r216",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r853",
      "r936",
      "r983",
      "r984",
      "r985",
      "r1109",
      "r1111"
     ]
    },
    "aytu_DebtInstrumentPrepaymentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DebtInstrumentPrepaymentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_DebtInstrumentPrepaymentFeeAmount",
        "terseLabel": "Debt Instrument, Prepayment Fee, Amount",
        "documentation": "The prepayment fee amount."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DebtInstrumentPrepaymentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_DebtInstrumentPrepaymentFeePercentage",
        "terseLabel": "Debt Instrument, Prepayment Fee, Percentage",
        "documentation": "Represents the percentage of loan that is payable as a prepayment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Year)",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DebtInstrumentTerminationFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DebtInstrumentTerminationFeePercentage",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_DebtInstrumentTerminationFeePercentage",
        "terseLabel": "Debt Instrument, Termination Fee, Percentage",
        "documentation": "The termination fee if the debt is terminated before or on a certain date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
        "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r390",
      "r570",
      "r571",
      "r572",
      "r826",
      "r827",
      "r853"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1093",
      "r1094"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFinanceCostsCurrentNet",
        "terseLabel": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1109",
      "r1111"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFinanceCostsNet",
        "terseLabel": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1108",
      "r1109",
      "r1111"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxExpenseBenefit",
        "totalLabel": "Total deferred tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r168",
      "r938"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "terseLabel": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r142",
      "r497"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1093",
      "r1094"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "aytu_DeferredTaxAssetsAccruedRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DeferredTaxAssetsAccruedRebates",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued rebates",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible accrued rebates."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 capitalization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant derivatives",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "terseLabel": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "aytu_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOther",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilities",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
        "negatedLabel": "Intangibles",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements",
        "negatedLabel": "ROU asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "negatedLabel": "Fixed assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r41"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r41"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, amortization and accretion",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r248",
      "r259",
      "r283",
      "r815",
      "r816"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Derivative warrant liabilities loss (gain)",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative warrant liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r977",
      "r978"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r468",
      "r469",
      "r471",
      "r840"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DistributionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DistributionRightsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights [Member]",
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r977",
      "r978"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898",
      "r900"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r234",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r518",
      "r524",
      "r539",
      "r540",
      "r647",
      "r665",
      "r808"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r246"
     ]
    },
    "aytu_EclipseBusinessCapitalLlcLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EclipseBusinessCapitalLlcLoanAgreementMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eclipse Business Capital LLC Loan Agreement [Member]",
        "documentation": "Relating to Eclipse Business Capital LLC Loan Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EclipseTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EclipseTermLoanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eclipse Term loan [Member]",
        "documentation": "Represents the Eclipse Term loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Net income tax expense",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r845"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r486",
      "r509",
      "r845"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r845",
      "r939",
      "r1086"
     ]
    },
    "aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent",
        "terseLabel": "Contingent consideration",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to contingent considerations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r939",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense, amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r845",
      "r939",
      "r1086"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "aytu_EmployeeRetentionCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EmployeeRetentionCredit",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee retention credit",
        "terseLabel": "Employee Retention Credit",
        "documentation": "Represents the amount of employee retention credit."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EmployeeRetentionCreditPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EmployeeRetentionCreditPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Retention Credit [Policy Text Block]",
        "documentation": "Represents the accounting policy for employee retention credits."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EmployeeRetentionCreditVendorFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EmployeeRetentionCreditVendorFee",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_EmployeeRetentionCreditVendorFee",
        "terseLabel": "Employee Retention Credit, Vendor Fee",
        "documentation": "Represents the amount of vendor fee from employee retention credit during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-document-and-entity-information",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-tables",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-tables",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r175",
      "r200",
      "r201",
      "r202",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r235",
      "r237",
      "r249",
      "r296",
      "r299",
      "r340",
      "r408",
      "r507",
      "r508",
      "r515",
      "r516",
      "r517",
      "r519",
      "r523",
      "r524",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r574",
      "r576",
      "r599",
      "r664",
      "r689",
      "r690",
      "r691",
      "r710",
      "r762"
     ]
    },
    "aytu_EquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "EquityWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants [Member]",
        "documentation": "Relating to Equity Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Error Correction, Type [Axis]",
        "documentation": "Information by type of error correction."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "aytu_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range One [Member]",
        "documentation": "Represents exercise price range one."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Represents exercise price range three."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Represents exercise price range two."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ExitAndDisposalActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ExitAndDisposalActivitiesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exit and Disposal Activities [Member]",
        "documentation": "Represents the exit and disposal activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ExtinguishmentOfDebtAmount",
        "terseLabel": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r849"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r554",
      "r555",
      "r557",
      "r604",
      "r605",
      "r606",
      "r826",
      "r827",
      "r834",
      "r835",
      "r836",
      "r846",
      "r849"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r846",
      "r1103",
      "r1106"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r645",
      "r846",
      "r850"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r421",
      "r426",
      "r543",
      "r555",
      "r604",
      "r834",
      "r835",
      "r836",
      "r846"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r421",
      "r426",
      "r543",
      "r544",
      "r555",
      "r605",
      "r826",
      "r827",
      "r834",
      "r835",
      "r836",
      "r846"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r543",
      "r544",
      "r545",
      "r546",
      "r555",
      "r606",
      "r826",
      "r827",
      "r834",
      "r835",
      "r836",
      "r846",
      "r849"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r551",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r846",
      "r1103",
      "r1106"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Included in earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r554",
      "r555",
      "r557",
      "r604",
      "r605",
      "r606",
      "r826",
      "r827",
      "r834",
      "r835",
      "r836",
      "r846",
      "r849"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r846",
      "r1103"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r556"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r586",
      "r855"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r589"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing leases",
        "terseLabel": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r592"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing cash flows from finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r589"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of leased assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r586",
      "r855"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease assets",
        "label": "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r855"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Finance lease assets (Year)",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r855"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, fair value",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101",
      "r1105"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablePortfolioSegmentAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable Portfolio Segment [Axis]",
        "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r301",
      "r302",
      "r822",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablePortfolioSegmentDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable Portfolio Segment [Domain]",
        "documentation": "Level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedLabel": "Finite-lived intangible assets, amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r312",
      "r331",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter, future amortization expense",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1171"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025, future amortization expense",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r792",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029, future amortization expense",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r792",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028, future amortization expense",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r792",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027, future amortization expense",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r792",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026, future amortization expense",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r792",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r334",
      "r335",
      "r613",
      "r614",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets, gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r331",
      "r614",
      "r824"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r334",
      "r335",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets, net",
        "totalLabel": "Total future amortization expense",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r974"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets, remaining life (Year)",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FinitelivedIntangibleAssetUsefulLifeRenewablePeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)",
        "documentation": "Represents the renewable period for a finite-lived intangible asset."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FirstThreePercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FirstThreePercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Three Percent Contribution By Employees [Member]",
        "documentation": "Represents the first 3% contribution by employees in an employee benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementAssumedFromCerecorIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementAssumedFromCerecorIncMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Payment Arrangement Assumed from Cerecor Inc. [Member]",
        "documentation": "Relating to the fixed payment arrangement assumed from Cerecor Inc."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementQuarterlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementQuarterlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FixedPaymentArrangementQuarterlyPayments",
        "terseLabel": "Fixed Payment Arrangement, Quarterly Payments",
        "documentation": "Represents the amount of quarterly payments on fixed payments arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangements",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed payment arrangements",
        "terseLabel": "Fixed Payment Arrangements",
        "documentation": "Represents the amount of fixed payment arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsBalloonPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementsBalloonPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FixedPaymentArrangementsBalloonPaymentAmount",
        "terseLabel": "Fixed Payment Arrangements, Balloon Payment Amount",
        "documentation": "Represents the amount of balloon payment on a fixed payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMeasurementInput": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementsMeasurementInput",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FixedPaymentArrangementsMeasurementInput",
        "terseLabel": "Fixed Payment Arrangements, Measurement Input",
        "documentation": "Represents the measurement input used in valuing fixed payment arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMonthlyPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementsMonthlyPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FixedPaymentArrangementsMonthlyPaymentAmount",
        "terseLabel": "Fixed Payment Arrangements, Monthly Payment Amount",
        "documentation": "Represents the amount of monthly payment amount on a fixed payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsPaymentAmountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementsPaymentAmountPaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FixedPaymentArrangementsPaymentAmountPaid",
        "terseLabel": "Fixed Payment Arrangements, Payment Amount, Paid",
        "documentation": "Represents the amount paid on fixed payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FixedPaymentArrangementsPeriodicPaymentObligationsNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber",
        "terseLabel": "Fixed Payment Arrangements, Periodic Payment Obligations, Number",
        "documentation": "Represents the number of fixed, periodic payment obligations."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FurnitureAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "FurnitureAndEquipmentMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Equipment [Member]",
        "documentation": "Represents furniture and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
        "terseLabel": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r45",
      "r46"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r746"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "aytu_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for going concern determination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r313",
      "r646",
      "r816",
      "r823",
      "r847",
      "r864",
      "r965",
      "r966"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r967"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r336",
      "r339"
     ]
    },
    "aytu_GrandPrairieTexasManufacturingSiteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "GrandPrairieTexasManufacturingSiteMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grand Prairie, Texas Manufacturing Site [Member]",
        "documentation": "Represents the Grand Prairie, Texas manufacturing site."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GrossProfit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r99",
      "r151",
      "r212",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r562",
      "r809",
      "r815",
      "r947",
      "r949",
      "r950",
      "r951",
      "r952",
      "r993"
     ]
    },
    "aytu_HealightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "HealightMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Healight [Member]",
        "documentation": "Represents licensing agreement related to used of Healight."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898"
     ]
    },
    "aytu_ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immaterial Error Correction of Prepaid Expenses from Current Asset to Noncurrent Asset [Member]",
        "documentation": "Pertains to immaterial correction of previously stated amounts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
        "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r980"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r325",
      "r336"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ImpairmentOfIntangibleAssetsFinitelived",
        "terseLabel": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r935",
      "r979"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r115"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income tax",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r147",
      "r151",
      "r648",
      "r662",
      "r809",
      "r815",
      "r947",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r151",
      "r212",
      "r225",
      "r232",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r518",
      "r524",
      "r540",
      "r562",
      "r662",
      "r809",
      "r947",
      "r949",
      "r950",
      "r951",
      "r952",
      "r993"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343",
      "r348",
      "r548",
      "r551",
      "r556",
      "r686",
      "r688",
      "r747",
      "r792",
      "r848",
      "r1133"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r348",
      "r548",
      "r551",
      "r556",
      "r686",
      "r688",
      "r747",
      "r792",
      "r848",
      "r1133"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r481",
      "r486",
      "r490",
      "r491",
      "r492",
      "r495",
      "r501",
      "r510",
      "r512",
      "r513",
      "r514",
      "r709",
      "r845"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "terseLabel": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Net income tax expense, amount",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r169",
      "r236",
      "r237",
      "r248",
      "r262",
      "r283",
      "r485",
      "r486",
      "r511",
      "r666",
      "r845"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r483",
      "r484",
      "r495",
      "r496",
      "r500",
      "r505",
      "r705"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r845",
      "r1086"
     ]
    },
    "aytu_IncomeTaxReconciliationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "IncomeTaxReconciliationContingentConsideration",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration, amount",
        "documentation": "Represents income tax reconciliation for contingent considerations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax at statutory rate, amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r845"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal benefit, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r845",
      "r1086"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r208",
      "r502",
      "r503"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities",
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
        "negatedLabel": "Other operating assets and liabilities, net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r974",
      "r976"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r386",
      "r392",
      "r828",
      "r829"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpenseNonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r930"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r206",
      "r207"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-4-inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r799"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r797",
      "r864"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r180",
      "r192",
      "r306",
      "r307",
      "r309",
      "r611",
      "r806"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r801"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work in process",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r800"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "aytu_InventoryWriteDownsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "InventoryWriteDownsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write Downs [Member]",
        "documentation": "Represents the Inventory Write Downs."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_June2023WarrantsTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "June2023WarrantsTrancheAMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2023 Warrants Tranche A [Member]",
        "documentation": "Represents the June 2023 Warrants Tranche A."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "documentation": "Represents lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r913"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r913"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LeaseCost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r855"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r593"
     ]
    },
    "aytu_LeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LeasesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Disclosure [Text Block]",
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalCostsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-document-and-entity-information",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-tables",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-tables",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "aytu_LesseeLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LesseeLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Liability, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseDiscountRate",
        "terseLabel": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
        "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r146",
      "r658",
      "r864",
      "r937",
      "r959",
      "r1107"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r179",
      "r212",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r527",
      "r528",
      "r529",
      "r562",
      "r864",
      "r993",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r77",
      "r78",
      "r79",
      "r82",
      "r212",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r527",
      "r528",
      "r529",
      "r562",
      "r993",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LiabilityPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LiabilityPrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Pre-Funded Warrants [Member]",
        "documentation": "Represents information pertaining to pre-funded warrants classified as liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LiabilityTrancheBPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LiabilityTrancheBPrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Tranche B Prefunded Warrants [Member]",
        "documentation": "Represents information pertaining to the tranche B prefunded warrants classified as liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LiabilityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LiabilityWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Warrants [Member]",
        "documentation": "Represents liability warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementInitialLicenseFeePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LicenseAgreementInitialLicenseFeePaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_LicenseAgreementInitialLicenseFeePaid",
        "terseLabel": "License Agreement, Initial License Fee Paid",
        "documentation": "Represents the initial license fee paid as part of a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementPatentProsecutionFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LicenseAgreementPatentProsecutionFeesPaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_LicenseAgreementPatentProsecutionFeesPaid",
        "terseLabel": "License Agreement, Patent Prosecution Fees Paid",
        "documentation": "Represents patent prosecution fees paid as part of a license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum",
        "terseLabel": "License Agreement, Up-front, Non-refundable License Fee Paid, Maximum",
        "documentation": "Represents a maximum, up-front, non-refundable license fee paid as part of a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicensingAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LicensingAgreementsTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Text Block]",
        "documentation": "The entire disclosure for licensing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LineOfCredit",
        "terseLabel": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r144",
      "r1127"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r936",
      "r991",
      "r992"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r936",
      "r991"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity",
        "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r363"
     ]
    },
    "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LineOfCreditFacilityTerminationFeePercentageOfCommitment",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment",
        "terseLabel": "Line of Credit Facility, Termination, Fee, Percentage of Commitment",
        "documentation": "Represents the percentage of commitment used as a termination fee of a line of credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
        "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoanProcessingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoanProcessingFee",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LoanProcessingFee",
        "terseLabel": "Loan Processing Fee",
        "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total debt, net of current portion",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r653"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent",
        "negatedLabel": "Less: current portion of debt",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "aytu_LongTermDebtAndCapitalLeaseObligationsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "LongTermDebtAndCapitalLeaseObligationsGross",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_LongTermDebtAndCapitalLeaseObligationsGross",
        "totalLabel": "Total future term loan principal payments",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
        "totalLabel": "Total debt",
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Less: current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details": {
       "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
        "terseLabel": "2025",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r216",
      "r384"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details": {
       "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
        "terseLabel": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r216",
      "r384"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details": {
       "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r216",
      "r384"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details": {
       "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r216",
      "r384"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, net of current portion",
        "terseLabel": "Total debt, net of current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r983",
      "r984",
      "r985"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r833",
      "r874",
      "r879",
      "r997",
      "r1130",
      "r1134",
      "r1135",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ManagementMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1116"
     ]
    },
    "aytu_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Represents manufacturing equipment."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_March2022CommonAndPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "March2022CommonAndPrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2022 Common and Prefunded Warrants [Member]",
        "documentation": "Represents the March 2022 Offering common and prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_March2022CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "March2022CommonWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2022 Common Warrants [Member]",
        "documentation": "Represents the March 2022 Offering common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_March2022PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "March2022PrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2022 Prefunded Warrants [Member]",
        "documentation": "Represents the March 2022 Offering prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r430",
      "r477",
      "r546",
      "r610",
      "r685",
      "r687",
      "r699",
      "r715",
      "r716",
      "r767",
      "r769",
      "r771",
      "r772",
      "r774",
      "r790",
      "r791",
      "r821",
      "r830",
      "r839",
      "r849",
      "r850",
      "r851",
      "r852",
      "r875",
      "r995",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r849"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r849"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r430",
      "r477",
      "r546",
      "r610",
      "r685",
      "r687",
      "r699",
      "r715",
      "r716",
      "r767",
      "r769",
      "r771",
      "r772",
      "r774",
      "r790",
      "r791",
      "r821",
      "r830",
      "r839",
      "r849",
      "r850",
      "r851",
      "r875",
      "r995",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r833",
      "r874",
      "r879",
      "r997",
      "r1130",
      "r1134",
      "r1135",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "aytu_Neos2015PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "Neos2015PlanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neos 2015 Plan [Member]",
        "documentation": "Represents Neos 2015 plan."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NeosPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NeosPlanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neos Plan [Member]",
        "documentation": "Represents the Neos Plan."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NeosTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NeosTherapeuticsIncMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neos Therapeutics, Inc. [Member]",
        "documentation": "Related to Neos Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash (used in) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      },
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r107",
      "r148",
      "r178",
      "r197",
      "r198",
      "r202",
      "r212",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r241",
      "r295",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r518",
      "r524",
      "r540",
      "r562",
      "r663",
      "r744",
      "r760",
      "r761",
      "r890",
      "r993"
     ]
    },
    "us-gaap_NetInvestmentInLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetInvestmentInLease",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Investment in Lease, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r305",
      "r595",
      "r962"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NextFivePercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NextFivePercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Five Percent Contribution By Employees [Member]",
        "documentation": "Represents the next 5% contribution by employees in a employee benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NextFourPercentAndFivePercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NextFourPercentAndFivePercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Four Percent and Five Percent Contribution By Employees [Member]",
        "documentation": "Represents the next 4% and 5% contribution by employees in employee benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NextFourPercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NextFourPercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Four Percent Contribution By Employees [Member]",
        "documentation": "Represents the next 4% contribution by employees in an employee benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "aytu_NoncashGainLossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NoncashGainLossOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_NoncashGainLossOnExtinguishmentOfDebt",
        "negatedLabel": "Non-cash loss on extinguishment of debt",
        "documentation": "The non-cash gain (loss) on the extinguishment of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonmonetaryTransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonmonetaryTransactionTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transaction Type [Axis]",
        "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_NonmonetaryTransactionTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonmonetaryTransactionTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transaction Type [Domain]",
        "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "aytu_NonplanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NonplanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-plan [Member]",
        "documentation": "Represents non-plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "aytu_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r948"
     ]
    },
    "aytu_NumberOfProducts": {
     "xbrltype": "pureItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "NumberOfProducts",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_NumberOfProducts",
        "terseLabel": "Number of Products",
        "documentation": "Represents the number of products."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfReportableSegments",
        "terseLabel": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r820",
      "r948"
     ]
    },
    "aytu_OfficeEquipmentFurnitureAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OfficeEquipmentFurnitureAndOtherMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment, Furniture and Other [Member]",
        "documentation": "Represents office equipment, furniture and other."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space And Manufacturing Facilities Grand Prairie Texas [Member]",
        "documentation": "Represents the office space and manufacturing facilities in Grand Prairie, Texas."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OfficeSpaceInBerwynPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OfficeSpaceInBerwynPennsylvaniaMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space in Berwyn, Pennsylvania [Member]",
        "documentation": "Relating to an office space in Berwyn, Pennsylvania."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OnOrBeforeJanuary262023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OnOrBeforeJanuary262023Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "On or Before January 26, 2023 [Member]",
        "documentation": "Relating to on or before January 26, 2023."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OnOrBeforeJune122025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OnOrBeforeJune122025Member",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "On or Before June 12 2025 [Member]",
        "documentation": "Termination is on or before the date of June 12 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r809",
      "r947",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "aytu_OperatingLeaseAndFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLeaseAndFinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total lease liabilities",
        "label": "aytu_OperatingLeaseAndFinanceLeaseLiability",
        "documentation": "Represents operating and finance lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLeaseAndFinanceLeaseRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLeaseAndFinanceLeaseRightofuseAsset",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease assets",
        "documentation": "Represents right-of-use asset for operating lease and finance lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r855"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseLiability",
        "terseLabel": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLeaseLiabilityIncludingLeaseNotYetCommenced",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities",
        "label": "aytu_OperatingLeaseLiabilityIncludingLeaseNotYetCommenced",
        "documentation": "Amount of lessee's discounted obligation for lease payments from operating lease, including operating lease that has not yet commenced."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r589"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLeaseUndiscountedMinimumMonthlyPayment",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment",
        "terseLabel": "Operating Lease, Undiscounted Minimum Monthly Payment",
        "documentation": "Represents the undiscounted minimum monthly payment on an operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease assets",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r855"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease assets (Year)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r855"
     ]
    },
    "aytu_OperatingLossCarryforwardExpirationsOwnershipChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLossCarryforwardExpirationsOwnershipChange",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_OperatingLossCarryforwardExpirationsOwnershipChange",
        "terseLabel": "Operating Loss Carryforward, Expirations, Ownership Change",
        "documentation": "The operating loss carryforward that will expire related to the ownership change."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLossCarryforwardSubjectToExpire": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLossCarryforwardSubjectToExpire",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_OperatingLossCarryforwardSubjectToExpire",
        "terseLabel": "Operating Loss Carryforward, Subject To Expire",
        "documentation": "The operating loss carryforward that will expire."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss",
        "terseLabel": "Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss",
        "documentation": "Represents disallowed recognized built-in loss, carried forward as an operating loss."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation",
        "terseLabel": "Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation",
        "documentation": "Post-change net operating loss determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_OperatingLossCarryforwardsNotSubjectToExpiration",
        "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Represents operating loss carryforwards not subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r136",
      "r701",
      "r702"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherAssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r864"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenseMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense [Member]",
        "documentation": "Primary financial statement caption encompassing other expense."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherLiabilities",
        "totalLabel": "Total other liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r652",
      "r719",
      "r720",
      "r892",
      "r1128",
      "r1163"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "negatedLabel": "Less: current portion of other liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r864"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r78",
      "r981"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total other liabilities, non-current",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherNoncashIncomeExpense",
        "negatedLabel": "Other non-cash adjustments",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-cash investing and financing activities",
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_OtherSundryLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSundryLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherSundryLiabilities",
        "terseLabel": "Other",
        "documentation": "The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r78",
      "r143"
     ]
    },
    "aytu_OtherWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "OtherWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Warrants [Member]",
        "documentation": "Relating to other warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentedTechnologyMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patented Technology [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r977",
      "r978"
     ]
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentOfFinancingAndStockIssuanceCosts",
        "terseLabel": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
        "negatedLabel": "Other investing activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r931"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfDebtIssuanceCosts",
        "negatedLabel": "Payment for debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "aytu_PaymentsOfFixedPaymentArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "PaymentsOfFixedPaymentArrangements",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_PaymentsOfFixedPaymentArrangements",
        "negatedLabel": "Payment made to fixed payment arrangement",
        "documentation": "The cash outflow for fixed payments arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r12",
      "r49"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r394"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, authorizzed (in shares)",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r724"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issued (in shares)",
        "terseLabel": "Preferred Stock, Shares Issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r394"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, outstanding (in shares)",
        "terseLabel": "Preferred Stock, Shares Outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r724",
      "r742",
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r655",
      "r864"
     ]
    },
    "aytu_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Relating to the Pre-Funded Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r310",
      "r311",
      "r798"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_PrincipalOfficeDenverColoradoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "PrincipalOfficeDenverColoradoMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Office Denver Colorado [Member]",
        "documentation": "Represents the principal office in Denver, Colorado."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "aytu_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of common stock and warrants",
        "documentation": "The cash inflow from the additional capital contribution to the entity from shares and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfDebt",
        "terseLabel": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings",
        "documentation": "Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r933"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r706"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds (payments) made on revolving credit facility",
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromWarrantExercises",
        "terseLabel": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r612",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r794",
      "r831",
      "r873",
      "r875",
      "r876",
      "r880",
      "r881",
      "r989",
      "r990",
      "r997",
      "r1130",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r612",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r794",
      "r831",
      "r873",
      "r875",
      "r876",
      "r880",
      "r881",
      "r989",
      "r990",
      "r997",
      "r1130",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r593"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r163",
      "r166",
      "r167"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r182",
      "r661"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r593",
      "r649",
      "r661",
      "r864"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r163",
      "r166",
      "r659"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r593"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r420",
      "r430",
      "r463",
      "r464",
      "r465",
      "r477",
      "r546",
      "r607",
      "r608",
      "r610",
      "r685",
      "r687",
      "r699",
      "r715",
      "r716",
      "r767",
      "r769",
      "r771",
      "r772",
      "r774",
      "r790",
      "r791",
      "r821",
      "r830",
      "r839",
      "r849",
      "r850",
      "r851",
      "r852",
      "r875",
      "r884",
      "r986",
      "r995",
      "r1103",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r420",
      "r430",
      "r463",
      "r464",
      "r465",
      "r477",
      "r546",
      "r607",
      "r608",
      "r610",
      "r685",
      "r687",
      "r699",
      "r715",
      "r716",
      "r767",
      "r769",
      "r771",
      "r772",
      "r774",
      "r790",
      "r791",
      "r821",
      "r830",
      "r839",
      "r849",
      "r850",
      "r851",
      "r852",
      "r875",
      "r884",
      "r986",
      "r995",
      "r1103",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "negatedLabel": "Payments made to borrowings",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r707"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r376",
      "r396",
      "r600",
      "r609",
      "r650",
      "r803",
      "r804"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r792",
      "r815",
      "r1125"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r247",
      "r297",
      "r298",
      "r516",
      "r517",
      "r518",
      "r519",
      "r523",
      "r524",
      "r537",
      "r538",
      "r539",
      "r540",
      "r573",
      "r575",
      "r598",
      "r599",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r703",
      "r953"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r247",
      "r297",
      "r298",
      "r516",
      "r517",
      "r518",
      "r519",
      "r523",
      "r524",
      "r537",
      "r538",
      "r539",
      "r540",
      "r573",
      "r575",
      "r598",
      "r599",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r703",
      "r953"
     ]
    },
    "aytu_RestrictedStockAndRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "RestrictedStockAndRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock and Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r347",
      "r350",
      "r355"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r351",
      "r352",
      "r987"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r352",
      "r353"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring costs",
        "label": "us-gaap_RestructuringCosts",
        "terseLabel": "Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r123",
      "r657",
      "r693",
      "r698",
      "r708",
      "r725",
      "r864"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r235",
      "r237",
      "r296",
      "r299",
      "r340",
      "r507",
      "r508",
      "r515",
      "r516",
      "r517",
      "r519",
      "r523",
      "r524",
      "r530",
      "r532",
      "r533",
      "r535",
      "r538",
      "r574",
      "r576",
      "r689",
      "r691",
      "r710",
      "r1165"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r839",
      "r909",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r839",
      "r909",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "aytu_ReturnReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ReturnReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return reserve",
        "documentation": "Represents the amount of return reserve classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ReturnReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ReturnReserveMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Reserve, Return [Member]",
        "documentation": "Represents return reserve."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue",
        "label": "Net revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r248",
      "r255",
      "r256",
      "r277",
      "r283",
      "r287",
      "r289",
      "r291",
      "r417",
      "r418",
      "r612"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r910"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r793",
      "r807"
     ]
    },
    "aytu_RevenuebasedRoyaltyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "RevenuebasedRoyaltyCosts",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_RevenuebasedRoyaltyCosts",
        "terseLabel": "Revenue-based Royalty Costs",
        "documentation": "The amount of revenue-based royalty revenue costs."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ReverseStockSplitMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split [Member]",
        "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "aytu_RxSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "RxSegmentMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rx Segment [Member]",
        "documentation": "Relating to the Rx Segment."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SabbyLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SabbyLitigationMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sabby Litigation [Member]",
        "documentation": "Relating to the Sabby Litigation."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SabbyLitigationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SabbyLitigationWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sabby Litigation Warrants [Member]",
        "documentation": "Relating to warrants calculated by the claimant in the Sabby Litigation."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SabbyVolatilityWarrantMasterFundLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SabbyVolatilityWarrantMasterFundLtdMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sabby Volatility Warrant Master Fund Ltd. [Member]",
        "documentation": "Relating to Sabby Volatility Warrant master Fund Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SaleOfStockMaximumAmountOfEquityIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SaleOfStockMaximumAmountOfEquityIssuable",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SaleOfStockMaximumAmountOfEquityIssuable",
        "terseLabel": "Sale of Stock, Maximum Amount of Equity Issuable",
        "documentation": "Represents the maximum monetary amount of equity issuable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SaleOfStockPricePerShare",
        "terseLabel": "Sale of Stock, Price Per Share (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r237",
      "r247",
      "r516",
      "r518",
      "r519",
      "r523",
      "r524",
      "r537",
      "r538",
      "r539",
      "r573",
      "r575",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r703",
      "r912",
      "r914",
      "r915",
      "r916",
      "r944",
      "r953",
      "r960",
      "r961",
      "r1099",
      "r1114",
      "r1115"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r435",
      "r905",
      "r945"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r47",
      "r48",
      "r67",
      "r121",
      "r122",
      "r826",
      "r828",
      "r940",
      "r1109"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r845",
      "r1086"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r973"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-4-inventories-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r92",
      "r93",
      "r94"
     ]
    },
    "aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ScheduleOfLeaseByBalanceSheetInformationTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease by Balance Sheet Information [Table Text Block]",
        "documentation": "Tabular disclosure of leases by balance sheet information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r116",
      "r117"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r125"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r844"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r975"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r65",
      "r138"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "aytu_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Relating to the Securities Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SecuritiesPurchaseAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SecuritiesPurchaseAgreementWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement Warrants [Member]",
        "documentation": "Relating to the Securities Purchase Agreement Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r248",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r291",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r338",
      "r349",
      "r354",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r812",
      "r815",
      "r816",
      "r823",
      "r878",
      "r1130",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r712",
      "r713",
      "r714",
      "r768",
      "r770",
      "r773",
      "r775",
      "r778",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r795",
      "r832",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r877",
      "r884",
      "r997",
      "r1130",
      "r1134",
      "r1135",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r266",
      "r268",
      "r269",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r291",
      "r810",
      "r813",
      "r814",
      "r815",
      "r817",
      "r819",
      "r820"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r286",
      "r289",
      "r811",
      "r812",
      "r818"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SettlementLiabilitiesCurrent",
        "terseLabel": "Settlement Liabilities, Current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SeveranceCosts1",
        "terseLabel": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "us-gaap_ShareBasedCompensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedLabel": "Forfeited/cancelled, shares (in shares)",
        "negatedTerseLabel": "Forfeited/cancelled, shares (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/cancelled, weighted average grant date fair value (in dollars per share)",
        "label": "Forfeited/cancelled, weighted average grant date fair value (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average grant date fair value (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)",
        "periodStartLabel": "Unvested, shares (in shares)",
        "periodEndLabel": "Unvested, shares (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Unvested, weighted average grant date fair value (in dollars per share)",
        "periodEndLabel": "Unvested, weighted average grant date fair value (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested, shares (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, options (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, options, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired, options (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeited/Cancelled, options (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding, options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r441",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options exercisable (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, options, weighted average remaining contractual life (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options, weighted average remaining contractual life (Year)",
        "documentation": "Weighted average remaining contractual term for option awards granted during the periof, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, options, weighted average remaining contractual life (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Grants Rescinded",
        "documentation": "Represents the percentage of grants rescinded under a share-based compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices (in dollars per share)",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of options outstanding (Year)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving credit facility",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r140",
      "r864",
      "r1126"
     ]
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Text Block]",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r855"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r210"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r177",
      "r248",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r291",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r338",
      "r342",
      "r349",
      "r354",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r812",
      "r815",
      "r816",
      "r823",
      "r878",
      "r1130",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r88",
      "r89",
      "r175",
      "r200",
      "r201",
      "r202",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r235",
      "r237",
      "r249",
      "r296",
      "r299",
      "r340",
      "r408",
      "r507",
      "r508",
      "r515",
      "r516",
      "r517",
      "r519",
      "r523",
      "r524",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r574",
      "r576",
      "r599",
      "r664",
      "r689",
      "r690",
      "r691",
      "r710",
      "r762"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r712",
      "r713",
      "r714",
      "r768",
      "r770",
      "r773",
      "r775",
      "r778",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r795",
      "r832",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r877",
      "r884",
      "r997",
      "r1130",
      "r1134",
      "r1135",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-tables",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-tables",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r249",
      "r576",
      "r612",
      "r704",
      "r711",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r743",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r762",
      "r885"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r435",
      "r905",
      "r906",
      "r945"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets-parentheticals",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition",
      "http://aytubio.com/20240630/role/statement-note-1-nature-of-business-and-financial-condition-details-textual",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility",
      "http://aytubio.com/20240630/role/statement-note-10-revolving-credit-facility-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-future-principal-payments-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-provision-for-income-taxes-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-option-activity-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-tables",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-details-textual",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-details-textual",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-schedule-of-segment-information-details",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-schedule-of-inventories-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-tables",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://aytubio.com/20240630/role/statement-note-6-leases",
      "http://aytubio.com/20240630/role/statement-note-6-leases-details-textual",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
      "http://aytubio.com/20240630/role/statement-note-6-leases-lease-cost-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details",
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-future-amortization-expense-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies",
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r249",
      "r292",
      "r576",
      "r612",
      "r704",
      "r711",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r743",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r762",
      "r885"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of $1,004 issuance cost (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r83",
      "r84",
      "r123",
      "r706",
      "r762",
      "r776"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r83",
      "r84",
      "r123"
     ]
    },
    "aytu_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from exercise of warrants (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised (in shares)",
        "documentation": "The number of shares issued for the warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of $1,004 issuance cost",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r83",
      "r84",
      "r123",
      "r710",
      "r762",
      "r776",
      "r891"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r83",
      "r84",
      "r123"
     ]
    },
    "aytu_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from exercise of warrants",
        "documentation": "The value of stock issued for warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets",
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r88",
      "r89",
      "r111",
      "r726",
      "r742",
      "r763",
      "r764",
      "r864",
      "r892",
      "r937",
      "r959",
      "r1107",
      "r1165"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r211",
      "r393",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r536",
      "r765",
      "r766",
      "r777"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1",
        "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r602"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r602"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events",
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r602"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-21-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r603"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-unaudited-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flows information:"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionAgreementExtensionTerm",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionAgreementExtensionTerm",
        "terseLabel": "Supply and Distribution Agreement, Extension Term (Year)",
        "documentation": "Represents the extension term of a supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues",
        "terseLabel": "Supply and Distribution Agreement, First Milestone, Minimum Net Revenues",
        "documentation": "The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionAgreementMaximumMilestoneObligations",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations",
        "terseLabel": "Supply and Distribution Agreement, Maximum Milestone Obligations",
        "documentation": "The maximum amount of milestone obligations of the supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionAgreementMaximumYearlyMakewholePayment",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment",
        "terseLabel": "Supply and Distribution Agreement, Maximum Yearly Make-whole Payment",
        "documentation": "The maximum amount of make-whole payment per year under supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionAgreementMinimumSalesPerYear",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear",
        "terseLabel": "Supply and Distribution Agreement, Minimum Sales Per Year",
        "documentation": "Th minimum amount of units to be sold per year under supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit",
        "terseLabel": "Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit",
        "documentation": "The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionCommitmentPeriod",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionCommitmentPeriod",
        "terseLabel": "Supply and Distribution Commitment, Period (Year)",
        "documentation": "Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales",
        "terseLabel": "Supply and Distribution Commitment, Royalty, Percentage of Net Sales",
        "documentation": "The percentage of net sales to be paid for royalties under supply and distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-tables",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-tables",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-tables",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-tables",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-tables",
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-tables",
      "http://aytubio.com/20240630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://aytubio.com/20240630/role/statement-note-20-segment-information-tables",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-tables",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-tables",
      "http://aytubio.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://aytubio.com/20240630/role/statement-note-6-leases-tables",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-tables",
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-tables",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r977",
      "r978"
     ]
    },
    "aytu_The2014LicenseAgreementShireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "The2014LicenseAgreementShireMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2014 License Agreement, Shire [Member]",
        "documentation": "Represents the 2014 License Agreement with Shire LLC."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_The2015PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "The2015PlanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2015 Plan [Member]",
        "documentation": "Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the \u201c2015 Plan\u201d)."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_The2020ShelfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "The2020ShelfMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2020 Shelf [Member]",
        "documentation": "Relating to the 2020 Shelf."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_The2021ShelfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "The2021ShelfMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Shelf [Member]",
        "documentation": "Relating to the 2021 Shelf."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_The2023EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "The2023EquityIncentivePlanMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2023 Equity Incentive Plan [Member]",
        "documentation": "Relating to the 2023 Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_The2024ShelfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "The2024ShelfMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2024 Shelf [Member]",
        "documentation": "Represents the The 2021 Shelf registration."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TheAugust2022OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TheAugust2022OfferingMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The August 2022 Offering [Member]",
        "documentation": "Relating to the August 2022 Offering."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TheMarch2022OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TheMarch2022OfferingMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The March 2022 Offering [Member]",
        "documentation": "Represents the March 2022 Offering."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ThePediatricPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "ThePediatricPortfolioMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Pediatric Portfolio [Member]",
        "documentation": "Represents the Pediatric Portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1116"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r956",
      "r957",
      "r958"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TrancheACommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TrancheACommonWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche A Common Warrants [Member]",
        "documentation": "Relating to Tranche A Common Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TrancheBCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TrancheBCommonWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche B Common Warrants [Member]",
        "documentation": "Relating to the Tranche B Common Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TrancheBPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TrancheBPrefundedWarrantsMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements",
      "http://aytubio.com/20240630/role/statement-note-12-fair-value-measurements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche B Pre-Funded Warrants [Member]",
        "documentation": "Represents the Tranche B Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TrisKarbinalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TrisKarbinalAgreementMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets",
      "http://aytubio.com/20240630/role/statement-note-7-intangible-assets-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tris Karbinal Agreement [Member]",
        "documentation": "Relating to Tris Karbinal Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TrisLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TrisLicenseAgreementMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tris License Agreement [Member]",
        "documentation": "Represents the Tris License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_TwoFormerBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "TwoFormerBoardMembersMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Former Board Members [Member]",
        "documentation": "Represents two former board members."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements",
      "http://aytubio.com/20240630/role/statement-note-19-license-agreements-details-textual",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities",
      "http://aytubio.com/20240630/role/statement-note-9-other-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
      "http://aytubio.com/20240630/role/statement-note-4-inventories",
      "http://aytubio.com/20240630/role/statement-note-4-inventories-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r352",
      "r353"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-3-revenue-revenue-by-geographic-location-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-details-textual",
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r493",
      "r844"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
        "negatedLabel": "Decrease resulting from current period tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase resulting from current period tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r844"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r160",
      "r161",
      "r164",
      "r165"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowancesAndReservesBalance",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r221"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense",
        "terseLabel": "Reduction of net revenue",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowancesAndReservesDeductions",
        "terseLabel": "Payments",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-8-accrued-liabilities-schedule-of-return-reserve-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt",
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans",
      "http://aytubio.com/20240630/role/statement-note-15-equity-incentive-plans-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "aytu_WalleyeOpportunitiesMasterFundLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "WalleyeOpportunitiesMasterFundLtdMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies",
      "http://aytubio.com/20240630/role/statement-note-18-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Walleye Opportunities Master Fund Ltd. [Member]",
        "documentation": "Relating to Walleye Opportunities Master Fund Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-11-longterm-debt-details-textual",
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-14-stockholders-equity-details-textual",
      "http://aytubio.com/20240630/role/statement-note-16-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "aytu_WarrantsOrRightsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "WarrantsOrRightsDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights Disclosure [Text Block]",
        "documentation": "The entire disclosure for warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r608",
      "r790",
      "r791",
      "r849",
      "r1119",
      "r1121",
      "r1124"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aytubio.com/20240630/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted weighted-average common shares outstanding (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r244"
     ]
    },
    "aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-11-longterm-debt-future-principal-payments-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Long-term Debt - Future Principal Payments (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-11-longterm-debt-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-11-longterm-debt-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Long-term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-12-fair-value-measurements-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-12-fair-value-measurements-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-12-fair-value-measurements-valuation-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Fair Value Measurements - Valuation Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-13-income-taxes-effective-income-tax-rate-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-13-income-taxes-provision-for-income-taxes-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-13-income-taxes-provision-for-income-taxes-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Provision for Income Taxes (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-13-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-13-income-taxes-schedule-of-unrecognized-tax-benefits-roll-forward-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-13-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-13-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-15-equity-incentive-plans-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-15-equity-incentive-plans-stock-options-outstanding-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-15-equity-incentive-plans-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-15-equity-incentive-plans-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Equity Incentive Plans"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-16-warrants-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-16-warrants-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-17-restructuring-costs-summary-of-restructuring-costs-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-17-restructuring-costs-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-17-restructuring-costs-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 17 - Restructuring Costs"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-credit-loss-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-concentration-of-credit-risk-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-accounts-receivable-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-securities-excluded-from-calculation-of-earnings-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-20-segment-information-schedule-of-segment-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-20-segment-information-schedule-of-segment-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 20 - Segment Information - Schedule of Segment Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-20-segment-information-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-20-segment-information-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 20 - Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-3-revenue-disaggregation-of-revenue-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Revenue - Disaggregation of Revenue (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-3-revenue-revenue-by-geographic-location-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-3-revenue-revenue-by-geographic-location-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Revenue - Revenue by Geographic Location (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-3-revenue-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-3-revenue-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-4-inventories-schedule-of-inventories-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-4-inventories-schedule-of-inventories-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Inventories - Schedule of Inventories (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-4-inventories-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-4-inventories-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Inventories"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-5-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-5-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Leases - Lease Balance Sheet Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-6-leases-lease-cost-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-6-leases-lease-cost-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Leases - Lease Cost (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-6-leases-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-6-leases-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Leases"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-7-intangible-assets-future-amortization-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Intangible Assets - Future Amortization Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-7-intangible-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-7-intangible-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-8-accrued-liabilities-schedule-of-return-reserve-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-8-accrued-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-8-accrued-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-note-9-other-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-note-9-other-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20240630",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481097/715-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "60",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "80",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-10"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>136
<FILENAME>0001437749-24-030062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-030062-xbrl.zip
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M6AMLQ!S[U^%O\G>E4Z2%TQQU!<O ,R]75:ZZ9/HUTZ:9DCUA"]" ^')PGJ!
M+L_X'..(=U-P786VE'LH-'J7412_SPHTG=.$IG,G:8Z:52C"72*Q+HGF.")"
M8ON*KM9O2^]'YGIW?KDI\?"?(Q"DHO+/W*53%V:E9#U@ 0/:JFVI_[A._7D"
M=^C4N<ZICWI7*(='U/L^IX&/&7?Q/V,Q'5H'@(J&+22\-D?"78&-OSCGDH\1
M$V;ZLC]/M"9I"S%OMD/,.)WD^HQ#%/L$E%FC60_QN3L-Z&-'T+0E8@LF;RLP
M^9;Q40>8,\&'<P%\["XJ0AIA]] -410S#,J9Q)R$F'.YT!/L"MN,H #4Z9/N
MR\?V9&PAXQVL(@GW LH%:?''5\&* RN1KY(9 ,)IRHPCF'$N,F8 .@DS.PZ/
M(Y?'BP5B*SGVDUE(IF(P!5^ )S?D2#ASEZ*/>01W'#;:D[$%C_=*>,@%2\*,
MG%G6S#@G.3/.3<K,CL/CV&7X 8<QWD+WZSIL*?:#4K&P%+E-*.VXUEZ[)!3M
M$%&V7:\MUV-)>X<'2NW!\N%R36W'-?C&3=W3J\0I*PS>):1NH4QME;;T>JC4
M*QCY-REA.0>?9X1W7,5OW0"+EMNF?^95V%+AD5*%8(!?24([KK)W8CR,4#B3
M._>(\\X.>6UMMA1YK%3D.SG&9C2=$TESQW7Z'DQ0%HN%;$#0A 0DVF[.5-=G
M2Z^OE7H%0_<DH>I<K:GNN&8_N#2:8V9)KZK:;&GUC5*K8.5> \U1IVLWPP$L
M)FCP  M&CV&QAG>GR(/&Z>@M;Z[6EI;?JKT5!\FR)2'NG$GBSD5*?-?5?>@&
M-)Q%F"U<'T^V,7\WJK*E5HT3"JSA*T'0!8K.9T%QUW5Y)+H48>X#"F+L+H0]
M*9I+^FNWT:J^4EOZ57N1I*E\(4@[?P!IYTN!]*XK^E@8MD)SV(W0TU9S;K4F
M6RI5^X^DT7PIZ3GW0&_7]?C:WIYT7866M'JD]BL=)OO2XX9S51EOLMU=T<4@
MZ.\!N\L =8TZ::C3EH[5/B9I0*>;PI<99><&*.^ZEM^ZCX@QM.4L6ZC%EB;5
MKB9I)/^9TMIUW;T3BQ(>L=B+8B87)I1'W-U&CYH:;>E4[762%O)MD:YS!G1W
M7;WO1?,O%B1*8B? )^]1N?F(PRUW6QNKMJ5PM3M*FLQG:P:DV_^LR,"NJ_Z#
M&Q Q37'LHAG#VZ^"E/794K+:.R6-Z*N$JG.24]UQS1X=N!S/Y-];'\NHJ]"6
M;M4^*6E*WR5DQR,9:UT<NCR><&'BPB>(--BJURJKLZ58M5=*VL]W.5'G_&&W
M^VQ#)-*6D4_&M=M1^H</;UZ_VYB1&^*;G%^R7SL</MLZ1,V-T"3X80%Q&36+
M,%'/Z>U"XYQ?[B5?NPZ</+YM>U1L5&51Y>JIOA T-^I3$?6VO4Z5U5G4JWJF
MKX33C;JM#X+;7LU--5O4N'I'2A]H-RJ_'"ZWO;*K-5E4KGIO:AV"-RI3&SVW
MO5YK*K6GXO?JC2IE<-ZH[9JHNNWU75NM18VKMZTT87NCSK41=]MKO*92B_I6
M;VXI _I&;:OCL[97M:Y&BWK6;'AMQGZ-6FZ*U[*@[\:Z+6I>L_-5$Q4V0D 9
MU&5![^H*+2I;LP-6C1<;-=P0!F1!UTU56]2Z)EY;'VLTZG\C7,B"QC<KLZAC
M3?!V,0IIU&IM\-#V"JZMUZ*N-8'<FNBD4>UU 0@6-L!JZ[6H=K5#31?B,*J]
M_7TN8G45(1*(/HN?HA@%/^@:F0VR]D#S01-+WNIF&>>7SPF#SGW"X*YCJM6>
MMSU,;476(J;43L"V>^XCIKHK%VY']^- CBYI.A?&AX?) PSZF?)_%-9,V;&(
M0;5CLB4&1>:4<\B=YN#"B,HXSU$ZHK,%'% 0T$=Y8Z^P1K)3R$)1_$?CLID1
MBXA4NU!;(_(DX]D1/&>GJ*\$SR,6NT! &%G@VDCNZY7W.B8H8(1__]%P-.+%
M(B+5KMW6B#PKLBVOI$Q >2O8'D'9:;[$GEB@RRT[_.0%L8_%NH#1A5MH%J@'
M(Q:*@MQ=8N;R.6(_?F;?GE.+@+82[ FKY4PHYSP5R@&AG+.U4%#3>2J4<X.9
M<P="C7#?B.^TM[S1UVD10@;!H^/"1*<6PM%LQN"QI;3;5Q1F1_F-5"S"0>TV
M+\)!IA<8@H&A"I41(IF*LO\G*W>&Z8RAY9QXPN1.GO&RBA-#4A;!HO:[E\&2
M_9JLG-]SKISL';,1,<I8<GMS2'V]%K&@=L9O!*N/<TF->HIN(X7:K,&@B8XU
M6+PY,+H2N.)W4@%FUX&B/81@;Z@P)F$1'FUO%AX'$%.E%?MXO5Z? S(MJ%M$
MD]H'7H.F\KC3 +E=AUI^-,;>D*.MTB(HU&[HXK&;<4A1*T7^)X-V+ P5=;5:
MU+;:Q5O0=OI#A@*-75NMG-+[DJ4@'NLX:"9E$1QJ=ZD"'*77+<M!1"-B.JG1
MRN-V5BA;Q)/:=]H-3^.;=QHU%TW)1.79":^5NX"0+?AA<5QJ1<\BF-2>UQ*8
MBL9J JSLN-G*^9*R-HY0-2=^[5FN)K5;!(?:TZHY6#S:LXVJ*GO -(JT# \S
MFA9!HW;)JD%3]<#I0#6":5-UTU@&-J,%91'Y5V)\X*>EO+7Q>:!D0M$>D#3O
MNNF ="&9<TX*S#GG"7,CC&JO)ZB$C6ZD;P^F[>A:A%2[>Q,VXE(W;U88@66H
M8(9%]PSA9!9F#S8&J,XD+<))[?DU@].MY Y.B@%W(Y)J[M.P9S^;U&X1'VHG
ML.;:CM%^;E15L7=K%6D9'F8T+8)&[4M6@Z8\I.A!M>M@JGN/S>9IPS9D+$)&
M<Y]$[4MPXX#3=+V/15PT56T1"YI;)E17"(T J-=2R2>KTI]-2#03LP@2XS<&
MJ^Y?-8)&Y%14EGI*EHR$'EFBP%VB57)SU#,@IYF81>1H+KU0(B=UR=QDC#DW
M*6,C<)JO&+,X^Y@3L0@4S9N(M1>:C1.2J>(8G)V2M]LTJ/9Y<&-.WAZB=.\Q
MUB$*[-^4TT;4C6C3*K-P4C' #SAPCUUOCL*9E47W=G0MXDOS%F0]O@HG'J^
M1>?8.4M8'(%E0\'V(GBLLF$1=IJ'*[>'W1C;8PP ^)3L9R(NP+"$G\\\MM63
MM(@OS9W"]?CZ(^,.-E@S[L8137-#K$5;O:%FB[C0W#B\>0GM:)77JFC)Z /A
MT)'A=AN5]BSBP8"818B8WE,L3[HD?,GK<I3X&7%3UA>>3K$G+QQ>?W:9* *K
M*QJ"E]Y6]/O6I"UB2N.?5F#J/..RD.#<"BYA45?@<D281LU%E[+@&3.&?:GJ
M-)X+3L;9W4"UQ8%%O&E<W0J\%1W=GU-F)>;2&#,XGS=NKK:#71S"B#(+R;]2
MQ4]P*,0 %Q(- IC$'A'SGQEY+9FP"#Z-M[P!?-\*_$H GJ;\.K>"7^<BX7?$
M7Z;ZURZ/J/=]3@,?,YY=Z&_1*#<C8!$W&N<YF.QW!4[^DCT<,-KH%8UIGW6P
MB IC&O: <:SQ@=>](3%"PU!MLH^[=)DX9<#RM'/&JRM%B[#1N+9K8),.-,[U
M,O$"I<R-DTXKI7*7QI$H&?JP5_:CH*2F:A%.&I>U,9RX<[UF<(14HW+E>R;$
MBX3YFNCYAXQ.S50M0DKCI:Z%U&W.8(JN<93JKMQ8\/^3<*4F;1%<&E=W.W!]
M$[1'A+6=!P5.X R>[>.)6Y&UB"R-A]Q@)CPK<#@>5*QYI,WBBJVF5HN8T'BX
MRV_ C:LRK6J*KKO\HV4[N@LYBQ Q>2:P[!/,/X^6L_%3@A9'#C,"%A'2]G'!
M<3PQ45@AT*M&G_:!8DC7(GXT'F0=?DH1974 VWE@O0?;<D&B)(H+-C ]*I^V
MP*'E=^9:D[('G]<:/S.,2F=KGN26Z%F1IW$@JBKQ@QL03RX_T(QA^X<[C.JW
MB R-*QG&FZN$$><D9V2$@]DKM?;P8$C (B T3P!JW\,=$6&BL.*JI$:A]I%B
M2M@B@C1/]ND05%X8U6%LY[%U*"S/"<?_C.$3/(EB=>XQJMXB3C0/Z1U*ZS7C
MPSE_V+F9Y]?])^Y_1,LE=%3Y+?T2"CVA7-9?X1L.I 8E7$#3_\C>6UT_MYJ_
M?7E!V=D<L1F>(._[2>A#XV=YZ0-FJSTG1 O\:6_+.D@00)E/>V+9@?<< %5$
MHA@8_YW1>/EI#W!!/A*!OCTG$H)G7Q8T%&IFJTN1 @VRYR3?T_MY/^TEMW!D
MGY>8$>K?RPK\.'E*<6^_<^/DLIBU0S'[3Q&9A. ZBFQ(G-PF @^BIKYK>'&)
M<1A/6C5%73W/V$8^GCP_*MKUDI?4,6X8\<2:<-WQ#7N(LMQ N\JF+(71;\ON
MT[GN@7:I6GD[8ZM2QXO!F75P[02BVHW6M>6'-&R?8K%N*IMKN;9O9/67H2 J
MK/#/./E?WT"=ZAH0@!)I[C%;U(PYY4S=I<MXK$K710ZXB_0LYA%=8"9&O1M&
M_=B+;K%8X&#_ F-^%C,X*EZ0JD61/@^<($;AT XL!D\#ZGVO2*K)TD4R/V(N
M_.(?HZPF6RH42I@QM$B54."Y(DU=OKXKZP[!;877TZF88"IB59+Z)@D2]!GR
MHHRAM63^W+^A+)K2@- O>#'!+)=,F;0=['RZ0*3SL*&78AIA]M\HC$7#';T]
M.C@Z/HVC9,0O?GU=$;!MJ6'(_EHIQ9L&V9M*]5CV.,2'1\"L$.$ZO&:I&-GG
MMRK)C<L,0.ZW:AG>U<G=6&:X<K_O(/?[7LB]EK/P4D2ZK+F>KE^62 []Y@(:
M9NZO,0L<7BZ6B#!($!;=GTPP0:?39 FSEM0@8]^DU&,YBN9X@=AW'$FS09@/
M%>#69.AG[XQGPB@7O>D(XC!H*$US/(U#'_M9C&!%Q#8E!B&SF9Q#D\U8C4/3
MW@,.8WR&EB1"P27G,73TBFRU6?HOU15%88U$I>3^2Z/!7VV67DIU2A'S$Q8K
MPBA3>F&5G,:<A)AS,89-2"CS\SS"+A*_./%Q4L^-6#-ZJPV/QE8U],7A<18@
MSJ^G*<ZNV2V9S:/S)\P\PC'X7G'VA_]9AJDF[L6L#;H7WZX!A)QWPDK"/T3^
M)6'=I5<5'H+L[06V(67RA8-X_+GD:ZM.6QI\?ME@1F\AFC+[4"0K=;.68E;+
M]KD__HGA7^P+LX"A&;[%,/O!AIB8:6 RCH790Z;U+6!>Q\_;1=$:%^5%QOE3
M<F&P+[<&:PWY+@5[:5[5+<:&M 0#DRA>8/9?& 71O"J',FT <J1QL77B5+/T
M4ZIL#[(BR<;G7G-_JN;^=!C<GZFY/^L%]SFW\.K,90A'UZ3CLN"Q+1L=!OEZ
ML&M?YO)"K.2"]/D<M1R5''W;'-7()::\]+6B"XR%*F*=>.J,/\,1O:60 F-P
M(82P=PP$+67>VAR$JNIPV5XRB'))?0P&HM7D[HELR:6O]^@IV=!)XPYN\01%
MZQV2YFS]A66%\]2=!Q>-PD/$B'ES"(J$%R7HLCS6="@YF&:X@E"T+$QFI95Y
M(UO/!-3.XY^I%Z>;>>>AX'!5."R52UN?9XOU=P0K7.NVR;D7D"7'N;<S=;4'
M'GC;\Q.H9<.E99E>VF2I##"6;FX[Z!)[89_E][DG5Q^+;@67N9?O<M<YJI,!
M/A?31DW//N68-<IB&= 5%LQ'XCOPG5I7J:3:Y-X:>!J6-;L5QKG[LC.A8?@/
M'/J4";.F0;!BOL&$4217F:D]/9JT?HZ=10?K+;C=KL/*5G1]EH%(=3\74UF3
M7.5,0Y'LD3;*]=CS0-KS)Q(E1X^6E*,@O5*2X&K':LS6BUG] DX[XT!,QGXE
M'NX;Q]-8>O!O<8@?@=6R(Z9;T1[N!5P0QB/9GU+S0NY@D(EDZG253045!;<N
MU4LT7Y G[*=^IQ.8!&:R@'PV#OL7C"[.,#QGP82M5I6_0\F>8%[)^?_&B$68
M!:OLG>L&257Y>VO6:61HDG&0,IVB(*!BK9"FE-R2+<L,3O;"0Y"7X3)NE%N1
MOQ?./"V_8I"=YUW.3+>:,H/3;4F &T3\)L%5!?I[N%4KA:R(>&G2]20@LR0N
M[FML,"&9E._>*"2,\ RSCG#73\LQ$\:5Z)C@SQ-+M.6F-ZP^2R\FVM]I$@[B
M8:8+=ZS/\I.]!EKU_"[0Y=\P1!C!@E_$OZ PGJ+TSLT[P4Y95RWR]])*A( #
M"/8I2[7QM9>\7RX62)AI! 7GC%%V1AD#[R,-KZ=RLX[XZ8D@+FW6Y%BT7,;<
MTZ\"F(4/9?&?H^)>=-NU6];$)9LW1]M2@_&?789P)QEE*WF4ZC-]#"M+P;H,
MO>P3<*@/#O-F?K][\:\WQY4@G<9<O93M"DTT,Z8RI1<]3FY-\O7E>!O39%V&
MOKC6K[ 8RM8;K%\0S&[1ZAZ84PADEKE?PETOY? 5SLI[R??T%(-Y+8; (/:S
MY*\T^CN.()02BT')+TN^94U]6[OH>V,F64-8K4&^?HXVN>:2P?'45,[F_/V6
MMT&\7DE3X%Y><9W'"ES"59\0IBX_0U13855MFKF_*^JJ!#<(-C-O&.78B],X
M+EXG<EV!X8C];3EEP@H5-G?2UX#MLA:_H">RB!>Z9FA30=^;1<PIZPO>-Z?E
M^CR]F8U)B*^GR9;\!?*2 543GBCRY4\>K,7L7+X7WM$K&LZ 7PC0/ G]+!(*
M;(6">TOPPW,'?[LB@[$O2HX4C=W?D*>7\^P7",EL<T]$FP)#D-A(RH%)9JK"
M@6GN*Z;\Z.#P#;R06)9(F=);&=3\#X/W^[E83RZQX,3C&UOU=1EZ*M%3=$$>
M6L5CM"S37[EIS%(9Q"#>J16ZUC"$-NG2"GV6>RTG#3W$Y[^+NN#"W>OP_ G\
M0S'A<[EM.07++1?0,'/O5B-Z-=-PN3G^5C[V$Z TPO<4#O"%'D'!7?;*2OJ"
MR7WV4$LFDF'NWAW9 ,ZYBG5>E$V;8T#RG*1%FN4JY/Q9\JWED=$,L/DH[WI>
M:V7S>W=>EW'W*RFTFKB>3N%6FVQE5HQLN(Z$W5(>%(QS]W*T2+B_6R(/&"XM
M35-/!,%\,UY T0*=Z^A[NUR&IY@]KL(;'(9\%3R@D"!M ]1F[J>DZ[M5BQ<K
M5R1LR-1WR?++@[5B;>;HA1E6WIB3]C.,^EA]R-0X=]\<:F;RRGM^Z#3F25R_
MD=2;97IVSE8C>JXMHUW<CF4' H-OH9^^K(/]+R2$K8UR$*VZ&4R*#: %*)PM
M9FPEAJE'Q'QY5UOB'K]^##'C<[(\D[<^;;9"FZ+][Q85:>[BR?]A+[JGR>UU
MC=)OYA^<R/R*+$B4:C#\QG%%C3>41\D-8%]Q5*KE,^%PI. 1+ECPZ"R$JQ9.
M8Q)$R8H=B!!Y;1B0.>&ELHTM^]/8VB$%7L1!L#IY$(MR&9-$A<TIIK,TC/-"
MC',H^#M&<.M;4CZ)?\PQOZ;[C-JTR>/P5"NFU_(08]C<VG(]:P*]G0W+7/4>
MDCJI%Y9U=DSN>MIT&,THYW!<FPW;?@/;[;MA)/3($@7)(OPS#A\P.Z,!9<BG
M5<E,LO8#G(QZ&/LR5#^[PCZ)_*#A743EV\>9?M;BM2HSF'CW6PP>24\8\9D4
ME2_?0A+Q6QY7@-RA7"]T?XNCF(5P#Q9[P)6G]#1I?5O%U.BRP']57:JDGFA$
M/E< C\?[MW2%@FAU)HP@OF9=FSZ<:2%YA17+GG&W#$A458\NN9?3PNV3\LK:
MS<^]Y/X.32:K*Q*E<7!E&72)0Y!$;7(T9>JO9'_00)0L1)A_03S"[$(84%>1
MKY#2L$ OAKT[% @#0O;X-* X.;I]/4VN:9)&AN!R+:!Q_KY-6&N9O3GV8Y!#
MNA!/5Z=)O7=SC*/")8;J8T2=2_?U9/$=]N @%,'\)F9BT5Z(0J^ VR!C/[NQ
MGG'-8-6B0#^Z,;S;(&T3L1: $\"R2&'Y>KI:9\D6M^"9N%ZF0=@(/.@&[RM
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MIM]6Z#(:.T(C42%%7HN_#$+YPN;3-QI5;S:B(+9HEP WI $F#Z*J;X]J79\
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M=0";GI8XK .H?GJB3ZI05B<,5>G05J4S4497)8\60H#9G>&O=YVR*J)UW^-
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M!M-H,>$Q&V^9 PNI7\0.,XS4YA-T<2_J/.P6'F)4 5GM]AR&;*%06*#7P@)
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M+MMN..ITX*(F5 T)E3E"98[CJ,QAD;L3WHP.;T:'B@XU/5<L$T(7+0A?'Y3
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M;;F05E;K:GGMO^"EF%Y7\D*MO9"B:T[1/7!33-.4/1%Q')PS7I_[ERS/J^
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M;0AJ0U ;@MIPO&H#Z!(<4:B,,U%S1,D@;14#CRK@SY-D5WIM0JH29.VT0?-
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M2^ Z^ABCW5IXZ<88W^;*G7=\06]&5_K(0M_\N=5'%BKG-D($"/[GT8$W1_P
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M%K 6IGF,2)6'+H,?=1AQF6] UEYZQP0X9-T#'15HTD#!QR.SB0A#E6;FYI[
MD ?JD$'U\BTZ]M2<^@QHM4')D^UNO"-)F8<+.#B9$B)K-1Z;NKA5E&SJ2@3M
MQ+AXTJPM+1OH&-="Q&SD7UUD.DK^=2R =V)C1TFLH63)\(4?0@V387000#@Y
M.G P";:5-P@-UM8UA;1A^'[E6L?G3YO\/K_R4$^ ;3(#_=Z<?@$WYA0" 3NJ
M_A *"X7"0L=76 @6>8SF\N@"#AZBB^;JZ +7<<TD;%6#'.1E^+T_G"&'.\V!
M +$5"0(&0 '18:L/9 A;!:+"4AFH;7(W$":V0D&N"B"AJ1?4IH( %",66<>J
M?@,4'#99QS+[  H3MXSS-EL&B@N+.-.BZ D4(C:YQ4%V Q0Z-HFF_Q*7'["(
M.:UKJ$"!8I%\FM>V8XK;?A+Z+[WW<3(G"9\\DK2D8AY(7O+JY[QK$3[K@;V4
MXVM)5:?"?.?)LU!AZO-M*K6VA_J3VT\<UM,QM750X$?UB2_[V;C(5F5CE2G;
MO@[(K9S'M1KX6=P6V4-]&];JX58+WJK\C=7$VHW@@'3I[(X6]$26[V69N2 ;
MI+U#LL21-"\E5\,I,W3!45T)%S6AUA,O_KFI4M_(8,K?^Z=*7"M:JII^[YVJ
M&WFJ*NHTO?G-#S7*&6KX%0]%^*H/A3I6XT2 CY..OHY5(Z57I=S7LWD5VE,9
M#DY)FM+X9/V::!O\]J-ZG8ESH;#\+O65D_6!F'W.Z5\ES:*FF[Y%SV$0-5&E
MW:,6/8\'T:"G3Q-]^17+N-PL4IG25F2P[.VW)LYR):BK3>,762'DAN0^I=,\
MIU(;C-)2NE)_8RQ^2O8!(Z^KY;09PRO*UYKYUAYE+-L"[S@HGKOU2E=[P-1\
M<-JUAX.YPUCI'[;*3*AF\M*NVD/JP?NHF]"LDS.#<HP)@>NT-/Q(C5<"LS^
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M$DPW]5%JR70V/ZMNV>JUHK=Q7:WZNB!WE^U[78H%(SF=/G!:R0KJ601WZI=
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MU+["9&KN@BB>Y/\@_#[)2 IX( S0W %1?\@@VS6=K58"=YE5@;? Z\RR*XX
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M_'ZRV<V3))LSOJP<5AV-JW:#^K"NMJ$(9EX-5J%W:A7:.DYNJ(Q\E3M[6ZU
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MF\YX<-F]X-9^) R(*^FKY4(V]T6#RL4R @;RCW>CG9R]4$Z:\#0V'"KRTF%
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MZ[,8]J*J\%-5KDHRDFZNSB:SD;DU#E,-+FJ"X>A-W8-#-CHEG*_KF--2:1J
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M2(N)M)A(BT&%8$1:C'UNPL>AQ;C@)GP<6HP=;L+'8<8$SDU89]UG>T9)R/J
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M8M@&DI?WM.D0\5:T/B<B,A$B$\%,X\A$4*X0"L<7W2P"35CK_?E >0:#<.U
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M#?7M#PK;W^7_R3!6_/)_4$L#!!0    ( *Z .EE-7)?L@*P  )_@"0 5
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MJ,5U>9<FU;LW(V\>H_I ;FFU:/G:EFJ!PGCKKD;MY$%E.'D,XG#CY)!987.
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M?AOBI]ISGQ_Q>F^8C,ZJF^V"2776X!N#SL&'HA?SSM'&P !)H(T! K%KA>Y
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M23M\6&^W/U_QO(HJ$60)IQLJD"?A)E-FD<=BENN<+I*JCD$6'ZT@G/C/G2<
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MJLYOT7=>?:IIDQ89Z4";D;N7ML54+M<;SF3O(U &T^.W1.[G+*;Y"1/GV N
M]Y'"@8=$ZE4^,2F5*^G:N=\$M,D&B),N=?*EHA^HHI$*L_<+Z"IQT)N(?1*G
M9Y?+]LF86O1E_OYH>Z1P2?OUY=)( 6 <&8NC0;@OG]H3T>W31FJC<:0GXT+#
MM'GGSP@O%A"9**[I@B:/L"!^HN7P-4^53[!&>*!K#YM709OD+7%1;2&,[57A
M,<,PSKOMK7P0@*1H?.4?&%K?PXY]F]]#!";VU\9XC SP%L T+/" Y/28X#'V
M32F(V:WBSG>UQS2CRZ0L^LN\0T 6']!$DW(7W-2&%.QBG 7L5FZC!>$A-M>O
M/@M9=  T(>2I1I#Q2J(733:<-<.#U-L\RA8/]/B*-X+=:9M"T+M)U_D$<ZPZ
MTK5KG:_)DV/" <S/!()M'JK:3MW'J'"'E'PQY'^%15"DQPP.UO_QI*I4,0Q3
MO:WSXKU:>/3B?+7.V:-X*J!?E32^0*ZZ SV[5J26-.G2#AOK4F$T0W O_-&>
M6C4:W<]M'_)YKCHS<@0VL3HSVI.C<AYFI9Z,Q&_8OM#-BN*$F]Z7)<N?HAR\
MFB07"U-Q^91Q=_$A69\\P"-<?;Z$03<8_P)!SDM&%P*7MA?B9>R84C7;U^LY
M,-)%-B,=;#/2HB-39@$^@XRUG$B!$XL.0.ZQ1241114I8*4DIRE4%FB2G5G+
MFX7 '2#!S$27F:T9<F76;C9W?Z>+\I8)('JV3/*M50.V1R.LU=H#8T]/C4=I
MVS[5@,@M(Y,;JQ]#-"5#(U.T4>LRR&N_#Q9\8EG+_JIP2ATGDKCU:A^9/&0@
M[=RUD:G>&4P$R7#G=(H,WG\80)%KX7>/QR^W',/1<R([M-/XTO:><4O!><1B
M6XKT=J<X-?D"Y">V*^SAO,J&4,;.\$((N#ZP591DND)X^*5M(=Q2""B$%8")
MB6$/[U7$4,90TZ.,!PJ_O'F@Z7+@]$+:"G5@<=";\S,*[I\!22)H&AQ*6$!N
MYQRB&M#;>D YO4^*LMKJ!? M!\2#*7+.7[KY7@:PQHOJZE]BT\C'*3A/&3](
M$]^"F,#;ZAI3P SX&K!NN&RWI7P5;[P':Q7&I91\5'CHVV^3&L TTB,49F*P
MLK<B>PT]@%_S*(NO\BC)$U"'J/@899MEM"A%H9.;I*1ROT#W6XRWH$K#^0,]
M@(/40&9$0"$[6 B P3L7[@9JQ>7H'?]J9_P%QQC _="60F;$\:#YCR?\WTFY
M8PW@9BU'\Z"1VJC0B\6LQ0%JKI6VH2-.LF/Z2%,F=E-D(3!-YR:VRHR,I,@I
ML]EPP8!;3-R<Y/].H[1\J'TK^1JAT!RS+ QTZUJH&M*DHKV].(FU_%;'8L78
M+YHA/E1#+"I, 8R[BO@P73[ZO<O9O'1[= =[](7T_M!06Y/;F_M].M>/G;?@
M_AKNDJ:4F?NW,X<YY"\V$8D[RI#[?94G"WI%<Y'1+ M(C#3'1B$DW?JZ/""C
MC[D 8&\LF"3^J+YZ#^1G1 " BKU5M5Y1F#=F:1KE!>%;O:K<7IBB$J.2Q'19
M:NAC-,4T!85KR%BYY>T'=J)*'V#\C,&.7:M$0[R6'4&>"/IX9\/R@(S=C;8J
M[EJ,,1=C+ %2 &]#38R8/BN]K2$G4?$ _P\'1X]<5<7E5[ZJ)8N2QO"'HRS>
M_46GY7FV2#=Q%2$5SRW^FK/-FG\!$5.6E4FVH7$=E^*^EF1="@$!N=;YA.IK
M_?0Y)LR:/&V>KZL:ZV64EWJK/0 58091?I=N(9.H)'?T/LDRB)%Q?Z B\;6R
M[C2++3*.P@O3:BQSY!L%L69L"G-NZL,MTF1=T%N:KRY8U%_ :+PARF?KZ]"Y
MKU81)4"5I)RL@8MF![^52-#!L (X98/RP=29YLT):Q\/4GSS?*0YTKF1=>OM
MW:?)W1@;973?6W;3>&&\BE,IA1"MQ@Y]!0TK:N1+0R]@;;=#!A[$"\T"A9(%
MLY6XW_.DI!_84S904&"T,6;AE';JS60009D(TO@%U.(XK"RBO<,+$-X8%QJF
MQT'C,%]25LZH<$Z/%F7R* I!#P7ZE#[!A?H&NW8?[$NJ&]<- +)%8!+NLSPH
M*PI!F['&S5BC%EB0L)^:4#$,4U]'Z*]ZT8KO%W.HX?"!5O]M]X^GS]45V>NH
MI*?+)96Z(&% A C_:8-]%0% [5%YCV-YX#OB:6Y(2:T(DR2K0EE],:W7%\+"
MZZ2M();AA!OZ*/]SD\'5A?=-J:2ZAM*1W$51^P+CH0SW[-J^ '6X=?)^6]ZK
MJ8=UA'=0;(_)BG\R--0 _HFB1#$$2_W5O:4EZ/55SAZ3F,;'+Y\+RI7Z+,DX
M.*[&6R=*XEGH=X"MBZM,R%N=7&5$J+JY#L>+74EAV7RS@?*72?8MO.8IH,$S
M%<L&5F?+$*:ZKKX\,G.F&ZYF'^A=>2Y>(:B>NLA7G"!8RC,*F3P+,)S]5:?T
MOL2L;FH4O%1I48.BO=:Y&B$B.0V@D"V6&>F@(1S.C$QPG/CJ+&5G=$O*??2E
M6.=CX$)2M'\&$T.7+*>$Y80WC<B"YF4$F7I1D+LMFEK'#"; 7YKKYJY(XB3*
M7SJYA .U-$;;8Q-=9?TZOV3;30P-62MCG+-,FUTALJ4_12O^([BY121>UQDL
MBZ'^H7D&M82 9PD+60A#@]O]6<9*+/17;VJW/A'<S96(V4!+;&6IPQ[='\P!
M)?(&[EA_6ST+SXRR_ZR, ;&K$'7HM/"[*HTU(!9,@T]6-P)'*ZB,\$_!EBK<
M-KX%D']C[OP?]AW [3\$8>@(VQB5#5>_BX-40)2>-/4R0+R/'V\JO88 _--#
MLGC8NOBB]F)4H0OOQ@]H3K\#/\;7T$&\UEAA@W@#'=@-XO40"AS$ZT%D,8AG
M9;PF0;PZAM<IUS+-L-V0!(Z'[4;9;'6UOLKI.GJ!G_AVGMN&S<&;A'H?F:_7
M/9T'6+![4!@N:%;&96/)W@*I@G/3&1U^O5YOQP0AN4@ "+XX#^E)_^H\RL;0
MRS,D\Q4FR_- !W:7YQY"@9?G'D06EV<KX[6Q/"<-D(DNST,2.+X\C[(Y1$VG
MBR2Z2](A;1QN;%ZAJ=.I+RWKIV[XMB-N'+]4X\CH/9S[W.*4**Y1D#)Z)JGJ
MB-P7ENJ3E_[Z45+F&;JLGSA>KHJ_1DD&P:O+[/09-'"3% ^P5%XN81'M<UNU
M/L2XKDH$O+BO2DBTG3S;X]M5%$T=8=E<+#2B2*=XP+2+!<XHXBF,T=B9S9J!
MWL-I<1TOY^.MLMW[QAS T]53+8;GM:'M.%KR/1-DL;U]Q__XT_&FO,PN\V-Q
M,M_^^B_R#$S,]QA+HD/'^04ZP%(E+KY]-X/DQ9]FY&Y3@A"RO$EKZ/[]+_BD
M3;<#MY+"*<GXZ/XZ*4BDS[4 >HN29V8\5X&]XE\9BR%P?Y1Q%[ZLWW:H[E_N
M_UO+@4;T:]77UJ ?UBW7 &K/@W?#'1,?9DMV2FX]1HI'=P!HYGLS%;_FW 7A
M^_ME(KN!UM,"J;Z=GGPI8H<D1J6,$"/B2((>I&>/XG6D&WV3S13X8>B@]JR@
M/\K=T?'6&.=3WJMK8;T4OM'QCF\$KM&/>(?2YF"0F[A=QW#'_Q-Y!'SA@*U;
M=[P!GG$<%R6FR5)_]Y-9P3>+L,04?'VYH?ECLJ#%#4OWDXW4/\#>^Y5V[+YV
M>"$" $44RIM08"K3YY2/#?_/AAO^GSUM^'^>ZH;_9\<;?O3 )[WA_WFB^_U]
M<=;:[_=.E;_4_<4#C3=MAO<#-R<T+^#*=_GRB96TN;AZF5\G]P]E,?HTFVE_
MV$1_+%WG^?\UL/8.0 WM3Z0"1P#=;'NYF4M^A9!\N8W@!<W0E=K,9Y19GR:K
M:]R/_7KYD^H:I_:]^1HW3,?_&O?CB+7^R=8:9WO@0=>X4:X%#VHKRG/_(J<S
M5_Z+@+8EU"2KE[RA:>'/MD-_]?N>@.0\YC0Q\2L;R!'IEGOU^13@NRY0>B@*
M?:5))5P*?&YS0:,"<JUR\98#V#R]\YF![ZV>P_30"7O>T@/(WKF*V6A-SD^N
M+S]7;T%-Z/1D2,9&3TE&66FF@$5>=I2/_VNK>/P?__DQRJ**:J^O.-1$4WWZ
MNG*M(5MZBHZ<9;$99!]3X8DWZWM5)9U?+K=%8[)8['#.BV+#?T,A>B>SO9I?
M(RVO(A5?=E<1#L;J.ALIPI^IL<#N_VQ;+BF+ZWH #2"B,%A'5EE7^I@AHWTK
M95''&C0T<? 3,_7K[=JSSO5B,% T2V/":U>Q+; Q'84:%J)#+5+@HL?SP0P*
M$U67N*^3XH_J16/X27I ./H%^H10VK/[(\(.:0(49Z2B7O]C8H]JJ$P"0W V
M\"[V*H<KR^7+%9\<*/8-X6+Q=KC67G:T%ZL[6BFUL/M:*2Q[NUL;(S?9XYXE
MSS2N7SR>T#9W7/Q&-[N*G/7G8.5L06E<G/'A-ZO695[5BZJ.=&1NEO*'6&=K
ME( WEVL4"<KQ<C ^C/M5PZBJ.;6N%\M)4_5,98BNW#!U(6-XSCJ-+]WPY3G*
M$_8Y*]9TD2P3&O>6TU-JBX@X2?MT?VA>$0Y3+T^-G4R+1T&,<GV:WCR.+-WU
M*GQBP1#O=QW"!.]C,#6^YF,R-KLU!*(X)@_65BI#$CL[S$1OF@-O50I8!1PI
MG-']VMNC[9 Z<M"?+\4X((S1!@OH$2H 5,F6+!D%[TCLY;+ E%GD3<"OZ2/-
M-A14CF_]Q:N)OR?EP\FF*-F*YJ?/]3,N<*N(_Q_L/B0J8- 34DD0%/4%\9'F
M=TQ7%&MD&-WQ,B@]VP"5-'*5$3E2*!/)8A8Y&W83O3QAJQ7+1#Q89P_=]YW-
M+72W_Z [Z"X0:QMHL]%9W#\O286$*(S/Y^ZY5[S&-L]RKCK=.]\F)>S9S[,X
M>4SB392"_E_3M*HW_9"L;]EI5O+]O'1'C>P!L<_6I.1:\P0<<4A]Q8I$G'T$
MVX=C)X%9X*R_X[9-GM.LO"FCDAYE\067G92O2*?/:YH5])AF5'['6NM;[!&<
M"@U?ZX$2&-13F&Y&B5@7!(0P)XA:TL2,F.?7_/>\:C/:SH8I]_&*39_!]O^4
MS3@[948YX-,US4G;CN!6#SVH6F!,%X9GS2JD?!\TJV R.65V,^9799U1DM9S
MK*S/2K?'7  'SK&;LQ2)K1YLASG>ZNO/W]%6& L]S$2FS!G?SO$9C6FN[1:/
M?67F$,MZ]^P*RV 8.,'V1H8PL#7QD [PJ-P<NKYJ+//NV-2P<"Z-VL>&SLPP
M$=]NS# :$P?&]CA?F69IRE2/VZ+#0-_+DYY^J7UDMC@%UJ=A% 9+DSW]T2^R
M)TK3DT4%1!2:IQ6(D&N5AB;IL-";!K67AZ[I@B:/4/3DBN7EDJ4)NZ'WX(8.
M/B*K_3U2KY3IN%:Q[46R+1+20B$UEK!OS>I/"C/FM,=Z$LU#H,T!<Y)M.-S+
M]CW3JOQ%JV>T.'TN\XCE,1]9_G+.-U<%U'*'HVF6IN)M4;Z<TT*V8'B@B*YP
MX0R9KZ7*X1!PE3<FQ%'L^[YU99ND>K28KY2!BGBX5QL68.:FM#;W!.N07[M;
MEWT$]E179?]A/^QTZ*W( 4.$1XL%//57;,$=I2E[@O23,Y97MQI!*T5!O;$*
MAF:=(6481]1YS;<:54>B9Z0%1K@I:Z[#"IL_D8*%AA/([,X*2@D*NOCNGCU^
M'].DDG_^PU;L^3_^\WRQS(\VG#[+C\J2+Q!B?3E+H_L]L59KK"FVPYTZ+W%V
M<G9-:M*D0YL <:\BI\A<IL>Q !4RQ#.J6@4RI%\8U\<XZ-E_>8P#"&;5,4Q&
M9'(5NBD^ X8:WCDC29-BNIA =0RY!/46QQAAHK^#E:2([N]SF ^NO9?+.M5<
MR;?0^A9[K*)"P[5*[8* C.8:QE2<!+V98$;L]7C!9]VJRP7+[N$AC9ZW/56;
MHZ_J]'?KRXS+Z.-NZ!B/Q8(!+\@JBBDI&;EC><Z>^#XLC/$>E1BFR[JI7'X;
ML]RZG[NYYN;-?C?66EQ,:9"0)PZ%-%BX)0]LP[7G1/V"6&A+?IMSA3_*XLOR
M@>:'V]"JWI1$5+6^1<JI$HT X8G)E.+2FP1FQ%E_N0Y1\<"AP7^@%LICE()Y
MKR"-&5"M;[&9#RHTG!>-@Z>G(1=?_-#!,;UR<5I3PHSX[$U&/V<Y7;#[+/FG
MN-5;IS;(XADCK9%R*.G5EP,L(8_Q?ZV-!)&LUJ5-.'$RB8&L:9XPR*#/2[WA
M'$<IA"XF /XTT]R&*$%W9*3&-)1ILLGWH13?JPG#F-#BZ*X0CN;PP=/ !V:'
M2ST=>_+0X%"T(4V^-,2#G@X-<?GP!&B4==ZDZB;A\KU,%E !\@#;Z.-L6A\C
MI4V-B/-K-EL4I%<*0SM?FG/!S!CL33Z/HR(I+I=[P%[4]@AZ'R/E4XV(:_D4
M*" NOL4QN?V!YG0P,Q[[,Z'U&X0%E";I5,"^7$+EZ^,7^-\S;N'9:%#0H">L
M<=6GZ/Y"8PVIJEO3K9@.QSZB3OK=B_B!5-"F<@9D,GT];UJBYR1PK:EN<%[L
MZM=)&:4W=+')1=GI3U3FL1KW9[4VE0)=U[JP6] I\&&-^>R,EG;29GGH,-!Y
MMLAI5-#BFA:;%%8F<0)078NY$KMCWKJIHJ$9-4)V;C?(I G">:Y6#8?D#9Q*
M-YH[5%5$0ERE6C>8IA1GP,[I>%C":*)"Z]$'ZE"/D)W;U2--$(%CNYIH+08A
MW?'))'&B0?5:S0Y6!<;-CM%\>=^CM7O( EZ'+Z"2<L$=C9[K"*I[-8,>#?=L
M",J^]FZ=0$0Q(P+>C B XB2S]VK+Q#9Q)O/:LYDSGBQ_EU%7ZRC)JW<8S[.2
M3V\"%Q7@_2..-BGI1?)8EWQJ&L'ML\O\A*W6.7V@6<$;5+\\?2[AG_S[TVRS
MJB^M213*&UWLQ537^+Q=3W4]$-0EU>EQ%_/:?#N*&=F.@HAAS$@UD+D8R8RT
M8P%C60&'EXYVQM/\_LMV2*0SIC 6TI^BLF#RX>B657U;YU.TVG\,1/)7Q#VJ
M3B_.CV/K.U- R_L]J3YNL1$6N)W6,RZ@Y[%\8G?_CI_:JA]?DPO4R/F'4/.[
MQS0VR@FW<PPE+GN<F($6^'EN>O(UTPV]4%-]P#FFP Y_*=31<W5#]R3*\Y<E
MRY^B/#Y:@4\O\6@5OL"F2\M[]N5%#D# ^']61X3PW" ?L+Y[WD4P(RI#<I7S
MK2 _#,%"CW=D"LK)/'RDJSN:2[2DOQ'ZODNW,_>W6BIJ1"(]Y$N%(]1UEE[&
M,C5N^<MKS,HD3M)-R?WS[4E?]:(2C:L+-:OUIJS/P$^C/(,CT"N:WSQ$.1VT
MP%;[QF9+VL#@/'!7 :,%H34P\B;)2 $(BF_#)%9:G3OF=$(".R'RBDFC[:TZ
M(#Z>II!9VG!ED,9Y/+I(ARMUU(L'-LZ#)3(5O[(I7-O> XG83(0YPE;!5.7[
MF,#)F.E-[.H*=MD]E#OJ(I,9LO$/D,(F[]C73DJ. +.1LCD>Q#ZJ)5^5\-(8
MCB.541 <IL\]?P?7VXAV?588I<UA^LC]'YU/L4?1"B2<NZ[=<Y061??EJJ#W
M@[1F@9FPUIM,_DZ3^X>2QD>/7%GNZ:<-[!XOE\([+BXW95%&&3R&"UG["XEP
MHOI 2JD6+1\7-18B"T+L0?A&ZZF&-X\J?&11/=9:;;X(VP(,OB?#S1JS,A7>
MQ/MTN:2+LCTMY [4-5?%:PK\2=)$; L%8 Z2QK!7I%DA?LOWD!2J-S;)47S+
M".G[$A5P1@>I)M;Q^'*@K /'^%T3X![J[3E(-+H#2&!V6DQ!WZ%PIQC,VWQ-
MREI5M5_BOV^*4A30,C!(LJX<VIQ]DE,R*_O87%D.<QY@]G) =+(60"J)FDH^
MS-K >MQ7\U]+>X<ZL*JS?83":FH?(GOZ:6>\"*ULX33)@1"O!$1D5ZYGQ+HW
M8VG,^D^ ?*)EY^F/"3HG@VHV:I#&^>JOWL*F2#+NWAPM_K%)ZFB#_'AII#6V
MHD)_K\YWYC59TJ$;\EQIC+E,DV/^EK*]$].A.-!@6^P"U=>G_[A.QHU6"D%P
MKM-5U$;$;V*6IE'>^6V84,XPXYD6-X-:)_@QI\/GE<K?6;18._V'L%TSTF (
M>VBISOP1BS; T2 E+W8J4@/:RV5UU"J10JUO+92RD-)P+8W@KJV;TA5O&A#?
M5E7'^:*:TT>6/D) >U&=LR\C<%O+E^!U+<:G15+#0I'7DPH+G3SP2>,-FO>0
M>2-QH:;X+4HWHD7[/)%!Q A!Q6$P20.-\\*^ @K?UY#'AC:)&N(3VMN83Z=F
M1 8]1R%.Y:%H\1E',U:-4^43\U/X@ZZ]GKZ+"M6"_(1.W>7<[C]M'V&A-QF[
M@*H*S5L"FR@5=9&&G-SQ#Y#R)>_8M70)RJ1#F@#ML.ZL IN9/N]"F"YQ^/?
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MYXZV-WT;8+]?Y_$CH->^!1 R'W><M7W%_H?Y9>P-%06E;7KCQP@R?\N7\>5
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M',@&%6]<"CRD>F@P8,D#S.PP"RR?@@!O\8W63$#V8E^0^ZB%%>;9CBB'K[Z
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M [F=%6,[F@ +Q8 X,$5.61';MTIBV]<*+[9O_8OM6SMB:X;<FMB^#2RVO>+
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MU@MF9<*MW.5_7]\,RZ!F&-^S7J5#98U4O\'?\Y?W[>G6__OVZF,#@0 &TRH
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M#5+?=<FYUO063^TM!I1C]$PP6^P-)+L#FR5Y0RORYV/[M"]AP?8C [R42E#
M'<K- \M%Q9TQ&9$W1">D[G?H_"@&*,Y+*(D46$@&F,G4.>0_V'(+05K96SF*
MK4T#,;N].K\: &1G! B3+X*T^B,XKB,>$O[VQ3^&F&;W/%>A;J/*!Q;.=SW7
M9]P_Y[50DM'N>,P/?K<70Z)TL4E%F)L/&LZ#%VF4K" A(LDF>CX\5HM1G=G3
MV'Q<TU5U>T?\$98)V;DQMAL7FX\><F$V'R&K(J(G1'4/,LKE0!'PLVA!CT0]
M+:5@]V%S*W'M;;=A0MA;^N;1:I.QV A, WVB,A@O >@>@9'&FF6<FWPIBT)R
MJ5_T)=$KI[0\EZ@8Q.1+HYV QYB#B7#1]';EJQ\Z]E;FJZIEHF8.+-0MT9BB
MR=MKR5!N:%FFHA-/M89Z"$ZCN% 'F/M7%%I2KTKQ-*;47=4@Z3P%VDT</2<R
MU9$WM+*#@ Y=B^J>JTV^ -$P$<<!;DK=ZT,6!9*23]&*?F"P'U:2E</F5B1F
MVZUGN9D1($V^5,2G(#\]')9*D8QMKW71/R^*#?6TWN_2FL927V%R7C,0J,1?
MPP*_-X?NUO:^B?&F9-WK'X.F6MX0*=Z'';J6S9T[/&'-\@ WF3J+/!82258"
M1>_1XD@K=*&0G=[<%P:!!R0JR5 Z-716'*.?B4R1,_[25Q8/--ZD]'*YZS<4
M8TD*ZA]BTUM&"3C?Z]8(X&&2"Y;=S\5C8'ON83&5K :-"6%X+@=9T@;VJ;)F
M%I8S'WO4O<4LW Y5RD?)0A9P=WJ8_GRT$ FCX*C11#AN$FG1^=3:38%#$N'N
M!1QBL7,+P&B,)CG_#6&2MY1G)*-ASE*UQ&LPH7^,G_ZW[\U&!\H*51NF^')O
M+W2P<]K=.(UY%"Y)F6[>+4)RK?R F0C0,]*!31K<4 >A15Y52)B1+G@BT)-=
M^%/Q<IP*25]TP-G,^WMR)_[[IB@KIXX=Q=7C>5%Z%27Q>782K9,R2D5!OBKJ
M _\+YZJ0]2KSNFQTB7V>QX"T:]7K8(-LSRTZ O @L[,&.*L?CZPPSDB#4J1)
MASE8LS*ES,4\^<O2YWL\V.+!3F@T1W^H+39#OZ]/Y_GYNQO;+Z$-_#!CF1:W
M FY)SK-'+OHL3Z2'%4K?6-N$=/H.M_OH@+"S[<"-RNP50,4A>-MB]$G-X-Y"
MRC3#>RSGJQ7G9YY$Z6F>L_R$Y3G4'V#9Y?+_:^_9EAO'C?T55.4DF:G2)./9
M;'8W>9)E>S)5,[;+]F1K:QY2E C9S%*$0E*^Y.L/&N!-$D'B#GK/><AF;!/H
M1J-O:#2ZJ_?)U;ODXH(N:<%?9+.WR7?DDJZ\\POQVQ=G0'3>RUA'QOF]7H,P
M8ABC%F4(<M8/Z&NL$? >JO!&#$_P:UK4J]]I/]"9  'U'O5<\]8OS,U+6J*N
M]LBYS?%C0G9%^H(*7M**M\(.T?W%G=P0/WOISPM,,GRU7M!S7@(I[NQRMWD.
M<DI719[H/Z@'2_]6OHC<0ZU)=/U&)6#>ZG I8:55K,OQNC6>=P!*(/H<*51C
M-4,-7JA!#,FMW96?K<>AQ [Y@TKSE^@YV>PV)K(\-H5%21:!"BG'(IQL2;&]
M-=N4X0JK*4OP*%^.R*\<X0T/"OLO+]L,*M9+M?[U)2E_P26TX\&4$G'?6<!D
M'AUW7P>>.L<^XGQ)E'F6/<SM-!A4=L7]+$Y-!6DC-M'5ZYTU^!M+T$@IIMXQ
M_F.!XJI$$MSF+-.Z8,*:'NCX"^TM;Z9>'>#(_OOM&4KJ91W^"94/48D>H@)E
MI$0O]&BWJE<;X,QB)-_$VLX&]56^9CMH'U^I8< P84'U"SQ>^-1X/HM>C!3<
MD"Z-%(*V_!M'U+#I[' 4&P\'*OC46"**9NBZJ>:\/>():6R1OZ3-]M[L; ?7
MT-?\\3!KJ,;^>QH!\F0# 9<]:W/ G 8SZ:9UJD-TGN<)*+U; EBP=PW<NI!H
M\%9[)KM$+)(^-(.SA P;_"TQD5WV'@ 8FKNGQ-$R^S+.T-+$]L?/D"^$XRMZ
MMLN@SM!%DD79BB+,&D*0=3[X(D-QM"[GRD%Q_\"<H8$:/%"#"$^2?G-[=7'S
M-NSS#M4=(89D-@RX?&;G1L%)Z(Z<8IZ5HQA^L3>K3C#&'+J7Z(4YFLJQC!"4
M,6Q^4L<K7L5:K45Q=IED'(?]9B"*PS^>0LC&HDX@CK;88V7H/@]D#F4Q[]EK
MX].7]I-KOM/SIRB/K[:L@L]'5C_S4\:=FH\Y*42I9 XA:=>FMHZ1:W7-0$(R
M+N$HF/:1GP0)-")"#*EW#"O4Q1QU4(>BM=WO*O01PW^&JA7,$%\#)#[S5<!O
MZ#K"'Z@="@SQR *O1I==D'R-DY)ZOLUR'.FR 4B!=%D/1KX"W0Y0#Z$*S2AH
MDNY;0<;QGQ?P.B%-M0S$1+78D*A8U&*CN^=-B]4UR>=9? -G[^)J5Q9EE('C
M"$\)!"I)=IBF?AF;WI>R&,-#1_+MKTW#HVD:"4 _,(X&ZN Q0^SY2\!RYM(,
M1G0I&_0.^S/.8IP/UB62'6;Q1KH[O?-'5J);5HY$V"I&TK0?N3$5$]3?4]?6
M*(%@7)(L:G]S1_]51"PEO;^YBN$LN@]:U:"Y9M4%2>D  L&61[QWY@/MV?V9
M]1:$C*$,[0\*RLVZFT<L[4CH.U)^FWN)GP8K):H-=G'5WP#Q4<N0O:VF^A="
MHX0Z[8 8*Q,"O_R?D]G[]W]!2?T=-#4S#OXX6KI./*?STAQQ9)IH#,=GABA&
M_(L)'&K4.%,VO4% \Z!^T4!9J['/+?I!/LI<56X.+Z0;KLC5*%5'/!S]HE>"
MB]GC,C\<(#CPAZPA/T#G.G5P8B\WI8,8*%\,6EZ/AMYM*E/=="I350< A@5Z
M<Q:]*%D7%RO3;6JWI7]E*>8K!KU )5L3W%1&QS6Y EQ%RHD*4:>J1YO1/.>@
M;B@S;P\DI8JT./_/;NB]FMPP;1LR/+V_).YA//1RM6VO33\QHE.Z"TY>10>9
M/_SNQP\G/_P=88F%.C.EDDQ&=*EK:%HO=GG&@LX4%$R_!24GKBLA\;F.61V8
MUGD=N!HT8Y\&N'ZQ!JMK,38[Z[WEX1J? (9&AG6(*@T-N?\C@<>;@'B>79,T
M6;V("EK)?J[#_0/3.L_F(.Q]+H>-OG'H\M4+72]&C_W/DF*5$JA!"'&+RLV"
M=6[Y\L#YNF<+7U4+CS&X94D6JH6P#&,150*'#K&Q_'+-"%O_6 >/#:8=7YM2
M:$FP)9+O#&P&E@J\^M,]>?PSD^O\A;-H]4/+G=4O_D6)O\\6QW]0Y*MV M=,
M\_7RT]WY&;J]F]^=WWIEAAXB$?'*/;;<RNFQ$ZY/FMS63E\:5E56H&@41FHW
MXAJ%X+XG5XU"<S!ZF:%-BP5* (U S;GD-X 84-5ZK'&>IN0)5/(%R:_S!!ZA
M+!ZB_!XOH]6ODN%'N3GL1"2'804*4@XC92&Z9WO5MD*9#5[,[:PP0]->NVF3
MY1F*]E:]:I"9[&)UVRJ_JJ4:1Q/*!WRPWFW%T"M9AO83PY;4M^*PM@KIG5J<
ML^KMDX:A.1IJW[XT("9@5AI<+$N>P1K=&)$)+M2VQ:A?_$UMA;;,Q/36Y\ V
MQ')\ZM\B'"M&.4,@(*^A_E_LBI)L<'XJOG81?**CSP^F<IXG68%#I_HW*L8H
M&_-VNXH P6'1YA,9\ECBS?DX;\[M\>;<,V_.S7E3&V5[O#D/R)N'FW_(F[WD
M,>3-RQU,"6732;Q;]3O(HF]TN/-P+B\N[R%0908UQUK#B>5 >:^$8'A;\6BR
M9B7;"I$ 4B;D8B)%+&_1^1L,W1YP?![E4-R\H-[4;K-+X3WI&5[30[0H."\_
M4#,V/P[ >=.S%B**.<@@87@%4A-]^EER.Q;C;L?"GMNQ\.QV+,S=#FV4[;D=
MBX!NQ^'F'[H=O>3Q$ZZ#YI:/.#_,/C69PF'XK@;EFO>K=^^%[WB(_OJ,!:5_
MH9#TS3!JBY#S-/ @]:AT&5(Q;-*_"W[DD>>I?R9%4?57NL$4E2)*#01T=$Z'
M$BN$[5J$;S"XF%7O+LA=RBG@;.<]Q&F1  YCG]6[#Y1"/:>F4')>H?IVNK(^
MSMN*PB^Y7Y[3-_3-]/A</M(Y0AMNC_?=OFUX6XHRJ9J#0H6VT>MO:!S?\[1K
MQIN,U&9_<H(OP<ZZM^5F9M\X*G&8+E9K)*@D/%C@0GZ@9E1B'(!KL>Y@@!@*
ML^9VF9>1#EH_6F$#B#Y5/5L<BXZHQN0^;-+D75./1BNXE]I:L2/OL_/+MXPN
M\,,* I0=IU5,NYG TKT"TV;+N=7>[V#&CY7Y +353)]HF"7#=SA] +/'4&#Y
MN1,S>D+2#YB\87IZ+(=+<E8:X PO2]'+2KF/M8O2]DWJO#D'0'W'RB4"7/1-
M^D&ELQ*H@[0E:@0S=)@H7V:K9!NE5^LUY= SG%$-N2 IR:.8B"]\%(;I.#D2
MTSL_8]<H((X#XDB@&@O]ZR(GB[,2-=LV:R9\S?2(S=&;->L.X%"H,!O1)7(P
M)X!9AG^2E.X<?T^EX D,CK7D#O3"". 3<&^@161:CL'P3@QX!Q+D-53Q7 )N
MM]$**CA\B;+=.EJ5[$UP520LP:QL?WR=1TF>8&IIHOYJH];FTS$*)G!=\VME
M(QARB&*']M!#+7ZLO42,*@P10U'?E/@EB14;4UF6@E$*2+'9H]2ZI10U/GO$
MFG%JA6CJ;(/CB?4]\V:R/E4A]S/,__]3UK0V6D3;I(S2^;(H<[H,@=U2GT#3
M>,D#<IY8] #5=QD7MUVPHJ+ 54WW3JVLOP6Q8!I[0LP)'<S-NDF*7R]R3!$M
M,=TV]0N'\0DL.5QB0 &\+D & 3:H1F>"5Q$26S/@@<G2VQOKLB+EEY0,4?%
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M;0^IKAOZ/R2E-R:]H<H_WU75_Q:D$":HB#_49+7C"=6YZ1'G2Z*:PK@'&*T
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M8C;AB'@BOUZKXMW@B'@BQEY#(Z+AR'@BT4(#S^"N4T]D6]TL33A G@B\UXJ
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M9^IWL^XQTR4.=.IW4E>,=().P1B-]#E PQBU1KA.'2.7&2.3?0\P9(Q(,T8
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MVD*:@ E(%Z<\S(L5HMRU55)^=U>":7M:@D:/(3FXP]$S?WX0(RTVA-V<\O+
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M'E.\.2X <,I4QV$<\THVB!9;OM(+M@FXZKBIEC[HA-#M[I2W!Y2CB,9<*_Z
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MY'PQWR :\:_0R*BB[2%L/Q#]]Y3$""7Y#9/8;_.\9%=\\VZF@ %QAQ%PT,3
M[?("11]!UF4@+H+A=8(*;A?I>'"S8+""66>^78 D"DENZEP#)$"B*W'Y@HG8
M&"A1-J9N"95N XG*-W6^X19@E;+D"Q+R(P%NB?.EC@, #X YT!<T7#B+1EZL
M8LS.HM'ZD<&ZM+UC='38:-G$[1T@H\-%WU1F[V@9+3APVPX8'.UZ-Z,%IY\Y
M$@S8C]X IF-E<QLT/<O+]3JB6^ZGSO$RPPL<,^IF41SSDX#GT&Q(BF/,".WG
MNS<QE:.0:V.4]O/=U[/E#RA&N'KVEI>-^L)/HAM"/^"\_KG5EP_KVLW VXE<
M7I>.GPFKB"[9;1S_V8'NMV-89J ^X;C> :3VJ(-1TJ[9@B=;Q/8Z6T]5>;!J
MHM;8B?:F+LCYG:UU0F_0J0T<U,<H@3>8YL43:X+NV2G+YKLB64'Q<UD'3^UH
MR<4A*-U&,$%Z23/,(X<NLH17--CP<TE"I[JY :)NV7'(+E?,M$]VN=,K=L7S
MMXIX^;I[BC813IJWG:H;[JJD_-JL7N1Y(I](%A_]0<R*M4E,1 PADO-:?&+J
MVUL8F?IK<8-?.J_D+OU-D4U*VDS+EF=O)GJ-9IZEODPX(WN$T6XAN.R,@LL^
M,KU02E7;[R'DS7;(FXHBM%>+1"BUMW!)6>N1(&UCG;I'=K9'%!,FL[Q@4N;I
MMH[@1XGP\T*[.*/]<Y9O4,S47I0($5:VM4_M[@OO2!&L4VD[IZ%"%\F_RKRH
M#/-,GST1<Z51F1H]'7/T@FB!<Z:7-]*YD('3A@.%E[VRA)#RN5B4Z5M-7L0%
MJ/- G%U&*2?M<850<=?4%Y>$)ZN:#TZ[=$.H.[BEO\GQN2+K9R8OUR7<*U-A
M+>GG.*D\<]S ?:@#?[7B_WF;U6X77D>^M<ON2=OM.Q$8;F8?:%U_0 O&77*L
M+W%-N]&8*G,F1?RO$=T>-Y(&BO<;=)Q(?(R*>,4MI,>_U\IF-Q0D TX.@?FB
M^M$X$,VX ^%Q(@GP![#OF83#;0R8)$=2PY% ?+D]^D?3,$OJA2VY+VQ.-4BB
M0BUD\PL;F*GPML- 7WU>K! ]V#R/GCQOU3%TNSE.6CBV[39F70$#K6V'2[;8
M,(FV>J*E.+:^7VZ?&!V2C:31<QP<<:JDPIA&SW%P]#E'3'*_PPN1H _H.="Z
M>V!2":W/4T8;CQ:7+#5YXX'IEBXI5?.0DA12DD)*4DA)ZIB+(3!=$Y#UV L$
MSC8IRZH>0WJ8;'T!6"%T$-U+WA=<E 97HF_>] 4;'9V(]% \IHZ7VI]%M-QS
M4\<#GC5DWWSE2XJB[0O21;2?+]]"D2TMB\"8.@0 .5TO<,+_)-'.%L:IKY6.
M8H1>"+7_&;9G6X%!'($X]4/#>N4)[;3&L2QV'1OYU%<_7#57)C/82]\<R\(
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MW:(ESBC=0S,6XXSR.32B/<XH3P,25G)&Z1EFX@7<9B"\FZ6-\6J6\,7<,^L
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M>#337NS5ZA@_0 ;/[;$?0^'YB!.>P_,1W@JU:L50)TIDZKM WUH'3Z/P9L6
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MB=(@2?3-?[Y@HTZ=4ANN?,FD4^T=(WD=OH"ED7.G-J)X!XI*NM&+V#J?/$V
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M*@'!QS,2'T_P-4S0&#S(O@U>AN!E"%Z&X&70-JB#C%'VELUTP5*;+6S[&OQ
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MXG;/)VXW%*,)82.Z82-J-YHO@,A9/<*D@ZO(E^T#Q@@>3>!+0!H8&K&#PIO
M92@4 .7;JYHX8&#4QD)?3A2=:TCE(O#K)I)P2[J8@'Q9,3KH:/@+_+J'8/#H
M^_G]NJ* BTCM!/'PEH)AHXI:LY?3,@E@.L,Q\D,&6%,,&%CAR[T-X+=%19*%
MB_MR9VLC XGD]F4SZ8&C=#3Y<D7KP:*,QO$E;U4/%E @A%>7M.:R448M^K*=
MM*_L<]&V82PK2Z5Z?W'#P-&*A/?P!M=0*4T"I%])?="3&;C1(-'-'M[K,'3
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MZ\O>0'&PO@CX@ \PD% *)U!Q G8?: S\\O66%SV^:,L X_JB+01V^Z* @<;
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M_A0PC89*'@!_I)_#O4AZY1&"D?XE('U:]P7D8_6GY@!$X^L:?&E!CQMR&7:
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M0UQQ*YT2N>D3^E+])%Y!.IW'PU?[^XU=F)2/- :.*SFRXX=L[SL:KDQ\1L!
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MK,HJS3VV$S @,I<!\-:1U-8IYJCJWAM*99%@CL'N;<>37"R:H[%[:R%IRSC
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MSO:F!_(2KT*5A#W%N:8OW[6KVM-RQ?[=+N.+>;O()7>/=!5]0F/A^6Z!TY*
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M"I;-.>/<N^LT'<K=TXH?YW&#A!Q$K6P(U0_]Y\0_O#\GOCT-OCGU_> L^-<
MX64#1)WF+$QXE[MQ*(')TT &OE408U6+YT0VJR=L5N7;&MH^</Y,PZ2,,*S-
MS'WR?>V,U5KO1HWV%S9=SK1?Q*S6^L@LN\YP4X>8NDZ<W]+H;@X_O$O(L-$Z
M6AJKT9I9_U6+KYA_WI#!ED9EL>NZHC%$P7:>&ITC#MIY?\]AM%>/O3Z-W5X.
M9E5@Z^/W18]MZZG?<F\OYX<2)HQL2(QQV;HC G%A:T4QQF7K_<#%A9GE);!O
MX0'($W\EQT.?>+1\AY*,RN+\F8BGYT=#%A\@2>3Z1Z[_$*[_4.@W[@.8SCX
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MXI/9JUGTO6JE7*F6]:IZ2>B7@\F8QYO89WZ/WJ+NX$,U-=SW@GGCHUNI!\+
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M#=DC%RQJ; F(:X@/)420B;C;XQSO2Y3J>^Y(8 ^SC= 6CTAA]B1C&C0F@AH
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M=^@+=;AYR3QT4/A' ;WL11T4V'*@Z>UDC?.$?"$7CDCB;P;D0IZ\8> 7<NA
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M0!DMZ4K6AXTV*U;E/ES@KGM,6P#WV,X+"XB^VOGAZJI; :3<:5/7CN&.^'T
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M>YTRX&^_W&[ <FO-6J73J)GU:B4+:YN=:KR26ORS'O]LY&)];;/3Z3'0^JI
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M!W$(*HYEM&GA M@\ ?<^GIS]SW^UJY7:QT^]L^_?KA\N+[3[A^[#Y?VG]ST
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M'N<46U1*IVF)8/4>![H$F8ZGEL R\) 61KD.14./7,S"2)38@W^L1THN*HD
MB;*0F"(22 3U@9XK0ZME4H8S$0%R&(@88K0K'5M.D=84_690Z2*B)B.\;[M/
M!^M?S<7YYOETPE!QFEGPN+SS.#1'AIP]8K!"%*ZHR1ROA-(AE8H,=40E$9YJ
M#^(0-!T%*=)=*:<P]N3)(Q]?I:, GV0VE^E:7.2FB Q&S%X3^2XJ[@5VCJ>/
M4E4@I?"SX[&1>@2Y,.:X89')XO2U(.&C)&%*8!-ZOF=&W@+RCSLAQG51"JDL
MM1JG_ H? 3Q2QD<FB=%T*"LR+"FFFDNZ-?"]2&2QDX!.96F8"8)P(B.KQK*Q
M1B@)/&61)/-JR9F13%;.5&P4F5/6(@[FR3S<@U5:"EHN:#DUSVLE6QTJR96D
M7X^L_!FJ)H_$Q:\7,1%AR&0L9_\2W3,M69L6SXOC<^2_J).FK(;A609%J:('
M0QPN1Q\4.1] FAR>"+AV<=G5<,W,5]E#V'',EKEW(K%5E%-PM8CDQUCO KV:
MQB]?;U5.OD@UEY*[CT<5DHM8T_I'(@4_K2#0AWI<"QUU@#CB/%!9&IC&@Z:;
M2-R8I <JS23AQE1ZR;&PE#>>IK%H[^.4C?JJ(?M%RD:1LK$P*6-]F3:7LG$O
M"Z=DH2&DYRGZ'8V$"9T^U%<27-3'LD:]$/1H')FJSR.<C&#PV\'0H(1H-B$9
M[@=EF9=,;Q?$1G602M*N%F61TM50$IIY)$V/38861/?&B0[S5F*/NG*CTVFY
M\)@I=YG4K?&(G8U<C%FF@T'8&*HQ%9O:1'31*3UHK"8='Z*Z&SI67$O@T"W<
M@H8*&HI,VPP"D)GOD;B2E=#\P!UAD9)^7&)#&+=@*?HHR."ZU4]+.6FYBLIG
M'&-%70TKB^$[1+2H>#)!560.2[=P:5J<T>BH3E*ZFE[V29HJSX0U4%YZU%UH
ME05Q[H\X5=D=T5M3%MJ1VN \]XZ479:7]$>5L+I'B<YR2J@FNIZJ8<F?$W]@
M>0NL&JC453 M097MA:+<1;IT8>PI4OG+%Y?=0Y6'><O&O4Z6/+J558.*4^N"
M7;V,7>UQSO($.W5R+43T=$=!6;HL#H[WHP(\\0':O"I@LD+4P(/Y"?+!N%P,
MCI5U&?#1V2\<"Y\J2"[O)+>'/!,0X98G3V$\RGNGG'86R&C70!;QF!N?%M5C
MEK$?I$Y/E]HH2*8@F:,@F9NT/2F*/HN33I.C8XBC#1N7?U/'JT SDIB0S#B6
M>)/Q#HM$T[&0S6MKQ#?>@#GRL+FDW0=>* [:D5?=1+9^H2(7S"?WS(?W@76(
M"$H0W2*6W!2)6E@V,A4R'L5U47%I#5LM6'T )IT$/7(_('7V(W*L9 Z++-8:
M.G& U\JI)-C=)"N;1(9I)'-)MIQ'4M!I0:<YH5-9#H&"I;%6OV4 L5A4T1WH
M2^5#&T259I):1;\.C4GZ*JBNH+J"ZE8^C'* !GP\<17=XD2V):>2D/_&',GH
M ';@H9FK"E0AT8DKS#"P. G>,KCU2 CUA.G69BCZL0P]GA:CT:F6^)PRGT71
M'Y%!N21]<O[14T&8!6$>!6&2S9Q!6O(\R)<GN09VX@DH1:% _0+UCP+USVUF
MC43( T)P) 2'.O=$UF^"#BAJ-)/C%)5%#)(0=EN4%!/7TL+"<B+P 5L<]">)
M+)Q4+(8AOLP&V).$<G94M+Q\+84VB6)<V!_3=?@D7;(+!\A^0@4]%O1X%/1X
M2PU$T$("*G,T*D9*A-##]G1(!Q2T)PPK2GJCPC[9P1)Q,T7X!8HFMD"QL?V2
M+:L!P!^SK6U5<0"A'28"<#-R_@^5[@J"*PA."D"9H*K::,5U,WSJ/L92YA38
M/I@"Q 8\]4 B+$G5A102$@BS;V.I.<I!F\ #AT\R;SRY:VJ[$PE=#?75(J&K
M2.A:!/_=]>#9G"-*Y$_VXT$]78^Z\<B_4KUX;KMW#W@H*3E$[^PZ=429MP9#
M5L!'\8+D7ZD%73]<?DTM2#_5/G^_O_YV>;]"AZ'C+SXDS2WMYA'[1O*G-[XG
MJS=EFFY52HUDW\ENM-3-5#:BE9TKZ;IJEJMNR<M/?/I*Z$=71+=+O C*AKSX
M$S9G8F*'QC0!@_JABMR?L6A<;5"'1*JKERZ4X8 18E-93]5&5;2 4KCPA/E]
M(-:Q+2JFZ3F&ZXUE^R>X=>?Z_,FB$&]QF2*Y'*T;#F!WM$Y)JU8JU:C,&35L
M%HP59!<S71$MR= Q5YY^M]K5>T-V$:5MG7[3!;?9$_51=;1_A@[7VOA-O7&J
M745=K$0>U5^A)1H"X6,9W6-34,/[\08[VE?JRUBM5'7M70*(])IN_&KU2"GI
MOQ!-V+GH*XP]/S,:$8NOW\@J2#!'H7I2FU!?Q9%^8[[)_M+.9:GDKU2/0$!>
M-"*E(LF6\0.[U5,W5#7/[K\>OI\J++H)DU7-A=,'D0ADM=C[0&MU*A7MD@$(
MOSNX8UTZK"AI]R$P5JU3K91@XQUJ1Q^!LEVIUEJE**$EX#8?#[%LG1..>C C
M^,*[5K7RDU:OM<K-1KNRI+_D*Q)TSOD-]DP=B\1852X[>'(CNQWT@P'%5GS0
MWED_$5+</:N+)2JZB^U)@3"H?Q#E38R),*;X1Y2DY(/-A"@S$@W(HH]&Q8$F
MU"^;8Y(&F%9)"H$OWXLO1^2$&/+.DC,3)8"C_.%XFNH4BR9+AU.J=O'4(X;L
MP9R8JG!KVC)(3HR6_>34W%7M(EZ6+)%C8?, HUC2"SA77_M53'!J-042OZ"3
M88P<">Q*@AS16C7^Q62?OFM;KA11?<OS@]3H=*MO[1T;C8<\@)4Z_"?1L=GD
M9AE;'S+TMWDDTL!D209&D%T.KXO$MWAG"GFG&H=K[T8\&$YL^)AC8;&Z=3\F
M(/4N0CCQ]NB3*F4QP.-D53>8!51?!H@6JPP;5J -)\@3L"$W'C;#E\C$C!=R
M\>M%],HD@E.MGUNUN1%>TQ[[',,YXDV.H0134.W292ONRSOMG4&7W&?:<T ,
M6'S LW=#ED3&,N$_19.,7ZGD*'-F'R?(EV5Q -&F.;"&,$'QV?C%*N&,>CVE
MIJ9Z?U.0)FTLBBGN(7\!2'%O(!RU(I1%IG4DN\)K,PWA$5>I*!'E:6#7S!1O
M[=LA*%(FV,3DJO7#L1P9(3A:S'YJRNX(=T.68^A'KZ!O Y1Q*5372'%&Y%ZJ
M!I(\]NDS1V:9&D/+-CWN"'=5]"Z!/J!A35)8<<M-BV$QB S4R"U/.0"6-U><
MX,R3S&R$45N (C,2,A)U(OQ;G !H-LR()R4B8O< 0)P^*Q"X/2EI0V9AY(<H
M"%X"=L%Z/( =0;QTL>&]:0VXCX<#\J7H=G@.Y8E"Z('6-R E0=VE0!8B29LJ
M@XB@L:2]$?=HEP(:ZVB*]R6DL*BR1>@/:K/#[601T&#^#L**_$1A4'6TD2Q$
MK/V!I9<'C'J\DMEBHA=XT4NM5%C/J78A*AD&D?SY*P3U!YO*]>5  4D8W: J
M9((C!+)'>_S1V8K)Y*.AM@U8GU23Q>-Q"7'O%6P)B?53J-6"^-*\F=-+QE0<
M&C8NL<'*&E36X2)EYX(^9F&X>D3]XK.(RV(JB2!"6 .]5;2OQ/R>1)>^#$VK
M%*EA&!'LB!,JBD+T7<"9@)LQ]O<\N$.XG)&Q4(H*W*G$/)$F8:FT8MF"V)>Y
M^U(7=&5 "-?",6[8WRNG#0VXA"VM1!FD)5FVYTY@4R:I/E R_RBJ-(NK@LDN
MI/*XN.T?E %%6<E4KO:1VA"#-!+4$A>RC4KK4]5_#2S>27QW^F-QR*;AAF,\
M-R2.3\>$))ILR;\PG1KV1>05RIDD/XLE-U&N4/"8XX9@A9N24=FN3[4"Z9Q$
M7/O%(QGI 6.Q .,>^#/SIPJ @I&,1.PFCUVH8<E0M#--M>R186GBY932[2&D
MDL7/'YFM.F[ED=_G7!S-])U-'H;)'K1H(3&PPR:<>7 ?H83_(I5&^"L<+@:3
M&^?O>N.T+9:MR$AIK_0&T0*#_#2U2DF&2LJX8\"EJ1M4\MFDOFV&$9)F0PTT
MA+X+X_]>JU9.*ZGOI8B*K#] )A% 2>M,+1+'.7*9,-*1V89$+H2,LINHU*H%
M-P$2(QDFTJSB3\FZ_:HDM)TPSH6=2Q,Q5^C!D5N,R3E"7X,:A$=&:F]1SD:B
M*8:AD+9@5'A.NK]*5".T9V&RW-!!)4=()+@RY1R!"8588@)Q@IQYL$HV$&):
M^<!Z+O,PK"J.LY*F7D+D?L8Q"0?O]"UR<L:/2P-.A'1X-@94H:_>%U5HN(<"
MB)&[%!#1'W,E$47M9>KZP(1LCBN4RN)K6)8U$?XA&3#B?T+4D,Z T]!;'R,5
ME+04&^6SP<9<>V>=\M,2*C0>&8JDE9$])4:[&+$,4I1[9"*A)($+V-"-A#PG
M70C3XN$J#XQ388SZ/%JK8EN@U$H5 62[\C[W$RM#WQ1\FS+V41S:-NM)-[6?
M[) QI^65VJZ$\QC=X5+Q(;7(ETVXL2\/W4L@#O66%*)M5FH1TD0;.84\ O**
M9XA\*WPL75EV0:.N"(A)&_)U&$L1<K PY&"U>K+-(OQ@0?C!FX@F>)U"7OM,
MGN9(,=IGQ;HN8LE<'$6O>A0M6CM&&I!48&-)(<6(\)J",NJ606-X(CTCLKS
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MA"#>]$_7HDAX?$D7X& 2[_CFGFH-"G2),_.!'4= 2P],LVA5B-EEPF/F@]5
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M7#TR()WNY'U[=A1.Y)$5V+_%_S8@9X?:N#<TP83('Q^M: J?O(RN2)=\N6K
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MHK1!%ME/1])R2I_4?#[W:D<ID$2)BK$REE!@;_.Y:^=OLO]3K#=_SAZ5SG<
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M0>R-1^%;$Y3DC\4AI!?#VK7ST",0<7LFU\XZ7:9WLUYQUU;$:[4+#EHIS ^
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M+G$Z"5F!*+FPJX 4I2%RI:'ATEKNKS5JYY"N*/BT<B(%9W2<Q;ET&2*Q6+$
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MX1T-GK]""H(&,(>W-??(Q^B=<'O=O#+P9OSM+;T.^K,X7A4#SBTJV^(JXF+
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M,=.?X@ 9_,<="MB"W*TD36<4K-?<=ANZ]N,^!F%Y#@W!@23#O2T%YAB&DK#
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MA00>_;^&.FA":,;&.!"T"Q(5<F=)&'HW1272#5+ D^;)KJ@-OXT:!- [,39
M%>B9%2&5LP]1IF%]\DC&66J7,3%Z60U"Q)TDV7TR49\@K.G#PMNMDSA<5C,>
M-((.5@7-R\JP"-H(S*+!D=275A1GPI-O9;WH*L8D":0#FEN.L[/YG/?(.??*
MTDR MVLM'^D:>;: @EICPYDD1M 0M%]?3;-P2.KZQCG4-(4JJ6)?[N5F7QE
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MPMU;^$@79=L/WHLGIYP\6X;NHB,(OX[%Z\#.,L84.IZ_^.W)S&3G35%UGJ)
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MD&MC;XQNY$OY')YKVR:TM>&YEGW,ELEIK1E8&(.B$;:EU4N89C_5VT#((9W
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M6:&?R"Y)#L6N%\A2>)73R-'O7T?S1[X:^4D:-0;:FE29(X^&2#N X[J%/,_
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M-@SOG"-3(#6;LSKD9WNZ7XX%,+F_A>X8DROI2C_.HDV%G[Q5):6*6X1DD!8
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MW8"N1U]L<!"_>9;2-;[:'3L6N'RE0>.;H>YV) H2HG?Z)N+I_R4+A00 %77
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M$HU@\AV5-CT!%YQRK_1!B7]T11B\U?&6V#$4L_:-_S4Z#C4AW$81QD'X]?P
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M2,9+3N"%8 _Q'E_E^BGA'<Q5<HIN:4;UUR! 2-J'"LLC5=JC)AP USV!(2%
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M8U'C"IIK/X0*MADA'U^O8S!$RSS83!+#J\H>+HTMM#_ H8V2R%-#Z .?DWQ
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MO!/H-X'^&#;.+]"1 ULBETBH\3W3W2%9N0>\+/Z> )Q*!BJ"$K_BR1B=Q^7
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M^'1WV;2"<F6,,%A7A2*D:;VC'9 X6S<!F.VI@'"H#(@V0G9Y6P1<U,DC1'/
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M?+K\<X/;-I7_\9-F*-@594-M=1?L?%QGQYQN-&+'CYM@.LRS/>7GWO(?\IO
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M6OJ'37,]C[U.(XGG;.S>B%Q*LI)E)^X_A>/R95WD",8,+/T\9O_#_B_IT-(
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M4_UZUFEFL@!@ < "0 UR&BS;M6S7(MVS(!V6C^4629;N6A"P(+"9(' N1EA
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M?U  +#^TFMM_TLX\\]3@<3G&4T<-=\3C\5*9GPR]#)@"?(_WHZ$"3LZ7HQ$
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MQ+O1"^6[S^&J&J8VOOC@O/K98R '\C^>+D=W'*9>>"61/?6!LB!GLM4;'[F
MMGGDFOO T<OBZ#TZ>A=^Q2K65#)U#*27ZOA376NL5\J( "^JPM7$. BM)> <
M5H8%ZIRDS%F6Y5D%*GM3D#&SO&6K+WI)J3CD$&@&4):*\:BZ[$ ,O3&2@0"9
M'Z^!%G[KQ7Y"JQ=8/7)4JFI=<[BH']X#2TSC3%>,/$#)PV+ZHV)ZAV2F6 PC
M$$H0A-^V&]VI*JPCQ OC'D@"--$>!([>S#LRO('U(;N^C64JME'RR+NAS*,.
M1OED7/1#VHD434B&092HRJBY.%M5EG2J(&D"JS1)2\6FER BN.RQ]R^0J-,[
MO>K22*H@]1#H'^AH0HG21:77JFKX%T(X@ XG42J<5J^P6;1:[YTY.**/FA;D
M#8FVAG?X2!@IB8HKS!H-Q482Y2B421*LP\H]65"8&64QE<:6X0CA$8FME57F
MT*QC.&@9$U0>,>NQ).NQA1,$1JKO#)-A669]X)K7(SV+\3V@46)"BF3>;6CV
MV9SDB!]2%4R6R21*4"TJT#0?4V%.%7FH0""'NRO!'S@J2/^HNWN#Z(9KP /Q
M]2-$2:/,^\Q268=+*BD.J*O7$M 9KLJBY!/QQ)1\RQ6P _3][4ZCY^3F%R7-
MD@H[<K;D._Q]-U?&*X1G!((MB0\V&ZW\0>Y$P,]P5?-B=L4Q_'*W*7^NS4*,
M /R+YEI&1W(%ZEI_S2TK^&4:RT'&+1G4BW-;QYC<J>=HOE2IHSFOC2&]3+GZ
M,ZHV5&7^@.[^"J$![U?ZRA9A>=8#+AADQA$@IW/C!8"4B'[>\-^9Y/+YVYK!
M#(NC'II'G12M4/!5P,%_@?@)7[ V2C3B#GE B#S (_5Y%/ CZ74<95?72 4B
MT$>C6).FAO-P1GJ50\6\I9;MRF];C69.L>[I:%C1FV&V:Y07! M.:8OU!I)R
M_W&>O,.M2FX_P,VF\",I"[XA:!?,LC-ELBU8K[8EA'=SI^?#@8D";/Q7[BQE
M^>["'E#'!)LN3)=:JO(TG9^D.F)LS(F8]7CVM=GQI[I=#N99\V:%5<NA'Z!%
MHI\>- RK0SX5YDA]PHICJ@YF<[&'_)J>X8!%X;_9:%<X8!_D?RUP;7I%]UF;
MC(:R< SP*X@<U]JOB:+$V]:.P:%A\#&P+R_$WKD!&JCA&^YYQ*/P3MZV.L9+
M1\- 3F#Z2WSY"[S,#\$OXRA&L><FBBE, $>_SX'UZ UK-CQ.9Q&&&3$[NS9F
MQ\;LV)B=F?9;A[#F&Z+TSE]>',/SSA?I#; K&1K\MKZ J/_.05UY3?VXZL97
M48,S%=T1L*?\"&_5$0;&$<K$ 6XUS%@!SJA]KY D4B+7^A@ 2=B^&%Y'V)(S
MTHTL)?87 _[BB\!16N57A&;GP(N#R$GD& >$9Q7KI0=9+Z:%^6@5%=[P&K[
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M*9V(^$8%+96"$,GXB8>@CB^/YYY%99<:H(\I7 ,#H<JX;^6YJG[4%"F$(>[
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M!&,1XT9JHJ0#%>=@%/8F+531F@35ST@7CS8+B'EW;*)]*41GK2OY-?GUWG(
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M:O-V^CPA^'96.^MKGM7J$4N:[[ SHJJYBO%T$VZ88@,4:N GVE\Y0$%?ZUD
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MQ&1JS<EWVY@G3J<^7,PR=S[%.F]GV;1K))1LE%X.LI,AS$*_SO_I7\SPM0L
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M,P@>O0%653+<!QN+6QA!P,*-AU'7G&+4B?7E!6DNR_K2]W\]N(IOOT>7OVI
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M7),2?.Y[UH3_!'\8?8?1'Y\_6/8C_Y3+D/XVM;:_?4K60<O(,!W!<P3+R2+
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MLN;$G6H+A;1.0/+;3M9"6<S:2ME/A51;XU5YU4G*9_I4P6_:1_I1JR;]3DM
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M V2 )BAUL >0C8T'OK<AF1(RPB0'W!S@*WWO^ERI,N]PRDF9<,R% .MZPF+
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M<0[JAC@EE4GE_)BO3'Y1RN2VZ5#G-2B37[9%E-IU(TH*B[:"1=W7H$QN!XM
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MI-J1[(@ 99-X0'S?KDB ND&=A&2E:^PL>0.DV&>AS=OCS)6:VLV:24UT,A=
M"KT)(/L7YK(!UE;&#:3/JP9@52,8SY&6,H(17^J0^C$5T*ENLT5TZMWO]_R-
M,9QZ5L?N3<*HY!!T9U(A%[JKH("\66G<X]GE5<>3(LK8>0K[#\JV$=AS&11$
MPP>.G*K%#HSCP>X3IY8BP"CI?.)B+T+0@X%XN_!!-A^[$S*'W-'5[5UL-1"M
M.9+.4\MO%]\$MF4.D27,-\ZW#_)\PSE>K=L,#O\$E"=3^4_F!?B%,*83O\.'
M[D!-PG9N]- E]I"['P+7%*;Q,WG"L)HO$XEE02ES^SD@HHO:63($+D ,XO_
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MG6O7X1HVP:WT8TB'!L0QOV-[O[A#U2/#JOE>'9L&L.^GD$ZMLPO; 7<1K[V
M90U!SVIZ.(A0>]%-6W-<S7(\3\/M,KVIX\$7SBAR.2D_&&DOP55(7M1!OCOQ
M-\$EO=@@I[@LMIH5,(W--'C-=7GO"SSI*[SSO?T#V.Y^E#  B\'7N@*V&'II
M@B$=F[Y_ZD:7@JFHS_S@$ZVA\E:@)[;J:Z G[D@]+^CB'"B+'8&RR-XR!ZKB
MOA:?"WM1#KAA6CW2_0Q: @0%=#;H HMNIZ:[B-'H:J:/&*O8I@7.R22!V@!_
MF9;IFWAU,IC%?^(/1Z:MVT,B[OE&^$TCV=!@,5YXP5A_):"X3'@I$"+ZH08+
M,QW#0XMLTL<^$_^-$'N%TFY0]HC@?3.O;M;.&3=]<SQ?+,:TAU9@P'JF5%MA
M%:+IP5^B:NQM; ['5.P1Z19W(4ME3O09T_A $M"R]'?L!4%I3\ZU*U!4J"A!
MW*LN@;<G'N(!A^2P/&=N19[F.]HT<(=C>A=Q/P-72M4>W=P%2K.'ZB\N8365
MV@NQ@?:6!0;(R7H%:G)PDU -X5)1TX<V!XRC:03PQZMN!41["7076)7 TH'>
M\:M\T&1H0^$VKP38P_<2ZP0>,+0L2]$I?"!\R[B1ZHNOIOZ,S#L+K4$M80W0
M]*)%> /3ZA%[/@ZPG45;X)()[ H5C"3;,P.-MI#"%>=V$<XY<)12:CF4VIV-
M7&$3QC!OIL]$\SMQ/&TP!'WCF?A-11N 901*(/HT4,2>UWS:X_U/_)HP!XE]
M9@EN6>G'=-+.@^O56K-:[_]).>\*OL5?@JP\@>3'^F!_3/4AMKXF<"1N0R7[
M!03*>'!UT()HR?5<U=#WXNWHLQ\QY+\?_?0(K;4JZ DUSQ=#8.$)5;A:=#$,
M\!"TB:DZ_B^N'3@&<"0Q7-7K,Z:2F*#@)7I$.LT +5+1!$ V,TH:XN,R\(/E
MQLG7Z-YI?/,@UL;M.]<&7DP-AQH1U&"V+@\5(34)!CX=.VLL<VCZFDL7J6/N
MPZ7XQO03*O=9;).6!MP7VSR :SC/-WCH3$B2>]"1= +;?X07"EFGVLC-.YAA
M3,&0_Y4&V0%:+C!H!D%[:-HDG6U& 06[2/++N;QJ*05[FKQ3*RY0H,'7%WA\
M#U]NGQXS@=UB2,\"1CIQA_&H"EP7?C7_'0)*:P]?OO_\MAH^;BF@\=PV?HZ>
MEB4TO1J3&;&P,,:9^T?B[W%X@O0P^')3O7R\&?RS.KA]NGG\!![1FS[S1)(1
MZ623Q 9]UL:$H04W$">7'SS]4J/_@=\MG$GQK\X^II+FC^MTTF!&;CN$>;J_
M^FK:?X5/P6C2TF>XBQ8(1/490[<DH]&'QPF@:V,79?H7WQF>)63AC6\&*%S?
M1(9F5,8KYC\,>3_Y<2%I@G"#PIR#[*(*8YV'^EI\0#5&0FKB8B0D;.$:V51!
M+&&4(2<C)W#],9.5_X(3#0))]9Z)^G9%S--B2-1B^ ;;&6Y(09.^FD[@X50(
MVP:V'X*^S3N6@]I7_)XG$OCE[ %IMG7.&(,!)\D,T9"%*CCIA&W)/7QB0P@!
MUUW!UH%)L4T=+(-+$-R1A"O(\31N^F?4P(OY%XG'LX6_N0ZUS//.B$M8G=52
MSY!'+.Q3X8_D?(&U]@RC</8#]$=]A_U-(V&".:>L4.*:#*FAUYIU&DYT8OG.
M-7\JDI6)!.CAV%S9UG>7O?LT!ER2(J8&FL[" 5=)1]X#!C- BV,& IAFGF5#
MIY;M"?R(?1YWGME7$,]?$O=M!A[\ [%M;V:]ZL# [,N1ZTR8T_UF,WVTX('[
M8W"SXTLU^6PE.KW']BW,"MMT:2Q]HFL>'@725;H@#B\D3 C%<@%>Y! :[!G@
M8YM>2N!6X1*F\P0.&/P)W''(?'IG&$X16K'YL% :?+/-?QJ'^T--82QG T%^
M&):$;[ORWDRD,,0/I9'M1UHDXL_M1<;=P?L!(_%*Z%VK-)D/^TW>,!G-$EA
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MG9]GO/LU,=F'W2SJ2B-@_IT)N &Q]FB/WF;JFL37W5GT8Q/=%2_+?RB,G_?
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M>AI/#E (!0!3.@ ,KSUZ%+5'"@KFB)/W<DB]Q (NG>0J*)@CE;A+W4(/KI*
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M->)H84 ,$JL>4<4/)<9<=T)4DT&7[C%,%X-B$&'5)<**(V\A"]#P*[^M0'5
M4!Y=/NDB]<<B9,#:S\ =CBDNWEAW6<,6UKLZ6#'@#/_B'9WD'8&9/>KQ#J,F
MB>QXH9<5+UQA2N]^]+]LH??N(R;=%OT]_GTJ]B+HGA^XZ'G/+O76-_P-'O %
MPB\]_JT7N7EK@I\W6N>-E AC"BJ#[FA6:"@6D;202RZ*QW=Z.(-$=.K$O 7"
M:N>B:CVD'[,*#A@N-IS)IS5F2$LPZP)L)YN:61',L5,SMTGG9U7Q25MSLO,F
M?!W=0.42U<Y$'8/L0D?4FL_3CG<8PKL\LU!TB>CRVD2F$:+JNV7\M;@PT$Q8
MQ@D;Z(\7"FNSF95R8;PLDN\"JW[$*M[W*5;5.OFT*K>^71[/#)#_AV2ZV)VL
M,S1.#M:0];KHL0#Y7?.5)7*XRHQ-ZM*]N7T.M2IMXER^;-OA_C4?=L<$-*'^
MV>Z-=-/57G4K"$.]I:N-55Y19VL*ZN =6)=N;K;@IDWLV*+@S@NLN'9@&TP:
M[Z/*A<)%'XNGF%JY!Y@GX-(PV)KN@D(3LC:$*)"/#EJT,,O5$DJ_D*2Y:N:<
M#2-M<1#S V\X=BSJS-S0%>#A0H5[+>%B0H6:+2AI)3 -[+RJ=?_\(;*F,QR9
M<C^BCUX4%"'DZU@X^J%W1_4T-6C1A06M6/L\;;!0Z)/0@B5_;'KQ'2+TV#"9
M/:;A)DU",\,S$V2.2OYRFD904DE&6NR3#XFT(G^1RI?ABZ!RG#BT_E_G+E+2
M_F8K6F9-EG NU< 4? ;[AL+[KE#=U!2B'4UUI5<R95JID6#*XW:[E&;?E68/
MX>O:2Y5[\OAO82[LRA,Y>F V=\ 5G@%B>$*S0@QS))%'F;*,DDAG 3/3KAB/
MV*AHV$$5RXB'Y61C HYK;%D<J21$ ^,.MN.:+W0(41*&*ZRP1G3@=[B_SRU1
MGF@_VCR1YHH.BU+?:Y6F9#?.C_3(P<SN4+% (&]#R,<\7]-C>^S%$!K25C3G
M/T?GH'2#Z((1;<7/T*6A7\QC#=I'9/\GL)DZ"QN)EA!@=2(A;21NHUJO51OM
MH]&!O?/.H@K$\V(7"RP=5OC+.5G$*G/D@-4Z0Y/V8X1[/M\QE6.0%VXNY^DY
M:Z\T\FXA7IN)\X!E8O0CRNT_B.Q=='BWMC<=0HT+5F8N=)9FSCX]U+WH'$=T
MXU&/B>8/6/Y=G",^._RE> *[RF:71?/?!)0ZL*&K ZLO7  ;/ U8$Q)/42Q;
M&75[$3O1HTW#2U\P_@*B:ZG T:L:X[R/9L.[1:0@VJ=FF![-!+'7Q'\%GB<:
M9N=L'D(BF&S@SXH2F-3IQ!N5,:RH$8?K'O#PS\/SUEM""B=0%JL1$E4PPC:S
MC)I%7CB8$F]9)V+ =6)ODP>0K"$P:C=Y)K&N,0[\F-JA5M$"3YPLI\"F38@_
M=@PNMNQ(A,91X94"93*3<%D#VS:NOZ%P)LF[/(3E$MO  :QW4C)@OP)),GOZ
MYA0AI7/4SS='REAW7X7%K-F2D%;0D]+"MRU)V%X'63-+%H"CA6)<IWDV>ZO2
M<"Y3VO7DVZK&JF8[+;7/CF_=CMKA<I+D7"QCT<+EM$$KVCLR36-RFHEJ;A'-
M+5W5W**:6XYO+M>6W=H]C01AL,$+M67+(+XH\OP<YN?BK^-I\7@9"O6',MP2
M"!4M2T#[T_PZA2-;J#I-^75VN20^=NY'2:C/;,<QJYETC6KE78/I[<S[7(7&
MR*.'%=YB6@:O_%V<'^":L8G%NQ!6 'S,0:V'B1+!]EPRQ';'$)4*LKTHY C+
M#;,IEP7!LZG'FK+IB*AB\;'5.Z@6"$\DZ',T_J"H &N=RI+$+5AK4%BK&@>^
MX@3%>*L21]6*)W:'8[ F1&,QLTN&Z,X8[' \%J71];G$Y[CF;(&IL(V5Z!@B
MN4S\+BPA0B V4G5&(X&J[(K^\Q#89S'@7X;[PI[("G]L?IC,>0VH.,0<'3<<
MEN/170&>@E\'IC<6"AZ?EL1\C/9BQ<]6<7*_EI:[V6'$^@51#K_"FHEW;]\D
MUGP_*AZ4:1YX%/#7"CZ? V:*F";#C@IR934/.)C0W6@0\_*X3!(73<(NVKQ>
MXX+K%FZV:KD]KA%]^Q]ZE<1%C>Q+1KBP'):(I^7%614';5IOV%2>$93S<Z?F
M%AD?IJK'YPCD<H[ZM:7!0;V19D?X*G 19?7#-C/Z82O+YC?1&4RK>CS[M5Z^
M>3YY-V:QPY,C[-R+$5*WP@.A+:[.R"V]\[.!G9\IT5)%=%KGF*+;K]>8H>7*
MNXK)579JPMI#41;SJ2,VF2:FE%@0GX0.9-48<72_Z*0WUW+K9Q<>'M^*J;\T
M&1R6U3"<7J9.F#9A3WS6+7INQ,NCL1I(%/_E>6ACV1[E&>C6KZ<516=X@ 4D
M-PZ$\HVU]8(2?Q0QI7<_>A#ZYL[^-RS_%EYGBS!/H2OH<\!W.A9E+<:)RL(2
M?<E)#YTU"L=S07.8^M%HP1PII/G2EGAY\#.QG+<HER0BXR7>+,\E/:6?*L;[
M_!<7NF)*4[^>-:6I /N4-6&IG@:&=U CEH[!M]S&U"7M) 8N]>M+82K7<2Q6
M#DL"[JXWBB1>E\TO*>A+I'EK"S-+YGS:_<]!ZM>7S$':!E58<C<DR&7@I]"I
M4S*=<LVORD.G<N83Q9N55PTHZM>W$?3D(G8GG=C=DHF=:SC5]HF]G<%!W<0P
MJM<5I%YZ;+,G4O?*)'7>F5&RDKKT&5&I(V<W&!15XV@*>)]<69^R!D=M,@N%
M;]/F U&B;4Y,1I)E(,K!>>E/J9R@QEFM&F?EI3/J0<VS$D]<>ZY57.(8ZDK1
M$5>+=PHGJJP_\DI7HZXV&'4EKXZ278<6F" E"@ $MX>3B!)%"1O-F>HWLJ8.
M[>(<YZ<=]D5<\]=X<,G$#"8#FPX0$#@"&T\6:N8N$5AP9Y>/'LH8-A0GG>BI
MX7[QBLE#L><N;5)8[#=)]BVL)'3.P4/;H?D^AP:MUZ\0+]M?=SJ.!%4<:GK$
MT@+[GBJP5P7VIUQ@3X<S4+M$;4>\P@,U7@AD^VF%ZOH_<XO_/Y^C9=-5)Q;-
MU\R7O+3K9[/1&C_XZ0TK'XSLDY<^9Z.7.F=#^]VGG,($FL(4H%A,T4^W7\)_
M>SAV2/R;"1!$>I3)D@P?IV-"+>3EAPI3=16(S5QS-$?I&N@4<!O]9\>8P?]S
M8VOY@^@<4HRM!GP2BBTK6.+9\2$@3Q.5WWUCU2MTX0U@P^988QG/5FU&U(AW
M$]\2W0-&]>#O)1?H%C LIIN\)1=,'1:1+A&.@EM]1I%):TW&H[]_](W,K>$L
M4F4;"Y]2V@@NYS\&)8^. 75PUK%]['VJJ&GY2S$&C3]-\QS+-#3WY?D#^"+X
M?[^= I%^?[X(';"PB',+U/KHNQ?_SQYDZ@1(M$,Y:B@YVIX<L8S0]D1(45E2
M*C>5HI22.NLHRMWY%B>PT2 &'^CAD1-XNFUXO^46B"6\OR:CIP3^J(D:M59%
M:S1[\#_M]F\G+PY/8H3.0N]!*JE$?/5KFF))MTL9/TF3BW\L^WWCUV3 [6*:
M(]\],Q.R&6.GUTFH7^FN.P.%/-<<T5RS.:)22P'.W7!+UZ;+H9(R8RCV_DG9
MWC4IBRK&4U=YL:.OE:<[>U""JWZR@;!\R)26#%R)_9PDKB%0S;.+1F>QPV1#
M:?KM2"F;5C190 _NB[+]E)&.VZ&L\AUWJ4@9KL,TPG601%OF2%8LBMT*UR(#
MA&0S9)$Y4:$#6ZI_$]>9EQ):4-7X?(C.X0X581;1FFE%-9EZL"#15NBW3K.G
M_$ YU1=#C[%@D61M7V^M[&S6??)F3G>D^7(_/U/6,N!MLWT.1@;R%6GP58R^
MDD0];HW$\K%*(7V['59I%'5/UV*5%4JYMV6?<YTLOO)&EZGS\+_]S;*:89&N
M)"[I+KR;# ")_+@0$,D)5#&4JONH6/].E,!>80FM'4.0*"AQ]4:EVUQL]E?^
MZU(*IV$\Y%*495&X5>GVE:\KN7+\2CQX_)#1/ [F4$1?GIQGDYEY:Q;.J>:3
M6"ZH1<6STFLOPNGOPNM9)[&J."C!085SM_O@H#TYS2I[NX^3_]!'QLY@VBLZ
M9Q,VM@7-@I*\4K;@QIKA!%A%/B=<VS]SSO_L3+E>.X&\GEP7-0FU2J^[:YM0
ME T4.RUEI];:J>W]L!,$ /7%AL]=LQ,S%!]YC\9'VEX2:RF*>E[VT6X3+S!<
M_K3YYKKUGA7O4*&M2&<7MP&%2(BJN 3*(\,[3[0D8:L^XG/03B1O51_2UI>Z
MP[:D*(2]'\4YG;8-I3<I]7?=I+38DU1DHM.VFI26^$;M-G6+N&^DI;M:BRY3
M@84O[ #?GUX[K>%I&P](<.CJP#JQL]4^9]D55</;6.?6"_:WL:CM%?KOCI1I
M&Y"<?X8@]LM[ED5S$^\KSRI3W@^=<]3[2R?')RV[\HFI=/*W3C/ UBDRGTK(
ME2%0TO.93HIHYTH$[$**=O>HK=6K[V@MF<%?V@'ZVKF$E8CPW^'^3V_$>B7?
MX&'CPC%AH:SSCK:U@$Y0%C5-)W2.4"=L<C10AAK82@% KL$03V_.B4I_>1Z!
M"!-@\3'Q3.B$Q8. +606J'AW]R7>R]YR?XY H07L6A4L652F.LB8"+)M=3!V
M"3DXA9"#T-*[!&'NP'>F+.T7?N(RV*_$9T+YO<<-_/OG/2F17@E*9/I._UM?
M?.6]:Y3-:+2'<H;#>]=,_5>XD7NS.5GKJ;]NI=7HEZS^\LF(] Z2#.&1**,8
ML=,W/P5-07"1"IA*#YB6#@G*[ ?+=V+^Q76\0BF2XK /\D1)IYLCJ?>6)4E8
MF6VP;; !I2$V9._,\LO6"8 B[&A?EQ1M*K=A38VQ26'^WJH0]LE:!Q()[:@@
MO+5T MHZ84T9C0.[V=2U*L:5NY+W2&=+U>"[4$#KE/UNX_F[+0[>BZHI6%2\
ME1KU[XX]W$S;%*M)WX^ZV:CX6!0(X__B%6G5R3@PXH)6H,:O$S,2-J^5O=5-
M]U^Z%1#T2RW'"UR2CM[?J:46QI8[9N7WY]5#&AML $E5PU?5Z+MJWR!:AS?E
MB9AG6:?&R#;*(CY+R2!L,AIAX_1&N+FO='/!5D0S^#"L!0ZMQCZA$R&UP*,#
MUY(_'9O$U=WA>"9&/1$/!<CTQO"8#"+[> +%Z&R15V+1*G?3G@8^&SV8;^#F
M,X%5L?E3$\8@\;7EKY OBUW6+E%/JTC/+B1?TGKG.]-D QV_):_P+\7)63J/
M!1DD4V-\XH6_RQT</? =V=[K+L;N+AE9.&<RL'4#KP"FQJ?#_YN"G2!TW"#:
MT5>"=_Z+B-_13I A7."9R$H@"(.9'Z"UUG"P):6Y$& '1V0RT!63>/%ZV@P3
MJ.3E^.2E<=#RPD;[D3GY0([W3%B=[@I^1TL68_B8"*%TV'/B1.?9<8ERGF'Q
MKY39Q)P[-K<U)D(SC9AL.K+I@N1:,W97\:_/^'@E8J<J8LW#%+&?=HSUX^X8
MG28>3#&5P.:)@P3X%I6DC%VP'>;B,1ECT@>2<[ZF7!3JET_9EH/WX<.9S)%S
M;D8SW$+-.-2],=5^] ^<6PT.,6%CM8=#,4%Y2,Q7-G0Y_# <PRR&.,?49P4"
M"!=^097FF^ZZ\&K)[S&8!:W 9YI[X'^X]&@U>15%  Q!9^E]7EA<QX9^\]P#
M'V+/@Y'$AYCD8F-BAQSH/9P+C5DO/FC;&P.OTIY9]JO4+4L,0]]PUZ(5I^P>
MSK-VG7=SHOMTRC8$*;%(!<=@LQFZ\!%=./"*J&,YUWCR5UNZ&U0\7<*E4_?Y
MG:*32S[$F([+93^;YRBD&.:VZ3S?9]VBIYH0Q8%I9'L-P3=L*VY4.O,EEI#Q
M)/9AQN-P_8*>3/?$MD[D-*/-\Q(3@\/WF<+=AS/-]'!C<0+TBPT[H?G ;MX(
M)[6C-V ;'T&!X0AV#(%3HEJ,(?G81UPJ_HB%N?@)V  V<7PX1AZF$\%-=QA,
M( 2VT2<9ZBPZ'4?/I8N%G7K#_\FA.:/U/A/_C1!;6QT-L3;(U1?R/ MRU6I[
MQJXUV<#E*7SJ&!X.7L<Q]<18-=!\)Z,P3W0^;U_-YU7S>8]O/B\>;6!Z^)&@
MCD<[DY[^9=E?<U4&>/L:1T:_,)Q%K+&XC2MDEN%=[C0N"9"IM:66B?LV8+PP
M_M7]1+88#"=:5$ZE9]T#(\OL9.X)\!66O\4%9!DH.H4/KJO0B(/:J#<(NKD5
M2C/8^YK)O  2LT4,E/"$9T#)-+"-KQ&1N"08]W8H*)=(@52 E'Z]==VK7U[#
M$P?=:NORLE/MUV_:U<MV_>:ZT^U?MJ[;<X=$W(L']W7@PQV:]<%EO=;L5YNM
MJZMJJ]6$']]TNM7;]N!R,*@U&H.;ED)<*0EQI=TX<<25/*@-NRR9DR!WPUW-
M50@I,5NJ^_N!2<F<<[M3XM=K"EIG6] ZQ;Y:<G*/GD3"#^"<&/U/.: B!Z3[
M3UK?*X2MLA&VXE);/LR6XK#CX; /+ =9_TUQE^*N77%70W&7XJZ=<5=3'NY2
MKNV!N;89T6Q+(5!^5@B4ARL^L>SU)Y4.W'HZL"3]I&BG:*=HIVBG:+==!^)T
M_>_EP K7F96G"EEA92B]K-.Y7W:C<P&DN%ZM5A@_.V*DF%.Z><-SH])MK3]9
M;Y_X"OL'3U1"4K*09*!+_QF6&%W.PC__$#54-)DU>#>]:O@=:[VB7]2_D<DS
M<7<B9[0WH/HW<9UY$:-%;(W/2L:D>+Z2,2YC&9#-F\A80\E8Z3Q>]O.5C'$9
MRX %WD3&FCN4L>/R%U7F>R-0KI/!W=K!F-[25581("[066L#%8?H3J)'(Z9O
M4A"?CE'Q[)M=RWZ^$I=07#) >W<>JFXH<8?J3BMI.UEIRP"DW7G0JJ1-2=MI
M25L&)NO.PU?E31;#>2VG?YAWWNH1#ZGN6PF/R57WK5AG:A_J*9:3J(Y<U9&[
MMV:#G7;D-E5'[M%DGU5'[C&K@32I+;_O2''8\7"8ZLA5W+5S[E(=N8J[5$>N
M<FWE<VU51Z[JR#U2\5$=N3M-!ZK.0$4[13M%.T4[N6FG.G)51^YFSS_-EHQZ
M6DU+L[S^VTZE56M*6H=R:FU+VY"('9(G1=BV(1&-VG*)4,VV2J*41*TM4?7=
M2)1JK2V?H\M^OFJMY3*6AJ.R!1DKL;7VL%Q!E<%6G;5;$?^3::=HI*':Y H]
M=]L+(;/>4<U')RLM:?@T^PI+5:N?DK;3DK8TI)I]A:Q*VI2TG9:TI6&L["MX
M5<YD[K[:>%=K*9VULLUMOM*],1V]/,0_R'\#\Q5X!'NQ^%QCV#&:RM%Q_O*S
M;@&G$<T;$T(OH9.YX6/[+^":J>.9?)#SQ+')#)?T%_&U46 ;'ML/_,XE(XL,
M?;R[Z<;G)NN^Q@IE,TIIZVS>?,;0Y?-R-GMA9\N<V+VP&#;-_+MC5[<TT?P4
M=C'OW/-=CC8'G5N='V]N!/0?*  SHKN>1F"AF;/+-YQW3I=*G3+0P#/D$HV6
M6;R(MDW;8'0R;1\^-=%XLE=7PIB/C6XS-A?V'CC >;'AV0;R"%.<^L1Q??K1
MT/%\SAJ!AYS!]:X^G;K.%-;G$\T -P Y37/A7XPC=<9_+D'V"Z::[_ [VPZ:
M1V#?D0ZZGC/C*W$U'W;F7/L!:S='YA#+;(#*P62*E^.SX3Z@F/$'@C\SF(8R
MU=RR1JXST9;[6=U^)R?&;4RAW;I@U8@]G"6=K'C?,>C%4,:8P_5G[&OJCCW-
MIH3>8/Z+:_X&C_ "_+>/^)+L8M,V)\%DP8E[H.X8\^+TF1]\HO1_8-LTB.W2
M_--"'Z[:R.W$U<%JULYK"R[<KTCQS,W."78JRV;K[^5O-B+1M,];BYL=^3\H
M=[3M!H0(!=I;[?4TA=>#@4&F\Z/=V9F&X)L^0QO0X#; C\Q70LDL%]S0D,TT
M9Z3](Y-_TI#T&M5:N]JL;Y-_TJ.C3%*'I.WDCX7:9Q?=\\X"936P'1:^NDLL
MB"M0\5%%"IK>G8 G0+<%M@H_>@K^-CW?U;6OYI#8'M$&+RZA*P*U2@A((_AH
MH*TS*-AGK%#5[N&&KO8U7N=H7E W8A2X]#O39J]&%V!GZ&*YK+3T,=.ECI;.
M85(X[_R9\$_395L,-G3FH5E#HIC(<=P/R?2ZV$1K+;][%A=BPX1?88&V^%W5
M(\.J^5X=FP:\V2<AFUVP"F#G?_^(UUY0V7=![NWX^H=CV![JAR[X=?,^Z+HN
M*%\Y"P?QT80^/-?*&V<7"XL4[[%*)77G_ >#JZ1NM5;/?7AW%S[]?G07[LR
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MI*]<7:%*.HXJDL[PW!6>]:NBK: U*%2_!@=0+K(,;K\>Y;(Y+?.9*)>MF@3
M0G[2EQ.#]V;VHYB><?WYT^V-<@! *KHG)O=E[K"8MWWO*?YJ_3N,&1K7G[__
M_FW[F('<"/IZE"-YFDKX7K*(6WRP.):S]H_,WTE$]GKR^6/[W<W'R3_:DT^W
M'V]^!2'T9*V"]:AJ)OPI@K:]G8*V(@2[AIJ_?9"CAL6'JT#,[=7[K[;[9_R4
MF1TL'6N%4*31S3L,3F4)C3X\C0#+6/C(YG\)O>F+#.$_<6#0X!U2+\,R7K'^
M84SHV8]+L<Z+MW0\)+(\^O2$AA*MG>B "I,,UZ392'#8QC6U\CV.C[+?[A(W
M^!K'#=@TBZT1O;I$6-.,X=]Q$R+5!TO?>[2#5&0:0R\M(XCN@A >!)1L3!=8
M!A-KD/69\MZ32_Q@82_!# 0CUB=!Y(1D)HS?5' GP) .WL)Z !E"#:3O5U^-
MJ>7[*]"53Y8_"]B8^2G8OG>$AVB83IM'802F.&W/[4A^AT.EX=3_ ?+!>;?D
M)P#99;87/SC^%/]8T6OC>_OD'F[@D(!"X&E!J&6!/T![G/X(;L "@/&O[XF+
M 2;X^0)\@SM"7#K! W7J"G!MA5%(,$H6OVOJ:""C8FO0L ,&(#:E%Y^*KR8.
M!Q;Z= K"&BQY9]5*@U]IM#]8*Y;_N,N%":8EEKX-_PW/"U+O Z\31/"J].,T
MH+3O6?I\$S33_%!PV#H'[2+R+-=R5H$-+@:P2,)ZC$>IHSHCF%D"Y4<IBO*D
M-Z5&\M9]#>OI,^!$RUAZ-M O\A! #ODC(P;0]X.+T-^)7)]8C*?N(MM!T!CW
MENU2-Q-IJA73=T)N,[I/@7']DFY52#@*N63*B!(L>2JM,![,WQ7O\]):@@#[
M"89T2)R5VMB_E$62E,8^W?UP)2+)N'?M?5KD)-HGN')_#\B5P,9[>L!K."L[
MZG<29N[R"?SQU>31LATZ<]J[FL_!Y^,.Q"<:H_@7B)UKG[#?,R_C!V/D6R]Y
M;AEG8X1!_<U&6>YFO)*0T!V+((#@$T?&3SUZZ((A%4:[N&R!(X^[,"GAA.A5
MW.6B^\MZKH#)5T&'\'9>YN!(43(>*<H,:_M0*"_(60!!AEY7+A?0' 30KLV.
M#>Q@<3TI1$(Y$;#.AVKZ5X1?CDO_'[@")#/<_W7O(K#>(:S8<D-\B$UFG]AC
M)D'FMQ4&;XUTJ#L^$B!&G&D-@6P!#N!ZR@YH<$"@RK1D6:?=YOSW^9*<PH'*
M04O0@R$65,-OU#2@*%D_>QJXD.0\=J6!//2[:[BGLBD@ZQ1!35;O$4"T;J]N
M$7_KTJA<=E6;<*7/=[LF:N<$/"A@MTVV9^N"U&RH2-RJXX[YG%B2*8;FI6QN
MAF"+<JM*J*2T@S1]IU+\+ZF%(9+LUAWPPZN.<<4486)CJ"#<*A >OU1D:DO)
MNN]>&-M@'W\N;;^T#891[XN1"N[< 5X7-4BIM)2,H#NX+;YM=G=.GJI!D'U]
M4M+\[/?[G<T2V/C5G^!_<=O6TB'4J"?T65NLM5ZW/^XP<2<(B?O=A+N^>),"
M9&-V%=WI96"64$JPIAQ+4DZ_=RGI$L^"C\,L<NG2(&O3WERWBG>N7(DY/2L6
MX2F$.I%(FS-<&>4ML5[:F(+%;8=;1:/954W9O+5^OJ?W20.89K5N^'.+Y+#D
M=Z'D4I:B%?0<UXXA7N[(/3K27E&B[@V%B3>C!@-U<E)2M:09P )3L:3%>!61
MRUG#5M*$ZX7LYG$T+?$,0^NG2$RAJY>$\)B;#_?>&R1E1<5EAX] UL'B8M&K
MW6O:-GQ3/(P7!9S8-N*WC":%_YZI!<SY!1H8,[(D] TPLFPMEYZ//Z0"AQ=#
M6!BY1EIA=W&LIU2(F4<$YK[WP*/#'OM?_($-9T<NR\2K:6@T>W!-13L;T" V
M<.<OK:U!+-KH$>&V6>#<)16@4\+C\J*&)?2)%5+$TL*T633E&04_Y5EEDP@6
M757+YV(E @:48AQ=_TSCD X:4S:U6(O(.AIS7 )00AH(BP*EY\8*=.COJ)\(
MOW;L*8NBB7H?)#?X WX"1AU6D!C!PHL<K$"EKJB/>7V+TV+.[ZU4L0G6"K@&
M^6\$YC.GW2=Q/YKPF>'+_PU<W4=\9$2S05/BAQ8@8&K[T^@!LS]33/J$A3,-
M:W!A&P;I*SO U2XKCJ876=Q 0-!9Q8#G\[L^P1>8&>5&'A;+&!9&F0,&'FG%
MC8_T(BA)<@4]S#V6!]'R'8P$L&Q.-L2(M1, .HP=WGFX '8Z1=C2:F";/-%
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M9-2!6L]V;(O[7 [D$NBB;9KI/Y4RGKUJXP(_K>YXV (MIO)BUG,A;UBH!T2
M8Y-HPQ[#;!3?,V/34F'/#\1B0&.*B_1:6\-$2G3D."X4!_E:($' :46(+L;;
M D2;^$F"1-9TRK@766AW4.>X'(5!?4)A(;/5&PU;P\%X%U#7'M,IX(Y<CGF
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M#(1X$__U6Z/.RLTUD$H<AP*3\%:&>9&W:B 6;VFIR)34(Y^*/0&[R'AG>]?
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M5E_H>WR@4W;8O!^V7Q#HB'Z5-^VIR%S!0;\UNMP,QQH!?8*0C^NCF*;>PP,
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MN,[=<AY^"SK\G:6AX!XT3IFF&;P';L(*Q O&U-GB"WC@0"X\%(_" _JY+^7
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M@SU,1*,K!#@$ZE_ZMCNUE\B&3+Q2:?/1O7?(D^?-6O (,.JLF1>GQ#X0ER;
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MW.**+/X'V@HK8EPM02"$&%M ?9+Y?3B+?\^O%G=H&=RLQ(,)$^V)G8'-28G
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MYAVCUHHN#S2)]:(TC88XA7=?DI\$?-J(T621>D\Q/E,XVY)K@&]ILR8FA;U
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MZO<?T7QE&YNO['5L&JLE\FHB7TJNVN+:V]-1NNP+N5>;Y A+Z36C],72UM9
MMF!>-VM)ME*?>YOV(F^,GW@O$._9_V*,:6A/\-3[[GLF7Y/_QB>F'L#O//_F
M/;[-S.?P2_JK],)B[<LFE.RLEXB_,T#-T0VRIDMX_T,0N=>O)"&T][:;._M
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M^3_8K:14D'08[G*5'$0>2KY/ ,@U5:I$T),H:16)-]@E\OMIB"7#+B0N\/^
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M1LE8?0)-<B+\XB_81O1 P+BQ+_/Z<OZU1'/%^@4LE]H4+G61N7@ ^ED ;&E
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M1)+[J9XGM&-%+!>W&-;9$[@S$\M 4!1@M-W$)24(W 6DDNO:1X=T2KSL*N(
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M/_FU8)\B((V4_1Z" (D3I(T+=Q!%E*J;1W41BQ\N<(+OQ>;3&">4\'O(XR@
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MC'<_Q])6& /1@BV-- V&>W'/X+<H].@*L0)X:7@[&M^M@X.FSJ10-(4Z)VY
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M\N2[::5.FOQ@[A_B3691C+J=I,T/<]XJ'G;0ZW0M C'.)[Y/-X=%^C8LY@1
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M# HN<<8JY?_?=TS?_JE\W"@Y^&E!:C7)N;W>?5DU;BPUS "I[>P<[%A:L+1
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M@<0-=AJR3Z(79SP>LU:'V #\^U9,K8_#4!Y\YJ''8I&D'%G,?1?=8+B%Q:/
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M7V\JY*6A$"1*ON>J'?U>/'L=HA8(B)$%^CS!>"K7^9?P)4581ED/I#;K^P%
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MGWNMZA?R)U45PYOB4MF+HT.<X6L6"D"IOB?L@YXYR=R!NOG*,2;$6Z;4#6C
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M\QLX9,QO L<=WUF#D%N"26&.!C,T@AT802/?1E MM1OZ<Z%O;@DU;@FUE9:
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MJ>L!TO@*CMBACAGOH.()E7@DS)U>.+RN9[E>;&>)349QY4F[$[O*0A;_SI^
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M>H:<>0;@5Q)#CQK6SUM=R(,<N'O@[PK_(,V0_T9TT[-2/@.BK^RM-H^_L;G
M#Y+CI:,^;,)L?3Q@!:TFAU9S)0I%,G&4 WJ?I9O8"U-)O@*]XTPZA0;Q@_C
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MRHO]\XE,=]7& #3/1^;9IS8P(S_],6,KK11.K 1G+;B7(_E+<@V_]%]O=4^
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M$MV61#>,2#D3YG.9RIN-[PWSCYW(5&GGODD6@M)[36A48H"JCT\YXT4![I<
MBQ;Q7H^XC<)XZ^(B;KVI-V/$K6M;A]R^SP+2#?EPJ,](@L!CN'UE!JZ V=H"
MS.ZSX)XQ)P':?AIHBV\<,^@NYR%V1NRL.M+3M8I>1^R,V'E/,PE$?XB=$3LK
M/#[EC!<%N%\"+%K$>SUVKA;&6Q<-.QMZM:UIAJ;5#,UH51C5JWJUV6 /1EG_
M"4BZ;[D[6[D^86:T<"T/6=#66[B^9&'@N<XS:]>7S/6A'99'IV+=&E>M$7FK
MCQ-UH\+!MZ&A1!%Y%SH/>?%^D-65BVO%\W>\_U+W_*HKO/H"FZN@@$-H+[V
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ME+-<%.!^";!HX6X+J'>C C:EW?5>H=ZWJFJ^X4#7'#/20="+H#<?$ U![QN
M7JQKSD\6L/-HJYS"$?0BZ%5E?,I9+@IPOP18M'"W!="[42&;TNZZ4* WZ6.E
M<_!KI/I8-:J:Z&/5WC+J/6&^Z5E3^ 3 [S4S0\\*+.:G0.]A8>;*;E&OKF%Y
M\Q9!;[MB-+&\>:N@=Z/M+CD3YJZ3 /ZR[PYFX@/^FO9M)E\G(\K$EN7Q:)U0
M!H/1&YH<"]Q@8-T1TZ:^__M!]^O1]R1Z)+.,3[,HL)5M-@RB$43OB'/MQ%L'
M\J&RUSN[Z1UD0DTD_6B"D=1-#F*AI"XP'I8]]_X@46?V(Y/9-NE^O?SSQ[/W
M>%Y6BX9R\$7>BQ#=,.+[5OB-$YTEK],OQUX\A&[GZVGYJ'?:^5[NG-V<]GXE
MU+ZG,_\SGW(>CZV0+4!TS<AWS*0<C>G#9V*ZMLN_]D$3__COJ'D[\EP>F<O9
MCPXJRV3^[62YS$%YVY#XS=7QA>7<)O<86/[4IER4E@-Y0[EON^9M-OT1MTXN
M2I(<Z$/@F@<9D[N/!&$Y/,^ E$IJ#[ZQ^&:2?67??E$^=_#E!DQ.;N/BT\8)
M?,AMUM5_ZM7RY/*1"RG)B5<B/O.LX9))^F0J";)\9,3"81!0SY0.!I8S^OU
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MS(+\']2A(\DGG)^3B\/N88DGQEY +2?9WB^X@:4= ;!C8+YF+C(&RNAH#<8
M6P;F0D^X2P 9@\*D5\40"C(&:#XHE)P$ F0,ML88%*._$#(&RQF#1KW6KM?T
M-M04U%J",?@)1$%]O9Z!$X[_R77@FK>D&_);49^1OZD'U0&(V=6=.XC9E='1
M6JO\6K.BMU%/:NNI,$</(6;/H=(0LR-F1_-!H>0W$"!FWQIF+\;: 6+VE^X#
M6 N]]Z)"_L#B&+YGC<:!O_Y. +%V#XOXC)ICX@[%/H![B?S)V+5AD1\9 '5G
M(C( RN@(Z_R+HB=D ) !*$RZ5 RA( . YH-"R4D@0 9@:PQ %=L!**65G=
MC75H@#,^6@#PN&RO_+Q!T*Z,CA"T%T5/<"QN(72$H#V'2D/0CJ =S0>%DM]
M@*!]:Z"]&.V>$:\OQ^NZ5FO4VT95:[3T:K423#A.K[;;[4%-5-R7:VOMS8_A
M>M>FIERIAYYZ9JJ)'R)X=6=2@N"ORWJE4PPEY=7_K@'A&Q6MCKOEE=<3CYVU
M8O LB.%SJ#3$\(CAT7Q0*/D-!(CAMX;ABU$ B!C^A1A^K0[\,8:/&O!;_.F3
MW?,(XW,PF1#&JZ,DA/%%T1/ ^&(HZ?VR-_ZR[PYFX@/^FO9M)E\G:LTXL>6Z
M6F.4J6%,Y0T&UATQ;>K[OQ]TOQY]3V)>,D]AHLJ;EVTV#*(11.]XL-],O!7E
MBMGKG=WTD@LNFSBIF\2Y9OH"XV'9<^_G66CV(Y/9-NE^O?SSQ[/W>(VLY'T)
MT8UJ/(8*'T2BO^1U^N4XR<.[G:^GY:/>:>=[N7-V<]K[E5#[GL[\SZ3O>@/F
M@54Y+".&SV3,I$R-Z<-G8KJVR[_V01/_^.^H>3ORW- 9E+,?'526R?_;R7+Y
M@R*W(?V;J^,+R[E-[C&P_*E-N5@MQ[8<5N[;KGF;]1GBULE%29+%?0A<\R#C
MP^XC05@.SZW ]4A-PC<6WTR\5/;M=92\Q%!OP/P@L3OF'T&;9$CAUM5_ZM5R
ME_S+PCA^6>F(G\Q?0):/#%HX#P+JF=+!P')&OQ]H!^)O?TK-^.]M!XM-W44\
M!7Z;^SV$L-N%L,4HAT,(NQS"&ARP\O^T^"M#:U>&NG9K\#\%?*WJ/Z&,O&^Y
MZ\#8I4?$GSZ8=NCS 9 +BT?2-*(M90Z,UV%'N=XJ9;>4'UGNM6DQQV2R'[RX
M^ \Z<BB1;>)-%@JM^_)S!,G*3M=TM3J>-Z\X]N*>0(,SYU%/:NL)CI(K1D=6
M7.K.H=)PJ1N7NM%\4"CY#03($VR-)VCB'G.EM/*.[>'7*E6/"( 2.6%WS':G
MD@/X09UPR+\8>I8SDN?0A].I/7O,$URZ=VS29QXQ)%6 8%_=Z89;TY71$7:4
M+XJ>\!0XQ/J%R8F*(13$^F@^*)2<! +$^EO#^JT/A4A$$.>OPOFM9J,]Q_GZ
MIG4 7EP'$*_^+P/X7!O!F'1,YH7^XV7]N$B _\)H"^3?1N2O[@1,D'\+5_E5
M!Y0:MW8#@;_R>H*(6P@=(?#/H=(0^"/P1_-!H>0W$"#PWQKP+T:NB+A_!>[7
MM59K4]P?;V.'W4Z6,P)@_Q>U0_;H,#F$[^K.(X3OJJAHK2)];K<%<<D%UA/"
M=X3OA<EUBB$4A.]H/BB4G 0"A._;@N^&5H@\!.'[*OAN5#5]4_AN>7Y Q.*]
M6)0/7-+Q?18LZ44G%^R/F<=,UY,;[Q\5Z>NX5*_ZI$.LKXJ*UL"0>D6K(=97
M7T^(]1'K%R4Q*H90$.NC^:!0<A(($.MO#>L7(P]!K+\*ZU=KK4VQ_M^47]H3
MQ?@9P!^,6;;2GBQMZO=<,?_CW?I8M*_\E$0F0!45K8$P#2S:SX6>D E )J H
M:5,QA(), )H/"B4G@0"9@*TQ <7H&H1,P'(FH%9M-FMM@T-_HUZK5MC#3Z/6
MUO6UB( ;YDTLAP:6ZP@T?^-1Q[?$G_/5_L6._'*+?JHA__*M^^38]::N)RX>
MLP(_*'\84A7% 8:.E("Z<Q,[^"FCHS5V M0K>K-2$,:WP'KBP;@8O UR CE4
M&G("R F@^:!0\AL(D!/8&B=0C)-UD1/8@!-HM!KK< )7TR?P?R^<3#G,_^OT
MY+I$+BZ.!?8_88Y[YP(M,!7P'SZ(T?X),Z,: -P-H/S$0\"OC(X0\!=%3U $
M4"N$DA#QYU!IB/@1\:/YH%#R&P@0\6\-\1<C#T'$OS;BKVOUJK8.XC]],.W0
MYU=/*OO7!/]_N&/')]_<Z:W%__NG [L*?"N8/28 -"0 5)^'2  HHR,D (JB
M)R  ZH50$A( .50:$@!( *#YH%#R&PB0 -@: 5#_%YU,/Q<B&4$68#D+4*^W
MJDU-L  MHRZZ I2ATEYK5+4': \P:+;7.L/OB<Y_F>/X9!6_5I**[,\$);!R
ML\"?G2/RKP\MP] ^'U.Q;X!_*V#FV'%M=V0Q_U!\JG]&JD#9R9JF"K!A@.(0
M5&M7C!92!<KKB8?H)NX.0*J@&"E5,82"5 &:#PHE)X$ J8*M404-I J4TLI.
MJ(+66L4#Z18"2W@"AT4=  V=K$L1=.X\RR5?F<.X8GU1;H"% ^K.1V0#E-$1
ML@%%T1./PJUBG-:#;$ .E89L +(!:#XHE/P& F0#ML8&-#\@':"46MZ.#C T
MK=6N&PD=8&C5JB[I@+4:"EZS(+#ES@'13S!%#KC#9[87P,D#/3:R?'[!^+>]
M\VN2Y@;F301G1#<$IV @+Z#NQ,0-!<KH:+T-!8U*05K%%EA/>*S QMD@?]EW
M!S/Q 7]-^S:3KY=K]9>%(?RR4I=/>D";#8/YV*8+=\W\;/D$64,VGQ_=8&#=
M$=.FOO_[0??KT?<D9"?& =8A;UZ&$48CB-[QK-%8OA5EO-GKG=WTD@LNFZVI
MF\09<_H"XV'9<^_GN73V(Y/9-NE^O?SSQ[/W>(VLY'T)3R!J\1@J?!#)K$E>
MIU^.$S31[7P]+1_U3CO?RYVSF]/>KX3:]W3F?R9]UQLP#TS981DQ?"9C)F5J
M3!\^$].U7?ZU#YKXQW]'S=N1YX;.H)S]Z*"R3/[?3I;+'Q2Y#>G?7!U?6,YM
M<H^!Y4]MRL5J.;;EL'+?=LW;Q[-\#H](DH5^"%SS(&-B]Y$@+,<*+/!W4I/P
MC<4W$]>8?7L=)2]Q#S=@])"!'O./^"SR(6U<5_^I5[OQ&,)E$5#/E X&EC/Z
M_4 [$'_[4VK&?V\[0FWJ+N(I\-O<VR(0WRX0;R$.5THK;[>/OZ9I-;W6AGW\
M#:.AM5KK@.]C=S)AGLF])<?(3CCDGX8>=P_DFGEW''K[:>"=78L'_,U_/J6.
M?/\;M=V%AOY9$)Z<[Z=7!1*O(A)7=VHB$E=&1VL@<:.BURH%:==28#TA$L<%
M^L+D3\40"B[0H_F@4'(2") 7V!HO4(QM@T@)/+LT7]7T1K5=39;FJ_-*_=JF
M], %RVSK3U?KZUJ)Z.UVNY1P W]3FS]&OT0N#KNR0%\2 T/:EYP (G]E9V""
M_*&I@E;]'/T'*_5SHS%=J^A&I2#GM>R#N@YKK4+H"FF!'"H-:0&D!=!\4"CY
M#01("VR+%J@68_\@T@(OI@76ZO5W9GE^0#H3Y@P$%Q"X$3T@28%K-@VBE7Y8
MZ->,9XF!L\X1_[.+E("ZLP\I@;QK#"F!G*GKL%8,AAXI@1PJ#2D!I 30?-00
M"HD*^)^/&D40&Y(&N4MB)&E0C)I&) U>2AK4U^KZ=\U,%SKUK68-:H(UJ,Y9
M@QM&S3'S?'+N^*%''9/)IG^.$UK!C'1\WS6MI&4 OX/']8SL0DZF*;(+>=<8
ML@LY4]=AO1A$/[(+.50:L@O(+J#YH%#R&PB0.]@:=U",[E'(';R8.UBK1^#-
MV/*>H0ZNS,"=EQM42^0H)@[..QWD 7(RY9 'R+O&D ?(F;H.Z\7@[I$'R*'2
MD = '@#-!X62WT" /,#6>(!BY(S( [R8!S#6VGC@AEXP?IH($'W^!0F0:D:0
MD "7S/7)S9AY="H:%/K ")"/0RX#YMFSA"3XA"R!NA,268*\:PQ9@IRIZ[!>
M#)8>68(<*@U9 F0)T'Q0*/D-!,@2;(TE*$:':V0)7LP25-=K3S!\CB3H3#W+
M)G6@":!SX7HT 5("ZLX^I 3RKC&D!'*FKL-Z,72%E$ .E8:4 %(":#XHE/P&
M J0$MD8)U N1AR E\&)*H+96\P'KX5E*(!SQX1)==![04YT'>GQPGF\-&#D*
M?<MAOD^^>OP#43F 9$$.YR62!7G7&)(%.5/78;T8O#V2!3E4&I(%2!:@^:!0
M\AL(D"S8&EG0@)S$J'TN1#J"G,%RSD"OU0RMIC>U:JNIM2MWM:9>;[1_ EM0
M7JO;@*'I=7(=N.8MN9J*KH* ],\=R&SYC4G7IDZ)4)]0X!/8@/!O_!':,V(T
M!'_01/RO[AQ+X$D+ ?]N5;1$*PLN6VM6C&9%;Z*>U-83#ZW81P 1?C'RH&((
M!1$^F@\*)2>! !'^UA!^$Q&^8GIY"X2OU1KUME'5FK6J4:\$$Z.JMVM&;:!O
M@/([LR D1Y;;'5,^Z!+@^T,"M07D]+_B6($LX$=,K^ZL2C#]=;D8!ZGGUB&O
M@>D;%:.*J_?*ZPDQ/6+ZPF0^Q1 *8GHT'Q1*3@(!8OJM8?IBY/0(YI\M\8?-
M^'6MG93X&UK#:,L2_[7@_!D?+9S^=^X,V,2QAEP38NF^,_(8@YI_!/#JSB1<
ME%=%16LMRFMZQ2A&2[@"ZPD!/ +XPF0[Q1 * G@T'Q1*3@(! OBM ?@V+LHK
MII>WQ/&:KNM:@N-UW:CJ$L>OU>*_Q_S LTS8E2]+\#OW%,[^BV%\LC5_Z?H]
M%.K_H-XMN;JU2H0-A\P4*_A_4">DWHSH3:C0-PPD ]2=C@D9H&OE?Q=#1WEU
MY6NP 49%KR$;H+R>>!@NAHZ0#<BATI -0#8 S0>%DM] @&S MMB FH9L@&)Z
MV4GCOEI]K2K]:(L] 'N@!D2[OM/)U'9G@@U(\0(S\:7GZ &I:/C6'ZX_#BGI
M'9(3R^][[GW4"/",]3U)%%0%45!%HD#=F?JXTQA6#^1&5=C#+U?J.JP5H]$N
MT@<Y5!K2!T@?H/F@4/(;") ^V!I]H"-]H)A>=D,?-'9('\0E!L@:Y&^"X@$
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MI7AX'LPE!?W+F_OKQ]',';E!<,W%9%'-#8-F+2V,CW\#4$L#!!0    ( *Z
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MZ-4$R,*+JP@<-L=JLU0O5)'QD)X5*I0Y1BDB9<EEJTB9,'(*&3HZ,4KL2KF
ML/1_NS(U<AX)&KA*+7*)#9 \G5'RAJ76VQ,RFT L]=C.L#1\**PS)&09%19V
MHY75);KLS)@U:_> _:D .]EAP&[O>..KOYZWFJ\[MD2H3!\H".@BZ?-^^AZ8
MX9X(]'!!+D JD%MR!V$3:D[-4@R % 3I.A(VE-KFV(]"H]&R0",S.N01%ELX
M0!(BCF@5[GX]"1.FAMPG;C>YQ!;-8^8-;'6:IP?\T _0/(V6RXI"01F8*O"D
MN8#"U!*U!45DUR,GC3=,&N.D,Q6\S#6V(PW=WK-Z'ZLS.[>R\PQ,L\/=9?J*
M6RQ!C_8:[W[TJB0_0Y;;AW<A'1AP1*><J5"6.D<WR#%ZC83U,1%;<>7'H1.(
M131=CLB&2^99+*7E$D.BD+4^\BNJSRU)3;\Y6:]+?5S4EN,T#N,P&I8Q\K]<
M,HKF:*L?>:%8L4.A?Y=E._XOX-00 R[VY]$^P.XDM,$/ ^V#(]@:NP^/?0]&
M&+$?B8C(9%8K[Y+,(M645!*NS$0SRA!FP0(AA9N2UMTT+6TD'DC/6K$'W&FZ
ME)1Z73$I;RC+38:H6Z_-PQ"A\ ;X]'3HGY=(1!YK>$:2F9I@ZEU@C;)?9!C.
M]V#O)-CA#H-]/6(R]X_RR.MY'--CBQ'ZJ]V0#LX%^ -"<'&Y.4/T'&-'3'9M
MD8<&.G?;+7B(2&#SUIR2[/C^@R (9NF[WYIXL1)H3X<&WZ.XBRA&.XSB5>'E
MZ[30,6V9^?F:C4@^(K*2V-5AF!MB8DF$;A@UU=9A.3TUQ+$L.@A\S5'#XM '
M6[K$"#?&O%FSTN(06?-'RW3JK/*Y08>%.0FS<_U-8=+O CSR^L$O1!G;IR#%
M%R[+<^:5]M5O7INUHY(]]<])\^G_W=&5?ZX9S3:"ZB)$4<1<AG$1K8BJ1PCR
MM3QV;AK+(^&TL7,-[ MPR#05SG&/[X9N@4:%37610-O\  =(+89>2Z$=/RF;
MGNTQ_&LNT'2_G^3*OR)A#_>G4#L9;'?Y%*HO,97#,O\N$3HC';.&@B,N: 6Z
M[_PP:,S9%]*B16;GU:C/2?U#T=F3E$<Q6![Q%*?4&^(:B["CY?.PMI77,I/%
M+@@>.FVU$,26UBM/<1%PH3S,I8[8^,QI+W9WEK]=/E#JHZ:-#4:8*N+ ?5!$
MH/RS_9*\:J$,A1II.>(D#Q4;EJ\HF#*.\C23>LJQ=ISH(GBR.U@CA]]%-.^Z
M,'S$VW2%WWB6"CMJDL>N[?VH+/ OK+;GGE7 M>I_JY %VCF==J#TRU,<_X^P
MNJ?[R;?U/EOO7GZC__6M;"?L6U]?[ :]*X2B#9_I[# -T$5;9[.WR\J71;=L
M CNWBC^00^QOI;R5IR/C<KJ6.BP;5^R3M<(F#%G9!*R6 @71,#AH5('^'';@
M00OZ=#=1M_7UMZ.WQ)O==,8GW1HW+-WZGKA?OFW+]R9A BN43Q3N^S'%C[*B
M7=$[&!2/W5#EK=TOZFK1>V:E%XD1A))9>U'Y>__S;6W0?W==N[RY[O]&OT):
MJAV\>WM[LU*6Q#4$8;V0U"$,WGW\_<-B-FQ!/Z7:\(%6U.FG5;@4_A=B_P%0
M2P,$%     @ KH Z6<1$N:-R"   G38   T   !E>%\V,C(U,#4N:'1M[5O;
M<MLX$GU.OJ)76Y.QJRCKXMCQ2+*JY,3)9#-)7([G89ZV0!(4L08!!@ E:[]^
MNT'J8EUB>V:<1%E5)5$(-( &V*?/ 4CV4I?)?B_E+.X_?=)SPDG>YS?_/FZW
MCYI'!UC;:Y2%6/N/>AW><,4-<SR&< )7::%B;E[IC,.%-HY)J,,OC=9)H]UL
M/X=6JW/4[#1/X.(]U.O]7L8=@RAEQG)W6BM<4C^I5:6*9?RTEFB3,5>/N>.1
M$UK5(-+*<876CDN>IUKQ4Z5K_:>]1NER+]3Q!*R;2-]<N;H5_^4=:#5SUP5?
MD+!,R$D'GGTNM.M>B8Q;^,#'<*DSILK"+N0LCH4:=J I%#0/6D)U(2J,U:8#
MK'"Z2V/FMP:J^EWJL#MWPOO@+T?,"*9<1]'\9-?Q&U=G4@Q5QXAAZKH9,T.A
M.F@/T[\GV!87)^R?WZ0B% X.6P?M7B/L]QIY_^FC^!+A0G.SX PZ\$R%-N]^
MW3%QTH,_KGZ'L[<?+WX=7+X?!/#VP\N#KS]Y=.0E-TXD(F(4CA3R+U/!$W@M
M%%.1P'C_F& M-]_$N0L,T );@-/PJ40,^5'=L[!_V&R#3L"E'#XQ$S+%;?WC
MC>03&$2.:MK-YH\24[=&>!O >V:NX=T!?+P6 43^+DYP)9CK/.; MZ;F6"@Y
MA-I@BCRM-3&9<2FK1#.[MCF+IM>50V,1NY126/.G+OBU%)AE<41,##>4B)X\
M?8*IVDSM1S2[B,EJR3$:<F]%1O%RIV5>\95K5P!^7EJ#GP/P)0%8;D3274ZR
M=ZY)Z\"O!XW8</$&OZ8Y=K-?7TC?2Q[">AZ8^@B5DU!Y"=YD(6;A/X6E<*%
M@I2-.!@^$GR,G.=28?$J1ZX#S >OL2<<HOX.1S >9Q/.#'"\77$5"@QBYEC=
MA5+JZ+1V=-.JS4I*TCLZ;+YH'<]+1Z>U8[P4\6E-\KBL?4U\VFH?MEXT3UX@
M,Q__TFH_K_7_52@.A\T J+K78/V 4#V8N +.A+Y ILT8)D\5'727[P'^&HHD
M_*4PW8B(E7#88>)OP$1[BS%QQBPB :,_F\"UTF,,TB$/;D$CUNB0TL[+-X:*
MBJD)%,J9@N,\4#UF>.LH5!D.B/Q 1)HPXB0#.A.>T+S=BH'B$;>6F0F99.R:
M>]3-^K18%J,S.*0D936EOTB8J,C03&%S\*(5QJF(4K %_3-O/^:&5YW0!#)A
M)0I-C$88"Y?B!&V.3$NC4[\YNJ9CG";&6RF)%Y9AA[GO"G.'/R+F."0S*3J/
MX@ !A^98;1;JA2KW5Z1DA8ID@2Q%2%D(V0!1)HR<0(Z!3A@E[$HY!V$5_W9I
M:,1Y+*CC@"P*B0:(/)W35A%+K?<G8C:%1.JQG<+2\*&PSI"$9518^HU>!@OH
MLE-G5KS= >R[ MCS+0;8U:UH?/;/DW;K1==6$*JV#T0"NMSN^3A]"\QPCPB,
M<$$A0"J06PH'85,R)[,,"9!(D*YC82.I;8'MB!J-EB4T<J,C'F.QA3U$0LP1
M6F6XG]]$*5-#[K=LEX5$B]8A\PZVNZVC/;[O.V@=Q8ME9:&@O9<JX4EC ='4
M FI+%)%?#QPT63-H@H-.5? BKM&.-'1GA]6[L#KU<R-VO@&FV?[V8OH5MUB"
M$>TUWMW0"TA^1JRP]V]".C#D")UJI%)9Z@+#H$#V&@GK.1&MN/+]T G$G$T7
M&=EPR3P6*VFY@"%1REK/_(KJ"TM2TR<GZW6IYT5M.0[CD(?1L9Q1_!62$9NC
MK[[GN6+%!J7^793M^+^0DR$2+K;G\8Y@MQ*TX0\#VGLSV IV[\]]]X8PPGXD
M8D(FLUKYD&0644V;2H(K,_$490AFP4(AA9N0UETW+"42#TB/M3('W#)=V)1Z
M77%332@O3(Y0MUZ;1Q&"PCO@MZ=#_W1&(N2QAN<DF<D$M]XEK%'VBQSI? ?L
MK01VM,7 /A\Q6?@'AQ3U/$GH@<4(X]6NV0[.!/@]*+B\7+]#]#C&AKC9M>4^
M--2%V^S!?40"FUESVF0G=Q\$03C=OOO4Q,N50'^ZU/D.BML(Q7B+H?BJC/)5
MM- Q;;7S\S5K(?D 9B6QJZ.H,(2)!1&ZIM=,6X?E]+P0^[(8(/"Y0 V+7>]M
M:)(@N)'SIF:5QQ%BS1\MTZFS*F8.[9?NI,S.]#?1I,\"//;ZP2]$Q>T3D.*:
MR^J<><D^^,MKLW)4LD/]MT3ST?_=T95_KAE/$T$PIRABS$4PSMF*4/4 0;ZR
MCYVYQHI8.&WL3 /[ NPRRX1SW,-W3;-0H\*FNEB@;[Z#/40M4J\E:L=?VDU/
M<PS_7 ATW>>30OF7(^S^[A1J*\EVFT^A!A*W<ECFWR+"8*1CUDAPA MZ@>$[
M.PP:<W9-6K3<V7DUZO>D_J'H]$G*@S!8'?&4I]1K>(W%V-#R&:UMQ&NUD\4F
M"#P,VJ 4Q);6J\AP$7"A/)@K';'VF=-.[&XM_K;Y0&F FC8QR# !PH%[4D1
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M!HQ#LZG3:?[2@9D]/;)'SLP8OWWM_ EV?ZXU-=.L_8S'[-/7U]TWW\8'*)R
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M^),=_W37445B]( &]7,R5-EAQSC\MALM'U8M$?WT=<ISR9/B98*[+SKT1AW
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M_O-#Y5? E<<>%D?Z3O=+-&F(*H\_6AI\2G>/5)EU "#B7R03T9\(%,5>[A\
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M,JA#O[]+\E@IEG*4K'$<>E)H1D$9M.%#&9_K><KUC"/YA.A+&Z7X)VAR5)A
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MVTZ'C>/9\W\<;M$K@<8)T)%F6[KS5UM/*3JK9ONH1/9;5DGV"Z+^'724!MG
MV+#FO=A8JB7!'X[O8.=Y_+AK#O8/ON4<G/W[[/33S<6_SMCE^?G%Z=EUAU%B
MLYPKE].<P3[ >9'&T!(,4:7TWJOQ<'NOQ_#?G0>QZG_M5'VS87@XN-FQ:PI
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MFW5:*)Y.6<]A$37_- ;J#)JN!]4Q/D6D_CKC\<T5FR'A'FJDYQ7  $#_@ME
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M&U%H@#E2T?[6T6[_('MN3;4@W%645B^2I!</CX"&*AEIC+I!UR5 "!7CD7L
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M\A?1P;I!$+,DBU)]*BV$4T5OIJK@0A1O &>J,G<QXS$2#B T.A_'M@8&UKQ
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M'Z](R(@OJ[Z"GU=+!*%>+TEI&I(,/0I#'B+HW^9*"$_J>0ET%L\B($[Z_*W
M7)?$C+ERHB8I/5>(1*-$JPWQ#_7IIN227@<'SS,+D.X-W59T[:#!T7!%[(?'
M6ACUJ-&B'IF1D-:+4>,^DR96<45#R1SBI<U#+B6?XM079$RAG,Z(GVI5:.9:
MY#OU>[-19\7^:B'V5-N0J'OKVI?&H-9M3RBT62@D#"3ZOD=$W ^C<7?)EG9+
M-BO%6,P,XX7J<? J!A1Z(];H&/#>:K?[UB5\*L#)Q[.S7O.# 0.KV;=LLW\)
MO38,;-.VU!_VJ;5\:%EGYB>S;QG0ZL&IU;=.+J%I]>U.^U)W-&W;;)Y:+>@,
MP 2[_Q&;NBUH]OI]JVGCY\5E.F<\K--,9C;/K6X+?VWU4"^RQHN_CBN54@W9
M-2_MCW#2Z0V:':O;1-J=;K.PZ%)670QH=\X4V2[.C;1[;9P9Y^UJ4O8GG+=C
MV:?0,C7]<_/2 +/0*@#&S1+^:</K:KD,O?\VE2C@HG"N"<3>^^<'WV\:OVG\
MIO%SIQQWS4QV9@QZC,NNTD&;V0;&%S8= _&P?O@\&Y;*A<_!&"44.MEG]*@X
M2SS=:OIQRT)O86U+8GVODF1=@[G&T>NC-P>'AW",RHCA\7WH#/I_Z4!T6'E3
M*A\?9/"8D=$],LFEKC(*$91X*QK)-&Q1R3?JX!%2FS7HF9&<X/*1-U7)5I5
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MV 7?<4GHS!S8^>6UFJW7?A[T.D]ZFP7_4-_9:M2+^LMG_P=02P,$%     @
MKH Z66OP<WZH#0  0PX   H   !L;V=O,#$N:G!GG91Y/-3M^L>_8ZQC&_L2
MIJ0HA1!.EI$>QOI,DH@R1R%,DCJ6&)0UZV0;)0_)]@C-(V-+]I \$2::L<Y,
M"&'&-H-9CI[7.;_?/[\_?N=\[NN_ZW-?K\_[=;_NB_>5-P= [6WL;  0'P"
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MIXO,7.V\T1\W(BN8T2/[FHH^])+!]!Z;$5+YFQ\\X (1G<_*H[5I4Y(?;O,
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MC^L8L-WJG:/^Y2E;@QNOT_4N8ZW$,3Q@7PMS;9P'^.+)E_H6WWO(,1,PIM0
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M-C,P7V-A;"YX;6Q02P$"% ,4    " "N@#I9Q;LI_=B,  !R:PP %0
M        @ %_,P  87ET=2TR,#(T,#8S,%]D968N>&UL4$L! A0#%     @
MKH Z64U<E^R K   G^ ) !4              ( !BL   &%Y='4M,C R-# V
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( *Z .EGU,8HJL)0  ,MP#0 5
M      "  3UM 0!A>71U+3(P,C0P-C,P7W!R92YX;6Q02P$"% ,4    " "N
M@#I9,L@0KNG/ P \,BT %               @ $@ @( 87ET=3(P,C0P-C,P
M7S$P:RYH=&U02P$"% ,4    " "N@#I90479Q3D$  #_*   #0
M    @ $[T@4 97A?-C(R-3 P+FAT;5!+ 0(4 Q0    ( *Z .EE)!C;Q"@,
M !$)   -              "  9_6!0!E>%\V,C(U,#(N:'1M4$L! A0#%
M  @ KH Z68Y9$6IR"   *#8   T              ( !U-D% &5X7S8R,C4P
M-"YH=&U02P$"% ,4    " "N@#I9Q$2YHW((  "=-@  #0
M@ %QX@4 97A?-C(R-3 U+FAT;5!+ 0(4 Q0    ( *Z .EFF.#6-$04  #P@
M   -              "  0[K!0!E>%\V,C(U,#8N:'1M4$L! A0#%     @
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M2P$"% ,4    " "N@#I9:_!S?J@-  !##@  "@              @ &E2@8
@;&]G;S Q+FIP9U!+!08     $  0 -@#  !U6 8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>aytu20240630_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aytu="http://aytubio.com/20240630"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aytu-20240630.xsd" xlink:type="simple"/>
    <context id="d_2023-07-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-12-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="i_2024-09-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2024-09-16</instant>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis-ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">aytu:ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-FirstThreePercentContributionByEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:FirstThreePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentAndFivePercentContributionByEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentAndFivePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentContributionByEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFivePercentContributionByEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFivePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-04-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ConsumerHealthMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AdhdPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AdhdPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementGeographicalAxis-US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementGeographicalAxis-US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_StatementGeographicalAxis-NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:InventoryWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:OfficeSpaceInBerwynPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:PrincipalOfficeDenverColoradoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OtherExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OtherExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_CounterpartyNameAxis-TrisKarbinalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentedTechnologyMember_StatementBusinessSegmentsAxis-AdhdPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AdhdPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2022-12-31_BusinessAcquisitionAxis-NeosTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NeosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">aytu:ReturnReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="d_2024-06-12_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-12</startDate>
            <endDate>2024-06-12</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-OnOrBeforeJanuary262023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:OnOrBeforeJanuary262023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-24</instant>
        </period>
    </context>
    <context id="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262023ButBeforeJanuary262024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJanuary262023ButBeforeJanuary262024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-24</instant>
        </period>
    </context>
    <context id="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJanuary262024ButBeforeJanuary262025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-24</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">aytu:EclipseBusinessCapitalLlcLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember_VariableRateAxis-PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:AvenueCapitalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:AvenueCapitalIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="i_2022-03-07_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:AvenueCapitalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="i_2022-10-25_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:AvenueCapitalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-25</instant>
        </period>
    </context>
    <context id="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJanuary262024ButBeforeJanuary262025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-12</startDate>
            <endDate>2024-06-12</endDate>
        </period>
    </context>
    <context id="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-12</startDate>
            <endDate>2024-06-12</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-OnOrBeforeJune122025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:OnOrBeforeJune122025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122025ButOnOrBeforeJune122026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJune122025ButOnOrBeforeJune122026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122027Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJune122026ButOnOrBeforeJune122027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122028Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:AfterJune122026ButOnOrBeforeJune122028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2022-05-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:June2023WarrantsTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:OtherWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-17_SubsidiarySaleOfStockAxis-The2020ShelfMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2020ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="i_2021-06-04_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-28_SubsidiarySaleOfStockAxis-The2021ShelfMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2021ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-28</instant>
        </period>
    </context>
    <context id="i_2023-06-30_SubsidiarySaleOfStockAxis-The2021ShelfMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2021ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_SubsidiarySaleOfStockAxis-The2024ShelfMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:The2024ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:TheMarch2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022CommonAndPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="d_2022-03-07_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:March2022CommonAndPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:TheAugust2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonAndPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:TheAugust2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-08-11_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheACommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsExchangedForPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:CommonWarrantsExchangedForPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="i_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="d_2023-06-08_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="d_2023-05-18_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="i_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aytu:RestrictedStockAndRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aytu:RestrictedStockAndRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_PlanNameAxis-The2023EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2020-02-13_PlanNameAxis-The2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-13</instant>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="i_2021-04-19_PlanNameAxis-Neos2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-19</instant>
        </period>
    </context>
    <context id="i_2021-04-19_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-Neos2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-19</instant>
        </period>
    </context>
    <context id="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-19</endDate>
        </period>
    </context>
    <context id="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-19</endDate>
        </period>
    </context>
    <context id="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-19</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2023EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-TwoFormerBoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aytu:TwoFormerBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-12-19_2022-12-19_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-BoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aytu:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember_TitleOfIndividualAxis-ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:The2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-06_2023-01-06_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">aytu:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:August2022CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:TrancheBPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityTrancheBPrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:LiabilityTrancheBPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:EquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:ExitAndDisposalActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-ConsumerHealthSegmentMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:ExitAndDisposalActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:InventoryWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:GrandPrairieTexasManufacturingSiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:ExitAndDisposalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">aytu:InventoryWriteDownsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i_2024-06-30_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2020-01-31_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ThePediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i_2020-05-29_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="d_2021-06-21_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementAssumedFromCerecorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-21</instant>
        </period>
    </context>
    <context id="i_2024-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:TrisKarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2015-02-28_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">aytu:PrincipalOfficeDenverColoradoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-02-28</instant>
        </period>
    </context>
    <context id="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:SabbyVolatilityWarrantMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SabbyLitigationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:SabbyVolatilityWarrantMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:WalleyeOpportunitiesMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:SabbyLitigationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="i_2023-02-22_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:WalleyeOpportunitiesMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:HealightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="d_2016-02-01_2016-02-29_TypeOfArrangementAxis-The2014LicenseAgreementShireMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:The2014LicenseAgreementShireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-07-31_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2023-07-01_2024-06-30"
      id="thunderdome-EntityCentralIndexKey">0001385818</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2023-07-01_2024-06-30"
      id="thunderdome-EntityRegistrantName">AYTU BIOPHARMA, INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2023-07-01_2024-06-30" id="ixv-20243">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2023-07-01_2024-06-30" id="ixv-20244">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2023-07-01_2024-06-30" id="ixv-20245">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2023-07-01_2024-06-30" id="ixv-20246">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-06-30"
      id="c117046828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-06-30"
      id="c117046829"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117046833"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117046835"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117046836"
      unitRef="Share">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117046837"
      unitRef="Share">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046838"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046840"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046839"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046841"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117046844"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117046845"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117046846"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117046847"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117046848"
      unitRef="Share">5972638</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117046850"
      unitRef="Share">5972638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117046849"
      unitRef="Share">5517174</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117046851"
      unitRef="Share">5517174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046943"
      unitRef="USD">1004000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2022-07-01_2023-06-30"
      decimals="INF"
      id="c117047052"
      unitRef="Pure">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047150"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047154"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <aytu:AccountsReceivableAllowanceForPricingChargebacks
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c117047174"
      unitRef="USD">1200000</aytu:AccountsReceivableAllowanceForPricingChargebacks>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MinimumMember"
      id="c117047191">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember_RangeAxis-MaximumMember"
      id="c117047194">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <aytu:AccountsReceivableCreditTerms
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-MinimumMember"
      id="c117047243">P30D</aytu:AccountsReceivableCreditTerms>
    <aytu:AccountsReceivableCreditTerms
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember"
      id="c117047245">P60D</aytu:AccountsReceivableCreditTerms>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047278"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2023-07-01_2024-04-29"
      decimals="INF"
      id="c117047295"
      unitRef="Pure">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117047466"
      unitRef="Pure">2</us-gaap:NumberOfReportableSegments>
    <aytu:NumberOfProducts
      contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ConsumerHealthMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c117047469"
      unitRef="Pure">10</aytu:NumberOfProducts>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047534"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember"
      decimals="-5"
      id="c117047564"
      unitRef="USD">3500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      id="c117047576">P5Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="i_2024-06-30" id="c117047624">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="i_2023-06-30" id="c117047625">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="i_2024-06-30" id="c117047635">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="i_2023-06-30" id="c117047636">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="i_2024-06-30" id="c117047641">http://fasb.org/us-gaap/2024#LongTermDebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="i_2023-06-30" id="c117047642">http://fasb.org/us-gaap/2024#LongTermDebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="i_2024-06-30" id="c117047648">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="i_2023-06-30" id="c117047649">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:Goodwill
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047687"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="d_2022-07-01_2023-06-30" id="c117047702">http://fasb.org/us-gaap/2024#AssetImpairmentCharges</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047809"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember"
      id="c117047910">P4Y</us-gaap:DebtInstrumentTerm>
    <aytu:DebtInstrumentAmortizationPeriod
      contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember"
      id="c117047911">P7Y</aytu:DebtInstrumentAmortizationPeriod>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember"
      id="c117047912">P4Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047971"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="d_2023-07-01_2024-06-30" id="c117047972">http://fasb.org/us-gaap/2024#AssetImpairmentCharges</us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="d_2022-07-01_2023-06-30" id="c117048033">http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="d_2023-07-01_2024-06-30" id="c117048039">http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048082"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048083"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048250"
      unitRef="Share">5972638</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117048252"
      unitRef="Share">5517174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048254"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048255"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048256"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"
      id="c117048288">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember"
      decimals="INF"
      id="c117048297"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember"
      id="c117048303">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048313"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"
      id="c117048317">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember"
      decimals="INF"
      id="c117050812"
      unitRef="USDPerShare">1.73</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember"
      decimals="INF"
      id="c117050820"
      unitRef="USDPerShare">2.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      decimals="INF"
      id="c117050827"
      unitRef="USDPerShare">4</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      decimals="INF"
      id="c117050829"
      unitRef="USDPerShare">290</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="5"
      id="c117048402"
      unitRef="Pure">0.33333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="5"
      id="c117048403"
      unitRef="Pure">0.08333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="5"
      id="c117048413"
      unitRef="Pure">0.33333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="5"
      id="c117048414"
      unitRef="Pure">0.08333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="5"
      id="c117048427"
      unitRef="Pure">0.33333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="5"
      id="c117048428"
      unitRef="Pure">0.08333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c117048434"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c117048435"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048560"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"
      id="c117048564">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048586"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      id="c117048589">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"
      id="c117048614">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"
      id="c117048743">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2015-02-28_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      id="c117048746">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      id="c117048749">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048787"
      unitRef="Pure">2</us-gaap:NumberOfReportableSegments>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2023-07-01_2024-06-30" id="c117048835">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2023-07-01_2024-06-30" id="c117048843">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2023-07-01_2024-06-30" id="c117048844">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2023-07-01_2024-06-30" id="c117048845">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2023-07-01_2024-06-30" id="ixv-22795">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2023-07-01_2024-06-30" id="ixv-22796">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2023-07-01_2024-06-30" id="ixv-22797">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2023-07-01_2024-06-30" id="ixv-22798">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2023-07-01_2024-06-30" id="ixv-22799">001-38247</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2023-07-01_2024-06-30" id="ixv-22800">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2023-07-01_2024-06-30" id="ixv-22801">47-0883144</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2023-07-01_2024-06-30" id="ixv-75">7900 East Union Avenue,&#160;Suite&#160;920</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2023-07-01_2024-06-30" id="ixv-22802">Denver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2023-07-01_2024-06-30" id="ixv-22803">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2023-07-01_2024-06-30" id="ixv-22804">80237</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2023-07-01_2024-06-30" id="ixv-22805">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2023-07-01_2024-06-30" id="ixv-22806">437-6580</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2023-07-01_2024-06-30" id="ixv-22807">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2023-07-01_2024-06-30" id="ixv-22808">AYTU</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2023-07-01_2024-06-30" id="ixv-22809">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2023-07-01_2024-06-30" id="ixv-22810">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2023-07-01_2024-06-30" id="ixv-22811">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2023-07-01_2024-06-30" id="ixv-22812">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2023-07-01_2024-06-30" id="ixv-22813">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2023-07-01_2024-06-30" id="ixv-22814">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2023-07-01_2024-06-30" id="ixv-22815">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2023-07-01_2024-06-30" id="ixv-22816">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2023-07-01_2024-06-30" id="ixv-22817">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2023-07-01_2024-06-30" id="ixv-22818">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2023-07-01_2024-06-30" id="ixv-22819">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2023-12-29"
      decimals="INF"
      id="ixv-22820"
      unitRef="USD">10712951</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2024-09-16"
      decimals="INF"
      id="ixv-22821"
      unitRef="Share">6148993</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2023-07-01_2024-06-30" id="ixv-22822">248</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2023-07-01_2024-06-30" id="ixv-22823">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2023-07-01_2024-06-30" id="ixv-22824">Denver, Colorado</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046780"
      unitRef="USD">20006000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046781"
      unitRef="USD">22985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046782"
      unitRef="USD">23617000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046783"
      unitRef="USD">28937000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046784"
      unitRef="USD">12633000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046785"
      unitRef="USD">11995000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046786"
      unitRef="USD">5635000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046787"
      unitRef="USD">7162000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046788"
      unitRef="USD">61891000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046789"
      unitRef="USD">71079000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046792"
      unitRef="USD">693000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046793"
      unitRef="USD">1815000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046795"
      unitRef="USD">829000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046796"
      unitRef="USD">2054000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046797"
      unitRef="USD">52453000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117046798"
      unitRef="USD">58970000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046799"
      unitRef="USD">2229000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046800"
      unitRef="USD">2545000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046801"
      unitRef="USD">56204000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046802"
      unitRef="USD">65384000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046803"
      unitRef="USD">118095000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046804"
      unitRef="USD">136463000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117046807"
      unitRef="USD">10440000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046808"
      unitRef="USD">13478000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046809"
      unitRef="USD">38574000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046810"
      unitRef="USD">46799000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046811"
      unitRef="USD">2395000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046812"
      unitRef="USD">1563000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046813"
      unitRef="USD">1857000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046814"
      unitRef="USD">85000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046815"
      unitRef="USD">8962000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117046816"
      unitRef="USD">7090000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046817"
      unitRef="USD">62228000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046818"
      unitRef="USD">69015000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046820"
      unitRef="USD">10877000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046821"
      unitRef="USD">14713000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046822"
      unitRef="USD">12745000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046823"
      unitRef="USD">6403000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046824"
      unitRef="USD">4529000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046825"
      unitRef="USD">6975000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046826"
      unitRef="USD">28151000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046827"
      unitRef="USD">28091000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046831"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046832"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046842"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046843"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046852"
      unitRef="USD">347688000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046853"
      unitRef="USD">343485000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046854"
      unitRef="USD">-319973000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046855"
      unitRef="USD">-304129000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046856"
      unitRef="USD">27716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046857"
      unitRef="USD">39357000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046858"
      unitRef="USD">118095000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046859"
      unitRef="USD">136463000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046866"
      unitRef="USD">81002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046867"
      unitRef="USD">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046868"
      unitRef="USD">26416000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046869"
      unitRef="USD">40767000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046870"
      unitRef="USD">54586000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046871"
      unitRef="USD">66632000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046873"
      unitRef="USD">26958000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046874"
      unitRef="USD">41448000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046875"
      unitRef="USD">22514000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-4"
      id="c117046876"
      unitRef="USD">28630000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046877"
      unitRef="USD">2791000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046878"
      unitRef="USD">4095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046879"
      unitRef="USD">5212000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046880"
      unitRef="USD">4788000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RestructuringCharges
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046881"
      unitRef="USD">2365000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046882"
      unitRef="USD">0</us-gaap:RestructuringCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046883"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046884"
      unitRef="USD">5705000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046885"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046886"
      unitRef="USD">-969000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-4"
      id="c117046887"
      unitRef="USD">59840000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046888"
      unitRef="USD">83697000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046889"
      unitRef="USD">-5254000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046890"
      unitRef="USD">-17065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046891"
      unitRef="USD">568000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046892"
      unitRef="USD">184000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046893"
      unitRef="USD">4792000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046894"
      unitRef="USD">4963000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046895"
      unitRef="USD">-4004000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046896"
      unitRef="USD">4793000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-3"
      id="c117046897"
      unitRef="USD">-594000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2022-07-01_2023-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-3"
      id="c117046898"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046899"
      unitRef="USD">-14076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046900"
      unitRef="USD">-17051000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046901"
      unitRef="USD">1768000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046902"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046903"
      unitRef="USD">-15844000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046904"
      unitRef="USD">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117046905"
      unitRef="Share">5537957</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-07-01_2023-06-30"
      decimals="INF"
      id="c117046906"
      unitRef="Share">3339906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117046907"
      unitRef="USDPerShare">-2.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-07-01_2023-06-30"
      decimals="INF"
      id="c117046908"
      unitRef="USDPerShare">-5.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046924"
      unitRef="Share">1928941</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046925"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c117046926"
      unitRef="USD">331386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046927"
      unitRef="USD">-287078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c117046928"
      unitRef="USD">44308000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046929"
      unitRef="Share">-18180</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046930"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c117046931"
      unitRef="USD">6046000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046932"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046933"
      unitRef="USD">6046000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046934"
      unitRef="Share">3606413</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046935"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c117046936"
      unitRef="USD">6053000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046937"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046938"
      unitRef="USD">6054000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046945"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046947"
      unitRef="USD">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046948"
      unitRef="USD">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046949"
      unitRef="Share">5517174</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046950"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c117046951"
      unitRef="USD">343485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046952"
      unitRef="USD">-304129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117046953"
      unitRef="USD">39357000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046954"
      unitRef="Share">14250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046955"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c117046956"
      unitRef="USD">2913000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046957"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046958"
      unitRef="USD">2913000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <aytu:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046959"
      unitRef="Share">441214</aytu:StockIssuedDuringPeriodSharesWarrantsExercised>
    <aytu:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046960"
      unitRef="USD">0</aytu:StockIssuedDuringPeriodValueWarrantsExercised>
    <aytu:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c117046961"
      unitRef="USD">1290000</aytu:StockIssuedDuringPeriodValueWarrantsExercised>
    <aytu:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046962"
      unitRef="USD">0</aytu:StockIssuedDuringPeriodValueWarrantsExercised>
    <aytu:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-4"
      id="c117046963"
      unitRef="USD">1290000</aytu:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046965"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046967"
      unitRef="USD">-15844000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046968"
      unitRef="USD">-15844000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c117046969"
      unitRef="Share">5972638</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c117046970"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c117046971"
      unitRef="USD">347688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c117046972"
      unitRef="USD">-319973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117046973"
      unitRef="USD">27716000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046981"
      unitRef="USD">-15844000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046982"
      unitRef="USD">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046984"
      unitRef="USD">8272000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046985"
      unitRef="USD">8815000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046986"
      unitRef="USD">2913000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046987"
      unitRef="USD">6046000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046988"
      unitRef="USD">-4004000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046989"
      unitRef="USD">4793000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046990"
      unitRef="USD">597000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046991"
      unitRef="USD">559000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InventoryWriteDown
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-4"
      id="c117046992"
      unitRef="USD">2270000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046993"
      unitRef="USD">2351000</us-gaap:InventoryWriteDown>
    <us-gaap:AssetImpairmentCharges
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046994"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046995"
      unitRef="USD">5705000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117046996"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046997"
      unitRef="USD">-969000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <aytu:NoncashGainLossOnExtinguishmentOfDebt
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117046998"
      unitRef="USD">-400000</aytu:NoncashGainLossOnExtinguishmentOfDebt>
    <aytu:NoncashGainLossOnExtinguishmentOfDebt
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117046999"
      unitRef="USD">-0</aytu:NoncashGainLossOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-4"
      id="c117047000"
      unitRef="USD">-660000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047001"
      unitRef="USD">-7000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-4"
      id="c117047003"
      unitRef="USD">-5320000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047004"
      unitRef="USD">7153000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047005"
      unitRef="USD">2908000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047006"
      unitRef="USD">3609000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047007"
      unitRef="USD">-1527000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047008"
      unitRef="USD">-846000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047009"
      unitRef="USD">-2879000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047010"
      unitRef="USD">2384000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047011"
      unitRef="USD">-9567000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047012"
      unitRef="USD">3605000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047013"
      unitRef="USD">-3847000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047014"
      unitRef="USD">1872000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047015"
      unitRef="USD">-1388000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047016"
      unitRef="USD">-5129000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047018"
      unitRef="USD">329000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047019"
      unitRef="USD">117000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047020"
      unitRef="USD">-329000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047021"
      unitRef="USD">-117000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <aytu:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047023"
      unitRef="USD">3467000</aytu:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <aytu:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047024"
      unitRef="USD">15575000</aytu:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <aytu:PaymentsOfFixedPaymentArrangements
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047025"
      unitRef="USD">2566000</aytu:PaymentsOfFixedPaymentArrangements>
    <aytu:PaymentsOfFixedPaymentArrangements
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047026"
      unitRef="USD">4266000</aytu:PaymentsOfFixedPaymentArrangements>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047027"
      unitRef="USD">832000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-4"
      id="c117047028"
      unitRef="USD">-2250000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047029"
      unitRef="USD">15722000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047030"
      unitRef="USD">96000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-6"
      id="c117047031"
      unitRef="USD">13000000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047032"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047033"
      unitRef="USD">273000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047034"
      unitRef="USD">92000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047035"
      unitRef="USD">-1262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047036"
      unitRef="USD">8871000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047037"
      unitRef="USD">-2979000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047038"
      unitRef="USD">3625000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047039"
      unitRef="USD">22985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-06-30"
      decimals="-4"
      id="c117047040"
      unitRef="USD">19360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047041"
      unitRef="USD">20006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047042"
      unitRef="USD">22985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047044"
      unitRef="USD">4039000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047045"
      unitRef="USD">3812000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047046"
      unitRef="USD">1608000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047047"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047049"
      unitRef="USD">787000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047050"
      unitRef="USD">147000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740527">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Nature of Business and Financial Condition&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Aytu BioPharma, Inc. (&#x201c;Aytu,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on &lt;em style="font: inherit;"&gt; August 9, 2002, &lt;/em&gt;in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on &lt;em style="font: inherit;"&gt; June 8, 2015. &lt;/em&gt;Following the acquisition of Neos Therapeutics, Inc. (&#x201c;Neos&#x201d;)&#160;in &lt;em style="font: inherit;"&gt; March 2021 (&lt;/em&gt;the&#160;&#x201c;Neos Acquisition&#x201d;),&#160;the Company changed its name to Aytu BioPharma, Inc.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a&#160;focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to&#160;continue building its portfolio of revenue-generating products and leveraging its commercial team&#x2019;s expertise to build leading brands within large therapeutic markets. The Company&#x2019;s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including attention deficit hyperactivity disorder (&#x201c;ADHD&#x201d;). The Company operates through &lt;span style="-sec-ix-hidden:c117047052"&gt;two&lt;/span&gt; business segments: (i) the Rx segment, consisting of prescription pharmaceutical products sold primarily through &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party wholesalers (the &#x201c;Rx Segment&#x201d;) and (ii) the consumer health segment, which consists of various consumer healthcare products sold directly to consumers&#160;through certain e-commerce platforms (the &#x201c;Consumer Health Segment&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Rx Segment primarily consists of &lt;em style="font: inherit;"&gt;two&lt;/em&gt; product portfolios. The &lt;em style="font: inherit;"&gt;first&lt;/em&gt; consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (&#x201c;Adzenys&#x201d;) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets&#160;(&#x201c;Cotempla&#x201d;) for the treatment of attention deficit hyperactivity disorder (&#x201c;ADHD&#x201d;) (the &#x201c;ADHD Portfolio&#x201d;). The &lt;em style="font: inherit;"&gt;second&lt;/em&gt; consists&#160;primarily of Karbinal&#xae; ER (carbinoxamine maleate extended-release oral suspension) (&#x201c;Karbinal&#x201d;), an extended-release &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, &lt;em style="font: inherit;"&gt;two&lt;/em&gt; complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the &#x201c;Pediatric Portfolio&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Consumer Health Segment&#160;consisted&#160;of multiple consumer health products competing in large healthcare categories&#160;including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health&#160;and general wellness, which was commercialized through direct mail and e-commerce marketing channels. The Company&#160;began to wind down the Consumer Health Segment in fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; During the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal&#160;&lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; the Company&#160;completed the wind down of operations and entered into a definitive agreement to divest the&#160;Consumer Health Segment to a private, e-commerce focused company (the &#x201c;Consumer Health Divestiture&#x201d;).&#160;The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for the&#160;Company to receive up to $0.5 million&#160;of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;During the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company concluded that it had alleviated the Company&#x2019;s previously disclosed substantial doubt about its ability to continue as a going concern. This was primarily the result of the extinguishment of its $15.0 million term loan that was due in &lt;em style="font: inherit;"&gt; January 2025, &lt;/em&gt;while entering into a new $13.0 million term loan on more favorable terms to the Company with a maturity date of &lt;em style="font: inherit;"&gt; June 2028. &lt;/em&gt;Further, the Company maintained and extended the maturity date of its revolving credit facility&#160;to &lt;em style="font: inherit;"&gt; June 2028 &lt;/em&gt;and had $5.6 million of remaining availability to draw upon as of &lt;em style="font: inherit;"&gt; June 30, 2024 (&lt;/em&gt;see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &#x2013; Revolving Credit Facility&lt;/i&gt; and &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; &#x2013; Long-Term Debt&lt;/i&gt; for further detail). In addition, during fiscal &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; the Company received $3.5 million of net proceeds from the exercise of warrants, was in compliance with all of its debt covenants as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and through the filing of this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; June 30, 2024 (&lt;/em&gt;&#x201c;Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K&#x201d; or &#x201c;Annual Report&#x201d;). The Company has implemented and continues to implement plans to achieve operating profitability and increase cash flows, including various margin improvement initiatives, the wind down and divestiture of the Company&#x2019;s unprofitable Consumer Health Segment, and the indefinite suspension of certain research and development activities. Considering these factors, management has concluded that as of the filing of this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K, substantial doubt about the Company&#x2019;s ability to continue as a going concern did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exist.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s consolidated financial Statements and notes thereto have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date the consolidated financial statements and notes thereto are available to be issued.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <aytu:RevenuebasedRoyaltyCosts
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember"
      decimals="-5"
      id="c117047062"
      unitRef="USD">500000</aytu:RevenuebasedRoyaltyCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-6"
      id="c117047065"
      unitRef="USD">15000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"
      decimals="-6"
      id="c117047066"
      unitRef="USD">13000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117047067"
      unitRef="USD">5600000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117047071"
      unitRef="USD">3500000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740528">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Principals of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s consolidated financial statements&#160;and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s consolidated financial statements&#160;and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;)&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Going Concern Determination&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the financial statements are available to be issued. The evaluation is based on relevant conditions and events that are known and reasonably knowable within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are available to be&#160;issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends. See&#160;&lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;&#x2013; Nature of Business and Financial Condition&lt;/i&gt;&#160;for further detail on the evaluation performed by the Company.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from estimates. In the accompanying consolidated financial statements and notes thereto, estimates are used for, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Prior Period Reclassification&lt;/i&gt;&lt;/b&gt;&lt;i&gt;. &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Certain prior year amounts in the Company&#x2019;s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impact operating results or cash flows for the fiscal years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; or its financial position as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, or &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Previously Reported Prepaid Expenses Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company identified that certain of the Company&#x2019;s prepaid expenses totaling $1.8 million that were previously reported as current assets as of &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;should have been classified as non-current assets as of &lt;em style="font: inherit;"&gt; June 30, 2023. &lt;/em&gt;The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) Staff Accounting Bulletin &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99,&lt;/em&gt; &#x201c;Materiality&#x201d; and concluded that the omission was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to any of the previously issued consolidated financial statements and began reporting the prepaid expenses as non-current within this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)&#160;insurance limits, and cash balances in the money market funds are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company&#x2019;s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company&#x2019;s customers&#x2019; financial condition;&#160;payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers&#160;and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts&#160;which were previously written off are&#160;recorded as a reduction of bad debt expense in the period the payment is collected. If the Company&#x2019;s actual collection experience changes, revisions to the&#160;Company&#x2019;s allowance for credit losses &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required. After attempts to collect a receivable have failed, the receivable is written off against the allowance for credit losses. The allowance for credit losses&#160;was &lt;span style="-sec-ix-hidden:c117047150"&gt;&lt;span style="-sec-ix-hidden:c117047154"&gt;zero&lt;/span&gt;&lt;/span&gt; for both years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The allowance for discounts was $0.6&#160;million and $1.8&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The allowance for chargebacks was $1.2&#160;million at both&#160;&lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The table below presents the opening and closing balances of accounts receivable, gross&#160;from customers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accounts Receivable, Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24,219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Increase in accounts receivable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,708&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;31,927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Decrease in accounts receivable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,439&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The table below details the change in allowance for discounts&#160;and allowance for chargebacks for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 55%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Allowance for Discounts&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Allowance for Chargebacks&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total Allowance&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,301&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,206&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,507&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;9,074&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,554&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;13,628&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,597&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,548&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(13,145&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,778&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,990&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,886&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3,812&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;8,698&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,842&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,866&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;640&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,182&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,822&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; alternate uses for the inventory, the Company will record a charge to cost of sales to reduce the value of the inventory to net realizable value in the period the impairment is identified.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally &lt;span style="-sec-ix-hidden:c117047191"&gt;two&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c117047194"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#x201c;ROU&#x201d;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily determinable based upon the information available at the lease commencement date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#x2019;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#x2019;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operating leases are included in other liabilities in the Company&#x2019;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of&#160;debt and debt, net of current portion in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Acquisitions&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in goodwill.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201d;&lt;/em&gt;) and ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201d;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company generates revenue from product sales through its Rx Segment&#160;and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;identify the contract with the customer; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;identify the performance obligations; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;)&#160;determine the transaction price; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;)&#160;allocate the transaction price to the performance obligations; and (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a recognized financing component related to product sales.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Rx Segment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#x201c;free-on-board&#x201d; destination when shipped domestically within the United States and &#x201c;free-on-board&#x201d; shipping point when shipped internationally consistent with the contractual terms.&#160;The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within &lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;year.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Rx Segment net&#160;revenue is recognized net of consideration paid to the Company&#x2019;s customers and other adjustments to the transaction price (known as &#x201c;Gross to Net&#x201d; adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Gross to Net adjustments include:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Savings offers.&lt;/i&gt;&#160;The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Prompt payment discounts.&lt;/i&gt;&#160;Prompt payment discounts are based on standard provisions of wholesalers&#x2019;&#160;services.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Wholesale distribution fees.&#160;&lt;/i&gt;Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#x2019;s products by wholesalers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Rebates.&#160;&lt;/i&gt;The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Wholesaler chargebacks.&lt;/i&gt;&#160;The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#x2019;&#160;end customers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Returns.&lt;/i&gt;&#160;Wholesalers&#x2019;&#160;contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months prior to expiry date to &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; follow historical trends. The Company&#x2019;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe variances between actual and estimated amounts have been material.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Consumer Health Segment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Consumer Health Segment, which was divested of&#160;in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; had net revenue which was from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue was&#160;generally recognized &#x201c;free-on-board&#x201d; shipping point, as those were&#160;the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer were&#160;excluded from net revenue. Shipping and handling costs associated with outbound freight after control over a product had&#160;transferred to a customer were accounted for as a fulfillment cost and were&#160;included in cost of sales.&#160;The Company expensed&#160;the incremental costs to obtain a contract as incurred, since they are satisfied within &lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;year.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;i&gt;. &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exposed to significant credit risk due to the financial position of those institutions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#x2019;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#x2019;s products to retailers. The loss of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more of these large customers could have a material adverse effect on the Company&#x2019;s business, operating results or financial condition. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; charge interest or require collateral related to its accounts receivable. Credit terms are generally &lt;span style="-sec-ix-hidden:c117047243"&gt;thirty&lt;/span&gt;&#160;to &lt;span style="-sec-ix-hidden:c117047245"&gt;sixty&lt;/span&gt; days.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table presents customers that contributed more than &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; of gross revenue and accounts receivable&lt;i&gt;: &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Percentage of Gross Revenue&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Percentage of Accounts Receivable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer B&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer C&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Costs of Sales&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Costs of sales consists primarily of manufactured product cost, products acquired from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party manufacturers, freight, production, inventory write-downs,&#160;indirect manufacturing overhead costs and United States Food and Drug Administration&#160;(&#x201c;FDA&#x201d;) fees for commercialized products. Certain of the Company&#x2019;s sales activities depend on licensing arrangements that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company&#x2019;s &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party logistics companies are included in costs of sales.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company accounts for stock-based payment&#160;compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#x2019;s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#x201c;simplified method,&#x201d; which is the midpoint between the vesting date and the end of the contractual term and is&#160;utilized&#160;by the Company as it does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have sufficient historical data to determine a more reliable expected term estimate. The risk-free interest rate is based on the United States&#160;Treasury yield in effect at the time of the grant for the expected term of the award. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Employee Benefits Plan&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company&#160;has a &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k)&#160;plan&#160;(&#x201c;Aytu &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan&#x201d;), which&#160;allows participants to contribute a portion of their salary, subject to eligibility requirements and annual Internal Revenue Service (&#x201c;IRS&#x201d;) limits.&#160;The Aytu &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan&#160;matches 100% of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; 3% contributed by employees and matches 50% of the next 4% and 5% contributed by employees. The Company&#x2019;s match for the Aytu &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan was $0.7&#160;million for both of the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Research and development costs are expensed as incurred and include salaries and benefits;&#160;facilities costs;&#160;overhead costs;&#160;raw materials;&#160;laboratory and clinical supplies;&#160;clinical trial costs;&#160;contract services;&#160;milestone payments and fees paid to regulatory authorities for review and approval of the Company&#x2019;s product candidates;&#160;and other related costs.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to amortization.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; or (iv)&#160;expectations that the asset will more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Contingent Consideration&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The consideration for the Company's&#160;acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of &lt;span style="-sec-ix-hidden:c117047278"&gt;zero&lt;/span&gt; and $1.0 million for the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any contingent consideration recorded on its consolidated balance sheets as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Advertising and Direct Marketing Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Advertising and direct marketing costs consist&#160;of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $4.9&#160;million and $17.2&#160;million of advertising costs for the&#160;years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the&#160;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of its deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be utilized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Debt Discount and Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Debt issuance costs reflect fees paid to lenders and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties directly related to issuing debt. Debt discount&#160;and issuance costs related to term loans are reported as direct deductions&#160;to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition to interest expense. Debt issuance costs related to a revolving credit facility are classified as assets and subsequently amortized using the straight-line method over the term of the revolving credit facility as additional interest expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s operating segments engage in business activities from which it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Company&#x2019;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#x2019;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has &lt;span style="-sec-ix-hidden:c117047295"&gt;two&lt;/span&gt; reportable segments: the Rx Segment and the Consumer Health Segment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Paragraph IV Litigation Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Legal costs incurred by the Company in the enforcement of the Company&#x2019;s intellectual property rights are charged to expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Employee Retention Credit&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; March 27, 2020, &lt;/em&gt;the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) to provide certain relief as a result of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (&#x201c;ERC&#x201d;), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to &lt;em style="font: inherit;"&gt;70%&lt;/em&gt; of the qualified wages paid to employees after &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;through &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;As there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (&#x201c;IAS&#x201d;) &lt;em style="font: inherit;"&gt;20,&lt;/em&gt; Accounting for Government Grants and Disclosure of Government Assistance (&#x201c;IAS &lt;em style="font: inherit;"&gt;20&#x201d;&lt;/em&gt;). In accordance with IAS &lt;em style="font: inherit;"&gt;20,&lt;/em&gt; the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; Further in accordance with IAS &lt;em style="font: inherit;"&gt;20,&lt;/em&gt; when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended (the &#x201c;IRC&#x201d;), the ERC accrual shall be recognized as a benefit in other income in the consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company incurred a net loss and did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include common equivalent shares in the computation of diluted net loss&#160;per share because the effect would have been anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The following table sets forth securities excluded from the calculation of diluted earnings per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 56.3%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants to purchase common stock - liability classified&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;em style="font: inherit;"&gt;(Note 16)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;6,057,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,498,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Warrants to purchase common stock - equity classified&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 16)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,114&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,072&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee unvested restricted stock&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,996&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee unvested restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,249,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,636,773&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;b&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements &lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Financial Instruments - Credit Losses&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments&#x2014;Credit Losses&lt;/i&gt; (&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;), which requires the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2019. &lt;/em&gt;However, in &lt;em style="font: inherit;"&gt; October 2019, &lt;/em&gt;the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2022. &lt;/em&gt;The effective dates for the amendments in ASU &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; align with those of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; The Company adopted ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05&lt;/em&gt; on &lt;em style="font: inherit;"&gt; July 1, 2023. &lt;/em&gt;The Company evaluated the impact of adoption of ASUs &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; and concluded that the application of the new standards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Recent Accounting Pronouncements &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Yet Adopted&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Debt&lt;/i&gt;&#160;-&#160;&lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06,&lt;/em&gt; &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;)&#x2014;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company&#160;adopted the guidance on &lt;em style="font: inherit;"&gt; July 1, 2024, &lt;/em&gt;and the adoption of the standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; &lt;i&gt;Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&#x201d;&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods in fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Other than the application of IAS &lt;em style="font: inherit;"&gt;20&lt;/em&gt; for the ERC, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; significant changes to the Company&#x2019;s significant accounting policies and there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other accounting guidance has been issued and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet adopted that is applicable to the Company and that the Company expects would have a material effect on the Company&#x2019;s consolidated financial statements and&#160;related disclosures as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, and through the filing of this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050705">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Principals of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s consolidated financial statements&#160;and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050706">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s consolidated financial statements&#160;and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;)&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <aytu:GoingConcernPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050707">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Going Concern Determination&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the financial statements are available to be issued. The evaluation is based on relevant conditions and events that are known and reasonably knowable within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are available to be&#160;issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends. See&#160;&lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;&#x2013; Nature of Business and Financial Condition&lt;/i&gt;&#160;for further detail on the evaluation performed by the Company.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</aytu:GoingConcernPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2023-07-01_2024-06-30" id="c117050708">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from estimates. In the accompanying consolidated financial statements and notes thereto, estimates are used for, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2023-07-01_2024-06-30" id="c117050709">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Prior Period Reclassification&lt;/i&gt;&lt;/b&gt;&lt;i&gt;. &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Certain prior year amounts in the Company&#x2019;s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impact operating results or cash flows for the fiscal years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; or its financial position as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, or &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Previously Reported Prepaid Expenses Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company identified that certain of the Company&#x2019;s prepaid expenses totaling $1.8 million that were previously reported as current assets as of &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;should have been classified as non-current assets as of &lt;em style="font: inherit;"&gt; June 30, 2023. &lt;/em&gt;The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) Staff Accounting Bulletin &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99,&lt;/em&gt; &#x201c;Materiality&#x201d; and concluded that the omission was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to any of the previously issued consolidated financial statements and began reporting the prepaid expenses as non-current within this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i_2023-06-30_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis-ImmaterialErrorCorrectionOfPrepaidExpensesFromCurrentAssetToNoncurrentAssetMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="-5"
      id="c117047117"
      unitRef="USD">1800000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050710">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)&#160;insurance limits, and cash balances in the money market funds are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2023-07-01_2024-06-30" id="c117050711">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company&#x2019;s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company&#x2019;s customers&#x2019; financial condition;&#160;payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers&#160;and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts&#160;which were previously written off are&#160;recorded as a reduction of bad debt expense in the period the payment is collected. If the Company&#x2019;s actual collection experience changes, revisions to the&#160;Company&#x2019;s allowance for credit losses &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required. After attempts to collect a receivable have failed, the receivable is written off against the allowance for credit losses. The allowance for credit losses&#160;was &lt;span style="-sec-ix-hidden:c117047150"&gt;&lt;span style="-sec-ix-hidden:c117047154"&gt;zero&lt;/span&gt;&lt;/span&gt; for both years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The allowance for discounts was $0.6&#160;million and $1.8&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The allowance for chargebacks was $1.2&#160;million at both&#160;&lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The table below presents the opening and closing balances of accounts receivable, gross&#160;from customers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accounts Receivable, Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24,219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Increase in accounts receivable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,708&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;31,927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Decrease in accounts receivable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,439&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The table below details the change in allowance for discounts&#160;and allowance for chargebacks for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 55%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Allowance for Discounts&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Allowance for Chargebacks&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total Allowance&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,301&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,206&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,507&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;9,074&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,554&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;13,628&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,597&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,548&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(13,145&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,778&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,990&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,886&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3,812&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;8,698&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,842&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,866&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;640&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,182&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,822&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <aytu:AccountsReceivableAllowanceForDiscounts
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117047160"
      unitRef="USD">600000</aytu:AccountsReceivableAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForDiscounts
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c117047164"
      unitRef="USD">1800000</aytu:AccountsReceivableAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForPricingChargebacks
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117047170"
      unitRef="USD">1200000</aytu:AccountsReceivableAllowanceForPricingChargebacks>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740529">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accounts Receivable, Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24,219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Increase in accounts receivable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,708&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;31,927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Decrease in accounts receivable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,439&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c117047386"
      unitRef="USD">24219000</us-gaap:AccountsReceivableGross>
    <aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047387"
      unitRef="USD">7708000</aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:AccountsReceivableGross
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047388"
      unitRef="USD">31927000</us-gaap:AccountsReceivableGross>
    <aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047389"
      unitRef="USD">-6488000</aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:AccountsReceivableGross
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047390"
      unitRef="USD">25439000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740530">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 55%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Allowance for Discounts&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Allowance for Chargebacks&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total Allowance&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,301&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,206&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,507&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;9,074&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,554&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;13,628&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,597&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,548&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(13,145&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,778&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,990&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,886&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3,812&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;8,698&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,842&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,866&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balances, June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;640&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,182&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,822&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <aytu:AccountsReceivableAllowanceForDiscounts
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c117047396"
      unitRef="USD">1301000</aytu:AccountsReceivableAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForPricingChargebacks
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c117047397"
      unitRef="USD">1206000</aytu:AccountsReceivableAllowanceForPricingChargebacks>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c117047398"
      unitRef="USD">2507000</aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts>
    <aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047399"
      unitRef="USD">9074000</aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047400"
      unitRef="USD">4554000</aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047401"
      unitRef="USD">13628000</aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForDiscountsRecovery
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047402"
      unitRef="USD">-8597000</aytu:AccountsReceivableAllowanceForDiscountsRecovery>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksRecovery
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047403"
      unitRef="USD">-4548000</aytu:AccountsReceivableAllowanceForPricingChargebacksRecovery>
    <aytu:AccountsReceivableAllowanceForChargebackAndDiscountsRecovery
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047404"
      unitRef="USD">13145000</aytu:AccountsReceivableAllowanceForChargebackAndDiscountsRecovery>
    <aytu:AccountsReceivableAllowanceForDiscounts
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047405"
      unitRef="USD">1778000</aytu:AccountsReceivableAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForPricingChargebacks
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047406"
      unitRef="USD">1212000</aytu:AccountsReceivableAllowanceForPricingChargebacks>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117047407"
      unitRef="USD">2990000</aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts>
    <aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047408"
      unitRef="USD">4886000</aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047409"
      unitRef="USD">3812000</aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047410"
      unitRef="USD">8698000</aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscountCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForDiscountsRecovery
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047411"
      unitRef="USD">-6024000</aytu:AccountsReceivableAllowanceForDiscountsRecovery>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksRecovery
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047412"
      unitRef="USD">-3842000</aytu:AccountsReceivableAllowanceForPricingChargebacksRecovery>
    <aytu:AccountsReceivableAllowanceForChargebackAndDiscountsRecovery
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047413"
      unitRef="USD">9866000</aytu:AccountsReceivableAllowanceForChargebackAndDiscountsRecovery>
    <aytu:AccountsReceivableAllowanceForDiscounts
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117047414"
      unitRef="USD">640000</aytu:AccountsReceivableAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForPricingChargebacks
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047415"
      unitRef="USD">1182000</aytu:AccountsReceivableAllowanceForPricingChargebacks>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047416"
      unitRef="USD">1822000</aytu:AccountsReceivableAllowanceForPricingChargebacksAndDiscounts>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050712">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; alternate uses for the inventory, the Company will record a charge to cost of sales to reduce the value of the inventory to net realizable value in the period the impairment is identified.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050713">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally &lt;span style="-sec-ix-hidden:c117047191"&gt;two&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c117047194"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050714">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#x201c;ROU&#x201d;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily determinable based upon the information available at the lease commencement date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#x2019;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#x2019;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operating leases are included in other liabilities in the Company&#x2019;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of&#160;debt and debt, net of current portion in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2023-07-01_2024-06-30" id="c117050715">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Acquisitions&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in goodwill.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201d;&lt;/em&gt;) and ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201d;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050716">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company generates revenue from product sales through its Rx Segment&#160;and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;identify the contract with the customer; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;identify the performance obligations; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;)&#160;determine the transaction price; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;)&#160;allocate the transaction price to the performance obligations; and (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a recognized financing component related to product sales.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Rx Segment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#x201c;free-on-board&#x201d; destination when shipped domestically within the United States and &#x201c;free-on-board&#x201d; shipping point when shipped internationally consistent with the contractual terms.&#160;The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within &lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;year.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Rx Segment net&#160;revenue is recognized net of consideration paid to the Company&#x2019;s customers and other adjustments to the transaction price (known as &#x201c;Gross to Net&#x201d; adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Gross to Net adjustments include:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Savings offers.&lt;/i&gt;&#160;The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Prompt payment discounts.&lt;/i&gt;&#160;Prompt payment discounts are based on standard provisions of wholesalers&#x2019;&#160;services.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Wholesale distribution fees.&#160;&lt;/i&gt;Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#x2019;s products by wholesalers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Rebates.&#160;&lt;/i&gt;The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Wholesaler chargebacks.&lt;/i&gt;&#160;The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#x2019;&#160;end customers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Returns.&lt;/i&gt;&#160;Wholesalers&#x2019;&#160;contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months prior to expiry date to &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; follow historical trends. The Company&#x2019;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe variances between actual and estimated amounts have been material.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Consumer Health Segment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Consumer Health Segment, which was divested of&#160;in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; had net revenue which was from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue was&#160;generally recognized &#x201c;free-on-board&#x201d; shipping point, as those were&#160;the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer were&#160;excluded from net revenue. Shipping and handling costs associated with outbound freight after control over a product had&#160;transferred to a customer were accounted for as a fulfillment cost and were&#160;included in cost of sales.&#160;The Company expensed&#160;the incremental costs to obtain a contract as incurred, since they are satisfied within &lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;year.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2023-07-01_2024-06-30" id="c117050717">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;i&gt;. &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exposed to significant credit risk due to the financial position of those institutions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#x2019;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#x2019;s products to retailers. The loss of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more of these large customers could have a material adverse effect on the Company&#x2019;s business, operating results or financial condition. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; charge interest or require collateral related to its accounts receivable. Credit terms are generally &lt;span style="-sec-ix-hidden:c117047243"&gt;thirty&lt;/span&gt;&#160;to &lt;span style="-sec-ix-hidden:c117047245"&gt;sixty&lt;/span&gt; days.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table presents customers that contributed more than &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; of gross revenue and accounts receivable&lt;i&gt;: &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Percentage of Gross Revenue&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Percentage of Accounts Receivable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer B&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer C&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740531">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Percentage of Gross Revenue&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Percentage of Accounts Receivable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer B&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Customer C&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"
      decimals="2"
      id="c117047429"
      unitRef="Pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"
      decimals="2"
      id="c117047430"
      unitRef="Pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"
      decimals="1"
      id="c117047431"
      unitRef="Pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"
      decimals="1"
      id="c117047432"
      unitRef="Pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"
      decimals="1"
      id="c117047433"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"
      decimals="2"
      id="c117047434"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"
      decimals="2"
      id="c117047435"
      unitRef="Pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"
      decimals="2"
      id="c117047436"
      unitRef="Pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"
      decimals="2"
      id="c117047437"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"
      decimals="2"
      id="c117047438"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2023-07-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"
      decimals="2"
      id="c117047439"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-07-01_2023-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember"
      decimals="2"
      id="c117047440"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050718">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Costs of Sales&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Costs of sales consists primarily of manufactured product cost, products acquired from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party manufacturers, freight, production, inventory write-downs,&#160;indirect manufacturing overhead costs and United States Food and Drug Administration&#160;(&#x201c;FDA&#x201d;) fees for commercialized products. Certain of the Company&#x2019;s sales activities depend on licensing arrangements that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company&#x2019;s &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party logistics companies are included in costs of sales.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2023-07-01_2024-06-30" id="c117050719">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company accounts for stock-based payment&#160;compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#x2019;s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#x201c;simplified method,&#x201d; which is the midpoint between the vesting date and the end of the contractual term and is&#160;utilized&#160;by the Company as it does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have sufficient historical data to determine a more reliable expected term estimate. The risk-free interest rate is based on the United States&#160;Treasury yield in effect at the time of the grant for the expected term of the award. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy contextRef="d_2023-07-01_2024-06-30" id="c117050720">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Employee Benefits Plan&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company&#160;has a &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k)&#160;plan&#160;(&#x201c;Aytu &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan&#x201d;), which&#160;allows participants to contribute a portion of their salary, subject to eligibility requirements and annual Internal Revenue Service (&#x201c;IRS&#x201d;) limits.&#160;The Aytu &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan&#160;matches 100% of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; 3% contributed by employees and matches 50% of the next 4% and 5% contributed by employees. The Company&#x2019;s match for the Aytu &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan was $0.7&#160;million for both of the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-FirstThreePercentContributionByEmployeesMember"
      decimals="0"
      id="c117047258"
      unitRef="Pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-FirstThreePercentContributionByEmployeesMember"
      decimals="2"
      id="c117047261"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentAndFivePercentContributionByEmployeesMember"
      decimals="1"
      id="c117047262"
      unitRef="Pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFourPercentContributionByEmployeesMember"
      decimals="2"
      id="c117047264"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2023-07-01_2024-06-30_RetirementPlanNameAxis-NeosPlanMember_StatementScenarioAxis-NextFivePercentContributionByEmployeesMember"
      decimals="2"
      id="c117047265"
      unitRef="Pure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117047268"
      unitRef="USD">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2023-07-01_2024-06-30" id="c117050721">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Research and development costs are expensed as incurred and include salaries and benefits;&#160;facilities costs;&#160;overhead costs;&#160;raw materials;&#160;laboratory and clinical supplies;&#160;clinical trial costs;&#160;contract services;&#160;milestone payments and fees paid to regulatory authorities for review and approval of the Company&#x2019;s product candidates;&#160;and other related costs.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="d_2023-07-01_2024-06-30" id="c117050722">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to amortization.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050723">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; or (iv)&#160;expectations that the asset will more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <aytu:BusinessCombinationsContingentConsiderationPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050724">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Contingent Consideration&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The consideration for the Company's&#160;acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of &lt;span style="-sec-ix-hidden:c117047278"&gt;zero&lt;/span&gt; and $1.0 million for the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any contingent consideration recorded on its consolidated balance sheets as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</aytu:BusinessCombinationsContingentConsiderationPolicyTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-6"
      id="c117047280"
      unitRef="USD">-1000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050725">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Advertising and Direct Marketing Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Advertising and direct marketing costs consist&#160;of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $4.9&#160;million and $17.2&#160;million of advertising costs for the&#160;years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117047286"
      unitRef="USD">4900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-5"
      id="c117047287"
      unitRef="USD">17200000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050726">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the&#160;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of its deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be utilized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050727">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Debt Discount and Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Debt issuance costs reflect fees paid to lenders and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties directly related to issuing debt. Debt discount&#160;and issuance costs related to term loans are reported as direct deductions&#160;to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition to interest expense. Debt issuance costs related to a revolving credit facility are classified as assets and subsequently amortized using the straight-line method over the term of the revolving credit facility as additional interest expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050728">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s operating segments engage in business activities from which it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Company&#x2019;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#x2019;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has &lt;span style="-sec-ix-hidden:c117047295"&gt;two&lt;/span&gt; reportable segments: the Rx Segment and the Consumer Health Segment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050729">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Paragraph IV Litigation Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Legal costs incurred by the Company in the enforcement of the Company&#x2019;s intellectual property rights are charged to expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="d_2023-07-01_2024-06-30" id="c117050730">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <aytu:EmployeeRetentionCreditPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050731">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Employee Retention Credit&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; March 27, 2020, &lt;/em&gt;the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) to provide certain relief as a result of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (&#x201c;ERC&#x201d;), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to &lt;em style="font: inherit;"&gt;70%&lt;/em&gt; of the qualified wages paid to employees after &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;through &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;As there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard (&#x201c;IAS&#x201d;) &lt;em style="font: inherit;"&gt;20,&lt;/em&gt; Accounting for Government Grants and Disclosure of Government Assistance (&#x201c;IAS &lt;em style="font: inherit;"&gt;20&#x201d;&lt;/em&gt;). In accordance with IAS &lt;em style="font: inherit;"&gt;20,&lt;/em&gt; the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; Further in accordance with IAS &lt;em style="font: inherit;"&gt;20,&lt;/em&gt; when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended (the &#x201c;IRC&#x201d;), the ERC accrual shall be recognized as a benefit in other income in the consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</aytu:EmployeeRetentionCreditPolicyTextBlock>
    <aytu:EmployeeRetentionCredit
      contextRef="i_2024-03-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-5"
      id="c117047306"
      unitRef="USD">3800000</aytu:EmployeeRetentionCredit>
    <aytu:EmployeeRetentionCreditVendorFee
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-5"
      id="c117047313"
      unitRef="USD">400000</aytu:EmployeeRetentionCreditVendorFee>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050732">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company incurred a net loss and did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include common equivalent shares in the computation of diluted net loss&#160;per share because the effect would have been anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The following table sets forth securities excluded from the calculation of diluted earnings per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 56.3%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants to purchase common stock - liability classified&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;em style="font: inherit;"&gt;(Note 16)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;6,057,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,498,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Warrants to purchase common stock - equity classified&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 16)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,114&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,072&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee unvested restricted stock&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,996&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee unvested restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,249,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,636,773&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740532">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 56.3%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13.7%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants to purchase common stock - liability classified&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;em style="font: inherit;"&gt;(Note 16)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;6,057,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,498,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Warrants to purchase common stock - equity classified&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 16)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,114&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,072&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee unvested restricted stock&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,996&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee unvested restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;em style="font: inherit;"&gt;(Note 15)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,249,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,636,773&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember"
      decimals="INF"
      id="c117047448"
      unitRef="Share">6057766</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-LiabilityWarrantsMember"
      decimals="INF"
      id="c117047449"
      unitRef="Share">6498980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember"
      decimals="INF"
      id="c117047451"
      unitRef="Share">18114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EquityWarrantsMember"
      decimals="INF"
      id="c117047452"
      unitRef="Share">39072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c117047454"
      unitRef="Share">146539</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c117047455"
      unitRef="Share">52762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"
      decimals="INF"
      id="c117047457"
      unitRef="Share">25360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember"
      decimals="INF"
      id="c117047458"
      unitRef="Share">40996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117047460"
      unitRef="Share">1775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117047461"
      unitRef="Share">4963</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117047463"
      unitRef="Share">6249554</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-07-01_2023-06-30"
      decimals="INF"
      id="c117047464"
      unitRef="Share">6636773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2023-07-01_2024-06-30" id="c117050733">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements &lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Financial Instruments - Credit Losses&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments&#x2014;Credit Losses&lt;/i&gt; (&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;), which requires the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard was effective for interim and annual reporting periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2019. &lt;/em&gt;However, in &lt;em style="font: inherit;"&gt; October 2019, &lt;/em&gt;the FASB approved deferral of the adoption date for smaller reporting companies for fiscal periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2022. &lt;/em&gt;The effective dates for the amendments in ASU &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; align with those of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; The Company adopted ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05&lt;/em&gt; on &lt;em style="font: inherit;"&gt; July 1, 2023. &lt;/em&gt;The Company evaluated the impact of adoption of ASUs &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; and concluded that the application of the new standards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Recent Accounting Pronouncements &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Yet Adopted&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Debt&lt;/i&gt;&#160;-&#160;&lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06,&lt;/em&gt; &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;)&#x2014;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company&#160;adopted the guidance on &lt;em style="font: inherit;"&gt; July 1, 2024, &lt;/em&gt;and the adoption of the standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; &lt;i&gt;Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&#x201d;&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods in fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Other than the application of IAS &lt;em style="font: inherit;"&gt;20&lt;/em&gt; for the ERC, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; significant changes to the Company&#x2019;s significant accounting policies and there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other accounting guidance has been issued and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet adopted that is applicable to the Company and that the Company expects would have a material effect on the Company&#x2019;s consolidated financial statements and&#160;related disclosures as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, and through the filing of this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740533">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; - Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company disaggregates its revenue into &lt;span style="-sec-ix-hidden:c117047466"&gt;two&lt;/span&gt; segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys&#160;and Cotempla; and the Pediatric Portfolio, comprised of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. The Company completed its&#160;wind down of the Consumer Health Segment and entered into a definitive agreement to effect the&#160;Consumer Health Divestiture in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal&#160;&lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Consumer Health Segment was&#160;comprised of over &lt;span style="-sec-ix-hidden:c117047469"&gt;ten&lt;/span&gt; consumer health products.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Revenues by Segment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Net revenue disaggregated by segment for the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, were as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Rx Segment net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;73,799&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Consumer Health Segment net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;33,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;81,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Revenues by Product Portfolio&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, were as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;ADHD Portfolio net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;57,784&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,855&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Pediatric Portfolio net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,280&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,377&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;119&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,567&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total Rx Segment net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;65,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;73,799&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment was&#160;comprised of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; product portfolio.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Revenues by Geographic Location&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Net revenue disaggregated by geographic location as determined by the billing address of the Company&#x2019;s customers for the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, were as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;United States net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80,911&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;106,918&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;International net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;481&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;81,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="d_2023-07-01_2024-06-30"
      id="c4EAECB60-5F52-4462-AD27-373E4052829A">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Rx Segment net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;73,799&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Consumer Health Segment net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;33,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;81,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;ADHD Portfolio net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;57,784&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,855&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Pediatric Portfolio net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,280&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,377&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;119&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,567&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total Rx Segment net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;65,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;73,799&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047481"
      unitRef="USD">65183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047482"
      unitRef="USD">73799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117047483"
      unitRef="USD">15819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-5"
      id="c117047484"
      unitRef="USD">33600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047485"
      unitRef="USD">81002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047486"
      unitRef="USD">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047493"
      unitRef="USD">57784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_ProductOrServiceAxis-AdhdPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047494"
      unitRef="USD">46855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-4"
      id="c117047495"
      unitRef="USD">7280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ThePediatricPortfolioMember_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047496"
      unitRef="USD">25377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047497"
      unitRef="USD">119000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_ProductOrServiceAxis-ProductAndServiceOtherMember_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047498"
      unitRef="USD">1567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047499"
      unitRef="USD">65183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117047500"
      unitRef="USD">73799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740536">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;United States net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80,911&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;106,918&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;International net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;481&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;81,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementGeographicalAxis-US"
      decimals="-3"
      id="c117047507"
      unitRef="USD">80911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementGeographicalAxis-US"
      decimals="-3"
      id="c117047508"
      unitRef="USD">106918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementGeographicalAxis-NonUsMember"
      decimals="-3"
      id="c117047509"
      unitRef="USD">91000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementGeographicalAxis-NonUsMember"
      decimals="-3"
      id="c117047510"
      unitRef="USD">481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047511"
      unitRef="USD">81002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047512"
      unitRef="USD">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740537">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; - Inventories&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Inventories consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Raw materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;266&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,301&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Work in process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,725&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,642&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,738&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,995&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company incurred inventory write-downs of&#160;$2.3&#160;million for the year ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;primarily a result of unsalable and slow-moving products&#160;and a $0.7&#160;million write-down as part of the wind down of the Consumer Health Segment.&#160;The Company incurred inventory write-downs of $2.4&#160;million for the year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;primarily as a result of unsalable and slow-moving products.&lt;/p&gt;
  </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740538">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Raw materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;266&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,301&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Work in process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,725&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,642&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,738&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,995&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047522"
      unitRef="USD">266000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047523"
      unitRef="USD">1301000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047524"
      unitRef="USD">5725000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047525"
      unitRef="USD">2956000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047526"
      unitRef="USD">6642000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047527"
      unitRef="USD">7738000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047528"
      unitRef="USD">12633000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047529"
      unitRef="USD">11995000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117047514"
      unitRef="USD">2300000</us-gaap:InventoryWriteDown>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"
      decimals="-5"
      id="c117047515"
      unitRef="USD">700000</us-gaap:RestructuringCosts>
    <us-gaap:InventoryWriteDown
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-5"
      id="c117047516"
      unitRef="USD">2400000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740539">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; - Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Property and equipment, net consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,117&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,433&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Office equipment, furniture and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;945&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lab equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;721&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;832&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;999&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Assets under construction&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;107&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Property and equipment, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,818&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,496&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,681&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;693&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,815&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Depreciation expense was $0.9&#160;million and $1.3&#160;million during the&#160;years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, respectively. During the year ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company did &lt;span style="-sec-ix-hidden:c117047534"&gt;not&lt;/span&gt; record a material gain or loss on disposal of equipment and during the year ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, the Company recognized a gain of $0.1 million on the disposal of equipment.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740540">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,117&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,433&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Office equipment, furniture and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;945&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lab equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;721&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;832&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;999&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Assets under construction&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;107&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Property and equipment, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,818&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,496&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,681&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;693&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,815&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"
      decimals="-3"
      id="c117047542"
      unitRef="USD">1117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"
      decimals="-3"
      id="c117047543"
      unitRef="USD">2433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember"
      decimals="-3"
      id="c117047544"
      unitRef="USD">945000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentFurnitureAndOtherMember"
      decimals="-3"
      id="c117047545"
      unitRef="USD">1125000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember"
      decimals="-3"
      id="c117047546"
      unitRef="USD">721000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LabEquipmentMember"
      decimals="-3"
      id="c117047547"
      unitRef="USD">832000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c117047548"
      unitRef="USD">35000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c117047549"
      unitRef="USD">999000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember"
      decimals="-3"
      id="c117047550"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-AssetUnderConstructionMember"
      decimals="-3"
      id="c117047551"
      unitRef="USD">107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047552"
      unitRef="USD">2818000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047553"
      unitRef="USD">5496000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047554"
      unitRef="USD">2125000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047555"
      unitRef="USD">3681000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047556"
      unitRef="USD">693000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047557"
      unitRef="USD">1815000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117047531"
      unitRef="USD">900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-5"
      id="c117047532"
      unitRef="USD">1300000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-5"
      id="c117047535"
      unitRef="USD">100000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <aytu:LeasesDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740541">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; - Leases&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases were for equipment. These leases have original lease periods expiring between &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2030.&lt;/em&gt; Most leases include option provisions under which the parties &lt;em style="font: inherit;"&gt; may &lt;/em&gt;extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company&#x2019;s lease agreements generally do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contain any material residual value guarantees or material restrictive covenants. The Company had no remaining finance leases recorded as of &lt;em style="font: inherit;"&gt; June 30, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $3.5 million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, a borrowing rate of 6.7% was used to determine the present value of future lease payments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;During the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; as part&#160;of the previously announced wind down of the Consumer Health Segment and the closure of the&#160;Grand Prairie, Texas manufacturing site, the Company ceased using the Oceanside, California warehouse and the Grand Prairie, Texas manufacturing facility. As a result, the Company&#160;wrote off the remaining related operating lease ROU assets. The lease for the Oceanside, California warehouse and the&#160;Grand Prairie, Texas manufacturing site are&#160;set to&#160;expire on &lt;em style="font: inherit;"&gt; December 31, 2026, &lt;/em&gt;and on &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2024, &lt;/em&gt;the Company entered into a forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;from the owner of the office space that the Company is&#160;currently renting under a sublease arrangement. The Company has determined that it is an operating lease, and that lease commencement occurred in &lt;em style="font: inherit;"&gt; July 2024. &lt;/em&gt;The&#160;initial lease termination date is&#160;&lt;em style="font: inherit;"&gt; July 31, 2030, &lt;/em&gt;and under the lease agreement the Company has &lt;em style="font: inherit;"&gt;one five&lt;/em&gt;-year renewal option to extend the lease through &lt;em style="font: inherit;"&gt; July 2035.&#160;&lt;/em&gt;Undiscounted minimum monthly rent payments average approximately $13,000&#160;over the initial term of the lease. The Company has elected to utilize the practical expedient to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company will record an operating lease ROU asset of $0.5 million and a lease liability of $0.5 million at lease commencement in &lt;em style="font: inherit;"&gt; July 2024.&#160;&lt;/em&gt;The ROU asset and lease liability will be&#160;recorded at present value using an incremental borrowing rate of 12.3%.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; May 2023, &lt;/em&gt;the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in &lt;em style="font: inherit;"&gt; September 2023 (&lt;/em&gt;lease commencement) with an initial term of &lt;span style="-sec-ix-hidden:c117047576"&gt;five&lt;/span&gt; and a half years. The Company recorded an operating lease ROU asset of $0.8&#160;million and a lease liability of $0.8&#160;million at lease commencement. The ROU asset and lease liability were recorded at present value using an incremental borrowing rate of 10.3%. The Company utilized the practical expedient to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separate lease and non-lease components upon recognition. See&#160;&lt;i&gt;Note &lt;em style="font: inherit;"&gt;18&lt;/em&gt; &#x2013; Commitments and Contingencies &lt;/i&gt;for further detail.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The components of lease expenses are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Statement of Operations Classification&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease cost:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,402&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Operating expenses&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Short-term lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;94&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;97&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Operating expenses&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease cost:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Amortization of leased assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Cost of sales&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Interest on lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Interest expense&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,397&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 34%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance Sheet Classification&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;829&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Operating lease right-of-use assets&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047624"&gt;&lt;span style="-sec-ix-hidden:c117047625"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;829&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,213&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 34%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;712&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,258&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047635"&gt;&lt;span style="-sec-ix-hidden:c117047636"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047641"&gt;&lt;span style="-sec-ix-hidden:c117047642"&gt;Current portion of debt&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Non-current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;577&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;832&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047648"&gt;&lt;span style="-sec-ix-hidden:c117047649"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,289&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,175&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The remaining weighted-average lease term and discount rate used are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average remaining lease term (years):&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average discount rate:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Supplemental cash flow information related to leases is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash flow classification of lease payments:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating cash flows from operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,812&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,436&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating cash flows from finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Financing cash flows from finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;96&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the&#160;Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any remaining finance leases. As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the&#160;Company&#x2019;s future minimum operating lease payments, including the new forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;were as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;970&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;377&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2029&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;359&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;249&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Less: imputed interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(555&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,185&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &#160;&#160;
  </aytu:LeasesDisclosureTextBlock>
    <us-gaap:FinanceLeaseLiability
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047562"
      unitRef="USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember"
      decimals="-5"
      id="c117047563"
      unitRef="USD">3500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i_2021-03-19_LeaseContractualTermAxis-OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember"
      decimals="3"
      id="c117047566"
      unitRef="Pure">0.067</us-gaap:LesseeOperatingLeaseDiscountRate>
    <aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment
      contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"
      decimals="INF"
      id="c117047571"
      unitRef="USD">13000</aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"
      decimals="-5"
      id="c117047573"
      unitRef="USD">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"
      decimals="-5"
      id="c117047574"
      unitRef="USD">500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"
      decimals="3"
      id="c117047575"
      unitRef="Pure">0.123</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      decimals="-5"
      id="c117047577"
      unitRef="USD">800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      decimals="-5"
      id="c117047578"
      unitRef="USD">800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      decimals="3"
      id="c117047579"
      unitRef="Pure">0.103</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="d_2023-07-01_2024-06-30"
      id="c57B29103-9D65-430D-B01E-5455C7FE5F5A">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Statement of Operations Classification&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease cost:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,402&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Operating expenses&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Short-term lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;94&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;97&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Operating expenses&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease cost:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Amortization of leased assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Cost of sales&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Interest on lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Interest expense&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,397&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average remaining lease term (years):&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average discount rate:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash flow classification of lease payments:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating cash flows from operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,812&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,436&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating cash flows from finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Financing cash flows from finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;96&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OperatingExpenseMember"
      decimals="-3"
      id="c117047595"
      unitRef="USD">2247000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OperatingExpenseMember"
      decimals="-3"
      id="c117047596"
      unitRef="USD">1402000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OperatingExpenseMember"
      decimals="-3"
      id="c117047598"
      unitRef="USD">94000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OperatingExpenseMember"
      decimals="-3"
      id="c117047599"
      unitRef="USD">97000</us-gaap:ShortTermLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember"
      decimals="-3"
      id="c117047602"
      unitRef="USD">53000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-CostOfSalesMember"
      decimals="-3"
      id="c117047603"
      unitRef="USD">66000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-OtherExpenseMember"
      decimals="-3"
      id="c117047605"
      unitRef="USD">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-OtherExpenseMember"
      decimals="-3"
      id="c117047606"
      unitRef="USD">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047608"
      unitRef="USD">2397000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047609"
      unitRef="USD">1574000</us-gaap:LeaseCost>
    <aytu:ScheduleOfLeaseByBalanceSheetInformationTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740543">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 34%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance Sheet Classification&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;829&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Operating lease right-of-use assets&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Finance lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047624"&gt;&lt;span style="-sec-ix-hidden:c117047625"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;829&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,213&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 34%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;712&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,258&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047635"&gt;&lt;span style="-sec-ix-hidden:c117047636"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047641"&gt;&lt;span style="-sec-ix-hidden:c117047642"&gt;Current portion of debt&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Non-current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;577&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;832&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c117047648"&gt;&lt;span style="-sec-ix-hidden:c117047649"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,289&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,175&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 34%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </aytu:ScheduleOfLeaseByBalanceSheetInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047618"
      unitRef="USD">829000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047619"
      unitRef="USD">2054000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047621"
      unitRef="USD">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047622"
      unitRef="USD">159000</us-gaap:FinanceLeaseRightOfUseAsset>
    <aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047627"
      unitRef="USD">829000</aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset>
    <aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047628"
      unitRef="USD">2213000</aytu:OperatingLeaseAndFinanceLeaseRightofuseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047632"
      unitRef="USD">712000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047633"
      unitRef="USD">1258000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047638"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047639"
      unitRef="USD">85000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047645"
      unitRef="USD">577000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047646"
      unitRef="USD">832000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <aytu:OperatingLeaseAndFinanceLeaseLiability
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047651"
      unitRef="USD">1289000</aytu:OperatingLeaseAndFinanceLeaseLiability>
    <aytu:OperatingLeaseAndFinanceLeaseLiability
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047652"
      unitRef="USD">2175000</aytu:OperatingLeaseAndFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2024-06-30" id="c117047659">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2023-06-30" id="c117047660">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2023-06-30" id="c117047662">P0Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2024-06-30"
      decimals="1"
      id="c117047664"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2023-06-30"
      decimals="3"
      id="c117047665"
      unitRef="Pure">0.078</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2024-06-30"
      decimals="0"
      id="c117047666"
      unitRef="Pure">0</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2023-06-30"
      decimals="3"
      id="c117047667"
      unitRef="Pure">0.065</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047669"
      unitRef="USD">1812000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047670"
      unitRef="USD">1436000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047671"
      unitRef="USD">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047672"
      unitRef="USD">9000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117047673"
      unitRef="USD">85000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117047674"
      unitRef="USD">96000</us-gaap:FinanceLeasePrincipalPayments>
    <aytu:LesseeLiabilityMaturityTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740546">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;970&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;377&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2029&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;359&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;249&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Less: imputed interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(555&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,185&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </aytu:LesseeLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117047676"
      unitRef="USD">970000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047677"
      unitRef="USD">399000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047678"
      unitRef="USD">377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047679"
      unitRef="USD">386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047680"
      unitRef="USD">359000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047681"
      unitRef="USD">249000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <aytu:LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117047682"
      unitRef="USD">2740000</aytu:LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047683"
      unitRef="USD">555000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <aytu:OperatingLeaseLiabilityIncludingLeaseNotYetCommenced
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047684"
      unitRef="USD">2185000</aytu:OperatingLeaseLiabilityIncludingLeaseNotYetCommenced>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740547">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; - Intangible Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;A summary of the Company&#x2019;s intangible assets&#160;as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, and &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;,&#160;is as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross Carrying Amount&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated Amortization&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Net Carrying Amount&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average Remaining Life&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired product technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,268&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(13,184&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,084&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,831&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;24,369&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total definite-lived intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;71,468&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(19,015&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;52,453&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-Average Remaining Life&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired product technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,176&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10,881&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31,295&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;26,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired product distribution rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,207&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,678&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,529&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total definite-lived intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;78,583&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(19,613&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;58,970&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with &lt;span style="-sec-ix-hidden:c117047687"&gt;zero&lt;/span&gt; net carrying amount at the end of a reporting period is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; presented in the table of a future reporting period. Certain of the Company&#x2019;s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $6.5&#160;million and $6.1&#160;million for the&#160;years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table summarizes the estimated future amortization expense of intangible assets to be recognized over the next&#160;&lt;em style="font: inherit;"&gt;five&lt;/em&gt; years and periods thereafter:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2029&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,508&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total future amortization expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;52,453&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Acquired Product Technology Rights&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisition&#160;of the Pediatric Portfolio in &lt;em style="font: inherit;"&gt; November 2019 &lt;/em&gt;and the Neos Acquisition in &lt;em style="font: inherit;"&gt; March 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Karbinal&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (&#x201c;Tris&#x201d;) for the exclusive rights to commercialize Karbinal&#160;in the United States (the &#x201c;Tris Karbinal Agreement&#x201d;). The Tris Karbinal Agreement&#x2019;s initial term terminates in &lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;of &lt;em style="font: inherit;"&gt;2033,&lt;/em&gt; with an optional initial 20-year extension.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Poly-Vi-Flor&lt;/i&gt;&#160;&lt;i&gt;and Tri-Vi-Flor&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the &#x201c;Poly-Tri Agreements&#x201d;) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;ADHD Portfolio&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys&#160;and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 16&#160;years.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Acquired Technology Right&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;TRRP Proprietary Technology&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As part of the Neos Acquisition, the Company acquired time release resin particle (&#x201c;TRRP&#x201d;) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Acquired Product Distribution Rights&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In connection with the acquisition of Innovus Pharmaceuticals, Inc. (&#x201c;Innovus&#x201d;)&#160;in &lt;em style="font: inherit;"&gt; February 2020 (&lt;/em&gt;the &#x201c;Innovus Acquisition&#x201d;), the Company obtained &lt;em style="font: inherit;"&gt;35&lt;/em&gt; products with a combination of over &lt;em style="font: inherit;"&gt;300&lt;/em&gt; registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. During the fiscal year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;this intangible asset was &lt;span style="-sec-ix-hidden:c117047702"&gt;impaired&lt;/span&gt; by $3.0 million due to the discontinuance of products in the Consumer Health Segment.&#160;As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;this intangible asset was fully amortized and removed from gross carrying value.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Acquired In-Process R&amp;amp;D&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;IPR&amp;amp;D &lt;/i&gt;&#x2013;&lt;i&gt; &lt;em style="font: inherit;"&gt;NT0502&lt;/em&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As part of the Neos Acquisition, the Company acquired in-process research and development associated with &lt;em style="font: inherit;"&gt;NT0502,&lt;/em&gt; a new chemical entity that was&#160;being developed for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;the Company terminated its development program of &lt;em style="font: inherit;"&gt;NT0502.&lt;/em&gt; As a result, the Company fully impaired the IPR&amp;amp;D of &lt;em style="font: inherit;"&gt;NT0502,&lt;/em&gt; recording impairment expense of $2.6 million to its Rx Segment during the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="d_2023-07-01_2024-06-30"
      id="c0115E975-B607-4B4E-A887-E59765D086EF">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross Carrying Amount&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated Amortization&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Net Carrying Amount&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-Average Remaining Life&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired product technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,268&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(13,184&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,084&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,831&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;24,369&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total definite-lived intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;71,468&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(19,015&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;52,453&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-Average Remaining Life&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired product technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,176&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10,881&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31,295&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired technology rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;26,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Acquired product distribution rights&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,207&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,678&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,529&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total definite-lived intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;78,583&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(19,613&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;58,970&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      decimals="-3"
      id="c117047720"
      unitRef="USD">41268000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      decimals="-3"
      id="c117047721"
      unitRef="USD">13184000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      decimals="-3"
      id="c117047722"
      unitRef="USD">28084000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      id="c117047723">P10Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      decimals="-5"
      id="c117047724"
      unitRef="USD">30200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      decimals="-3"
      id="c117047725"
      unitRef="USD">5831000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      decimals="-3"
      id="c117047726"
      unitRef="USD">24369000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      id="c117047727">P13Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047728"
      unitRef="USD">71468000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047729"
      unitRef="USD">19015000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047730"
      unitRef="USD">52453000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="i_2024-06-30" id="c117047731">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      decimals="-3"
      id="c117047732"
      unitRef="USD">42176000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      decimals="-3"
      id="c117047733"
      unitRef="USD">10881000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      decimals="-3"
      id="c117047734"
      unitRef="USD">31295000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TechnologyBasedIntangibleAssetsMember"
      id="c117047735">P11Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      decimals="-5"
      id="c117047736"
      unitRef="USD">30200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      decimals="-3"
      id="c117047737"
      unitRef="USD">4054000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      decimals="-3"
      id="c117047738"
      unitRef="USD">26146000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember"
      id="c117047739">P14Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember"
      decimals="-3"
      id="c117047740"
      unitRef="USD">6207000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember"
      decimals="-3"
      id="c117047741"
      unitRef="USD">4678000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember"
      decimals="-3"
      id="c117047742"
      unitRef="USD">1529000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember"
      id="c117047743">P1Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047744"
      unitRef="USD">78583000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047745"
      unitRef="USD">19613000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117047746"
      unitRef="USD">58970000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="i_2023-06-30" id="c117047747">P12Y8M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <aytu:FinitelivedIntangibleAssetUsefulLifeRenewablePeriod
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-MinimumMember"
      id="c117047689">P1Y</aytu:FinitelivedIntangibleAssetUsefulLifeRenewablePeriod>
    <aytu:FinitelivedIntangibleAssetUsefulLifeRenewablePeriod
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-MaximumMember"
      id="c117047690">P20Y</aytu:FinitelivedIntangibleAssetUsefulLifeRenewablePeriod>
    <aytu:AmortizationExpenseOfIntangibleAssets
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117047691"
      unitRef="USD">6500000</aytu:AmortizationExpenseOfIntangibleAssets>
    <aytu:AmortizationExpenseOfIntangibleAssets
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-5"
      id="c117047692"
      unitRef="USD">6100000</aytu:AmortizationExpenseOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740550">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2029&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,508&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total future amortization expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;52,453&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047749"
      unitRef="USD">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047750"
      unitRef="USD">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047751"
      unitRef="USD">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047752"
      unitRef="USD">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047753"
      unitRef="USD">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047754"
      unitRef="USD">27508000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047755"
      unitRef="USD">52453000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <aytu:SupplyAndDistributionAgreementExtensionTerm
      contextRef="d_2022-07-01_2023-06-30_CounterpartyNameAxis-TrisKarbinalAgreementMember"
      id="c117047696">P20Y</aytu:SupplyAndDistributionAgreementExtensionTerm>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2023-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentedTechnologyMember_StatementBusinessSegmentsAxis-AdhdPortfolioMember"
      id="c117047697">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-6"
      id="c117047703"
      unitRef="USD">3000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="d_2022-10-01_2022-12-31_BusinessAcquisitionAxis-NeosTherapeuticsIncMember"
      decimals="-5"
      id="c117047708"
      unitRef="USD">2600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <aytu:AccruedLiabilitiesTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740551">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; - Accrued liabilities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Accrued liabilities consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued savings offers&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,054&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,739&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued program liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,964&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,012&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued customer and product related fees&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,395&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,579&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued compensation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,935&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,675&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Return reserve&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,835&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,777&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other accrued liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,391&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,017&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total accrued liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;38,574&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;46,799&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Accrued savings offers represent programs for the Company&#x2019;s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. The return reserve represents the Company&#x2019;s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, &lt;em style="font: inherit;"&gt;none&lt;/em&gt; of which individually or in the aggregate represent greater than &lt;em style="font: inherit;"&gt;five&lt;/em&gt; percent of total liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table details the change in return reserve for the periods presented:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Return Reserve&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,770&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,353&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Payments&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,346&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2023&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,777&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,128&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Payments&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,070&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2024&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,835&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
    &#160;&#160;
  </aytu:AccruedLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740552">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued savings offers&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,054&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,739&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued program liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,964&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,012&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued customer and product related fees&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,395&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,579&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accrued compensation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,935&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,675&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Return reserve&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,835&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,777&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other accrued liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,391&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,017&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total accrued liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;38,574&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;46,799&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <aytu:AccruedSavingOffers
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047764"
      unitRef="USD">11054000</aytu:AccruedSavingOffers>
    <aytu:AccruedSavingOffers
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047765"
      unitRef="USD">15739000</aytu:AccruedSavingOffers>
    <aytu:AccruedProgramRelatedLiabilities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047766"
      unitRef="USD">9964000</aytu:AccruedProgramRelatedLiabilities>
    <aytu:AccruedProgramRelatedLiabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047767"
      unitRef="USD">11012000</aytu:AccruedProgramRelatedLiabilities>
    <aytu:AccruedCustomerAndProductRelatedFeesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047768"
      unitRef="USD">5395000</aytu:AccruedCustomerAndProductRelatedFeesCurrent>
    <aytu:AccruedCustomerAndProductRelatedFeesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047769"
      unitRef="USD">6579000</aytu:AccruedCustomerAndProductRelatedFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047770"
      unitRef="USD">4935000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047771"
      unitRef="USD">5675000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <aytu:ReturnReserveCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047772"
      unitRef="USD">4835000</aytu:ReturnReserveCurrent>
    <aytu:ReturnReserveCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047773"
      unitRef="USD">5777000</aytu:ReturnReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047774"
      unitRef="USD">2391000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047775"
      unitRef="USD">2017000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047776"
      unitRef="USD">38574000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047777"
      unitRef="USD">46799000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740553">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Return Reserve&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,770&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,353&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Payments&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,346&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2023&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,777&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Reduction of net revenue&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,128&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Payments&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,070&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Balance, June 30, 2024&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,835&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2022-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-4"
      id="c117047779"
      unitRef="USD">5770000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2022-07-01_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-3"
      id="c117047780"
      unitRef="USD">8353000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2022-07-01_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-3"
      id="c117047781"
      unitRef="USD">-8346000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2023-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-3"
      id="c117047782"
      unitRef="USD">5777000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2023-07-01_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-3"
      id="c117047783"
      unitRef="USD">6128000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2023-07-01_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-4"
      id="c117047784"
      unitRef="USD">-7070000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2024-06-30_ValuationAllowancesAndReservesTypeAxis-ReturnReserveMember"
      decimals="-3"
      id="c117047785"
      unitRef="USD">4835000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740554">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; - Other Liabilities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Other liabilities consist of the following:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Fixed payment arrangements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,337&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,420&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee retention credit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,759&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,289&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,090&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;106&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,555&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total other liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;13,491&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,065&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less: current portion of other liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,090&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total other liabilities, non-current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,529&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,975&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Fixed payment arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; including fixed and variable payments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; May 2022, &lt;/em&gt;the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated &lt;em style="font: inherit;"&gt; November 2, 2018, &lt;/em&gt;related to Tuzistra XR (the &#x201c;Tuzistra License Agreement&#x201d;). Pursuant to such termination, as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company has accrued a settlement liability of $6.2&#160;million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the Company&#160;to pay interest on any principal amounts due but remaining unpaid past &lt;em style="font: inherit;"&gt; July 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from &lt;em style="font: inherit;"&gt; August 1 &lt;/em&gt;through &lt;em style="font: inherit;"&gt; July 31, &lt;/em&gt;of 70,000 units annually through &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in &lt;em style="font: inherit;"&gt; August &lt;/em&gt;of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; of which is triggered at $40.0 million. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the fixed payment arrangement balance was $1.9 million in other current liabilities, and $0.2&#160;million in other non-current liabilities on the consolidated balance sheet.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Employee Retention Credit&#160;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The $3.8 million ERC accrual in other non-current liabilities as of &lt;em style="font: inherit;"&gt; June 30,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; represents the proceeds the Company received from the ERC program during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; Please see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; -&#160;Significant of Significant Accounting Policies&lt;/i&gt; for further detail.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Operating Lease Liabilities&#160;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to &lt;i&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; - Leases&lt;/i&gt; for further detail.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Other consists of taxes payable, deferred cost related to the Company&#x2019;s technology transfer, and various other accruals, &lt;span style="-sec-ix-hidden:c117047809"&gt;none&lt;/span&gt; of which individually or in the aggregate represent greater than &lt;em style="font: inherit;"&gt;five&lt;/em&gt; percent of total liabilities.&lt;/p&gt;
  </us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740555">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Fixed payment arrangements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,337&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,420&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Employee retention credit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,759&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,289&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,090&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;106&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,555&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total other liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;13,491&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,065&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less: current portion of other liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,090&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total other liabilities, non-current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,529&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,975&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:OtherLiabilitiesTableTextBlock>
    <aytu:FixedPaymentArrangements
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047815"
      unitRef="USD">8337000</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangements
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117047816"
      unitRef="USD">10420000</aytu:FixedPaymentArrangements>
    <aytu:EmployeeRetentionCredit
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047817"
      unitRef="USD">3759000</aytu:EmployeeRetentionCredit>
    <aytu:EmployeeRetentionCredit
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047818"
      unitRef="USD">0</aytu:EmployeeRetentionCredit>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047819"
      unitRef="USD">1289000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117047820"
      unitRef="USD">2090000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherSundryLiabilities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047823"
      unitRef="USD">106000</us-gaap:OtherSundryLiabilities>
    <us-gaap:OtherSundryLiabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047824"
      unitRef="USD">1555000</us-gaap:OtherSundryLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047825"
      unitRef="USD">13491000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047826"
      unitRef="USD">14065000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047827"
      unitRef="USD">8962000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117047828"
      unitRef="USD">7090000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047829"
      unitRef="USD">4529000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047830"
      unitRef="USD">6975000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisLicenseAgreementMember"
      decimals="-5"
      id="c117047788"
      unitRef="USD">6200000</us-gaap:SettlementLiabilitiesCurrent>
    <aytu:SupplyAndDistributionCommitmentPeriod
      contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      id="c117047789">P20Y</aytu:SupplyAndDistributionCommitmentPeriod>
    <aytu:SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales
      contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="3"
      id="c117047790"
      unitRef="Pure">0.235</aytu:SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales>
    <aytu:SupplyAndDistributionAgreementMinimumSalesPerYear
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="INF"
      id="c117047791"
      unitRef="Pure">70000</aytu:SupplyAndDistributionAgreementMinimumSalesPerYear>
    <aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="INF"
      id="c117047793"
      unitRef="USD">30</aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit>
    <aytu:SupplyAndDistributionAgreementMinimumSalesPerYear
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="INF"
      id="c117047794"
      unitRef="Pure">70000</aytu:SupplyAndDistributionAgreementMinimumSalesPerYear>
    <aytu:SupplyAndDistributionAgreementMaximumYearlyMakewholePayment
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-5"
      id="c117047796"
      unitRef="USD">2100000</aytu:SupplyAndDistributionAgreementMaximumYearlyMakewholePayment>
    <aytu:SupplyAndDistributionAgreementMaximumMilestoneObligations
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-6"
      id="c117047797"
      unitRef="USD">3000000</aytu:SupplyAndDistributionAgreementMaximumMilestoneObligations>
    <aytu:SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues
      contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-7"
      id="c117047799"
      unitRef="USD">40000000</aytu:SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues>
    <aytu:FixedPaymentArrangements
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-5"
      id="c117047800"
      unitRef="USD">1900000</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangements
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-5"
      id="c117047801"
      unitRef="USD">200000</aytu:FixedPaymentArrangements>
    <aytu:EmployeeRetentionCredit
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-5"
      id="c117047802"
      unitRef="USD">3800000</aytu:EmployeeRetentionCredit>
    <us-gaap:ShortTermDebtTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740556">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; - Revolving Credit Facility&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 12,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company and certain of its subsidiaries entered into&#160;consent, joinder and amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt;&#160;&lt;em style="font: inherit;"&gt;5&lt;/em&gt; (the &#x201c;Eclipse Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;5&#x201d;&lt;/em&gt;) to the loan and security agreement dated &lt;em style="font: inherit;"&gt; October 2, 2019, &lt;/em&gt;as amended by amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;1,&lt;/em&gt; dated &lt;em style="font: inherit;"&gt; March 19, 2021, &lt;/em&gt;amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2,&lt;/em&gt; dated &lt;em style="font: inherit;"&gt; January 26, 2022, &lt;/em&gt;amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;3,&lt;/em&gt; dated &lt;em style="font: inherit;"&gt; June 1, 2022, &lt;/em&gt;amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;4&lt;/em&gt; dated &lt;em style="font: inherit;"&gt; March 24, 2023, &lt;/em&gt;and the Eclipse Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;5&lt;/em&gt; (together the &#x201c;Eclipse Agreement&#x201d;) with Eclipse Business Capital LLC (&#x201c;Eclipse&#x201d;), as agent, and the lenders party thereto (agent and such lenders, collectively, the &#x201c;Eclipse Lender&#x201d;).&#160;Under the Eclipse Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;5,&lt;/em&gt; which provided for among&#160;other things, &lt;em style="font: inherit;"&gt;two&lt;/em&gt; loan agreements, a term loan (the &#x201c;Eclipse Term Loan&#x201d;) and a revolving credit facility (the &#x201c;Eclipse Revolving Loan&#x201d;). The Eclipse Term Loan is described further in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; - Long-Term Debt&lt;/i&gt;. The Eclipse Revolving Loan&#160;provides for a&#160;maximum amount available under the revolving credit facility provided under the Eclipse Agreement of&#160;$14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (&#x201c;SOFR&#x201d;)&#160;plus 4.5%. In addition, the Company is&#160;required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan&#160;amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is &lt;em style="font: inherit;"&gt; June 12, 2028, &lt;/em&gt;and the effective interest rate was 9.9% as of &lt;em style="font: inherit;"&gt; June 30, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In the event that, for any reason, all or any portion of the Eclipse&#160;Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) 2.0% of the Eclipse Revolving Loan&#160;commitment if such event occurs on or before &lt;em style="font: inherit;"&gt; June 12, 2025, (&lt;/em&gt;ii) 1.0% of the Eclipse Revolving Loan&#160;commitment if such event occurs after &lt;em style="font: inherit;"&gt; June 12, 2025,&#160;&lt;/em&gt;but on or before &lt;em style="font: inherit;"&gt; June 12, 2026, &lt;/em&gt;and (iii) 0.5% of the Eclipse Revolving Loan&#160;commitment if such event occurs after &lt;em style="font: inherit;"&gt; June 12, 2026,&#160;&lt;/em&gt;but on or before &lt;em style="font: inherit;"&gt; June 12, 2028. &lt;/em&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be required to pay an early termination fee related to the Eclipse Term Loan&#160;as further described in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; - Long-Term Debt&lt;/i&gt;. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;permanently terminate the Eclipse Agreement upon written notice to Eclipse.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The&#160;Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company&#x2019;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company&#x2019;s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the Company was in compliance with the covenants under the Eclipse Agreement. The Company&#x2019;s obligations under the Eclipse Agreement are secured by substantially all of the Company&#x2019;s assets, as defined further in the Eclipse Agreement.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff"&gt;The Company allocated debt issuance costs of $0.1&#160;million related to the Eclipse Revolving&lt;/span&gt;&lt;span style="background-color:#ffffff"&gt;&#160;Loan, bringing to the total debt issuance costs related to the Eclipse Revolving&#160;Loan&#160;to $0.2 million, which will be amortized straight-line over the term of the loan. &lt;/span&gt;Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was $0.1 million&#160;and $0.7&#160;million&#160;for the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the outstanding amounts drawn on the Eclipse Revolving Loan were&#160;$2.4&#160;million and $1.6&#160;million, respectively. The unused revolving credit facility amount as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, was $5.6&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

  </us-gaap:ShortTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047851"
      unitRef="USD">14500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2024-06-12_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="3"
      id="c117047852"
      unitRef="Pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="d_2024-06-12_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="3"
      id="c117047853"
      unitRef="Pure">0.005</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="3"
      id="c117047854"
      unitRef="Pure">0.099</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment
      contextRef="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-OnOrBeforeJanuary262023Member"
      decimals="2"
      id="c117047855"
      unitRef="Pure">0.02</aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment>
    <aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment
      contextRef="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262023ButBeforeJanuary262024Member"
      decimals="2"
      id="c117047856"
      unitRef="Pure">0.01</aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment>
    <aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment
      contextRef="i_2024-03-24_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member"
      decimals="3"
      id="c117047857"
      unitRef="Pure">0.005</aytu:LineOfCreditFacilityTerminationFeePercentageOfCommitment>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047859"
      unitRef="USD">100000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047860"
      unitRef="USD">200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2023-07-01_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047861"
      unitRef="USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2022-07-01_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047862"
      unitRef="USD">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:LineOfCredit
      contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047865"
      unitRef="USD">2400000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i_2023-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047866"
      unitRef="USD">1600000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i_2024-06-30_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c117047867"
      unitRef="USD">5600000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LongTermDebtTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740557">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; - Long-Term Debt&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Avenue Capital Loan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 26, 2022&#160;(&lt;/em&gt;&#x201c;Closing Date&#x201d;), the Company entered into a loan and security agreement (the &#x201c;Avenue Capital Agreement&#x201d;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the &#x201c;Avenue Capital Lenders&#x201d;), and Avenue Capital Management II, L.P. as administrative agent (the &#x201c;Avenue Capital Agent&#x201d;), collectively (&#x201c;Avenue Capital&#x201d;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan was&#160;the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was&#160;&lt;em style="font: inherit;"&gt; January 26, 2025. &lt;/em&gt;The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;18&lt;/em&gt; months following the Closing Date (the &#x201c;Interest-only Period&#x201d;). The Interest-only Period could be extended automatically without any action by any party for &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to &lt;em style="font: inherit;"&gt; June 15, 2023, &lt;/em&gt;a specified amount of net proceeds from the sale and issuance of its equity securities (&#x201c;Interest-only Milestone &lt;em style="font: inherit;"&gt;1&#x201d;&lt;/em&gt;). The Interest-only Period was able to be further&#160;extended automatically without any action by any party for an additional &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months provided, the Company had achieved, prior to &lt;em style="font: inherit;"&gt; December 31, 2023, (&lt;/em&gt;i) Interest-only Milestone &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and (ii) a specified amount of trailing &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months revenue as of the date of determination.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 26, 2022&#160;(&lt;/em&gt;&#x201c;Issuance Date&#x201d;), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#x201c;Avenue Capital Warrants&#x201d;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to &lt;em style="font: inherit;"&gt; June 30, 2022, &lt;/em&gt;the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on &lt;em style="font: inherit;"&gt; January 31, 2027. &lt;/em&gt;At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 7, 2022, &lt;/em&gt;the Company closed on an equity offering of shares of common stock and warrants, as described in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt; - Stockholders Equity&lt;/i&gt;, at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to &lt;em style="font: inherit;"&gt; July 7, 2022, &lt;/em&gt;and the effective price of the &lt;em style="font: inherit;"&gt; March 7, 2022, &lt;/em&gt;offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 25, 2022, &lt;/em&gt;the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (&#x201c;Avenue&#x201d;) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in &lt;em style="font: inherit;"&gt; January 2022, &lt;/em&gt;extended&#160;the interest-only period to &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company&#x2019;s &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;equity financing.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 13, 2023, &lt;/em&gt;in conjunction with the Securities Purchase Agreement described in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/i&gt;, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended&#160;to&#160;&lt;em style="font: inherit;"&gt; January 26, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff"&gt;In addition to the debt discount&#160;discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs were&#160;being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $3.4 million and&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff"&gt;$2.7&#160;million for the years ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;span style="background-color:#ffffff"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="text-indent: 36pt; text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;On &lt;em style="font: inherit;"&gt; June 12,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company used proceeds from the Eclipse Term Loan&#160;and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full.&#160;Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to 1.0% of the loan or $0.2 million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of $0.6 million (&#x201c;Final Payment&#x201d;). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee,&#160;the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs&#160;were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of $0.6 million related to the retirement of the Avenue Capital loan in the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of fiscal &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="background-color:#ffffff;"&gt;Eclipse Term Loan&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 12,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company and certain of its subsidiaries entered into Eclipse Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;5,&lt;/em&gt; which provided for among other things,&#160;the Eclipse Term Loan&#160;and the Eclipse Revolving Loan&#160;described&#160;further in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; - Revolving Credit Facility&lt;/i&gt;. The Eclipse Term Loan&#160;consists of a principal amount of $13.0 million, at an interest rate of SOFR plus 7.0%, with a &lt;span style="-sec-ix-hidden:c117047910"&gt;four&lt;/span&gt;-year term maturing on &lt;em style="font: inherit;"&gt; June 12, 2028,&#160;&lt;/em&gt;and a straight-line loan amortization period of &lt;span style="-sec-ix-hidden:c117047911"&gt;seven&lt;/span&gt; years, which would provide for a loan balance at the end of the &lt;span style="-sec-ix-hidden:c117047912"&gt;four&lt;/span&gt;-year term of&#160;$5.6 million to be repaid on &lt;em style="font: inherit;"&gt; June 12, 2028, &lt;/em&gt;the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan.&#160;The effective interest rate on the Eclipse Term Loan was 12.4% as of &lt;em style="font: inherit;"&gt; June 30, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) 3.0% of the Eclipse Term Loan&#160;if such event occurs on or before &lt;em style="font: inherit;"&gt; June 12, 2025, (&lt;/em&gt;ii) 2.0% of the Eclipse Term Loan&#160;if such event occurs after &lt;em style="font: inherit;"&gt; June 12, 2025,&#160;&lt;/em&gt;but on or before &lt;em style="font: inherit;"&gt; June 12, 2026,&#160;(&lt;/em&gt;iii) 1.0% of the Eclipse Term Loan&#160;if such event occurs after &lt;em style="font: inherit;"&gt; June 12, 2026,&#160;&lt;/em&gt;but on or before &lt;em style="font: inherit;"&gt; June 12, 2027, &lt;/em&gt;and (iv) 0.5% of the Eclipse Term Loan&#160;if such event occurs after &lt;em style="font: inherit;"&gt; June 12, 2026,&#160;&lt;/em&gt;but on or before &lt;em style="font: inherit;"&gt; June 12, 2028. &lt;/em&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be required to pay an early termination fee related to the Eclipse Revolving Loan&#160;as further described in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt;&#160;- Revolving Credit Facility&lt;/i&gt;. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Company&#x2019;s obligations under the Eclipse Agreement&#160;are secured by substantially all of the Company&#x2019;s assets, as further defined in the Eclipse Agreement.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company&#x2019;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender&#160;to declare the Company&#x2019;s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the Company was in compliance with the covenants under the Eclipse Agreement.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff"&gt;The Company recorded&#160;total debt discount and allocated debt issuance costs of $0.3 million related to the Eclipse Term Loan, which will be amortized over the term of the loan. The Company incurred&#160;interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $0.1 million&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff"&gt;for the year ended &lt;em style="font: inherit;"&gt; June 30, 2024.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Long-term debt consists of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Term loan principal amount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;13,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;15,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Unamortized debt discount and issuance costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(266&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(925&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Final payment fee&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;638&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Financing leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;85&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;12,734&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;14,798&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Less: current portion of debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,857&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(85&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total debt, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,877&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,713&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Future principal payments of long-term debt are as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total future term loan principal payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less: unamortized debt discount and issuance costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(266&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less: current portion of debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total debt, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,877&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &#160;&#160;
  </us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-6"
      id="c117047870"
      unitRef="USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="4"
      id="c117047871"
      unitRef="Pure">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember_VariableRateAxis-PrimeRateMember"
      decimals="3"
      id="c117047872"
      unitRef="Pure">0.074</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="INF"
      id="c117047880"
      unitRef="USDPerShare">24.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="INF"
      id="c117047881"
      unitRef="USDPerShare">24.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="-5"
      id="c117047883"
      unitRef="USD">600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember"
      decimals="INF"
      id="c117047885"
      unitRef="USDPerShare">25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="INF"
      id="c117047886"
      unitRef="USDPerShare">24.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-10-25_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="INF"
      id="c117047888"
      unitRef="USDPerShare">8.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LoanProcessingFee
      contextRef="d_2022-01-26_2022-01-26_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-5"
      id="c117047890"
      unitRef="USD">400000</us-gaap:LoanProcessingFee>
    <aytu:DebtInstrumentPrepaymentFeePercentage
      contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="3"
      id="c117047891"
      unitRef="Pure">0.166</aytu:DebtInstrumentPrepaymentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-5"
      id="c117047892"
      unitRef="USD">3400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2022-07-01_2023-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-5"
      id="c117047893"
      unitRef="USD">2700000</us-gaap:InterestExpenseDebt>
    <aytu:DebtInstrumentPrepaymentFeePercentage
      contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member"
      decimals="2"
      id="c117047897"
      unitRef="Pure">0.01</aytu:DebtInstrumentPrepaymentFeePercentage>
    <aytu:DebtInstrumentPrepaymentFeeAmount
      contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember_StatementScenarioAxis-AfterJanuary262024ButBeforeJanuary262025Member"
      decimals="-5"
      id="c117047898"
      unitRef="USD">200000</aytu:DebtInstrumentPrepaymentFeeAmount>
    <aytu:DebtInstrumentFinalPayment
      contextRef="i_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-5"
      id="c117047899"
      unitRef="USD">600000</aytu:DebtInstrumentFinalPayment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-AvenueCapitalLoanMember"
      decimals="-5"
      id="c117047900"
      unitRef="USD">-600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember"
      decimals="-6"
      id="c117047907"
      unitRef="USD">13000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2024-06-12_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember"
      decimals="2"
      id="c117047908"
      unitRef="Pure">0.07</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"
      decimals="-5"
      id="c117047913"
      unitRef="USD">5600000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"
      decimals="3"
      id="c117047914"
      unitRef="Pure">0.124</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <aytu:DebtInstrumentTerminationFeePercentage
      contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-OnOrBeforeJune122025Member"
      decimals="2"
      id="c117047915"
      unitRef="Pure">0.03</aytu:DebtInstrumentTerminationFeePercentage>
    <aytu:DebtInstrumentTerminationFeePercentage
      contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122025ButOnOrBeforeJune122026Member"
      decimals="2"
      id="c117047916"
      unitRef="Pure">0.02</aytu:DebtInstrumentTerminationFeePercentage>
    <aytu:DebtInstrumentTerminationFeePercentage
      contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122027Member"
      decimals="2"
      id="c117047917"
      unitRef="Pure">0.01</aytu:DebtInstrumentTerminationFeePercentage>
    <aytu:DebtInstrumentTerminationFeePercentage
      contextRef="i_2024-06-12_DebtInstrumentAxis-EclipseTermLoanMember_StatementScenarioAxis-AfterJune122026ButOnOrBeforeJune122028Member"
      decimals="3"
      id="c117047918"
      unitRef="Pure">0.005</aytu:DebtInstrumentTerminationFeePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"
      decimals="-5"
      id="c117047920"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2023-07-01_2024-06-30_DebtInstrumentAxis-EclipseTermLoanMember"
      decimals="-5"
      id="c117047921"
      unitRef="USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740558">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;June 30, &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Term loan principal amount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;13,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;15,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Unamortized debt discount and issuance costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(266&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(925&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Final payment fee&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;638&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Financing leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;85&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;12,734&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;14,798&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt;"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt 0pt 0pt 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Less: current portion of debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,857&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(85&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total debt, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,877&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,713&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-06-30"
      decimals="-6"
      id="c117047925"
      unitRef="USD">13000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2023-06-30"
      decimals="-6"
      id="c117047926"
      unitRef="USD">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047927"
      unitRef="USD">266000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047928"
      unitRef="USD">925000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <aytu:DebtInstrumentFinalPayment
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047929"
      unitRef="USD">0</aytu:DebtInstrumentFinalPayment>
    <aytu:DebtInstrumentFinalPayment
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047930"
      unitRef="USD">638000</aytu:DebtInstrumentFinalPayment>
    <us-gaap:FinanceLeaseLiability
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047931"
      unitRef="USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047932"
      unitRef="USD">85000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047933"
      unitRef="USD">12734000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047934"
      unitRef="USD">14798000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047937"
      unitRef="USD">1857000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047938"
      unitRef="USD">85000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047939"
      unitRef="USD">10877000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117047940"
      unitRef="USD">14713000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740559">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total future term loan principal payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less: unamortized debt discount and issuance costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(266&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Less: current portion of debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,857&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total debt, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,877&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047942"
      unitRef="USD">1857000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047943"
      unitRef="USD">1857000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047944"
      unitRef="USD">1857000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047945"
      unitRef="USD">7429000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <aytu:LongTermDebtAndCapitalLeaseObligationsGross
      contextRef="i_2024-06-30"
      decimals="-6"
      id="c117047946"
      unitRef="USD">13000000</aytu:LongTermDebtAndCapitalLeaseObligationsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047947"
      unitRef="USD">266000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047948"
      unitRef="USD">1857000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117047949"
      unitRef="USD">10877000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740560">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;12&lt;/em&gt; - Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company determines the fair value of financial and non-financial assets using the fair value hierarchy, which establishes &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels of inputs that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be used to measure fair value as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current&#160;and non-current&#160;debt. The carrying amounts of certain short-term&#160;financial instruments, including cash and cash equivalents, accounts receivable, accounts payable&#160;and accrued liabilities approximate their fair value due to their short maturities. Current and non-current&#160;debt are reported at their amortized costs on the&#160;Company&#x2019;s consolidated balance sheets. The remaining financial instruments are reported on the&#160;Company&#x2019;s&#160;consolidated balance sheets at amounts that approximate current fair values. The Company&#x2019;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; transfers between Level &lt;em style="font: inherit;"&gt;1,&lt;/em&gt; Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; and Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; in the periods presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Recurring Fair Value Measurement&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, by level within the fair value hierarchy:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value at&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements at June 30, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 3)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Derivative warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value at&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements at June 30, 2023&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 3)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Derivative warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds&#160;and reflect their fair value at Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; in the fair value hierarchy.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Non-Recurring Fair Value Measurement&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, were fixed payment arrangements and&#160;intangible assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from 10.0% to 15.4%&#160;and are classified as Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs in the fair value hierarchy. In &lt;em style="font: inherit;"&gt; May 2022, &lt;/em&gt;the Company recognized a fixed payment arrangement liability of $7.6 million relating to the termination of the Tuzistra License Agreement. See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; - Other Liabilities&lt;/i&gt; for further information on fixed payment arrangements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Based on the Company&#x2019;s impairment analyses for fiscal&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company did &lt;span style="-sec-ix-hidden:c117047971"&gt;not&lt;/span&gt; record an impairment charge on intangible assets during the year ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, and recorded an &lt;span style="-sec-ix-hidden:c117047972"&gt;impairment charge&lt;/span&gt; of $5.6&#160;million on intangible assets for the year ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;. Valuation of&#160;intangible assets involves significant Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted earnings before interest, taxes, depreciation, and amortization margins, and the selection of a discount rate. These assumptions &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be affected by expectations about future market or economic conditions. See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; - Intangible Assets&lt;/i&gt; and &lt;i&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Summary of Significant Accounting Policies&lt;/i&gt;, for further discussion on the fair value measurement of intangible assets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Summary of Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; Input Changes &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table sets forth a summary of changes to those fair value measures using Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs for the&#160;year ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Derivative Warrant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Liabilities&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,796&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,998&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Settlements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;&lt;span style="-sec-ix-hidden:c117048033"&gt;Included in earnings&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,391&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Settlements &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;&lt;span style="-sec-ix-hidden:c117048039"&gt;Included in earnings&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,004&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 8pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="font-size:10pt;"&gt;Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company&#x2019;s &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;equity financing that were exercised in &lt;em style="font: inherit;"&gt; June 2024. &lt;/em&gt;The warrants were converted into 367,478 shares of common stock (&#x201c;Settlements&#x201d;) and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (&#x201c;Issued&#x201d;). See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;14&lt;/em&gt; - Stockholders&#x2019;&#160;Equity&lt;/i&gt; and&#160;&lt;i&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/i&gt; for further detail.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; Inputs&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Significant assumptions as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;used in valuing the derivative warrant liabilities, marked to market, were as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 2023 Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Tranche A&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Other &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Monte Carlo &amp;amp; Black-Scholes&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Black-Scholes&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Aytu closing stock price&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equivalent term (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.6 - 3.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.2% - 87.5%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.5% - 4.6%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;0%&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto; font-size: 10pt;"&gt;Includes &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;Warrants, &lt;em style="font: inherit;"&gt; March 2022 &lt;/em&gt;Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/i&gt; for definitions of these terms and further information.&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="d_2023-07-01_2024-06-30"
      id="c914D81BD-06A7-4BB6-91E5-B51ED679B4D5">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value at&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements at June 30, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 3)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Derivative warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value at&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements at June 30, 2023&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 3)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Derivative warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048002"
      unitRef="USD">12745000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c117048003"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c117048004"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048005"
      unitRef="USD">12745000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048006"
      unitRef="USD">12745000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c117048007"
      unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c117048008"
      unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048009"
      unitRef="USD">12745000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048019"
      unitRef="USD">6403000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c117048020"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c117048021"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048022"
      unitRef="USD">6403000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048023"
      unitRef="USD">6403000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c117048024"
      unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c117048025"
      unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048026"
      unitRef="USD">6403000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <aytu:FixedPaymentArrangementsMeasurementInput
      contextRef="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c117047964"
      unitRef="Pure">0.10</aytu:FixedPaymentArrangementsMeasurementInput>
    <aytu:FixedPaymentArrangementsMeasurementInput
      contextRef="i_2024-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c117047965"
      unitRef="Pure">0.154</aytu:FixedPaymentArrangementsMeasurementInput>
    <aytu:FixedPaymentArrangements
      contextRef="i_2022-05-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsNonrecurringMember"
      decimals="-5"
      id="c117047967"
      unitRef="USD">7600000</aytu:FixedPaymentArrangements>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-5"
      id="c117047974"
      unitRef="USD">5600000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740563">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Derivative Warrant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Liabilities&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,796&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,998&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Settlements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;&lt;span style="-sec-ix-hidden:c117048033"&gt;Included in earnings&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,391&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Settlements &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;&lt;span style="-sec-ix-hidden:c117048039"&gt;Included in earnings&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,004&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,745&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2022-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048029"
      unitRef="USD">1796000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048030"
      unitRef="USD">10998000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048031"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2022-07-01_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048032"
      unitRef="USD">-6391000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048034"
      unitRef="USD">6403000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048035"
      unitRef="USD">5148000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-4"
      id="c117048036"
      unitRef="USD">-2810000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2023-07-01_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048038"
      unitRef="USD">4004000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c117048040"
      unitRef="USD">12745000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117047983"
      unitRef="Share">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <aytu:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117047984"
      unitRef="Share">367478</aytu:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117047985"
      unitRef="Share">1806434</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117047986"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740564">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 2023 Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Tranche A&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Other &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Monte Carlo &amp;amp; Black-Scholes&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Black-Scholes&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Aytu closing stock price&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equivalent term (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.6 - 3.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.2% - 87.5%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.5% - 4.6%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;0%&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c117048053"
      unitRef="Pure">2.92</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c117048055"
      unitRef="Pure">2.92</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c117048057"
      unitRef="Pure">3.9</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c117048058"
      unitRef="Pure">2.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c117048060"
      unitRef="Pure">3.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c117048061"
      unitRef="Pure">0.803</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c117048062"
      unitRef="Pure">0.832</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c117048064"
      unitRef="Pure">0.875</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c117048065"
      unitRef="Pure">0.044</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c117048066"
      unitRef="Pure">0.045</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c117048068"
      unitRef="Pure">0.046</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c117048069"
      unitRef="Pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-OtherWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c117048071"
      unitRef="Pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740565">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;13&lt;/em&gt; - Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For fiscal&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, there was $1.8&#160;million of income tax expense, which was an effective tax rate of negative 12.6%. This was&#160;primarily driven by Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; limitation of the IRC on post-Tax Cuts and Jobs Act&#160;(&#x201c;TCJA&#x201d;) net operating loss (&#x201c;NOL&#x201d;) utilization, as further described below, coupled with existing valuation allowances. As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;,&#160;the Company had&#160;$0.8&#160;million&#160;of deferred tax assets (&#x201c;DTAs&#x201d;), net of valuation allowance, included in other non-current assets;&#160;$0.8&#160;million of deferred tax liabilities&#160;(&#x201c;DTLs&#x201d;) included in other non-current&#160;liabilities; and $0.3&#160;million of accrued income taxes payable included in accrued liabilities in the consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For fiscal &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt;&#160;there was &lt;span style="-sec-ix-hidden:c117048082"&gt;zero&lt;/span&gt;&#160;income tax expense with&#160;an effective tax rate of &lt;span style="-sec-ix-hidden:c117048083"&gt;zero&lt;/span&gt; percent, reflecting the full valuation allowance. As of &lt;em style="font: inherit;"&gt; June 30, 2023,&#160;&lt;/em&gt;the Company had&#160;$1.4&#160;million&#160;of DTAs, net of valuation allowance, included in other non-current assets;&#160;$1.4&#160;million of DTLs included in other non-current&#160;liabilities; and $0.1&#160;million of accrued income taxes payable included in accrued liabilities in the consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; Limitation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Under the provisions of the IRC, substantial changes in the Company&#x2019;s ownership have resulted&#160;in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to examination for prior NOLs generated as such NOLs are utilized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As part of the Company&#x2019;s Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; analysis, an ownership change was determined to have occurred in &lt;em style="font: inherit;"&gt; March 2022 &lt;/em&gt;at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $12 million) was determined to be fully available to offset fiscal &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; pre-change income subject to the &lt;em style="font: inherit;"&gt;80%&lt;/em&gt; limitation. The Company also determined that an ownership change occurred in &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;at a time when the Company was in a net unrealized built-in loss position. As a result of the Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; analysis, the Company had $0.3 million of disallowed recognized built-in loss that was carried forward as a net operating loss as of &lt;em style="font: inherit;"&gt; June 30, 2023. &lt;/em&gt;For fiscal &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; an additional $8.8 million of disallowed recognized built-in loss was carried forward as an operating loss. These operating loss carryovers are subject to the &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; limitation.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company had federal net operating losses of $519.6 million as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;that is subject to limitation (as described above). Of the available federal net operating losses,&#160;$186.6 million can be carried forward indefinitely, and $333.0 million will completely expire in &lt;em style="font: inherit;"&gt;2037.&lt;/em&gt; Of the amount set to expire,&#160;$329.2 million will expire unused as a result of the ownership change. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company had research and development credits of $3.0 million, which will begin to expire in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and are also subject to Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; limitation. The available state net operating losses, if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; utilized to offset taxable income in future periods, will begin to expire in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and will completely expire in &lt;em style="font: inherit;"&gt;2039.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized. Generally, it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; appropriate to use &lt;em style="font: inherit;"&gt;zero&lt;/em&gt; as an applicable tax rate and rather, a DTA should be recorded at the applicable tax rate and a valuation of an equal amount would be provided. However, under certain circumstances it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be appropriate to follow an alternative approach and use a &lt;em style="font: inherit;"&gt;zero&lt;/em&gt; rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross DTAs disclosed. The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; apply a &lt;em style="font: inherit;"&gt;zero&lt;/em&gt; rate to NOL carryforwards expected to expire unutilized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In review of the Company&#x2019;s consolidated deferred position, excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; utilized against a net DTL.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The provision for income taxes consisted of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total current tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(109&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Total deferred tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Income tax expense&#160;resulting from applying statutory rates in jurisdictions in which the Company is taxed (federal and various states) differs from the income tax expense&#160;in the financial statements. A reconciliation of the United States&#160;federal statutory income tax rates to the Company&#x2019;s effective tax rate is as follows.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands, except tax rate)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tax at statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,581&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(779&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(430&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Contingent consideration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(193&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,447&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(38.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,087&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;117&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Net income tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(12.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences, which comprise the deferred tax assets and liabilities, are as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Net operating loss carry forward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119,170&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,845&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,188&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Accrued rebates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,994&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Warrant derivatives&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,061&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,504&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,416&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,416&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,027&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;758&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Section 174 capitalization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;780&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Inventory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;256&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;743&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;492&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Fixed assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;975&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,332&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;138,012&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;137,332&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Less: valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(137,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(135,954&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,378&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred tax liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Intangibles&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(563&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(845&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;ROU asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(199&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Fixed assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,378&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company has recorded a valuation allowance of $137.3&#160;million and $136.0&#160;million at &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, respectively, to reserve its net DTAs. In assessing the realizability of DTAs, management considers whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the DTAs&#160;will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. The ultimate realization of DTAs&#160;is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;that it will realize the benefits of these deductible differences, net of the valuation allowance provided.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company&#x2019;s NOL, interest expense carryover or research and development credit carryover and therefore do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; require recognition. As a result of these timing differences, at &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company had gross unrecognized tax benefits related to uncertain tax positions of $1.3&#160;million and $2.9&#160;million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;A tabular roll-forward of the Company&#x2019;s gross unrecognized tax benefit related to uncertain tax positions&#160;is below.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Beginning balances&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,948&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Decrease resulting from current period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,996&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(120&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Increase resulting from current period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;361&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Ending balances&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,313&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,948&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The change in the Company&#x2019;s gross unrecognized tax benefits relates to filed method changes with the IRS for the tax return year ending &lt;em style="font: inherit;"&gt; June 30, 2023. &lt;/em&gt;Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to &lt;em style="font: inherit;"&gt;2005&lt;/em&gt; being subject to examination&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-5"
      id="c117048075"
      unitRef="USD">1800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-07-01_2024-06-30"
      decimals="3"
      id="c117048076"
      unitRef="Pure">-0.126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-5"
      id="c117048078"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-5"
      id="c117048079"
      unitRef="USD">800000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048080"
      unitRef="USD">300000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-5"
      id="c117048084"
      unitRef="USD">1400000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-5"
      id="c117048085"
      unitRef="USD">1400000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c117048086"
      unitRef="USD">100000</us-gaap:AccruedIncomeTaxesCurrent>
    <aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation
      contextRef="i_2023-06-30"
      decimals="-6"
      id="c117048090"
      unitRef="USD">12000000</aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPrechangeIncomeSubjectToLimitation>
    <aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c117048094"
      unitRef="USD">300000</aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss>
    <aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048096"
      unitRef="USD">8800000</aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostchangeNetOperatingLossDisallowedRecognizedBuiltinLossCarriedForwardAsOperatingLoss>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048098"
      unitRef="USD">519600000</us-gaap:OperatingLossCarryforwards>
    <aytu:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048099"
      unitRef="USD">186600000</aytu:OperatingLossCarryforwardsNotSubjectToExpiration>
    <aytu:OperatingLossCarryforwardSubjectToExpire
      contextRef="i_2024-06-30"
      decimals="-6"
      id="c117048100"
      unitRef="USD">333000000</aytu:OperatingLossCarryforwardSubjectToExpire>
    <aytu:OperatingLossCarryforwardExpirationsOwnershipChange
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048102"
      unitRef="USD">329200000</aytu:OperatingLossCarryforwardExpirationsOwnershipChange>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2024-06-30_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-6"
      id="c117048103"
      unitRef="USD">3000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740566">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;219&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total current tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(109&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Total deferred tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(126&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048134"
      unitRef="USD">1549000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-4"
      id="c117048135"
      unitRef="USD">80000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048136"
      unitRef="USD">219000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048137"
      unitRef="USD">46000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048138"
      unitRef="USD">1768000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048139"
      unitRef="USD">126000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048141"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048142"
      unitRef="USD">-109000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048143"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048144"
      unitRef="USD">-17000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048145"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048146"
      unitRef="USD">-126000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048147"
      unitRef="USD">1768000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048148"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740567">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands, except tax rate)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tax at statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,581&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(779&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(430&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Contingent consideration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(193&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,447&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(38.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,087&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;117&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Net income tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,768&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(12.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048157"
      unitRef="USD">-2956000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-07-01_2024-06-30"
      decimals="2"
      id="c117048158"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048159"
      unitRef="USD">-3581000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-07-01_2023-06-30"
      decimals="2"
      id="c117048160"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048161"
      unitRef="USD">-779000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-07-01_2024-06-30"
      decimals="3"
      id="c117048162"
      unitRef="Pure">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-4"
      id="c117048163"
      unitRef="USD">-430000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2022-07-01_2023-06-30"
      decimals="3"
      id="c117048164"
      unitRef="Pure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048165"
      unitRef="USD">19000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="d_2023-07-01_2024-06-30"
      decimals="3"
      id="c117048166"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048167"
      unitRef="USD">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="d_2022-07-01_2023-06-30"
      decimals="0"
      id="c117048168"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <aytu:IncomeTaxReconciliationContingentConsideration
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048169"
      unitRef="USD">0</aytu:IncomeTaxReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="d_2023-07-01_2024-06-30"
      decimals="0"
      id="c117048170"
      unitRef="Pure">0</aytu:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <aytu:IncomeTaxReconciliationContingentConsideration
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048171"
      unitRef="USD">-193000</aytu:IncomeTaxReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="d_2022-07-01_2023-06-30"
      decimals="3"
      id="c117048172"
      unitRef="Pure">0.012</aytu:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048173"
      unitRef="USD">5447000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-07-01_2024-06-30"
      decimals="3"
      id="c117048174"
      unitRef="Pure">-0.387</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048175"
      unitRef="USD">4087000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-07-01_2023-06-30"
      decimals="2"
      id="c117048176"
      unitRef="Pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048177"
      unitRef="USD">37000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2023-07-01_2024-06-30"
      decimals="3"
      id="c117048178"
      unitRef="Pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048179"
      unitRef="USD">117000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2022-07-01_2023-06-30"
      decimals="3"
      id="c117048180"
      unitRef="Pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048181"
      unitRef="USD">1768000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-07-01_2024-06-30"
      decimals="3"
      id="c117048182"
      unitRef="Pure">-0.126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048183"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048184"
      unitRef="Pure">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740568">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Net operating loss carry forward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119,170&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,845&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,188&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Accrued rebates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,994&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Warrant derivatives&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,061&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,504&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,416&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,416&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,027&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;758&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Section 174 capitalization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;780&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Inventory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;256&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;743&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;492&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Fixed assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;975&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,332&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;138,012&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;137,332&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Less: valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(137,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(135,954&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,378&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Deferred tax liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Intangibles&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(563&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(845&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;ROU asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(199&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Fixed assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,378&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117048190"
      unitRef="USD">119170000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048191"
      unitRef="USD">113819000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048192"
      unitRef="USD">4845000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048193"
      unitRef="USD">4188000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <aytu:DeferredTaxAssetsAccruedRebates
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048194"
      unitRef="USD">3819000</aytu:DeferredTaxAssetsAccruedRebates>
    <aytu:DeferredTaxAssetsAccruedRebates
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048195"
      unitRef="USD">6994000</aytu:DeferredTaxAssetsAccruedRebates>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048196"
      unitRef="USD">3061000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048197"
      unitRef="USD">1504000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048198"
      unitRef="USD">2416000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048199"
      unitRef="USD">2416000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048200"
      unitRef="USD">1259000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117048201"
      unitRef="USD">4250000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048202"
      unitRef="USD">1027000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048203"
      unitRef="USD">758000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <aytu:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117048204"
      unitRef="USD">780000</aytu:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <aytu:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048205"
      unitRef="USD">836000</aytu:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048206"
      unitRef="USD">256000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048207"
      unitRef="USD">743000</us-gaap:DeferredTaxAssetsInventory>
    <aytu:DeferredTaxAssetsLeaseLiability
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048208"
      unitRef="USD">305000</aytu:DeferredTaxAssetsLeaseLiability>
    <aytu:DeferredTaxAssetsLeaseLiability
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048209"
      unitRef="USD">492000</aytu:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048210"
      unitRef="USD">99000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048211"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048212"
      unitRef="USD">975000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048213"
      unitRef="USD">1332000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048214"
      unitRef="USD">138012000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048215"
      unitRef="USD">137332000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c117048216"
      unitRef="USD">137250000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048217"
      unitRef="USD">135954000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048218"
      unitRef="USD">762000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048219"
      unitRef="USD">1378000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048221"
      unitRef="USD">563000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048222"
      unitRef="USD">845000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048223"
      unitRef="USD">199000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048224"
      unitRef="USD">483000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048225"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c117048226"
      unitRef="USD">50000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048227"
      unitRef="USD">762000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048228"
      unitRef="USD">1378000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048229"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048230"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048117"
      unitRef="USD">137300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-06-30"
      decimals="-6"
      id="c117048118"
      unitRef="USD">136000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c117048126"
      unitRef="USD">1300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c117048127"
      unitRef="USD">2900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740569">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Beginning balances&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,948&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Decrease resulting from current period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,996&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(120&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Increase resulting from current period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;361&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Ending balances&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,313&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,948&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048235"
      unitRef="USD">2948000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c117048236"
      unitRef="USD">2822000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048237"
      unitRef="USD">1996000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-4"
      id="c117048238"
      unitRef="USD">120000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048239"
      unitRef="USD">361000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048240"
      unitRef="USD">246000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048241"
      unitRef="USD">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c117048242"
      unitRef="USD">2948000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740570">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;14&lt;/em&gt; - Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company had 5,972,638 and 5,517,174&#160;common shares issued and outstanding, respectively, and no preferred shares issued and outstanding. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;included in common stock outstanding are 25,360 shares of unvested restricted stock issued to executives, directors and employees.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 8, 2020, &lt;/em&gt;the Company filed a shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3,&lt;/em&gt; which was declared effective by the SEC on &lt;em style="font: inherit;"&gt; June 17, 2020. &lt;/em&gt;This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units. On &lt;em style="font: inherit;"&gt; June 4, 2021, &lt;/em&gt;the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Shelf (the &#x201c;ATM Sales Agreement&#x201d;). During the year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of&#160;$2.9 million. The &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Shelf expired in &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;and the ATM Agreement was terminated in &lt;em style="font: inherit;"&gt; July 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; September 28, 2021, &lt;/em&gt;the Company filed a shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3,&lt;/em&gt; which was declared effective by the SEC on &lt;em style="font: inherit;"&gt; October 7, 2021. &lt;/em&gt;This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the &lt;em style="font: inherit;"&gt;&#x201c;2021&lt;/em&gt; Shelf&#x201d;). As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;$82.4 million remained available under the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Shelf. This availability is subject to SEC &lt;em style="font: inherit;"&gt;1.B.6&lt;/em&gt; limitation to the Form S-&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&#160;The &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Shelf expires in &lt;em style="font: inherit;"&gt; October 2024. &lt;/em&gt;Given the upcoming expiration of the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Shelf, concurrent with the filing of this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K the Company&#160;expects to file&#160;a new shelf registration statement to cover the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the &lt;em style="font: inherit;"&gt;&#x201c;2024&lt;/em&gt; Shelf&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 7, 2022, &lt;/em&gt;the Company closed on an underwritten public offering utilizing the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Shelf, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants to purchase up to 333,300 shares of common stock (the &lt;em style="font: inherit;"&gt; &#x201c;March 2022 &lt;/em&gt;Offering&#x201d;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with &lt;em style="font: inherit;"&gt;one&lt;/em&gt; common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in &lt;em style="font: inherit;"&gt; April 2022. &lt;/em&gt;The common warrants have an exercise price of $26.00 per share of common stock and are exercisable &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months after the date of issuance and have a term of &lt;span style="-sec-ix-hidden:c117048288"&gt;five&lt;/span&gt; years from the date of exercisability. The Company raised gross proceeds of $7.6 million through the &lt;em style="font: inherit;"&gt; March 2022 &lt;/em&gt;Offering before commission and other costs of $0.8 million. The pre-funded and common warrants have a combined fair value of approximately $2.8 million at issuance and are classified as&#160;derivative warrant liabilities with the offset in additional paid in capital in stockholders&#x2019; equity in the Company&#x2019;s consolidated financial statements (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; August 11, 2022, &lt;/em&gt;the Company closed on an underwritten public offering (the &lt;em style="font: inherit;"&gt; &#x201c;August 2022 &lt;/em&gt;Offering&#x201d;) utilizing the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with &lt;span style="-sec-ix-hidden:c117048297"&gt;one&lt;/span&gt; common warrant to purchase &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in &lt;em style="font: inherit;"&gt; August 2022. &lt;/em&gt;The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of &lt;span style="-sec-ix-hidden:c117048303"&gt;five&lt;/span&gt; years from issuance. The Company raised $10.0 million in gross proceeds through the &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants had a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#x2019; equity in the Company&#x2019;s consolidated financial statements (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 8, 2023, &lt;/em&gt;using a placement agent, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company&#x2019;s common stock; (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the &lt;em style="font: inherit;"&gt; &#x201c;June 2023 &lt;/em&gt;Pre-Funded Warrants&#x201d;); (iii) accompanying tranche A&#160;warrants to purchase 2,173,912 shares of common stock (the &#x201c;Tranche A Warrants&#x201d;); and (iv) accompanying tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the &#x201c;Tranche B&#160;Warrants&#x201d;&#160;and the&#160;Tranche A Warrants together with the Tranche B Warrants, the &#x201c;Common Warrants&#x201d;). The Common Warrants &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants (the &#x201c;Exchange Warrants&#x201d;). Each pre-funded warrant is exercisable for &lt;span style="-sec-ix-hidden:c117048313"&gt;one&lt;/span&gt; share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) &lt;span style="-sec-ix-hidden:c117048317"&gt;five&lt;/span&gt; years after the date of issuance or (ii) &lt;em style="font: inherit;"&gt;30&lt;/em&gt; days following the closing price of the Company&#x2019;s common stock equaling &lt;em style="font: inherit;"&gt;200%&lt;/em&gt; of the exercise price ($3.18 per share) for at least &lt;em style="font: inherit;"&gt;40&lt;/em&gt; consecutive trading days. The Tranche B Warrants were exercised in &lt;em style="font: inherit;"&gt; June 2024 &lt;/em&gt;as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain&#160;along with the issuance costs of $0.6 million in the consolidated financial statement of operations (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 14, 2024, &lt;/em&gt;the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 pre-funded&#160;warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the &#x201c;Tranche B Pre-Funded Warrants&#x201d;). The Tranche B Pre-Funded Warrants had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#x2019;&#160;equity in the Company&#x2019;s consolidated financial statements. The Company&#160;used a portion of the&#160;proceeds from the Tranche B Warrants exercise&#160;as part of the Avenue Capital loan&#160;repayment described further in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; - Long-Term Debt&lt;/i&gt;.&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-06-30"
      decimals="-8"
      id="c117048244"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048245"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-06-30"
      decimals="-7"
      id="c117048246"
      unitRef="Share">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048247"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048249"
      unitRef="Share">5972638</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117048251"
      unitRef="Share">5517174</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048253"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048257"
      unitRef="Share">25360</us-gaap:CommonStockSharesOutstanding>
    <aytu:SaleOfStockMaximumAmountOfEquityIssuable
      contextRef="i_2020-06-17_SubsidiarySaleOfStockAxis-The2020ShelfMember"
      decimals="-8"
      id="c117048259"
      unitRef="USD">100000000</aytu:SaleOfStockMaximumAmountOfEquityIssuable>
    <aytu:SaleOfStockMaximumAmountOfEquityIssuable
      contextRef="i_2021-06-04_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember"
      decimals="-7"
      id="c117048260"
      unitRef="USD">30000000</aytu:SaleOfStockMaximumAmountOfEquityIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-07-01_2023-06-30_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember"
      decimals="INF"
      id="c117048262"
      unitRef="Share">699929</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-07-01_2023-06-30_SubsidiarySaleOfStockAxis-AtthemarketOfferingMember"
      decimals="-5"
      id="c117048263"
      unitRef="USD">2900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <aytu:SaleOfStockMaximumAmountOfEquityIssuable
      contextRef="i_2021-09-28_SubsidiarySaleOfStockAxis-The2021ShelfMember"
      decimals="-8"
      id="c117048266"
      unitRef="USD">100000000</aytu:SaleOfStockMaximumAmountOfEquityIssuable>
    <aytu:SaleOfStockMaximumAmountOfEquityIssuable
      contextRef="i_2023-06-30_SubsidiarySaleOfStockAxis-The2021ShelfMember"
      decimals="-5"
      id="c117048268"
      unitRef="USD">82400000</aytu:SaleOfStockMaximumAmountOfEquityIssuable>
    <aytu:SaleOfStockMaximumAmountOfEquityIssuable
      contextRef="i_2024-06-30_SubsidiarySaleOfStockAxis-The2024ShelfMember"
      decimals="-8"
      id="c117048276"
      unitRef="USD">100000000</aytu:SaleOfStockMaximumAmountOfEquityIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember"
      decimals="INF"
      id="c117048280"
      unitRef="Share">151500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048281"
      unitRef="Share">151500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember"
      decimals="INF"
      id="c117048282"
      unitRef="Share">333300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"
      decimals="INF"
      id="c117048284"
      unitRef="Share">1.1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048285"
      unitRef="USDPerShare">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember"
      decimals="INF"
      id="c117048286"
      unitRef="USDPerShare">26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember"
      decimals="-5"
      id="c117048289"
      unitRef="USD">7600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember"
      decimals="-5"
      id="c117048290"
      unitRef="USD">800000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="d_2022-03-07_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"
      decimals="-5"
      id="c117048291"
      unitRef="USD">2800000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember"
      decimals="INF"
      id="c117048294"
      unitRef="Share">1075290</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048295"
      unitRef="Share">87500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048296"
      unitRef="Share">1265547</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember"
      decimals="INF"
      id="c117048299"
      unitRef="USDPerShare">8.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember"
      decimals="INF"
      id="c117048300"
      unitRef="USDPerShare">8.58</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048301"
      unitRef="USDPerShare">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048302"
      unitRef="USDPerShare">8.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember"
      decimals="-7"
      id="c117048304"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="d_2022-08-11_2022-08-11_SubsidiarySaleOfStockAxis-TheAugust2022OfferingMember"
      decimals="-5"
      id="c117048305"
      unitRef="USD">900000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember"
      decimals="-6"
      id="c117048306"
      unitRef="USD">6000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c117048308"
      unitRef="Share">1743695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048309"
      unitRef="Share">430217</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"
      decimals="INF"
      id="c117048310"
      unitRef="Share">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117048311"
      unitRef="Share">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048312"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048314"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsMember"
      decimals="INF"
      id="c117048315"
      unitRef="USDPerShare">1.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsExchangedForPrefundedWarrantsMember"
      decimals="INF"
      id="c117048316"
      unitRef="USDPerShare">1.5899</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"
      decimals="INF"
      id="c117048320"
      unitRef="USDPerShare">3.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="-6"
      id="c117048322"
      unitRef="USD">4000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="c117048323"
      unitRef="USD">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember"
      decimals="-6"
      id="c117048325"
      unitRef="USD">5000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-06-08_2023-06-08_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantsMember"
      decimals="-5"
      id="c117048326"
      unitRef="USD">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="-5"
      id="c117048329"
      unitRef="USD">3500000</us-gaap:ProceedsFromWarrantExercises>
    <aytu:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117048330"
      unitRef="Share">367478</aytu:StockIssuedDuringPeriodSharesWarrantsExercised>
    <aytu:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117048331"
      unitRef="Share">1806434</aytu:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117048332"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="-5"
      id="c117048333"
      unitRef="USD">5100000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740571">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt; - Equity Incentive Plans&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan&lt;/b&gt;&lt;/i&gt;&lt;br/&gt; &#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; May 18, 2023, &lt;/em&gt;the Company&#x2019;s stockholders approved the Aytu BioPharma, Inc. &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2023&lt;/em&gt; Equity Incentive Plan&#x201d;). Prior to the Company&#x2019;s adoption of the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Stock Option and Incentive Plan (the &#x201c;Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan&#x201d;) and the Neos Therapeutics, Inc. &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Stock Options and Incentive Plan (the &#x201c;Neos &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan&#x201d;, and collectively with the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan, the &lt;em style="font: inherit;"&gt;&#x201c;2015&lt;/em&gt; Plans&#x201d;). For the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan, the stockholders approved (i) 200,000 new shares; (ii) 87,129 shares available for grant under the &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plans be &#x201c;rolled over&#x201d; to the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan; and (iii) any shares that are returned to the Company under the &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plans be added to the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan. With the approval of the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional awards will be granted under the &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the Company had 182,322&#160;shares that are available for grant under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2015,&lt;/em&gt; the Company&#x2019;s stockholders approved the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan, which, as amended in &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2017,&lt;/em&gt; provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company&#x2019;s stockholders approved an increase to 250,000 total shares of common stock in the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan will be added back to the shares of common stock available for issuance under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;b&gt;Neos &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan. Accordingly, on &lt;em style="font: inherit;"&gt; April 19, 2021, &lt;/em&gt;the Company registered 5,272 shares of its common stock under the Neos &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, 113,500&#160;stock options were granted. The weighted-average grant date fair value of options granted during the year ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, was $1.74. During the year ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, there was $0.2&#160;million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#x2019;s equity incentive plan. During the fiscal year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;49,212 stock options were granted. The weighted-average grant date fair value of options granted during the year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;was $4.00. During the year ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;there was $0.1 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#x2019;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9&#160;years.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Stock option activity is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Life in Years&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding at June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;113,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;9.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Forfeited/cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(16,610&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;3.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,113&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;66.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercisable at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;26.06&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table details the options outstanding at &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, by range of exercise prices:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" rowspan="1" style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;$1.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:c117050812"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;102,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" rowspan="1" style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;$2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:c117050820"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;$4.00 - $290.00&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;span style="-sec-ix-hidden:c117050827"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c117050829"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;43,039&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;25,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;225.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;225.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company granted a total of 12,500 shares of restricted stock, with certain accelerated vesting conditions, to members of its non-employee directors pursuant to the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan, of which &lt;span style="-sec-ix-hidden:c117048402"&gt;1/3&lt;/span&gt; vest on the grant date and &lt;span style="-sec-ix-hidden:c117048403"&gt;1/12&lt;/span&gt; on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; day of each quarter thereafter, subject to continuing service to the Company through each vesting date. These restricted stock grants have a weighted average grant date fair value of $1.77 per share.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;as a result of the change in members of the Company&#x2019;s board, the Company accelerated unvested shares for &lt;em style="font: inherit;"&gt;two&lt;/em&gt; former members and recorded $1.5 million of non-cash equity compensation expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; December 19, 2022, &lt;/em&gt;the Company entered into a stipulation of compromise and settlement (the &#x201c;Stipulation&#x201d;). As a part of the terms of the Stipulation, the Company agreed to rescind 25% of the aggregate &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; grants to board members. As a result of the recission of the shares, the Company recorded $0.6 million in non-cash compensation during the year ended &lt;em style="font: inherit;"&gt; June 30, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;the Company granted a total of 6,825 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan, of which &lt;span style="-sec-ix-hidden:c117048413"&gt;1/3&lt;/span&gt; vest on the grant date and &lt;span style="-sec-ix-hidden:c117048414"&gt;1/12&lt;/span&gt; on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; day of each quarter thereafter, subject to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $3.31 per-share to $13.4 per-share.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Restricted stock activity under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Equity Incentive Plan&#160;is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average Grant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Date Fair&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;38,075&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;142.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;12,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.77&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(25,971&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;113.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Forfeited/cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;147.15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,105&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, there was $1.0&#160;million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company&#x2019;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.5&#160;years. The total fair value of restricted stock vested during the year ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, was $0.1&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company previously issued 4 shares of restricted stock outside of the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan, which vest in &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; On &lt;em style="font: inherit;"&gt; January 17, 2022, &lt;/em&gt;the Company granted 5,000 shares of restricted stock to a member of its management team outside of the Aytu &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Plan, of which &lt;span style="-sec-ix-hidden:c117048427"&gt;1/3&lt;/span&gt; vest on &lt;em style="font: inherit;"&gt; January 17, 2023, &lt;/em&gt;and &lt;span style="-sec-ix-hidden:c117048428"&gt;1/12&lt;/span&gt; each quarter thereafter, subject to continuing employment with the Company through each vesting date until &lt;em style="font: inherit;"&gt; January 17, 2025. &lt;/em&gt;This restricted stock grant has a grant date fair value of $27.00 per share. As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, there was $0.2&#160;million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company&#x2019;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.6&#160;years.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For the years ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company did &lt;span style="-sec-ix-hidden:c117048434"&gt;&lt;span style="-sec-ix-hidden:c117048435"&gt;not&lt;/span&gt;&lt;/span&gt; grant restricted stock units (&#x201c;RSU&#x201d;). RSU activity is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average Grant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Date Fair&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25.62&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,249&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;24.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Forfeited/cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;31.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, there was no material unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company&#x2019;s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.7&#160;years. The total fair value of RSUs vested during the year ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, was immaterial.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Cost of sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Selling and marketing&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,905&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,965&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,046&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2023-05-18_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember"
      decimals="INF"
      id="c117048347"
      unitRef="Share">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2023-05-18_PlanNameAxis-The2023EquityIncentivePlanMember"
      decimals="INF"
      id="c117048348"
      unitRef="Share">87129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember"
      id="c117048357">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember"
      id="c117048358">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember"
      id="c117048359">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MinimumMember"
      id="c117048360">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-05-18_2023-05-18_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsRsusMember_PlanNameAxis-The2023EquityIncentivePlanMember_RangeAxis-MaximumMember"
      id="c117048361">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2024-06-30_PlanNameAxis-The2023EquityIncentivePlanMember"
      decimals="INF"
      id="c117048362"
      unitRef="Share">182322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-02-13_PlanNameAxis-The2015PlanMember"
      decimals="INF"
      id="c117048371"
      unitRef="Share">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember"
      id="c117048375">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember"
      id="c117048376">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember"
      id="c117048377">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember"
      id="c117048378">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember"
      id="c117048379">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2015PlanMember"
      id="c117048380">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-04-19_PlanNameAxis-Neos2015PlanMember"
      decimals="INF"
      id="c117048383"
      unitRef="Share">3486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2021-04-19_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-Neos2015PlanMember"
      decimals="INF"
      id="c117048384"
      unitRef="Share">1786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-04-19_PlanNameAxis-Neos2015PlanMember"
      decimals="INF"
      id="c117048386"
      unitRef="Share">5272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember"
      id="c117048389">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MinimumMember"
      id="c117048390">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-04-19_2021-04-19_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-Neos2015PlanMember_RangeAxis-MaximumMember"
      id="c117048391">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048392"
      unitRef="Share">113500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048393"
      unitRef="USDPerShare">1.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c117048394"
      unitRef="USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-07-01_2023-06-30"
      decimals="INF"
      id="c117048395"
      unitRef="Share">49212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-07-01_2023-06-30"
      decimals="INF"
      id="c117048396"
      unitRef="USDPerShare">4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c117048397"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c117048398">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740572">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Life in Years&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding at June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;113,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;9.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Forfeited/cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(16,610&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;3.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,113&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;66.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercisable at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;26.06&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117048454"
      unitRef="Share">52762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117048455"
      unitRef="USDPerShare">18.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2022-07-01_2023-06-30" id="c117048456">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048457"
      unitRef="Share">113500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048458"
      unitRef="USDPerShare">1.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <aytu:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="d_2023-07-01_2024-06-30" id="c117048459">P9Y2M12D</aytu:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048460"
      unitRef="Share">16610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048461"
      unitRef="USDPerShare">3.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048463"
      unitRef="Share">3113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048464"
      unitRef="USDPerShare">66.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048466"
      unitRef="Share">146539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048467"
      unitRef="USDPerShare">6.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-07-01_2024-06-30" id="c117048468">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048469"
      unitRef="Share">25068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048470"
      unitRef="USDPerShare">26.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2023-07-01_2024-06-30" id="c117048471">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740637">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" rowspan="1" style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;$1.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:c117050812"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;102,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" rowspan="1" style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;$2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:c117050820"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;$4.00 - $290.00&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;span style="-sec-ix-hidden:c117050827"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c117050829"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;43,039&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;25,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;225.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 14%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;146,539&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 154px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;225.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember"
      decimals="INF"
      id="c117050814"
      unitRef="Share">102000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember"
      decimals="INF"
      id="c117050815"
      unitRef="USDPerShare">1.73</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeOneMember"
      id="c117050816">P9Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember"
      decimals="INF"
      id="c117050822"
      unitRef="Share">1500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember"
      decimals="INF"
      id="c117050823"
      unitRef="USDPerShare">2.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeTwoMember"
      id="c117050824">P9Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      decimals="INF"
      id="c117050830"
      unitRef="Share">43039</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      decimals="INF"
      id="c117050831"
      unitRef="USDPerShare">16.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-07-01_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      id="c117050832">P8Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      decimals="INF"
      id="c117050833"
      unitRef="Share">25068</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-06-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRangeThreeMember"
      decimals="INF"
      id="c117050834"
      unitRef="USDPerShare">225.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117050838"
      unitRef="Share">146539</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117050839"
      unitRef="USDPerShare">6.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2023-07-01_2024-06-30" id="c117050840">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117050841"
      unitRef="Share">25068</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117050842"
      unitRef="USDPerShare">225.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048400"
      unitRef="Share">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2023EquityIncentivePlanMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048405"
      unitRef="USDPerShare">1.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-TwoFormerBoardMembersMember"
      decimals="-5"
      id="c117048407"
      unitRef="USD">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <aytu:SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded
      contextRef="d_2022-12-19_2022-12-19_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-BoardMembersMember"
      decimals="2"
      id="c117048408"
      unitRef="Pure">0.25</aytu:SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfGrantsRescinded>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-12-19_2022-12-19_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-BoardMembersMember"
      decimals="-5"
      id="c117048410"
      unitRef="USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048411"
      unitRef="Share">6825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MinimumMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048416"
      unitRef="USDPerShare">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-07-01_2023-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember_RangeAxis-MaximumMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048417"
      unitRef="USDPerShare">13.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740574">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average Grant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Date Fair&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;38,075&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;142.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;12,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.77&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(25,971&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;113.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Forfeited/cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(499&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;147.15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,105&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048512"
      unitRef="Share">38075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048513"
      unitRef="USDPerShare">142.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048514"
      unitRef="Share">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048515"
      unitRef="USDPerShare">1.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048516"
      unitRef="Share">25971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048517"
      unitRef="USDPerShare">113.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048518"
      unitRef="Share">499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048519"
      unitRef="USDPerShare">147.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048520"
      unitRef="Share">24105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c117048521"
      unitRef="USDPerShare">100.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember"
      decimals="-6"
      id="c117048419"
      unitRef="USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember"
      id="c117048420">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2015PlanMember"
      decimals="-5"
      id="c117048421"
      unitRef="USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2015-06-01_2015-06-01_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember"
      decimals="INF"
      id="c117048422"
      unitRef="Share">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048425"
      unitRef="Share">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-17_2022-01-17_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember_TitleOfIndividualAxis-ManagementMember"
      decimals="INF"
      id="c117048429"
      unitRef="USDPerShare">27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember"
      decimals="-5"
      id="c117048430"
      unitRef="USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-NonplanMember"
      id="c117048431">P0Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740575">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average Grant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Date Fair&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25.62&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,249&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;24.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Forfeited/cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;31.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Unvested at June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048530"
      unitRef="Share">4963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048531"
      unitRef="USDPerShare">25.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048532"
      unitRef="Share">2249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048533"
      unitRef="USDPerShare">24.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048534"
      unitRef="Share">939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2023-07-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048535"
      unitRef="USDPerShare">31.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048536"
      unitRef="Share">1775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c117048537"
      unitRef="USDPerShare">24.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c117048436"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2023-07-01_2024-06-30" id="c117048437">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740576">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Cost of sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Selling and marketing&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,905&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,965&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,046&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-CostOfSalesMember"
      decimals="-3"
      id="c117048544"
      unitRef="USD">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-CostOfSalesMember"
      decimals="-3"
      id="c117048545"
      unitRef="USD">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c117048546"
      unitRef="USD">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c117048547"
      unitRef="USD">30000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember"
      decimals="-3"
      id="c117048548"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-SellingAndMarketingExpenseMember"
      decimals="-3"
      id="c117048549"
      unitRef="USD">23000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c117048550"
      unitRef="USD">2905000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c117048551"
      unitRef="USD">5965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048552"
      unitRef="USD">2913000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048553"
      unitRef="USD">6046000</us-gaap:AllocatedShareBasedCompensationExpense>
    <aytu:WarrantsOrRightsDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740577">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt; - Warrants&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Liability Classified Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 8, 2023, &lt;/em&gt;using a placement agent, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company&#x2019;s common stock; (ii) &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants in lieu of shares to purchase 430,217 shares of common stock; (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock; and (iv) accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche A Warrants together with the Tranche B Warrants, the &#x201c;Common Warrants&#x201d;). The Common Warrants &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants (the &#x201c;Exchange Warrants&#x201d;). Each pre-funded warrant is exercisable for &lt;span style="-sec-ix-hidden:c117048560"&gt;one&lt;/span&gt; share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) &lt;span style="-sec-ix-hidden:c117048564"&gt;five&lt;/span&gt; years after the date of issuance or (ii) &lt;em style="font: inherit;"&gt;30&lt;/em&gt; days following the closing price of the Company&#x2019;s common stock equaling &lt;em style="font: inherit;"&gt;200%&lt;/em&gt; of the exercise price ($3.18 per share) for at least &lt;em style="font: inherit;"&gt;40&lt;/em&gt; consecutive trading days. The Tranche B Warrants were exercised in &lt;em style="font: inherit;"&gt; June 2024 &lt;/em&gt;as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain along with the issuance costs of $0.6 million in the consolidated financial statement of operations&#160;(see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;14&lt;/em&gt;&#160;- Stockholders&#x2019; Equity&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 14, 2024, &lt;/em&gt;the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 Tranche B Pre-Funded Warrants to purchase shares of common stock with an exercise price of $0.0001 per share. The Tranche B Pre-Funded Warrants, which do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an expiration date, had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders&#x2019; equity in the Company&#x2019;s consolidated financial statements. The Company used a portion of the proceeds from the Tranche B Warrants exercise as part of the Avenue Capital loan repayment described further in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; - Long-Term Debt&lt;/i&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; August 11, 2022, &lt;/em&gt;the Company closed on the &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;Offering, pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which &lt;em style="font: inherit;"&gt;one&lt;/em&gt; common warrant to purchase &lt;span style="-sec-ix-hidden:c117048586"&gt;one&lt;/span&gt; share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in &lt;em style="font: inherit;"&gt; August 2022. &lt;/em&gt;The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of &lt;span style="-sec-ix-hidden:c117048589"&gt;five&lt;/span&gt; years from issuance. The common warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a &#x201c;Stock Combination Event&#x201d;), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (&lt;em style="font: inherit;"&gt;x&lt;/em&gt;) the sum of the VWAP of the common stock for each of the &lt;em style="font: inherit;"&gt;five&lt;/em&gt; lowest trading days during the &lt;em style="font: inherit;"&gt;20&lt;/em&gt; consecutive trading day period ending immediately preceding the &lt;em style="font: inherit;"&gt;16th&lt;/em&gt; trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;14&lt;/em&gt; - Stockholders&#x2019; Equity&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2022 &lt;/em&gt;and throughout the quarter ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the associated common warrants exercise price was adjusted to $3.30. On &lt;em style="font: inherit;"&gt; January 6, 2023, &lt;/em&gt;the Company consummated a 20 to &lt;em style="font: inherit;"&gt;1&lt;/em&gt; reverse stock split. Pursuant to the aforementioned warrant agreement, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest &lt;em style="font: inherit;"&gt;five&lt;/em&gt; trading days during the &lt;em style="font: inherit;"&gt;twenty&lt;/em&gt;-day consecutive trading day period beginning on &lt;em style="font: inherit;"&gt; December 30, 2022. &lt;/em&gt;Subsequently, as a result of the Securities Purchase Agreement in &lt;em style="font: inherit;"&gt; June 2023, &lt;/em&gt;the common warrants from the &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;Offering had an adjusted exercise price of $2.32.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 7, 2022, &lt;/em&gt;the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common warrants to purchase up to 333,300 shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with &lt;em style="font: inherit;"&gt;one&lt;/em&gt; common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in &lt;em style="font: inherit;"&gt; April 2022. &lt;/em&gt;The common warrants have an exercise price of $26.00 per share of common stock and are exercisable &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months after the date of issuance and have a term of &lt;span style="-sec-ix-hidden:c117048614"&gt;five&lt;/span&gt; years from the date of exercisability (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;14&lt;/em&gt; - Stockholders&#x2019; Equity&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 26, 2022, &lt;/em&gt;as consideration for entering into the Avenue Capital Agreement as described in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; &#x2013; Long-Term Debt&lt;/i&gt;, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#x201c;Avenue Capital Warrants&#x201d;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to &lt;em style="font: inherit;"&gt; June 30, 2022, &lt;/em&gt;the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on &lt;em style="font: inherit;"&gt; January 31, 2027. &lt;/em&gt;At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; fixed at the issuance (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; &#x2013; Long-Term Debt&lt;/i&gt; for further details).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Outstanding warrants that are classified as derivative warrant liabilities in the consolidated balance sheets&#160;are marked to market at each reporting period (see &lt;i&gt;Note &lt;em style="font: inherit;"&gt;12&lt;/em&gt; &#x2013; Fair Value Considerations&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;A summary of warrants is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life in Years &lt;sup style="vertical-align:top;line-height:120%;"&gt;(4)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding June 30, 2023 &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,538,052&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants issued &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;1,806,434&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.0001&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(2,247,648&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1.61&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20,958&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding June 30, 2024 &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,075,880&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The number of warrants outstanding as of &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;is comprised of 6,068,763 liability classified warrants, 430,217 liability classified &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants and 39,072 equity classified warrants.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;The warrants issued during fiscal &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The number of warrants outstanding as of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;is comprised of 3,821,115 liability classified warrants, 430,217 liability classified &lt;em style="font: inherit;"&gt; June 2023 &lt;/em&gt;Pre-Funded Warrants, 1,806,434&#160;liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;As pre-funded warrants do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
  </aytu:WarrantsOrRightsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c117048555"
      unitRef="Share">1743695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048556"
      unitRef="Share">430217</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"
      decimals="INF"
      id="c117048557"
      unitRef="Share">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117048558"
      unitRef="Share">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048559"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c117048561"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsMember"
      decimals="INF"
      id="c117048562"
      unitRef="USDPerShare">1.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-CommonWarrantsExchangedForPrefundedWarrantsMember"
      decimals="INF"
      id="c117048563"
      unitRef="USDPerShare">1.5899</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-08_ClassOfWarrantOrRightAxis-TrancheACommonWarrantsMember"
      decimals="INF"
      id="c117048567"
      unitRef="USDPerShare">3.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="-6"
      id="c117048569"
      unitRef="USD">4000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="c117048570"
      unitRef="USD">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember"
      decimals="-6"
      id="c117048572"
      unitRef="USD">5000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-06-08_2023-06-08_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementWarrantsMember"
      decimals="-5"
      id="c117048573"
      unitRef="USD">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="-5"
      id="c117048575"
      unitRef="USD">3500000</us-gaap:ProceedsFromWarrantExercises>
    <aytu:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2024-06-14_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117048576"
      unitRef="Share">367478</aytu:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117048577"
      unitRef="Share">1806434</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117048578"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-06-14_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="-5"
      id="c117048580"
      unitRef="USD">5100000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048583"
      unitRef="Share">87500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048584"
      unitRef="Share">1265547</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048587"
      unitRef="USDPerShare">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048588"
      unitRef="USDPerShare">8.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c117048594"
      unitRef="USDPerShare">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c117048595"
      unitRef="Share">2325581</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c117048597"
      unitRef="USDPerShare">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048599"
      unitRef="USDPerShare">8.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048600"
      unitRef="USDPerShare">3.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2023-01-06_2023-01-06_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c117048601"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-August2022CommonWarrantsMember"
      decimals="INF"
      id="c117048605"
      unitRef="USDPerShare">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-03-07_2022-03-07_SubsidiarySaleOfStockAxis-TheMarch2022OfferingMember"
      decimals="INF"
      id="c117048606"
      unitRef="Share">151500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048607"
      unitRef="Share">151500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember"
      decimals="INF"
      id="c117048608"
      unitRef="Share">333300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonAndPrefundedWarrantsMember"
      decimals="INF"
      id="c117048610"
      unitRef="Share">1.1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022PrefundedWarrantsMember"
      decimals="INF"
      id="c117048611"
      unitRef="USDPerShare">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-03-07_ClassOfWarrantOrRightAxis-March2022CommonWarrantsMember"
      decimals="INF"
      id="c117048612"
      unitRef="USDPerShare">26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="INF"
      id="c117048617"
      unitRef="USDPerShare">24.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-01-26_ClassOfWarrantOrRightAxis-AvenueCapitalWarrantsMember"
      decimals="INF"
      id="c117048618"
      unitRef="USDPerShare">24.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740578">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life in Years &lt;sup style="vertical-align:top;line-height:120%;"&gt;(4)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding June 30, 2023 &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,538,052&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants issued &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;1,806,434&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.0001&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;N/A&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(2,247,648&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1.61&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20,958&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding June 30, 2024 &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,075,880&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c117048654"
      unitRef="Share">6538052</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-06-30_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c117048655"
      unitRef="USDPerShare">4.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife contextRef="d_2022-07-01_2023-06-30" id="c117048656">P4Y8M12D</aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <aytu:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048657"
      unitRef="Share">1806434</aytu:ClassOfWarrantOrRightIssuedDuringPeriod>
    <aytu:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c117048658"
      unitRef="USDPerShare">0.0001</aytu:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <aytu:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048660"
      unitRef="Share">2247648</aytu:ClassOfWarrantOrRightExercisedDuringPeriod>
    <aytu:ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c117048661"
      unitRef="USDPerShare">1.61</aytu:ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod>
    <aytu:ClassOfWarrantOrRightExpiredDuringPeriod
      contextRef="d_2023-07-01_2024-06-30"
      decimals="INF"
      id="c117048663"
      unitRef="Share">20958</aytu:ClassOfWarrantOrRightExpiredDuringPeriod>
    <aytu:ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod
      contextRef="d_2023-07-01_2024-06-30_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c117048664"
      unitRef="USDPerShare">300</aytu:ClassOfWarrantOrRightExercisePriceExpiredDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c117048666"
      unitRef="Share">6075880</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-06-30_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c117048667"
      unitRef="USDPerShare">3.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife contextRef="d_2023-07-01_2024-06-30" id="c117048668">P3Y1M6D</aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember"
      decimals="INF"
      id="c117048624"
      unitRef="Share">6068763</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember"
      decimals="INF"
      id="c117048625"
      unitRef="Share">430217</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember"
      decimals="INF"
      id="c117048626"
      unitRef="Share">39072</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBCommonWarrantsMember"
      decimals="INF"
      id="c117048629"
      unitRef="Share">1806434</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117048630"
      unitRef="Share">1806434</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityWarrantsMember"
      decimals="INF"
      id="c117048632"
      unitRef="Share">3821115</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityPrefundedWarrantsMember"
      decimals="INF"
      id="c117048633"
      unitRef="Share">430217</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityTrancheBPrefundedWarrantsMember"
      decimals="INF"
      id="c117048634"
      unitRef="Share">1806434</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-EquityWarrantsMember"
      decimals="INF"
      id="c117048635"
      unitRef="Share">18114</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740579">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;17&lt;/em&gt; - Restructuring Costs&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;As part of the Company&#x2019;s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site (Rx Segment), the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations and expense associated with inventory write-downs&#160;is recorded in cost of sales in the consolidated statements of operations. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to incur&#160;any additional significant restructuring costs related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site during fiscal &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any material accruals related to the wind down of the Consumer Health Segment. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the Company had accrued $0.9 million and $0.4 million related to accrued severance and employee benefits&#160;and accrued exit and disposal activity costs, respectively, related to the closure of the Grand Prairie, Texas manufacturing facility.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;A summary of restructuring costs incurred during the year ended &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended June 30, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Severance and Employee Benefits &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exit and Disposal Activities &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inventory Write-Down &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Wind down of Consumer Health Segment &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;189&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closure of Grand Prairie, Texas manufacturing site &lt;sup style="vertical-align:top;line-height:120%;"&gt;(4)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,031&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,156&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,220&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,095&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;)&lt;/sup&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &#160;&#160;
  </us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember"
      decimals="-5"
      id="c117048673"
      unitRef="USD">900000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-GrandPrairieTexasManufacturingSiteMember"
      decimals="-5"
      id="c117048674"
      unitRef="USD">400000</us-gaap:BusinessExitCosts1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740580">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended June 30, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Severance and Employee Benefits &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exit and Disposal Activities &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inventory Write-Down &lt;sup style="vertical-align:top;line-height:120%;"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Wind down of Consumer Health Segment &lt;sup style="vertical-align:top;line-height:120%;"&gt;(3)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;189&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closure of Grand Prairie, Texas manufacturing site &lt;sup style="vertical-align:top;line-height:120%;"&gt;(4)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,031&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,156&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,220&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,095&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"
      decimals="-4"
      id="c117048688"
      unitRef="USD">20000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"
      decimals="-3"
      id="c117048689"
      unitRef="USD">189000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"
      decimals="-4"
      id="c117048690"
      unitRef="USD">730000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_FinancingReceivablePortfolioSegmentAxis-ConsumerHealthSegmentMember_StatementBusinessSegmentsAxis-ConsumerHealthSegmentMember"
      decimals="-3"
      id="c117048691"
      unitRef="USD">939000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"
      decimals="-3"
      id="c117048692"
      unitRef="USD">1125000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"
      decimals="-3"
      id="c117048693"
      unitRef="USD">1031000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"
      decimals="-3"
      id="c117048694"
      unitRef="USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-GrandPrairieTexasManufacturingSiteMember"
      decimals="-3"
      id="c117048695"
      unitRef="USD">2156000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"
      decimals="-3"
      id="c117048696"
      unitRef="USD">1145000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-ExitAndDisposalActivitiesMember"
      decimals="-4"
      id="c117048697"
      unitRef="USD">1220000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30_RestructuringCostAndReserveAxis-InventoryWriteDownsMember"
      decimals="-4"
      id="c117048698"
      unitRef="USD">730000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048699"
      unitRef="USD">3095000</us-gaap:RestructuringCosts>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740581">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;18&lt;/em&gt; - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Pediatric Portfolio Fixed Payments and Product Milestone&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company assumed two fixed, periodic payment obligations to an investor (the &#x201c;Fixed Obligation&#x201d;). Under the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; fixed obligation, the Company was to pay a monthly payment of $0.1 million beginning &lt;em style="font: inherit;"&gt; November&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; through &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; with a balloon payment of $15.0 million that was to be due in &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; (&#x201c;Balloon Payment Obligation&#x201d;). A &lt;em style="font: inherit;"&gt;second&lt;/em&gt; fixed obligation required the Company pay a minimum of $0.1 million&#160;monthly through &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2026,&lt;/em&gt; except for $0.2 million paid in &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; May&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;29,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company entered into an early payment agreement and escrow instruction (the &#x201c;Early Payment Agreement&#x201d;) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the waiver or the investor agreement other than as expressly set forth therein. The &lt;em style="font: inherit;"&gt;first&lt;/em&gt; fixed obligation was fully paid as of &lt;em style="font: inherit;"&gt; January 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; June 21, 2021, &lt;/em&gt;the Company entered into a waiver, release and consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in &lt;em style="font: inherit;"&gt;six&lt;/em&gt; equal quarterly payments of $0.5 million over the next &lt;em style="font: inherit;"&gt;six&lt;/em&gt; quarters commencing &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;The Company accounted for the waiver, release and consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by &lt;em style="font: inherit;"&gt; January 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company acquired the Tris Karbinal Agreement, under which the Company is granted the exclusive right to distribute and sell Karbinal&#160;in the United States. The initial term of the agreement was&#160;20&#160;years. The Company pays&#160;Tris a royalty equal to&#160;23.5% of net revenue&#160;from&#160;the product.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from &lt;em style="font: inherit;"&gt; August 1 &lt;/em&gt;through &lt;em style="font: inherit;"&gt; July 31, &lt;/em&gt;of 70,000 units annually through &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the &lt;em style="font: inherit;"&gt;70,000&lt;/em&gt;-unit annual minimum sales commitment through &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in &lt;em style="font: inherit;"&gt; August &lt;/em&gt;of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;first&lt;/em&gt; of which is triggered at $40.0 million. As of &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the fixed payment arrangement balance was $1.9 million in other current liabilities, and $0.2 million in other non-current liabilities on the consolidated balance sheet.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2024, &lt;/em&gt;the Company entered into a forward-starting operating lease agreement&#160;to lease office space&#160;in Berwyn, Pennsylvania&#160;from the owner of the office space that the Company is&#160;currently renting under a sublease arrangement. The Company has determined that it is an operating lease, and that lease commencement occurred in &lt;em style="font: inherit;"&gt; July 2024. &lt;/em&gt;The&#160;initial is from &lt;em style="font: inherit;"&gt; March 1, 2025, &lt;/em&gt;through &lt;em style="font: inherit;"&gt; July 31, 2030, &lt;/em&gt;and under the lease agreement the Company has &lt;span style="-sec-ix-hidden:c117048743"&gt;one five&lt;/span&gt;-year renewal option to extend the lease through &lt;em style="font: inherit;"&gt; July 2035.&#160;&lt;/em&gt;Undiscounted minimum monthly rent payments average approximately $13,000&#160;over the initial term of the lease.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; May 2023, &lt;/em&gt;the Company entered into an operating lease agreement to relocate its principal office from Englewood, Colorado to&#160;Denver, Colorado. The lease has a commencement date of &lt;em style="font: inherit;"&gt; October 1, 2023, &lt;/em&gt;with an initial term of &lt;span style="-sec-ix-hidden:c117048746"&gt;five&lt;/span&gt; and a half years. Undiscounted minimum monthly rent payments average approximately $15,500 over the initial term of the lease. Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has &lt;span style="-sec-ix-hidden:c117048749"&gt;one five&lt;/span&gt;-year renewal option through &lt;em style="font: inherit;"&gt; March 2034.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Witmer Class-Action Securities Litigation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;A stockholder derivative suit was filed on &lt;em style="font: inherit;"&gt;September12,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#x2019;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on &lt;em style="font: inherit;"&gt; April 5, 2023. &lt;/em&gt;The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and Innovus in &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants&#x2019; breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#x2019; fees. While the Company believes&#160;that this lawsuit is without merit and have vigorously defended against it, the Company&#160;agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#x2019;s attorneys&#x2019; fees. That settlement is subject to court approval, the hearing on which has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been scheduled.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Sabby Litigation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;A complaint was filed on &lt;em style="font: inherit;"&gt; February 22, 2023, &lt;/em&gt;in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#x201c;Sabby&#x201d;) and Walleye Opportunities Master Fund Ltd (&#x201c;Walleye&#x201d;), holders of certain warrants to purchase common stock, against the Company. The complaint alleged&#160;that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrant holders &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive, and that the Company failed to provide prompt notice to the warrant holders of such adjustment. The complaint sought&#160;a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. In&#160;&lt;em style="font: inherit;"&gt; October 2023,&#160;&lt;/em&gt;the Company entered into a settlement agreement and general release with Sabby and Walleye.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Stein Litigation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Cielo Stein (&#x201c;Stein&#x201d;), a former sales specialist, filed a complaint on &lt;em style="font: inherit;"&gt; February 1, 2023, &lt;/em&gt;in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos. The complaint alleged&#160;that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleged&#160;that the Company&#x2019;s response to Stein&#x2019;s subsequent complaint to human resources was inadequate. The complaint sought&#160;an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#x2019; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky. A Section&#160;&lt;em style="font: inherit;"&gt;16&lt;/em&gt;&#160;pretrial conference was held on&#160;&lt;em style="font: inherit;"&gt; June 3, 2024.&#160;&lt;/em&gt;During the pretrial conference the parties agreed to settle the matter. The parties entered into a settlement and release agreement on &lt;em style="font: inherit;"&gt; August 5, 2024. &lt;/em&gt;The&#160;matter has been closed.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <aytu:FixedPaymentArrangementsPeriodicPaymentObligationsNumber
      contextRef="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="INF"
      id="c117048701"
      unitRef="Pure">2</aytu:FixedPaymentArrangementsPeriodicPaymentObligationsNumber>
    <aytu:FixedPaymentArrangementsMonthlyPaymentAmount
      contextRef="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="-5"
      id="c117048703"
      unitRef="USD">100000</aytu:FixedPaymentArrangementsMonthlyPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmount
      contextRef="i_2019-11-01_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="-6"
      id="c117048707"
      unitRef="USD">15000000</aytu:FixedPaymentArrangementsBalloonPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmount
      contextRef="i_2024-06-30_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember"
      decimals="-5"
      id="c117048710"
      unitRef="USD">100000</aytu:FixedPaymentArrangementsBalloonPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmount
      contextRef="i_2020-01-31_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember_StatementBusinessSegmentsAxis-ThePediatricPortfolioMember"
      decimals="-5"
      id="c117048712"
      unitRef="USD">200000</aytu:FixedPaymentArrangementsBalloonPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmount
      contextRef="i_2020-05-29_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="-6"
      id="c117048716"
      unitRef="USD">15000000</aytu:FixedPaymentArrangementsBalloonPaymentAmount>
    <aytu:FixedPaymentArrangementsPaymentAmountPaid
      contextRef="d_2021-06-21_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="-5"
      id="c117048718"
      unitRef="USD">2800000</aytu:FixedPaymentArrangementsPaymentAmountPaid>
    <aytu:FixedPaymentArrangements
      contextRef="i_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="-6"
      id="c117048720"
      unitRef="USD">3000000</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangementQuarterlyPayments
      contextRef="i_2021-06-21_OtherCommitmentsAxis-FixedPaymentArrangementAssumedFromCerecorIncMember"
      decimals="-5"
      id="c117048722"
      unitRef="USD">500000</aytu:FixedPaymentArrangementQuarterlyPayments>
    <aytu:SupplyAndDistributionCommitmentPeriod
      contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      id="c117048724">P20Y</aytu:SupplyAndDistributionCommitmentPeriod>
    <aytu:SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales
      contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="3"
      id="c117048725"
      unitRef="Pure">0.235</aytu:SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales>
    <aytu:SupplyAndDistributionAgreementMinimumSalesPerYear
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="INF"
      id="c117048727"
      unitRef="Pure">70000</aytu:SupplyAndDistributionAgreementMinimumSalesPerYear>
    <aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="INF"
      id="c117048731"
      unitRef="USD">30</aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit>
    <aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit
      contextRef="i_2024-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-2"
      id="c117048734"
      unitRef="USD">2100</aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit>
    <aytu:SupplyAndDistributionAgreementMaximumMilestoneObligations
      contextRef="i_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-6"
      id="c117048735"
      unitRef="USD">3000000</aytu:SupplyAndDistributionAgreementMaximumMilestoneObligations>
    <aytu:SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues
      contextRef="d_2023-07-01_2024-06-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-7"
      id="c117048737"
      unitRef="USD">40000000</aytu:SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues>
    <aytu:FixedPaymentArrangements
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-5"
      id="c117048738"
      unitRef="USD">1900000</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangements
      contextRef="i_2024-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember"
      decimals="-5"
      id="c117048740"
      unitRef="USD">200000</aytu:FixedPaymentArrangements>
    <aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment
      contextRef="i_2024-06-30_LeaseContractualTermAxis-OfficeSpaceInBerwynPennsylvaniaMember"
      decimals="INF"
      id="c117048744"
      unitRef="USD">13000</aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment>
    <aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment
      contextRef="i_2023-05-31_LeaseContractualTermAxis-PrincipalOfficeDenverColoradoMember"
      decimals="INF"
      id="c117048747"
      unitRef="USD">15500</aytu:OperatingLeaseUndiscountedMinimumMonthlyPayment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"
      decimals="INF"
      id="c117048756"
      unitRef="Share">575000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-02-22_CounterpartyNameAxis-SabbyVolatilityWarrantMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"
      decimals="INF"
      id="c117048758"
      unitRef="Share">312908</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-02-22_ClassOfWarrantOrRightAxis-SabbyLitigationWarrantsMember_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"
      decimals="INF"
      id="c117048759"
      unitRef="Share">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-02-22_CounterpartyNameAxis-WalleyeOpportunitiesMasterFundLtdMember_LitigationCaseAxis-SabbyLitigationMember"
      decimals="INF"
      id="c117048760"
      unitRef="Share">54146</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <aytu:LicensingAgreementsTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740582">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;19&lt;/em&gt; - License Agreements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Healight&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; April 2020, &lt;/em&gt;the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; years after the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency.&#160;Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and $0.1 million in earlier patent prosecution fees.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As a result of the Company&#x2019;s focus on the revenue growth of its commercial business, the Company&#160;terminated the licensing agreement with Cedars-Sinai Medical Center, effective &lt;em style="font: inherit;"&gt; May 9, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;NeuRx&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; October 2018, &lt;/em&gt;Neos entered into an exclusive license agreement (&#x201c;NeuRx License&#x201d;) with NeuRx Pharmaceuticals LLC (&#x201c;NeuRx&#x201d;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture&#160;and commercialize certain pharmaceutical products containing NeuRx&#x2019;s proprietary compound designated as NRX-&lt;em style="font: inherit;"&gt;101,&lt;/em&gt; referred to by Neos as &lt;em style="font: inherit;"&gt;NT0502.&lt;/em&gt; &lt;em style="font: inherit;"&gt;NT0502&lt;/em&gt; is a new chemical entity that was&#160;being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of such licensed product in such country and continuing until the later of: (i)&#160;the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii)&#160;expiration of regulatory exclusivity of such licensed product in such country.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; April 2023, &lt;/em&gt;the Company returned the &lt;em style="font: inherit;"&gt;NT0502&lt;/em&gt; rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on &lt;em style="font: inherit;"&gt;NT0502.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Teva&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; December 21, 2018, &lt;/em&gt;the Company&#160;and Teva&#160;entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under an&#160;abbreviated new drug application&#160;(&#x201c;ANDA&#x201d;)&#160;filed by Teva beginning on &lt;em style="font: inherit;"&gt; July 1, 2026, &lt;/em&gt;or earlier under certain circumstances. The ANDA was approved by the FDA on &lt;em style="font: inherit;"&gt; June 19, 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Actavis&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 17, 2017, &lt;/em&gt;the Company entered into an agreement granting Actavis a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on &lt;em style="font: inherit;"&gt; September 1, 2025, &lt;/em&gt;or earlier under certain circumstances. The ANDA was approved by the FDA on &lt;em style="font: inherit;"&gt; June 22, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Shire&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; July 2014, &lt;/em&gt;Neos entered into a settlement agreement and an associated license agreement (the &lt;em style="font: inherit;"&gt;&#x201c;2014&lt;/em&gt; License Agreement&#x201d;) with Shire LLC (&#x201c;Shire&#x201d;) for a non-exclusive license to certain patents for certain activities with respect to Neos&#x2019; New Drug Application (the &#x201c;NDA&#x201d;) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;204326&lt;/em&gt; for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the &lt;em style="font: inherit;"&gt;2014&lt;/em&gt; License Agreement, following the receipt of the approval from the FDA for Adzenys, Neos paid a lump sum, non-refundable license fee of an amount less than $1.0 million in &lt;em style="font: inherit;"&gt; February 2016. &lt;/em&gt;Neos is paying a single digit royalty on net sales of Adzenys&#160;during the life of the patents. The settlement agreement expired&#160;in &lt;em style="font: inherit;"&gt; May 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

  </aytu:LicensingAgreementsTextBlock>
    <aytu:LicenseAgreementInitialLicenseFeePaid
      contextRef="d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember"
      decimals="-5"
      id="c117048771"
      unitRef="USD">300000</aytu:LicenseAgreementInitialLicenseFeePaid>
    <aytu:LicenseAgreementPatentProsecutionFeesPaid
      contextRef="d_2020-04-01_2020-04-30_TypeOfArrangementAxis-HealightMember"
      decimals="-5"
      id="c117048772"
      unitRef="USD">100000</aytu:LicenseAgreementPatentProsecutionFeesPaid>
    <aytu:LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum
      contextRef="d_2016-02-01_2016-02-29_TypeOfArrangementAxis-The2014LicenseAgreementShireMember"
      decimals="-6"
      id="c117048784"
      unitRef="USD">1000000</aytu:LicenseAgreementUpfrontNonrefundableLicenseFeePaidMaximum>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740583">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;20&lt;/em&gt; - Segment Information&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s CODM,&#160;who is the Company&#x2019;s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company manages and aggregates its operational and financial information in accordance with &lt;span style="-sec-ix-hidden:c117048787"&gt;two&lt;/span&gt; reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company&#x2019;s prescription products. The Consumer Health Segment contained&#160;the Company&#x2019;s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; regularly review asset information by segment, accordingly, asset information is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provided by segment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Select financial information for these segments is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Rx&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Consumer Health&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Consolidated&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Year Ended June 30, 2024&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;65,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;81,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss from operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,590&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(3,664&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(5,254&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,909&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,547&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,456&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,373&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;540&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restructuring costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,156&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;209&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,365&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Year Ended June 30, 2023&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;73,799&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;33,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;107,399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss from operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(7,358&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(9,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(17,065&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,271&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,722&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;324&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,046&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Impairment expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,975&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &#160;&#160;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740584">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Rx&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Consumer Health&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Consolidated&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Year Ended June 30, 2024&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;65,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;81,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss from operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,590&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(3,664&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(5,254&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,909&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,547&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,456&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,373&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;540&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restructuring costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,156&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;209&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,365&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Year Ended June 30, 2023&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;73,799&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;33,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;107,399&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss from operations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(7,358&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(9,707&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(17,065&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,271&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,722&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;324&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,046&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Impairment expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,975&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048795"
      unitRef="USD">65183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048796"
      unitRef="USD">15819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048797"
      unitRef="USD">81002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-4"
      id="c117048798"
      unitRef="USD">-1590000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048799"
      unitRef="USD">-3664000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048800"
      unitRef="USD">-5254000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048801"
      unitRef="USD">5909000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048802"
      unitRef="USD">1547000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048803"
      unitRef="USD">7456000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048804"
      unitRef="USD">2373000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-4"
      id="c117048805"
      unitRef="USD">540000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048806"
      unitRef="USD">2913000</us-gaap:ShareBasedCompensation>
    <us-gaap:RestructuringCharges
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048807"
      unitRef="USD">2156000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="d_2023-07-01_2024-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048808"
      unitRef="USD">209000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="d_2023-07-01_2024-06-30"
      decimals="-3"
      id="c117048809"
      unitRef="USD">2365000</us-gaap:RestructuringCharges>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048811"
      unitRef="USD">73799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-5"
      id="c117048812"
      unitRef="USD">33600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048813"
      unitRef="USD">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048814"
      unitRef="USD">-7358000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048815"
      unitRef="USD">-9707000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048816"
      unitRef="USD">-17065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048817"
      unitRef="USD">6271000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048818"
      unitRef="USD">1116000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048819"
      unitRef="USD">7387000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-3"
      id="c117048820"
      unitRef="USD">5722000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048821"
      unitRef="USD">324000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048822"
      unitRef="USD">6046000</us-gaap:ShareBasedCompensation>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-RxSegmentMember"
      decimals="-4"
      id="c117048823"
      unitRef="USD">2730000</aytu:AssetImpairmentAndWriteoffCharges>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="d_2022-07-01_2023-06-30_StatementBusinessSegmentsAxis-ConsumerHealthMember"
      decimals="-3"
      id="c117048824"
      unitRef="USD">2975000</aytu:AssetImpairmentAndWriteoffCharges>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="d_2022-07-01_2023-06-30"
      decimals="-3"
      id="c117048825"
      unitRef="USD">5705000</aytu:AssetImpairmentAndWriteoffCharges>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2023-07-01_2024-06-30" id="c2740585">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;21&lt;/em&gt;&#160;- Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Wind Down and Subsequent Divestiture of Consumer Health Business&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; July 2024, &lt;/em&gt;the Company&#160;completed the wind down of its&#160;Consumer Health Segment and on &lt;em style="font: inherit;"&gt; July 31, 2024, &lt;/em&gt;the Company&#160;entered into a definitive agreement to divest its&#160;Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company affiliated with the Company&#x2019;s&#160;former Vice President of Consumer Health, Jonathan Hughes. Pursuant to the definitive agreement, Mr. Hughes resigned from the Company effective &lt;em style="font: inherit;"&gt; July 31, 2024. &lt;/em&gt;The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for the Company&#160;to receive up to $0.5 million of revenue-based royalty payments and recovery of cost on certain future sales of former Consumer Health business products. Upon consummation of this agreement, the Company has&#160;completed its&#160;wind down of the Consumer Health Segment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

  </us-gaap:SubsequentEventsTextBlock>
    <aytu:RevenuebasedRoyaltyCosts
      contextRef="d_2024-07-01_2024-07-31_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c117048827"
      unitRef="USD">500000</aytu:RevenuebasedRoyaltyCosts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c117048060"
          xlink:label="c117048060"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048064"
          xlink:label="c117048064"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048058"
          xlink:label="c117048058"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048071"
          xlink:label="c117048071"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048055"
          xlink:label="c117048055"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048068"
          xlink:label="c117048068"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048066"
          xlink:label="c117048066"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048062"
          xlink:label="c117048062"
          xlink:type="locator"/>
        <link:footnote id="f98c7406b-0164-46c7-a651-4ef0eae9f56d" xlink:label="f98c7406b-0164-46c7-a651-4ef0eae9f56d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">	Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048060"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048064"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048058"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048071"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048055"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048068"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048066"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048062"
          xlink:to="f98c7406b-0164-46c7-a651-4ef0eae9f56d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048657"
          xlink:label="c117048657"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048658"
          xlink:label="c117048658"
          xlink:type="locator"/>
        <link:footnote id="fb35717a1-d432-4eda-915f-5e96136e3a49" xlink:label="fb35717a1-d432-4eda-915f-5e96136e3a49" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048657"
          xlink:to="fb35717a1-d432-4eda-915f-5e96136e3a49"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048658"
          xlink:to="fb35717a1-d432-4eda-915f-5e96136e3a49"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048688"
          xlink:label="c117048688"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048689"
          xlink:label="c117048689"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048690"
          xlink:label="c117048690"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048691"
          xlink:label="c117048691"
          xlink:type="locator"/>
        <link:footnote id="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4" xlink:label="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048688"
          xlink:to="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048689"
          xlink:to="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048690"
          xlink:to="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048691"
          xlink:to="fac24fe3a-5486-4955-9a5a-d5e2c0b805f4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048692"
          xlink:label="c117048692"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048694"
          xlink:label="c117048694"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048693"
          xlink:label="c117048693"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048695"
          xlink:label="c117048695"
          xlink:type="locator"/>
        <link:footnote id="f9b398ddb-deb9-406f-853a-3630953d420d" xlink:label="f9b398ddb-deb9-406f-853a-3630953d420d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048692"
          xlink:to="f9b398ddb-deb9-406f-853a-3630953d420d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048694"
          xlink:to="f9b398ddb-deb9-406f-853a-3630953d420d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048693"
          xlink:to="f9b398ddb-deb9-406f-853a-3630953d420d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048695"
          xlink:to="f9b398ddb-deb9-406f-853a-3630953d420d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048035"
          xlink:label="c117048035"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048036"
          xlink:label="c117048036"
          xlink:type="locator"/>
        <link:footnote id="f8d99ba23-2066-44d9-91b0-1100337ca445" xlink:label="f8d99ba23-2066-44d9-91b0-1100337ca445" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company&#x2019;s June 2023 equity financing that were exercised in June 2024. The warrants were converted into 367,478 shares of common stock (&#x201c;Settlements&#x201d;) and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (&#x201c;Issued&#x201d;). See Note 14 - Stockholders&#x2019; Equity and Note 16 - Warrants for further detail.  </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048035"
          xlink:to="f8d99ba23-2066-44d9-91b0-1100337ca445"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048036"
          xlink:to="f8d99ba23-2066-44d9-91b0-1100337ca445"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048656"
          xlink:label="c117048656"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048654"
          xlink:label="c117048654"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048655"
          xlink:label="c117048655"
          xlink:type="locator"/>
        <link:footnote id="f2743343a-4318-4cd7-9fe7-1f7853d6462f" xlink:label="f2743343a-4318-4cd7-9fe7-1f7853d6462f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048656"
          xlink:to="f2743343a-4318-4cd7-9fe7-1f7853d6462f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048654"
          xlink:to="f2743343a-4318-4cd7-9fe7-1f7853d6462f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048655"
          xlink:to="f2743343a-4318-4cd7-9fe7-1f7853d6462f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048697"
          xlink:label="c117048697"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048696"
          xlink:label="c117048696"
          xlink:type="locator"/>
        <link:footnote id="fbe5c3633-abc1-4561-8c2d-346405b663d4" xlink:label="fbe5c3633-abc1-4561-8c2d-346405b663d4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048697"
          xlink:to="fbe5c3633-abc1-4561-8c2d-346405b663d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048689"
          xlink:to="fbe5c3633-abc1-4561-8c2d-346405b663d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048693"
          xlink:to="fbe5c3633-abc1-4561-8c2d-346405b663d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048692"
          xlink:to="fbe5c3633-abc1-4561-8c2d-346405b663d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048696"
          xlink:to="fbe5c3633-abc1-4561-8c2d-346405b663d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048688"
          xlink:to="fbe5c3633-abc1-4561-8c2d-346405b663d4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048668"
          xlink:label="c117048668"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048666"
          xlink:label="c117048666"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c117048667"
          xlink:label="c117048667"
          xlink:type="locator"/>
        <link:footnote id="f6fbcc151-5929-4771-adba-8b2dfa3026fa" xlink:label="f6fbcc151-5929-4771-adba-8b2dfa3026fa" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048668"
          xlink:to="f6fbcc151-5929-4771-adba-8b2dfa3026fa"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048666"
          xlink:to="f6fbcc151-5929-4771-adba-8b2dfa3026fa"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048667"
          xlink:to="f6fbcc151-5929-4771-adba-8b2dfa3026fa"
          xlink:type="arc"/>
        <link:footnote id="f094dbb3e-1687-4c38-b1d9-1da7b273debb" xlink:label="f094dbb3e-1687-4c38-b1d9-1da7b273debb" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048668"
          xlink:to="f094dbb3e-1687-4c38-b1d9-1da7b273debb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048656"
          xlink:to="f094dbb3e-1687-4c38-b1d9-1da7b273debb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c117048698"
          xlink:label="c117048698"
          xlink:type="locator"/>
        <link:footnote id="f68dc4532-adfe-4b08-8152-47796f88bec8" xlink:label="f68dc4532-adfe-4b08-8152-47796f88bec8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048698"
          xlink:to="f68dc4532-adfe-4b08-8152-47796f88bec8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048694"
          xlink:to="f68dc4532-adfe-4b08-8152-47796f88bec8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c117048690"
          xlink:to="f68dc4532-adfe-4b08-8152-47796f88bec8"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
